<SEC-DOCUMENT>0000882095-21-000008.txt : 20210225
<SEC-HEADER>0000882095-21-000008.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225161523
ACCESSION NUMBER:		0000882095-21-000008
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		21680516

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gild-20201231.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:c95e6174-aa16-488c-b0f6-cc28c1f33ed5,g:86b29b2d-a791-4b12-a644-3051a1d6b3ea,d:b93766b38a794f83a6a283fa0a85c17d--><html xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:gild="http://www.gilead.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl8zLTEtMS0xLTA_203a70ed-334a-4ed0-9a78-215e8b3a2e04">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl81LTEtMS0xLTA_11f14248-f569-400d-aa58-27f2174c38d4">2020</ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl82LTEtMS0xLTA_4dcb0c9e-aa19-4ff4-97db-c27c66d2b517">FY</ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl83LTEtMS0xLTA_da271d22-3be1-4c74-b120-1f4d6557d88c">false</ix:nonNumeric><ix:nonNumeric contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8yMTI2L2ZyYWc6YWE4YmQ5MDUzMmI0NDRlYzgyZjNhNjI3ZGVmOGU0ZDgvdGV4dHJlZ2lvbjphYThiZDkwNTMyYjQ0NGVjODJmM2E2MjdkZWY4ZTRkOF8yNzQ4Nzc5MDY5NDc4_267e84f6-6e71-4775-b36b-3b9c34d26ca1">us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8yMTI2L2ZyYWc6YWE4YmQ5MDUzMmI0NDRlYzgyZjNhNjI3ZGVmOGU0ZDgvdGV4dHJlZ2lvbjphYThiZDkwNTMyYjQ0NGVjODJmM2E2MjdkZWY4ZTRkOF8yNzQ4Nzc5MDY5NDc4_77fd3619-2e1c-4b6c-93d9-6da205eabd6a">us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaa1d5481adee40849cb658b58a5e6799_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0Nzg_3e0bf107-df4c-42b5-99e9-a7dcf78020b1">P3Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="ied46b5b50bca4d0998e9bb06b1fc9bc4_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNjQ_4b3408a6-98fc-4b69-98be-510a6fbd1b22">P3Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="i37406a81513b4400ab5caf494643ae52_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDA_af92dcc3-2fe4-41b3-aed3-392d48d636df">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="iede55c4650474e14803be5cd10e0b4b9_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDU_17e1fc1d-af04-402c-9a3d-30ce2e48473b">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie96afe3a1df84576aaaff813a6240267_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if218098f852d48df84d6fe5e15c309b0_I20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa2d477c63034d369b25d6854cf06afa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i85124ea043f44d21b8b54a8de5bdf919_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1854fd7993394c05bb3e013f00d725cb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c26f4bd16b4406da90ed77b81c4e690_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id688d136833640ac9c6d94d4ddc9632a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8670361a0047c5abdca258af5b3b44_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0d2f065cd0476e9fe09cf97a3daa95_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4434b84f088145049b702ceb08c39437_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i835488bd375d4a09af99788bd9e27362_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6356b044964174974ec7dc3f4bbd36_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e30e15c134641879f2e452fd14665e2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb5c937c29a64935bd5513af5cd17eb8_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3219b6982b334ae49d4a68c7befc5d27_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad04f35896042aeb313604ac52c806c_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6f63899ea2f45c8b3d163ffca4733cc_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2747bd2827c1444bb8598c30d980ccac_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c9515f11a04c63b1fc167cf59c9e73_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93892be161ed46f0b59daf9d2cb4f947_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5da7a2ef9a64a11a7b170d14e808fd2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54dde75a77af4f3b89a86ac2a4228e70_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70493ea7576f4f75bf9315161efe8129_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31731035ecc946909f7611c79f589644_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7af2bcb42b64317aa982dc29f82941d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1fdea1fe7d4a078ed1a4602d02bb20_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65708ddeaac5432bbbd3d6edf2afc67b_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide81d63cf6c54f098b1ff7c66544b644_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecfc48f8ba344985b35fcd2a8cb7d81c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fcd6ecd6054ae299896dca5929ff08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8823d4c8e7b94b01a4ee9918a81621f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169f1c5f92244d9c9d8b552d1f30c6c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7814341554194d39a8d33cf13d7c7a78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38c06042926b4ec6a8d780769c247d9f_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481ded537ec44be2aa528514e17583c9_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida37295fbd814545a3765e7f4773f2f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia719d90905124e9b9418db557c451735_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644e2dd1361545818a945c69c56a8198_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7100af96680046f2a2500612bc8d8730_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1aad86406e4fb6bb4aa4b7bd2a85cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5ad62f62cb4ef6968f09d3363ab76e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2e43234fc04521af2344e4b1244e9f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i987c3ed14ae840e7ba9dc6b6834ee87b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398df6a52dd9464d8dd45e089b73014d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27efdec092714a19b30f4a1ad8aa6133_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf9fe67d86404ee58fc08434776ac75a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a198ee4eaba43a9be336a94d8a87b2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa4ce37886b4a34b696be088b6209dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if280de1dfeb24360a98d1085d3ec01d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42acdb68c96f40139d8ef2dd48ec4aad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93a08630ddf4d8daa910c80941d2f49_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1fc5480ae54692850a590af2530f85_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia42eea57788b437d80b0100bf5308e5e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b227c5b6d24b36a063e59f6b31eddb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd51a66da7cf40eb80804c8cb98cf1a4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia729850536324dc7a891febe1ef57425_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a2f412468e04e8e990eda8c053e9023_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i573540eac6ce41b9ba0a37a14d578dcd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e0aaddda8242649f4cce16f7480e3f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e6f27d389c4470791b5097d66ee6fb2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec241db8005b4fb59360d2304f6a40ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dce80f6a5d043fabec1581e37b038e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba9195c2f9b45e392656f86c6f8865c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5630aee9b8e34051b2267852a2167c72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bf33c47a6342328f4b4a359e831dc0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01bd5e69cc2242e9937e99d06f49412c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7657c224364338aaec9e8f7e531475_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479222aa62ba4959b945991f45167506_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i732f9de4021249caa5c12dd71d663337_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51323f6fd23840a6a3a8153facb4a542_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8120081236ab4ada86875183d3516a0d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d9ac1bed894e8ebd3a9a07adec3780_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i423cb85373ec46cd90ab88681133fed7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bca99eea6724544b1989f1c71ff8e7b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib925542d3c9a449f9451287b1948794d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fe1a6f3e2a4443bfadf5e3b18575a8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397a1aaa80ac42d8b7d7547d7a425c70_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e6650f4df60426daa34dc4ca653bc0c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96967e4c10914e109e43c4c43838be39_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbd726607304250949dffcf3aa8a682_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaac1e36447014421822582a862cdaadd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e01036f80124b668ee600a97070f563_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9ad0800ab14c06a5eb9fc8ed1492dd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f83bbac170c4124b1506d033c0044f6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff45aaf7fa4b4df1b955bc6bf7844c83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fcce9db6610413494337c100307fc4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba09d37db0e466f905cbca86c3d7dc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914f59558f254e77910de66c2a838a2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05a4d813f594dffabe58b494a022cce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b7ceb3521340179dc6fb26acff9127_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ed9dfdc9e84991bcf49d834722ae9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6155a1372b794cfc98808510fd0f6aa0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1451f5b027bb41a4847584b7f596fd2f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d167e5e90304b3cb0fa2437ed97d58d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i148057a263804622a6ab50305a09929a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30b81a7f7314bf597308792e530d56d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24aca176c89041e39835e536b01a5caa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa4c3f449f34e3ca5b0429151183789_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee8311b76724420b4e775d0c80dce90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82451c9a5fc840db91ee5a3c49612ddf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a33cadbf614a8480b0f3f1046c5ae5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb475376a1c4eab860991d825204c02_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31b4a13728764a0eba034f51b801c879_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46aeadee3584d9d87c1b87143a83acd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d8548ebbc24499af4a1bfcc9d5e0ac_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb71020bf354a20a7eb5c17cbe9527a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73e2d26072ce41babea393a33fe5028b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1334107b9d4287be103de88544e8c2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56b0d69dc4443c38f7f201f8cf0560a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19165ee38eb44b368716095e6b79b8ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a83d33cd594375ad102b2d5a901d14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e25273ce6ff4d95913b6a378db136fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1354418ec0a142bf80aa75673f9dc7ff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50ed561675c40659815e6bbfcfe85f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d77fd8a2cd542c187eb7beb450a9bd5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ce8efc83ec4d46a7d9d78b23565594_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307fd96efd864668a53c14e22b45b3df_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51752bd1d33b45d99eeaeb4bc0e7aa30_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837c38f09aec40bea2af72ce62bb55e4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a72addb6d6c4f8f901283e58f4db7e5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e16d8591f64ebd8ed80e3b3d51a9bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5568bc36104cc3bd4575c08d5bd2a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb6ef7264624b6b88e49bf1fdcc8084_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b4931148e643fcbe49c4f9d12ba1d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3245979d6cb647f1a9f0228da2e8828a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib830ff48e9c547759f55cd54a403715f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bffa555d06d4f78813ba77778839fd2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33ba5d575e9416a8fbf45cdcba038c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383f0ccfdd634300bb105e23b2743b3e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8fc3d812ef541ae8ae75cfd0c10bd4b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971bd58c2a104fa58633b760bd1bcc49_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bff96a7eee3471ea92c5a5728abafb6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e671960e24493caa9e67137c00b67f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601dd6fe3b1a427b9e877264c2a50cc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae5bb92838f42e185c2fdac7cb74c5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id82ff04803a44a739676620ac878f839_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99fb37b1c0334cada10080d435ac5f5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id136b7bd1fbf487ca2f4096e63868995_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09c63bb8f77347f5b4447f81ccb53bce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5f53f6dc9d4ac08d0693f368244332_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e084e4904f4eec869ea6250e39cb0f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e0d6d757fe42eb80d7eace0eca26d4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5873767e398449f49bed3571f29dfb2c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63723f5c740941a983de991985232fb3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3efda2c81540b28f3d08dd5de9755f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b99b05d92954eca83863f0bf00a778f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i881bd67c6b4d4c32ae44c9cecd6b6cb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0469e8d7b3941ffa027e0d65422b55f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1378a285d3541119968e5a408b282db_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade7d753f59a4127a6ee33601d7bb46f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86f743bdebd4241a992f10cc32afce2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0499c86d7cb249e79e4e9514392025b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4380b2c4b087466e96212e805752c452_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c65abc055694fa093ee3d1a90844e56_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id536d58f3ef742cfa5620869742d07f2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7cb86cb8124bfba88a83abe2dbea50_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41251b77296c4f1c896b094d88169d6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6faa09d5af4cbb9ffd71fb56eb0943_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfe492680a244d69a015e5f447b30fb9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc9c5bcc6ec24e9fbf91a218a0ec316c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f80e96782c40c7ae4aeb93329d6569_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibefbcda1973840c1a30941cf065c6d7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id549332482954a04928a406aa2aa8ce1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3153057cb844d0f85ec934a049701a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52fb0ee83c0e437385e9166f9c973f27_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddbe44d21304dbdb6f1f137c5fbf5e2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f62e6dfb68b40d2a30db38faaef056c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55935a228d7349a0b68ecf40aea95522_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d7a8c92b7b499c925cd2e1b63d5674_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09483a086d8344418fea4c38597c601d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816c10bfc97f4bd3a31a63ce6248693a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e93f9118e4d40739ac1f86ecf2503a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e010182efaf422cb20cdb14830ec5b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c5df52b2384dad827ce8d5ed8becd0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b5382709394ef0902ac805a3fba467_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a796d1ca3647aca0c0cf94e9e84834_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed79b72cddf47108dc5adb16f1c6e0d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308e3d02bbe24f73995a88d9dffbeb6e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e9639e6b4f4a93bef391904c7ba7c9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e99b9e4abc6439caf1635dde53641e6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784a2e611fc6427c9c5e4418b57df0b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f26b0b8d9a42e1b8b6392b60d37f56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id210bf00395f48528f93b74e8bcf8963_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356cdb8eb49e4b5fa6d74cde3aee0fa5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0399583abbfa4b70a9826bd3f34fc3e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971e8c17f58441c796ae21856d69fecd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3c000c64e74a5997c3ce62426eab73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4791ac34254f20a211ff631970f1df_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a776ce3ca04751a6acd137246eadbf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if61ad645329c4f84a5ca1f8858e4a105_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789b3a29153346629c85ec22950b2443_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2449c7232a1542d8961f78873606cd5c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98307d1f71d4a57b90d117c72387c97_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709dc81b1e0b4ad18ed1a3516087e006_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52257540c09044d483783ee0e873ddb2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d14fe1cf6741a38f337376d9b09937_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ead59eb11954802b58faf4295471c59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fce49b484e4fbe8b7118a57fd949ff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b3fa2ba952448ab0308cc83860110a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19c5edf94af43d38aea8ff9a812b9bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1510ef46b1564c908317e3e7ed9ae838_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf8fc952f7ea48e19ed2627867ef4e34_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e85b0a40a6f4651aeb814864a67e2d5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1520f66d45ff4fc99578172eae43f525_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafba755ee21149148b5687e8c622242c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3418497bf64641e89450ddf47541cc00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a0f15448df4521b3252b863920fd4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa04a1897acb43a8935771581a2294d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25cf3186547645e18a12e54737ff3f20_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a055454e634859b9e4d1183c8ce86b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f360e299e954e01a740de35c1825eda_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbfb0cd1316443b2a3450b33ba196076_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909b8bd81dd94054add30d019a9039b1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81493ecf2c148c3b066878a096034fc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d6ae2564f7486fb11225a0eaadac69_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c76d4fd2017462795348867f8cdcf28_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7742e26504ad407fbe00062a7dd0687f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a76126042a4ae6b749183870511d1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea13b5f060d4a69a6a698a8df908663_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b63e3d135704c9abeb409724a97d925_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ef5470931747bb983f03b0991cd741_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8780e4b3e8474e2cbe7f7e27d5ca7b6a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67fc940422441b0ad55ee1a90ed0adf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f7a3e3e83d47fba6ac8b13a9f5610d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce8b095baec43b9a6b48fa3f625b855_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcdb328dbec54ee98bcab35be1c9d7be_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23482e8bcdc43c88946e03e12a9d121_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09f10d7c83d4df6818e86cf8d921ffa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859d13747a854b698617069a85edd654_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65fb0f65e47c4aebad73abab7f3d668c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb1c210d43842dc83ff399b1433b853_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630b6c887763456b9fc85ec6d3ce087a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief9f1a4dc71044d6a03833cd32ab6427_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6b44faba3c4c3997faba3148afcff0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida618eeb5e0c4c0fa85d55c4d046e885_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba2cc8ba7fa4f4ea047c155d67eb4bc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109a8b80496843409ed73dee8466e5f2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib288b9089b0c44789133829c737173c8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d4ab01235446e18963ca74e84b4ee4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce39b3aecd24bc6b4e8956650a90f41_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0e1109ab13490eb642fa4d06a36587_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413eb3a40a8b42d988fa602ebb2ca91f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dea6420e00e4e8d9730f2afce5768f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f3a8d6d4864089b0117d15c03f54c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9a38838e3584d7098ad47e06cbd413d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580e219bcf66429da65491757ea55918_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55279b9ee5c4b128d5d5228052e4f29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a3932fa2ff4271b07b0b741b9f2e16_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i201995b3520443f09a408794644c73ca_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889b1eb7b37749da92f1bf1c86dea272_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35db01b6963a4942bb80c530e3cf0eab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468e6f1044534b1fa35b2fbd7924b327_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08394a404854722bf7e616cb19ae8fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d4c798eb7224a9cacdb473b8ff5c063_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb8d59cb650742a4a8ec1678152225c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1749278d3a468faec493fac747a15a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb15b0bfbfcf4fecb6e417adb32d14cc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5679c3ac945499eaa165d356e44c345_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2021dd665b74bfd84ef3c205aee77de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef427af36e6444fb807bafc1dd97ed2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983b0b11a6c84a078f5acef269da5f01_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f00902a9e047f1bf5e98edae0c114d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1527f16620140d3b0bc8763e514b4e2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b4cf44e0b44448a2dcdc6b970704a1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc912cbab8848d1af83924b72da7f38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738e00cc411942688a5f051bbc58789a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc84cbd707c4080b153a838a03d48c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e9650394f04aeb94d242d32a12e8bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedebf7a896304b22ace657a8e1c8486c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib09a5278cb5a49f0a7699635ac23b161_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief07e0bd49214929beab0135a7c7dc3c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e0f3e3ca6b14a30b76b4f150c9ee957_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b3071aa2974bbf9886daa645933440_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i883994858d314ba48462d6cb3c2af453_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab10c90724184ec98c3bd8679e022adc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bd06fa86a24206ad6519770cbbf504_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d46f4d0a9742b3811281fb61e7d0e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f879d917734de09114d93c9296efc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829cfcdf44354f36b769778dcca6ea95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c157b8f9e44197a7c0c60493c89067_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c23f8c25d144cd7be8fbb3776eb33c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54469a0949b4fc0a59210e6ef5f4c5f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857e28fb6733458686888944ec0abcec_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4fd0e8f161841919bc51b121342b374_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2079180ac67341b99d32045a11aef376_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94b0e9d86a249e7ba66251f8d5f185f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1967de1c5a82446488fc2307733a2f25_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib157d6d05afd413fbf032738706b0c74_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a212bda0e54ab3b525dd5891bf887e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79495b272c824538bfb4875c67e764f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5738b64989fe4499bd71a4261fe9cd53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0a03686d6ac48f48e3b9bc50f36d666_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc02389377974b6585a7c609eb64806c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b0e346a3004c339a6cd887facee047_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5896ac21bdf49a6a7472cad2027abf6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22cc8196c9ec45ab9f1de39dc4a69f10_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief49933c94874a7288705eed5a22b841_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a28ab5c7fb4105aefaa14b53daf143_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id68873060904412cae3451300eaf1465_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9385611a51014144a8857f90be3bf8df_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e1f5ddacd74e36860d63ef63816443_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e5f0db282f4e87a91f73ee0f751c64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1da7341e9594d21a608bad106da29bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356273c8d56b44b0b5a77cf594e9c798_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b29db06821842aa88c87560b1140102_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46fbf481784d46df9cd01a3ed0d6545d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea757664b6d4a1ab8eec797ffb2d767_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ddef75a147542598e9eeae5bd12bd75_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec4e20f64114d7d9926a8c80f9a5728_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i268bb32842bd412986cc0065b81f5ec3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395a7db3cb484d78bbf89146a3e077d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba42c93200d4f8b8304c65a06ccf517_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33bcf8c71124c9f9f2ac08771f1c913_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9314f39916471fa92a7b99ba58f5cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f91458243294b9c9c142625d0f38738_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21c75ed2e5e4a0785b473551c580aaf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad692520c784ea4abc27df55521f56e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e47ad7e13b4bf69d68ce9974de21b2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6f0bfe6a0f4a34812997b067f29ed4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43afc88178954f07b425ff4523b10503_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b488bb036614037b341e5cf1b62388d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1acd6c6fbb76414daa5db831c8743f1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib433847287a34715a932ae68acaeb709_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18325e923e9c47fcbb342e3aa696ccfc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc0423d455d47bea3200f2044dda0b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b200ae598541c98d2a1ed430747f3a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib937cdde175b4314b5243e750587f636_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4f48c959ab41ee88040efcbcea0d9f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e97d5163a44218b733238cd69431ad_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb3da24a50f484bbfcb5f5691037fd3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9885f4a5984a4acfac50c45d81501317_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide045b122d2b4c9da0649764f92f82cf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ba333691004582b0bfe3cf23e00905_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98481f2446747c5b3c54ea39b7ef10c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f307f1d85849869339a3dd1db1df84_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db84ac85e404173a8e1cb30a6decd26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91187b7f1d854ab7ba6257b9a17a971b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5da15e7f08745208039280810556724_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a59d3e994e417497f2f6e81c591584_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37fab06fed904a5da3ee5fbccc5f0375_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a89708946c4f75aeffc28c28e30c9d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eec496ec02f4593bd2a62da7c33299b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad31f51a98be414c964b9e2b9a577bc1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf02763ce85454bba606a3d45b058a0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf2157f2cecf4cd0a6d21dfba9a135ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e5df38c8d924b2893c58f2be02de301_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b69aedcfde94c8f985123b13ec54c43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b05d44e0ea438ab49cc731f8134505_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c52e1ae94bc42c58506819cae4f100f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e3fa876eab46ff9f325ca98b6b49d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec928fa7546b459695f84f5045fdd004_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403ec9cdcb59480d92d5fa47b3653c0f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89b449def3646cd95f5c38f3912f3eb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73020476831d48dc952d089610d805a1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia15d33d7c7794a1690e9ff92bfdeccba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891f5e003fe345e49586b7f0ea1a1a45_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01f5ca90cb941ada3953be0fb43eb53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73acf81cff124012959bdba4df022c6e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25e47d06bc5444c9881da32e0c8c1cee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c3894232694ae58965e4dd7cbc5b54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81cae5d5fb646aaa416523f96ff4dc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67c94bcb38db4efab1dd4b707e869ea4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5904987b8e054f0e8bd5a3b2351b251c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfe8e689257463db42f9737c01eba0a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6606449fe534eb2a6045bd62f8f24cd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd40469a0a4494997d70f0d4a34aaec_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cccf7ba7db24688a39f333d661af293_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4038976843844c049725bed7eedc17c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711402d60b6842f9bf49e2f038e529c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02968faa82754adb9368cdefe9c4fe3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ca668f89aa4b6c8e0216455acf3560_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471af2619c5a4230a84f5531a471377a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007512ae8dda41e5a9f544b584b8b898_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7995dc4952d4992b95339207eb9a85c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie748c67418e941ab866c173f95e2e4c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ead5f4db724373bbe26f3ea23629f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia787882ee4864cee85ddd5bdd5978cc9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0fa5cf50f94ef79e636b3c7f721374_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115f5c61450a4ca3a4ae2df3bbb688e6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9493b54209da48aaa35d8e714d4decc6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5749630d7d6b4757afcd624c8e7ba7af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f9086e97774b9ca925fc4a60860be7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0fc749c3c7c4c0797d0c18e3830a490_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff38adcd98344d5688d2b7c42eb4d546_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b68dc0514ef48d4959838e63c0ec733_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c409ba8f5914054bea31b89ef69134a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ea489570e94e849c567c2748c27b83_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e40bb38a566430ba935851046aca72c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87b24e3cc774ee496e9f4e9fe3259a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b37655a4024424baec1bc2e6b93c53b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b386ce4d117451092994876209c5a7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8fc9a58a4ab4e06acb145d4d9fc938c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbf1b72c9bc5437e93fbb59118a89b11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d1dcf382f0457c87f65fd2c8d9ff06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e1d16ebcc6c4a9ca3e4100c1dac49d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18a5881f11747ddbaf96b26b1d744c9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70edfabacb9d4ab89289cb74d03d9883_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7faea72409640a49a435de615dc7102_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ccc7e7e5524a3280968384eaa7914d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff4f9ede79c4c67aa7a3250803dc3d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065f333a6d934bca92cd111bef4577bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i423ab7bdc2094bf0abc5c971cd107ff1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd28ea07c0f45ddb0ee2c099f46b450_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83da63a7df68404bb8a5d3bf6f9e82d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02abe7b617b74a5399a1101c5b6f2a83_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3649ae2389f94d3892ad79a3dd0a2c98_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51835942cfa4433ba52343a2cc2e074_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia3d5490822d34a2a99d663996669b4f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9126e641d024fb0b335f3046e9ed3ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd8f355bff34661aa70ef78c021e5e9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72e0cdd23483485f9ed6c6ee0844369f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13c70a71c4c421abd1362ea62569117_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5c0818833647d3a25ea25ebe359b5c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74eda1b891b4ab79e2ca96ed9eada38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087aad162b0642ff8db64f6a05885c60_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33ce3a5097547a6b8d4a0f1ba3e9fe4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a2652179d8b4b0ea00c6e7c08a3f988_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc8462d720446f4b9207d710a136bcb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b3598bfff834885b69c49aee403e0db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:ChangeinestimatevariableconsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3429c7b8484213bf017f41a196b549_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:ChangeinestimatevariableconsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cdc1a99bb8647ea8e9692070dabd0e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b90eadc154444fb19c9a01d59bf33f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6397a7dd8a4e959ad085826f07f21e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19b4456b05d409e95fc69cc5a327fe7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i689f540e21ea4cc0ab92a8b3e7bc2336_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33fb3025f9a545e3b9aa62b16b54b596_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c0dd0b8e294840a0967d56255d0758_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71dcab1fa94847e09339d54b040213a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d9226cf83c47e8975915ff0788e426_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e924b85a8594cbb8c57fd8d907feee8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f4d18853c24b45892069de276317e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992f0d769b004f95844a081bc36172fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b2c1dd010f46709c3e2a7ecbecafe1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53dde5e597fc4c8c9f9392994230aefd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e7ddb0e37dc4971959f70137bd43e78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6980afe038e45579c072cc6b1f18611_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0313e101274d4d69af2e1f0fe44be664_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2b91e05cc6441ea9289dac6014f9d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1569fa49e674423a1c2924dd5b61f56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb3c647adb04138be2978c1bc0e7c55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e53260d7b76425c956afc0063e9e182_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i589cf24d12624979854f176c47f77cc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69b13783318c438397f0b5c7220581e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id230907331084b6ebd637c4cbd8e25f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb2069f86d24b03827a9e9d8f97e538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6caabcbcf4dc4ebd86cd6edd6a29e8f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cae3a2b8ad849299af80dca8054aee7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847c77713b0c4b30952627ab78b5d9c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i102f4590cd5742c1899de653a60628e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc748cd30e344577abfa0acf8a8c1844_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0bfeb4f55a1452cb6a3d4b5b1ec025b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2044183092a4b149a34f91bca641feb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b95610d80114557965c7323d44db873_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cacafade6b2473683f93e114273f77e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55cea2844ac74eb395212db775cb345a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91268be96b54e30bdf5db6bd9878dbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7513aaabb5f4272b2cacd3804a15a28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee66dbb093f14358827b89e7e0dcd966_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e78ecedd654614959bcb071f7acadc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2ed1b955d740f2b0927118ddcb4df3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia906d2214220429abfdad1e08150f915_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib97dd6c44c604681b3098926fc081208_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4ac453a767416c8e1f4e02b40d3382_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1ef2a73f9a48a4986b5abce37bdb95_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79fe00c16824d8d9660be7d01074024_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245cd04d75b64741b3e002da6bb2c48f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0413ebf760a34b8898709dbf0402b2ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a81f06d2f0d45df85572d4243c7b338_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cb997734a76456bbb02c472d8bda07c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35fb84b762b84b7aa1431739434b9b21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3e9c9d067843908408309f57f08a32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a64ac1b4c94676835b5826fa5f20c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d69c8fb1e1480c8b25d127290a2aaa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fd341ae13d453bb4c6a2495482ad7f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41eb8f855f04ab18ec5a45dc18339c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4d7e36c9834ea2a50375607652e3ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2dffdc39d4e4c498f9847e218524a71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d94a45eedcf462b8e2ad22dd4dc36e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf015395242a44bda73d3642656c5f16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad52fe076ec4556b05b0b1bd02f7c11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014468a50cb14ec0b4f015914180f3c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01262868b33640a197ec1f4edf4d999e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c40eca549f4c34976283d9d6ed1e15_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a4193ff8f34e439051dd12ffb9dbb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5cae775b7f463ea40bc9792ac6e442_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eccad0947fb47f0ab3c1aa00d140b19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb4f3afe2714d6db05b71cdf7349336_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4710ffafb664853b06fb84f1f903262_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb3298102714119abcc23920b0fbc5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc33840c250349a384747a52147ce1b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab16ab242dcd40f99168ba8f52458d66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db613f5d89d457781afd75124915704_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6760924221ed4b5cba60ea7d2547a8cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823810b00b57487a84c912f0198b1fc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a2765b359a4c069d0d5da473baa6c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f2798614104859bbe54d4ec9712a0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63750d09d394e93bf20d847c07a673e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd825c3a419d40c89740d90e5802b238_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6a848a7d8944b99e06faadeba12110_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620b03a7ceff4498b7ef8db0524ac079_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1ffad7978e479885f4f62b24f36dc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i284a56e4feb84fa9b3f54659b24ed623_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17a07fc344b4439808bd61c45decb70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98db09bcfe5b4e588506f6849925a677_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d3b63ebc98b4fc8bc4ead7f256ad433_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia600e92a5fee4aec9bd9a77aa48c46f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eefcd80ffa146259d29c8ec79bcd8fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451fd8be53df45b88a7acf78165a771b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1257e571bc436ebc3359c9c23418d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i501409456a97436db0b9b79612bb915b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c91186d780d4a76b4dcca46016e88b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d13c3320274c64bc19f9627e57686b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31162f66edd14b10a6a33b68539c40b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe5dab1d5f643f9bce8a2eadf2aa51e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c54d9501afc40c6a54d229dda2f8f02_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88622965efe4116a7e9094e9f179d61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16426d78ce7c4baeb60f73d40c7360a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5e7f31b83842cd95af2e19292bd16e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3e3a8f25534e47821628e02a0a3563_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1322bc486afc430a880d2d9343dc7c55_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2100cafa2bd04f0fa1ca7fd4b3cfcbfe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc2d816fd7043748729bb6623b61959_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eded22e6e7b4c3b9606256b7f9aa791_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i053b4f6a4ee446758474a88c7466df66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743c158a26c1458b8cc125718d80bd03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120926cc5cde493e8d537eff1e3bf7e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0847197eb84c4ea6b02eec2146463bd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7fb21110182421cb22d46b7cd3b631f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595ca0a2d84447909de4d92345625390_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bfed0ec9b354312b4fddd01563207c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i390292299b6b4a5486f594d72b417724_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b54212c105142999597c1d3fb250563_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie18832e6e6f64234bff6179e17fdedbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb1445e2fcc4c789894cb276a5414d5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9150b394a9d4e499d6e0b58b1920391_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8f006f881a4957896607c58789822b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61fc82ab7f9c4eaba8049dcccb0fabcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e58eabfb144b2b803232b6b3af397d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d35182bfdc94f2e9d411da9d4df6871_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28cbe18165a844a88047e90985c3a97c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>gild:security</xbrli:measure></xbrli:unit><xbrli:context id="i993dfcf3896148f697a431026afd4f27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10964ae7f7a549f6ab1ff180665f69ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf3fc79d1fa49ce89bbe681181cd43d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61bac09c30bc4649b266ae9b0b2f845d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedaad0d104904edbae770e12c309829c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ac161d27eca4bbdbc92850f94d7212a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70691dc9abb4d69a28b5f9142fd5dd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82be8c76fac444ae8b5be2464102adda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b7ffc02a4648be92cdc6a03d99c1c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i784d730b592f4dda968b2f2a0865acb7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7830a932cee94f22aa34ced72f487d72_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd75011da414b8599c1d9723149a895_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c3d1c8982e40339444fa81b506c130_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4066de7a73468a997dd8cb92bf3a1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab6fcb4f58b4822ad8e346558c2c980_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85193bddbf1d4369b3eed33741718ebf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38a8065706742818aa8f128c9d384dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dad5026e5bc4d748d8400db3eeac8e2_I20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ebcc5583e8449d2977a0c7e88f011e4_D20200407-20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-07</xbrli:startDate><xbrli:endDate>2020-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94aca37dece54db88d94195652d7be2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c056cec2314052b0ad7bf56bb9f361_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007de77796ce442bb17cf6397fc2f2b4_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gild:PaymentstoOutstandingCommonStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead588e99e254c5682217485bb77e1dd_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gild:PaymentsToEquityAwardHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b27400d62ea401b8ae3613d26aae982_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8644568592004cfc961c871471a2665e_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d0d69f623804c20b69d4aaa63420c60_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48328e269350428eaf5fc46371917dc9_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7d2971f9e04bd8a1de84efaccec570_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07cc7232a64946abb68b060bdcf121a6_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia544b37590e74cd9b7228b42939d36ed_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8903c926354a40a881da8a83728d0f0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="id970621751c6420ca530ab3e07f6cbca_D20201210-20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51626d380ad4bb2aa86f7539b1a1a7c_I20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9420f0406eae42c8b4f99ad3276f48ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01ff2fb62994e059a1d6fa4ee99a6c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8678846271ab442c97e55730184bbb1f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfef2fedfcb34cf49d5ac0ac1e7e9e08_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4279a507124f3ca8496850b7e31956_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91dd4f13fd1443a0bb2d19e5d92b1991_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e9d6e5f883421587e150d19ce229b1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f76f60b0dc144768d3cda731d8c7cd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife2f98a6a4fe4a41b4e2e388608c97f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f7a6ee87fc404481ff08ed83281586_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58f1f76b76904d83b316fbb983869d34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca166c8883f43c39c1ddefe732e5d75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic66b58065448410d88d6fe6479e1992b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca01e23b54043618df5703b720be264_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0508d4b5e1c46bf97925917f958f9b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c593b70322648b8855aec1be0938cc8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8000203400804727bf1a4e40c93f3c16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb578eac6714200a5377073798b8f1b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4376a44dc14cc2a76b854d11662987_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df8c75c0ccd41708b9a841f5afbd2fa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:FinitelivedintangibleassetimpairmentbyprogramAxis">gild:Kite585ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16ced64a7e645e781114e8469e73643_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if681ee16d60745e59f58ea94a5a22cc6_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iffef91ebd0344347af71595936327ea0_I20210208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedArcusCommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52b270d003824c77b29b5398d6d3083c_I20210208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedArcusCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af407247e1d4bb483def9e87402f03a_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80831b6a43e144288ee6887aa81b9527_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99b5612dbd4404ba21f6f1b905e2fff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37eb10dcc178427ab1244846e835f528_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i93263403f73c4d28b597082de10c84d1_I20200619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc35450bfed4ce1b3b6d598e9f11a83_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f9442c5e7f742a5918ea65c554e30f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78171fbfd924018a723f12dc3bd832a_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d3771f3eacb401d97c063d22f14874f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a6b60bf1fb4c95bf249cf35ab97877_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c05527ff1f41b18c4eaf4e2b69ad93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="study"><xbrli:measure>gild:study</xbrli:measure></xbrli:unit><xbrli:context id="icd832b1814dc41c2855ec98618a3809f_D20210201-20210225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb304537d4c49c5921792c6d16c44b1_I20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffcb20e38446438fac262691e10ede58_D20200825-20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-25</xbrli:startDate><xbrli:endDate>2020-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia485fc53f8774d4bbbe1c1dbe9ba40a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33df116f5f941209af85885b37007ea_I20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aa72b0e47084ac4b180eb22cea3779e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-17</xbrli:startDate><xbrli:endDate>2020-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida137ca5e8244cb0ae5f91885ad73166_I20200827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>gild:program</xbrli:measure></xbrli:unit><xbrli:context id="ia9888aea06ac4afc8425a218b65655b0_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454bf1f356114d009c08e1da60df6588_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740dfff7a05d4e5e8dd476392363eb90_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9917b07dc845fa8fe5d3c889a19c8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic14136643b7342e68c68c63cc70e88de_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ea464b37414fe3830d04118e06ee1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68443d5a14c140e5b3fb3ff26e44562f_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b08c2b1e8994a8386e2f87e19b2f94e_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809a5f73da45450ca7e822b925dcfa95_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8146d0695ec4432692851cb70914ad5f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9933f47e878d468f83ba0ec2b8775652_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b237db0dba14d1f8cd562ae2e0c1500_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960fec8ecc464f7f9fdf9acc6db7076c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba7404849984dafb0475afcb806dc0e_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e3ac2edb384dcd87ba36967240d6a6_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if741a8ddd11548bca6696dcc16ea06ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee332949c6714cb9ac12a12334a0d199_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf43160183dd4615964265dbc7e94547_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6d33288a694080a10decb9745df341_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32869178bb374083a5691c4c47f7e162_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia23e8ec8f5a94be1a0800fd9ca20d3e2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e8f707b4a2423885556304b9c14459_D20181201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4142852a6d94d81b33b11f3c2bf3444_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie52274b0a3fd40f79ccc454513656539_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia16d123600754634a5bcf2ed111b7be5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37d42b05ac242459b8ca53417f3c881_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:BristolMyersSquibbCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife61ff89d12b4fd3ace02e9f26886498_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:BristolMyersSquibbCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f211cb92aa41f0a97038b010abc03d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:BristolMyersSquibbCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c008f74ae7741bebc87087598c24b61_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie87f8e54cb4a410db675109bd66255a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4a90e396444c1698d4940439fd9f6c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1af6afc5f8e54ba59cb9793eef93e885_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueInFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied16c88db1234c66aedf0dc0e80bf0da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueInFebruary2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33544e3e9bf8466189835e7d6f721350_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76142ba97a5247fd8b93aaddb16c8fd9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ad657ef10246598ee1f2d6d2eb3a7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb35118d4c9442e94273ba0799d1e3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a7777335ed04cf59f807114fe7a66bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079f3e090c534879a46df4da2d4f54af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5cfc1706eed466ea24db728b779b02d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5975f2be2634b6193ebe5e4518e0b67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3670ca9b3f7f4e67bf432cd8f3e3dd6e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068021f3eade41599edf59a5a127fefd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4a14e35256c4e9b99448ff4ab266069_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3bff642f2142629af6b9cd0108692d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e913054de0540cfa8dfe947549c1af3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d7b8db766a40b4915b3e488cb97f03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7f8e63064f4893a1648dc50ce5ffd8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6845673544a4170be8f0594b2341c6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a2ab9d1b9a48a0964021dec398e682_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4e35afb27045a0a512b4300478000b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0cf198ca9f14127aac65bf348fd3646_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie429e3caea7d425b84413a3c28d65099_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c543bc5eea4422e9442c1624ec8ab90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7238cb6a890463c9d26c7c09431cb24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib268c4735aac4a7894a222f05f1e7ebe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f80a26646664c12af8af332d1630212_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588786d4c5b04ceb86b3104e6b1dbde9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f90cd187b864231b694a710210de89a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86263ea980a0478086ecfafe984d7563_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e89e8f308084febab4d3c4b09ec137b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f36c3515ec9482dba6b429c4a71e17b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbe5e2da225448318d6e7ce30d2a5b44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2644728c1aa4257bb5ac872b6fa8552_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2d0ff77d1d4377995f3b52034e38fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47a08b08ea6742dab3cb313aea60e574_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4ff001607a4d4e86f6ece76b1cb4a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i601d3d19bbbd40c9be8b03ece2ad21ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i917a67bd025e47c18737842312fd65e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d1d8ac11bc404f91be62f8fd6239e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c65c238d0cd4bdaa6748c4a0d9248e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie386ac3bda26490e9b7780e1e62a038d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i116ad184d5dc456e90f07d8331609037_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3d522c920c4eaf98d9423edd359180_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28f0ddee26a6400e90f15437dbf5aafd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cb38188cc44e84a8c402adba11be30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c50be0096dd408eb2b0af525d5453d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3341333ea70c407da5e3d68a2db6c9dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d3e46a170ac41afb9968e742e88e06e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i861f7cc25fb44ef5a805d427c6d41708_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2a2c92c9bc4c019c117fcccc6fbd78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99295727180471890cc95afa2e4192a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624388aa63954f5c96041bc516796f34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e043d95be44884a92667d375737a0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016f2c24896d41729056d15a9007c6e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b17acdedffc4fc1bd0b4b188bb173cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61afb70e61ba4c8aa5270a4e11c0914b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i180ad2d40440498ea05cf2425660478c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd068f90f2441228adf1a8ce9668e2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5f5e11f4c842dfbe349568ca25c17d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af8fb6957bc4c20b9649de1e7fe1110_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71abf35a67c349dabfb936d03b474a47_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c1faea29102437aa26bf1071aaa87fc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff57f2a7eef4231a0e859065a5afd5d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e55cf66183242569e946df901102514_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796d7c545dcd490c93f7b990f3264b66_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f8b79007ae445a3bfd27b69829de9a4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e3e8a86c104591a0f8120347df1468_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedSeptember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20d9ac4b58549aab5a3e792776164f4_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedSeptember2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if038f51729a24a2da8b265e610a51eee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4137a356fc414084a24897805d41c93b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca5a2ac1db347aeab2b0dc69d1d1bc0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50551ba0e3694af9afb0a78f8b769781_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c456ffa7a147bbbcc6146cf6a5c52e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362bd4a2c0a74dd5b55702363f9ac9ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b239e1b3ad417081b0cd98df44abaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie106ddcf610645b9a3a7b3fe329ce835_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f85bd04d2e648e9b5df6a64f170cf3f_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561ca9ac62a24c86b2e01e36240808fc_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48284e9ef26a4194b5c4901f6e5e4bc6_D20160531-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-31</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204030d3773f4af78e0d6df4e9417215_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc7aa7015ec49fcb95e9effaeaa1a5b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa41df238d34894bcd7a6ba42b01248_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdfdb0b6b6174cdaae4a05f26000ab2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919f90af93194b0f8ce1c1dfb232c4eb_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:IdenixPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f82513a9f94dd7a549cc436cc58d8c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:IdenixPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f7210bf9b704da3b00654f5387c8418_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4a501179a0c4d10a7471e189ee30e56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed6db4dd53c4a86afcc8c65e474d496_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844383cc25214e31ad2596ee61b72eee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4281b1de2ca446dacc33382d882ca0a_D20180207-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-07</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="ie2902027c39a417f91f8f33f93f2f77c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">gild:ActivePharmaceuticalIngredientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676b993c500e4814bfc126d01c700bce_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib489d1a178c64897a715f8a20a2aa447_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9aac36dbf242fbbc1e60f05511aa07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4830709842f45418b3c333d24ffd5a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6402e854a642ccaecbd191f676e641_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib10c7000f4c647a2b89591cb924c9b7e_D20210204-20210204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-04</xbrli:startDate><xbrli:endDate>2021-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80decbd404fa4810a481f263b6dbbc28_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d477cb7874f4bfd96a09be4ca3fd0c7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6040cf00a6f04094a6d26c4f32df7e7c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14ff8312abf74fc68d269603e3776270_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99fd8d434aa478fa9b18fec33d3e230_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3593a4df8f4b348d04321ee946cf2a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5468af7521ac455985434b5f19b7bbb9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fecafa85db046288d32b5acb380096d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed215bd7b494fbe89f89a8b6e2b2a64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5707d2a1fdef4bd29d50dcedf69cf5db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf73804142f4a5a8699854aa476d33f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f513a45782a4d148af987a580b897fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b95bfbb00a4bee81e1cd96a5d51ca7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3903462c6c24250b51ed2304b4c2329_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8565010ef19410480a12c5243b09982_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f11fdc536f400994934dad7faee301_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2004EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade23e2d742345dd981025a2118869e5_I20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b3338567b348fd91d9138a1c4c1f6d_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1d5481adee40849cb658b58a5e6799_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d7b35235ad4232b8705dbc79802f56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60943a7163f448b5a6c2157080ad7985_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc447ebbb9884a78a958aa20b56841f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied46b5b50bca4d0998e9bb06b1fc9bc4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db8741b4d8842f1bb640976d2a45d96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62891fc164b04b4e8264bd225dfeb876_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa115e88017417cb54eaf2b28abc9ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37406a81513b4400ab5caf494643ae52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede55c4650474e14803be5cd10e0b4b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic717d0c503c143968d6471b329f28be4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131142515dae41e291f717d69305bc41_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4423b8d04646d3a954612daf594dac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982d3c7d11dc4c84a981217fe59bf232_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109c30251de2477081720f87d8a28594_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6dd7d6dd0d45e6a2043541078d3796_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76feedf9c6014726a00c27da12c8de28_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b4c383c26c48c892d88beb1d9d2292_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc506af41e54853895ac3a3ed8d114c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d54fab5ace4e28898af9b5fd4628d8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3702dbcc04054cdd86bc26be99367a19_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i347b4c9b1da2453f8b5c69693ae0fe5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29bb89cacab4917ad78178e3cc39d53_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c985006e29e4ce693bf89616e366745_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c93d478ae74471acc0268f5b36f929_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009c4559c5ee4dcca45e50ed6dafe35f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia929926fabb04040b30c9fcb5647aad5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42fad2d6b4d14144ac2fb0e8b3cd8fab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c99d40ca3b4653938ea4dd23e12064_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be4f110329145dfbfde538bee9a676d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff3394e3bd2e4809af80fd7faf8770e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80dd52732e7f44da975a903d2cf2542d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e09efc6fa77468ea8742717d97b0509_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia623662c706d409a83107f00f6077a04_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f77d5dbabfc4c67bbc7902204dbe301_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89c7b93f0a5477d94803cdd6f0a3319_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9779a570996452dbbd3c83239ccf707_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3086aba7396431180029057c2ad4ece_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id342243123964d40bc3ebc4517f36cd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67c62aea4714cc1bdf529a34a43a13a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ce6de3160c42fcbad2f1b836b16a69_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcde38bda2ec4ee2a91607db91272226_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:UnrealizedGainComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911b942fdd1a48718de383949eab2834_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9604006e3f48c2b90d9c9dd73c4174_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gild:EPSImpactbyTransactionAxis">gild:FavorableEPSImpactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib93766b38a794f83a6a283fa0a85c17d_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">&#160;UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV85MQ_8470be95-8de6-47d4-a55c-a159a386a304">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> </span></div><div style="padding-left:218.25pt;padding-right:218.25pt;text-indent:-220.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One) </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6MzhkNWQ1ZThhYzY4NDEwYjk2MDI4NTVmMDFjMTk4NzIvdGFibGVyYW5nZTozOGQ1ZDVlOGFjNjg0MTBiOTYwMjg1NWYwMWMxOTg3Ml8wLTAtMS0xLTA_39fd5779-0d92-4ee2-944c-a118d054034d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xMTM_9e0b3e6d-2c6f-41d0-b71a-83c1f6a361d1"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xMTM_f320e9b6-4606-47b6-9c30-ca0ac629d05e">December 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6OWViYWM3YjMyMmFiNDFmMjk4NTVjYzZmZWFjYmVmMzEvdGFibGVyYW5nZTo5ZWJhYzdiMzIyYWI0MWYyOTg1NWNjNmZlYWNiZWYzMV8wLTAtMS0xLTA_42a8f5cc-fcf2-4ada-9dd8-fdaa1b291858">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:29.25pt;text-indent:-29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yMTk_d20e5789-57ff-4c27-9b5c-d8be21ec3a12">0-19731</ix:nonNumeric> </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yMjY_2a7af509-a17d-4db9-b259-7f215c52b5ef">GILEAD SCIENCES, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.161%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6NTEwMjc2MDQ5MTE3NDBhNGE2NzY4MWViZWYzMGFmYWEvdGFibGVyYW5nZTo1MTAyNzYwNDkxMTc0MGE0YTY3NjgxZWJlZjMwYWZhYV8wLTAtMS0xLTA_207d1ec7-c817-4854-9559-3c1716b75052">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6NTEwMjc2MDQ5MTE3NDBhNGE2NzY4MWViZWYzMGFmYWEvdGFibGVyYW5nZTo1MTAyNzYwNDkxMTc0MGE0YTY3NjgxZWJlZjMwYWZhYV8wLTEtMS0xLTA_4fd85ff0-c295-445c-ab0f-a17187f9d4fb">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yOTE_71b7f887-9ccf-4de3-8a40-6c8c06da1ba0">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yOTU_5921d1e7-6f61-48df-b073-a554c2e3bf9d">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yOTk_c4f9bbc7-570d-406f-beea-5410d2aaeb25">California</ix:nonNumeric> <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zMDI_44c1fc00-30b1-4880-84fb-817e3ee85354">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNTg_26e84ac4-aac7-4045-a251-bef3439c6643">650</ix:nonNumeric>-<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNjE_12803a4d-5c31-4a5c-9688-34e5324cc668">574-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.026%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6YzkzYmJhYTZmMTRmNGI1Njk2MjdjMzQyMzVkNWM4OTQvdGFibGVyYW5nZTpjOTNiYmFhNmYxNGY0YjU2OTYyN2MzNDIzNWQ1Yzg5NF8xLTAtMS0xLTA_962c87e3-5ffd-41e0-a998-f10bd7840aac">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6YzkzYmJhYTZmMTRmNGI1Njk2MjdjMzQyMzVkNWM4OTQvdGFibGVyYW5nZTpjOTNiYmFhNmYxNGY0YjU2OTYyN2MzNDIzNWQ1Yzg5NF8xLTItMS0xLTA_cfd87f97-a950-4f1f-be1b-4a129aca26e4">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6YzkzYmJhYTZmMTRmNGI1Njk2MjdjMzQyMzVkNWM4OTQvdGFibGVyYW5nZTpjOTNiYmFhNmYxNGY0YjU2OTYyN2MzNDIzNWQ1Yzg5NF8xLTQtMS0xLTA_5480bfd0-76f0-4dae-b8af-60852a510d51">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV82MDQ_b3876a28-45f6-4d64-9784-a81bf59ebf05">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV83NTQ_f2f22ec2-fcba-4303-a700-23160f91985b">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xMTA4_6929e4d0-9a17-4fb3-9937-6ac684815299">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xNDQ1_81d37c7e-9ac0-4e84-ae84-7acefa35cc19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xNzc2_3b14efd4-8c48-494a-a704-0cf10e3638ee">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                  Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">       Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNDM2_e1ce8e0c-bcbc-40fb-a794-41a9bc688271">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">         Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNDM3_e1e03fac-9c97-4125-959a-8d143cf9a04a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zMjk4NTM0ODg4Mjgx_9057183f-e722-477a-a471-fd587bc63b72">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNDM4_004a1762-977c-493e-85b4-a65eb0d57c94">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie96afe3a1df84576aaaff813a6240267_I20200630" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yNTAz_e700179a-6211-42bc-91d7-360a6d97e4a4">69.9</ix:nonFraction> billion.* </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s Common Stock on February&#160;18, 2021 was <ix:nonFraction unitRef="shares" contextRef="if218098f852d48df84d6fe5e15c309b0_I20210218" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yNTg1_a7ffd7c5-3e8b-44b5-9d49-b7052fd74363">1,256,593,156</ix:nonFraction> </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yNzQ4Nzc5MDcyODgx_fd0093bc-d9e2-4a61-ac81-16dcfe568f6c" escape="true">Specified portions of the registrant&#8217;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders, to be held on May 12, 2021, are incorporated by reference into Part&#160;III of this Report.</ix:nonNumeric> </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Based on a closing price of $76.94 per share on June&#160;30, 2020. Excludes 346,304,310 shares of the registrant&#8217;s Common Stock held by executive officers, directors and any stockholders whose ownership exceeds 5% of registrant&#8217;s common stock outstanding at June&#160;30, 2020. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-bottom:5pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Form 10-K Annual Report</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_16">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_19">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_22">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_25">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_28">28</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_34">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_37">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_40">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_64">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_64">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_67">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_193">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_193">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_196">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_196">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_202">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_202">106</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;III</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_208">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_208">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_211">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_211">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_214">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_214">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_217">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_217">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_220">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_220">106</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_226">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_226">106</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_232">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_232">110</a></span></div></td></tr><tr style="height:6pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_235">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_235">111</a></span></div></td></tr></table></div><div style="margin-top:13.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. LEXISCAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Astellas U.S. LLC. MACUGEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Bausch Health Ireland Limited. SYMTUZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Janssen Sciences Ireland Unlimited Company. TAMIFLU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Hoffmann-La Roche Inc. HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of MYR GmbH. This report also refers to trademarks, service marks and trade names of other companies.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; &#8220;forecast,&#8221; variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends, operating cost and revenue trends, liquidity and capital needs, collaboration and licensing arrangements, ongoing litigation and investigation matters, statements regarding the anticipated future impact on our business of the ongoing coronavirus disease 2019 (&#8220;COVID-19&#8221;) and related public health measures, statements regarding the development, manufacturing and distribution of Veklury as a treatment for COVID-19 and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part I, Item 1A of this Annual Report on Form 10-K under the heading &#8220;Risk Factors.&#8221; Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. Except as required under federal securities laws and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;), we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_13"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative medicines represent advancements by offering first-in-class treatments, greater efficacy, enhanced modes of delivery, more convenient treatment regimens, improved resistance profiles and reduced side effects. Our focus on innovation has allowed us to deliver marketed products across multiple therapeutic areas. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our primary revenue-generating products and the approved indications in the United States are as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HIV/AIDS</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Biktarvy is a single tablet regimen of a fixed-dose combination of our antiretroviral medications, bictegravir, emtricitabine and tenofovir alafenamide (&#8220;TAF&#8221;).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Genvoya is a single tablet regimen of a fixed-dose combination of our antiretroviral medicines, elvitegravir, cobicistat, emtricitabine and TAF.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Descovy is a fixed-dose combination of our antiretroviral medications, emtricitabine and TAF. Descovy is also approved by U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a pre-exposure prophylaxis (&#8220;PrEP&#8221;) indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Odefsey is a single tablet regimen of a fixed-dose combination of our antiretroviral medications, emtricitabine and TAF, and rilpivirine marketed by Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (&#8220;Janssen&#8221;).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. It is a fixed-dose combination of our antiretroviral medications, TDF and emtricitabine. Truvada is also approved by FDA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">/Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The product, marketed in the United States as Complera and in Europe as Eviplera, is a single tablet regimen of a fixed-dose combination of our antiretroviral medications, tenofovir disoproxil fumarate (&#8220;TDF&#8221;) and emtricitabine, and Janssen&#8217;s rilpivirine hydrochloride.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Stribild is a single tablet regimen of a fixed-dose combination of our antiretroviral medications, elvitegravir, cobicistat, TDF and emtricitabine.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated as a complete regimen for the treatment of HIV-1 infection in certain patients. Atripla is a fixed-dose combination of our antiretroviral medications, TDF and emtricitabine, and Bristol-Myers Squibb Company (&#8220;BMS&#8221;)&#8217;s efavirenz. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(remdesivir), an injection for intravenous use, is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of coronavirus disease 2019 (&#8220;COVID-19&#8221;) requiring hospitalization. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Liver Diseases</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (&#8220;HCV&#8221;) infection in adults and certain pediatric patients with genotype 1, 2, 3, 4, 5 or 6: (i) without cirrhosis or with compensated cirrhosis or (ii) with decompensated cirrhosis for use in combination with ribavirin. In addition, we have an authorized generic version of Epclusa distributed by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily, single tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic HCV infection in: (i) adults with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis, (ii) adults with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin, (iii) adults with genotype 1 or 4 who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin, or (iv) certain pediatric patients with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis. In addition, we have an authorized generic version of Harvoni distributed by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily, single tablet regimen of sofosbuvir, velpatasvir and voxilaprevir for the re-treatment of chronic HCV infection in adults: (i) with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen or (ii) with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of TAF dosed once a day for the treatment of chronic hepatitis B virus (&#8220;HBV&#8221;) infection in adults with compensated liver disease.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of TDF dosed once a day for the treatment of chronic HBV infection in adults and certain pediatric patients. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Hematology/Oncology/Cell Therapy</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (axicabtagene ciloleucel), a suspension for intravenous infusion, is a chimeric antigen receptor (&#8220;CAR&#8221;) T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma. </span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(brexucabtagene autoleucel), a suspension for intravenous infusion, is a CAR T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. </span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(sacituzumab govitecan-hziy), an injection for intravenous use, is a Trop-2 directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (idelalisib) is an oral formulation of a kinase inhibitor for the treatment of patients with: (i) relapsed chronic lymphocytic leukemia (&#8220;CLL&#8221;), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, (ii) relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies or (iii) relapsed small lymphocytic lymphoma who have received at least two prior systemic therapies. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ambrisentan) is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;) (WHO Group I) (i) to improve exercise capacity and delay clinical worsening or (ii) in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. </span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ranolazine) is an oral formulation of an extended-release tablet of an antianginal for the treatment of chronic angina. </span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amphotericin B liposome for injection) is a proprietary liposomal formulation of amphotericin B, an antifungal agent, for the treatment of serious invasive fungal infections caused by various fungal species in adults.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our revenue-generating products, including the amount of revenue contributed by the products listed above, see Note 2. Revenues of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Share and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenues from other activities, including revenue share from combination products, royalties for outbound licenses of our intellectual property and other payments received from our collaborations with third-party partners. For example, pursuant to our collaboration with Janssen, we receive revenue share from cobicistat, emtricitabine and TAF that are components of Symtuza (darunavir/cobicistat/emtricitabine/TAF), a fixed-dose combination product commercialized by Janssen. We include our revenue share from Symtuza in our Product sales. For a description of our collaborations with Janssen and other partners, see Note 11. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization and Distribution</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have U.S. and international commercial sales operations, with marketing subsidiaries in more than 35 countries. Our products are marketed through our commercial teams and/or in conjunction with third-party distributors and corporate partners. Our commercial teams promote our products through direct field contact with physicians, hospitals, clinics and other healthcare providers. We generally grant our third-party distributors the exclusive right to promote our product in a territory for a specified period of time. Most of our agreements with these distributors provide for collaborative efforts between the distributor and Gilead in obtaining and maintaining regulatory approval for the product in the specified territory.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. During the twelve months ended December 31, 2020, approximately 92% of our product sales in the United States and approximately 68% of our total worldwide revenues were to three large wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. We sell and distribute our products in Europe and countries outside the United States where the product is approved, either through our commercial teams, third-party distributors or corporate partners.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers. Our products compete with other commercially available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. As our products mature, private insurers and government payers often reduce the amount they will reimburse patients, which increases pressure on us to reduce prices. Further, as new branded or generic products are introduced into major markets, our ability to maintain pricing and market share may be affected. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development (&#8220;R&amp;D&#8221;) mission is to discover and develop transformational therapies in areas of high unmet medical need. Our product development efforts are focused primarily in viral diseases, inflammatory diseases and oncology. Our team of research scientists is engaged in the discovery and development of new molecules and technologies that we hope will lead to the approval of innovative medicines and therapies that will advance the current standard of care and address unmet medical needs. We intend to continue committing significant resources to internal R&amp;D opportunities and external business development activity to drive innovation and growth of our business. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties. These risks and uncertainties include our ability to enroll patients in clinical trials, the possibility of unfavorable results of our clinical trials, the need to modify or delay our clinical trials or to perform additional trials and the risk of failing to obtain regulatory approvals. As a result, our product candidates and investigational therapies may never be successfully commercialized. Drug development is inherently risky, and many product candidates and investigational therapies fail during the development process.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we continued to invest in and advance our R&amp;D pipeline across our therapeutic areas. Below is a summary of our product candidates that are in Phase 3 or registrational Phase 2 clinical trials or are pending marketing authorization review by FDA or European Medicines Agency (&#8220;EMA&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates in Viral Diseases</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Product Candidates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Phase 3 or Phase 2/3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Remdesivir (injection)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Remdesivir for injection is being evaluated for the outpatient treatment of COVID-19 (expanded indication).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lenacapavir</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lenacapavir, an HIV capsid inhibitor, is being evaluated as a component of a long-acting regimen for the treatment of HIV infection in heavily treatment-experienced people living with HIV. It has been granted Breakthrough Therapy designation by FDA for this indication.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bulevirtide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bulevirtide is being evaluated for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;) infection. It has been granted both Orphan Drug and Breakthrough Therapy designations by FDA for chronic HDV infection. It has also been granted Breakthrough Therapy designation and PRIority MEdicines (&#8220;PRIME&#8221;) scheme eligibility by the European Commission for chronic HDV infection. </span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    In December 2020, we entered into a definitive agreement to acquire MYR GmbH. Upon closing, which is subject to regulatory clearances and other conditions, the acquisition will provide us with Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(bulevirtide), which was conditionally approved by the European Commission for the treatment for chronic HDV infection in July 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates in Inflammatory Diseases</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Product Candidates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Regulatory Filing</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Filgotinib</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A marketing authorization application has been filed with EMA for filgotinib, a JAK1 inhibitor, for the treatment of ulcerative colitis.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Phase 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Filgotinib</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Filgotinib is being evaluated for the treatment of Crohn&#8217;s disease.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cilofexor</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cilofexor, an FXR agonist, is being evaluated for the treatment of primary sclerosing cholangitis.</span></div></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates in Oncology</span></div><div style="margin-bottom:3pt;margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Product Candidates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Description</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Regulatory Filing</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A supplemental Biologics License Application for axicabtagene ciloleucel, a CAR T cell therapy for the treatment of relapsed or refractory indolent non-Hodgkin&#8217;s lymphoma (&#8220;iNHL&#8221;), has been filed with FDA. It has been granted Breakthrough Therapy designation by FDA for the iNHL indication.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel, a CAR T cell therapy, has received accelerated approval from FDA and conditional marketing authorization from the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy, including a Bruton&#8217;s tyrosine kinase inhibitor. Conditional marketing authorization in Europe is initially valid for one year but can be extended or converted into an unconditional authorization after the submission and assessment of additional confirmatory data.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A supplemental Biologics License Application for full approval of sacituzumab govitecan-hziy, a Trop-2 directed antibody and topoisomerase inhibitor conjugate for the treatment of patients with metastatic triple-negative breast cancer (&#8220;mTNBC&#8221;) who have received at least two prior therapies, has been filed with FDA. It has been granted Breakthrough Therapy designation by FDA for the mTNBC indication.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A supplemental Biologics License Application for accelerated approval of sacituzumab govitecan-hziy for the treatment of heavily-pretreated patients with metastatic urothelial cancer, has been filed with FDA.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Phase 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel is being evaluated for the treatment of second line diffuse large B cell lymphoma.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Magrolimab</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Magrolimab, an anti-CD47, is being evaluated for the treatment of myelodysplastic syndrome (&#8220;MDS&#8221;). It has been granted Breakthrough Therapy designation by FDA and PRIME scheme eligibility by the European Commission for the MDS indication.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy is being evaluated for the treatment of hormone receptor positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;), metastatic breast cancer patients who have failed at least two prior chemotherapy regimens.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registrational Phase 2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel, a CAR T cell therapy, is being evaluated for the treatment of adult acute lymphoblastic leukemia (&#8220;ALL&#8221;). It has been granted Breakthrough Therapy designation by FDA for the adult ALL indication.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel, a CAR T cell therapy, is being evaluated for the treatment of pediatric ALL. It has been granted Breakthrough Therapy designation by FDA for the pediatric ALL indication.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Magrolimab</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Magrolimab is being evaluated for the treatment of diffuse large B cell lymphoma.</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to add to our portfolio of products and product candidates through acquisitions, in-licensing and strategic collaborations. In 2020, we entered into 18 strategic partnerships and acquisitions to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas. For example, the acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;) added Trodelvy and other pipeline programs to our oncology portfolio. Our strategic business development activity reflects our commitment to focus on transformative science, build a sustainable and diverse portfolio and position ourselves for the near, medium and long-term growth of our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. and European Patent Expiration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of U.S. and foreign patents, patent applications and rights to patents related to our compounds, products and technology, but we cannot be certain that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the estimated expiration dates (including patent term extensions, supplementary protection certificates and/or pediatric exclusivity where granted) in the United States and the European Union for the primary (typically compound) patents for our key product candidates as described above. For our product candidates that are fixed-dose combinations of single tablet regimens, the estimated patent expiration date provided corresponds to the latest expiring compound patent for one of the active ingredients in the single tablet regimen.</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Key Product Candidates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E.U.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Viral Diseases:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Remdesivir</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lenacapavir</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2037</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2037</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bulevirtide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Inflammatory Diseases:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Filgotinib</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cilofexor</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Oncology:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Magrolimab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   In December 2020, we entered into a definitive agreement to acquire MYR GmbH. Upon closing, which is subject to regulatory clearances and other conditions, the acquisition will provide us with bulevirtide.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   The composition of matter patent has expired in the European Union. In the European Union and the United States, patent applications are pending relating to proprietary manufacturing processes of Kite, a Gilead company (&#8220;Kite&#8221;).</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   An application for patent term extension was filed in the United States that, if granted, would extend the U.S. expiration date to at least 2028. Regulatory exclusivity in the United States expires in 2032.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the actual or estimated expiration dates (including patent term extensions, supplementary protection certificates and/or pediatric exclusivity where granted) in the United States and the European Union for the primary (typically compound) patents for our principal products. For our products that are fixed-dose combinations or single tablet regimens, the estimated patent expiration dates provided correspond to the latest expiring compound patent for one of the active ingredients in the single tablet regimen.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Products</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">U.S.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E.U.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ranexa</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2019</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Atripla</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2017</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Truvada</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2017</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Descovy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vemlidy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Complera/Eviplera</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Zydelig</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Odefsey</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Yescarta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2027</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stribild</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2028</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Genvoya</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2028</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Harvoni</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Epclusa</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2032</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biktarvy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vosevi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2034</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2033</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Veklury</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2035</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tecartus</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2027</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Trodelvy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Jyseleca</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">These estimated expiration dates do not include any potential additional exclusivity (e.g., patent term extensions, supplementary protection certificates or pediatric exclusivity) that has not yet been granted.</span></div></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">__________________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   In 2013, Gilead and Lupin Limited reached an agreement to settle a patent litigation matter related to Ranexa. </span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   In 2014, Gilead and Teva Pharmaceuticals (&#8220;Teva&#8221;) reached an agreement to settle the patent litigation concerning patents that protect emtricitabine in our Truvada and Atripla products, pursuant to which Teva was permitted to launch generic fixed-dose combinations of emtricitabine and TDF and generic fixed-dose combinations of emtricitabine, TDF and efavirenz in the United States on September 30, 2020.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   Supplementary protection certificates (&#8220;SPC&#8221;s) have been granted in several European countries. The validity of these SPCs has been challenged by several generic manufacturers, many of whom launched their competing products in 2017. </span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  Applications for patent term extensions are pending in the United States and/or SPCs are pending in one or more countries in the European Union for these products.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The composition of matter patent has expired in the European Union. In the European Union and the United States, patent applications are pending relating to proprietary manufacturing processes of Kite.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">   In 2018, Gilead and Mylan Pharmaceuticals reached an agreement to settle the patent litigation concerning patents that protect cobicistat in our Stribild and Genvoya products.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  An application for patent term extension was filed in the United States that, if granted, would extend the U.S. expiration date to at least 2028. Regulatory exclusivity in the United States expires in 2032.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  In December 2020, we entered into a definitive agreement to acquire MYR GmbH. Upon closing, which is subject to regulatory clearances and other conditions, the acquisition will provide us with Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(bulevirtide), which was conditionally approved by the European Commission for the treatment for chronic HDV infection in July 2020. Bulevirtide has not been approved by FDA for any use, and its safety and efficacy have not been established.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Protection and Certain Challenges </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents covering certain of the active pharmaceutical ingredients (&#8220;API&#8221;) of most of our HIV products as well as cell therapy products are held by third parties. We acquired exclusive rights to these patents in the agreements we have with these parties. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may obtain patents for certain products many years before marketing approval is obtained. Because patents have a limited life that may begin to run prior to the commercial sale of the related product, the commercial value of the patent may be limited. However, we may be able to apply for patent term extensions or supplementary protection certificates in some countries. For example, extensions for the patents or supplementary protection certificates on many of our products have been granted in the United States and in a number of European countries, compensating in part for delays in obtaining marketing approval. Similar patent term extensions may be available for other products we are developing, but we cannot be certain we will obtain them in some countries.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also important that we do not infringe the valid patents of third parties. If we infringe the valid patents of third parties, our reputation may be harmed and we may be required to pay significant monetary damages, we may be prevented from commercializing products or we may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by other parties that such parties may claim to cover the use of sofosbuvir, axicabtagene ciloleucel, brexucabtagene autoleucel, tenofovir disoproxil, tenofovir alafenamide and bictegravir.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time until a patent is issued, we may not know if our competitors have filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. Competitors may have filed patent applications or received patents and may obtain additional patents and proprietary rights that block or compete with our products. In addition, if competitors file patent applications covering our technology, we may have to participate in interference/derivation proceedings or litigation to determine the right to a patent. Litigation and interference/derivation proceedings are unpredictable and expensive, such that, even if we are ultimately successful, our results of operations may be adversely affected by such events.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Future litigation or other proceedings regarding the enforcement or validity of our existing patents or any future patents could result in the invalidation of our patents or substantially reduce their protection. From time to time, certain individuals or entities may challenge our patents.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications and the patent applications filed by our collaborative partners may not result in the issuance of any patents or may result in patents that do not provide adequate protection. As a result, we may not be able to prevent third parties from developing compounds or products that are closely related to those which we have developed or are developing. In addition, certain countries do not provide effective enforcement of our patents, and third-party manufacturers may be able to sell generic versions of our products in those countries.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. See also Item 1A. Risk Factors &#8220;Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Secrets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. These agreements provide that all confidential information developed or made known to an individual during the course of their relationship with us will be kept confidential and will not be used or disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions made by an individual while employed by us will be our exclusive property. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partners and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. If our trade secrets or confidential information become known or independently discovered by competitors, or if we enter into disputes over ownership of inventions, our business and results of operations could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Raw Materials</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are manufactured either at our own facilities or by third-party contract manufacturers. We depend on third parties to perform manufacturing activities for the majority of our API and drug products. For most of our products, including our HIV and HCV products, we use multiple third-party contract manufacturers so that we have primary and back-up suppliers and manufacturing sites. For our cell therapy products, we have established clinical and commercial manufacturing facilities for cell processing activities. For our future products, we continue to develop additional manufacturing capabilities and establish additional third-party suppliers to manufacture sufficient quantities of our product candidates to undertake clinical trials and to manufacture sufficient quantities of any product that is approved for commercial sale.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Manufacturing Facilities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease manufacturing facilities to manufacture and distribute certain products and API for clinical and/or commercial uses. These facilities are located in Foster City, San Dimas, La Verne, Oceanside and El Segundo, California; Morris Plains, New Jersey; Dublin and Cork, Ireland; Hoofddorp, Netherlands; and Edmonton, Canada.</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foster City, California: We conduct process chemistry research and formulation development activities, manufacture API and drug product for our clinical trials and oversee our third-party contract manufacturers.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">San Dimas and La Verne, California: We manufacture AmBisome and also package and label the majority of our commercial products for distribution to the Americas and Pacific Rim.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oceanside, California: We utilize the facility for clinical manufacturing and process development of our biologics candidates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">El Segundo, California: We utilize the facility for clinical and commercial manufacturing and processing of our cell therapy products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morris Plains, New Jersey: We utilize the facility for commercial manufacturing and process optimization of our antibody drug conjugate products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cork and Dublin, Ireland: We utilize the Cork facility for commercial manufacturing, packaging and labeling of our products. We also perform quality control testing, labeling, packaging and final release of many of our products at the Cork facility, which are distributed to the European Union and other international markets through our facility in Dublin. We utilize our other facility in central Dublin as a drug development hub for our pediatric programs where we perform clinical development, safety, quality, biostatistics and data sciences, regulatory and compliance functions. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Edmonton, Canada: We conduct process chemistry research and scale-up activities for our clinical development candidates, manufacture API for both investigational and commercial products and conduct chemical development activities to improve existing commercial manufacturing processes.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hoofddorp, Netherlands: We utilize the facility for commercial manufacturing and processing of our cell therapy products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third-Party Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the technology we use to manufacture our products is proprietary. For products manufactured by our third-party contract manufacturers, we have disclosed all necessary aspects of this technology to enable them to manufacture the products for us. We have agreements with these third-party manufacturers that are intended to restrict them from using or revealing this technology, but we cannot be certain that these third-party manufacturers will comply with these restrictions. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about our third-party manufacturers, see Item 1A. Risk Factors &#8220;We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Manufacturing Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. We, our third-party manufacturers and our corporate partners are subject to current Good Manufacturing Practices, which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the European Medicines Agency. Similar regulations are in effect in other jurisdictions. Our manufacturing operations are subject to routine inspections by regulatory agencies. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our cell therapy products, we are required by FDA to comply with the Risk Evaluation and Mitigation Strategy program, which includes educating and certifying medical personnel regarding the therapy procedures and the potential side effect profile of our therapy, such as the potential adverse side effects related to cytokine release syndrome and neurologic toxicities. Additionally, we are required to maintain a complex chain of identity and custody with respect to patient material as such material moves to the manufacturing facilities, through the manufacturing process, and back to the patient.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access to Raw Materials </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain raw materials to conduct our clinical trials and manufacture our products. These raw materials are generally available from multiple sources, purchased worldwide and normally available in quantities adequate to meet the needs of our business. We attempt to manage the risks associated with our supply chain by inventory management, relationship management and evaluation of alternative sources when feasible. For more information, see Item 1A. Risk Factors &#8220;We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead&#8217;s success depends on the work of its dedicated employees who embrace a shared sense of purpose and a culture of excellence. Our human capital objective is to make Gilead the employer of choice for the best talent in our industry. Gilead&#8217;s key priorities for human capital management include inclusion and diversity, health and safety, total rewards, employee development and engagement. Our Board&#8217;s Compensation and Talent Committee oversees our overall human capital management. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion &amp; Diversity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusion is a Gilead core value. We are committed to advancing inclusion and diversity (&#8220;I&amp;D&#8221;) in our workforce and have established a Global Diversity Council responsible for governance of these matters, tracking progress on our goals and promoting a culture of inclusion. The Global Diversity Council is chaired by our Chairman and Chief Executive Officer. In 2020, Gilead implemented multiple programs to train managers on I&amp;D topics to build awareness and drive inclusive behaviors. Our employee resource groups (&#8220;ERGs&#8221;) support diverse employees and aim to raise awareness of different cultures within the workplace, cultivate diversity as a business strength and support Gilead&#8217;s talent acquisition strategy to source, attract and recruit diverse candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Gilead&#8217;s inclusive and diverse workforce is the foundation for innovation and productivity. Gilead&#8217;s commitment to equal employment opportunity furthers its efforts to cultivate and celebrate an equitable culture of belonging. At December 31, 2020, Gilead had approximately 13,600 employees, and Gilead&#8217;s global workforce was approximately 52% female and 48% male. Additionally, women represented 34% of Gilead&#8217;s leadership (defined as vice president level and above). In the U.S., based on our employees&#8217; voluntary self-identification, our workforce was 41% White, 38% Asian, 11% Hispanic, 6% Black and 4% Other.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health and Safety</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead is committed to providing a safe, healthy and secure workplace for its employees. We have an environmental health and safety policy and maintain various compliance programs to support this commitment. We routinely train and educate our employees on workplace safety and security. During 2020, due to the COVID-19 pandemic, most Gilead sites required flexible location employees to work from home, while employees who needed to be physically present for their positions (such as laboratory technicians) continued to work at Gilead sites. We implemented site enhancements and risk protocols, including health screenings, COVID-19 testing, reconfiguration of work and common spaces to allow for social distancing, in our effort to support the safe occupancy of our sites. Gilead also maintains a robust contact tracing and notification process for any employee who reports COVID-19 infection. To date, we have not identified any cases of viral transmission of COVID-19 in our workplace. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead&#8217;s compensation and benefits programs are designed to help attract, cultivate and retain the industry&#8217;s most talented workforce. Our Total Rewards program (which varies by country) includes competitive base salary and incentive compensation, stock awards, an employee stock purchase plan, a 401(k) savings plan with a company match that vests immediately, health and welfare and other valuable benefits, such as flexible spending accounts, paid time off, family leave, family care resources, adoption and surrogacy assistance, employee assistance programs, global wellness reimbursement and tuition assistance, among many others. Each year, we reassess our Total Rewards package to confirm whether it offers benefits and incentives that align with our total reward philosophy.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, in response to the COVID-19 pandemic, we implemented a number of temporary COVID-19-specific benefits, such as cost reimbursements for essential home office equipment, monthly reimbursements for childcare and home-schooling costs, and a special pay enhancement for our physical location dependent workers who are required to be onsite at Gilead due to the nature of their role, to support our workforce during the unique challenges presented by the pandemic.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to address pay equity. Our employee salaries are informed by market-based ranges and are assessed annually through performance and career development reviews. Our policy is that compensation decisions are made without regard to personal characteristics such as gender, race, color, national or ethnic origin, age, disability, sexual orientation, gender identity or expression, genetic information, religion, or veteran status. We also conduct an annual pay equity review of employee compensation in an effort to strive to make our pay practices gender and race neutral. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Development and Engagement</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead offers a number of professional, management and leadership development training programs to help our employees develop cross-functional skills and tools to grow their careers. In addition, employees can receive reimbursement for tuition expenses incurred while pursuing undergraduate, graduate or certificate courses at an accredited college or university.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we make changes to pursue our ambition of becoming an employer of choice in our industry, it is important that we consider the input of employees. Our listening strategy helps to gather employee input and measure our progress. During 2020, we conducted several global surveys to assess and improve employee retention and engagement, gather feedback and take actions to address areas of employee concern. Employee responses from these surveys were key to determining meaningful benefits related to the COVID-19 pandemic as well as the direction of our culture going forward.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental, Social and Governance (&#8220;ESG&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead has also built a corporate social responsibility program to continue to execute its mission of providing lifesaving medicines in areas of unmet need. Additional information about this program and ESG highlights are available in Gilead&#8217;s 2019 year in review under Gilead&#8217;s website at https://www.gilead.com/news-and-press/annual-report/year-in-review-2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality of Operations</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our worldwide product sales do not reflect any significant degree of seasonality in end-user demand. However, in the United States, fluctuations in wholesaler inventory levels impact our product sales. We typically observe strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter resulting in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. Several other factors, including government budgets, annual grant cycles for federal and state funds, the COVID-19 pandemic, and other buying patterns, also could impact the product sales recorded in a particular quarter. For more information, see Item 1A. Risk Factors &#8220;We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and activities are subject to extensive regulation by numerous government authorities in the United States, the European Union and other countries, including laws and regulations governing the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product development and product approval processes are very expensive and time consuming, which has a significant impact on our capital expenditures and results of operations. The regulatory requirements applicable to drug development and approval are subject to change. Any legal and regulatory changes may impact our operations in the future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A country&#8217;s regulatory agency, such as FDA in the United States and the European Medicines Agency and European Commission for the European Union, as well as the national authorities of the European Union Member States, must approve a drug before it can be sold in the respective country or countries. The general process for drug approval in the United States is summarized below. Many other countries, including countries in the European Union (and the European Union under a centralized procedure), have similar regulatory structures.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Testing</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can test a drug candidate in humans, we must study the drug in laboratory experiments and in animals to generate data to support the drug candidate&#8217;s potential benefits and safety. We submit this data to FDA in an investigational new drug (&#8220;IND&#8221;) application seeking its approval to test the compound in humans.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If FDA accepts the IND, the drug candidate can then be studied in human clinical trials to determine if the drug candidate is safe and effective. These clinical trials involve three separate phases that often overlap, can take many years and are very expensive. These three phases, which are subject to considerable regulation, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. The drug candidate is given to a small number of healthy human control subjects or patients suffering from the indicated disease, to test for safety, dose tolerance, pharmacokinetics, metabolism, distribution and excretion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. The drug candidate is given to a limited patient population to determine the effect of the drug candidate in treating the disease, the best dose of the drug candidate, and the possible side effects and safety risks of the drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 1 clinical trials to fail in the more rigorous and extensive Phase 2 clinical trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. If a drug candidate appears to be effective and have an appropriate safety profile in Phase 2 clinical trials, Phase 3 clinical trials are commenced to confirm those results. Phase 3 clinical trials are conducted over a longer term, involve a significantly larger population, are conducted at numerous sites in different geographic regions and are carefully designed to provide reliable and conclusive data regarding the safety and benefits of a drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 2 clinical trials to fail in the more rigorous and extensive Phase 3 clinical trials.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we believe that the data from our clinical trials show an acceptable benefit-risk profile, we submit the appropriate filing, usually in the form of a New Drug Application (&#8220;NDA&#8221;), Biologics License Application (&#8220;BLA&#8221;) or supplemental application, with FDA seeking approval to sell the drug candidate for a particular use. At FDA&#8217;s discretion, FDA may hold a public hearing where an independent advisory committee of expert advisors asks additional questions and makes recommendations regarding the drug candidate. This committee makes a recommendation to FDA that is not binding but is generally followed by FDA. If FDA agrees that the drug has met the required level of safety and efficacy for a particular use, it will approve the application and allow us to sell the drug in the United States for that use. It is not unusual, however, for FDA to decline to approve an application because it believes that the drug candidate is not safe enough or efficacious enough (i.e. does not have an appropriate benefit versus risk profile) or because it does not believe that the data submitted is reliable or conclusive.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any point in this process, the development of a drug candidate can be stopped for a number of reasons including safety concerns and lack of treatment benefit. We cannot be certain that any clinical trials that we are currently conducting or any that we conduct in the future will be completed successfully or within any specified time period. We may choose, or FDA may require us, to delay or suspend our clinical trials at any time if it appears that patients are being exposed to an unacceptable health risk or if the drug candidate does not appear to have sufficient treatment benefit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA may also require Phase 4 non-registrational studies to explore scientific questions to further characterize safety and efficacy during commercial use of our drug. FDA may also require us to provide additional data or information, improve our manufacturing processes, procedures or facilities or may require extensive surveillance to monitor the safety or benefits of our product candidates if it determines that our filing does not contain adequate evidence of the safety and benefits of the drug. In addition, even if FDA approves a drug, it could limit the uses of the drug. FDA can withdraw approvals if it does not believe that we are complying with regulatory standards or if concerns about the safety or efficacy are uncovered or occur after approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining FDA approval for each drug, we obtain FDA approval of the manufacturing facilities for any drug we sell, including those of companies who manufacture our drugs for us. All of these facilities are subject to periodic inspections by FDA. FDA must also approve foreign establishments that manufacture products to be sold in the United States and these facilities are subject to periodic regulatory inspection. Our manufacturing facilities located in California also must be licensed by the State of California in compliance with local regulatory requirements. Our manufacturing facilities in Canada, Ireland and Netherlands also must obtain local licenses and permits in compliance with local regulatory requirements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA may employ one of several tools to facilitate and expedite the development and review of a drug, including fast track designation, Breakthrough Therapy designation, accelerated approval and Priority Review designation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation is designed to facilitate the development and review of a drug that treats a serious condition and fills an unmet medical need. Breakthrough Therapy designation is designed to expedite the development and review of a drug that treats a serious condition and preliminary clinical evidence demonstrates substantial improvement over available therapies. Accelerated approval of a drug may be granted by FDA where the drug treats a serious condition, fills an unmet medical need and has been studied for safety and efficacy. Priority Review designation means FDA&#8217;s goal is to take action on an application within six months of filing. FDA may grant Priority Review designation to a drug that would provide significant improvement in the safety or effectiveness of a treatment, diagnosis or prevention of a serious condition. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union Regulatory System and Approval Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union (&#8220;EU&#8221;), our products are subject to a variety of EU and EU Member State regulations governing clinical trials, commercial sales and distribution. We are required to obtain a marketing authorization in the EU before we can market our medicinal products on the relevant market. The conduct of clinical trials in the EU is governed by, among others, Directive 2001/20/EC and Directive 2005/28/EC and the EU (ICH) Good Clinical Practice rules. These impose legal and regulatory obligations that are similar to those provided in applicable U.S. laws. The conduct of clinical trials in the EU must be approved by the competent authorities of each EU Member States in which the clinical trials take place, and a positive opinion must be obtained from the relevant Ethics Committee in the relevant Member State. In 2014, the EU legislator adopted Regulation (EU) No 536/2014 to replace Directive 2001/20/EC and to introduce a coordinated procedure for authorization of clinical trials. This Regulation is expected to apply in 2021 or 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorization holders, manufacturers, importers, wholesalers and distributors of medicinal products placed on the market in the EU are required to comply with a number of regulatory requirements including pharmacovigilance, Good Manufacturing Practices compliance and the requirement to obtain manufacturing, import and/or distribution licenses issued by the competent authorities of the EU Member States. Failure to comply with these requirements may lead to the imposition of civil, criminal or administrative sanctions, including suspension of marketing or manufacturing authorizations.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing and Reimbursement</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. In the United States, the European Union and other significant or potentially significant markets for our products and product candidates, government authorities and private payers are increasingly attempting to limit or regulate the price of medical products and services. A significant portion of our sales of the majority of our products are subject to substantial discounts from their list prices, including rebates we may be required to pay to Medicaid agencies or discounts we may be required to pay to 340B covered entities. As a result, the price increases we implement from time to time on certain products may have a limited effect on our product sales in certain markets. In addition, standard reimbursement structures may not adequately reimburse for innovative therapies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our products mature, private insurers and government payers often reduce the amount they will reimburse providers, which increases pressure on us to reduce prices. Further, as new branded or generic products are introduced into major markets, our ability to maintain pricing and market share may be affected. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Item 1A. Risk Factors &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures&#8221; and &#8220;We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Assistance Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, there has been enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal and civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Fraud and Abuse Laws; Anti-Bribery Laws</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various U.S. federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claim laws. Anti-kickback laws make it illegal for a prescription drug manufacturer to knowingly and willingly solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business reimbursed by a federal healthcare program, including the purchase or prescription of a particular drug. False claims laws generally prohibit anyone from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment by federal and certain state payers (including Medicare and Medicaid), or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. Due to the breadth of the statutory provisions and the attention being given to them by law enforcement authorities, our sales, marketing, patient support and medical activities may be subject to scrutiny under these laws. For example, recently there has been enhanced scrutiny by government enforcement authorities of company-sponsored patient assistance programs, including co-pay assistance programs and manufacturer donations to third-party charities that provide such assistance, reimbursement support offerings, clinical education programs and promotional speaker programs. Similarly, in Europe, interactions between pharmaceutical companies and physicians are subject to strict laws, regulations, industry self&#8209;regulation codes of conduct and physicians&#8217; codes of professional conduct, as applicable, including the EU Member States anti-corruption laws and the UK Bribery Act 2010.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than local custom. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our training and compliance program, our internal control policies and procedures may not protect us from unlawful acts committed by our employees or agents. Violations of fraud and abuse laws or anti-bribery laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal health care programs (including Medicare and Medicaid). Violations can also lead to the imposition of a Corporate Integrity Agreement or similar government oversight program. Any similar violations by our competitors could also negatively impact the reputation of our industry and increase governmental and public scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Healthcare Reform</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the healthcare industry, including legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Item 1A. Risk Factors &#8220;We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of laws and regulations that require compliance with federal, state, and local regulations for the protection of the environment. The regulatory landscape continues to evolve, and we anticipate additional regulations in the future. Laws and regulations are implemented and under consideration to mitigate the effects of climate change mainly caused by greenhouse gas emissions. Our business is not energy intensive. Therefore, we do not anticipate being subject to a cap and trade system or other mitigation measure that would materially impact our capital expenditures, operations or competitive position. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information requirements of the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;). Therefore, we file periodic reports, proxy and information statements and other information with the SEC. The SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mailing address of our headquarters is 333 Lakeside Drive, Foster City, California 94404, and our telephone number at that location is 650-574-3000. Our website is www.gilead.com. Through a link on the &#8220;Investors&#8221; page of our website (under &#8220;SEC Filings&#8221; section), we make available the following filings free of charge as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Website references are provided throughout this document for convenience. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Annual Report on Form 10-K. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIV Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During the twelve months ended December 31, 2020, sales of our HIV products accounted for approximately 70% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, most of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), tenofovir disoproxil fumarate (&#8220;TDF&#8221;) and/or emtricitabine (&#8220;FTC&#8221;), which belong to the nucleoside class of antiviral therapeutics, and any changes to the treatment paradigm for HIV may cause nucleoside-based therapeutics to fall out of favor.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Veklury (remdesivir)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our significant investment in the rapid development, manufacturing and distribution of Veklury (remdesivir), which was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2020 as a treatment for hospitalized patients with COVID-19. Given the severity and urgency of the COVID-19 pandemic, we committed significant capital and resources for clinical trials and the scale-up of the production of remdesivir. We expect our investment will continue through 2021 and beyond, as we continue to manufacture large quantities of finished product and conduct additional studies of specific patient populations, develop and evaluate new formulations and delivery methods and combinations with other therapies. While the utilization of remdesivir has largely tracked the level of infections, we are unable to accurately predict our revenues or supply needs over the short and long term due to the potential for new and better therapeutics, the availability and effectiveness of vaccines and fluctuating hospital utilization rates. If we are unable to accurately forecast demand or manufacture Veklury at levels to meet actual demand, then this may result in shortages or excess inventory that may be written off. We are subject to significant public attention and scrutiny over the complex decisions made regarding the clinical data, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Yescarta, which is a Chimeric Antigen Receptor (&#8220;CAR&#8221;) T cell therapy, creates significant challenges, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of Yescarta;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. We may not be able to demonstrate to the medical community and payers the potential advantages of Yescarta compared to existing and future therapeutics. For challenges related to the reimbursement of Yescarta, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Yescarta to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the United States, which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not necessarily mirror patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels. We may continue to see this trend in the future. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the United States exclusively through the wholesale channel. For the year ended December 31, 2020, approximately 92% of our product sales in the United States were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end user demand and may not be completely effective in matching their inventory levels to actual end user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of technologies which are competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. As our products mature, private insurers and government payers often reduce the amount they will reimburse patients for these products, which increases pressure on us to reduce prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. In addition, in November 2020, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) issued an interim final rule that would substantially alter the Medicare Part B reimbursement system for physician-administered medicines as of January 1, 2021. This rule is subject to ongoing litigation and CMS has been preliminarily enjoined from implementing the rule. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. In the United States, the volume of drug pricing-related bills has dramatically increased in recent years. For example, Congress proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate when list prices for drugs grow faster than inflation and to increase manufacturer contributions in some or all of the benefit phases. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain. Many countries outside the United States, including the European Union member states, have established complex and lengthy procedures to obtain price approvals, coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of this review cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medicinal products in the European Union member states. Reductions in the pricing of our medicinal products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to 340B covered entities. Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, in December 2020, CMS issued a final rule that will make certain changes to the calculation of rebates under the Medicaid Drug Rebate Program. Among other changes, effective January 1, 2023, the final rule will change the requirements for excluding manufacturer co-pay coupons from the Medicaid &#8220;best price.&#8221; If these changes go into effect, they could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B covered entities. The continued growth of the 340B program also limits the prices we may charge to an increasing number of customers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity adjusted diagnosis related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the European Union, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the United States, actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may experience adverse impacts resulting from imports from countries where our products are available at lower prices or imports of unapproved generic or counterfeit versions of our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. For example, U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allows generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the United States, Europe or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, we are required to permit products purchased in one European Union member state to be sold in another member state. Purchases of our products in countries where our selling prices are relatively low for resale in countries in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the efficacy of the products and could harm patients, and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various &#8220;Buyers Clubs&#8221; around the world that promote the personal importation of generic versions of our products that have not been approved for use in the countries into which they are imported. As a result, patients may be at risk of taking unapproved medications which may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties may illegally distribute and sell counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. Counterfeit medicines pose a serious risk to patient health and safety and may raise the risk of product recalls. Our actions to discourage the distribution and sale of counterfeit versions of our medicines around the world may not be successful, and we may be adversely affected as a result. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of products that we develop for each intended use through extensive preclinical studies and clinical trials. The results from preclinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products. If any of our product candidates fails to achieve its primary endpoint in clinical trials, if safety issues arise or if the results from our clinical trials are otherwise inadequate to support regulatory approval of our product candidates, commercialization of that product candidate could be delayed or halted. In addition, we may also face challenges in clinical trial protocol design.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be adversely impacted if the clinical trials for any of the product candidates in our pipeline are delayed or terminated. We face numerous risks and uncertainties with our product candidates that could prevent completion of development of these product candidates. These risks include our ability to enroll patients in clinical trials, the possibility of unfavorable results of our clinical trials, the need to modify or delay our clinical trials or to perform additional trials and the risk of failing to obtain FDA and other regulatory agency approvals. As a result, our product candidates may never be successfully commercialized. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. In 2021, our key anticipated milestones for our product candidates include, among others, Phase 3 data readouts for (1) sacituzumab govitecan-hziy for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer patients and (2) axicabtagene ciloleucel for the treatment of second line diffuse large B cell lymphoma. We may be adversely impacted if we do not have favorable results from these studies and other programs in our pipeline cannot be completed on a timely basis or at all. In addition, clinical trials involving our commercial products could raise new safety issues for our existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and the European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also need to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications and quality standards, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our currently marketed products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase sufficient quantities of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers were interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the United States. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the United States from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will file, for marketing approval in additional countries and for additional indications and products over the next several years. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is subject to various federal, state and international laws and regulations pertaining to drug reimbursement, rebates, price reporting, health care fraud and abuse, and data privacy and security. In the United States, these laws include anti-kickback and false claims laws, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, the Medicaid Rebate Statute, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state health care programs, including Medicare, Medicaid and Department of Veterans Affairs and Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. For example, in the United States, a challenge to the Affordable Care Act (&#8220;ACA&#8221;) is currently pending before the U.S. Supreme Court, which has resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted subsequent to obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or patients taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the United States and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications are confidential for a period of time before a patent is issued, we may not know if our competitors filed patent applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that such parties may claim cover the use of sofosbuvir, axicabtagene ciloleucel or bictegravir. For example, in February 2018, ViiV filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with TAF and FTC as Biktarvy, infringes on ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;), covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the claims of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $11.46 billion through December 31, 2020 Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. See a description of our litigation related to these and other matters in Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources, including ongoing litigation related to our Yescarta and Biktarvy products and ongoing product liability litigation related to our TDF products. These matters could require us to pay significant monetary damages, including royalty payments for past and future sales. We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigations and other dispute-related matters, see Note 14. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the recent COVID-19 outbreak.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, such as COVID-19, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. For example, the COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets and has resulted in increased risks to our operations. In addition to the developments discussed in Part II, Item 7 &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; we are monitoring a number of risks related to the pandemic, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: The pandemic could result in disruptions to our supply chain and distribution in the future. For example, quarantines, shelter-in-place and other governmental orders and policies, travel restrictions, airline capacity and route reductions, safety guidelines and health impacts of the pandemic, could impact the availability or productivity of products and personnel at manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in higher costs, disruptions in our supply chain and interruptions in our distribution capabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Trials: This pandemic has adversely affected and may continue to adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. For ongoing trials, clinical trial sites have imposed restrictions on patient visits to limit risks of possible COVID-19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. There is also a risk that closures at clinical sites may be necessary as the pandemic and related guidance and restrictions continue to evolve. For the foregoing reasons, we have experienced delays with new subject enrollment for most clinical trials, and may continue to experience overall delays in our clinical trials. There is also the risk of biased data collection if only certain clinical trial sites remain open. As a result of these challenges, our anticipated filing and marketing timelines for certain products may be adversely impacted.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory Reviews: The operations of FDA, EMA or other regulatory agencies may be adversely affected. We may also experience delays in necessary interactions with regulatory authorities around the world, including with respect to any anticipated filing, which together with other factors resulting from the pandemic may adversely impact our ability to launch new commercial products.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient Access: The pandemic has limited patients&#8217; ability or willingness to access and seek care from healthcare providers and initiate new therapies, which has resulted in lower demand for our products, particularly with respect to HIV prevention and hepatitis C virus (&#8220;HCV&#8221;) treatment. For example, we have seen a reduction in prescription refills for HIV prevention as a result of higher discontinuations. In addition, with the rising unemployment, we have experienced a shift in payer mix towards more government-funded coverage and the uninsured segment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employees: We face risks related to the health, safety, morale and productivity of our employees, including the safe occupancy of our sites during the pandemic. Currently, most Gilead sites are requiring flexible location employees to work from home while physical location dependent workers and mixed location workers continue to work on Gilead sites. Our job site enhancements and risk protocols, which include health screenings and COVID-19 testing, do not guarantee that we can maintain the continued safe occupancy of our sites. On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns of office locations and manufacturing plants.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Financial: The pandemic has had, and may continue to have, an adverse financial impact in the short-term and potentially beyond. As a result of reduced patient access and a shift in payer mix, our HCV treatment and HIV businesses have been adversely impacted. For example, our product sales, excluding Veklury, for the fourth quarter and full year 2020 decreased 7% and 3%, respectively, compared to the same periods in 2019, due in part to the continued effects of the pandemic on our HCV and HIV franchises. We may continue to experience fluctuating revenues from these businesses as infection rates rise and fall and as shelter in place restrictions are periodically tightened and eased. We have also experienced, and may continue to experience, volatility in our short-term revenues due to fluctuations in inventory channel purchases during the pandemic. We could also have additional unexpected expenses related to the pandemic, which could negatively affect our results of operations. These factors together with the overall uncertainty and disruption caused by the pandemic could result in increased volatility and decreased predictability in our results of operations and volatility in our stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic may also amplify many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. The extent to which the pandemic impacts our business and results will depend on future developments, which are uncertain and cannot be predicted with confidence, including any potential future waves of the pandemic, new variants of the virus that impact the severity and duration of the pandemic, the development, distribution, effectiveness and public acceptance of vaccines, and any other ongoing and future actions taken to contain the pandemic.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign Currency Exchange: For the year ended December 31, 2020, approximately 26% of our product sales were outside the United States. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation or the imposition of compulsory licenses.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the United States or other governments.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we or they may be uninsured or inadequately insured. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry adequate earthquake insurance and significant recovery time could be required to resume operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes. For example, on January 31, 2020, the United Kingdom withdrew from the European Union, which initiated a transition period during which the United Kingdom and the European Union will negotiate their future relationship. There is uncertainty concerning any changes in the laws and regulations governing the conduct of clinical trials and marketing of medicinal products in the United Kingdom following the country&#8217;s exit from the European Union. This uncertainty may lead to significant complexity and risks for our company and our ability to research, develop and market medicinal products in the European Union and the United Kingdom.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. For example, we have collaboration arrangements with Janssen Sciences Ireland UC for Odefsey, Complera/Eviplera and Symtuza. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks, security breaches and legal claims.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and random attack. Likewise, data privacy or security breaches by employees or others pose a risk that sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public. Cyberattacks are increasing in their frequency, sophistication and intensity, including during the pandemic. Cyberattacks include, for example, the deployment of harmful malware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture. There can be no assurance that our efforts, or the efforts of our partners and vendors, to invest in the protection of information technology infrastructure and data will prevent future service interruptions or identify breaches in our systems. Such interruptions or breaches could cause the loss of critical or sensitive information, including personal information. In addition, our insurance may not be sufficient in type or amount to cover the losses that may result from an interruption or breach of our systems.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) that became effective in Europe in 2018 established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;) that became effective in January 2020, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. The GDPR, CCPA and other changes, or new laws or regulations associated with the enhanced protection of personal information, including in some cases healthcare data or other personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges if the products, intellectual property and technologies that are acquired or licensed are not successful. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic transactions, such as in connection with our collaboration with Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics in 2020, S&amp;P downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes and tax return audits in the United States and various foreign jurisdictions including Ireland. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, significant judgment is required in determining our worldwide provision for income taxes. Various factors may have favorable or unfavorable effects on our income tax rate including, but not limited to, our portion of the non-deductible annual branded prescription drug fee, the accounting for stock options and other share-based awards, mergers/acquisitions and restructurings, ability to maintain manufacturing and other operational activities in our Irish facilities, changes in the mix of earnings in the various tax jurisdictions in which we operate, changes in overall levels of pre-tax earnings, resolution of federal, state and foreign income tax audits. The impact on our income tax provision resulting from the above mentioned factors may be significant.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_19"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNRESOLVED STAFF COMMENTS </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_22"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPERTIES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Foster City, California, where we house our administrative and certain of our R&amp;D activities. We also have R&amp;D facilities in Emeryville, Oceanside and Santa Monica, California; Gaithersburg, Maryland; Seattle, Washington; Morris Plains, New Jersey; Edmonton, Canada; and Dublin, Ireland. Our principal manufacturing facilities are in El Segundo, La Verne, Oceanside and San Dimas, California; Morris Plains, New Jersey; Edmonton, Canada; Cork, Ireland; and Hoofddorp, Netherlands. For more information about our manufacturing facilities, see Item 1 - Business &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Manufacturing Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Our global operations include offices in Europe, North America, Asia, South America, Africa, Australia and the Middle East.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing properties, including both owned and leased sites, are in good condition and suitable for the conduct of our business. We believe our capital resources are sufficient to purchase, lease or construct any additional facilities required to meet our expected long-term growth needs.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_25"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, please see&#160;Note 14. Commitments and Contingencies - Legal Proceedings of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_28"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MINE SAFETY DISCLOSURES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_31"></div><div style="margin-top:13.5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_34"></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;GILD.&#8221; </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;18, 2021, we had approximately 1,402 stockholders of record of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares our cumulative total stockholder return for the past five years to&#160;two indices: the&#160;Standard&#160;&amp; Poor&#8217;s 500 Stock Index (&#8220;S&amp;P 500 Index&#8221;) and the Nasdaq Biotechnology Index (&#8220;NBI Index&#8221;). The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns. </span></div><div style="margin-top:9pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Cumulative Total Return on Investment for the Past Five Years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><img src="gild-20201231_g1.jpg" alt="gild-20201231_g1.jpg" style="height:479px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This section is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference in any of our filings under the Securities Act or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shows the cumulative return on investment assuming an investment of $100 in our common stock, the NBI Index and the S&amp;P 500 Index on December&#160;31, 2015, and assuming that all dividends were reinvested.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to our equity compensation plans in effect as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Common Shares to be Issued Upon Exercise of Outstanding Options, Warrants and Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-average Exercise Price of Outstanding Options, Warrants and Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(c) </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation plans approved by security holders:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2004 Equity Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation plans approved by security holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation plans not approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Does not take into account</span><span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20 million restricted stock units, performance share awards or units and phantom shares, which have no exercise price and were granted under our 2004 and 2018 Equity Incentive Plans.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes awards and shares previously issuable under The Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (the &#8220;Immunomedics Plan&#8221;), which was assumed in connection with our acquisition of Immunomedics, Inc. and subsequently merged into the 2004 Equity Incentive Plan.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under our Employee Stock Purchase Plan, participants are permitted to purchase our common stock at a discount on certain dates through payroll deductions within a pre-determined purchase period. Accordingly, these numbers are not determinable.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes awards and shares issuable under the Forty Seven, Inc. 2018 Equity Incentive Plan, which was assumed in connection with our acquisition of Forty Seven, Inc. (&#8220;Forty Seven&#8221;) and subsequently amended and restated as our 2018 Equity Incentive Plan.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material Features of the Gilead Sciences, Inc. 2018 Equity Incentive Plan</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Forty Seven, Inc. 2018 Equity Incentive Plan was originally established by Forty Seven in June 2018. In connection with Gilead&#8217;s acquisition of Forty Seven in April 2020, Gilead assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, and amended and restated it as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any affiliate, and provide a means by which the eligible recipients may benefit from increases in value of Gilead common stock. From and after April 7, 2020, only employees and consultants of Forty Seven as of immediately prior to such date and employees and consultants of Gilead hired on or following such date are eligible to receive grants of new awards under the 2018 Plan.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Plan provides for the award of incentive stock options and Nonstatutory stock options, each of which must generally have an exercise price equal to at least the fair market value of our common stock on the date of grant; stock appreciation rights; restricted stock awards; restricted stock unit awards; performance stock awards; other stock awards; and performance cash awards.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April 7, 2020, the aggregate number of shares of common stock issuable under the 2018 Plan (from and after such date) was 12,069,378. From and after April 7, 2020, Gilead has granted restricted stock units and stock options under the 2018 Plan, and these are the only types of equity awards outstanding under the plan. As of December 31, 2020, 10.3 million shares of Gilead common stock remained available for issuance under the 2018 Plan.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We made repurchases under the 2016 Program starting in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we repurchased and retired 22 million shares of our common stock for $1.6 billion through open market transactions under the 2016 Program.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the remaining authorized repurchase amount from both programs was $6.8 billion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>Price Paid<br/>per Share (in dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>as Part of a Publicly<br/>Announced Program (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Fair<br/>Value of Shares<br/>that May Yet Be<br/>Purchased Under<br/>the Programs (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A total of 232 thousand shares were transferred to us from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock units during the period. We did not purchase any shares of our common stock in the open market pursuant to our repurchase program.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_37"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM &#160;6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC. </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED FINANCIAL DATA </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENT OF INCOME DATA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:700;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash dividends declared per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CONSOLIDATED BALANCE SHEET DATA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:700;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Working capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in Item 7 of this Annual Report on Form 10-K for a description of our results of operations for 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2020, we recorded acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses of $5.9 billion primarily related to our acquisition of Forty Seven, Inc. (&#8220;Forty Seven&#8221;) as well as other collaborations and investments we entered into during the year. In 2019, we recorded acquired IPR&amp;D expenses of $5.1 billion primarily due to $3.92 billion of upfront collaboration and licensing expenses related to our global research and development collaboration with Galapagos NV, and a pre-tax impairment charge of $800 million from assets obtained in our acquisition of Kite Pharma, Inc. (&#8220;Kite&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2020, we recorded discrete tax benefits of $167 million related to settlements with taxing authorities. In 2019, we recorded a deferred tax benefit of $1.2 billion related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In 2018, we recorded a deferred tax charge of $588 million related to a transfer of acquired intangible assets from a foreign subsidiary to the United States. In December 2017, we recorded an estimated $5.5 billion net charge related to the enactment of the Tax Cuts and Jobs Act (&#8220;Tax Reform&#8221;). Tax Reform also lowered the corporate tax rate in the United States from 35% to 21% effective for tax years beginning after December 31, 2017.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2020, in connection with the acquisition of Immunomedics, we issued $7.25 billion principal amount of senior unsecured notes and borrowed an aggregate principal amount of $1.0&#160;billion under a three-year term loan facility. Also in 2020, we repaid $2.5 billion principal amount of our senior unsecured notes at maturity. In 2019, we repaid $2.8 billion principal amount of our senior unsecured notes at maturity. In 2018, we repaid $1.8 billion principal amount of our senior unsecured notes at maturity and repaid $4.5 billion of term loans borrowed in connection with our acquisition of Kite. In 2017, in connection with the acquisition of Kite, we issued $3.0 billion aggregate principal amount of senior unsecured notes and borrowed $6.0 billion aggregate principal amount term loan facility credit agreement, of which $1.5 billion was repaid in 2017. In 2016, we issued $5.0 billion principal amount of senior unsecured notes and repaid $285 million of principal balance of convertible senior notes and $700 million of principal balance of senior unsecured notes at maturity. See Note 12. Debt and Credit Facilities of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In 2020, we made cash payments of $25.7 billion primarily related to our acquisitions of Immunomedics in October 2020 and Forty Seven in April 2020. See Note 6. Acquisitions of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_40"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM &#160;7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements and other disclosures included in this Annual Report on Form 10-K (including the disclosures under Part I, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Additional i</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nformation related to the comparison of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results of operations</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> between the years 2019 and 2018 is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 7. Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882095/000088209520000006/a2019form10-k.htm#s11F232EE80B7FBB9B77B8F27BF3A0F35">2019 Form 10-K</a> filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), and is </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporated by reference into this Annual Report on Form 10-K. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars. </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT OVERVIEW</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Jyseleca varies worldwide, and Jyseleca is not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Business Highlights</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial performance was strong in 2020, despite the global impact of the COVID-19 pandemic, which is a clear reflection of the solid underlying fundamentals of our business driven by the HIV franchise and the increased demand we saw for Veklury amid the COVID-19 pandemic. We also continued to expand and strengthen our commercial portfolio and clinical pipeline across various therapeutic areas to drive future growth potential. </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April, we acquired Forty Seven, Inc. (&#8220;Forty Seven&#8221;) for approximately $4.7 billion, gaining an investigational drug candidate, magrolimab, which is currently in Phase 2/3 clinical studies for a number of hematological cancers, including myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors. </span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October, we acquired Immunomedics, Inc. (&#8220;Immunomedics&#8221;) for approximately $20.6 billion and gained Trodelvy, a Trop-2-directed antibody-drug conjugate, which was granted accelerated approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of adult patients with metastatic triple-negative breast cancer (&#8220;mTNBC&#8221;). Trodelvy has potential broader applicability for multiple tumor types, and is being studied as a monotherapy and combination agent for additional tumor types, including HR+/HER2- breast cancer, urothelial cancer, non-small cell lung cancer and other solid tumors.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December, we entered into a definitive agreement to acquire MYR GmbH. Upon closing, which is subject to regulatory clearances and other conditions, the acquisition will provide us with Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bulevirtide), which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) for the treatment for chronic hepatitis delta virus (&#8220;HDV&#8221;) in July 2020.</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We significantly expanded our oncology portfolio through licensing, strategic collaboration as well as equity investments with our third-party collaboration partners. Additional information is included in Note 11. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets we acquired pursuant to our strategic transactions, we developed several other therapies and treatments in our portfolio: Jyseleca, Tecartus and Veklury, the first FDA-approved antiviral therapy for COVID-19. These efforts demonstrate our continued commitment to advancing innovative medicines in areas of unmet need. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Product, Pipeline and Corporate Updates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Therapeutic Area and Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory Approval &amp; Submission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viral Diseases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA, European Commission (&#8220;EC&#8221;) and Japanese Ministry of Health, Labour and Welfare (&#8220;JMHLW&#8221;) granted full approval, conditional marketing authorization and regulatory approval, respectively, to Veklury for the treatment of patients with COVID-19.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA approved a supplemental New Drug Application for Epclusa for the treatment of children ages 6 and older (or weighing at least 17 kg) with hepatitis C virus (&#8220;HCV&#8221;).</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA and EC granted accelerated approval and conditional marketing authorization, respectively, for Tecartus for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We submitted a supplemental Biologics License Application (&#8220;sBLA&#8221;) to FDA for approval of Trodelvy as a treatment for adult patients with mTNBC based on the overall efficacy and safety results in the Phase 3 ASCENT trial.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Kite Pharma, Inc. (&#8220;Kite&#8221;) submitted an sBLA to FDA for Yescarta for the treatment of relapsed or refractory indolent non-Hodgkin&#8217;s lymphoma. Kite also received EMA approval to implement a variation to the Yescarta Marketing Authorization for end-to-end manufacturing. </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational, monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inflammatory Diseases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EMA validated and is reviewing the application of Gilead and Galapagos NV (&#8220;Galapagos&#8221;) for a new indication to the approved license for filgotinib 200mg. The proposed indication is for the treatment of adults with moderately to severely active ulcerative colitis.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">JMHLW and EC granted regulatory approval and marketing authorization of Jyseleca, respectively, for the treatment of adults with moderate to severe active rheumatoid arthritis.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Viral Diseases</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gilead and Vir Biotechnology, Inc. established a clinical collaboration related to hepatitis B virus in January 2021.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gilead and Gritstone Oncology, Inc. announced that the companies have entered into a collaboration, option and license agreement related to a curative treatment of HIV in February 2021.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Veklury Distribution:</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Beginning October 1, 2020, we started distributing Veklury in the United States upon conclusion of the previous distribution agreement with the U.S. Federal government.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Gilead and European Union signed a joint procurement agreement, which covers purchases of Veklury for a six-month period through April 2021 and has the option to be extended by the parties for additional six-month periods.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Board Appointments: </span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Jeffrey A. Bluestone, Ph.D., the President and Chief Executive Officer (&#8220;CEO&#8221;) of Sonoma Biotherapeutics. </span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Sandra J. Horning, retired Chief Medical Officer and Global Head of Product Development for Roche.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Javier J. Rodriguez, the CEO of DaVita Inc.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Anthony Welters, retired Senior Advisor to the Office of the CEO of UnitedHealth Group, Inc.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Community Support: </span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In February 2021, we announced a new partnership with the Wake Forest University School of Divinity, as part of the ongoing COMPASS Initiative, to help mitigate the HIV epidemic in the Southern United States. </span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We launched the Racial Equity Community Impact Fund to initially provide $10 million in grants to 20 organizations working in community advocacy and mobilization, social justice and educational innovation. </span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">COVID-19: We donated 1.5 million individual doses of remdesivir free of charge.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We made various donations to support current nonprofit grantees through the global Gilead COVID-19 Acute Relief and Emergency Support Grantee Fund.</span></div><div style="margin-top:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">We also made donations to the San Mateo Strong Fund and the Mayor&#8217;s Fund for Los Angeles.</span></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We announced and discussed these updates in further detail in press releases available on our website at https://www.gilead.com/news-and-press/press-room/press-releases. Additional information can be found in our disclosures filed or furnished with the SEC, including its Current Reports on Form 8-K and on Quarterly Reports on Form 10-Q, as applicable. Readers are also encouraged to review all other press releases available on our website mentioned above. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Financial Highlights</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Compared to 2019</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues increased by 10% to $24.7 billion in 2020, compared to $22.4 billion in 2019, primarily due to Veklury sales and higher product sales in our HIV products, including the continued patient uptake of Biktarvy and growth of Descovy for pre-exposure prophylaxis (&#8220;PrEP&#8221;). The increase was partially offset by lower sales volume of our Truvada (emtricitabine (&#8220;FTC&#8221;) and tenofovir disoproxil fumarate (&#8220;TDF&#8221;))-based products primarily due to the loss of exclusivity of Truvada and Atripla in the United States in October 2020, lower sales of HCV products due to the impact of the COVID-19 pandemic and the expected declines in sales of Letairis and Ranexa after generic entries in the first half of 2019. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead was $123 million or $0.10 per diluted share in 2020, compared to $5.4 billion or $4.22 per diluted share in 2019, primarily due to unfavorable changes in the fair value of our equity investments in Galapagos, the $1.2 billion discrete tax benefit recorded in 2019 related to intra-entity transfers of intangible assets to different tax jurisdictions, higher acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses related to our acquisition of Forty Seven and our collaborations and other investments we entered into during the year, as well as higher acquisition-related expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy and Outlook 2021</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our purpose is to deliver life-changing medications to patients in need through scientific breakthroughs, innovation and strong operational execution. Our strategic ambitions are to (i) bring 10+ transformative therapies to patients by 2030; (ii) be the biotech employer and partner of choice; and (iii) deliver shareholder value in a sustainable and responsible manner. Our strategic priorities reflect how we will deliver those ambitions: (i) expand internal and external innovation; (ii) strengthen portfolio strategy and decision making; (iii) increase patient benefit and access; and (iv) continue to evolve our culture. In 2021, we will continue to focus on executing our strategy to expand and strengthen our commercial portfolio and clinical pipelines in new therapeutic areas, including oncology and inflammation, while maintaining our leadership in antiviral medications through the continued growth of Biktarvy, the development of lenacapavir, the expansion of our viral hepatitis business and our on-going efforts to develop safe and effective antivirals to patients suffering from viral infections. Beyond expanding our products and pipeline, we also continue to focus on our employees, the evolution of our culture and our efforts to promote racial equity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to impact our business and broader market dynamics. We expect a gradual recovery in underlying market dynamics starting the second quarter 2021. Truvada and Atripla sales are expected to continue to decline in the first quarter of 2021 and beyond as multiple generics are expected to enter the market starting in the second quarter of 2021. Biktarvy, Trodelvy, Vemlidy and cell therapy are expected to be key growth drivers in 2021 absorbing the full year impact of the loss of exclusivity for Truvada and Atripla in the United States. Veklury sales are generated in a highly dynamic and complex global environment, which continues to evolve. As a result, Veklury sales are subject to significant volatility and uncertainty. Future product demand will depend on the nature of the COVID-19 pandemic, including duration of the pandemic, infection rates, hospitalizations, and availability of alternative therapies and vaccines being developed. The acquisition of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics will continue to contribute to our revenue growth in 2021. Our capital allocation priorities remain unchanged from 2020 and we plan to prioritize investment in our business and R&amp;D pipeline and maintain a rigorous focus on disciplined expense management.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to deliver on our strategy and 2021 objectives is subject to a number of uncertainties, including, but not limited to, the effects of the COVID-19 pandemic, which remains unpredictable; the continuation of an uncertain global macroeconomic environment; our ability to realize the potential benefits of our acquisitions, collaborations or licensing arrangements; our ability to initiate, progress or complete clinical trials within currently anticipated timeframes; the possibility of unfavorable results from new and ongoing clinical trials; additional pricing pressures from payers and competitors; higher than anticipated effects of the loss of exclusivity from Truvada and Atripla; slower than anticipated growth in Biktarvy, Trodelvy, Vemlidy and cell therapy products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; market share and price erosion caused by the introduction of generics; loss of exclusivity of our products; inaccuracies in our HCV patient start estimates; potential government actions that could have the effect of lowering prices; a larger-than anticipated shift in payer mix to more highly discounted payer segment; and volatility in foreign currency exchange rates.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_46"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenues </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our revenues:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HCV products</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cell therapy products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Compared to 2019</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Total Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total product sales increased by 10% to $24.4 billion in 2020, compared to $22.1 billion in 2019, primarily due to Veklury sales and higher product sales in our HIV products, including the continued patient uptake of Biktarvy and growth of Descovy for PrEP. The increase was partially offset by lower sales volume of our Truvada (FTC/TDF)-based products primarily due to the loss of exclusivity of Truvada and Atripla in the United States in October 2020, lower HCV sales due to lower patient starts due to the COVID-19 pandemic and the expected declines in sales of Letairis and Ranexa after generic entries in the first half of 2019.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HIV Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales increased by 3% to $16.9 billion in 2020, compared to $16.4 billion in 2019, primarily due to the continued patient uptake of Biktarvy and growth of Descovy for PrEP, partially offset by lower sales volume of our Truvada (FTC/TDF)-based products driven by the loss of exclusivity of Truvada and Atripla in the United States in October 2020 and lower average net selling price driven by unfavorable payer mix primarily due to higher public health service utilization. Our HIV franchise, including PrEP was also unfavorably impacted by the COVID-19 pandemic. HIV product sales in 2019 included favorable net adjustments primarily due to government rebates and discounts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Descovy (FTC/TAF)-based product sales increased in all major markets in 2020 compared to 2019. The increase in the United States was primarily due to the continued patient uptake of Biktarvy and growth of Descovy for PrEP, partially offset by lower sales volume of Genvoya. The increase in Europe and other international locations was primarily due to higher sales volume of Biktarvy, partially offset by lower sales volume of Genvoya.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:7pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Truvada (FTC/TDF)-based product sales decreased in the United States and Europe in 2020 compared to 2019. The decrease in the United States was primarily due to lower sales volume driven by the loss of exclusivity of Truvada and Atripla in October 2020 and patients switching to regimens containing FTC/TAF. We expect Truvada sales to continue to decline in 2021 and beyond as multiple generics are expected to enter the market starting in the second quarter 2021. The decrease in European sales was primarily due to lower sales volume as a result of the broader availability of generic versions of Truvada and patients switching to regimens containing FTC/TAF.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HCV Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 30% to $2.1 billion in 2020, compared to $2.9 billion in 2019, primarily due to lower sales volume driven by lower patient starts in the United States and Europe attributable to the COVID-19 pandemic and the continuing decline of total market patient starts unrelated to the pandemic, as well as lower average net selling price reflecting higher sales return provisions and discounts. HCV product sales in 2019 included favorable net adjustments primarily due to government rebates and discounts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in HCV product sales in the United States and Europe in 2020 compared to 2019 was primarily due to lower patient starts, including declines attributable to a decrease in health care provider visits and screenings due to the COVID-19 pandemic as well as lower average net selling price. The decrease in Europe was also impacted by favorable net adjustments primarily due to government rebates and discounts in 2019, which did not reoccur in 2020. The decrease in HCV product sales in other international locations in 2020 compared to 2019 was primarily due to lower sales volume.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury generated $2.8 billion in sales in 2020 primarily in the United States and Europe, reflecting higher hospitalization and treatment rates due to the fourth quarter COVID-19 surge. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy product sales, which include Yescarta and Tecartus, increased by 33% to $607 million in 2020, compared to $456 million in 2019, primarily due to the continued uptake of Yescarta in Europe and the third quarter 2020 product launch of Tecartus in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy generated $49 million in sales in the United States, following our acquisition of Immunomedics on October 23, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales, which include Vemlidy, Viread, Letairis, Ranexa, Zydelig, AmBisome, Cayston and Jyseleca, decreased by 18% to $1.9 billion in 2020, compared to $2.3 billion in 2019, primarily due to the expected declines in sales of Letairis and Ranexa after generic entries in the first half of 2019, partially offset by higher sales volume of Vemlidy in other international locations.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Gross-to-Net Deductions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record product sales net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related costs. These deductions to product sales are generally referred to as gross-to-net (&#8220;GTN&#8221;) deductions, which totaled $15.3 billion, or 39% of gross product sales in 2020, compared to $15.3 billion, or 41% of gross product sales in 2019. Of the $15.3 billion in 2020, $13.0 billion or 33% of gross product sales was related to government and other rebates and chargebacks, $1.7 billion was related to cash discounts for prompt payment, distributor fees and other related costs and $572&#160;million was related to sales return provisions.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Sales by Geographic Area</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of our total product sales, 26% and 25% were generated outside the United States in 2020 and 2019, respectively. We faced exposure to movements in foreign currency exchange rates, primarily in the Euro. We used foreign currency exchange contracts to hedge a percentage of our foreign currency exposure. Foreign currency exchange, net of hedges, had an unfavorable impact on our product sales of $29 million in 2020, based on a comparison using foreign currency exchange rates from 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in the United States increased by 10% to $18.1 billion in 2020, compared to $16.6 billion in 2019, primarily due to sales of Veklury, the continued patient uptake of Biktarvy and growth of Descovy for PrEP, partially offset by decreases in sales of Truvada (FTC/TDF)-based products driven by the loss of exclusivity of Truvada and Atripla in the United States in October 2020. The increase was also partially offset by lower sales volume of Letairis and Ranexa and lower sales of our HCV products. The decrease in sales of our HCV products was primarily due to lower patient starts and average net selling price as discussed above.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in Europe increased by 9% to $3.9 billion in 2020, compared to $3.6 billion in 2019, primarily due to sales of Veklury, and the continued patient uptake of Biktarvy and Yescarta. The increase was partially offset by lower patient starts and average net selling price as discussed above. Product sales in Europe in 2019 included favorable net adjustments primarily due to government rebates and discounts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales in other international locations increased by 17% to $2.3 billion in 2020, compared to $2.0 billion in 2019, primarily due to higher sales volumes of Biktarvy, Veklury and Vemlidy.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our product sales: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HIV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy (FTC/TAF) Based Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biktarvy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Descovy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genvoya &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Odefsey &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue share &#8211; Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Descovy (FTC/TAF) Based Products &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,618&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,203&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,066&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada (FTC/TDF) Based Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atripla &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 31pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complera / Eviplera &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stribild &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Truvada &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Truvada (FTC/TDF) Based Products &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HIV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HCV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ledipasvir / Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sofosbuvir / Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total HCV &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cell Therapy Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Yescarta &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tecartus &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Cell Therapy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trodelvy - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmBisome &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Letairis &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ranexa &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vemlidy &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viread &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zydelig &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; U.S.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211; Europe</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8211; Other International</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Other &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product sales &#8211; Other International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 25.75pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Hepsera and Jyseleca.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our costs and expenses: </span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">230 bps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">130 bps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development (&#8220;R&amp;D&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Goods Sold and Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, cost of goods sold decreased by $103 million compared to 2019, primarily due to the 2019 inventory write-down charges of $649 million, of which $547 million was related to slow moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products. The decrease in cost of goods sold was partially offset by higher manufacturing ramp-up expenses related to Veklury as a treatment for COVID-19 and acquisition-related expenses from amortization of finite-lived intangible assets and inventory step-up charges, as well as accelerated stock-based compensation expenses related to our acquisition of Immunomedics. In addition, royalty expenses decreased by $126 million in 2020, compared to 2019, primarily due to lower sales of products containing elvitegravir, Letairis and Atripla. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, product gross margin increased compared to 2019, primarily due to factors described above. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of clinical studies performed by contract research organizations, materials and supplies, payments under collaborative and other arrangements including milestone payments, licenses and fees, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track total R&amp;D expenses by product candidate, therapeutic area or development phase. However, we manage our R&amp;D expenses by identifying the R&amp;D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of technical and regulatory successful development, market potential, available human and capital resources and other considerations. We continually review our R&amp;D projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities that we believe will best support the long-term growth of our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a breakout of our R&amp;D expenses by major cost type:</span></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies and outside services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel, infrastructure and other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, R&amp;D expenses increased by $1.0 billion compared to 2019, primarily due to higher clinical trial expenses related to the investigation of remdesivir as a treatment for COVID-19 including material costs, the fourth quarter charge of $190 million (&#8364;160 million) in connection with the agreement to amend the existing arrangement with Galapagos for the commercialization and development of Jyseleca, accelerated stock-based compensation expenses of $166 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to our acquisitions of Immunomedics and Forty Seven, higher investments in oncology programs including magrolimab, an investigational anti-CD47 monoclonal antibody, and to a lesser extent, Trodelvy, and accruals for milestone payments of $70 million to Pionyr Immunotherapeutics, Inc. (&#8220;Pionyr&#8221;). The increase was partially offset by lower clinical trial expenses from the completion of certain inflammation programs and lower costs as a result of our pause or postponement of certain clinical trials due to the COVID-19 pandemic. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. Beginning in the second quarter of 2020, acquired IPR&amp;D expenses were reported separately from Research and development expenses on our Consolidated Statements of Income. IPR&amp;D assets capitalized are tested for impairment in the fourth quarter of each year, or earlier if impairment indicators exist. No IPR&amp;D impairment charges were recorded in 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses of $5.9 billion for 2020 were primarily related to our acquisition of Forty Seven as well as collaborations and other investments we entered into during the year with Arcus Biosciences, Inc., Pionyr, Tango Therapeutics, Inc., Tizona Therapeutics, Inc. and Jounce Therapeutics, Inc.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D expenses of $5.1 billion for 2019 included $3.9 billion in upfront charges related to our global research and development collaboration agreement with Galapagos and the $800 million impairment charge from assets obtained in our Kite acquisition. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to sales and marketing, finance, human resources, legal and other administrative activities, including information technology investments. Expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses and other general and administrative costs. SG&amp;A expenses also include the Branded Prescription Drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales and is trued-up upon receipt of invoices from the Internal Revenue Service.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, SG&amp;A expenses increased by $770 million compared to 2019, primarily due to accelerated stock-based compensation expenses of $204 million related to our acquisitions of Immunomedics and Forty Seven, a $97 million charge related to a previously disclosed legal settlement, increased corporate grants, costs associated with the commercialization efforts for Veklury and to a lesser extent, Trodelvy, higher marketing expenses related to Biktarvy and donations of remdesivir. The increases were partially offset by lower travel and other spend due to the COVID-19 pandemic.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BPD fee expenses were $198 million, $247 million and $229 million in 2020, 2019 and 2018, respectively. BPD fee expenses are not tax-deductible.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net and Interest Expense</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Other income (expense), net and Interest expense:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,418)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(995)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-bottom:4.5pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrealized losses primarily relating to our investments in Galapagos unfavorably impacted Other income (expense), net in 2020, compared to unrealized gains in 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our income tax expense (benefit):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate increased in 2020, compared to 2019, primarily due to a $4.5 billion acquired IPR&amp;D charge recorded in connection with our acquisition of Forty Seven, $511 million of certain other acquired IPR&amp;D charges and $1.8 billion of unfavorable changes in the fair value of our equity investments in Galapagos that are non-deductible for tax purposes. The 2019 effective tax rate included a $1.2 billion discrete tax benefit related to intra-entity intangible asset transfers to different tax jurisdictions. </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_49"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash, cash equivalents, and marketable debt securities and working capital:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable debt securities as of December&#160;31, 2020, decreased by $17.9 billion, or 69%, compared to December&#160;31, 2019. During 2020, we generated $8.2 billion in operating cash flow, utilized $25.7 billion on acquisitions, including IPR&amp;D, net of cash acquired, issued senior unsecured notes in an aggregate principal amount of $7.2 billion, net of issuance costs, borrowed an aggregate principal amount of $1.0&#160;billion under a three-year term loan facility, repaid $2.5 billion of principal amount of debt, paid cash dividends of $3.4 billion and utilized $1.6 billion on repurchases of common stock. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to repay certain of our long-term debt obligations prior to their maturity dates based on our assessment of current and long-term liquidity and capital requirements. Our acquisition of MYR GmbH is expected to close in the first quarter of 2021. Per the agreement, we will make a consideration payment of approximately &#8364;1.2 billion in cash (or approximately $1.4 billion) upon closing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital, which is current assets less current liabilities, decreased by $15.9 billion, or 78%, compared to December&#160;31, 2019, primarily due to the utilization of significant cash, cash equivalents and marketable debt securities for our acquisitions of Immunomedics and Forty Seven as noted above and reclassifications of senior unsecured notes from Long-term debt, net. The decrease was partially offset by increased accounts receivables due to Veklury sales and the reclassification of a portion of our Galapagos equity investments from Other long-term assets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable increased by $1.3 billion, compared to December&#160;31, 2019, primarily reflecting increased sales driven by Veklury due to COVID-19 surge in the fourth quarter of 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities increased by $1.3 billion compared to December&#160;31, 2019, primarily due to a reclassification from long-term income taxes payable for certain tax payments expected to be made within a year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:20.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Cash provided by operating activities decreased by $976 million to $8.2 billion in 2020 compared to 2019. The decrease was primarily the result of changes in working capital reflecting increases in accounts receivable from the fourth quarter 2020 Veklury sales and certain tax payments made to taxing authorities.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in / provided by investing activities primarily consists of purchases, sales and maturities of our marketable debt securities, capital expenditures, acquisitions, including IPR&amp;D, net of cash acquired, purchases of equity securities and other investments.&#160;Cash used in investing activities was $14.6 billion in 2020 compared to $7.8 billion in 2019. The change in cash used in / provided by investing activities was due to $25.7 billion of payments made primarily related to our acquisitions of Immunomedics and Forty Seven in 2020, compared to $4.3 billion of payments made primarily related to our collaboration with and equity investments in Galapagos in 2019.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in cash provided by / used in financing activities in 2020 compared to 2019, was primarily due to $7.2 billion in proceeds from the September 2020 senior unsecured notes offering, net of issuance costs and $995 million borrowed under a three-year term loan facility, net of issuance costs in October 2020 in connection with our acquisition of Immunomedics.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary of our borrowings under various financing arrangements is included in Note 12. Debt and Credit Facilities of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K. We may choose to repay certain of our long-term debt obligations prior to maturity dates based on our assessment of current and long-term liquidity and capital requirements.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes Offering</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, in connection with our acquisition of Immunomedics, we issued senior unsecured notes consisting of (i) $500 million principal amount of floating rate notes due September 2021 and $500 million principal amount of floating rate notes due September 2023; and (ii) $2.0 billion principal amount of 0.75% senior notes due September 2023, $750 million principal amount of 1.20% senior notes due October 2027, $1.0 billion principal amount of 1.65% senior notes due October 2030, $1.0 billion principal amount of 2.60% senior notes due October 2040 and $1.5 billion principal amount of 2.80% senior notes due October 2050.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes Repayments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, we repaid at maturity $2.5 billion and $2.8 billion principal amount of senior unsecured notes, respectively. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term Loan Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, in connection with our acquisition of Immunomedics, we borrowed an aggregate principal amount of $1.0&#160;billion under a three-year term loan facility (&#8220;Term Loan Facility&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;). The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we terminated our $2.5 billion revolving credit facility maturing in May 2021 (the &#8220;2016 Revolving Credit Facility&#8221;) and entered into a new $2.5 billion revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;), which had terms substantially similar to the 2016 Revolving Credit Facility. The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2020 and 2019, there were no amounts outstanding under these revolving credit facilities. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with certain covenants under our notes indentures, and as of December&#160;31, 2020, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Return Program</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of our Stock Repurchase Programs and Dividends are included in Note 15. Stockholders&#8217; Equity of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;), under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchased 22 million and 26 million shares of our common stock under the 2016 Program for $1.6 billion and $1.7 billion in 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the&#160;2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the remaining authorized repurchase amount from both programs was $6.8 billion.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We declared and paid quarterly cash dividends for an aggregate amount of $3.4 billion or $2.72 per share of our common stock and $3.2 billion or $2.52 per share of our common stock in 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;4, 2021, we announced that our Board of Directors declared a quarterly cash dividend increase of 4.4% from $0.68 to $0.71 per share of our common stock, with a payment date of March&#160;30, 2021 to all stockholders of record as of the close of business on March&#160;15, 2021. Future dividends are subject to declaration by our Board of Directors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Resources</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing capital resources, supplemented by cash flows generated from our operations, will be adequate to satisfy our capital needs for the foreseeable future. Our future capital requirements will depend on many factors, including but not limited to the following:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the commercial performance of our current and future products;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the progress and scope of our R&amp;D efforts, including preclinical studies and clinical trials;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost, timing and outcome of regulatory reviews;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the expansion of our sales and marketing capabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of acquiring additional manufacturing capabilities or office facilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of acquiring other companies or new products;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">debt service requirements;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the establishment of additional collaborative relationships with other companies; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs associated with the defense, settlement and adverse results of government investigations and litigation.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future require additional funding, which could be in the form of proceeds from equity or debt financings. If such funding is required, we cannot guarantee that it will be available to us on favorable terms, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations is based on our Consolidated Financial Statements included in Item&#160;8 of this Annual Report on Form 10-K, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate and base our estimates on historical experience and on various other market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the following critical accounting policies reflect the more significant judgments and estimates used in the preparation of our Consolidated Financial Statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized, net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as GTN deductions, and are estimated and recorded in the period in which the related product sales occur. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks represent the majority of our GTN deductions and are subject to a complex estimation process, which requires significant judgment by management in part due to the lag between the date of the product sales and the date the related rebates or chargeback claims are settled. Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates of government and other rebates and chargebacks, we consider the following factors: </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historical and estimated payer mix;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">statutory discount requirements and contractual terms;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historical claims experience and processing time lags;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimated patient population;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">known market events or trends; </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market research;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">channel inventory data obtained from our major U.S. wholesalers; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other pertinent internal or external information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess and update our estimates every quarter to reflect actual claims and other current information. Our actual government and other rebates and chargebacks claimed for prior periods have varied from our estimates by less than 3% of the amounts deducted from product sales for the years ended December 31, 2020 and 2019. We believe the methodology that we use to estimate our government and other rebates and chargebacks is reasonable and appropriate given the current facts and circumstances. However, actual results may differ significantly from our estimates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are classified as reductions of Accounts receivable in our Consolidated Balance Sheets and totaled $552 million and $655 million at December&#160;31, 2020 and 2019, respectively. See Note 10. Other Financial Information of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. Government and other rebates that are payable to third party payers and healthcare providers are generally recorded in Accrued government and other rebates on our Consolidated Balance Sheets and totaled $3.5 billion at December&#160;31, 2020 and 2019. The allowance for sales returns is generally recorded in Other accrued liabilities on our Consolidated Balance Sheets and totaled $587&#160;million and $137&#160;million at December&#160;31, 2020 and 2019, respectively. The increase in the allowance for sales returns in 2020 reflects the estimated Veklury sales returns and an increase of HCV and HIV sales return provisions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consolidated activities and ending balances in our government and other rebates and chargebacks accounts:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease/(Increase) to Product Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2020:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2020 sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to sales prior to 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,060)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2019:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2019 sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to sales prior to 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,512&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,824)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions and Valuation of Intangibles</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs associated with the acquired set of activities. If the assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which requires that assets acquired and liabilities assumed generally be recorded at their fair values as of the acquisition date. Excess of consideration over the fair value of net assets acquired is recorded as goodwill. Estimating fair value requires us to make significant judgments and assumptions. We perform impairment testing of goodwill annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions accounted for as acquisitions of assets, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date are expensed unless there is an alternative future use. In addition, product development milestones are expensed upon achievement. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have acquired, and expect to continue to acquire, intangible assets through asset acquisition, business combination or consolidation of variable interest entities. The identifiable intangible assets are measured at their respective fair values as of the acquisition date. Intangible assets acquired through business combinations are subject to potential adjustments within the measurement period, which is up to one year from the acquisition date. The fair values of the intangible assets are generally determined using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows are discounted using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets require the use of significant estimates and assumptions including but not limited to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of product candidates with sufficient substance requiring separate recognition;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of projected future cash flows including revenues and operating profits related to the products or product candidates;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the probability of technical and regulatory success for unapproved product candidates considering their stages of development;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and resources needed to complete the development and approval of product candidates;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate discount rate;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the life of the potential commercialized products and associated risks, including the inherent difficulties and uncertainties in developing a product candidate such as obtaining FDA and other regulatory approvals; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the viability of and potential alternative treatments in any future target markets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the fair values used to record intangible assets acquired are based upon reasonable estimates and assumptions given the facts and circumstances as of the related valuation dates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment and Amortization of Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects acquired in a business combination are capitalized as indefinite-lived intangible assets until the completion or abandonment of the associated R&amp;D efforts. During the period the assets are considered indefinite-lived, they are not amortized. When development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and then be amortized based on their respective estimated useful lives at that point in time primarily on a straight-line basis. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Estimates of fair value result from a complex series of judgments about future events and uncertainties and make assumptions at a point in time (acquisition date or subsequent impairment assessment date). Changes in estimates and assumptions, including the timing of product launch, pricing reductions, failure to obtain anticipated regulatory approval, deterioration in U.S. and global financial markets or other unanticipated events and circumstances, may decrease the projected cash flows or increase the discount rate and could potentially result in an impairment charge.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The eventual realized value of the acquired IPR&amp;D project may vary from its fair value at the date of acquisition. If the carrying value of an intangible asset exceeds its estimated fair value, an impairment charge is recorded to write down the intangible asset to its estimated fair value. For example, in 2019, we recognized an $800 million impairment charge related to IPR&amp;D projects primarily for the treatment of indolent non-Hodgkin lymphoma due to changes in estimated market opportunities. A high rate of failure is inherent in the discovery and development of new products. For example, in 2018, we concluded that the KITE-585 program acquired in connection with our acquisition of Kite did not justify further efforts based on the totality of the clinical data gathered and discontinued the program. As a result, the carrying value of the IPR&amp;D relating to the KITE-585 program was written down to zero and we recorded an impairment charge of $820 million.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9. Goodwill and Intangible Assets of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information on the impairment charges related to our indefinite-lived IPR&amp;D intangible assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described in Note 14. Commitments and Contingencies - Legal Proceedings of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K. It is not possible to determine the outcome of these matters. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of the inherent uncertainty and unpredictability related to these matters, accruals are based on what we believe to be the best information available at the time of our assessment, including the legal facts and circumstances of the case, status of the proceedings, applicable law and the views of legal counsel. Upon the final resolution of such matters, it is possible that there may be a loss in excess of the amount recorded, and such amounts could have a material adverse effect on our results of operations, cash flows or financial position. We periodically reassess these matters when additional information becomes available and adjust our estimates and assumptions when facts and circumstances indicate the need for any changes. We did not have any material accruals in our Consolidated Balance Sheets for such matters as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our income tax provision, including deferred tax assets and liabilities, based on significant management judgment. We evaluate the realization of all or a portion of our deferred tax assets on a quarterly basis. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the United States and various foreign jurisdictions including Ireland. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws. For example, the United States enacted significant tax reform, and certain provisions of the new law will continue to significantly affect us. We cannot predict the form or timing of potential legislative changes that could have a material adverse impact on our results of operations. In addition, significant judgment is required in determining our worldwide provision for income taxes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18. Income Taxes of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_58"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations represent future cash commitments related to significant enforceable and legally binding obligations and certain purchase obligations that we are likely to continue regardless of the fact that they may be cancelable. The expected timing and payment amounts presented below are estimated based on existing contracts and do not reflect any future modifications to, or terminations of, existing contracts or anticipated or potential new contracts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate maturities of our contractual obligations as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022-2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024-2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transition tax payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,606&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Debt includes principal and future interest payments of senior unsecured notes and the Term Loan Facility. Interest payments for our fixed rate senior unsecured notes are incurred and calculated based on terms of the related notes. Debt also includes a liability related to future royalty obligations we assumed through the acquisition of Immunomedics. See Note 6. Acquisitions and Note 12. Debt and Credit Facilities&#160;of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See Note 13. Leases of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts primarily relate to active pharmaceutical ingredients (&#8220;API&#8221;) with minimum purchase commitments and certain inventory-related items, R&amp;D commitments and capital commitments. Significant R&amp;D commitments related to clinical studies performed by contract research organizations (&#8220;CRO&#8221;s) are excluded from the table as material CRO contracts are cancelable by us.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with Tax Reform we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. The amounts included in the table above represent the remaining federal income tax payable at December 31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of&#160;December 31, 2020, our long-term income taxes payable includes unrecognized tax benefits, interest and penalties totaling $1.1 billion. Due to the high degree of uncertainty on the timing of future cash settlement and other events that could extinguish these unrecognized tax benefits, we are unable to estimate the period of cash settlement and therefore we have excluded these unrecognized tax benefits from the table above. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have committed to make potential future&#160;milestone&#160;and other&#160;payments to&#160;third parties as part of licensing, collaboration, development&#160;and other&#160;arrangements. Payments under these agreements generally&#160;are contingent upon certain future events including&#160;achievement of certain developmental, regulatory or commercial milestones. Because the achievement of these events is neither probable nor reasonably estimable and&#160;such potential payments have not been recorded in our Consolidated Balance Sheets, they have not been included in the table above. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The consideration payment of approximately &#8364;1.2 billion in cash (or approximately $1.4 billion) for our acquisition of MYR GmbH, which is expected to close by the end of the first quarter of 2021, is excluded from the table above. See Note 6. Acquisitions of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is included in Note 1. Organization and Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_64"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in foreign currency exchange rates, interest rates, credit risks and market price. To reduce certain of these risks, we enter into various types of foreign currency or interest rate derivative hedging transactions, follow investment guidelines and monitor outstanding receivables as part of our risk management program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in more than 35 countries worldwide. As a result, our financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which we distribute our products. Our operating results are exposed to changes in foreign currency exchange rates between the U.S. dollar and various foreign currencies, the most significant of which is the Euro. When the U.S. dollar strengthens against these currencies, the relative value of sales made in the respective foreign currency decreases. Conversely, when the U.S. dollar weakens against these currencies, the relative amounts of such sales increase. Overall, we are a net receiver of foreign currencies and, therefore, benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar relative to those foreign currencies in which we transact significant amounts of business. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 26% of our product sales were denominated in foreign currencies during 2020. To partially mitigate the impact of changes in currency exchange rates on net cash flows from our foreign currency denominated sales, we may enter into foreign currency exchange forward and option contracts. We also hedge certain monetary assets and liabilities denominated in foreign currencies, which reduces but does not eliminate our exposure to currency fluctuations between the date a transaction is recorded and the date that cash is collected or paid. In general, the market risks of these contracts are offset by corresponding gains and losses on the transactions being hedged. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we had open foreign currency forward contracts with notional amounts of $2.4 billion and $2.9 billion, respectively. A hypothetical 10% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates at December&#160;31, 2020 and 2019 would have resulted in a reduction in fair value of these contracts of approximately $249 million and $285 million, respectively, on this date and, if realized, would negatively affect earnings over the remaining life of the contracts. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign currency sensitive instruments were designed to offset.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of available-for-sale debt securities and our senior unsecured notes create an exposure to interest rate risk. With respect to our investment portfolio, we adhere to an investment policy that requires us to limit amounts invested in securities based on credit rating, maturity, industry group and investment type and issuer, except for securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> safety and preservation of principal and diversification of risk; </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> liquidity of investments sufficient to meet cash flow requirements; and </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> competitive after-tax rate of return. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the expected maturities and average interest rates of our interest-generating assets and interest-bearing liabilities at December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.515%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;Total Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior unsecured fixed rate notes, including current portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior unsecured floating rate notes and term loan, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts represent principal balances. In addition to the senior unsecured fixed rate notes, we have a $2.5 billion five-year revolving credit facility that matures in June 2025. There were no amounts outstanding under the five-year revolving credit facility as of December 31, 2020. See Note 12. Debt and Credit Facilities of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Price Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold shares of common stock of certain publicly traded biotechnology companies primarily in connection with license and collaboration agreements. These equity securities are measured at fair value with any changes in fair value recognized in earnings. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of these equity securities was approximately $2.4 billion and $3.8 billion as of December&#160;31, 2020 and 2019, respectively. Changes in fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. A hypothetical 20% increase or decrease in the stock prices of these equity securities would increase or decrease their fair value at December&#160;31, 2020 and 2019 by approximately $478 million and $760 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_70"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2020, 2019 and 2018 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_73">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_73">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_76">Audited Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_79">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_79">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_85">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_85">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_88">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_88">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_94">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_94">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_100">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_100">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_103">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_103">60</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Gilead Sciences, Inc.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Gilead Sciences, Inc. (the Company) as of December&#160;31, 2020 and 2019, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;25, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:4.5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government and commercial rebates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully described in Note 1, the Company estimates reductions to its revenues for amounts payable to payers and healthcare providers in the United States under various government and commercial rebate programs in the period that the related sales occur. Rebates may vary by product, payer and individual payer plans, which may not be known at the point of sale. Estimated reductions to revenue are based on product sales, historical and expected payer mix, discount rates, and various other estimated and actual data, adjusted for current period expectations.</span></div><div style="margin-bottom:12pt;margin-top:4.5pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s estimated reductions to revenue for rebates was complex and involved significant judgment, particularly in assessing the reasonableness of estimated payer mix applied to sales during the period. This estimate relies heavily on historical data that is adjusted for changes in payer mix expectations over time.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over management&#8217;s estimation and review of reductions from revenue for rebate programs, including controls to assess the payer mix assumption. We also tested the completeness and accuracy of data utilized in the controls, and the accuracy of calculations supporting management&#8217;s estimates.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimation methodology for determining the payer mix, our audit procedures included, among others, evaluating evidence contrary to the estimated amounts, performing a sensitivity analysis on the rates used in the estimates and performing a comparison of actual payments related to amounts accrued during the current and prior years.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Valuation of in-process research and development intangible assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company&#8217;s in-process research and development (&#8220;IPR&amp;D&#8221;) intangible assets from acquisitions prior to 2020 were $1.1 billion. As discussed in Note 1, intangible assets with indefinite useful lives related to purchased IPR&amp;D projects are measured at their respective fair values as of the acquisition date and are considered indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. The Company tests indefinite-lived intangible assets for impairment on an annual basis and in between annual tests if they become aware of any events or changes that would indicate the fair values of the assets are below their carrying amounts.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the impairment test was complex due to the significant judgment required in estimating the fair values of the IPR&amp;D intangible assets. In particular, the fair value estimates required the use of valuation methodologies that were sensitive to significant assumptions (e.g., discount rate, projected research and development costs, probability of technical success, addressable patient population, projected market share and product profitability), which were affected by expected future market or economic conditions. </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over the determination of the estimated fair value of the IPR&amp;D intangible assets. For example, we tested controls over management's review of the valuation methodologies and the significant assumptions used to develop the fair value estimates. We also tested management's controls to validate that the data used in the fair value estimates were complete and accurate. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the Company&#8217;s IPR&amp;D intangible assets, our audit procedures, among others, included evaluating the Company&#8217;s use of appropriate valuation methodologies with the assistance of a valuation specialist, performing sensitivity analyses to determine which assumptions had the greatest impact on the overall determination of value, and testing the completeness and accuracy of the underlying data. Our audit procedures over the most significant assumptions included comparing the assumptions to current industry, market and economic trends, to historical results of the Company&#8217;s business and other guideline companies within the same industry and to other relevant factors. For example, to evaluate the probability of technical success, we considered the phase of development of the IPR&amp;D projects, and the Company's history of obtaining regulatory approval. </span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Valuation of intangible assets acquired in a business combination</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 6, on October 23, 2020, the Company completed its acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;) for $20.6 billion in cash consideration. The transaction was accounted for as a business combination using the acquisition method of accounting. The acquisition date fair values of acquired finite-lived intangible assets, comprised of commercial product rights, and indefinite-lived intangible assets, comprised of IPR&amp;D intangible assets, was estimated to be $4.6 billion and $15.8 billion, respectively, using a probability-weighted income approach that discounts expected future cash flows to present value. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the acquisition date fair values of the intangible assets acquired from Immunomedics was complex due to the significant judgment required in estimating the fair values of each asset. In particular, the fair value estimates required the use of valuation methodologies that were sensitive to significant assumptions (e.g., discount rate, projected research and development costs, probability of technical success, addressable patient population, treatment duration, projected market share and product profitability), which were affected by expected future market or economic conditions. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over the determination of the estimated fair value of the intangible assets. For example, we tested controls over management's review of the valuation methodologies and the significant assumptions used to develop the fair value estimates of the intangible assets. We also tested management's controls to validate that the data used in the fair value estimates were complete and accurate. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of the Company's intangible assets acquired from Immunomedics, our audit procedures, among others, included evaluating the Company's use of appropriate valuation methodologies with the assistance of a valuation specialist, performing sensitivity analyses to determine which assumptions had the greatest impact on the overall determination of value and testing the completeness and accuracy of the underlying data used to develop the assumptions. Our audit procedures over the significant assumptions included comparing the most significant assumptions to current industry, market and economic trends, to historical results of the Company's business and other guideline companies within the same industry and to other relevant factors. For example, we evaluated the probability of technical success by considering the phase of development of the clinical projects, and the Company's history of obtaining regulatory approval. In addition, we evaluated the expected addressable patient populations by comparing the Company&#8217;s estimates to external industry forecasts.</span></div></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1988.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNC0xLTEtMS0w_028f1eda-bf40-4fc4-8b9b-5b433ad33259">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNC0zLTEtMS0w_0e32991b-20d2-4555-94fc-58a9f5014ca7">11,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNS0xLTEtMS0w_6650ca7c-9280-498b-a30c-a9c184dbefb9">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNS0zLTEtMS0w_b14471f4-cacb-4ff9-a5fb-6a8aedf9c39a">12,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNi0xLTEtMS0w_b5bf9d16-aec8-4de1-91d0-5f3ec0ba4374">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNi0zLTEtMS0w_5bd0a820-38f0-42b1-9d95-cee1bdc48a68">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNy0xLTEtMS0w_7c105b41-e882-445d-9574-53328bbcb0e2">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNy0zLTEtMS0w_9cdbeda2-9c1b-4a48-8e3e-b05f46184547">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOC0xLTEtMS0w_5255fd4e-f592-483b-bb9d-432e172534d2">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOC0zLTEtMS0w_24b5bda5-d2a4-4aff-89c2-78d105c899d5">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOS0xLTEtMS0w_399b7759-a4de-4079-bd02-291fa5932b06">15,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOS0zLTEtMS0w_720660a1-c7e1-44c2-b92f-a75d64361ec9">30,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTAtMS0xLTEtMA_36e72c8f-e635-47ca-b9b5-e629af4045bd">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTAtMy0xLTEtMA_d9f7377f-bfed-480e-a4cf-42af0a224686">4,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTEtMS0xLTEtMA_d1f9dbe6-0943-45e3-8aec-22c8ba76ad62">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTEtMy0xLTEtMA_2c479097-e33e-4367-8a89-aaaa9d86a374">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTItMS0xLTEtMA_2afc35c8-696d-4f51-a48a-17f2a7ed4236">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTItMy0xLTEtMA_92567c06-9363-4d97-a194-aa303da1f6d1">13,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTMtMS0xLTEtMA_d69c9561-4fbd-4a19-97c0-b671ec46c7a9">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTMtMy0xLTEtMA_a53d41c6-d6ee-44df-bb8d-160051da533d">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTQtMS0xLTEtMA_a4e77731-ab4e-49fe-9de9-ac4c703e6125">5,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTQtMy0xLTEtMA_485515c4-af28-49ea-8a09-24b58ca1d6ea">7,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTUtMS0xLTEtMA_259a38ac-b9aa-4553-ada0-8b78fcfff9bf">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTUtMy0xLTEtMA_6625c65a-97b1-4f0d-b775-371395d9c38a">61,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTgtMS0xLTEtMA_22f93ecf-aa8a-47df-90ad-123d7b67c5ac">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTgtMy0xLTEtMA_f7b4776f-0ca0-482a-a02b-7a59ac77b923">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued government and other rebates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:Accruedgovernmentandotherrebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTktMS0xLTEtMA_37339287-8e11-4885-a240-adb2ef64ddd8">3,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:Accruedgovernmentandotherrebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTktMy0xLTEtMA_e0d57f80-42d1-4ca4-b490-4da38c8dac56">3,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjAtMS0xLTEtMA_a3b6f10d-3823-4ff9-87db-dcfaf6a65b66">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjAtMy0xLTEtMA_e755bc45-ad92-4809-a038-d1d2f09b5fff">3,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjEtMS0xLTEtMA_c2e29151-25a3-4276-8b85-83c231df3ae7">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjEtMy0xLTEtMA_ac99cd76-a32d-47f7-91bc-227c8b28484f">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjItMS0xLTEtMA_eb6037bb-141f-44b0-b95c-a073e570806e">11,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjItMy0xLTEtMA_0685dff4-4217-4b68-ae6e-d75070d8d173">9,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjMtMS0xLTEtMA_882f40eb-a127-47fd-84ff-8701810dd639">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjMtMy0xLTEtMA_aea6fd42-7962-47b5-86a5-0618b59da5d4">22,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjQtMS0xLTEtMA_122596b0-0bcc-4b02-9da5-eb3732eb037b">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjQtMy0xLTEtMA_66410e62-53f4-4e83-a7f5-85d1dd0441b3">6,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjUtMS0xLTEtMA_66449bbf-f88e-4345-a3ca-510a7613ef90">5,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjUtMy0xLTEtMA_1eb237c4-edc9-4377-b7d7-0d5aebae4265">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjYtMS0xLTEtMA_16c8390a-16b6-455b-97bd-0356645bd695"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjYtMy0xLTEtMA_44bff6f0-ed21-46d1-88c5-09fddf93f472"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc4Njk_6667fac0-1a47-4fd6-8dae-7571ab568fc2"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc4Njk_d06f7966-efa7-4376-b4b7-89ca5fce0bf2">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTE_eae52c01-6823-4235-a18c-82961f44a59c"><ix:nonFraction unitRef="shares" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTE_f2ed3f04-2ee5-477e-8f30-0f481e912f21">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTg_b72e9655-c82c-429e-8f33-6584e96028cd"><ix:nonFraction unitRef="shares" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTg_b916ca6a-6e46-4750-bf31-fdd0c45c48e5">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMS0xLTEtMA_bed57806-75a0-4c6b-9e3d-2e1c7c295951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMy0xLTEtMA_c9226f11-4912-4ce6-94a1-5b2a44b6aca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MTU_5587c431-00c5-4629-b6b1-c55991f0e4e1"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MTU_66e8c7f7-6d8f-44d7-9545-ca256c3d8f77">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MzM_0a9ea8d0-ce60-4fc9-9399-d5efb6bf9223"><ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MzM_2b47cd6b-274a-41b9-9bab-697c33fe1ccb">5,600</ix:nonFraction></ix:nonFraction> authorized; <ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4Mzg_1fb0dfad-9d6a-481e-9bda-2110fa7f800a"><ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4Mzg_58a5842f-c628-4478-8f53-9f4d30335755">1,254</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4NDY_caf1b514-7623-40bb-8cb4-a1d880280af8"><ix:nonFraction unitRef="shares" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4NDY_dee3b335-ee1e-4dcc-984c-08b7498c0b8d">1,266</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMS0xLTEtMA_83dc5dfa-fa0b-4b37-8ff4-d6f2465a4f26">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMy0xLTEtMA_ea240297-58d6-48b3-82c6-4cebb2ab0c3b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzAtMS0xLTEtMA_c4438fbe-5513-4100-bfa3-9d7936c4dbf2">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzAtMy0xLTEtMA_f6909c23-7c93-4280-a43e-7b55a43046d2">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzEtMS0xLTEtMA_c6b9a2ae-0a6a-4906-9446-c94dbcbf0a04">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzEtMy0xLTEtMA_c26879c9-edb7-44be-b073-00963c74f91e">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzItMS0xLTEtMA_3e9cfa5b-e8c6-4054-9e5b-90e9b54cc464">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzItMy0xLTEtMA_3d7ed5c3-94c6-4588-8377-cb3f57e7cac3">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzMtMS0xLTEtMA_0d72fd04-39d9-4b74-91e7-fcbafc761eda">18,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzMtMy0xLTEtMA_1e584330-e833-48ef-a8d8-524f8b7f7b4a">22,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzQtMS0xLTEtMA_266b836e-0475-4f50-b1a4-3c4f445fd2aa">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzQtMy0xLTEtMA_ef94cd3c-ce53-475b-bdff-a492059544b2">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzUtMS0xLTEtMA_6b93ecaa-7a83-49f6-9b0a-f91c824cdf14">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzUtMy0xLTEtMA_2e2c9ec7-4eaa-4ebf-8e57-e59e8eb62864">22,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzYtMS0xLTEtMA_2ab441b1-0278-44c2-9d55-ea259d4fc38f">68,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzYtMy0xLTEtMA_31d76e0a-baf6-4f00-be34-d59154e74ef1">61,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85124ea043f44d21b8b54a8de5bdf919_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMy0yLTEtMS0w_bf1cdd2d-6c04-4936-b54e-e84b8565c07d">24,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1854fd7993394c05bb3e013f00d725cb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMy00LTEtMS0w_cc529563-a003-4234-86fc-ca5e2fdf08ba">22,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c26f4bd16b4406da90ed77b81c4e690_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMy02LTEtMS0w_ea2a3b52-8ec6-4457-bf11-a1f9c37e8fa9">21,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id688d136833640ac9c6d94d4ddc9632a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNC0yLTEtMS0w_9aa9140f-e895-4c7b-8b18-5e9862f48bc3">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8670361a0047c5abdca258af5b3b44_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNC00LTEtMS0w_87fd81ba-6dc8-4dc2-bf4b-a0af51bb2c2e">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0d2f065cd0476e9fe09cf97a3daa95_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNC02LTEtMS0w_36856f63-34bb-4f70-8887-d71abd903f74">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNS0yLTEtMS0w_e55d29a6-f11c-4d37-9b07-b54efb58cc52">24,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNS00LTEtMS0w_4a57d4b3-9cc8-4368-8429-8841c509c025">22,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNS02LTEtMS0w_9ffbb873-c3e6-4b64-b2f3-75e4ae68fd61">22,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNy0yLTEtMS0w_c9dfae79-8394-4a65-a0de-35360fff195d">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNy00LTEtMS0w_1ae36cc4-e041-4fcb-9663-2ef21ffb4902">4,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNy02LTEtMS0w_4db1a570-b91d-4a39-9032-4d59e788e098">4,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOC0yLTEtMS0w_01eec112-8756-4aa7-b2db-7f516a77c131">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOC00LTEtMS0w_22f32163-0c74-4728-ba94-aa9f5ed56e75">4,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOC02LTEtMS0w_fc9b73e3-e0e5-4e48-a6e5-7b1c80478fdf">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:ResearchAndDevelopmentInProcessIncludingImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS0yLTEtMS0yODEw_a9516ea6-f07d-4edd-858d-c326fedf7c48">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:ResearchAndDevelopmentInProcessIncludingImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS00LTEtMS0yODEw_1d4a7ded-8f45-472a-bca4-52c5fb2f024e">5,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="gild:ResearchAndDevelopmentInProcessIncludingImpairment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS02LTEtMS0yODEw_17afaf3e-0e9f-47fe-8c3f-8012c1217a4f">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS0yLTEtMS0w_c9547426-de9a-4e59-970d-f53f29db308e">5,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS00LTEtMS0w_0c5826ec-4362-43f6-be79-4ded1ff5af1e">4,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS02LTEtMS0w_7df8a041-187a-4d1a-8b4b-ad9759f61055">4,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTAtMi0xLTEtMA_282ae9b9-ed98-4bc7-a93b-36dd78fa0991">20,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTAtNC0xLTEtMA_8533cc95-3556-4484-8f26-1d3aaf73fed0">18,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTAtNi0xLTEtMA_676b07cf-1088-4c5d-aa04-7548f2227eed">13,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTEtMi0xLTEtMA_35b4fa7e-bf87-486d-a8e6-997cc726303a">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTEtNC0xLTEtMA_50ad79b0-0666-46f7-afcf-28c1a8882f8b">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTEtNi0xLTEtMA_68bafbbc-4cef-4112-9865-4cbc87585750">8,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTItMi0xLTEtMA_f5dd9c79-eae4-401f-b841-258ffc6845e0">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTItNC0xLTEtMA_6144e580-5f10-486b-9501-cf92815d1cd2">995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTItNi0xLTEtMA_4f822c26-57d9-40db-8a3c-b763131acc92">1,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTMtMi0xLTEtMA_e3c84094-a8a8-4169-8a8a-3b7a4d36109f">1,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTMtNC0xLTEtMA_4c015e98-84bf-4fd8-a228-8750ab2245c8">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTMtNi0xLTEtMA_799baed5-7fd5-41af-9b7b-52ff9075c11e">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTQtMi0xLTEtMA_9c513f54-8ae3-4e87-b0e0-ed69f08e8213">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTQtNC0xLTEtMA_c3cb1366-23ca-4c93-81f9-85bad92e16eb">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTQtNi0xLTEtMA_69bec4c7-1f64-4b83-aa0f-d59d1ee70813">7,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTUtMi0xLTEtMA_066288b9-af94-4c38-b6c4-b821012269e0">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTUtNC0xLTEtMA_4e5a9856-395c-4c9f-b60d-2a4a16c23e58">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTUtNi0xLTEtMA_cb68f8b2-35f5-4653-8ff2-8ed10244957d">2,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTYtMi0xLTEtMA_d3b20e9f-817f-4dfe-9cca-af6f287e40a3">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTYtNC0xLTEtMA_657c7bb9-035a-487a-a2e5-cbf5f296e535">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTYtNi0xLTEtMA_bab184d8-25c8-4724-b089-4dd18c652b02">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTctMi0xLTEtMA_45d5844b-8579-4319-9278-bd2768e8ed4a">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTctNC0xLTEtMA_fe35d2a6-8975-4e0d-8733-7b29ac2ec05c">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTctNi0xLTEtMA_e2899c5a-ef3f-46fd-b6de-d01a15d1968c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTgtMi0xLTEtMA_c46efd6b-8e9f-41de-bee2-216161b5d925">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTgtNC0xLTEtMA_fcde1c31-3ed6-4668-979c-512f73c1ae73">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTgtNi0xLTEtMA_4052b884-9aa5-45e1-ba0e-fdf3d71b01e0">5,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTktMi0xLTEtMA_6a3db572-386c-4231-b8b3-b3b0351d3567">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTktNC0xLTEtMA_1eb20a22-2260-49f6-afbb-d5c6004eb201">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTktNi0xLTEtMA_a0d0b0d9-c4eb-47dd-a6cd-87a9745bea93">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjAtMi0xLTEtMA_fcec0690-ed87-44f1-b673-4a50221bc2a4">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjAtNC0xLTEtMA_95b43e39-7e25-4659-8f3e-0cf7c7f921e0">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjAtNi0xLTEtMA_e4eddad7-cbfc-414b-80f7-83086cc39cff">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjEtMi0xLTEtMA_2e59c578-2e2b-4c3f-a20d-12a6dc11d78a">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjEtNC0xLTEtMA_a1181978-2403-4fc5-84d6-cac0f0285eb7">4.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjEtNi0xLTEtMA_032a4a55-478f-4dff-9e78-885f6cbecb49">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjItMi0xLTEtMA_59a22b3c-0ba9-47ff-8a30-18e1594bf181">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjItNC0xLTEtMA_45acfb25-7ca7-4821-ae8b-63d0974bec38">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjItNi0xLTEtMA_db1858b3-be01-40a4-967d-0a6627c9cb31">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMi0yLTEtMS0w_d3b20e9f-817f-4dfe-9cca-af6f287e40a3">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMi00LTEtMS0w_657c7bb9-035a-487a-a2e5-cbf5f296e535">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMi02LTEtMS0w_bab184d8-25c8-4724-b089-4dd18c652b02">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation gain (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNC0yLTEtMS0w_fb37cc92-394b-42a6-b50f-60fcb49e5cd5">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNC00LTEtMS0w_03a85dee-6a2a-49f5-9c41-d1b3896f3a56">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNC02LTEtMS0w_aadc8fc3-f01d-4ba5-9b7c-58958ef38ff8">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain, net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNi0yLTEtMS0w_eea44bb1-6f25-4268-b490-2fc86ad21171">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNi00LTEtMS0w_e49e8a0d-afee-4ffe-8828-fafe96870049">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNi02LTEtMS0w_defac6f2-a632-44f5-b3c6-cc30be7d0f16">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNy0yLTEtMS0w_93f3a898-7116-4b3e-89cd-e26fa6698970">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNy00LTEtMS0w_8440872d-7cce-440c-95af-90a0ad4660df">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNy02LTEtMS0w_39deb842-26bd-4e6f-b593-397ecd5c0cb6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfOC0yLTEtMS0w_9730cc45-fe69-4a36-99e4-5e6d8834b257">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfOC00LTEtMS0w_df9b545d-1e97-4af1-95df-26858b231c0a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfOC02LTEtMS0w_4162f58f-e6c7-4402-9ac1-9b79a992a3be">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTAtMi0xLTEtMA_0e82571a-5a04-4112-891c-168332cdd5f4">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTAtNC0xLTEtMA_5d9286a3-6090-44a9-9558-67213506699b">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTAtNi0xLTEtMA_32f8bf52-c890-409c-99dd-cac33ea0f6d9">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to net income, net of tax </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTEtMi0xLTEtMA_693dd512-7f4a-4506-888a-b81e57076aa8">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTEtNC0xLTEtMA_3fff6632-cdfa-4464-a1bc-bda47e2df707">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTEtNi0xLTEtMA_42b79a87-2221-4b94-a446-557b26849bde">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTItMi0xLTEtMA_727718ae-0b9b-42a5-af33-f141eed7dffd">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTItNC0xLTEtMA_7a74234d-0fc3-4664-9ccb-bb39a336ca1e">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTItNi0xLTEtMA_2e38828d-ada5-4824-aee9-7ed41c40f88b">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTMtMi0xLTEtMA_517944cd-c89b-4d4f-8259-11b8a5b6efe3">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTMtNC0xLTEtMA_f7fd6627-6fbe-486b-9d19-55f80e27ebd4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTMtNi0xLTEtMA_2a69cc08-fdc6-43e4-a8d1-6876f3c005b9">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTQtMi0xLTEtMA_59dcc39c-36e2-429c-a7c6-6b782465cf98">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTQtNC0xLTEtMA_995a027b-b738-4e36-a397-9a4061920b69">5,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTQtNi0xLTEtMA_383e7190-3456-4e51-9a06-076d0a529165">5,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTUtMi0xLTEtMA_4da5bbbc-7690-402d-8256-91b4724d3195">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTUtNC0xLTEtMA_db8a2d2e-ffe0-4b53-9ce5-9ed1b21be69d">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTUtNi0xLTEtMA_441b18d9-95cc-42a4-a708-65ba11222600">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTYtMi0xLTEtMA_cb1e081c-1d3b-46a9-9f2b-41d1cbc0e8b3">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTYtNC0xLTEtMA_a557b89a-2621-43e8-acd9-a465233a9c26">5,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTYtNi0xLTEtMA_fe12cb7b-6e79-4804-a2c7-2530dab89d4c">5,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions, except per share amounts)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMi0xLTEtMA_1654a1f8-c1c3-4030-a255-350f845a0e5c">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItNC0xLTEtMA_2dabce6f-f2aa-40a9-b241-bd49a9206fb4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835488bd375d4a09af99788bd9e27362_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItNi0xLTEtMA_fde60e22-1401-46a2-8256-5c52cf25691d">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6356b044964174974ec7dc3f4bbd36_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItOC0xLTEtMA_13ce52e2-3b28-408d-ac83-fdaee1e39748">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e30e15c134641879f2e452fd14665e2_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMTAtMS0xLTA_b32690d9-c6ea-43c6-9f53-ce50b53738df">19,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5c937c29a64935bd5513af5cd17eb8_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMTItMS0xLTA_f827977c-43e6-49a4-b6ad-09f5e01b3f49">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3219b6982b334ae49d4a68c7befc5d27_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMTQtMS0xLTA_b799f581-c34a-4fa6-8952-29dbde4641a6">20,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ad04f35896042aeb313604ac52c806c_I20180101" decimals="-6" sign="-" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfNC04LTEtMS0xODkwNw_3c2f3e8a-b30b-458b-ac6d-0ec60a2a2882">293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f63899ea2f45c8b3d163ffca4733cc_I20180101" decimals="-6" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfNC0xMC0xLTEtMTg5MDc_d4f316ec-7491-4bad-8fb2-f4821d13c247">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2747bd2827c1444bb8598c30d980ccac_I20180101" decimals="-6" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfNC0xNC0xLTEtMTg5MDk_effefcb5-4fff-4cc3-a0fc-93295bbd927b">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTMtNi0xLTEtMA_097f5188-376c-46a3-baae-eea968098fff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c9515f11a04c63b1fc167cf59c9e73_D20180101-20181231" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTMtMTItMS0xLTA_a16d53db-3e20-42fa-83d1-6d45328cd4d9">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTMtMTQtMS0xLTA_017c86d9-6357-4d7a-b791-a39a35a63de5">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTAtMS0xLTA_53425d50-7438-4807-afc6-36cdfaa0ed82">5,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c9515f11a04c63b1fc167cf59c9e73_D20180101-20181231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTItMS0xLTA_6eca3bf4-82a7-44a5-a00d-aa909dee3d52">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTQtMS0xLTA_2ec54a27-dc37-4adf-a713-6314e7240b17">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTUtOC0xLTEtMA_983a5fd9-36c7-4567-8116-d34429cd0ee8">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTUtMTQtMS0xLTA_d7d9972d-d89e-4fa6-bc6a-4dd9be45c879">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTYtMi0xLTEtMA_2604bdb8-2b12-44a5-a350-168525a71e50">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTYtNi0xLTEtMA_fe0fd69f-0c07-4d5d-8c71-62d00c1aa1e5">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTYtMTQtMS0xLTA_002675b0-6883-45b7-8daf-a306ed1c004b">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTctMi0xLTEtMA_d9f695aa-6274-43b6-9f67-0c4d3824efc4">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTctNi0xLTEtMA_1ee22f44-ab5c-4bcf-bcf7-772f14e35684">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTctMTQtMS0xLTA_01bfa4d6-1998-4efd-bb24-7cd9b1fca54f">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTgtNi0xLTEtMA_5446afc7-57bf-4ba3-85ba-f0d59ab264ef">842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTgtMTQtMS0xLTA_62212bac-d9af-440f-a66b-804552fc3aef">842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktMi0xLTEtMA_0ee4cfca-2dd3-4dbb-96f3-fce248e7732e">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktNi0xLTEtMA_8729ae01-6c11-434b-9f9f-d24a93cd994c">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktMTAtMS0xLTA_c8b4a9a1-6c0e-4576-99ff-e523272cae65">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktMTQtMS0xLTA_f28fdcec-6320-460b-acd9-646b9d7c3b56">3,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMDQzMmJhYThkNzRjNzg5ZTYwOWE5OGI2NGJkYjUwXzEwOTk1MTE2Mjc4MjE_b9964440-0f1b-4fec-936f-4dc106015a3e">2.28</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjAtMTAtMS0xLTA_e080565e-e414-4a10-89f6-9c6dbf91ac00">2,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjAtMTQtMS0xLTA_ea2a3b0b-0cc2-468e-a629-8703601c52c5">2,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93892be161ed46f0b59daf9d2cb4f947_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMi0xLTEtMA_6865d6c2-7881-4b74-977c-7c85978ac127">1,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93892be161ed46f0b59daf9d2cb4f947_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItNC0xLTEtMA_c9b7f36d-0f70-44d5-89bf-9be84f15e5fe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5da7a2ef9a64a11a7b170d14e808fd2_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItNi0xLTEtMA_3f5686b8-6ab9-4a3e-86bf-e31f1c5a1c5e">2,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54dde75a77af4f3b89a86ac2a4228e70_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItOC0xLTEtMA_bf00e0dd-f146-4bc7-bba7-bd23657f7b20">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70493ea7576f4f75bf9315161efe8129_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMTAtMS0xLTA_e7632627-b36b-406a-8578-f168193fad23">19,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31731035ecc946909f7611c79f589644_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMTItMS0xLTA_82f8b7d8-c994-4941-bc5d-e6370a6bec5a">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMTQtMS0xLTA_2b631d94-8a98-445d-a2a9-dfabb7fd6b5d">21,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standards </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1fdea1fe7d4a078ed1a4602d02bb20_I20190101" decimals="-6" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTAtMS0xLTE4OTEx_59ff0fc9-34aa-4aa0-b744-5ec543ea13a3">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65708ddeaac5432bbbd3d6edf2afc67b_I20190101" decimals="-6" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTQtMS0xLTE4OTEz_7af5e074-65a5-43bf-b158-779abffc4f8a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTAtMS0xLTA_e71b558b-c473-48a7-93e2-959e9ca6e88b">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide81d63cf6c54f098b1ff7c66544b644_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTItMS0xLTA_12173d8f-0fef-4ecc-98ed-d20ca9d3675b">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTQtMS0xLTA_87b53e50-4fd1-4dbd-a56c-a577122afbcb">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtOC0xLTEtMA_5cee8ac5-0b8d-4f4e-81a3-e80dbec18662">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtMTQtMS0xLTA_3f3ca3c2-cd79-40ba-8dc8-472c7959f569">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMi0xLTEtMA_ae6c6c74-c82a-404d-9c16-6fa79793dbff">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtNi0xLTEtMA_168cc869-ef7d-4d19-a74b-725eb8096290">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTQtMS0xLTA_3613184f-427c-47c2-99c7-792fe9396ebd">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMi0xLTEtMA_5d66a8f2-73a4-4027-896a-8c73fc0aae0f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtNi0xLTEtMA_e223ae0f-005e-459c-b25e-53c44d8b25ec">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMTQtMS0xLTA_49a3bd42-4e30-45c2-bc24-747ee45f3a8f">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctNi0xLTEtMA_bbb8a234-042f-4073-8770-0549f21f7d5f">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctMTQtMS0xLTA_6dee79c3-9f2f-4296-820c-ba03a2b6c0fc">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMi0xLTEtMA_778f440f-8ef9-4931-8df4-5d0dfd3b4daf">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtNi0xLTEtMA_24c67644-409e-42b4-adff-f543b25ea24e">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMTAtMS0xLTA_0aa65644-75dc-4d12-986a-59a4de60b576">1,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMTQtMS0xLTA_47a106fb-e524-40c7-82e6-b11ba73fd893">1,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmJmMWZlMWM0ODdjYjRjMTI5ZmNlNTUwMWViYzZkNTg3XzEwOTk1MTE2Mjc4MjE_24d4dd52-3670-4fd7-b7d5-68bfc04df7dc">2.52</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMTAtMS0xLTA_4819c352-95ea-4a48-8f1b-28f225d253dd">3,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMTQtMS0xLTA_48f6ced7-2101-4445-9cef-1589cd4ab44a">3,239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecfc48f8ba344985b35fcd2a8cb7d81c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMi0xLTEtMA_2bd5b356-a45e-4f8d-9386-2796b7ea1762">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecfc48f8ba344985b35fcd2a8cb7d81c_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtNC0xLTEtMA_2b94ac48-4e1c-44b1-b788-7dd00c8b7392">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36fcd6ecd6054ae299896dca5929ff08_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtNi0xLTEtMA_83cb3a6a-18cd-4422-9b97-1ad585a4f506">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8823d4c8e7b94b01a4ee9918a81621f1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtOC0xLTEtMA_47db3c6e-bbcb-4120-913c-614190d802d4">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169f1c5f92244d9c9d8b552d1f30c6c4_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTAtMS0xLTA_cbc40000-2a09-4b68-8c56-fc12b0c7691e">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7814341554194d39a8d33cf13d7c7a78_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTItMS0xLTA_0ee145e1-6715-4648-a514-18a910c15c13">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTQtMS0xLTA_5626e4ea-3544-4088-a034-bf6b80e96adf">22,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standard (Note 1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38c06042926b4ec6a8d780769c247d9f_I20200101" decimals="-6" sign="-" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTAtMS0xLTI5MDk_2cb10d7b-de9a-4087-b585-028ec2392b40">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i481ded537ec44be2aa528514e17583c9_I20200101" decimals="-6" sign="-" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTQtMS0xLTI5MDk_9cd8e268-8b7b-4f45-87f1-6a1ed4e82287">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida37295fbd814545a3765e7f4773f2f4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtMTItMS0xLTI5MDk_e7e4fc73-57eb-43a8-ac56-34b3ac773e52">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtMTQtMS0xLTI5MDk_9a8905d2-6d47-4112-b442-4c8f13e9c0df">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTAtMS0xLTI5MDk_34217256-761d-4028-94dd-7ecafa5da5f4">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida37295fbd814545a3765e7f4773f2f4_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTItMS0xLTI5MDk_c951787b-66ca-46d2-9e46-8c2278530923">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTQtMS0xLTI5MDk_580b3d3f-0f68-42e3-bd2c-409ebe6ed6a7">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtNi0xLTEtMjkwOQ_94ef02a4-19e5-4dd1-a35e-11dd74d0fd20">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtOC0xLTEtMjkwOQ_4331e484-0415-464e-9926-7c06c1af0b4c">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMTAtMS0xLTI5MDk_d497a55a-b651-4060-9357-b637fc589a99">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMTQtMS0xLTI5MDk_598491c3-a533-40d1-9647-70b81c543e49">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i644e2dd1361545818a945c69c56a8198_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctMi0xLTEtMjkwOQ_949b5aa7-c044-4b74-bd17-dfea2818c24a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctNi0xLTEtMjkwOQ_72140b87-1352-40be-96ab-8db0703df0b7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctMTQtMS0xLTI5MDk_03628d08-da60-4e2e-a4b8-f3c7661e3d25">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i644e2dd1361545818a945c69c56a8198_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMi0xLTEtMjkwOQ_061e3d6c-fe15-4658-9e67-5ca885a227d8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtNi0xLTEtMjkwOQ_018ecf1c-d592-4ffb-982c-09104f04c1d9">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMTQtMS0xLTI5MDk_53945778-3d09-4447-8743-45c1503e6ec9">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktNi0xLTEtMjkwOQ_6b5ee246-3437-4bdd-b99c-495074c45998">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMTQtMS0xLTI5MDk_018f128f-0243-44ac-8f48-c53a21a338c0">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i644e2dd1361545818a945c69c56a8198_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtMi0xLTEtMjkwOQ_afd52a2f-b0c8-4800-8ab4-08d3cb583db8">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtNi0xLTEtMjkwOQ_d470c41c-d221-4a7f-b7ae-95a4bc995891">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtMTAtMS0xLTI5MDk_9523053a-27d2-457b-b285-aba638c45ad1">1,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtMTQtMS0xLTI5MDk_9daa09ac-e8a1-4c70-8d02-6d03438f00d7">1,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMC0xLTEtMjkwOS90ZXh0cmVnaW9uOjI1NmU5NzQyZjFmZjRmNjJhZDVhZjZmZGY1OTc0MjE0XzEwOTk1MTE2Mjc4MjA_9763beca-e2be-418c-8de7-581d6344805a">2.72</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTAtMS0xLTI5MDk_6aec0be3-780e-4dbd-a6b9-2d27d8796f68">3,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTQtMS0xLTI5MDk_6d154c3a-629c-4b9b-b71a-7b9a9ac24f75">3,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7100af96680046f2a2500612bc8d8730_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMi0xLTEtMjkwOQ_cff7c74e-c642-45a8-a51b-04d168ad9d51">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7100af96680046f2a2500612bc8d8730_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItNC0xLTEtMjkwOQ_13b69ea4-c04a-4058-a065-8a852d6e8d3f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1aad86406e4fb6bb4aa4b7bd2a85cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItNi0xLTEtMjkwOQ_3d3103b6-a701-4950-8f22-56abbff2c619">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a5ad62f62cb4ef6968f09d3363ab76e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItOC0xLTEtMjkwOQ_6088d103-b24c-4948-93af-67ddcfd73218">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b2e43234fc04521af2344e4b1244e9f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMTAtMS0xLTI5MDk_a1105dcd-7750-498e-9c40-776565d51ab4">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i987c3ed14ae840e7ba9dc6b6834ee87b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMTItMS0xLTI5MDk_45c1a86f-2cfa-4aa4-b8c8-47936347a317">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMTQtMS0xLTI5MDk_a07bb7c5-023c-4998-988d-d21332d99454">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMtMi0xLTEtMA_d3b20e9f-817f-4dfe-9cca-af6f287e40a3">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMtNC0xLTEtMA_657c7bb9-035a-487a-a2e5-cbf5f296e535">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMtNi0xLTEtMA_b92b3c2c-ee22-48d4-b277-2dea53ee9ce6">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzUtMi0xLTEtMA_14f3e8ea-4b1d-4b52-ad63-f748ebab65e9">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzUtNC0xLTEtMA_91e8d048-4772-47c9-8706-e6c3c84b4be3">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzUtNi0xLTEtMA_b74ff89a-dcd4-4a21-a59b-4308633ff352">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzYtMi0xLTEtMA_600e5792-a2e3-423d-b7ae-94896d1f79d8">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzYtNC0xLTEtMA_caea76c2-f77c-4b74-8e69-fb9e62e5c847">1,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzYtNi0xLTEtMA_994563c6-cf84-492e-a169-8a4babf064df">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzctMi0xLTEtMA_af35204a-9d03-4729-9c4e-97b397c964cf">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzctNC0xLTEtMA_6fea776d-35dd-4a5c-8b66-679836842927">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzctNi0xLTEtMA_76c98886-db2a-4b58-97b5-defa43b5a53e">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzgtMi0xLTEtMA_f8e872f6-e651-4b80-94ca-a00ed0efcc4e">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzgtNC0xLTEtMA_18cbb2d8-71b0-4fbd-a204-4b102a830f0c">2,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzgtNi0xLTEtMA_a1764aa4-a436-40df-b539-e52abef85b49">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Net (gains) losses from equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzktMi0xLTEtMA_ba4d98d7-2b17-4bb4-afb6-49cc14ab968a">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzktNC0xLTEtMA_fa8d4514-e90b-4f95-9367-262bb0f8ba0e">1,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzktNi0xLTEtMA_def20ecc-90db-42ee-a7cc-4a14d77b61cb">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEwLTItMS0xLTA_f46579f1-6342-4505-8c87-d1c27d39e3db">5,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEwLTQtMS0xLTA_111ee775-6763-4548-8403-b5766afa3016">4,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEwLTYtMS0xLTA_13ce674d-16ee-4ae0-afd9-636f7151b734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzExLTItMS0xLTA_3e6f53bc-7690-4e03-bcb6-db7c583af287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzExLTQtMS0xLTA_4dbeecb2-1bc5-40b3-8ddd-01272cf1eafa">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzExLTYtMS0xLTA_d43abc9b-a60e-4a58-b47f-02af3d050ef6">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Write-downs for slow moving and excess raw material and work in process inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="gild:Inventoryreserveforexcessrawmaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEyLTItMS0xLTA_19745028-c10f-40bc-8bbc-ecab9848278c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="gild:Inventoryreserveforexcessrawmaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEyLTQtMS0xLTA_8ed87eb8-480b-4f3c-aaea-845e93c39c0c">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="gild:Inventoryreserveforexcessrawmaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEyLTYtMS0xLTA_e6cbe99a-3555-4f37-98f4-e64e6ab5bc30">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEzLTItMS0xLTA_441b5243-4497-4bb6-92d4-08ce89246df2">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEzLTQtMS0xLTA_99bb9c47-bb70-4df5-8a89-f7a4eb51f7b9">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEzLTYtMS0xLTA_8bc754b9-1892-401a-80c5-0339c9e9a633">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE1LTItMS0xLTA_572d60ec-f819-484f-897d-2c8242337f4c">1,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE1LTQtMS0xLTA_e99270be-4611-4711-81f1-0663f02d622f">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE1LTYtMS0xLTA_62608f23-06f1-43dc-9681-1a59d37bcd11">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE2LTItMS0xLTA_382902f9-b77b-4d07-8345-66e5ff762acd">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE2LTQtMS0xLTA_841d9512-8b1c-45af-b532-5c354ec5f919">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE2LTYtMS0xLTA_44cb3743-097d-46c0-bf22-ed82e9361505">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE3LTItMS0xLTA_a41f1dc5-c70e-4cd4-b2a7-2e9439e2c96e">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE3LTQtMS0xLTA_7e4167a6-093b-4c98-9661-2c91d6be8c3e">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE3LTYtMS0xLTA_67fbd5d2-8a08-4f26-a765-cb4d137dee1f">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE4LTItMS0xLTA_594c8295-47ee-4108-a920-c293db84e1bd">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE4LTQtMS0xLTA_4ad015c0-aad8-444f-b9ad-8a1ee7afe8e6">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE4LTYtMS0xLTA_7811840d-adf8-468e-a34a-616c0cc90d1b">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE5LTItMS0xLTA_ab7b4521-2f2d-4c66-875a-642a5089dd8b">778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE5LTQtMS0xLTA_deffc69f-b8db-4d38-8313-3ae9481ccee9">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE5LTYtMS0xLTA_543bc0b8-6d26-4883-beae-2e0b97a75c32">1,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIwLTItMS0xLTA_9807cb5a-91d1-4abe-ad05-045ed89e5005">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIwLTQtMS0xLTA_beb6fc30-9269-4880-ac1f-3dc0d74fbaf9">389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIwLTYtMS0xLTA_19776ea3-5a80-440b-858e-03df4887d0b9">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIxLTItMS0xLTA_682c23a9-0ca6-4f87-b3e2-78a78024bba4">8,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIxLTQtMS0xLTA_6b2cf796-caf8-429a-8966-ddf397a23021">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIxLTYtMS0xLTA_7b251d67-c79b-41ed-8d8b-da3963550416">8,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI0LTItMS0xLTA_c61a3b91-ce33-4e5b-9f1b-728538da582a">20,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI0LTQtMS0xLTA_70ef8a34-421f-4cea-a7ed-9f1e6454b60e">30,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI0LTYtMS0xLTA_6bb12eb2-f040-4556-bb0b-a32646aaf900">10,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI1LTItMS0xLTA_295ae059-574c-4d30-ad6a-6705b0de6062">23,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI1LTQtMS0xLTA_f8d4dbb4-3c6d-450a-9758-e05dab8d17cc">7,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI1LTYtMS0xLTA_d286cda7-fb4a-4f4e-b598-6d93e7dc928a">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI2LTItMS0xLTA_accc9800-957d-4225-9b99-1a0dd51532c7">9,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI2LTQtMS0xLTA_1a409b4c-8af2-4106-a6ef-0507cb0a4519">22,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI2LTYtMS0xLTA_a0addc4c-1b7d-4e77-ac21-390a0974783b">24,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI3LTItMS0xLTA_d6aac05f-9f79-4958-a5ea-f455982c1ece">25,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI3LTQtMS0xLTA_71b31114-e680-415f-96ea-8491ee9e036f">4,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI3LTYtMS0xLTA_520af8f8-6a65-4038-b7e5-b83ccf628a5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI4LTItMS0xLTA_992f1c66-f62d-4725-85b8-e46ba0fc6cc8">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI4LTQtMS0xLTA_4d278262-2e1f-4f68-a8d8-a090e9fea0ad">1,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI4LTYtMS0xLTA_4e61cd09-80e0-4483-9402-4ef2bc7a7d0b">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMwLTItMS0xLTA_7434268b-369a-44f9-85ed-edb22f67449e">650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMwLTQtMS0xLTA_26ba3b6d-1b2e-4397-8e82-449d55426dda">825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMwLTYtMS0xLTA_46a712a9-bfc0-48b0-94e9-f4c2b47150e2">924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMxLTItMS0xLTA_8a9caf87-6dd7-48da-a638-85d76d2951eb">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMxLTQtMS0xLTA_c068221f-a351-4633-a1f5-aecad16723f2">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMxLTYtMS0xLTA_86a8c786-5c9c-41dc-824b-9c34f900c74c">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMyLTItMS0xLTA_0e26bf4b-3f82-41fd-a062-b7d8cce8a062">14,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMyLTQtMS0xLTA_abc25051-42fc-4f55-9487-3586ba99dc55">7,817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMyLTYtMS0xLTA_c0609089-0bac-4dc4-8bca-17e09c851038">14,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Proceeds from debt financing, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM1LTItMS0xLTA_9edbdd36-7bf6-4d91-9222-16976d487719">8,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM1LTQtMS0xLTA_74c47e18-6299-4a78-9fdd-045acdf89a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM1LTYtMS0xLTA_f9de1519-8aa9-42f1-8f56-b6718201c899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM2LTItMS0xLTA_8f46a4ec-798c-4135-a987-fa032ee7d6a5">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM2LTQtMS0xLTA_1879d63f-d02e-41e3-ae1b-7d0229a5c619">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM2LTYtMS0xLTA_45158e8f-1c86-4bd3-95dd-920691ca5a21">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM3LTItMS0xLTA_8f001fae-06cf-4815-9f1a-375f83c3d171">1,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM3LTQtMS0xLTA_23b96232-6d41-433f-9045-f754c763514d">1,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM3LTYtMS0xLTA_61c2bfdc-5cba-4fee-acb1-bd3b639af65c">2,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM4LTItMS0xLTA_c051c418-c6be-4131-a738-85f429b01f1e">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM4LTQtMS0xLTA_57beeadd-f6ed-435e-8d0a-52cb6a692b20">2,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM4LTYtMS0xLTA_fbfa4270-ee3e-4c85-aa71-0af2e709a1ac">6,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Payment of dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM5LTItMS0xLTA_f248d40f-1bbb-45dd-b72f-0b022f0f914f">3,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM5LTQtMS0xLTA_bfc50581-f135-4343-930d-abf3ed7566ae">3,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM5LTYtMS0xLTA_4d4dafbd-9254-401b-ad42-aa495cf455cd">2,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQwLTItMS0xLTA_3a53e406-60ea-4bfb-bb83-7afb30e8208c">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQwLTQtMS0xLTA_ade4048e-3bb3-4312-9e50-2ac37547e8fa">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQwLTYtMS0xLTA_a4b46dba-b48e-49e6-9f6b-0070531f1ea4">486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQxLTItMS0xLTA_76d3eedb-0d48-4392-8b7b-f0eb7e8dcf05">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQxLTQtMS0xLTA_fd2f6b4e-96b1-4269-9115-7e158368ade9">7,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQxLTYtMS0xLTA_916597b3-97b5-4453-906b-b46008d0894f">12,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQyLTItMS0xLTA_cea84141-d8d7-418c-a8c5-b90aa5c54869">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQyLTQtMS0xLTA_04365520-6167-44d4-bdd6-7e5b762398f9">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQyLTYtMS0xLTA_9d6709d1-72c5-49a9-bcdb-c4ebb3988699">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQzLTItMS0xLTA_093d9baf-ded0-4367-add1-73868d1232d9">5,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQzLTQtMS0xLTA_39ffc5b3-bfc0-453a-b2a3-2a96f0060057">6,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQzLTYtMS0xLTA_85da6464-6f3c-4f79-b1af-6b40d8c68d6b">10,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTItMS0xLTA_66295759-d36e-4eea-9b17-6e4f68bbb1e0"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTItMS0xLTA_6db309da-b098-440a-b992-867d8a3c8e3b">11,631</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTQtMS0xLTA_7f1b2fea-817c-4533-96bd-cd7574fbafde">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3219b6982b334ae49d4a68c7befc5d27_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTYtMS0xLTA_a3a8f75c-563b-460b-a46c-b0321346ef35">7,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTItMS0xLTA_98be3f51-4ce9-4de7-a374-ed5ea811adce">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTQtMS0xLTA_66295759-d36e-4eea-9b17-6e4f68bbb1e0"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTQtMS0xLTA_6db309da-b098-440a-b992-867d8a3c8e3b">11,631</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTYtMS0xLTA_259c3b78-5c5a-4d7b-868d-9e53612b72f0">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Interest paid, net of amounts capitalized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ4LTItMS0xLTA_3819e9a1-ef1d-4c82-9516-fc2477b1e056">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ4LTQtMS0xLTA_50bdcecf-4439-4496-907f-23da72c09475">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ4LTYtMS0xLTA_dabff689-d93f-4e0c-8779-da34169b7cac">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ5LTItMS0xLTA_e490ef21-e63c-4d32-a3a9-08becb541b19">2,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ5LTQtMS0xLTA_dd3ffcd9-c459-4ec5-bbf3-e67b9c8cc102">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ5LTYtMS0xLTA_87870973-7310-4473-8024-1a8c82a848ec">3,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_106"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjUx_683ea991-fbe4-4b07-ae33-a748d4a60b6b" continuedAt="ib2b31824cce54ec19f033255bfe2f197" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ib2b31824cce54ec19f033255bfe2f197" continuedAt="ib8c93a2da78d42fa817425e5de4894b5"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;), incorporated in Delaware on June&#160;22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we strive to transform and simplify care for people with life-threatening illnesses around the world. We have operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead&#8217;s primary areas of focus include HIV, viral hepatitis and cancer. We seek to add to our existing portfolio of products through our internal discovery and clinical development programs, product acquisition, in-licensing and strategic collaborations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Jyseleca varies worldwide, and Jyseleca is not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTU_0f8fcdae-b01c-4994-aa9d-fbaca2218b0e" continuedAt="i8563a79dc0f44604ad5a80070735d311" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8563a79dc0f44604ad5a80070735d311">We assess whether we are the primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTQ_3338a658-40d0-4b74-9214-b4cb36da77a4" continuedAt="ib7ec7358688d4ce68236cb6c27a4c807" escape="true">Segment Information</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7ec7358688d4ce68236cb6c27a4c807">We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer (&#8220;CEO&#8221;), as the chief operating decision-maker, manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.</ix:continuation> See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzYx_e27fe0d2-bce0-49ff-9664-bac28364ae08" continuedAt="i7f95f79261394295bc3218c6f4c1700c" escape="true">Significant Accounting Policies, Estimates and Judgments </ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f95f79261394295bc3218c6f4c1700c">The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib8c93a2da78d42fa817425e5de4894b5" continuedAt="i1b9fcd43508543ae83fe7e8d53176c05"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxMTY0MTE_69562ac8-ed72-4ffe-87ed-a5eacca22f18" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Acquired IPR&amp;D expenses on our Consolidated Statements of Income reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. Our Consolidated Statements of Income for the years ended December 31, 2019 and 2018 have been conformed to separately present acquired IPR&amp;D expenses. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Statement of Cash Flows for the year ended December 31, 2019, has been conformed to separately present acquired IPR&amp;D expenses exclusive of IPR&amp;D impairments. Comparative amounts in our Consolidated Statement of Cash Flows for the year ended December 31, 2018 were not material. There was no change in income from operations or operating cash flow as a result of these reclassifications.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjkz_5f89fdc4-21ab-4f91-aa6c-3c1e0b60dc26" continuedAt="i1dd9d998360f43d09c65cc0e864acddb" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized, net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions, and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and in some instances by type of product. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a significant financing component. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross to Net Deductions</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates every quarter to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i1b9fcd43508543ae83fe7e8d53176c05" continuedAt="ie329c21d83d841d9b570c899c27f77dc"><ix:continuation id="i1dd9d998360f43d09c65cc0e864acddb" continuedAt="i89c03d97185a455a85da3ae666254921"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty, Contract and Other Revenues</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i89c03d97185a455a85da3ae666254921">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur.</ix:continuation> </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzUx_2a527c97-6e8e-46c6-9335-cde788129916" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, payments under collaborative and other arrangements, including milestone payments, license and option fees, as well as expense reimbursements to the collaboration partners and overhead allocations consisting of various support and infrastructure costs. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge R&amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzYy_f697836e-7c42-407f-8aee-0d17b98a224a" continuedAt="i6665dae44e0440a9b32c3c786f8d7b25" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;A expenses also include the branded prescription drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6665dae44e0440a9b32c3c786f8d7b25">We expense the costs of advertising, including promotional expenses, as incurred.</ix:continuation> Advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3Xzk5NzQ_f0f250f3-f8b3-4525-80ff-a23a0debc236">795</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3Xzk5Nzg_fedae04d-fd78-49f1-8411-5549a3c5bcdd">784</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3Xzk5ODU_650156e4-d70f-4dc7-ada7-c72b7fdd7f12">587</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjA0_8af82562-c79a-4dbe-9bf4-55d6635a2baf" continuedAt="i0af02f75225e45d8a684b27f1278408b" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0af02f75225e45d8a684b27f1278408b">We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie329c21d83d841d9b570c899c27f77dc" continuedAt="i8304cc162f5c4f8f8cdce379b21565ed"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjQx_9302a789-8cff-4837-a1a8-5c2947e66535" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable and Nonmarketable Securities</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) as a separate component of stockholders&#8217; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and Non-Marketable Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investment in Galapagos NV (&#8220;Galapagos&#8221;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of the investment. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjMz_7289b943-42fd-4b09-88e2-b0d997c0d309" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were <ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzEwOTk1MTE2Njk2MjU_f7afe135-0661-4cae-b158-6bd615339aba">no</ix:nonFraction> material write-offs charged against the allowance for the year ended December&#160;31, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i8304cc162f5c4f8f8cdce379b21565ed" continuedAt="id471f81ce9b84ed5aacbc8c3be0c1cef"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzAy_8fe6d336-0157-42bf-a17c-30c2529e7130" continuedAt="i0b93eff82d0d4003accc0f9be37aae49" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b93eff82d0d4003accc0f9be37aae49">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.</ix:continuation> </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjk3_a9afd276-010a-421b-a8ac-cbf2ea24c4bc" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMTk4_91f729ad-892d-4a56-a579-48e9bbecafbe" continuedAt="icb22039fd63a4f8880cb08826df0b253" escape="true">Estimated useful lives in years are generally as follows: </ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="icb22039fd63a4f8880cb08826df0b253"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;<ix:nonNumeric contextRef="i398df6a52dd9464d8dd45e089b73014d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzEtMS0xLTEtMC90ZXh0cmVnaW9uOjliYWQxZjhmZWZiMTRhZmJiYzY4MWVmZTUzNTliZGNhXzEwOTk1MTE2Mjc4MTY_94e82f7e-5a83-46d2-b145-06417eaef140">35</ix:nonNumeric> years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27efdec092714a19b30f4a1ad8aa6133_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzItMS0xLTEtMC90ZXh0cmVnaW9uOmI5ZWRkZDZjMDQ3ZDRiNmZhM2NiNjljNjc4ZDliYWUwXzEwOTk1MTE2Mjc3ODU_e28698a2-58dc-49ef-9e93-bb37864b7e33">4</ix:nonNumeric>-<ix:nonNumeric contextRef="icf9fe67d86404ee58fc08434776ac75a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzItMS0xLTEtMC90ZXh0cmVnaW9uOmI5ZWRkZDZjMDQ3ZDRiNmZhM2NiNjljNjc4ZDliYWUwXzEwOTk1MTE2Mjc3OTA_cd5bdca3-f192-4e20-b461-f3a33d3ea3a1">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a198ee4eaba43a9be336a94d8a87b2e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjVhM2FmNGU1ZjU0OTQyMjJhMDJkMDZmM2M3MTcwM2QzXzEwOTk1MTE2Mjc3ODQ_48e824bb-9cf5-4c35-86e3-3b3004b11d76">3</ix:nonNumeric>-<ix:nonNumeric contextRef="i0fa4ce37886b4a34b696be088b6209dc_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjVhM2FmNGU1ZjU0OTQyMjJhMDJkMDZmM2M3MTcwM2QzXzEwOTk1MTE2Mjc3ODg_08663da4-0666-4792-9649-83e9b97b8146">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTE_e55910a1-b9e3-4825-93c7-cc0e6f7cb778" continuedAt="icba34b76b4f84a72a97e26e3d22fbb09" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted Accounting Standards Update No. 2016-02 (Topic 842) &#8220;Leases,&#8221; which requires lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. We adopted Topic 842 using the modified retrospective method. As such, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840 &#8220;Leases.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icba34b76b4f84a72a97e26e3d22fbb09">As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.</ix:continuation> </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjY4_a5033e0b-88b7-424b-9f86-af82a0f3f9e8" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in our Consolidated Statements of Income unless there is an alternative future use.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="id471f81ce9b84ed5aacbc8c3be0c1cef" continuedAt="ia4a8a93c3374438280fc197e68606caa"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzAz_5bff3921-b112-4150-8f55-883a1e9d6057" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjgy_31ff852b-f705-44a3-9b3e-769f5200bb0b" continuedAt="i27a199bd52fe4921892a6f41f6fa3454" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i27a199bd52fe4921892a6f41f6fa3454">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTc_faf0917c-3ab2-4c45-af49-86f4daaba2f5" escape="true"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Contingent Consideration Resulting from a Business Combination</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value in R&amp;D expense within our Consolidated Statement of Income until such time that the related product candidate receives marketing approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzQ3_5d8846cf-81e0-4d3b-9ae5-6e9eb2ea7bc4" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia4a8a93c3374438280fc197e68606caa"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjU3_2ae1b181-2eab-4ac5-841e-2fb570814a61" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjE1_161c883b-db16-4070-ac9c-98431e5b5615" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Changes in the fair value of derivatives designated as part of a hedge transaction are recorded each period in current earnings or AOCI. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in current earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMTk5_65fc3811-8ab0-409f-865e-4b16a8cbc237" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities related to unrecognized tax benefits in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;), enacted as part of the Tax Cuts and Jobs Act (&#8220;Tax Reform&#8221;), as a component of tax expense in the period in which the tax is incurred (&#8220;period cost method&#8221;).</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the Consolidated Financial Statements.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzI2_11c58c13-8369-45f6-8a47-eef4e1d9aa27" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016,&#160;the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13 &#8220;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; and has since modified the standard with several ASUs (collectively, &#8220;Topic 326&#8221;).&#160;Topic 326 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, we adopted this standard using a modified retrospective approach.&#160;The adoption did not have a material impact on our Consolidated Financial Statements. In connection with the adoption of Topic 326, we made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018,&#160;the FASB issued Accounting Standards Update No. 2018-18 &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221; (&#8220;ASU 2018-18&#8221;).&#160;ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606, &#8220;Revenue from Contracts with Customers&#8221; when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as customer revenue if the counterparty is not a customer for that transaction. On January 1, 2020, we adopted this standard and applied it retrospectively to January 1, 2018 when we initially adopted Topic 606. The adoption did not have an impact on our Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzk3OQ_961df134-2dec-4ea2-bf1f-e668f79098d8" continuedAt="ica63f7587ca34008a10533ba26ce4ae3" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="ica63f7587ca34008a10533ba26ce4ae3" continuedAt="i99d0b2db1b274fcdbe0f91085003585b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzk3Nw_ab66848f-ab95-461e-91d0-6d179cd9cd35" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">HIV Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if280de1dfeb24360a98d1085d3ec01d0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMi0xLTEtNjEw_babb792c-9285-45b7-9279-9f2052fd861d">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42acdb68c96f40139d8ef2dd48ec4aad_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtNC0xLTEtNjEw_76c23358-cc58-49bb-840e-901d8be6ddb4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93a08630ddf4d8daa910c80941d2f49_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtNi0xLTEtNjEw_962cf6d3-2651-4fe2-b9ab-a9b6329cead0">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1fc5480ae54692850a590af2530f85_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtOC0xLTEtNjEw_5575e731-377b-4a7b-941e-f5bd732c97bb">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia42eea57788b437d80b0100bf5308e5e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTAtMS0xLTYxMA_d96ed5dc-0a99-4273-9b3e-de969b8a386d">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b227c5b6d24b36a063e59f6b31eddb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTItMS0xLTYxMA_e2db55d8-cb60-4373-b532-7994a30f240b">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd51a66da7cf40eb80804c8cb98cf1a4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTQtMS0xLTYxMA_958208ad-7c22-484f-a43a-4aacef82d972">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia729850536324dc7a891febe1ef57425_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTYtMS0xLTYxMA_81f848f3-1f0f-4354-a7ad-0a96194848bd">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2f412468e04e8e990eda8c053e9023_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTgtMS0xLTg3MDk_207e06b2-8b2e-4ce7-81f5-5ae40c421297">967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573540eac6ce41b9ba0a37a14d578dcd_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMjAtMS0xLTg3MTg_3c8937a2-c3f1-477f-8e55-a2f2137ff326">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e0aaddda8242649f4cce16f7480e3f_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMjItMS0xLTg3MjA_823baaf9-ede6-4811-b4ad-79da4467d989">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6f27d389c4470791b5097d66ee6fb2_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMjQtMS0xLTg3MjI_daa4cfaa-ef17-4cfc-b4e4-e554ee3b30cc">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec241db8005b4fb59360d2304f6a40ca_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMi0xLTEtNjEw_221a0709-e181-44f7-a67b-337d36f7f02a">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dce80f6a5d043fabec1581e37b038e5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtNC0xLTEtNjEw_08b45953-a33f-4b71-8fa0-a9391f935e69">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba9195c2f9b45e392656f86c6f8865c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtNi0xLTEtNjEw_c0b19c35-c7e4-45f7-af77-a45410718456">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5630aee9b8e34051b2267852a2167c72_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtOC0xLTEtNjEw_c68f4ad3-2469-4940-9337-abde038ddab8">7,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bf33c47a6342328f4b4a359e831dc0_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTAtMS0xLTYxMA_9cb997db-b58e-4afd-83f7-e0ed4f67d082">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01bd5e69cc2242e9937e99d06f49412c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTItMS0xLTYxMA_e4c511b8-0093-4029-a8f1-3350e51ce812">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7657c224364338aaec9e8f7e531475_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTQtMS0xLTYxMA_9671fc75-f2f6-48b4-a965-d89366dc8459">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479222aa62ba4959b945991f45167506_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTYtMS0xLTYxMA_e1141edd-6397-4e94-822f-c6f10ac9b3ae">4,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732f9de4021249caa5c12dd71d663337_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTgtMS0xLTg3MjQ_ccc4677f-e2f9-40f7-a4ba-9edb11aef801">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51323f6fd23840a6a3a8153facb4a542_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMjAtMS0xLTg3MzE_4fd6ceb6-8378-4242-9629-bf90a21f5154">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8120081236ab4ada86875183d3516a0d_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMjItMS0xLTg3MzM_1292a0de-6230-498c-bc2c-5e32eac5baf0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d9ac1bed894e8ebd3a9a07adec3780_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMjQtMS0xLTg3MzU_25c3a89d-9031-4f57-b4c6-391d4cb7a1e2">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423cb85373ec46cd90ab88681133fed7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMi0xLTEtNjEw_998996ae-5eaa-4197-9717-430fecee20ac">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bca99eea6724544b1989f1c71ff8e7b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtNC0xLTEtNjEw_14ec27b0-44b2-411f-9346-9aa8eb5ac356">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib925542d3c9a449f9451287b1948794d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtNi0xLTEtNjEw_f4cd7e5b-1643-491f-b180-cab33ef8818f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7fe1a6f3e2a4443bfadf5e3b18575a8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtOC0xLTEtNjEw_c7960d3a-a291-46b0-a254-c80d34f9826e">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397a1aaa80ac42d8b7d7547d7a425c70_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTAtMS0xLTYxMA_dc3d3d49-dd07-40a2-9bfc-5de333c8a8c8">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e6650f4df60426daa34dc4ca653bc0c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTItMS0xLTYxMA_66905b25-ce45-47f0-9629-edba37433b31">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96967e4c10914e109e43c4c43838be39_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTQtMS0xLTYxMA_1462b120-080d-4425-b0eb-f75e0427af29">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbd726607304250949dffcf3aa8a682_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTYtMS0xLTYxMA_711f0d04-5697-409b-bf5e-775bfbd10443">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac1e36447014421822582a862cdaadd_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTgtMS0xLTg3Mzc_7dc7600c-479a-4c49-ada8-e56ffffa5bf6">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e01036f80124b668ee600a97070f563_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMjAtMS0xLTg3Mzk_f4f6c663-554c-4163-96cc-64ab5fabe61e">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9ad0800ab14c06a5eb9fc8ed1492dd_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMjItMS0xLTg3NDE_8ae999a1-8bdb-4ec9-a87f-fced83de7e4d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f83bbac170c4124b1506d033c0044f6_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMjQtMS0xLTg3NDM_2d45c94d-a44c-4f1c-b4d0-4526a63cef6b">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff45aaf7fa4b4df1b955bc6bf7844c83_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMi0xLTEtNjEw_b4a93531-a758-4e2a-8d51-fcf403f89187">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fcce9db6610413494337c100307fc4a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctNC0xLTEtNjEw_54500995-c950-4d77-a63d-5409a9a4f350">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba09d37db0e466f905cbca86c3d7dc6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctNi0xLTEtNjEw_83e5003a-10f1-499f-856a-d83c5ff9747a">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914f59558f254e77910de66c2a838a2d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctOC0xLTEtNjEw_2402eaa8-84e0-43ab-ac56-302d4c0251fa">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05a4d813f594dffabe58b494a022cce_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTAtMS0xLTYxMA_5e9b6454-7a78-4b44-b9d2-d9f4c1072f88">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b7ceb3521340179dc6fb26acff9127_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTItMS0xLTYxMA_371d66f5-d55c-42cd-a288-2e175702668e">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ed9dfdc9e84991bcf49d834722ae9b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTQtMS0xLTYxMA_fc5011a6-28d4-4e5d-9865-86636aa4fbed">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6155a1372b794cfc98808510fd0f6aa0_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTYtMS0xLTYxMA_b0d39657-beda-4ef6-82d1-2d55e79acd8e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1451f5b027bb41a4847584b7f596fd2f_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTgtMS0xLTg3NDU_802dd58c-394d-4803-82a8-0077034a75e6">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d167e5e90304b3cb0fa2437ed97d58d_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMjAtMS0xLTg3NDc_f352e108-754a-4ac1-bf9b-4353cf15dd4e">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148057a263804622a6ab50305a09929a_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMjItMS0xLTg3NDk_11a4bf88-76f0-4b61-ab7c-e7a001972c4b">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30b81a7f7314bf597308792e530d56d_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMjQtMS0xLTg3NTE_7a27bbdb-bf55-4fc2-84e7-f4ecc7f9f164">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24aca176c89041e39835e536b01a5caa_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMi0xLTEtNjEw_6e7bf092-2f58-498b-b493-fe326b608d71">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa4c3f449f34e3ca5b0429151183789_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtNC0xLTEtNjEw_7b73c859-d461-42ca-ae82-e7308dbcfbc1">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee8311b76724420b4e775d0c80dce90_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtNi0xLTEtNjEw_72c4b1a6-dbe4-4a6a-9735-b4d94b7c3b86">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82451c9a5fc840db91ee5a3c49612ddf_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtOC0xLTEtNjEw_655a5742-f472-4d57-8e3e-77056d586d2f">3,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a33cadbf614a8480b0f3f1046c5ae5_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTAtMS0xLTYxMA_05615b75-8291-41ba-b608-827348088f3e">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb475376a1c4eab860991d825204c02_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTItMS0xLTYxMA_bb98ea06-bb2d-4cec-b7df-92f557228915">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b4a13728764a0eba034f51b801c879_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTQtMS0xLTYxMA_f587b4be-91af-479d-a529-9a29a4c6c7c6">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic46aeadee3584d9d87c1b87143a83acd_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTYtMS0xLTYxMA_d143d787-6083-4665-8685-9e7e225478b8">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d8548ebbc24499af4a1bfcc9d5e0ac_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTgtMS0xLTg3NTM_7db3d3ec-7335-48cd-99b9-7c9761d05cf8">3,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb71020bf354a20a7eb5c17cbe9527a_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMjAtMS0xLTg3NTU_65e5f925-ff91-4f3d-b59f-be0bcc685ff5">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e2d26072ce41babea393a33fe5028b_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMjItMS0xLTg3NTc_15556ebe-fa7f-4fd3-abbc-90758e085187">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1334107b9d4287be103de88544e8c2_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMjQtMS0xLTg3NTk_ef55cba4-28b2-4cbe-9641-656004c51034">4,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56b0d69dc4443c38f7f201f8cf0560a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMi0xLTEtNjEw_32b7d3c0-969b-4aa8-8bde-3ed879606445">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19165ee38eb44b368716095e6b79b8ee_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktNC0xLTEtNjEw_f1e39922-857e-4dd5-a92b-1fd0ca5041bb">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a83d33cd594375ad102b2d5a901d14_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktNi0xLTEtNjEw_7a5ce950-8482-46db-8872-040107a3e71c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e25273ce6ff4d95913b6a378db136fd_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktOC0xLTEtNjEw_e6f4ff6d-67db-4eee-8863-9a8a9662e5de">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1354418ec0a142bf80aa75673f9dc7ff_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTAtMS0xLTYxMA_42d70c15-6b9e-46c7-b91a-a5f5408d6968">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic50ed561675c40659815e6bbfcfe85f0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTItMS0xLTYxMA_e626213f-af3c-4ec5-be4c-ba33ddc3326f">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d77fd8a2cd542c187eb7beb450a9bd5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTQtMS0xLTYxMA_0454b2a0-7c1a-4804-8af4-9cdd0eac835f">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ce8efc83ec4d46a7d9d78b23565594_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTYtMS0xLTYxMA_7a763d2e-e610-4473-9b70-e07b8452d536">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307fd96efd864668a53c14e22b45b3df_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTgtMS0xLTg3NjE_3eba8fbf-fdb0-417b-9ae6-78fc507ae49b">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51752bd1d33b45d99eeaeb4bc0e7aa30_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMjAtMS0xLTg3NjM_34cfe874-14bf-43d8-a63a-692ae5bd0d4f">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837c38f09aec40bea2af72ce62bb55e4_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMjItMS0xLTg3NjU_4345dd46-92e9-4f37-a8e4-4b045173899e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a72addb6d6c4f8f901283e58f4db7e5_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMjQtMS0xLTg3Njc_2e6297d0-134b-42b3-adfe-a715b09c4c12">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85e16d8591f64ebd8ed80e3b3d51a9bb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTItMS0xLTYxMA_d19f304e-c240-495a-a525-888d2c885538">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5568bc36104cc3bd4575c08d5bd2a7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTQtMS0xLTYxMA_85aa12f7-3779-4948-9214-9114f2a47e62">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb6ef7264624b6b88e49bf1fdcc8084_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTYtMS0xLTYxMA_056fc7c4-c11d-40cb-9b6f-91169621ee39">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b4931148e643fcbe49c4f9d12ba1d9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTgtMS0xLTYxMA_79fa4c87-7a5b-4705-bf0b-9c9d37e861c2">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3245979d6cb647f1a9f0228da2e8828a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTEwLTEtMS02MTA_d1c5e877-07ca-4ba9-93f1-5dac1c0a2fdb">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib830ff48e9c547759f55cd54a403715f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTEyLTEtMS02MTA_7ce78926-bb1a-4391-b451-1dfa985dd8b0">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bffa555d06d4f78813ba77778839fd2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTE0LTEtMS02MTA_48f80b3f-e926-4bdc-9ed5-59d024e0f3c8">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33ba5d575e9416a8fbf45cdcba038c1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTE2LTEtMS02MTA_8f56036a-cbe1-48bc-aabb-833433fbe46d">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383f0ccfdd634300bb105e23b2743b3e_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTE4LTEtMS04NzY5_694f066b-82ef-4941-9ec1-8774c7591bc8">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fc3d812ef541ae8ae75cfd0c10bd4b_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTIwLTEtMS04Nzcx_32d8bb71-3c81-4059-acec-7c91dd8c98f4">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971bd58c2a104fa58633b760bd1bcc49_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTIyLTEtMS04Nzcz_28895d9c-7864-4fab-a8fc-b18a6bafb0f7">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bff96a7eee3471ea92c5a5728abafb6_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTI0LTEtMS04Nzc1_72dc9586-22c7-4bbc-a988-544e2b5aa4be">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7e671960e24493caa9e67137c00b67f_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTItMS0xLTYxMA_17608c79-6f38-4ae6-b8d7-4ff12267c594">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601dd6fe3b1a427b9e877264c2a50cc1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTQtMS0xLTYxMA_1b34689a-8cab-4bfc-bcd3-d8902c2b4c86">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae5bb92838f42e185c2fdac7cb74c5f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTYtMS0xLTYxMA_b63af4ac-c829-4b1c-9295-c69f644d4579">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ff04803a44a739676620ac878f839_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTgtMS0xLTYxMA_7b3baa2d-e0ce-42de-a152-5394d563cea6">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99fb37b1c0334cada10080d435ac5f5d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTEwLTEtMS02MTA_21bcd450-95b2-4fce-86d0-3fde8b01b3f5">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id136b7bd1fbf487ca2f4096e63868995_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTEyLTEtMS02MTA_4a3749f8-61e1-4049-8014-b01774f5d03e">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c63bb8f77347f5b4447f81ccb53bce_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTE0LTEtMS02MTA_f5a39756-cc53-4335-9fac-5b6f04cdcc3a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5f53f6dc9d4ac08d0693f368244332_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTE2LTEtMS02MTA_2538d565-bb38-4900-9468-e3c248984ebb">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e084e4904f4eec869ea6250e39cb0f_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTE4LTEtMS04Nzc3_bad01bff-d55f-4b1f-bbfc-87bdd60e9cf5">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e0d6d757fe42eb80d7eace0eca26d4_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTIwLTEtMS04Nzc5_8321a65d-ce81-4678-8f09-b8d65fd34dfb">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5873767e398449f49bed3571f29dfb2c_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTIyLTEtMS04Nzgx_2252c4a4-7ea0-4fbe-a64f-5c369757795d">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63723f5c740941a983de991985232fb3_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTI0LTEtMS04Nzgz_5650ce75-84ed-4198-b274-95101d943266">2,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3efda2c81540b28f3d08dd5de9755f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTItMS0xLTg0MTE_36123ed9-526f-4d35-aefc-be88f53ebff2">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b99b05d92954eca83863f0bf00a778f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTQtMS0xLTg0MTM_d94534d0-d686-4cc9-b8fe-5f3130224bb7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881bd67c6b4d4c32ae44c9cecd6b6cb3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTYtMS0xLTg0MTU_fbbe9cf3-2dad-4e26-9289-dc71d66a38b1">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0469e8d7b3941ffa027e0d65422b55f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTgtMS0xLTg0MTc_37621bcc-5c73-4b3e-a5f8-421623283909">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1378a285d3541119968e5a408b282db_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTEwLTEtMS04NDE5_5373c94e-c3f8-48ce-b563-8fb4067583be">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade7d753f59a4127a6ee33601d7bb46f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTEyLTEtMS04NDIx_fb3a1b6f-790e-463c-8ebb-94daf4b7301b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86f743bdebd4241a992f10cc32afce2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTE0LTEtMS04NDIz_9211cf00-9a2d-4196-aee8-b8e0b1bdeb25">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0499c86d7cb249e79e4e9514392025b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTE2LTEtMS04NDI1_ca19424f-ad15-4827-a59d-7353bdff78e7">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4380b2c4b087466e96212e805752c452_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTE4LTEtMS04Nzg1_55a2bc7f-26bc-45f8-8f0a-61c18e69f9ee">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c65abc055694fa093ee3d1a90844e56_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTIwLTEtMS04Nzg3_9046a473-c1c2-45fa-9b2b-986fab498fa0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id536d58f3ef742cfa5620869742d07f2_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTIyLTEtMS04Nzg5_0812cc2e-028e-467b-87f7-95df528c616f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7cb86cb8124bfba88a83abe2dbea50_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTI0LTEtMS04Nzkx_7781e7d1-aca0-40f9-94f9-37063f3e5aa9">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41251b77296c4f1c896b094d88169d6a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTItMS0xLTg0Mjc_c7c1bd07-7ab7-4c9d-a922-ea28de6738c2">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6faa09d5af4cbb9ffd71fb56eb0943_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTQtMS0xLTg0Mjk_327e2459-fc2c-4ef4-95c1-c6f7e91bda4b">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe492680a244d69a015e5f447b30fb9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTYtMS0xLTg0MzE_227e9611-ed28-47ba-84f0-a16989a383d0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9c5bcc6ec24e9fbf91a218a0ec316c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTgtMS0xLTg0MzM_9408f383-55f7-4323-885a-e324293e84e3">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f80e96782c40c7ae4aeb93329d6569_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTEwLTEtMS04NDM1_46f8397f-2287-4288-9ead-709641230b4f">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibefbcda1973840c1a30941cf065c6d7f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTEyLTEtMS04NDM3_95cb6f0b-c1ac-4b09-a38f-c9e2cc0af52a">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id549332482954a04928a406aa2aa8ce1_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTE0LTEtMS04NDM5_2891552b-2a70-4848-b892-4ef8294ca1b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3153057cb844d0f85ec934a049701a6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTE2LTEtMS04NDQx_7cada7de-55f7-4173-adfa-15eaa1005066">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52fb0ee83c0e437385e9166f9c973f27_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTE4LTEtMS04Nzkz_a952e39d-48a3-4db1-8e9b-2ce3784b0aad">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ddbe44d21304dbdb6f1f137c5fbf5e2_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTIwLTEtMS04Nzk1_e8e433c0-fc09-426a-ac96-f8644939c435">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f62e6dfb68b40d2a30db38faaef056c_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTIyLTEtMS04Nzk3_a5362d98-719c-4ff6-b314-b20b26a3b819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55935a228d7349a0b68ecf40aea95522_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTI0LTEtMS04Nzk5_8b7cf01a-dfe4-4516-a816-6dbccb3c3d17">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d7a8c92b7b499c925cd2e1b63d5674_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTItMS0xLTEwNjIz_e4608499-2987-49f0-ad73-364385a3c299">13,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09483a086d8344418fea4c38597c601d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTQtMS0xLTEwNjIz_48285788-f9bf-4b94-b9fe-5f4995ad19b4">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816c10bfc97f4bd3a31a63ce6248693a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTYtMS0xLTEwNjIz_83eb1cf8-51c1-437f-89ec-9901b02bd788">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e93f9118e4d40739ac1f86ecf2503a0_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTgtMS0xLTEwNjIz_463d443b-6e4e-4a4a-adeb-7d7694703f72">16,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e010182efaf422cb20cdb14830ec5b7_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTEwLTEtMS0xMDYyOA_fca639f9-dac1-444f-90a6-cd25258d7aeb">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c5df52b2384dad827ce8d5ed8becd0_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTEyLTEtMS0xMDYyOA_1ed2c186-4424-4689-ae56-f808f5b96d8c">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b5382709394ef0902ac805a3fba467_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTE0LTEtMS0xMDYyOA_407968e8-5ef6-47bf-ab68-d1825af3da24">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a796d1ca3647aca0c0cf94e9e84834_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTE2LTEtMS0xMDYyOA_3a3dfab7-8936-4117-a285-1117a03a8c2d">16,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibed79b72cddf47108dc5adb16f1c6e0d_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTE4LTEtMS0xMDYzMA_6c8649f6-4369-409b-89dc-49ecf0b6b67f">11,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308e3d02bbe24f73995a88d9dffbeb6e_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTIwLTEtMS0xMDYzMA_45a692be-f6bc-4ad3-8083-0cee96ea52f3">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e9639e6b4f4a93bef391904c7ba7c9_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTIyLTEtMS0xMDYzMA_9cd2c2e8-d8e8-4aef-8a71-1072a2a840be">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e99b9e4abc6439caf1635dde53641e6_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTI0LTEtMS0xMDYzMA_49955d77-1b99-4201-9e4a-0407b14bb7e4">14,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;) Products</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784a2e611fc6427c9c5e4418b57df0b6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTItMS0xLTYxMA_ead1c823-8e92-492f-92d3-d059abbcbd4c">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f26b0b8d9a42e1b8b6392b60d37f56_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTQtMS0xLTYxMA_21629bf6-1d82-4c0f-b8e7-7cbae97596f2">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id210bf00395f48528f93b74e8bcf8963_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTYtMS0xLTYxMA_ece1415c-36c1-4328-b857-d116f6f8d598">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i356cdb8eb49e4b5fa6d74cde3aee0fa5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTgtMS0xLTYxMA_f9e655a4-017d-4c65-80e4-07d7e33460f7">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0399583abbfa4b70a9826bd3f34fc3e5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTEwLTEtMS02MTA_044a76a2-1d93-45ab-b200-d293eff729b9">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971e8c17f58441c796ae21856d69fecd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTEyLTEtMS02MTA_0731bdcd-9d98-4693-9b61-8eb7b11e42d3">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e3c000c64e74a5997c3ce62426eab73_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTE0LTEtMS02MTA_dbe0b252-2fd8-4a67-abd0-a4ba73b27fe8">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4791ac34254f20a211ff631970f1df_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTE2LTEtMS02MTA_b8c66b4f-3131-4d2b-99b7-ebca3f78b166">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a776ce3ca04751a6acd137246eadbf_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTE4LTEtMS04ODAx_997620b1-bc00-4fb7-88b4-723a32813feb">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61ad645329c4f84a5ca1f8858e4a105_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTIwLTEtMS04ODAz_fb118636-07ee-4806-b10d-d16c0dddd995">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789b3a29153346629c85ec22950b2443_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTIyLTEtMS04ODA1_e60a7d93-a05e-46bf-accf-5401c33a65b2">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2449c7232a1542d8961f78873606cd5c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTI0LTEtMS04ODA3_2a60cacb-8e22-4d65-bc53-9c9dffd532ba">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98307d1f71d4a57b90d117c72387c97_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTItMS0xLTYxMA_3ef4ba23-0382-42a9-9a3c-c288604eb99d">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709dc81b1e0b4ad18ed1a3516087e006_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTQtMS0xLTYxMA_d1ad1aae-b53f-4c0f-8522-39dfddb29510">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52257540c09044d483783ee0e873ddb2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTYtMS0xLTYxMA_a836fd69-3f97-4b39-9038-02985276df58">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d14fe1cf6741a38f337376d9b09937_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTgtMS0xLTYxMA_53377215-69e2-47cc-a293-ed000da44643">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ead59eb11954802b58faf4295471c59_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTEwLTEtMS02MTA_845cc650-1beb-44b3-a463-2be09bade431">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fce49b484e4fbe8b7118a57fd949ff_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTEyLTEtMS02MTA_743199e6-63a4-4f01-b7a4-2744c3fff23d">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b3fa2ba952448ab0308cc83860110a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTE0LTEtMS02MTA_a9951964-9078-4daf-9085-ad592b177bca">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19c5edf94af43d38aea8ff9a812b9bb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTE2LTEtMS02MTA_7411e64e-1c62-4bde-beea-0b09753e73ff">1,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1510ef46b1564c908317e3e7ed9ae838_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTE4LTEtMS04ODA5_5f548f95-d874-4a3f-a96f-4e65d339ad6a">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8fc952f7ea48e19ed2627867ef4e34_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTIwLTEtMS04ODEx_5b9ecf0a-e9c0-4dbf-a6da-cb3ae1fe4c47">654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e85b0a40a6f4651aeb814864a67e2d5_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTIyLTEtMS04ODEz_47fe71af-fb74-48dc-a0d8-c8cab215d2a3">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1520f66d45ff4fc99578172eae43f525_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTI0LTEtMS04ODE1_e4541956-419c-460b-8e57-c1ec62db1c45">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafba755ee21149148b5687e8c622242c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTItMS0xLTg0NzY_665292e2-0ec9-442c-aeb7-6130aec4d0f9">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3418497bf64641e89450ddf47541cc00_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTQtMS0xLTg0Nzg_651a5faf-945a-47dd-a066-e89c562ea877">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a0f15448df4521b3252b863920fd4f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTYtMS0xLTg0ODA_dd2bcde8-96a7-4857-a5d5-d5abdea93dea">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa04a1897acb43a8935771581a2294d0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTgtMS0xLTg0ODI_550c0dbd-6780-4fc9-9aaf-34f5a9b281d5">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25cf3186547645e18a12e54737ff3f20_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTEwLTEtMS04NDg0_99beb593-d07d-4cd1-b13b-6462b9feff70">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a055454e634859b9e4d1183c8ce86b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTEyLTEtMS04NDg2_4dee8464-d9cc-415f-9501-15113eacbf2b">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f360e299e954e01a740de35c1825eda_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTE0LTEtMS04NDg4_f7e8e102-9342-44dd-a637-919f63196cc4">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfb0cd1316443b2a3450b33ba196076_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTE2LTEtMS04NDkw_fd86ac56-e158-4b04-80eb-08667d8b6286">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909b8bd81dd94054add30d019a9039b1_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTE4LTEtMS04ODE3_0088b78b-1d21-4f43-b049-71e26c5ab477">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81493ecf2c148c3b066878a096034fc_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTIwLTEtMS04ODE5_e3ada6a7-e186-4027-98e6-3375e3f0d5e6">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d6ae2564f7486fb11225a0eaadac69_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTIyLTEtMS04ODIx_2e3d7222-da46-4e0c-ad9a-ff6c645b31c7">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c76d4fd2017462795348867f8cdcf28_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTI0LTEtMS04ODIz_2627c1f6-4d29-4a3f-83f5-03f02730d549">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7742e26504ad407fbe00062a7dd0687f_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTItMS0xLTEwNjQ5_4a339fba-9eb5-41c9-b80e-2b4fda8735f8">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a76126042a4ae6b749183870511d1d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTQtMS0xLTEwNjQ5_3e5d5063-9925-4e5c-9ce5-3e907e0bcf91">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibea13b5f060d4a69a6a698a8df908663_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTYtMS0xLTEwNjQ5_944e0de3-7283-4c57-a292-0b78d17b68d5">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b63e3d135704c9abeb409724a97d925_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTgtMS0xLTEwNjQ5_01a51f88-0dd3-43cc-9475-3c94d04ca370">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ef5470931747bb983f03b0991cd741_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTEwLTEtMS0xMDY0OQ_0eed799f-78c0-41d7-8065-b2e62908e80b">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8780e4b3e8474e2cbe7f7e27d5ca7b6a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTEyLTEtMS0xMDY0OQ_8738ede4-ca5f-4d3e-9078-eb103bfc0458">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67fc940422441b0ad55ee1a90ed0adf_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTE0LTEtMS0xMDY0OQ_8ae6745e-f880-4a6e-a98f-8d7b872ebd62">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f7a3e3e83d47fba6ac8b13a9f5610d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTE2LTEtMS0xMDY0OQ_5f25d29b-85b4-4a87-8d9d-8282c42fb236">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce8b095baec43b9a6b48fa3f625b855_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTE4LTEtMS0xMDY0OQ_de578a62-d564-409c-b354-670cdc2a84b0">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdb328dbec54ee98bcab35be1c9d7be_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTIwLTEtMS0xMDY0OQ_727eaa76-2558-45c3-8e3d-5dca7a50f502">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23482e8bcdc43c88946e03e12a9d121_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTIyLTEtMS0xMDY0OQ_612e06b4-70d4-44a0-89af-e89cbc4e87ea">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09f10d7c83d4df6818e86cf8d921ffa_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTI0LTEtMS0xMDY0OQ_f87da01b-5a6f-4bb7-bba4-cb08b1b9c5ed">3,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859d13747a854b698617069a85edd654_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTItMS0xLTg0OTM_c4a43af4-45c0-41c5-aa7c-38d8a984c776">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65fb0f65e47c4aebad73abab7f3d668c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTQtMS0xLTg0OTU_e519d05e-364f-4cd3-8555-cde8f4d8b2d6">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb1c210d43842dc83ff399b1433b853_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTYtMS0xLTg0OTc_77bfad0d-9c25-4b14-88a9-c7b72856584a">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b6c887763456b9fc85ec6d3ce087a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTgtMS0xLTg0OTk_8683bf0f-c020-416b-9924-8cac8bfbfdb8">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9f1a4dc71044d6a03833cd32ab6427_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTEwLTEtMS04NTAx_c6f16861-3a95-49b2-b5dd-3e9b0996dcfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6b44faba3c4c3997faba3148afcff0_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTEyLTEtMS04NTAz_8b3fe92b-6c3f-47ed-8743-069aaead668a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida618eeb5e0c4c0fa85d55c4d046e885_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTE0LTEtMS04NTA1_6cf1a05f-8a04-465d-92be-9759fac8c831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ba2cc8ba7fa4f4ea047c155d67eb4bc_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTE2LTEtMS04NTA3_56f497c1-79aa-4e31-9a54-43dcb7bdf78e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109a8b80496843409ed73dee8466e5f2_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTE4LTEtMS04ODI1_9f8ba82b-93aa-438f-9967-e4e03d310db7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib288b9089b0c44789133829c737173c8_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTIwLTEtMS04ODI3_a7908744-ea60-4aba-a025-a98797c627b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d4ab01235446e18963ca74e84b4ee4_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTIyLTEtMS04ODI5_74bd2d17-71a3-4eee-abfa-7748201238be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce39b3aecd24bc6b4e8956650a90f41_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTI0LTEtMS04ODMx_33d70546-9523-4aef-af4e-d83f2efc9f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy Products </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0e1109ab13490eb642fa4d06a36587_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTItMS0xLTYxMA_c12fd205-871f-461d-8d78-61ac3610d196">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413eb3a40a8b42d988fa602ebb2ca91f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTQtMS0xLTYxMA_19a78557-94f7-4591-8c90-659a739037b0">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dea6420e00e4e8d9730f2afce5768f2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTYtMS0xLTYxMA_febc33c2-23ca-4fe3-a5e2-a6ec926459a6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f3a8d6d4864089b0117d15c03f54c9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTgtMS0xLTYxMA_6fde7fba-1e86-45b1-baac-becd607172c8">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9a38838e3584d7098ad47e06cbd413d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTEwLTEtMS02MTA_52f4527c-6ff1-4065-913a-edbdccd80e42">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580e219bcf66429da65491757ea55918_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTEyLTEtMS02MTA_b9542fc0-ebf2-4d18-8357-6acfc314b803">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55279b9ee5c4b128d5d5228052e4f29_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTE0LTEtMS02MTA_0679bd64-9b0f-4d94-9997-0d8eefbf33ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a3932fa2ff4271b07b0b741b9f2e16_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTE2LTEtMS02MTA_7c237008-ec4f-4184-b5d9-8bb4d6b7d2a3">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201995b3520443f09a408794644c73ca_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE4LTEtMS04ODQ1_8e81941b-f9bb-474a-b18b-6dd4782fc814">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i889b1eb7b37749da92f1bf1c86dea272_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTIwLTEtMS04ODQ3_c807391a-6684-487a-a0d8-d989c0227745">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35db01b6963a4942bb80c530e3cf0eab_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTIyLTEtMS04ODUz_8c69ed63-2934-4d0e-b478-fa842fa18ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468e6f1044534b1fa35b2fbd7924b327_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTI0LTEtMS04ODU1_dee70116-8c9f-47d7-9cbb-ab632f78f683">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08394a404854722bf7e616cb19ae8fc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTItMS0xLTg1NTM_6f671d0e-8142-47de-84b2-e12b7b8f0081">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d4c798eb7224a9cacdb473b8ff5c063_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTQtMS0xLTg1NTU_8016b4d5-fa5c-42b1-a08f-b6ce62725d93">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8d59cb650742a4a8ec1678152225c6_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTYtMS0xLTg1NTc_69d0fb65-3adf-4fbf-a713-eb5951496ae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1749278d3a468faec493fac747a15a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTgtMS0xLTg1NTk_1f2a5531-adb6-49b7-a60c-32a623759b50">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb15b0bfbfcf4fecb6e417adb32d14cc_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEwLTEtMS04NTYx_224af4fa-1309-413a-ae16-55692cebee67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5679c3ac945499eaa165d356e44c345_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEyLTEtMS04NTYz_5f8d4aaf-c865-4a1e-b73d-2aa8bbf11a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2021dd665b74bfd84ef3c205aee77de_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE0LTEtMS04NTY1_a7bb8f87-5de3-44b4-a8d3-9bae3390c711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef427af36e6444fb807bafc1dd97ed2_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE2LTEtMS04NTY3_049d5c17-94d1-446a-85c5-8571df781cda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983b0b11a6c84a078f5acef269da5f01_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE4LTEtMS04ODU3_cbdcaa8c-d774-4492-aae1-b526bf57ed8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9f00902a9e047f1bf5e98edae0c114d_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTIwLTEtMS04ODU5_7c3eca73-13ac-4ddd-8196-d45bb51f17a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1527f16620140d3b0bc8763e514b4e2_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTIyLTEtMS04ODYx_7aae85ae-1683-4999-a9a9-88051b4e3b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b4cf44e0b44448a2dcdc6b970704a1_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTI0LTEtMS04ODYz_3c3c4ac9-68a1-4b79-9699-6c91e395c8c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Cell Therapy product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc912cbab8848d1af83924b72da7f38_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTItMS0xLTEwNjc3_4d2e59cb-0f4a-4e03-8eca-65b4fdd5ffd7">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738e00cc411942688a5f051bbc58789a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTQtMS0xLTEwNjc3_14933ab4-7e64-4842-b72d-caad298beaa6">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc84cbd707c4080b153a838a03d48c7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTYtMS0xLTEwNjc3_45c5d6e3-6bbf-40c7-a587-f86c6f5705c8">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e9650394f04aeb94d242d32a12e8bb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTgtMS0xLTEwNjc3_699ac47e-f78b-406a-bad1-8a59932099dd">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedebf7a896304b22ace657a8e1c8486c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEwLTEtMS0xMDY3Nw_ab1dc61a-7e41-474f-86c0-c0188f92d796">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09a5278cb5a49f0a7699635ac23b161_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEyLTEtMS0xMDY3Nw_d871ab11-908f-45bc-9dad-f8d68249649f">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief07e0bd49214929beab0135a7c7dc3c_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE0LTEtMS0xMDY3Nw_617df4d8-b81c-423f-8a41-d00d63c59162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e0f3e3ca6b14a30b76b4f150c9ee957_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE2LTEtMS0xMDY3Nw_d048c093-c47a-4b31-9ffd-9feeb9cea883">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0b3071aa2974bbf9886daa645933440_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE4LTEtMS0xMDY3Nw_4fe0e10c-8f69-4f37-b3a5-851629184e3c">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883994858d314ba48462d6cb3c2af453_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTIwLTEtMS0xMDY3Nw_db0c6f5c-80fc-462f-94ed-fab76f5a6d7e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab10c90724184ec98c3bd8679e022adc_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTIyLTEtMS0xMDY3Nw_47ce4070-9610-4071-8c00-d73c9adeb5f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88bd06fa86a24206ad6519770cbbf504_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTI0LTEtMS0xMDY3Nw_f0497950-d6e0-4943-8433-398f38c140d9">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d46f4d0a9742b3811281fb61e7d0e3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTItMS0xLTEzNDA0_7fef90cb-6ae3-40cd-876f-af6976c8d355">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f879d917734de09114d93c9296efc0_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTQtMS0xLTEzNDA0_ec7a3d05-ec86-4701-9af8-64d03a839736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i829cfcdf44354f36b769778dcca6ea95_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTYtMS0xLTEzNDA0_7b6be9d8-21f3-4e83-9a38-5dfed9259c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c157b8f9e44197a7c0c60493c89067_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTgtMS0xLTEzNDA0_ced87f97-1f5f-46a5-94c9-026f36778f94">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c23f8c25d144cd7be8fbb3776eb33c4_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTEwLTEtMS0xMzQwNA_17030e96-50ae-4421-b7c1-7015e05fc85c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54469a0949b4fc0a59210e6ef5f4c5f_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTEyLTEtMS0xMzQwNA_48f9cb64-d220-46b5-90b4-86fcd693b9e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857e28fb6733458686888944ec0abcec_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE0LTEtMS0xMzQwNA_59a3e585-ddf3-48e2-84b3-7389553eed05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fd0e8f161841919bc51b121342b374_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE2LTEtMS0xMzQwNA_929d9951-259a-4227-9e6a-0e2a4b5f4b69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2079180ac67341b99d32045a11aef376_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE4LTEtMS0xMzQwNA_ac450c69-6b62-4c24-bc4c-68c579d2a3f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94b0e9d86a249e7ba66251f8d5f185f_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIwLTEtMS0xMzQwNA_ce524371-26c1-4842-9d09-f56e3ae2d58c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1967de1c5a82446488fc2307733a2f25_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIyLTEtMS0xMzQwNA_b97f67ad-55a0-4c46-a333-b6b2438f2028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib157d6d05afd413fbf032738706b0c74_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTI0LTEtMS0xMzQwNA_73812517-54df-4c9f-b777-de6bb4ffd2ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Other Products </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a212bda0e54ab3b525dd5891bf887e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTItMS0xLTYxMA_4f37de32-c619-4c27-a32f-3993ce7f17b0">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79495b272c824538bfb4875c67e764f7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTQtMS0xLTYxMA_609f8365-baa9-4921-a09d-928d0a51fb4f">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5738b64989fe4499bd71a4261fe9cd53_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTYtMS0xLTYxMA_f1d5e60c-edb1-4844-9836-dc49412bf0bd">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a03686d6ac48f48e3b9bc50f36d666_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTgtMS0xLTYxMA_f4838584-b31b-4d46-aed9-9db8a1601922">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc02389377974b6585a7c609eb64806c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTEwLTEtMS02MTA_9e472feb-9f37-471f-b354-9631fe64f671">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b0e346a3004c339a6cd887facee047_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTEyLTEtMS02MTA_2623d6df-dcde-4f11-bd5d-4df4296adf38">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5896ac21bdf49a6a7472cad2027abf6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTE0LTEtMS02MTA_02340608-4bec-4dc4-b44f-7b7a1b9fc0b6">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cc8196c9ec45ab9f1de39dc4a69f10_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTE2LTEtMS02MTA_04ab9297-69db-4da7-828d-0c67b52e6e48">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief49933c94874a7288705eed5a22b841_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE4LTEtMS04ODY1_11313474-5b2e-4a34-b615-8fe988886e4b">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a28ab5c7fb4105aefaa14b53daf143_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIwLTEtMS04ODY3_6ca89cc2-43ad-418c-ba99-bc7eb5cd9997">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68873060904412cae3451300eaf1465_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIyLTEtMS04ODY5_1aabbb9e-629b-4248-9b79-353f8578eb4f">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9385611a51014144a8857f90be3bf8df_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTI0LTEtMS04ODcx_d6a591f1-101e-4472-8b1e-74318c1adc17">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTItMS0xLTYxMA_788fbbd7-8e00-47bf-ad71-e42016eef486"><ix:nonFraction unitRef="usd" contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTItMS0xLTYxMA_a84ad2ba-41dc-4362-a749-248a6ddd5f9f">314</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e1f5ddacd74e36860d63ef63816443_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTQtMS0xLTYxMA_ff95cfcd-5a22-47dd-aa3f-a10d24ffcbab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0e5f0db282f4e87a91f73ee0f751c64_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTYtMS0xLTYxMA_13e65b29-2027-4238-a172-0e2d3306f59f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTgtMS0xLTYxMA_788fbbd7-8e00-47bf-ad71-e42016eef486"><ix:nonFraction unitRef="usd" contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTgtMS0xLTYxMA_a84ad2ba-41dc-4362-a749-248a6ddd5f9f">314</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1da7341e9594d21a608bad106da29bb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTEwLTEtMS02MTA_bf4325aa-610e-474c-aa97-e8688121eba7"><ix:nonFraction unitRef="usd" contextRef="i356273c8d56b44b0b5a77cf594e9c798_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTEwLTEtMS02MTA_d9e04581-148d-4853-a6bc-7f29e980976b">618</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b29db06821842aa88c87560b1140102_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTEyLTEtMS02MTA_911fc0cb-ad90-4647-b901-a423b44e3993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46fbf481784d46df9cd01a3ed0d6545d_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTE0LTEtMS02MTA_c936e78f-d0b9-4b8f-b3cd-9d1a043d9c2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1da7341e9594d21a608bad106da29bb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTE2LTEtMS02MTA_bf4325aa-610e-474c-aa97-e8688121eba7"><ix:nonFraction unitRef="usd" contextRef="i356273c8d56b44b0b5a77cf594e9c798_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTE2LTEtMS02MTA_d9e04581-148d-4853-a6bc-7f29e980976b">618</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea757664b6d4a1ab8eec797ffb2d767_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTE4LTEtMS04ODcz_045c2825-5533-42e0-b4af-2e0ddd436c29"><ix:nonFraction unitRef="usd" contextRef="i5ddef75a147542598e9eeae5bd12bd75_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTE4LTEtMS04ODcz_c5fc439e-10cd-4512-a125-bcbb8174be61">943</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec4e20f64114d7d9926a8c80f9a5728_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTIwLTEtMS0xMDY4MQ_944a5b36-e516-4fab-9a07-d1d2a0c4bc25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268bb32842bd412986cc0065b81f5ec3_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTIyLTEtMS0xMDY4MQ_ef24407b-965a-40e0-a599-8f87b1117f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ea757664b6d4a1ab8eec797ffb2d767_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTI0LTEtMS04ODc1_045c2825-5533-42e0-b4af-2e0ddd436c29"><ix:nonFraction unitRef="usd" contextRef="i5ddef75a147542598e9eeae5bd12bd75_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTI0LTEtMS04ODc1_c5fc439e-10cd-4512-a125-bcbb8174be61">943</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTItMS0xLTYxMA_15021001-1dd9-47a9-ae50-a111e010fa28"><ix:nonFraction unitRef="usd" contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTItMS0xLTYxMA_4d6ef00d-6ed4-4230-bf31-1a75a8fb8cfc">9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395a7db3cb484d78bbf89146a3e077d0_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTQtMS0xLTYxMA_4a9012f3-7b71-4178-a5dd-914c248da4da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba42c93200d4f8b8304c65a06ccf517_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTYtMS0xLTYxMA_dfe3c717-2852-4b02-8fae-af5ed6404978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTgtMS0xLTYxMA_15021001-1dd9-47a9-ae50-a111e010fa28"><ix:nonFraction unitRef="usd" contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTgtMS0xLTYxMA_4d6ef00d-6ed4-4230-bf31-1a75a8fb8cfc">9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33bcf8c71124c9f9f2ac08771f1c913_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTEwLTEtMS02MTA_b6a1b8b4-73d8-47d0-bc6d-9b5f6acad0d8"><ix:nonFraction unitRef="usd" contextRef="i5e9314f39916471fa92a7b99ba58f5cd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTEwLTEtMS02MTA_e4723bf6-2ce0-48d6-a029-55539f949c7c">216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f91458243294b9c9c142625d0f38738_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTEyLTEtMS02MTA_ade97b74-9dbc-488c-bfb6-3f9ffd166a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib21c75ed2e5e4a0785b473551c580aaf_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE0LTEtMS02MTA_d94c83e8-89c1-4b0f-a35b-2ce18e6ca710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33bcf8c71124c9f9f2ac08771f1c913_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE2LTEtMS02MTA_b6a1b8b4-73d8-47d0-bc6d-9b5f6acad0d8"><ix:nonFraction unitRef="usd" contextRef="i5e9314f39916471fa92a7b99ba58f5cd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE2LTEtMS02MTA_e4723bf6-2ce0-48d6-a029-55539f949c7c">216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad692520c784ea4abc27df55521f56e_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTE4LTEtMS04ODc3_53e95773-f0cd-4855-bb01-361e56011c12"><ix:nonFraction unitRef="usd" contextRef="i57e47ad7e13b4bf69d68ce9974de21b2_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTE4LTEtMS04ODc3_b6a4437c-cf1a-4bd5-b8d6-9daf65d4109d">758</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6f0bfe6a0f4a34812997b067f29ed4_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTIwLTEtMS0xMDY4MQ_1e46aef9-e2e3-4860-bad8-983b0bf120c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43afc88178954f07b425ff4523b10503_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTIyLTEtMS0xMDY4MQ_18ed777c-b1b1-4b75-a17b-3bf72bc10fa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad692520c784ea4abc27df55521f56e_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTI0LTEtMS04ODc5_53e95773-f0cd-4855-bb01-361e56011c12"><ix:nonFraction unitRef="usd" contextRef="i57e47ad7e13b4bf69d68ce9974de21b2_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTI0LTEtMS04ODc5_b6a4437c-cf1a-4bd5-b8d6-9daf65d4109d">758</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b488bb036614037b341e5cf1b62388d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTItMS0xLTYxMA_76706578-0d73-4919-bc4a-218a5ebb957b">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1acd6c6fbb76414daa5db831c8743f1d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTQtMS0xLTYxMA_f4bf23ca-daf7-4c07-b95c-324ee13a2c59">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib433847287a34715a932ae68acaeb709_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTYtMS0xLTYxMA_e633ab06-c7ba-4831-9363-7640e7be264e">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18325e923e9c47fcbb342e3aa696ccfc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTgtMS0xLTYxMA_550d8244-e302-48cc-a8f3-da5c3534fa8d">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc0423d455d47bea3200f2044dda0b7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEwLTEtMS02MTA_c8ca7b63-d8ce-403d-aefc-354e78b12cfd">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b200ae598541c98d2a1ed430747f3a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEyLTEtMS02MTA_805ea715-6ee5-4a5c-8bf3-88064a4e73db">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib937cdde175b4314b5243e750587f636_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE0LTEtMS02MTA_7fd6c7c8-a946-4a9c-8b17-8a6b7f3c4171">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4f48c959ab41ee88040efcbcea0d9f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE2LTEtMS02MTA_df2d9b92-f232-457d-89fa-8dd8c9b51414">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e97d5163a44218b733238cd69431ad_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTE4LTEtMS04ODgx_e9046ad7-e337-4442-857e-1e8cbc8804da">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb3da24a50f484bbfcb5f5691037fd3_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTIwLTEtMS04ODgz_285e8ba2-6c4c-41e3-a1b9-a790dfa8fa3b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9885f4a5984a4acfac50c45d81501317_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTIyLTEtMS04ODg1_836f268d-b454-4b27-9c08-a72754b61f45">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide045b122d2b4c9da0649764f92f82cf_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTI0LTEtMS04ODg3_ebc02520-fdb3-473b-bd6c-391a5b2f061b">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ba333691004582b0bfe3cf23e00905_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTItMS0xLTYxMA_46520c06-ce68-49ac-a718-e4ff519952d5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98481f2446747c5b3c54ea39b7ef10c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTQtMS0xLTYxMA_3f3234bf-10b1-47d0-868c-f7101b9cd1ad">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f307f1d85849869339a3dd1db1df84_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTYtMS0xLTYxMA_f408821b-2691-48df-9997-3a56caa756c9">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db84ac85e404173a8e1cb30a6decd26_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTgtMS0xLTYxMA_68d3e162-bad3-4ec7-9e23-db8bba137648">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91187b7f1d854ab7ba6257b9a17a971b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEwLTEtMS02MTA_d8a678ef-3467-41ce-9cef-8feba5d80e90">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5da15e7f08745208039280810556724_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEyLTEtMS02MTA_51abbfa2-0aa2-4932-814b-0e1296758472">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a59d3e994e417497f2f6e81c591584_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE0LTEtMS02MTA_ef92c4dc-e0af-4fc5-ae6a-1c18dacb3f7b">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37fab06fed904a5da3ee5fbccc5f0375_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE2LTEtMS02MTA_ca7314ed-68da-42f6-b960-d65a866964a8">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a89708946c4f75aeffc28c28e30c9d_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTE4LTEtMS04ODg5_852d9856-46d4-48c2-a555-4c86b2eec42d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eec496ec02f4593bd2a62da7c33299b_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTIwLTEtMS04ODkx_a7910776-3c6d-42eb-aed4-b778d8f2b178">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad31f51a98be414c964b9e2b9a577bc1_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTIyLTEtMS04ODkz_52fdeafb-64a0-425a-9062-0aa5c96ec669">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf02763ce85454bba606a3d45b058a0_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTI0LTEtMS04ODk1_72940025-434c-47f9-87f4-14a14f89792b">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2157f2cecf4cd0a6d21dfba9a135ba_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTItMS0xLTYxMA_2347d01a-9897-442d-99c0-ae73654a9690">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5df38c8d924b2893c58f2be02de301_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTQtMS0xLTYxMA_904dfe55-6886-40b4-b9a0-1fd690dace8a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b69aedcfde94c8f985123b13ec54c43_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTYtMS0xLTYxMA_dbe14f42-4323-4e15-9af0-fb523cd54318">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b05d44e0ea438ab49cc731f8134505_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTgtMS0xLTYxMA_6e61d2eb-33fd-44f8-bcae-e0ddcf61c272">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c52e1ae94bc42c58506819cae4f100f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTEwLTEtMS02MTA_2977be68-d91d-4e2a-94f3-cb0ae09938c1">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e3fa876eab46ff9f325ca98b6b49d5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTEyLTEtMS02MTA_29d4699c-4f0d-4d19-82ff-43bc92599c09">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec928fa7546b459695f84f5045fdd004_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTE0LTEtMS02MTA_b216e102-59ed-45ca-82b7-7bce2df4d603">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403ec9cdcb59480d92d5fa47b3653c0f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTE2LTEtMS02MTA_82655ef8-d77a-42c7-8b18-65a4526f91ee">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89b449def3646cd95f5c38f3912f3eb_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTE4LTEtMS04ODk3_316e8564-58f4-40ed-8e5c-f802e9088956">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73020476831d48dc952d089610d805a1_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTIwLTEtMS04OTAw_70553295-d379-4220-9500-46bf6a2795c9">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15d33d7c7794a1690e9ff92bfdeccba_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTIyLTEtMS04OTAz_1e9c02a8-65c6-4ec2-b451-eb9f26d726ce">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891f5e003fe345e49586b7f0ea1a1a45_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTI0LTEtMS04OTA1_b7bcaab8-b202-4ae4-99da-f7fa5d93ba8a">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01f5ca90cb941ada3953be0fb43eb53_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTItMS0xLTg2NTE_9f4793ef-c103-4882-8916-470961f84d33">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73acf81cff124012959bdba4df022c6e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTQtMS0xLTg2NTM_0b3252fe-e4a8-42d4-b86f-54d68f7b2edd">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25e47d06bc5444c9881da32e0c8c1cee_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTYtMS0xLTg2NTU_40a0bf65-b6db-4068-9ddb-cc19d5a7e7f6">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c3894232694ae58965e4dd7cbc5b54_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTgtMS0xLTg2NTc_121d9268-8618-4f69-88e6-e7c48aa565c4">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81cae5d5fb646aaa416523f96ff4dc6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTEwLTEtMS04NjU5_1437aeb8-f2c0-4ce5-a870-927f159a818f">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67c94bcb38db4efab1dd4b707e869ea4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTEyLTEtMS04NjYx_62fe0c9c-9707-4adb-848f-881776b427d8">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5904987b8e054f0e8bd5a3b2351b251c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTE0LTEtMS04NjYz_48502f27-358a-44ef-9eea-2601965b2ef2">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dfe8e689257463db42f9737c01eba0a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTE2LTEtMS04NjY1_f9c218c4-9227-4c18-86d6-92cc2ba43747">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6606449fe534eb2a6045bd62f8f24cd_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTE4LTEtMS04OTE3_06f416d7-9b86-4d1f-b5fe-84380759983a">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd40469a0a4494997d70f0d4a34aaec_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTIwLTEtMS04OTE5_a950435c-6196-46df-95f0-f81b984e6c9a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cccf7ba7db24688a39f333d661af293_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTIyLTEtMS04OTI1_a7e8b734-538f-4da6-8798-83cd99762080">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4038976843844c049725bed7eedc17c0_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTI0LTEtMS04OTI3_5318a6e8-0c47-4243-bd0a-8baee593ef38">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711402d60b6842f9bf49e2f038e529c5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTItMS0xLTEwNjgx_708024f1-892e-48e1-a711-7eead83e53da">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02968faa82754adb9368cdefe9c4fe3f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTQtMS0xLTEwNjgx_aca861d1-d0e7-4cfc-8705-9d285b52bca9">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ca668f89aa4b6c8e0216455acf3560_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTYtMS0xLTEwNjgx_57099c15-0d95-478c-83f5-01a762cbd18c">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471af2619c5a4230a84f5531a471377a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTgtMS0xLTEwNjgx_981becf2-26aa-4334-995e-84b539a4d0a6">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007512ae8dda41e5a9f544b584b8b898_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTEwLTEtMS0xMDY4MQ_3d14db50-a16e-4493-9b9c-bfad40ac4953">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7995dc4952d4992b95339207eb9a85c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTEyLTEtMS0xMDY4MQ_5156ee8a-fdc0-40ab-a724-0072f23e6d4c">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie748c67418e941ab866c173f95e2e4c9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTE0LTEtMS0xMDY4MQ_8a9e8565-aa9b-42f3-97fc-03ad2c555563">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32ead5f4db724373bbe26f3ea23629f3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTE2LTEtMS0xMDY4MQ_ed3d7759-9bb5-4542-97fb-0da7d03ca90e">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia787882ee4864cee85ddd5bdd5978cc9_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTE4LTEtMS0xMDY4MQ_9ca6eda1-025d-4e80-a10e-82106b1b484d">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0fa5cf50f94ef79e636b3c7f721374_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTIwLTEtMS0xMDY4MQ_bac121ba-869b-46ad-adb1-803cbd07e57b">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115f5c61450a4ca3a4ae2df3bbb688e6_D20180101-20181231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTIyLTEtMS0xMDY4MQ_e973c96f-ffa3-45cd-a7be-ef24ca251dba">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9493b54209da48aaa35d8e714d4decc6_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTI0LTEtMS0xMDY4MQ_0e2474a6-0118-4e2b-bfc8-417c442e0596">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5749630d7d6b4757afcd624c8e7ba7af_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTItMS0xLTEwNjU4_f071a54b-e34f-4fc7-943e-83f5cb93644c">18,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f9086e97774b9ca925fc4a60860be7_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTQtMS0xLTEwNjU4_c31e0a8b-3b0c-4d8d-a17c-68bd62d569b8">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fc749c3c7c4c0797d0c18e3830a490_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTYtMS0xLTEwNjU4_7301cd1e-a373-4b99-bfcf-693455084bb1">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85124ea043f44d21b8b54a8de5bdf919_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTgtMS0xLTEwNjU4_3774ee0c-1190-4970-84fc-18888bcea3ce">24,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff38adcd98344d5688d2b7c42eb4d546_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTEwLTEtMS0xMDY2MA_cb2c8086-c441-4131-8eb1-ef5f34185810">16,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b68dc0514ef48d4959838e63c0ec733_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTEyLTEtMS0xMDY2MA_89b1a35d-3863-4ee8-a3cc-49050591f242">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c409ba8f5914054bea31b89ef69134a_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTE0LTEtMS0xMDY2MA_be531a0d-2e70-447a-86dc-c78453c0a3f4">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1854fd7993394c05bb3e013f00d725cb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTE2LTEtMS0xMDY2MA_02e80804-2e98-4baf-ac3e-60a039cce2b9">22,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ea489570e94e849c567c2748c27b83_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTE4LTEtMS0xMDY2Mg_56648cb2-950f-4754-9253-3541f06b86fc">16,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e40bb38a566430ba935851046aca72c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTIwLTEtMS0xMDY2Mg_54aa0412-11a7-4e80-9b96-32ed754d68ce">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87b24e3cc774ee496e9f4e9fe3259a6_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTIyLTEtMS0xMDY2Mg_aa33028c-922d-4501-80ef-7ddab7b516a9">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c26f4bd16b4406da90ed77b81c4e690_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTI0LTEtMS0xMDY2Mg_f165e446-ae14-42b1-8452-2d596c4bb149">21,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b37655a4024424baec1bc2e6b93c53b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTItMS0xLTYxMA_94bd4566-eccf-4231-9d34-dae46cb673c6">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b386ce4d117451092994876209c5a7a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTQtMS0xLTYxMA_7b1e482b-9d2b-4932-81e3-701906caac16">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fc9a58a4ab4e06acb145d4d9fc938c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTYtMS0xLTYxMA_6ca277ed-87fc-4cea-aa7e-2f5ec1496632">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id688d136833640ac9c6d94d4ddc9632a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTgtMS0xLTYxMA_8332b228-ad6b-4317-9c41-055e2f6513b3">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbf1b72c9bc5437e93fbb59118a89b11_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTEwLTEtMS02MTA_84e1d2a6-9fdf-4fbb-a555-a1587214feee">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d1dcf382f0457c87f65fd2c8d9ff06_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTEyLTEtMS02MTA_2d342304-21bb-4cc8-927e-af4824aed43b">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1d16ebcc6c4a9ca3e4100c1dac49d3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTE0LTEtMS02MTA_302caa8e-5fdd-428b-81ba-19c651ea7146">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8670361a0047c5abdca258af5b3b44_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTE2LTEtMS02MTA_25577644-cca3-4610-8b82-ab9c42759c2d">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18a5881f11747ddbaf96b26b1d744c9_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTE4LTEtMS04Njgx_93e7c72a-79d4-4482-a2af-089bf6848019">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70edfabacb9d4ab89289cb74d03d9883_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTIwLTEtMS04Njg0_2f47bc16-8e95-48aa-8cfb-a7f91b5c566c">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7faea72409640a49a435de615dc7102_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTIyLTEtMS04Njg3_f799f0e8-d43b-4c55-89ed-43a601ff3fff">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0d2f065cd0476e9fe09cf97a3daa95_D20180101-20181231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTI0LTEtMS04Njkw_4e26658a-0f13-4bbd-9042-326055be3904">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ccc7e7e5524a3280968384eaa7914d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTItMS0xLTEwNjg5_d0477bca-9b53-46ad-b780-72a2ae70530f">18,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff4f9ede79c4c67aa7a3250803dc3d9_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTQtMS0xLTEwNjg5_2dd0c6e8-1d44-48bc-9d09-f8b93757368f">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065f333a6d934bca92cd111bef4577bc_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTYtMS0xLTEwNjg5_0d83fe34-aa5e-4bc5-874d-010802a435ed">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTgtMS0xLTEwNjg5_6adac766-b1cd-41f3-b108-57ac9f5e9f06">24,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423ab7bdc2094bf0abc5c971cd107ff1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTEwLTEtMS0xMDY4OQ_9d7a619a-8c43-40dd-a54d-a374a4a236d5">16,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd28ea07c0f45ddb0ee2c099f46b450_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTEyLTEtMS0xMDY4OQ_9f9d252b-305f-4818-bcc4-cbb93aa65ddb">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83da63a7df68404bb8a5d3bf6f9e82d3_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTE0LTEtMS0xMDY4OQ_24c8fd1f-3993-4abf-8877-181ad0b55edf">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTE2LTEtMS0xMDY4OQ_e073d9f0-e136-4179-9e4d-2575214fabf5">22,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02abe7b617b74a5399a1101c5b6f2a83_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTE4LTEtMS0xMDY4OQ_92fcf3b3-6617-4beb-aef2-53dcffe00d6f">16,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3649ae2389f94d3892ad79a3dd0a2c98_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTIwLTEtMS0xMDY4OQ_58035d70-b568-4769-bc07-b4660a5ea15d">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51835942cfa4433ba52343a2cc2e074_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTIyLTEtMS0xMDY4OQ_db78f70c-5199-4415-967f-64dee1620845">1,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTI0LTEtMS0xMDY4OQ_aea903fb-56fd-441a-b9bd-13c36643d8b8">22,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Hepsera and Jyseleca.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i99d0b2db1b274fcdbe0f91085003585b"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues From Major Customers</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzI3NDg3NzkwNzQ3MTI_9c58e3bb-cb66-442c-80de-854b9d38cc00" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3d5490822d34a2a99d663996669b4f1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzItMi0xLTEtMjI4MTQ_39dc68fd-2e42-4a12-8c74-0b656113df8c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9126e641d024fb0b335f3046e9ed3ef_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzItNC0xLTEtMjI4MTQ_17f3b17a-64fe-442f-8822-3a8d29c7bda7">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadd8f355bff34661aa70ef78c021e5e9_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzItNi0xLTEtMjI4MTQ_ffa27423-e0a8-4e91-803d-de2d639d02c5">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72e0cdd23483485f9ed6c6ee0844369f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzMtMi0xLTEtMjI4MTQ_c5f4fdbf-2d6e-433c-a539-13e8e25f98d0">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie13c70a71c4c421abd1362ea62569117_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzMtNC0xLTEtMjI4MTQ_6241aa77-2fb1-494f-bdef-b5708161b93f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf5c0818833647d3a25ea25ebe359b5c_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzMtNi0xLTEtMjI4MTQ_3287edf7-b219-4885-9806-fd4510268a91">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if74eda1b891b4ab79e2ca96ed9eada38_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzQtMi0xLTEtMjI4MTQ_9df2753d-5687-40f8-ba9c-a67a9c40ca70">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i087aad162b0642ff8db64f6a05885c60_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzQtNC0xLTEtMjI4MTQ_3ae05aeb-f590-4058-82df-904cf47165fb">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib33ce3a5097547a6b8d4a0f1ba3e9fe4_D20180101-20181231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzQtNi0xLTEtMjI4MTQ_ac1d71ca-945e-4598-bad6-5ca3b35ac0c8">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $<ix:nonFraction unitRef="usd" contextRef="i6a2652179d8b4b0ea00c6e7c08a3f988_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzQ0NQ_3e426941-16bd-492f-b1fe-e728d77d4a47">841</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifbc8462d720446f4b9207d710a136bcb_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzQ1Mg_b5fe6d93-71a0-4fb5-9876-954f2b7b0b5a">741</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $<ix:nonFraction unitRef="usd" contextRef="i0b3598bfff834885b69c49aee403e0db_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzU5OQ_78fcc73c-ea94-463c-bdd5-4cdb23962f7d">101</ix:nonFraction> million increase and a $<ix:nonFraction unitRef="usd" contextRef="ifc3429c7b8484213bf017f41a196b549_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzYxMQ_6d9699eb-5fc4-4126-8959-f46a51e632e2">257</ix:nonFraction> million increase in revenues for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzg4MA_fc38fb1d-990c-4230-addc-4b45474b8825">198</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzg4Nw_de84d300-8fee-46f2-8e3c-382dd08573c2">144</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. Contract liabilities were</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzExNTQ0ODcyMDk0MjY5_31ae3af2-483c-4a42-846e-12b5ec227f81">97</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzExNTQ0ODcyMDk0Mjc4_b56b9b82-4e39-4417-b4d3-e38ea3626a14">45</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. During 2020 and 2019, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_115"></div><div style="-sec-extract:summary;margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzY0Nzc_275100cc-22fc-4931-bfb5-c962ea9c95cf" continuedAt="ia616c44bf52f48dda0400571ce711ce0" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="ia616c44bf52f48dda0400571ce711ce0" continuedAt="i21b106b2583f48bd8d30b813165897be"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities; </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities, and foreign currency exchange contracts are reported at their respective fair values in our Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs in our Consolidated Balance Sheets. The remaining financial instruments are reported in our Consolidated Balance Sheets at amounts that approximate current fair values. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i21b106b2583f48bd8d30b813165897be" continuedAt="ie967afbc7c5146a09cbe9a9fac8224ed"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzY0NjE_4c8b6c47-11ab-411b-b32b-3da6500da74c" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdc1a99bb8647ea8e9692070dabd0e7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMS0xLTEtMA_e864aaed-d54f-41d9-96ad-d388e1fe3e80">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b90eadc154444fb19c9a01d59bf33f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMy0xLTEtMA_15a75190-6591-42a5-afd2-c517ca0bd3d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb6397a7dd8a4e959ad085826f07f21e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtNS0xLTEtMA_057226e4-723e-4f8e-932c-e86097591c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19b4456b05d409e95fc69cc5a327fe7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtNy0xLTEtMA_c28b4e12-58ff-456e-b964-9315530b216f">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689f540e21ea4cc0ab92a8b3e7bc2336_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtOS0xLTEtMA_71f6cfd7-f96c-4ed9-881b-7e177012e319">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33fb3025f9a545e3b9aa62b16b54b596_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMTEtMS0xLTA_6664be8e-8faf-4645-82ae-3b5c41baeca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c0dd0b8e294840a0967d56255d0758_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMTMtMS0xLTA_d1be6431-17be-488a-be8d-bccb816b3f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71dcab1fa94847e09339d54b040213a8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMTUtMS0xLTA_769dca4e-ee94-4d6c-b118-56f580b983dc">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d9226cf83c47e8975915ff0788e426_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMS0xLTEtMA_0c51e3d3-d4ae-4a66-a072-00155b8656f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e924b85a8594cbb8c57fd8d907feee8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMy0xLTEtMA_45e73c1d-f18b-4b65-b7fa-7b1c3b414704">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f4d18853c24b45892069de276317e8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtNS0xLTEtMA_0990e058-c2b1-49d3-904c-108907551444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992f0d769b004f95844a081bc36172fe_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtNy0xLTEtMA_5c52fb8b-9831-41c4-89ae-0499eadecfdf">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b2c1dd010f46709c3e2a7ecbecafe1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtOS0xLTEtMA_0e6b3bd0-8e3e-4b0f-8821-964515caced9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dde5e597fc4c8c9f9392994230aefd_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMTEtMS0xLTA_bdd5bdb8-720c-4feb-b4f9-d88c31a28cd3">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7ddb0e37dc4971959f70137bd43e78_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMTMtMS0xLTA_d155d57e-34a1-4f67-936e-6a2247e915f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6980afe038e45579c072cc6b1f18611_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMTUtMS0xLTA_b4d2bc37-fa9e-45c0-9a2a-4ff816866fa6">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0313e101274d4d69af2e1f0fe44be664_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMS0xLTEtMA_5ffdb508-7407-40f1-bebd-997c92afeb63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2b91e05cc6441ea9289dac6014f9d7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMy0xLTEtMA_ae5af3b5-8247-4ddd-ba85-61767408733a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1569fa49e674423a1c2924dd5b61f56_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtNS0xLTEtMA_97216bd8-1d2c-4918-8ab6-157e60c170d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb3c647adb04138be2978c1bc0e7c55_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtNy0xLTEtMA_e3dde888-a8aa-4d51-a21b-c45e36cf9eca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e53260d7b76425c956afc0063e9e182_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtOS0xLTEtMA_c95f98f2-b374-4033-b475-8d1d964f9946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i589cf24d12624979854f176c47f77cc6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMTEtMS0xLTA_993d8c0b-1881-4b2e-8d97-f9fdbff1a035">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69b13783318c438397f0b5c7220581e1_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMTMtMS0xLTA_ba3f8566-289b-456b-b777-1a55d712a898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id230907331084b6ebd637c4cbd8e25f0_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMTUtMS0xLTA_d7bb2718-2ea9-471e-a75e-4339132218bb">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb2069f86d24b03827a9e9d8f97e538_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMS0xLTEtMA_f9782c29-178c-462f-900f-0cc2cd216dd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6caabcbcf4dc4ebd86cd6edd6a29e8f8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMy0xLTEtMA_7248f426-07a9-4dc4-b9d6-bf9266ec46eb">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cae3a2b8ad849299af80dca8054aee7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctNS0xLTEtMA_52bd0f34-939c-4df9-848e-54f027bd2824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847c77713b0c4b30952627ab78b5d9c4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctNy0xLTEtMA_e0b47c9e-b97b-4a30-b669-dfc3b8911cfc">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i102f4590cd5742c1899de653a60628e5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctOS0xLTEtMA_e19a1976-fc2c-4f3c-b7a0-d3d2322cd956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc748cd30e344577abfa0acf8a8c1844_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMTEtMS0xLTA_9905b264-967f-4d6a-801f-a0b0c3a97239">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bfeb4f55a1452cb6a3d4b5b1ec025b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMTMtMS0xLTA_a7c401d3-28df-4f1a-8c1a-dad67dbe5a25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2044183092a4b149a34f91bca641feb_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMTUtMS0xLTA_f72434b2-2699-445c-88bf-63eeb7b8d2c8">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b95610d80114557965c7323d44db873_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMS0xLTEtMA_5795836e-6b68-4998-b7d3-24093dc057fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cacafade6b2473683f93e114273f77e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMy0xLTEtMA_53084f19-9523-4b56-bac9-07dd466c2a6c">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55cea2844ac74eb395212db775cb345a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtNS0xLTEtMA_413d9ffb-651d-4375-bb9b-268e3fbd2626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91268be96b54e30bdf5db6bd9878dbc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtNy0xLTEtMA_6c4caa5c-8c8a-4cd5-8e73-499c3e429299">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7513aaabb5f4272b2cacd3804a15a28_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtOS0xLTEtMA_35818662-8cce-4909-b52f-df6df6dea4d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee66dbb093f14358827b89e7e0dcd966_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMTEtMS0xLTA_182264f2-a4b6-4df9-85fa-d638d1dbe3cf">9,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e78ecedd654614959bcb071f7acadc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMTMtMS0xLTA_19a2c074-0580-4bb3-8adb-ea8e458eb6f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2ed1b955d740f2b0927118ddcb4df3_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMTUtMS0xLTA_570baead-a9cd-48c9-acef-6d7d7335a852">9,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia906d2214220429abfdad1e08150f915_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMS0xLTEtMA_30560fc9-5bce-430d-8bc6-6ef98cb51c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97dd6c44c604681b3098926fc081208_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMy0xLTEtMA_99788287-baaf-427c-8c0b-c9ffc72b8acc">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4ac453a767416c8e1f4e02b40d3382_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktNS0xLTEtMA_276f2ba8-c0ee-4e48-a4fa-d1ba43ea4cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1ef2a73f9a48a4986b5abce37bdb95_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktNy0xLTEtMA_d7838381-7c67-4733-8d72-adc8efb429a1">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib79fe00c16824d8d9660be7d01074024_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktOS0xLTEtMA_b2226cbf-1d1f-4e85-879d-6324e373063a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245cd04d75b64741b3e002da6bb2c48f_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMTEtMS0xLTA_9087435d-1b91-4783-a053-0adb5bef15b2">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0413ebf760a34b8898709dbf0402b2ac_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMTMtMS0xLTA_26dc0120-f1cb-40c7-b078-949427a679c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a81f06d2f0d45df85572d4243c7b338_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMTUtMS0xLTA_09299480-9fe8-4e44-9dc9-c9e57a85bf63">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cb997734a76456bbb02c472d8bda07c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTEtMS0xLTA_1485acfd-3019-44fa-aaf9-8fd450d178c7">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35fb84b762b84b7aa1431739434b9b21_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTMtMS0xLTA_ab744c05-f48d-4d08-abd3-39dfba5e334e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3e9c9d067843908408309f57f08a32_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTUtMS0xLTA_217f7df2-b59c-45e0-b113-833cde37edb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a64ac1b4c94676835b5826fa5f20c8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTctMS0xLTA_ff97b625-e5d3-4243-8b64-aa85c40f3674">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d69c8fb1e1480c8b25d127290a2aaa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTktMS0xLTA_34716170-807e-485f-bc55-da4a3be736f5">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fd341ae13d453bb4c6a2495482ad7f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTExLTEtMS0w_8cb09849-1d37-40fe-962f-dd4bec18ae32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41eb8f855f04ab18ec5a45dc18339c9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTEzLTEtMS0w_01cb047f-95bd-412d-b9d4-1823d681a844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c4d7e36c9834ea2a50375607652e3ba_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTE1LTEtMS0w_ea1f8359-44d3-4a2c-a803-4df53ccd624d">3,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2dffdc39d4e4c498f9847e218524a71_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTEtMS0xLTA_fd581fb5-eb01-4cf5-a96c-c0c52c99070d">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d94a45eedcf462b8e2ad22dd4dc36e6_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTMtMS0xLTA_1f5f070b-caf5-42cc-9e40-32a3ed5b59b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf015395242a44bda73d3642656c5f16_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTUtMS0xLTA_f5b14ca5-e2db-4a0c-bc86-701f8e7f8a54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifad52fe076ec4556b05b0b1bd02f7c11_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTctMS0xLTA_3162fbfe-2851-4667-8536-17ca749582e9">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i014468a50cb14ec0b4f015914180f3c2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTktMS0xLTA_8ab7210f-831f-4730-84ba-473131a9246e">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01262868b33640a197ec1f4edf4d999e_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTExLTEtMS0w_d4df1021-dcb3-4c59-9c75-523dfcb72a05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c40eca549f4c34976283d9d6ed1e15_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTEzLTEtMS0w_b2c72f60-c886-433a-8646-da00c3dcf064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a4193ff8f34e439051dd12ffb9dbb8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTE1LTEtMS0w_fe9c7c0c-e33b-4be0-a3bb-27f647aaf55d">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5cae775b7f463ea40bc9792ac6e442_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTEtMS0xLTA_c8bbedc2-f406-4c46-96e3-73e4126d7695">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eccad0947fb47f0ab3c1aa00d140b19_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTMtMS0xLTA_f1116b5c-3a66-44ef-8ffa-c4f6169b68bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb4f3afe2714d6db05b71cdf7349336_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTUtMS0xLTA_00f19146-ce18-4158-b332-e2cef48730dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4710ffafb664853b06fb84f1f903262_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTctMS0xLTA_00005436-b523-4b74-adb2-c0bb2b76dbc4">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb3298102714119abcc23920b0fbc5f_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTktMS0xLTA_cffcb696-a0f4-4344-acb2-aea06a1be3aa">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc33840c250349a384747a52147ce1b4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTExLTEtMS0w_4825a42e-dddf-4cd7-bdea-3a689646f3fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab16ab242dcd40f99168ba8f52458d66_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTEzLTEtMS0w_2782ad9f-e846-4a02-a7d4-d6fd1fefbb70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db613f5d89d457781afd75124915704_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTE1LTEtMS0w_4e4d9ff1-7e99-4b4c-9a54-12fdab4385b9">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6760924221ed4b5cba60ea7d2547a8cc_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTEtMS0xLTA_6848f293-85ed-4c1d-aff7-38014634617f">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823810b00b57487a84c912f0198b1fc2_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTMtMS0xLTA_91c2343d-5d59-47b6-8767-0a7cf77e2623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5a2765b359a4c069d0d5da473baa6c0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTUtMS0xLTA_18e1140a-a116-444f-a07f-ff4ee650ffe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f2798614104859bbe54d4ec9712a0b_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTctMS0xLTA_1f6e783c-4b76-4581-82b1-65b46e7eed35">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63750d09d394e93bf20d847c07a673e_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTktMS0xLTA_9dab7fa7-f316-47f2-8a7a-d640a0520d74">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd825c3a419d40c89740d90e5802b238_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTExLTEtMS0w_596f3529-22f4-49e8-ad1b-226824b1501d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6a848a7d8944b99e06faadeba12110_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTEzLTEtMS0w_23bc6ba2-cc01-41e0-b1c6-8089c221ccf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620b03a7ceff4498b7ef8db0524ac079_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTE1LTEtMS0w_7003ec90-6884-416b-b06e-076431288cd3">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1ffad7978e479885f4f62b24f36dc4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTEtMS0xLTA_004556e7-4537-4272-9095-eb536417e783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i284a56e4feb84fa9b3f54659b24ed623_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTMtMS0xLTA_2d1ff0d2-26a9-4725-bd51-05d6f4400446">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17a07fc344b4439808bd61c45decb70_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTUtMS0xLTA_8aec9d0a-8329-46aa-b074-10ad7172279d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98db09bcfe5b4e588506f6849925a677_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTctMS0xLTA_9d2f7345-2ba0-4723-bc81-d980916e3657">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d3b63ebc98b4fc8bc4ead7f256ad433_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTktMS0xLTA_d421e8da-ee6c-4997-886f-2308d4556baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia600e92a5fee4aec9bd9a77aa48c46f5_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTExLTEtMS0w_b41590f4-54b5-4474-87e9-65033d379128">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eefcd80ffa146259d29c8ec79bcd8fc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTEzLTEtMS0w_fec578f8-e951-4756-b830-ff7ecddf6836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451fd8be53df45b88a7acf78165a771b_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTE1LTEtMS0w_68eb38b9-f957-4ce7-b6bc-d04acd3ff588">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1257e571bc436ebc3359c9c23418d7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTEtMS0xLTA_385b5f07-1f70-4211-9601-6ed1ba3c6af9">7,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501409456a97436db0b9b79612bb915b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTMtMS0xLTA_1941f880-507b-4cc9-b996-6891565c26f1">1,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c91186d780d4a76b4dcca46016e88b0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTUtMS0xLTA_8c5bdf58-c912-44c8-b61d-ce8533fc4832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d13c3320274c64bc19f9627e57686b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTctMS0xLTA_d25287e2-2868-463c-a03e-e5e16a6bacd7">9,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31162f66edd14b10a6a33b68539c40b9_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTktMS0xLTA_84542bf9-85d2-497c-96b5-faf02d52682d">13,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe5dab1d5f643f9bce8a2eadf2aa51e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTExLTEtMS0w_66196afa-bfcc-468c-b4fd-a50505e884c4">14,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c54d9501afc40c6a54d229dda2f8f02_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTEzLTEtMS0w_3a00c508-e262-460a-85f0-38a0b7dfca54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88622965efe4116a7e9094e9f179d61_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTE1LTEtMS0w_8737786c-46e8-4ed0-9911-046ede677f91">27,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6760924221ed4b5cba60ea7d2547a8cc_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTEtMS0xLTA_275f339f-c95a-4770-a09a-ee6b8dabc023">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823810b00b57487a84c912f0198b1fc2_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTMtMS0xLTA_f94e889b-27ad-4d3c-aff6-0cc47708133f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5a2765b359a4c069d0d5da473baa6c0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTUtMS0xLTA_08612b06-a22e-4931-9d61-a71af45cd83f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f2798614104859bbe54d4ec9712a0b_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTctMS0xLTA_ba343366-7c8a-41f0-af1b-bd04276def1f">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63750d09d394e93bf20d847c07a673e_I20191231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTktMS0xLTA_52bb6420-48ac-4e6b-9449-d59902e75fcb">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd825c3a419d40c89740d90e5802b238_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTExLTEtMS0w_44286abc-2564-4630-9d14-ca72ccc4c4bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6a848a7d8944b99e06faadeba12110_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTEzLTEtMS0w_e5f7da11-c3fb-4bff-9c9a-e9ca1a9d5cf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620b03a7ceff4498b7ef8db0524ac079_I20191231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTE1LTEtMS0w_91e88250-b263-414b-a083-c5e95ec33366">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1ffad7978e479885f4f62b24f36dc4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTEtMS0xLTA_576a3b32-69db-4594-a643-b9cbfa852eef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i284a56e4feb84fa9b3f54659b24ed623_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTMtMS0xLTA_d17457a7-bbea-4f40-902b-b59c0fafd200">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17a07fc344b4439808bd61c45decb70_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTUtMS0xLTA_907357db-915f-414a-b17b-046bfaaec010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98db09bcfe5b4e588506f6849925a677_I20201231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTctMS0xLTA_9e86673b-2fa5-4529-af52-223fe1f18656">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d3b63ebc98b4fc8bc4ead7f256ad433_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTktMS0xLTA_f07d97b8-a0e4-4900-817f-0e0863f1eda6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia600e92a5fee4aec9bd9a77aa48c46f5_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTExLTEtMS0w_8cb0208e-8e3b-40ec-a5f1-48633d43ccfa">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eefcd80ffa146259d29c8ec79bcd8fc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTEzLTEtMS0w_2fe6c38f-210e-4615-9c71-0fdd795d6312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451fd8be53df45b88a7acf78165a771b_I20191231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTE1LTEtMS0w_dac04bbe-f3f3-4462-a035-7f43f6b8bbd8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1257e571bc436ebc3359c9c23418d7_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTEtMS0xLTA_c5111e76-81fd-434c-80d1-f544e73f9e90">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501409456a97436db0b9b79612bb915b_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTMtMS0xLTA_ac685721-61cc-4932-840a-10663d94c581">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c91186d780d4a76b4dcca46016e88b0_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTUtMS0xLTA_a526a89f-9fe4-4bf3-8305-b7685b445601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d13c3320274c64bc19f9627e57686b_I20201231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTctMS0xLTA_66ab0741-52e6-48d2-949c-6d822e2e897f">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31162f66edd14b10a6a33b68539c40b9_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTktMS0xLTA_affb58e1-b381-42eb-9e40-8ed274067395">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe5dab1d5f643f9bce8a2eadf2aa51e_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTExLTEtMS0w_cc8ebaea-b597-432a-96e1-89b38f5416a0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c54d9501afc40c6a54d229dda2f8f02_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTEzLTEtMS0w_b84657aa-4a7d-454c-bc58-f490d59a5e6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88622965efe4116a7e9094e9f179d61_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTE1LTEtMS0w_2a482361-9900-4b48-b55e-78bef9152439">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments not measured at fair value and excluded from the above table were limited partnerships and other equity method investments of $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzIzODQ_f204faad-3fe8-473c-9215-243d1ef37cf7">58</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzI0MDE_a3b00820-1062-46e9-a25a-b5cd118b7ea4">24</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively and other equity investments without readily determinable fair values of $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzI0MjA_dfdfdf63-0f9d-4672-853c-8cca77ff14f6">204</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzI0MzY_85e766fd-03c0-4e9f-8954-241e23b21b1e">82</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzI3MTA_eff3d97d-c491-44d6-9a29-7031bd2f9ff6">1.7</ix:nonFraction> billion and net unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzI3MTc_5f057a17-6b3d-4066-99da-41e42b31345e">1.2</ix:nonFraction> billion for the years ended December&#160;31, 2020 and 2019, respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzY0NjM_1c5f0713-5273-468a-90c2-1e93f222348e" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities in our Consolidated Balance Sheets:</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16426d78ce7c4baeb60f73d40c7360a7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzEtMS0xLTEtMA_2217bf26-34e1-4881-9584-7072607cb525">4,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e7f31b83842cd95af2e19292bd16e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzEtMy0xLTEtMA_a94c8c3a-b05c-40e0-9ff5-41206543d8ba">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3e3a8f25534e47821628e02a0a3563_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzItMS0xLTEtMA_f22b9b42-9548-449d-9653-ef470ab5a16a">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1322bc486afc430a880d2d9343dc7c55_I20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzItMy0xLTEtMA_830779f6-e7fe-4a0b-9c48-d946e0f0f512">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2100cafa2bd04f0fa1ca7fd4b3cfcbfe_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzMtMS0xLTEtMA_117fb482-77d7-4d49-865c-45325185d703">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc2d816fd7043748729bb6623b61959_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzMtMy0xLTEtMA_727a595d-afa8-40f8-92ca-6c7a625df44e">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzQtMS0xLTEtMA_951df179-af07-444d-a9c2-6e29b46fe645">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzQtMy0xLTEtMA_7b80822f-de65-4956-92ba-409062e80694">11,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Consolidated Balance Sheets. See Note 4. Available-for-Sale Debt Securities for additional information. See Note 11. Collaborations and Other Arrangements for additional information on our equity investment in Galapagos.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie967afbc7c5146a09cbe9a9fac8224ed"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18 month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term senior unsecured notes and term loan facility, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="i3eded22e6e7b4c3b9606256b7f9aa791_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQ5NDk_11de2ad1-22ad-4019-8112-2d6f94f603f3">34.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i053b4f6a4ee446758474a88c7466df66_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQ5NTY_563b51dc-dac1-40cf-8047-a3a519ac8901">27.3</ix:nonFraction> billion at December&#160;31, 2020 and 2019, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="i743c158a26c1458b8cc125718d80bd03_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzUwMTY_bb848566-255f-486d-a103-f3c517f1b489">30.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i120926cc5cde493e8d537eff1e3bf7e5_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzUwMjM_f1b5ee63-d8a7-473b-b21a-41bc336e1a65">24.6</ix:nonFraction> billion at December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, in connection with our acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;). See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, in connection with collaborations and other equity arrangements we entered into separately with Pionyr Immunotherapeutics, Inc. (&#8220;Pionyr&#8221;) and Tizona Therapeutics, Inc. (&#8220;Tizona&#8221;), we also measured fair values of our exclusive options to acquire the remaining outstanding capital stock of Pionyr and Tizona on a nonrecurring basis. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019 and 2018, we measured IPR&amp;D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (&#8220;Kite&#8221;) at fair value on a nonrecurring basis, and recognized pre-tax impairment charges of $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQzOTgwNDY1NDA2MTY_8a18dc50-79da-47b0-91c2-98148d479d91">800</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQzOTgwNDY1NDA2MzE_7a9e9845-de54-49d3-8c5f-f86b1914c453">820</ix:nonFraction> million, respectively. The fair values of the acquired IPR&amp;D assets are estimated based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts. See Note 9. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other level 3 liabilities were our contingent consideration liabilities, which were not material at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_118"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTQ_03976de2-b6d0-4150-88e7-5f6a2e53de54" continuedAt="ief8e752c4b75478aacf64c2b69761e0d" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES </ix:nonNumeric></span></div><ix:continuation id="ief8e752c4b75478aacf64c2b69761e0d" continuedAt="i1b72c0cd86b948eeba2dfe3342e6f5cc"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMTM_4a24dff9-e4d9-4fb2-b3c5-99c7575e3631" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMi0xLTEtMA_c6fad58b-c964-4df3-81df-08daf8f81707">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItNC0xLTEtMA_c28a2771-3717-4c21-b73c-4c96f4fb13a7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItNi0xLTEtMA_7f7fc449-6f4c-4104-bc53-3429de658838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItOC0xLTEtMA_8c1608f7-fd18-44bf-8438-ab406b8308b6">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTAtMS0xLTA_1b05fc2f-8138-4bba-910c-165c6e2a8695">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTItMS0xLTA_9778835e-e0d2-4873-925b-518b0f0f2298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTQtMS0xLTA_c13baf2f-0873-4ee2-9933-26c5b0832115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTYtMS0xLTA_fba4c363-2c50-40e0-82c7-a39157163e2b">2,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595ca0a2d84447909de4d92345625390_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMi0xLTEtMA_55c1babb-4518-4f61-9c04-35325a30e6a8">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595ca0a2d84447909de4d92345625390_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtNC0xLTEtMA_a270f7c4-84de-4afe-9c5e-c2e270f2a3f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595ca0a2d84447909de4d92345625390_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtNi0xLTEtMA_1b5e052b-634a-4103-8770-fe958e4a81be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595ca0a2d84447909de4d92345625390_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtOC0xLTEtMA_eac6c4ad-7514-484d-a41e-c564f996b3fb">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTAtMS0xLTA_9655b1d6-158e-4dc9-9d5b-8474ceddbf9b">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTItMS0xLTA_dee0e7ba-2ee1-406d-a20a-9cb9e34a537d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTQtMS0xLTA_7edf7677-079f-4302-84b0-5eefcb1b92b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTYtMS0xLTA_1aa1146c-4adf-4565-8707-e362835aa053">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390292299b6b4a5486f594d72b417724_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMi0xLTEtMA_61816ff5-6d1e-4f36-9158-65f6df8d7286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390292299b6b4a5486f594d72b417724_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtNC0xLTEtMA_d47f0e83-b2c7-4cb2-a481-ef1136f6b800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390292299b6b4a5486f594d72b417724_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtNi0xLTEtMA_3b0c9eaf-b5ae-4a41-a6e3-1507111c96e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390292299b6b4a5486f594d72b417724_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtOC0xLTEtMA_0df7388f-a718-4d6a-8437-164d75346e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b54212c105142999597c1d3fb250563_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTAtMS0xLTA_fa3aa130-cdd7-4f09-ad94-f3acb500591b">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b54212c105142999597c1d3fb250563_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTItMS0xLTA_7f78b66a-5b2e-40a7-9258-a11e946ef9b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b54212c105142999597c1d3fb250563_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTQtMS0xLTA_13629ae0-1051-4875-8ea4-e808217b84a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b54212c105142999597c1d3fb250563_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTYtMS0xLTA_76b2ccce-45dd-4f48-bf57-11f24375eaf5">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMi0xLTEtMA_e4d66bec-a815-40ba-856b-239f48adaee2">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtNC0xLTEtMA_ab533db2-9ecc-471a-a560-6a7c2a27374c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtNi0xLTEtMA_69540feb-fa45-460b-a97f-56418cb66329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtOC0xLTEtMA_2ec66c17-0c11-4415-afa2-9d1a61e67a71">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTAtMS0xLTA_76f731f1-90fc-4dfd-8340-da1144e49c25">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTItMS0xLTA_2f4d844e-8e6e-4590-b833-43b1fc18bb84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTQtMS0xLTA_91ca76fe-59a0-4a5c-919f-8e10b33918a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTYtMS0xLTA_793fc35b-486f-4285-8324-086d86c014df">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMi0xLTEtMA_cff4f806-926b-4ae8-97a2-a0344ca2f5f1">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtNC0xLTEtMA_b4cc6bf8-748a-4024-9f93-7ca2b42a305c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtNi0xLTEtMA_c3ab8796-77b8-4637-9734-214d4c70785b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtOC0xLTEtMA_beec92c1-25dc-4475-b436-69882625a78d">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTAtMS0xLTA_2f193496-5987-4837-9e40-f3e827515447">9,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTItMS0xLTA_76745d66-998a-4a5d-b5a7-e821f77a7aa4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTQtMS0xLTA_b49baa26-79f7-4029-aa9f-f2ae0889f6b3">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTYtMS0xLTA_28e18c1d-4bf7-4b96-98b9-4db79df24a52">9,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMi0xLTEtMA_37fa6f0c-c752-4926-9067-f333ff874a85">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctNC0xLTEtMA_886cdc1d-c06e-455b-83fd-af02bd6beb77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctNi0xLTEtMA_9cf596fe-c144-490d-ab24-df29d43f0571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctOC0xLTEtMA_da872f57-90f6-4e53-8165-342fb6d7fdde">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8f006f881a4957896607c58789822b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTAtMS0xLTA_12eba07b-2d12-4686-b3b2-831d794471ef">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8f006f881a4957896607c58789822b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTItMS0xLTA_9c1ac3a1-db1c-4cbe-af39-c76aed29c68a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8f006f881a4957896607c58789822b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTQtMS0xLTA_9d0390ee-bc60-444b-8570-357a92bba59e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8f006f881a4957896607c58789822b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTYtMS0xLTA_7fa1f1ad-ef6c-40c0-97c4-aabfa168517d">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMi0xLTEtMA_88658ddc-38ce-4b87-9a42-e07574c25a3c">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtNC0xLTEtMA_2608dc84-59b7-4af9-b7cf-c5abd361a377">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtNi0xLTEtMA_95f7cf74-748d-4f36-91f6-042a92e34d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtOC0xLTEtMA_6a88803a-ffe6-4c6b-9b7a-9080f7304b86">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTAtMS0xLTA_734bef67-9084-4b86-96eb-097277acbdf8">16,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTItMS0xLTA_db63755c-5616-4b30-8344-4d6ce858b9e9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTQtMS0xLTA_fc6c039e-9640-448e-a8e8-06b784b1a3c2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTYtMS0xLTA_cb436c84-18b7-44f8-8147-f1d82f2316b3">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMTU_5ff2a813-92a4-42a0-8ed1-404f84e05489" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16426d78ce7c4baeb60f73d40c7360a7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzEtMS0xLTEtMA_cd3da68b-45c4-4feb-b2a4-7f5dac68747e">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5e7f31b83842cd95af2e19292bd16e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzEtMy0xLTEtMA_746a4156-42e1-4b3e-a627-a40b68459741">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fc82ab7f9c4eaba8049dcccb0fabcc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzItMS0xLTEtMA_df081b93-7cfc-4a6f-8ec6-9faeea715ff2">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e58eabfb144b2b803232b6b3af397d_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzItMy0xLTEtMA_579ab7b4-586a-4278-9da2-7650f17fd9ac">12,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d35182bfdc94f2e9d411da9d4df6871_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzMtMS0xLTEtMA_13bbce5b-7ba6-44d6-9b35-986f51780dd7">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28cbe18165a844a88047e90985c3a97c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzMtMy0xLTEtMA_51aaf5c7-6b95-440d-9bac-6377c52a002e">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzQtMS0xLTEtMA_e07b6bf5-21c8-4968-ae0c-bcbbc8c39e47">2,026</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzQtMy0xLTEtMA_52375883-6acb-4c05-b400-7bb1f0fcd400">16,500</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i1b72c0cd86b948eeba2dfe3342e6f5cc"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzAzODQ_d124de41-8645-4a71-b455-2db3c09e3458">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzAzOTg_6e9fb634-e1d4-4c0a-9e8b-ee32a1aae41f">37</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively, and is recorded in Prepaid and other current assets on our Consolidated Balance Sheets. There were no write-offs of accrued interest receivable during the years ended December&#160;31, 2020 and 2019.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMTc_bbc93a08-7fc4-44a9-b400-85a87d885b87" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzItMS0xLTEtMA_75943f8d-9355-48a3-a503-f676c389e61c">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzItMy0xLTEtMA_983a3c3d-3321-4b3f-bad9-a9ad4b9d354f">1,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzMtMS0xLTEtMA_1a1174fe-630a-4e5f-a85e-0106f41494ab">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzMtMy0xLTEtMA_e43de84a-ef3e-4aa9-89d2-85419d2d65a3">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="gild:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzQtMS0xLTEtMA_c8839e0e-bd72-423b-b84e-554da0723dd2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="gild:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzQtMy0xLTEtMA_68b55fb0-08cd-4dad-94ff-dac0f78fca6c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzUtMS0xLTEtMA_5099f728-59fd-4275-ad3b-e67702e9a210">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzUtMy0xLTEtMA_add346e0-513e-4192-a4f0-c87201e564d3">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMDg_3612590a-1e11-49ae-9adf-ee57e85cf77d" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTItMS0xLTA_88bcaf60-733b-4a92-b4f3-e33438a4d3d2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTQtMS0xLTA_2daa7bac-ed2b-43f4-9361-d0ba5a581282">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTYtMS0xLTA_4cac7063-fc80-421c-9b80-24745432c046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTgtMS0xLTA_f2b85c0f-3f21-426b-97f0-5fd14914f3f9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTEwLTEtMS0w_2ac2d499-fca9-42ad-8de8-3da83834d494">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTEyLTEtMS0w_f61fe5fd-2ddc-4386-985a-0eb13bbe96dc">1,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a total of <ix:nonFraction unitRef="security" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzU3NA_49c27b6d-55b0-4ee9-8b68-9f7601ab679f">75</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzU4MQ_b4a05796-23dd-43dd-afac-1a26b354331f">305</ix:nonFraction> positions which were in an unrealized loss position as of December&#160;31, 2020 and 2019, respectively. Aggregated gross unrealized losses on available-for-sale corporate debt securities were not material, and accordingly, <ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzA0MjA_96c54133-0a5f-40f5-8989-19a31c6807d0"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzA0MjA_e7a23423-3416-4849-b5b5-1fd4bd0e7d8f">no</ix:nonFraction></ix:nonFraction> impairments were recognized for the years ended December&#160;31, 2020 and 2019. Gross realized gains and gross realized losses on available-for-sale debt securities were not material for the years ended December&#160;31, 2020 and 2019.</span></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_124"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM1Nzk_cc481c77-4f8c-4e68-8099-c0a1aea90ec8" continuedAt="i2eebe97e4acf4abfa8cf8f88e26594f2" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i2eebe97e4acf4abfa8cf8f88e26594f2" continuedAt="ia82fcf4eb64b4b5d9fd7c381ec2bc05f"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates, and as a result, varies over time. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in Other income (expense), net, on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="i993dfcf3896148f697a431026afd4f27_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzE5NDg_1fd8cc3c-e544-45ae-817b-8a02df8cc5c4">18</ix:nonNumeric> months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI at December&#160;31, 2020 are expected to be reclassified to product sales within <ix:nonNumeric contextRef="i993dfcf3896148f697a431026afd4f27_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzIzNjc_9882b12f-5fac-4cdd-a99b-1b881a064644">12</ix:nonNumeric> months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the years ended December&#160;31, 2020, 2019 and 2018 are included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding totaling $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzI2NDc_ec73a101-ab5b-44ef-8839-48fb6b75f5e8">2.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzI2NTQ_c02dacff-d981-40af-8e72-33d406333476">2.9</ix:nonFraction> billion at December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia82fcf4eb64b4b5d9fd7c381ec2bc05f" continuedAt="i44b3dc35ac1343d494fc89dd3e465208"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM2MDc_13a61721-fb48-4515-9e90-95d6e12deaa9" continuedAt="i8f7849ad97ef4521bcca7f5be6135247" escape="true">The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: </ix:nonNumeric></span></div><ix:continuation id="i8f7849ad97ef4521bcca7f5be6135247"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10964ae7f7a549f6ab1ff180665f69ba_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzQtNC0xLTEtMA_f3579cd1-cb6e-4d4f-89b3-c9192367c601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bf3fc79d1fa49ce89bbe681181cd43d_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzQtOC0xLTEtMA_8d9f7af2-77c1-4037-b6c4-9c239c7e0779">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bac09c30bc4649b266ae9b0b2f845d_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzUtNC0xLTEtMA_52eeb7f6-a32a-47e9-a0f1-ef50ed3572fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedaad0d104904edbae770e12c309829c_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzUtOC0xLTEtMA_1f8d0155-0f2b-4e34-9b06-b891c309bd4c">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac161d27eca4bbdbc92850f94d7212a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzYtNC0xLTEtMA_f0b43d09-f8f5-455d-846c-64c527b7b8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ac161d27eca4bbdbc92850f94d7212a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzYtOC0xLTEtMA_384fe2f8-3466-4f19-9d13-592afd1588f2">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70691dc9abb4d69a28b5f9142fd5dd6_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzgtNC0xLTEtMA_440fccee-83bd-4e49-9e8d-d5430c2c26c4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82be8c76fac444ae8b5be2464102adda_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzgtOC0xLTEtMA_6b27b0a9-fcad-467a-a6fb-17cc965eba79">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b7ffc02a4648be92cdc6a03d99c1c1_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzktNC0xLTEtMA_bf331011-00f4-42e3-ab6d-9adbef917388">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18b7ffc02a4648be92cdc6a03d99c1c1_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzktOC0xLTEtMA_9752df41-7ba1-476a-b08b-bb648e8d11d5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzEwLTQtMS0xLTA_b6ae89ab-38cb-49b8-9afd-d4fbd76ef541">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzEwLTgtMS0xLTA_67bcbb3c-a7f2-4f7b-ad10-8d063093d27a">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.339%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784d730b592f4dda968b2f2a0865acb7_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzQtNC0xLTEtMA_87707c6b-3e32-4fa3-ad3b-f03e49e72b76">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7830a932cee94f22aa34ced72f487d72_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzQtOC0xLTEtMA_48865e3d-502f-41e3-be55-60444a6017f3">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd75011da414b8599c1d9723149a895_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzUtNC0xLTEtMA_aa2172ca-b003-440c-8be0-65f8904540a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89c3d1c8982e40339444fa81b506c130_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzUtOC0xLTEtMA_ce819ee9-6533-43cc-b4d8-110ccb868418">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4066de7a73468a997dd8cb92bf3a1b_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzYtNC0xLTEtMA_e2df348e-b88d-4caa-8c62-3ba0b789ac3e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac4066de7a73468a997dd8cb92bf3a1b_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzYtOC0xLTEtMA_f9792245-2c25-48e5-a345-dd3c8c2d8fa4">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab6fcb4f58b4822ad8e346558c2c980_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzgtNC0xLTEtMA_d965461e-3d8c-410b-9d22-791723149a35">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85193bddbf1d4369b3eed33741718ebf_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzgtOC0xLTEtMA_dbe98eca-049c-443e-af0f-59e334736688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38a8065706742818aa8f128c9d384dc_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzktNC0xLTEtMA_7f2b23e5-ad18-45ce-8a84-80e1e93f3e0d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38a8065706742818aa8f128c9d384dc_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzktOC0xLTEtMA_96c88bc7-8db0-4043-a42b-0d3fd46a98c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzEwLTQtMS0xLTA_5da90f9f-676e-41f0-a14a-80cf1fa56a9d">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzEwLTgtMS0xLTA_58a6882e-754d-4180-a866-3ec6c213b39b">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM1ODE_ec6c5064-06cf-40ee-8a69-77d9bb551862" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzMtMi0xLTEtMA_6cad157c-698a-48e8-ad6b-f4ec3c1ae221">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzMtNC0xLTEtMA_d38d3f04-e8ab-4291-9211-d1cbf24a2170">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzMtNi0xLTEtMA_5d219869-7356-4c3f-bf9e-243dde4ee17f">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzQtMi0xLTEtMA_f92b52ca-b349-40e5-bc45-d8daed210789">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzQtNC0xLTEtMA_1e0d9c08-f2fe-484d-9710-99f1c82b6ec0">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzQtNi0xLTEtMA_b87abd02-d94d-4093-8309-eab3df48dd1c">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzctMi0xLTEtMA_408df38a-0c09-43f2-8117-e148cd1d0daf">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzctNC0xLTEtMA_c81fb7eb-dc3e-4421-b1bf-cb560d0afeef">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzctNi0xLTEtMA_73e766ef-ff23-4ca0-acd0-4c7eef690d48">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Consolidated Statements of Income. There were <ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzMyODg_695ea1b0-4ec0-4532-9cbc-de4ff0e09423"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzMyODg_97d1c896-5720-402b-a5ce-0e52591b3447"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzMyODg_d1741cda-97db-4063-ae8e-b8e1e87ccc2e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the years presented.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i44b3dc35ac1343d494fc89dd3e465208"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we only held foreign currency exchange contracts.&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM2MDE_11ac2c4a-5e25-4f4e-abdf-267a780fae74" continuedAt="i95350a05bb9540cdbf7a25ffc85e0e5a" escape="true">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i95350a05bb9540cdbf7a25ffc85e0e5a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtMi0xLTEtMA_d373a732-dbd3-401a-8d07-f9f11fef219a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtNC0xLTEtMA_a2e9a722-1f5b-484d-b54f-d05ded3defc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtNi0xLTEtMA_fe7b9ca3-049b-4567-8d08-6b0cce131c68">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtOC0xLTEtMA_057cf406-b160-400d-b95a-574eedc93693">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtMTAtMS0xLTA_02f586be-3b41-43ff-b7bf-fb03de985302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtMTItMS0xLTA_ea2cc2c3-a8d2-48af-9a9e-c81bab40c786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtMi0xLTEtMA_30412c7d-201c-4bbd-b260-38dce4434ddb">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtNC0xLTEtMA_45c098df-717b-4690-b918-fc6ecd7b548c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtNi0xLTEtMA_13275c5d-66f6-4f34-b16b-8427edcd497a">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtOC0xLTEtMA_a09581fb-cc3e-4f31-a04f-ea5bdddd8eb0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtMTAtMS0xLTA_a95f3d5f-e0d1-4dbc-9cec-7e762af44a1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtMTItMS0xLTA_078cdb05-e124-4827-81d3-9f6523325799">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtMi0xLTEtMA_3e9e8e4b-1f55-47c6-b274-df1023f8c431">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtNC0xLTEtMA_4fff6864-7c32-4fd6-af09-a44832a13681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtNi0xLTEtMA_039abb73-46a2-4e9c-838e-2ee312a61070">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtOC0xLTEtMA_896f773b-d961-43f6-b37e-618bec9519ed">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtMTAtMS0xLTA_5cb96dc0-8bc5-4dfa-95b2-ebca9f2b164d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtMTItMS0xLTA_dc954eeb-5f78-4f52-9ae4-b8ed46602bd8">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctMi0xLTEtMA_3fa6e350-970f-4d8f-a3e3-98ac62cf58c7">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctNC0xLTEtMA_967181ea-2e5b-4600-a5a5-89dedc39ee28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctNi0xLTEtMA_68d93832-d174-41c0-b7dd-3df8a7de249c">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctOC0xLTEtMA_ea550c60-8fbe-4fa0-adbd-02a56ee979b0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctMTAtMS0xLTA_3e00ce15-c63b-436c-9ec8-85b9ccd662a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctMTItMS0xLTA_0c63bad6-ada9-44cc-bc66-eeeac9d170b6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_130"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzQ3ODQ_5cb77ec7-c58b-4354-ae55-74acd5c8f7ad" continuedAt="i4ede062daf904b0b9e1010eee780ea0a" escape="true">ACQUISITIONS </ix:nonNumeric></span></div><ix:continuation id="i4ede062daf904b0b9e1010eee780ea0a" continuedAt="i87251194dfdc469c9502e009bc3df0e9"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forty Seven, Inc. (&#8220;Forty Seven&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On&#160;April 7, 2020, we acquired all of the then issued and outstanding common stock of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8dad5026e5bc4d748d8400db3eeac8e2_I20200407" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5MjA_eaed6e16-c3b3-4448-a9fe-61553a26add8">95.50</ix:nonFraction> per share in cash, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i8dad5026e5bc4d748d8400db3eeac8e2_I20200407" decimals="-8" format="ixt:numdotdecimal" name="gild:AssetAcquisitionCashOutflowNetOfCashAcquired" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5MzU_efbad826-a46a-4f84-aba8-f4abf7b54587">4.7</ix:nonFraction> billion, net of acquired cash. As a result, Forty Seven became our wholly-owned subsidiary. Forty Seven&#8217;s lead program, magrolimab, is an investigational monoclonal antibody in clinical development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. At the acquisition date, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i1ebcc5583e8449d2977a0c7e88f011e4_D20200407-20200407" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5NTM_fdeb498a-e1d7-4aae-bbb6-6377e57ee26a">4.5</ix:nonFraction> billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses on our Consolidated Statements of Income. In connection with this acquisition, we recorded $<ix:nonFraction unitRef="usd" contextRef="i1ebcc5583e8449d2977a0c7e88f011e4_D20200407-20200407" decimals="-6" format="ixt:numdotdecimal" name="gild:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5NzE_b438e919-5f8a-47e6-b73c-7af37e5146e8">202</ix:nonFraction> million of assets acquired primarily consisting of deferred tax assets. Liabilities assumed were not material. We also recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i94aca37dece54db88d94195652d7be2a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5OTA_053312f0-7678-4f0c-a6da-70dd1616d630">144</ix:nonFraction> million related to the cash settlement of unvested Forty Seven employee stock awards attributable to post-acquisition services, which was primarily recorded in Research and development expenses on our Consolidated Statements of Income, for the year ended December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 13, 2020, we entered into an agreement and plan of merger (&#8220;Agreement and Plan of Merger&#8221;) to acquire Immunomedics, a company focused on the development of antibody-drug conjugate (&#8220;ADC&#8221;) technology. Immunomedics researches and develops biopharmaceutical products, particularly antibody-based products for patients with solid tumors and blood cancers, and manufactures and markets Trodelvy. Trodelvy, a Trop-2-directed ADC developed by Immunomedics, is the first ADC FDA approved for the treatment of adult patients with metastatic triple-negative breast cancer (&#8220;mTNBC&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the acquisition was completed and Immunomedics became a wholly-owned subsidiary of Gilead. The financial results of Immunomedics were included in our consolidated financial results for the year ended December 31, 2020 from the date of the acquisition. Immunomedics contributed $<ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwOTI_f128f593-f2eb-4a84-9c22-20988e4ac38d">49</ix:nonFraction> million of revenues and an immaterial net loss from the date of the acquisition through December&#160;31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration for the acquisition was $<ix:nonFraction unitRef="usd" contextRef="i91c056cec2314052b0ad7bf56bb9f361_D20201023-20201023" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwMTk_ad16f880-953d-4eb2-9084-1798a6445bfc">20.6</ix:nonFraction> billion, consisting of a $<ix:nonFraction unitRef="usd" contextRef="i007de77796ce442bb17cf6397fc2f2b4_D20201023-20201023" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwMzg_fe3da8bd-a4ae-4e5c-8836-273781b1729a">20.4</ix:nonFraction> billion cash payment to the outstanding Immunomedics common stockholders and a $<ix:nonFraction unitRef="usd" contextRef="iead588e99e254c5682217485bb77e1dd_D20201023-20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwNTY_aa020f6e-4a07-435f-9935-56a6cb181985">242</ix:nonFraction> million cash payment to equity award holders of Immunomedics for the vested equity awards and accelerated vesting of stock-based awards attributable to the pre-combination period. We financed the acquisition with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $<ix:nonFraction unitRef="usd" contextRef="i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwNzU_6b92a0a8-4320-40b7-a979-71e525a50a2b">1.0</ix:nonFraction> billion borrowing under a new senior unsecured term loan facility and cash on hand. See Note 12. Debt and Credit Facilities for additional information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i87251194dfdc469c9502e009bc3df0e9" continuedAt="i69efa4abefc749e6a9ea3ae844e5b9a9"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcxMTE_6dee6ca2-bdef-40ac-910d-ec0fd65d40f8">289</ix:nonFraction> million related to the cash settlement of the accelerated share-based compensation expense attributable to the post combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. We also recorded other acquisition-related expenses of $<ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcxMjk_322c6ff3-d090-4d2c-86cb-bc2fe9d8c851">39</ix:nonFraction> million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2020.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1Xzk4OTU2MDQ3MjM1MDU_daa21937-129c-4bd5-8e3d-aa1761585d6b" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzAtMi0xLTEtMTAwNjM_ab47e772-e83b-458b-85ab-0155f650b5d0">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzEtMi0xLTEtMTAwNjY_574135eb-6182-4548-970e-47ad3a4a8b93">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8644568592004cfc961c871471a2665e_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzMtMi0xLTEtMTAwNjk_f93a1d77-869d-456c-b78f-9235d9f84362">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0d69f623804c20b69d4aaa63420c60_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzQtMi0xLTEtMTAwNzI_9686dd85-a640-42b6-81c2-6350e4794b86">15,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzUtMi0xLTEtMTAwNzU_39ae15c3-b53c-4c84-b2d3-a12891ad4ae7">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzYtMi0xLTEtMTAwNzg_8657ce19-8af3-4235-aadd-f69e8f6d5e42">4,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" format="ixt:numdotdecimal" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzctMi0xLTEtMTAwODE_68c6d88e-2ea1-448b-968d-7abf504f7c94">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzgtMi0xLTEtMTAwODQ_1fac414b-7382-4aee-940a-1f5fa1c7c2d6">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzktMi0xLTEtMTIxMTk_5270191a-39c9-4155-a484-39d3ab2897b4">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzEwLTItMS0xLTEwMDg3_c46ba93e-6ea0-4ae0-86a6-d491ddb087ca">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzExLTItMS0xLTEyMTIz_d31e4f1c-0712-4985-b996-2025ecdf38c2">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value step-up adjustment of $<ix:nonFraction unitRef="usd" contextRef="i91c056cec2314052b0ad7bf56bb9f361_D20201023-20201023" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzcwMTY_82fd04ce-b785-45c0-b6bd-d885465f380f">881</ix:nonFraction> million, included in the inventories of $<ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTM5NjM_81dd7866-5e04-4749-b113-2e03c5ecc8a6">946</ix:nonFraction> million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment is being recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory is sold to customers from the acquisition date. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i8644568592004cfc961c871471a2665e_I20201023" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTM5OTU_441983f2-83be-4238-97d5-6d1f18ef4ebc">4.6</ix:nonFraction> billion represents the estimated fair value of Trodelvy for mTNBC as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for mTNBC and a discount rate of <ix:nonFraction unitRef="number" contextRef="i8644568592004cfc961c871471a2665e_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzExNzI_6064fa87-fa0b-4bbe-87a0-98d41ee48c69">7.0</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i48328e269350428eaf5fc46371917dc9_D20201023-20201023" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcyMjY_07dd4b80-e609-4f15-8df3-6076b2ba6277">12</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets related to IPR&amp;D consist of Trodelvy for hormone receptor positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;), metastatic breast cancer, Trodelvy for non-small cell lung cancer (&#8220;NSCLC&#8221;) and Trodelvy for urothelial cancer. The estimated aggregate fair value of&#160;$<ix:nonFraction unitRef="usd" contextRef="i3d0d69f623804c20b69d4aaa63420c60_I20201023" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQwMjc_9bc6c725-ff5f-440a-babd-39fa2c5ef791">15.8</ix:nonFraction> billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to these assets and a discount rate of <ix:nonFraction unitRef="number" contextRef="i3d0d69f623804c20b69d4aaa63420c60_I20201023" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzEyODU_937f3b91-620d-49d8-99af-d4cb64bc0f77">7.0</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development costs, sales and marketing expenses); probability of success; the discount rate selected to measure inherent risk of future cash flows; and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;D efforts. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i69efa4abefc749e6a9ea3ae844e5b9a9" continuedAt="i733f88b198a342b8bfcf8faa53d5afbc"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded an intangible asset related to a license and supply agreement with a third party, which was entered into by Immunomedics prior to the acquisition. Under the agreement, the third party was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $<ix:nonFraction unitRef="usd" contextRef="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQwNjM_970f892a-52ea-4452-89e4-c6415f44087f">175</ix:nonFraction> million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of <ix:nonFraction unitRef="number" contextRef="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzEzOTA_36f6929f-f17d-47e6-a55f-2771ae04c586">7.0</ix:nonFraction>%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i8a7d2971f9e04bd8a1de84efaccec570_D20201023-20201023" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcyNTA_e2ae0e10-88fb-4a80-a535-a1162c601de8">15</ix:nonNumeric> years on a straight-line basis. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust, a Delaware statutory trust (&#8220;RPI&#8221;), prior to the completion of our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $<ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-8" format="ixt:numdotdecimal" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQwOTc_bcc172c1-27a7-443d-ab71-24bdf0d255ab">1.1</ix:nonFraction> billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and effective annual interest rate of <ix:nonFraction unitRef="number" contextRef="i07cc7232a64946abb68b060bdcf121a6_I20201023" decimals="3" name="gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQ0ODE_9cb8e5da-0e0a-4e8e-abe9-c299b59de04f">2.5</ix:nonFraction>%. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over <ix:nonFraction unitRef="number" contextRef="ia544b37590e74cd9b7228b42939d36ed_I20201023" decimals="0" name="gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcyNzc_1933944a-2ace-4fc0-873a-b369123fc890">16</ix:nonFraction> years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQxMzE_a585d17a-c49f-4cc5-9169-43587d8ab50e">4.0</ix:nonFraction> billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Pro Forma Information</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1Xzk4OTU2MDQ3MjM1MDc_d3c96589-e61d-430a-ac53-0ae502fd9275" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following pro forma information presents the combined results of operations of Gilead and Immunomedics as if the acquisition of Immunomedics had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzItMi0xLTEtMTAxNzA_376f6697-6b07-4638-adc6-1eedf2cfd31b">24,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903c926354a40a881da8a83728d0f0e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzItNC0xLTEtMTAxNjY_c7941405-66e7-449b-937b-b5aa6bd9dd5d">22,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzMtMi0xLTEtMTAxNzA_f1498d2d-47d5-45b4-94b2-229231e8e083">323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8903c926354a40a881da8a83728d0f0e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzMtNC0xLTEtMTAxNjY_6a74b76c-34df-49be-97cf-380d612f6802">4,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary adjustments include: (i) post-combination compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczMTM_6dee6ca2-bdef-40ac-910d-ec0fd65d40f8">289</ix:nonFraction> million related to the acceleration of unvested share-based awards of Immunomedics, (ii) the impact of additional interest expense in connection with the Immunomedics acquisition borrowings as well as the liability related to future royalties, (iii) amortization of the finite-lived intangible asset related to Trodelvy for mTNBC beginning on April 22, 2020 when it received FDA accelerated approval, (iv) amortization of the acquired Immunomedics&#8217; inventory related to Trodelvy mTNBC over the period in which the inventory was expected to be sold beginning on April 22, 2020, (v) amortization of the license and supply agreement with a third party over an estimated useful life of <ix:nonNumeric contextRef="i8a7d2971f9e04bd8a1de84efaccec570_D20201023-20201023" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzQzOTgwNDY1ODkxODg_e2ae0e10-88fb-4a80-a535-a1162c601de8">15</ix:nonNumeric> years, (vi) the impacts of the sale of marketable securities based on their use as a source of liquidity to fund the acquisition, and (vii) acquisition-related transaction costs. The unaudited pro forma financial results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the operations of Gilead and Immunomedics. Accordingly, these unaudited pro forma financial results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of 2019, nor are they indicative of future results of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i733f88b198a342b8bfcf8faa53d5afbc"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYR GmbH (&#8220;MYR&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2020, we entered into a definitive agreement pursuant to which we expect to acquire MYR, a German biotechnology company, for approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="id970621751c6420ca530ab3e07f6cbca_D20201210-20201210" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczMjk_5ee4cc7e-d1fa-4529-bce3-9fbc78de9307">1.2</ix:nonFraction> billion in cash (or approximately $<ix:nonFraction unitRef="usd" contextRef="id970621751c6420ca530ab3e07f6cbca_D20201210-20201210" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczNDU_6e9204d2-5c0a-4539-a3af-079a1c05aae9">1.4</ix:nonFraction> billion using a foreign currency exchange rate of <ix:nonFraction unitRef="number" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="1" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczNTI_aa1fab0b-e3ce-4e54-bad2-9ce947798491">1.2</ix:nonFraction> at December 31, 2020), which is payable upon closing of the transaction and a potential future milestone payment of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="if51626d380ad4bb2aa86f7539b1a1a7c_I20201210" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialFutureMilestonePaymentsMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczNjc_6059ef7d-8261-48a7-b06b-fed9dc3e73c6">300</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="if51626d380ad4bb2aa86f7539b1a1a7c_I20201210" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialFutureMilestonePaymentsMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzA5NjI_569c5900-b974-4de3-8e96-2b2233c5f697">360</ix:nonFraction> million using a foreign currency exchange rate of <ix:nonFraction unitRef="number" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="1" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzEwNDM_aa1fab0b-e3ce-4e54-bad2-9ce947798491">1.2</ix:nonFraction> at December 31, 2020), upon FDA approval of Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both payments are subject to customary adjustments. MYR focuses on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;). The acquisition will provide Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consummation of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act, and receipt of merger control and foreign direct investment approvals in certain European jurisdictions and certain other customary closing conditions. We anticipate that the closing of the transaction will occur by the end of the first quarter of 2021 and expect our acquisition of MYR to be accounted for as a business combination using the acquisition method of accounting upon closing.</span></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_133"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzY3Ng_87149127-b821-4e4d-be93-7895118adbc2" continuedAt="ibb3f167ffd214e8395471bea0a9a4283" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="ibb3f167ffd214e8395471bea0a9a4283" continuedAt="ibe08c5d2f1b243008a593655a5a12fbc"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzY2OA_6fde85e2-82c4-449b-934d-4ae08c9034ea" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzItMi0xLTEtMA_5d7f4195-3672-4df2-8236-717f9425d453">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzItNC0xLTEtMA_0ef6ddfc-ef44-4796-a4a2-73a4508bd400">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzMtMi0xLTEtMA_4909bdb7-d261-4eb7-b4c3-9ca1206881b7">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzMtNC0xLTEtMA_ea58855b-25a8-4b3d-a18b-8d1119c761f1">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzQtMi0xLTEtMA_234ef1e4-edc4-40d3-8238-129f42f468f4">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzQtNC0xLTEtMA_68fbc693-daae-4213-b2ff-c6b637af212c">549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9420f0406eae42c8b4f99ad3276f48ba_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzUtMi0xLTEtMA_d05a2cf3-cc2f-47df-839b-55357d15d56f">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01ff2fb62994e059a1d6fa4ee99a6c2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzUtNC0xLTEtMA_24e5daac-78f6-48d5-9bcf-ef1a669d45cc">2,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzgtMi0xLTEtMA_225e7ef0-783e-44e1-b876-1f7086bb0cfc">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzgtNC0xLTEtMA_2b7b196e-dcbe-4a83-991d-322cdcadcd0f">922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzktMi0xLTEtMA_5906195d-bca3-49b7-9c15-119bb5236e0d">1,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzktNC0xLTEtMA_93f56417-f4df-43e7-93fe-711dba01474e">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9420f0406eae42c8b4f99ad3276f48ba_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzEwLTItMS0xLTA_5e384d74-06d9-4c77-bfd2-a044a8a86145">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01ff2fb62994e059a1d6fa4ee99a6c2_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzEwLTQtMS0xLTA_83f6b7ba-235f-4c6a-86c3-31f6367f3cc7">2,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported as other long-term assets primarily consisted of raw materials as of December&#160;31, 2020 and 2019. Total inventories at December 31, 2020 include fair value adjustments resulting from the Immunomedics acquisition which will be recognized in future periods. See Note 6. Acquisitions for additional information.</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe08c5d2f1b243008a593655a5a12fbc">Inventory write down charges for the year ended December&#160;31, 2020 were not material. During the year ended December&#160;31, 2019, we recorded inventory write down charges of $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzQ3OQ_79effa1f-ed6b-400e-83ce-0f4d2a6a8ea5">649</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i8678846271ab442c97e55730184bbb1f_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzQ5Mg_9ca9eb52-2b34-4022-b7d0-a73e8ac9e02b">547</ix:nonFraction> million was related to slow moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products. During the year ended December&#160;31, 2018, we recorded inventory write down charges of $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzEwOTk1MTE2Mjk5NDU_b81ae776-62e4-4ea1-952c-eb43d1d01f59">572</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="idfef2fedfcb34cf49d5ac0ac1e7e9e08_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzEwOTk1MTE2Mjk5NTE_82b04826-ec4f-4d1d-b342-628872f7229f">440</ix:nonFraction> million was related to excess raw materials primarily due to a sustained decrease in demand for Harvoni.</ix:continuation> </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_136"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzQ0NA_67f6a62d-b03d-4f83-9996-e6ae712a4e25" continuedAt="i1aee9098b45649dd82c84f666f6caf92" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i1aee9098b45649dd82c84f666f6caf92" continuedAt="i5ab3abe3266944d78c9035c77c926fec"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzQzNQ_ddb101db-99fc-49d2-84e3-7761d088eaae" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzItMi0xLTEtMA_19ea4a00-d896-4a3a-9865-c2c4869d6cde">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzItNC0xLTEtMA_225e1c0c-1db1-46d8-8d4c-689d47c158c6">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzMtMi0xLTEtMA_31bc1aa7-ec6e-4a39-9060-83b7122f6b9c">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzMtNC0xLTEtMA_97ec93e5-d22d-4ffc-9ddf-79c8047a1e60">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzQtMi0xLTEtMA_6481cd65-8a29-4259-8626-594158b5f754">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzQtNC0xLTEtMA_4fc2eaa1-2911-4cde-9f1a-a0df1a68f9e9">805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzUtMi0xLTEtMA_adebf5c3-582c-4cec-bcd6-7ed6f1dfc0b7">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzUtNC0xLTEtMA_47c85cf3-c8ac-4429-8200-7b761055892b">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzYtMi0xLTEtMA_c63c558c-3277-4159-a432-73873b076898">856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzYtNC0xLTEtMA_7858cf34-64f4-40bd-9588-0bc6c10ef4e8">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzctMi0xLTEtMA_c5ee8e38-7a4f-4141-8382-c537c6ee2789">6,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzctNC0xLTEtMA_9f16c0c2-17c2-448b-949d-faa2de0f0c5c">5,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzgtMi0xLTEtMA_1255624f-3343-4461-a2d5-e167a27ae3a6">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzgtNC0xLTEtMA_d869ad93-a847-4de8-9b63-c27bce46de3a">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzktMi0xLTEtMA_1e580e54-4218-4a4e-9dde-65c4200dc181">4,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzktNC0xLTEtMA_13d01f2f-1219-4e01-8850-2453180d2eae">4,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i5ab3abe3266944d78c9035c77c926fec"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had unamortized capitalized software costs, included in Office, computer equipment and other, of $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzI0MQ_be89405f-d23f-49f2-a32b-65a3a4f1a8a6">124</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzI0OA_f8da8d5f-0108-45d7-910e-ccfa41659a5d">108</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. Capitalized interest on construction in-progress is included in Property, plant and equipment. Interest capitalized in 2020, 2019 and 2018 was not material.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net book value of our property, plant and equipment (less office, computer equipment and other) in the United States was $<ix:nonFraction unitRef="usd" contextRef="i6d4279a507124f3ca8496850b7e31956_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg2NDQ_c1083498-35d2-49c7-b47e-ce57667863f2">3.8</ix:nonFraction> billion as of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i91dd4f13fd1443a0bb2d19e5d92b1991_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg2NTk_22325a7f-7f69-4bc4-9c25-d86f28bad74e">3.5</ix:nonFraction> billion as of December&#160;31, 2019 and $<ix:nonFraction unitRef="usd" contextRef="i81e9d6e5f883421587e150d19ce229b1_I20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg2Nzc_0e52bcd3-fc2e-4b62-bea6-68c6052d5b4b">3.2</ix:nonFraction> billion as of December&#160;31, 2018. The corresponding amount in international locations was $<ix:nonFraction unitRef="usd" contextRef="i4f76f60b0dc144768d3cda731d8c7cd0_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg3NDg_a43d54c6-3977-441b-9adf-1f3d8045abef">897</ix:nonFraction> million as of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ife2f98a6a4fe4a41b4e2e388608c97f5_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg3NjM_b14e7119-4319-490a-9dba-8da3ae65c1fb">791</ix:nonFraction> million as of December&#160;31, 2019 and $<ix:nonFraction unitRef="usd" contextRef="i47f7a6ee87fc404481ff08ed83281586_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg3ODE_c1cb4ad4-378e-4bbc-8dac-e07f636a71b0">620</ix:nonFraction> million as of December&#160;31, 2018. All individual international locations accounted for less than 10% of the total balances.</span></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_139"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzNTU_33299275-9cf6-4934-8d35-263ac5dd3752" continuedAt="ia0c70ffda0d84009ae12bad9e8880ead" escape="true">GOODWILL AND INTANGIBLE ASSETS </ix:nonNumeric></span></div><ix:continuation id="ia0c70ffda0d84009ae12bad9e8880ead" continuedAt="ic3ffe11a6f814b6c94ddccd47ed608a1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzI3NDg3NzkwODE2MzM_c2b685b1-6614-4dc5-896c-9d78bd417c7f" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo4ZjI3MDc5YTRhYzI0ZDg2YjdkZjE2MTY1ZjVlMTYwNS90YWJsZXJhbmdlOjhmMjcwNzlhNGFjMjRkODZiN2RmMTYxNjVmNWUxNjA1XzAtMS0xLTEtMTI1ODg_2b5c9080-7ab4-44f8-8d44-8f9dd4ceab74">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of Immunomedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo4ZjI3MDc5YTRhYzI0ZDg2YjdkZjE2MTY1ZjVlMTYwNS90YWJsZXJhbmdlOjhmMjcwNzlhNGFjMjRkODZiN2RmMTYxNjVmNWUxNjA1XzEtMS0xLTEtMTI1ODg_17b8ee13-bd0f-4de7-b58c-29683f52a703">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo4ZjI3MDc5YTRhYzI0ZDg2YjdkZjE2MTY1ZjVlMTYwNS90YWJsZXJhbmdlOjhmMjcwNzlhNGFjMjRkODZiN2RmMTYxNjVmNWUxNjA1XzItMS0xLTEtMTI1ODg_6a35ebe4-89ad-43d0-b12c-eba64f007fcc">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an annual goodwill impairment assessment in the fourth quarter, or earlier if impairment indicators exist. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzI3NDg3NzkwODE2Mzg_ab0c12f0-f94a-4ac2-9481-9f662e62ee5b">no</ix:nonFraction> accumulated goodwill impairment losses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzMTg_075aa6b5-3205-4a8f-a246-cbec05c895eb" escape="true"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzNTY_4426aba9-e5ca-456d-8685-03bb88401a60" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMi0xLTEtMA_1cdbd959-4358-4c84-b19f-7b24d037902f">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtNC0xLTEtMA_863d5412-592e-4462-97be-ef9094455ba4">4,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtNi0xLTEtMA_e6625518-4c9c-46a9-8580-cdbec9f970f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtOC0xLTEtMA_0e304820-3eae-4fa0-aea7-db9ab51564d2">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTAtMS0xLTA_a4c8ce6f-0301-4cf3-bb01-bf505ee6f21d">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTItMS0xLTA_edc54c0d-0701-4669-9a40-04b04736b68b">4,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTQtMS0xLTA_4bbbffd1-bb6d-457a-a183-5c6134eed488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTYtMS0xLTA_6c72b8b8-8a7d-402a-b285-31f53d2d6892">6,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel (DLBCL)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMi0xLTEtMA_207da6a3-dbc0-462b-bed7-1f56c6dceb6d">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtNC0xLTEtMA_900f6d61-63f5-4e38-9eae-6f787427ab7e">1,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtNi0xLTEtMA_dc677b4e-cb04-4479-950f-c781853ee44b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtOC0xLTEtMA_cfb6c0ce-81ea-4ec0-b0d2-0ab5d208e609">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTAtMS0xLTA_ec0a8828-c3fa-472d-af1e-3ad9ea75db77">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTItMS0xLTA_ac383fb3-02a8-47fe-af0d-522206586067">761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTQtMS0xLTA_253b11b6-6990-4467-86e5-f5bcb4c89ec3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTYtMS0xLTA_d6df3c88-3279-4ab7-b8cf-4340f68fca95">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy for mTNBC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMi0xLTEtMTM4NzQ_c6169dad-dfd1-469c-9560-410415980b05">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtNC0xLTEtMTM4NzQ_db902cae-55df-4a11-8ee6-92efebb2f558">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtNi0xLTEtMTM4NzQ_6be01809-bbf7-455c-99b1-0b978f8ce710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtOC0xLTEtMTM4NzQ_12534249-8986-44ec-b100-64f078fcf68c">4,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca01e23b54043618df5703b720be264_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTAtMS0xLTEzODc0_86c43366-dcdd-4039-93f3-b6fb0e551f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca01e23b54043618df5703b720be264_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTItMS0xLTEzODc0_bdcd28c7-fa28-4131-a893-0eb49ea7fd6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca01e23b54043618df5703b720be264_I20191231" decimals="-6" format="ixt:zerodash" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTQtMS0xLTEzODc0_58be42f6-d07d-4489-9e16-063f6506b62e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca01e23b54043618df5703b720be264_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTYtMS0xLTEzODc0_d564bc3f-0e38-466e-8bb3-6d38ce0c4fe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMi0xLTEtMA_1be2db12-9b7e-4fe1-9d8c-5d8c55b84bef">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtNC0xLTEtMA_013b325a-b3e1-4d9f-ac3c-22f89838fdb3">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtNi0xLTEtMA_dca842bb-b9ed-4510-b126-bd559dd15145">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtOC0xLTEtMA_0748cf1a-2ca5-440a-b0de-bc6dc9decad0">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTAtMS0xLTA_76614134-679e-4035-9882-cc9cfee6033b">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTItMS0xLTA_3395d91e-6420-499a-b2bb-3c51d245dbbe">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTQtMS0xLTA_26362272-f4bd-49a0-afe1-b59e6f635aa8">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTYtMS0xLTA_6885feec-e6ad-41f0-8880-29d475998e9f">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMi0xLTEtMA_bf78164b-3592-4b2b-8c8c-5714e980f5e2">22,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctNC0xLTEtMA_28e7970b-29c8-4cf6-ba03-a25e91c038c3">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctNi0xLTEtMA_aa521f83-7bb9-403a-8b57-18413ee25695">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctOC0xLTEtMA_cf9eca88-ee32-4543-9192-b7b537e94599">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTAtMS0xLTA_c8fdfaa9-4cab-436d-a13c-f681042840f2">18,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTItMS0xLTA_74f67fb5-321d-4a4e-b9d9-841a34e5ffde">5,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" sign="-" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTQtMS0xLTA_613d7981-36af-464c-897c-e7240a9e732f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTYtMS0xLTA_4926e29d-d47b-4c95-adda-12e4413e9efc">12,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMi0xLTEtMA_6c121a2a-b771-485c-b7f1-afa8cacfdc5e">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231" decimals="-6" format="ixt:zerodash" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtNi0xLTEtMA_51dedebd-2ff7-4316-88fd-b86d5f825418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtOC0xLTEtMA_890d1922-83f8-4876-beec-8887a3a38026">16,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c593b70322648b8855aec1be0938cc8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMTAtMS0xLTA_629b6bee-5ccd-4648-aaae-7d7cab6a02e7">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c593b70322648b8855aec1be0938cc8_I20191231" decimals="-6" sign="-" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMTQtMS0xLTA_349de998-b309-417d-a635-d038d5785dc6">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c593b70322648b8855aec1be0938cc8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMTYtMS0xLTA_7e14e391-7609-4c28-adef-a766431a38b1">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMi0xLTEtMA_898195d9-938c-43bc-b7d3-36191e6b4829">39,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktNC0xLTEtMA_8e3f24e4-3128-4c43-bd73-0e46827f9652">6,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" sign="-" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktNi0xLTEtMA_97c9904d-ef97-40d2-b9ae-7fab094a60cb">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktOC0xLTEtMA_06de0195-016c-4e02-8eaf-f4e76be6668b">33,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTAtMS0xLTA_1c2e0aca-520e-494e-9598-eca344f17893">19,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTItMS0xLTA_84935d18-10c5-4bb9-aed6-da21255922dd">5,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" sign="-" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTQtMS0xLTA_223d1817-f9d3-44e0-8ad7-a9d5bb29944d">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTYtMS0xLTA_bf63a618-5e84-484f-83c5-f1d9dac715fb">13,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i8000203400804727bf1a4e40c93f3c16_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE2NQ_e131fc66-ec27-4696-aa36-2171a1b96398">1.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="icbb578eac6714200a5377073798b8f1b_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE2OQ_227b0989-c6eb-4a06-8fea-e0d5cec96e42">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibe4376a44dc14cc2a76b854d11662987_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE3Ng_79bec1a4-7103-471a-8696-beda5bd78b41">1.2</ix:nonFraction> billion for the years ended December&#160;31, 2020, 2019 and 2018, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ic3ffe11a6f814b6c94ddccd47ed608a1"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we performed quantitative impairment testing of our IPR&amp;D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="2" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIxOTkwMjMyNjY2Nzg_4543e4eb-49f4-4e9a-8729-4756b4e152df">8</ix:nonFraction>%. No IPR&amp;D impairment charges were recorded in 2020. During 2019, we performed quantitative impairment testing of our IPR&amp;D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of <ix:nonFraction unitRef="number" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzczNA_7e89543b-e826-4445-a6fb-a85dc761b658">9.5</ix:nonFraction>%, which is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. In comparison to the 2018 assessment, we used lower estimated revenues in 2019 due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&amp;D intangible assets, primarily related to axicabtagene ciloleucel for the treatment of indolent B-cell non-Hodgkin lymphoma (&#8220;iNHL&#8221;), below carrying value resulting in the recognition of an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE2MDk_8a18dc50-79da-47b0-91c2-98148d479d91">800</ix:nonFraction> million, which was recorded within Research and development expenses on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we concluded that the KITE-585 program did not justify further efforts based on the totality of the clinical data gathered and discontinued the program. As a result, the carrying value of the IPR&amp;D relating to the KITE-585 program was written down to <ix:nonFraction unitRef="usd" contextRef="i8df8c75c0ccd41708b9a841f5afbd2fa_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE5NzU_b1a7f4e7-58c2-4052-98dd-9e1a3d851455">zero</ix:nonFraction> and we recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIwMTg_7a9e9845-de54-49d3-8c5f-f86b1914c453">820</ix:nonFraction> million within Research and development expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2020:</span></div><div style="margin-top:9pt;text-align:center"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzMjc_c19bb117-a5b8-4d09-be78-783f327c2b17" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzEtMS0xLTEtMA_1c85cdbf-cf82-4807-9da9-16e9989b587f">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzItMS0xLTEtMA_667891f6-41b6-44bc-b79e-98581d892016">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzMtMS0xLTEtMA_90a74f2d-3f93-4395-942f-06b7d6531dad">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzQtMS0xLTEtMA_c25495cb-6cb0-4607-8681-5599001e4e10">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzUtMS0xLTEtMA_2c03ccf3-595f-4eeb-90d1-fc76dc997bbd">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzYtMS0xLTEtMA_6db81031-3fc5-49b3-a700-3c82d61d6a07">8,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzctMS0xLTEtMA_ec9d631f-ee2b-46d5-b5ee-443088310533">16,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_142"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90ZXh0cmVnaW9uOmRhNWIyY2MxZThmNzRmY2FhY2VlZmU0Y2M5M2VjMTZmXzEzOQ_3e0d9db6-4f1c-43c0-8c82-fbd8d245d1b9" continuedAt="i0b053f4c9f42468eb5d946d1d5b0927a" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i0b053f4c9f42468eb5d946d1d5b0927a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90ZXh0cmVnaW9uOmRhNWIyY2MxZThmNzRmY2FhY2VlZmU0Y2M5M2VjMTZmXzI3NDg3NzkwNzAwMTg_59bfe910-d3e1-429d-b9d3-ab01f9b42c18" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzEtMi0xLTEtMjU4NTY_ffafaab8-af14-454c-a0bc-8daece841c1d">5,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzEtNC0xLTEtMjU4NTY_5bca1275-abdf-4237-abc0-9c7516cd5bdd">4,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtMi0xLTEtMjY2MjE_931af6b7-9e56-4d1b-bdb6-c850f1b4f7af">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtNC0xLTEtMjY2MjE_8d3b66d9-928b-45a7-b948-c96d0391df2c">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzItMi0xLTEtMjU4NTY_7714a9fa-e101-4b7b-ba97-6d5fff362b14">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzItNC0xLTEtMjU4NTY_a7f97b15-1086-4ecb-b503-407d09c03dc7">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtMi0xLTEtMjU4NTY_47bf08ce-6d72-48d2-a13f-63a4128121d6">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtNC0xLTEtMjU4NTY_7be77b2e-be04-42db-8518-1e3923d01f16">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzQtMi0xLTEtMjU4NTY_2ddc1576-ca4d-4fe6-88da-91c239de3995">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzQtNC0xLTEtMjU4NTY_d82acd21-e0d9-4702-9223-5ba8e180b21e">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Accrued Liabilities</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90ZXh0cmVnaW9uOmRhNWIyY2MxZThmNzRmY2FhY2VlZmU0Y2M5M2VjMTZmXzEzMg_3a2ceeaa-bb81-42d9-973e-924eb2dcb50a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other accrued liabilities:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzItMi0xLTEtMA_c981acee-48ca-4f84-ab57-1b820ed18ddf">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzItNC0xLTEtMA_821c2e4a-66f0-44df-99c8-f045f1739f94">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzMtMi0xLTEtMA_5c4216c8-dfbf-4fd5-b030-41e7372c9978">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzMtNC0xLTEtMA_993ec2c8-37fd-4606-b3de-61eb5bad5db5">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzQtMi0xLTEtMjc0MzQ_e90a9fb8-b545-45f1-a626-35bded095072">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzQtNC0xLTEtMjc0MzQ_73be9ac1-1be4-41c9-9d78-5fa846643253">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzUtMi0xLTEtMA_a4f01bfa-d3e0-43b0-96a3-c60657624bb8">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzUtNC0xLTEtMA_48e5cc74-df95-4b8c-a85f-47593c108859">2,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzYtMi0xLTEtMA_98c7b92b-efdb-4f22-afa5-b9a6a36f2791">4,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzYtNC0xLTEtMA_85d0657c-9a87-45a8-a4b1-f225ac11c843">3,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="gild:CollaborativeandOtherArrangementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3MjM_2e679000-6c14-4805-8dd7-2ce82c1474ff" continuedAt="ifacddddc00ff4dc08ca032fd9e8b8f5b" escape="true">COLLABORATIONS AND OTHER ARRANGEMENTS </ix:nonNumeric></span></div><ix:continuation id="ifacddddc00ff4dc08ca032fd9e8b8f5b" continuedAt="iebee3310a8fd4f8089321ce5a1a95339"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for, and equity investments in third parties focused on, the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2020, we acquired <ix:nonFraction unitRef="shares" contextRef="ia16ced64a7e645e781114e8469e73643_I20200529" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4NTM_39b50b63-e146-4884-9fcb-e2021f7e5801">2.2</ix:nonFraction> million shares of the common stock of Arcus, a publicly traded oncology-focused biopharmaceutical company, for approximately $<ix:nonFraction unitRef="usd" contextRef="ia16ced64a7e645e781114e8469e73643_I20200529" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4Njk_7467fe1f-29aa-4f06-85ea-a1ac3f6b63e6">61</ix:nonFraction> million in a secondary equity offering. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, on&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#8220;Arcus Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended, the &#8220;Arcus Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Arcus Collaboration Agreement and Arcus Stock Purchase Agreements, on July 13, 2020, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4ODU_761015b0-6ff3-482e-950d-8937f9340595">175</ix:nonFraction> million and acquired approximately <ix:nonFraction unitRef="shares" contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713" decimals="-5" format="ixt:numdotdecimal" name="gild:InvestmentOwnedBalanceAdditionalShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5MDE_c065d522-dd65-4049-aad5-5470aa231e4c">6.0</ix:nonFraction> million additional shares of Arcus&#8217; common stock for $<ix:nonFraction unitRef="usd" contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5MzA_bd4095e0-a33a-49da-a5fb-a20a2953f521">200</ix:nonFraction> million in accordance with the terms of the Arcus Collaboration Agreement and Arcus Stock Purchase Agreements. Of the total $<ix:nonFraction unitRef="usd" contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:TotalUpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5NDk_37e7bb3d-9556-4d2e-a571-ce399357806e">391</ix:nonFraction> million initial cash payments made under the agreements and direct transactional costs, we recorded $<ix:nonFraction unitRef="usd" contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5Njg_d20e0eff-6841-4416-8774-5005f2d09f0a">135</ix:nonFraction> million as an equity investment, which was calculated based on Arcus&#8217; closing stock price of $<ix:nonFraction unitRef="eurPerShare" contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5ODE_2377e560-bb0d-4e94-90c7-eeeebba086df">22.67</ix:nonFraction> on the closing date of the transaction. We recorded our equity investments in Arcus in Other long-term assets on our Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions for a period up to 2 years from the closing date of the agreements, subject to certain conditions. We account for our equity investments in Arcus at fair value with changes in fair value recognized in Other income (expense), net for each reporting period. The remaining $<ix:nonFraction unitRef="usd" contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwMjA_c75ca038-44fc-42e3-ad20-ab055667c113">256</ix:nonFraction> million was attributed to the acquired license and option rights of $<ix:nonFraction unitRef="usd" contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwMzk_02d3bbda-dc7b-41f0-8ab3-8d173c519607">175</ix:nonFraction> million representing IPR&amp;D assets with no alternative future use, $<ix:nonFraction unitRef="usd" contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713" decimals="-6" sign="-" format="ixt:numdotdecimal" name="gild:IssuanceDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwNTc_b7546605-664b-40cd-ac9b-604d6ec9c474">65</ix:nonFraction> million of an issuance premium for the equity purchase and $<ix:nonFraction unitRef="usd" contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:PaymentsForDirectTransactionalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwNzU_ca8d58a5-ea20-4a9b-957f-61f356ad4325">16</ix:nonFraction> million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income. In an event subsequent to December 31, 2020, on January 31, 2021, we amended and restated the common stock purchase agreement, pursuant to which we acquired approximately <ix:nonFraction unitRef="shares" contextRef="iffef91ebd0344347af71595936327ea0_I20210208" decimals="-5" format="ixt:numdotdecimal" name="gild:InvestmentOwnedBalanceAdditionalShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIwMjM_4095fa66-c232-44e0-a4b1-d731165978ab">5.7</ix:nonFraction> million additional shares of Arcus&#8217; common stock for $<ix:nonFraction unitRef="usd" contextRef="iffef91ebd0344347af71595936327ea0_I20210208" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIwNzI_9002b5c6-ec9c-41e1-9dba-b3654c6e34b1">220</ix:nonFraction> million on February 8, 2021. As a result, combined with our existing share holdings, we own <ix:nonFraction unitRef="shares" contextRef="iffef91ebd0344347af71595936327ea0_I20210208" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIxNjA_33c59f2e-f870-4288-aad6-586bbb52334a">13.8</ix:nonFraction> million shares of Arcus, representing approximately <ix:nonFraction unitRef="number" contextRef="i52b270d003824c77b29b5398d6d3083c_I20210208" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIyMDg_dd51b46c-ef92-4f15-a42e-0b05e1265fb3">19.5</ix:nonFraction>% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead has the right to opt-in to all current and future investigational product candidates that emerge from Arcus&#8217; research portfolio for the ten years following the closing of the transaction. Upon our exercise of an option for a program, unless Arcus opts out according to the terms of the Arcus Collaboration Agreement, the companies will co-develop and share global development costs and co-commercialize and share profits in the U.S. We will obtain exclusive rights to commercialize any optioned programs outside of the U.S., subject to any rights of Arcus&#8217; existing partners, for which we will pay to Arcus tiered royalties ranging from the high teens to the low twenties on net sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Arcus Collaboration Agreement, subject to certain limited exceptions, we are required to provide $<ix:nonFraction unitRef="usd" contextRef="i8af407247e1d4bb483def9e87402f03a_I20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA4NzI_6945403a-fe00-4d2e-864a-335aefd36453">100</ix:nonFraction>&#160;million to Arcus on the second anniversary of the agreement and may pay an additional $<ix:nonFraction unitRef="usd" contextRef="i8af407247e1d4bb483def9e87402f03a_I20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxMzY_a1ed7d77-379a-4070-ad35-23b52bc8d8ec">100</ix:nonFraction> million at our option on each of the fourth, sixth, and eighth anniversaries of the agreement, unless terminated early, as ongoing research and development support to extend our collaboration term to up to <ix:nonNumeric contextRef="i80831b6a43e144288ee6887aa81b9527_D20200713-20200713" format="ixt-sec:duryear" name="gild:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA4OTM_3442d42f-9e9f-479d-9a7c-3ea32dba49bc">10</ix:nonNumeric> years. Accordingly, during the year ended December 31, 2020, we recorded a $<ix:nonFraction unitRef="usd" contextRef="id99b5612dbd4404ba21f6f1b905e2fff_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNTU_616a4e62-bbfb-4995-bfd7-4ce2a4239eb4">100</ix:nonFraction> million charge representing the contractually committed payment in Acquired in-process research and development expenses on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Arcus Collaboration Agreement, we will potentially provide up to $<ix:nonFraction unitRef="usd" contextRef="i8af407247e1d4bb483def9e87402f03a_I20200713" decimals="-8" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNIFutureMaximumMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwOTg_9ae643ad-3a39-4159-a381-8cd79a1b9248">1.2</ix:nonFraction> billion in opt-in and milestone payments with respect to current clinical product candidates, if and when such payments are triggered under the Arcus Collaboration Agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Arcus Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the next <ix:nonNumeric contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713" format="ixt-sec:durwordsen" name="gild:EquitySecuritiesFVNIPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3MjQ_bffe21bb-8c2b-455d-bff9-8dc5e04d09a2">five years</ix:nonNumeric>, up to a maximum of <ix:nonFraction unitRef="number" contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNjE_097b6557-456e-465b-8098-f9bdf15db225">35</ix:nonFraction>% of the outstanding voting stock. We are subject to a <ix:nonNumeric contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713" format="ixt-sec:durwordsen" name="gild:EquitySecuritiesFVNIRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3NDg_f56713f9-4722-42ad-bd9a-baa9cdd89518">three-year</ix:nonNumeric> standstill restricting our ability to acquire voting stock of Arcus exceeding more than <ix:nonFraction unitRef="number" contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNjc_097b6557-456e-465b-8098-f9bdf15db225">35</ix:nonFraction>% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Arcus Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iebee3310a8fd4f8089321ce5a1a95339" continuedAt="i1e5579f9a5004433b641f783779a775f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into <ix:nonFraction unitRef="agreement" contextRef="i93263403f73c4d28b597082de10c84d1_I20200619" decimals="INF" format="ixt-sec:numwordsen" name="gild:NumberOfAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3NTM_5a5909bb-f05e-4e02-a218-d0c4ba750f2f">two</ix:nonFraction> separate merger agreements, one contemplating the initial acquisition of <ix:nonFraction unitRef="number" contextRef="i93263403f73c4d28b597082de10c84d1_I20200619" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNzU_3dacabbd-c593-4a4d-ba7d-2194d84e5d8a">49.9</ix:nonFraction>% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#8220;Pionyr Merger and Option Agreements&#8221;) and a research and development service agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, we closed the transaction with Pionyr and paid $<ix:nonFraction unitRef="usd" contextRef="ifbc35450bfed4ce1b3b6d598e9f11a83_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxOTA_0d2cf698-a875-49ed-89ec-529d387d10d5">269</ix:nonFraction> million in cash and accrued an additional $<ix:nonFraction unitRef="usd" contextRef="ifbc35450bfed4ce1b3b6d598e9f11a83_D20200713-20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:InvestmentOwnedBalanceAdditionalPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyMDc_556212a7-77c2-405f-8b2a-89b1c851853e">6</ix:nonFraction> million payable, subject to certain customary adjustments, to Pionyr&#8217;s shareholders in accordance with the terms of the Pionyr Merger and Option Agreements. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#8217;s IPR&amp;D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, we immediately recorded a charge for this basis difference of $<ix:nonFraction unitRef="usd" contextRef="i6f9442c5e7f742a5918ea65c554e30f1_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyMjY_780af2db-4d83-4523-a4fb-b9c193716e0a">215</ix:nonFraction> million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $<ix:nonFraction unitRef="usd" contextRef="if78171fbfd924018a723f12dc3bd832a_I20200713" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyNDQ_04958d62-2810-4561-94bc-3f2e9416e7f9">70</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount was recorded in Other long-term assets on our Consolidated Balance Sheets. From the first anniversary of the closing date, we may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#8217;s current shareholders for a $<ix:nonFraction unitRef="usd" contextRef="if78171fbfd924018a723f12dc3bd832a_I20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:EquityMethodInvestmentOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyNjM_0b4c4ae9-588c-40fd-a09a-8a4ad45f3b12">315</ix:nonFraction> million option exercise fee and up to $<ix:nonFraction unitRef="usd" contextRef="if78171fbfd924018a723f12dc3bd832a_I20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialFutureMilestonePaymentsMaximum" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyODI_6a8cd345-814d-4c94-aa99-5c1bc6bdb0ad">1.2</ix:nonFraction> billion in potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the research and development service agreement, we made an initial cash funding of $<ix:nonFraction unitRef="usd" contextRef="i2d3771f3eacb401d97c063d22f14874f_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyOTk_eef3ce8c-b0d5-4184-9d6e-b01932ebcb65">80</ix:nonFraction> million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="ib0a6b60bf1fb4c95bf249cf35ab97877_I20200713" decimals="-6" format="ixt:numdotdecimal" name="gild:ResearchAndDevelopmentFutureMaximumPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzMTg_cc92aa02-fb24-4604-95e9-e1f9ad9320ce">115</ix:nonFraction> million to Pionyr upon achievement of certain development milestones. We accrued $<ix:nonFraction unitRef="usd" contextRef="i34c05527ff1f41b18c4eaf4e2b69ad93_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:AccruedResearchAndDevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA5MDc_b54fece7-696b-4ac2-a9b2-3cb249f1104d">70</ix:nonFraction>&#160;million milestone payments, related to the initiation of <ix:nonFraction unitRef="study" contextRef="i34c05527ff1f41b18c4eaf4e2b69ad93_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="gild:NumberOfStudies" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA5MjQ_30a82417-5d74-420f-b0c0-4fc96d37817f">two</ix:nonFraction> Phase-1 studies, with a charge to Research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. Subsequently, in February 2021, milestone cash payments of $<ix:nonFraction unitRef="usd" contextRef="icd832b1814dc41c2855ec98618a3809f_D20210201-20210225" decimals="-6" format="ixt:numdotdecimal" name="gild:PaymentsForResearchAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NTQzMzk_8d767ce9-c0e5-409b-9194-575d096aaafd">70</ix:nonFraction> million were made.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tizona</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into <ix:nonFraction unitRef="agreement" contextRef="i9eb304537d4c49c5921792c6d16c44b1_I20200717" decimals="INF" format="ixt-sec:numwordsen" name="gild:NumberOfAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3NjA_16bd7cc0-83a1-4bd4-a9fc-4b7a580f1a99">two</ix:nonFraction> separate merger agreements, one contemplating the initial acquisition of a <ix:nonFraction unitRef="number" contextRef="i9eb304537d4c49c5921792c6d16c44b1_I20200717" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzMzA_8fb2caa8-55ad-4d5a-80c6-ca703369f7e2">49.9</ix:nonFraction>% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#8220;Tizona Merger and Option Agreements&#8221;) and a development agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, we closed the transaction with Tizona and paid $<ix:nonFraction unitRef="usd" contextRef="iffcb20e38446438fac262691e10ede58_D20200825-20200825" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzNDU_368f3298-660a-4dc4-bd68-00c1762459c7">302</ix:nonFraction> million in cash to Tizona&#8217;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#8217;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#8217;s IPR&amp;D with no alternative future use and that Tizona is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $<ix:nonFraction unitRef="usd" contextRef="ia485fc53f8774d4bbbe1c1dbe9ba40a7_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NzAwOTU_fddd4fc4-4616-49cd-b35f-5ec265ee5b0f">272</ix:nonFraction> million in Acquired in-process research and development expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $<ix:nonFraction unitRef="usd" contextRef="if33df116f5f941209af85885b37007ea_I20200825" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzNjM_ac956f6e-8649-4326-8dee-0b1df643f48e">41</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount was recorded in Other long-term assets on our Consolidated Balance Sheets. From the first anniversary of the closing date, we may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#8217;s current shareholders for up to $<ix:nonFraction unitRef="usd" contextRef="if33df116f5f941209af85885b37007ea_I20200825" decimals="-8" format="ixt:numdotdecimal" name="gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzODI_64cb1e7e-cea5-470b-81f2-9eafdafbc166">1.3</ix:nonFraction> billion, including an option fee and potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i1e5579f9a5004433b641f783779a775f" continuedAt="if8192550ea2544728c7aeb86bf57111a"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the development agreement, we committed to provide funding to Tizona of $<ix:nonFraction unitRef="usd" contextRef="i7aa72b0e47084ac4b180eb22cea3779e_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0MDA_7cac058d-4ed4-419c-852e-b644a54d8fe5">115</ix:nonFraction> million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tango Therapeutics, Inc. (&#8220;Tango&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#8220;Tango Collaboration and Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0MTk_c1c193cd-cc23-4057-b89b-8482d2d3d77d">125</ix:nonFraction> million and a $<ix:nonFraction unitRef="usd" contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0Mzc_56791e5f-577d-4835-b087-a7302544dd73">20</ix:nonFraction> million equity investment in Tango, representing approximately <ix:nonFraction unitRef="number" contextRef="ida137ca5e8244cb0ae5f91885ad73166_I20200827" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0NDY_6a630d8f-14a7-44d4-8918-cbc7f9663dd2">7</ix:nonFraction>% of the issued and outstanding voting stock of Tango immediately following the transaction, in accordance with the terms of the Tango Collaboration and Stock Purchase Agreements. During the year ended December 31, 2020, we recorded the $<ix:nonFraction unitRef="usd" contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0NjE_4c05a652-344f-4cf7-9b89-caf212c7b9b8">125</ix:nonFraction> million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. Our equity investment in Tango is recorded at cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of Tango.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to <ix:nonFraction unitRef="program" contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817" decimals="INF" name="gild:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3Njc_3c4a1446-fe23-4c8a-8c2c-e93b18004291">15</ix:nonFraction> programs over the <ix:nonNumeric contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817" format="ixt-sec:durwordsen" name="gild:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3ODI_f4d81bbe-082d-406b-9586-70aab0a9a0bc">seven-year</ix:nonNumeric> collaboration for up to $<ix:nonFraction unitRef="usd" contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817" decimals="-6" format="ixt:numdotdecimal" name="gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0ODA_8e76ecc2-42a8-4ce8-836b-7b7163efec1a">410</ix:nonFraction> million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#8220;Jounce License and Stock Purchase Agreement&#8221;). In October 2020, we closed this transaction and made a total payment of $<ix:nonFraction unitRef="usd" contextRef="ia9888aea06ac4afc8425a218b65655b0_D20201001-20201031" decimals="-6" format="ixt:numdotdecimal" name="gild:TotalUpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0OTk_d2f276ab-5040-47bb-b3c8-aa3a60301a2a">120</ix:nonFraction> million in accordance with the terms of the Jounce License and Stock Purchase Agreement and recorded $<ix:nonFraction unitRef="usd" contextRef="ia9888aea06ac4afc8425a218b65655b0_D20201001-20201031" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1MTc_e883d58c-8d11-4637-8f39-4b9610048262">56</ix:nonFraction> million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately <ix:nonFraction unitRef="number" contextRef="i454bf1f356114d009c08e1da60df6588_I20201031" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1Mjc_019658de-f83b-4ab5-8079-06093a478885">14</ix:nonFraction>% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#8217;s closing stock price of $<ix:nonFraction unitRef="eurPerShare" contextRef="i740dfff7a05d4e5e8dd476392363eb90_I20201031" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1MzY_475c8cef-e8a0-464a-a10a-abba2d9c6117">10.06</ix:nonFraction> on the closing date of the transaction. During the year ended December 31, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i8f9917b07dc845fa8fe5d3c889a19c8e_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjkwMTE_879d7de8-285a-4c4a-9541-63a664d9222f">64</ix:nonFraction> million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In addition, we will provide up to $<ix:nonFraction unitRef="usd" contextRef="i740dfff7a05d4e5e8dd476392363eb90_I20201031" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1NTE_4f8630e6-fc89-4ba2-bbb3-536f36688532">685</ix:nonFraction> million in future potential clinical, regulatory and commercial milestone payments upon achievement of certain milestones, and pay Jounce royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Galapagos</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filgotinib Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#8220;filgotinib agreement&#8221;). Upon closing, we made an upfront license fee payment and an equity investment in Galapagos by subscribing for <ix:nonFraction unitRef="shares" contextRef="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEyMDI_ae93240f-613e-4a39-b50f-c9518a344636">6.8</ix:nonFraction> million new ordinary shares of Galapagos at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEyNTI_f3c96be5-fd62-48c0-ae9d-2f42421d74a6">58</ix:nonFraction> per share. The equity investment, net of issuance premium, was $<ix:nonFraction unitRef="usd" contextRef="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMTg_915d028c-43e1-42af-b473-1fd0215880f6">357</ix:nonFraction> million. We amended the terms of the filgotinib agreement in 2019 and then in 2020 agreed to amend the terms further. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the filgotinib agreement, as amended in 2019 (the &#8220;2019 Agreement&#8221;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. As of December&#160;31, 2019, Galapagos was eligible to receive from us potential future development and regulatory milestone-based payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE2Mzk_7692745f-ea6a-4fba-af67-bbf037db258e">640</ix:nonFraction> million, sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialFutureSalesbasedMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE2ODM_8daa9552-61ee-4728-967c-da985478953d">600</ix:nonFraction> million, plus tiered royalties on global net sales ranging from <ix:nonFraction unitRef="number" contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231" decimals="2" name="gild:PotentialFutureTieredRoyaltyPaymentLowend" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE3NDI_ee721b43-8729-4c48-9c62-f5186018dfa4">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231" decimals="2" name="gild:PotentialFutureTieredRoyaltyPaymentHighend" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE3NDg_926cd4c7-7c0e-4b05-8e84-f79d26346226">30</ix:nonFraction>%, with the exception of certain co-commercialization territories where profits would be shared equally. The co-commercialization territories were the UK, Germany, France, Italy, Spain, Belgium, the Netherlands and Luxembourg. We shared global development costs for filgotinib equally. Termination of the agreement could be on a country-by-country basis and depends on the circumstances, including expiration of royalty term or in the co-commercialization territories, sale of a generic product, or material breach by either party. We could also terminate the entire agreement without cause following a certain period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if8192550ea2544728c7aeb86bf57111a" continuedAt="iab299adcabe244b4b49e389c52de4e8b"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, following a Type A meeting with FDA to discuss the points raised in the Complete Response Letter related to the New Drug Application for filgotinib in the treatment of rheumatoid arthritis, Gilead and Galapagos agreed to amend the 2019 Agreement where Galapagos will assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe. Through a phased transition including the transfer of filgotinib&#8217;s marketing authorization to Galapagos, the parties intend to transfer most activities by December 31, 2021 and complete the transition by December 31, 2022. The transfer will be subject to applicable local legal, regulatory and consultation requirements. Beginning on January 1, 2021, Galapagos bears the development costs for certain studies, in lieu of the equal cost split contemplated by the 2019 Agreement. All commercial economics on filgotinib in Europe will transfer to Galapagos as of January 1, 2022, subject to payment of tiered royalties of <ix:nonFraction unitRef="number" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU3NDA_88f77905-3a41-4437-a3e9-df9924dc0696">8</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU3NTM_1e47b5dd-e6e9-43cd-82b4-9432995e2122">15</ix:nonFraction>% of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#8364;<ix:nonFraction unitRef="eur" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU3MDE_d6a21ca2-f030-445b-8aa7-c3cc4fe5add6">160</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NTA3NTg_cafe2594-7d83-4fea-b422-5f6f12f9c43c">190</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is subject to certain adjustments for higher than budgeted development costs. Of this total amount, Gilead paid &#8364;<ix:nonFraction unitRef="eur" contextRef="i68443d5a14c140e5b3fb3ff26e44562f_D20210101-20210131" decimals="-6" format="ixt:numdotdecimal" name="gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDkzMjk_f146c4d7-687d-4605-a912-c5cbba3baccd">35</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i68443d5a14c140e5b3fb3ff26e44562f_D20210101-20210131" decimals="-6" format="ixt:numdotdecimal" name="gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjI5NzM_da3ef070-a7bf-4b27-beb5-3fb8f3ee4a88">42</ix:nonFraction> million) in January 2021 and will pay an additional &#8364;<ix:nonFraction unitRef="eur" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY5MzE_70924372-420e-41ba-8060-9a4c52e87128">75</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjI5ODc_99d99783-7c9d-43ac-a6c3-d9ef2bd8f688">89</ix:nonFraction> million) in 2021 and will pay &#8364;<ix:nonFraction unitRef="eur" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY5NDg_e973068e-bd43-4504-ba76-bb64a629e852">50</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjMwMTM_07afb82e-ee1f-4a5e-8833-cbf2badea5bb">60</ix:nonFraction> million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe. For the periods presented, the payments between Galapagos and us for the development costs and milestones were not material.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;August 2019, we closed an option, license and collaboration Agreement (the &#8220;Galapagos Collaboration Agreement&#8221;) and a subscription agreement (the &#8220;Galapagos Subscription Agreement&#8221;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#8217; current and future product portfolio (other than filgotinib). Upon closing, we paid $<ix:nonFraction unitRef="usd" contextRef="i8b08c2b1e8994a8386e2f87e19b2f94e_D20190801-20190831" decimals="-7" format="ixt:numdotdecimal" name="gild:PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI4Njg_d3a210dc-ddf1-4659-8845-130c5bc5dd29">5.05</ix:nonFraction> billion for the license and option rights and for <ix:nonFraction unitRef="shares" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI5MTM_d6dc7397-dd2b-401b-921e-a776461a9d5d">6.8</ix:nonFraction> million new ordinary shares of Galapagos at a subscription price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI5NzY_d6f5756e-af4c-4071-a124-e04ffc65a0bb">140.59</ix:nonFraction> per share with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzMwMTA_2fe4ff32-422e-40dd-af2f-71386a74dac7">1.13</ix:nonFraction> billion, which included an issuance discount of $<ix:nonFraction unitRef="usd" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="-6" format="ixt:numdotdecimal" name="gild:Issuancediscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzMwNTM_0f52a440-d47e-41c9-be13-3d450d528a39">63</ix:nonFraction> million calculated based on Galapagos&#8217; closing stock price on the date of closing of the Galapagos Subscription Agreement. The remaining $<ix:nonFraction unitRef="usd" contextRef="i8146d0695ec4432692851cb70914ad5f_D20190101-20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzMxNzU_4e6b816d-64f4-4ee0-be60-4e970af89e21">3.92</ix:nonFraction> billion of the payment was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2019. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Galapagos Subscription Agreement, we were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to <ix:nonFraction unitRef="number" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="3" name="gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM1MTc_b2cebfd5-bdaf-4839-88d0-f25b0c847aba">29.9</ix:nonFraction>% of the issued and outstanding shares at the time of our exercises. In 2019, we exercised a warrant to subscribe for <ix:nonFraction unitRef="shares" contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231" decimals="-5" format="ixt:numdotdecimal" name="gild:InvestmentOwnedBalanceAdditionalShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM2NTg_34f85c1a-83b0-4160-8980-da6783670b5a">2.6</ix:nonFraction> million ordinary shares of Galapagos at &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA5Nzc_d6f5756e-af4c-4071-a124-e04ffc65a0bb">140.59</ix:nonFraction> per share and purchased shares on the open market with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM3Nzg_46247729-4d4c-4ea5-bfcd-284e7ebea76b">586</ix:nonFraction> million, which brought the number of shares owned by us to <ix:nonFraction unitRef="shares" contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4MzI_a3bd8a62-ba1e-4a4b-85c3-7a28e2dcfa21">16.7</ix:nonFraction> million or approximately <ix:nonFraction unitRef="number" contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NTI_0079206d-6af0-4509-8106-391a31effa3d">25.8</ix:nonFraction>% of the shares then issued and outstanding. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, our equity investment in Galapagos was initially classified as Other long-term assets on our Consolidated Balance Sheets as it is subject to contractual lock-up provisions. We are subject to a <ix:nonNumeric contextRef="i8b08c2b1e8994a8386e2f87e19b2f94e_D20190801-20190831" format="ixt-sec:durwordsen" name="gild:StandstillRestrictingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxMzUyNzk_18effe1b-31f4-4994-9911-91aa4745d38e">10-year</ix:nonNumeric> standstill restricting our ability to acquire voting securities of Galapagos exceeding more than <ix:nonFraction unitRef="number" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="3" name="gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQxODY_e0d70c98-e3fc-4f03-b7c8-f2f2700e17f6">29.9</ix:nonFraction>% of the then issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than <ix:nonFraction unitRef="number" contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831" decimals="3" name="gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQ2MTc_fa5f26da-5f51-4352-b2f5-a165beff344d">20.1</ix:nonFraction>% of the then issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. We have two designees appointed to Galapagos&#8217; board of directors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the initial contractual lock-up provision for certain Galapagos shares will expire in August 2021, the corresponding equity investment balance of $<ix:nonFraction unitRef="usd" contextRef="i2b237db0dba14d1f8cd562ae2e0c1500_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NDYxMDQ_1eeed056-5e69-4955-907a-0433efe1ecb6">351</ix:nonFraction> million was included within Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2020. At December 31, 2020 and 2019, Gilead&#8217;s total investment balance in Galapagos was $<ix:nonFraction unitRef="usd" contextRef="i2b237db0dba14d1f8cd562ae2e0c1500_I20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEwOTk1MTE2OTk1OTM_874e205d-9751-4d8a-9fa0-6e37276ae5a2">1.65</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEwOTk1MTE2OTk1OTc_2bf299cd-b5d2-4ada-bfd5-370dbf18cc0b">3.48</ix:nonFraction> billion, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos&#8217; shares. We believe the fair value option best reflects the underlying economics of the investment. During the year ended December 31, 2020, we recorded a pre-tax unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i960fec8ecc464f7f9fdf9acc6db7076c_D20200101-20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEwOTk1MTE2ODEyOTk_2f97b417-6525-4c78-8471-14c30c565d8e">1.83</ix:nonFraction> billion related to our investment in Galapagos in Other income (expense), net on our Consolidated Statements of Income due to a decline in Galapagos&#8217; stock price. See Note 3. Fair Value Measurements for additional information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iab299adcabe244b4b49e389c52de4e8b" continuedAt="ie4a9c79a182e4fa1a8135090e8bca953"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Galapagos Collaboration Agreement, we have an exclusive license for the development and commercialization of GLPG-1690, a Phase 3 candidate for idiopathic pulmonary fibrosis, in our territories and have an option to participate in the development and commercialization of Galapagos&#8217; other current and future clinical programs that have entered clinical development during the first ten years of the collaboration, subject to extension in certain circumstances. We may exercise our option for a program after the receipt of a data package from a completed, qualifying Phase 2 study for such program (or, in certain circumstances, the first Phase 3 study). If GLPG-1690 receives marketing approval in the U.S., we will pay Galapagos $<ix:nonFraction unitRef="usd" contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialMilestonePaymentUponMarketingApprovalGLPG1690" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzU5NTk_6f7da248-8ecc-4201-92ce-b3d483920be8">325</ix:nonFraction> million as well as tiered royalties described below. With respect to all other programs in Galapagos&#8217; current and future pipeline, if we exercise our option to a program, we will pay a $<ix:nonFraction unitRef="usd" contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831" decimals="-6" format="ixt:numdotdecimal" name="gild:PotentialOptionExerciseFeePerProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzYzNzg_d6b6b6ec-9b4e-4829-857a-4a760c584e2e">150</ix:nonFraction> million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzY0ODA_c5e045d0-c88a-476a-92a3-8b2c9bb86b0a">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzY0ODY_e4ce2f62-9770-4d31-a4c8-bd1c750927f3">24</ix:nonFraction>% on net sales in our territories of each Galapagos product optioned by us (including GLPG-1690). If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. Galapagos retains exclusive commercialization rights for the optioned programs in the European Union, the UK, Iceland, Norway, Lichtenstein and Switzerland, and we have exclusive commercialization rights for all other countries globally. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. In 2020, Galapagos delivered to us a data package with respect to our option to participate in the development and commercialization of GLPG-1972, a Phase 2b candidate for osteoarthritis, under the Galapagos Collaboration Agreement, which we declined to exercise in November 2020. In addition, Gilead and Galapagos announced the decision to halt the ISABELA Phase 3 clinical studies with GLPG-1690 in February 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Complera/Eviplera and Odefsey</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#8217;s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and European Union in 2011 and is sold under the brand name Complera in the U.S. and Eviplera in the European Union.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#8217;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#8220;Odefsey&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#8217;s share of revenues, including up to <ix:nonFraction unitRef="number" contextRef="i70e3ac2edb384dcd87ba36967240d6a6_I20141231" decimals="2" name="gild:PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkwMjU_e206938a-814c-419b-9a4e-ee218d3cd1d0">30</ix:nonFraction>% in major markets. Sales of these products are included in Product sales and Janssen&#8217;s shares of revenues are included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#8217;s shares were $<ix:nonFraction unitRef="usd" contextRef="if741a8ddd11548bca6696dcc16ea06ff_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkyNjM_49cc0ddb-70f3-46c1-b373-582ed9c927fc">570</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iee332949c6714cb9ac12a12334a0d199_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkyNjc_0a6fefd3-9a94-4bcd-b67b-1556edb3d3eb">574</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf43160183dd4615964265dbc7e94547_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkyNzQ_35334625-088a-4e8a-a7b6-4c1f7578e61f">608</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symtuza</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#8217;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide. This combination was approved in the U.S. and European Union in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to cobicistat, emtricitabine and tenofovir alafenamide (&#8220;Gilead Compounds&#8221;) and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie4a9c79a182e4fa1a8135090e8bca953" continuedAt="ie77cecdfccf546b2bc2551e04bc9250f"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza. See Note 2. Revenues for additional information on revenue recognized for the periods presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights and paid a royalty to us based on its product sales in Japan. Under the agreement, we are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Japan Tobacco also marketed and distributed certain other products in our HIV portfolio in Japan and paid a royalty to us based on these product sales.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval for Stribild and Genvoya (elvitegravir-containing products) in 2012 and 2015, respectively. Our sales of these products are included in Product sales. Royalties due to Japan Tobacco based on our product sales are included in Cost of goods sold. Royalties due from Japan Tobacco based on its product sales in Japan are included in Royalty, contract and other revenues on our Consolidated Statements of Income. Royalty expenses recognized were $<ix:nonFraction unitRef="usd" contextRef="i6c6d33288a694080a10decb9745df341_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMzIz_cabfd85f-f671-4a47-8f58-264b7c737b99">291</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i32869178bb374083a5691c4c47f7e162_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMzI3_81e91d0b-1988-482d-a928-1cbc9856f786">358</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia23e8ec8f5a94be1a0800fd9ca20d3e2_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMzM0_b8274968-a982-4421-a01c-ce81eda8369c">452</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Royalty income recognized was not material for the periods presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we paid Japan Tobacco $<ix:nonFraction unitRef="usd" contextRef="i10e8f707b4a2423885556304b9c14459_D20181201-20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzODQz_f3cc405f-da33-4f5b-8874-1675d702456e">559</ix:nonFraction> million in cash, of which $<ix:nonFraction unitRef="usd" contextRef="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireManagementContractRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzODY0_2b4c4e30-5dd6-4fff-80f7-40f86982a363">194</ix:nonFraction> million was paid as an upfront payment in 2018, and the remaining $<ix:nonFraction unitRef="usd" contextRef="i32869178bb374083a5691c4c47f7e162_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireManagementContractRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzOTI0_8992d291-1fb3-4941-a2fd-ab36c103c081">365</ix:nonFraction> million was paid in 2019. We recognized an intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzOTgw_82998a66-4931-459e-82d6-9fa1677bce45">550</ix:nonFraction> million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco with the remaining $<ix:nonFraction unitRef="usd" contextRef="if4142852a6d94d81b33b11f3c2bf3444_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE0MDk4_46cee162-d8ba-4a6f-aeb4-8140e514ba6d">9</ix:nonFraction> million recorded as Prepaid and other current assets on our Consolidated Balance Sheets. The intangible asset is being amortized over <ix:nonNumeric contextRef="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE0MjI3_c82e0bfc-cb9b-4a8b-a6d3-6d5559b3675f">nine years</ix:nonNumeric>, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gadeta</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we entered into a collaboration arrangement with Gadeta and made a purchase of equity in Gadeta from Gadeta&#8217;s shareholders. We determined that Gadeta was a VIE, and we were its primary beneficiary because we had the power to direct the activities of Gadeta that most significantly impact its economic performance. Upon the initial consolidation of Gadeta, we recorded $<ix:nonFraction unitRef="usd" contextRef="ie52274b0a3fd40f79ccc454513656539_I20180731" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4MzU_ba81d709-e32b-40c1-8d52-32c4c63c6af9">82</ix:nonFraction> million to Noncontrolling interest, primarily reflecting acquired intangible assets related to IPR&amp;D on our Consolidated Balance Sheets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we effectively terminated the agreement with Gadeta. Upon the effective termination, we ceased to have a controlling interest and deconsolidated this VIE by removing the related net assets and noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="ia16d123600754634a5bcf2ed111b7be5_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestInVariableInterestEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4MDk_29570ac3-e35d-45e9-9289-f38532f57c06">82</ix:nonFraction> million from our Consolidated Balance Sheets. The net loss from the deconsolidation was not material.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie77cecdfccf546b2bc2551e04bc9250f" continuedAt="ic9adea893b114c53b1984cec1c3e3665"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (&#8220;BMS&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">North America</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a collaboration arrangement with BMS to develop and commercialize a single tablet regimen containing our Truvada and BMS&#8217;s Sustiva (efavirenz) in the U.S. and Canada. This combination is sold under the brand name Atripla. We and BMS structured this collaboration as a joint venture that operated as a limited liability company, which we consolidated. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2017, we terminated BMS&#8217;s participation in the collaboration following the launch of a generic version of&#160;Sustiva&#160;in the U.S. and became the sole owner of the joint venture. BMS is not permitted to commercialize Atripla in the U.S. and Canada but is entitled to receive from us certain fees based on net sales of Atripla in 2018, 2019 and 2020 on a declining annual scale. BMS supplies Sustiva to us at cost plus a markup during this three-year period but may terminate the supply agreement after a notice period. BMS notified us of their voluntary termination of the supply agreement in 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="ia37d42b05ac242459b8ca53417f3c881_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTA4OTA_6b743a33-92e5-4241-936a-a54a37d307a4">19</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ife61ff89d12b4fd3ace02e9f26886498_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE3MTk2_2873587d-275e-4110-8acc-8b3b17896144">58</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i32f211cb92aa41f0a97038b010abc03d_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTA5Mjc_1c8f4221-b63b-4b2c-8488-c3749d0badec">198</ix:nonFraction> million, respectively, of fee expenses within Cost of goods sold on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Europe</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences Ireland UC, our wholly-owned subsidiary, and BMS have a collaboration agreement which sets forth the terms and conditions under which we and BMS commercialize and distribute Atripla in the European Union, Iceland, Liechtenstein, Norway and Switzerland (collectively, the &#8220;European Territory&#8221;). The parties formed a limited liability company which we consolidate, to manufacture Atripla for distribution in the European Territory using efavirenz that it purchases from BMS at BMS&#8217;s estimated net selling price of efavirenz in the European Territory. The parties also formed a limited liability company to hold the marketing authorization for Atripla in the European Territory.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2012, except for a limited number of activities that are jointly managed, the parties no longer coordinate detailing and promotional activities in the European Territory. We are responsible for manufacturing, product distribution, inventory management and warehousing and have primary responsibility for regulatory activities. Through our local subsidiaries, we have primary responsibility for order fulfillment, collection of receivables, customer relations and handling of sales returns in all the territories where we and BMS promote Atripla. In general, the parties share revenues and out-of-pocket expenses in proportion to the net selling prices of the components of Atripla, Truvada and efavirenz. As of December&#160;31, 2020 and 2019, efavirenz purchased from BMS at BMS&#8217;s estimated net selling price of efavirenz in the European Territory was included in Inventories on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, BMS elected to voluntarily terminate the agreement effective March 31, 2020. Post termination, BMS is not permitted to commercialize Atripla in the European territory but is entitled to receive from us certain fees based on net sales of Atripla on a declining annual scale for a three-year period following the effective date of the termination. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other collaboration arrangements that are not individually significant </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, we entered into several other collaborative, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $<ix:nonFraction unitRef="usd" contextRef="i3c008f74ae7741bebc87087598c24b61_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTUzNzI_ce83fd2a-b900-4ba3-a0c6-c3cb4ccf6745">129</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie87f8e54cb4a410db675109bd66255a6_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE5NzMz_a7dfae80-203d-4c3f-a68c-207bd7a96bec">331</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief4a90e396444c1698d4940439fd9f6c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE5NzQw_e4d79573-c117-4ab3-b707-d72e1cab5671">278</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income. Cash payments made related to our equity investments for the years ended December&#160;31, 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usd" contextRef="i3c008f74ae7741bebc87087598c24b61_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTUzNTY_1c3c101e-6670-4ebb-9a50-8c70ce28e162">72</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie87f8e54cb4a410db675109bd66255a6_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTUzODc_d988cf03-7edf-496e-bc4b-53ee7b23285f">118</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ief4a90e396444c1698d4940439fd9f6c_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="gild:CashPaymentsMadeRelatedToEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTU0MDM_860826c9-1cf8-4518-90ca-b81e1a2b1c8d">156</ix:nonFraction> million, respectively, which were primarily recorded within Prepaid and other current assets and Other long-term assets on our Consolidated Balance Sheets. </span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic9adea893b114c53b1984cec1c3e3665">Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made were capitalized as intangible assets and are being amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwNDQ1MzYwNDg3Nzk3_62f5b0b3-8035-4d8d-afcc-7572e1e9d4e3" continuedAt="i50cbdd6cf0ac4d35b9e7f2e1ebcbd876" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="i50cbdd6cf0ac4d35b9e7f2e1ebcbd876" continuedAt="ia8ba24b207e2494795bcac2bb34e0071"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM5MzY_f6c95b1b-f5fe-4e33-97dd-74c757129e90" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-bottom:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1af6afc5f8e54ba59cb9793eef93e885_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzYtNi0xLTEtMA_549672d8-4fb5-487b-b7b4-f3b89872de69">2.35</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1af6afc5f8e54ba59cb9793eef93e885_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzYtOC0xLTEtMA_f67ee16b-b98f-49b3-a121-8c33f0be8aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied16c88db1234c66aedf0dc0e80bf0da_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzYtMTAtMS0xLTA_1400bb3b-0421-469b-ad94-1a2370b3c299">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33544e3e9bf8466189835e7d6f721350_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzctNi0xLTEtMA_6e3a6578-6221-40d3-ae6e-fee78ab617ff">2.55</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33544e3e9bf8466189835e7d6f721350_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzctOC0xLTEtMA_b474b62d-45e5-4f34-a667-a9ed7ab119cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76142ba97a5247fd8b93aaddb16c8fd9_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzctMTAtMS0xLTA_009bc552-4535-4705-aa98-e9392857dcb9">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8ad657ef10246598ee1f2d6d2eb3a7b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzgtNi0xLTEtMA_cbf32969-fbf9-4e67-875f-48e790e211c0">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ad657ef10246598ee1f2d6d2eb3a7b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzgtOC0xLTEtMA_0cd9af25-f0f6-43c5-809d-1d9c38317d5e">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb35118d4c9442e94273ba0799d1e3d_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzgtMTAtMS0xLTA_1928c13e-1fad-4f54-835b-669a074055f2">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="i0a7777335ed04cf59f807114fe7a66bd_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzUtNC0xLTEtNDM4Ni90ZXh0cmVnaW9uOmI4MjE5YzZiZTMwNDRkN2FhYzI4NGQzNmZkMmVmYTAwXzE2NDkyNjc0NDE2OTU_c35aff8f-016c-4de7-8678-1123acfb8c69">0.15</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i079f3e090c534879a46df4da2d4f54af_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzUtNi0xLTEtNDM5OQ_e7f5a5be-c119-4e2e-8368-19a8c2dab3de">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5cfc1706eed466ea24db728b779b02d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzUtOC0xLTEtNDM5OQ_1937bd92-c06e-4315-aecb-054809a8eaa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5975f2be2634b6193ebe5e4518e0b67_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzktNi0xLTEtMA_c8714531-cd96-45ba-bdb3-10a0dc86ce0c">4.40</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5975f2be2634b6193ebe5e4518e0b67_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzktOC0xLTEtMA_2d952d4c-d12a-4d0c-b03b-bd4ee9514abf">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3670ca9b3f7f4e67bf432cd8f3e3dd6e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzktMTAtMS0xLTA_3c2fdbc2-5a92-4d44-ac4b-66560a375f6e">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i068021f3eade41599edf59a5a127fefd_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTYtMS0xLTA_143eb346-9af7-4848-859e-800d19660198">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i068021f3eade41599edf59a5a127fefd_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTgtMS0xLTA_e14d7f86-8948-49fe-a373-1345105aa09b">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4a14e35256c4e9b99448ff4ab266069_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTEwLTEtMS0w_b5b09c87-99cb-42fe-991b-f0c0e0a26f7a">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d3bff642f2142629af6b9cd0108692d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTYtMS0xLTA_c308696c-22c4-4bc3-9666-0f023f8add80">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3bff642f2142629af6b9cd0108692d_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTgtMS0xLTA_b7862736-8ff8-486f-92f4-b1734e8f14cf">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e913054de0540cfa8dfe947549c1af3_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTEwLTEtMS0w_6714874d-5a6f-4d1e-94e2-80686479972e">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11d7b8db766a40b4915b3e488cb97f03_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTYtMS0xLTA_6ffb72e6-324c-488b-b5fe-f60e44c7b0ff">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d7b8db766a40b4915b3e488cb97f03_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTgtMS0xLTA_f27ac786-0a8e-4f51-a730-47038243a2b9">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7f8e63064f4893a1648dc50ce5ffd8_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTEwLTEtMS0w_f3b367a0-8ad5-4e00-a442-8b7999d6930c">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + <ix:nonFraction unitRef="number" contextRef="id6845673544a4170be8f0594b2341c6f_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTQtMS0xLTQ0MDMvdGV4dHJlZ2lvbjpjNWM3ZTZlYzcwMDI0ZjY1YTFlNmFhY2E0NGZlYzc5NV8xNjQ5MjY3NDQxNjk0_4e74caa7-6ea5-4e02-afbe-68445508cc9c">0.52</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a2ab9d1b9a48a0964021dec398e682_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTYtMS0xLTQ0MDM_c0557cd3-2b6c-49ca-bb92-8a3a26920d5f">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d4e35afb27045a0a512b4300478000b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTgtMS0xLTQ0MDM_63dd7256-69d1-422c-ad46-99fababb2759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0cf198ca9f14127aac65bf348fd3646_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTQtMS0xLTQ0MDM_cbbcf466-83ea-407c-a7be-2533c7035056">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie429e3caea7d425b84413a3c28d65099_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTYtMS0xLTQ0MDM_799aa726-d12b-4029-ab09-db5820363b70">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c543bc5eea4422e9442c1624ec8ab90_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTgtMS0xLTQ0MDM_0c48ae51-ee12-44d4-b3f1-af24572bfbdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7238cb6a890463c9d26c7c09431cb24_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTgtMS0xLTEyMDE1_6d55a80d-bf50-4666-8f61-d54701578294">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib268c4735aac4a7894a222f05f1e7ebe_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTEwLTEtMS0xMjAxNQ_9a4cfc6c-68be-43ba-baf3-05a4ce2ffa79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f80a26646664c12af8af332d1630212_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEzLTYtMS0xLTA_38d73195-1601-4e6d-b0ae-c728bb10878b">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f80a26646664c12af8af332d1630212_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEzLTgtMS0xLTA_f6e342f1-d20b-438f-8698-74a5bf1e8fb6">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588786d4c5b04ceb86b3104e6b1dbde9_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEzLTEwLTEtMS0w_a4b6454e-8c73-411a-9b37-e12a4f990355">1,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f90cd187b864231b694a710210de89a_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE0LTYtMS0xLTA_6062f838-2303-4bc2-875e-ff313c90fab2">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f90cd187b864231b694a710210de89a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE0LTgtMS0xLTA_351bbc68-24a8-40b1-be17-c1714f23860a">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86263ea980a0478086ecfafe984d7563_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE0LTEwLTEtMS0w_ac040e00-4984-44e0-8347-c99ccc5064f5">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e89e8f308084febab4d3c4b09ec137b_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE1LTYtMS0xLTA_a4987c12-fd48-489b-9886-3c40aa5e2309">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e89e8f308084febab4d3c4b09ec137b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE1LTgtMS0xLTA_4b9cd38c-b44a-4b8b-a847-ff4fa6c44e96">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f36c3515ec9482dba6b429c4a71e17b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE1LTEwLTEtMS0w_7a7779a5-5c25-4de5-81c9-985d66dd8331">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbe5e2da225448318d6e7ce30d2a5b44_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTYtMS0xLTA_50ee1b33-4b23-4a9a-96f6-e8ffbef59e73">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe5e2da225448318d6e7ce30d2a5b44_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTgtMS0xLTA_7733354a-458c-4554-8955-5a73ce60b0d9">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2644728c1aa4257bb5ac872b6fa8552_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTEwLTEtMS0w_50c4dcb3-3533-42ea-83d1-653033f8082e">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief2d0ff77d1d4377995f3b52034e38fe_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTQtMS0xLTQ0MDc_fb445a8c-01ba-46e6-905f-797d5ceb0691">1.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2d0ff77d1d4377995f3b52034e38fe_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTYtMS0xLTQ0MDc_b2061330-8c08-4b85-a2f9-0bbd060310f2">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a08b08ea6742dab3cb313aea60e574_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTgtMS0xLTQ0MDc_0c8e21f5-8018-4b29-a858-40181dc9f280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b4ff001607a4d4e86f6ece76b1cb4a8_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTQtMS0xLTQ0MDc_4d0b736f-c336-4ab7-9985-394e7000626b">1.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4ff001607a4d4e86f6ece76b1cb4a8_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTYtMS0xLTQ0MDc_a45a534a-eb91-4e25-91ce-cd41fad4f71d">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601d3d19bbbd40c9be8b03ece2ad21ad_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTgtMS0xLTQ0MDc_852a1233-cc3b-40a0-948d-f8b5f60fb89e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i917a67bd025e47c18737842312fd65e1_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTYtMS0xLTA_47a2c919-b8cb-48bb-9779-a68ee0edda15">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i917a67bd025e47c18737842312fd65e1_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTgtMS0xLTA_4a727767-b904-4adf-b223-bf605ccda578">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d1d8ac11bc404f91be62f8fd6239e4_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTEwLTEtMS0w_ce463b40-1dc6-49e6-ba11-af63fa3663b4">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c65c238d0cd4bdaa6748c4a0d9248e5_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE4LTYtMS0xLTA_7dae33bb-c433-45d2-889c-4d49fc807e14">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c65c238d0cd4bdaa6748c4a0d9248e5_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE4LTgtMS0xLTA_dc04424f-142d-4c90-a35d-953ff1036179">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie386ac3bda26490e9b7780e1e62a038d_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE4LTEwLTEtMS0w_0789c5ac-c269-47b7-aad1-864c75df71d7">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i116ad184d5dc456e90f07d8331609037_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTQtMS0xLTQ0MTE_fbe77f8d-4e07-443d-bb4f-5a47e4093a68">2.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116ad184d5dc456e90f07d8331609037_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTYtMS0xLTQ0MTE_617dcf1f-a797-4237-999b-600f3b16b4dd">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3d522c920c4eaf98d9423edd359180_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTgtMS0xLTQ0MTE_686f2b38-dced-4bfb-b7a5-4ed3c3792384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28f0ddee26a6400e90f15437dbf5aafd_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE5LTYtMS0xLTA_58a6935a-8012-49df-9603-28408150f5da">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f0ddee26a6400e90f15437dbf5aafd_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE5LTgtMS0xLTA_9b88ecf8-5fa3-446b-8342-2f8c0c0c4dd3">996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25cb38188cc44e84a8c402adba11be30_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE5LTEwLTEtMS0w_b63b6dea-4d89-44af-bfe3-98c45c648e9b">995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c50be0096dd408eb2b0af525d5453d9_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTYtMS0xLTA_40f57f20-f32b-4197-8eec-2903fae725ac">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c50be0096dd408eb2b0af525d5453d9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTgtMS0xLTA_1c629003-0efd-4be2-9636-d81fe6c7123c">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3341333ea70c407da5e3d68a2db6c9dc_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTEwLTEtMS0w_92fa6100-aba4-4ff5-b7df-5cadc425ef0d">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d3e46a170ac41afb9968e742e88e06e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIxLTYtMS0xLTA_1acb79ba-2c43-4296-bc3c-cf359cb956a5">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3e46a170ac41afb9968e742e88e06e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIxLTgtMS0xLTA_fde6b6be-5393-4b23-9124-0650b6b939cf">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861f7cc25fb44ef5a805d427c6d41708_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIxLTEwLTEtMS0w_c5339e71-dcd5-4907-9ff8-09db7c12b511">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b2a2c92c9bc4c019c117fcccc6fbd78_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIyLTYtMS0xLTA_85590423-699c-47be-9712-59d30cd9c5b4">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2a2c92c9bc4c019c117fcccc6fbd78_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIyLTgtMS0xLTA_c2c2bcb1-c9ae-4036-a800-0cc7d4f948a9">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99295727180471890cc95afa2e4192a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIyLTEwLTEtMS0w_17ea0e92-148a-4007-89f2-e397cda17e20">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i624388aa63954f5c96041bc516796f34_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIzLTYtMS0xLTA_b19634cc-2864-43f3-b490-049b25180afd">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624388aa63954f5c96041bc516796f34_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIzLTgtMS0xLTA_77136c3a-f7a5-41ff-b625-46b929735495">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e043d95be44884a92667d375737a0d_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIzLTEwLTEtMS0w_6a45ca70-b921-4ad6-b730-5b9349b90f35">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016f2c24896d41729056d15a9007c6e4_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTQtMS0xLTQ0MjU_bdf02767-becc-4f56-86b0-cdca6fd60ffa">2.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016f2c24896d41729056d15a9007c6e4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTYtMS0xLTQ0MjU_92c829bc-4572-4431-8a25-3bbf985c73c7">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b17acdedffc4fc1bd0b4b188bb173cf_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTgtMS0xLTQ0MjU_d5f7d605-e7b9-4c0d-a1ef-4ce2531a1672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61afb70e61ba4c8aa5270a4e11c0914b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI0LTgtMS0xLTA_9ce47af7-bf53-46c5-a2f9-f2d9507258e2">30,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i180ad2d40440498ea05cf2425660478c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI0LTEwLTEtMS0w_855e6597-e187-4f8a-aa22-0f0d863568bd">24,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd068f90f2441228adf1a8ce9668e2e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI5LTgtMS0xLTE4MjE0_8bd6765a-27dd-4426-8ab0-0b36f8ddc28b">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5f5e11f4c842dfbe349568ca25c17d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI5LTEwLTEtMS0xODIxNA_597007ec-4adc-4a31-ad4b-bc799c3adf68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzMwLTgtMS0xLTE4MjE0_97272474-f5de-4045-a284-f5934e4d5e68">31,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzMwLTEwLTEtMS0xODIxNA_e303c06d-76af-4837-8dd6-d76108da0921">24,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI1LTgtMS0xLTA_63dc47e8-930b-4ec7-acac-d897ebfc2c87">2,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI1LTEwLTEtMS0w_bdf1acc7-6fa5-404f-bd27-70799d1caddd">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTgtMS0xLTA_e0dcd9a4-1c53-4411-93d2-c1491feeb4b5">28,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTEwLTEtMS0w_eb6390a1-4f15-4a7d-81c8-2f911a42a114">22,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we issued senior unsecured notes consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="i7af8fb6957bc4c20b9649de1e7fe1110_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NTU_09e78203-5307-4dae-9eae-7d448b5ee0ae">500</ix:nonFraction> million principal amount of floating rate notes due September 2021 and $<ix:nonFraction unitRef="usd" contextRef="i71abf35a67c349dabfb936d03b474a47_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NjM_07c1ef50-884c-49ad-8042-84a10ad44e24">500</ix:nonFraction> million principal amount of floating rate notes due September 2023 (together, the &#8220;Floating Rate Notes&#8221;); and (ii) $<ix:nonFraction unitRef="usd" contextRef="i5c1faea29102437aa26bf1071aaa87fc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5Njc_3cdeac64-43be-4fe0-a5aa-1c9ae49f4bd5">2.0</ix:nonFraction> billion principal amount of <ix:nonFraction unitRef="number" contextRef="i5c1faea29102437aa26bf1071aaa87fc_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMDc_52b6f71f-4489-4b91-801b-1213d6c13700">0.75</ix:nonFraction>% senior notes due September 2023, $<ix:nonFraction unitRef="usd" contextRef="i9ff57f2a7eef4231a0e859065a5afd5d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NzE_9bd7450a-3f0d-4555-886a-6f85f487faf2">750</ix:nonFraction> million principal amount of <ix:nonFraction unitRef="number" contextRef="i9ff57f2a7eef4231a0e859065a5afd5d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMTE_d2a36625-d448-48f2-9a96-276b048ded8b">1.20</ix:nonFraction>% senior notes due October 2027, $<ix:nonFraction unitRef="usd" contextRef="i2e55cf66183242569e946df901102514_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NzU_b2bd9516-6ff6-4654-850f-64e0149571d6">1.0</ix:nonFraction> billion principal amount of <ix:nonFraction unitRef="number" contextRef="i2e55cf66183242569e946df901102514_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMTU_79a940cb-cdd8-4c8c-857d-90361cc642c2">1.65</ix:nonFraction>% senior notes due October 2030, $<ix:nonFraction unitRef="usd" contextRef="i796d7c545dcd490c93f7b990f3264b66_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5ODM_bca24ae9-6138-41d0-ab66-f0fd2724ca7a">1.0</ix:nonFraction> billion principal amount of <ix:nonFraction unitRef="number" contextRef="i796d7c545dcd490c93f7b990f3264b66_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMjY_fa657085-1d63-46a7-ba41-46cab4dd72db">2.60</ix:nonFraction>% senior notes due October 2040 and $<ix:nonFraction unitRef="usd" contextRef="i1f8b79007ae445a3bfd27b69829de9a4_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5ODc_bac15d09-6761-4166-8ef1-3ece1fb697a7">1.5</ix:nonFraction> billion principal amount of <ix:nonFraction unitRef="number" contextRef="i1f8b79007ae445a3bfd27b69829de9a4_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMzA_806b2c00-4b9b-4041-b730-df4bcb901d3c">2.80</ix:nonFraction>% senior notes due October 2050, the terms of which are summarized in the table above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we repaid at maturity $<ix:nonFraction unitRef="usd" contextRef="i66e3e8a86c104591a0f8120347df1468_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjYzNTU_2b0ba957-6cd1-45e3-b67a-38db4ca8283d">500</ix:nonFraction> million of principal balance related to our 2014 senior unsecured notes. In September 2020, we repaid at maturity $<ix:nonFraction unitRef="usd" contextRef="id20d9ac4b58549aab5a3e792776164f4_D20200901-20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjY0NDg_5993a8c2-8778-4325-93ab-e0ee2677f1bb">2.0</ix:nonFraction>&#160;billion principal balance related to our 2015 senior unsecured notes. In 2019, we repaid $<ix:nonFraction unitRef="usd" contextRef="if038f51729a24a2da8b265e610a51eee_D20190101-20191231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjY1OTU_4dbe97a1-afdd-49b6-87e2-8414524a0492">2.75</ix:nonFraction> billion of our senior unsecured notes upon maturity. In January 2021, we repaid $<ix:nonFraction unitRef="usd" contextRef="i4137a356fc414084a24897805d41c93b_D20210101-20210131" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0ODYwOTQ_47ea1fda-b873-4cc4-8c66-8957c5cd9007">1.0</ix:nonFraction> billion of senior unsecured notes prior to the April 2021 maturity.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia8ba24b207e2494795bcac2bb34e0071" continuedAt="i8330f4c50eef4eaca553eb62179c1504"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i8ca5a2ac1db347aeab2b0dc69d1d1bc0_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzk4OA_d2264517-0e38-48ea-b58f-bc921eacabcf">100</ix:nonFraction>% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. The senior unsecured fixed rate notes also have a call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from <ix:nonNumeric contextRef="i50551ba0e3694af9afb0a78f8b769781_D20200101-20201231" format="ixt-sec:durwordsen" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjQzMzA_bed51c8d-d892-4f35-b411-a223b706a563">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="ib2c456ffa7a147bbbcc6146cf6a5c52e_D20200101-20201231" format="ixt-sec:durwordsen" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjQzMzc_723f1d90-8804-4de0-a427-0ac4b3dffd0d">two years</ix:nonNumeric> prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The September 2023 floating rate notes also have a call feature, exercisable at our option, to redeem the notes at par, in whole, or in part, approximately <ix:nonNumeric contextRef="i362bd4a2c0a74dd5b55702363f9ac9ea_D20200101-20201231" format="ixt-sec:durwordsen" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjQ2MTc_b162327a-3337-4c02-bc54-a378be6b21bd">two years</ix:nonNumeric> prior to maturity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the occurrence of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to <ix:nonFraction unitRef="number" contextRef="ib3b239e1b3ad417081b0cd98df44abaa_D20200101-20201231" decimals="3" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE5ODA_589a8f04-8450-4e73-872f-1f3828e84ed7">101</ix:nonFraction>% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our senior unsecured notes and as of December&#160;31, 2020 and 2019, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a commitment letter with a group of institutional lenders to provide for a <ix:nonNumeric contextRef="i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwNDQ1MzYwNDg3Nzk2_6c883aea-77a2-45fa-8c69-fee4c3b6e95f">three-year</ix:nonNumeric> senior unsecured term loan facility in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ie106ddcf610645b9a3a7b3fe329ce835_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjI5NjI_2c3c8f8b-dd87-4a84-a785-14d0b5efb0d2">1.0</ix:nonFraction>&#160;billion. Pursuant to the commitment letter, in October 2020, in connection with our acquisition of Immunomedics, we entered into a term loan credit agreement (the &#8220;Term Loan Facility&#8221;) and borrowed an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i9f85bd04d2e648e9b5df6a64f170cf3f_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjI5NzA_a10b7b64-6b26-4dfc-ac6b-434639191318">1.0</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan Facility contains customary representations, warranties, affirmative and negative covenants and events of default. The Term Loan Facility bears interest at the Eurodollar Rate plus the Applicable Percentage as defined in the Term Loan Facility. We may terminate or reduce the amount borrowed under the Term Loan Facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI, prior to the completion of our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, we entered into a $<ix:nonFraction unitRef="usd" contextRef="i561ca9ac62a24c86b2e01e36240808fc_I20160531" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTEwNjk_bd633166-b012-4239-ac15-930aa9a8cfb8">2.5</ix:nonFraction> billion <ix:nonNumeric contextRef="i48284e9ef26a4194b5c4901f6e5e4bc6_D20160531-20160531" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzI3NDg3NzkxMTUyNTI_b693dc59-1b66-498f-98a6-9638a2da1a7e">five-year</ix:nonNumeric> revolving credit facility agreement maturing in May 2021 (the &#8220;2016 Revolving Credit Facility&#8221;). In June 2020, we terminated the 2016 Revolving Credit Facility. As of December&#160;31, 2019, there were <ix:nonFraction unitRef="usd" contextRef="i204030d3773f4af78e0d6df4e9417215_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjM4MDg_16528239-6b78-4ecb-9fb5-9707d99ff9e3">no</ix:nonFraction> amounts outstanding under the 2016 Revolving Credit Facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a new $<ix:nonFraction unitRef="usd" contextRef="ibdc7aa7015ec49fcb95e9effaeaa1a5b_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjQxMTM_ea89a923-f35e-431f-aa66-2caba3c9d8b3">2.5</ix:nonFraction> billion <ix:nonNumeric contextRef="i6aa41df238d34894bcd7a6ba42b01248_D20200601-20200630" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzI3NDg3NzkxMTUyNTM_a8374cf0-13f8-4ad6-8f1f-72f0cafd4c85">five-year</ix:nonNumeric> revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;), which has terms substantially similar to the 2016 Revolving Credit Facility. The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="ibdfdb0b6b6174cdaae4a05f26000ab2f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjM4MTc_4f3a3515-e83d-4a88-bdad-df1f5a1f822e">no</ix:nonFraction> amounts outstanding under the 2020 Revolving Credit Facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. At December&#160;31, 2020, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Eurodollar Rate plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the new credit facility in whole or in part at any time without premium or penalty.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i8330f4c50eef4eaca553eb62179c1504" continuedAt="ieabe5292da6044ab9eadb152c9bc3e6f"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM5MzA_6cd03020-f0c5-4d81-a978-bb9f171cd75e" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes and Term Loan Facility as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzEtMS0xLTEtMjU5MzA_7d1cac96-6c22-4ff7-9680-b085acdb4dac">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzItMS0xLTEtMjU5MzA_20f737dc-4087-4a9c-a4a5-a9a0844aaec9">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzMtMS0xLTEtMjU5MzA_f78dce10-b8c2-421b-a908-a4d3bf409568">4,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzQtMS0xLTEtMjU5MzA_86f29fda-ce9c-481f-bd0c-09df525b81b3">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzUtMS0xLTEtMjU5MzA_e6dc365c-f36e-4d66-aa84-2a2614df888d">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzYtMS0xLTEtMjU5MzA_c86aa6a1-469c-4163-a785-2df2b7c51f96">18,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzctMS0xLTEtMjU5MzA_4af035c7-b5c1-4a5a-be16-ba8d11bf99f1">30,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div></ix:continuation><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ieabe5292da6044ab9eadb152c9bc3e6f">Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM4NDgyOTA3NDIzNjA_ff4ca8ec-de9a-4530-9ccf-57d183b6b209">994</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM4NDgyOTA3NDIzNjU_5c63abbf-a47a-4f78-8e93-b4acdcce0c8d">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseLongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM4NDgyOTA3NDIzNzM_63ef18ef-ccfa-46e0-8498-2175f6d11042">1.1</ix:nonFraction> billion in 2020, 2019 and 2018, respectively.</ix:continuation> </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_157"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDM_5f1b970e-53d1-4465-8f55-275bce976458" continuedAt="id214c3e3118245e88aad42e00fbfdddc" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="id214c3e3118245e88aad42e00fbfdddc"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;D activities. Some of our leases include options to extend the terms for up to <ix:nonNumeric contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzU4OA_635ea2ec-8548-4e35-b2a4-93a86710d6d1">15</ix:nonNumeric> years and some include options to terminate the lease within <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzY0Ng_b7c98600-ab5e-4c13-8d3a-5d3d83af291f">one year</ix:nonNumeric> after the lease commencement date. As of December&#160;31, 2020 and 2019, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzEzMjM_059adc3f-22b0-4ebf-9989-53b808fec419">171</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzEwOTk1MTE2MzA3MjM_7ec3542a-cb43-4f26-a77d-f4d81e1b7f07">162</ix:nonFraction> million in 2020 and 2019, respectively. Operating lease expense under the prior lease accounting standard was $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzEzOTY_3b6c619b-2a01-4152-b10f-8718905e518e">109</ix:nonFraction> million in 2018.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDQ_03349fd1-c22f-4ad2-aa48-dbb5e46da0c5" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.109%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzEtNC0xLTEtMA_6f2a21c3-08d0-418a-bfce-94904c522d5b">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzItNi0xLTEtNTMyMw_cc426cc8-a4c1-4650-8a41-9c57e425534d">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzItNC0xLTEtMA_ec3a94d5-8130-41bb-acbf-8dbf93271e62">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtNi0xLTEtNTMzMA_56340a10-9a49-492a-9987-0290d0b926f6">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtNC0xLTEtMA_db8fd0f2-5a35-40ea-8132-531618a0ec75">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzQtNi0xLTEtNTMzMA_3a51ff1b-1b28-46e6-b027-119706482e66">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzQtNC0xLTEtMA_8cc67176-b04c-4d54-b8e5-20e7c31dee40">8.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzUtNi0xLTEtNTMzNg_9e233c57-b578-4eac-b847-62f988284453">8.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzUtNC0xLTEtMA_d5a41399-22b2-4587-ac5b-def3fe0d6bb8">3.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzYtNi0xLTEtNTMzNg_b78b1ce6-83c7-40c9-a6de-1d2710fe127c">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDU_cdacdd1e-7da8-4c04-97d7-4517dc4432ed" escape="true"><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzItMi0xLTEtMA_7c217443-5622-42b0-926d-63bdd1b2944f">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzItNC0xLTEtNTMxMg_fb52b9cd-7caf-44aa-91eb-7abb32d95300">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzMtMi0xLTEtMA_ef6508a5-0747-4b36-8cc7-0d139c91a286">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzMtNC0xLTEtNTMxMg_3b494136-9615-4da5-ab1f-9416d780bdfc">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDY_f721b988-bbf3-43a0-a6d2-b2ffdb1e2ffb" escape="true"><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzEtMi0xLTEtMA_abca38f3-020a-4883-942f-323cbc5e7593">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzItMi0xLTEtMA_8fa3fe90-aca5-4939-950c-67126a891842">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzMtMi0xLTEtMA_570c8aec-ce66-419d-b0e8-ed28df54718b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzQtMi0xLTEtMA_f59fad2c-867a-4b6a-ac87-df175ced4397">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzUtMi0xLTEtMA_bf74d463-af4f-4389-b03e-73ef2b2b0f91">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzYtMi0xLTEtMA_a88ab244-76ad-4e60-bea8-c3f03c814381">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzctMi0xLTEtMA_3ac03fb5-9131-432d-aadf-5c03392eca78">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzgtMi0xLTEtMA_b1019544-581b-4b99-927d-76f84d5331f8">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzktMi0xLTEtMA_b83d28bf-ed3f-4a79-a773-294fa5d5fae2">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIzMDg0_07f44a9e-6b79-48fb-acc2-8a82124f4d13" continuedAt="ib45ddcc2ac6c4b4c9b996a5ae22005ff" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="ib45ddcc2ac6c4b4c9b996a5ae22005ff" continuedAt="ib9a27f13a9b04ac19a2a4d44d7aae19a"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. It is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below in our Consolidated Balance Sheets as of December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Litigation with Idenix Pharmaceuticals, Inc. (&#8220;Idenix&#8221;), Universita Degli Studi di Cagliari (&#8220;UDSG&#8221;), Centre National de la Recherche Scientifique and L&#8217;Universit&#233; Montpellier II</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Idenix, UDSG, Centre National de la Recherche Scientifique and L&#8217;Universit&#233; Montpellier II sued us in the U.S. District Court for the District of Delaware alleging that the commercialization of sofosbuvir infringes U.S. Patent No. 7,608,600 (the &#8220;&#8217;600 patent&#8221;). We prevailed at all phases of litigation concerning the &#8217;600 patent, and in 2018, the U.S. Supreme Court denied Idenix&#8217;s petition for certiorari. Also in 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the &#8220;&#8217;054 patent&#8221;) and 7,608,597 (the &#8220;&#8217;597 patent&#8221;). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the &#8217;054 patent related to sofosbuvir and withdrew that patent from the trial. A jury trial was held in 2016 on the &#8217;597 patent, and the jury found that we willfully infringed the asserted claims of the &#8217;597 patent and awarded Idenix $<ix:nonFraction unitRef="usd" contextRef="i919f90af93194b0f8ce1c1dfb232c4eb_D20161201-20161231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzNjA_3a760e54-75d5-487b-913c-dd938e98acb2">2.54</ix:nonFraction>&#160;billion in past damages. In 2018, the judge invalidated Idenix&#8217;s &#8217;597 patent and vacated the jury&#8217;s award of $<ix:nonFraction unitRef="usd" contextRef="if9f82513a9f94dd7a549cc436cc58d8c_D20180101-20181231" decimals="-7" format="ixt:numdotdecimal" name="gild:LossContingencyMotionInvalidatedForPastDamagesValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzNDU_eafae0ee-f32f-4b90-865d-657f3e9a036a">2.54</ix:nonFraction>&#160;billion in past damages. Idenix appealed this decision to the U.S. Court of Appeals for the Federal Circuit (&#8220;CAFC&#8221;), and in October 2019, the CAFC issued an opinion affirming the trial court&#8217;s decision that the &#8217;597 patent is invalid. In April 2020, the CAFC denied Idenix&#8217;s petition for rehearing en banc. In January 2021, the U.S. Supreme Court denied Idenix&#8217;s petition for review, making the judgment against Idenix final. </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and has scheduled a merits hearing for February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated, which we expect will occur in 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib9a27f13a9b04ac19a2a4d44d7aae19a" continuedAt="ie10dd71d3a7e4ba585ad80956a741670"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $<ix:nonFraction unitRef="usd" contextRef="i5f7210bf9b704da3b00654f5387c8418_D20191201-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzNzU_355cacd5-2ae3-4837-9b87-e079fc55c8b5">585</ix:nonFraction>&#160;million in an up-front payment and a <ix:nonFraction unitRef="number" contextRef="i5f7210bf9b704da3b00654f5387c8418_D20191201-20191231" decimals="3" name="gild:JudgmentRoyaltyRateFromOctober2017" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzODk_7bb10bd5-ea9d-42cd-a2b0-3fdd22bc6354">27.6</ix:nonFraction>% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by <ix:nonFraction unitRef="number" contextRef="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesonPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzOTY_5554ffce-bd85-4047-8ec0-c26200428cdf">50</ix:nonFraction>% and maintained the royalties on future Yescarta sales at <ix:nonFraction unitRef="number" contextRef="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430" decimals="3" name="gild:JudgmentRoyaltyRateOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MDE_dc2c8dc8-f580-4c73-93cb-6d1ecf7694fd">27.6</ix:nonFraction>%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether we should accrue a liability for this litigation in our Consolidated Financial Statements, we considered various factors, including the legal and factual circumstances of the case, the jury&#8217;s verdict, the district court&#8217;s pre- and post-trial orders, the current status of the proceedings, applicable law, the views of legal counsel and the likelihood that the judgment will be upheld on appeal. As a result of this review, we have determined, in accordance with applicable accounting standards, that it is not probable that we will incur a material loss as a result of this litigation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the judgment is reversed on appeal, the loss is expected to be <ix:nonFraction unitRef="usd" contextRef="id4a501179a0c4d10a7471e189ee30e56_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0NzQ_a9e45729-0381-4ea0-8e84-bb98ec10011b">zero</ix:nonFraction>. If the judgment is upheld in its entirety on appeal, we estimate a loss through the fourth quarter of 2020 to be approximately $<ix:nonFraction unitRef="usd" contextRef="ieed6db4dd53c4a86afcc8c65e474d496_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MDg_fbf69962-5a80-47ce-bf07-2bd0bfdfa8ef">1.4</ix:nonFraction>&#160;billion, which consists primarily of (i) approximately $<ix:nonFraction unitRef="usd" contextRef="i844383cc25214e31ad2596ee61b72eee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:LossContingencyEstimateofPossibleLossPastSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MjI_671d7433-7618-41be-872e-9c386f5eef7f">811</ix:nonFraction>&#160;million, which represents damages on Yescarta revenues through December 12, 2019, and prejudgment interest thereon, (ii) approximately $<ix:nonFraction unitRef="usd" contextRef="i844383cc25214e31ad2596ee61b72eee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MzY_77044f10-b1af-4749-873f-7d091111cc4c">389</ix:nonFraction>&#160;million, which represents a <ix:nonFraction unitRef="number" contextRef="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesonPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzMyOTg1MzUxMDUzODQ_5554ffce-bd85-4047-8ec0-c26200428cdf">50</ix:nonFraction>% enhancement of past damages and (iii) approximately</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i844383cc25214e31ad2596ee61b72eee_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0NTU_da980250-0059-491e-a7da-9d4e22ad2a3a">172</ix:nonFraction>&#160;million for royalties on Yescarta revenues from December 13, 2019 to December 31, 2020. The estimated loss does not include post-judgment interest on the foregoing, which is not estimated to be material as of December 31, 2020. Although we cannot predict with certainty the ultimate outcome of this litigation on appeal, we believe the jury&#8217;s verdict and the judgment to be in error. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the sole asserted claim of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $<ix:nonFraction unitRef="usd" contextRef="ia4281b1de2ca446dacc33382d882ca0a_D20180207-20201231" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE2NDk_06b072f0-f588-42d9-b03a-5c70910d3139">11.46</ix:nonFraction>&#160;billion through December 31, 2020. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and ViiV. The &#8217;282 patent is the compound patent covering ViiV&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In January 2020, the court held a summary trial to assess ViiV&#8217;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#8217;282 patent and dismissed the case. ViiV has appealed this decision. Argument on the appeal is expected to take place later in 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#8220;EP &#8217;206&#8221;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#8220;KR &#8217;819&#8221;) and 1363875. These patents all relate to molecules which ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#8217;s patents. In 2019, we filed an opposition in the European Patent Office (&#8220;EPO&#8221;) requesting revocation of EP &#8217;206. The EPO hearing is scheduled for 2021. In 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#8217;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#8217;819 to be invalid. ViiV may appeal this decision. The court in Germany has scheduled a hearing on the issue of infringement in April 2021. In all jurisdictions, to the extent that the claims of ViiV&#8217;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie10dd71d3a7e4ba585ad80956a741670" continuedAt="i4352bac5debb43f69cb42bafbbd0958d"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#8220;TAF&#8221;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing is scheduled for July 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing is scheduled for March 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i4352bac5debb43f69cb42bafbbd0958d" continuedAt="i5740fdfab7cb46f1b6fd3745bf3062de"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations and Related Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, we received a subpoena from the U.S. Attorney&#8217;s Office for the Northern District of California requesting documents related to the manufacture, quality and distribution practices of Complera, Atripla, Truvada, Viread, Emtriva, Hepsera and Letairis. We cooperated with the government&#8217;s inquiry. In 2014, the U.S. Department of Justice informed us that it had declined to intervene in a False Claims Act lawsuit filed by two former employees. In 2019, the District Court granted the Department of Justice&#8217;s motion to dismiss plaintiffs&#8217; federal claims. In April 2020, plaintiffs refiled their California False Claims Act and California retaliation claims in the Superior Court of California, County of San Mateo. In July 2020, the California Attorney General declined to intervene in the case, and the state court complaint was unsealed. In September 2020, we filed a demurrer requesting that the Superior Court dismiss plaintiffs&#8217; claims, which was overruled in November 2020. We have sought an appeal of the Superior Court&#8217;s order overruling our demurrer. Although we cannot predict the ultimate outcome of this lawsuit, we believe the action is without merit and we intend to vigorously defend against it.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a voluntary request for information from the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania requesting information related to our reimbursement support offerings, clinical education programs and interactions with specialty pharmacies for Sovaldi and Harvoni. In 2018, we received another voluntary request for information related to our speaker programs and advisory boards for our HCV and HBV products. In October 2019, the government informed us that, following its investigation, it declined to intervene in two False Claims Act lawsuits against us. Notwithstanding the government&#8217;s declination, relators have continued to pursue the lawsuit relating to HBV speaker programs and advisory boards and served us with the Second Amended Complaint in November 2019. In December 2020, the lawsuit relating to HCV sales and marketing issues was unsealed. The relator has indicated that he intends to pursue the case against Gilead. Although we cannot predict the ultimate outcome of these lawsuits, we believe the actions are without merit and we intend to vigorously defend against them. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we also received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Health Choice Advocates, LLC (&#8220;Health Choice Advocates&#8221;) filed a qui tam lawsuit against us under seal in New Jersey state court alleging violations of the New Jersey False Claims Act through our clinical education programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In July 2020, the New Jersey Attorney General&#8217;s Office declined to intervene in the lawsuit and the complaint was unsealed. In May 2020, Health Choice Advocates filed a qui tam lawsuit under seal against us in Texas state court making similar allegations under the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;). This lawsuit seeks all available relief under the TMFPA. In October 2020, the Texas Attorney General&#8217;s Office declined to intervene in the lawsuit and the complaint was unsealed. Health Choice Advocates previously filed a lawsuit making similar allegations under the federal False Claims Act and various state False Claims Acts, including the TMFPA, in federal court in the Eastern District of Texas in June 2017 and the court entered an order dismissing that matter without prejudice in July 2018. Although we cannot predict the ultimate outcome of these lawsuits, we believe these actions are without merit.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in two class action lawsuits and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, New Jersey and Missouri, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0ODA_3580033e-e63e-4907-a91b-356da922412a">21,000</ix:nonFraction> plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i5740fdfab7cb46f1b6fd3745bf3062de" continuedAt="i24d6b71ddf544ed78069666d7a17b9c6"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Japan Tobacco, BMS and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#8217; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been or may be consolidated, are all pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesales, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (&#8220;Cipla&#8221;) were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019. The lawsuits were consolidated in September 2019, and plaintiffs filed a consolidated complaint in November 2019. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the United States District Court for the District of New Jersey. In January 2020, Immunomedics filed a motion to dismiss the consolidated complaint, which was denied in July 2020. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments </span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i24d6b71ddf544ed78069666d7a17b9c6">In the normal course of business, we enter into various firm purchase commitments primarily related to active pharmaceutical ingredients (&#8220;API&#8221;) and certain inventory related items. As of December&#160;31, 2020, these commitments for the next five years were approximately $<ix:nonFraction unitRef="usd" contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzIy_230374c4-46e2-4d2b-936f-28d57dc32e0c">1.2</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzMy_62a394a5-63d4-4ba6-9610-4caf19c0d840">486</ix:nonFraction> million in 2022, $<ix:nonFraction unitRef="usd" contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzQy_77d8adb4-c8a0-4739-8a7f-b00dc64705d8">192</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzUy_59b79af4-eefb-4bd5-bd11-78d4be8d5f36">70</ix:nonFraction> million in 2024 and $<ix:nonFraction unitRef="usd" contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzY1_5ff7350b-bd91-4211-80ff-1f8e1d5432eb">55</ix:nonFraction> million in 2025. The amounts related to API represent minimum purchase commitments.</ix:continuation> </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_166"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwODA_97d0c7b5-9b41-49c9-a5b3-dff2f9f51b27" continuedAt="ic66ce15ce5434cc3826b0e40b434dd5c" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="ic66ce15ce5434cc3826b0e40b434dd5c" continuedAt="ia8b8a6ecc0ff42e582571b913f5e0343"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="i676b993c500e4814bfc126d01c700bce_I20160331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzEwNQ_691f4df7-b65f-41c7-beb1-60d6bf78ea0e">12.0</ix:nonFraction> billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $<ix:nonFraction unitRef="usd" contextRef="ib489d1a178c64897a715f8a20a2aa447_I20200331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzEwOTk1MTE2MzE2NDM_a9581861-21e6-4aa7-bc9d-50d66dd73b67">5.0</ix:nonFraction> billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the remaining authorized repurchase amount from both programs was $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMyNA_0f6ebc07-74f6-4b57-aa66-0492353699c3">6.8</ix:nonFraction> billion.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwNzI_aa6b1b74-927c-4ac8-8445-f2fa4861ddcc" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases under the 2016 Program:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d9aac36dbf242fbbc1e60f05511aa07_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzItMi0xLTEtMA_867bfe99-2888-43c4-b145-5cfa03bc1c38">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4830709842f45418b3c333d24ffd5a0_D20190101-20191231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzItNC0xLTEtMA_ad6ac2d0-74ce-4aa0-9cb0-a26fef06c78f">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b6402e854a642ccaecbd191f676e641_D20180101-20181231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzItNi0xLTEtMA_624daac9-9fa9-4a49-a262-75a7c23f3d8b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzMtMi0xLTEtMA_4a1b87fb-6fce-4274-bdaf-6a9763f34480">1,583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzMtNC0xLTEtMA_368f1f02-3866-4940-a9d5-352a3cbad66a">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzMtNi0xLTEtMA_7dbbd340-10c5-4c74-a6d1-a51a6440499d">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzQtMi0xLTEtMA_8d5d42c7-1a7d-4aef-ad35-739d60242b11">70.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzQtNC0xLTEtMA_57d28c10-3322-4875-a95c-d6f69f9f0756">66.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzQtNi0xLTEtMA_f730b624-4ad1-40ba-a774-5f33ad0580c7">72.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia8b8a6ecc0ff42e582571b913f5e0343" continuedAt="i5971cdb5b058482d80bdef02d4272d63"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to repurchases from the 2016 Program and 2020 Program, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations, which are immaterial and excluded from the table above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital (&#8220;APIC&#8221;) based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DividendsDeclaredTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwNDQ_0720659e-1bc9-4bcb-b429-1683c6e48657" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItMi0xLTEtMA_82e35860-830f-4d73-aec4-f4ad60026055">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItNC0xLTEtMA_f3105e85-41a7-40a8-aded-004440464b77">867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItNi0xLTEtMA_15333856-a193-4f94-88af-3eb07a4f93fe">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItOC0xLTEtMA_e027c968-cd22-4322-a930-74ef955c8dec">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtMi0xLTEtMA_125bb56b-7f44-406a-9ad2-5892829bb5f6">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtNC0xLTEtMA_943b7bbd-6f0b-49f1-bbba-09621c0b4fa2">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtNi0xLTEtMA_83c9bf9f-d8ca-4cb4-be74-84a8bdce74aa">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtOC0xLTEtMA_ab5270ee-cc2f-4386-a49d-d4acc415a443">810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtMi0xLTEtMA_600e3687-fe36-4d4c-a6b5-f66284c0ada0">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtNC0xLTEtMA_5d5d2334-111e-48e7-941d-507a0d9167a6">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtNi0xLTEtMA_0788ac66-42f6-4a25-91e9-072fce736fbd">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtOC0xLTEtMA_933e2b2f-7444-4d32-9dfa-f7124d1a4adc">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtMi0xLTEtMA_8e057370-d0fd-4a25-8df5-160aafd8971b">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtNC0xLTEtMA_0a81ac1b-4d83-4253-afd4-7e7bea30255e">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtNi0xLTEtMA_0c85d9e0-3b72-4529-8e5f-8b49d9769cfd">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtOC0xLTEtMA_ef25000b-0dfa-47f6-a71f-6e7f644a704f">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtMi0xLTEtMA_8f593842-fb9b-472b-964f-97769f68c008">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtNC0xLTEtMA_f3dbf4fa-6368-45b5-95fd-63c50f5390b4">3,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtNi0xLTEtMA_bdc2f86b-ad78-4b6b-87b6-e994fc671513">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtOC0xLTEtMA_9697ae6f-6e0f-4943-a4ee-dcd92f2990cc">3,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock and performance share awards or units have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;4, 2021, we announced that our Board of Directors declared a quarterly cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib10c7000f4c647a2b89591cb924c9b7e_D20210204-20210204" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzE5NDQ_059a2d88-32cf-4342-9e71-fa3c450c39fa">0.71</ix:nonFraction> per share of our common stock, with a payment date of March&#160;30, 2021 to all stockholders of record as of the close of business on March&#160;15, 2021. Future dividends are subject to declaration by our Board of Directors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzIxNjU_d6ff3117-b2c4-4818-96df-c46a9ddec216">5</ix:nonFraction> million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was <ix:nonFraction unitRef="shares" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzIzNDA_1658bf10-4dff-4c4a-b87b-49b3e8d622ac"><ix:nonFraction unitRef="shares" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzIzNDA_27bb08b5-c97b-48ed-a779-11da0a3abbb3">no</ix:nonFraction></ix:nonFraction> preferred stock outstanding as of December&#160;31, 2020 and 2019. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwNzY_87c49297-7b8b-4895-9a12-dc5e537b2803" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80decbd404fa4810a481f263b6dbbc28_I20171231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtMi0xLTEtMA_e3a5dafd-0628-4c1f-903d-2aec40a01243">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d477cb7874f4bfd96a09be4ca3fd0c7_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtNC0xLTEtMA_57c3094c-9ef0-4938-aab8-66ab46f69731">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040cf00a6f04094a6d26c4f32df7e7c_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtNi0xLTEtMA_9993b041-d839-4035-aa8d-0c5c67f453ab">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f6356b044964174974ec7dc3f4bbd36_I20171231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtOC0xLTEtMA_36ac4789-02eb-4fea-9aeb-06c21d4c2b2d">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14ff8312abf74fc68d269603e3776270_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtMi0xLTEtMA_d5cbd1f9-b026-499a-ac0e-76141b67ba0e">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtNC0xLTEtMA_a37bea47-8486-4608-a019-d4d0b6b7928d">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtNi0xLTEtMA_2c554d25-af51-43a0-9b36-0ef23deab93d">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtOC0xLTEtMA_b831e12d-3913-4c0d-90d3-96c17cace769">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ff8312abf74fc68d269603e3776270_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtMi0xLTEtMA_6283c079-c6b5-4e47-915b-b8f4a474155d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtNC0xLTEtMA_168f2504-a4a8-4959-9b56-90a709717cea">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtNi0xLTEtMA_873eae28-6deb-4af7-88d8-fe3ad6140a22">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtOC0xLTEtMA_4473f5b1-be98-4dea-be2f-811739a3ea7a">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14ff8312abf74fc68d269603e3776270_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtMi0xLTEtMA_e6dd996d-7dfc-490c-848e-9a3a72c3a7dd">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtNC0xLTEtMA_f9087775-d403-4a1a-9c0a-965771489b57">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtNi0xLTEtMA_4de48bcd-0739-43b1-b61b-c133f0c87524">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtOC0xLTEtMA_86d9676c-56c9-4c25-a79e-9b8b4a1ab82f">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99fd8d434aa478fa9b18fec33d3e230_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctMi0xLTEtMA_33385067-9365-46a9-b723-10c10f98b037">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3593a4df8f4b348d04321ee946cf2a_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctNC0xLTEtMA_d5113b64-9669-4008-aee8-be50185f492e">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5468af7521ac455985434b5f19b7bbb9_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctNi0xLTEtMA_15ea493b-e0d3-49ec-8708-4462d122c1e5">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54dde75a77af4f3b89a86ac2a4228e70_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctOC0xLTEtMA_d143b9e1-a104-42fb-9281-3da0a4987b47">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fecafa85db046288d32b5acb380096d_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtMi0xLTEtMA_e0b31f5e-fb6c-40f1-900c-0a20f2266366">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtNC0xLTEtMA_15abe48f-7b10-426f-8e14-be4742e983e0">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtNi0xLTEtMA_beaf69ac-492f-432d-8aa3-d7447de6a82e">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtOC0xLTEtMA_320bf6fa-d0eb-4545-b9be-1b8d3bdc163c">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fecafa85db046288d32b5acb380096d_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktMi0xLTEtMA_3b303164-5261-4d35-8363-1b770d8f87a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktNC0xLTEtMA_978d0640-4f4f-4742-a8e8-bf4a9a4a19e4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktNi0xLTEtMA_41657835-21e5-4a41-aa27-ff69bed0f91a">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktOC0xLTEtMA_865efbe1-b538-4297-aff3-fada865a04b4">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fecafa85db046288d32b5acb380096d_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTItMS0xLTA_d9bca810-a6f8-489c-a47f-68d6099847d3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTQtMS0xLTA_b18eba03-b854-44fd-98c0-c56104232185">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTYtMS0xLTA_d7871301-43cf-4da6-9429-ab1631809469">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTgtMS0xLTA_8cd999d4-bb55-4df6-91a7-7a5d8baa6e94">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ed215bd7b494fbe89f89a8b6e2b2a64_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTItMS0xLTA_db3919f9-6c7a-4374-a7af-b6ea45e1f392">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5707d2a1fdef4bd29d50dcedf69cf5db_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTQtMS0xLTA_b35ca758-5907-4698-9428-fc6b2f16e100">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf73804142f4a5a8699854aa476d33f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTYtMS0xLTA_c354c3de-8182-456c-817b-5c114c0b6fd9">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8823d4c8e7b94b01a4ee9918a81621f1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTgtMS0xLTA_826be518-d19c-47b0-9258-5bdcdb39e69f">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTItMS0xLTY1MDg_c7a12aca-93f9-45f3-beca-40e6948f52fa">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f513a45782a4d148af987a580b897fa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTQtMS0xLTY1MDg_fa31006e-1a08-4571-871f-3b9910539525">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTYtMS0xLTY1MDg_21bbb94c-9a81-401b-a612-62794df4feaf">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTgtMS0xLTY1MDg_84ddf5e6-779f-4495-b5a1-3068b8f7befb">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTItMS0xLTY1MDg_d0f140b7-9037-4349-91f7-38f8f50623b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f513a45782a4d148af987a580b897fa_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTQtMS0xLTY1MDg_c399bc48-6891-4624-a5bc-52a8dd349cca">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTYtMS0xLTY1MDg_a9ffef43-0c88-44b6-909c-6806bc53fe0f">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTgtMS0xLTY1MDg_d5214fa8-2614-44c2-9aa6-e55e6360b110">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTItMS0xLTY1MDg_fa620d3b-eb42-4e04-8a5d-5e972482262e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f513a45782a4d148af987a580b897fa_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTQtMS0xLTY1MDg_4b4c7253-dc00-41e1-a389-eb077f5a9a67">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTYtMS0xLTY1MDg_6e6da711-74a8-439c-ba68-2b247efde319">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTgtMS0xLTY1MDg_4e27243a-5b11-42e4-bb2b-27bd1f7e66bf">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b95bfbb00a4bee81e1cd96a5d51ca7_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTItMS0xLTY1MDg_57f47bb1-9b5e-413c-b38b-f87a85dd7c31">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3903462c6c24250b51ed2304b4c2329_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTQtMS0xLTY1MDg_fd1b512f-e126-48a2-8f5e-17e9b01d164f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8565010ef19410480a12c5243b09982_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTYtMS0xLTY1MDg_93a5b291-a5ce-4bf9-bde0-b9068ca4baea">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a5ad62f62cb4ef6968f09d3363ab76e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTgtMS0xLTY1MDg_f9b58984-3e33-4f5d-bb1a-afc710d63ae3">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5971cdb5b058482d80bdef02d4272d63">The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net, on our Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for the periods presented.</ix:continuation></span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_169"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NjQ_a9714988-b8e4-4970-8dd9-a31d6503ff2d" continuedAt="i381e8517483d4521819f988c600c7959" escape="true">EMPLOYEE BENEFITS </ix:nonNumeric></span></div><ix:continuation id="i381e8517483d4521819f988c600c7959" continuedAt="id3c6b877e58c451d891acf9c6526009e"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSU&#8221;s), performance share awards or units (&#8220;PSU&#8221;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, estimated fair value is based on either the Monte Carlo valuation methodology or the stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#8220;2004 Plan&#8221;). The 2004 Plan authorized the issuance of a total of <ix:nonFraction unitRef="shares" contextRef="ic2f11fdc536f400994934dad7faee301_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExMTY_ace01837-0b38-4bf5-afce-195bfadae1e0">309</ix:nonFraction> million&#160;shares of common stock. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Forty Seven acquisition, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#8220;2018 Plan&#8221;). The aggregate amount of shares that may be issued under the 2018 Plan on or after the assumption date will not exceed <ix:nonFraction unitRef="shares" contextRef="iade23e2d742345dd981025a2118869e5_I20200407" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwMDI_a13c4216-efd7-4d5d-afc4-7b77d6b7ebfe">12</ix:nonFraction>&#160;million shares. As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan (the &#8220;Immunomedics Plan&#8221; and referred together with the 2004 Plan and 2018 Plan as the &#8220;Plans&#8221;), which we subsequently merged into the 2004 Plan. The aggregate amount of shares that may be issued under the Immunomedics Plan on or after the assumption date will not exceed <ix:nonFraction unitRef="shares" contextRef="i86b3338567b348fd91d9138a1c4c1f6d_I20201023" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwMTQ_3533a2fe-20df-4231-8dbb-bdf254cc6b0a">26</ix:nonFraction>&#160;million shares. See Note 6. Acquisitions for additional information on the settlement of stock awards.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans are broad based incentive plans that provide for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. As of December&#160;31, 2020, a total of <ix:nonFraction unitRef="shares" contextRef="ic2f11fdc536f400994934dad7faee301_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA3MzE2_dbf9cc49-e091-4962-8137-a674be1a7942">96</ix:nonFraction>&#160;million shares remain available for future grant under the Plans. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans provide for option grants designated as either non-qualified or incentive stock options. All stock options granted after January&#160;1, 2006 have been non-qualified stock options. Employee stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0Nzg_3e0bf107-df4c-42b5-99e9-a7dcf78020b1">three</span> or <ix:nonNumeric contextRef="i75d7b35235ad4232b8705dbc79802f56_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0ODQ_f3b9f600-9d4e-4133-beaf-890fa54c7e40">four years</ix:nonNumeric>. All options are exercisable over a period not to exceed the contractual term of <ix:nonNumeric contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE1Njg_fc883cbf-5c5c-4d4d-8f98-c877f3616dcb">ten years</ix:nonNumeric> from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the Plans&#8217; previously authorized and available pool of shares. </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1Mzg_5056c96f-da46-4d1a-afe6-0e3bd4747eff" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: </span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average <br/>Remaining <br/>Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/> Intrinsic <br/>Value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60943a7163f448b5a6c2157080ad7985_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzEtMi0xLTEtMA_9a0102e9-83bf-4bcd-beb1-cb32c90c7ac6">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60943a7163f448b5a6c2157080ad7985_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzEtNC0xLTEtMA_1fdd41b1-d459-4e67-a5ae-66f32d8c6867">61.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzItMi0xLTEtMA_7b37f512-1cd3-4465-bc4a-0cf72d14b646">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzItNC0xLTEtMA_f1ba7e92-392c-43a3-852c-bb907512f07d">71.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzMtMi0xLTEtMA_89e8a1b3-0da8-421f-a904-da7b0ffdaf06">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzMtNC0xLTEtMA_d3442a08-a201-4ccb-8b3b-ea852e6ec8c0">72.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzQtMi0xLTEtMA_99410ee4-e36e-4a3a-b308-6f80f920090f">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzQtNC0xLTEtMA_22e5fe5d-fca9-4981-b493-d8cd78a26656">81.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzUtMi0xLTEtMA_20e213f5-b486-48c7-9312-445924470627">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzUtNC0xLTEtMA_a3a1b5b0-14eb-40f3-a3ad-d901fd807cb8">34.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtMi0xLTEtMA_c83088bc-9855-468c-9eb6-350d9c016d27">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtNC0xLTEtMA_4933cbe2-1fee-4504-b7f8-fcc407a5532b">69.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtNi0xLTEtMA_abf9c6c0-ecaa-42ff-b3c5-d0bcebf30454">5.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtOC0xLTEtMA_719c3b45-caef-4a81-9414-1d8dcd741f3f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctMi0xLTEtMA_4b3fe57f-14e2-44c5-8ff9-68ff758b79f9">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctNC0xLTEtMA_450337a6-8fb7-4982-bb7a-811a931c8bfb">68.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctNi0xLTEtMA_5828aa95-ce04-41f7-aad2-a72e0e5b099b">3.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctOC0xLTEtMA_8ebc458d-d947-49e2-89bc-0361ab443e22">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtMi0xLTEtMA_d9c18e1e-d7f2-4c41-8a2c-b51c6f7aabda">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtNC0xLTEtMA_cc495105-2ada-4408-9f15-b62b072637fd">70.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtNi0xLTEtMA_253e5a45-3ffb-4ddd-9d6b-69e4c6da23c8">8.49</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtOC0xLTEtMA_b467c20f-f7d7-40c9-aad3-dd7d54440f7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzIzNDk_d41ea683-72b3-427a-9bc6-58e1d626f01a">179</ix:nonFraction> million for 2020, $<ix:nonFraction unitRef="usd" contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzIzNjA_ecc8d987-b453-4797-881f-42ce71a5b00d">209</ix:nonFraction> million for 2019 and $<ix:nonFraction unitRef="usd" contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzIzNzQ_a5d0946e-1e88-4f64-a36a-acfd3aa80510">412</ix:nonFraction> million for 2018. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="id3c6b877e58c451d891acf9c6526009e" continuedAt="i7a3bb80c27d541c89a00a24ec73c3d16"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of the stock options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI0NjI_9cf97a2c-681e-43a1-85c5-df9563bb3d02">11.69</ix:nonFraction> per share for 2020, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI0ODM_c76f1a53-53cd-4b78-b745-c3c1221b6ace">12.15</ix:nonFraction> per share for 2019 and $<ix:nonFraction unitRef="usdPerShare" contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI1MDc_e2bc088e-9570-4421-8559-0d1157122a0a">17.03</ix:nonFraction> per share for 2018. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3MzM_2f3d6079-1f1d-43b7-9cbc-0ff89735c771">55</ix:nonFraction> million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of <ix:nonNumeric contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI4NzY_1fe82ccd-8e54-4c08-9a6a-6aa0d03f8d65">2.3</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock and Performance Share Awards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNjQ_4b3408a6-98fc-4b69-98be-510a6fbd1b22">three</span> or <ix:nonNumeric contextRef="i9db8741b4d8842f1bb640976d2a45d96_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNzA_45369d85-d47b-4e91-b869-789198a34d93">four years</ix:nonNumeric> from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="i62891fc164b04b4e8264bd225dfeb876_I20201231" decimals="INF" name="gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzM3NDQ_5d377f66-74d9-4a13-ac13-1c845c6062b8">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6aa115e88017417cb54eaf2b28abc9ec_I20201231" decimals="INF" name="gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzM3NTA_7c2b7860-46ef-4e96-8074-f0007c9a107b">200</ix:nonFraction>%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDA_af92dcc3-2fe4-41b3-aed3-392d48d636df">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDU_17e1fc1d-af04-402c-9a3d-30ce2e48473b">two</span> year period. The fair value of such an award is equal to the closing price of our common stock on the grant date.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NTY_109f4854-5d92-4f3b-93de-8acd9772da4b" continuedAt="i5c1acf1635154e319d354b904683e5bf" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity and related information:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic717d0c503c143968d6471b329f28be4_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItMi0xLTEtMA_01de1809-b74f-4efc-aac8-fefc3c81f437">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic717d0c503c143968d6471b329f28be4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItNC0xLTEtMA_ad351f57-8646-4a10-9486-d327579b97f3">70.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i131142515dae41e291f717d69305bc41_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItNi0xLTEtMA_8c8d138e-aeef-4218-a2ea-0417d95bbc24">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i131142515dae41e291f717d69305bc41_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItOC0xLTEtMA_ad2989a4-9cd8-4cac-8270-94feef69a831">80.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtMi0xLTEtMA_305253d6-4713-426e-8fca-d083c0ace87d">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtNC0xLTEtMA_e89aa23f-8efe-4dc1-872e-a4ac018641bd">70.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtNi0xLTEtMA_7e8fe931-7339-4af0-af37-2376a6d2092e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtOC0xLTEtMA_16b1f8ce-910f-46c5-8949-d7c51e5d3a26">83.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtMi0xLTEtMA_0c9a5b69-7dec-4414-a255-febe81c07900">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtNC0xLTEtMA_555ab616-a2e9-4e6f-809a-ae90289d4605">72.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtNi0xLTEtMA_64e9d64a-a0ff-4f51-937d-b9e3a369f435">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtOC0xLTEtMA_8ab44d21-97c5-48f3-b58c-280f092cbff7">73.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtMi0xLTEtMA_9ed1a82e-8ce2-4059-aa2a-8f843db0280d">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtNC0xLTEtMA_4840bc6d-bfc6-4e4f-a936-09a27dcd8b54">70.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtNi0xLTEtMA_b5d72f6a-6399-446b-ac39-2f82b62b1802">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtOC0xLTEtMA_050fe4ef-c13f-40b3-9f6f-adb1d3c006de">81.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d4423b8d04646d3a954612daf594dac_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtMi0xLTEtMA_55ccc54f-e13a-48fd-ba52-c8950ae9678c">19.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d4423b8d04646d3a954612daf594dac_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtNC0xLTEtMA_c09125c7-cddf-4faf-bd77-6bb3f71f48e4">69.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i982d3c7d11dc4c84a981217fe59bf232_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtNi0xLTEtMA_3d778d75-7598-4327-854c-12e85eb874b0">0.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i982d3c7d11dc4c84a981217fe59bf232_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtOC0xLTEtMA_626cc4cb-50b1-4a0d-9eec-0685bc6bc040">84.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i5c1acf1635154e319d354b904683e5bf" continuedAt="i93558f8cad4b46928a0b64365fd3f8ee">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i93558f8cad4b46928a0b64365fd3f8ee"> &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzQ5MzM_a014d66a-ab00-4289-8264-fe04562640a5">70.94</ix:nonFraction> per share for 2020, $<ix:nonFraction unitRef="usdPerShare" contextRef="i109c30251de2477081720f87d8a28594_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzQ5NTQ_ab61732e-261e-4968-8cc9-34064d15379a">64.31</ix:nonFraction> per share for 2019, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c6dd7d6dd0d45e6a2043541078d3796_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzQ5Nzk_12ce19d2-8b07-4291-aea9-c791d70d3493">77.98</ix:nonFraction> per share for 2018. The weighted-average grant date fair value of PSUs granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUwNjM_16b1f8ce-910f-46c5-8949-d7c51e5d3a26">83.64</ix:nonFraction> per share for 2020, $<ix:nonFraction unitRef="usdPerShare" contextRef="i76feedf9c6014726a00c27da12c8de28_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUwODQ_f6334b49-3494-49ce-8706-d81d7d62612b">68.30</ix:nonFraction> per share for 2019, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i22b4c383c26c48c892d88beb1d9d2292_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUxMDk_6e1926e8-188c-48f2-8f67-55eb52b5e704">88.76</ix:nonFraction> per share for 2018. The total grant date fair value of our vested RSUs and PSUs was $<ix:nonFraction unitRef="usd" contextRef="ifdc506af41e54853895ac3a3ed8d114c_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUxOTQ_30886fab-ebdd-44d7-bf71-5bdc821edfa3">479</ix:nonFraction> million for 2020, $<ix:nonFraction unitRef="usd" contextRef="i38d54fab5ace4e28898af9b5fd4628d8_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyMDM_637a2a5c-d8ed-4fdb-bc12-4e8f37b39f96">450</ix:nonFraction> million for 2019 and $<ix:nonFraction unitRef="usd" contextRef="i3702dbcc04054cdd86bc26be99367a19_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyMTc_d1884078-ba28-41ac-9527-8c079119c3dc">481</ix:nonFraction> million for 2018, and total fair value as of the respective vesting dates was $<ix:nonFraction unitRef="usd" contextRef="i347b4c9b1da2453f8b5c69693ae0fe5d_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyODg_54fdca19-ebdf-4a51-a120-d3894cb309ec">459</ix:nonFraction> million for 2020, $<ix:nonFraction unitRef="usd" contextRef="ia29bb89cacab4917ad78178e3cc39d53_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyOTk_42fb9553-b77c-462f-b26d-31272dd08a0a">372</ix:nonFraction> million for 2019 and $<ix:nonFraction unitRef="usd" contextRef="i5c985006e29e4ce693bf89616e366745_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUzMTM_d38680d3-1f0d-4df9-93e0-9c41f18d5a1c">446</ix:nonFraction> million for 2018. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ie2c93d478ae74471acc0268f5b36f929_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUzNDU_86e3080a-3d88-4d97-9557-c21bf2c7910d">860</ix:nonFraction> million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i009c4559c5ee4dcca45e50ed6dafe35f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzU0ODY_d1ff6a94-e5be-4093-af4f-7ef85d2ec06e">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the ESPP), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of <ix:nonFraction unitRef="number" contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzU4MjQ_8f3f39ad-783a-40dd-9636-a5a9350c457c">85</ix:nonFraction>% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP&#8217;s previously authorized and available pool of shares. During 2020, <ix:nonFraction unitRef="shares" contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzYzMDI_2ce57e9b-4bf8-42ec-8280-d7d24148cb71">2</ix:nonFraction> million shares were issued under the ESPP for $<ix:nonFraction unitRef="usd" contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzYzNDM_be7fa176-b95a-47be-9725-b1dae84071d4">100</ix:nonFraction> million. A total of <ix:nonFraction unitRef="shares" contextRef="ia929926fabb04040b30c9fcb5647aad5_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzYzNTg_5a569a09-4ca1-46c4-bf9d-9903d9f9766b">79</ix:nonFraction> million shares of common stock have been authorized for issuance under the ESPP, and there were <ix:nonFraction unitRef="shares" contextRef="ia929926fabb04040b30c9fcb5647aad5_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzY0NDk_74c8f768-2835-4a93-8126-6ef7eeb47a17">7</ix:nonFraction> million shares available for issuance under the ESPP as of December&#160;31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i7a3bb80c27d541c89a00a24ec73c3d16" continuedAt="iee95407e06a2429ca0a233a7a3e49334"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NTk_5736913a-5738-4509-952e-8b38efc539c8" continuedAt="i0835ec386335498c948efe6ec94779c6" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8000203400804727bf1a4e40c93f3c16_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzItMi0xLTEtMA_7d539bed-8448-41d9-9d0f-270d57b6f19a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb578eac6714200a5377073798b8f1b_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzItNC0xLTEtMA_65336efb-d13b-4821-af1f-b12e3fca4639">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe4376a44dc14cc2a76b854d11662987_D20180101-20181231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzItNi0xLTEtMA_30617146-8949-4a3f-87ff-aaef3596509c">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42fad2d6b4d14144ac2fb0e8b3cd8fab_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzMtMi0xLTEtMA_830e48d9-1660-4ea9-a22b-2be0ba41674a">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c99d40ca3b4653938ea4dd23e12064_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzMtNC0xLTEtMA_9eabfc68-7122-4f7d-9d03-904c443fa74d">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be4f110329145dfbfde538bee9a676d_D20180101-20181231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzMtNi0xLTEtMA_6d5efdef-e1f6-478b-a9ae-cdd0e7687633">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3394e3bd2e4809af80fd7faf8770e9_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzQtMi0xLTEtMA_164f2c8f-6bc9-4c9f-82f0-9dde0ab4db7f">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80dd52732e7f44da975a903d2cf2542d_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzQtNC0xLTEtMA_83ae9db2-21a2-4e2b-a868-d97d950a4bd4">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e09efc6fa77468ea8742717d97b0509_D20180101-20181231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzQtNi0xLTEtMA_4e959a26-3e08-4e91-85bc-efc55964843e">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzUtMi0xLTEtMA_5370ac95-3eb1-4fa8-ae04-8864bdae2e4b">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzUtNC0xLTEtMA_335fb418-3ac9-4cf3-a460-04a6a94199e1">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzUtNi0xLTEtMA_03075bdd-27b2-4f81-93a4-d90afdff6dab">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzYtMi0xLTEtMA_3bb7ebe1-e3ca-4c88-83e9-c658eb527c0c">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzYtNC0xLTEtMA_6e75bab8-7ed0-43d6-8b77-ece88f67bb90">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzYtNi0xLTEtMA_76eb3031-daa9-43aa-8ec7-bc8819eb734d">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzctMi0xLTEtMA_07c21b8f-0b11-4764-b9ed-f6e53e485a42">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzctNC0xLTEtMA_17fc2bdc-6b2c-4c69-80f1-632c6fb26d2b">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzctNi0xLTEtMA_c826e605-0042-4100-9fca-0168189a117d">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTEwNjQx_5370ac95-3eb1-4fa8-ae04-8864bdae2e4b">1,076</ix:nonFraction>&#160;million included $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzEwOTk1MTE2NDY2MDA_c1965d3f-3996-4264-92b5-24e2d0032f20">643</ix:nonFraction> million non-cash stock-based expense and $<ix:nonFraction unitRef="usd" contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA5NTQ1_6dee6ca2-bdef-40ac-910d-ec0fd65d40f8">289</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i94aca37dece54db88d94195652d7be2a_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA5NTk3_053312f0-7678-4f0c-a6da-70dd1616d630">144</ix:nonFraction> million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="i0835ec386335498c948efe6ec94779c6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA3MzY4_69773122-2cdf-43bd-88c1-c87c0d640d65">114</ix:nonFraction> million income tax expense following the U.S. Court of Appeals decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Altera Corp v. Commissioner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.</span></ix:continuation><span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of options granted under our 2004 Plan and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NzQ_6de98495-c975-4acf-aaea-00c58b51a255" continuedAt="ic9c4b4fbc9f548b2a424e3354ae5cbf3" escape="true">We used the following assumptions to calculate the estimated fair value of the awards: </ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><ix:continuation id="ic9c4b4fbc9f548b2a424e3354ae5cbf3"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzMtMi0xLTEtMA_4c8e9f4a-b814-4bff-9c6e-a018867b6a28">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzMtNC0xLTEtMA_4d1d42d6-246d-489c-b696-c4eeb0417ebc">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzMtNi0xLTEtMA_021538ee-2504-433f-b226-51cdcd838958">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzQtMi0xLTEtMA_397aea4f-b4b2-457f-88fe-c84c9d1d2b7d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzQtNC0xLTEtMA_c5822fcc-661d-461f-9d14-dfc3fd7ce238">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia623662c706d409a83107f00f6077a04_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzQtNi0xLTEtMA_0fae5ad0-06fb-460d-83d0-63852450804b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzYtMi0xLTEtMA_902adf58-899f-45f7-bb6e-da8c7fc3f6be">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzYtNC0xLTEtMA_896d287a-70d9-4afa-88e7-c0272b8db44a">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzYtNi0xLTEtMA_c01e2638-ed15-4597-97d7-dcc3f95dc975">5.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzctMi0xLTEtMA_37ad728a-73d6-4e6c-8361-2a9d4887f92a">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzctNC0xLTEtMA_d7911968-f454-44be-85f0-bbcb69f7e7d2">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia623662c706d409a83107f00f6077a04_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzctNi0xLTEtMA_6dfee5bc-aaed-4a05-8d9b-dcda1d41f5aa">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzktMi0xLTEtMA_6bc65c12-3e4e-4b71-ba0d-995b8c6d768f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzktNC0xLTEtMA_317e1df4-6e2b-44e8-b8e7-7acb3cb36dd6">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzktNi0xLTEtMA_54660604-0b56-44c2-a636-cc3930a212ca">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzEwLTItMS0xLTA_12dc2f55-3c3a-4ef2-8707-d76c1b6c7a7a">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzEwLTQtMS0xLTA_f1835b8f-b19b-4ef5-8c55-f351bf4c1b35">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia623662c706d409a83107f00f6077a04_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzEwLTYtMS0xLTA_137e110c-361a-4735-9783-ed35bf659b44">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzExLTItMS0xLTA_ae0969e0-f30b-4df5-bac8-3c5fb11b5432">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzExLTQtMS0xLTA_59c75e80-0e72-4e8b-a0e4-8dc17c5fa5d4">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzExLTYtMS0xLTA_530886bf-a198-4031-b7e6-0b4f6e675b2c">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iee95407e06a2429ca0a233a7a3e49334"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzkyMDQ_32444193-5fb6-47d2-ae5b-c784df06f749">144</ix:nonFraction> million during 2020, $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzkyMTg_7c1e3ed8-2207-42c6-a90e-a8a60d27e1d3">110</ix:nonFraction> million during 2019 and $<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzkyMzU_edbea6a2-c1eb-475e-a919-60d8c48e8bbc">91</ix:nonFraction> million during 2018.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $<ix:nonFraction unitRef="usd" contextRef="i6760924221ed4b5cba60ea7d2547a8cc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1MTA_6848f293-85ed-4c1d-aff7-38014634617f">218</ix:nonFraction> million as of December&#160;31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i620b03a7ceff4498b7ef8db0524ac079_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTAxNjg0_7003ec90-6884-416b-b06e-076431288cd3">171</ix:nonFraction> million as of December&#160;31, 2019.</span></div></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_175"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzEwMTY_74c9cab6-daa0-4925-9023-67cd3e92f566" continuedAt="ie1180e88a11340e3816aee9470872748" escape="true">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS</ix:nonNumeric></span></div><ix:continuation id="ie1180e88a11340e3816aee9470872748"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common shareholders because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzc4Mw_e01abb5f-bbba-43ec-9686-e94773daf323">13</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzc4Nw_ab415ecf-4f48-40f4-a3b0-dd9d2c8112a7">14</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzc5NA_bd0f59a6-ab58-4de1-a34e-a9dd0c6b5a61">13</ix:nonFraction> million during 2020, 2019 and 2018, respectively.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzEwMDc_9afd4f0f-a238-46fa-bc7b-95ff72eb7f64" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzItMi0xLTEtMA_c46efd6b-8e9f-41de-bee2-216161b5d925">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzItNC0xLTEtMA_fcde1c31-3ed6-4668-979c-512f73c1ae73">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzItNi0xLTEtMA_4052b884-9aa5-45e1-ba0e-fdf3d71b01e0">5,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzMtMi0xLTEtMA_fcec0690-ed87-44f1-b673-4a50221bc2a4">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzMtNC0xLTEtMA_95b43e39-7e25-4659-8f3e-0cf7c7f921e0">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzMtNi0xLTEtMA_e4eddad7-cbfc-414b-80f7-83086cc39cff">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzQtMi0xLTEtMA_d375a579-8e00-41c3-854d-fca792d66172">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzQtNC0xLTEtMA_84676e79-d74f-49ca-9669-d635d5467fec">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzQtNi0xLTEtMA_6c3e20a8-f083-4066-b4b0-579919dc5e8f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzUtMi0xLTEtMA_12b3f5c5-a7ee-43c2-af0f-f82f08691868">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzUtNC0xLTEtMA_b48c7525-9365-4b94-b8d7-8d6858e423d4">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzUtNi0xLTEtMA_b097c157-2586-47a6-910f-f99d1e418fa1">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzYtMi0xLTEtMA_6a3db572-386c-4231-b8b3-b3b0351d3567">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzYtNC0xLTEtMA_1eb20a22-2260-49f6-afbb-d5c6004eb201">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzYtNi0xLTEtMA_a0d0b0d9-c4eb-47dd-a6cd-87a9745bea93">4.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzctMi0xLTEtMA_2e59c578-2e2b-4c3f-a20d-12a6dc11d78a">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzctNC0xLTEtMA_a1181978-2403-4fc5-84d6-cac0f0285eb7">4.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzctNi0xLTEtMA_032a4a55-478f-4dff-9e78-885f6cbecb49">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib93766b38a794f83a6a283fa0a85c17d_181"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY2ODI_b6ae4b3f-9961-497d-a80b-d4e37f282b47" continuedAt="ic0b43ef81b0a430daeb950dfe4c9ca95" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="ic0b43ef81b0a430daeb950dfe4c9ca95" continuedAt="i6876bb31f7104e11b933de06afa65b7a"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY3MTc_37f3d5aa-e5d2-4ffd-a8ae-1e7ea3417120" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzItMi0xLTEtMA_e59ad15e-cb9f-4e05-9757-e96c0f1f28da">2,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzItNC0xLTEtMA_2bc97978-aa24-4fe5-955b-a21267e03dfa">4,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzItNi0xLTEtMA_acaf3c5c-4af9-4f1e-a000-bbb5997f2c48">7,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzMtMi0xLTEtMA_ac9288de-3258-48cf-ab7b-6c60ea08b4de">836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzMtNC0xLTEtMA_7fc45188-1c16-4658-a60f-6867fa5e3f28">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzMtNi0xLTEtMA_b37dae04-564f-490b-a3d7-30d9925a5abf">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzQtMi0xLTEtMA_2f037272-69cc-424f-b438-e9e30fdf4915">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzQtNC0xLTEtMA_5c3e62f0-0c34-48df-b8d2-a6b1c5112522">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzQtNi0xLTEtMA_e6641c71-2a0b-4c44-84e8-b90f0031430b">7,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6876bb31f7104e11b933de06afa65b7a" continuedAt="ie5f68332348a483c84159f152a7565a9"><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY2OTU_e8b70716-6c3d-4ef4-a5d5-733bd8ba510d" escape="true"><div style="margin-top:4.59pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzMtMi0xLTEtMA_71accbd1-09eb-498c-a687-01121d57864e">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzMtNC0xLTEtMA_a2e08e91-f744-411e-b87c-eeb2fed9df4c">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzMtNi0xLTEtMA_30ebefda-b639-4b1e-b4a5-7524d5413571">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzQtMi0xLTEtMA_2d20979c-8bea-4aa3-80e4-600a79797628">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzQtNC0xLTEtMA_314426d4-20e1-4adb-9d51-789b8ba34f17">843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzQtNi0xLTEtMA_27cb4108-907b-492d-b625-73e4aee1ae9f">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzUtMi0xLTEtMA_7104eac7-348a-45a9-bea3-dc7637ad7e87">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzUtNC0xLTEtMA_b1265d80-2e0b-4f41-b386-84cdad53fc1d">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzUtNi0xLTEtMA_09c465aa-10a7-4e59-84d1-4fb1d900504e">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzctMi0xLTEtMA_be84cb39-937a-44fe-83c1-0331ec473f87">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzctNC0xLTEtMA_b56c4ce0-aa04-4e7d-9185-2c7053e5d87d">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzctNi0xLTEtMA_bc649543-73ac-4917-9cd3-783efa9b9223">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzgtMi0xLTEtMA_edb0c4ef-7be0-4c54-acec-857fc79c6097">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzgtNC0xLTEtMA_abb7b94c-e44a-4596-a748-4aad5dc67fae">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzgtNi0xLTEtMA_dc84acae-089c-4571-82b1-ba85c5fe611c">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzktMi0xLTEtMA_be46d200-27a0-4e8b-81b2-d8e825f6f9d5">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzktNC0xLTEtMA_67397f80-97e3-470b-9c54-4ae1c1901a97">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzktNi0xLTEtMA_d6aee982-d9a9-4d33-be06-b08bb2033d2b">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzExLTItMS0xLTA_c4a631cf-110c-46e3-8a15-a6c8f573afb0">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzExLTQtMS0xLTA_048341e5-1067-471c-838a-91a23bae6203">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzExLTYtMS0xLTA_7099d3f8-21af-4d78-94a6-d6f9f6a7f8b4">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEyLTItMS0xLTA_0d57f3c3-974e-491e-a883-6b12b0736a7d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEyLTQtMS0xLTA_112827fa-47b8-4e8d-8cb7-fd07d4cad22f">1,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEyLTYtMS0xLTA_5aaa8b7c-3c74-4588-87b0-e6d0d04d73b7">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEzLTItMS0xLTA_2f59ff37-d4fe-43a4-ac6c-bc10a4efaf45">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEzLTQtMS0xLTA_e3e6d397-f9f5-43ce-bf73-d965338eab0f">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEzLTYtMS0xLTA_50f35f1b-5cde-446d-b9da-5c166865f819">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzE0LTItMS0xLTA_889651f8-1dcb-43a2-93de-c7ae71a0c85a">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzE0LTQtMS0xLTA_32fb746c-9a42-4977-9b05-c08d13157706">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzE0LTYtMS0xLTA_b26e498b-ff68-4b6b-9e4e-4b87b48cc962">2,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 income tax benefit included a $<ix:nonFraction unitRef="usd" contextRef="i2f77d5dbabfc4c67bbc7902204dbe301_D20190101-20191231" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzIxOA_cd11b35a-a159-4149-9d28-a29483c88e35">1.2</ix:nonFraction> billion deferred tax benefit related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In the fourth quarter of 2019, we completed an intra-entity asset transfer of certain intangible assets from a foreign subsidiary to Ireland. The transaction resulted in a step-up of the Irish tax-deductible basis in the transferred assets, and accordingly, created a temporary difference where the tax basis exceeded the book basis of such intangible assets. As a result, we recognized a deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="if89c7b93f0a5477d94803cdd6f0a3319_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2Xzc1MQ_8174e4cd-2150-4cc2-807c-028de74c7cf6">1.2</ix:nonFraction> billion on our Consolidated Financial Statements. We expect to be able to realize the deferred tax asset resulting from this intra-entity asset transfer. The impact of the intangible asset transfer from a foreign subsidiary to the United States was not material. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 income tax expense included a $<ix:nonFraction unitRef="usd" contextRef="ic9779a570996452dbbd3c83239ccf707_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEyNDg_f7fda088-f6bf-4c62-a90e-d5feb1d2422c">588</ix:nonFraction> million deferred tax charge related to a transfer of acquired intangible assets from a foreign subsidiary to the United States. This transaction did not result in a step-up of the U.S. tax-deductible basis; and as a result, we recognized a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="id3086aba7396431180029057c2ad4ece_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzE1MDk_6e891aff-5e25-45e3-9443-aa57c24278bc">588</ix:nonFraction> million for the temporary difference where the book basis exceeded the tax basis of these acquired intangible assets. </span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY2OTY_8e19ceb7-d082-4c05-827f-92713cf48def" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to income before taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzItMi0xLTEtMA_750f3676-dc71-4c31-91c6-ba480c4ba1f4">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzItNC0xLTEtMA_5c75a518-8be4-4a40-b908-3196ee97c709">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzItNi0xLTEtMA_74e4111c-b3dc-499e-8284-0b35a9daefe1">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzMtMi0xLTEtMA_519f7ce7-f5ef-4f2e-b8f5-aaf3cede2a75">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzMtNC0xLTEtMA_8ebe1c3f-a4ee-4c56-bbe5-fefb07f159be">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzMtNi0xLTEtMA_1f0a2da6-1278-4787-bfce-a7a8e5b799f1">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzQtMi0xLTEtMA_06758358-c130-4502-922b-4da5f7364f09">10.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzQtNC0xLTEtMA_82eab6f4-7df0-4dee-a8be-2b43653530bc">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzQtNi0xLTEtMA_9457e1fe-7a7a-49d3-977e-e0dfb15a181a">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzUtMi0xLTEtMA_4d168804-776f-41c0-94b8-13de9016f19e">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzUtNC0xLTEtMA_ce3f52cf-bfa6-45ca-b5da-df1c3494de80">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzUtNi0xLTEtMA_92634e1a-7590-419c-ace5-18a245a05f57">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzYtMi0xLTEtMA_416b11b0-2508-46b5-8ee4-97d4998ae6ff">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzYtNC0xLTEtMA_9da6a8cc-2956-4c6c-8330-da6cd888db1d">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzYtNi0xLTEtMA_2c30b36b-242b-41e3-8dc6-dc18b5d7ab77">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax - intra-entity transfer of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzctMi0xLTEtMA_492f72f7-6d85-4bee-a067-e1b3be77fcbf">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzctNC0xLTEtMA_191d8a73-d7bb-43e7-8885-7fd0d1edfe57">24.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzctNi0xLTEtMA_c3036878-e9d6-4125-9908-58a7ea0c394e">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTItMS0xLTA_e1ceb80d-0be5-44bc-abbb-0c0164a4ccf0">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTQtMS0xLTA_ff4cdb1a-23ba-42cf-8c62-b7b097b58c84">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTYtMS0xLTA_3b6c71ea-4e8e-4b00-81c4-c4fa529d85a5">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and related charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTItMS0xLTEyODg2_7fab425f-f8c9-4315-8601-4f5b985c4046">56.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzktNC0xLTEtMjY4NzE_388a62ae-eca2-4e11-96eb-5befcbda5d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzktNi0xLTEtMjY4NzE_307443f8-e2d4-4653-8510-1a3ae975e43c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTItMS0xLTEyODg2_3c7a2fb0-0e09-4a8e-9d2f-4c73f8f6bcfa">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTQtMS0xLTI2ODcx_698d2f1e-59bf-43ef-8892-ad4070c06130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTYtMS0xLTI2ODcx_25605df5-256a-4a55-9d03-dc002b9267e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized gain / loss on investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEzLTItMS0xLTEyODg2_a9bf4f8e-a750-40d8-bbf8-561d1eb0b62a">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTQtMS0xLTE4MTY1_8d80a880-8381-4a71-88b2-31f9cf0a4b2f">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTYtMS0xLTI2ODcx_52937d4e-6a14-4167-bea5-56b804a720d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTItMS0xLTA_9f03d7de-0ed1-4666-9c4c-fbdcacca87e8">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTQtMS0xLTA_d0d2e325-a1c5-4945-85ef-5e8b59d60df3">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTYtMS0xLTA_9e40a662-4d17-45f5-8222-3e6f5972ab60">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTItMS0xLTA_176acc95-2cb6-450f-a346-cdcdfd8df7e0">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTQtMS0xLTA_d592e0e8-3bac-478a-9072-54516331fa61">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTYtMS0xLTA_bc91a366-c5d7-4528-935a-7f4238f5c992">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie5f68332348a483c84159f152a7565a9" continuedAt="id3faedbf5a5a400080e2288b02e19395"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY3MDM_3cf75024-9324-404e-982e-f24cead27811" continuedAt="iff21f492b2204cffa2b9dd5ce9e3092a" escape="true">Significant components of our deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="iff21f492b2204cffa2b9dd5ce9e3092a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzMtMi0xLTEtMA_9bc3833a-0925-4b96-9a5a-502a4397e191">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzMtNC0xLTEtMA_43571bb6-99d3-4311-af47-371aeefe1a07">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzQtMi0xLTEtMA_55f39679-9ab6-4c48-83e3-721dc32aa5e9">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzQtNC0xLTEtMA_b57ed7f5-1e93-4619-9a53-55f25740c8ab">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzUtMi0xLTEtMA_705d317e-8b1b-45ac-973f-674bc8240bc8">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzUtNC0xLTEtMA_10b10ed1-8b2d-45b3-a85a-e96c62f2f905">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzYtMi0xLTEtMA_ff15cc92-c5a2-4fc5-9a28-61e703d745f6">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzYtNC0xLTEtMA_901ac9ae-a754-42c0-bac4-b18481254913">1,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="gild:DeferredTaxAssetsUpfrontAndMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzctMi0xLTEtMA_d0492209-70bb-49f7-9108-1af3ecfbdf69">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="gild:DeferredTaxAssetsUpfrontAndMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzctNC0xLTEtMA_ef77b876-55fb-4298-ad38-b6e4f92591f8">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzgtMi0xLTEtMA_98ef2f54-fb16-44f8-8c1a-3e73368ff9d8">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzgtNC0xLTEtMA_56e535be-62d3-403e-97f8-9762fbf32178">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktMi0xLTEtMTI4OTA_ee90c456-e340-434d-bd37-536d2affa2d1">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktNC0xLTEtMjYxODE_14303c00-46e6-403c-b712-a88524ebfb1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTItMS0xLTEyODkw_edbf2190-8612-40b1-ae3a-c513256099a7">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTQtMS0xLTI2MTgx_d520cf9c-49cc-407e-8314-dc3ab56bf416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktMi0xLTEtMA_90a189c2-fea6-41f6-8c9a-de3bdcd5d0b3">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktNC0xLTEtMA_8ae9312b-e88b-4291-9fce-3a79c4e0e3e7">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTItMS0xLTA_87b31ec1-5ab1-403b-8a49-e57c92b23f6a">4,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTQtMS0xLTA_b713c702-365d-46d0-b23f-076856f2c7c4">3,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzExLTItMS0xLTA_a3b7177b-9304-413f-be1c-305544056bd2">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzExLTQtMS0xLTA_b64d45bb-3ecf-4e24-b9b1-88a50192abb0">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEyLTItMS0xLTA_6c2a534e-b609-4955-8c09-e457a2cc6c64">3,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEyLTQtMS0xLTA_dfb01586-499c-4f20-8183-2d82b24ff97f">3,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE0LTItMS0xLTA_15f70c94-cfd5-4169-8bae-23bfc2f1190c">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE0LTQtMS0xLTA_9b1be412-5ca3-48a3-b5bc-c98298680f13">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE1LTItMS0xLTA_45c6f660-713d-4459-818d-82c7f9229359">6,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE1LTQtMS0xLTA_4f78f19d-edde-400f-9ab0-ea14ad04e01a">1,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE2LTItMS0xLTA_3609742c-2331-4960-9c4e-937ca4b404a8">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE2LTQtMS0xLTA_255362da-1711-46f6-b396-18289c92fae6">93</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE3LTItMS0xLTA_b93d3b2b-48bb-4f95-9b4e-a1c807c94e28">6,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE3LTQtMS0xLTA_69d6813a-7eca-4c73-b2b1-961e4b34afb6">1,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE4LTItMS0xLTA_040f6cb8-005b-42d9-a2c2-688f2753ba7d">2,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE4LTQtMS0xLTA_5fc79638-dafe-4370-8948-dfde64976ad3">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzI3Njk_c316353c-2961-4c41-afbd-8ca1ab0c0691">398</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzI3NzY_3fb7b5b1-b075-487b-b9b5-34568a89c403">217</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively. The increase of our valuation allowance in 2020 was primarily related to acquired attributes related to Forty Seven and Immunomedics acquisitions, and unrealized losses on our equity method investments reflected as acquired IPR&amp;D expenses. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance decreased to $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzExNTQ0ODcyMTA3MDEx_3fb7b5b1-b075-487b-b9b5-34568a89c403">217</ix:nonFraction> million at December&#160;31, 2019 from $<ix:nonFraction unitRef="usd" contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzExNTQ0ODcyMTA3MjE4_8d997281-5f69-4d4c-bff6-77f487fe7fbc">331</ix:nonFraction>&#160;million at December&#160;31, 2018, primarily due to a reduction in net operating loss carryforwards under the asset recognition framework and corresponding valuation allowance with respect to certain foreign jurisdictions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had U.S. federal net operating loss and tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="id342243123964d40bc3ebc4517f36cd7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEwOTk1MTE2Mzk0ODI_a807536b-5568-4e2a-8e5d-f7a1e449d9c6">1.5</ix:nonFraction> billion. and $<ix:nonFraction unitRef="usd" contextRef="id342243123964d40bc3ebc4517f36cd7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzMyODg_c64dc5a9-4e71-446b-bec5-6ecf410c1291">61</ix:nonFraction> million, respectively, which will start to expire in 2021, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ic67c62aea4714cc1bdf529a34a43a13a_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzM0MzU_3de6796c-00a1-4332-8654-db0f4d55b91c">1.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic67c62aea4714cc1bdf529a34a43a13a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzM0NDI_1ca9e7af-8ce1-49b7-b86d-51d99f9a3472">673</ix:nonFraction> million, respectively. The state net operating loss will start to expire in 2021 if not utilized and state tax credit carryforwards will start to expire in 2022 if not utilized.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2013 and onwards and 2010 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="id3faedbf5a5a400080e2288b02e19395"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits, $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzQ5NzY_0525f093-52e6-4908-ba1c-29279d16997f">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzQ5ODM_a1d177d6-37af-4ded-a391-97c0856c5751">1.6</ix:nonFraction> billion at December&#160;31, 2020 and 2019, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included as part of income tax expense (benefit) on our Consolidated Statements of Income were $(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEwOTk1MTE2Mzk1MDE_53b3c329-e9ac-4534-a994-152bc57f7e8e">82</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEwOTk1MTE2MzU1Mjk_b6e040a0-daf0-45df-af96-d0a69fe8c201">105</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively. Interest and penalties related to unrecognized tax benefits for the year ended December 31, 2018 was not material. Accrued interest and penalties related to unrecognized tax benefits were $<ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzU0NzQ_e4975096-e575-4444-9c12-3930ed2ffec7">177</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzU0ODE_d840fc72-0c1c-43d2-965e-321460232390">259</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we do not believe that it is reasonably possible that our unrecognized tax benefits will significantly change in the next 12 months.</span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY3MDY_cd293575-16b4-4935-9bc1-e1b518e46bbf" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzItMi0xLTEtMA_3fb89553-80da-441e-9220-9e5c915dbd4b">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzItNC0xLTEtMA_4bfce405-2ed9-4828-9857-091b14b7a668">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3219b6982b334ae49d4a68c7befc5d27_I20171231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzItNi0xLTEtMA_aef63622-1ac5-45f2-9f9b-0101f6c4dd01">2,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzQtMi0xLTEtMA_4c0722d1-6f01-4e72-8a96-9df418eb8d9f">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzQtNC0xLTEtMA_81314ab4-e6be-4ccb-83cc-9b83bf65fd61">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzQtNi0xLTEtMA_f0edb34a-67f5-4b70-bb1f-874f725bfca1">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzUtMi0xLTEtMA_ea558acd-92ce-43f3-b35d-d484f60c478f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzUtNC0xLTEtMA_e5a0023a-d4fb-4d6f-9715-4df5195db77e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzUtNi0xLTEtMA_6ef30095-45f1-43b1-bc7c-a1573de6ecc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzctMi0xLTEtMA_ba387e03-51be-479b-a423-4e4e7f3c59eb">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzctNC0xLTEtMA_bafcdfb2-8713-437e-b476-bff40610296e">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzctNi0xLTEtMA_d5eb2d5a-3f12-4c89-82db-946f1726387c">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzgtMi0xLTEtMA_c3f8016f-ef9d-4d55-a81e-1b215c631e02">481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzgtNC0xLTEtMA_94550528-b0ae-489e-9875-12be3008e57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzgtNi0xLTEtMA_4bc7a0b7-4527-4c9b-974c-cd028383fb59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzktMi0xLTEtMA_5da4d534-96f7-46a8-bf5d-d3c2c1e2f380">454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzktNC0xLTEtMA_eacb8210-7470-4741-94e5-1501d83ff76a">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzktNi0xLTEtMA_8ea095cc-3f3e-4a0d-add3-7e0a336b26bc">774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzEwLTItMS0xLTA_99d9196d-96e0-4579-8f57-21592334dc40">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzEwLTQtMS0xLTA_823f5266-d6ec-4d4e-8ffc-4d16c0ac4d58">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzEwLTYtMS0xLTA_42ff9123-136a-4a31-970c-949a376eb97b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzExLTItMS0xLTA_076bf62d-73c1-4368-8e6f-c2e32067852a">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzExLTQtMS0xLTA_4bdabb9b-91c4-49d4-992d-49ea337ba793">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzExLTYtMS0xLTA_6971f786-bd3e-46b7-8c94-d973ad69b7a4">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2OTU_1754b449-44e5-4567-b152-3e2a35ff96b2" continuedAt="i9664fb2ec3a344fd94e2dea06d4521e4" escape="true"><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)</span></div><div style="margin-bottom:9pt;margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE3MDM_8c299c1a-b0d7-4986-a21e-ebd284fcba3f" continuedAt="ibaf41e3618be49b3b31cb7ac2acb6690" escape="true"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1st&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2nd&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3rd&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4th&#160;Quarter</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItMi0xLTEtMA_19b95157-1327-4251-a786-1993f1f602c4">5,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItNC0xLTEtMA_1441604a-5def-4f02-8ea5-e676dbb5fcf2">5,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItNi0xLTEtMA_a02f4329-47a4-4c33-9085-7dcc8fca0e12">6,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItOC0xLTEtMA_c3fdde12-61b4-41b9-bf15-572ab307a7b7">7,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit on product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtMi0xLTEtMA_e749a3d6-ffd8-466f-ab79-434e424c6566">4,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtNC0xLTEtMA_4c366f7f-268d-4e2d-85f0-14f0297ea317">4,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtNi0xLTEtMA_a9d0380c-2537-4806-9d3a-990bc1a148dc">5,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtOC0xLTEtMA_58c0923d-d701-4170-975a-0b3c98ec24f9">5,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtMi0xLTEtMA_2e7b1a56-31a4-4227-89aa-987ccba286ee">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtNC0xLTEtMA_ab97887c-a93f-4834-bfbe-688f7cdea8fb">3,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtNi0xLTEtMA_9f6bc14f-5636-4a65-8f2b-a0fc70de119f">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtOC0xLTEtMA_2ac3ce4f-36a7-4499-a943-d6f6df279c56">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtMi0xLTEtMA_ef84ebbb-8c75-4aa6-a412-13e2c41bc2bf">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtNC0xLTEtMA_2071bb95-a40c-4dc0-8e43-bf249928b38d">3,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtNi0xLTEtMA_a3e92725-6d04-428e-b8ec-0b8c3a2af508">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtOC0xLTEtMA_390e443d-2385-4fd7-8a5c-ca6d6a811777">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtMi0xLTEtMA_26b0fac4-55a2-431b-8f3f-110986ad6dce">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtNC0xLTEtMA_58486946-7a0e-4b1d-9236-8338917673c1">2.66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtNi0xLTEtMA_b3501333-5613-44c1-8ef4-961a328cbe93">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtOC0xLTEtMA_a1dc9452-173e-4b13-b766-80ccfa4a97c1">1.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctMi0xLTEtMA_cbca6b48-3fac-4fd9-9ada-84497532fdd3">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctNC0xLTEtMA_7f816c6b-0ab0-46f5-a1ff-76d828abbaef">2.66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctNi0xLTEtMA_c3184e0e-9240-437c-b81d-3525656846a3">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctOC0xLTEtMA_251b1c27-6673-4518-b9b0-9ae3f9d9c231">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktMi0xLTEtMA_46df461b-a428-44a3-b1b1-86ade95aeb12">5,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktNC0xLTEtMA_c3f74033-a42b-4eb3-8a95-1e7814c8e3d3">5,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktNi0xLTEtMA_68cc0bf8-edf2-489a-abdb-fc6bd7ad46db">5,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktOC0xLTEtMA_b804db79-ec81-4927-b508-05df28697ea0">5,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit on product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTItMS0xLTA_bfaf0192-f704-4c63-ab31-5d1534954e9c">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTQtMS0xLTA_5fa878e4-0b45-4a8a-880b-3bc820122c75">4,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTYtMS0xLTA_c2cc8b3c-dbaf-4c26-8a42-bde7ac89a06a">4,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTgtMS0xLTA_9fda3f61-5ec5-497a-bce2-54045c118093">4,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTItMS0xLTA_f7733950-acc3-4aa0-a099-4f2014ff3462">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTQtMS0xLTA_8bd3e0dd-2189-43d6-ad05-f3c7bd5a1a88">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTYtMS0xLTA_7c367c9c-02fa-44fd-9877-69590e993a94">1,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTgtMS0xLTA_82fab593-c4af-4c7d-bd25-d4a2f400c76c">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTItMS0xLTA_c9512055-1cca-4cba-b08b-565308a3980c">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTQtMS0xLTA_9276baca-2d90-4a34-810e-193e34b71375">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTYtMS0xLTA_fbf89c91-306f-477e-a823-e9242c5cd498">1,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTgtMS0xLTA_af0be3ed-e703-47f0-bad5-f7e064fc6a60">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTItMS0xLTA_3d98c38b-d79e-43e9-b890-1c704848a597">1.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTQtMS0xLTA_6be0ef00-c4d6-4f61-8781-5d4e2c3dbffd">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTYtMS0xLTA_3297227e-0854-41aa-ad38-e94dbcd3005c">0.92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTgtMS0xLTA_90d3ce29-4e97-4adb-819a-3973e0260ff3">2.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTItMS0xLTA_b3a79f09-6fff-43c9-ad7c-78a91154ff39">1.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTQtMS0xLTA_b6812613-ed23-4c2a-9652-cb967f85ac2a">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTYtMS0xLTA_78c16e42-42d2-406c-8bbc-642d23d6ad2f">0.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTgtMS0xLTA_ab181423-fb1c-4484-9253-f67f529a21da">2.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the second quarter of 2020 included an acquired IPR&amp;D expenses of $<ix:nonFraction unitRef="usd" contextRef="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5Mzc_c7af923c-85cc-41bd-bb17-771a27157db3">4.5</ix:nonFraction>&#160;billion, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4Njg_8863507a-8d16-4ed2-b169-bf4184430d9e"><ix:nonFraction unitRef="usdPerShare" contextRef="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4Njg_a426c3ff-e5c8-42eb-90c1-f34a930435ba">3.58</ix:nonFraction></ix:nonFraction> per basic and diluted share, primarily related to our acquisition of Forty Seven. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the third quarter of 2020 included acquired IPR&amp;D expenses of $<ix:nonFraction unitRef="usd" contextRef="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4NTQ_342f7a50-3b60-45d5-bb04-8dbd8068cb0b">1.0</ix:nonFraction>&#160;billion, or $<ix:nonFraction unitRef="usdPerShare" contextRef="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4NzU_2ccf23be-7c08-40d3-9e91-c02be0d097d7"><ix:nonFraction unitRef="usdPerShare" contextRef="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4NzU_8a2b1ca3-faac-4151-a672-ff0ab39601a4">0.82</ix:nonFraction></ix:nonFraction> per basic and diluted share, related to collaborations and other investments we entered into separately with Arcus, Pionyr, Tango and Tizona and $<ix:nonFraction unitRef="usd" contextRef="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4ODI_7c6cc2c3-5e22-4c4b-89fc-89fa41eff96f">983</ix:nonFraction>&#160;million or $<ix:nonFraction unitRef="usdPerShare" contextRef="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4OTY_26c12b8b-52c5-4c32-955f-1c8c84f5524e"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4OTY_f47aab2d-240d-4905-a4f9-2955ce958220">0.78</ix:nonFraction></ix:nonFraction> per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos. See Note 3. Fair Value Measurements and Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2020 included $<ix:nonFraction unitRef="usd" contextRef="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2NDkyNjc0NTU1NTE_3219e5d1-53be-4d9b-89cb-d2bebf8e92c7">628</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2Mzc5MjI_bcb173d1-b2a3-4f54-a71a-49e67a768466"><ix:nonFraction unitRef="usdPerShare" contextRef="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2Mzc5MjI_f36668b7-b721-468f-9c17-b0981f627a1f">0.50</ix:nonFraction></ix:nonFraction> per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos and $<ix:nonFraction unitRef="usd" contextRef="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5MDM_92d6def2-28d3-4349-9b01-b2047d34e996">615</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5MTc_5f44d77e-200b-483b-bdd4-6e58e41aa199"><ix:nonFraction unitRef="usdPerShare" contextRef="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5MTc_a39964db-6fcc-4e67-b49b-af110c01cc98">0.49</ix:nonFraction></ix:nonFraction> per basic and diluted share of acquisition-related expenses primarily from amortization of intangible assets, inventory step-up charges and accelerated stock-based compensation expenses related to our acquisition of Immunomedics. See Note 3. Fair Value Measurements, Note 6. Acquisitions and Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the third quarter of 2019 included upfront collaboration and licensing expenses of $<ix:nonFraction unitRef="usd" contextRef="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5NjU_500349de-406e-400a-b4d9-c3d83ce28f73">3.92</ix:nonFraction>&#160;billion, or $<ix:nonFraction unitRef="usdPerShare" contextRef="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzIwOA_46824141-bd55-41b5-be57-8b5d60190101"><ix:nonFraction unitRef="usdPerShare" contextRef="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzIwOA_f07398ac-73a6-4c14-85de-9c56dfd368eb">2.40</ix:nonFraction></ix:nonFraction> per basic and diluted share related to the collaboration with Galapagos. See Note 11. Collaborations and Other Arrangements for additional information.</span></div></ix:nonNumeric></ix:nonNumeric><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i9664fb2ec3a344fd94e2dea06d4521e4" continuedAt="ie57ebfc5b4f84e1f9b6d74212aebbec1"><ix:continuation id="ibaf41e3618be49b3b31cb7ac2acb6690" continuedAt="i1146fab23edf43519eba3d7a00be0699">(5)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="ie57ebfc5b4f84e1f9b6d74212aebbec1"><ix:continuation id="i1146fab23edf43519eba3d7a00be0699"> &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2019 included a $<ix:nonFraction unitRef="usd" contextRef="ia2ce6de3160c42fcbad2f1b836b16a69_D20191001-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5OTM_c84293aa-20a3-4196-923d-8457d6bee3e5">1.2</ix:nonFraction>&#160;billion favorable tax effect related to intra-entity intangible asset transfers and $<ix:nonFraction unitRef="usd" contextRef="ifcde38bda2ec4ee2a91607db91272226_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2MzQxMzU_d93719f4-515c-4b1f-bfde-bf3f8383b372">929</ix:nonFraction> million of pre-tax net gains from equity securities primarily our equity investment in Galapagos, partially offset by an $<ix:nonFraction unitRef="usd" contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDMwMjA_70d4231b-3508-4aad-bffa-ac2a214121ea">800</ix:nonFraction>&#160;million pre-tax impairment charge related to IPR&amp;D intangible assets acquired in connection with the acquisition of Kite and pre-tax write-down charges of $<ix:nonFraction unitRef="usd" contextRef="i911b942fdd1a48718de383949eab2834_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2MzkyODc_91f75d54-1466-4dec-b1e3-17c2a59e2659">500</ix:nonFraction> million for slow moving and excess raw material and work in process inventory. The impact of these factors resulted in a net favorable impact of $<ix:nonFraction unitRef="usdPerShare" contextRef="idf9604006e3f48c2b90d9c9dd73c4174_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2NDkyNjc0NTY1Mjg_3807f0de-3144-46df-95d2-753f056fc454">0.83</ix:nonFraction> per basic share and $<ix:nonFraction unitRef="usdPerShare" contextRef="idf9604006e3f48c2b90d9c9dd73c4174_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2NDkyNjc0NTY1NTI_71cc463a-50bf-40fd-ae2a-f03b83d4a194">0.81</ix:nonFraction> per diluted share. See Note 3. Fair Value Measurements, Note 7. Inventories, Note 9. Goodwill and Intangible Assets and Note 18. Income Taxes for additional information</ix:continuation></ix:continuation>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Gilead Sciences, Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Gilead Sciences, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Gilead Sciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2020, based on the COSO criteria.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Immunomedics, Inc., which is included in the 2020 consolidated financial statements of the Company and constituted 3% and 11% of total assets and liabilities, respectively, as of December&#160;31, 2020 and less than 1% of revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Immunomedics, Inc.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2020 and 2019, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2020, and the related notes and our report dated February&#160;25, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of December&#160;31, 2020 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to the company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at December&#160;31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Management&#8217;s Report on Internal Control over Financial Reporting </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting, based on criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in its 2013 Internal Control-Integrated Framework. Based on our evaluation, we concluded that our internal control over financial reporting was effective as of December&#160;31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope of management&#8217;s assessment of the effectiveness of internal control over financial reporting excluded Immunomedics, Inc., which Gilead acquired in a business combination on October 23, 2020. Total assets, excluding goodwill and intangibles assets, total liabilities, and total revenues of Immunomedics represented approximately 3%, 11% and less than 1% of the total assets, total liabilities and total revenues of Gilead&#8217;s Consolidated Financial Statements as of and for the year ended December&#160;31, 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Ernst&#160;&amp; Young LLP, has audited our Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K and have issued a report on our internal control over financial reporting as of December&#160;31, 2020. Their report on the audit of internal control over financial reporting appears below. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2020, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_205"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_208"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning our directors and executive officers is incorporated by reference to the sections of our Definitive Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with our 2021 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) under the headings &#8220;The Gilead Board of Directors - Nominees,&#8221; &#8220;Board Structure,&#8221; &#8220;Executive Officers,&#8221; and, if applicable, &#8220;Delinquent Section&#160;16(a) Reports.&#8221; </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our written Code of Ethics applies to all of our directors and employees, including our executive officers, including without limitation our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Ethics is available on our website at http://www.gilead.com in the Investors section under &#8220;Corporate Governance.&#8221; We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver.</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_211"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections of the Proxy Statement under the headings &#8220;Executive Compensation,&#8221; &#8220;Committees of our Board of Directors,&#8221; &#8220;Compensation Committee Report,&#8221; and &#8220;Compensation of Non-Employee Board Members.&#8221; </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_214"></div><div style="margin-top:13.5pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to Item 5 of our Annual Report on Form 10-K under the heading &#8220;Equity Compensation Plan Information&#8221; and the section of the Proxy Statement under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_217"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM  13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections of the Proxy Statement under the headings &#8220;The Gilead Board of Directors,&#8221; and &#8220;Board Processes.&#8221; </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_220"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the section&#160;of the Proxy Statement under the heading &#8220;Principal Accountant Fees and Services.&#8221; </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_223"></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV </span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_226"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div id="ib93766b38a794f83a6a283fa0a85c17d_229"></div><div style="-sec-extract:summary;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form&#160;10-K: </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Index list to Consolidated Financial Statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:94.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.613%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_73">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_73">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_76">Audited Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_79">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_79">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_85">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_85">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_88">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_88">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_94">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_94">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_100">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_100">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_103">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib93766b38a794f83a6a283fa0a85c17d_103">60</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Exhibits.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed herewith or incorporated by reference:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000095010320017822/dp136480_ex0201.htm">Agreement and Plan of Merger, dated September 13, 2020, among Immunomedics, Inc., Gilead Sciences, Inc. and Maui Merger Sub, Inc.</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920027472/tm2011253d2_ex2-1.htm">.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920027472/tm2011253d2_ex2-1.htm">Agreement and Plan of Merger, by and among Forty Seven, Inc., Registrant and Toro Merger Sub, Inc., dated March 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d3.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Reference is made to Exhibit 3.1 and Exhibit 3.2</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2021 Note, Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note, Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2020 Note, Form of 2025 Note, Form of 2045 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2020 Note, Form of 2022 Note, Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2022 Note, Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the Company and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209516000046/gildq12016ex1041.htm">Form of performance share award agreement - TSR Goals (U.S.) with Director Retirement Provisions under 2004 Equity Incentive Plan (for grants made in 2016 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1012.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209516000046/gildq12016ex1043.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2016 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209516000046/gildq12016ex1044.htm">Form of performance share award agreement - Revenue Goals (U.S.) with Director Retirement Provisions under 2004 Equity Incentive Plan (for grants made in 2016 through 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1015.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1057.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1019.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (3 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1018.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1023.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (3 year vest) (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants commencing in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209518000029/gildq32018ex1028.htm">Gilead Sciences, Inc. Retention Program for Executive Officers</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1030.htm">Gilead Sciences, Inc. Retention Program for Senior Vice Presidents and Executive Vice Presidents</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1028.htm">Performance share award agreement for Daniel O&#8217;Day (for TSR Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Performance share award agreement for Daniel O&#8217;Day (for Revenue Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1043housin.htm">Letter Agreement between Registrant and Johanna Mercier, dated May 4, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1041.htm">Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1043.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1045.htm">Global restricted stock unit issuance agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(35)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(36)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">21.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2020form10-kexhibit211.htm">Subsidiaries of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2020form10-kexhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2020form10-kexhibit311.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2020form10-kexhibit312.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2020form10-kexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt 0 19pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2020, and incorporated herein by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 2, 2020, and incorporated herein by reference.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(29)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(36)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified confidential portions are (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="ib93766b38a794f83a6a283fa0a85c17d_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:43.859%"><tr><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel P. O&#8217;Day and Brett A. Pletcher, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel P. O&#8217;Day</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew D. Dickinson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DIANE E. WILFONG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diane E. Wilfong</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;JACQUELINE K. BARTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline K. Barton, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;JEFFREY A. BLUESTONE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey A. Bluestone, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;SANDRA J. HORNING</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra J. Horning, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;KELLY A. KRAMER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly A. Kramer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;KEVIN E. LOFTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin E. Lofton</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;HARISH MANWANI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harish Manwani</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAVIER J. RODRIGUEZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANTHONY WELTERS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony Welters</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;RICHARD J. WHITLEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard J. Whitley, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PER WOLD-OLSEN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per Wold-Olsen</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>gild20ormex102amendmentto2.htm
<DESCRIPTION>2004 EQUITY INCENTIVE PLAN AMENDMENT NO. 1 (AMENDED AND RESTATED MAY 10, 2017)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7a565b4bd7b64dd3b8da9b9eb13429c0_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDMENT NO. 1 TO GILEAD SCIENCES, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2004 EQUITY INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS AMENDED AND RESTATED MAY 10, 2017 </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMENDMENT NO. 1 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended and restated May 10, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Gilead Sciences, Inc., a Delaware corporation (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is effective as of October 23, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Plan. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company maintains the Plan and pursuant to Section 13 thereof, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) may amend the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in connection with the transactions contemplated by that certain Agreement and Plan of Merger, dated as of September 13, 2020, between the Company, Immunomedics, Inc., a Delaware corporation and Maui Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company, the Board approved the Company&#8217;s assumption of 25,857,187 shares of common stock, par value $0.001 per share, of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Assumed Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) previously available for issuance under the Immunomedics, Inc. Amended &#38; Restated 2014 Long-Term Incentive Plan, to be issued pursuant to the Plan in accordance with, and subject to the terms and conditions of, an exception under Nasdaq Rule 5635(c)(3) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Immunomedics Plan Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company wishes to amend the Plan to reflect the Immunomedics Plan Assumption. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, pursuant to the powers enumerated in Section 13 of the Plan, the Company amends the Plan as follows, effective as of the Amendment Effective Date&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Section 3(a) of the Plan is hereby amended and restated to read as follows&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Subject to the provisions of Section 10 below, the maximum number of Shares which may be issued in the aggregate under the Plan pursuant to all Awards made hereunder (including, without limitation, Restricted Stock, Restricted Stock Units, Performance Shares, Options, SARs, Dividend Equivalent Rights, and Phantom Shares) shall be limited to 335,045,553 Shares, which includes 25,857,187 shares assumed from the Immunomedics, Inc. Amended &#38; Restated 2014 Long-Term Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Immunomedics Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that became available as of October 23, 2020.  Notwithstanding anything to the contrary contained herein, (i) the Immunomedics Shares may not be granted pursuant to Awards to individuals who were employed immediately prior to October 23, 2020 by the Company or any of its Subsidiaries and (ii) the Immunomedics Shares will not be available for grant under this Plan after April 16, 2030. The Shares to be issued pursuant to Awards may be authorized, but unissued, or reacquired Common Stock.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company executed this Amendment effective as of the Amendment Effective Date.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.047%"><tr><td style="width:1.0%"></td><td style="width:48.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;&#160;&#160;&#160;JYOTI MEHRA</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jyoti Mehra</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executive Vice President, Human Resources</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>gild2020form10-kexhibit211.htm
<DESCRIPTION>EXHIBIT 21.1 LISTING OF SUBSIDIARIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia8bacaaacd994f56a73b9aa446d51d20_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.249%"><tr><td style="width:1.0%"></td><td style="width:52.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES OF GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(as of December 31, 2020)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NAME OF SUBSIDIARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY OF FORMATION</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asegua Therapeutics LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forty Seven, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forty Seven Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Alberta, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Apollo, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Biopharmaceutics US LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Calistoga, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Connecticut, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Pharmasset LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Holding, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomedics, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">neoKite, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Argentina S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cytopia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences YM Australia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YM BioSciences Australia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences GesmbH.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Belgium BVBA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Farmac&#234;utica do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Alberta ULC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Canada, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead YM ULC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fosun Pharma Kite Biotechnology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (Shanghai) Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hangzhou Pharmaceutical Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EpiTherapeutics ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Denmark ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Finland Oy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences SAS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomedics GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hellas EPE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hong Kong Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences India Private Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bristol-Myers Squibb and Gilead Sciences Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Apollo Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.249%"><tr><td style="width:1.0%"></td><td style="width:52.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES OF GILEAD SCIENCES, INC. (continued)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(as of December 31, 2020)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NAME OF SUBSIDIARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY OF FORMATION</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Biopharmaceutics Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Ireland Research UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Oncology Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Therapeutics A1 Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Therapeutics A2 Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tri-Supply Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Israel Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences S.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences KK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Luxembourg S.a.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Malaysia Sdn. Bhd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Netherlands BV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma EU B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KP EU C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (NZ)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Norway AS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Americas S. de R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Poland Sp. z o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Lda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Russia LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Singapore Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Slovakia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences South Africa (Pty) Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Korea Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Sweden AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Switzerland Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilead Sciences Ilac Ticaret Limited Sirketi</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Europe Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences International Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>gild2020form10-kexhibit231.htm
<DESCRIPTION>EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9f5a742d5c50442b8cb654867da1f66f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-81670, 33-46058, 333-58893, 333-84719, 333-117480, 333-126012, 333-135412, 333-143920, 333-151624, 333-161069, 333-163871, 333-207813, 333-219772, 333-223248, 333-238525 and 333-249836) pertaining to the Employee Stock Purchase Plan, the International Employee Stock Purchase Plan, the 2004 Equity Incentive Plan and the 2018 Equity Incentive Plan of Gilead Sciences, Inc. and the Amended &#38; Restated 2014 Long-Term Incentive Plan of Immunomedics, Inc., and the Registration Statement on Form S-3 (No. 333-242321) of Gilead Sciences, Inc. and in the related Prospectuses, as applicable, of our reports dated February&#160;25, 2021, with respect to the consolidated financial statements of Gilead Sciences, Inc., and the effectiveness of internal control over financial reporting of Gilead Sciences, Inc., included in this Annual Report (Form 10-K) for the year ended December&#160;31, 2020.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>gild2020form10-kexhibit311.htm
<DESCRIPTION>SECTION 302 CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4992f0cf260f48b5b77f6142f0dcd1b2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O&#8217;Day<br>Chairman and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>gild2020form10-kexhibit312.htm
<DESCRIPTION>SECTION 302 CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if26ff174d4c544beb22d545ab7f3169e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:24.75pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>gild2020form10-kexhibit32.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1f78f12c5db64485b735093fcd08bb77_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form&#160;10-K for the annual period ended December&#160;31, 2020 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021 </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:47.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O&#8217;Day<br>Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:15pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>gild-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c95e6174-aa16-488c-b0f6-cc28c1f33ed5,g:86b29b2d-a791-4b12-a644-3051a1d6b3ea-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.gilead.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome">
        <link:definition>1003004 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.gilead.com/role/Revenues">
        <link:definition>2105102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.gilead.com/role/RevenuesTables">
        <link:definition>2306302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails">
        <link:definition>2407402 - Disclosure - Revenues - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummarizedRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails">
        <link:definition>2408403 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails">
        <link:definition>2409404 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.gilead.com/role/FairValueMeasurements">
        <link:definition>2110103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.gilead.com/role/FairValueMeasurementsTables">
        <link:definition>2311303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails">
        <link:definition>2412405 - Disclosure - Fair Value Measurements - Summary of assets and liabilities recorded at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Summary of Classification on Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecurities" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecurities">
        <link:definition>2115104 - Disclosure - Available-for-Sale Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesTables" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables">
        <link:definition>2316304 - Disclosure - Available-for-Sale Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>2417408 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>2418409 - Disclosure - Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>2419410 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>2420411 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleDebtSecuritiesAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails">
        <link:definition>2421412 - Disclosure - Available-for-Sale Debt Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments">
        <link:definition>2122105 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2323305 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>2424413 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>2425414 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails">
        <link:definition>2426415 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2427416 - Disclosure - Derivative Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.gilead.com/role/Acquisitions">
        <link:definition>2128106 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.gilead.com/role/AcquisitionsTables">
        <link:definition>2329306 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails">
        <link:definition>2430417 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2431418 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSupplementalProFormaInformationDetails" roleURI="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails">
        <link:definition>2432419 - Disclosure - Acquisitions - Supplemental Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.gilead.com/role/Inventories">
        <link:definition>2133107 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.gilead.com/role/InventoriesTables">
        <link:definition>2334307 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofinventoriesDetails" roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails">
        <link:definition>2435420 - Disclosure - Inventories - Schedule of inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails">
        <link:definition>2436421 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.gilead.com/role/PropertyPlantandEquipment">
        <link:definition>2137108 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables">
        <link:definition>2338308 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails">
        <link:definition>2439422 - Disclosure - Property, Plant and Equipment - Schedule of property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>2440423 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets">
        <link:definition>2141109 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2342309 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails">
        <link:definition>2443424 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>2444425 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails">
        <link:definition>2445426 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails">
        <link:definition>2446427 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.gilead.com/role/OtherFinancialInformation">
        <link:definition>2147110 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.gilead.com/role/OtherFinancialInformationTables">
        <link:definition>2348310 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails">
        <link:definition>2449428 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherAccruedLiabilitiesDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails">
        <link:definition>2450429 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements">
        <link:definition>2151111 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsDetails" roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails">
        <link:definition>2452430 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilities" roleURI="http://www.gilead.com/role/DebtandCreditFacilities">
        <link:definition>2153112 - Disclosure - Debt and Credit Facilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesTables" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables">
        <link:definition>2354311 - Disclosure - Debt and Credit Facilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails">
        <link:definition>2455431 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesNarrativeDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails">
        <link:definition>2456432 - Disclosure - Debt and Credit Facilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails">
        <link:definition>2457433 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.gilead.com/role/Leases">
        <link:definition>2158113 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.gilead.com/role/LeasesTables">
        <link:definition>2359312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.gilead.com/role/LeasesNarrativeDetails">
        <link:definition>2460434 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetLocationDetailDetails" roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails">
        <link:definition>2461435 - Disclosure - Leases - Balance Sheet Location Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationRelatedtoLeasesDetails" roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails">
        <link:definition>2462436 - Disclosure - Leases - Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails">
        <link:definition>2463437 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1">
        <link:definition>2463437 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.gilead.com/role/CommitmentsandContingencies">
        <link:definition>2164114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2465438 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.gilead.com/role/StockholdersEquity">
        <link:definition>2166115 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.gilead.com/role/StockholdersEquityTables">
        <link:definition>2367313 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRepurchasesofCommonStockDetails" roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails">
        <link:definition>2468439 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDividendsDetails" roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails">
        <link:definition>2469440 - Disclosure - Stockholders' Equity - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>2470441 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2471442 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.gilead.com/role/EmployeeBenefits">
        <link:definition>2172116 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsTables" roleURI="http://www.gilead.com/role/EmployeeBenefitsTables">
        <link:definition>2373314 - Disclosure - Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsStockOptionsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails">
        <link:definition>2474443 - Disclosure - Employee Benefits - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails">
        <link:definition>2475444 - Disclosure - Employee Benefits - Restricted Stock and Performance Share Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsSummaryofStockBasedCompensationDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails">
        <link:definition>2476445 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails">
        <link:definition>2477446 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsNarrativeDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails">
        <link:definition>2478447 - Disclosure - Employee Benefits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholders" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders">
        <link:definition>2179117 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholdersTables" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables">
        <link:definition>2380315 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails">
        <link:definition>2481448 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>2482449 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.gilead.com/role/IncomeTaxes">
        <link:definition>2183118 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.gilead.com/role/IncomeTaxesTables">
        <link:definition>2384316 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>2485450 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails">
        <link:definition>2486451 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails">
        <link:definition>2487452 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2488453 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails">
        <link:definition>2489454 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2490455 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialInformationUnaudited" roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited">
        <link:definition>2191119 - Disclosure - Selected Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialInformationUnauditedTables" roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables">
        <link:definition>2392317 - Disclosure - Selected Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2493456 - Disclosure - Selected Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_AssetAcquisitionDomain" abstract="true" name="AssetAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" abstract="true" name="RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GadetaBVCollaborationArrangementMember" abstract="true" name="GadetaBVCollaborationArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_COVID19ProductsTrodelvyMember" abstract="true" name="COVID19ProductsTrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TotalUpfrontPaymentsMade" abstract="false" name="TotalUpfrontPaymentsMade" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_JudgmentEnhancedDamagesonPastSales" abstract="false" name="JudgmentEnhancedDamagesonPastSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" abstract="false" name="LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" abstract="true" name="LicenseRegistrationRightsAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" abstract="false" name="UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" abstract="true" name="AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FortySevenIncMember" abstract="true" name="FortySevenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsRanexaMember" abstract="true" name="OtherProductsRanexaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" abstract="false" name="AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_UnrealizedGainComponentDomain" abstract="true" name="UnrealizedGainComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsZydeligMember" abstract="true" name="OtherProductsZydeligMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIPurchasePeriod" abstract="false" name="EquitySecuritiesFVNIPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_SeniorUnsecuredNoteIssuedSeptember2015Member" abstract="true" name="SeniorUnsecuredNoteIssuedSeptember2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" abstract="false" name="PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2047Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyMotionInvalidatedForPastDamagesValue" abstract="false" name="LossContingencyMotionInvalidatedForPastDamagesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquityinvestmentinGalapagosMember" abstract="true" name="EquityinvestmentinGalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" abstract="false" name="PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentInProcessIncludingImpairment" abstract="false" name="ResearchAndDevelopmentInProcessIncludingImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" abstract="false" name="EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_JounceTherapeuticsIncMember" abstract="true" name="JounceTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ScheduleofInventoryLineItems" abstract="true" name="ScheduleofInventoryLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" abstract="false" name="MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2022Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AssetAcquisitionCashOutflowNetOfCashAcquired" abstract="false" name="AssetAcquisitionCashOutflowNetOfCashAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CreditFacilityDueMay2021Member" abstract="true" name="CreditFacilityDueMay2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialFutureSalesbasedMilestone" abstract="false" name="PotentialFutureSalesbasedMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A2016StockRepurchaseProgramMember" abstract="true" name="A2016StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GalapagosMember" abstract="true" name="GalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_StandstillRestrictingTerm" abstract="false" name="StandstillRestrictingTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantandEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2020Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PaymentsForDirectTransactionalExpense" abstract="false" name="PaymentsForDirectTransactionalExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" abstract="false" name="IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PaymentsToEquityAwardHoldersMember" abstract="true" name="PaymentsToEquityAwardHoldersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" abstract="false" name="PotentialSalesBasedTieredRoyaltiesHighEndPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_PotentialFutureTieredRoyaltyPaymentHighend" abstract="false" name="PotentialFutureTieredRoyaltyPaymentHighend" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIRestrictionPeriod" abstract="false" name="EquitySecuritiesFVNIRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CollaborativeandOtherArrangementsTextBlock" abstract="false" name="CollaborativeandOtherArrangementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gild_StockRepurchasesAbstract" abstract="true" name="StockRepurchasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueInSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" abstract="true" name="ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialOptionExerciseFeePerProgram" abstract="false" name="PotentialOptionExerciseFeePerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" abstract="false" name="PaymentForAdjustmentsOfBudgetedDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" abstract="false" name="MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinApril2024Member" abstract="true" name="SeniorUnsecuredNotesDueinApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ViiVHealthcareCompanyMember" abstract="true" name="ViiVHealthcareCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PionyrMergerAndOptionAgreementsMember" abstract="true" name="PionyrMergerAndOptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueApril2021Member" abstract="true" name="SeniorUnsecuredNotesDueApril2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" abstract="true" name="ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AssetAcquisitionAxis" abstract="true" name="AssetAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" abstract="false" name="BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="gild_DeferredIncomeTaxExpenseBenefitComponentAxis" abstract="true" name="DeferredIncomeTaxExpenseBenefitComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" abstract="false" name="ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gild_PubliclyAnnouncedProgramMember" abstract="true" name="PubliclyAnnouncedProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TizonaTherapeuticsIncMember" abstract="true" name="TizonaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueDecember2021Member" abstract="true" name="SeniorUnsecuredNotesDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" abstract="true" name="RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_GalapagosSubscriptionAgreementMember" abstract="true" name="GalapagosSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" abstract="false" name="LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2027Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" abstract="false" name="EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ArcusStockPurchaseAgreementMember" abstract="true" name="ArcusStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FairValueatVestingDateMember" abstract="true" name="FairValueatVestingDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_InvestmentOwnedBalanceAdditionalPayable" abstract="false" name="InvestmentOwnedBalanceAdditionalPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" abstract="false" name="EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_OtherCollaborationArrangementsMember" abstract="true" name="OtherCollaborationArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CallTherapyProductsTecartusMember" abstract="true" name="CallTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FinitelivedintangibleassetimpairmentbyprogramDomain" abstract="true" name="FinitelivedintangibleassetimpairmentbyprogramDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SelectedQuarterlyFinancialInformationTable" abstract="true" name="SelectedQuarterlyFinancialInformationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_FavorableEPSImpactMember" abstract="true" name="FavorableEPSImpactMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AxicabtageneciloleucelDLBCLMember" abstract="true" name="AxicabtageneciloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TizonaMergerAndOptionAgreementsMember" abstract="true" name="TizonaMergerAndOptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AmendedArcusCommonStockPurchaseAgreementMember" abstract="true" name="AmendedArcusCommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PaymentstoOutstandingCommonStockholdersMember" abstract="true" name="PaymentstoOutstandingCommonStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TangoTherapeuticsIncMember" abstract="true" name="TangoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateFromOctober2017" abstract="false" name="JudgmentRoyaltyRateFromOctober2017" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_EPSImpactbyTransactionDomain" abstract="true" name="EPSImpactbyTransactionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" abstract="true" name="ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" abstract="false" name="PotentialSalesBasedTieredRoyaltyLowEndPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinFebruary2045Member" abstract="true" name="SeniorUnsecuredNotesDueinFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_Kite585ProgramMember" abstract="true" name="Kite585ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_DeferredIncomeTaxExpenseBenefitComponentDomain" abstract="true" name="DeferredIncomeTaxExpenseBenefitComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_Issuancediscount" abstract="false" name="Issuancediscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_DevelopmentAgreementMember" abstract="true" name="DevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_InventoryWritedownsforExcessRawMaterialsMember" abstract="true" name="InventoryWritedownsforExcessRawMaterialsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EPSImpactbyTransactionAxis" abstract="true" name="EPSImpactbyTransactionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_SelectedQuarterlyFinancialInformationLineItems" abstract="true" name="SelectedQuarterlyFinancialInformationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" abstract="true" name="A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2035Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IntangibleAssetTransferMember" abstract="true" name="IntangibleAssetTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinApril2044Member" abstract="true" name="SeniorUnsecuredNotesDueinApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" abstract="true" name="A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FairValueatGrantDateMember" abstract="true" name="FairValueatGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" abstract="true" name="ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsAtriplaMember" abstract="true" name="HIVProductsAtriplaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentFutureMaximumPayments" abstract="false" name="ResearchAndDevelopmentFutureMaximumPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PionyrImmunotherapeuticsIncMember" abstract="true" name="PionyrImmunotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ActivePharmaceuticalIngredientMember" abstract="true" name="ActivePharmaceuticalIngredientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IdenixPharmaceuticalsIncMember" abstract="true" name="IdenixPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" abstract="true" name="FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_NumberOfPrograms" abstract="false" name="NumberOfPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_A2020StockRepurchaseProgramMember" abstract="true" name="A2020StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" abstract="true" name="FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FinitelivedintangibleassetimpairmentbyprogramAxis" abstract="true" name="FinitelivedintangibleassetimpairmentbyprogramAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_DeferredTaxAssetsUpfrontAndMilestonePayments" abstract="false" name="DeferredTaxAssetsUpfrontAndMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_RestrictedStockandPerformanceShareAwardsMember" abstract="true" name="RestrictedStockandPerformanceShareAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" abstract="false" name="EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherProductsVemlidyMember" abstract="true" name="OtherProductsVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GalapagosCollaborationAgreementMember" abstract="true" name="GalapagosCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" abstract="false" name="PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateOnFutureSales" abstract="false" name="JudgmentRoyaltyRateOnFutureSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_InvestmentOwnedBalanceAdditionalShares" abstract="false" name="InvestmentOwnedBalanceAdditionalShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_VariableTermLoanNoteDueOctober2023Member" abstract="true" name="VariableTermLoanNoteDueOctober2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_AgreementWithJapanTobaccoIncMember" abstract="true" name="AgreementWithJapanTobaccoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" abstract="false" name="AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherHCVMember" abstract="true" name="OtherHCVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2036Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ScheduleofInventoryTable" abstract="true" name="ScheduleofInventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_CollaborativeandOtherArrangementsAbstract" abstract="true" name="CollaborativeandOtherArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GileadSciencesInc2004EquityIncentivePlanMember" abstract="true" name="GileadSciencesInc2004EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsYescartaMember" abstract="true" name="OtherProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" abstract="false" name="InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_UnrealizedGainComponentAxis" abstract="true" name="UnrealizedGainComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" abstract="false" name="EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="AcquiredFiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_PotentialFutureMilestonePaymentsMaximum" abstract="false" name="PotentialFutureMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNoteIssuedSeptember2014Member" abstract="true" name="SeniorUnsecuredNoteIssuedSeptember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TotalGrantDateFairValueDomain" abstract="true" name="TotalGrantDateFairValueDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_COVID19ProductsVekluryMember" abstract="true" name="COVID19ProductsVekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2022Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNoteIssuedSeptember2020Member" abstract="true" name="SeniorUnsecuredNoteIssuedSeptember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" abstract="true" name="RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_InventoryWritedownAbstract" abstract="true" name="InventoryWritedownAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_OtherProductsVireadMember" abstract="true" name="OtherProductsVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_AccruedResearchAndDevelopmentMilestonePayments" abstract="false" name="AccruedResearchAndDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementMember" abstract="true" name="ArcusCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_BristolMyersSquibbCollaborativeArrangementMember" abstract="true" name="BristolMyersSquibbCollaborativeArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" abstract="true" name="ThreeYearSeniorUnsecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" abstract="true" name="FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" abstract="true" name="AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2046Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TotalFairValueAxis" abstract="true" name="TotalFairValueAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_PaymentsForResearchAndDevelopmentMilestones" abstract="false" name="PaymentsForResearchAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_IssuanceDiscountPremium" abstract="false" name="IssuanceDiscountPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" abstract="false" name="PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" abstract="true" name="AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" abstract="false" name="EquitySecuritiesFVNIFutureMaximumMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2026Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_CashPaymentsMadeRelatedToEquityInvestments" abstract="false" name="CashPaymentsMadeRelatedToEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" abstract="false" name="PotentialMilestonePaymentUponMarketingApprovalGLPG1690" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" abstract="false" name="AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2023Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_Inventoryreserveforexcessrawmaterials" abstract="false" name="Inventoryreserveforexcessrawmaterials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_Accruedgovernmentandotherrebates" abstract="false" name="Accruedgovernmentandotherrebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_GileadSciencesInc2018EquityIncentivePlanMember" abstract="true" name="GileadSciencesInc2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_JanssenPharmaceuticalsMember" abstract="true" name="JanssenPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentServiceAgreementMember" abstract="true" name="ResearchAndDevelopmentServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_NumberOfStudies" abstract="false" name="NumberOfStudies" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinFebruary2025Member" abstract="true" name="SeniorUnsecuredNotesDueinFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ChangeinestimatevariableconsiderationMember" abstract="true" name="ChangeinestimatevariableconsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" abstract="true" name="ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_EquityMethodInvestmentOptionExerciseFee" abstract="false" name="EquityMethodInvestmentOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_LossContingencyEstimateofPossibleLossPastSales" abstract="false" name="LossContingencyEstimateofPossibleLossPastSales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PotentialFutureTieredRoyaltyPaymentLowend" abstract="false" name="PotentialFutureTieredRoyaltyPaymentLowend" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" abstract="false" name="DebtInstrumentCallFeaturePeriodBeforeMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" abstract="false" name="EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" abstract="true" name="JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_TrodelvyForMTNBCMember" abstract="true" name="TrodelvyForMTNBCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueInFebruary2020Member" abstract="true" name="SeniorUnsecuredNotesDueInFebruary2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>gild-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c95e6174-aa16-488c-b0f6-cc28c1f33ed5,g:86b29b2d-a791-4b12-a644-3051a1d6b3ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/Cover" xlink:type="simple" xlink:href="gild-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e9b7a33b-3b7a-4165-8499-72e32148d85f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:to="loc_us-gaap_LiabilitiesCurrent_e9b7a33b-3b7a-4165-8499-72e32148d85f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9c9bc0e9-4488-4939-b188-5263b5ce5c1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9c9bc0e9-4488-4939-b188-5263b5ce5c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_95e5d477-1116-4b71-a92f-9f2a61b57dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_95e5d477-1116-4b71-a92f-9f2a61b57dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6ea6b30f-9f23-44fb-be61-7d6cd5f147fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6ea6b30f-9f23-44fb-be61-7d6cd5f147fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0c1509b6-fc6c-4322-90ef-95c7e2da8754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0c1509b6-fc6c-4322-90ef-95c7e2da8754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02c74ea6-77f8-4f74-9f80-8c746fbcbeee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8f41608d-d708-4544-afc0-b88ebe55c6ac" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02c74ea6-77f8-4f74-9f80-8c746fbcbeee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e41b7209-db19-4d8d-90dc-99f4ac9cc8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8c49d661-d3aa-48ca-a392-04c34262a4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e41b7209-db19-4d8d-90dc-99f4ac9cc8bd" xlink:to="loc_us-gaap_PreferredStockValue_8c49d661-d3aa-48ca-a392-04c34262a4ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cbc0b45d-cbef-41f8-bd85-3a7cb889f743" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e41b7209-db19-4d8d-90dc-99f4ac9cc8bd" xlink:to="loc_us-gaap_CommonStockValue_cbc0b45d-cbef-41f8-bd85-3a7cb889f743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_46a4eb40-556a-46af-b258-80a711e5b746" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e41b7209-db19-4d8d-90dc-99f4ac9cc8bd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_46a4eb40-556a-46af-b258-80a711e5b746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_81d9f6c0-17fd-4257-b129-2b76d7fd8821" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e41b7209-db19-4d8d-90dc-99f4ac9cc8bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_81d9f6c0-17fd-4257-b129-2b76d7fd8821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aab68896-aaac-412f-bbfc-9665080f17b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e41b7209-db19-4d8d-90dc-99f4ac9cc8bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aab68896-aaac-412f-bbfc-9665080f17b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6766d88b-bea0-4505-b5a0-7ea3153ef17a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:to="loc_us-gaap_AssetsCurrent_6766d88b-bea0-4505-b5a0-7ea3153ef17a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69e7f5ac-1fcc-4021-b16a-bb4a6aa42bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69e7f5ac-1fcc-4021-b16a-bb4a6aa42bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8be702d4-9fda-4b01-8257-d1cd262d0382" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8be702d4-9fda-4b01-8257-d1cd262d0382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91501015-472e-4274-8d4d-7c2192f24243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91501015-472e-4274-8d4d-7c2192f24243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4425d008-5111-46d4-a183-7b0edc83bf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:to="loc_us-gaap_Goodwill_4425d008-5111-46d4-a183-7b0edc83bf5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ec49dfc4-6bd5-4232-9b7a-4bfa9201d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_06114b60-824a-4395-a890-9b129a702583" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ec49dfc4-6bd5-4232-9b7a-4bfa9201d36c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2df4e9cd-9526-4ba3-92aa-dd0d66272419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c7b9017b-70e8-4083-964c-df8c9d4b1be6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2df4e9cd-9526-4ba3-92aa-dd0d66272419" xlink:to="loc_us-gaap_AccountsPayableCurrent_c7b9017b-70e8-4083-964c-df8c9d4b1be6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Accruedgovernmentandotherrebates_2e977107-f34a-49eb-a1bb-c5e8570dc38f" xlink:href="gild-20201231.xsd#gild_Accruedgovernmentandotherrebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2df4e9cd-9526-4ba3-92aa-dd0d66272419" xlink:to="loc_gild_Accruedgovernmentandotherrebates_2e977107-f34a-49eb-a1bb-c5e8570dc38f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_051f7870-2500-4683-ba32-4e44171d9fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2df4e9cd-9526-4ba3-92aa-dd0d66272419" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_051f7870-2500-4683-ba32-4e44171d9fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_8a012484-a56a-4f4b-aa68-d7f8f915ea74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2df4e9cd-9526-4ba3-92aa-dd0d66272419" xlink:to="loc_us-gaap_DebtCurrent_8a012484-a56a-4f4b-aa68-d7f8f915ea74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8bb23e0a-52cf-4b39-9d0d-d23c1205bd88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ba3fb198-db1d-4f34-9a94-42ea826d2a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb23e0a-52cf-4b39-9d0d-d23c1205bd88" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ba3fb198-db1d-4f34-9a94-42ea826d2a97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_63f657d8-3bdd-4049-92e6-ae54d67ee9b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb23e0a-52cf-4b39-9d0d-d23c1205bd88" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_63f657d8-3bdd-4049-92e6-ae54d67ee9b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b25562f7-6587-4c7b-85f8-65f06e48afd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb23e0a-52cf-4b39-9d0d-d23c1205bd88" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b25562f7-6587-4c7b-85f8-65f06e48afd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9999b963-396f-461a-8147-b90ad6cdfba3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb23e0a-52cf-4b39-9d0d-d23c1205bd88" xlink:to="loc_us-gaap_InventoryNet_9999b963-396f-461a-8147-b90ad6cdfba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d947d73-d076-4065-8ec4-aba7d50e3244" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bb23e0a-52cf-4b39-9d0d-d23c1205bd88" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d947d73-d076-4065-8ec4-aba7d50e3244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_727ee39f-1be3-4540-80b5-3b15de60b0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6ef4047b-44ac-49c6-ac3a-615e7433e49c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_727ee39f-1be3-4540-80b5-3b15de60b0c8" xlink:to="loc_us-gaap_StockholdersEquity_6ef4047b-44ac-49c6-ac3a-615e7433e49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b8a6fbd8-81f1-4933-a034-c42881aa37d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_727ee39f-1be3-4540-80b5-3b15de60b0c8" xlink:to="loc_us-gaap_MinorityInterest_b8a6fbd8-81f1-4933-a034-c42881aa37d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d03cf873-6ae9-4284-b0dd-e203d9f942a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5f136097-61b8-409b-9e5f-3243a0a0501e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d03cf873-6ae9-4284-b0dd-e203d9f942a2" xlink:to="loc_us-gaap_CostsAndExpenses_5f136097-61b8-409b-9e5f-3243a0a0501e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65b560aa-8b66-4e89-9f02-bb0430c58d06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d03cf873-6ae9-4284-b0dd-e203d9f942a2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65b560aa-8b66-4e89-9f02-bb0430c58d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8a0ad1df-b910-4cb9-8514-45e923750f3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c23c44d2-6cea-4864-81d8-1b6da64bec49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8a0ad1df-b910-4cb9-8514-45e923750f3c" xlink:to="loc_us-gaap_OperatingIncomeLoss_c23c44d2-6cea-4864-81d8-1b6da64bec49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_87b9d831-4286-4f81-acba-10ae7d4886f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8a0ad1df-b910-4cb9-8514-45e923750f3c" xlink:to="loc_us-gaap_InterestExpense_87b9d831-4286-4f81-acba-10ae7d4886f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_111a2884-882a-4bb4-ab1c-5dc80c88eb78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8a0ad1df-b910-4cb9-8514-45e923750f3c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_111a2884-882a-4bb4-ab1c-5dc80c88eb78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f80f288-f271-4dae-a5a3-733e54adb3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6f27edc1-b99f-485d-a4d5-cb7d23a25649" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1f80f288-f271-4dae-a5a3-733e54adb3d8" xlink:to="loc_us-gaap_ProfitLoss_6f27edc1-b99f-485d-a4d5-cb7d23a25649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_039ee393-418e-421d-b028-5559add98de9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1f80f288-f271-4dae-a5a3-733e54adb3d8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_039ee393-418e-421d-b028-5559add98de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_893029f0-8739-4710-8d59-10b9fab7f210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_23cf5b19-946d-46ff-aca9-1cca94c58236" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_893029f0-8739-4710-8d59-10b9fab7f210" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_23cf5b19-946d-46ff-aca9-1cca94c58236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e11aba8a-22fb-4cb5-b76d-55e632fd3c98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_893029f0-8739-4710-8d59-10b9fab7f210" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e11aba8a-22fb-4cb5-b76d-55e632fd3c98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_068a8a4c-9f73-4571-9cd5-7301777ac4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dd96aabe-0022-4200-9a83-a70a6c12e16f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_068a8a4c-9f73-4571-9cd5-7301777ac4a8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dd96aabe-0022-4200-9a83-a70a6c12e16f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_90d9465b-fde1-498d-a254-a6f8de945cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_068a8a4c-9f73-4571-9cd5-7301777ac4a8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_90d9465b-fde1-498d-a254-a6f8de945cb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29517781-c916-405c-be31-d36a35fda5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_068a8a4c-9f73-4571-9cd5-7301777ac4a8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29517781-c916-405c-be31-d36a35fda5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_6cc3d272-968c-4d25-b030-647cadc5e5a0" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_068a8a4c-9f73-4571-9cd5-7301777ac4a8" xlink:to="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_6cc3d272-968c-4d25-b030-647cadc5e5a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_95e5d260-27c0-4160-8432-0a7996a0f5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eb088cbb-99e9-4dfc-a486-5d5f4f7e46c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_95e5d260-27c0-4160-8432-0a7996a0f5bb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eb088cbb-99e9-4dfc-a486-5d5f4f7e46c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_894fec49-fc75-43df-87ce-f127af80bbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_95e5d260-27c0-4160-8432-0a7996a0f5bb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_894fec49-fc75-43df-87ce-f127af80bbb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5913f39e-74e6-45c7-88fe-be476ad17ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0616cf6e-8425-4bae-a370-c91be237cd79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5913f39e-74e6-45c7-88fe-be476ad17ae1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0616cf6e-8425-4bae-a370-c91be237cd79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_45c14af2-5a1f-4926-9b36-b8fc50a0422a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5913f39e-74e6-45c7-88fe-be476ad17ae1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_45c14af2-5a1f-4926-9b36-b8fc50a0422a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_26a2ed5d-7bb7-46e4-91fa-08f4bcf9b938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_f03f41cc-b05d-4158-8db6-cf5f9b4af4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_26a2ed5d-7bb7-46e4-91fa-08f4bcf9b938" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_f03f41cc-b05d-4158-8db6-cf5f9b4af4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ac0d2a8d-2d89-4673-95c2-c4a1903d6aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_26a2ed5d-7bb7-46e4-91fa-08f4bcf9b938" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ac0d2a8d-2d89-4673-95c2-c4a1903d6aa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88c9c55d-1203-475f-b444-a70ecdf95551" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9747d4f5-afde-462a-9e66-1fb19f105fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88c9c55d-1203-475f-b444-a70ecdf95551" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9747d4f5-afde-462a-9e66-1fb19f105fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_447238f1-8616-4b57-88a1-a9a65d0648d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88c9c55d-1203-475f-b444-a70ecdf95551" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_447238f1-8616-4b57-88a1-a9a65d0648d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_39838919-2b90-4cef-9b9f-99522c6cc9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88c9c55d-1203-475f-b444-a70ecdf95551" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_39838919-2b90-4cef-9b9f-99522c6cc9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3b8d241b-6383-48fd-9b83-36869a445049" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d163830-40c2-4ee0-a336-5d163dfeb1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3b8d241b-6383-48fd-9b83-36869a445049" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d163830-40c2-4ee0-a336-5d163dfeb1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2c9a06a6-7ee8-4cd1-a2cd-893be907006c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3b8d241b-6383-48fd-9b83-36869a445049" xlink:to="loc_us-gaap_ProfitLoss_2c9a06a6-7ee8-4cd1-a2cd-893be907006c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_357f15d1-b83a-4037-9c4f-f610088045d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_357f15d1-b83a-4037-9c4f-f610088045d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_787cb036-e945-46b1-b3e1-2c8decae0db2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_787cb036-e945-46b1-b3e1-2c8decae0db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7b09ddf1-ccb7-4fbf-8687-490bb5200b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7b09ddf1-ccb7-4fbf-8687-490bb5200b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_46f9bd17-0e35-4b81-9696-bbc9c9a6a09b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_46f9bd17-0e35-4b81-9696-bbc9c9a6a09b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_8aa63470-c967-4f30-b9b7-292cae96fba6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_8aa63470-c967-4f30-b9b7-292cae96fba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_14f54186-57a9-47b5-8d1c-60e1febe472e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_14f54186-57a9-47b5-8d1c-60e1febe472e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9b739200-2eb1-4921-92f1-5b4c2ec45ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37a9e7ab-b532-4159-97f8-002337c8fe19" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9b739200-2eb1-4921-92f1-5b4c2ec45ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b84f68e-288f-4e37-b819-d145f7c597e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_ProfitLoss_0b84f68e-288f-4e37-b819-d145f7c597e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d7439280-8acf-4ae4-9dd4-2dfafe5fa3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_Depreciation_d7439280-8acf-4ae4-9dd4-2dfafe5fa3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_f525d440-65b6-4940-8bb0-cfbae4514d18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_AdjustmentForAmortization_f525d440-65b6-4940-8bb0-cfbae4514d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5f67c5d6-d480-4109-a748-d47e934da5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_ShareBasedCompensation_5f67c5d6-d480-4109-a748-d47e934da5a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f6b3fe82-8676-43d4-b600-cb0bfe395928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_f6b3fe82-8676-43d4-b600-cb0bfe395928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_67187756-eca3-4848-acd7-08111c862778" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_67187756-eca3-4848-acd7-08111c862778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2a97edc4-060a-4af8-bf13-4771e285583f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2a97edc4-060a-4af8-bf13-4771e285583f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_869d1c79-204d-4173-84f9-7134e9b31fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_869d1c79-204d-4173-84f9-7134e9b31fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Inventoryreserveforexcessrawmaterials_dbc29273-0ec4-4595-ab71-db887bc0b4e8" xlink:href="gild-20201231.xsd#gild_Inventoryreserveforexcessrawmaterials"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_gild_Inventoryreserveforexcessrawmaterials_dbc29273-0ec4-4595-ab71-db887bc0b4e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_005aa004-6f17-4266-95e0-37422d8949bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_005aa004-6f17-4266-95e0-37422d8949bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_43321906-96e4-4d8f-9a21-625e9227f276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_43321906-96e4-4d8f-9a21-625e9227f276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ae800632-1783-47b0-8d64-585d33f155e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ae800632-1783-47b0-8d64-585d33f155e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9c23aaed-57be-4b30-b9fb-98d592b31d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9c23aaed-57be-4b30-b9fb-98d592b31d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f72c8a4-4d65-4f80-a383-6f41dbd9d60b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f72c8a4-4d65-4f80-a383-6f41dbd9d60b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e28bf377-b031-476c-958a-1063898ed274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e28bf377-b031-476c-958a-1063898ed274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9bd4447-385f-4726-8fc4-cee788f253e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e4723143-5498-4c61-88e6-6313fd07dcdf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9bd4447-385f-4726-8fc4-cee788f253e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_182b4b1c-93bb-46dc-a61e-08a80cf35ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c858f8c2-da75-4331-a101-0bd19aae2917" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_182b4b1c-93bb-46dc-a61e-08a80cf35ee4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c858f8c2-da75-4331-a101-0bd19aae2917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f84a9442-86a0-44c0-948f-39941d5e5d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_182b4b1c-93bb-46dc-a61e-08a80cf35ee4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f84a9442-86a0-44c0-948f-39941d5e5d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ae53110-c91a-415a-9ece-5bcde547f572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_182b4b1c-93bb-46dc-a61e-08a80cf35ee4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ae53110-c91a-415a-9ece-5bcde547f572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f06c9f2-687f-4cfc-870e-56d0d7f832b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_182b4b1c-93bb-46dc-a61e-08a80cf35ee4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0f06c9f2-687f-4cfc-870e-56d0d7f832b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_bf6a91cf-16fe-4e22-9728-4fa37df1b3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_bf6a91cf-16fe-4e22-9728-4fa37df1b3ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9f46e78f-cdd1-427c-81a2-e2f4c28f5a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9f46e78f-cdd1-427c-81a2-e2f4c28f5a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_96769950-7578-4dc5-9021-39883867fdf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_96769950-7578-4dc5-9021-39883867fdf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e188652b-0e3e-48fe-9322-4d0d54b70fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:to="loc_us-gaap_RepaymentsOfDebt_e188652b-0e3e-48fe-9322-4d0d54b70fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_98e8c89f-2c4b-474c-aaf3-30ea66753f70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:to="loc_us-gaap_PaymentsOfDividends_98e8c89f-2c4b-474c-aaf3-30ea66753f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_941092e1-4b33-4f51-b73f-c521d1433466" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb360ea8-c63e-4cbd-bb39-55853c8c3372" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_941092e1-4b33-4f51-b73f-c521d1433466" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/Revenues" xlink:type="simple" xlink:href="gild-20201231.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a2dfa088-b4ea-46aa-9dd4-08350f013a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_bfce42fc-a11f-4baf-9e84-260a31c3cea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a2dfa088-b4ea-46aa-9dd4-08350f013a1c" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_bfce42fc-a11f-4baf-9e84-260a31c3cea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c5f0b0a8-583e-4ca1-a1a6-775576ea91b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a2dfa088-b4ea-46aa-9dd4-08350f013a1c" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_c5f0b0a8-583e-4ca1-a1a6-775576ea91b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_41c60418-c607-4896-b163-dfd40639beff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_790f3255-2708-4ddc-9f6d-1880e8fae5df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_41c60418-c607-4896-b163-dfd40639beff" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_790f3255-2708-4ddc-9f6d-1880e8fae5df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08b8d4aa-2981-4e23-af52-6d94d40a9dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_41c60418-c607-4896-b163-dfd40639beff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08b8d4aa-2981-4e23-af52-6d94d40a9dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_23b1e61f-1f4a-40cc-9987-b5bbb4ccc1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_41c60418-c607-4896-b163-dfd40639beff" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_23b1e61f-1f4a-40cc-9987-b5bbb4ccc1ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecurities"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3d1d822a-e07b-496b-b303-9c4d0fd3b544" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ecad7dd-e629-4df3-a183-1cfcdb2c2c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3d1d822a-e07b-496b-b303-9c4d0fd3b544" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0ecad7dd-e629-4df3-a183-1cfcdb2c2c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef871ad4-7859-4368-9da5-d94b58d64d33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3d1d822a-e07b-496b-b303-9c4d0fd3b544" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef871ad4-7859-4368-9da5-d94b58d64d33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_98e14211-daec-4a2b-9caa-bc18df4dc490" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3d1d822a-e07b-496b-b303-9c4d0fd3b544" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_98e14211-daec-4a2b-9caa-bc18df4dc490" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe77f7f4-83e9-4680-a815-7634f210c659" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d91bb613-41ca-42ed-a8e6-0262bec12bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe77f7f4-83e9-4680-a815-7634f210c659" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d91bb613-41ca-42ed-a8e6-0262bec12bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_42b7a87a-c3d5-476e-8a40-4c6d0f1cd44c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe77f7f4-83e9-4680-a815-7634f210c659" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_42b7a87a-c3d5-476e-8a40-4c6d0f1cd44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ee8289-bfb1-4cdc-9863-2fe435ceab28" xlink:href="gild-20201231.xsd#gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe77f7f4-83e9-4680-a815-7634f210c659" xlink:to="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ee8289-bfb1-4cdc-9863-2fe435ceab28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_948e2aea-ae5f-4a1b-b443-f19eaaefb49f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_482e556f-c482-4e94-9536-2a04184f7823" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_948e2aea-ae5f-4a1b-b443-f19eaaefb49f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_482e556f-c482-4e94-9536-2a04184f7823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c5846129-ca8f-4512-87df-ca7349063f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_948e2aea-ae5f-4a1b-b443-f19eaaefb49f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c5846129-ca8f-4512-87df-ca7349063f91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_645b67e1-a467-4a30-a25f-a3b626f07ebd" xlink:href="gild-20201231.xsd#gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_948e2aea-ae5f-4a1b-b443-f19eaaefb49f" xlink:to="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_645b67e1-a467-4a30-a25f-a3b626f07ebd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cf4469ed-ecbe-4f51-8986-cae7208e574e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fd8385ac-244d-46c1-a5db-37d39b0f6fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cf4469ed-ecbe-4f51-8986-cae7208e574e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fd8385ac-244d-46c1-a5db-37d39b0f6fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_dae1cb90-ba21-45c5-9c00-87d6e7e24f50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_cf4469ed-ecbe-4f51-8986-cae7208e574e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_dae1cb90-ba21-45c5-9c00-87d6e7e24f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4e99bed2-017a-466c-a4c9-3d3ce871c1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9552ad57-6057-4f9d-b62c-f65a9ab27044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4e99bed2-017a-466c-a4c9-3d3ce871c1a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9552ad57-6057-4f9d-b62c-f65a9ab27044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6f91b62c-6e57-473a-a8f4-05c7dd033c19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4e99bed2-017a-466c-a4c9-3d3ce871c1a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6f91b62c-6e57-473a-a8f4-05c7dd033c19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_079c74c8-0094-43f6-8d5c-510788e00bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3c6c0502-c30a-4b67-b280-fb5d7c65ad77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_079c74c8-0094-43f6-8d5c-510788e00bc1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3c6c0502-c30a-4b67-b280-fb5d7c65ad77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_086c535b-dcc9-428c-bbbc-6d10b13de914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_079c74c8-0094-43f6-8d5c-510788e00bc1" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_086c535b-dcc9-428c-bbbc-6d10b13de914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f2cb3133-d1d1-43e4-b365-820ff33c632a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9e24e134-8958-43e1-95d0-7bff0f345c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_f2cb3133-d1d1-43e4-b365-820ff33c632a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9e24e134-8958-43e1-95d0-7bff0f345c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2263569d-3692-4a42-bd66-04d795b50fab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_f2cb3133-d1d1-43e4-b365-820ff33c632a" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2263569d-3692-4a42-bd66-04d795b50fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1098f531-a921-470a-9394-8043df6c134b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ce8dd270-7b75-4c66-909d-e355747059d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1098f531-a921-470a-9394-8043df6c134b" xlink:to="loc_us-gaap_DerivativeLiabilities_ce8dd270-7b75-4c66-909d-e355747059d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_d7802190-c4b7-4634-b512-b1b5e2e018c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1098f531-a921-470a-9394-8043df6c134b" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_d7802190-c4b7-4634-b512-b1b5e2e018c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_e2b66fdc-0f72-4b41-90cd-f0024c366156" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1098f531-a921-470a-9394-8043df6c134b" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_e2b66fdc-0f72-4b41-90cd-f0024c366156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_03e41efe-5c6a-450b-ac6c-2ccd6f768542" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9a5bf57f-c042-42ce-a370-0621a98729b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_03e41efe-5c6a-450b-ac6c-2ccd6f768542" xlink:to="loc_us-gaap_DerivativeAssets_9a5bf57f-c042-42ce-a370-0621a98729b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_e8a780b5-b3c0-4427-8942-281f573bf691" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_03e41efe-5c6a-450b-ac6c-2ccd6f768542" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_e8a780b5-b3c0-4427-8942-281f573bf691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_ea2b04b5-9838-47d9-873c-324dd6e84312" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_03e41efe-5c6a-450b-ac6c-2ccd6f768542" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_ea2b04b5-9838-47d9-873c-324dd6e84312" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/Acquisitions" xlink:type="simple" xlink:href="gild-20201231.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AcquisitionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a997317b-8055-4a29-b6d7-5cbcd06d4aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a997317b-8055-4a29-b6d7-5cbcd06d4aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_fbd78027-54c0-4ed0-887c-207fc5fab507" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_fbd78027-54c0-4ed0-887c-207fc5fab507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_498a1f3f-575f-4b75-8495-f6b68730c249" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_498a1f3f-575f-4b75-8495-f6b68730c249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_345ed155-28e0-4557-9af4-a26a048fb7e2" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_345ed155-28e0-4557-9af4-a26a048fb7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_91b0cf9b-0aa0-4f27-a5bc-6b6ea4831cab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_91b0cf9b-0aa0-4f27-a5bc-6b6ea4831cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4b1074cd-551e-44d2-b871-236779ecf1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_4b1074cd-551e-44d2-b871-236779ecf1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6222587e-bdf6-4209-ba59-8dc0fbc4a9fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7bcdbf4c-aa28-4672-9d8f-3f21c2ca859b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6222587e-bdf6-4209-ba59-8dc0fbc4a9fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7c06bb53-25e3-4d64-8d18-1b102da8b5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_66903652-6066-4be4-be5f-916cfd8ebe85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7c06bb53-25e3-4d64-8d18-1b102da8b5b7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_66903652-6066-4be4-be5f-916cfd8ebe85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_25578e8b-cfab-49c7-a216-0680eea41e12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_7c06bb53-25e3-4d64-8d18-1b102da8b5b7" xlink:to="loc_us-gaap_GoodwillGross_25578e8b-cfab-49c7-a216-0680eea41e12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsSupplementalProFormaInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/Inventories" xlink:type="simple" xlink:href="gild-20201231.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesScheduleofinventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipment"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aac67f07-04a5-42d5-9a4d-5f15f84ca07a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_efab2999-fcc4-4e65-a6b8-bf2ce7a8bb40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_aac67f07-04a5-42d5-9a4d-5f15f84ca07a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_efab2999-fcc4-4e65-a6b8-bf2ce7a8bb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a86ec80d-87ee-4a92-ba83-1b05608e0cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_aac67f07-04a5-42d5-9a4d-5f15f84ca07a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a86ec80d-87ee-4a92-ba83-1b05608e0cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1f149927-9d6c-41ec-8f2b-d303fe6c03a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_5f447e0f-452d-4c1b-8aef-caab1ecfded4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1f149927-9d6c-41ec-8f2b-d303fe6c03a2" xlink:to="loc_us-gaap_Land_5f447e0f-452d-4c1b-8aef-caab1ecfded4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_1f632c92-1d89-4311-aca7-7090ba86f757" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1f149927-9d6c-41ec-8f2b-d303fe6c03a2" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_1f632c92-1d89-4311-aca7-7090ba86f757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_c823d578-8896-488d-a94d-e42df512384c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1f149927-9d6c-41ec-8f2b-d303fe6c03a2" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_c823d578-8896-488d-a94d-e42df512384c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_7bd12c30-b920-4871-919d-3cb0eec7139c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1f149927-9d6c-41ec-8f2b-d303fe6c03a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_7bd12c30-b920-4871-919d-3cb0eec7139c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_13fcbe84-cb24-411a-9298-ca87e74a1833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_1f149927-9d6c-41ec-8f2b-d303fe6c03a2" xlink:to="loc_us-gaap_ConstructionInProgressGross_13fcbe84-cb24-411a-9298-ca87e74a1833" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_6bf9b20b-5ced-4ef0-a17b-702a119de5c8" xlink:href="gild-20201231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ea4c268b-1271-4c56-b0d6-db9020fbb239" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_6bf9b20b-5ced-4ef0-a17b-702a119de5c8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ea4c268b-1271-4c56-b0d6-db9020fbb239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c82360ee-40c6-4a78-808f-13832fa40738" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_6bf9b20b-5ced-4ef0-a17b-702a119de5c8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c82360ee-40c6-4a78-808f-13832fa40738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_180da3e3-ca73-4693-976a-196b17c72dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c0d3b417-f0a3-4136-8b6b-1676b22f84d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_180da3e3-ca73-4693-976a-196b17c72dbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c0d3b417-f0a3-4136-8b6b-1676b22f84d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ebdf4406-4701-4ca2-934d-d766e5f9d796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_180da3e3-ca73-4693-976a-196b17c72dbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ebdf4406-4701-4ca2-934d-d766e5f9d796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_69bdd04d-e6c0-483e-888a-d6eb0caa81be" xlink:href="gild-20201231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_180da3e3-ca73-4693-976a-196b17c72dbd" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_69bdd04d-e6c0-483e-888a-d6eb0caa81be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6ef7561b-6f09-43c8-94bd-1044524776a5" xlink:href="gild-20201231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_09dcaa86-d945-4fee-b88a-cefbf45ea9ec" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6ef7561b-6f09-43c8-94bd-1044524776a5" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_09dcaa86-d945-4fee-b88a-cefbf45ea9ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_3ae41b2f-0336-4993-9e34-5e551aa513cc" xlink:href="gild-20201231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6ef7561b-6f09-43c8-94bd-1044524776a5" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_3ae41b2f-0336-4993-9e34-5e551aa513cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_718d19eb-7166-4331-9a61-ec0fb3d34720" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c27c56a-6815-4132-9317-1d67ae1160ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_718d19eb-7166-4331-9a61-ec0fb3d34720" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2c27c56a-6815-4132-9317-1d67ae1160ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_54814dcb-f609-48c6-baa0-6e4833566d94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_718d19eb-7166-4331-9a61-ec0fb3d34720" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_54814dcb-f609-48c6-baa0-6e4833566d94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f18e2d53-632d-46ad-8fb8-8a4222384170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ed14aab0-5901-4149-a6d3-115e998ba39b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f18e2d53-632d-46ad-8fb8-8a4222384170" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ed14aab0-5901-4149-a6d3-115e998ba39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a4643919-81a9-4953-9303-70563f66fc28" xlink:href="gild-20201231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f18e2d53-632d-46ad-8fb8-8a4222384170" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_a4643919-81a9-4953-9303-70563f66fc28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bfaaf52c-ad0e-4b6a-b201-99c4c99a974f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bfaaf52c-ad0e-4b6a-b201-99c4c99a974f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6bd8a0bf-8dcd-44f7-bf26-5d9e71fab2df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6bd8a0bf-8dcd-44f7-bf26-5d9e71fab2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c817fb02-f073-4487-a573-ee522125e4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c817fb02-f073-4487-a573-ee522125e4ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bc1789aa-65fd-4d4a-b2c9-bfb171d0aa64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bc1789aa-65fd-4d4a-b2c9-bfb171d0aa64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_48afa0f5-59c0-4972-8b8d-884e9f7dec1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_48afa0f5-59c0-4972-8b8d-884e9f7dec1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_20116317-0858-4d5f-adf3-8a2b41f0228e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5296c2b6-76ac-4549-9a71-df321894e902" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_20116317-0858-4d5f-adf3-8a2b41f0228e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformation"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8f5dd8eb-b09a-4135-a0c5-275c0b35d160" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_200933b7-64c1-4923-8222-088bb426dc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8f5dd8eb-b09a-4135-a0c5-275c0b35d160" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_200933b7-64c1-4923-8222-088bb426dc4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_c31e0709-1d25-48ae-b86b-87a8d9a28e8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8f5dd8eb-b09a-4135-a0c5-275c0b35d160" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_c31e0709-1d25-48ae-b86b-87a8d9a28e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_aeaeb9f1-b573-476c-9f51-b256ed9f8de6" xlink:href="gild-20201231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8f5dd8eb-b09a-4135-a0c5-275c0b35d160" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_aeaeb9f1-b573-476c-9f51-b256ed9f8de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_9f5a81aa-fa5b-4052-be8a-68136f060c04" xlink:href="gild-20201231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_8f5dd8eb-b09a-4135-a0c5-275c0b35d160" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_9f5a81aa-fa5b-4052-be8a-68136f060c04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d707fba5-8f7a-48c9-82e7-b8fbffb293b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_908a1087-120c-4c2d-8f56-64966a53e122" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d707fba5-8f7a-48c9-82e7-b8fbffb293b8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_908a1087-120c-4c2d-8f56-64966a53e122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_2c226a3e-8496-4453-a21e-a2e101dbafaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d707fba5-8f7a-48c9-82e7-b8fbffb293b8" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_2c226a3e-8496-4453-a21e-a2e101dbafaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_8348ee0d-7e44-4db6-85e5-91327799062f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d707fba5-8f7a-48c9-82e7-b8fbffb293b8" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_8348ee0d-7e44-4db6-85e5-91327799062f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2f438f04-39b9-4954-b431-a07d103a3f89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d707fba5-8f7a-48c9-82e7-b8fbffb293b8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2f438f04-39b9-4954-b431-a07d103a3f89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="gild-20201231.xsd#CollaborationsandOtherArrangements"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilities"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ecac0d09-f94b-488f-bde6-c3374c6d43a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_34cea1ae-eff6-46d2-9375-21f440ca8048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ecac0d09-f94b-488f-bde6-c3374c6d43a7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_34cea1ae-eff6-46d2-9375-21f440ca8048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_162ae815-d523-41a2-98c0-b898044546ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_ecac0d09-f94b-488f-bde6-c3374c6d43a7" xlink:to="loc_us-gaap_LongTermDebtCurrent_162ae815-d523-41a2-98c0-b898044546ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba9829b2-0209-4396-957c-9916916c1e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba9829b2-0209-4396-957c-9916916c1e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e53b4271-2e74-46ce-b3bc-37f2d87e7e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e53b4271-2e74-46ce-b3bc-37f2d87e7e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9472a6e3-3d67-4193-8f52-c8b8b7bacb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9472a6e3-3d67-4193-8f52-c8b8b7bacb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_75cd2731-ccdc-4386-bd16-bc3f52e7485c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_75cd2731-ccdc-4386-bd16-bc3f52e7485c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_56b19967-87a9-4cc7-a862-01fa62c81b45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_56b19967-87a9-4cc7-a862-01fa62c81b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_67db531f-c937-493d-839a-0b4029b44697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1ee9deef-b8ad-4f33-874a-6344c6846787" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_67db531f-c937-493d-839a-0b4029b44697" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Leases" xlink:type="simple" xlink:href="gild-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesBalanceSheetLocationDetailDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSupplementalInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ba35308b-9bf7-4923-babd-2a36c4130695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b78a210-036d-4fc7-8f4a-82dc0ec7eeaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ba35308b-9bf7-4923-babd-2a36c4130695" xlink:to="loc_us-gaap_OperatingLeaseLiability_0b78a210-036d-4fc7-8f4a-82dc0ec7eeaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84be2a5b-372b-4b57-a8c8-c2caceb0d02e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ba35308b-9bf7-4923-babd-2a36c4130695" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_84be2a5b-372b-4b57-a8c8-c2caceb0d02e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dafcae70-a40c-42e8-9ae8-b2f71754ae33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dafcae70-a40c-42e8-9ae8-b2f71754ae33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c341cced-d67c-4ddf-a31a-6f45256d36bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c341cced-d67c-4ddf-a31a-6f45256d36bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f00af70-0776-4b28-a2dd-245a33da11c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6f00af70-0776-4b28-a2dd-245a33da11c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b908605d-1922-4c04-823b-7034137601a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b908605d-1922-4c04-823b-7034137601a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9227d742-bea7-4f4b-9495-208503cd0cac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9227d742-bea7-4f4b-9495-208503cd0cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8bab8f7-9876-43bd-8847-7fbeae54c587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9e93bf27-5c43-4201-a890-f95b169d0e5d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a8bab8f7-9876-43bd-8847-7fbeae54c587" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gild-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#CommitmentsandContingenciesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityDividendsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d980395-6e92-415a-bd07-dbce0a30926b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_dfbf8a42-bcf7-4ef4-8706-e1bddf872eab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d980395-6e92-415a-bd07-dbce0a30926b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_dfbf8a42-bcf7-4ef4-8706-e1bddf872eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c670492e-6f62-4c01-8c67-1e69d2059ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6d980395-6e92-415a-bd07-dbce0a30926b" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_c670492e-6f62-4c01-8c67-1e69d2059ee9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefits"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefits" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2328d4fb-8ee5-4d10-a512-6833646bbb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_972b7183-131a-4833-a7f3-caf2cb3a8f65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2328d4fb-8ee5-4d10-a512-6833646bbb8c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_972b7183-131a-4833-a7f3-caf2cb3a8f65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_eb00ed37-1f07-4245-b0b8-3f1b1fb2ffb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2328d4fb-8ee5-4d10-a512-6833646bbb8c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_eb00ed37-1f07-4245-b0b8-3f1b1fb2ffb4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholders"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0be5e128-b598-4b39-af03-c94d702df1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fdaa92c-e84d-4728-ab4a-ba0658d52198" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0be5e128-b598-4b39-af03-c94d702df1ac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fdaa92c-e84d-4728-ab4a-ba0658d52198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_75479416-b006-470d-89d5-c2c8238563b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0be5e128-b598-4b39-af03-c94d702df1ac" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_75479416-b006-470d-89d5-c2c8238563b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ff48a3f9-ec18-444a-8bd9-68ec624acdda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70519f9d-e289-42d7-b2c0-9288bd222689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ff48a3f9-ec18-444a-8bd9-68ec624acdda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_70519f9d-e289-42d7-b2c0-9288bd222689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_609b1605-c929-4192-978e-76cac48b22d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ff48a3f9-ec18-444a-8bd9-68ec624acdda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_609b1605-c929-4192-978e-76cac48b22d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0854801a-daef-4dba-b803-4571ce34c1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_2364bf9c-1d0b-4ecf-941b-908e85422734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0854801a-daef-4dba-b803-4571ce34c1ee" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_2364bf9c-1d0b-4ecf-941b-908e85422734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_4e45e8a6-a61b-46b9-9c82-01079d8b5e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0854801a-daef-4dba-b803-4571ce34c1ee" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_4e45e8a6-a61b-46b9-9c82-01079d8b5e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_bad76be7-525a-430b-b007-19fc2ae86fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0854801a-daef-4dba-b803-4571ce34c1ee" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_bad76be7-525a-430b-b007-19fc2ae86fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_19033706-5ce7-40c7-9353-6f78082f9a58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5a7f5a38-ee43-405d-a7ea-b72e5798478b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_19033706-5ce7-40c7-9353-6f78082f9a58" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5a7f5a38-ee43-405d-a7ea-b72e5798478b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_61079127-24e9-4c48-94b9-32b80213a317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_19033706-5ce7-40c7-9353-6f78082f9a58" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_61079127-24e9-4c48-94b9-32b80213a317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_e1b71c42-fe7e-4b2f-8208-dd2a996cb57b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f0dee846-aaa7-414e-9ef3-5eda3eb705b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_e1b71c42-fe7e-4b2f-8208-dd2a996cb57b" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f0dee846-aaa7-414e-9ef3-5eda3eb705b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_605cfe46-c89f-4c66-86f9-3402eb551583" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_e1b71c42-fe7e-4b2f-8208-dd2a996cb57b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_605cfe46-c89f-4c66-86f9-3402eb551583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_6cbd2aff-b577-4ea7-9bc8-648f4b53e435" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_592e44b9-0fd6-496e-abe5-9ddb66e48edd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_6cbd2aff-b577-4ea7-9bc8-648f4b53e435" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_592e44b9-0fd6-496e-abe5-9ddb66e48edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_67820bef-6a34-4ede-bf9b-3c4ecd87a644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_6cbd2aff-b577-4ea7-9bc8-648f4b53e435" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_67820bef-6a34-4ede-bf9b-3c4ecd87a644" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1d45f5e7-a763-4f8d-85d0-b6c25a287c43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1d45f5e7-a763-4f8d-85d0-b6c25a287c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0557cf88-b0df-4c6d-9eaf-7affbe89b3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0557cf88-b0df-4c6d-9eaf-7affbe89b3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_60677140-7761-40b9-acb8-dcb94f8d201f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_60677140-7761-40b9-acb8-dcb94f8d201f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_914d39f0-e75f-474c-a785-0fba21ad40ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_914d39f0-e75f-474c-a785-0fba21ad40ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_447ed89c-2b88-434b-84d3-7b0b34333b41" xlink:href="gild-20201231.xsd#gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_447ed89c-2b88-434b-84d3-7b0b34333b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb3a4e0c-6319-44cc-ba57-a147f1bd0e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb3a4e0c-6319-44cc-ba57-a147f1bd0e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e90126de-0c74-4317-99eb-d9b4e1e3073e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e90126de-0c74-4317-99eb-d9b4e1e3073e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_9eba9f5a-a262-434d-ba4c-bd39de6b82a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_9eba9f5a-a262-434d-ba4c-bd39de6b82a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_61d0f648-91ae-47ae-b55f-e2c249c22e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_61d0f648-91ae-47ae-b55f-e2c249c22e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_11bc5b0a-fa4b-45d1-8dfd-feec3d29b98a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_11bc5b0a-fa4b-45d1-8dfd-feec3d29b98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_aacce517-d573-4db6-8b9f-93b183f30188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b887059-f144-4ef1-bafc-005abe25c560" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_aacce517-d573-4db6-8b9f-93b183f30188" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_bd09155b-e7d5-4dbb-8157-f492469574b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3e5bd0e5-2ec3-466e-80fa-eac8afc48fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bd09155b-e7d5-4dbb-8157-f492469574b1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3e5bd0e5-2ec3-466e-80fa-eac8afc48fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c087f6ec-243f-463a-9329-d2462a8b13f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_bd09155b-e7d5-4dbb-8157-f492469574b1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c087f6ec-243f-463a-9329-d2462a8b13f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2813dddf-4d88-4f10-a36c-cd345dc166c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f8cf782c-5d01-4e91-a3fb-db937fbbc4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2813dddf-4d88-4f10-a36c-cd345dc166c0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f8cf782c-5d01-4e91-a3fb-db937fbbc4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_291a17c6-4c41-41a9-bb90-23d7c165cdec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2813dddf-4d88-4f10-a36c-cd345dc166c0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_291a17c6-4c41-41a9-bb90-23d7c165cdec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8ff0cf4a-1f03-4b08-9965-e89afdee0bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6378cbe-9634-49c8-b9de-143589d1617d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8ff0cf4a-1f03-4b08-9965-e89afdee0bbb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e6378cbe-9634-49c8-b9de-143589d1617d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7c770da9-8110-480d-a4b8-b8d5d23f6e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8ff0cf4a-1f03-4b08-9965-e89afdee0bbb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7c770da9-8110-480d-a4b8-b8d5d23f6e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f901d8e4-50e0-46d2-8bfb-967cdd13be37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f901d8e4-50e0-46d2-8bfb-967cdd13be37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f37e8bcf-76c1-494e-b04e-217f4062295c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f37e8bcf-76c1-494e-b04e-217f4062295c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_131a0a47-e105-4c84-99d4-7078387f5153" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_131a0a47-e105-4c84-99d4-7078387f5153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_cd45b6b0-81d7-4e40-beaf-2e9fd645a658" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_cd45b6b0-81d7-4e40-beaf-2e9fd645a658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_21b96bd4-9480-442a-879a-762a8b827a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_21b96bd4-9480-442a-879a-762a8b827a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ffb2db1c-98e0-4bcf-854e-f012383522c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_ffb2db1c-98e0-4bcf-854e-f012383522c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_74e522eb-b277-4b0e-8d6c-8f47f112e222" xlink:href="gild-20201231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_74e522eb-b277-4b0e-8d6c-8f47f112e222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_61c8974a-2b7d-4bb4-83fb-b1278bf177f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_61c8974a-2b7d-4bb4-83fb-b1278bf177f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_893b4806-3b20-404e-9fa0-231fe058efca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8dafcea5-6d88-4eed-a6c6-e7a184548605" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_893b4806-3b20-404e-9fa0-231fe058efca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_872b591e-9b4b-4f31-acfe-d6f8ae1e3fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e719757a-650f-4eb6-83a3-d92838aa5863" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_872b591e-9b4b-4f31-acfe-d6f8ae1e3fbc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e719757a-650f-4eb6-83a3-d92838aa5863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8b6c6231-8d16-42c6-9f19-7d6763b62e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_872b591e-9b4b-4f31-acfe-d6f8ae1e3fbc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8b6c6231-8d16-42c6-9f19-7d6763b62e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d967a611-d156-4f81-915c-2534d1362b17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_872b591e-9b4b-4f31-acfe-d6f8ae1e3fbc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d967a611-d156-4f81-915c-2534d1362b17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnaudited"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>gild-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c95e6174-aa16-488c-b0f6-cc28c1f33ed5,g:86b29b2d-a791-4b12-a644-3051a1d6b3ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/Cover" xlink:type="simple" xlink:href="gild-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/Cover" xlink:type="extended" id="i6d707e8516374473be027234ea767cba_Cover"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i6b3d1d2fe2384ed6833c18304d356aa8_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i373e644120e3463cb49795f0a0fb8326_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="ib14e6c531c544dc6a93e62040a45da73_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_93ed57e8-f0c6-4396-a6b3-7adbd4056b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_RevenuesAbstract_93ed57e8-f0c6-4396-a6b3-7adbd4056b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1536cc22-3c16-4ad9-881f-6eb21463fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_93ed57e8-f0c6-4396-a6b3-7adbd4056b7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1536cc22-3c16-4ad9-881f-6eb21463fd71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_bdeb5a64-d9f7-48ba-9894-97ada93e0091" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_bdeb5a64-d9f7-48ba-9894-97ada93e0091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_192e7dcf-f150-4b86-ab24-a93b0c2e33bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_192e7dcf-f150-4b86-ab24-a93b0c2e33bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_dbc47daf-93df-4bdd-a853-036204c91d90" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_dbc47daf-93df-4bdd-a853-036204c91d90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bf2a7bb-6547-4434-84be-1756e147af3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bf2a7bb-6547-4434-84be-1756e147af3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a1f62e4d-3b62-4799-becc-83e06c49f7df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_CostsAndExpenses_a1f62e4d-3b62-4799-becc-83e06c49f7df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_954fd858-5fd9-45e8-a7cb-787c74b12061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_OperatingIncomeLoss_954fd858-5fd9-45e8-a7cb-787c74b12061" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5fc5b46-45d0-4994-b284-c3ed7c1511a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_InterestExpense_f5fc5b46-45d0-4994-b284-c3ed7c1511a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5e32f89a-db7e-49ee-846e-8677b3215067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5e32f89a-db7e-49ee-846e-8677b3215067" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e045f24a-97ef-47d1-bab0-529d3cd0c6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e045f24a-97ef-47d1-bab0-529d3cd0c6e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0130731b-abf4-416f-bf9b-cdd16859088f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0130731b-abf4-416f-bf9b-cdd16859088f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8d95fdb5-6760-43a3-a0b3-4dee023894ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_ProfitLoss_8d95fdb5-6760-43a3-a0b3-4dee023894ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9db62a9a-37da-4471-9a1d-ce7a769aeae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9db62a9a-37da-4471-9a1d-ce7a769aeae4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6d77ad9-7c16-4998-98a0-b562201635cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_NetIncomeLoss_a6d77ad9-7c16-4998-98a0-b562201635cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_de903cf3-f19e-4184-96b5-b20440c2a9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_EarningsPerShareBasic_de903cf3-f19e-4184-96b5-b20440c2a9ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cb103b0d-0178-46c9-9ccb-dab1bd11d2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cb103b0d-0178-46c9-9ccb-dab1bd11d2fb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eec6e7b3-c7a0-43ce-9d2f-5ba78435621d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eec6e7b3-c7a0-43ce-9d2f-5ba78435621d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74421a28-1033-48a2-8d47-7eea7b1e7978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74421a28-1033-48a2-8d47-7eea7b1e7978" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:to="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a5ce1ed-2242-402c-b07b-796581dd4fd9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:to="loc_srt_ProductsAndServicesDomain_2a5ce1ed-2242-402c-b07b-796581dd4fd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:to="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_60216d46-8fb9-415d-bec9-d05cb856385f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:to="loc_us-gaap_ProductMember_60216d46-8fb9-415d-bec9-d05cb856385f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_2c7d669f-4877-4b7c-b02b-b8ca6d3e42f9" xlink:href="gild-20201231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:to="loc_gild_RoyaltyContractAndOtherMember_2c7d669f-4877-4b7c-b02b-b8ca6d3e42f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="i7113ee0487f54e1d953add748cc01164_ConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i86bcfb46b0e542e08d27910560d5d23e_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0d0c0ea0-95aa-4655-a3b9-fad58f8073cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0d0c0ea0-95aa-4655-a3b9-fad58f8073cb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21d13480-1708-4243-8d39-bf2b1db344c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21d13480-1708-4243-8d39-bf2b1db344c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6cc3b75c-711c-42c1-affa-4fabebda03f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6cc3b75c-711c-42c1-affa-4fabebda03f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3c97efd7-bbae-4f26-9ca6-214a3323252d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3c97efd7-bbae-4f26-9ca6-214a3323252d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_09d6fcdf-66f5-4d59-a8c5-cca1a3365cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_09d6fcdf-66f5-4d59-a8c5-cca1a3365cfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28306820-31ea-40bc-bb50-46032b0911f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_ProfitLoss_28306820-31ea-40bc-bb50-46032b0911f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6acb7be9-cf95-4130-a1e0-656216023d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6acb7be9-cf95-4130-a1e0-656216023d8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f6fe1ca6-1279-4fff-ab25-dd615ae38f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f6fe1ca6-1279-4fff-ab25-dd615ae38f1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8691cf6a-aaf4-4eb5-88f5-1c7177d42e63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8691cf6a-aaf4-4eb5-88f5-1c7177d42e63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d308d818-aca3-4ebd-9ca8-ef22daec3a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d308d818-aca3-4ebd-9ca8-ef22daec3a8d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824faff8-2496-4812-997f-a5242692108e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824faff8-2496-4812-997f-a5242692108e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7c201ec2-14c2-4102-bc5b-fea3a755bbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7c201ec2-14c2-4102-bc5b-fea3a755bbf9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f292961-7b5d-4509-89a4-b0c834cef9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f292961-7b5d-4509-89a4-b0c834cef9bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_5a79596c-f15a-4f9e-9b0b-81bdaf3a5423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_5a79596c-f15a-4f9e-9b0b-81bdaf3a5423" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_47c1c3a2-2b25-408e-9c82-fcea43bf5c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_Dividends_47c1c3a2-2b25-408e-9c82-fcea43bf5c2f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ea6c844-a603-4330-a210-5e20117abd84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df4162c3-088f-4c3b-8282-19b8735d2209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0d0c0ea0-95aa-4655-a3b9-fad58f8073cb" xlink:to="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_82cd32bc-9fe2-4134-9d6e-187511d5a4a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_82cd32bc-9fe2-4134-9d6e-187511d5a4a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_24a04f08-6f2c-46f0-8759-8bedd99f5cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_24a04f08-6f2c-46f0-8759-8bedd99f5cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_c103acf1-6135-4e85-814d-6c59463603dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_c103acf1-6135-4e85-814d-6c59463603dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_b685d388-6d55-4c2f-a8fc-9dd6b5118bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_b685d388-6d55-4c2f-a8fc-9dd6b5118bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:to="loc_us-gaap_EquityComponentDomain_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:to="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_089df8b9-9964-480e-bb70-889bfb6d5d47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_CommonStockMember_089df8b9-9964-480e-bb70-889bfb6d5d47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d6f941d1-78c8-4de8-9bd7-99e0a94ac64a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d6f941d1-78c8-4de8-9bd7-99e0a94ac64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7a0714c5-1d18-4fe0-b554-2b2138b1c394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7a0714c5-1d18-4fe0-b554-2b2138b1c394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_160201e0-4e10-406b-9ac0-05376a838923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_RetainedEarningsMember_160201e0-4e10-406b-9ac0-05376a838923" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_5b7c1496-4682-4a40-bfc4-6f462bbc6e75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_NoncontrollingInterestMember_5b7c1496-4682-4a40-bfc4-6f462bbc6e75" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="ifcc8746bebbb4d1f8526d39ecbb57b22_ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i7909f8284e254b09a523ca62b04eb81e_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i1b79aaa9485b4e2382edfc746a4c5acd_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ie953280a3bbd48428ed90e5ac0a2d149_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i8c3c9d1a14404536b97a8a98c97a4aeb_OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i4e7bbed56777427d85a301296d08ced8_OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:href="gild-20201231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_36ad7ea1-9c6b-416e-bc42-3a341e67ea78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_us-gaap_AdvertisingExpense_36ad7ea1-9c6b-416e-bc42-3a341e67ea78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8236c826-03cb-4a12-bb5e-844591beef68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8236c826-03cb-4a12-bb5e-844591beef68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_789765a6-c8a0-43bd-83c7-f26a33cdbb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_789765a6-c8a0-43bd-83c7-f26a33cdbb8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:href="gild-20201231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:to="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e887ff7c-edec-4810-91fb-10520ea015bb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:to="loc_srt_RangeMember_e887ff7c-edec-4810-91fb-10520ea015bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:to="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8191961b-0622-4174-86da-5c8f98dd5198" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:to="loc_srt_MinimumMember_8191961b-0622-4174-86da-5c8f98dd5198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d32ab6d7-13ea-4f97-a682-02cdb35770a4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:to="loc_srt_MaximumMember_d32ab6d7-13ea-4f97-a682-02cdb35770a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6be1f0ed-5091-42df-9b5c-3723cde1338f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6be1f0ed-5091-42df-9b5c-3723cde1338f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ac5beec3-5736-46f0-bc5a-eb9c72384d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ac5beec3-5736-46f0-bc5a-eb9c72384d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_cf02f6a0-2d03-46c6-8355-2d6a09f2432d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_cf02f6a0-2d03-46c6-8355-2d6a09f2432d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3e4629db-f6cc-4e27-8edf-fde6704c8ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:to="loc_us-gaap_ComputerEquipmentMember_3e4629db-f6cc-4e27-8edf-fde6704c8ac4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Revenues" xlink:type="simple" xlink:href="gild-20201231.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/Revenues" xlink:type="extended" id="ife791af2ea3b4016b71dec4aa5e23894_Revenues"/>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesTables" xlink:type="extended" id="i2b3db61289f34dda9aedf3accf1061a4_RevenuesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended" id="i021d7bd81bcc421daa168e11566b6dd5_RevenuesDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880f2156-7ec4-4139-8659-144d1f2da59e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880f2156-7ec4-4139-8659-144d1f2da59e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0d44816a-f456-42bf-aa7e-74d664b93750" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:to="loc_us-gaap_Revenues_0d44816a-f456-42bf-aa7e-74d664b93750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:to="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a017e93-7af5-41b7-a133-40761101d586_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:to="loc_srt_ProductsAndServicesDomain_5a017e93-7af5-41b7-a133-40761101d586_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:to="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:to="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:href="gild-20201231.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_368d8662-c327-45b0-90df-a5e8625be6ea" xlink:href="gild-20201231.xsd#gild_HIVProductsAtriplaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsAtriplaMember_368d8662-c327-45b0-90df-a5e8625be6ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_1f6002a6-5837-4da6-857f-743488283650" xlink:href="gild-20201231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsBiktarvyMember_1f6002a6-5837-4da6-857f-743488283650" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_080ec4fb-9b46-4001-831c-dc0d9e25ca85" xlink:href="gild-20201231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_080ec4fb-9b46-4001-831c-dc0d9e25ca85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_b52e904a-3f58-4aab-a812-b947f108bf50" xlink:href="gild-20201231.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsDescovyMember_b52e904a-3f58-4aab-a812-b947f108bf50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_7c6513b3-f008-47b4-97b0-914e4d729ee7" xlink:href="gild-20201231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsGenvoyaMember_7c6513b3-f008-47b4-97b0-914e4d729ee7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_4bda15be-46c7-4b11-a8ad-c618ef39f8b9" xlink:href="gild-20201231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsOdefseyMember_4bda15be-46c7-4b11-a8ad-c618ef39f8b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_4fde103f-35b7-45c3-a034-73d8dc25a7b0" xlink:href="gild-20201231.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsStribildMember_4fde103f-35b7-45c3-a034-73d8dc25a7b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_f77cc515-09c1-4fdd-b4a4-e6cb521ba1de" xlink:href="gild-20201231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsTruvadaMember_f77cc515-09c1-4fdd-b4a4-e6cb521ba1de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_bc6c5df7-4533-4794-977f-8af1b1c8e53f" xlink:href="gild-20201231.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_ProductsOtherHIVMember_bc6c5df7-4533-4794-977f-8af1b1c8e53f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_eff57357-8670-4e6d-941f-275b913388ad" xlink:href="gild-20201231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_eff57357-8670-4e6d-941f-275b913388ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:href="gild-20201231.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_f0c464b6-26ea-4970-9281-70da529a7452" xlink:href="gild-20201231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_f0c464b6-26ea-4970-9281-70da529a7452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_77599a6a-d31c-4f6f-aaf7-c613760b6c4c" xlink:href="gild-20201231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_77599a6a-d31c-4f6f-aaf7-c613760b6c4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember_ab762c4b-e9cb-4e09-920c-3172502d5d92" xlink:href="gild-20201231.xsd#gild_OtherHCVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:to="loc_gild_OtherHCVMember_ab762c4b-e9cb-4e09-920c-3172502d5d92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_COVID19ProductsVekluryMember_a0c7d01b-d8ac-46eb-905c-0deff12c904a" xlink:href="gild-20201231.xsd#gild_COVID19ProductsVekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_COVID19ProductsVekluryMember_a0c7d01b-d8ac-46eb-905c-0deff12c904a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:href="gild-20201231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember_c1681003-b568-4026-9aa3-59eeec8b213c" xlink:href="gild-20201231.xsd#gild_OtherProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:to="loc_gild_OtherProductsYescartaMember_c1681003-b568-4026-9aa3-59eeec8b213c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CallTherapyProductsTecartusMember_bddf08d1-ea9f-4135-bbb5-a6c17fe96b8c" xlink:href="gild-20201231.xsd#gild_CallTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:to="loc_gild_CallTherapyProductsTecartusMember_bddf08d1-ea9f-4135-bbb5-a6c17fe96b8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_COVID19ProductsTrodelvyMember_574a568d-6e38-4275-9885-fc402583e8f6" xlink:href="gild-20201231.xsd#gild_COVID19ProductsTrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_COVID19ProductsTrodelvyMember_574a568d-6e38-4275-9885-fc402583e8f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:href="gild-20201231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_be48c6b8-850b-4c89-80ee-f637ac2fd15a" xlink:href="gild-20201231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsAmBisomeMember_be48c6b8-850b-4c89-80ee-f637ac2fd15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_d5709489-81c7-494c-a844-eaab18e0948d" xlink:href="gild-20201231.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsLetairisMember_d5709489-81c7-494c-a844-eaab18e0948d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_d3dd4caf-77e2-4b06-b186-54a8fd758b6e" xlink:href="gild-20201231.xsd#gild_OtherProductsRanexaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsRanexaMember_d3dd4caf-77e2-4b06-b186-54a8fd758b6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsVemlidyMember_206f28e1-cb1b-4354-9517-daa50613e5df" xlink:href="gild-20201231.xsd#gild_OtherProductsVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsVemlidyMember_206f28e1-cb1b-4354-9517-daa50613e5df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsVireadMember_f0d7fd73-b1a2-4cb0-b09f-7e47b0b83f0c" xlink:href="gild-20201231.xsd#gild_OtherProductsVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsVireadMember_f0d7fd73-b1a2-4cb0-b09f-7e47b0b83f0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_acbbfaef-dabb-4dfb-9829-25c7f389490b" xlink:href="gild-20201231.xsd#gild_OtherProductsZydeligMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsZydeligMember_acbbfaef-dabb-4dfb-9829-25c7f389490b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_93db3286-8a0c-4108-a02e-8c31de67f178" xlink:href="gild-20201231.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsOtherMember_93db3286-8a0c-4108-a02e-8c31de67f178" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_757bcfa7-c550-45c4-b19b-2ada43efa2db" xlink:href="gild-20201231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:to="loc_gild_RoyaltyContractAndOtherMember_757bcfa7-c550-45c4-b19b-2ada43efa2db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:to="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1fb83a76-4e2e-4512-ae20-d534ccd62818_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:to="loc_srt_SegmentGeographicalDomain_1fb83a76-4e2e-4512-ae20-d534ccd62818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:to="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1eaa1c97-405a-4bff-b359-fdfdb51e86cc" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:to="loc_country_US_1eaa1c97-405a-4bff-b359-fdfdb51e86cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c9243d31-302f-415c-a988-4ace5250d280" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:to="loc_srt_EuropeMember_c9243d31-302f-415c-a988-4ace5250d280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_99bc083e-971f-4d00-9b11-a112c429f831" xlink:href="gild-20201231.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:to="loc_gild_OtherInternationalMember_99bc083e-971f-4d00-9b11-a112c429f831" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i2df70ecea9a644ef9ca51c952c499864_RevenuesSummarizedRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_644c49d5-1cee-4794-bcf5-1615dc1cbcda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a55dcc38-3a3f-48e0-bf3c-73392794036e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_644c49d5-1cee-4794-bcf5-1615dc1cbcda" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a55dcc38-3a3f-48e0-bf3c-73392794036e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_644c49d5-1cee-4794-bcf5-1615dc1cbcda" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_045dc333-9307-4007-bf3f-f1814efc3d46_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_045dc333-9307-4007-bf3f-f1814efc3d46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_34601b13-f56c-42ba-95b5-5c208912ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_34601b13-f56c-42ba-95b5-5c208912ff1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_e6d27ecd-0504-44ed-b65e-aec94a2cf000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_34601b13-f56c-42ba-95b5-5c208912ff1a" xlink:to="loc_us-gaap_SalesRevenueNetMember_e6d27ecd-0504-44ed-b65e-aec94a2cf000" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c777ca4c-cabb-4884-9e1b-01e4401a5cbb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c777ca4c-cabb-4884-9e1b-01e4401a5cbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_40c84e42-b1cc-4a00-b011-b812b81508d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_40c84e42-b1cc-4a00-b011-b812b81508d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e210b231-7888-4d34-b65b-37bc3532bd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_40c84e42-b1cc-4a00-b011-b812b81508d2" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e210b231-7888-4d34-b65b-37bc3532bd3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_88443f9d-bcb2-41e5-9aae-e5c8a871ab32_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:to="loc_srt_NameOfMajorCustomerDomain_88443f9d-bcb2-41e5-9aae-e5c8a871ab32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:to="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_49c5b04c-c3db-4dae-969d-fde988f4654e" xlink:href="gild-20201231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:to="loc_gild_AmerisourcebergenCorpMember_49c5b04c-c3db-4dae-969d-fde988f4654e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_80c82a56-d695-48eb-b40d-b90b2b1495a6" xlink:href="gild-20201231.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:to="loc_gild_CardinalHealthIncMember_80c82a56-d695-48eb-b40d-b90b2b1495a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_ee433998-32cc-4d9b-9d26-86c2c8d24a4b" xlink:href="gild-20201231.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:to="loc_gild_MckessonCorpMember_ee433998-32cc-4d9b-9d26-86c2c8d24a4b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i6a736145ef3b4a2da0bd6260ea4d5069_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:href="gild-20201231.xsd#gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_510213d3-ec54-4af1-a40f-02ac7043775f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_510213d3-ec54-4af1-a40f-02ac7043775f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5bf1ac3b-05d8-418f-a897-a086da74fe34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5bf1ac3b-05d8-418f-a897-a086da74fe34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e49c64c-78a8-416c-8933-f063356fcd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e49c64c-78a8-416c-8933-f063356fcd0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:href="gild-20201231.xsd#gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:to="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_dfef2168-ca87-4b7f-9336-bd0992f0d0c8_default" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:to="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_dfef2168-ca87-4b7f-9336-bd0992f0d0c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:to="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_b56bcb10-e20b-43ba-9477-ff5b5843a4e0" xlink:href="gild-20201231.xsd#gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:to="loc_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_b56bcb10-e20b-43ba-9477-ff5b5843a4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ChangeinestimatevariableconsiderationMember_7c619aa7-fb9f-4e32-bdce-13d5fcde074f" xlink:href="gild-20201231.xsd#gild_ChangeinestimatevariableconsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:to="loc_gild_ChangeinestimatevariableconsiderationMember_7c619aa7-fb9f-4e32-bdce-13d5fcde074f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurements" xlink:type="extended" id="i7d19debeaf8e4a4da98c8fd424d22c9e_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="extended" id="id2313e1e4aa14979875f9a75ecacfef1_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" xlink:type="extended" id="if2ac626abc274a29befa6d64dbe4748c_FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:to="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11b8a46a-749f-42e6-baa7-ab081f1adce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11b8a46a-749f-42e6-baa7-ab081f1adce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_40fcf00a-a223-4c6c-bac5-c8987b1b3058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_40fcf00a-a223-4c6c-bac5-c8987b1b3058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_0571c1bc-cfa8-49e9-a14b-8c8a25d50b61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_0571c1bc-cfa8-49e9-a14b-8c8a25d50b61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_337b890f-d1cb-477c-b456-92264e3ccde1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_337b890f-d1cb-477c-b456-92264e3ccde1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:to="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_0bfdf52f-f53b-406a-a63f-c61cd360bdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_0bfdf52f-f53b-406a-a63f-c61cd360bdb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3505f633-ddee-49f9-a3d8-17ee008a24a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3505f633-ddee-49f9-a3d8-17ee008a24a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_36b391d8-8532-4517-b781-dfe9df40db0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_36b391d8-8532-4517-b781-dfe9df40db0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_df4df4ca-3d26-40cd-aae0-e659689edeb2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_df4df4ca-3d26-40cd-aae0-e659689edeb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dedd5694-84a2-4549-a55e-7888213d46d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dedd5694-84a2-4549-a55e-7888213d46d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d9b91c12-c043-4f4a-a422-bd0636609e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dedd5694-84a2-4549-a55e-7888213d46d7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d9b91c12-c043-4f4a-a422-bd0636609e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fe27cdb8-c29f-4525-9da5-c7f76e7d8338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fe27cdb8-c29f-4525-9da5-c7f76e7d8338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2ead9c12-71c9-4091-a6d2-41a7a81afdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2ead9c12-71c9-4091-a6d2-41a7a81afdb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_22a48b89-795f-404e-bf5e-ca5fac873792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_22a48b89-795f-404e-bf5e-ca5fac873792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8636d83d-2ba8-4088-a07f-94b5dfd859b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8636d83d-2ba8-4088-a07f-94b5dfd859b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_34a2c77c-264c-4d52-b0ca-21b3e8908b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_34a2c77c-264c-4d52-b0ca-21b3e8908b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e7ae6347-88c8-4fd7-98b0-36b8a61300db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_34a2c77c-264c-4d52-b0ca-21b3e8908b66" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e7ae6347-88c8-4fd7-98b0-36b8a61300db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1cf0c581-f64a-46ec-92b0-104028d0c741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e7ae6347-88c8-4fd7-98b0-36b8a61300db" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1cf0c581-f64a-46ec-92b0-104028d0c741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_148616e2-2208-4f08-9b17-3d5ae85fad44_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_148616e2-2208-4f08-9b17-3d5ae85fad44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_93b23ccf-1b68-4714-bfa7-26edcbedc49d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_93b23ccf-1b68-4714-bfa7-26edcbedc49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_199ef9c6-a874-451d-bfb5-c335afccbace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_199ef9c6-a874-451d-bfb5-c335afccbace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79d79a58-7a27-4aeb-a6f9-74a2df192b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79d79a58-7a27-4aeb-a6f9-74a2df192b1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a69d691c-15eb-4517-94bf-0402271c9bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a69d691c-15eb-4517-94bf-0402271c9bad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_33d4956e-516c-4d10-9d60-a5761ab9e55f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_33d4956e-516c-4d10-9d60-a5761ab9e55f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_7a40644b-cc64-42a1-a784-d1de2881fa2d" xlink:href="gild-20201231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_7a40644b-cc64-42a1-a784-d1de2881fa2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember_ad7e725d-911a-4c6f-8be8-9e41b008a62d" xlink:href="gild-20201231.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_EquityinvestmentinGalapagosMember_ad7e725d-911a-4c6f-8be8-9e41b008a62d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_21e96404-f56a-4dec-ae27-173aa2d96ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_21e96404-f56a-4dec-ae27-173aa2d96ab1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_100ae98c-eb92-482c-a230-32cce73d25d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_EquitySecuritiesMember_100ae98c-eb92-482c-a230-32cce73d25d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_b7f4f2ef-8fb8-4d05-9c3c-f5b896f9f890" xlink:href="gild-20201231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_DeferredCompensationPlanMember_b7f4f2ef-8fb8-4d05-9c3c-f5b896f9f890" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_435f0209-0d31-4d2f-80c2-3b27024fae24" xlink:href="gild-20201231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_435f0209-0d31-4d2f-80c2-3b27024fae24" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i0da14acd9d334a4786f38165034cf7c4_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a553f87-ca7d-4fee-ade4-428912980562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a553f87-ca7d-4fee-ade4-428912980562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8572c0ee-0b4e-4df9-b8d9-8528938b3a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8572c0ee-0b4e-4df9-b8d9-8528938b3a5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_bbb27a1d-8f09-4972-80ec-752a06a30132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_bbb27a1d-8f09-4972-80ec-752a06a30132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_823aa7b7-a835-46e8-86ab-f6ac960e5316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_823aa7b7-a835-46e8-86ab-f6ac960e5316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_0935042d-61cf-409a-b1dc-379be37d3811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_LongTermDebtFairValue_0935042d-61cf-409a-b1dc-379be37d3811" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_30acdbfe-3484-4006-a041-45ac2d284eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_30acdbfe-3484-4006-a041-45ac2d284eb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96d7aa3c-2e6c-49ff-ad9c-33707c2eb376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96d7aa3c-2e6c-49ff-ad9c-33707c2eb376" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5039fd0a-daac-4eb3-bf0c-df48068ed0cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_5039fd0a-daac-4eb3-bf0c-df48068ed0cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_63eb2df6-bce0-4216-a445-f035a2cb7258" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_63eb2df6-bce0-4216-a445-f035a2cb7258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_63eb2df6-bce0-4216-a445-f035a2cb7258" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_981bfa6a-0bfa-48e8-a022-e08922bbbafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_981bfa6a-0bfa-48e8-a022-e08922bbbafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d185335f-d8fe-44de-b5f2-30c4ef0742f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d185335f-d8fe-44de-b5f2-30c4ef0742f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_654f1cae-6282-4079-8cd4-e9ceb38fcb54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_654f1cae-6282-4079-8cd4-e9ceb38fcb54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a8e08d1c-ebb2-4e51-8ef5-4e7a7c841065" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a8e08d1c-ebb2-4e51-8ef5-4e7a7c841065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c93f262f-b798-4f17-bd51-f64da88d2161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c93f262f-b798-4f17-bd51-f64da88d2161" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="extended" id="ifb1cfb12228a42f2844e9621ab8b3f7a_FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_50bfac5e-a66d-4fda-ab58-e75b6d16986b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_50bfac5e-a66d-4fda-ab58-e75b6d16986b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b540e53a-abf4-4fcc-af45-3783485907d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b540e53a-abf4-4fcc-af45-3783485907d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7238a851-009d-459e-96e2-06bd0d870782_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7238a851-009d-459e-96e2-06bd0d870782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1d394301-b3a8-4caa-86e0-1fb655a23c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1d394301-b3a8-4caa-86e0-1fb655a23c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_91dd4350-3137-495d-b42b-940d7302f41e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_91dd4350-3137-495d-b42b-940d7302f41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_f5ba4a72-4252-4f53-bd65-0bc7a55a9c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_f5ba4a72-4252-4f53-bd65-0bc7a55a9c9d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecurities"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="extended" id="i64c449634d054b77a96dd3257b891dd1_AvailableforSaleDebtSecurities"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended" id="i2375abfe8aa24692863e44a9b3e34608_AvailableforSaleDebtSecuritiesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="if17e9c904bec41baaf4af01a3629d79e_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55adc54c-3642-4d40-8e7b-eaca7fc42522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55adc54c-3642-4d40-8e7b-eaca7fc42522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dda90c4d-137e-4e3c-9d0e-edbf20af34ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dda90c4d-137e-4e3c-9d0e-edbf20af34ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e634fa28-eddc-402e-abb4-bb6b5743d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e634fa28-eddc-402e-abb4-bb6b5743d46a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c688999f-c0fe-4cf3-ae23-5bcb93625a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c688999f-c0fe-4cf3-ae23-5bcb93625a43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a40044f-fb57-4da1-aa2d-1eb9982fada6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a40044f-fb57-4da1-aa2d-1eb9982fada6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e9e905ea-5a4e-4b55-bfcd-98f8d68cf0db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e9e905ea-5a4e-4b55-bfcd-98f8d68cf0db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e25574c4-9c5d-4aaa-8de2-3ca4d4afd954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e25574c4-9c5d-4aaa-8de2-3ca4d4afd954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c4006ed6-efd1-47ee-a540-f579421d5799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c4006ed6-efd1-47ee-a540-f579421d5799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f9856795-0e0b-40b4-a015-ace47671292b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f9856795-0e0b-40b4-a015-ace47671292b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_475e31a0-6ded-4598-8a41-b43529e46d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_475e31a0-6ded-4598-8a41-b43529e46d73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_96bcfd40-d09d-40af-b887-f6c2b4a7d350" xlink:href="gild-20201231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_96bcfd40-d09d-40af-b887-f6c2b4a7d350" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i6f34bf0aa2644e78b3cb277817e31f87_AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dcde3fc-fbff-478d-a918-c6f11da6ad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cbe2da-b529-4bbe-8682-1dbf67f75bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dcde3fc-fbff-478d-a918-c6f11da6ad7a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cbe2da-b529-4bbe-8682-1dbf67f75bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dcde3fc-fbff-478d-a918-c6f11da6ad7a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4d24b1ba-83cf-4c4a-a922-d73968ad6097_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4d24b1ba-83cf-4c4a-a922-d73968ad6097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_d61504cb-efc1-4c93-8270-8128af31dbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_d61504cb-efc1-4c93-8270-8128af31dbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_28690339-850f-4c44-9864-f69ed6fb3419" xlink:href="gild-20201231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_28690339-850f-4c44-9864-f69ed6fb3419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_3c83c944-ace7-4c3c-aeed-c6ab0e91037e" xlink:href="gild-20201231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_3c83c944-ace7-4c3c-aeed-c6ab0e91037e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended" id="if450fc9eb6b54b679fc73f244c972478_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended" id="i0a1f4c15ea58436fba6d0a21b8711731_AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d4039b07-c274-4ff4-8c37-f977ca8cfa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d4039b07-c274-4ff4-8c37-f977ca8cfa0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f48561d3-2c99-47c9-81c5-bae3e7a66959" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f48561d3-2c99-47c9-81c5-bae3e7a66959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b84ff1b-9c69-4a0b-a556-5954c2b01f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b84ff1b-9c69-4a0b-a556-5954c2b01f2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3a963fe5-b2a3-4446-97f1-6c45b33cefb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3a963fe5-b2a3-4446-97f1-6c45b33cefb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_234caceb-bb56-48d2-86bc-2b438f7cadf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_234caceb-bb56-48d2-86bc-2b438f7cadf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bb3b9ac9-5807-4c4e-adb1-3f1be3f33440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bb3b9ac9-5807-4c4e-adb1-3f1be3f33440" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c0fe15-bdfc-46d2-8acc-80deeb41c687_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e6c0fe15-bdfc-46d2-8acc-80deeb41c687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a949c94-7bd1-4d9c-be18-dfb88f70a954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a949c94-7bd1-4d9c-be18-dfb88f70a954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e23ed102-42bf-4b68-9c0c-2a0b5e1a9cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a949c94-7bd1-4d9c-be18-dfb88f70a954" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e23ed102-42bf-4b68-9c0c-2a0b5e1a9cb7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="extended" id="i3c1e2caf188b475d8852b9b811501bba_AvailableforSaleDebtSecuritiesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="extended" id="i067b343e0f6b48bd83ae1cbcae1974fb_DerivativeFinancialInstruments"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended" id="if2e6c2fd9eed43bba35ef0006c9afb6a_DerivativeFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="ic6c3d652a63b48068c35fe2130656cf2_DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_deb83448-d49d-46ca-81b1-aeb432f77194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_deb83448-d49d-46ca-81b1-aeb432f77194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8654b52a-992c-4045-aaea-4f8042fd37aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8654b52a-992c-4045-aaea-4f8042fd37aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:to="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f3b80146-abfc-48aa-b144-a84dc648f46b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:to="loc_us-gaap_HedgingDesignationDomain_f3b80146-abfc-48aa-b144-a84dc648f46b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:to="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_483a1831-89ce-4f39-9f73-420cb7838ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_483a1831-89ce-4f39-9f73-420cb7838ce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_71f795f9-ae46-460c-af9c-ea24a29bdcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:to="loc_us-gaap_NondesignatedMember_71f795f9-ae46-460c-af9c-ea24a29bdcc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_48c82a03-f8f6-4b91-b104-d06be00d671d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_48c82a03-f8f6-4b91-b104-d06be00d671d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_92ac77e0-15d9-46de-9753-ad98ff3e67c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_92ac77e0-15d9-46de-9753-ad98ff3e67c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7d946ebb-a1c8-4e83-adf7-54935e743f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7d946ebb-a1c8-4e83-adf7-54935e743f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_8b299c56-c118-480d-b151-9f16a6308dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_8b299c56-c118-480d-b151-9f16a6308dcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4534146b-2b50-4163-8d89-f378b693f643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4534146b-2b50-4163-8d89-f378b693f643" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended" id="i41ea79df4a42442fb90907d23d446ae5_DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended" id="ic5414d012f234cc1be0acffb94844a34_DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i3bf3461979154370aabebbd935edc55c_DerivativeFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_3a7bd88d-907c-4823-8c1b-20d4b35bc7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_3a7bd88d-907c-4823-8c1b-20d4b35bc7ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_dd6fc093-7761-4e56-8388-eb782a88897a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_dd6fc093-7761-4e56-8388-eb782a88897a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_5abb9e50-09b9-4e6e-a901-458076ead0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeNotionalAmount_5abb9e50-09b9-4e6e-a901-458076ead0cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_633d3987-8b32-4e04-9549-e6afa9897e47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_633d3987-8b32-4e04-9549-e6afa9897e47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:to="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f26c054-2dd8-4df0-b2ff-07752dfa4578_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:to="loc_srt_RangeMember_6f26c054-2dd8-4df0-b2ff-07752dfa4578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd7f1957-3cc6-4410-9067-bfae1e07faae" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:to="loc_srt_RangeMember_dd7f1957-3cc6-4410-9067-bfae1e07faae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9755a174-1649-446e-a8c9-4985826dda13" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd7f1957-3cc6-4410-9067-bfae1e07faae" xlink:to="loc_srt_MaximumMember_9755a174-1649-446e-a8c9-4985826dda13" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Acquisitions" xlink:type="simple" xlink:href="gild-20201231.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/Acquisitions" xlink:type="extended" id="i86eb6a9c37a347c1b181b4302fca7849_Acquisitions"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsTables" xlink:type="extended" id="i7e2d3038a0e94306be1188aca84422af_AcquisitionsTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="i093c7a70c169476a82b7ae47fca4c360_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7c2cf233-7c4b-407b-8c6f-cdc6f83a4aae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_SharePrice_7c2cf233-7c4b-407b-8c6f-cdc6f83a4aae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_ab98086a-bf8b-4fe3-a8b0-a1d72ec2b616" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionCashOutflowNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_ab98086a-bf8b-4fe3-a8b0-a1d72ec2b616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f8224cfa-b6fc-4452-b10f-3b8af32728e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f8224cfa-b6fc-4452-b10f-3b8af32728e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_da9fbf77-14fb-403f-9b40-5775636d4ea1" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_da9fbf77-14fb-403f-9b40-5775636d4ea1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f5dc92b3-baf8-4236-bee6-28443d51feff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ShareBasedCompensation_f5dc92b3-baf8-4236-bee6-28443d51feff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_9818d680-c494-492f-a950-290519844469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_9818d680-c494-492f-a950-290519844469" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7db81039-ce7c-480a-8fa3-5f9aeebcebc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7db81039-ce7c-480a-8fa3-5f9aeebcebc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c8574e3-850d-4941-b81d-2ce36a35df1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c8574e3-850d-4941-b81d-2ce36a35df1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5413ae45-6748-408b-9505-644ea209af95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5413ae45-6748-408b-9505-644ea209af95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_0eb77703-fe67-45c4-a5b6-0ff5f342bc18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_0eb77703-fe67-45c4-a5b6-0ff5f342bc18" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a9e1d984-abba-4bbb-b73c-25bc5ef4374d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a9e1d984-abba-4bbb-b73c-25bc5ef4374d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_8802e5b6-4700-4994-bbd5-234dcc47c190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_8802e5b6-4700-4994-bbd5-234dcc47c190" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3f5f7d62-a45d-4e1d-a3c3-3ee7ff106847" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3f5f7d62-a45d-4e1d-a3c3-3ee7ff106847" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c1ee5c9a-d3b6-4297-8568-97c2297820c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c1ee5c9a-d3b6-4297-8568-97c2297820c7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_8a6e064c-1d86-461e-b7b6-e518ee2de75d" xlink:href="gild-20201231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_8a6e064c-1d86-461e-b7b6-e518ee2de75d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_398d49ec-4e53-46a4-8b49-c0ae73f0d9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_398d49ec-4e53-46a4-8b49-c0ae73f0d9a1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_08bd28cc-0ab8-492d-b0e4-697e3142f0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_08bd28cc-0ab8-492d-b0e4-697e3142f0ac" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f827fab2-b5a2-41a1-bdbf-1a0fc08c5418" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f827fab2-b5a2-41a1-bdbf-1a0fc08c5418" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_2f53d5a9-4b42-4293-bc1f-231240903bfc" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_2f53d5a9-4b42-4293-bc1f-231240903bfc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_a6b14d93-b4f6-490f-bdf3-1a8df85c3255" xlink:href="gild-20201231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_a6b14d93-b4f6-490f-bdf3-1a8df85c3255" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_cddc2ae1-edfe-4784-980c-1d8f7d10a9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_GoodwillGross_cddc2ae1-edfe-4784-980c-1d8f7d10a9a1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e9e50ad8-6598-42a1-806a-e429850d5947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e9e50ad8-6598-42a1-806a-e429850d5947" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_3361b269-3be6-447d-8db5-ad4d8f3fd785" xlink:href="gild-20201231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_3361b269-3be6-447d-8db5-ad4d8f3fd785" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4_default" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:to="loc_gild_AssetAcquisitionDomain_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_abf1938f-186e-4ed2-9a99-1d359c5ed884" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:to="loc_gild_AssetAcquisitionDomain_abf1938f-186e-4ed2-9a99-1d359c5ed884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_e4981754-c679-42ec-97bc-2fcd0537b84e" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_AssetAcquisitionDomain_abf1938f-186e-4ed2-9a99-1d359c5ed884" xlink:to="loc_gild_FortySevenIncMember_e4981754-c679-42ec-97bc-2fcd0537b84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25efcabf-0275-462b-a396-dedef293af54_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25efcabf-0275-462b-a396-dedef293af54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_04a65d93-c084-40a8-bbb8-cf4a1bce612a" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:to="loc_gild_ImmunomedicsIncMember_04a65d93-c084-40a8-bbb8-cf4a1bce612a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_50bd9b9c-6d7d-4226-bfe0-076125946a94" xlink:href="gild-20201231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:to="loc_gild_MYRGmbHMember_50bd9b9c-6d7d-4226-bfe0-076125946a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fffd04aa-b42d-4213-a425-60f90d6fb452_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fffd04aa-b42d-4213-a425-60f90d6fb452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_b77eb36f-c4b7-441e-bb5c-ed0d063fa7e3" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:to="loc_gild_TrodelvyForMTNBCMember_b77eb36f-c4b7-441e-bb5c-ed0d063fa7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b68f571b-6406-457e-94e2-863d16cbc76e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:to="loc_us-gaap_LicensingAgreementsMember_b68f571b-6406-457e-94e2-863d16cbc76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e33f106c-805c-4a2e-b6c8-e9f85ea00599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e33f106c-805c-4a2e-b6c8-e9f85ea00599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e90bee95-fe22-40f6-8cee-5f27c10128a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e33f106c-805c-4a2e-b6c8-e9f85ea00599" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e90bee95-fe22-40f6-8cee-5f27c10128a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5c221e80-2452-4293-b8bf-0df20a10542d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:to="loc_us-gaap_ClassOfStockDomain_5c221e80-2452-4293-b8bf-0df20a10542d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:to="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentstoOutstandingCommonStockholdersMember_b16fae72-b9c9-427b-bd08-8c49ab0e1289" xlink:href="gild-20201231.xsd#gild_PaymentstoOutstandingCommonStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:to="loc_gild_PaymentstoOutstandingCommonStockholdersMember_b16fae72-b9c9-427b-bd08-8c49ab0e1289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToEquityAwardHoldersMember_7001b2d5-ca82-4ad1-a75a-db99d84a568b" xlink:href="gild-20201231.xsd#gild_PaymentsToEquityAwardHoldersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:to="loc_gild_PaymentsToEquityAwardHoldersMember_7001b2d5-ca82-4ad1-a75a-db99d84a568b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6aeb016-7adb-4252-99fb-c1d89e44b42e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6aeb016-7adb-4252-99fb-c1d89e44b42e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e31f1ca2-7130-485a-ace6-8d5e957e3daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e31f1ca2-7130-485a-ace6-8d5e957e3daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_da43491d-6503-4f8e-9ea6-4e0816913213" xlink:href="gild-20201231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e31f1ca2-7130-485a-ace6-8d5e957e3daf" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_da43491d-6503-4f8e-9ea6-4e0816913213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4ee72ff5-d400-46f1-925a-8d3db2922559_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4ee72ff5-d400-46f1-925a-8d3db2922559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_67a0b52f-4341-4111-8189-79beeff6cb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_67a0b52f-4341-4111-8189-79beeff6cb4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_508cc827-b465-4285-8bfe-d3322d537eba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_67a0b52f-4341-4111-8189-79beeff6cb4c" xlink:to="loc_us-gaap_MediumTermNotesMember_508cc827-b465-4285-8bfe-d3322d537eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_49b45f23-b943-4f77-9c00-a1f8e41bdf44_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_49b45f23-b943-4f77-9c00-a1f8e41bdf44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c91b0b42-3f92-4893-96dd-735272c3183a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c91b0b42-3f92-4893-96dd-735272c3183a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_b9e112dd-be3b-4ab7-ade7-598a15f765dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_b9e112dd-be3b-4ab7-ade7-598a15f765dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ic226fe496dff453180a139afd45d3c27_AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e8cec4fd-6d8d-486a-8cc2-71019f0470cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e8cec4fd-6d8d-486a-8cc2-71019f0470cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d693f739-4b73-4801-9303-e00c7cb10046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d693f739-4b73-4801-9303-e00c7cb10046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c13af9c7-8d6f-4dc0-a53b-f7da860351df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c13af9c7-8d6f-4dc0-a53b-f7da860351df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1d19d7f5-412b-437c-afb4-911576c6464b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1d19d7f5-412b-437c-afb4-911576c6464b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_648617ca-e005-4ea5-9801-4c20b05c18c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_648617ca-e005-4ea5-9801-4c20b05c18c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_9d152c2d-5d75-44bc-87ee-0edbbf60e0e5" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_9d152c2d-5d75-44bc-87ee-0edbbf60e0e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_cbb75c24-7f4d-4be3-a231-38b7d6614dbc" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_cbb75c24-7f4d-4be3-a231-38b7d6614dbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9784321d-e99b-4a4d-bbd9-8a0b0fe3ec6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9784321d-e99b-4a4d-bbd9-8a0b0fe3ec6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_e7244c2c-02d6-4b50-8a4b-63ea3e3e7916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_GoodwillGross_e7244c2c-02d6-4b50-8a4b-63ea3e3e7916" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3a91bde7-e0c6-44db-b3be-64174b057ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3a91bde7-e0c6-44db-b3be-64174b057ba7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e64026d-7398-4a31-8409-8d6323b94d16_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e64026d-7398-4a31-8409-8d6323b94d16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cecd8a72-ea3c-4616-9ba5-2270cd2c2c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cecd8a72-ea3c-4616-9ba5-2270cd2c2c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_4d63b749-c546-4c35-9c1a-facc64db489c" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cecd8a72-ea3c-4616-9ba5-2270cd2c2c5e" xlink:to="loc_gild_ImmunomedicsIncMember_4d63b749-c546-4c35-9c1a-facc64db489c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f4f89ba-7666-4b4e-91e8-9825d172b69d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f4f89ba-7666-4b4e-91e8-9825d172b69d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_21abf9a7-5c7b-45aa-bba5-7153c65be587" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:to="loc_gild_TrodelvyForMTNBCMember_21abf9a7-5c7b-45aa-bba5-7153c65be587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_18db8469-d9ad-4c1c-8f12-306ca300ea16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:to="loc_us-gaap_LicensingAgreementsMember_18db8469-d9ad-4c1c-8f12-306ca300ea16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1439c9ad-9560-4f25-8bb0-e7a68577eee1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1439c9ad-9560-4f25-8bb0-e7a68577eee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ce908d7-fc79-4a77-8532-de70ed61d41f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ce908d7-fc79-4a77-8532-de70ed61d41f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_15d1db85-50f5-49bd-a35e-1dadf0cf90c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ce908d7-fc79-4a77-8532-de70ed61d41f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_15d1db85-50f5-49bd-a35e-1dadf0cf90c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsSupplementalProFormaInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails" xlink:type="extended" id="ida2edbf474e74732b0208aefe7c146d9_AcquisitionsSupplementalProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ea7174c6-4283-42b0-bfcc-f01884389b74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ea7174c6-4283-42b0-bfcc-f01884389b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e75e143e-0bda-4123-bc07-860c3274bbac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e75e143e-0bda-4123-bc07-860c3274bbac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_71e36182-b0b9-410a-842c-3c55fc4cd7bf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_71e36182-b0b9-410a-842c-3c55fc4cd7bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c28137e5-edc0-4463-906b-6ea4d1a3e27e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c28137e5-edc0-4463-906b-6ea4d1a3e27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_94eb340e-3d09-41d9-8311-3bb18b28ce33" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c28137e5-edc0-4463-906b-6ea4d1a3e27e" xlink:to="loc_gild_ImmunomedicsIncMember_94eb340e-3d09-41d9-8311-3bb18b28ce33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Inventories" xlink:type="simple" xlink:href="gild-20201231.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/Inventories" xlink:type="extended" id="ic4e2496bd9194564b9fc0e9911aa4fac_Inventories"/>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/InventoriesTables" xlink:type="extended" id="ibc3ade126cbe4ffda0dbead0a7b53a16_InventoriesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesScheduleofinventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="extended" id="i3898a08ef0564fea99dcccbb4171e5d4_InventoriesScheduleofinventoriesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_48b48c77-6760-4bbb-be85-aeaa5811e3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_48b48c77-6760-4bbb-be85-aeaa5811e3a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ee4ce79e-5e07-4a87-97e1-3afb5bdcf271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ee4ce79e-5e07-4a87-97e1-3afb5bdcf271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_073a9a95-e1df-4cac-89b2-cab009b4872c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_073a9a95-e1df-4cac-89b2-cab009b4872c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_323a788e-687f-482f-97b7-78c71c1236c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryNet_323a788e-687f-482f-97b7-78c71c1236c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c0c7de28-d68a-4307-a148-34c1c22d6880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryNoncurrent_c0c7de28-d68a-4307-a148-34c1c22d6880" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_127c0095-c9ee-43a2-bca4-f08468b17a28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_127c0095-c9ee-43a2-bca4-f08468b17a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_36e91c76-3b1b-4bac-8efc-425d048a0489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_127c0095-c9ee-43a2-bca4-f08468b17a28" xlink:to="loc_us-gaap_AssetsTotalMember_36e91c76-3b1b-4bac-8efc-425d048a0489" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i3b36dd6013484bdfb27d0f709d48b7d6_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems_bc35e0fb-823f-450d-9f59-6fd5f0a3c9f3" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_2871e146-a835-4e2f-89bf-223a3f6b30d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleofInventoryLineItems_bc35e0fb-823f-450d-9f59-6fd5f0a3c9f3" xlink:to="loc_us-gaap_InventoryWriteDown_2871e146-a835-4e2f-89bf-223a3f6b30d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_ScheduleofInventoryLineItems_bc35e0fb-823f-450d-9f59-6fd5f0a3c9f3" xlink:to="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_bd44578c-5b92-4cab-9bc3-8ee59305026f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_bd44578c-5b92-4cab-9bc3-8ee59305026f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b11c3ec2-4541-4868-b72d-0fc708e2d045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b11c3ec2-4541-4868-b72d-0fc708e2d045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_14686651-dc38-44b3-b5f3-1956b6e1e526" xlink:href="gild-20201231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b11c3ec2-4541-4868-b72d-0fc708e2d045" xlink:to="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_14686651-dc38-44b3-b5f3-1956b6e1e526" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipment"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="extended" id="ic788457605bd406f8ad36beb62752d76_PropertyPlantandEquipment"/>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="extended" id="ib5dd2bef5d1a413c9f7dd7499787bffc_PropertyPlantandEquipmentTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" xlink:type="extended" id="if03f9d56c23647c280125f59092ebbe5_PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended" id="i395c52609cfe478ab0233cbb7ce3024c_PropertyPlantandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_9af6eb46-8297-4a22-aadd-2ab178bc9cde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_9af6eb46-8297-4a22-aadd-2ab178bc9cde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_754229b6-8cc5-4e7b-82a7-2742291d3973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:to="loc_us-gaap_NoncurrentAssets_754229b6-8cc5-4e7b-82a7-2742291d3973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:to="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a8a1030-0e72-4dd3-b877-454f823acbba_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:to="loc_srt_SegmentGeographicalDomain_6a8a1030-0e72-4dd3-b877-454f823acbba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:to="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_73109ddf-013b-4e06-a0bf-115379c89566" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:to="loc_country_US_73109ddf-013b-4e06-a0bf-115379c89566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_399c4ba9-c354-4712-a882-e0610b57458d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:to="loc_us-gaap_NonUsMember_399c4ba9-c354-4712-a882-e0610b57458d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="extended" id="i01042d90968e4dccb57b2b5f6de0352f_GoodwillandIntangibleAssets"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended" id="i23dfa05b98cc49d1951550d77e178de6_GoodwillandIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended" id="icf095f3b4e8e459da4431387b76cfab9_GoodwillandIntangibleAssetsGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_441f8837-3d17-449b-9fc9-69bd23a4ad45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_441f8837-3d17-449b-9fc9-69bd23a4ad45" xlink:to="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e84fdcf-57c3-40c4-9596-b4d7123a5e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:to="loc_us-gaap_Goodwill_3e84fdcf-57c3-40c4-9596-b4d7123a5e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b9a4df08-d2f2-4f3d-a100-4c4977b85756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b9a4df08-d2f2-4f3d-a100-4c4977b85756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79ececfd-0913-4982-af60-f2dcf60c02f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_441f8837-3d17-449b-9fc9-69bd23a4ad45" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa213e6a-704f-420a-855f-1ac60967133f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa213e6a-704f-420a-855f-1ac60967133f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbb51eb7-5d3c-46fe-b979-2233a95da587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbb51eb7-5d3c-46fe-b979-2233a95da587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_1be876b1-53ed-4f7b-9fda-b4770f404602" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbb51eb7-5d3c-46fe-b979-2233a95da587" xlink:to="loc_gild_ImmunomedicsIncMember_1be876b1-53ed-4f7b-9fda-b4770f404602" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="ieb2cda94d4b24e7f9a8ba1255ba32f59_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d48a092a-ff0f-44d7-a0e2-7112920c97ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d48a092a-ff0f-44d7-a0e2-7112920c97ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2cee70fd-5b06-4df7-ac1c-0e5c96bbd0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2cee70fd-5b06-4df7-ac1c-0e5c96bbd0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_55018577-0582-4c4c-87fe-a623364bfbb0" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_55018577-0582-4c4c-87fe-a623364bfbb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5cf6c679-45fa-483c-8d8a-9b8e3ef49f68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5cf6c679-45fa-483c-8d8a-9b8e3ef49f68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_71ff7710-b67c-461f-afe2-c656d4de29f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_71ff7710-b67c-461f-afe2-c656d4de29f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:to="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245_default" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:to="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_457a58c7-f2a5-4a91-995b-569b500e2567" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:to="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_457a58c7-f2a5-4a91-995b-569b500e2567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Kite585ProgramMember_a51acbd3-9f43-4f5b-934a-4b23ed5b6aa2" xlink:href="gild-20201231.xsd#gild_Kite585ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_457a58c7-f2a5-4a91-995b-569b500e2567" xlink:to="loc_gild_Kite585ProgramMember_a51acbd3-9f43-4f5b-934a-4b23ed5b6aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_016f74fb-2aae-4ff4-864a-81fdf8b746a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_016f74fb-2aae-4ff4-864a-81fdf8b746a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bbed6156-756c-49aa-b97d-79264c3574b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_016f74fb-2aae-4ff4-864a-81fdf8b746a1" xlink:to="loc_us-gaap_CostOfSalesMember_bbed6156-756c-49aa-b97d-79264c3574b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended" id="i6e3b3fe7b4894aa5ab13875199059564_GoodwillandIntangibleAssetsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3001d1fb-94af-41cd-a067-b1310767b5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3001d1fb-94af-41cd-a067-b1310767b5ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b97a7e89-ef2d-4a78-972a-8001c8f862d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b97a7e89-ef2d-4a78-972a-8001c8f862d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca602ffb-333c-4320-87e5-a2310304aa92" xlink:href="gild-20201231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca602ffb-333c-4320-87e5-a2310304aa92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4452746b-c17f-4145-ae4e-adce84216c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4452746b-c17f-4145-ae4e-adce84216c7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_263ed69e-7497-40c9-b92c-34149d2b46e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_263ed69e-7497-40c9-b92c-34149d2b46e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1e5a0229-fdcb-49dc-842a-5625777f1dc0" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1e5a0229-fdcb-49dc-842a-5625777f1dc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_66b214bc-a191-44a3-a39b-9a910246bd54" xlink:href="gild-20201231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_66b214bc-a191-44a3-a39b-9a910246bd54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_abaf8d91-3ec9-4d98-850e-36650f0abf32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_abaf8d91-3ec9-4d98-850e-36650f0abf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfd11261-9afe-4aa9-b835-dbb996605f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_829ac659-a50d-4355-b4bb-4ee03d6cc2d0" xlink:href="gild-20201231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_829ac659-a50d-4355-b4bb-4ee03d6cc2d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_db41c023-58ff-4735-8f9d-7d383c911f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_db41c023-58ff-4735-8f9d-7d383c911f9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0221c64f-125a-48bf-9c1a-d41a928e669c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0221c64f-125a-48bf-9c1a-d41a928e669c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_f40588da-1f0f-447d-9cfe-a2dc41f922ca" xlink:href="gild-20201231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_f40588da-1f0f-447d-9cfe-a2dc41f922ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_be6df20e-0cbf-43a9-80de-68c1d5486b0e" xlink:href="gild-20201231.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_be6df20e-0cbf-43a9-80de-68c1d5486b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_f440c791-7a83-4caf-870c-5e318dae4c0b" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_gild_TrodelvyForMTNBCMember_f440c791-7a83-4caf-870c-5e318dae4c0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_95965d99-260d-40d9-9986-c30b7f5a5a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_95965d99-260d-40d9-9986-c30b7f5a5a4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8de2033a-c7b3-4c8f-a894-23f8b6bd3b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8de2033a-c7b3-4c8f-a894-23f8b6bd3b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_181ed1ac-2c0d-4526-82ea-eeafe5a032e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8de2033a-c7b3-4c8f-a894-23f8b6bd3b31" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_181ed1ac-2c0d-4526-82ea-eeafe5a032e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended" id="i9f19135a56544f9f8312588fa551e0cf_GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformation"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="extended" id="i34ec1cf149544996a39219bb3b66f8fe_OtherFinancialInformation"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="extended" id="i84500372e80f4ca1b4a3aaf22cecfc9e_OtherFinancialInformationTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended" id="i1e56531d63584704bd9e4443dcc6c429_OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended" id="i09153c41021141379ea728c9f4360e97_OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="gild-20201231.xsd#CollaborationsandOtherArrangements"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="extended" id="i95952e4c75284fceba78541dd237b657_CollaborationsandOtherArrangements"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended" id="iff80da81321746e49229e5bba3e101a0_CollaborationsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_76636e1b-356d-4d2e-a660-2c2d1ed6bceb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_76636e1b-356d-4d2e-a660-2c2d1ed6bceb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71a79901-c38d-499e-87b2-b57253b8adcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71a79901-c38d-499e-87b2-b57253b8adcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent_b27e8c13-b194-4aae-b52f-db7e3f564680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent_b27e8c13-b194-4aae-b52f-db7e3f564680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares_45e2e29c-9645-4e53-8fd4-a0bf656b4958" xlink:href="gild-20201231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalShares_45e2e29c-9645-4e53-8fd4-a0bf656b4958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade_62b28ec9-8e51-4147-9a1d-406cf2ae803f" xlink:href="gild-20201231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_TotalUpfrontPaymentsMade_62b28ec9-8e51-4147-9a1d-406cf2ae803f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4551231e-7c52-4057-87bb-c8677053ad45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4551231e-7c52-4057-87bb-c8677053ad45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_94397b60-f547-47e6-a35d-c02de0127520" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_SharePrice_94397b60-f547-47e6-a35d-c02de0127520" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_95cd995a-8fa6-4cc9-ab9a-f3522836a0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquityMethodInvestments_95cd995a-8fa6-4cc9-ab9a-f3522836a0a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1ec8fad9-d73b-4b67-b245-cf70c1f8be59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1ec8fad9-d73b-4b67-b245-cf70c1f8be59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f22f354d-53a7-4e2a-931b-93275870e825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f22f354d-53a7-4e2a-931b-93275870e825" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium_e17a9a17-108f-4748-b274-fa45ca9c8808" xlink:href="gild-20201231.xsd#gild_IssuanceDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_IssuanceDiscountPremium_e17a9a17-108f-4748-b274-fa45ca9c8808" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense_ad8c9fd4-5419-4dbf-83f9-d50382a9417e" xlink:href="gild-20201231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentsForDirectTransactionalExpense_ad8c9fd4-5419-4dbf-83f9-d50382a9417e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_5bfe2aa8-f42a-4cd2-9e23-ae79346d4907" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_5bfe2aa8-f42a-4cd2-9e23-ae79346d4907" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_405f0e6e-c525-4665-9794-e1204e0c2938" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_405f0e6e-c525-4665-9794-e1204e0c2938" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_a5531bfe-fb95-4303-b372-11f487d35be2" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_a5531bfe-fb95-4303-b372-11f487d35be2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_633d8f19-9b2b-456e-81db-b105ee26e5d3" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_633d8f19-9b2b-456e-81db-b105ee26e5d3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_69b951aa-caeb-4b05-9094-84d00d13e416" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_69b951aa-caeb-4b05-9094-84d00d13e416" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_6682dee6-473f-45b4-ad7c-a3521fd690cf" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_6682dee6-473f-45b4-ad7c-a3521fd690cf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2be75a10-4347-4de8-a704-6ad53ed99912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2be75a10-4347-4de8-a704-6ad53ed99912" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfAgreements_c4cfe7b5-3d6a-46d0-9c33-e3e58ccf0014" xlink:href="gild-20201231.xsd#gild_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_NumberOfAgreements_c4cfe7b5-3d6a-46d0-9c33-e3e58ccf0014" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b626fad3-ec8f-48d0-880c-9a86c29eaaef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b626fad3-ec8f-48d0-880c-9a86c29eaaef" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b969921f-a157-46c2-a793-7c3481b9848a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b969921f-a157-46c2-a793-7c3481b9848a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e4df3bf4-fcc2-4b12-aa96-6abb168d4986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e4df3bf4-fcc2-4b12-aa96-6abb168d4986" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalPayable_515b2a33-1eb7-4d00-895c-c69f14904ba9" xlink:href="gild-20201231.xsd#gild_InvestmentOwnedBalanceAdditionalPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalPayable_515b2a33-1eb7-4d00-895c-c69f14904ba9" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_9e49a637-8542-404b-a852-c9d9b5d896f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_9e49a637-8542-404b-a852-c9d9b5d896f3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee_bd8485a2-4dea-4e31-ad57-ac0cdc121eff" xlink:href="gild-20201231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquityMethodInvestmentOptionExerciseFee_bd8485a2-4dea-4e31-ad57-ac0cdc121eff" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_d0848bf1-6c49-4aab-b3ea-13d0da891ff2" xlink:href="gild-20201231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_d0848bf1-6c49-4aab-b3ea-13d0da891ff2" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_180a1864-9035-489e-9538-8308ebd9534f" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_180a1864-9035-489e-9538-8308ebd9534f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_33f469de-1b6a-4edb-8158-d90ddf9470b7" xlink:href="gild-20201231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_33f469de-1b6a-4edb-8158-d90ddf9470b7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_71597b4d-c94e-46d5-af4f-328ed66cf379" xlink:href="gild-20201231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_71597b4d-c94e-46d5-af4f-328ed66cf379" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms_266613d7-657a-4d13-a27b-67e69c213393" xlink:href="gild-20201231.xsd#gild_NumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_NumberOfPrograms_266613d7-657a-4d13-a27b-67e69c213393" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedResearchAndDevelopmentMilestonePayments_297f8b50-d5bf-44a6-a22b-27bf4523d9a1" xlink:href="gild-20201231.xsd#gild_AccruedResearchAndDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_AccruedResearchAndDevelopmentMilestonePayments_297f8b50-d5bf-44a6-a22b-27bf4523d9a1" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfStudies_ab63b341-a08f-4fef-95d3-4d3b511fe997" xlink:href="gild-20201231.xsd#gild_NumberOfStudies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_NumberOfStudies_ab63b341-a08f-4fef-95d3-4d3b511fe997" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForResearchAndDevelopmentMilestones_2312fc1b-d7a8-46bb-b72e-5f6caaab13b7" xlink:href="gild-20201231.xsd#gild_PaymentsForResearchAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentsForResearchAndDevelopmentMilestones_2312fc1b-d7a8-46bb-b72e-5f6caaab13b7" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_028894b2-a047-4ecf-a62c-ab6cd59eb964" xlink:href="gild-20201231.xsd#gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_028894b2-a047-4ecf-a62c-ab6cd59eb964" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm_1b0d7a7b-c300-4e94-88da-1e1cfe59e433" xlink:href="gild-20201231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_CollaborativeArrangementTerm_1b0d7a7b-c300-4e94-88da-1e1cfe59e433" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_c2f161ee-081f-4fcb-8cf6-29fe809ba57e" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_c2f161ee-081f-4fcb-8cf6-29fe809ba57e" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm_0d1c2084-0385-4415-ae0f-e5cdca8f47eb" xlink:href="gild-20201231.xsd#gild_StandstillRestrictingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_StandstillRestrictingTerm_0d1c2084-0385-4415-ae0f-e5cdca8f47eb" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ccbad71-d4e8-4347-b9f8-5f313e2f1461" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ccbad71-d4e8-4347-b9f8-5f313e2f1461" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7aa2c410-e258-49be-b174-59f2c3b5f12f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a059596e-2c0a-479e-80d6-6e950783e7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a059596e-2c0a-479e-80d6-6e950783e7c1" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_4ec53d28-5874-4e4b-bac0-f456bbce8554" xlink:href="gild-20201231.xsd#gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_4ec53d28-5874-4e4b-bac0-f456bbce8554" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_7a9d089f-fa73-4dc3-95d7-a45279da286d" xlink:href="gild-20201231.xsd#gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_7a9d089f-fa73-4dc3-95d7-a45279da286d" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_151fe7c2-2d76-4f50-8910-8ef0d5c1c64f" xlink:href="gild-20201231.xsd#gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_151fe7c2-2d76-4f50-8910-8ef0d5c1c64f" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_10fda4c9-60c0-42b1-ae04-cd82b2f404a6" xlink:href="gild-20201231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_10fda4c9-60c0-42b1-ae04-cd82b2f404a6" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f8db5e18-e0c3-47a6-bf3e-49f441a8f19c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f8db5e18-e0c3-47a6-bf3e-49f441a8f19c" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c4ac3eff-3aa0-4576-bb47-db167197d539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c4ac3eff-3aa0-4576-bb47-db167197d539" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_6f16eb7b-c973-4503-925c-a8c9aeffdefe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_RoyaltyExpense_6f16eb7b-c973-4503-925c-a8c9aeffdefe" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_bfab5f0d-e605-46ab-b58d-23110f788e26" xlink:href="gild-20201231.xsd#gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_bfab5f0d-e605-46ab-b58d-23110f788e26" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireManagementContractRights_e2c65f02-3fee-4998-9fc8-8df94d7c07fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireManagementContractRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PaymentsToAcquireManagementContractRights_e2c65f02-3fee-4998-9fc8-8df94d7c07fd" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialDevelopmentAndRegulatoryMilestones_a95ae3fe-412b-498b-a665-a7d743637a6d" xlink:href="gild-20201231.xsd#gild_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialDevelopmentAndRegulatoryMilestones_a95ae3fe-412b-498b-a665-a7d743637a6d" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureSalesbasedMilestone_38aeba73-f70e-4378-83df-c3e834ae7435" xlink:href="gild-20201231.xsd#gild_PotentialFutureSalesbasedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureSalesbasedMilestone_38aeba73-f70e-4378-83df-c3e834ae7435" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureTieredRoyaltyPaymentLowend_bb8a60d3-f070-49f8-9490-c06388303a9b" xlink:href="gild-20201231.xsd#gild_PotentialFutureTieredRoyaltyPaymentLowend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureTieredRoyaltyPaymentLowend_bb8a60d3-f070-49f8-9490-c06388303a9b" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureTieredRoyaltyPaymentHighend_022ac83c-147a-4ba9-b9c0-36817d5540a8" xlink:href="gild-20201231.xsd#gild_PotentialFutureTieredRoyaltyPaymentHighend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureTieredRoyaltyPaymentHighend_022ac83c-147a-4ba9-b9c0-36817d5540a8" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_04ae2fd9-f707-4b7f-a391-5c095d2f5728" xlink:href="gild-20201231.xsd#gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_04ae2fd9-f707-4b7f-a391-5c095d2f5728" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Issuancediscount_a7910b4c-2cda-46ef-a56f-f00e8486a156" xlink:href="gild-20201231.xsd#gild_Issuancediscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_Issuancediscount_a7910b4c-2cda-46ef-a56f-f00e8486a156" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_f4a9f2b1-cc13-49cc-afd9-a4ad56ddad14" xlink:href="gild-20201231.xsd#gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_f4a9f2b1-cc13-49cc-afd9-a4ad56ddad14" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram_d29393fb-4560-418f-bda2-f75207f08c11" xlink:href="gild-20201231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialOptionExerciseFeePerProgram_d29393fb-4560-418f-bda2-f75207f08c11" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_b640ba2c-ca81-4dfa-a41e-6139ddb049c2" xlink:href="gild-20201231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_b640ba2c-ca81-4dfa-a41e-6139ddb049c2" xlink:type="arc" order="58"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_01f7f3d8-bad2-4de2-aa65-cbc364a878a8" xlink:href="gild-20201231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_01f7f3d8-bad2-4de2-aa65-cbc364a878a8" xlink:type="arc" order="59"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_0de1a599-f699-4a1a-946a-6b0a784f82ba" xlink:href="gild-20201231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_0de1a599-f699-4a1a-946a-6b0a784f82ba" xlink:type="arc" order="60"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_c715d844-ca30-4e26-8b03-0882bed92a51" xlink:href="gild-20201231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_c715d844-ca30-4e26-8b03-0882bed92a51" xlink:type="arc" order="61"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_35c3626a-9384-4e19-ac28-2abb4df1af58" xlink:href="gild-20201231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_35c3626a-9384-4e19-ac28-2abb4df1af58" xlink:type="arc" order="62"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_95b366fd-f905-4f7e-b993-f7a87e9b0d90" xlink:href="gild-20201231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_95b366fd-f905-4f7e-b993-f7a87e9b0d90" xlink:type="arc" order="63"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5bbb404f-4fb6-4970-9727-594ae14a626d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5bbb404f-4fb6-4970-9727-594ae14a626d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_e024fbfa-6946-42d8-b6b2-619c8817417d" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_ArcusBiosciencesIncMember_e024fbfa-6946-42d8-b6b2-619c8817417d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_2e5127f9-6b06-4294-98fa-ad26c54f3cc6" xlink:href="gild-20201231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_2e5127f9-6b06-4294-98fa-ad26c54f3cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember_047dc090-0dbe-4f43-ad82-8e1270799e4e" xlink:href="gild-20201231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_TizonaTherapeuticsIncMember_047dc090-0dbe-4f43-ad82-8e1270799e4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_6d8fe69f-41f7-47b9-a083-b1c3174d6fb4" xlink:href="gild-20201231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_TangoTherapeuticsIncMember_6d8fe69f-41f7-47b9-a083-b1c3174d6fb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_5a7fb4f0-2e05-4798-a06d-e75f0d29a9c1" xlink:href="gild-20201231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_JounceTherapeuticsIncMember_5a7fb4f0-2e05-4798-a06d-e75f0d29a9c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_b9e2c444-cd84-4f6e-9a98-44cfcf16f497" xlink:href="gild-20201231.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_GalapagosMember_b9e2c444-cd84-4f6e-9a98-44cfcf16f497" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eb033e1-a63c-42ae-9f6f-f9375e7fc637_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0eb033e1-a63c-42ae-9f6f-f9375e7fc637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_78052b42-6df0-4a4e-b2ec-ea337086bd5d" xlink:href="gild-20201231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_78052b42-6df0-4a4e-b2ec-ea337086bd5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedArcusCommonStockPurchaseAgreementMember_f8644245-18c8-4852-8d49-7cae0cf194ae" xlink:href="gild-20201231.xsd#gild_AmendedArcusCommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedArcusCommonStockPurchaseAgreementMember_f8644245-18c8-4852-8d49-7cae0cf194ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_c5a30c5b-b8c9-4859-a92c-c1bea8f0c44d" xlink:href="gild-20201231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ArcusCollaborationAgreementMember_c5a30c5b-b8c9-4859-a92c-c1bea8f0c44d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_32a7a5cd-ad23-4a12-9cdc-fd82a9115657" xlink:href="gild-20201231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_32a7a5cd-ad23-4a12-9cdc-fd82a9115657" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember_8980d36d-cf18-4070-96b3-8aaf6d134a77" xlink:href="gild-20201231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_PionyrMergerAndOptionAgreementsMember_8980d36d-cf18-4070-96b3-8aaf6d134a77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember_773d1b01-99b0-45d0-8020-c33b010016a4" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ResearchAndDevelopmentServiceAgreementMember_773d1b01-99b0-45d0-8020-c33b010016a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember_79ca2b2a-580e-4362-a70e-cd980bb32cc3" xlink:href="gild-20201231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_TizonaMergerAndOptionAgreementsMember_79ca2b2a-580e-4362-a70e-cd980bb32cc3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember_df01aefb-dd5c-4529-8f49-2b42c5bf55af" xlink:href="gild-20201231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_JanssenPharmaceuticalsMember_df01aefb-dd5c-4529-8f49-2b42c5bf55af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_65ade41e-0049-4f77-9dde-6e5b48b40914" xlink:href="gild-20201231.xsd#gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_65ade41e-0049-4f77-9dde-6e5b48b40914" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_49eeb5ef-8e02-4854-b456-f2287e978b77" xlink:href="gild-20201231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_49eeb5ef-8e02-4854-b456-f2287e978b77" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_d5eb648d-a966-49c1-88de-a53a1875c87f" xlink:href="gild-20201231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_d5eb648d-a966-49c1-88de-a53a1875c87f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_aafe1f14-9495-4ec9-ba85-ddce2fdbacd4" xlink:href="gild-20201231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_aafe1f14-9495-4ec9-ba85-ddce2fdbacd4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosCollaborationAgreementMember_1258c9b0-a7f0-4406-87a1-74c9e88662bb" xlink:href="gild-20201231.xsd#gild_GalapagosCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_GalapagosCollaborationAgreementMember_1258c9b0-a7f0-4406-87a1-74c9e88662bb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember_5b6c6c5c-61ad-4f86-901e-1da027caccf5" xlink:href="gild-20201231.xsd#gild_DevelopmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_DevelopmentAgreementMember_5b6c6c5c-61ad-4f86-901e-1da027caccf5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_0d76f2ef-9368-49b4-8597-c78b4eefb085" xlink:href="gild-20201231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_0d76f2ef-9368-49b4-8597-c78b4eefb085" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_66423b0f-43b7-469f-a6ee-2681a1d68859" xlink:href="gild-20201231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_66423b0f-43b7-469f-a6ee-2681a1d68859" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember_d40cfffc-7855-455f-b4e1-909d12754e57" xlink:href="gild-20201231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AgreementWithJapanTobaccoIncMember_d40cfffc-7855-455f-b4e1-909d12754e57" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GadetaBVCollaborationArrangementMember_ce247c57-657b-40ed-bbf6-6ba15b8e0023" xlink:href="gild-20201231.xsd#gild_GadetaBVCollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_GadetaBVCollaborationArrangementMember_ce247c57-657b-40ed-bbf6-6ba15b8e0023" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BristolMyersSquibbCollaborativeArrangementMember_c7b2758b-ab66-491d-b074-1bb6d54ce8d2" xlink:href="gild-20201231.xsd#gild_BristolMyersSquibbCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_BristolMyersSquibbCollaborativeArrangementMember_c7b2758b-ab66-491d-b074-1bb6d54ce8d2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_1655d91d-679c-4754-b37c-219dc6576f36" xlink:href="gild-20201231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_OtherCollaborationArrangementsMember_1655d91d-679c-4754-b37c-219dc6576f36" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a04485a5-0c33-41ef-b990-3fee3248b5b6_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:to="loc_srt_OwnershipDomain_a04485a5-0c33-41ef-b990-3fee3248b5b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:to="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_7ba40ac6-6b9a-4b45-9c52-61ce0838e920" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:to="loc_gild_ArcusBiosciencesIncMember_7ba40ac6-6b9a-4b45-9c52-61ce0838e920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_2e5424c5-98f8-4614-9adc-7fe2f2fa6556" xlink:href="gild-20201231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:to="loc_gild_TangoTherapeuticsIncMember_2e5424c5-98f8-4614-9adc-7fe2f2fa6556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_790797c5-6551-4800-8bdc-5ed6ec10c1c0" xlink:href="gild-20201231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:to="loc_gild_JounceTherapeuticsIncMember_790797c5-6551-4800-8bdc-5ed6ec10c1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_14e83308-a194-4a02-860e-578d6c0a01a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_14e83308-a194-4a02-860e-578d6c0a01a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0a28c77c-161b-40e5-ab13-ea3bf476d792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0a28c77c-161b-40e5-ab13-ea3bf476d792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_52e02216-1896-417d-ad6a-605928990ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0a28c77c-161b-40e5-ab13-ea3bf476d792" xlink:to="loc_us-gaap_SubsequentEventMember_52e02216-1896-417d-ad6a-605928990ba1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilities"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="extended" id="id971c12b89f94e708691eecce2cfe8c7_DebtandCreditFacilities"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="extended" id="i04504217f30c413d8cea3bd294dda8db_DebtandCreditFacilitiesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="i8ec72caf46524bc3aa7bfc34afc7d6a8_DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e4aae1b3-af01-4d18-8739-1b64ba951441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e4aae1b3-af01-4d18-8739-1b64ba951441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_75c6a481-1dbd-4309-8204-13efe7663a16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_75c6a481-1dbd-4309-8204-13efe7663a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_099c8648-0fb4-4379-84ab-37ea9445cc2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_LongTermDebt_099c8648-0fb4-4379-84ab-37ea9445cc2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d9b8cb7d-0a23-4a09-a413-1b477636a480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d9b8cb7d-0a23-4a09-a413-1b477636a480" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_19d236d9-495d-43a4-9826-9cda1fdebaca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_LongTermDebtCurrent_19d236d9-495d-43a4-9826-9cda1fdebaca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_de4b77e2-1a4f-4fdd-96cf-7dddc4ced33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_de4b77e2-1a4f-4fdd-96cf-7dddc4ced33d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f8625887-12d5-419b-b6e8-2d52e91cc3fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:to="loc_us-gaap_VariableRateDomain_f8625887-12d5-419b-b6e8-2d52e91cc3fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e04ce685-8109-4708-8506-6a780a757e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:to="loc_us-gaap_VariableRateDomain_e04ce685-8109-4708-8506-6a780a757e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_61c51177-a74f-4597-9381-5c93f7b7b1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e04ce685-8109-4708-8506-6a780a757e46" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_61c51177-a74f-4597-9381-5c93f7b7b1d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f3992626-8668-489b-92f0-b483776eb2e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f3992626-8668-489b-92f0-b483776eb2e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d9ebdd74-6649-48ab-8341-357feeffdc18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:to="loc_us-gaap_SeniorNotesMember_d9ebdd74-6649-48ab-8341-357feeffdc18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_0ee30048-29ab-46df-9c8e-46523ff06299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_0ee30048-29ab-46df-9c8e-46523ff06299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueInFebruary2020Member_0774b52a-7e69-4781-ac7c-e86cd2930a31" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueInFebruary2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueInFebruary2020Member_0774b52a-7e69-4781-ac7c-e86cd2930a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2020Member_c2feda6f-a7e5-40ed-a928-031549cba7f9" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2020Member_c2feda6f-a7e5-40ed-a928-031549cba7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4a4da20f-3382-4aca-93e0-03b1c1b3601a" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4a4da20f-3382-4aca-93e0-03b1c1b3601a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_be91b833-1510-4e94-aa88-9d2c8af7181f" xlink:href="gild-20201231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_be91b833-1510-4e94-aa88-9d2c8af7181f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_a2e1006b-61aa-46c8-82d5-cf53b64f4fdb" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_a2e1006b-61aa-46c8-82d5-cf53b64f4fdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_f1fd64ed-01ca-4887-bf51-808745f7630f" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_f1fd64ed-01ca-4887-bf51-808745f7630f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_7a166a44-b958-4857-8cfa-620d554a69db" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_7a166a44-b958-4857-8cfa-620d554a69db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_27214d36-71b1-4ee0-9ccd-2d544ca69401" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_27214d36-71b1-4ee0-9ccd-2d544ca69401" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1a09d994-19e6-4295-a438-e15c58dc9868" xlink:href="gild-20201231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1a09d994-19e6-4295-a438-e15c58dc9868" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_d3de3356-4163-4349-af20-b1dbe4584eda" xlink:href="gild-20201231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_d3de3356-4163-4349-af20-b1dbe4584eda" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_ea920a81-4913-4448-8f17-466d2466a295" xlink:href="gild-20201231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_ea920a81-4913-4448-8f17-466d2466a295" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a6025084-7b21-4fac-9a37-081e8f194b0e" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a6025084-7b21-4fac-9a37-081e8f194b0e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_d846c26f-3a1c-4f76-8bac-e6661c87e4ca" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_d846c26f-3a1c-4f76-8bac-e6661c87e4ca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_714427c8-f4cc-4910-af2f-79893bfdfc7e" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_714427c8-f4cc-4910-af2f-79893bfdfc7e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_c57d4a17-6b2f-477f-9dae-f93e3d9fb3a0" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_c57d4a17-6b2f-477f-9dae-f93e3d9fb3a0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_49ce7cbf-0951-4bbc-b53a-6a4e6de243d2" xlink:href="gild-20201231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_49ce7cbf-0951-4bbc-b53a-6a4e6de243d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d49a4097-3340-472d-9a61-626f6e73d435" xlink:href="gild-20201231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d49a4097-3340-472d-9a61-626f6e73d435" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_c4931aa3-f43d-4b0f-9f60-d8e63c028463" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_c4931aa3-f43d-4b0f-9f60-d8e63c028463" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_2d45af01-4cce-48a7-b0e8-c6061ca0d1b4" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_2d45af01-4cce-48a7-b0e8-c6061ca0d1b4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_11ee54b3-c5b6-409a-8b04-daa317a0cc1a" xlink:href="gild-20201231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_11ee54b3-c5b6-409a-8b04-daa317a0cc1a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_66ec4839-2ce7-4f0b-9e6f-2d601edfbc45" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_66ec4839-2ce7-4f0b-9e6f-2d601edfbc45" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_4bb32b2d-68ed-4a3b-b5fc-14b025a9f2a4" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_4bb32b2d-68ed-4a3b-b5fc-14b025a9f2a4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_5c12d254-7203-4a5b-81eb-7d471bf002d7" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_5c12d254-7203-4a5b-81eb-7d471bf002d7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_8dc3f0d5-8503-461f-8015-47e8bbff8397" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_8dc3f0d5-8503-461f-8015-47e8bbff8397" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_f2db10d4-9f8b-4039-98ba-fb36e79cffb3" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_f2db10d4-9f8b-4039-98ba-fb36e79cffb3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_e948869f-92ac-483c-aa8f-d7095119d8b1" xlink:href="gild-20201231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_e948869f-92ac-483c-aa8f-d7095119d8b1" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended" id="i9249c8ce253447469d7bff961e5a90d7_DebtandCreditFacilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_59ab5495-99a6-45bd-b996-f6bc02c6380e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_59ab5495-99a6-45bd-b996-f6bc02c6380e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c25b731-ae2a-45bd-a66d-f589e97eb039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c25b731-ae2a-45bd-a66d-f589e97eb039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f8f4b44d-d0bf-4c16-be3d-04393878fa1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f8f4b44d-d0bf-4c16-be3d-04393878fa1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_6f35b6c3-7aa3-42aa-bead-8f2fa63481c6" xlink:href="gild-20201231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_6f35b6c3-7aa3-42aa-bead-8f2fa63481c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_4026b13c-7ff8-4188-94e1-05d28217f37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_4026b13c-7ff8-4188-94e1-05d28217f37a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_4c17e673-7086-4c81-af83-32ae0a171dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_4c17e673-7086-4c81-af83-32ae0a171dd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d25bd678-1474-4d56-96a0-ad98d72ada7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentTerm_d25bd678-1474-4d56-96a0-ad98d72ada7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efcaa428-6c36-4873-8852-52580acddf31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efcaa428-6c36-4873-8852-52580acddf31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cba3e1a9-889b-4639-846d-093c4719fdd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_LongTermDebt_cba3e1a9-889b-4639-846d-093c4719fdd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_e4056e2d-d91d-4e1e-bb42-7dd5266d491b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_LineOfCredit_e4056e2d-d91d-4e1e-bb42-7dd5266d491b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_a3fe64d0-2426-48f0-882f-a16310a79994" xlink:href="gild-20201231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_a3fe64d0-2426-48f0-882f-a16310a79994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_3724eef1-cc1b-4e76-a2d2-ff3cc03269b1" xlink:href="gild-20201231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_3724eef1-cc1b-4e76-a2d2-ff3cc03269b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87e864e1-1c09-4106-9d2e-042f05a89f12" xlink:href="gild-20201231.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87e864e1-1c09-4106-9d2e-042f05a89f12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_d0389a4f-7a4e-4f6c-aebd-7233f30387b3" xlink:href="gild-20201231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_d0389a4f-7a4e-4f6c-aebd-7233f30387b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d81ed6f1-e0b6-4d9e-8749-2802c9f6af7b" xlink:href="gild-20201231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d81ed6f1-e0b6-4d9e-8749-2802c9f6af7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_95b6d6aa-d4c5-4293-9a0e-7b60c01d3887" xlink:href="gild-20201231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_95b6d6aa-d4c5-4293-9a0e-7b60c01d3887" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b1d816c6-732c-482e-8eac-ae5712f4b5cc" xlink:href="gild-20201231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b1d816c6-732c-482e-8eac-ae5712f4b5cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_947c66c3-2411-43e1-843f-71347521440d" xlink:href="gild-20201231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_947c66c3-2411-43e1-843f-71347521440d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_3c2637c3-ec58-4eec-a8aa-35d8f844f78c" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_3c2637c3-ec58-4eec-a8aa-35d8f844f78c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_551fbdb6-a3a5-4fcc-972e-d3e6353f42a6" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_551fbdb6-a3a5-4fcc-972e-d3e6353f42a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_e49c4f2f-1607-490c-aec2-77ee58c98c03" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_e49c4f2f-1607-490c-aec2-77ee58c98c03" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_2fd694fa-253f-4683-a5c3-9bfe9ec7a873" xlink:href="gild-20201231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_2fd694fa-253f-4683-a5c3-9bfe9ec7a873" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueMay2021Member_497491ee-b475-4473-b436-5edca776fe2e" xlink:href="gild-20201231.xsd#gild_CreditFacilityDueMay2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_CreditFacilityDueMay2021Member_497491ee-b475-4473-b436-5edca776fe2e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_02531837-e175-4055-b3fb-64f039883fcb" xlink:href="gild-20201231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_CreditFacilityDueJune2025Member_02531837-e175-4055-b3fb-64f039883fcb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_847c93e7-caf0-4763-af2f-5f4499fe4bdc" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_847c93e7-caf0-4763-af2f-5f4499fe4bdc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f404e66a-197f-4a64-a2d9-63a14283ab41_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f404e66a-197f-4a64-a2d9-63a14283ab41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f4fdfcd4-82ef-40eb-918a-1b38ce6362b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:to="loc_us-gaap_SeniorNotesMember_f4fdfcd4-82ef-40eb-918a-1b38ce6362b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_6a656759-3ebb-478f-bd9d-d1372dc32be4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:to="loc_us-gaap_MediumTermNotesMember_6a656759-3ebb-478f-bd9d-d1372dc32be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_66207b55-e9e8-47e8-a5a5-371cc4050ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:to="loc_us-gaap_LineOfCreditMember_66207b55-e9e8-47e8-a5a5-371cc4050ca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6664c6d7-2dfb-4945-b9c4-f8f928738be1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:to="loc_srt_RangeMember_6664c6d7-2dfb-4945-b9c4-f8f928738be1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:to="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1391b3b0-9b3e-47e4-b3aa-3ac942afac78" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:to="loc_srt_MinimumMember_1391b3b0-9b3e-47e4-b3aa-3ac942afac78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1cae556b-a569-4e2a-8b14-c4013b348328" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:to="loc_srt_MaximumMember_1cae556b-a569-4e2a-8b14-c4013b348328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:to="loc_us-gaap_CreditFacilityDomain_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a73289dc-dd0c-4ada-b3d7-9ea90fb91ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:to="loc_us-gaap_CreditFacilityDomain_a73289dc-dd0c-4ada-b3d7-9ea90fb91ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_33f56a0e-6df9-4944-a04b-e324dea8ce82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a73289dc-dd0c-4ada-b3d7-9ea90fb91ae9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_33f56a0e-6df9-4944-a04b-e324dea8ce82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_750c567f-5608-419d-8762-bee30b42d5f5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_750c567f-5608-419d-8762-bee30b42d5f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61a9c337-893d-4283-9a09-c667141c6a87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61a9c337-893d-4283-9a09-c667141c6a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1ef9535-2cf2-4e66-8bce-2cc038bef847" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61a9c337-893d-4283-9a09-c667141c6a87" xlink:to="loc_us-gaap_SubsequentEventMember_e1ef9535-2cf2-4e66-8bce-2cc038bef847" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended" id="i774bc1da34104f7989a7e4b06223815a_DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/Leases" xlink:type="simple" xlink:href="gild-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/Leases" xlink:type="extended" id="i8cf9b01cc3dc407ca496cd8e40c1e173_Leases"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/LeasesTables" xlink:type="extended" id="i8b295a769cf74e3f970791673ad3865d_LeasesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i1507768bc44b45a2abff1726e5f19ff3_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesBalanceSheetLocationDetailDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="extended" id="ie74631cef1c3410dbbe61b043738c587_LeasesBalanceSheetLocationDetailDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSupplementalInformationRelatedtoLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended" id="i2e13e371060441ec9772549e951dd01a_LeasesSupplementalInformationRelatedtoLeasesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended" id="i0e2c6afada9e46828ae78be34c10fcde_LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gild-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="extended" id="if46e04302d994726b46b0b91aff626e2_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i4abd8d44fdc44b2595465ab6c520c1c4_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6082128b-b0b9-4fe1-88d0-b7ffbfa0f02a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6082128b-b0b9-4fe1-88d0-b7ffbfa0f02a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMotionInvalidatedForPastDamagesValue_5de7b9dd-a30e-43e2-9157-f94d2496d2e6" xlink:href="gild-20201231.xsd#gild_LossContingencyMotionInvalidatedForPastDamagesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyMotionInvalidatedForPastDamagesValue_5de7b9dd-a30e-43e2-9157-f94d2496d2e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_8e389c63-eae2-48a2-ace9-dc75cf39d860" xlink:href="gild-20201231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_8e389c63-eae2-48a2-ace9-dc75cf39d860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesonPastSales_25b74c24-17af-4f0f-a561-700251626e9b" xlink:href="gild-20201231.xsd#gild_JudgmentEnhancedDamagesonPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_JudgmentEnhancedDamagesonPastSales_25b74c24-17af-4f0f-a561-700251626e9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_dfc53fcf-d520-4be9-bdf7-e9780615b52d" xlink:href="gild-20201231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_dfc53fcf-d520-4be9-bdf7-e9780615b52d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_bd857bb5-53bc-4e88-9f80-b7e56e7a7e88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_bd857bb5-53bc-4e88-9f80-b7e56e7a7e88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLossPastSales_2ca32275-a5b4-4b63-9c6c-615f3e9bc9d7" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateofPossibleLossPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyEstimateofPossibleLossPastSales_2ca32275-a5b4-4b63-9c6c-615f3e9bc9d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_78f24944-b33f-424b-b122-be43ac34d94f" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_78f24944-b33f-424b-b122-be43ac34d94f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_65640659-a0d2-4a5f-ade6-4615121af92a" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_65640659-a0d2-4a5f-ade6-4615121af92a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cee5823b-440d-47d1-bed8-2287e438faa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cee5823b-440d-47d1-bed8-2287e438faa7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_aea9b3ff-5df6-4e3b-a98c-e4034668d599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_aea9b3ff-5df6-4e3b-a98c-e4034668d599" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_7eb2ae86-2c6e-4c15-9248-6ae874a98783" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_7eb2ae86-2c6e-4c15-9248-6ae874a98783" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_2dfe75f0-c081-4b86-84a6-4a7096b3b9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_2dfe75f0-c081-4b86-84a6-4a7096b3b9c9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_89cdc798-ce87-4109-b713-5348f0277e19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_89cdc798-ce87-4109-b713-5348f0277e19" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_6619d784-eec6-41e1-80e2-53a6b102f9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_6619d784-eec6-41e1-80e2-53a6b102f9b8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_7545847e-44c1-4b0b-9b12-659a091133ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_7545847e-44c1-4b0b-9b12-659a091133ad" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_94556e79-713b-4ff4-9350-1a45c4ca6aa2_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:to="loc_srt_RangeMember_94556e79-713b-4ff4-9350-1a45c4ca6aa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:to="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ddee2747-0d57-43be-a708-d5365d103ad3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:to="loc_srt_MinimumMember_ddee2747-0d57-43be-a708-d5365d103ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b5f813dc-4a8b-4126-aac6-b0064d2500e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:to="loc_srt_MaximumMember_b5f813dc-4a8b-4126-aac6-b0064d2500e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_05e40193-39d4-44d0-bf19-a63644621198_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:to="loc_srt_LitigationCaseTypeDomain_05e40193-39d4-44d0-bf19-a63644621198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:to="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IdenixPharmaceuticalsIncMember_c2bc591d-7bfe-46a1-a21a-79409c06b15c" xlink:href="gild-20201231.xsd#gild_IdenixPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:to="loc_gild_IdenixPharmaceuticalsIncMember_c2bc591d-7bfe-46a1-a21a-79409c06b15c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_7e3af210-ab51-4d63-be0a-2c237a69330e" xlink:href="gild-20201231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_7e3af210-ab51-4d63-be0a-2c237a69330e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_19276772-d452-4c29-b021-ed9fa4cb5b55" xlink:href="gild-20201231.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:to="loc_gild_ViiVHealthcareCompanyMember_19276772-d452-4c29-b021-ed9fa4cb5b55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2a9f659b-f053-41fb-91c2-4fe4ab20d55f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:to="loc_us-gaap_LitigationStatusDomain_2a9f659b-f053-41fb-91c2-4fe4ab20d55f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a4ae65ce-4f67-43ab-9200-bfb65e51c0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:to="loc_us-gaap_LitigationStatusDomain_a4ae65ce-4f67-43ab-9200-bfb65e51c0bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_408ea93c-7186-4b9b-8325-681f08e80726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a4ae65ce-4f67-43ab-9200-bfb65e51c0bd" xlink:to="loc_us-gaap_PendingLitigationMember_408ea93c-7186-4b9b-8325-681f08e80726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:to="loc_us-gaap_OtherCommitmentsDomain_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_7f6a33ff-a63a-44cb-98f4-9fe765055aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:to="loc_us-gaap_OtherCommitmentsDomain_7f6a33ff-a63a-44cb-98f4-9fe765055aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ActivePharmaceuticalIngredientMember_5640d39f-c259-43da-98e9-c5f29e826762" xlink:href="gild-20201231.xsd#gild_ActivePharmaceuticalIngredientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_7f6a33ff-a63a-44cb-98f4-9fe765055aea" xlink:to="loc_gild_ActivePharmaceuticalIngredientMember_5640d39f-c259-43da-98e9-c5f29e826762" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquity" xlink:type="extended" id="i22350ce86b86418484e62e09b534c9f7_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="extended" id="if059a318da9e4c71b72397ea6c92e45e_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended" id="iefdce0f7aa454131b46cb4e4f8bad4bc_StockholdersEquityRepurchasesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65fb24d9-075f-4b86-8a78-145e184f412b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65fb24d9-075f-4b86-8a78-145e184f412b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_fd5a2742-4115-4561-800f-4d19e2bf8282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_fd5a2742-4115-4561-800f-4d19e2bf8282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_064307b4-9436-47d7-82ed-ead995287892" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_064307b4-9436-47d7-82ed-ead995287892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4001ed08-01c1-454e-bf68-46ec215088be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4001ed08-01c1-454e-bf68-46ec215088be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2743c9d3-f684-47a4-9b11-9e3e57c89498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2743c9d3-f684-47a4-9b11-9e3e57c89498" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0bf1343e-d1e6-409e-8423-849e751fb4c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0bf1343e-d1e6-409e-8423-849e751fb4c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_887821f6-d84f-48fa-83bc-8bbeda9fb6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_887821f6-d84f-48fa-83bc-8bbeda9fb6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37177129-8fbd-416b-97ff-f97a0c6b7eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_887821f6-d84f-48fa-83bc-8bbeda9fb6d5" xlink:to="loc_us-gaap_SubsequentEventMember_37177129-8fbd-416b-97ff-f97a0c6b7eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_33fb4515-fc83-4585-95c1-2b9e8509a12f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_33fb4515-fc83-4585-95c1-2b9e8509a12f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_8bcd10f0-422a-4ddd-a5db-cdf89db488f4" xlink:href="gild-20201231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_8bcd10f0-422a-4ddd-a5db-cdf89db488f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_cd3d9221-d10c-44aa-9bd2-222a9ade74ff" xlink:href="gild-20201231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_cd3d9221-d10c-44aa-9bd2-222a9ade74ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PubliclyAnnouncedProgramMember_063e39f8-30f4-4a96-b23d-f8955700befe" xlink:href="gild-20201231.xsd#gild_PubliclyAnnouncedProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:to="loc_gild_PubliclyAnnouncedProgramMember_063e39f8-30f4-4a96-b23d-f8955700befe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended" id="i5c8368246ea54bbabd91721b43576f0b_StockholdersEquityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_aba38248-39dc-4a96-ada2-7e7952639280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_aba38248-39dc-4a96-ada2-7e7952639280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_03c47f30-aab3-4a67-919e-e7d2ecdedb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:to="loc_us-gaap_DividendsCommonStockCash_03c47f30-aab3-4a67-919e-e7d2ecdedb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:to="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02838bfe-6fe6-4972-9022-2de5b09148f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02838bfe-6fe6-4972-9022-2de5b09148f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c507f898-28ac-41cf-a440-729d71249c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c507f898-28ac-41cf-a440-729d71249c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2996e0d0-f14a-4ef3-96fc-2522453dff3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c507f898-28ac-41cf-a440-729d71249c4b" xlink:to="loc_us-gaap_SubsequentEventMember_2996e0d0-f14a-4ef3-96fc-2522453dff3d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended" id="i35be91163c864a238ef886ae645d784a_StockholdersEquityPreferredStockDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="iece59b72e4734e20ac7841a75b4bbfb1_StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9540feef-6ec2-4733-b6d8-6c0960e136b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9540feef-6ec2-4733-b6d8-6c0960e136b7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_30af8c05-45f3-47fd-8941-cdc2aea24243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_30af8c05-45f3-47fd-8941-cdc2aea24243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4efe1862-d251-4061-9925-b648cb202c28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4efe1862-d251-4061-9925-b648cb202c28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a357d8cd-02af-481f-bd1f-cd6080bf9608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a357d8cd-02af-481f-bd1f-cd6080bf9608" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3349c832-f95a-4f9c-bede-0d0a0fe89935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3349c832-f95a-4f9c-bede-0d0a0fe89935" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7bb7dd46-1cc9-4ac2-acee-8615ee61ad00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7bb7dd46-1cc9-4ac2-acee-8615ee61ad00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb459249-1fc0-4d97-8d13-1b3fc2ecb1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9540feef-6ec2-4733-b6d8-6c0960e136b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9ea97eb-024b-41a3-8794-ef406b1a291b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:to="loc_us-gaap_EquityComponentDomain_f9ea97eb-024b-41a3-8794-ef406b1a291b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:to="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_62bbfa3e-0ce1-4d33-82be-5c21ec7b5dee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_62bbfa3e-0ce1-4d33-82be-5c21ec7b5dee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_91e7c676-8513-4453-9d6f-73ec1947bc20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_91e7c676-8513-4453-9d6f-73ec1947bc20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_850673eb-9ec8-49f0-87d6-83d149c5977b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_850673eb-9ec8-49f0-87d6-83d149c5977b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3b423dd-0c64-4a39-b550-6dd44042c644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3b423dd-0c64-4a39-b550-6dd44042c644" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefits"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefits" xlink:type="extended" id="ie1ffa18886a74634880828f26101f17a_EmployeeBenefits"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="extended" id="i54144fe6de9149b3bd2a1da54b8f2411_EmployeeBenefitsTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended" id="ia8cb197e32194e0d9bb83be6af4831f8_EmployeeBenefitsStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b9937fc-42ab-476e-b2b8-0b8a7bee5f23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b9937fc-42ab-476e-b2b8-0b8a7bee5f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb8f4605-d39e-4ca7-9472-873a2e0541ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb8f4605-d39e-4ca7-9472-873a2e0541ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_956dc754-c3f1-4bcd-bf11-ba72a47bfdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_956dc754-c3f1-4bcd-bf11-ba72a47bfdb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0b2be3e8-f936-4284-91c9-2240465e6dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0b2be3e8-f936-4284-91c9-2240465e6dd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4a669cc0-b436-41a5-b63b-ac498da3293d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4a669cc0-b436-41a5-b63b-ac498da3293d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79366731-044b-4e9e-87fe-51cbc479a547" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5448900-9060-43bc-a29d-47f7537069d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5448900-9060-43bc-a29d-47f7537069d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f447379a-87d7-4f17-ae4e-bb13bc845313" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f447379a-87d7-4f17-ae4e-bb13bc845313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b1be798-09a8-4ae7-9a2b-85c9f5fc0c19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b1be798-09a8-4ae7-9a2b-85c9f5fc0c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96650264-5e7e-4757-a28f-085a1b696b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96650264-5e7e-4757-a28f-085a1b696b5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5f9f6c79-8183-4652-a671-4f7a1aec03a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5f9f6c79-8183-4652-a671-4f7a1aec03a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_87fe2b74-50ee-49ec-80f3-620b53cd457b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_87fe2b74-50ee-49ec-80f3-620b53cd457b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01ad6c3e-791f-42b1-b25f-256cd653b6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01ad6c3e-791f-42b1-b25f-256cd653b6ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60e2329e-b601-4e07-a143-419fd0657336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_facfb68d-34dd-4fc7-9ebd-93ea3df5fa44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_facfb68d-34dd-4fc7-9ebd-93ea3df5fa44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f4ca878-5982-41f5-8b88-6fd5f1b2379a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f4ca878-5982-41f5-8b88-6fd5f1b2379a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6689f831-e245-4bfd-955d-577c787466be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6689f831-e245-4bfd-955d-577c787466be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21244b38-21f4-4e36-b42f-1efdcbdf8d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21244b38-21f4-4e36-b42f-1efdcbdf8d81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6423674b-b6c5-4d03-8adc-83c207ece0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6423674b-b6c5-4d03-8adc-83c207ece0d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_82de98cb-b597-4837-9580-7b60afaf8513" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_82de98cb-b597-4837-9580-7b60afaf8513" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42d4cd9e-e343-4b7a-bf45-e81028833f31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42d4cd9e-e343-4b7a-bf45-e81028833f31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2eec7e9f-a668-47e1-9241-d958068a57aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2eec7e9f-a668-47e1-9241-d958068a57aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:to="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66697d36-0c6a-4d92-a356-e134f2fb8760_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66697d36-0c6a-4d92-a356-e134f2fb8760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2294da45-9db9-4a29-afce-6e12ce9f67b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2294da45-9db9-4a29-afce-6e12ce9f67b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ce3d73d5-753b-451f-b636-063f1dc5e17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2294da45-9db9-4a29-afce-6e12ce9f67b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ce3d73d5-753b-451f-b636-063f1dc5e17b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="extended" id="i155983b944c64110b6b80197c24142ac_EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_633cfd7e-8077-4fe4-9c3d-eec4d9db05ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_633cfd7e-8077-4fe4-9c3d-eec4d9db05ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_777c2db4-7ef4-4818-83a1-83e6ab0e50b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_777c2db4-7ef4-4818-83a1-83e6ab0e50b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6ea684e-d67f-474b-9285-dea2f63ed100" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6ea684e-d67f-474b-9285-dea2f63ed100" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afbd0707-ef25-4860-94a8-4cf95116abba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afbd0707-ef25-4860-94a8-4cf95116abba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf32f905-dd3b-4d2a-8ce5-4459ec11b858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf32f905-dd3b-4d2a-8ce5-4459ec11b858" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2237bef-43b8-44db-af11-5254ada054f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_455aabd2-5b98-4a4d-a49a-2662a72093e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_455aabd2-5b98-4a4d-a49a-2662a72093e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_672c0ef4-654a-4649-b25f-ed7346e9428c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_672c0ef4-654a-4649-b25f-ed7346e9428c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f199c584-a93c-4d8e-92f6-1b3534e7897d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f199c584-a93c-4d8e-92f6-1b3534e7897d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b4ac426-b208-4b34-a3ff-b9c809ce5212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b4ac426-b208-4b34-a3ff-b9c809ce5212" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e64e9ff-9b44-4476-9d39-a06f0a1c9bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_f1516210-f5a7-4715-a98c-89e8155cf518" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_f1516210-f5a7-4715-a98c-89e8155cf518" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_98fffff5-e622-491f-ad3c-072344b4f4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_98fffff5-e622-491f-ad3c-072344b4f4b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:to="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64dfd99b-dd3e-43ed-a31d-51624d173b53_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:to="loc_srt_RangeMember_64dfd99b-dd3e-43ed-a31d-51624d173b53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:to="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c0087bde-bbe5-4fdd-aa27-f8ab7b99c495" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:to="loc_srt_MinimumMember_c0087bde-bbe5-4fdd-aa27-f8ab7b99c495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_255a3e9f-755d-49f2-b3a7-788025db6e91" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:to="loc_srt_MaximumMember_255a3e9f-755d-49f2-b3a7-788025db6e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:to="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c7f96b-5205-4abd-b382-9a2acace9657_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c7f96b-5205-4abd-b382-9a2acace9657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_da24b575-d32c-4790-95fa-3efbe940f053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:to="loc_us-gaap_PerformanceSharesMember_da24b575-d32c-4790-95fa-3efbe940f053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_42417599-7762-442f-bd2b-31eac04417ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_42417599-7762-442f-bd2b-31eac04417ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember_c7fca1ae-6652-4d2a-b72f-d36b74491af0" xlink:href="gild-20201231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:to="loc_gild_RestrictedStockandPerformanceShareAwardsMember_c7fca1ae-6652-4d2a-b72f-d36b74491af0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended" id="i0973faba453843be921ae0fd271f375e_EmployeeBenefitsSummaryofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_de69c1c0-6fff-43a9-96fc-295c7fd993df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_de69c1c0-6fff-43a9-96fc-295c7fd993df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a6d4f2a0-6813-4701-8f2c-2499201526fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a6d4f2a0-6813-4701-8f2c-2499201526fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_af25ed75-eaa1-41ff-889a-9dbb0a508b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_af25ed75-eaa1-41ff-889a-9dbb0a508b36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fd5b2a04-de14-4ca0-90ff-5c087483e6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_ShareBasedCompensation_fd5b2a04-de14-4ca0-90ff-5c087483e6d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_09f3bed3-1f75-418d-a292-0c2dd5339a85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_09f3bed3-1f75-418d-a292-0c2dd5339a85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_1248c105-c2f0-4757-b4bf-48da077c5326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_1248c105-c2f0-4757-b4bf-48da077c5326" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_babb5c50-b22a-4b1b-af7e-0bc910af39d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:to="loc_us-gaap_CostOfSalesMember_babb5c50-b22a-4b1b-af7e-0bc910af39d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f58af20-9e70-4f31-bcf0-9061f10d978f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f58af20-9e70-4f31-bcf0-9061f10d978f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_760104a4-ed3a-413a-bb18-a46401825bee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_760104a4-ed3a-413a-bb18-a46401825bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_218bce5b-5087-4774-b9a4-cbf37674113b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_218bce5b-5087-4774-b9a4-cbf37674113b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_8f136475-fc0d-46f9-9632-46f338a6ede3" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_218bce5b-5087-4774-b9a4-cbf37674113b" xlink:to="loc_gild_ImmunomedicsIncMember_8f136475-fc0d-46f9-9632-46f338a6ede3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_47892b18-56ed-4546-994e-430c0f9954fa_default" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:to="loc_gild_AssetAcquisitionDomain_47892b18-56ed-4546-994e-430c0f9954fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_65bc066f-bd58-466d-90f6-b3e467293a80" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:to="loc_gild_AssetAcquisitionDomain_65bc066f-bd58-466d-90f6-b3e467293a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_bd47a989-9e35-412b-aac9-8822365404ed" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_AssetAcquisitionDomain_65bc066f-bd58-466d-90f6-b3e467293a80" xlink:to="loc_gild_FortySevenIncMember_bd47a989-9e35-412b-aac9-8822365404ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended" id="i59da598b5c0f49c6a304625d51e6286d_EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8bc93963-bb2d-4708-86bd-cef5db0d7cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8bc93963-bb2d-4708-86bd-cef5db0d7cb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_058f436c-c4f7-44b0-9fe7-407496db7a71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_058f436c-c4f7-44b0-9fe7-407496db7a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9a296b3e-e19c-4ff6-b2d9-d448d67b7bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9a296b3e-e19c-4ff6-b2d9-d448d67b7bd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d810ab21-60d0-487a-9148-743a33880d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d810ab21-60d0-487a-9148-743a33880d24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:to="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_463fd23b-1b73-4d29-997e-7df1e3b23fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_463fd23b-1b73-4d29-997e-7df1e3b23fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c15b707d-1c05-4fd5-8e28-4aee923a5d11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:to="loc_us-gaap_EmployeeStockMember_c15b707d-1c05-4fd5-8e28-4aee923a5d11" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended" id="ib0bfd92469cb43d8882687f636442a50_EmployeeBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e37cd14c-258c-408d-b572-6436639e654d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e37cd14c-258c-408d-b572-6436639e654d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f52e43c2-5594-4021-9628-acd46f16718e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f52e43c2-5594-4021-9628-acd46f16718e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9ac99fad-1d09-4c55-91d3-866f09bcd713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9ac99fad-1d09-4c55-91d3-866f09bcd713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f17875e-2d6b-46ea-a95a-573c7b9ef742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f17875e-2d6b-46ea-a95a-573c7b9ef742" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_67f43362-edca-492c-9ca8-f0d753251d74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_67f43362-edca-492c-9ca8-f0d753251d74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_16fd2a66-3f12-4702-bb9d-f4312b4668e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_16fd2a66-3f12-4702-bb9d-f4312b4668e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_06b26cdc-7d02-4b41-b08d-d6c882346911" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_06b26cdc-7d02-4b41-b08d-d6c882346911" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e094123a-204f-48f6-ab80-e3cfaa015854" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e094123a-204f-48f6-ab80-e3cfaa015854" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_885b6059-7c0f-4df3-936f-c3f23238c4c3" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_885b6059-7c0f-4df3-936f-c3f23238c4c3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e89f08c2-52d1-4a27-9450-692b7d5a7279" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e89f08c2-52d1-4a27-9450-692b7d5a7279" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_009f2e72-0d88-4fa4-a41d-a79c78d04932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_009f2e72-0d88-4fa4-a41d-a79c78d04932" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3953a73c-dfca-4594-aefe-e30423658cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3953a73c-dfca-4594-aefe-e30423658cd6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5231e5b9-ac4c-44d2-bd0d-835f06c7489e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5231e5b9-ac4c-44d2-bd0d-835f06c7489e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d04de5d3-8fdd-4485-a194-63f91f69b75d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d04de5d3-8fdd-4485-a194-63f91f69b75d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3083f51e-60c5-4ef3-8980-379db080fd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3083f51e-60c5-4ef3-8980-379db080fd8b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f5b436b2-c67e-4474-9e7b-6f603c20dc35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f5b436b2-c67e-4474-9e7b-6f603c20dc35" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_3da6445f-bbb6-4c11-a6e2-2418833e8910" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_3da6445f-bbb6-4c11-a6e2-2418833e8910" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b8f0b4df-f9bf-48cc-ab25-3ebc685c2eed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b8f0b4df-f9bf-48cc-ab25-3ebc685c2eed" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:href="gild-20201231.xsd#gild_TotalFairValueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain_201f6998-d6f2-4bcb-9425-c906e6d2b954_default" xlink:href="gild-20201231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:to="loc_gild_TotalGrantDateFairValueDomain_201f6998-d6f2-4bcb-9425-c906e6d2b954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:href="gild-20201231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:to="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatGrantDateMember_3aa35cf6-68aa-46f9-b4a0-b5d0c8ef08cf" xlink:href="gild-20201231.xsd#gild_FairValueatGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:to="loc_gild_FairValueatGrantDateMember_3aa35cf6-68aa-46f9-b4a0-b5d0c8ef08cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatVestingDateMember_5f6f7c46-a1dc-4547-baf4-6093a76fc734" xlink:href="gild-20201231.xsd#gild_FairValueatVestingDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:to="loc_gild_FairValueatVestingDateMember_5f6f7c46-a1dc-4547-baf4-6093a76fc734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f7b78f8a-db98-4b42-b0bd-98c8488ccf21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f7b78f8a-db98-4b42-b0bd-98c8488ccf21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_a24f6908-362d-4646-abdb-d0dcce96b55d" xlink:href="gild-20201231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f7b78f8a-db98-4b42-b0bd-98c8488ccf21" xlink:to="loc_gild_DeferredCompensationPlanMember_a24f6908-362d-4646-abdb-d0dcce96b55d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26718ef3-d714-40f2-9f3e-7ddd7e20df66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_26718ef3-d714-40f2-9f3e-7ddd7e20df66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670b7518-275d-4885-9aec-c9705e44cd98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670b7518-275d-4885-9aec-c9705e44cd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dc6f8656-c136-46f2-80bc-c601db46cd53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670b7518-275d-4885-9aec-c9705e44cd98" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dc6f8656-c136-46f2-80bc-c601db46cd53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_13de4988-e095-41ab-a989-97af4027558f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_13de4988-e095-41ab-a989-97af4027558f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6328fc5-4396-4889-ba60-34dddf56d228" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6328fc5-4396-4889-ba60-34dddf56d228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_89da4f19-3f59-421b-858f-25e4d72d76e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6328fc5-4396-4889-ba60-34dddf56d228" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_89da4f19-3f59-421b-858f-25e4d72d76e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c82c303-c5e7-4397-87b9-e14aa57b2ecb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c82c303-c5e7-4397-87b9-e14aa57b2ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f8cfdba7-96b9-4e62-8d18-c9dcd81fcd2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f8cfdba7-96b9-4e62-8d18-c9dcd81fcd2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6216b0d9-518b-46a3-b68d-7c9fff4da8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6216b0d9-518b-46a3-b68d-7c9fff4da8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3815c184-22e9-40bf-90db-5987ad577637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_PerformanceSharesMember_3815c184-22e9-40bf-90db-5987ad577637" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember_277243c1-a375-423e-b280-949702ea4f9d" xlink:href="gild-20201231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_gild_RestrictedStockandPerformanceShareAwardsMember_277243c1-a375-423e-b280-949702ea4f9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b7674f52-538f-4ff6-a9d4-5899cd1e964b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_EmployeeStockMember_b7674f52-538f-4ff6-a9d4-5899cd1e964b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e959e9e0-874c-4f76-a886-b2338b583c19_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:to="loc_srt_RangeMember_e959e9e0-874c-4f76-a886-b2338b583c19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:to="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b5ae760b-20d6-472d-a94b-57462423c879" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:to="loc_srt_MinimumMember_b5ae760b-20d6-472d-a94b-57462423c879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6de94285-5e29-4d59-80b2-ce7c16133791" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:to="loc_srt_MaximumMember_6de94285-5e29-4d59-80b2-ce7c16133791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7d1def92-632a-4a47-8f79-90487d8eccaf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:to="loc_us-gaap_PlanNameDomain_7d1def92-632a-4a47-8f79-90487d8eccaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:to="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_e968102c-c764-4016-bedb-7387bb2ea403" xlink:href="gild-20201231.xsd#gild_GileadSciencesInc2004EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:to="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_e968102c-c764-4016-bedb-7387bb2ea403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_42162efc-eaca-43a3-b1f8-82b8d62b9c41" xlink:href="gild-20201231.xsd#gild_GileadSciencesInc2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:to="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_42162efc-eaca-43a3-b1f8-82b8d62b9c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_2aceaed1-2ffe-4dcc-b217-d629f7147c34" xlink:href="gild-20201231.xsd#gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:to="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_2aceaed1-2ffe-4dcc-b217-d629f7147c34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86b5d76b-f21c-431e-b915-d508da92ed88_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:to="loc_us-gaap_ClassOfStockDomain_86b5d76b-f21c-431e-b915-d508da92ed88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef23b67d-8489-481b-afc0-799b3744ffd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:to="loc_us-gaap_ClassOfStockDomain_ef23b67d-8489-481b-afc0-799b3744ffd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b42376ac-227a-4f75-91c1-af680326caef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ef23b67d-8489-481b-afc0-799b3744ffd3" xlink:to="loc_us-gaap_CommonStockMember_b42376ac-227a-4f75-91c1-af680326caef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholders"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="extended" id="i552fac8899c2423cb4c0a07d1aaaad3c_NetIncomePerShareAttributabletoGileadCommonShareholders"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="extended" id="i0adec4e20e144e7eb8f41fb946aa5bd1_NetIncomePerShareAttributabletoGileadCommonShareholdersTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="extended" id="i9253a4ed227743369e7393231ce831b0_NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended" id="i7cb3e65114c34694be1b764d90ca918c_NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxes" xlink:type="extended" id="ibfbdf54e9f774be6960156ed11f266cf_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="extended" id="i1ae74f371acd46249927a52c524f5498_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended" id="i6a1c81cd45d0475a948983e5cabc3cc5_IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="extended" id="i818f10af6b1343459f809a8ca66aff04_IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended" id="i93a83acaf21c4e7ab167c23f20ee2ea0_IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="ib793e66a9dda47d3b52d8c20c4b8d895_IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="extended" id="i22caaed777554170abbb4250c2a66656_IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i0917e751658b44e18920b164017f360c_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2f994e80-100b-4985-9b28-3788f53832a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2f994e80-100b-4985-9b28-3788f53832a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4b4ab7df-6d9e-4224-9b88-ad1ec411e9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4b4ab7df-6d9e-4224-9b88-ad1ec411e9e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_abcc9540-6a92-4764-8f5e-64d7e14f3d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_abcc9540-6a92-4764-8f5e-64d7e14f3d26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_47c37ded-d72c-4496-b432-2e065ac197b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_47c37ded-d72c-4496-b432-2e065ac197b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c6cbacf4-1ab3-4dba-a2ec-bf4e7421d7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c6cbacf4-1ab3-4dba-a2ec-bf4e7421d7fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_13d90a65-e104-475b-8d20-caa5b1d85200" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_13d90a65-e104-475b-8d20-caa5b1d85200" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8eb498af-cece-4acf-adb2-da114bfb6948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8eb498af-cece-4acf-adb2-da114bfb6948" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_57aed4a7-9c2d-4a10-a184-6e1637a9b7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_57aed4a7-9c2d-4a10-a184-6e1637a9b7a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e48338c1-2fbc-4dd0-b5b3-b4f729678a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e48338c1-2fbc-4dd0-b5b3-b4f729678a8d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ad9937be-874c-4af8-893a-be618b6bde39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ad9937be-874c-4af8-893a-be618b6bde39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6a35a745-8a78-4c55-9a15-796d9fa35cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6a35a745-8a78-4c55-9a15-796d9fa35cd6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_53498ec0-7ea3-438b-a7f6-002e7282df49_default" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_53498ec0-7ea3-438b-a7f6-002e7282df49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_2814bb5e-8ef7-4632-a596-b78e98bd1a37" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_2814bb5e-8ef7-4632-a596-b78e98bd1a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_60d5fba1-0e40-431d-ba1a-2ff89bd3ca17" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_2814bb5e-8ef7-4632-a596-b78e98bd1a37" xlink:to="loc_gild_IntangibleAssetTransferMember_60d5fba1-0e40-431d-ba1a-2ff89bd3ca17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_193be21e-c264-491f-95e9-1709512f6c73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_193be21e-c264-491f-95e9-1709512f6c73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a9e5dabc-453f-4b87-9099-4c9f6721b2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:to="loc_us-gaap_DomesticCountryMember_a9e5dabc-453f-4b87-9099-4c9f6721b2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a67f57fd-5e0a-40d2-8455-4927f59c69a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a67f57fd-5e0a-40d2-8455-4927f59c69a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnaudited"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited" xlink:type="extended" id="i78e03246351743b48790c025a924defe_SelectedQuarterlyFinancialInformationUnaudited"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables" xlink:type="extended" id="i6e37a2aabad5431999c809c2ae251402_SelectedQuarterlyFinancialInformationUnauditedTables"/>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" id="ia5ed94aa043e481fa3fcf6fc88bc8ea8_SelectedQuarterlyFinancialInformationUnauditedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:href="gild-20201231.xsd#gild_SelectedQuarterlyFinancialInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_69a10312-b11a-45a9-8030-c44e142f15d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_Revenues_69a10312-b11a-45a9-8030-c44e142f15d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_53381454-0b45-44d3-9bcb-d5380b88d87a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_GrossProfit_53381454-0b45-44d3-9bcb-d5380b88d87a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28c3eeb5-a101-4ff0-be05-0042245313df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_ProfitLoss_28c3eeb5-a101-4ff0-be05-0042245313df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33fee853-34ea-42f9-9cb9-8d84650fd47a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_NetIncomeLoss_33fee853-34ea-42f9-9cb9-8d84650fd47a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_034c0bac-b36e-4db7-b1ce-77d4906557d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EarningsPerShareBasic_034c0bac-b36e-4db7-b1ce-77d4906557d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c491d5a7-1c69-44a3-a2a7-40e8239d650e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c491d5a7-1c69-44a3-a2a7-40e8239d650e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_375ca4e5-8ea5-4986-8957-55761bec8529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_375ca4e5-8ea5-4986-8957-55761bec8529" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_97ccbfa2-3c7e-4262-ada9-08272888b78c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_97ccbfa2-3c7e-4262-ada9-08272888b78c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f7096ea4-8ec5-4941-98f2-7cfcdd8be70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f7096ea4-8ec5-4941-98f2-7cfcdd8be70a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_061911e5-fba1-4ec5-8c9c-41dfd5d7ef26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_061911e5-fba1-4ec5-8c9c-41dfd5d7ef26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_ea267d10-4751-463d-8efd-3a5c778d439b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_ea267d10-4751-463d-8efd-3a5c778d439b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e570ea6f-7783-417b-befc-a9ec3528fa59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e570ea6f-7783-417b-befc-a9ec3528fa59" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9efcb9c7-b0e7-4032-9567-6d4399a59468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_InventoryWriteDown_9efcb9c7-b0e7-4032-9567-6d4399a59468" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:href="gild-20201231.xsd#gild_SelectedQuarterlyFinancialInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_485ddb21-3ea1-41d3-8f7d-6da9250bedb8_default" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:to="loc_gild_AssetAcquisitionDomain_485ddb21-3ea1-41d3-8f7d-6da9250bedb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_593883b4-d7a9-4b53-96c4-eefcd289c533" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:to="loc_gild_AssetAcquisitionDomain_593883b4-d7a9-4b53-96c4-eefcd289c533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_4beb9cd5-b711-45e1-9e4a-eb2a71132bd7" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_AssetAcquisitionDomain_593883b4-d7a9-4b53-96c4-eefcd289c533" xlink:to="loc_gild_FortySevenIncMember_4beb9cd5-b711-45e1-9e4a-eb2a71132bd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7b76980-e13e-4486-bcd7-3edf18ec10f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7b76980-e13e-4486-bcd7-3edf18ec10f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7014f29b-9865-4d65-801d-6b0897a4a539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7014f29b-9865-4d65-801d-6b0897a4a539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_a3d8cb75-a865-49f4-8482-de3afa56cf06" xlink:href="gild-20201231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7014f29b-9865-4d65-801d-6b0897a4a539" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_a3d8cb75-a865-49f4-8482-de3afa56cf06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eee597de-0565-4861-965e-1b46ab7f0a96_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eee597de-0565-4861-965e-1b46ab7f0a96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_9c6eb00b-454c-44c8-bf5d-90f651fb71b7" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:to="loc_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_9c6eb00b-454c-44c8-bf5d-90f651fb71b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_d43319a3-f005-474f-8024-be95a4b37af5" xlink:href="gild-20201231.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:to="loc_gild_GalapagosMember_d43319a3-f005-474f-8024-be95a4b37af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6905dd3f-ff22-40e5-aa9e-d7b33b795c96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6905dd3f-ff22-40e5-aa9e-d7b33b795c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c0e7734-c526-4b80-b79f-6ce6b5c9fe7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c0e7734-c526-4b80-b79f-6ce6b5c9fe7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_3b6fc3d5-9d0a-413d-b223-e89f779a5bf1" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c0e7734-c526-4b80-b79f-6ce6b5c9fe7d" xlink:to="loc_gild_ImmunomedicsIncMember_3b6fc3d5-9d0a-413d-b223-e89f779a5bf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_a4ed276f-24af-48a6-b601-7e03517e3850_default" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_a4ed276f-24af-48a6-b601-7e03517e3850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_1fe0a33a-8a40-4880-ab4d-0c22938e130c" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_1fe0a33a-8a40-4880-ab4d-0c22938e130c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_2ea2dd6f-c16f-40d3-99b1-c1307969609d" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_1fe0a33a-8a40-4880-ab4d-0c22938e130c" xlink:to="loc_gild_IntangibleAssetTransferMember_2ea2dd6f-c16f-40d3-99b1-c1307969609d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentDomain_a1894f0f-4b85-4b70-831f-117b5eeaee95_default" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:to="loc_gild_UnrealizedGainComponentDomain_a1894f0f-4b85-4b70-831f-117b5eeaee95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentDomain_45a3fd2e-359c-4d6e-afcb-a413cb9962ae" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:to="loc_gild_UnrealizedGainComponentDomain_45a3fd2e-359c-4d6e-afcb-a413cb9962ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_c92e51c7-7706-4752-9b4c-f82086c56a8a" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_UnrealizedGainComponentDomain_45a3fd2e-359c-4d6e-afcb-a413cb9962ae" xlink:to="loc_gild_IntangibleAssetTransferMember_c92e51c7-7706-4752-9b4c-f82086c56a8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2ce4a009-fa48-4b01-af47-04efef9ba6eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_2ce4a009-fa48-4b01-af47-04efef9ba6eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a3ce4e27-af77-4f9c-a73e-221e5cd50035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a3ce4e27-af77-4f9c-a73e-221e5cd50035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_1831b637-36b6-44a6-9fb0-f7e4a699db0e" xlink:href="gild-20201231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a3ce4e27-af77-4f9c-a73e-221e5cd50035" xlink:to="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_1831b637-36b6-44a6-9fb0-f7e4a699db0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionDomain_754133a1-65e0-4263-8e29-c0498e6d0ccb_default" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:to="loc_gild_EPSImpactbyTransactionDomain_754133a1-65e0-4263-8e29-c0498e6d0ccb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionDomain_424d841b-a102-496b-8388-311d967d273a" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:to="loc_gild_EPSImpactbyTransactionDomain_424d841b-a102-496b-8388-311d967d273a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FavorableEPSImpactMember_08fa2190-848c-4403-8dcf-4ac74081a5d7" xlink:href="gild-20201231.xsd#gild_FavorableEPSImpactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_EPSImpactbyTransactionDomain_424d841b-a102-496b-8388-311d967d273a" xlink:to="loc_gild_FavorableEPSImpactMember_08fa2190-848c-4403-8dcf-4ac74081a5d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>gild-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c95e6174-aa16-488c-b0f6-cc28c1f33ed5,g:86b29b2d-a791-4b12-a644-3051a1d6b3ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d8e2b7bd-b21c-4bf7-afcd-a6068b5c6802_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a7d2b72-1258-47e7-9691-bb0f675071a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f2ae0ed8-604c-4236-8f4c-77ba410abcf7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofInventoryLineItems_03a8c78c-43a2-443e-aaed-3c9506c5125d_terseLabel_en-US" xlink:label="lab_gild_ScheduleofInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryLineItems_label_en-US" xlink:label="lab_gild_ScheduleofInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryLineItems_documentation_en-US" xlink:label="lab_gild_ScheduleofInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Disclosure of information about inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofInventoryLineItems" xlink:to="lab_gild_ScheduleofInventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ActivePharmaceuticalIngredientMember_2399fda2-a87f-4914-82ae-01971d423fe4_terseLabel_en-US" xlink:label="lab_gild_ActivePharmaceuticalIngredientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Active pharmaceutical ingredient</link:label>
    <link:label id="lab_gild_ActivePharmaceuticalIngredientMember_label_en-US" xlink:label="lab_gild_ActivePharmaceuticalIngredientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Active Pharmaceutical Ingredient [Member]</link:label>
    <link:label id="lab_gild_ActivePharmaceuticalIngredientMember_documentation_en-US" xlink:label="lab_gild_ActivePharmaceuticalIngredientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Active Pharmaceutical Ingredient [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ActivePharmaceuticalIngredientMember" xlink:href="gild-20201231.xsd#gild_ActivePharmaceuticalIngredientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ActivePharmaceuticalIngredientMember" xlink:to="lab_gild_ActivePharmaceuticalIngredientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_adc8ebcc-7bfe-4f98-8df2-e153e0e3a163_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_1ce69818-ac3b-4688-b44f-858306d5ad37_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under the facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1287725f-19d4-423a-9c38-a98298495ae6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34713e37-d7d5-416a-848f-bacd02291e5b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_428f770b-a211-4b07-9ed8-230b4d23a87d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8c3d3f23-5c57-4891-871e-ba5d3a66e74d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_ac6a25de-130d-43b6-92b9-6e36b96ab0bf_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate on future sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:href="gild-20201231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:to="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_60fbe533-8ea9-4aaf-bcfd-1aff3b69c287_terseLabel_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss representing royalties and prejudgment interest</link:label>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_label_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (Royalties and Post-Judgment Interest)</link:label>
    <link:label id="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_documentation_en-US" xlink:label="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (Royalties and Post-Judgment Interest)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" xlink:to="lab_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_248393f6-decb-4988-8b1c-dfeaf7b6d351_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contribution expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb2e1291-b565-4a02-9091-3ab3cf3da436_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bec99f9d-64df-43d7-a316-417bc5b50ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_927dc823-354f-4579-8333-fd30990feaaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1a5bbe32-4977-45a5-b6ce-9fbb47af89c9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_3cf33326-d5c2-4a09-82f7-60b8b8c7a200_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant-Date Fair Value Per Share</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_d4fba0e2-f846-4171-97a6-c6d584e29cfb_terseLabel_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 stock repurchase program</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember" xlink:href="gild-20201231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2020StockRepurchaseProgramMember" xlink:to="lab_gild_A2020StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ab1889c6-267c-46ed-b4e2-9e913ca6f11a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_5829124f-c8e6-48d6-a728-0b0bca616c39_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties, measurement Input</link:label>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Future Royalties, Liability, Measurement Input</link:label>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Future Royalties, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:href="gild-20201231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:to="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsYescartaMember_0eab5a42-f0bb-4b86-b003-06e413b5915a_terseLabel_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Yescarta</link:label>
    <link:label id="lab_gild_OtherProductsYescartaMember_label_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_OtherProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember" xlink:href="gild-20201231.xsd#gild_OtherProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsYescartaMember" xlink:to="lab_gild_OtherProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f081d528-0e11-4885-b933-92d8f9f554b8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_69f1ff94-5f19-4a68-b347-106a63242790_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_86905a1b-28a8-4c97-a71f-05518c567b91_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_665df6e5-9044-4336-93fb-561084aa319a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_7ddceace-0f35-49cf-b4de-645024ced110_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related to Current Year: Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4220963c-35e1-4aa2-bdcb-dc504e21958a_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_242429b2-3c25-4c5d-b5f3-6a0b0559f1b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9794e48b-eeb4-4e30-8052-b3878db06fdd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_7ab3f582-85a0-4837-af8c-64a3647f79b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly financial information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_d19ac2d6-be96-49c8-bb0d-c21b38024f59_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock acquired</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_145c3757-227b-4f14-862b-063f6e9a5882_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock-based expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f81571ef-26ef-4f05-9646-f6277184e27f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ba72a01d-442c-4662-aceb-cd80dca85d33_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_3af113e2-0472-465c-a6f5-1fa9f7e965d0_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR rate</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05c7856f-620a-4e4e-b617-c1fe6e74ab35_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_676ccfff-5eff-48a1-854e-59114923e1d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_9cb0dedf-eacc-46fa-adaa-0a3ebd4089bf_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus collaboration agreement and stock purchase agreements</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:href="gild-20201231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:to="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3c053f33-ca0d-4f4d-9a5c-bda8755871f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures at December 31, 2020, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_51bc6448-0aad-4e4d-b42c-e1af15537e64_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_7b687fef-a2c5-497b-b913-5c1bd6af08fb_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20201231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_937471bb-3975-4dd7-b9e1-7bce16f986f5_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2020</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2020 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2020Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNoteIssuedSeptember2020Member" xlink:to="lab_gild_SeniorUnsecuredNoteIssuedSeptember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee3ec81f-d58d-4275-b3aa-3ff6fb3eb2b3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_14abf4a0-aa5f-4bc8-8e01-7b55e7ae6830_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UnrealizedGainComponentDomain_847b5f2f-107c-445d-b786-2957fcc0035b_terseLabel_en-US" xlink:label="lab_gild_UnrealizedGainComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain Component [Domain]</link:label>
    <link:label id="lab_gild_UnrealizedGainComponentDomain_label_en-US" xlink:label="lab_gild_UnrealizedGainComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain Component [Domain]</link:label>
    <link:label id="lab_gild_UnrealizedGainComponentDomain_documentation_en-US" xlink:label="lab_gild_UnrealizedGainComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Unrealized Gain Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentDomain" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UnrealizedGainComponentDomain" xlink:to="lab_gild_UnrealizedGainComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3e9e1d0a-edaf-4878-be8f-cd72e7e4530f_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e02d2eef-ef0b-4322-ab0f-90993c601c19_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_3a6f6cf2-346d-48a7-9684-8a9fa10500b2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0c0d821e-e3f6-47ef-b93c-155f5173b831_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ceeaa50b-2f4e-453f-b474-f43e37a29782_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_5bd4cfa4-b087-4297-8660-8c12cf77aa73_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6a41cea2-80d7-435e-b911-32d0fa18a9c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_511e1f8e-07de-4749-8b44-d64cdd8a481a_terseLabel_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Domain]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_label_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Domain]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_documentation_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:to="lab_gild_DeferredIncomeTaxExpenseBenefitComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95843056-5582-4998-b20a-2cf90dde928b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeArrangementTerm_f689bc30-9593-488b-81b6-3b42f2f8c17b_terseLabel_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_gild_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_gild_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm" xlink:href="gild-20201231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeArrangementTerm" xlink:to="lab_gild_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e8ee5d8b-565c-47ed-82e3-3ff4f11b464e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e483af90-bf87-44d6-948f-d8632057a143_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c7503859-6332-44bf-b6c6-cedf81a34090_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_cef7f8ec-2324-4c77-a627-8dc7f308c3f6_terseLabel_en-US" xlink:label="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions to calculate the estimated fair value of awards</link:label>
    <link:label id="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="gild-20201231.xsd#gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_e18ba28c-47b1-4484-ab53-2771bb5993dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_f1ea4c6b-10c6-44a9-b11e-5bb258c897ee_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20201231.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d7a15499-4c06-4268-af57-475c3f88a28a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c3033f9-e938-4d6e-8ec5-5c7c10c743d4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5ad3c288-6376-475a-b711-de2024aa55db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_2ab79e17-eb26-4888-89cb-e9238442e3df_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6eff940e-f03d-43e3-b978-310cdb65d2d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_df081c69-dd2c-453e-8eaf-f0e487cc07ae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_abee655a-1389-47fd-a6d0-e94741558d8e_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tiered royalties, high-end percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties High-end, Percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties High-end, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:href="gild-20201231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_79df169a-d419-4b5e-940d-3cd1930f571a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_bd58f3b9-86a7-41f2-8619-57862c67a567_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_9570e788-904f-4db6-a981-7a67ae921979_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_323b9cae-8a4e-4c2b-90d5-20dc373d2cee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_cdc08226-c036-4ed0-bcda-10e7aca77598_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20201231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember_fcb6b9a0-bc0b-4708-b718-88fdedd5ed73_terseLabel_en-US" xlink:label="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:href="gild-20201231.xsd#gild_GileadSciencesInc2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:to="lab_gild_GileadSciencesInc2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39885cc5-4a57-4617-b23f-3db918a8f119_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_d9522132-9816-44a2-88e5-425518ee4fb2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_01813306-e39a-4aa6-bef1-b901aab2fecb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_ad86b5e5-12de-4ef4-9fc0-aa571ec4e77b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_82e85d76-a77b-4081-9973-a5f428f37a57_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge related to IPR&amp;D intangible asset</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_2fe9e002-8837-46d9-ae9c-cfbf454254e9_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:to="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_97eb7219-0899-4848-93fd-34ca2446162c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, noncurrent [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_3f0da5d1-4357-46a4-b95a-77661429a754_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_3e3f49c6-eb66-487a-a982-9e89a446e595_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20201231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5560e9b1-37a3-4e79-bde4-ea8eddd0a97a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_1cff03fa-e358-42f7-97eb-f2d5cf2794c1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_0ca9b8f2-9570-4390-bcdc-fb0cd8cb10d3_terseLabel_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential option exercise fee</link:label>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_label_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Option Exercise Fee Per Program</link:label>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_documentation_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Option Exercise Fee Per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram" xlink:href="gild-20201231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialOptionExerciseFeePerProgram" xlink:to="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_43b445de-bd5d-4729-961b-412887594153_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_b7ca0d69-6fc0-449b-b77a-134796cd5ecf_terseLabel_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment for adjustments of budgeted development costs in 2021</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_documentation_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:href="gild-20201231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:to="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_f752daab-bcd2-45f6-8361-cdaffc95c2ff_terseLabel_en-US" xlink:label="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]</link:label>
    <link:label id="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_label_en-US" xlink:label="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]</link:label>
    <link:label id="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_documentation_en-US" xlink:label="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" xlink:href="gild-20201231.xsd#gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" xlink:to="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b8036f14-2478-4e3a-a18d-69c78a785fb7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579ce50d-e0ad-4cda-a863-e3c2851aaaae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_59bc2239-79c2-4609-a423-a07a8716a386_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_54438c30-a48a-4daa-a3e8-5efacc60f7ac_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due in December 2041</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FavorableEPSImpactMember_5a0be9db-70cf-4291-b047-37567599cf8d_terseLabel_en-US" xlink:label="lab_gild_FavorableEPSImpactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable EPS Impact</link:label>
    <link:label id="lab_gild_FavorableEPSImpactMember_label_en-US" xlink:label="lab_gild_FavorableEPSImpactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable EPS Impact [Member]</link:label>
    <link:label id="lab_gild_FavorableEPSImpactMember_documentation_en-US" xlink:label="lab_gild_FavorableEPSImpactMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable EPS Impact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FavorableEPSImpactMember" xlink:href="gild-20201231.xsd#gild_FavorableEPSImpactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FavorableEPSImpactMember" xlink:to="lab_gild_FavorableEPSImpactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_85a73baa-e9c1-4919-b35a-0b8f0a53de2a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_f5ee8741-d1ae-4614-a08e-f07a87c9ab04_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_99026466-8fe2-4494-b1bc-7624052ba053_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract_86dc2fc3-e311-4ac4-ba03-3737f51dc765_terseLabel_en-US" xlink:label="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements summary of classification on the balance sheet [Abstract]</link:label>
    <link:label id="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract_label_en-US" xlink:label="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements summary of classification on the balance sheet [Abstract]</link:label>
    <link:label id="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract_documentation_en-US" xlink:label="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements summary of classification on the balance sheet [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" xlink:href="gild-20201231.xsd#gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" xlink:to="lab_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_97f6975f-3f87-4cdd-be1d-32891a674618_terseLabel_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2020 Fixed Rate Notes"</link:label>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_label_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate Senior Unsecured Note Issued September 2020 [Member]</link:label>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_documentation_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate Senior Unsecured Note Issued September 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:href="gild-20201231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:to="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofInventoryTable_2ec709ad-db83-4872-a620-63076fb54737_terseLabel_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryTable_label_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryTable_documentation_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofInventoryTable" xlink:to="lab_gild_ScheduleofInventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_57aaf96f-852f-4bbb-81b4-0f1d61b12577_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_cc369f95-4259-40ec-a3c1-1dbb989aab28_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_3f8ad315-ba8b-45d7-96c2-9ee8327b58da_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_947eb7d8-49b5-480b-98da-14b60e533121_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f877b852-9dbd-4678-8ceb-1e156763b4bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_14fcd969-bc49-46b1-914d-9f4d7341f795_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_860fa1f9-012b-43e1-933e-daaabed69784_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_49e3c75d-75a5-4b41-9953-92ad5879f0a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_df62b253-ce1c-4149-a84f-c425eba83134_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a2452976-5c7b-467d-9a1a-ea6c446140ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4279dfa9-8da2-4fbf-9e7b-2efbae91162c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1da2ac39-60b9-447d-b009-74a9520a9752_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7f8ea560-3811-48b8-8112-3eac269e10c8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c0d47d9a-5ac9-4d60-ae0f-11f84a50ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_af3d0860-5309-4d7f-b8af-b46e4ee3807b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2eabd49e-3674-49e9-82d2-301bd3290b59_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_261c4357-3642-41b9-b667-6862da04f12c_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outlicense contract</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bc9d4d59-7232-4135-bbe5-d73c208f6e3b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_389d1b3d-4ae4-4de7-bbe0-db6f786faaf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0c3247f3-98fc-4c9a-b985-b1c43ed12eb4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_870a2757-9980-4e05-9d91-7fc96f84bcc1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_60dd0ee1-f099-40b7-a9a1-92d763c52544_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d7ffdca4-a3ef-480e-996c-d5c604a1ba03_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_63a9bfd5-7634-4389-a532-c98dbbf9b30f_terseLabel_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_label_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_documentation_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:href="gild-20201231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:to="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a8fbef63-975c-4761-a0cc-ef0cbf686291_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_58e20854-d30b-4499-ac88-f35c84d130d8_terseLabel_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payment for adjustments of budgeted development costs</link:label>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_label_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_documentation_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:href="gild-20201231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:to="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_af08ffa0-193c-41a8-84cc-16e0ad06ca5d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f6dd008d-1eea-4123-89fd-798653f328aa_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies, Estimates and Judgments</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_de503f50-7c00-4916-ab02-9d18e5044025_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-downs</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_127271d8-d132-4300-8b4e-55e394966721_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_74219e38-7c6e-4030-8710-eea183fe61af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_60dcdfa9-f856-43da-b152-6d0e99f23511_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_2ced90d7-649a-4ae5-8086-6a469ecfadcb_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20201231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_3f2a2384-c476-4250-b445-c6f7ed006653_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense under ASC 842</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock_acf94d53-8c6d-4dbe-a56b-aae48d73d8d0_terseLabel_en-US" xlink:label="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet and other information related to operating leases</link:label>
    <link:label id="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock_label_en-US" xlink:label="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Other Information [Table Text Block]</link:label>
    <link:label id="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock_documentation_en-US" xlink:label="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Schedule of Lease Assets and Liabilities and Other Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" xlink:href="gild-20201231.xsd#gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" xlink:to="lab_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_a65e85cf-baff-4880-a88a-97130fb9806d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Financing Obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ed2aa4cb-2933-4f6e-9258-13705f50b455_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_d9cc8b3a-6bea-40bc-a72a-513e24431093_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2724b70e-1828-4d06-b3f3-adcdcb04a296_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_857ff695-3cb1-4ef2-9bf1-9ba3e6d0152c_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due in March 2027</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2027 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_ea114dc2-ca60-4f58-9ce2-716dc1106aa4_terseLabel_en-US" xlink:label="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_label_en-US" xlink:label="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Consideration for Acquisition of Rights to Market and Distribute Certain Products in Japan</link:label>
    <link:label id="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_documentation_en-US" xlink:label="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial consideration for acquisition of rights to market and distribute certain products in Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:href="gild-20201231.xsd#gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:to="lab_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cccb0adb-1eb8-4422-ab72-2a1115f10394_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_a00f1e29-c418-4a8e-b3b5-c34085a008b6_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20201231.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_328b3be3-8fdc-4cfc-82c5-a847b32af76f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3d28e4cd-22d1-4daa-85e3-49aebb3fa206_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_c97421a1-cc8e-4ebb-9d9a-0909548f09aa_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (and liabilities), net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_bfcd3edb-27e7-4dad-942b-b036300bb8ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_Kite585ProgramMember_8e3a5306-7370-4cbc-926b-b56c0cff3286_terseLabel_en-US" xlink:label="lab_gild_Kite585ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite 585 Program</link:label>
    <link:label id="lab_gild_Kite585ProgramMember_label_en-US" xlink:label="lab_gild_Kite585ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite 585 Program [Member]</link:label>
    <link:label id="lab_gild_Kite585ProgramMember_documentation_en-US" xlink:label="lab_gild_Kite585ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite-585 Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Kite585ProgramMember" xlink:href="gild-20201231.xsd#gild_Kite585ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_Kite585ProgramMember" xlink:to="lab_gild_Kite585ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a2977907-cb6b-47ca-90c2-a0c50bbb1136_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_060a1286-44f0-4c45-8f5d-6e55811f88b8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_f5d5f9bb-2ea5-4d0d-9fbc-15ff464702d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Not Offset, Policy Election Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2a511a6-bd80-4cfe-85a3-1fc575467a8f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_94f6f433-b841-45c9-a8af-29eb7968444c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_234e3762-b9f6-45cf-9a86-8b97380e1caa_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_Accruedgovernmentandotherrebates_e05dacfb-1a8a-4902-84d1-d964e29cb9d6_terseLabel_en-US" xlink:label="lab_gild_Accruedgovernmentandotherrebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:label id="lab_gild_Accruedgovernmentandotherrebates_label_en-US" xlink:label="lab_gild_Accruedgovernmentandotherrebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:label id="lab_gild_Accruedgovernmentandotherrebates_documentation_en-US" xlink:label="lab_gild_Accruedgovernmentandotherrebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government and other rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Accruedgovernmentandotherrebates" xlink:href="gild-20201231.xsd#gild_Accruedgovernmentandotherrebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_Accruedgovernmentandotherrebates" xlink:to="lab_gild_Accruedgovernmentandotherrebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a8ec8021-615b-4f8b-85a1-486ca12c9018_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_a742a376-cd75-417e-a40b-001afeff0e67_terseLabel_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona merger and option agreements</link:label>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_label_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Merger and Option Agreements [Member]</link:label>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_documentation_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Merger and Option Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember" xlink:href="gild-20201231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TizonaMergerAndOptionAgreementsMember" xlink:to="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_e762a735-971c-4441-9f38-cb828303714b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent_2bc69145-6335-4922-9451-fce3529c981e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and stock purchase agreement</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_26620111-b66e-4494-a5b9-680e3afe8762_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b4cc2431-fefa-4736-b7c6-a8927de8e932_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_2d7a7877-2f3a-4fca-ab90-6ef12c0ebf0d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_38cae83d-4c0b-4aad-a0e8-be03b5fac940_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_af4f93ae-dbc0-40fe-97ba-f7ce4b262156_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures at December 31, 2020, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_fee91f5c-06de-480a-917f-1045d9295387_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b239cbf3-faa2-4619-b76f-a4a30ccbda49_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryWritedownsforExcessRawMaterialsMember_8bc8a2ee-b50a-4baa-bb0a-bd6abe20c0ad_terseLabel_en-US" xlink:label="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-downs for Excess Raw Materials</link:label>
    <link:label id="lab_gild_InventoryWritedownsforExcessRawMaterialsMember_label_en-US" xlink:label="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-downs for Excess Raw Materials [Member]</link:label>
    <link:label id="lab_gild_InventoryWritedownsforExcessRawMaterialsMember_documentation_en-US" xlink:label="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-downs for Excess Raw Materials [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:href="gild-20201231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:to="lab_gild_InventoryWritedownsforExcessRawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_43bb0b54-d834-49f6-8fcd-03d8b479b399_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_73335203-dbdd-4b73-8dab-3f3c72fbaed4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f98b07e4-6746-4d04-a006-e1101f6babbb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c25a2fc0-9803-4159-ad8a-4e5ff44d92c5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_948f4e07-d24f-4ca5-9a52-50d1881a4ebd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalPayable_5621fc0d-b580-478c-93e3-5ee7337d71fc_terseLabel_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payable</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalPayable_label_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Payable</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalPayable_documentation_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalPayable" xlink:href="gild-20201231.xsd#gild_InvestmentOwnedBalanceAdditionalPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InvestmentOwnedBalanceAdditionalPayable" xlink:to="lab_gild_InvestmentOwnedBalanceAdditionalPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0e1d0d81-a455-4716-9423-fa908a46c140_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of effect of foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_COVID19ProductsTrodelvyMember_e81d2852-108c-4419-b268-11e891dbbb27_terseLabel_en-US" xlink:label="lab_gild_COVID19ProductsTrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_COVID19ProductsTrodelvyMember_label_en-US" xlink:label="lab_gild_COVID19ProductsTrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Products, Trodelvy [Member]</link:label>
    <link:label id="lab_gild_COVID19ProductsTrodelvyMember_documentation_en-US" xlink:label="lab_gild_COVID19ProductsTrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Products, Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_COVID19ProductsTrodelvyMember" xlink:href="gild-20201231.xsd#gild_COVID19ProductsTrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_COVID19ProductsTrodelvyMember" xlink:to="lab_gild_COVID19ProductsTrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_037ba2b1-644c-46aa-b313-c9180700f579_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_93b6fead-79a8-48f7-92e0-dacbffc39a13_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ccae778b-062c-4109-b5ba-b9192c495566_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_41f8dbf2-ea50-4fc0-be6a-27afa4538044_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_c3e8f3bd-d4cf-415e-aebf-8b1c199784ca_terseLabel_en-US" xlink:label="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</link:label>
    <link:label id="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="gild-20201231.xsd#gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_49e1fe3d-a80b-4166-8ca2-280bd5617ff8_terseLabel_en-US" xlink:label="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]</link:label>
    <link:label id="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_label_en-US" xlink:label="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]</link:label>
    <link:label id="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_documentation_en-US" xlink:label="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" xlink:href="gild-20201231.xsd#gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" xlink:to="lab_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5bd92c20-d535-4263-83ee-0bc00cd863e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5d2999f5-d4c1-4b3f-bc47-d54d383f6528_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_5eae299b-47ac-4ee2-8d67-588585b45292_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1630705f-ef1c-45d8-b989-9512931597dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_ae704c3b-34ba-427a-a06a-df46ae99c79d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_88e0eb4c-d2de-4aa9-9c7c-31bfc0b92ad4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_3c3e93fe-62fc-49cc-bfbc-3894826ec635_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_e73503a0-a196-4a3c-93f7-ae6d5a1723e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a2bb5051-5a3e-4696-9d89-7b2f4dfeb771_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f205de3c-74c5-4626-9a07-1dc057c72ac4_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_0b655e1b-c57e-4d54-9f66-6cc0d4189977_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dbe2d316-6789-49c8-bcce-b00f2702b03f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsAtriplaMember_8db453a0-b279-4e1a-a4ae-e81f0fd3e585_terseLabel_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_label_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:label id="lab_gild_HIVProductsAtriplaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsAtriplaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Atripla [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember" xlink:href="gild-20201231.xsd#gild_HIVProductsAtriplaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsAtriplaMember" xlink:to="lab_gild_HIVProductsAtriplaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3a4ddb1c-2187-4cb0-bc52-c2e5a3828618_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of book basis over tax basis of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_056ef906-09d3-4f2d-b648-e1aca5cd61b5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7b0dc135-b1fd-4dfa-ba3a-6d97cf51b4f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_65966c1c-5e77-416c-9c40-d70d9172b576_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due in March 2022</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2022 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_fbdeef6c-8467-476c-b85e-e0b12fbf9d0f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_5cdcda21-8109-456d-8daf-1dbdf434f6dd_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue_60ef037e-d8bd-4bc9-ac4b-49afc6bd53e4_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past damages vacated</link:label>
    <link:label id="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue_label_en-US" xlink:label="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Motion Invalidated For Past Damages, Value</link:label>
    <link:label id="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue_documentation_en-US" xlink:label="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Motion Invalidated For Past Damages, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMotionInvalidatedForPastDamagesValue" xlink:href="gild-20201231.xsd#gild_LossContingencyMotionInvalidatedForPastDamagesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMotionInvalidatedForPastDamagesValue" xlink:to="lab_gild_LossContingencyMotionInvalidatedForPastDamagesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_c98dc9d4-6fb6-49eb-8124-b0245b997177_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing under the senior unsecured term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_e660101c-a81e-46d9-b379-d106d19adbeb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt financing, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_9622b1ce-dc63-4195-bfa6-99183622502f_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3a3aab53-9dda-450c-a6b3-a0f7f672c0ff_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a9b51ccf-dbc5-46fe-93ba-921fc1489c2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16f8bb4e-2896-4ee7-bbff-d1c69671f643_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_3b175007-34cf-42df-9abe-d9fe48d0a636_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_5612c2e8-71b1-4503-8d84-f7661d497a2a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_e12f1f8d-4a7b-4c1f-afa9-703a96f996aa_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on discontinuance of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f5348a3c-d39f-4630-8ae6-dff27d20c82f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8fa032c3-fb89-4ac7-9479-102a8872406f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_71008090-1151-47cb-acf8-b898fca1c453_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_e46d438f-c3de-45be-b9b1-6c5e0679b7dc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_550d6de2-cf01-49d1-9cda-d60dd95b1738_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of unsecured debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_17510f42-f04c-422a-8ad0-b70bbd50241c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign - current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_cd7dfdfa-325a-4a15-981c-1dce1fa74b1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_ad7e63b9-a3ed-497c-bf59-fd2772d2fe79_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20201231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_a24ec49c-07fe-4b23-9b14-b4958e9968ea_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due in March 2026</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2026 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3e27a300-26bf-41f9-b315-33a138db5a7a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f7ca1449-5210-4930-aa2a-a3f7be68f632_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized from performance obligations satisfied in prior years</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8f028bba-ea2f-4896-bd1e-eabb07253388_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of vested stock awards as of vesting date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_87411032-7dda-4c5c-ac89-29187639eb3f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a2c7eb29-b42c-4e43-9f37-dd777b158061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_06c76311-64c0-4554-be29-b6a6452043a0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0c96ba3d-c9c0-4fe5-94e7-2293ce59c8a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_cbd99b30-b5b9-4181-a347-72244836b9e4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_d6a0dba9-25ce-402d-aa7d-9b8e9d56dde2_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FortySevenIncMember_3d97635e-9de6-40fa-b2e1-ed63d2c37843_terseLabel_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc.</link:label>
    <link:label id="lab_gild_FortySevenIncMember_label_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:label id="lab_gild_FortySevenIncMember_documentation_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FortySevenIncMember" xlink:to="lab_gild_FortySevenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_bbc7d8fb-d412-4689-b020-a766e69bab61_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_00b9e6f7-9515-4033-9b3a-f54a43f935be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2020, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d6ae24c-03e8-4a76-9e70-fd4d12906e1e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8a6faf84-62d1-47ab-982d-e64524a22dd3_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0f34ce26-131f-4a14-9b78-aefdcb735e5e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_545040fe-5e80-4f41-8ab2-ef76dd5039bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_41bcd040-023b-415a-80a8-f45a4fa0f621_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20201231.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8612879e-3636-4072-85db-4861096e72a9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_f58429cf-c799-4a56-9bd3-3f604b195447_terseLabel_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 stock repurchase program</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember" xlink:href="gild-20201231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2016StockRepurchaseProgramMember" xlink:to="lab_gild_A2016StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bb1af06d-076d-4282-809e-0d4bfe9daec2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f28fddbf-c98e-480d-989e-a8b2daa4cb15_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and income tax penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_1acfd9cd-e67b-4e7b-abc0-6293a8c38b77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsZydeligMember_da620cbd-8408-4432-a81c-3d6cc589ce35_terseLabel_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_label_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:label id="lab_gild_OtherProductsZydeligMember_documentation_en-US" xlink:label="lab_gild_OtherProductsZydeligMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Zydelig [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember" xlink:href="gild-20201231.xsd#gild_OtherProductsZydeligMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsZydeligMember" xlink:to="lab_gild_OtherProductsZydeligMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_ccf4fb47-84a7-44bf-81c9-72007adeea10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_afb1f7cd-5ced-4300-af74-a06933d17f05_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in, extension and milestone payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:to="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5f7ed1ce-db4c-41af-a573-86033e6b4108_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_cd01eb86-b6ca-4f0b-acc4-4cbe967d4ca4_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_09065375-35b6-445d-b141-84832439ec89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized fair values of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CallTherapyProductsTecartusMember_9ccacc76-092a-43e6-bc92-b743d3863a3f_terseLabel_en-US" xlink:label="lab_gild_CallTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Therapy Products, Tecartus</link:label>
    <link:label id="lab_gild_CallTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CallTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CallTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CallTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CallTherapyProductsTecartusMember" xlink:href="gild-20201231.xsd#gild_CallTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CallTherapyProductsTecartusMember" xlink:to="lab_gild_CallTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_eda0a2e0-9efc-46fb-a2e0-9c1070c57313_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ad7514ae-6a4a-43b0-819f-04b1f76923cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, current [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d5512a4a-8152-4dae-b831-e539887d2d58_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_1f31cbfa-1370-4745-a0cd-512b84ea8a3a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c6c9419a-a6b1-44a0-a2f1-ce67eecc4af8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5fe0cb4a-3ab1-46f9-9ba7-cb49d928d0d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity under stock option plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_c6d6095f-ecef-458c-beac-762f4c81340a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3abcc7b5-c70d-4464-ade8-429fd2928f54_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90c2e09e-8cf4-4838-85f7-453c9eb83e39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0b6f0dff-d6bc-4821-aa02-74a69110e233_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited partnerships and other equity method investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_61d5d05a-de6c-4196-8997-289fea124328_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0ccf76e4-edf4-4e59-a4fb-40fc8e6817e0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0ff27ed3-2486-4a68-8294-45215857ebec_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1b28d8b3-f03f-478a-8a6d-648d3be323fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Summary of Aggregate Future Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2dd3409c-c176-4f16-96fd-6c74df0decb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_540777d3-230a-4efd-96d7-632704d4a7e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_713d61f5-0a68-447e-8918-374d00e59914_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_4d66ef79-19fd-4771-a4be-8cf1791505b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_3244ff55-db02-4aae-af5e-cfa5f5b135e8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_60301758-6673-4513-86e1-1c7e0add9679_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office, computer equipment and other</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a4340ce2-2e13-4793-91ae-0da33a6895c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_b238192d-4e41-4a3e-9a04-079e7a611cc5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D and related charges</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d7934552-070c-4498-8d43-16d3bd362349_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_34b1cb6d-5b4d-4383-9e4b-f6a81fb0b51b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d9b4dab9-f936-45be-bf21-cda1f7e47993_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_42ac5514-2223-414d-9a79-a4f799123ab0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b2440f2f-dc8a-4b8f-82cc-7efddd6c329c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f6b6d9b0-e90f-4976-8253-f35a0540232b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_7e6e16a0-75de-433c-8424-b834f52182d5_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional option fee on fourth, sixth, and eighth anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:to="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_400c00e4-5a11-4c41-9338-dc44f521ff85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_7331a4c1-47e3-4d2c-a648-6f156ae8c168_terseLabel_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage</link:label>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_label_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_documentation_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:href="gild-20201231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:to="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_af7e2c4e-70a2-45c7-87ea-50d5e0473cd7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in unrealized loss positions, number of positions (securities)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_3e1863c4-074b-4543-81bf-0fff7ea3b32f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ff580558-d484-4565-8f96-afd5d21a6924_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9b1b1331-f879-4336-b866-99328dae4c31_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireManagementContractRights_b0c205cb-fa15-45a2-bba8-58c179517751_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireManagementContractRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire management contract rights</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireManagementContractRights_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireManagementContractRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Management Contract Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireManagementContractRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireManagementContractRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireManagementContractRights" xlink:to="lab_us-gaap_PaymentsToAcquireManagementContractRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5251d667-1743-4955-ae03-8e025556a2e2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_645d6703-5c19-4541-8754-4d8bcbbd244c_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional option fee on second anniversary</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Second Anniversary</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" xlink:to="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87dd7001-3b1a-45c4-8b27-154cf19bf420_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8b85ef76-37f2-487b-a040-0df0e8f55b42_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_32c3390d-3be0-4c55-99d0-a39b2eec0260_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accumulated OCI by component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_42d31d17-1345-4b69-9957-c715f3171079_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0a97f88d-7767-430b-8c00-1d3f0b3ca03b_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_9cde1fd7-e2c3-4ab3-854a-b27b2623f100_terseLabel_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce license and stock purchase agreement</link:label>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Registration Rights and Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Registration Rights and Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:href="gild-20201231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:to="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_aff76d39-8ae6-4826-a60c-d01e719909e0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseLongTermDebt" xlink:to="lab_us-gaap_InterestExpenseLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_54aa369e-8eab-4f05-b690-8a2cd5542cb9_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_564e4f68-7bdb-4fb9-8453-162836885e05_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax - intra-entity transfer of intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_463ef79a-470c-49be-a05d-7f3e16f75ced_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_93909bfb-c36e-483d-8058-9ae4d312b0cb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_fd63cd25-5199-4dbe-9dfa-91f832224372_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_3f7edf3b-8795-46ed-a4af-986561a0f7bf_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity on derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_415fefb8-a740-41fd-a18e-6ca2dfb003d5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_5d69e527-c84d-44eb-bd43-d99f909465fb_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20201231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8a531fe8-aebf-4189-84c1-511abf2e1ab9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_91d3b5ac-679e-4f91-9742-30a75772956e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_28027d3b-50b9-458a-81ed-2e81e4c2bedf_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9d67967d-9709-4c0e-a720-85838cc4735c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_327d29ff-2e67-4da3-bed7-e6d13ac8cf85_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsTotalMember_848d1ade-f704-4658-9a0f-f9618ad01834_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsTotalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsTotalMember_label_en-US" xlink:label="lab_us-gaap_AssetsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsTotalMember" xlink:to="lab_us-gaap_AssetsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a573d479-74d5-4ded-89d5-b4884e6d9fac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_d0fd39bc-68ec-445e-aa57-78610a570fab_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:to="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a6aef54c-c086-499c-a4c2-7ff47206a577_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_abe1feb4-91a2-40d8-bddd-1e7ba2de4246_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_e0d8bdf6-d2db-4e5a-915a-f4f22faacaed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding notional amounts on foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1bce0854-862b-4006-a1d4-ad88d7435f0c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_d17752fc-2906-4058-b8ce-471ea0c70213_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_Inventoryreserveforexcessrawmaterials_3538cb80-9911-409c-9065-7b09fa9e7a6b_terseLabel_en-US" xlink:label="lab_gild_Inventoryreserveforexcessrawmaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs for slow moving and excess raw material and work in process inventory</link:label>
    <link:label id="lab_gild_Inventoryreserveforexcessrawmaterials_label_en-US" xlink:label="lab_gild_Inventoryreserveforexcessrawmaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserve for excess raw materials</link:label>
    <link:label id="lab_gild_Inventoryreserveforexcessrawmaterials_documentation_en-US" xlink:label="lab_gild_Inventoryreserveforexcessrawmaterials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserve for excess raw materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Inventoryreserveforexcessrawmaterials" xlink:href="gild-20201231.xsd#gild_Inventoryreserveforexcessrawmaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_Inventoryreserveforexcessrawmaterials" xlink:to="lab_gild_Inventoryreserveforexcessrawmaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_e72cfe5a-00fb-4539-b69c-d51387673444_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8182e96a-9863-4536-9d37-839d8b825c5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and credit facilities</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_cd261310-4b78-4b0d-88d1-390713b4e78b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_COVID19ProductsVekluryMember_d7e73465-f5a9-4960-975b-c70962aa24b4_terseLabel_en-US" xlink:label="lab_gild_COVID19ProductsVekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_COVID19ProductsVekluryMember_label_en-US" xlink:label="lab_gild_COVID19ProductsVekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Products, Veklury [Member]</link:label>
    <link:label id="lab_gild_COVID19ProductsVekluryMember_documentation_en-US" xlink:label="lab_gild_COVID19ProductsVekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Products, Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_COVID19ProductsVekluryMember" xlink:href="gild-20201231.xsd#gild_COVID19ProductsVekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_COVID19ProductsVekluryMember" xlink:to="lab_gild_COVID19ProductsVekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_fe874c5d-87c9-4df1-b2c5-779e966161b1_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ChangeinestimatevariableconsiderationMember_462005f9-ae4b-48b2-803a-36e30113148f_terseLabel_en-US" xlink:label="lab_gild_ChangeinestimatevariableconsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate variable consideration</link:label>
    <link:label id="lab_gild_ChangeinestimatevariableconsiderationMember_label_en-US" xlink:label="lab_gild_ChangeinestimatevariableconsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate variable consideration [Member]</link:label>
    <link:label id="lab_gild_ChangeinestimatevariableconsiderationMember_documentation_en-US" xlink:label="lab_gild_ChangeinestimatevariableconsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate variable consideration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ChangeinestimatevariableconsiderationMember" xlink:href="gild-20201231.xsd#gild_ChangeinestimatevariableconsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ChangeinestimatevariableconsiderationMember" xlink:to="lab_gild_ChangeinestimatevariableconsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_0ff24dce-ee80-4520-850b-431d412029d3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_06231e90-1fae-4fa9-a372-0f83148ae8a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_af507c56-ee9e-4396-b094-683fc03c79a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ff74c91d-35fd-4ab8-baf7-7c841468ffe8_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_445a5744-3a1d-4db8-87c1-253a3c7e9ffc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_52fe7d3a-9900-4b75-82a2-b2100a26bb05_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70dd0ea7-32d6-4b50-be3d-cbb4d78fdcc1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_2619a04c-7123-4b7e-b3dc-91f2cbc502fb_terseLabel_en-US" xlink:label="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years</link:label>
    <link:label id="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</link:label>
    <link:label id="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="gild-20201231.xsd#gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e62ecf2c-c523-440b-b83f-77f97470e637_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_fa70f30c-0c1e-48ab-91ba-eab4b29f487e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_eb90922a-2a98-44e6-ae75-b07141cc4e45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_dc42f094-784e-4574-9894-0796dacd6587_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8f7f9cde-2f81-46b9-8594-f1a70cfcf78d_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_f8330dc3-344a-4045-9b70-9dc3b29919e7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4ca87060-eda8-457e-8560-5db65a348e47_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f44c4686-cb51-494f-81f5-509eab6c5342_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_c4134905-53fd-479b-b5dc-779b91b5a918_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a4592d2f-55cc-461d-9f93-8ed894db7047_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_42d0e3b5-ef0e-422e-b824-c9d514adb51f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment_d2cefabd-be36-466a-a627-57e03cdb9b2b_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process, Including Impairment</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process, Including Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:to="lab_gild_ResearchAndDevelopmentInProcessIncludingImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2021Member_b981d04e-c0bf-4154-97fc-05c27b927093_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.40% Senior Unsecured Notes Due In December 2021</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2021Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2021 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2021Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_8152f8d7-29da-4f38-846d-3059ad6de19f_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_866f859d-0cca-4f4d-bfd5-9eb51ca3e490_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_90521eb9-7b3a-4745-b382-ed65a3afe4f4_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential future milestone payments</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_label_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:href="gild-20201231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:to="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f52f575e-0d40-4272-bb9a-8c15f107de85_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_8f80d9ca-ab0d-4a28-8d9b-7debf8364fd6_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20201231.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5bc9fa4a-93cc-447b-987f-34190f978d8e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_f026fdaf-79ec-480d-99d6-11c87ab70dcb_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc.</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ea10a455-6c9f-47de-9eda-58e11868d62b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_0455ebee-1e2f-4eb8-b0a4-def442d6c7bf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65fdb71b-83a3-4f60-8070-cae55862e78a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d1b11956-e41c-4208-ade6-2c4b49d9f564_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_686ab315-f31e-4018-b8b6-707e62f56da1_terseLabel_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_label_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Exercise Fee</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_documentation_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee" xlink:href="gild-20201231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityMethodInvestmentOptionExerciseFee" xlink:to="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_417a69a1-a6a9-4647-a22a-cee6f5a35493_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_853f4ba8-b461-48af-b9ae-b7924dc26d1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EPSImpactbyTransactionAxis_c8ac1289-a36b-4e63-9201-d0d1af44f663_terseLabel_en-US" xlink:label="lab_gild_EPSImpactbyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Impact by Transaction [Axis]</link:label>
    <link:label id="lab_gild_EPSImpactbyTransactionAxis_label_en-US" xlink:label="lab_gild_EPSImpactbyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Impact by Transaction [Axis]</link:label>
    <link:label id="lab_gild_EPSImpactbyTransactionAxis_documentation_en-US" xlink:label="lab_gild_EPSImpactbyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Impact by Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionAxis" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EPSImpactbyTransactionAxis" xlink:to="lab_gild_EPSImpactbyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f8d7d7da-ec2a-4058-b137-e0b55bf974f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1fd9c07b-4bf4-416a-b04d-9d607ad5111f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a03867a9-59b8-49c3-a5a4-deef9b07b7ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_c04eb016-ef56-49b5-8a54-d8cfa0f9d919_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_9c473e8b-ede6-4412-bd29-ae6ee2038eaa_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_c76e1982-8caa-4bd0-8c96-27b7a32cae70_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_5debb366-0ca3-4689-9eeb-d129a4e54af1_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate of acquired IPR&amp;D</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired, Discount Rate</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_efccede0-6cd5-4bfb-bda6-105c2949ff4f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7b62c45c-d09b-48b1-b980-5af107b419d4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74df6fe2-22f1-4bc6-a092-09b7ba22f92d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_0a27ae55-7db1-47a3-b18d-b334843c026e_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development service agreement</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Service Agreement [Member]</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:to="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_88a58b04-3aee-40e0-8ec7-4af37ceecee4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_fea94661-89a9-4cbc-99c4-4e7f77bf243d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DevelopmentAgreementMember_5e442edd-0ff9-4e08-afb8-1f5f23b8b103_terseLabel_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development agreement</link:label>
    <link:label id="lab_gild_DevelopmentAgreementMember_label_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement [Member]</link:label>
    <link:label id="lab_gild_DevelopmentAgreementMember_documentation_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember" xlink:href="gild-20201231.xsd#gild_DevelopmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DevelopmentAgreementMember" xlink:to="lab_gild_DevelopmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_b21ab98a-1013-4937-b734-6f57cc3f05ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value step-up adjustment of inventories acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_4932f197-c254-4fed-bbb9-d82f325788a1_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due in September 2023</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_c5e44876-ebde-4889-a58d-869a78ff5dc8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f8837e9e-5982-4edd-9ca2-faa9a108d9b9_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a2b24428-a26e-4f2a-99c0-8d226b968404_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_9c1f3ba1-2212-4182-a15d-0733fe65ae0e_terseLabel_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce</link:label>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember" xlink:href="gild-20201231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JounceTherapeuticsIncMember" xlink:to="lab_gild_JounceTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c062a386-3e2a-42ac-bf91-d8a92588fdfd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d52354a7-9c7e-4a49-a32c-5e3084fcef95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_df91bd13-5be0-462b-bda1-87fb936cf9bf_terseLabel_en-US" xlink:label="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront collaboration expenses</link:label>
    <link:label id="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_label_en-US" xlink:label="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant</link:label>
    <link:label id="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_documentation_en-US" xlink:label="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:href="gild-20201231.xsd#gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:to="lab_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_56c6af41-2951-4e89-a2e0-6f82735be32c_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_0c3924e9-f458-481b-a75f-e2c66a69c5a3_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_89080574-a746-4410-bcfc-c936279ad1a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of tax basis over book basis of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_b8c361ec-34bf-4125-93a6-94031fc566e0_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20201231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_66a5ad4b-703b-42a4-b1c0-b92fa4684c25_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign - deferred</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfPrograms_dad7badd-a018-45a4-906c-93280110ef30_terseLabel_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_gild_NumberOfPrograms_label_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs</link:label>
    <link:label id="lab_gild_NumberOfPrograms_documentation_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms" xlink:href="gild-20201231.xsd#gild_NumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfPrograms" xlink:to="lab_gild_NumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_571fd9e0-450d-4318-82fc-4664f878e3b8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c9bee428-7fd4-467f-90ed-ecd2437c9294_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_6c1846b2-045f-4d1b-8d4c-93055e66b026_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due in March 2047</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2047 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_ef732f71-9ff6-462e-b260-c962acf532e7_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due in April 2044</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2044 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_c910ea39-ad43-4141-87f3-dfa3b7d04ab6_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit on product sales</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c7e1a777-8aed-4aa1-a52a-206e1d3abad2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4cd88a23-2e9f-43b3-893d-9b6e0267fdd0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_50a47099-441a-4aac-ba5b-ed8e15a8a30d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_3ba2af0f-a587-44c9-a511-f45001852116_terseLabel_en-US" xlink:label="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US tax on foreign earnings</link:label>
    <link:label id="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_label_en-US" xlink:label="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings</link:label>
    <link:label id="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_documentation_en-US" xlink:label="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate impacts related to US tax on foreign earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" xlink:href="gild-20201231.xsd#gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" xlink:to="lab_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_f868a5e5-b1f3-42cc-8a9d-2c7ba7afb175_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived assets - IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsTextBlock_ba19c2cb-5756-411c-a385-78f56ce4fc3f_terseLabel_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and other arrangements</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsTextBlock_label_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Text Block]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsTextBlock_documentation_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsTextBlock" xlink:href="gild-20201231.xsd#gild_CollaborativeandOtherArrangementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeandOtherArrangementsTextBlock" xlink:to="lab_gild_CollaborativeandOtherArrangementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_fefa7617-0b6b-4f9a-b23e-8eb04dc13aac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ed216da-fdd1-43e2-91b1-9c5e8bac43bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8a24f848-1c12-411b-8fd5-f895473c804b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_38f9e18c-5e62-4c6e-8ab5-2d6bc979976d_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2015 Senior Notes"</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2015 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2015Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNoteIssuedSeptember2015Member" xlink:to="lab_gild_SeniorUnsecuredNoteIssuedSeptember2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8f98d95f-3038-4297-81d7-8b70554d86ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_e0cdb70a-5e9b-4c43-9ffc-acc9d7a82c9a_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus, Pionyr, Tango and Tizona</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc., Pionyr Immunotherapeutics, Inc., Tango and Tizona [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc., Pionyr Immunotherapeutics, Inc., Tango Therapeutics, Inc. and Tizona Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" xlink:to="lab_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_d7646374-08ac-46bb-8296-93bd4d569baf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due within Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_43772ba1-2fad-4e45-aa62-de9756fc392c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a03b4984-b125-461e-8021-bd5bb95d3abb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_7b88d604-6497-4fcf-bcb3-d4f85e33f55c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_5c457fd1-524c-427c-8132-2de57366529e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of potential effect of offsetting derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e1fcdff6-53fa-4403-8dfc-142e089c43c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_f9fde27f-e0cd-41a8-b9ee-c21ae16c23ad_terseLabel_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr merger and option agreements</link:label>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_label_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Merger and Option Agreements [Member]</link:label>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_documentation_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Merger and Option Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember" xlink:href="gild-20201231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrMergerAndOptionAgreementsMember" xlink:to="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_428c8316-bcf1-4080-96a7-6f8513c66d06_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PubliclyAnnouncedProgramMember_09e90155-43b8-4c65-a3a4-c5db30cfd63f_terseLabel_en-US" xlink:label="lab_gild_PubliclyAnnouncedProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly announced program</link:label>
    <link:label id="lab_gild_PubliclyAnnouncedProgramMember_label_en-US" xlink:label="lab_gild_PubliclyAnnouncedProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Program [Member]</link:label>
    <link:label id="lab_gild_PubliclyAnnouncedProgramMember_documentation_en-US" xlink:label="lab_gild_PubliclyAnnouncedProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly Announced Program(s)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PubliclyAnnouncedProgramMember" xlink:href="gild-20201231.xsd#gild_PubliclyAnnouncedProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PubliclyAnnouncedProgramMember" xlink:to="lab_gild_PubliclyAnnouncedProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_8f76e1b5-78d2-4720-917d-28c22079cf5c_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_53c276d5-d406-49b0-bd85-76b4ec69a00f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a0ff6712-1268-4988-8c65-209e55a6fb72_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f3dbf9db-36ed-4c67-967e-7c7fda4f354e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f58f7d4b-6f47-40fd-9a86-ed16b04e9fc3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_78fd62f9-9420-43f5-ae13-014a40d5095a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_66d1bf39-c97e-41ce-b42b-79f8e1c7edfb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d4107efe-fa2b-4153-a313-1b53ac57d0dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_0dbb823d-3e67-4069-8b58-e89d94968ce1_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_19f6c800-b287-4084-8c8d-1f512bd6d54c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsAbstract_d0680aed-2c12-422c-974f-bd0b2f8e47e2_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Abstract]</link:label>
    <link:label id="lab_us-gaap_DividendsAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAbstract" xlink:to="lab_us-gaap_DividendsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_4869f5b8-1428-4a1c-acaa-65c2f2064213_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics Plan</link:label>
    <link:label id="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_label_en-US" xlink:label="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics Amended and Restated 2014 Long-Term Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics Amended and Restated 2014 Long-Term Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:href="gild-20201231.xsd#gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:to="lab_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_42a8a002-2eef-4018-9d36-51b419ef7011_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV product sales</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20201231.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_0c648221-7d68-497d-8dce-ca92b8bca98e_terseLabel_en-US" xlink:label="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for license and option rights</link:label>
    <link:label id="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_label_en-US" xlink:label="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for License, Option Rights and Equity Investments Upon Closing</link:label>
    <link:label id="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_documentation_en-US" xlink:label="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">payment for license, option rights and equity investments upon closing of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:href="gild-20201231.xsd#gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:to="lab_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_3a654e69-999c-42ab-9d98-b275988c9aa3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsAbstract" xlink:to="lab_us-gaap_DerivativeAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_e5f0e698-71bd-440e-ba23-f6ebd3904145_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements (including leasehold improvements)</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_f6093884-c3ea-4ad6-8c31-5fb0f46f7ee2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueMay2021Member_7a7c404e-a828-44c0-a194-176824667339_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueMay2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 revolving credit facility</link:label>
    <link:label id="lab_gild_CreditFacilityDueMay2021Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueMay2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due May 2021 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueMay2021Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueMay2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due May 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueMay2021Member" xlink:href="gild-20201231.xsd#gild_CreditFacilityDueMay2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueMay2021Member" xlink:to="lab_gild_CreditFacilityDueMay2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_a2e25f10-3453-4c75-8ac0-1e2eef857334_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f689091d-c2f3-48b2-84fe-01af9de74fb3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fc0c5c80-3c98-4b4c-8ace-2dfaffef64fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1c0ab874-b51e-4f55-9d39-09ddfe582500_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_edd512e3-026d-4102-b3d8-dc08b19faab0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7a58cfaa-9555-4c20-86d6-ada41f6fbd19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueatVestingDateMember_99aed776-aeba-473b-b53f-cd66c5c32e75_terseLabel_en-US" xlink:label="lab_gild_FairValueatVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at vesting date</link:label>
    <link:label id="lab_gild_FairValueatVestingDateMember_label_en-US" xlink:label="lab_gild_FairValueatVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Vesting Date [Member]</link:label>
    <link:label id="lab_gild_FairValueatVestingDateMember_documentation_en-US" xlink:label="lab_gild_FairValueatVestingDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Vesting Date [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatVestingDateMember" xlink:href="gild-20201231.xsd#gild_FairValueatVestingDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueatVestingDateMember" xlink:to="lab_gild_FairValueatVestingDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_ceaaab7f-43ae-46b7-8bc4-0a202f006daa_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_99335e8a-4cc8-4154-932c-aef469a6c2d3_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20201231.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_c94e9dcb-622b-4117-bb00-22106bd67d05_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_cd1af3a4-e1a4-4fff-adb3-17f1ceaa58dc_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_a3e17987-5bb9-40aa-9d50-136b5631aacc_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2014 Senior Notes"</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2014 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Note Issued September 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2014Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNoteIssuedSeptember2014Member" xlink:to="lab_gild_SeniorUnsecuredNoteIssuedSeptember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_76595daa-00f0-4d19-afb9-b41d2a5e0c7c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7bde0fd-6478-49cf-aef7-800aa33ee4b3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_9de2ed11-c7e3-4d57-8e2f-e689ff818218_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_fe913d36-a189-4bfb-a2b5-094ec0119a0a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_5d1e14a5-bb55-476c-9852-2d033818a146_terseLabel_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan tobacco</link:label>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_label_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Japan Tobacco, Inc. [Member]</link:label>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_documentation_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Japan Tobacco, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember" xlink:href="gild-20201231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AgreementWithJapanTobaccoIncMember" xlink:to="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_da666d45-70a4-4902-8c4c-679d019e231c_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20201231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_27c7dc38-bb8a-49c1-b568-023bdb5ef03d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8b75bff6-b828-4541-b4a2-b4139b9f5d18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_589f990b-bbf9-4eb3-9af4-19a603f15b10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of difference between provision for income taxes and federal statutory income tax rate to income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d2172ce7-a055-458b-820a-226ee63b9c57_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 authorized; 1,254 and 1,266 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_4f6784b8-b768-4ef6-b9ac-01839c6fe051_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20201231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_722b08d9-4b14-47f3-8d26-df8459239c86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU and PSU activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member_91018de5-b7b4-42a5-bf4d-62e226aa9a6d_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.55% Senior Unsecured Notes Due in September 2020</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2020 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2020Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2020Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_bdc20b84-e79f-4041-8ba6-01b1940deed3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of classification of other equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend_dea4e9ff-a54f-4b6c-993b-66aec4778cc2_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future tiered royalty payment high-end</link:label>
    <link:label id="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend_label_en-US" xlink:label="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Tiered Royalty Payment High-end</link:label>
    <link:label id="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend_documentation_en-US" xlink:label="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Tiered Royalty Payment High-end</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureTieredRoyaltyPaymentHighend" xlink:href="gild-20201231.xsd#gild_PotentialFutureTieredRoyaltyPaymentHighend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureTieredRoyaltyPaymentHighend" xlink:to="lab_gild_PotentialFutureTieredRoyaltyPaymentHighend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_fb2c23a9-f27e-4500-a3ce-51a57841e267_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_2d880a38-3ae8-4854-8353-f4c0cb94f72e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Temporary Impairment Losses, Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_71f9bbc9-66a1-4360-ac43-2decddda2401_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_06be9da6-1752-406a-b21f-54f8ddecdf67_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_0db12e64-0580-4a16-9dfb-a1b47f8a58d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsVemlidyMember_3d4b0879-fdce-4aba-b6b0-c7db65f229a6_terseLabel_en-US" xlink:label="lab_gild_OtherProductsVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Vemlidy</link:label>
    <link:label id="lab_gild_OtherProductsVemlidyMember_label_en-US" xlink:label="lab_gild_OtherProductsVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_OtherProductsVemlidyMember_documentation_en-US" xlink:label="lab_gild_OtherProductsVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsVemlidyMember" xlink:href="gild-20201231.xsd#gild_OtherProductsVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsVemlidyMember" xlink:to="lab_gild_OtherProductsVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_5559889d-f33c-4ecd-81a6-a4909d9de72f_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3578e492-4db1-4a6e-9f65-86d5daad6ef8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3b8e9ed0-184b-4a92-8a27-4a0b675009ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_5a83cbf5-6aae-4edd-97d8-275b64c330d3_terseLabel_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona</link:label>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember" xlink:href="gild-20201231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TizonaTherapeuticsIncMember" xlink:to="lab_gild_TizonaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_7b476019-6658-42c8-9261-96fbb5c04f5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_3432b0b6-a8fd-497e-9bf3-a0c6f39c0d5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_583425d6-8899-4161-9d19-c7f47e099865_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_68bb873a-35ea-4963-867d-cae19e4c7065_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_25f634c2-fef7-4c4f-befb-e181ed6c2742_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due in March 2046</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2046 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2046</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6aa097a9-e48d-4a3e-94c3-cbd995312939_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related to Prior Years: Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_cfe35a82-479f-4393-a429-6d9f7e988b94_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a1ccc99d-1e49-42ed-a5c2-d69c0f23e74b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_c36d27fd-fd83-42e9-aad7-c2c819ee6c95_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_66a8ea4e-4676-47b5-846a-8ca5a38fb3be_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_b6312704-a3b4-48b7-bf7d-8b938fdf397f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_ca41c69b-d07d-4230-b57d-301cab76af24_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_98620d07-4925-440e-8478-0d20889228eb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f8d46637-268d-424b-9ec6-6f86d8bc3128_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_d029c55e-d0b3-4530-b592-fc5bf1181ce0_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20201231.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_15530f0f-9d18-45ab-a62b-5069bc6f0722_terseLabel_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen pharmaceuticals</link:label>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_label_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals [Member]</link:label>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_documentation_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the collaboration with Janssen Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember" xlink:href="gild-20201231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JanssenPharmaceuticalsMember" xlink:to="lab_gild_JanssenPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a05e3108-9135-4106-87ac-4daa6693aaa6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9fea1544-17b9-456e-8f2c-018460a09585_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_cb1487b0-b192-48d3-b975-3e2c8efaa952_terseLabel_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_label_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]</link:label>
    <link:label id="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_documentation_en-US" xlink:label="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.15% LIBOR Senior Unsecured Notes Due September 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:href="gild-20201231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:to="lab_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_6fb48736-8453-4b36-98d6-d7483811c880_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfStudies_8d30870b-8431-4a87-91a5-3cdfba25fd96_terseLabel_en-US" xlink:label="lab_gild_NumberOfStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of studies</link:label>
    <link:label id="lab_gild_NumberOfStudies_label_en-US" xlink:label="lab_gild_NumberOfStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Studies</link:label>
    <link:label id="lab_gild_NumberOfStudies_documentation_en-US" xlink:label="lab_gild_NumberOfStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfStudies" xlink:href="gild-20201231.xsd#gild_NumberOfStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfStudies" xlink:to="lab_gild_NumberOfStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_1999bda6-343e-4a39-82ac-ccd8954c6f0f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_da50d5df-2b72-43e9-b7a6-9c302610d0a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_838be553-976e-4bb8-ba96-52914018680b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_6f8468e5-4fd1-4665-9404-abe80539566b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal - current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8be3d134-f7f2-4279-8e02-4f47c477c2f7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_538d7d5c-16b1-4c05-8217-9c33398562af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office, computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_627c75dd-9ad0-4010-ae42-18de79cdb74a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7ef44e2c-1755-42dd-8a2b-0d6a81bfc027_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental information related to operating leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_033425aa-8f51-49d4-935b-7396c1da5e5e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b9ec0527-c4e3-4c5f-a901-d8f7dccfc32e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_996d6c50-c014-4010-9822-5a3868cb0d2a_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_be8f4645-d1e9-41e5-8bd4-338e2f1db33e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_StockRepurchasesAbstract_f73e5455-973a-4d88-8b9e-bb824494bb3e_terseLabel_en-US" xlink:label="lab_gild_StockRepurchasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchases [Abstract]</link:label>
    <link:label id="lab_gild_StockRepurchasesAbstract_label_en-US" xlink:label="lab_gild_StockRepurchasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchases [Abstract]</link:label>
    <link:label id="lab_gild_StockRepurchasesAbstract_documentation_en-US" xlink:label="lab_gild_StockRepurchasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StockRepurchasesAbstract" xlink:href="gild-20201231.xsd#gild_StockRepurchasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_StockRepurchasesAbstract" xlink:to="lab_gild_StockRepurchasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_9dbc99fb-0c54-41ed-91c6-e6a7ee694376_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_98756c08-823c-401f-90f5-1295c85fb8df_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_d4709fbb-b653-4a0e-9d2f-7bafe1303133_terseLabel_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos subscription agreement</link:label>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_label_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Subscription Agreement [Member]</link:label>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_documentation_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember" xlink:href="gild-20201231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosSubscriptionAgreementMember" xlink:to="lab_gild_GalapagosSubscriptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_92b94586-86ef-41f3-b8dd-dd3a46b9098f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToEquityAwardHoldersMember_6df2d645-851f-477a-83ca-ee8557dc522a_terseLabel_en-US" xlink:label="lab_gild_PaymentsToEquityAwardHoldersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to equity award holders</link:label>
    <link:label id="lab_gild_PaymentsToEquityAwardHoldersMember_label_en-US" xlink:label="lab_gild_PaymentsToEquityAwardHoldersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Equity Award Holders [Member]</link:label>
    <link:label id="lab_gild_PaymentsToEquityAwardHoldersMember_documentation_en-US" xlink:label="lab_gild_PaymentsToEquityAwardHoldersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Equity Award Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToEquityAwardHoldersMember" xlink:href="gild-20201231.xsd#gild_PaymentsToEquityAwardHoldersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToEquityAwardHoldersMember" xlink:to="lab_gild_PaymentsToEquityAwardHoldersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_d9fa37e5-3bed-44c4-84f9-ca80fe14fd6e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-taxable unrealized gain / loss on investment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e56ba8a2-1682-4d1b-a64f-69db81269993_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_8b12a7bd-a012-49f1-95c2-9c6c1cef07e8_terseLabel_en-US" xlink:label="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite- lived intangible asset impairment by program [Domain]</link:label>
    <link:label id="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_label_en-US" xlink:label="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite- lived intangible asset impairment by program [Domain]</link:label>
    <link:label id="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_documentation_en-US" xlink:label="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Finite- lived intangible asset impairment by program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain" xlink:to="lab_gild_FinitelivedintangibleassetimpairmentbyprogramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4d5eff25-aca8-46ce-8811-0ec13d6897a2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related to Prior Years: Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_432b037d-896c-4b88-aa2e-1241f8a5fb47_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments balancce</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_76c7e8a5-7bfb-4d80-8b89-a77fe7df6769_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_de1b76ad-7232-45b5-803f-b5ecadbcd329_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_125aa114-e329-410b-8648-36c11862debc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities at Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_234d4edf-5611-4499-a330-926efe0fb8c2_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20201231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_f19064ea-84f9-4f80-b3bb-5f099eb81353_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;accrued&#160;liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_85391609-9710-4c14-bb11-65b494af664f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_c21a57dd-15e6-4aa9-99d3-ac84eac96430_terseLabel_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage</link:label>
    <link:label id="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_label_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:label id="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_documentation_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:href="gild-20201231.xsd#gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:to="lab_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3132342b-8a38-4b15-a51f-6dd47df57045_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_41e3cd18-f8fb-4c8f-91ed-40ae5e1a1a71_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a0ddcda6-eddd-4d10-a5e2-e96d062192a4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GadetaBVCollaborationArrangementMember_35b8d43d-515d-4ea1-ba94-cb72566c5d4c_terseLabel_en-US" xlink:label="lab_gild_GadetaBVCollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gadeta collaboration arrangement</link:label>
    <link:label id="lab_gild_GadetaBVCollaborationArrangementMember_label_en-US" xlink:label="lab_gild_GadetaBVCollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gadeta B.V. Collaboration Arrangement [Member]</link:label>
    <link:label id="lab_gild_GadetaBVCollaborationArrangementMember_documentation_en-US" xlink:label="lab_gild_GadetaBVCollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gadeta B.V. Collaboration Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GadetaBVCollaborationArrangementMember" xlink:href="gild-20201231.xsd#gild_GadetaBVCollaborationArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GadetaBVCollaborationArrangementMember" xlink:to="lab_gild_GadetaBVCollaborationArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f300ad8c-61b9-4758-a390-2f3bb29ccdda_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureSalesbasedMilestone_403b08b1-5dea-48ce-ac47-d07c3fb70c94_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureSalesbasedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future sales-based milestone payments</link:label>
    <link:label id="lab_gild_PotentialFutureSalesbasedMilestone_label_en-US" xlink:label="lab_gild_PotentialFutureSalesbasedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Sales-based Milestone</link:label>
    <link:label id="lab_gild_PotentialFutureSalesbasedMilestone_documentation_en-US" xlink:label="lab_gild_PotentialFutureSalesbasedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureSalesbasedMilestone" xlink:href="gild-20201231.xsd#gild_PotentialFutureSalesbasedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureSalesbasedMilestone" xlink:to="lab_gild_PotentialFutureSalesbasedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_4a4c58d0-4fb7-4718-aa31-60887393de0a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_263b8199-4d29-4edd-9458-302d2bd9d321_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RestrictedStockandPerformanceShareAwardsMember_fb8046d5-f3cd-45bc-89a3-68eedfcbf2d0_terseLabel_en-US" xlink:label="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock and performance share awards</link:label>
    <link:label id="lab_gild_RestrictedStockandPerformanceShareAwardsMember_label_en-US" xlink:label="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Share Awards [Member]</link:label>
    <link:label id="lab_gild_RestrictedStockandPerformanceShareAwardsMember_documentation_en-US" xlink:label="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Performance Share Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:href="gild-20201231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:to="lab_gild_RestrictedStockandPerformanceShareAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_c057d4bb-3c94-43c2-8cd2-2ee63ce805a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_301d6748-d227-495d-8df3-a60490c3cb8b_totalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_7dc0bf8b-d7e9-4d89-9c90-887689c8a280_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5a73454f-34a3-4361-a1a9-b368e80b757d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_ff8212cd-01ef-4112-bc79-9229e974f6ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_684128b8-a537-470d-b690-63896f0e3706_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fad7fefc-177b-4f31-a256-7a42a2ac8e7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_889892ae-1c80-4d29-abe1-3f4d066ee040_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20201231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_313a64de-7b23-4c9a-ad83-6d4c8e9495a7_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_8c41e839-9371-46c8-a801-99c17bb9ac82_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20201231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d6e5a220-8926-462e-9c2b-c8c060663871_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e9e96e1c-0207-49b9-bdd6-21b777b11ed6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f9d3d6e6-aa48-4193-b0cd-d6b3b4e3084e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_49565695-b613-44fa-abb4-7bc2ad2ffccc_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_b2c8b7d2-f7b5-4f4f-b900-66fd95ea2402_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable and Nonmarketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_733a167e-bef8-49a9-9099-6bede5db21b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) reclassified from AOCI into product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_f649f64d-ad97-4f5e-bb9e-8098c135c87f_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due in September 2022</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2022 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_8613abea-c4ed-4d99-82d3-a4fa129127e3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in variable interest entity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest in Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:to="lab_us-gaap_NoncontrollingInterestInVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0163316a-55b2-4584-960e-4f116adb31f1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_be901f72-3e59-438c-8796-ad59b7e93052_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_db82c023-3e03-4c94-9604-9e3c186d7597_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c4c6eeb5-a8c4-449c-b9eb-b5384c226803_totalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_37e24e77-e5a4-4076-ba4d-bd0a81613df7_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cell Therapy product sales</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20201231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f43329c6-c422-4957-890d-aea5d169032e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_307e3334-0b53-4058-9d06-bee8cccd7483_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus collaboration agreement</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember" xlink:href="gild-20201231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementMember" xlink:to="lab_gild_ArcusCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_86035a7e-f6d0-4b20-ba01-f58f35ca465d_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6f0b7180-c5b8-4a8a-ab46-a42e0c70e32b_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8b198ded-3659-4973-809d-4bd690fbfb8b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_072a5e64-bb33-4f4b-9510-608ee9c89301_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill resulting from the acquisition of Immunomedics</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_eafffdaa-8c41-4700-ba55-b4bfd37b5141_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_27fd7cea-eafd-4e83-81b4-97f1139c6fb3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6aadac98-c48c-437e-b55c-61aa39d4e618_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_732f6771-83a8-49a6-8143-99dabf8d9860_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9e704b88-2bae-40a8-b859-3f56f93ebdc4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1231fec3-05db-4d1d-986e-4c75d64ef0d0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9d2380ef-4097-4d09-829c-82e25f0c4fb2_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in per share calculation - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_fb8d77bc-b485-4ddb-ac72-ce4496497765_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b6e384b8-c858-4db3-8447-e66e1f4eeb19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ad15d8fe-eaba-4bff-bb06-99029cdbebca_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MediumTermNotesMember_a8e0e0d7-692c-467c-a778-53303eb79f8d_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term notes</link:label>
    <link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetTransferMember_49e5c031-1ffd-4ed1-bd84-8d7dbd6c423d_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Transfer</link:label>
    <link:label id="lab_gild_IntangibleAssetTransferMember_label_en-US" xlink:label="lab_gild_IntangibleAssetTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Transfer [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetTransferMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Transfer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetTransferMember" xlink:to="lab_gild_IntangibleAssetTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_878760a7-18c0-452e-b142-ceca68341362_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9464ef40-af45-46e9-a142-8ecde4acfb78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d6fa8834-6553-404d-a754-4f47989b2b77_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_66f26c65-04c8-4278-a1dc-1602f220f37b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01fbc008-2c44-4f64-ac4e-9baa204ce199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e5a4d6ea-fdbf-4a7d-ba3f-a8c688c8330a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_32726437-c79f-4fb4-8dea-e3c3c2298449_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total discounted lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_62ed3d30-eb6d-49ef-b852-43334ece5fdf_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development future maximum payments</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Future Maximum Payments</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Future Maximum Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:to="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_4426b696-c691-4cc0-8eab-7e4360988b33_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_519c548d-86a7-412a-a84f-6ba009bd3dfb_terseLabel_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos</link:label>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_label_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos [Member]</link:label>
    <link:label id="lab_gild_EquityinvestmentinGalapagosMember_documentation_en-US" xlink:label="lab_gild_EquityinvestmentinGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in Galapagos [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember" xlink:href="gild-20201231.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityinvestmentinGalapagosMember" xlink:to="lab_gild_EquityinvestmentinGalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a462cc3e-849e-4139-92fc-b999a303e70a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_86e286fc-ea8e-438a-9b70-aa0658b9d002_terseLabel_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call feature, period prior to maturity</link:label>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_label_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Call Feature, Period Before Maturity</link:label>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_documentation_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Call Feature, Period Before Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:href="gild-20201231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:to="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_54a9208f-3dc7-411a-b2cd-f69d59a6a058_terseLabel_en-US" xlink:label="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite- lived intangible asset impairment by program [Axis]</link:label>
    <link:label id="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_label_en-US" xlink:label="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite- lived intangible asset impairment by program [Axis]</link:label>
    <link:label id="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_documentation_en-US" xlink:label="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite- lived intangible asset impairment by program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis" xlink:to="lab_gild_FinitelivedintangibleassetimpairmentbyprogramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ec126dbe-ca37-48ea-a6f6-044a56fdc74e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_61ef17f8-71cd-4df7-a462-7e28cab145a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves and accruals not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_47d0d366-6e11-4e43-9358-1002322f51e8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_d43cfe71-c6c6-4b9e-9e55-9051b66f3d4b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialDevelopmentAndRegulatoryMilestones_ea4d9714-cd1d-4488-8d82-0e8ecd6bc390_terseLabel_en-US" xlink:label="lab_gild_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone-based payments</link:label>
    <link:label id="lab_gild_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_gild_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestones</link:label>
    <link:label id="lab_gild_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_gild_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development and Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="gild-20201231.xsd#gild_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_gild_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3f173d5c-d8d0-4613-94b1-2b88c769b712_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1d678aea-cf6d-4b28-810c-993ee2380b6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_fb5404d3-8195-48ad-bfd7-65347db25c70_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_621f9861-86c6-4ebf-add4-43b8ecf1e998_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentstoOutstandingCommonStockholdersMember_8692d38a-fdc8-43cb-954b-1468adf37f68_terseLabel_en-US" xlink:label="lab_gild_PaymentstoOutstandingCommonStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to outstanding common stockholders</link:label>
    <link:label id="lab_gild_PaymentstoOutstandingCommonStockholdersMember_label_en-US" xlink:label="lab_gild_PaymentstoOutstandingCommonStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Outstanding Common Stockholders [Member]</link:label>
    <link:label id="lab_gild_PaymentstoOutstandingCommonStockholdersMember_documentation_en-US" xlink:label="lab_gild_PaymentstoOutstandingCommonStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Outstanding Common Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentstoOutstandingCommonStockholdersMember" xlink:href="gild-20201231.xsd#gild_PaymentstoOutstandingCommonStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentstoOutstandingCommonStockholdersMember" xlink:to="lab_gild_PaymentstoOutstandingCommonStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_f22ed5c7-ab37-4b1f-b3e6-768fa2a04c10_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV product sales</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20201231.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_ae33aad1-5901-4503-8a8c-5688c819fc74_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c0bda0df-d6f8-4d6b-a4f5-fd1e6f27c1a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Greater, Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_1722f4b1-12a0-4169-8ad0-61767b75d75d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognized</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_20df873f-1003-4c41-9ccf-5d7c550439cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember_e8d3e6b2-ed31-4e4f-b561-b01891502403_terseLabel_en-US" xlink:label="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Plan</link:label>
    <link:label id="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember_label_en-US" xlink:label="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2004 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2004 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:href="gild-20201231.xsd#gild_GileadSciencesInc2004EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:to="lab_gild_GileadSciencesInc2004EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_2c3d771b-80b3-4f31-8446-18ef7b8e7763_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsRanexaMember_72bb6118-6df9-4564-a8f9-936eec31db31_terseLabel_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranexa</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_label_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:label id="lab_gild_OtherProductsRanexaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsRanexaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Ranexa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember" xlink:href="gild-20201231.xsd#gild_OtherProductsRanexaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsRanexaMember" xlink:to="lab_gild_OtherProductsRanexaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_cf3a17aa-49a6-419b-91ff-1f722aef27df_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_7a7ef19d-5e30-4c5a-a794-b3a1c7cb7dee_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_7333f688-f277-4d2b-94a7-277ff95b8b1e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7b3d9b9a-7765-438a-8d23-521bc96848e0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e04cb9c1-c29b-4fe4-b07d-0f99382f67ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_b54129a1-61f7-4ebe-b87c-7725e5171eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of time to transfer</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_00aade46-1124-4831-8d9d-9c1846df8d04_terseLabel_en-US" xlink:label="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of goods less specified amount, maximum percentage</link:label>
    <link:label id="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_label_en-US" xlink:label="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price of Goods Less Specified Amount, Maximum Percentage</link:label>
    <link:label id="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_documentation_en-US" xlink:label="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price of Goods Less Specified Amount, Maximum Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:href="gild-20201231.xsd#gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:to="lab_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_76dce5e4-7504-4a16-ac3e-15f3e828b895_terseLabel_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2019 agreement</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_label_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in December 2020 [Member]</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_documentation_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in December 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:href="gild-20201231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:to="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ae6e2516-7588-4cc0-a1e0-10a9f96f2944_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_f7bf646e-cdb8-4979-bf8f-0c5410953fd0_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_772f9533-7086-4e82-9b39-f72a3b100f15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_83966309-a8fd-47db-9a48-48d0d7535608_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect from the adoption of new accounting standards</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19de29da-494f-457e-9538-381b463260f3_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_75069a3b-4a4e-4da8-8194-e75866e1281c_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20201231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_bf5910ed-622e-4b50-85d1-998038393d5a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_d0c35be5-992b-4e1a-ad34-06cccbfad149_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_5c191794-6422-40b0-ae33-4d6dd877db2e_terseLabel_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus stock purchase agreement</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember" xlink:href="gild-20201231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusStockPurchaseAgreementMember" xlink:to="lab_gild_ArcusStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_06fad256-9a1e-4f40-8898-1d9b1fc9d89a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_20520036-0e58-4685-82eb-5f451945dae1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_319a3608-4515-4682-9bf4-595acb8f379b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due within Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ffae27b7-cf0d-4f16-9408-d6952357e89b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_208cf674-8767-4001-a257-da261db9a000_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20201231.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_346c6c88-7915-4efc-be06-1cb5d3c6df21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_89929f3b-553c-469f-aa51-97a0c08cfc90_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due in February 2045</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2045 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_eb919338-cb17-4fe2-b379-1450b5735eb1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_7e0e1c99-1f86-4e84-8722-8d3595074857_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_Goodwill_4ce34b41-9e1c-45a2-a1f5-01f3d5f6b7b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_1648d735-7fc7-45b1-913c-55788024c8b5_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_cad4112e-bed3-404a-a65e-5d402c17d6a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_6e6acf6c-9088-4c51-9eee-89a9c26ec6c9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ea3cd39e-bca1-4366-8b4d-922b424780ed_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dc5cb86e-33b0-4708-a3aa-59b5a1219334_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_aa167a0b-d6da-4604-a7d6-27c73a7ed752_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_44bfa0bc-2edb-4e4d-b021-1bfbde5b3d4d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueatGrantDateMember_1d1f6ea6-b74d-4356-b056-2f2c9f938074_terseLabel_en-US" xlink:label="lab_gild_FairValueatGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at grant date</link:label>
    <link:label id="lab_gild_FairValueatGrantDateMember_label_en-US" xlink:label="lab_gild_FairValueatGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Grant Date [Member]</link:label>
    <link:label id="lab_gild_FairValueatGrantDateMember_documentation_en-US" xlink:label="lab_gild_FairValueatGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value at Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatGrantDateMember" xlink:href="gild-20201231.xsd#gild_FairValueatGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueatGrantDateMember" xlink:to="lab_gild_FairValueatGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ec58ab7d-08e1-4a48-be70-c64436250e8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_e3a5c324-553f-4ca9-bcc7-bdea317ea26e_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_adaf2903-1ccc-4d1f-b802-e05d85a9d430_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_578b6eea-067b-401e-b84f-9b0d0327cf25_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Per Share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_be7f3e1c-dd7a-4876-8802-0b5ba7566a9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member_65486142-6011-431a-bcf8-e773c1d272ac_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.35% Senior Unsecured Notes Due In February 2020</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due In February 2020 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due In February 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueInFebruary2020Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueInFebruary2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueInFebruary2020Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueInFebruary2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9f3c5014-b3da-45de-9475-f6934f56eb33_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_de257e13-6ceb-43b0-bf2c-5dc80122dd28_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20201231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ea0f804e-9d0e-400c-a5eb-cca313dfac4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_6f3ed241-3c4a-4a0a-90ad-3f69d8c8a520_terseLabel_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for adjustments of budgeted development costs</link:label>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_label_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_documentation_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:href="gild-20201231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:to="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_3476a365-8f3b-4d52-87f4-996a562a13b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5c78dd1c-6808-4ea1-9318-08549096bd4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_63d856eb-6206-4104-beb6-027979766d4b_terseLabel_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_label_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023 [Member]</link:label>
    <link:label id="lab_gild_VariableTermLoanNoteDueOctober2023Member_documentation_en-US" xlink:label="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Term Loan Note Due October 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:href="gild-20201231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VariableTermLoanNoteDueOctober2023Member" xlink:to="lab_gild_VariableTermLoanNoteDueOctober2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_e803ca93-cc1c-499b-9dc3-f4b969f30006_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_83bf32c5-8777-4aa7-8893-c48f73dc8a52_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7377f901-6063-444c-accf-3dbf16870e8e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f4864db0-e1ac-4c6b-bcf4-b6caad330b3b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_51f476e9-9ec7-45e0-9e33-adc9dd412633_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7e62be66-5b59-4eb2-94c1-0a7ed1adaccd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_757622cf-db12-4d3a-9992-755e57aa83b5_terseLabel_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct transactional costs</link:label>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_label_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Direct Transactional Expense</link:label>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_documentation_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Direct Transactional Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense" xlink:href="gild-20201231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForDirectTransactionalExpense" xlink:to="lab_gild_PaymentsForDirectTransactionalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b7196619-e301-4ce1-bc49-85b6c935a51f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_b8f328ec-6e97-4e27-adfc-f3c877debf4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_df5cb323-63ef-4b8f-8021-861f6831a271_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_e8a90217-0a67-42f4-bc34-fb153ef611ec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8269a60a-5338-4092-83e4-1aa821dcfc94_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a379d9bf-6031-4f75-93da-f413c8a51376_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f70c9d79-acca-4ff7-a1d0-61b131ca63ab_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_d72fff11-7b45-427a-9c92-0c452a97eb14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a836847f-abcd-4370-8df4-20b26c47c831_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6b70c13a-0df7-4f12-b94e-7081dcf2f88e_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_d0c57ae3-9072-4610-aaca-273384fd0544_terseLabel_en-US" xlink:label="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Life</link:label>
    <link:label id="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Lives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:href="gild-20201231.xsd#gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:to="lab_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_40643d80-faf6-42a8-8892-262b0ae0be65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a4199bd8-dcaa-432c-8ff0-8089940603dc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_58f0fd43-646d-4b4e-aebf-0338eadfda6f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_006f5b7f-fd77-431a-a611-76d379e25325_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_cd7fa1d3-cc4a-4ed6-bec5-879170c75a19_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b1c94ca2-42b2-45ad-a8da-d7b5e8801564_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expenses -included in consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_33096c8f-4474-4ca5-8c88-f788069cda2f_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due in April 2024</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2024 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_64d1931b-17d8-40c4-b919-cb8209395d95_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20201231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a6b16ad9-e44a-462a-93ad-d5f066ae5780_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_dbdc0ce5-0abe-4be7-8d9a-5e8a4704297c_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense following U.S. Court of Appeals decision</link:label>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_label_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b6048ae5-6ec7-4807-8b30-e6e64b1c08d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_fa738453-41d0-45e0-99a5-da31d6641dd7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_4659ddc5-3a69-460c-b8a7-ac9c59f56b1d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8f25afb8-871a-46a2-b689-c121be358fee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_35d66c87-66b9-4365-93be-51e76d2a0d4b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State - deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_f198d2a7-3b99-400d-845f-2a8314b7d5b5_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20201231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_5fbf76cc-09c7-4153-9604-25db22a12034_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of tax examinations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a6cd2504-2d89-4826-b58f-478e6565b374_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_784dc5dd-d315-4d48-acc1-0dcdf66341b0_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future milestone payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Future Maximum Milestone Payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Future Maximum Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" xlink:to="lab_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ca2f9345-39b7-4114-bb66-1914986ad0a5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_89685b06-e350-45be-a53e-99d7be819b6d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6ab715d8-29ce-4714-b6a0-96407249edef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_fdd626b4-7815-4061-9c30-64974b019005_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_cbb87a53-a34a-45f3-8cb7-f0771f5f7026_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20201231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b28c67fb-2f05-473d-92bb-7f3d565f4d69_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_705eb101-e734-4ae9-bb2b-9f1ddbf7a28c_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_b439a378-63b5-4290-80d5-6e4359fc98be_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH (&#8220;MYR&#8221;), a German biotechnology company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20201231.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_654a0243-3489-4f12-a947-070834cbbf54_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_a73dd4e4-ba37-4397-92bb-000c735f81bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_53bfef54-98bd-4f52-8046-341d49faac50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_dff6602d-9cff-4b81-b2f0-90852df4d591_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_d8b02b26-3f41-4be7-9ff4-15dcf9db1fdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_173b19d2-48d1-4236-a65e-d9e8709e4990_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5c4b518e-df1f-4785-ba9a-586636accec3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d7fd4b80-464a-4b9e-bf13-d39468e13522_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_7a068a3f-8029-405e-b5ad-88571a7237ab_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_18b104d3-3178-4102-82ad-e6fcd766e0d5_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_c8c51fa2-cd5b-4e32-b9f8-874386fda8e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_3e5f6f3c-4688-454a-b009-599ec8e42a0b_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tiered royalties, low-end percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalty, Low-end, Percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalty, Low-end, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:href="gild-20201231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_ca1c4240-efc1-4ec6-b758-65f164462a6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d438f2dd-629a-4ece-bbf1-0a0767c2601b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueApril2021Member_b49b20c8-d57f-4769-a401-ce4508139ee8_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due in April 2021</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueApril2021Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due April 2021 Member</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueApril2021Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due April 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueApril2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_cb4815a6-9d41-4a3f-a955-4315c74fd6af_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_45f873da-7a4d-44ba-9868-62affc9a844f_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_35aaa1f3-52a5-46b7-a797-63fc680cab26_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State - current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ff4d5697-afcf-4d82-ab3d-5450c3fd3945_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_74508aca-cf71-4a6f-9f39-020644c3a726_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_40d96301-842f-49df-9520-1fa3b7a3a30d_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20201231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d23f85b5-f369-4cb6-9010-efd1e2f50be1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4981eadb-f317-4614-a6c2-e48e4afac5b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_119476dd-6078-4f5b-88dc-9c257ddaeb61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_44d26c1c-8e1b-4724-a127-8ff5aab9fd95_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9fe3eea7-23a7-4b2d-aca7-1b8ea910baa0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_72b0597a-e4a8-475c-b852-29dcc8c5b163_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts Offset on the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_01706710-05f2-4e78-a5c6-144f6701a33a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_edb41675-88a8-4ecd-a5c1-c2c6abbfd75d_terseLabel_en-US" xlink:label="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period [Domain]</link:label>
    <link:label id="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_label_en-US" xlink:label="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period [Domain]</link:label>
    <link:label id="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_documentation_en-US" xlink:label="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" xlink:to="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_fc61fb17-7027-4185-a869-c9fb3e9af114_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2d311814-bde4-49e2-8f10-634b087c31cd_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ded5f8db-7553-417f-bf30-e28c1fcd1e64_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_2de31aa3-af93-4f2b-a31c-e0be5468a746_terseLabel_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 agreement</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_label_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in 2019 [Member]</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_documentation_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" xlink:href="gild-20201231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" xlink:to="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a12b76e7-b633-4fa4-ab86-3a0e3e1b66ec_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c3b60003-1393-457e-9173-162fb366a372_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5f0817e4-7e9c-46fa-9c17-0e22f011d1f5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_d0064db0-cb73-4c97-bd36-69b3a4696863_terseLabel_en-US" xlink:label="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired</link:label>
    <link:label id="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_label_en-US" xlink:label="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Net of Cash</link:label>
    <link:label id="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_documentation_en-US" xlink:label="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Net of Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" xlink:to="lab_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_5348559f-c2dd-4c99-bfc7-cff63452c7ec_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due in September 2036</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2036 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IssuanceDiscountPremium_4a5c9fff-a8f3-432d-9df9-024a96f4e3d1_terseLabel_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount (premium)</link:label>
    <link:label id="lab_gild_IssuanceDiscountPremium_label_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Discount (Premium)</link:label>
    <link:label id="lab_gild_IssuanceDiscountPremium_documentation_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium" xlink:href="gild-20201231.xsd#gild_IssuanceDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IssuanceDiscountPremium" xlink:to="lab_gild_IssuanceDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9df5f29a-0d04-4363-b060-c57143f29f3e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_3c319ddd-4dae-411c-9fdd-4a5d18f5d4ad_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ae9cbfa7-dd8f-4539-b3d3-1873067ac6c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_45d2942a-fd83-43e4-a19d-176992d51647_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfAgreements_3351e2e5-7aa2-4774-8446-c6aa8d509b6f_terseLabel_en-US" xlink:label="lab_gild_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_gild_NumberOfAgreements_label_en-US" xlink:label="lab_gild_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Agreements</link:label>
    <link:label id="lab_gild_NumberOfAgreements_documentation_en-US" xlink:label="lab_gild_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfAgreements" xlink:href="gild-20201231.xsd#gild_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfAgreements" xlink:to="lab_gild_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_9f31fbe0-7ae4-448e-901b-5a67a66fd3c5_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20201231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_db0e0a86-ed49-49f4-8f43-261ee20ba5cd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4cd310e9-34c5-4037-b617-5885d1f601bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AssetAcquisitionAxis_3d4e963d-a821-4897-8d16-fa376c0117db_terseLabel_en-US" xlink:label="lab_gild_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_gild_AssetAcquisitionAxis_label_en-US" xlink:label="lab_gild_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_gild_AssetAcquisitionAxis_documentation_en-US" xlink:label="lab_gild_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AssetAcquisitionAxis" xlink:to="lab_gild_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_44748d9a-f464-4ffa-91be-3fbad2ff6d3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes - Narrative (Details)</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ccb7681d-29f5-4e72-8ebd-bc0f4b312870_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fa931929-96a1-445c-b9b7-d0ae07180f41_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_798dc076-78dd-45b1-8626-23a931e92ca2_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_7aa319b8-5b2e-400c-b8bd-199f819a5a3a_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due in February 2025</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2025 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_95be913b-6016-4f44-b750-809186199249_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1c22697f-f6bf-48e0-97f9-ec1bff6092f5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_b712210b-ebbf-4ea6-bcc9-980a1193a69a_terseLabel_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate of finite-lived intangible asset acquired</link:label>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:href="gild-20201231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_8c8035c8-6d32-44d3-aa87-a4649445330a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_3601ed61-9611-45b7-b1e6-f07c7aeaeff4_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20201231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08f3fc1d-f94a-4fa1-be86-6a0f935d572d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_d07c5932-2788-44fe-83a2-a695813dd31f_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForResearchAndDevelopmentMilestones_94bded22-84bc-4766-8bbc-d56f64fbaaba_terseLabel_en-US" xlink:label="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made for research and development milestones</link:label>
    <link:label id="lab_gild_PaymentsForResearchAndDevelopmentMilestones_label_en-US" xlink:label="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Research and Development Milestones</link:label>
    <link:label id="lab_gild_PaymentsForResearchAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Research and Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:href="gild-20201231.xsd#gild_PaymentsForResearchAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:to="lab_gild_PaymentsForResearchAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_4d7e072b-4fb4-477d-a592-2243bd022154_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8f1e90de-3bf0-477c-9ef2-3f71c538db78_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic tax authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_70ec096d-0a14-4425-be87-ebb2799287a6_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3da04417-b095-46b1-8a8d-9157d5f6e074_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_08809250-6ae1-4c3c-a98e-f84b800735fb_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount (Legal Offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_6aacc0cc-d623-4d7b-9e5f-d4ed27e1018c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized capitalized software costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_961d1047-d68f-444a-ac70-be4d5fa240d0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_213ef5c0-5398-4fba-833b-a14fb11db26f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_73f861a7-9a4f-4155-9a0a-43a2fcd9eeb9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_aa96229f-6263-4b67-84e9-9ca8152e6d82_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_c401e952-af40-44e0-92bf-c8cf65615026_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected quarterly financial information (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9d365828-9de0-4949-8609-1d5594917623_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_583659bb-4962-484f-a812-03eefd99173c_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_66e8e4ce-8673-47ef-89e9-75b264082806_negatedTerseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_055d55cd-b611-4a7c-8644-bcc6f0b148b7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_a875fd43-e2c1-45ed-b017-c6bba419b0a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d91508b2-e9e9-48f3-a552-c4d979af06a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_79d008f0-738b-457d-a3a9-c58a9f72e41d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net book value of long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744d77-f440-4221-a109-75a1348727e9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_b96a860b-e840-4ca0-b217-da673a941069_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_61a05818-77a4-49a2-9737-127a04c0aefb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire in process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_77a25d72-fb12-432b-a531-b7696d3ffd22_terseLabel_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango collaboration and stock purchase agreement</link:label>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:href="gild-20201231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:to="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e6c8148e-0290-41a4-bae4-de108208f6a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_17de684e-39b0-4c86-b60b-6e51e618270c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ea0085d1-f121-42c6-9131-8bfe3fe340df_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend_785cd9e1-ec45-4af5-8081-b5d04948594d_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future tiered royalty payment low-end</link:label>
    <link:label id="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend_label_en-US" xlink:label="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Tiered Royalty Payment Low-end</link:label>
    <link:label id="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend_documentation_en-US" xlink:label="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Tiered Royalty Payment Low-end</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureTieredRoyaltyPaymentLowend" xlink:href="gild-20201231.xsd#gild_PotentialFutureTieredRoyaltyPaymentLowend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureTieredRoyaltyPaymentLowend" xlink:to="lab_gild_PotentialFutureTieredRoyaltyPaymentLowend" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_56bf3c04-f2b0-4c7b-acee-3a1bcb67d7c3_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 revolving credit facility</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20201231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_22da3f96-ebfd-47cf-b781-0618b2b7bac8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_4dfc8eb7-005c-490a-9595-f5c7d9866044_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_bea97151-4488-4ce7-9520-99ecfa575442_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financial information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0fe1ae5a-b207-4e91-a217-99ffafbc828d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_219c866c-2213-4b86-b72c-a08cabf764a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at December 31, 2020, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_d9cdfbcb-cbfe-4d11-bb29-4332fdd3845e_terseLabel_en-US" xlink:label="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment upon marketing approval GLPG-1690</link:label>
    <link:label id="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_label_en-US" xlink:label="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Upon Marketing Approval GLPG-1690</link:label>
    <link:label id="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_documentation_en-US" xlink:label="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Upon Marketing Approval GLPG-1690</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" xlink:href="gild-20201231.xsd#gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" xlink:to="lab_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_57ed6978-1630-4f39-b297-d43f4c771b8e_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due in September 2035</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2035 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636ee47e-a21b-4cad-8628-146c49a36fd4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_75becf9d-f253-4de0-945e-d658901f02dd_terseLabel_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_label_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Upfront and Milestone Payments</link:label>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_documentation_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Upfront and Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:href="gild-20201231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:to="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b74d9516-6724-4601-a9c7-48d7ae185548_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures at December 31, 2020, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UnrealizedGainComponentAxis_06f87ae3-a778-4eaa-ad11-3e450a35de72_terseLabel_en-US" xlink:label="lab_gild_UnrealizedGainComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain Component [Axis]</link:label>
    <link:label id="lab_gild_UnrealizedGainComponentAxis_label_en-US" xlink:label="lab_gild_UnrealizedGainComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain Component [Axis]</link:label>
    <link:label id="lab_gild_UnrealizedGainComponentAxis_documentation_en-US" xlink:label="lab_gild_UnrealizedGainComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentAxis" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UnrealizedGainComponentAxis" xlink:to="lab_gild_UnrealizedGainComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_d5186250-8f05-4ca9-ba90-38350cf2ec1b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ec49a815-0afe-4fc5-8d6b-2170014a6f79_terseLabel_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="gild-20201231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3c908be9-8553-40c3-8624-6179d7cf0ac0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6a4f20f9-9890-4b29-bc48-0b02c8cceb5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b57770c8-f7d9-4930-984f-1269b6cfd26d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f97cce8b-d12e-406c-b9a8-5ab489d6820e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_7ce46f79-ebcf-422d-bb64-ad76e0218e68_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1dcf3c4a-b178-4d38-8f75-26465264d54d_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_40ba1580-c7dd-4cbb-9e36-88240f36dc4c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_ef55f1b6-1fa2-4147-af52-7cd5a230eaa7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_751b2e13-3e41-4efe-a099-c68a687cd810_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_52862cad-3c7a-46f4-894a-00bf3f20ec99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_99093dcf-c32b-4fb2-9b6d-7567899dcc1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_fb23d3ef-ee4c-4c98-ae38-14952eaebec9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at January 1, 2018</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_45df1174-b403-4590-bad3-50033f927584_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_352755d5-56af-422f-8700-1bcd2c3d3562_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_af0602a1-952f-4fe1-a4b6-258621427507_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_526d6f84-ea83-4ab1-a827-e6e13bc67b28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease aggregate future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81babfb5-2930-46da-9bc9-027a6101b834_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b05bcb99-2079-4ffe-bdf2-022bc8752a03_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_06112d7b-6ea1-4bf7-8781-8d7c657e3d5e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense under ASC 840</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_54bc80cd-ea24-4780-8d6f-b0e34658a8cb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_79f11a1b-b5d3-4a81-b7cd-03b73b72ac28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_edc82539-a10a-454c-943e-3896e7a38fa2_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0098affb-7bd2-42e5-8e28-96faef8bdbd4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedResearchAndDevelopmentMilestonePayments_2591154b-1fa0-4688-b8d0-6901ee5a907e_terseLabel_en-US" xlink:label="lab_gild_AccruedResearchAndDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development milestone payments</link:label>
    <link:label id="lab_gild_AccruedResearchAndDevelopmentMilestonePayments_label_en-US" xlink:label="lab_gild_AccruedResearchAndDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Milestone Payments</link:label>
    <link:label id="lab_gild_AccruedResearchAndDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_gild_AccruedResearchAndDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedResearchAndDevelopmentMilestonePayments" xlink:href="gild-20201231.xsd#gild_AccruedResearchAndDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedResearchAndDevelopmentMilestonePayments" xlink:to="lab_gild_AccruedResearchAndDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AssetAcquisitionDomain_ef0cd74d-7c19-4ca6-9052-8e251f54964f_terseLabel_en-US" xlink:label="lab_gild_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_gild_AssetAcquisitionDomain_label_en-US" xlink:label="lab_gild_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_gild_AssetAcquisitionDomain_documentation_en-US" xlink:label="lab_gild_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AssetAcquisitionDomain" xlink:to="lab_gild_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f296756c-d80f-4071-a7ac-97a76384cd31_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_5b48c6d8-0c73-45e6-8756-00033dc034d7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_ea58e9a3-baa3-44e0-a805-5232a569aaf3_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_de77e98f-3fa1-4d3f-a0dd-d6dfd624cb90_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_75afe837-c0c4-4707-97fb-9b9f2e751902_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Amortization Expense of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be3ffb17-1aab-4ac3-bb9d-7b4f49425600_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3fb749a6-ce1e-47fb-8993-0693cbb53a62_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_cf9ba40e-ac83-441d-a189-10c765c4b84b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Obligation to Return Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_9fc6d614-966f-4d65-9591-7c7c7ebd1832_totalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9e4db6bd-1ea9-4fe0-bc3c-5fe9ed923018_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_92360e8e-800e-45c6-9933-c7c11668fbae_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_760b9338-c29a-4b40-bcf7-fe8c9091ceb5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_f9ab3974-3b16-48dc-bfbe-d2ec5809621d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SelectedQuarterlyFinancialInformationLineItems_10fb4491-e953-4e65-ab47-c91f36268b47_terseLabel_en-US" xlink:label="lab_gild_SelectedQuarterlyFinancialInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Line Items]</link:label>
    <link:label id="lab_gild_SelectedQuarterlyFinancialInformationLineItems_label_en-US" xlink:label="lab_gild_SelectedQuarterlyFinancialInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Line Items]</link:label>
    <link:label id="lab_gild_SelectedQuarterlyFinancialInformationLineItems_documentation_en-US" xlink:label="lab_gild_SelectedQuarterlyFinancialInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Selected Quarterly Financial Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SelectedQuarterlyFinancialInformationLineItems" xlink:href="gild-20201231.xsd#gild_SelectedQuarterlyFinancialInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems" xlink:to="lab_gild_SelectedQuarterlyFinancialInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_150e90bb-d13b-466a-8332-2d7c7a287132_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding stock allowed to be purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:to="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalFairValueAxis_6f9a6261-4139-44e1-b8c1-2bd4e1632201_terseLabel_en-US" xlink:label="lab_gild_TotalFairValueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value [Axis]</link:label>
    <link:label id="lab_gild_TotalFairValueAxis_label_en-US" xlink:label="lab_gild_TotalFairValueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value [Axis]</link:label>
    <link:label id="lab_gild_TotalFairValueAxis_documentation_en-US" xlink:label="lab_gild_TotalFairValueAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalFairValueAxis" xlink:href="gild-20201231.xsd#gild_TotalFairValueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalFairValueAxis" xlink:to="lab_gild_TotalFairValueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_1fb6e82f-7b2e-450e-ad42-a5fae62965e1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Due within Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7b3a407e-175d-4317-859b-01f8bd15ce5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d8217b3b-a82e-43a0-b3bc-4e063931f29c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of contractual maturities of financing obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_471682ff-a868-4e17-98dc-e2d1fe907518_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_43e7b66c-d911-4aa3-9b66-464c405f1e93_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_0b6d25a1-a2c4-474e-ae60-7b45a8e8ef57_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20201231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_cc742b20-ec99-4a7b-9b7f-2cd677104361_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f1074c61-ca99-4fd9-9c16-c068bd1b2ffa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_7f0f2572-a2dd-4a98-bbf8-4762ce3d91ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_d0480de4-f821-4ce8-a7c7-93ad75b41048_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_8b369bf4-d536-47a8-8ea5-1388d392cdec_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d4c6154a-6c9d-423e-ae4c-d98c178475e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2020, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b92d5828-de34-4231-a1e2-2a4cb4969a48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal - deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_7fd2e71d-e155-49fc-97ff-05a4eaf08c9b_terseLabel_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango</link:label>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember" xlink:href="gild-20201231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TangoTherapeuticsIncMember" xlink:to="lab_gild_TangoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_cab6bc78-2e48-446c-af26-32a901a23acf_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:href="gild-20201231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:to="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_8078bc28-fdd8-4a1e-a672-24ec064813e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental pro forma information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_899b85bb-7541-43dd-9caf-9bee88965a28_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0296e4e1-b5c1-4720-933d-2bc63a65fb08_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_587f13f6-d39b-41e6-bdf0-6b7dcafacbf3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_eb91b487-12c9-4111-9185-23f1f142d2f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c268c94b-04e5-4cf4-9f5f-82031356ccc8_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_415199b9-6131-4c97-b3d6-3e4d571754eb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_beb0a898-521f-4736-89b5-8b4dfb57b898_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_f702da11-b7ff-4da2-a117-d313ca26ef41_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_34425f46-3ed5-4185-aabb-d4ea79291843_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_113e43f0-d744-426e-9a39-328d18c34353_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_45341081-ef4e-4fee-ab7d-078d5cacaec3_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHCVMember_5daa123c-19e6-482d-92b3-596088ecf94b_terseLabel_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHCVMember_label_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV [Member]</link:label>
    <link:label id="lab_gild_OtherHCVMember_documentation_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember" xlink:href="gild-20201231.xsd#gild_OtherHCVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHCVMember" xlink:to="lab_gild_OtherHCVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ad2a3601-b580-4a9f-b471-099e4e75469b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_134d1b1f-d392-4169-be74-fcad0858e861_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_7c8e26cd-f5ad-44c5-8418-59183a3b0b0e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9f76f66e-0db9-4504-b7a7-1ec89a1cdf0d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Positions Related to Current Year: Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_ca530ced-f086-4668-899f-05097b662b7f_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_be37e349-a85e-4ba5-b6f6-0bf51e858682_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e47c245e-ca80-4080-ba8c-10e067cebbc4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bdacba3b-d64b-4179-9e4e-1973d7fa37e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of earnings per share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_7bf87630-5a5b-41ce-995a-e4e29605dcf0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1f47464a-7476-4302-a6a9-ae663df88935_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3c7c6d93-2e25-4b29-98f2-f38210b170b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a9fb6642-b7f1-4fdc-9204-47bd1c3ddd95_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_648f0768-6a37-442d-8f72-039de9138bb8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IdenixPharmaceuticalsIncMember_a0273b78-afd8-4b12-9de7-b890b374b5c5_terseLabel_en-US" xlink:label="lab_gild_IdenixPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indenix</link:label>
    <link:label id="lab_gild_IdenixPharmaceuticalsIncMember_label_en-US" xlink:label="lab_gild_IdenixPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idenix Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_gild_IdenixPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_gild_IdenixPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idenix Pharmaceuticals, Inc. (&#8220;Idenix&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IdenixPharmaceuticalsIncMember" xlink:href="gild-20201231.xsd#gild_IdenixPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IdenixPharmaceuticalsIncMember" xlink:to="lab_gild_IdenixPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c177ab62-cfb9-4364-afe3-2a2af9faf976_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsVireadMember_62124cbd-aeb2-4690-acb3-d932ddbc8a76_terseLabel_en-US" xlink:label="lab_gild_OtherProductsVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Viread</link:label>
    <link:label id="lab_gild_OtherProductsVireadMember_label_en-US" xlink:label="lab_gild_OtherProductsVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Viread [Member]</link:label>
    <link:label id="lab_gild_OtherProductsVireadMember_documentation_en-US" xlink:label="lab_gild_OtherProductsVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsVireadMember" xlink:href="gild-20201231.xsd#gild_OtherProductsVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsVireadMember" xlink:to="lab_gild_OtherProductsVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_9cf1173b-8dcf-4341-85b1-aa2f6a02dab9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_b5791e16-2177-4c24-89ef-0576b5d5db64_terseLabel_en-US" xlink:label="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future potential clinical, regulatory and commercial milestone payments</link:label>
    <link:label id="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_label_en-US" xlink:label="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum</link:label>
    <link:label id="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:href="gild-20201231.xsd#gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:to="lab_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_b37be4dd-236b-4f52-80e2-8724e3a7c0de_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:href="gild-20201231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_8e49168a-8bfc-4e29-9adf-550a79b296f9_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e2528cc6-cd92-482a-a74f-38afe4fdb18c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_c8207be5-81e9-43f8-a0aa-64161bf98e19_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_64288e57-260f-4873-ae4e-9ae2491c0f74_terseLabel_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront payments made</link:label>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_label_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Upfront Payments Made</link:label>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_documentation_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Upfront Payments Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade" xlink:href="gild-20201231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalUpfrontPaymentsMade" xlink:to="lab_gild_TotalUpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_23ff26e5-683c-42ac-a54d-8548ede98400_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5f0bff6c-8824-436c-87d3-00f3141ca232_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_d8904539-d8f3-4b66-b56c-2e7bcf5900d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_75020b02-56e1-4190-bf08-eb28ab9ab5e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_bd8f180f-4dcc-4b8c-9539-96f927ff6776_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_3ee58910-58c1-434c-b42c-f3b02da90b12_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5953b179-31d4-4e5a-a6e2-d8aa17489375_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_d5b664ee-95bc-4e46-afe0-a50ea9055043_terseLabel_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_label_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_documentation_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:href="gild-20201231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:to="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b6404b7a-71b4-4c8e-9aa1-46a58e92d899_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalGrantDateFairValueDomain_81454395-de03-4df5-ad55-84f357b65dc1_terseLabel_en-US" xlink:label="lab_gild_TotalGrantDateFairValueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Grant Date Fair Value [Domain]</link:label>
    <link:label id="lab_gild_TotalGrantDateFairValueDomain_label_en-US" xlink:label="lab_gild_TotalGrantDateFairValueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Grant Date Fair Value [Domain]</link:label>
    <link:label id="lab_gild_TotalGrantDateFairValueDomain_documentation_en-US" xlink:label="lab_gild_TotalGrantDateFairValueDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Total Grant Date Fair Value [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain" xlink:href="gild-20201231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalGrantDateFairValueDomain" xlink:to="lab_gild_TotalGrantDateFairValueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_a170df67-ffb1-42fc-8a4c-b32c7a5f0a57_terseLabel_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss representing enhancement of past damages</link:label>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_label_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)</link:label>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_documentation_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:to="lab_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_120371d9-f3fe-4d00-965b-4017ed61525a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_9a47f3d2-3e59-4a3d-9e42-f1ab3a5b8731_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of asset derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_5bdb3043-81c3-4061-aa4d-611f0bb16953_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of classification and fair value of derivative instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_4423f256-f28f-4569-9aea-95fe602ac0bc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_4497a1dc-bf1a-4fa2-beb2-3db456e0fe7b_terseLabel_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_label_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:href="gild-20201231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:to="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EPSImpactbyTransactionDomain_3c90b77b-9cf4-49f0-904f-3e6c5375821d_terseLabel_en-US" xlink:label="lab_gild_EPSImpactbyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Impact by Transaction [Domain]</link:label>
    <link:label id="lab_gild_EPSImpactbyTransactionDomain_label_en-US" xlink:label="lab_gild_EPSImpactbyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Impact by Transaction [Domain]</link:label>
    <link:label id="lab_gild_EPSImpactbyTransactionDomain_documentation_en-US" xlink:label="lab_gild_EPSImpactbyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for EPS Impact by Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionDomain" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EPSImpactbyTransactionDomain" xlink:to="lab_gild_EPSImpactbyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c7f14a0e-3dc7-4090-8997-41d73fadf4c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7167b37b-235c-4bd0-89ed-4a4e243ca99a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1bd55259-af08-4aac-b11e-947cd2bc4853_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_c7638d98-bb49-4691-9cec-49e157dc49dd_terseLabel_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - Trodelvy for mTNBC</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_label_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC [Member]</link:label>
    <link:label id="lab_gild_TrodelvyForMTNBCMember_documentation_en-US" xlink:label="lab_gild_TrodelvyForMTNBCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy for mTNBC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyForMTNBCMember" xlink:to="lab_gild_TrodelvyForMTNBCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3ab36d7d-a3f0-47bf-964e-7d77132fba6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_a4db3c1d-3883-4517-929f-0819bd32d08c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_36e19c8e-00d7-4c0f-9ff7-0ae83766d943_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_969ecebf-0422-4e57-9e30-a4feb93d3196_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f2ae6bb3-b154-415f-85d2-fa1e65dc9135_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_d52c1876-0f66-440a-b97f-10f3149afbb1_terseLabel_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.52% LIBOR Senior Unsecured Notes Due September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20201231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_333563ea-385d-4157-a159-f9c21c7a3bee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_c5da6fa6-6b5a-41ab-814f-9ba18a214233_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20201231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_e1b40492-d955-4432-9033-8dc2c7ee2e9e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_661e38bf-e45d-42a5-adea-1228db2998d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized tax benefits roll forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37d24a49-e917-43a7-baf4-f884cd35e8c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6b8fcc1c-66ba-4f37-83f5-249bbc85eac8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_590f64d6-42c6-49d1-8511-7c806bb6ffb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_c2fe83b6-5c86-4967-83e5-0ec7e79a519a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_dfd37dc0-5b7e-4b0b-8d7b-372157d52cf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5be7f39a-c5fe-4f99-bd65-6a9bd059356e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_15256b80-2d10-49b0-a1e8-1b47248a604b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_769492e2-667d-44ed-a667-f55388083fda_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_46b70134-1b95-4053-8124-b9e4a275f2f6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c12956b7-1194-4013-8bf7-c39e25b967bd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryWritedownAbstract_4260baa0-0bc7-4882-a5d6-a91ad80272c4_terseLabel_en-US" xlink:label="lab_gild_InventoryWritedownAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down [Abstract]</link:label>
    <link:label id="lab_gild_InventoryWritedownAbstract_label_en-US" xlink:label="lab_gild_InventoryWritedownAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down [Abstract]</link:label>
    <link:label id="lab_gild_InventoryWritedownAbstract_documentation_en-US" xlink:label="lab_gild_InventoryWritedownAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownAbstract" xlink:href="gild-20201231.xsd#gild_InventoryWritedownAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryWritedownAbstract" xlink:to="lab_gild_InventoryWritedownAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f735fcd1-0513-4bbd-8fb4-0e315a32e40a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_4b6cf181-d569-469e-aca5-cf6d8c08ac8a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_5d721b2e-7df2-43a5-aa10-997a73e5d027_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_5ea3735c-8bc3-4df8-8c9a-834c00ea93e2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_4cbbf10b-0ea1-40b9-8d22-b1569101826e_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20201231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_7ebbaff2-3a36-43ef-9a9f-6df88bcd4ce4_terseLabel_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration arrangements</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_label_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_documentation_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember" xlink:href="gild-20201231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherCollaborationArrangementsMember" xlink:to="lab_gild_OtherCollaborationArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_3da1938c-2de3-47e0-8dfb-3c71074eb174_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20201231.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_007b9022-bcb4-4623-b6cb-e3b7f77ab359_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liability derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_53a4a4f2-69ed-4549-b6c4-c5ee5b55083e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Contingent Consideration Resulting from a Business Combination</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6a0b9cd7-db9a-4e3d-a036-ee2debb721b1_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_2c50181e-b3a6-4821-a016-d9895c1f9854_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20201231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3b0bbcf8-52ce-4a6b-9e47-9d8e4768b623_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c9c5d05-e7c5-4b4b-89e9-3b95fddbf9a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b2073057-7ad5-4dd1-988e-a0f4b18f2e83_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d16a1cd5-0dd0-42e0-980c-96d2c07543b7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_614a6377-14eb-434a-ac01-87978771170f_terseLabel_en-US" xlink:label="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized related to royalties for licenses of our intellectual property</link:label>
    <link:label id="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_label_en-US" xlink:label="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized related to royalties for licenses of our intellectual property [Member]</link:label>
    <link:label id="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_documentation_en-US" xlink:label="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized related to royalties for licenses of our intellectual property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" xlink:href="gild-20201231.xsd#gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" xlink:to="lab_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosMember_4cff5ffd-1b72-4829-a001-ed4620aaade8_terseLabel_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos</link:label>
    <link:label id="lab_gild_GalapagosMember_label_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos [Member]</link:label>
    <link:label id="lab_gild_GalapagosMember_documentation_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos, a clinical-stage biotechnology company based in Belgium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember" xlink:href="gild-20201231.xsd#gild_GalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosMember" xlink:to="lab_gild_GalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_StandstillRestrictingTerm_4c0abeb2-b765-477b-983a-a5f7e4209fb0_terseLabel_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restricting term</link:label>
    <link:label id="lab_gild_StandstillRestrictingTerm_label_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill Restricting Term</link:label>
    <link:label id="lab_gild_StandstillRestrictingTerm_documentation_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill Restricting Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm" xlink:href="gild-20201231.xsd#gild_StandstillRestrictingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_StandstillRestrictingTerm" xlink:to="lab_gild_StandstillRestrictingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_015df804-e73d-4a9c-90d6-5b2237ece771_terseLabel_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_label_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:label id="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_documentation_en-US" xlink:label="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:to="lab_gild_DeferredIncomeTaxExpenseBenefitComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_9e1288f4-147e-4c72-9430-e3fd14c2f19f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_f55d774e-7f55-46c8-9dba-c5e602612f09_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_89ffe40e-8994-465f-9c76-7eacf35d6bb9_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20201231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a87e2453-5c7c-4470-9d84-78ff606a36cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_02c50a69-d9df-4a46-ab1d-d964a665e6ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share attributable to GIlead common stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_46b0c791-7aad-411e-8fd9-a5fe1278a039_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20201231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee4bcd1d-a31c-4246-b742-0b1cac6cbeab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_33a6249f-57f6-4f54-98e1-1a764e08e13f_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bf0c08a0-d665-41a0-9f41-da95a6270be3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1590f672-0a6a-4e86-8b5f-47f54a0e8962_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_706bb2b3-5ebc-4b52-b0e3-719a0117fca1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d576a226-9498-41ce-be7b-328fe53bd9c0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_7f6205c0-00a9-4bea-be09-8f2e7a945622_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember_334b4f26-29c3-4f1d-ace4-e1b8d9278351_terseLabel_en-US" xlink:label="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended arcus common stock purchase agreement</link:label>
    <link:label id="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Arcus Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Arcus Common Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedArcusCommonStockPurchaseAgreementMember" xlink:href="gild-20201231.xsd#gild_AmendedArcusCommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedArcusCommonStockPurchaseAgreementMember" xlink:to="lab_gild_AmendedArcusCommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_94e099d4-7dd4-4a52-b2b2-e1421461011c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_85f1f2bd-331d-4600-8522-f9dc7c133e3d_terseLabel_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_label_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company [Member]</link:label>
    <link:label id="lab_gild_ViiVHealthcareCompanyMember_documentation_en-US" xlink:label="lab_gild_ViiVHealthcareCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Company (&#8220;ViiV&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember" xlink:href="gild-20201231.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ViiVHealthcareCompanyMember" xlink:to="lab_gild_ViiVHealthcareCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_fafda9e4-6791-4ae5-a1d3-b73b8d99cc57_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_aa62482a-6a40-4048-b049-f4a956f7f81a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b02a5c70-e9f9-4526-bc25-df71e85c5c25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financing arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ca45c232-3a55-42fd-b1c0-d9ae0372a986_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_331b36d8-b7d6-4f3b-9627-e837d8eb2eca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2892289a-413c-4192-8bc9-b6073a41b77c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_4077c171-a3a1-41d2-9fd3-886d0dcff5e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_682c4ba5-da70-4c7f-b6e2-3e7a74872334_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b6659060-8b2f-4e11-99c5-802cd7056cc9_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_387aa2c6-e6c6-4824-9561-034e166d9497_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings at different rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c597b09-476d-4203-a4cc-3f275d4707b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_3c290d73-59af-407a-b898-fc5b064e9d71_terseLabel_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:href="gild-20201231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_ad686401-b7c9-45a0-b2b1-2a96da9c22a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentEnhancedDamagesonPastSales_e831f804-8e24-455f-8a45-c83282b3eace_terseLabel_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesonPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhancement rate on past damages</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesonPastSales_label_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesonPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages on Past Sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesonPastSales_documentation_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesonPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages on Past Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesonPastSales" xlink:href="gild-20201231.xsd#gild_JudgmentEnhancedDamagesonPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentEnhancedDamagesonPastSales" xlink:to="lab_gild_JudgmentEnhancedDamagesonPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_Issuancediscount_06e10be4-7b2c-4eb3-8d05-59e1bbfa431f_terseLabel_en-US" xlink:label="lab_gild_Issuancediscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount</link:label>
    <link:label id="lab_gild_Issuancediscount_label_en-US" xlink:label="lab_gild_Issuancediscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount</link:label>
    <link:label id="lab_gild_Issuancediscount_documentation_en-US" xlink:label="lab_gild_Issuancediscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Issuancediscount" xlink:href="gild-20201231.xsd#gild_Issuancediscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_Issuancediscount" xlink:to="lab_gild_Issuancediscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f21b7b7-5278-43c6-a6c5-231bfd59c2a0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6587a8ad-ad79-457f-b4d6-b5dd341c9256_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7552402b-983f-413a-99ff-e0bcc3d79c67_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_9ebd0116-e76f-4de8-b5f9-52b7a50a0148_terseLabel_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares acquired (in shares)</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_label_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Shares</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_documentation_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares" xlink:href="gild-20201231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InvestmentOwnedBalanceAdditionalShares" xlink:to="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_a5629072-a4c1-4cf9-9671-ebfb489039e5_terseLabel_en-US" xlink:label="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filgotinib agreement</link:label>
    <link:label id="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_label_en-US" xlink:label="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filgotinib License and Collaboration Agreement with Galapagos [Member]</link:label>
    <link:label id="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_documentation_en-US" xlink:label="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Filgotinib License and Collaboration Agreement with Galapagos [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:href="gild-20201231.xsd#gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:to="lab_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_ecaa749d-6e98-42eb-94f7-7067377165e7_terseLabel_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three year senior unsecured term loan facility</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility [Member]</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:href="gild-20201231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:to="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_88028a23-b638-4c73-acfb-db222624abfc_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a45333d0-0fae-4ba6-be0b-3310e73fc269_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_dd072c56-847b-4a67-a8e5-5c20d198f0a5_terseLabel_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made related to equity investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_label_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related to Equity Investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_documentation_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related to Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:href="gild-20201231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:to="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fc6afd10-7b94-45d3-aaee-50764c6b9e66_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_6a9a9a70-8ffd-4692-b378-b649ec1e083d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Narrative [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_006fdfa0-f779-430c-8b24-a6146c3f743b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_e90a3fc4-5b71-47fa-a376-35c2f0984f5b_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:href="gild-20201231.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ca89a478-d0ad-4543-ba83-868b3c068fba_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_20e4a602-1001-418d-a8bf-2ddb01100613_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_b50f8033-e37a-46c9-b98b-01f03dbb02d0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_87dca9b8-b4fd-413f-845d-c7dd54750562_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_0c9796a5-378d-45fe-8bec-a118f7e7a53e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_4dfc56e1-3474-4776-a6f1-244d117ae631_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8e047105-bd1f-44b4-a2ff-4bbeb5cece1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5ab4ddb4-01ac-4108-b6de-39ad5b9c6a67_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_0d4a6675-f666-4464-9e6d-9142bb811b55_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ebfdca1d-345e-46ab-a97b-2a0732c1c263_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20201231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_64934171-e192-4a83-aa6d-045e01a94eb0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_84a4216c-b692-44f8-9248-9ea738e3ee55_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_4e6d8f34-10ab-4f9c-b3f7-5eb227074f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized revenues from major customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f071fa96-e6f8-45a5-85b1-6a543e3253fe_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BristolMyersSquibbCollaborativeArrangementMember_ffeaeac4-137b-470c-b054-bdf0cb7ad0d8_terseLabel_en-US" xlink:label="lab_gild_BristolMyersSquibbCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS collaborative arrangement</link:label>
    <link:label id="lab_gild_BristolMyersSquibbCollaborativeArrangementMember_label_en-US" xlink:label="lab_gild_BristolMyersSquibbCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers-Squibb Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_gild_BristolMyersSquibbCollaborativeArrangementMember_documentation_en-US" xlink:label="lab_gild_BristolMyersSquibbCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers-Squibb Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BristolMyersSquibbCollaborativeArrangementMember" xlink:href="gild-20201231.xsd#gild_BristolMyersSquibbCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BristolMyersSquibbCollaborativeArrangementMember" xlink:to="lab_gild_BristolMyersSquibbCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_615e4156-1b1d-49ba-b1ed-7b4966385e36_terseLabel_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for adjustments of budgeted development costs in 2022</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_label_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Year Two</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_documentation_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" xlink:href="gild-20201231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" xlink:to="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_a56b117e-44c0-4def-a19b-0ea90148a40c_terseLabel_en-US" xlink:label="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration, net of acquired cash</link:label>
    <link:label id="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_label_en-US" xlink:label="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Cash Outflow Net Of Cash Acquired</link:label>
    <link:label id="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_documentation_en-US" xlink:label="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Cash Outflow Net Of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionCashOutflowNetOfCashAcquired" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionCashOutflowNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AssetAcquisitionCashOutflowNetOfCashAcquired" xlink:to="lab_gild_AssetAcquisitionCashOutflowNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7d6b959c-aec4-4877-8099-aab730bd154e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_fdf43071-a617-4952-b6a9-e91f27ce270a_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset - axicabtagene ciloleucel (DLBCL)</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:href="gild-20201231.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_91af8230-2d13-44f3-a2ec-7a391747df64_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_99bb4d05-98d6-4db0-9cc7-abf16cfcf416_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_27d1fc0a-0df7-4702-a4a9-91791bec4d2f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dae68253-c0c3-4653-9db6-34a5aa345a90_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_69e352c9-0ced-4b0b-9c8f-8a4a1cdab734_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_93fbe591-dea2-4a31-9f26-1896a8ab5abd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years:</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_9693372c-8888-4019-987b-e8b74d5e9228_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Collateral Received/ Pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Collateral, Right to Reclaim Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLossPastSales_52aacb13-78ca-4939-af17-a916560cab94_terseLabel_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLossPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss representing past sales</link:label>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLossPastSales_label_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLossPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (Past Sales)</link:label>
    <link:label id="lab_gild_LossContingencyEstimateofPossibleLossPastSales_documentation_en-US" xlink:label="lab_gild_LossContingencyEstimateofPossibleLossPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss (Past Sales)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLossPastSales" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateofPossibleLossPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyEstimateofPossibleLossPastSales" xlink:to="lab_gild_LossContingencyEstimateofPossibleLossPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_bb1d0b10-da71-42bf-976a-7b157169f4d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SelectedQuarterlyFinancialInformationTable_86b594f4-1f4b-4c2c-8b04-765750c6aef1_terseLabel_en-US" xlink:label="lab_gild_SelectedQuarterlyFinancialInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Table]</link:label>
    <link:label id="lab_gild_SelectedQuarterlyFinancialInformationTable_label_en-US" xlink:label="lab_gild_SelectedQuarterlyFinancialInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Table]</link:label>
    <link:label id="lab_gild_SelectedQuarterlyFinancialInformationTable_documentation_en-US" xlink:label="lab_gild_SelectedQuarterlyFinancialInformationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SelectedQuarterlyFinancialInformationTable" xlink:href="gild-20201231.xsd#gild_SelectedQuarterlyFinancialInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable" xlink:to="lab_gild_SelectedQuarterlyFinancialInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_9844719d-cdd7-49c9-90bb-8136d0b161ad_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_e672b9d7-60e7-4b5d-a8ad-3bcf49e83907_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other product sales</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20201231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7d7b3c13-ef21-43f3-b9e5-a6673fb873c9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_4287673b-a27d-4d58-b4ff-19fd6d414078_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosCollaborationAgreementMember_29716e9b-5e06-4b76-8208-a4b52cca0f74_terseLabel_en-US" xlink:label="lab_gild_GalapagosCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos collaboration agreement</link:label>
    <link:label id="lab_gild_GalapagosCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_GalapagosCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_GalapagosCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_GalapagosCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosCollaborationAgreementMember" xlink:href="gild-20201231.xsd#gild_GalapagosCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosCollaborationAgreementMember" xlink:to="lab_gild_GalapagosCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_c25c430f-6f76-4784-87a4-b65c2ebf2cef_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of finite-lived intangible asset acquired</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_ce464062-e0b6-4994-9f6d-55d8d5d2d13b_terseLabel_en-US" xlink:label="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]</link:label>
    <link:label id="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_label_en-US" xlink:label="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]</link:label>
    <link:label id="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_documentation_en-US" xlink:label="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" xlink:to="lab_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_f8988fe4-c1d3-481e-9828-d4acf5b65b4e_terseLabel_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee and potential future milestone payments</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_label_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Fee And Potential Future Milestone Payments</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Fee And Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:href="gild-20201231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:to="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_f3016591-f30a-43d6-90d3-dfe7c1be8fa5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Amounts of Recognized Assets/Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7b051229-d5ff-4435-b91a-776e6776ed92_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_67d68607-1a41-4033-9ec3-0df80f2a2e1c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>gild-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:c95e6174-aa16-488c-b0f6-cc28c1f33ed5,g:86b29b2d-a791-4b12-a644-3051a1d6b3ea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/Cover" xlink:type="simple" xlink:href="gild-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_11ac2cc3-ad0d-463b-91db-678c5a622f92" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentType_11ac2cc3-ad0d-463b-91db-678c5a622f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3d76f89b-d2e6-4859-ab82-0831d6b1a38a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentAnnualReport_3d76f89b-d2e6-4859-ab82-0831d6b1a38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d0640d59-cc9f-4c7b-ad79-27c72eb16a74" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentPeriodEndDate_d0640d59-cc9f-4c7b-ad79-27c72eb16a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9408c98f-31d5-495d-8e5a-e4d593e89496" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_CurrentFiscalYearEndDate_9408c98f-31d5-495d-8e5a-e4d593e89496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6a5a832e-d1c9-420d-836d-fd31b87e2c37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentTransitionReport_6a5a832e-d1c9-420d-836d-fd31b87e2c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_185a4b6e-99d0-42a4-a79d-adcaa2ff627d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityFileNumber_185a4b6e-99d0-42a4-a79d-adcaa2ff627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f552e8d2-8573-4679-a6fb-c84ce10fbb3c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityRegistrantName_f552e8d2-8573-4679-a6fb-c84ce10fbb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4ecfc0dc-2df8-457b-847a-08466d9b1b7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4ecfc0dc-2df8-457b-847a-08466d9b1b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_174d1a85-139e-4518-812c-9204c6eda22a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityTaxIdentificationNumber_174d1a85-139e-4518-812c-9204c6eda22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ba9e0a76-372e-47c6-aa59-50d5f15d7260" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityAddressAddressLine1_ba9e0a76-372e-47c6-aa59-50d5f15d7260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d8be76fa-727a-45f8-b60a-075e778b6be8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityAddressCityOrTown_d8be76fa-727a-45f8-b60a-075e778b6be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9adc3e9c-82dc-4a9d-84c8-f01fb3e187e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityAddressStateOrProvince_9adc3e9c-82dc-4a9d-84c8-f01fb3e187e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9d8be3da-fbb3-4dcb-bcd8-a0b0097967a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityAddressPostalZipCode_9d8be3da-fbb3-4dcb-bcd8-a0b0097967a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1f58115b-1368-45e7-bbf9-795365f0f033" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_CityAreaCode_1f58115b-1368-45e7-bbf9-795365f0f033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cbdc2d3f-a286-4ed5-b9fb-7bf4b2d6a02f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_LocalPhoneNumber_cbdc2d3f-a286-4ed5-b9fb-7bf4b2d6a02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a1a9d506-9c06-47b8-b6e9-29e4a0fa3786" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_Security12bTitle_a1a9d506-9c06-47b8-b6e9-29e4a0fa3786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b507b4a4-34cb-4e4e-82c5-1601048e97f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_TradingSymbol_b507b4a4-34cb-4e4e-82c5-1601048e97f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a6294fbc-31f2-41d6-8607-58e612ea52f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_SecurityExchangeName_a6294fbc-31f2-41d6-8607-58e612ea52f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d8aa4346-8bd6-4658-8c8a-341cd8e5c8e1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d8aa4346-8bd6-4658-8c8a-341cd8e5c8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e4615c0a-bb74-49ec-8445-101517387dc1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityVoluntaryFilers_e4615c0a-bb74-49ec-8445-101517387dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_aa1a5370-7f02-4e7c-b1cf-71156e409811" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityCurrentReportingStatus_aa1a5370-7f02-4e7c-b1cf-71156e409811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fb9b9198-de84-475b-9c30-6502e0f85273" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityInteractiveDataCurrent_fb9b9198-de84-475b-9c30-6502e0f85273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ab6366c7-3400-4d08-b6c5-bd4298768c06" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityFilerCategory_ab6366c7-3400-4d08-b6c5-bd4298768c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_514a00b8-79ea-446c-8ec7-418fb1251613" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntitySmallBusiness_514a00b8-79ea-446c-8ec7-418fb1251613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fe59b551-f2af-40c1-8dcc-1d622a23d208" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityEmergingGrowthCompany_fe59b551-f2af-40c1-8dcc-1d622a23d208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9b2efbd1-4b72-4e69-b3b5-35df07e9c81d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityShellCompany_9b2efbd1-4b72-4e69-b3b5-35df07e9c81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_b325fb5c-68db-409e-b53e-68cebbea6472" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_b325fb5c-68db-409e-b53e-68cebbea6472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5bbc5d65-1bf0-49e1-a368-daed3b2242ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityPublicFloat_5bbc5d65-1bf0-49e1-a368-daed3b2242ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e2f029c8-e55e-4a4e-ac8c-f98e97d132ba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e2f029c8-e55e-4a4e-ac8c-f98e97d132ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f26d2d5a-3440-41af-80a1-ddf49cff4445" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f26d2d5a-3440-41af-80a1-ddf49cff4445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_61207e74-e55d-449c-8fef-45f987e9a5c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_EntityCentralIndexKey_61207e74-e55d-449c-8fef-45f987e9a5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f09098b2-06be-4a93-be6c-eb1b3c3cb97b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentFiscalYearFocus_f09098b2-06be-4a93-be6c-eb1b3c3cb97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3a529fe9-591c-437d-97a9-04893ed63401" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3a529fe9-591c-437d-97a9-04893ed63401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3af3f977-83e4-485b-984a-d37715a04181" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b3821722-7f57-40bd-beb2-d278c40dbbd6" xlink:to="loc_dei_AmendmentFlag_3af3f977-83e4-485b-984a-d37715a04181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_abccd678-d01b-48d5-a3f4-c88e0a7df798" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abccd678-d01b-48d5-a3f4-c88e0a7df798" xlink:to="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72821e15-8427-4016-ba4e-4ec3d67957d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72821e15-8427-4016-ba4e-4ec3d67957d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ddce8589-d535-43a7-9643-2847dfe6a22a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ddce8589-d535-43a7-9643-2847dfe6a22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8f07c470-0e0f-40ee-929f-09439edae78c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8f07c470-0e0f-40ee-929f-09439edae78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b5829b04-b196-4b68-be8f-9e812758ee92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:to="loc_us-gaap_InventoryNet_b5829b04-b196-4b68-be8f-9e812758ee92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c604f323-e49b-4a5e-96d3-5036c8b8e4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c604f323-e49b-4a5e-96d3-5036c8b8e4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c694445-19e1-466e-8df0-b1d55f5eaf9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_15fe193f-0c21-42fd-8740-c615be21a303" xlink:to="loc_us-gaap_AssetsCurrent_1c694445-19e1-466e-8df0-b1d55f5eaf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_86d96096-16f3-43c1-9cb3-221c86eb13b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_86d96096-16f3-43c1-9cb3-221c86eb13b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_1e3df62e-e12f-4a85-a326-3171fc24241a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_1e3df62e-e12f-4a85-a326-3171fc24241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_50a9dba8-65d7-4d24-bf97-f8a2f398ffac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_50a9dba8-65d7-4d24-bf97-f8a2f398ffac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_52716ac0-97e5-47a6-ad09-79db8d357175" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_Goodwill_52716ac0-97e5-47a6-ad09-79db8d357175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb82e687-b453-427d-aea4-0c633e5eaf89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb82e687-b453-427d-aea4-0c633e5eaf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_db55369f-25e5-462e-864b-157f3f58b5c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_40059c87-5636-45ae-9627-219e9097038b" xlink:to="loc_us-gaap_Assets_db55369f-25e5-462e-864b-157f3f58b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_abccd678-d01b-48d5-a3f4-c88e0a7df798" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ae3e4eb7-7b47-47c8-9509-cb4fa25ee808" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:to="loc_us-gaap_AccountsPayableCurrent_ae3e4eb7-7b47-47c8-9509-cb4fa25ee808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Accruedgovernmentandotherrebates_dc49a2b6-c813-4d63-af03-3b8a82537b72" xlink:href="gild-20201231.xsd#gild_Accruedgovernmentandotherrebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:to="loc_gild_Accruedgovernmentandotherrebates_dc49a2b6-c813-4d63-af03-3b8a82537b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d0be7c4b-25c8-4bb2-b120-1ddc7ba9356f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d0be7c4b-25c8-4bb2-b120-1ddc7ba9356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_7f3416c1-6ba7-4ec2-8739-ded34fb9d0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:to="loc_us-gaap_DebtCurrent_7f3416c1-6ba7-4ec2-8739-ded34fb9d0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bae77d9a-8e9e-4a11-b3ac-afcecf9d07fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cd923cbc-5e1f-4753-9694-d53b92ceb6b3" xlink:to="loc_us-gaap_LiabilitiesCurrent_bae77d9a-8e9e-4a11-b3ac-afcecf9d07fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7bd81762-6acb-4f38-a8b5-71f584248720" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7bd81762-6acb-4f38-a8b5-71f584248720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_deb1d259-bdb4-4021-bcf2-1f4e29023849" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_deb1d259-bdb4-4021-bcf2-1f4e29023849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3eeeda7c-a26f-4d47-b7d0-930e71d5455a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3eeeda7c-a26f-4d47-b7d0-930e71d5455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_01b8e1d1-0c8c-4b55-a8ed-d90a640cfd72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_01b8e1d1-0c8c-4b55-a8ed-d90a640cfd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_97799924-fe14-463f-aa8d-c17c6fffb3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_PreferredStockValue_97799924-fe14-463f-aa8d-c17c6fffb3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_57183061-fe0c-4238-b5ee-d515ef969669" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_CommonStockValue_57183061-fe0c-4238-b5ee-d515ef969669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bb0904cb-13fc-4ef4-8755-3bd3da823b73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bb0904cb-13fc-4ef4-8755-3bd3da823b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d6d2a407-6334-441b-a833-ac5f9dd43629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d6d2a407-6334-441b-a833-ac5f9dd43629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4097ca5f-5258-49cc-a329-5cf07fa16999" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4097ca5f-5258-49cc-a329-5cf07fa16999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0edf46f-e280-44d8-ab41-4850d043d499" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_StockholdersEquity_c0edf46f-e280-44d8-ab41-4850d043d499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f98e58df-5b6d-452f-b06d-1bb498202185" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_MinorityInterest_f98e58df-5b6d-452f-b06d-1bb498202185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98ea01d5-e994-46ca-8db1-da3616d284d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1221a26b-ca83-41be-b120-1e461222e413" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_98ea01d5-e994-46ca-8db1-da3616d284d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f82cd2c-a020-4c52-90a2-80f2723a6bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd7f49da-e3f8-49a2-8947-e0fe7e7e50a1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f82cd2c-a020-4c52-90a2-80f2723a6bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a52d98fc-e2b8-4817-a08d-7abce0d94460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a52d98fc-e2b8-4817-a08d-7abce0d94460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_00cb2dac-95bd-44ce-b2c4-b8907c9c963c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_00cb2dac-95bd-44ce-b2c4-b8907c9c963c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_41b41993-70c9-4274-9363-206e497316fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_41b41993-70c9-4274-9363-206e497316fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2b364580-aaa2-4767-b240-ce5f1d65c2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2b364580-aaa2-4767-b240-ce5f1d65c2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5676b78e-44ba-4311-907f-42b2b162b4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5676b78e-44ba-4311-907f-42b2b162b4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a73bc359-7925-4f69-95d9-b030661c442c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_CommonStockSharesIssued_a73bc359-7925-4f69-95d9-b030661c442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_32099294-996d-45ae-b836-688dd9a824c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0cb6a73d-c69c-405f-a215-1fdc6ded8533" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_32099294-996d-45ae-b836-688dd9a824c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_109997bf-3e38-4475-8224-280bc745861d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_109997bf-3e38-4475-8224-280bc745861d" xlink:to="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:to="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2a5ce1ed-2242-402c-b07b-796581dd4fd9" xlink:to="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_60216d46-8fb9-415d-bec9-d05cb856385f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:to="loc_us-gaap_ProductMember_60216d46-8fb9-415d-bec9-d05cb856385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_2c7d669f-4877-4b7c-b02b-b8ca6d3e42f9" xlink:href="gild-20201231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f61b3dc1-1635-4ba1-8a6c-1505a123a1a3" xlink:to="loc_gild_RoyaltyContractAndOtherMember_2c7d669f-4877-4b7c-b02b-b8ca6d3e42f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_35274a43-374b-4efd-a47a-0c2236b76473" xlink:to="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_93ed57e8-f0c6-4396-a6b3-7adbd4056b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_RevenuesAbstract_93ed57e8-f0c6-4396-a6b3-7adbd4056b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1536cc22-3c16-4ad9-881f-6eb21463fd71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_93ed57e8-f0c6-4396-a6b3-7adbd4056b7c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1536cc22-3c16-4ad9-881f-6eb21463fd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_bdeb5a64-d9f7-48ba-9894-97ada93e0091" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_bdeb5a64-d9f7-48ba-9894-97ada93e0091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_192e7dcf-f150-4b86-ab24-a93b0c2e33bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_192e7dcf-f150-4b86-ab24-a93b0c2e33bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_dbc47daf-93df-4bdd-a853-036204c91d90" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentInProcessIncludingImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_gild_ResearchAndDevelopmentInProcessIncludingImpairment_dbc47daf-93df-4bdd-a853-036204c91d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bf2a7bb-6547-4434-84be-1756e147af3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4bf2a7bb-6547-4434-84be-1756e147af3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a1f62e4d-3b62-4799-becc-83e06c49f7df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_29dff8ff-5780-414b-ab71-d4f41aa15db9" xlink:to="loc_us-gaap_CostsAndExpenses_a1f62e4d-3b62-4799-becc-83e06c49f7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_954fd858-5fd9-45e8-a7cb-787c74b12061" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_OperatingIncomeLoss_954fd858-5fd9-45e8-a7cb-787c74b12061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f5fc5b46-45d0-4994-b284-c3ed7c1511a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_InterestExpense_f5fc5b46-45d0-4994-b284-c3ed7c1511a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5e32f89a-db7e-49ee-846e-8677b3215067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5e32f89a-db7e-49ee-846e-8677b3215067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e045f24a-97ef-47d1-bab0-529d3cd0c6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e045f24a-97ef-47d1-bab0-529d3cd0c6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0130731b-abf4-416f-bf9b-cdd16859088f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0130731b-abf4-416f-bf9b-cdd16859088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8d95fdb5-6760-43a3-a0b3-4dee023894ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_ProfitLoss_8d95fdb5-6760-43a3-a0b3-4dee023894ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9db62a9a-37da-4471-9a1d-ce7a769aeae4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9db62a9a-37da-4471-9a1d-ce7a769aeae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6d77ad9-7c16-4998-98a0-b562201635cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_NetIncomeLoss_a6d77ad9-7c16-4998-98a0-b562201635cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_de903cf3-f19e-4184-96b5-b20440c2a9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_EarningsPerShareBasic_de903cf3-f19e-4184-96b5-b20440c2a9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cb103b0d-0178-46c9-9ccb-dab1bd11d2fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cb103b0d-0178-46c9-9ccb-dab1bd11d2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eec6e7b3-c7a0-43ce-9d2f-5ba78435621d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eec6e7b3-c7a0-43ce-9d2f-5ba78435621d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74421a28-1033-48a2-8d47-7eea7b1e7978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b630f6d1-c1f7-4a3a-8bef-74a3a53ab973" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74421a28-1033-48a2-8d47-7eea7b1e7978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61813842-3209-4f22-8e34-059924a847c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff6ef7a2-3de7-496f-b603-ceee4167060e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61813842-3209-4f22-8e34-059924a847c3" xlink:to="loc_us-gaap_ProfitLoss_ff6ef7a2-3de7-496f-b603-ceee4167060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1f973add-e75f-442f-8541-8186e7eba827" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61813842-3209-4f22-8e34-059924a847c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1f973add-e75f-442f-8541-8186e7eba827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_389e61fa-bed9-4db8-9ac0-fb7fc981ffb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1f973add-e75f-442f-8541-8186e7eba827" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_389e61fa-bed9-4db8-9ac0-fb7fc981ffb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3c4eb95a-b624-4a83-9c2f-edce74bb316e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1f973add-e75f-442f-8541-8186e7eba827" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3c4eb95a-b624-4a83-9c2f-edce74bb316e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_08ba0d04-8c4d-4a33-941b-b4d27418f408" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3c4eb95a-b624-4a83-9c2f-edce74bb316e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_08ba0d04-8c4d-4a33-941b-b4d27418f408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_f8e4df49-d9d1-454d-ab8e-5661ebe5003b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3c4eb95a-b624-4a83-9c2f-edce74bb316e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_f8e4df49-d9d1-454d-ab8e-5661ebe5003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fab70704-9ff8-422c-baae-6ac3a4d2dd71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3c4eb95a-b624-4a83-9c2f-edce74bb316e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fab70704-9ff8-422c-baae-6ac3a4d2dd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6eaf6fb3-1460-44d8-942e-6aaae092e4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1f973add-e75f-442f-8541-8186e7eba827" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6eaf6fb3-1460-44d8-942e-6aaae092e4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9018d55a-4de7-43ba-98e8-c0196fd4cf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6eaf6fb3-1460-44d8-942e-6aaae092e4a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_9018d55a-4de7-43ba-98e8-c0196fd4cf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_15cc0f9d-22e9-48a4-8c07-b3bdffb5a7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6eaf6fb3-1460-44d8-942e-6aaae092e4a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_15cc0f9d-22e9-48a4-8c07-b3bdffb5a7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_05d0230b-4e41-4333-acb2-eaa9f9e0a5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_6eaf6fb3-1460-44d8-942e-6aaae092e4a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_05d0230b-4e41-4333-acb2-eaa9f9e0a5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e7e65cb-109f-4730-8e90-170129c03bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1f973add-e75f-442f-8541-8186e7eba827" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9e7e65cb-109f-4730-8e90-170129c03bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c7ce6435-10f1-4f83-8f6e-e2e705eedbe9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61813842-3209-4f22-8e34-059924a847c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c7ce6435-10f1-4f83-8f6e-e2e705eedbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_281c1864-c062-41d7-9d3a-53f5760147bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61813842-3209-4f22-8e34-059924a847c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_281c1864-c062-41d7-9d3a-53f5760147bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a7ad084-a46c-4e24-9807-8053ae9f4091" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_61813842-3209-4f22-8e34-059924a847c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0a7ad084-a46c-4e24-9807-8053ae9f4091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d19d77df-ce42-48b8-ae1c-a05177333630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d19d77df-ce42-48b8-ae1c-a05177333630" xlink:to="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_82cd32bc-9fe2-4134-9d6e-187511d5a4a0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_24a04f08-6f2c-46f0-8759-8bedd99f5cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_24a04f08-6f2c-46f0-8759-8bedd99f5cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_c103acf1-6135-4e85-814d-6c59463603dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_c103acf1-6135-4e85-814d-6c59463603dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_b685d388-6d55-4c2f-a8fc-9dd6b5118bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ad7e2a49-4a65-4911-a370-a674599e3946" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_b685d388-6d55-4c2f-a8fc-9dd6b5118bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd68c44f-3ba4-4dc8-b3dd-a8c44fc422b3" xlink:to="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_089df8b9-9964-480e-bb70-889bfb6d5d47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_CommonStockMember_089df8b9-9964-480e-bb70-889bfb6d5d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d6f941d1-78c8-4de8-9bd7-99e0a94ac64a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d6f941d1-78c8-4de8-9bd7-99e0a94ac64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7a0714c5-1d18-4fe0-b554-2b2138b1c394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7a0714c5-1d18-4fe0-b554-2b2138b1c394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_160201e0-4e10-406b-9ac0-05376a838923" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_RetainedEarningsMember_160201e0-4e10-406b-9ac0-05376a838923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_5b7c1496-4682-4a40-bfc4-6f462bbc6e75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8280cae5-4f15-4fc5-be90-e1b4777a2166" xlink:to="loc_us-gaap_NoncontrollingInterestMember_5b7c1496-4682-4a40-bfc4-6f462bbc6e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0d0c0ea0-95aa-4655-a3b9-fad58f8073cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_990315c3-bb67-455c-b8db-ce2167a18cd4" xlink:to="loc_us-gaap_StatementLineItems_0d0c0ea0-95aa-4655-a3b9-fad58f8073cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0d0c0ea0-95aa-4655-a3b9-fad58f8073cb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21d13480-1708-4243-8d39-bf2b1db344c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21d13480-1708-4243-8d39-bf2b1db344c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6cc3b75c-711c-42c1-affa-4fabebda03f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6cc3b75c-711c-42c1-affa-4fabebda03f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3c97efd7-bbae-4f26-9ca6-214a3323252d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_3c97efd7-bbae-4f26-9ca6-214a3323252d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_09d6fcdf-66f5-4d59-a8c5-cca1a3365cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_09d6fcdf-66f5-4d59-a8c5-cca1a3365cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28306820-31ea-40bc-bb50-46032b0911f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_ProfitLoss_28306820-31ea-40bc-bb50-46032b0911f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6acb7be9-cf95-4130-a1e0-656216023d8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6acb7be9-cf95-4130-a1e0-656216023d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f6fe1ca6-1279-4fff-ab25-dd615ae38f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f6fe1ca6-1279-4fff-ab25-dd615ae38f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8691cf6a-aaf4-4eb5-88f5-1c7177d42e63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8691cf6a-aaf4-4eb5-88f5-1c7177d42e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d308d818-aca3-4ebd-9ca8-ef22daec3a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d308d818-aca3-4ebd-9ca8-ef22daec3a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824faff8-2496-4812-997f-a5242692108e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_824faff8-2496-4812-997f-a5242692108e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7c201ec2-14c2-4102-bc5b-fea3a755bbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7c201ec2-14c2-4102-bc5b-fea3a755bbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f292961-7b5d-4509-89a4-b0c834cef9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_5f292961-7b5d-4509-89a4-b0c834cef9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_5a79596c-f15a-4f9e-9b0b-81bdaf3a5423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_5a79596c-f15a-4f9e-9b0b-81bdaf3a5423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_47c1c3a2-2b25-408e-9c82-fcea43bf5c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_Dividends_47c1c3a2-2b25-408e-9c82-fcea43bf5c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2ea6c844-a603-4330-a210-5e20117abd84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2ea6c844-a603-4330-a210-5e20117abd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df4162c3-088f-4c3b-8282-19b8735d2209" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b271ffeb-4579-4e21-a595-e7bed66fba4e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_df4162c3-088f-4c3b-8282-19b8735d2209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_60a95e53-e618-4a9f-a2d0-c23b9655b6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_60baa983-5189-46c7-b430-d8e205a0e828" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_60a95e53-e618-4a9f-a2d0-c23b9655b6d7" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_60baa983-5189-46c7-b430-d8e205a0e828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="gild-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e8f5381d-1a5c-4608-8843-678ac18803b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e8f5381d-1a5c-4608-8843-678ac18803b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3ca3abc8-fbae-419c-b2c5-dc227036b7bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e8f5381d-1a5c-4608-8843-678ac18803b8" xlink:to="loc_us-gaap_ProfitLoss_3ca3abc8-fbae-419c-b2c5-dc227036b7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e8f5381d-1a5c-4608-8843-678ac18803b8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3ddb0bbd-e7de-43fe-a2fb-0bd4f0261721" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_Depreciation_3ddb0bbd-e7de-43fe-a2fb-0bd4f0261721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_deec96d1-da94-4c25-836f-307efd92af00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_AdjustmentForAmortization_deec96d1-da94-4c25-836f-307efd92af00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9c48e40d-e4fa-4dc9-a2d5-30cc792cb1c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_ShareBasedCompensation_9c48e40d-e4fa-4dc9-a2d5-30cc792cb1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1eb96223-89b3-45ac-9831-6ccfb7f07c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1eb96223-89b3-45ac-9831-6ccfb7f07c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_7309be7b-8ada-449e-995c-8a12ea1ad664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_7309be7b-8ada-449e-995c-8a12ea1ad664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3b22e6ec-0df2-4816-b272-5feb60870097" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3b22e6ec-0df2-4816-b272-5feb60870097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3a438724-9def-4a7d-9afa-4c5ba103df77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3a438724-9def-4a7d-9afa-4c5ba103df77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Inventoryreserveforexcessrawmaterials_fc1c17d9-976d-41de-b6e6-9e0285b11aa2" xlink:href="gild-20201231.xsd#gild_Inventoryreserveforexcessrawmaterials"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_gild_Inventoryreserveforexcessrawmaterials_fc1c17d9-976d-41de-b6e6-9e0285b11aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1611dd85-26d9-4efa-aaf3-e26a9061ef76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1611dd85-26d9-4efa-aaf3-e26a9061ef76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faa8a397-a640-4477-b83e-ede94a496331" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5d51fdf4-dcc9-4af7-8f8b-c8154fb688cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5d51fdf4-dcc9-4af7-8f8b-c8154fb688cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_458c4356-dfd8-4130-921d-7618c146b66c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_458c4356-dfd8-4130-921d-7618c146b66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3f0a9320-7e55-4fe9-8703-def3125ddd48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3f0a9320-7e55-4fe9-8703-def3125ddd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_51ba7454-a612-4689-9ca0-d5eab73246b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_51ba7454-a612-4689-9ca0-d5eab73246b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d5c1c68e-9e69-433f-9e4f-114de308b429" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_d5c1c68e-9e69-433f-9e4f-114de308b429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e3f84ba7-caa0-4f69-8f57-2274aaa0fa4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e3f84ba7-caa0-4f69-8f57-2274aaa0fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a28044c-d624-475a-9362-1e91fb2b7253" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e33cacd9-9f92-4bff-a499-55829160a96a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a28044c-d624-475a-9362-1e91fb2b7253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_58996a7f-1115-4c63-b233-c262ef014299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_58996a7f-1115-4c63-b233-c262ef014299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_371b65ff-59bc-454a-9e05-3411521acf10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_371b65ff-59bc-454a-9e05-3411521acf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_51561b2a-175f-4610-b975-d0fbbd2eb34e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_51561b2a-175f-4610-b975-d0fbbd2eb34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_96d276ab-7b25-41a1-8401-f25841562c39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_96d276ab-7b25-41a1-8401-f25841562c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_1a0949cf-2289-4573-bd47-ec0b338c906e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_1a0949cf-2289-4573-bd47-ec0b338c906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ccd6a962-4308-4725-8117-9bbd6114ee77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ccd6a962-4308-4725-8117-9bbd6114ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0f6b9f1b-6ed7-4b61-8a5b-ec9330513e18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0f6b9f1b-6ed7-4b61-8a5b-ec9330513e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15304f46-43fc-4a9b-9513-c529e88fc416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c363353c-3130-4695-a4be-088df91d4319" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15304f46-43fc-4a9b-9513-c529e88fc416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6f2416cc-01f2-48e1-ba44-2999662acd99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6f2416cc-01f2-48e1-ba44-2999662acd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3e1466c8-cb5b-491d-ab6a-33664eed09ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3e1466c8-cb5b-491d-ab6a-33664eed09ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c99b8b85-ee39-43db-8d21-1a7edd50a798" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c99b8b85-ee39-43db-8d21-1a7edd50a798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_abbf6523-705e-4acf-b31e-b52c7b0ee360" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_RepaymentsOfDebt_abbf6523-705e-4acf-b31e-b52c7b0ee360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_82783f36-27ef-464f-9046-a15fff74a1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_PaymentsOfDividends_82783f36-27ef-464f-9046-a15fff74a1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_61d5293a-97b8-4086-be9d-f773cecd9934" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_61d5293a-97b8-4086-be9d-f773cecd9934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ec3eb00-866a-4434-97f0-44673392ce4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37c1df90-0f1f-484c-923f-9cf40357af23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4ec3eb00-866a-4434-97f0-44673392ce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82d5b50c-fe42-4e52-8c11-2e59097374b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82d5b50c-fe42-4e52-8c11-2e59097374b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee1b7b4d-4513-4c05-808c-5b120dd5fa14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee1b7b4d-4513-4c05-808c-5b120dd5fa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af98ac01-9fb3-418e-a113-3e62a31d8152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af98ac01-9fb3-418e-a113-3e62a31d8152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01a50123-69f4-46a1-9b19-e9318a2df106" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01a50123-69f4-46a1-9b19-e9318a2df106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_166ed87f-19d4-4ec7-9eb2-7a4315445332" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_60b07baf-54cd-4a7a-bad7-1f7e48f8efb2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_166ed87f-19d4-4ec7-9eb2-7a4315445332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4110cc59-c237-4b2c-ad80-494a4465412a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_166ed87f-19d4-4ec7-9eb2-7a4315445332" xlink:to="loc_us-gaap_InterestPaidNet_4110cc59-c237-4b2c-ad80-494a4465412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_9b5a02e5-ddc8-4ea4-a6c4-4e73a2015c81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_166ed87f-19d4-4ec7-9eb2-7a4315445332" xlink:to="loc_us-gaap_IncomeTaxesPaid_9b5a02e5-ddc8-4ea4-a6c4-4e73a2015c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_082af630-7fde-4d14-96a4-bdc45f33bffe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_84fd4375-ffeb-4942-be45-189db1e0ecf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_082af630-7fde-4d14-96a4-bdc45f33bffe" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_84fd4375-ffeb-4942-be45-189db1e0ecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61d0e9b7-74f8-41f9-9d8d-217f53db6ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_61d0e9b7-74f8-41f9-9d8d-217f53db6ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_94f0d69a-6bc5-484c-b286-c3dd4711df1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_94f0d69a-6bc5-484c-b286-c3dd4711df1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fc377b24-f19e-4f5f-8534-beba8f9ae7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_UseOfEstimates_fc377b24-f19e-4f5f-8534-beba8f9ae7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d6449b82-1d1b-45b7-8278-579e498040b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d6449b82-1d1b-45b7-8278-579e498040b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f6b6d961-7144-447f-8e24-571cea0d05e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f6b6d961-7144-447f-8e24-571cea0d05e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7e08d088-2943-4be8-b32a-cd43372a7041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7e08d088-2943-4be8-b32a-cd43372a7041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_85211c1e-94a4-40c6-96f2-e1517a096e76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_85211c1e-94a4-40c6-96f2-e1517a096e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f29c9665-1615-49a8-8e5d-21266c1345c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f29c9665-1615-49a8-8e5d-21266c1345c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_bea65ca5-8f4a-4dd9-b830-408784c69255" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_bea65ca5-8f4a-4dd9-b830-408784c69255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e9606e47-ddba-407a-a22d-6e65c8df3a30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e9606e47-ddba-407a-a22d-6e65c8df3a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_e3d34058-4f62-4d2e-9a2b-72bf7346e0ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_e3d34058-4f62-4d2e-9a2b-72bf7346e0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b2d2dab-df66-4540-9c7e-1d04755c5966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b2d2dab-df66-4540-9c7e-1d04755c5966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_940a4426-acb6-4ba1-85d7-ea85de56e5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_940a4426-acb6-4ba1-85d7-ea85de56e5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_908fd484-3025-4039-821d-c87867323264" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_908fd484-3025-4039-821d-c87867323264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_df86da6f-3278-4fa1-b94d-f2c16e81ca07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_df86da6f-3278-4fa1-b94d-f2c16e81ca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d0305f07-0f29-4aef-8053-a9edc54c43fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d0305f07-0f29-4aef-8053-a9edc54c43fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_9b9b7e81-d722-4acb-bdd0-07d04234c92d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_9b9b7e81-d722-4acb-bdd0-07d04234c92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_11bda511-9413-48ad-8037-47c3d19c9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_11bda511-9413-48ad-8037-47c3d19c9aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_489d8241-f005-49a6-a112-85ca8a01676b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_489d8241-f005-49a6-a112-85ca8a01676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5efe90de-fb1b-4119-b228-a3e3febbfb57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5efe90de-fb1b-4119-b228-a3e3febbfb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_73ed009c-a3ea-46ec-af9f-04506ad6c35f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_73ed009c-a3ea-46ec-af9f-04506ad6c35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6be56b50-5499-4b00-b31f-e3965997e51d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b00fe405-cca2-416a-ab41-e7ec3532b71d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6be56b50-5499-4b00-b31f-e3965997e51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a6a9f495-9de6-4d67-9db2-8ef2672d0f67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_63b7cf04-03f0-4228-86c3-55f05b196abc" xlink:href="gild-20201231.xsd#gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6a9f495-9de6-4d67-9db2-8ef2672d0f67" xlink:to="loc_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock_63b7cf04-03f0-4228-86c3-55f05b196abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e61dd55-e7a7-4635-b6f1-72245af49b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:href="gild-20201231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e61dd55-e7a7-4635-b6f1-72245af49b31" xlink:to="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:to="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e887ff7c-edec-4810-91fb-10520ea015bb" xlink:to="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8191961b-0622-4174-86da-5c8f98dd5198" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:to="loc_srt_MinimumMember_8191961b-0622-4174-86da-5c8f98dd5198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d32ab6d7-13ea-4f97-a682-02cdb35770a4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9b5e293e-2b6a-4d70-aa66-624579852a45" xlink:to="loc_srt_MaximumMember_d32ab6d7-13ea-4f97-a682-02cdb35770a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6be1f0ed-5091-42df-9b5c-3723cde1338f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ac5beec3-5736-46f0-bc5a-eb9c72384d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ac5beec3-5736-46f0-bc5a-eb9c72384d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_cf02f6a0-2d03-46c6-8355-2d6a09f2432d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_cf02f6a0-2d03-46c6-8355-2d6a09f2432d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_3e4629db-f6cc-4e27-8edf-fde6704c8ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ebf42ea-08a4-4de1-abae-c49863339c99" xlink:to="loc_us-gaap_ComputerEquipmentMember_3e4629db-f6cc-4e27-8edf-fde6704c8ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:href="gild-20201231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_12043a57-a4a8-4d6b-8e8a-d05092526f29" xlink:to="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_36ad7ea1-9c6b-416e-bc42-3a341e67ea78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_us-gaap_AdvertisingExpense_36ad7ea1-9c6b-416e-bc42-3a341e67ea78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8236c826-03cb-4a12-bb5e-844591beef68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8236c826-03cb-4a12-bb5e-844591beef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_789765a6-c8a0-43bd-83c7-f26a33cdbb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_53dbb7e4-b580-4172-a73f-db7b743543b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_789765a6-c8a0-43bd-83c7-f26a33cdbb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Revenues" xlink:type="simple" xlink:href="gild-20201231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6e44cb72-250f-4fb8-948f-d5aa18162b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6024756b-fdff-459d-a027-db49721bb319" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6e44cb72-250f-4fb8-948f-d5aa18162b6c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_6024756b-fdff-459d-a027-db49721bb319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2337124f-735c-4793-a52a-3adc5b5b397a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_47fa0bc5-5230-40d2-9816-5f60a7994932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2337124f-735c-4793-a52a-3adc5b5b397a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_47fa0bc5-5230-40d2-9816-5f60a7994932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_9ee850d7-c154-4c02-90db-bc0aa380c460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2337124f-735c-4793-a52a-3adc5b5b397a" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_9ee850d7-c154-4c02-90db-bc0aa380c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8bd10965-3c7a-40aa-b802-11b5ed734b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8bd10965-3c7a-40aa-b802-11b5ed734b6a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:to="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5a017e93-7af5-41b7-a133-40761101d586" xlink:to="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:to="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:href="gild-20201231.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsAtriplaMember_368d8662-c327-45b0-90df-a5e8625be6ea" xlink:href="gild-20201231.xsd#gild_HIVProductsAtriplaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsAtriplaMember_368d8662-c327-45b0-90df-a5e8625be6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_1f6002a6-5837-4da6-857f-743488283650" xlink:href="gild-20201231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsBiktarvyMember_1f6002a6-5837-4da6-857f-743488283650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_080ec4fb-9b46-4001-831c-dc0d9e25ca85" xlink:href="gild-20201231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_080ec4fb-9b46-4001-831c-dc0d9e25ca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_b52e904a-3f58-4aab-a812-b947f108bf50" xlink:href="gild-20201231.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsDescovyMember_b52e904a-3f58-4aab-a812-b947f108bf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_7c6513b3-f008-47b4-97b0-914e4d729ee7" xlink:href="gild-20201231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsGenvoyaMember_7c6513b3-f008-47b4-97b0-914e4d729ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_4bda15be-46c7-4b11-a8ad-c618ef39f8b9" xlink:href="gild-20201231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsOdefseyMember_4bda15be-46c7-4b11-a8ad-c618ef39f8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_4fde103f-35b7-45c3-a034-73d8dc25a7b0" xlink:href="gild-20201231.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsStribildMember_4fde103f-35b7-45c3-a034-73d8dc25a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_f77cc515-09c1-4fdd-b4a4-e6cb521ba1de" xlink:href="gild-20201231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_HIVProductsTruvadaMember_f77cc515-09c1-4fdd-b4a4-e6cb521ba1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_bc6c5df7-4533-4794-977f-8af1b1c8e53f" xlink:href="gild-20201231.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_ProductsOtherHIVMember_bc6c5df7-4533-4794-977f-8af1b1c8e53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_eff57357-8670-4e6d-941f-275b913388ad" xlink:href="gild-20201231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_8aaa9ec8-4240-4a29-a32f-cfaa6e5f2c98" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_eff57357-8670-4e6d-941f-275b913388ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:href="gild-20201231.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_f0c464b6-26ea-4970-9281-70da529a7452" xlink:href="gild-20201231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_f0c464b6-26ea-4970-9281-70da529a7452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_77599a6a-d31c-4f6f-aaf7-c613760b6c4c" xlink:href="gild-20201231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_77599a6a-d31c-4f6f-aaf7-c613760b6c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember_ab762c4b-e9cb-4e09-920c-3172502d5d92" xlink:href="gild-20201231.xsd#gild_OtherHCVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_fc189295-360b-4a24-9a6e-c3d15d8d9d8a" xlink:to="loc_gild_OtherHCVMember_ab762c4b-e9cb-4e09-920c-3172502d5d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_COVID19ProductsVekluryMember_a0c7d01b-d8ac-46eb-905c-0deff12c904a" xlink:href="gild-20201231.xsd#gild_COVID19ProductsVekluryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_COVID19ProductsVekluryMember_a0c7d01b-d8ac-46eb-905c-0deff12c904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:href="gild-20201231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember_c1681003-b568-4026-9aa3-59eeec8b213c" xlink:href="gild-20201231.xsd#gild_OtherProductsYescartaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:to="loc_gild_OtherProductsYescartaMember_c1681003-b568-4026-9aa3-59eeec8b213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CallTherapyProductsTecartusMember_bddf08d1-ea9f-4135-bbb5-a6c17fe96b8c" xlink:href="gild-20201231.xsd#gild_CallTherapyProductsTecartusMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_0d5de9ff-ceac-418b-9f69-e06dcb6af2bf" xlink:to="loc_gild_CallTherapyProductsTecartusMember_bddf08d1-ea9f-4135-bbb5-a6c17fe96b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_COVID19ProductsTrodelvyMember_574a568d-6e38-4275-9885-fc402583e8f6" xlink:href="gild-20201231.xsd#gild_COVID19ProductsTrodelvyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_COVID19ProductsTrodelvyMember_574a568d-6e38-4275-9885-fc402583e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:href="gild-20201231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_6180eaae-85e8-4379-8289-ce2b58b4c03f" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_be48c6b8-850b-4c89-80ee-f637ac2fd15a" xlink:href="gild-20201231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsAmBisomeMember_be48c6b8-850b-4c89-80ee-f637ac2fd15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_d5709489-81c7-494c-a844-eaab18e0948d" xlink:href="gild-20201231.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsLetairisMember_d5709489-81c7-494c-a844-eaab18e0948d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsRanexaMember_d3dd4caf-77e2-4b06-b186-54a8fd758b6e" xlink:href="gild-20201231.xsd#gild_OtherProductsRanexaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsRanexaMember_d3dd4caf-77e2-4b06-b186-54a8fd758b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsVemlidyMember_206f28e1-cb1b-4354-9517-daa50613e5df" xlink:href="gild-20201231.xsd#gild_OtherProductsVemlidyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsVemlidyMember_206f28e1-cb1b-4354-9517-daa50613e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsVireadMember_f0d7fd73-b1a2-4cb0-b09f-7e47b0b83f0c" xlink:href="gild-20201231.xsd#gild_OtherProductsVireadMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsVireadMember_f0d7fd73-b1a2-4cb0-b09f-7e47b0b83f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsZydeligMember_acbbfaef-dabb-4dfb-9829-25c7f389490b" xlink:href="gild-20201231.xsd#gild_OtherProductsZydeligMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsZydeligMember_acbbfaef-dabb-4dfb-9829-25c7f389490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_93db3286-8a0c-4108-a02e-8c31de67f178" xlink:href="gild-20201231.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_bc3dcbc1-2ad9-48ba-8815-323368401eef" xlink:to="loc_gild_OtherProductsOtherMember_93db3286-8a0c-4108-a02e-8c31de67f178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_757bcfa7-c550-45c4-b19b-2ada43efa2db" xlink:href="gild-20201231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5dcef71-e802-4e15-8c34-16f096847868" xlink:to="loc_gild_RoyaltyContractAndOtherMember_757bcfa7-c550-45c4-b19b-2ada43efa2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:to="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1fb83a76-4e2e-4512-ae20-d534ccd62818" xlink:to="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1eaa1c97-405a-4bff-b359-fdfdb51e86cc" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:to="loc_country_US_1eaa1c97-405a-4bff-b359-fdfdb51e86cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c9243d31-302f-415c-a988-4ace5250d280" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:to="loc_srt_EuropeMember_c9243d31-302f-415c-a988-4ace5250d280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_99bc083e-971f-4d00-9b11-a112c429f831" xlink:href="gild-20201231.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0beb58e-bfff-4f65-aa57-76ea2e5aec87" xlink:to="loc_gild_OtherInternationalMember_99bc083e-971f-4d00-9b11-a112c429f831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_32b9e168-fa96-4813-a9bf-eabc551f4030" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880f2156-7ec4-4139-8659-144d1f2da59e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_880f2156-7ec4-4139-8659-144d1f2da59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0d44816a-f456-42bf-aa7e-74d664b93750" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_999dcff8-d0df-4fee-8a0b-60b09c4d7a1b" xlink:to="loc_us-gaap_Revenues_0d44816a-f456-42bf-aa7e-74d664b93750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6dd64717-0ed3-4abf-b2c2-c99d2d523700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6dd64717-0ed3-4abf-b2c2-c99d2d523700" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_34601b13-f56c-42ba-95b5-5c208912ff1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_045dc333-9307-4007-bf3f-f1814efc3d46" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_34601b13-f56c-42ba-95b5-5c208912ff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_e6d27ecd-0504-44ed-b65e-aec94a2cf000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_34601b13-f56c-42ba-95b5-5c208912ff1a" xlink:to="loc_us-gaap_SalesRevenueNetMember_e6d27ecd-0504-44ed-b65e-aec94a2cf000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_40c84e42-b1cc-4a00-b011-b812b81508d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c777ca4c-cabb-4884-9e1b-01e4401a5cbb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_40c84e42-b1cc-4a00-b011-b812b81508d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e210b231-7888-4d34-b65b-37bc3532bd3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_40c84e42-b1cc-4a00-b011-b812b81508d2" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e210b231-7888-4d34-b65b-37bc3532bd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_88443f9d-bcb2-41e5-9aae-e5c8a871ab32" xlink:to="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_49c5b04c-c3db-4dae-969d-fde988f4654e" xlink:href="gild-20201231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:to="loc_gild_AmerisourcebergenCorpMember_49c5b04c-c3db-4dae-969d-fde988f4654e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_80c82a56-d695-48eb-b40d-b90b2b1495a6" xlink:href="gild-20201231.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:to="loc_gild_CardinalHealthIncMember_80c82a56-d695-48eb-b40d-b90b2b1495a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_ee433998-32cc-4d9b-9d26-86c2c8d24a4b" xlink:href="gild-20201231.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fe920617-1670-4ffe-a3e3-5a6ad540c63e" xlink:to="loc_gild_MckessonCorpMember_ee433998-32cc-4d9b-9d26-86c2c8d24a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_644c49d5-1cee-4794-bcf5-1615dc1cbcda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cb12d34a-c4cf-41f3-b0f5-76c747a418f7" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_644c49d5-1cee-4794-bcf5-1615dc1cbcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a55dcc38-3a3f-48e0-bf3c-73392794036e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_644c49d5-1cee-4794-bcf5-1615dc1cbcda" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a55dcc38-3a3f-48e0-bf3c-73392794036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2df78b33-6a51-4495-b446-ef40c11440d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:href="gild-20201231.xsd#gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2df78b33-6a51-4495-b446-ef40c11440d5" xlink:to="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:to="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:href="gild-20201231.xsd#gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis_dfef2168-ca87-4b7f-9336-bd0992f0d0c8" xlink:to="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_b56bcb10-e20b-43ba-9477-ff5b5843a4e0" xlink:href="gild-20201231.xsd#gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:to="loc_gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember_b56bcb10-e20b-43ba-9477-ff5b5843a4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ChangeinestimatevariableconsiderationMember_7c619aa7-fb9f-4e32-bdce-13d5fcde074f" xlink:href="gild-20201231.xsd#gild_ChangeinestimatevariableconsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain_461629b2-2344-4a05-b48b-a084457e2b5e" xlink:to="loc_gild_ChangeinestimatevariableconsiderationMember_7c619aa7-fb9f-4e32-bdce-13d5fcde074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:href="gild-20201231.xsd#gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable_19e11f7b-90d2-4d8e-a220-80bdc374b846" xlink:to="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_510213d3-ec54-4af1-a40f-02ac7043775f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_510213d3-ec54-4af1-a40f-02ac7043775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5bf1ac3b-05d8-418f-a897-a086da74fe34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5bf1ac3b-05d8-418f-a897-a086da74fe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8e49c64c-78a8-416c-8933-f063356fcd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems_1251f4be-a1b3-4f5c-ac5b-3620874a1e5b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8e49c64c-78a8-416c-8933-f063356fcd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_abb5bfc7-1f43-4fab-a145-5abf1f6d2274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0395afad-92e8-45f3-9407-e6b55e3093e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_abb5bfc7-1f43-4fab-a145-5abf1f6d2274" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0395afad-92e8-45f3-9407-e6b55e3093e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14c6b926-7655-4259-a633-78d45ddd70f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3984dd75-e7a0-4e40-a3b6-dd6b680e5865" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14c6b926-7655-4259-a633-78d45ddd70f4" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3984dd75-e7a0-4e40-a3b6-dd6b680e5865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_98ab6e95-12a5-4679-8b4e-d6c422cd3ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14c6b926-7655-4259-a633-78d45ddd70f4" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_98ab6e95-12a5-4679-8b4e-d6c422cd3ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ee138d17-a3e4-4151-bb64-ead222d27c64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ee138d17-a3e4-4151-bb64-ead222d27c64" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dedd5694-84a2-4549-a55e-7888213d46d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_df4df4ca-3d26-40cd-aae0-e659689edeb2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dedd5694-84a2-4549-a55e-7888213d46d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d9b91c12-c043-4f4a-a422-bd0636609e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dedd5694-84a2-4549-a55e-7888213d46d7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d9b91c12-c043-4f4a-a422-bd0636609e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4ee21b09-3c0f-45e9-a2de-89e6c52fcfe8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fe27cdb8-c29f-4525-9da5-c7f76e7d8338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fe27cdb8-c29f-4525-9da5-c7f76e7d8338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2ead9c12-71c9-4091-a6d2-41a7a81afdb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2ead9c12-71c9-4091-a6d2-41a7a81afdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_22a48b89-795f-404e-bf5e-ca5fac873792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5fa229c7-bf51-4261-a01c-3e0e035adae6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_22a48b89-795f-404e-bf5e-ca5fac873792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_34a2c77c-264c-4d52-b0ca-21b3e8908b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8636d83d-2ba8-4088-a07f-94b5dfd859b4" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_34a2c77c-264c-4d52-b0ca-21b3e8908b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e7ae6347-88c8-4fd7-98b0-36b8a61300db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_34a2c77c-264c-4d52-b0ca-21b3e8908b66" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e7ae6347-88c8-4fd7-98b0-36b8a61300db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1cf0c581-f64a-46ec-92b0-104028d0c741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e7ae6347-88c8-4fd7-98b0-36b8a61300db" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_1cf0c581-f64a-46ec-92b0-104028d0c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_148616e2-2208-4f08-9b17-3d5ae85fad44" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_93b23ccf-1b68-4714-bfa7-26edcbedc49d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_93b23ccf-1b68-4714-bfa7-26edcbedc49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_199ef9c6-a874-451d-bfb5-c335afccbace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_199ef9c6-a874-451d-bfb5-c335afccbace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79d79a58-7a27-4aeb-a6f9-74a2df192b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_79d79a58-7a27-4aeb-a6f9-74a2df192b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a69d691c-15eb-4517-94bf-0402271c9bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a69d691c-15eb-4517-94bf-0402271c9bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_33d4956e-516c-4d10-9d60-a5761ab9e55f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_33d4956e-516c-4d10-9d60-a5761ab9e55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_7a40644b-cc64-42a1-a784-d1de2881fa2d" xlink:href="gild-20201231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_7a40644b-cc64-42a1-a784-d1de2881fa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityinvestmentinGalapagosMember_ad7e725d-911a-4c6f-8be8-9e41b008a62d" xlink:href="gild-20201231.xsd#gild_EquityinvestmentinGalapagosMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_EquityinvestmentinGalapagosMember_ad7e725d-911a-4c6f-8be8-9e41b008a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_21e96404-f56a-4dec-ae27-173aa2d96ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_21e96404-f56a-4dec-ae27-173aa2d96ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_100ae98c-eb92-482c-a230-32cce73d25d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_us-gaap_EquitySecuritiesMember_100ae98c-eb92-482c-a230-32cce73d25d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_b7f4f2ef-8fb8-4d05-9c3c-f5b896f9f890" xlink:href="gild-20201231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_DeferredCompensationPlanMember_b7f4f2ef-8fb8-4d05-9c3c-f5b896f9f890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_435f0209-0d31-4d2f-80c2-3b27024fae24" xlink:href="gild-20201231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_04d10266-d2ce-4259-9052-b892e73e1bd1" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_435f0209-0d31-4d2f-80c2-3b27024fae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b0b14514-136d-4949-a6b8-7269279b166d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:to="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11b8a46a-749f-42e6-baa7-ab081f1adce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_11b8a46a-749f-42e6-baa7-ab081f1adce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_40fcf00a-a223-4c6c-bac5-c8987b1b3058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_40fcf00a-a223-4c6c-bac5-c8987b1b3058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_0571c1bc-cfa8-49e9-a14b-8c8a25d50b61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_0571c1bc-cfa8-49e9-a14b-8c8a25d50b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_337b890f-d1cb-477c-b456-92264e3ccde1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fc2c3d5d-8fe4-42d9-ae3a-ccb725dc46d2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_337b890f-d1cb-477c-b456-92264e3ccde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2acc0f53-8c85-465f-8dcd-1986c33cb994" xlink:to="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_0bfdf52f-f53b-406a-a63f-c61cd360bdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_0bfdf52f-f53b-406a-a63f-c61cd360bdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3505f633-ddee-49f9-a3d8-17ee008a24a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3505f633-ddee-49f9-a3d8-17ee008a24a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_36b391d8-8532-4517-b781-dfe9df40db0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0f61ec37-f723-40c2-9f5c-39d14ec6b322" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_36b391d8-8532-4517-b781-dfe9df40db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fc6e451e-7419-4e8b-a305-20d8ed1dc77b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fc6e451e-7419-4e8b-a305-20d8ed1dc77b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_63eb2df6-bce0-4216-a445-f035a2cb7258" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5039fd0a-daac-4eb3-bf0c-df48068ed0cc" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_63eb2df6-bce0-4216-a445-f035a2cb7258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_63eb2df6-bce0-4216-a445-f035a2cb7258" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_981bfa6a-0bfa-48e8-a022-e08922bbbafa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_981bfa6a-0bfa-48e8-a022-e08922bbbafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d185335f-d8fe-44de-b5f2-30c4ef0742f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2efa9d34-583e-4475-906a-8191092b3262" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d185335f-d8fe-44de-b5f2-30c4ef0742f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_654f1cae-6282-4079-8cd4-e9ceb38fcb54" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a8e08d1c-ebb2-4e51-8ef5-4e7a7c841065" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a8e08d1c-ebb2-4e51-8ef5-4e7a7c841065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c93f262f-b798-4f17-bd51-f64da88d2161" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53c0cbe3-d4cb-4399-87de-2117f631cec0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c93f262f-b798-4f17-bd51-f64da88d2161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5f1bb555-74d2-40bb-8f16-e4cb0ecfcb66" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a553f87-ca7d-4fee-ade4-428912980562" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4a553f87-ca7d-4fee-ade4-428912980562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8572c0ee-0b4e-4df9-b8d9-8528938b3a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_8572c0ee-0b4e-4df9-b8d9-8528938b3a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_bbb27a1d-8f09-4972-80ec-752a06a30132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_bbb27a1d-8f09-4972-80ec-752a06a30132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_823aa7b7-a835-46e8-86ab-f6ac960e5316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_823aa7b7-a835-46e8-86ab-f6ac960e5316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_0935042d-61cf-409a-b1dc-379be37d3811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_LongTermDebtFairValue_0935042d-61cf-409a-b1dc-379be37d3811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_30acdbfe-3484-4006-a041-45ac2d284eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_30acdbfe-3484-4006-a041-45ac2d284eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96d7aa3c-2e6c-49ff-ad9c-33707c2eb376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13cc8c9e-066f-4a06-9570-fe71c84ddaf4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_96d7aa3c-2e6c-49ff-ad9c-33707c2eb376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract_1a9fd345-12fc-43b2-90f1-b58cdab6278f" xlink:href="gild-20201231.xsd#gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract_1a9fd345-12fc-43b2-90f1-b58cdab6278f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7238a851-009d-459e-96e2-06bd0d870782" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_1d394301-b3a8-4caa-86e0-1fb655a23c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_1d394301-b3a8-4caa-86e0-1fb655a23c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_91dd4350-3137-495d-b42b-940d7302f41e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_91dd4350-3137-495d-b42b-940d7302f41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_f5ba4a72-4252-4f53-bd65-0bc7a55a9c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c832b0a8-d329-45cf-8a55-fbb903dd573a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_f5ba4a72-4252-4f53-bd65-0bc7a55a9c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_9a4442cc-0862-4f72-9581-17c9a67f04f1" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_50bfac5e-a66d-4fda-ab58-e75b6d16986b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_50bfac5e-a66d-4fda-ab58-e75b6d16986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b540e53a-abf4-4fcc-af45-3783485907d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ee4fa17e-25e0-44de-9dce-45a5c3fdaf26" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b540e53a-abf4-4fcc-af45-3783485907d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecurities"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4f15deb6-2f02-4bd3-9d39-202ddc56f178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fc9178c5-5f3c-4b2c-8a89-5e32345e7737" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_4f15deb6-2f02-4bd3-9d39-202ddc56f178" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fc9178c5-5f3c-4b2c-8a89-5e32345e7737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1d53fa57-2fd2-40c2-820b-743fd29249fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_bc38ac1a-ca5a-44ca-b5fb-b8dff6ceb591" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1d53fa57-2fd2-40c2-820b-743fd29249fd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_bc38ac1a-ca5a-44ca-b5fb-b8dff6ceb591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5d66cecf-abc2-4283-b31c-89c85c4d242a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1d53fa57-2fd2-40c2-820b-743fd29249fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5d66cecf-abc2-4283-b31c-89c85c4d242a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_38a03a1e-5a72-46d6-9203-f720d14a0be5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1d53fa57-2fd2-40c2-820b-743fd29249fd" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_38a03a1e-5a72-46d6-9203-f720d14a0be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_54c89269-4dc6-41d1-864b-4636272ef0ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_1d53fa57-2fd2-40c2-820b-743fd29249fd" xlink:to="loc_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_54c89269-4dc6-41d1-864b-4636272ef0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3c55e504-4878-4a94-937e-513d8e3949ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3c55e504-4878-4a94-937e-513d8e3949ab" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a40044f-fb57-4da1-aa2d-1eb9982fada6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e9e905ea-5a4e-4b55-bfcd-98f8d68cf0db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e9e905ea-5a4e-4b55-bfcd-98f8d68cf0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_e25574c4-9c5d-4aaa-8de2-3ca4d4afd954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_e25574c4-9c5d-4aaa-8de2-3ca4d4afd954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c4006ed6-efd1-47ee-a540-f579421d5799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c4006ed6-efd1-47ee-a540-f579421d5799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f9856795-0e0b-40b4-a015-ace47671292b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_f9856795-0e0b-40b4-a015-ace47671292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_475e31a0-6ded-4598-8a41-b43529e46d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_475e31a0-6ded-4598-8a41-b43529e46d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_96bcfd40-d09d-40af-b887-f6c2b4a7d350" xlink:href="gild-20201231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eeb3c96b-a0a0-4db8-ac82-2107ef88721d" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_96bcfd40-d09d-40af-b887-f6c2b4a7d350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_83a9231d-1262-474d-9a53-8157e5ada67e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55adc54c-3642-4d40-8e7b-eaca7fc42522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55adc54c-3642-4d40-8e7b-eaca7fc42522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dda90c4d-137e-4e3c-9d0e-edbf20af34ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dda90c4d-137e-4e3c-9d0e-edbf20af34ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e634fa28-eddc-402e-abb4-bb6b5743d46a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e634fa28-eddc-402e-abb4-bb6b5743d46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c688999f-c0fe-4cf3-ae23-5bcb93625a43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6cb40de8-0fcd-470d-9bc6-591497421426" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c688999f-c0fe-4cf3-ae23-5bcb93625a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_275699aa-f7dc-4502-9e0d-cfeed0832d02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_275699aa-f7dc-4502-9e0d-cfeed0832d02" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4d24b1ba-83cf-4c4a-a922-d73968ad6097" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_d61504cb-efc1-4c93-8270-8128af31dbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_d61504cb-efc1-4c93-8270-8128af31dbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_28690339-850f-4c44-9864-f69ed6fb3419" xlink:href="gild-20201231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_28690339-850f-4c44-9864-f69ed6fb3419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_3c83c944-ace7-4c3c-aeed-c6ab0e91037e" xlink:href="gild-20201231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_93726cda-b435-453d-b554-a2bac0bcfd0d" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_3c83c944-ace7-4c3c-aeed-c6ab0e91037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dcde3fc-fbff-478d-a918-c6f11da6ad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f116a686-4c5c-49d4-a39d-c3bf9452d99e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dcde3fc-fbff-478d-a918-c6f11da6ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cbe2da-b529-4bbe-8682-1dbf67f75bca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7dcde3fc-fbff-478d-a918-c6f11da6ad7a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cbe2da-b529-4bbe-8682-1dbf67f75bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8788b7c0-a900-48ab-9fe2-5b89b84eeef5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_9d8033e4-f0f6-4c07-8698-22476064a2f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8788b7c0-a900-48ab-9fe2-5b89b84eeef5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_9d8033e4-f0f6-4c07-8698-22476064a2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f0a82b30-fae1-4564-88c1-f95f74f86d40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_9d8033e4-f0f6-4c07-8698-22476064a2f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_f0a82b30-fae1-4564-88c1-f95f74f86d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2e58552a-e604-4024-bc85-0461eb9ad860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_9d8033e4-f0f6-4c07-8698-22476064a2f8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2e58552a-e604-4024-bc85-0461eb9ad860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_ef7d99ec-3d13-494e-91e7-c8f1ed200aee" xlink:href="gild-20201231.xsd#gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_9d8033e4-f0f6-4c07-8698-22476064a2f8" xlink:to="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_ef7d99ec-3d13-494e-91e7-c8f1ed200aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca2dd0dd-ff1f-4ea1-8400-7807674cede1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_9d8033e4-f0f6-4c07-8698-22476064a2f8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ca2dd0dd-ff1f-4ea1-8400-7807674cede1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d53b5708-9872-4022-8aba-ee29923f9cda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_8788b7c0-a900-48ab-9fe2-5b89b84eeef5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d53b5708-9872-4022-8aba-ee29923f9cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d7794e83-5bb3-4804-b5f3-239220223969" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d53b5708-9872-4022-8aba-ee29923f9cda" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d7794e83-5bb3-4804-b5f3-239220223969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c6fdeaee-fb3b-4b77-84a3-e29c4511f02b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d53b5708-9872-4022-8aba-ee29923f9cda" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c6fdeaee-fb3b-4b77-84a3-e29c4511f02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_5de4fce5-07b3-47b2-8091-f94f419143fa" xlink:href="gild-20201231.xsd#gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d53b5708-9872-4022-8aba-ee29923f9cda" xlink:to="loc_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_5de4fce5-07b3-47b2-8091-f94f419143fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79c17016-2f23-456c-9b10-ce31ffcb2754" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_d53b5708-9872-4022-8aba-ee29923f9cda" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_79c17016-2f23-456c-9b10-ce31ffcb2754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_bb97a230-3bea-48e2-8f08-6d6359d78075" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_bb97a230-3bea-48e2-8f08-6d6359d78075" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a949c94-7bd1-4d9c-be18-dfb88f70a954" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e6c0fe15-bdfc-46d2-8acc-80deeb41c687" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a949c94-7bd1-4d9c-be18-dfb88f70a954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_e23ed102-42bf-4b68-9c0c-2a0b5e1a9cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9a949c94-7bd1-4d9c-be18-dfb88f70a954" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_e23ed102-42bf-4b68-9c0c-2a0b5e1a9cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0975a39b-ab42-4ca5-8967-5723c3d37fa2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d4039b07-c274-4ff4-8c37-f977ca8cfa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_d4039b07-c274-4ff4-8c37-f977ca8cfa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f48561d3-2c99-47c9-81c5-bae3e7a66959" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f48561d3-2c99-47c9-81c5-bae3e7a66959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b84ff1b-9c69-4a0b-a556-5954c2b01f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_3b84ff1b-9c69-4a0b-a556-5954c2b01f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3a963fe5-b2a3-4446-97f1-6c45b33cefb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_3a963fe5-b2a3-4446-97f1-6c45b33cefb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_234caceb-bb56-48d2-86bc-2b438f7cadf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_234caceb-bb56-48d2-86bc-2b438f7cadf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bb3b9ac9-5807-4c4e-adb1-3f1be3f33440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6530f032-94db-4f9b-9ef3-ad677069d4a2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bb3b9ac9-5807-4c4e-adb1-3f1be3f33440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AvailableforSaleDebtSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_628dfe72-075f-49f2-ae8a-6ad75488870a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_3d590c7e-92b5-4258-87c7-82044d8e2294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_628dfe72-075f-49f2-ae8a-6ad75488870a" xlink:to="loc_us-gaap_InterestReceivableCurrent_3d590c7e-92b5-4258-87c7-82044d8e2294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ac9a2297-46ff-4501-9cab-9f1949b87457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_628dfe72-075f-49f2-ae8a-6ad75488870a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ac9a2297-46ff-4501-9cab-9f1949b87457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9ffd282e-753a-426e-ad0b-7f9f3c380fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_628dfe72-075f-49f2-ae8a-6ad75488870a" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9ffd282e-753a-426e-ad0b-7f9f3c380fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5a6ab0df-1a1d-449b-b8a2-698998e75f12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2b98ec7f-84df-4a3a-9653-31c96ee0b1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5a6ab0df-1a1d-449b-b8a2-698998e75f12" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2b98ec7f-84df-4a3a-9653-31c96ee0b1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eca769f-a189-428d-ab21-a53b96594005" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_641cb26b-ed7c-48ed-966b-beec550bd539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eca769f-a189-428d-ab21-a53b96594005" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_641cb26b-ed7c-48ed-966b-beec550bd539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1a997cdd-2bcb-4b37-9a33-471babd02c02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eca769f-a189-428d-ab21-a53b96594005" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_1a997cdd-2bcb-4b37-9a33-471babd02c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_55d1e3ae-350a-4a19-bacc-9e954aaadbf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4eca769f-a189-428d-ab21-a53b96594005" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_55d1e3ae-350a-4a19-bacc-9e954aaadbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c1b5f74-9c9b-4667-ae4e-2d215ce7328e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2c1b5f74-9c9b-4667-ae4e-2d215ce7328e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:to="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f3b80146-abfc-48aa-b144-a84dc648f46b" xlink:to="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_483a1831-89ce-4f39-9f73-420cb7838ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_483a1831-89ce-4f39-9f73-420cb7838ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_71f795f9-ae46-460c-af9c-ea24a29bdcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_19ad8a77-7dea-422b-b63a-b59f14d279e0" xlink:to="loc_us-gaap_NondesignatedMember_71f795f9-ae46-460c-af9c-ea24a29bdcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_48c82a03-f8f6-4b91-b104-d06be00d671d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_92ac77e0-15d9-46de-9753-ad98ff3e67c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_92ac77e0-15d9-46de-9753-ad98ff3e67c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_7d946ebb-a1c8-4e83-adf7-54935e743f94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_7d946ebb-a1c8-4e83-adf7-54935e743f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_8b299c56-c118-480d-b151-9f16a6308dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_8b299c56-c118-480d-b151-9f16a6308dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4534146b-2b50-4163-8d89-f378b693f643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_38f8dc7a-39f2-4c71-b924-fc2c8f12b21d" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4534146b-2b50-4163-8d89-f378b693f643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c2e4d2f0-a79b-4612-ac9d-92600e863a03" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_deb83448-d49d-46ca-81b1-aeb432f77194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_deb83448-d49d-46ca-81b1-aeb432f77194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8654b52a-992c-4045-aaea-4f8042fd37aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0d5e6335-5e02-47b6-a901-e85920d5b395" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_8654b52a-992c-4045-aaea-4f8042fd37aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8602a2a-7a24-4302-a53f-d88c1f497bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4b67e4bb-8e34-4452-b6fc-765b688ae74b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8602a2a-7a24-4302-a53f-d88c1f497bfd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_4b67e4bb-8e34-4452-b6fc-765b688ae74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_47fbedfb-22a0-42da-a7a5-8b97950f945d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8602a2a-7a24-4302-a53f-d88c1f497bfd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_47fbedfb-22a0-42da-a7a5-8b97950f945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_6f2c48d5-96f1-4aaa-b397-e30c0c52cead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c8602a2a-7a24-4302-a53f-d88c1f497bfd" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_6f2c48d5-96f1-4aaa-b397-e30c0c52cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_caf75cb1-8f0b-4960-97d9-d071656a105b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_caf75cb1-8f0b-4960-97d9-d071656a105b" xlink:to="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_14b32160-d756-41e0-9aa0-bc783a4268bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_14b32160-d756-41e0-9aa0-bc783a4268bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2d300c4c-7380-4f76-9ccc-dea6c99af1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2d300c4c-7380-4f76-9ccc-dea6c99af1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_73968779-f46a-48e9-80b6-6f5dcf66f66f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:to="loc_us-gaap_DerivativeAssets_73968779-f46a-48e9-80b6-6f5dcf66f66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_626d98cc-1168-4dbb-9974-4d369e0ca531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_626d98cc-1168-4dbb-9974-4d369e0ca531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_c94d2597-77f3-4707-bb7a-63698d83fdc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_c94d2597-77f3-4707-bb7a-63698d83fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_78e3f61b-2d1a-4ec9-a734-cca97320758a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsAbstract_6ebf82fe-82ea-4d40-9af9-740c4739cc18" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_78e3f61b-2d1a-4ec9-a734-cca97320758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_caf75cb1-8f0b-4960-97d9-d071656a105b" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bfce7ab0-39e7-4178-87a4-e63e58be48bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_bfce7ab0-39e7-4178-87a4-e63e58be48bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_b692d977-2179-487d-a624-196480509c5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_b692d977-2179-487d-a624-196480509c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_86ee149f-f290-49ef-8a8c-aeb3419d8dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:to="loc_us-gaap_DerivativeLiabilities_86ee149f-f290-49ef-8a8c-aeb3419d8dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e1ac6239-35ad-4532-a0f7-b83bece59186" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_e1ac6239-35ad-4532-a0f7-b83bece59186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_20e5bd5d-6e38-4d8c-b19d-7d73e4ecb65b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_20e5bd5d-6e38-4d8c-b19d-7d73e4ecb65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_18512756-46e0-4dbf-8d20-96935df66afb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_b7c54b8a-36f0-4004-9cca-a89814842301" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_18512756-46e0-4dbf-8d20-96935df66afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a1e62686-6ebd-4520-bf7a-dd171c240bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a1e62686-6ebd-4520-bf7a-dd171c240bb2" xlink:to="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:to="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd7f1957-3cc6-4410-9067-bfae1e07faae" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f26c054-2dd8-4df0-b2ff-07752dfa4578" xlink:to="loc_srt_RangeMember_dd7f1957-3cc6-4410-9067-bfae1e07faae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9755a174-1649-446e-a8c9-4985826dda13" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd7f1957-3cc6-4410-9067-bfae1e07faae" xlink:to="loc_srt_MaximumMember_9755a174-1649-446e-a8c9-4985826dda13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_5333e4d5-67fe-4aaa-bd7d-1c96911d8012" xlink:to="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_3a7bd88d-907c-4823-8c1b-20d4b35bc7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_3a7bd88d-907c-4823-8c1b-20d4b35bc7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_dd6fc093-7761-4e56-8388-eb782a88897a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_dd6fc093-7761-4e56-8388-eb782a88897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_5abb9e50-09b9-4e6e-a901-458076ead0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_DerivativeNotionalAmount_5abb9e50-09b9-4e6e-a901-458076ead0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_633d3987-8b32-4e04-9549-e6afa9897e47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_149fb170-22fd-426d-ad5c-8c1af6cd13bc" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_633d3987-8b32-4e04-9549-e6afa9897e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Acquisitions" xlink:type="simple" xlink:href="gild-20201231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_131cdede-2aed-4ac1-940e-191a7e6f1ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_985b00c5-0282-480b-856b-27409c779f35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_131cdede-2aed-4ac1-940e-191a7e6f1ef9" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_985b00c5-0282-480b-856b-27409c779f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3596973e-05db-4e7b-a7fc-f683aeb7c002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_60d33c7e-3408-43ef-889d-15e3ac99177f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3596973e-05db-4e7b-a7fc-f683aeb7c002" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_60d33c7e-3408-43ef-889d-15e3ac99177f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d8cdbdc1-89bd-4550-b3dc-b4922fbdaf45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3596973e-05db-4e7b-a7fc-f683aeb7c002" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_d8cdbdc1-89bd-4550-b3dc-b4922fbdaf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b11551a1-9b90-45ea-b175-e00907143dae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b11551a1-9b90-45ea-b175-e00907143dae" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_abf1938f-186e-4ed2-9a99-1d359c5ed884" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AssetAcquisitionAxis_68bf9afc-ff69-4f33-98d4-5a94dac7b1c4" xlink:to="loc_gild_AssetAcquisitionDomain_abf1938f-186e-4ed2-9a99-1d359c5ed884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_e4981754-c679-42ec-97bc-2fcd0537b84e" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AssetAcquisitionDomain_abf1938f-186e-4ed2-9a99-1d359c5ed884" xlink:to="loc_gild_FortySevenIncMember_e4981754-c679-42ec-97bc-2fcd0537b84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_25efcabf-0275-462b-a396-dedef293af54" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_04a65d93-c084-40a8-bbb8-cf4a1bce612a" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:to="loc_gild_ImmunomedicsIncMember_04a65d93-c084-40a8-bbb8-cf4a1bce612a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_50bd9b9c-6d7d-4226-bfe0-076125946a94" xlink:href="gild-20201231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f18365a6-8392-4702-8591-8b4ffd6d6188" xlink:to="loc_gild_MYRGmbHMember_50bd9b9c-6d7d-4226-bfe0-076125946a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fffd04aa-b42d-4213-a425-60f90d6fb452" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_b77eb36f-c4b7-441e-bb5c-ed0d063fa7e3" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:to="loc_gild_TrodelvyForMTNBCMember_b77eb36f-c4b7-441e-bb5c-ed0d063fa7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b68f571b-6406-457e-94e2-863d16cbc76e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c92c4c9b-004a-476d-b9ef-28bf4b83c32d" xlink:to="loc_us-gaap_LicensingAgreementsMember_b68f571b-6406-457e-94e2-863d16cbc76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e33f106c-805c-4a2e-b6c8-e9f85ea00599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e4bd2b05-ecb3-43d6-b5d4-a46a620682a4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e33f106c-805c-4a2e-b6c8-e9f85ea00599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e90bee95-fe22-40f6-8cee-5f27c10128a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e33f106c-805c-4a2e-b6c8-e9f85ea00599" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e90bee95-fe22-40f6-8cee-5f27c10128a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c221e80-2452-4293-b8bf-0df20a10542d" xlink:to="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentstoOutstandingCommonStockholdersMember_b16fae72-b9c9-427b-bd08-8c49ab0e1289" xlink:href="gild-20201231.xsd#gild_PaymentstoOutstandingCommonStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:to="loc_gild_PaymentstoOutstandingCommonStockholdersMember_b16fae72-b9c9-427b-bd08-8c49ab0e1289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToEquityAwardHoldersMember_7001b2d5-ca82-4ad1-a75a-db99d84a568b" xlink:href="gild-20201231.xsd#gild_PaymentsToEquityAwardHoldersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ed0811ff-cb4a-4fd1-abe2-183708e7fc60" xlink:to="loc_gild_PaymentsToEquityAwardHoldersMember_7001b2d5-ca82-4ad1-a75a-db99d84a568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e31f1ca2-7130-485a-ace6-8d5e957e3daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6aeb016-7adb-4252-99fb-c1d89e44b42e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e31f1ca2-7130-485a-ace6-8d5e957e3daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_da43491d-6503-4f8e-9ea6-4e0816913213" xlink:href="gild-20201231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e31f1ca2-7130-485a-ace6-8d5e957e3daf" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_da43491d-6503-4f8e-9ea6-4e0816913213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_67a0b52f-4341-4111-8189-79beeff6cb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4ee72ff5-d400-46f1-925a-8d3db2922559" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_67a0b52f-4341-4111-8189-79beeff6cb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_508cc827-b465-4285-8bfe-d3322d537eba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_67a0b52f-4341-4111-8189-79beeff6cb4c" xlink:to="loc_us-gaap_MediumTermNotesMember_508cc827-b465-4285-8bfe-d3322d537eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_49b45f23-b943-4f77-9c00-a1f8e41bdf44" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c91b0b42-3f92-4893-96dd-735272c3183a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c91b0b42-3f92-4893-96dd-735272c3183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_b9e112dd-be3b-4ab7-ade7-598a15f765dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_59dc54a7-071a-4865-b4f8-dae648ffdffd" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_b9e112dd-be3b-4ab7-ade7-598a15f765dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ff8cd51c-aafd-42bf-9157-bcbf9a19de70" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7c2cf233-7c4b-407b-8c6f-cdc6f83a4aae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_SharePrice_7c2cf233-7c4b-407b-8c6f-cdc6f83a4aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_ab98086a-bf8b-4fe3-a8b0-a1d72ec2b616" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionCashOutflowNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_AssetAcquisitionCashOutflowNetOfCashAcquired_ab98086a-bf8b-4fe3-a8b0-a1d72ec2b616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f8224cfa-b6fc-4452-b10f-3b8af32728e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f8224cfa-b6fc-4452-b10f-3b8af32728e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_da9fbf77-14fb-403f-9b40-5775636d4ea1" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash_da9fbf77-14fb-403f-9b40-5775636d4ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f5dc92b3-baf8-4236-bee6-28443d51feff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ShareBasedCompensation_f5dc92b3-baf8-4236-bee6-28443d51feff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_9818d680-c494-492f-a950-290519844469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_9818d680-c494-492f-a950-290519844469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7db81039-ce7c-480a-8fa3-5f9aeebcebc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7db81039-ce7c-480a-8fa3-5f9aeebcebc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c8574e3-850d-4941-b81d-2ce36a35df1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9c8574e3-850d-4941-b81d-2ce36a35df1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5413ae45-6748-408b-9505-644ea209af95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5413ae45-6748-408b-9505-644ea209af95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_0eb77703-fe67-45c4-a5b6-0ff5f342bc18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_0eb77703-fe67-45c4-a5b6-0ff5f342bc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a9e1d984-abba-4bbb-b73c-25bc5ef4374d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a9e1d984-abba-4bbb-b73c-25bc5ef4374d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_8802e5b6-4700-4994-bbd5-234dcc47c190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_8802e5b6-4700-4994-bbd5-234dcc47c190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3f5f7d62-a45d-4e1d-a3c3-3ee7ff106847" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3f5f7d62-a45d-4e1d-a3c3-3ee7ff106847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c1ee5c9a-d3b6-4297-8568-97c2297820c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c1ee5c9a-d3b6-4297-8568-97c2297820c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_8a6e064c-1d86-461e-b7b6-e518ee2de75d" xlink:href="gild-20201231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_8a6e064c-1d86-461e-b7b6-e518ee2de75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_398d49ec-4e53-46a4-8b49-c0ae73f0d9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_398d49ec-4e53-46a4-8b49-c0ae73f0d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_08bd28cc-0ab8-492d-b0e4-697e3142f0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_08bd28cc-0ab8-492d-b0e4-697e3142f0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f827fab2-b5a2-41a1-bdbf-1a0fc08c5418" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f827fab2-b5a2-41a1-bdbf-1a0fc08c5418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_2f53d5a9-4b42-4293-bc1f-231240903bfc" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_2f53d5a9-4b42-4293-bc1f-231240903bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_a6b14d93-b4f6-490f-bdf3-1a8df85c3255" xlink:href="gild-20201231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_a6b14d93-b4f6-490f-bdf3-1a8df85c3255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_cddc2ae1-edfe-4784-980c-1d8f7d10a9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_GoodwillGross_cddc2ae1-edfe-4784-980c-1d8f7d10a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e9e50ad8-6598-42a1-806a-e429850d5947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e9e50ad8-6598-42a1-806a-e429850d5947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_3361b269-3be6-447d-8db5-ad4d8f3fd785" xlink:href="gild-20201231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ec0314dc-8366-4d4f-9e89-86ad0bfedac8" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_3361b269-3be6-447d-8db5-ad4d8f3fd785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b2a7735f-a532-4792-a782-8f85dcbc5dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b2a7735f-a532-4792-a782-8f85dcbc5dd1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cecd8a72-ea3c-4616-9ba5-2270cd2c2c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4e64026d-7398-4a31-8409-8d6323b94d16" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cecd8a72-ea3c-4616-9ba5-2270cd2c2c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_4d63b749-c546-4c35-9c1a-facc64db489c" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cecd8a72-ea3c-4616-9ba5-2270cd2c2c5e" xlink:to="loc_gild_ImmunomedicsIncMember_4d63b749-c546-4c35-9c1a-facc64db489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f4f89ba-7666-4b4e-91e8-9825d172b69d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_21abf9a7-5c7b-45aa-bba5-7153c65be587" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:to="loc_gild_TrodelvyForMTNBCMember_21abf9a7-5c7b-45aa-bba5-7153c65be587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_18db8469-d9ad-4c1c-8f12-306ca300ea16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0bbaf9fd-81a7-4635-b603-9b5ff922b735" xlink:to="loc_us-gaap_LicensingAgreementsMember_18db8469-d9ad-4c1c-8f12-306ca300ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ce908d7-fc79-4a77-8532-de70ed61d41f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1439c9ad-9560-4f25-8bb0-e7a68577eee1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ce908d7-fc79-4a77-8532-de70ed61d41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_15d1db85-50f5-49bd-a35e-1dadf0cf90c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ce908d7-fc79-4a77-8532-de70ed61d41f" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_15d1db85-50f5-49bd-a35e-1dadf0cf90c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3d9cef02-ef9a-4b97-af37-b78937522a97" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e8cec4fd-6d8d-486a-8cc2-71019f0470cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e8cec4fd-6d8d-486a-8cc2-71019f0470cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d693f739-4b73-4801-9303-e00c7cb10046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d693f739-4b73-4801-9303-e00c7cb10046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c13af9c7-8d6f-4dc0-a53b-f7da860351df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c13af9c7-8d6f-4dc0-a53b-f7da860351df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1d19d7f5-412b-437c-afb4-911576c6464b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_90036e98-8deb-41af-915f-122527fa0b11" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1d19d7f5-412b-437c-afb4-911576c6464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_648617ca-e005-4ea5-9801-4c20b05c18c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_648617ca-e005-4ea5-9801-4c20b05c18c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_9d152c2d-5d75-44bc-87ee-0edbbf60e0e5" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_9d152c2d-5d75-44bc-87ee-0edbbf60e0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_cbb75c24-7f4d-4be3-a231-38b7d6614dbc" xlink:href="gild-20201231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_cbb75c24-7f4d-4be3-a231-38b7d6614dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9784321d-e99b-4a4d-bbd9-8a0b0fe3ec6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9784321d-e99b-4a4d-bbd9-8a0b0fe3ec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_e7244c2c-02d6-4b50-8a4b-63ea3e3e7916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_GoodwillGross_e7244c2c-02d6-4b50-8a4b-63ea3e3e7916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3a91bde7-e0c6-44db-b3be-64174b057ba7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7edd4b9d-0c7f-47fb-8a8a-f5553f8ecf53" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3a91bde7-e0c6-44db-b3be-64174b057ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#AcquisitionsSupplementalProFormaInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_fd03911c-6fd4-41aa-ab8c-68b0da644f99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_fd03911c-6fd4-41aa-ab8c-68b0da644f99" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c28137e5-edc0-4463-906b-6ea4d1a3e27e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_71e36182-b0b9-410a-842c-3c55fc4cd7bf" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c28137e5-edc0-4463-906b-6ea4d1a3e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_94eb340e-3d09-41d9-8311-3bb18b28ce33" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c28137e5-edc0-4463-906b-6ea4d1a3e27e" xlink:to="loc_gild_ImmunomedicsIncMember_94eb340e-3d09-41d9-8311-3bb18b28ce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea4b4e81-54aa-431f-8108-d3b407b95471" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ea7174c6-4283-42b0-bfcc-f01884389b74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_ea7174c6-4283-42b0-bfcc-f01884389b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e75e143e-0bda-4123-bc07-860c3274bbac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f6545f1d-658e-412c-8a15-578244a8f91a" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_e75e143e-0bda-4123-bc07-860c3274bbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Inventories" xlink:type="simple" xlink:href="gild-20201231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_61220929-2c78-44ac-b8e0-47271faf8e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c39819e0-c27e-4948-9c4a-7e2f6f47d885" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_61220929-2c78-44ac-b8e0-47271faf8e2a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c39819e0-c27e-4948-9c4a-7e2f6f47d885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bd1f8ad7-0163-4dca-b52c-e388dc61d6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_842a0c9d-11e3-4c4d-9ffe-7eb0b4da7523" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bd1f8ad7-0163-4dca-b52c-e388dc61d6a6" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_842a0c9d-11e3-4c4d-9ffe-7eb0b4da7523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesScheduleofinventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5bdc1f2a-41f9-4c00-bca2-1e970b296e91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5bdc1f2a-41f9-4c00-bca2-1e970b296e91" xlink:to="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_127c0095-c9ee-43a2-bca4-f08468b17a28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c2e4fbe-13d6-419f-8df4-1cb9c2f97756" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_127c0095-c9ee-43a2-bca4-f08468b17a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsTotalMember_36e91c76-3b1b-4bac-8efc-425d048a0489" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsTotalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_127c0095-c9ee-43a2-bca4-f08468b17a28" xlink:to="loc_us-gaap_AssetsTotalMember_36e91c76-3b1b-4bac-8efc-425d048a0489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_77e14f8b-a1e8-4029-b980-9ba9f9119125" xlink:to="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_48b48c77-6760-4bbb-be85-aeaa5811e3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_48b48c77-6760-4bbb-be85-aeaa5811e3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ee4ce79e-5e07-4a87-97e1-3afb5bdcf271" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_ee4ce79e-5e07-4a87-97e1-3afb5bdcf271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_073a9a95-e1df-4cac-89b2-cab009b4872c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_073a9a95-e1df-4cac-89b2-cab009b4872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_323a788e-687f-482f-97b7-78c71c1236c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryNet_323a788e-687f-482f-97b7-78c71c1236c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_c0c7de28-d68a-4307-a148-34c1c22d6880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_b0e6b477-a2ce-4026-bb87-e3c6af2b9c99" xlink:to="loc_us-gaap_InventoryNoncurrent_c0c7de28-d68a-4307-a148-34c1c22d6880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownAbstract_f799efdd-6b57-49ff-938c-e5bee056bfed" xlink:href="gild-20201231.xsd#gild_InventoryWritedownAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_InventoryWritedownAbstract_f799efdd-6b57-49ff-938c-e5bee056bfed" xlink:to="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b11c3ec2-4541-4868-b72d-0fc708e2d045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_bd44578c-5b92-4cab-9bc3-8ee59305026f" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b11c3ec2-4541-4868-b72d-0fc708e2d045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_14686651-dc38-44b3-b5f3-1956b6e1e526" xlink:href="gild-20201231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b11c3ec2-4541-4868-b72d-0fc708e2d045" xlink:to="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_14686651-dc38-44b3-b5f3-1956b6e1e526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryLineItems_bc35e0fb-823f-450d-9f59-6fd5f0a3c9f3" xlink:href="gild-20201231.xsd#gild_ScheduleofInventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_16867807-0bda-4818-a98f-29159a96ceef" xlink:to="loc_gild_ScheduleofInventoryLineItems_bc35e0fb-823f-450d-9f59-6fd5f0a3c9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_2871e146-a835-4e2f-89bf-223a3f6b30d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryLineItems_bc35e0fb-823f-450d-9f59-6fd5f0a3c9f3" xlink:to="loc_us-gaap_InventoryWriteDown_2871e146-a835-4e2f-89bf-223a3f6b30d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e4b9848d-8d0b-4cda-9aef-b77643a059b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_913dba63-dd0f-47b6-8649-fa1e2ea1b1e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e4b9848d-8d0b-4cda-9aef-b77643a059b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_913dba63-dd0f-47b6-8649-fa1e2ea1b1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7efe4cd2-18be-4b69-90cd-59c7ddb428e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c478768b-7394-45eb-a25b-40aa8e570c37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7efe4cd2-18be-4b69-90cd-59c7ddb428e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c478768b-7394-45eb-a25b-40aa8e570c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_bd481c77-680f-4c5b-9308-a79abf2e723a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_Land_bd481c77-680f-4c5b-9308-a79abf2e723a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_155d7e9a-582b-4f9f-b469-ff3997fe7c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_155d7e9a-582b-4f9f-b469-ff3997fe7c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_06188488-c1b7-4cb6-be69-cf8d808f24d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_06188488-c1b7-4cb6-be69-cf8d808f24d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_c5198505-9121-4841-a76b-1abd9ce7175f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_c5198505-9121-4841-a76b-1abd9ce7175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_dfaca9ff-e897-4b70-95ea-fbfc38a4dfcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_ConstructionInProgressGross_dfaca9ff-e897-4b70-95ea-fbfc38a4dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d8feca1f-d6ef-4659-a4f1-2a81deb75e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d8feca1f-d6ef-4659-a4f1-2a81deb75e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7bdb979e-8831-4063-8632-9f2a8bcafca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7bdb979e-8831-4063-8632-9f2a8bcafca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b3b5947-0501-4e7d-b2d1-98e29cfc4208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_512a6c96-bac8-4ea9-b16d-49588f0516b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1b3b5947-0501-4e7d-b2d1-98e29cfc4208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b50dc139-97b1-40c3-98e7-c856fd8501ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b50dc139-97b1-40c3-98e7-c856fd8501ce" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:to="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6a8a1030-0e72-4dd3-b877-454f823acbba" xlink:to="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_73109ddf-013b-4e06-a0bf-115379c89566" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:to="loc_country_US_73109ddf-013b-4e06-a0bf-115379c89566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_399c4ba9-c354-4712-a882-e0610b57458d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ef915720-7936-4b5e-b9d6-77f9df0340fe" xlink:to="loc_us-gaap_NonUsMember_399c4ba9-c354-4712-a882-e0610b57458d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_969eb5ae-547a-41ce-9e65-d3848139af63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_9af6eb46-8297-4a22-aadd-2ab178bc9cde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_9af6eb46-8297-4a22-aadd-2ab178bc9cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_754229b6-8cc5-4e7b-82a7-2742291d3973" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1bc37a82-91ae-4620-854d-b6d3a4bd6bc5" xlink:to="loc_us-gaap_NoncurrentAssets_754229b6-8cc5-4e7b-82a7-2742291d3973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d3838461-1d36-4587-a321-7b396f92e33c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f919015a-1ad7-43db-88d4-207894659ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d3838461-1d36-4587-a321-7b396f92e33c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f919015a-1ad7-43db-88d4-207894659ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ffc642-f49a-495a-9b1f-c7734d74a0df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ac9d057f-58b0-4e64-9f84-2bbb5346fc47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ffc642-f49a-495a-9b1f-c7734d74a0df" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ac9d057f-58b0-4e64-9f84-2bbb5346fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_1166279e-3d4d-4ff6-a3dc-4d184b36b3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ffc642-f49a-495a-9b1f-c7734d74a0df" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_1166279e-3d4d-4ff6-a3dc-4d184b36b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5dda8908-6981-4095-a8de-be97db4646ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ffc642-f49a-495a-9b1f-c7734d74a0df" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5dda8908-6981-4095-a8de-be97db4646ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_dd3f4ebb-0f5a-4aa6-92fb-166358524d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3ffc642-f49a-495a-9b1f-c7734d74a0df" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_dd3f4ebb-0f5a-4aa6-92fb-166358524d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e1afa4d2-b877-465d-a92a-9560c8d60f96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e1afa4d2-b877-465d-a92a-9560c8d60f96" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbb51eb7-5d3c-46fe-b979-2233a95da587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa213e6a-704f-420a-855f-1ac60967133f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbb51eb7-5d3c-46fe-b979-2233a95da587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_1be876b1-53ed-4f7b-9fda-b4770f404602" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fbb51eb7-5d3c-46fe-b979-2233a95da587" xlink:to="loc_gild_ImmunomedicsIncMember_1be876b1-53ed-4f7b-9fda-b4770f404602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_441f8837-3d17-449b-9fc9-69bd23a4ad45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_134c8b2a-772b-4d1d-8701-7e10aaa5dd93" xlink:to="loc_us-gaap_GoodwillLineItems_441f8837-3d17-449b-9fc9-69bd23a4ad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_441f8837-3d17-449b-9fc9-69bd23a4ad45" xlink:to="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3e84fdcf-57c3-40c4-9596-b4d7123a5e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:to="loc_us-gaap_Goodwill_3e84fdcf-57c3-40c4-9596-b4d7123a5e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b9a4df08-d2f2-4f3d-a100-4c4977b85756" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b9a4df08-d2f2-4f3d-a100-4c4977b85756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_79ececfd-0913-4982-af60-f2dcf60c02f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_d07ebf46-60d8-4965-82c6-7c3dc23e4208" xlink:to="loc_us-gaap_Goodwill_79ececfd-0913-4982-af60-f2dcf60c02f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cbf4344e-b23e-43fd-b011-e16ce0abd677" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cbf4344e-b23e-43fd-b011-e16ce0abd677" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:to="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_457a58c7-f2a5-4a91-995b-569b500e2567" xlink:href="gild-20201231.xsd#gild_FinitelivedintangibleassetimpairmentbyprogramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramAxis_8d7ee8fd-c5f1-4ba6-9cbd-5f12a08c0245" xlink:to="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_457a58c7-f2a5-4a91-995b-569b500e2567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Kite585ProgramMember_a51acbd3-9f43-4f5b-934a-4b23ed5b6aa2" xlink:href="gild-20201231.xsd#gild_Kite585ProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_FinitelivedintangibleassetimpairmentbyprogramDomain_457a58c7-f2a5-4a91-995b-569b500e2567" xlink:to="loc_gild_Kite585ProgramMember_a51acbd3-9f43-4f5b-934a-4b23ed5b6aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_016f74fb-2aae-4ff4-864a-81fdf8b746a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5a64cb1-daff-4008-8fe1-ede97ec6f1f5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_016f74fb-2aae-4ff4-864a-81fdf8b746a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_bbed6156-756c-49aa-b97d-79264c3574b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_016f74fb-2aae-4ff4-864a-81fdf8b746a1" xlink:to="loc_us-gaap_CostOfSalesMember_bbed6156-756c-49aa-b97d-79264c3574b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f35aafd-2199-4abc-912f-b107288bc1f0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d48a092a-ff0f-44d7-a0e2-7112920c97ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_d48a092a-ff0f-44d7-a0e2-7112920c97ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2cee70fd-5b06-4df7-ac1c-0e5c96bbd0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2cee70fd-5b06-4df7-ac1c-0e5c96bbd0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_55018577-0582-4c4c-87fe-a623364bfbb0" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_55018577-0582-4c4c-87fe-a623364bfbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5cf6c679-45fa-483c-8d8a-9b8e3ef49f68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5cf6c679-45fa-483c-8d8a-9b8e3ef49f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_71ff7710-b67c-461f-afe2-c656d4de29f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_cac08202-5961-4021-a58b-896c071741bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_71ff7710-b67c-461f-afe2-c656d4de29f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_92b9eee0-626d-4783-b3b6-eef68ec0e150" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_92b9eee0-626d-4783-b3b6-eef68ec0e150" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0221c64f-125a-48bf-9c1a-d41a928e669c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_f40588da-1f0f-447d-9cfe-a2dc41f922ca" xlink:href="gild-20201231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_f40588da-1f0f-447d-9cfe-a2dc41f922ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_be6df20e-0cbf-43a9-80de-68c1d5486b0e" xlink:href="gild-20201231.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_be6df20e-0cbf-43a9-80de-68c1d5486b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyForMTNBCMember_f440c791-7a83-4caf-870c-5e318dae4c0b" xlink:href="gild-20201231.xsd#gild_TrodelvyForMTNBCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_gild_TrodelvyForMTNBCMember_f440c791-7a83-4caf-870c-5e318dae4c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_95965d99-260d-40d9-9986-c30b7f5a5a4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b56de484-f877-433a-ac6e-22732668ee9b" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_95965d99-260d-40d9-9986-c30b7f5a5a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8de2033a-c7b3-4c8f-a894-23f8b6bd3b31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bf0f7bc3-a695-47b2-a9af-b6cc1bca7740" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8de2033a-c7b3-4c8f-a894-23f8b6bd3b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_181ed1ac-2c0d-4526-82ea-eeafe5a032e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8de2033a-c7b3-4c8f-a894-23f8b6bd3b31" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_181ed1ac-2c0d-4526-82ea-eeafe5a032e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ebc79663-5ff8-43f1-881f-85644999061e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3001d1fb-94af-41cd-a067-b1310767b5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3001d1fb-94af-41cd-a067-b1310767b5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b97a7e89-ef2d-4a78-972a-8001c8f862d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b97a7e89-ef2d-4a78-972a-8001c8f862d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca602ffb-333c-4320-87e5-a2310304aa92" xlink:href="gild-20201231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_ca602ffb-333c-4320-87e5-a2310304aa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4452746b-c17f-4145-ae4e-adce84216c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_3c7e08c4-0886-4687-8021-3c45591e621b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4452746b-c17f-4145-ae4e-adce84216c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_263ed69e-7497-40c9-b92c-34149d2b46e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_263ed69e-7497-40c9-b92c-34149d2b46e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1e5a0229-fdcb-49dc-842a-5625777f1dc0" xlink:href="gild-20201231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_1e5a0229-fdcb-49dc-842a-5625777f1dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_66b214bc-a191-44a3-a39b-9a910246bd54" xlink:href="gild-20201231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_9c69b672-2e97-4521-ae67-140c4d56368d" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_66b214bc-a191-44a3-a39b-9a910246bd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_44ff3381-1388-49c3-91b2-cf2c79e34476" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_abaf8d91-3ec9-4d98-850e-36650f0abf32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_abaf8d91-3ec9-4d98-850e-36650f0abf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfd11261-9afe-4aa9-b835-dbb996605f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfd11261-9afe-4aa9-b835-dbb996605f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_829ac659-a50d-4355-b4bb-4ee03d6cc2d0" xlink:href="gild-20201231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_829ac659-a50d-4355-b4bb-4ee03d6cc2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_db41c023-58ff-4735-8f9d-7d383c911f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_96379d09-b0c8-4807-a69d-a31a5bbf7049" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_db41c023-58ff-4735-8f9d-7d383c911f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b70fb4fb-52d9-4700-baac-42ae335ea9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b70fb4fb-52d9-4700-baac-42ae335ea9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1752191c-a070-4992-ae87-387dde60758b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1752191c-a070-4992-ae87-387dde60758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_469b4153-7ada-4a26-9f71-83251e1b65dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_469b4153-7ada-4a26-9f71-83251e1b65dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d913a416-1310-44a8-840c-ed08bd1d4b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d913a416-1310-44a8-840c-ed08bd1d4b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_88a4d855-deca-4d8e-ad9a-342c63db4a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_88a4d855-deca-4d8e-ad9a-342c63db4a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5b3bd395-ed7f-4ad4-a89b-8615a186796c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5b3bd395-ed7f-4ad4-a89b-8615a186796c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_41b6b092-f02e-4a27-bd58-370acd79b0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00c214c1-4b02-4329-9073-5d9aaaac00ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_41b6b092-f02e-4a27-bd58-370acd79b0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_b10a40d0-dbad-4420-a666-09883e567ebe" xlink:href="gild-20201231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9f9da4ff-128e-43b6-91d1-8d46bb588e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b10a40d0-dbad-4420-a666-09883e567ebe" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9f9da4ff-128e-43b6-91d1-8d46bb588e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_b4e23957-83f9-4e76-9e08-8a7b5c70db9d" xlink:href="gild-20201231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_624d17a9-525d-462a-ab7b-23c741066e58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b4e23957-83f9-4e76-9e08-8a7b5c70db9d" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_624d17a9-525d-462a-ab7b-23c741066e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_17e08b49-a707-4a2a-b630-5e7c310a9efe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_b4e23957-83f9-4e76-9e08-8a7b5c70db9d" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_17e08b49-a707-4a2a-b630-5e7c310a9efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_16c431a6-7f77-4ec5-a00e-2e73d04f38bd" xlink:href="gild-20201231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_329526ff-e2fa-4c62-8cca-2bd758b91045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_16c431a6-7f77-4ec5-a00e-2e73d04f38bd" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_329526ff-e2fa-4c62-8cca-2bd758b91045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_07289134-cd0e-4340-a4d7-1412cf0917fe" xlink:href="gild-20201231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_16c431a6-7f77-4ec5-a00e-2e73d04f38bd" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_07289134-cd0e-4340-a4d7-1412cf0917fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_54c8bb1b-42fc-429b-b86e-e9134f4de505" xlink:href="gild-20201231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_16c431a6-7f77-4ec5-a00e-2e73d04f38bd" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_54c8bb1b-42fc-429b-b86e-e9134f4de505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b4da70f3-c585-4ae9-9243-30e68d86e4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_16c431a6-7f77-4ec5-a00e-2e73d04f38bd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b4da70f3-c585-4ae9-9243-30e68d86e4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_632706c0-abaa-422d-9700-4f790864019b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_16c431a6-7f77-4ec5-a00e-2e73d04f38bd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_632706c0-abaa-422d-9700-4f790864019b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_2f000623-07a9-4f3a-9422-3c897e55a4e4" xlink:href="gild-20201231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_53bd690e-aedf-457d-b5c5-57e49f501fda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_2f000623-07a9-4f3a-9422-3c897e55a4e4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_53bd690e-aedf-457d-b5c5-57e49f501fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_951e1f53-344a-48ae-98b9-75a4bfed2d68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_2f000623-07a9-4f3a-9422-3c897e55a4e4" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_951e1f53-344a-48ae-98b9-75a4bfed2d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_46047ba3-ed8b-452b-97d0-86ed6e1d9a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_2f000623-07a9-4f3a-9422-3c897e55a4e4" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_46047ba3-ed8b-452b-97d0-86ed6e1d9a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8815a8df-bee0-41e1-bcb7-d9326a23961d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_2f000623-07a9-4f3a-9422-3c897e55a4e4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8815a8df-bee0-41e1-bcb7-d9326a23961d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c831366d-bb37-4e8e-99c9-c3837239234b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_2f000623-07a9-4f3a-9422-3c897e55a4e4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c831366d-bb37-4e8e-99c9-c3837239234b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="gild-20201231.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_c31adede-aee6-4a03-bdf1-d90225aacaf1" xlink:href="gild-20201231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsTextBlock_c2ff35de-b1cb-4ad1-93ff-bc84e1c77334" xlink:href="gild-20201231.xsd#gild_CollaborativeandOtherArrangementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_c31adede-aee6-4a03-bdf1-d90225aacaf1" xlink:to="loc_gild_CollaborativeandOtherArrangementsTextBlock_c2ff35de-b1cb-4ad1-93ff-bc84e1c77334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_053bd053-a253-492a-8a67-f0b81f2a33c4" xlink:href="gild-20201231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_053bd053-a253-492a-8a67-f0b81f2a33c4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5bbb404f-4fb6-4970-9727-594ae14a626d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_e024fbfa-6946-42d8-b6b2-619c8817417d" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_ArcusBiosciencesIncMember_e024fbfa-6946-42d8-b6b2-619c8817417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_2e5127f9-6b06-4294-98fa-ad26c54f3cc6" xlink:href="gild-20201231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_2e5127f9-6b06-4294-98fa-ad26c54f3cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember_047dc090-0dbe-4f43-ad82-8e1270799e4e" xlink:href="gild-20201231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_TizonaTherapeuticsIncMember_047dc090-0dbe-4f43-ad82-8e1270799e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_6d8fe69f-41f7-47b9-a083-b1c3174d6fb4" xlink:href="gild-20201231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_TangoTherapeuticsIncMember_6d8fe69f-41f7-47b9-a083-b1c3174d6fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_5a7fb4f0-2e05-4798-a06d-e75f0d29a9c1" xlink:href="gild-20201231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_JounceTherapeuticsIncMember_5a7fb4f0-2e05-4798-a06d-e75f0d29a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_b9e2c444-cd84-4f6e-9a98-44cfcf16f497" xlink:href="gild-20201231.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ebea8e7-5c45-4a17-b396-20c9dd9b08d4" xlink:to="loc_gild_GalapagosMember_b9e2c444-cd84-4f6e-9a98-44cfcf16f497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0eb033e1-a63c-42ae-9f6f-f9375e7fc637" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_78052b42-6df0-4a4e-b2ec-ea337086bd5d" xlink:href="gild-20201231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_78052b42-6df0-4a4e-b2ec-ea337086bd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedArcusCommonStockPurchaseAgreementMember_f8644245-18c8-4852-8d49-7cae0cf194ae" xlink:href="gild-20201231.xsd#gild_AmendedArcusCommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedArcusCommonStockPurchaseAgreementMember_f8644245-18c8-4852-8d49-7cae0cf194ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_c5a30c5b-b8c9-4859-a92c-c1bea8f0c44d" xlink:href="gild-20201231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ArcusCollaborationAgreementMember_c5a30c5b-b8c9-4859-a92c-c1bea8f0c44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_32a7a5cd-ad23-4a12-9cdc-fd82a9115657" xlink:href="gild-20201231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_32a7a5cd-ad23-4a12-9cdc-fd82a9115657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember_8980d36d-cf18-4070-96b3-8aaf6d134a77" xlink:href="gild-20201231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_PionyrMergerAndOptionAgreementsMember_8980d36d-cf18-4070-96b3-8aaf6d134a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember_773d1b01-99b0-45d0-8020-c33b010016a4" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_ResearchAndDevelopmentServiceAgreementMember_773d1b01-99b0-45d0-8020-c33b010016a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember_79ca2b2a-580e-4362-a70e-cd980bb32cc3" xlink:href="gild-20201231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_TizonaMergerAndOptionAgreementsMember_79ca2b2a-580e-4362-a70e-cd980bb32cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember_df01aefb-dd5c-4529-8f49-2b42c5bf55af" xlink:href="gild-20201231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_JanssenPharmaceuticalsMember_df01aefb-dd5c-4529-8f49-2b42c5bf55af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_65ade41e-0049-4f77-9dde-6e5b48b40914" xlink:href="gild-20201231.xsd#gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember_65ade41e-0049-4f77-9dde-6e5b48b40914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_49eeb5ef-8e02-4854-b456-f2287e978b77" xlink:href="gild-20201231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member_49eeb5ef-8e02-4854-b456-f2287e978b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_d5eb648d-a966-49c1-88de-a53a1875c87f" xlink:href="gild-20201231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_d5eb648d-a966-49c1-88de-a53a1875c87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_aafe1f14-9495-4ec9-ba85-ddce2fdbacd4" xlink:href="gild-20201231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_aafe1f14-9495-4ec9-ba85-ddce2fdbacd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosCollaborationAgreementMember_1258c9b0-a7f0-4406-87a1-74c9e88662bb" xlink:href="gild-20201231.xsd#gild_GalapagosCollaborationAgreementMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_GalapagosCollaborationAgreementMember_1258c9b0-a7f0-4406-87a1-74c9e88662bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember_5b6c6c5c-61ad-4f86-901e-1da027caccf5" xlink:href="gild-20201231.xsd#gild_DevelopmentAgreementMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_DevelopmentAgreementMember_5b6c6c5c-61ad-4f86-901e-1da027caccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_0d76f2ef-9368-49b4-8597-c78b4eefb085" xlink:href="gild-20201231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_0d76f2ef-9368-49b4-8597-c78b4eefb085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_66423b0f-43b7-469f-a6ee-2681a1d68859" xlink:href="gild-20201231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_66423b0f-43b7-469f-a6ee-2681a1d68859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember_d40cfffc-7855-455f-b4e1-909d12754e57" xlink:href="gild-20201231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_AgreementWithJapanTobaccoIncMember_d40cfffc-7855-455f-b4e1-909d12754e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GadetaBVCollaborationArrangementMember_ce247c57-657b-40ed-bbf6-6ba15b8e0023" xlink:href="gild-20201231.xsd#gild_GadetaBVCollaborationArrangementMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_GadetaBVCollaborationArrangementMember_ce247c57-657b-40ed-bbf6-6ba15b8e0023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BristolMyersSquibbCollaborativeArrangementMember_c7b2758b-ab66-491d-b074-1bb6d54ce8d2" xlink:href="gild-20201231.xsd#gild_BristolMyersSquibbCollaborativeArrangementMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_BristolMyersSquibbCollaborativeArrangementMember_c7b2758b-ab66-491d-b074-1bb6d54ce8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_1655d91d-679c-4754-b37c-219dc6576f36" xlink:href="gild-20201231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9baac890-986b-4b85-a11d-1ab5ec276534" xlink:to="loc_gild_OtherCollaborationArrangementsMember_1655d91d-679c-4754-b37c-219dc6576f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a04485a5-0c33-41ef-b990-3fee3248b5b6" xlink:to="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_7ba40ac6-6b9a-4b45-9c52-61ce0838e920" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:to="loc_gild_ArcusBiosciencesIncMember_7ba40ac6-6b9a-4b45-9c52-61ce0838e920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_2e5424c5-98f8-4614-9adc-7fe2f2fa6556" xlink:href="gild-20201231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:to="loc_gild_TangoTherapeuticsIncMember_2e5424c5-98f8-4614-9adc-7fe2f2fa6556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_790797c5-6551-4800-8bdc-5ed6ec10c1c0" xlink:href="gild-20201231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_910df9bc-ea80-4e23-92f8-2e5a372a6384" xlink:to="loc_gild_JounceTherapeuticsIncMember_790797c5-6551-4800-8bdc-5ed6ec10c1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0a28c77c-161b-40e5-ab13-ea3bf476d792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_14e83308-a194-4a02-860e-578d6c0a01a6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0a28c77c-161b-40e5-ab13-ea3bf476d792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_52e02216-1896-417d-ad6a-605928990ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0a28c77c-161b-40e5-ab13-ea3bf476d792" xlink:to="loc_us-gaap_SubsequentEventMember_52e02216-1896-417d-ad6a-605928990ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_79f6e29c-66ba-4146-afc5-5002ac72573b" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_76636e1b-356d-4d2e-a660-2c2d1ed6bceb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_76636e1b-356d-4d2e-a660-2c2d1ed6bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71a79901-c38d-499e-87b2-b57253b8adcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71a79901-c38d-499e-87b2-b57253b8adcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent_b27e8c13-b194-4aae-b52f-db7e3f564680" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent_b27e8c13-b194-4aae-b52f-db7e3f564680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares_45e2e29c-9645-4e53-8fd4-a0bf656b4958" xlink:href="gild-20201231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalShares_45e2e29c-9645-4e53-8fd4-a0bf656b4958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade_62b28ec9-8e51-4147-9a1d-406cf2ae803f" xlink:href="gild-20201231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_TotalUpfrontPaymentsMade_62b28ec9-8e51-4147-9a1d-406cf2ae803f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4551231e-7c52-4057-87bb-c8677053ad45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4551231e-7c52-4057-87bb-c8677053ad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_94397b60-f547-47e6-a35d-c02de0127520" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_SharePrice_94397b60-f547-47e6-a35d-c02de0127520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_95cd995a-8fa6-4cc9-ab9a-f3522836a0a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquityMethodInvestments_95cd995a-8fa6-4cc9-ab9a-f3522836a0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1ec8fad9-d73b-4b67-b245-cf70c1f8be59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_1ec8fad9-d73b-4b67-b245-cf70c1f8be59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_f22f354d-53a7-4e2a-931b-93275870e825" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_f22f354d-53a7-4e2a-931b-93275870e825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium_e17a9a17-108f-4748-b274-fa45ca9c8808" xlink:href="gild-20201231.xsd#gild_IssuanceDiscountPremium"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_IssuanceDiscountPremium_e17a9a17-108f-4748-b274-fa45ca9c8808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense_ad8c9fd4-5419-4dbf-83f9-d50382a9417e" xlink:href="gild-20201231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentsForDirectTransactionalExpense_ad8c9fd4-5419-4dbf-83f9-d50382a9417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_5bfe2aa8-f42a-4cd2-9e23-ae79346d4907" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary_5bfe2aa8-f42a-4cd2-9e23-ae79346d4907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_405f0e6e-c525-4665-9794-e1204e0c2938" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_405f0e6e-c525-4665-9794-e1204e0c2938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_a5531bfe-fb95-4303-b372-11f487d35be2" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments_a5531bfe-fb95-4303-b372-11f487d35be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_633d8f19-9b2b-456e-81db-b105ee26e5d3" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_633d8f19-9b2b-456e-81db-b105ee26e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_69b951aa-caeb-4b05-9094-84d00d13e416" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_69b951aa-caeb-4b05-9094-84d00d13e416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_6682dee6-473f-45b4-ad7c-a3521fd690cf" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_6682dee6-473f-45b4-ad7c-a3521fd690cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2be75a10-4347-4de8-a704-6ad53ed99912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_2be75a10-4347-4de8-a704-6ad53ed99912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfAgreements_c4cfe7b5-3d6a-46d0-9c33-e3e58ccf0014" xlink:href="gild-20201231.xsd#gild_NumberOfAgreements"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_NumberOfAgreements_c4cfe7b5-3d6a-46d0-9c33-e3e58ccf0014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b626fad3-ec8f-48d0-880c-9a86c29eaaef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_b626fad3-ec8f-48d0-880c-9a86c29eaaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b969921f-a157-46c2-a793-7c3481b9848a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b969921f-a157-46c2-a793-7c3481b9848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e4df3bf4-fcc2-4b12-aa96-6abb168d4986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e4df3bf4-fcc2-4b12-aa96-6abb168d4986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalPayable_515b2a33-1eb7-4d00-895c-c69f14904ba9" xlink:href="gild-20201231.xsd#gild_InvestmentOwnedBalanceAdditionalPayable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalPayable_515b2a33-1eb7-4d00-895c-c69f14904ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_9e49a637-8542-404b-a852-c9d9b5d896f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_9e49a637-8542-404b-a852-c9d9b5d896f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee_bd8485a2-4dea-4e31-ad57-ac0cdc121eff" xlink:href="gild-20201231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquityMethodInvestmentOptionExerciseFee_bd8485a2-4dea-4e31-ad57-ac0cdc121eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_d0848bf1-6c49-4aab-b3ea-13d0da891ff2" xlink:href="gild-20201231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_d0848bf1-6c49-4aab-b3ea-13d0da891ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_180a1864-9035-489e-9538-8308ebd9534f" xlink:href="gild-20201231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_180a1864-9035-489e-9538-8308ebd9534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_33f469de-1b6a-4edb-8158-d90ddf9470b7" xlink:href="gild-20201231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_33f469de-1b6a-4edb-8158-d90ddf9470b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_71597b4d-c94e-46d5-af4f-328ed66cf379" xlink:href="gild-20201231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_71597b4d-c94e-46d5-af4f-328ed66cf379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms_266613d7-657a-4d13-a27b-67e69c213393" xlink:href="gild-20201231.xsd#gild_NumberOfPrograms"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_NumberOfPrograms_266613d7-657a-4d13-a27b-67e69c213393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedResearchAndDevelopmentMilestonePayments_297f8b50-d5bf-44a6-a22b-27bf4523d9a1" xlink:href="gild-20201231.xsd#gild_AccruedResearchAndDevelopmentMilestonePayments"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_AccruedResearchAndDevelopmentMilestonePayments_297f8b50-d5bf-44a6-a22b-27bf4523d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfStudies_ab63b341-a08f-4fef-95d3-4d3b511fe997" xlink:href="gild-20201231.xsd#gild_NumberOfStudies"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_NumberOfStudies_ab63b341-a08f-4fef-95d3-4d3b511fe997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForResearchAndDevelopmentMilestones_2312fc1b-d7a8-46bb-b72e-5f6caaab13b7" xlink:href="gild-20201231.xsd#gild_PaymentsForResearchAndDevelopmentMilestones"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentsForResearchAndDevelopmentMilestones_2312fc1b-d7a8-46bb-b72e-5f6caaab13b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_028894b2-a047-4ecf-a62c-ab6cd59eb964" xlink:href="gild-20201231.xsd#gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum_028894b2-a047-4ecf-a62c-ab6cd59eb964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm_1b0d7a7b-c300-4e94-88da-1e1cfe59e433" xlink:href="gild-20201231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_CollaborativeArrangementTerm_1b0d7a7b-c300-4e94-88da-1e1cfe59e433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_c2f161ee-081f-4fcb-8cf6-29fe809ba57e" xlink:href="gild-20201231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_c2f161ee-081f-4fcb-8cf6-29fe809ba57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm_0d1c2084-0385-4415-ae0f-e5cdca8f47eb" xlink:href="gild-20201231.xsd#gild_StandstillRestrictingTerm"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_StandstillRestrictingTerm_0d1c2084-0385-4415-ae0f-e5cdca8f47eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ccbad71-d4e8-4347-b9f8-5f313e2f1461" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ccbad71-d4e8-4347-b9f8-5f313e2f1461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7aa2c410-e258-49be-b174-59f2c3b5f12f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a059596e-2c0a-479e-80d6-6e950783e7c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a059596e-2c0a-479e-80d6-6e950783e7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_4ec53d28-5874-4e4b-bac0-f456bbce8554" xlink:href="gild-20201231.xsd#gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage_4ec53d28-5874-4e4b-bac0-f456bbce8554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_7a9d089f-fa73-4dc3-95d7-a45279da286d" xlink:href="gild-20201231.xsd#gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant_7a9d089f-fa73-4dc3-95d7-a45279da286d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_151fe7c2-2d76-4f50-8910-8ef0d5c1c64f" xlink:href="gild-20201231.xsd#gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_151fe7c2-2d76-4f50-8910-8ef0d5c1c64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_10fda4c9-60c0-42b1-ae04-cd82b2f404a6" xlink:href="gild-20201231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_10fda4c9-60c0-42b1-ae04-cd82b2f404a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f8db5e18-e0c3-47a6-bf3e-49f441a8f19c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestInVariableInterestEntity"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_NoncontrollingInterestInVariableInterestEntity_f8db5e18-e0c3-47a6-bf3e-49f441a8f19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c4ac3eff-3aa0-4576-bb47-db167197d539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c4ac3eff-3aa0-4576-bb47-db167197d539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_6f16eb7b-c973-4503-925c-a8c9aeffdefe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_RoyaltyExpense_6f16eb7b-c973-4503-925c-a8c9aeffdefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_bfab5f0d-e605-46ab-b58d-23110f788e26" xlink:href="gild-20201231.xsd#gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan_bfab5f0d-e605-46ab-b58d-23110f788e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireManagementContractRights_e2c65f02-3fee-4998-9fc8-8df94d7c07fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireManagementContractRights"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_us-gaap_PaymentsToAcquireManagementContractRights_e2c65f02-3fee-4998-9fc8-8df94d7c07fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialDevelopmentAndRegulatoryMilestones_a95ae3fe-412b-498b-a665-a7d743637a6d" xlink:href="gild-20201231.xsd#gild_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialDevelopmentAndRegulatoryMilestones_a95ae3fe-412b-498b-a665-a7d743637a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureSalesbasedMilestone_38aeba73-f70e-4378-83df-c3e834ae7435" xlink:href="gild-20201231.xsd#gild_PotentialFutureSalesbasedMilestone"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureSalesbasedMilestone_38aeba73-f70e-4378-83df-c3e834ae7435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureTieredRoyaltyPaymentLowend_bb8a60d3-f070-49f8-9490-c06388303a9b" xlink:href="gild-20201231.xsd#gild_PotentialFutureTieredRoyaltyPaymentLowend"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureTieredRoyaltyPaymentLowend_bb8a60d3-f070-49f8-9490-c06388303a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureTieredRoyaltyPaymentHighend_022ac83c-147a-4ba9-b9c0-36817d5540a8" xlink:href="gild-20201231.xsd#gild_PotentialFutureTieredRoyaltyPaymentHighend"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialFutureTieredRoyaltyPaymentHighend_022ac83c-147a-4ba9-b9c0-36817d5540a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_04ae2fd9-f707-4b7f-a391-5c095d2f5728" xlink:href="gild-20201231.xsd#gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing_04ae2fd9-f707-4b7f-a391-5c095d2f5728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_Issuancediscount_a7910b4c-2cda-46ef-a56f-f00e8486a156" xlink:href="gild-20201231.xsd#gild_Issuancediscount"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_Issuancediscount_a7910b4c-2cda-46ef-a56f-f00e8486a156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_f4a9f2b1-cc13-49cc-afd9-a4ad56ddad14" xlink:href="gild-20201231.xsd#gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690_f4a9f2b1-cc13-49cc-afd9-a4ad56ddad14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram_d29393fb-4560-418f-bda2-f75207f08c11" xlink:href="gild-20201231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialOptionExerciseFeePerProgram_d29393fb-4560-418f-bda2-f75207f08c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_b640ba2c-ca81-4dfa-a41e-6139ddb049c2" xlink:href="gild-20201231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:presentationArc order="59" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_b640ba2c-ca81-4dfa-a41e-6139ddb049c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_01f7f3d8-bad2-4de2-aa65-cbc364a878a8" xlink:href="gild-20201231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_01f7f3d8-bad2-4de2-aa65-cbc364a878a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_0de1a599-f699-4a1a-946a-6b0a784f82ba" xlink:href="gild-20201231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:presentationArc order="61" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_0de1a599-f699-4a1a-946a-6b0a784f82ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_c715d844-ca30-4e26-8b03-0882bed92a51" xlink:href="gild-20201231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:presentationArc order="62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_c715d844-ca30-4e26-8b03-0882bed92a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_35c3626a-9384-4e19-ac28-2abb4df1af58" xlink:href="gild-20201231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="63" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_35c3626a-9384-4e19-ac28-2abb4df1af58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_95b366fd-f905-4f7e-b993-f7a87e9b0d90" xlink:href="gild-20201231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo"/>
    <link:presentationArc order="64" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a0f2d07b-08a2-4131-83fa-07f06b5c2dad" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo_95b366fd-f905-4f7e-b993-f7a87e9b0d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilities"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0f622652-15f5-4c9b-82fb-0ac07527bd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ba88a23b-f526-42ff-a98c-e54d56bc07f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0f622652-15f5-4c9b-82fb-0ac07527bd4b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ba88a23b-f526-42ff-a98c-e54d56bc07f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63987777-0ce5-46bf-b914-511779c92bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5b7c83ea-c3ba-4190-8c12-f43ba590e37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63987777-0ce5-46bf-b914-511779c92bfc" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5b7c83ea-c3ba-4190-8c12-f43ba590e37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_70269248-1eb4-4cf4-af9c-97663c466df1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63987777-0ce5-46bf-b914-511779c92bfc" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_70269248-1eb4-4cf4-af9c-97663c466df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_13ef569a-e401-4834-9a6c-fb1a260916e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_13ef569a-e401-4834-9a6c-fb1a260916e1" xlink:to="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e04ce685-8109-4708-8506-6a780a757e46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f8625887-12d5-419b-b6e8-2d52e91cc3fd" xlink:to="loc_us-gaap_VariableRateDomain_e04ce685-8109-4708-8506-6a780a757e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_61c51177-a74f-4597-9381-5c93f7b7b1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e04ce685-8109-4708-8506-6a780a757e46" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_61c51177-a74f-4597-9381-5c93f7b7b1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f3992626-8668-489b-92f0-b483776eb2e9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_d9ebdd74-6649-48ab-8341-357feeffdc18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:to="loc_us-gaap_SeniorNotesMember_d9ebdd74-6649-48ab-8341-357feeffdc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_0ee30048-29ab-46df-9c8e-46523ff06299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_00c289c1-737f-43b4-9bc2-f29debf0f9c5" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_0ee30048-29ab-46df-9c8e-46523ff06299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b49c3f44-b29f-4ee2-9a29-d3a03c5f2a7a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueInFebruary2020Member_0774b52a-7e69-4781-ac7c-e86cd2930a31" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueInFebruary2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueInFebruary2020Member_0774b52a-7e69-4781-ac7c-e86cd2930a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2020Member_c2feda6f-a7e5-40ed-a928-031549cba7f9" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2020Member_c2feda6f-a7e5-40ed-a928-031549cba7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4a4da20f-3382-4aca-93e0-03b1c1b3601a" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_4a4da20f-3382-4aca-93e0-03b1c1b3601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_be91b833-1510-4e94-aa88-9d2c8af7181f" xlink:href="gild-20201231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_be91b833-1510-4e94-aa88-9d2c8af7181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_a2e1006b-61aa-46c8-82d5-cf53b64f4fdb" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueDecember2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2021Member_a2e1006b-61aa-46c8-82d5-cf53b64f4fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_f1fd64ed-01ca-4887-bf51-808745f7630f" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_f1fd64ed-01ca-4887-bf51-808745f7630f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_7a166a44-b958-4857-8cfa-620d554a69db" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_7a166a44-b958-4857-8cfa-620d554a69db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_27214d36-71b1-4ee0-9ccd-2d544ca69401" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_27214d36-71b1-4ee0-9ccd-2d544ca69401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1a09d994-19e6-4295-a438-e15c58dc9868" xlink:href="gild-20201231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_1a09d994-19e6-4295-a438-e15c58dc9868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_d3de3356-4163-4349-af20-b1dbe4584eda" xlink:href="gild-20201231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_d3de3356-4163-4349-af20-b1dbe4584eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VariableTermLoanNoteDueOctober2023Member_ea920a81-4913-4448-8f17-466d2466a295" xlink:href="gild-20201231.xsd#gild_VariableTermLoanNoteDueOctober2023Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_VariableTermLoanNoteDueOctober2023Member_ea920a81-4913-4448-8f17-466d2466a295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a6025084-7b21-4fac-9a37-081e8f194b0e" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a6025084-7b21-4fac-9a37-081e8f194b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_d846c26f-3a1c-4f76-8bac-e6661c87e4ca" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_d846c26f-3a1c-4f76-8bac-e6661c87e4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_714427c8-f4cc-4910-af2f-79893bfdfc7e" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_714427c8-f4cc-4910-af2f-79893bfdfc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_c57d4a17-6b2f-477f-9dae-f93e3d9fb3a0" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_c57d4a17-6b2f-477f-9dae-f93e3d9fb3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_49ce7cbf-0951-4bbc-b53a-6a4e6de243d2" xlink:href="gild-20201231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_49ce7cbf-0951-4bbc-b53a-6a4e6de243d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d49a4097-3340-472d-9a61-626f6e73d435" xlink:href="gild-20201231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d49a4097-3340-472d-9a61-626f6e73d435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_c4931aa3-f43d-4b0f-9f60-d8e63c028463" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_c4931aa3-f43d-4b0f-9f60-d8e63c028463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_2d45af01-4cce-48a7-b0e8-c6061ca0d1b4" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_2d45af01-4cce-48a7-b0e8-c6061ca0d1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_11ee54b3-c5b6-409a-8b04-daa317a0cc1a" xlink:href="gild-20201231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_11ee54b3-c5b6-409a-8b04-daa317a0cc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_66ec4839-2ce7-4f0b-9e6f-2d601edfbc45" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_66ec4839-2ce7-4f0b-9e6f-2d601edfbc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_4bb32b2d-68ed-4a3b-b5fc-14b025a9f2a4" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_4bb32b2d-68ed-4a3b-b5fc-14b025a9f2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_5c12d254-7203-4a5b-81eb-7d471bf002d7" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_5c12d254-7203-4a5b-81eb-7d471bf002d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_8dc3f0d5-8503-461f-8015-47e8bbff8397" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_8dc3f0d5-8503-461f-8015-47e8bbff8397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_f2db10d4-9f8b-4039-98ba-fb36e79cffb3" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_f2db10d4-9f8b-4039-98ba-fb36e79cffb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_e948869f-92ac-483c-aa8f-d7095119d8b1" xlink:href="gild-20201231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_625ff4a9-af1d-4b99-9466-378a4b359348" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_e948869f-92ac-483c-aa8f-d7095119d8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1c6cabf-4760-4c2d-9f34-b04789f4b8bf" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e4aae1b3-af01-4d18-8739-1b64ba951441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e4aae1b3-af01-4d18-8739-1b64ba951441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_75c6a481-1dbd-4309-8204-13efe7663a16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_75c6a481-1dbd-4309-8204-13efe7663a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_099c8648-0fb4-4379-84ab-37ea9445cc2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_LongTermDebt_099c8648-0fb4-4379-84ab-37ea9445cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d9b8cb7d-0a23-4a09-a413-1b477636a480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d9b8cb7d-0a23-4a09-a413-1b477636a480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_19d236d9-495d-43a4-9826-9cda1fdebaca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_LongTermDebtCurrent_19d236d9-495d-43a4-9826-9cda1fdebaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_de4b77e2-1a4f-4fdd-96cf-7dddc4ced33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1790cb11-218d-4190-93df-80607df5389c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_de4b77e2-1a4f-4fdd-96cf-7dddc4ced33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5eea9932-72c5-4298-af07-6e856c203741" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5eea9932-72c5-4298-af07-6e856c203741" xlink:to="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9fdd7388-97a7-4f9b-a4e8-e2364061b5ba" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_a3fe64d0-2426-48f0-882f-a16310a79994" xlink:href="gild-20201231.xsd#gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member_a3fe64d0-2426-48f0-882f-a16310a79994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_3724eef1-cc1b-4e76-a2d2-ff3cc03269b1" xlink:href="gild-20201231.xsd#gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member_3724eef1-cc1b-4e76-a2d2-ff3cc03269b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87e864e1-1c09-4106-9d2e-042f05a89f12" xlink:href="gild-20201231.xsd#gild_A075SeniorUnsecuredNotesDueSeptember2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueSeptember2023Member_87e864e1-1c09-4106-9d2e-042f05a89f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_d0389a4f-7a4e-4f6c-aebd-7233f30387b3" xlink:href="gild-20201231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_d0389a4f-7a4e-4f6c-aebd-7233f30387b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d81ed6f1-e0b6-4d9e-8749-2802c9f6af7b" xlink:href="gild-20201231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_d81ed6f1-e0b6-4d9e-8749-2802c9f6af7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_95b6d6aa-d4c5-4293-9a0e-7b60c01d3887" xlink:href="gild-20201231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_95b6d6aa-d4c5-4293-9a0e-7b60c01d3887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b1d816c6-732c-482e-8eac-ae5712f4b5cc" xlink:href="gild-20201231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b1d816c6-732c-482e-8eac-ae5712f4b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_947c66c3-2411-43e1-843f-71347521440d" xlink:href="gild-20201231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_947c66c3-2411-43e1-843f-71347521440d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_3c2637c3-ec58-4eec-a8aa-35d8f844f78c" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2014Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedSeptember2014Member_3c2637c3-ec58-4eec-a8aa-35d8f844f78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_551fbdb6-a3a5-4fcc-972e-d3e6353f42a6" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2015Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedSeptember2015Member_551fbdb6-a3a5-4fcc-972e-d3e6353f42a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueApril2021Member_e49c4f2f-1607-490c-aec2-77ee58c98c03" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNotesDueApril2021Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNotesDueApril2021Member_e49c4f2f-1607-490c-aec2-77ee58c98c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_2fd694fa-253f-4683-a5c3-9bfe9ec7a873" xlink:href="gild-20201231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_2fd694fa-253f-4683-a5c3-9bfe9ec7a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueMay2021Member_497491ee-b475-4473-b436-5edca776fe2e" xlink:href="gild-20201231.xsd#gild_CreditFacilityDueMay2021Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_CreditFacilityDueMay2021Member_497491ee-b475-4473-b436-5edca776fe2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_02531837-e175-4055-b3fb-64f039883fcb" xlink:href="gild-20201231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_CreditFacilityDueJune2025Member_02531837-e175-4055-b3fb-64f039883fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_847c93e7-caf0-4763-af2f-5f4499fe4bdc" xlink:href="gild-20201231.xsd#gild_SeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fb09e6d2-86d7-4c1f-91f2-e08c242c4a6d" xlink:to="loc_gild_SeniorUnsecuredNoteIssuedSeptember2020Member_847c93e7-caf0-4763-af2f-5f4499fe4bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f404e66a-197f-4a64-a2d9-63a14283ab41" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_f4fdfcd4-82ef-40eb-918a-1b38ce6362b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:to="loc_us-gaap_SeniorNotesMember_f4fdfcd4-82ef-40eb-918a-1b38ce6362b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_6a656759-3ebb-478f-bd9d-d1372dc32be4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:to="loc_us-gaap_MediumTermNotesMember_6a656759-3ebb-478f-bd9d-d1372dc32be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_66207b55-e9e8-47e8-a5a5-371cc4050ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c26bfa2-8be3-4117-ac46-99d76d804a81" xlink:to="loc_us-gaap_LineOfCreditMember_66207b55-e9e8-47e8-a5a5-371cc4050ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6664c6d7-2dfb-4945-b9c4-f8f928738be1" xlink:to="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1391b3b0-9b3e-47e4-b3aa-3ac942afac78" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:to="loc_srt_MinimumMember_1391b3b0-9b3e-47e4-b3aa-3ac942afac78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1cae556b-a569-4e2a-8b14-c4013b348328" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_46c43f5b-aa7e-4490-a263-71ad31b44864" xlink:to="loc_srt_MaximumMember_1cae556b-a569-4e2a-8b14-c4013b348328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a73289dc-dd0c-4ada-b3d7-9ea90fb91ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6fce7aa7-4a2d-4b2d-9819-8b30953a7b18" xlink:to="loc_us-gaap_CreditFacilityDomain_a73289dc-dd0c-4ada-b3d7-9ea90fb91ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_33f56a0e-6df9-4944-a04b-e324dea8ce82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a73289dc-dd0c-4ada-b3d7-9ea90fb91ae9" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_33f56a0e-6df9-4944-a04b-e324dea8ce82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61a9c337-893d-4283-9a09-c667141c6a87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_750c567f-5608-419d-8762-bee30b42d5f5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61a9c337-893d-4283-9a09-c667141c6a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e1ef9535-2cf2-4e66-8bce-2cc038bef847" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61a9c337-893d-4283-9a09-c667141c6a87" xlink:to="loc_us-gaap_SubsequentEventMember_e1ef9535-2cf2-4e66-8bce-2cc038bef847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_543640fc-7539-47c1-bd17-3d08cbbb0e42" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_59ab5495-99a6-45bd-b996-f6bc02c6380e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_59ab5495-99a6-45bd-b996-f6bc02c6380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c25b731-ae2a-45bd-a66d-f589e97eb039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c25b731-ae2a-45bd-a66d-f589e97eb039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f8f4b44d-d0bf-4c16-be3d-04393878fa1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f8f4b44d-d0bf-4c16-be3d-04393878fa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_6f35b6c3-7aa3-42aa-bead-8f2fa63481c6" xlink:href="gild-20201231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_6f35b6c3-7aa3-42aa-bead-8f2fa63481c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_4026b13c-7ff8-4188-94e1-05d28217f37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_4026b13c-7ff8-4188-94e1-05d28217f37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_4c17e673-7086-4c81-af83-32ae0a171dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_4c17e673-7086-4c81-af83-32ae0a171dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d25bd678-1474-4d56-96a0-ad98d72ada7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_DebtInstrumentTerm_d25bd678-1474-4d56-96a0-ad98d72ada7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efcaa428-6c36-4873-8852-52580acddf31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_efcaa428-6c36-4873-8852-52580acddf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cba3e1a9-889b-4639-846d-093c4719fdd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_LongTermDebt_cba3e1a9-889b-4639-846d-093c4719fdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_e4056e2d-d91d-4e1e-bb42-7dd5266d491b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ea6d3c8e-8483-444b-8793-5a741a66ed2f" xlink:to="loc_us-gaap_LineOfCredit_e4056e2d-d91d-4e1e-bb42-7dd5266d491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d74cbd32-863d-47c0-91d0-d737d4119788" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d74cbd32-863d-47c0-91d0-d737d4119788" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_124609b2-1597-47c5-b48e-bc1f1e0819e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_124609b2-1597-47c5-b48e-bc1f1e0819e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_436fdbd9-5177-4b67-802a-36dd43626121" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_436fdbd9-5177-4b67-802a-36dd43626121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f478066-970a-4971-b8e1-652fdf1f32a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f478066-970a-4971-b8e1-652fdf1f32a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2e7e8f65-498c-47ef-9707-541cf1e6e8fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2e7e8f65-498c-47ef-9707-541cf1e6e8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b576b779-d66c-43c3-bafe-9fdc19622498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b576b779-d66c-43c3-bafe-9fdc19622498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2e6b363b-f978-402b-91e3-3f44b3cf5aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2e6b363b-f978-402b-91e3-3f44b3cf5aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1272f6aa-fff1-48de-8b82-74dcef6000f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_bccfd268-94b3-45df-bac5-b1e2a0b7a034" xlink:to="loc_us-gaap_LongTermDebt_1272f6aa-fff1-48de-8b82-74dcef6000f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Leases" xlink:type="simple" xlink:href="gild-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1070dc5b-6542-436e-936a-71fa1b119cc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_982a4e7a-1517-4125-b7d2-391c351f8bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1070dc5b-6542-436e-936a-71fa1b119cc0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_982a4e7a-1517-4125-b7d2-391c351f8bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c6cadca1-30d9-4d3c-af69-e01012cba4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock_f472cc9d-2902-49b4-b566-796786a826db" xlink:href="gild-20201231.xsd#gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6cadca1-30d9-4d3c-af69-e01012cba4ff" xlink:to="loc_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock_f472cc9d-2902-49b4-b566-796786a826db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cd5fe880-c2d4-4a39-a6cf-0800f9a890b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6cadca1-30d9-4d3c-af69-e01012cba4ff" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cd5fe880-c2d4-4a39-a6cf-0800f9a890b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a0a66764-eda4-4473-bcca-a46d955cbef1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c6cadca1-30d9-4d3c-af69-e01012cba4ff" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_a0a66764-eda4-4473-bcca-a46d955cbef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fd962741-916d-452f-b4b2-abc5e1242bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4578d45a-fc9f-4872-8293-f2fe8e10c14c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd962741-916d-452f-b4b2-abc5e1242bd8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_4578d45a-fc9f-4872-8293-f2fe8e10c14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_0cfb53ca-4694-44c7-91b3-eeeb6509b9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd962741-916d-452f-b4b2-abc5e1242bd8" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_0cfb53ca-4694-44c7-91b3-eeeb6509b9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9fb218d7-fbf7-46f3-a195-e21494e8b34a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd962741-916d-452f-b4b2-abc5e1242bd8" xlink:to="loc_us-gaap_OperatingLeaseExpense_9fb218d7-fbf7-46f3-a195-e21494e8b34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_23c78485-9fa6-487b-b8e9-8507779048e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fd962741-916d-452f-b4b2-abc5e1242bd8" xlink:to="loc_us-gaap_LeaseAndRentalExpense_23c78485-9fa6-487b-b8e9-8507779048e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesBalanceSheetLocationDetailDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1210401b-d94c-408b-9691-4e4e94ba66fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1210401b-d94c-408b-9691-4e4e94ba66fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_719ce2fe-ec15-4020-9a09-5e6702edd953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_719ce2fe-ec15-4020-9a09-5e6702edd953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_04f41a81-e6c2-457a-b322-07382ab03d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_04f41a81-e6c2-457a-b322-07382ab03d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bdabdd2c-a151-4d7b-9732-9d64dc9185ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_bdabdd2c-a151-4d7b-9732-9d64dc9185ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_386c1c4b-a704-4fc0-a06d-1cce4d3fb238" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_386c1c4b-a704-4fc0-a06d-1cce4d3fb238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f21068aa-a7de-465b-a8e1-57c9cc886000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f21068aa-a7de-465b-a8e1-57c9cc886000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b4ceb048-3b4f-4267-aa7f-87b55a204a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_769d2249-e82d-4582-aab4-ceb0b0907a54" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b4ceb048-3b4f-4267-aa7f-87b55a204a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSupplementalInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d5b8075d-7b47-4e28-a595-57e9bb83a821" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5b00bb47-4179-4087-a704-0c4dfbff8399" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5b8075d-7b47-4e28-a595-57e9bb83a821" xlink:to="loc_us-gaap_OperatingLeasePayments_5b00bb47-4179-4087-a704-0c4dfbff8399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a49b4677-b096-465a-9ba2-95cdf98c7cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d5b8075d-7b47-4e28-a595-57e9bb83a821" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a49b4677-b096-465a-9ba2-95cdf98c7cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_65a425c6-1f5a-4d13-b764-daabeaeb259a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_65a425c6-1f5a-4d13-b764-daabeaeb259a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_22ab5016-78ea-4bb2-8b78-470303f2e930" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_22ab5016-78ea-4bb2-8b78-470303f2e930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10c1bffb-fec7-4b31-9be1-9835ad78cafd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_10c1bffb-fec7-4b31-9be1-9835ad78cafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eddb3767-d7ae-4144-a20d-ac8f84fcecae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eddb3767-d7ae-4144-a20d-ac8f84fcecae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e3e5d730-8461-4ea1-9dd6-b5e35c77fa6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e3e5d730-8461-4ea1-9dd6-b5e35c77fa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0684fc77-9f77-4400-94e4-5935b8e854ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0684fc77-9f77-4400-94e4-5935b8e854ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4b13b82f-9bb9-401b-b817-72017bd210cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4b13b82f-9bb9-401b-b817-72017bd210cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27a852f5-0c1f-41b9-b2cc-60b98e9e8e78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27a852f5-0c1f-41b9-b2cc-60b98e9e8e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b6cf72ac-d9e0-47c7-a593-be437610d550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b6cf72ac-d9e0-47c7-a593-be437610d550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3adad7f1-1f9c-4283-9049-3674c6c65c86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fefad768-8bb7-4f48-9f2f-b3b2b8810514" xlink:to="loc_us-gaap_OperatingLeaseLiability_3adad7f1-1f9c-4283-9049-3674c6c65c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="simple" xlink:href="gild-20201231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gild-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6651640-a06f-4a10-bf91-b6dc070eaf05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3c36d7f2-e510-431d-939c-41cb602ae873" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6651640-a06f-4a10-bf91-b6dc070eaf05" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3c36d7f2-e510-431d-939c-41cb602ae873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60d78868-543d-4f98-b02d-b5824e20b8f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60d78868-543d-4f98-b02d-b5824e20b8f7" xlink:to="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_94556e79-713b-4ff4-9350-1a45c4ca6aa2" xlink:to="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ddee2747-0d57-43be-a708-d5365d103ad3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:to="loc_srt_MinimumMember_ddee2747-0d57-43be-a708-d5365d103ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b5f813dc-4a8b-4126-aac6-b0064d2500e4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_be35eca7-53ea-4b00-882a-6c9d200402c7" xlink:to="loc_srt_MaximumMember_b5f813dc-4a8b-4126-aac6-b0064d2500e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_05e40193-39d4-44d0-bf19-a63644621198" xlink:to="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IdenixPharmaceuticalsIncMember_c2bc591d-7bfe-46a1-a21a-79409c06b15c" xlink:href="gild-20201231.xsd#gild_IdenixPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:to="loc_gild_IdenixPharmaceuticalsIncMember_c2bc591d-7bfe-46a1-a21a-79409c06b15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_7e3af210-ab51-4d63-be0a-2c237a69330e" xlink:href="gild-20201231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_7e3af210-ab51-4d63-be0a-2c237a69330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ViiVHealthcareCompanyMember_19276772-d452-4c29-b021-ed9fa4cb5b55" xlink:href="gild-20201231.xsd#gild_ViiVHealthcareCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aa00979a-f60b-4659-9a69-065ce40a82d8" xlink:to="loc_gild_ViiVHealthcareCompanyMember_19276772-d452-4c29-b021-ed9fa4cb5b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a4ae65ce-4f67-43ab-9200-bfb65e51c0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_2a9f659b-f053-41fb-91c2-4fe4ab20d55f" xlink:to="loc_us-gaap_LitigationStatusDomain_a4ae65ce-4f67-43ab-9200-bfb65e51c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_408ea93c-7186-4b9b-8325-681f08e80726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a4ae65ce-4f67-43ab-9200-bfb65e51c0bd" xlink:to="loc_us-gaap_PendingLitigationMember_408ea93c-7186-4b9b-8325-681f08e80726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_7f6a33ff-a63a-44cb-98f4-9fe765055aea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_c1d3fa8a-efa1-4cfc-91b2-20931e4c2566" xlink:to="loc_us-gaap_OtherCommitmentsDomain_7f6a33ff-a63a-44cb-98f4-9fe765055aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ActivePharmaceuticalIngredientMember_5640d39f-c259-43da-98e9-c5f29e826762" xlink:href="gild-20201231.xsd#gild_ActivePharmaceuticalIngredientMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_7f6a33ff-a63a-44cb-98f4-9fe765055aea" xlink:to="loc_gild_ActivePharmaceuticalIngredientMember_5640d39f-c259-43da-98e9-c5f29e826762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_52b592db-bbdb-4101-b757-7734cc7ef8a0" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6082128b-b0b9-4fe1-88d0-b7ffbfa0f02a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6082128b-b0b9-4fe1-88d0-b7ffbfa0f02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMotionInvalidatedForPastDamagesValue_5de7b9dd-a30e-43e2-9157-f94d2496d2e6" xlink:href="gild-20201231.xsd#gild_LossContingencyMotionInvalidatedForPastDamagesValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyMotionInvalidatedForPastDamagesValue_5de7b9dd-a30e-43e2-9157-f94d2496d2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_8e389c63-eae2-48a2-ace9-dc75cf39d860" xlink:href="gild-20201231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_8e389c63-eae2-48a2-ace9-dc75cf39d860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesonPastSales_25b74c24-17af-4f0f-a561-700251626e9b" xlink:href="gild-20201231.xsd#gild_JudgmentEnhancedDamagesonPastSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_JudgmentEnhancedDamagesonPastSales_25b74c24-17af-4f0f-a561-700251626e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_dfc53fcf-d520-4be9-bdf7-e9780615b52d" xlink:href="gild-20201231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_dfc53fcf-d520-4be9-bdf7-e9780615b52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_bd857bb5-53bc-4e88-9f80-b7e56e7a7e88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_bd857bb5-53bc-4e88-9f80-b7e56e7a7e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLossPastSales_2ca32275-a5b4-4b63-9c6c-615f3e9bc9d7" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateofPossibleLossPastSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyEstimateofPossibleLossPastSales_2ca32275-a5b4-4b63-9c6c-615f3e9bc9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_78f24944-b33f-424b-b122-be43ac34d94f" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages_78f24944-b33f-424b-b122-be43ac34d94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_65640659-a0d2-4a5f-ade6-4615121af92a" xlink:href="gild-20201231.xsd#gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest_65640659-a0d2-4a5f-ade6-4615121af92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_cee5823b-440d-47d1-bed8-2287e438faa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_cee5823b-440d-47d1-bed8-2287e438faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_aea9b3ff-5df6-4e3b-a98c-e4034668d599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_aea9b3ff-5df6-4e3b-a98c-e4034668d599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_7eb2ae86-2c6e-4c15-9248-6ae874a98783" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_7eb2ae86-2c6e-4c15-9248-6ae874a98783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_2dfe75f0-c081-4b86-84a6-4a7096b3b9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_2dfe75f0-c081-4b86-84a6-4a7096b3b9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_89cdc798-ce87-4109-b713-5348f0277e19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_89cdc798-ce87-4109-b713-5348f0277e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_6619d784-eec6-41e1-80e2-53a6b102f9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_6619d784-eec6-41e1-80e2-53a6b102f9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_7545847e-44c1-4b0b-9b12-659a091133ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f5563cb5-ccca-4604-b47d-67f8f1cf8eb8" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_7545847e-44c1-4b0b-9b12-659a091133ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c63c11d0-23be-495a-afe4-761554c6819c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_db77df94-e66a-48b7-ac95-dcad2e028cee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c63c11d0-23be-495a-afe4-761554c6819c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_db77df94-e66a-48b7-ac95-dcad2e028cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f2c4ab47-684f-417b-9e83-7ad330147d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_4945343e-1431-4899-9afe-2997d6b3991d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f2c4ab47-684f-417b-9e83-7ad330147d91" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_4945343e-1431-4899-9afe-2997d6b3991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_700cd81c-e47d-47cc-b8bb-d29416e970c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f2c4ab47-684f-417b-9e83-7ad330147d91" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_700cd81c-e47d-47cc-b8bb-d29416e970c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6093c2d5-88e7-4fc1-833b-db763d3556f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f2c4ab47-684f-417b-9e83-7ad330147d91" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6093c2d5-88e7-4fc1-833b-db763d3556f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_StockRepurchasesAbstract_0b454fc6-2ee6-4902-8516-d56db12c4b5c" xlink:href="gild-20201231.xsd#gild_StockRepurchasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_StockRepurchasesAbstract_0b454fc6-2ee6-4902-8516-d56db12c4b5c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_887821f6-d84f-48fa-83bc-8bbeda9fb6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0bf1343e-d1e6-409e-8423-849e751fb4c8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_887821f6-d84f-48fa-83bc-8bbeda9fb6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_37177129-8fbd-416b-97ff-f97a0c6b7eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_887821f6-d84f-48fa-83bc-8bbeda9fb6d5" xlink:to="loc_us-gaap_SubsequentEventMember_37177129-8fbd-416b-97ff-f97a0c6b7eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_33fb4515-fc83-4585-95c1-2b9e8509a12f" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_8bcd10f0-422a-4ddd-a5db-cdf89db488f4" xlink:href="gild-20201231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_8bcd10f0-422a-4ddd-a5db-cdf89db488f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_cd3d9221-d10c-44aa-9bd2-222a9ade74ff" xlink:href="gild-20201231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_cd3d9221-d10c-44aa-9bd2-222a9ade74ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PubliclyAnnouncedProgramMember_063e39f8-30f4-4a96-b23d-f8955700befe" xlink:href="gild-20201231.xsd#gild_PubliclyAnnouncedProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_84d72d8c-78ea-47d8-88f3-6326307e104c" xlink:to="loc_gild_PubliclyAnnouncedProgramMember_063e39f8-30f4-4a96-b23d-f8955700befe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_66b1b2a9-c6ca-4f65-b36f-d2c101ff842f" xlink:to="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65fb24d9-075f-4b86-8a78-145e184f412b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_65fb24d9-075f-4b86-8a78-145e184f412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_fd5a2742-4115-4561-800f-4d19e2bf8282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_fd5a2742-4115-4561-800f-4d19e2bf8282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_064307b4-9436-47d7-82ed-ead995287892" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_064307b4-9436-47d7-82ed-ead995287892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4001ed08-01c1-454e-bf68-46ec215088be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4001ed08-01c1-454e-bf68-46ec215088be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2743c9d3-f684-47a4-9b11-9e3e57c89498" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ef21425e-0f8f-4796-a334-531e4188c2b3" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2743c9d3-f684-47a4-9b11-9e3e57c89498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAbstract_5a93ed4f-077d-42b1-b2d6-2c35f3904007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_5a93ed4f-077d-42b1-b2d6-2c35f3904007" xlink:to="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c507f898-28ac-41cf-a440-729d71249c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_02838bfe-6fe6-4972-9022-2de5b09148f2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c507f898-28ac-41cf-a440-729d71249c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2996e0d0-f14a-4ef3-96fc-2522453dff3d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c507f898-28ac-41cf-a440-729d71249c4b" xlink:to="loc_us-gaap_SubsequentEventMember_2996e0d0-f14a-4ef3-96fc-2522453dff3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b446e76e-d3d3-418c-9dac-94e14357827c" xlink:to="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_aba38248-39dc-4a96-ada2-7e7952639280" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_aba38248-39dc-4a96-ada2-7e7952639280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_03c47f30-aab3-4a67-919e-e7d2ecdedb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_07a6c00e-5b32-4f6a-9c67-4356417ac661" xlink:to="loc_us-gaap_DividendsCommonStockCash_03c47f30-aab3-4a67-919e-e7d2ecdedb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_afbcfd28-4053-4d57-80d2-3616e85a84ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_28617549-c7c4-415f-b694-fc7ed5e78c57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afbcfd28-4053-4d57-80d2-3616e85a84ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_28617549-c7c4-415f-b694-fc7ed5e78c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c8d97c68-5a33-4dd8-9dd2-df870bfd9629" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_afbcfd28-4053-4d57-80d2-3616e85a84ce" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c8d97c68-5a33-4dd8-9dd2-df870bfd9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c674be67-7f39-455c-a667-ac14863ffd08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c674be67-7f39-455c-a667-ac14863ffd08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f9ea97eb-024b-41a3-8794-ef406b1a291b" xlink:to="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_62bbfa3e-0ce1-4d33-82be-5c21ec7b5dee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_62bbfa3e-0ce1-4d33-82be-5c21ec7b5dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_91e7c676-8513-4453-9d6f-73ec1947bc20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_91e7c676-8513-4453-9d6f-73ec1947bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_850673eb-9ec8-49f0-87d6-83d149c5977b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_850673eb-9ec8-49f0-87d6-83d149c5977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3b423dd-0c64-4a39-b550-6dd44042c644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b7ef0acf-bbc7-43a3-be41-7dc7a68bfdb3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3b423dd-0c64-4a39-b550-6dd44042c644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9540feef-6ec2-4733-b6d8-6c0960e136b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_10b3ac73-ec16-43a6-ac2b-e634431e60dd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9540feef-6ec2-4733-b6d8-6c0960e136b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9540feef-6ec2-4733-b6d8-6c0960e136b7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_30af8c05-45f3-47fd-8941-cdc2aea24243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1_30af8c05-45f3-47fd-8941-cdc2aea24243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4efe1862-d251-4061-9925-b648cb202c28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4efe1862-d251-4061-9925-b648cb202c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a357d8cd-02af-481f-bd1f-cd6080bf9608" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a357d8cd-02af-481f-bd1f-cd6080bf9608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3349c832-f95a-4f9c-bede-0d0a0fe89935" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3349c832-f95a-4f9c-bede-0d0a0fe89935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7bb7dd46-1cc9-4ac2-acee-8615ee61ad00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7bb7dd46-1cc9-4ac2-acee-8615ee61ad00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb459249-1fc0-4d97-8d13-1b3fc2ecb1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff85cf18-d2c6-471a-ba7f-3d59c84e1e03" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb459249-1fc0-4d97-8d13-1b3fc2ecb1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_5db3973a-de33-4fdc-8ad5-1c52d4645f54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dc85b9d5-d37c-4deb-9b3e-cc1a040b79bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_5db3973a-de33-4fdc-8ad5-1c52d4645f54" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dc85b9d5-d37c-4deb-9b3e-cc1a040b79bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_8f76162a-69d5-4443-aafd-e28598e9d7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_96ca6380-a484-445a-adb8-da33135e56ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_8f76162a-69d5-4443-aafd-e28598e9d7f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_96ca6380-a484-445a-adb8-da33135e56ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_7c74fc84-cddb-4fd5-9487-5b0866a52ee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_8f76162a-69d5-4443-aafd-e28598e9d7f3" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_7c74fc84-cddb-4fd5-9487-5b0866a52ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a28219b2-0872-4084-8efb-e3cda4bf72a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_8f76162a-69d5-4443-aafd-e28598e9d7f3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a28219b2-0872-4084-8efb-e3cda4bf72a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1c7c13f6-5302-45fb-b4d6-451f5330ee77" xlink:href="gild-20201231.xsd#gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_8f76162a-69d5-4443-aafd-e28598e9d7f3" xlink:to="loc_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_1c7c13f6-5302-45fb-b4d6-451f5330ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f870bfd-b6bd-4077-8364-a4f05dfd65e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f870bfd-b6bd-4077-8364-a4f05dfd65e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:to="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2294da45-9db9-4a29-afce-6e12ce9f67b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_66697d36-0c6a-4d92-a356-e134f2fb8760" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2294da45-9db9-4a29-afce-6e12ce9f67b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ce3d73d5-753b-451f-b636-063f1dc5e17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2294da45-9db9-4a29-afce-6e12ce9f67b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ce3d73d5-753b-451f-b636-063f1dc5e17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a831404d-d026-49ac-9451-a8c99adf2ec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b9937fc-42ab-476e-b2b8-0b8a7bee5f23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b9937fc-42ab-476e-b2b8-0b8a7bee5f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb8f4605-d39e-4ca7-9472-873a2e0541ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bb8f4605-d39e-4ca7-9472-873a2e0541ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_956dc754-c3f1-4bcd-bf11-ba72a47bfdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_956dc754-c3f1-4bcd-bf11-ba72a47bfdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0b2be3e8-f936-4284-91c9-2240465e6dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0b2be3e8-f936-4284-91c9-2240465e6dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4a669cc0-b436-41a5-b63b-ac498da3293d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4a669cc0-b436-41a5-b63b-ac498da3293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79366731-044b-4e9e-87fe-51cbc479a547" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0a483833-d17b-465e-afba-adf13617edf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79366731-044b-4e9e-87fe-51cbc479a547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5448900-9060-43bc-a29d-47f7537069d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b5448900-9060-43bc-a29d-47f7537069d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f447379a-87d7-4f17-ae4e-bb13bc845313" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f447379a-87d7-4f17-ae4e-bb13bc845313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b1be798-09a8-4ae7-9a2b-85c9f5fc0c19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0b1be798-09a8-4ae7-9a2b-85c9f5fc0c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96650264-5e7e-4757-a28f-085a1b696b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_96650264-5e7e-4757-a28f-085a1b696b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5f9f6c79-8183-4652-a671-4f7a1aec03a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5f9f6c79-8183-4652-a671-4f7a1aec03a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_87fe2b74-50ee-49ec-80f3-620b53cd457b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_87fe2b74-50ee-49ec-80f3-620b53cd457b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01ad6c3e-791f-42b1-b25f-256cd653b6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_01ad6c3e-791f-42b1-b25f-256cd653b6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60e2329e-b601-4e07-a143-419fd0657336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_207898ee-057d-4bca-9470-89180c0b1c01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60e2329e-b601-4e07-a143-419fd0657336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_facfb68d-34dd-4fc7-9ebd-93ea3df5fa44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_facfb68d-34dd-4fc7-9ebd-93ea3df5fa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f4ca878-5982-41f5-8b88-6fd5f1b2379a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f4ca878-5982-41f5-8b88-6fd5f1b2379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd1dfefb-3ad6-4473-afb0-f556956462a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6689f831-e245-4bfd-955d-577c787466be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6689f831-e245-4bfd-955d-577c787466be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21244b38-21f4-4e36-b42f-1efdcbdf8d81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21244b38-21f4-4e36-b42f-1efdcbdf8d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6423674b-b6c5-4d03-8adc-83c207ece0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6423674b-b6c5-4d03-8adc-83c207ece0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_82de98cb-b597-4837-9580-7b60afaf8513" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_82de98cb-b597-4837-9580-7b60afaf8513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42d4cd9e-e343-4b7a-bf45-e81028833f31" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_42d4cd9e-e343-4b7a-bf45-e81028833f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2eec7e9f-a668-47e1-9241-d958068a57aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4b854315-086c-4bd9-80b1-3fd159442350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2eec7e9f-a668-47e1-9241-d958068a57aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0989282-3c3d-4310-9027-53a59515697a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0989282-3c3d-4310-9027-53a59515697a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:to="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_64dfd99b-dd3e-43ed-a31d-51624d173b53" xlink:to="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c0087bde-bbe5-4fdd-aa27-f8ab7b99c495" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:to="loc_srt_MinimumMember_c0087bde-bbe5-4fdd-aa27-f8ab7b99c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_255a3e9f-755d-49f2-b3a7-788025db6e91" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fc94ee0-efcf-4035-a95f-784e2421df10" xlink:to="loc_srt_MaximumMember_255a3e9f-755d-49f2-b3a7-788025db6e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:to="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a7c7f96b-5205-4abd-b382-9a2acace9657" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_da24b575-d32c-4790-95fa-3efbe940f053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:to="loc_us-gaap_PerformanceSharesMember_da24b575-d32c-4790-95fa-3efbe940f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_42417599-7762-442f-bd2b-31eac04417ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_42417599-7762-442f-bd2b-31eac04417ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember_c7fca1ae-6652-4d2a-b72f-d36b74491af0" xlink:href="gild-20201231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3aae8f2-761f-4c5a-8829-46d53796d036" xlink:to="loc_gild_RestrictedStockandPerformanceShareAwardsMember_c7fca1ae-6652-4d2a-b72f-d36b74491af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4f48437-6bfd-4d6c-8cea-64446013e173" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_633cfd7e-8077-4fe4-9c3d-eec4d9db05ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_633cfd7e-8077-4fe4-9c3d-eec4d9db05ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_777c2db4-7ef4-4818-83a1-83e6ab0e50b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_777c2db4-7ef4-4818-83a1-83e6ab0e50b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6ea684e-d67f-474b-9285-dea2f63ed100" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6ea684e-d67f-474b-9285-dea2f63ed100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afbd0707-ef25-4860-94a8-4cf95116abba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_afbd0707-ef25-4860-94a8-4cf95116abba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf32f905-dd3b-4d2a-8ce5-4459ec11b858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf32f905-dd3b-4d2a-8ce5-4459ec11b858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2237bef-43b8-44db-af11-5254ada054f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8bb2d653-2f62-4149-a768-37d8692c431b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2237bef-43b8-44db-af11-5254ada054f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_455aabd2-5b98-4a4d-a49a-2662a72093e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_455aabd2-5b98-4a4d-a49a-2662a72093e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_672c0ef4-654a-4649-b25f-ed7346e9428c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_672c0ef4-654a-4649-b25f-ed7346e9428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f199c584-a93c-4d8e-92f6-1b3534e7897d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f199c584-a93c-4d8e-92f6-1b3534e7897d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b4ac426-b208-4b34-a3ff-b9c809ce5212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4b4ac426-b208-4b34-a3ff-b9c809ce5212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e64e9ff-9b44-4476-9d39-a06f0a1c9bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ea235fec-3c64-44d0-b3f1-66cb98b8061e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e64e9ff-9b44-4476-9d39-a06f0a1c9bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_f1516210-f5a7-4715-a98c-89e8155cf518" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_f1516210-f5a7-4715-a98c-89e8155cf518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_98fffff5-e622-491f-ad3c-072344b4f4b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_442c0da1-43b2-4593-b432-09489da9853f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_98fffff5-e622-491f-ad3c-072344b4f4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_73428d1c-e20a-4756-b72e-4fc086fc9767" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_73428d1c-e20a-4756-b72e-4fc086fc9767" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2c7fe93e-78b3-4ddf-a6fd-3b0edb990ec9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_babb5c50-b22a-4b1b-af7e-0bc910af39d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:to="loc_us-gaap_CostOfSalesMember_babb5c50-b22a-4b1b-af7e-0bc910af39d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f58af20-9e70-4f31-bcf0-9061f10d978f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f58af20-9e70-4f31-bcf0-9061f10d978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_760104a4-ed3a-413a-bb18-a46401825bee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_98c3ab55-0a24-4049-9002-ff40d03800b1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_760104a4-ed3a-413a-bb18-a46401825bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_218bce5b-5087-4774-b9a4-cbf37674113b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9cc6a5d7-62c8-4c40-ade6-4ed7137adb1d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_218bce5b-5087-4774-b9a4-cbf37674113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_8f136475-fc0d-46f9-9632-46f338a6ede3" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_218bce5b-5087-4774-b9a4-cbf37674113b" xlink:to="loc_gild_ImmunomedicsIncMember_8f136475-fc0d-46f9-9632-46f338a6ede3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_65bc066f-bd58-466d-90f6-b3e467293a80" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AssetAcquisitionAxis_47892b18-56ed-4546-994e-430c0f9954fa" xlink:to="loc_gild_AssetAcquisitionDomain_65bc066f-bd58-466d-90f6-b3e467293a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_bd47a989-9e35-412b-aac9-8822365404ed" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AssetAcquisitionDomain_65bc066f-bd58-466d-90f6-b3e467293a80" xlink:to="loc_gild_FortySevenIncMember_bd47a989-9e35-412b-aac9-8822365404ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d0dac000-9baf-4b6d-bf5b-1f50ccc7e772" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_de69c1c0-6fff-43a9-96fc-295c7fd993df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_de69c1c0-6fff-43a9-96fc-295c7fd993df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a6d4f2a0-6813-4701-8f2c-2499201526fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a6d4f2a0-6813-4701-8f2c-2499201526fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_af25ed75-eaa1-41ff-889a-9dbb0a508b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_af25ed75-eaa1-41ff-889a-9dbb0a508b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fd5b2a04-de14-4ca0-90ff-5c087483e6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_ShareBasedCompensation_fd5b2a04-de14-4ca0-90ff-5c087483e6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_09f3bed3-1f75-418d-a292-0c2dd5339a85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_09f3bed3-1f75-418d-a292-0c2dd5339a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_1248c105-c2f0-4757-b4bf-48da077c5326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_647035aa-f52d-42e5-863a-2e08e26c1086" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_1248c105-c2f0-4757-b4bf-48da077c5326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_28288cbb-4d13-4126-8cac-63e1e7f1ded4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_28288cbb-4d13-4126-8cac-63e1e7f1ded4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:to="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5dcebfb-1fc3-400c-8844-b8c8772a1c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_463fd23b-1b73-4d29-997e-7df1e3b23fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_463fd23b-1b73-4d29-997e-7df1e3b23fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c15b707d-1c05-4fd5-8e28-4aee923a5d11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_901c0430-4b42-4c41-9ad0-915dd1f0e3b5" xlink:to="loc_us-gaap_EmployeeStockMember_c15b707d-1c05-4fd5-8e28-4aee923a5d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4956858a-0aa0-43d4-ad14-a9366b98f2cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8bc93963-bb2d-4708-86bd-cef5db0d7cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8bc93963-bb2d-4708-86bd-cef5db0d7cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_058f436c-c4f7-44b0-9fe7-407496db7a71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_058f436c-c4f7-44b0-9fe7-407496db7a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9a296b3e-e19c-4ff6-b2d9-d448d67b7bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9a296b3e-e19c-4ff6-b2d9-d448d67b7bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d810ab21-60d0-487a-9148-743a33880d24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_36bd1aef-ae37-42cc-86c2-b4c3d4c4e905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d810ab21-60d0-487a-9148-743a33880d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cd5737b-bc42-4ce6-9e07-505b704b75d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9cd5737b-bc42-4ce6-9e07-505b704b75d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:href="gild-20201231.xsd#gild_TotalFairValueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:href="gild-20201231.xsd#gild_TotalGrantDateFairValueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_TotalFairValueAxis_201f6998-d6f2-4bcb-9425-c906e6d2b954" xlink:to="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatGrantDateMember_3aa35cf6-68aa-46f9-b4a0-b5d0c8ef08cf" xlink:href="gild-20201231.xsd#gild_FairValueatGrantDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:to="loc_gild_FairValueatGrantDateMember_3aa35cf6-68aa-46f9-b4a0-b5d0c8ef08cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueatVestingDateMember_5f6f7c46-a1dc-4547-baf4-6093a76fc734" xlink:href="gild-20201231.xsd#gild_FairValueatVestingDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_TotalGrantDateFairValueDomain_f63e6bfa-367a-4265-bc5a-f4787c5e7fb1" xlink:to="loc_gild_FairValueatVestingDateMember_5f6f7c46-a1dc-4547-baf4-6093a76fc734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f7b78f8a-db98-4b42-b0bd-98c8488ccf21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9e92b1f8-b7da-47fd-b0fc-378ccb1e4dde" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f7b78f8a-db98-4b42-b0bd-98c8488ccf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_a24f6908-362d-4646-abdb-d0dcce96b55d" xlink:href="gild-20201231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f7b78f8a-db98-4b42-b0bd-98c8488ccf21" xlink:to="loc_gild_DeferredCompensationPlanMember_a24f6908-362d-4646-abdb-d0dcce96b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670b7518-275d-4885-9aec-c9705e44cd98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_26718ef3-d714-40f2-9f3e-7ddd7e20df66" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670b7518-275d-4885-9aec-c9705e44cd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dc6f8656-c136-46f2-80bc-c601db46cd53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670b7518-275d-4885-9aec-c9705e44cd98" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dc6f8656-c136-46f2-80bc-c601db46cd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6328fc5-4396-4889-ba60-34dddf56d228" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13de4988-e095-41ab-a989-97af4027558f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6328fc5-4396-4889-ba60-34dddf56d228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_89da4f19-3f59-421b-858f-25e4d72d76e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6328fc5-4396-4889-ba60-34dddf56d228" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_89da4f19-3f59-421b-858f-25e4d72d76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6c82c303-c5e7-4397-87b9-e14aa57b2ecb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f8cfdba7-96b9-4e62-8d18-c9dcd81fcd2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f8cfdba7-96b9-4e62-8d18-c9dcd81fcd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6216b0d9-518b-46a3-b68d-7c9fff4da8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6216b0d9-518b-46a3-b68d-7c9fff4da8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3815c184-22e9-40bf-90db-5987ad577637" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_PerformanceSharesMember_3815c184-22e9-40bf-90db-5987ad577637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RestrictedStockandPerformanceShareAwardsMember_277243c1-a375-423e-b280-949702ea4f9d" xlink:href="gild-20201231.xsd#gild_RestrictedStockandPerformanceShareAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_gild_RestrictedStockandPerformanceShareAwardsMember_277243c1-a375-423e-b280-949702ea4f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_b7674f52-538f-4ff6-a9d4-5899cd1e964b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7be80ea9-11a4-448c-9bf8-c0e42e977919" xlink:to="loc_us-gaap_EmployeeStockMember_b7674f52-538f-4ff6-a9d4-5899cd1e964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e959e9e0-874c-4f76-a886-b2338b583c19" xlink:to="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b5ae760b-20d6-472d-a94b-57462423c879" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:to="loc_srt_MinimumMember_b5ae760b-20d6-472d-a94b-57462423c879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6de94285-5e29-4d59-80b2-ce7c16133791" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_12dabcf2-1c33-478f-978b-51a454f9121c" xlink:to="loc_srt_MaximumMember_6de94285-5e29-4d59-80b2-ce7c16133791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7d1def92-632a-4a47-8f79-90487d8eccaf" xlink:to="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_e968102c-c764-4016-bedb-7387bb2ea403" xlink:href="gild-20201231.xsd#gild_GileadSciencesInc2004EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:to="loc_gild_GileadSciencesInc2004EquityIncentivePlanMember_e968102c-c764-4016-bedb-7387bb2ea403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_42162efc-eaca-43a3-b1f8-82b8d62b9c41" xlink:href="gild-20201231.xsd#gild_GileadSciencesInc2018EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:to="loc_gild_GileadSciencesInc2018EquityIncentivePlanMember_42162efc-eaca-43a3-b1f8-82b8d62b9c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_2aceaed1-2ffe-4dcc-b217-d629f7147c34" xlink:href="gild-20201231.xsd#gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e5b59688-dd48-4fab-8dd1-c5f9ab00c1dc" xlink:to="loc_gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember_2aceaed1-2ffe-4dcc-b217-d629f7147c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef23b67d-8489-481b-afc0-799b3744ffd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86b5d76b-f21c-431e-b915-d508da92ed88" xlink:to="loc_us-gaap_ClassOfStockDomain_ef23b67d-8489-481b-afc0-799b3744ffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b42376ac-227a-4f75-91c1-af680326caef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ef23b67d-8489-481b-afc0-799b3744ffd3" xlink:to="loc_us-gaap_CommonStockMember_b42376ac-227a-4f75-91c1-af680326caef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2076187-c032-4338-95cb-0469271840be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e37cd14c-258c-408d-b572-6436639e654d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e37cd14c-258c-408d-b572-6436639e654d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f52e43c2-5594-4021-9628-acd46f16718e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f52e43c2-5594-4021-9628-acd46f16718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9ac99fad-1d09-4c55-91d3-866f09bcd713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9ac99fad-1d09-4c55-91d3-866f09bcd713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f17875e-2d6b-46ea-a95a-573c7b9ef742" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f17875e-2d6b-46ea-a95a-573c7b9ef742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_67f43362-edca-492c-9ca8-f0d753251d74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_67f43362-edca-492c-9ca8-f0d753251d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_16fd2a66-3f12-4702-bb9d-f4312b4668e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_16fd2a66-3f12-4702-bb9d-f4312b4668e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_06b26cdc-7d02-4b41-b08d-d6c882346911" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_06b26cdc-7d02-4b41-b08d-d6c882346911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e094123a-204f-48f6-ab80-e3cfaa015854" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e094123a-204f-48f6-ab80-e3cfaa015854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_885b6059-7c0f-4df3-936f-c3f23238c4c3" xlink:href="gild-20201231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_885b6059-7c0f-4df3-936f-c3f23238c4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e89f08c2-52d1-4a27-9450-692b7d5a7279" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e89f08c2-52d1-4a27-9450-692b7d5a7279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_009f2e72-0d88-4fa4-a41d-a79c78d04932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_009f2e72-0d88-4fa4-a41d-a79c78d04932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3953a73c-dfca-4594-aefe-e30423658cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3953a73c-dfca-4594-aefe-e30423658cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5231e5b9-ac4c-44d2-bd0d-835f06c7489e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5231e5b9-ac4c-44d2-bd0d-835f06c7489e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d04de5d3-8fdd-4485-a194-63f91f69b75d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d04de5d3-8fdd-4485-a194-63f91f69b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3083f51e-60c5-4ef3-8980-379db080fd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3083f51e-60c5-4ef3-8980-379db080fd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f5b436b2-c67e-4474-9e7b-6f603c20dc35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f5b436b2-c67e-4474-9e7b-6f603c20dc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_3da6445f-bbb6-4c11-a6e2-2418833e8910" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_3da6445f-bbb6-4c11-a6e2-2418833e8910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b8f0b4df-f9bf-48cc-ab25-3ebc685c2eed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50f63b7b-a52a-426c-8d49-c85009980d03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b8f0b4df-f9bf-48cc-ab25-3ebc685c2eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholders"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4069150a-64c4-4d99-8dce-3952f9f867fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3aae9367-7eb8-4fa4-aad8-53585a89423b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4069150a-64c4-4d99-8dce-3952f9f867fe" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3aae9367-7eb8-4fa4-aad8-53585a89423b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_53e7ef02-e2e2-4a41-ad6c-ba116de878f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_12f581ef-c0f8-4fcd-8c81-8ea5b743ac79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53e7ef02-e2e2-4a41-ad6c-ba116de878f0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_12f581ef-c0f8-4fcd-8c81-8ea5b743ac79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_363a1d48-5855-4bbd-9195-de2afef2b96c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e5b4b713-c84e-4e7e-a8cb-b7494f1f9852" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_363a1d48-5855-4bbd-9195-de2afef2b96c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e5b4b713-c84e-4e7e-a8cb-b7494f1f9852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_859ce9b8-e5f6-44fc-9cf7-b7c38c7e5fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:to="loc_us-gaap_NetIncomeLoss_859ce9b8-e5f6-44fc-9cf7-b7c38c7e5fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1f6d225-56b1-4013-9c2d-432cb4593085" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1f6d225-56b1-4013-9c2d-432cb4593085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5a80a02a-7cda-419b-9800-b5507d659f26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5a80a02a-7cda-419b-9800-b5507d659f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_715f5b26-408d-4425-b032-aadbf7676df3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_715f5b26-408d-4425-b032-aadbf7676df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e6b7c885-dd88-419b-b639-6fb728ad57dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:to="loc_us-gaap_EarningsPerShareBasic_e6b7c885-dd88-419b-b639-6fb728ad57dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_43fabf36-c139-47ae-9a9a-cf972559467b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0db47800-9548-45e8-bc81-a490db66b42f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_43fabf36-c139-47ae-9a9a-cf972559467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_626ebe15-abb7-4cc5-97fa-eb22b01eeee9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_984b891d-a5cc-4baa-a518-6d288e0ed2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_626ebe15-abb7-4cc5-97fa-eb22b01eeee9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_984b891d-a5cc-4baa-a518-6d288e0ed2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_da59df2b-9e21-4f9f-909b-45a2eb276b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e442f417-5234-4a40-a567-3b034e6cb56a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da59df2b-9e21-4f9f-909b-45a2eb276b3b" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e442f417-5234-4a40-a567-3b034e6cb56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8e00e1c6-7a5a-44f0-836b-47aa695071d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da59df2b-9e21-4f9f-909b-45a2eb276b3b" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8e00e1c6-7a5a-44f0-836b-47aa695071d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_050b3da9-9a72-44dd-a52b-0ca34174548d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da59df2b-9e21-4f9f-909b-45a2eb276b3b" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_050b3da9-9a72-44dd-a52b-0ca34174548d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a5495003-2d23-48e5-91e8-3daccb17ee3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da59df2b-9e21-4f9f-909b-45a2eb276b3b" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a5495003-2d23-48e5-91e8-3daccb17ee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ff88ad51-a91f-4055-995a-85c156ebf08f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da59df2b-9e21-4f9f-909b-45a2eb276b3b" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ff88ad51-a91f-4055-995a-85c156ebf08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93ef2f1e-ebfa-49b0-871b-413c900965e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_24230c7a-9750-42d8-8b5b-4bb9e0ecfcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93ef2f1e-ebfa-49b0-871b-413c900965e4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_24230c7a-9750-42d8-8b5b-4bb9e0ecfcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ac14f26b-cf5e-4837-a4c4-518f0941c6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93ef2f1e-ebfa-49b0-871b-413c900965e4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ac14f26b-cf5e-4837-a4c4-518f0941c6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_70038805-9655-457c-bf3d-e16ac5d8e1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93ef2f1e-ebfa-49b0-871b-413c900965e4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_70038805-9655-457c-bf3d-e16ac5d8e1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_37c5046a-7c10-4d91-bd1e-67db9eadd61a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_37c5046a-7c10-4d91-bd1e-67db9eadd61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5dac4539-23a0-4e81-8fab-428450fbd2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5dac4539-23a0-4e81-8fab-428450fbd2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_018cee05-fa35-4d40-b599-cbfb978a0c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_018cee05-fa35-4d40-b599-cbfb978a0c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ed08937-4b98-4f96-a168-7c25cff1baa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ed08937-4b98-4f96-a168-7c25cff1baa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3dfbb7fb-3e26-45a1-b98c-40d92b3cd9d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3dfbb7fb-3e26-45a1-b98c-40d92b3cd9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_0041fd25-51fd-4e27-ac3b-1b35ddae587b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_0041fd25-51fd-4e27-ac3b-1b35ddae587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_27865f64-a056-412e-8614-9011b0ce53e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_27865f64-a056-412e-8614-9011b0ce53e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1ceeae74-d47c-4ef1-a2a9-afc87a836513" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1ceeae74-d47c-4ef1-a2a9-afc87a836513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_5065ebe7-d438-4694-8215-0bebcafec0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_5065ebe7-d438-4694-8215-0bebcafec0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b35485dd-dc06-402f-b964-d26a337308b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_d249b434-a42f-4303-943f-f9bb32acc2a0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b35485dd-dc06-402f-b964-d26a337308b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0f8b25f6-3170-4405-83a3-1d05c384f92b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0f8b25f6-3170-4405-83a3-1d05c384f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f44d4594-0745-45a7-959e-1c16e45e974c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f44d4594-0745-45a7-959e-1c16e45e974c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_34daf52e-6c46-4b87-b2ee-f725ae2474af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_34daf52e-6c46-4b87-b2ee-f725ae2474af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f39eaedf-a251-470f-abf9-7cbb6999e075" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f39eaedf-a251-470f-abf9-7cbb6999e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_c084a31b-3972-4dff-b408-0c785cb05869" xlink:href="gild-20201231.xsd#gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings_c084a31b-3972-4dff-b408-0c785cb05869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_e44658ed-78fd-481d-b140-03a81d77f0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_e44658ed-78fd-481d-b140-03a81d77f0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_230e67ba-a0b8-429a-9b79-45f01238b277" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_230e67ba-a0b8-429a-9b79-45f01238b277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dc714769-b196-451b-85d1-72967d2e8c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dc714769-b196-451b-85d1-72967d2e8c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2a145b73-c32f-4a37-b705-228d5f5591c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2a145b73-c32f-4a37-b705-228d5f5591c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_7c4e13e4-2494-4c15-ac36-c3af9fd1ebf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_7c4e13e4-2494-4c15-ac36-c3af9fd1ebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8964b25e-68ed-4408-a6ed-f97e6d55c4c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_8964b25e-68ed-4408-a6ed-f97e6d55c4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a4675c-54ae-4b43-851b-228c2939c0af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_183ce44a-5524-4fb2-a393-4253a0f4141f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a4675c-54ae-4b43-851b-228c2939c0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_845938c6-d760-4181-a8d1-ede9a8f75251" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845938c6-d760-4181-a8d1-ede9a8f75251" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0cbdd9ca-f2c7-4c8b-a2f0-78433aac784e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0cbdd9ca-f2c7-4c8b-a2f0-78433aac784e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0048326e-cfca-420f-9292-75e3542b6ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0048326e-cfca-420f-9292-75e3542b6ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_e50337b9-8d8c-4055-9d81-5f0b35360cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_e50337b9-8d8c-4055-9d81-5f0b35360cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b15b0af1-8e0e-439e-828c-95e6e2ba26ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b15b0af1-8e0e-439e-828c-95e6e2ba26ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_55666d73-45b3-421e-8ff2-b0b296880d7a" xlink:href="gild-20201231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_55666d73-45b3-421e-8ff2-b0b296880d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_204ddb81-50da-4b57-9025-aba8fa21cc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_204ddb81-50da-4b57-9025-aba8fa21cc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_32ec9817-fe70-45ac-8156-f9b183b4a8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_32ec9817-fe70-45ac-8156-f9b183b4a8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_6d5ea07d-a073-4969-a1ed-94b5e75309b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_6d5ea07d-a073-4969-a1ed-94b5e75309b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_75c4db26-791e-4beb-a6b6-e11fe5f26347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_75c4db26-791e-4beb-a6b6-e11fe5f26347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0baf6102-2920-459f-a37c-1695c1fb2913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0baf6102-2920-459f-a37c-1695c1fb2913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b84dc1d4-c132-4430-b7e9-69c797b8300b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b84dc1d4-c132-4430-b7e9-69c797b8300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5d0d657a-e1ad-4aa0-856b-960be0b5e30a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bcf383be-784f-42fc-9747-ff5655c8c5d0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5d0d657a-e1ad-4aa0-856b-960be0b5e30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e7fa417b-9633-48b3-9c21-9e087bd915b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845938c6-d760-4181-a8d1-ede9a8f75251" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e7fa417b-9633-48b3-9c21-9e087bd915b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f310471e-ab69-4fa0-92e0-a294da8a247e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e7fa417b-9633-48b3-9c21-9e087bd915b6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f310471e-ab69-4fa0-92e0-a294da8a247e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_08d1bf3b-436e-4a8a-bd2f-2d9d2a16572a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e7fa417b-9633-48b3-9c21-9e087bd915b6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_08d1bf3b-436e-4a8a-bd2f-2d9d2a16572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d0f032a7-c78f-4610-8935-01560113261d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e7fa417b-9633-48b3-9c21-9e087bd915b6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d0f032a7-c78f-4610-8935-01560113261d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f18f0803-29d9-4075-b462-25d183b5c7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_e7fa417b-9633-48b3-9c21-9e087bd915b6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f18f0803-29d9-4075-b462-25d183b5c7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d5b993d5-9a4a-4ad7-9916-51af7def4510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845938c6-d760-4181-a8d1-ede9a8f75251" xlink:to="loc_us-gaap_DeferredTaxLiabilities_d5b993d5-9a4a-4ad7-9916-51af7def4510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6180cce0-bf26-40c3-a13e-9f2ff2ed53ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_845938c6-d760-4181-a8d1-ede9a8f75251" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_6180cce0-bf26-40c3-a13e-9f2ff2ed53ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ba186b86-91e1-4246-9295-b235ca80c2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ba186b86-91e1-4246-9295-b235ca80c2a3" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f2575d70-b8d5-4b0b-9e35-bdb4b0922e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f2575d70-b8d5-4b0b-9e35-bdb4b0922e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4940bb1d-409e-47ab-8815-ada7bbec3d33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4940bb1d-409e-47ab-8815-ada7bbec3d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_34481bc9-28c3-4829-8b0f-3ecd54e7e37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_34481bc9-28c3-4829-8b0f-3ecd54e7e37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_700f5490-e107-46b2-92ed-370d0861f56f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_700f5490-e107-46b2-92ed-370d0861f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_41a0d952-a4ce-4f51-8010-d04521af4c3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_41a0d952-a4ce-4f51-8010-d04521af4c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_cb9ce969-def9-48b0-83b4-73952cd64279" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_cb9ce969-def9-48b0-83b4-73952cd64279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_694fa80e-fa98-4694-b4a7-33793e88a3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_694fa80e-fa98-4694-b4a7-33793e88a3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e4dd28c4-9954-4053-bd2d-ae8f5ce38e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3dd73c35-ab4f-4345-ab75-6bae2334a86c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e4dd28c4-9954-4053-bd2d-ae8f5ce38e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ef6fa181-7cfd-425a-9375-0b1dab4fe4c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ef6fa181-7cfd-425a-9375-0b1dab4fe4c2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_2814bb5e-8ef7-4632-a596-b78e98bd1a37" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_53498ec0-7ea3-438b-a7f6-002e7282df49" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_2814bb5e-8ef7-4632-a596-b78e98bd1a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_60d5fba1-0e40-431d-ba1a-2ff89bd3ca17" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_2814bb5e-8ef7-4632-a596-b78e98bd1a37" xlink:to="loc_gild_IntangibleAssetTransferMember_60d5fba1-0e40-431d-ba1a-2ff89bd3ca17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_193be21e-c264-491f-95e9-1709512f6c73" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a9e5dabc-453f-4b87-9099-4c9f6721b2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:to="loc_us-gaap_DomesticCountryMember_a9e5dabc-453f-4b87-9099-4c9f6721b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a67f57fd-5e0a-40d2-8455-4927f59c69a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5a9aaa7e-ee69-4d52-b919-18ad702f0470" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a67f57fd-5e0a-40d2-8455-4927f59c69a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_fe151c7c-fb90-4d66-9086-ddd71ae8bc8b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2f994e80-100b-4985-9b28-3788f53832a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2f994e80-100b-4985-9b28-3788f53832a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4b4ab7df-6d9e-4224-9b88-ad1ec411e9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4b4ab7df-6d9e-4224-9b88-ad1ec411e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_abcc9540-6a92-4764-8f5e-64d7e14f3d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_abcc9540-6a92-4764-8f5e-64d7e14f3d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_47c37ded-d72c-4496-b432-2e065ac197b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_47c37ded-d72c-4496-b432-2e065ac197b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c6cbacf4-1ab3-4dba-a2ec-bf4e7421d7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c6cbacf4-1ab3-4dba-a2ec-bf4e7421d7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_13d90a65-e104-475b-8d20-caa5b1d85200" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_13d90a65-e104-475b-8d20-caa5b1d85200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_8eb498af-cece-4acf-adb2-da114bfb6948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_8eb498af-cece-4acf-adb2-da114bfb6948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_57aed4a7-9c2d-4a10-a184-6e1637a9b7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_57aed4a7-9c2d-4a10-a184-6e1637a9b7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e48338c1-2fbc-4dd0-b5b3-b4f729678a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e48338c1-2fbc-4dd0-b5b3-b4f729678a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ad9937be-874c-4af8-893a-be618b6bde39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ad9937be-874c-4af8-893a-be618b6bde39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6a35a745-8a78-4c55-9a15-796d9fa35cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_da94c3a5-dec2-47ca-9ab2-5ffe8a0eae6d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6a35a745-8a78-4c55-9a15-796d9fa35cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_2317bb8e-ec64-4a85-9ee3-1565f2473f64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1fee8d45-7661-4be0-b9d4-d3d832a4d966" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_2317bb8e-ec64-4a85-9ee3-1565f2473f64" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1fee8d45-7661-4be0-b9d4-d3d832a4d966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_b1e8d4a4-9a15-41f4-bbb7-36c8f601b366" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b7942c35-e07c-4902-84c0-516421ef8437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_b1e8d4a4-9a15-41f4-bbb7-36c8f601b366" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_b7942c35-e07c-4902-84c0-516421ef8437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="gild-20201231.xsd#SelectedQuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_5b84e406-c1f3-47c9-b9c2-7433bf90a011" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:href="gild-20201231.xsd#gild_SelectedQuarterlyFinancialInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_5b84e406-c1f3-47c9-b9c2-7433bf90a011" xlink:to="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AssetAcquisitionDomain_593883b4-d7a9-4b53-96c4-eefcd289c533" xlink:href="gild-20201231.xsd#gild_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AssetAcquisitionAxis_485ddb21-3ea1-41d3-8f7d-6da9250bedb8" xlink:to="loc_gild_AssetAcquisitionDomain_593883b4-d7a9-4b53-96c4-eefcd289c533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_4beb9cd5-b711-45e1-9e4a-eb2a71132bd7" xlink:href="gild-20201231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AssetAcquisitionDomain_593883b4-d7a9-4b53-96c4-eefcd289c533" xlink:to="loc_gild_FortySevenIncMember_4beb9cd5-b711-45e1-9e4a-eb2a71132bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7014f29b-9865-4d65-801d-6b0897a4a539" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f7b76980-e13e-4486-bcd7-3edf18ec10f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7014f29b-9865-4d65-801d-6b0897a4a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_a3d8cb75-a865-49f4-8482-de3afa56cf06" xlink:href="gild-20201231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7014f29b-9865-4d65-801d-6b0897a4a539" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_a3d8cb75-a865-49f4-8482-de3afa56cf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eee597de-0565-4861-965e-1b46ab7f0a96" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_9c6eb00b-454c-44c8-bf5d-90f651fb71b7" xlink:href="gild-20201231.xsd#gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:to="loc_gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember_9c6eb00b-454c-44c8-bf5d-90f651fb71b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_d43319a3-f005-474f-8024-be95a4b37af5" xlink:href="gild-20201231.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ef2b1673-3d89-48c0-a25c-723fbbe6c2ee" xlink:to="loc_gild_GalapagosMember_d43319a3-f005-474f-8024-be95a4b37af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c0e7734-c526-4b80-b79f-6ce6b5c9fe7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6905dd3f-ff22-40e5-aa9e-d7b33b795c96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c0e7734-c526-4b80-b79f-6ce6b5c9fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_3b6fc3d5-9d0a-413d-b223-e89f779a5bf1" xlink:href="gild-20201231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c0e7734-c526-4b80-b79f-6ce6b5c9fe7d" xlink:to="loc_gild_ImmunomedicsIncMember_3b6fc3d5-9d0a-413d-b223-e89f779a5bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_1fe0a33a-8a40-4880-ab4d-0c22938e130c" xlink:href="gild-20201231.xsd#gild_DeferredIncomeTaxExpenseBenefitComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentAxis_a4ed276f-24af-48a6-b601-7e03517e3850" xlink:to="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_1fe0a33a-8a40-4880-ab4d-0c22938e130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_2ea2dd6f-c16f-40d3-99b1-c1307969609d" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_DeferredIncomeTaxExpenseBenefitComponentDomain_1fe0a33a-8a40-4880-ab4d-0c22938e130c" xlink:to="loc_gild_IntangibleAssetTransferMember_2ea2dd6f-c16f-40d3-99b1-c1307969609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrealizedGainComponentDomain_45a3fd2e-359c-4d6e-afcb-a413cb9962ae" xlink:href="gild-20201231.xsd#gild_UnrealizedGainComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrealizedGainComponentAxis_a1894f0f-4b85-4b70-831f-117b5eeaee95" xlink:to="loc_gild_UnrealizedGainComponentDomain_45a3fd2e-359c-4d6e-afcb-a413cb9962ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetTransferMember_c92e51c7-7706-4752-9b4c-f82086c56a8a" xlink:href="gild-20201231.xsd#gild_IntangibleAssetTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrealizedGainComponentDomain_45a3fd2e-359c-4d6e-afcb-a413cb9962ae" xlink:to="loc_gild_IntangibleAssetTransferMember_c92e51c7-7706-4752-9b4c-f82086c56a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a3ce4e27-af77-4f9c-a73e-221e5cd50035" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_2ce4a009-fa48-4b01-af47-04efef9ba6eb" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a3ce4e27-af77-4f9c-a73e-221e5cd50035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_1831b637-36b6-44a6-9fb0-f7e4a699db0e" xlink:href="gild-20201231.xsd#gild_InventoryWritedownsforExcessRawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a3ce4e27-af77-4f9c-a73e-221e5cd50035" xlink:to="loc_gild_InventoryWritedownsforExcessRawMaterialsMember_1831b637-36b6-44a6-9fb0-f7e4a699db0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EPSImpactbyTransactionDomain_424d841b-a102-496b-8388-311d967d273a" xlink:href="gild-20201231.xsd#gild_EPSImpactbyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_EPSImpactbyTransactionAxis_754133a1-65e0-4263-8e29-c0498e6d0ccb" xlink:to="loc_gild_EPSImpactbyTransactionDomain_424d841b-a102-496b-8388-311d967d273a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FavorableEPSImpactMember_08fa2190-848c-4403-8dcf-4ac74081a5d7" xlink:href="gild-20201231.xsd#gild_FavorableEPSImpactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_EPSImpactbyTransactionDomain_424d841b-a102-496b-8388-311d967d273a" xlink:to="loc_gild_FavorableEPSImpactMember_08fa2190-848c-4403-8dcf-4ac74081a5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:href="gild-20201231.xsd#gild_SelectedQuarterlyFinancialInformationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationTable_b51a0970-9d5e-40ec-b49f-482343f51a57" xlink:to="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_69a10312-b11a-45a9-8030-c44e142f15d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_Revenues_69a10312-b11a-45a9-8030-c44e142f15d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_53381454-0b45-44d3-9bcb-d5380b88d87a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_GrossProfit_53381454-0b45-44d3-9bcb-d5380b88d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_28c3eeb5-a101-4ff0-be05-0042245313df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_ProfitLoss_28c3eeb5-a101-4ff0-be05-0042245313df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33fee853-34ea-42f9-9cb9-8d84650fd47a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_NetIncomeLoss_33fee853-34ea-42f9-9cb9-8d84650fd47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_034c0bac-b36e-4db7-b1ce-77d4906557d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EarningsPerShareBasic_034c0bac-b36e-4db7-b1ce-77d4906557d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c491d5a7-1c69-44a3-a2a7-40e8239d650e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c491d5a7-1c69-44a3-a2a7-40e8239d650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_375ca4e5-8ea5-4986-8957-55761bec8529" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_375ca4e5-8ea5-4986-8957-55761bec8529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_97ccbfa2-3c7e-4262-ada9-08272888b78c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_97ccbfa2-3c7e-4262-ada9-08272888b78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f7096ea4-8ec5-4941-98f2-7cfcdd8be70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f7096ea4-8ec5-4941-98f2-7cfcdd8be70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_061911e5-fba1-4ec5-8c9c-41dfd5d7ef26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_061911e5-fba1-4ec5-8c9c-41dfd5d7ef26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_ea267d10-4751-463d-8efd-3a5c778d439b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_ea267d10-4751-463d-8efd-3a5c778d439b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e570ea6f-7783-417b-befc-a9ec3528fa59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e570ea6f-7783-417b-befc-a9ec3528fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_9efcb9c7-b0e7-4032-9567-6d4399a59468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SelectedQuarterlyFinancialInformationLineItems_ee6d721f-ad24-42f5-8892-476e9d5cb4b9" xlink:to="loc_us-gaap_InventoryWriteDown_9efcb9c7-b0e7-4032-9567-6d4399a59468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gild-20201231_g1.jpg
<DESCRIPTION>PERFORMANCE GRAPH
<TEXT>
begin 644 gild-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO;B!+<G5E
M9V5R   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,W.0  DI(
M @    ,W.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( FP#=0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M** "BBB@ HHHH **** "BBB@ HHHH *S-:L[^]A2.RU>32(U#-+<01QM+QC
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M'_0F^'__  5P?_$T?\*X\$?]";X?_P#!7!_\30!TE%<W_P *X\$?]";X?_\
M!7!_\31_PKCP1_T)OA__ ,%<'_Q- '245S?_  KCP1_T)OA__P %<'_Q-'_"
MN/!'_0F^'_\ P5P?_$T =)17-_\ "N/!'_0F^'__  5P?_$T?\*X\$?]";X?
M_P#!7!_\30!TE%<W_P *X\$?]";X?_\ !7!_\31_PKCP1_T)OA__ ,%<'_Q-
M '245S?_  KCP1_T)OA__P %<'_Q-'_"N/!'_0F^'_\ P5P?_$T =)17-_\
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M(_Z$WP__ ."N#_XF@#I**YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\
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M_P!";X?_ /!7!_\ $US]YX!\'K\2=&M5\)Z&MO)I-_(\0TV'8S+-9A6(VX)
M=@#VW'U- 'HE%<W_ ,*X\$?]";X?_P#!7!_\31_PKCP1_P!";X?_ /!7!_\
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MKCP1_P!";X?_ /!7!_\ $T =)17-_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\
M0F^'_P#P5P?_ !- '245S?\ PKCP1_T)OA__ ,%<'_Q-'_"N/!'_ $)OA_\
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M?;+*#3X([>YQ_KHUC4*_X@ _C0!KT444 %%%% !1110 4444 %%%% !1110
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M&MVL+P=>W%_H=Q->2M-(NJZC"&;J$CO9D1?H%51^%;M !1110 4444 %%%%
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M2?\ IOO*W;*\M]1L+>]L95GMKF)9H94Z.C#*L/8@@UA>*/\ D8O!G_8:D_\
M3?>4 =)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MD>&KJSN])FDTZU^RPKJ%[&T>>LB74J2/_P "=6;_ (%6O61X:TW^RM)FM_M$
M=QOU"]N-\?0>;=2R[?JN_:?<&M>@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#(UFZL[?5O#\=W:^?-<:@\=K)G_42"UG<O\ ]\*Z_P#
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MMNGR3#'DKA=HF0JPZ$DG..@KM*QO!VIW&M>!M"U2^*FYOM-M[F8JN 7>)6;
M[#)- #M-MO$<7G_VOJNEW6Y,0_9=,D@V-ZMNG?</8;?K52.R\:"5#-K^@M&&
M&]5T.921W /VLX/O@UT5% &-J=KXFEO"VC:OI-I;;1B.ZTJ6=\]SO6X08]MM
M.^S>(_[&\K^U=+_M/?G[3_9DGD[?3RO/W9]]_P"%:]% &-IEKXFBO VLZOI-
MW;;3F.UTJ6!\]CO:X<8]MM5I++QH97,.OZ"L98[%;0YF('8$_:QD^^!7144
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M8Z;;VTP5L@.D2JV#W&0: -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBBF;A7-_$?_ ))9XK_[ MY_Z(>NDKF_B/\ \DL\5_\ 8%O/_1#T =)1110
M4444 %%%% !1110 5S?BC_D8O!G_ &&I/_3?>5TE<WXH_P"1B\&?]AJ3_P!-
M]Y0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.
M^!Y'E\/W+2NSL-8U-06.3@7\X ^@  _"NBK(\-:E_:NDS7'V>.WV:A>V^R/H
M?*NI8MWU;9N/N36O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS[MU_&L/QAXIT^V\5^%X9+?5B]IK$C2&/1[N16'V&Z7Y&6(B0Y8<(3QD] 2
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M3=7&!_M>7&VT^S8/M0!KT5D6OB6QN]-N;Z*#5%AMOOK+I-U'(?\ <C:,._\
MP$&H;+QCIE_>16L%MK2R2MM5I]"O84!]W>(*H]R10!NT5A7OC'3+"\EM9[;6
MFDB;:S0:%>S(3[.D15A[@FIKKQ+8VFFVU]+!JC0W/W%BTFZDD'^_&L9=/^!
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MHH **** "N;\4?\ (Q>#/^PU)_Z;[RNDKF_%'_(Q>#/^PU)_Z;[R@#I****
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MWOMQF@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y3Q+XX@TJ?\
MLW28O[0U9SM6",$A#_M8[^P_2DW8SJ5(TX\TF;6MZ]I_A^Q-UJ<WEKT1!RTA
M]%'>N)CM=<^(LJS7Y?3- #;DB4_/,/7W^IX'8&K^B>"+B\OAK7C*7[9?,=R6
MQ.8XO0$=#]!Q]:[@    8 Z 4M7N<_).OK4TCVZOU_R*FF:79Z/8I::= L,*
M=EZD^I/<^]4;K4[B+QSI>EH5^S7.FWES(-O.^*6V5<'TQ,_Z>E;-9%S_ &=_
MPFFF^=YG]I_V?=_9\?<\GS+?S<^^[R<?C5'6DDK(UZ***!A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<W\1_^26>*_P#L"WG_ *(>NDKF_B/_
M ,DL\5_]@6\_]$/0!TE%%% !1110 5S7Q#U_5/"_@/4]:T2VM+BYLH3*5O'9
M4"@<G"C+'_9RN?45TM<W\0=$U+Q)X#U31=&6U^TZA 8-UW,T:1AARV51B2/3
M SZB@"IXW\;_ /"-36UA9HK7MPC322O;S3I:0+]Z5HX5+OUX4;0<-EE S23>
M(=8O[S3],\-W6EW-R^F+J5Q?20.8)D8[8UC19,KYA#'<6;:%Z/GA^H:1XB76
MX?$&DV^E-?SZ>+*]LKJZD$*X8NC)*(R6VLS@@HNX-U7'-2U\&:EX7ATMO"3V
M5Q<6NE+I4WVYWB5E4[DF&U6Y5B_[O@$/]Y=O(!TWAW6H?$?AK3M9MD:**_MD
MG$;_ 'DW*"5/N#Q^%9OBC_D8O!G_ &&I/_3?>5I>'=%A\.>&M.T:V=I8K"V2
M 2/]Y]J@%C[D\_C7*>,/"VGW/BOPO-)<:LKW>L2+((]8NXU4?8;IOD590(SE
M1R@'&1T)! .]HK&TSPMI^DW@NK6XU:20*5VW6L7=RF#_ +$LK+GWQ5:3P/I4
MLKR-=Z\&=BQ"^(;]1D^@$V /84 =%161J7AJQU7R/M4^J1^0FQ/LNK75OD?[
M7ER+N/NV3[T6OAJQM--N;&*?5&AN?OM+JUU)(/\ <D:0NG_ 2* ->BL*R\':
M987D5U!<ZTTD3;E6?7;V9"?='E*L/8@T7O@[3+^\ENI[G6EDE;<RP:[>PH#[
M(DH51[ "@#=HK(NO#5C=Z;;6,L^J+#;?<:+5KJ.0_P"_(L@=_P#@1-&F^&K'
M2O/^RSZI)YZ;'^U:M=7&!_L^9(VT^ZX/O0!KT5SL?@?2HI4D6[UXLC!@&\0W
M[#(]09L$>QJSJ?A;3]6O#=75QJT<A4+MM=8N[9,#_8BE5<^^* -FBLC_ (1J
MQ_L;^R_/U3[/OW[_ .UKKSL_]=O,\S'MNQ[4W3/"VGZ3>"ZM;C5I) I7;=:Q
M=W*8/^Q+*RY]\4 ;-%<[)X'TJ65Y&N]>#.Q8A?$-^HR?0"; 'L*MZEX:L=5\
MC[5/JD?D)L3[+JUU;Y'^UY<B[C[MD^] &O161:^&K&TTVYL8I]4:&Y^^TNK7
M4D@_W)&D+I_P$BH;+P=IEA>174%SK321-N59]=O9D)]T>4JP]B#0!NT5A7O@
M[3+^\ENI[G6EDE;<RP:[>PH#[(DH51[ "IKKPU8W>FVUC+/JBPVWW&BU:ZCD
M/^_(L@=_^!$T :]%9&F^&K'2O/\ LL^J2>>FQ_M6K75Q@?[/F2-M/NN#[U4C
M\#Z5%*DBW>O%D8, WB&_89'J#-@CV- %GPMIEQI.CSV]X%$CZE?7(VMD;);N
M65/QVNM;-<)X:\-6>MZ7=7E_=ZP)O[6U./\ T?6KNW0*M_.%&R.55X  Z=JZ
M3_A&K'^QO[+\_5/L^_?O_M:Z\[/_ %V\SS,>V['M0!KT5C:9X6T_2;P75K<:
MM)(%*[;K6+NY3!_V)967/OBJTG@?2I97D:[UX,[%B%\0WZC)] )L >PH Z*B
MLC4O#5CJOD?:I]4C\A-B?9=6NK?(_P!KRY%W'W;)]Z+7PU8VFFW-C%/JC0W/
MWVEU:ZDD'^Y(TA=/^ D4 :]%85EX.TRPO(KJ"YUII(FW*L^NWLR$^Z/*58>Q
M!HO?!VF7]Y+=3W.M+)*VYE@UV]A0'V1)0JCV % &[161=>&K&[TVVL99]46&
MV^XT6K74<A_WY%D#O_P(FC3?#5CI7G_99]4D\]-C_:M6NKC _P!GS)&VGW7!
M]Z ->BN=C\#Z5%*DBW>O%D8, WB&_89'J#-@CV-6=3\+:?JUX;JZN-6CD*A=
MMKK%W;)@?[$4JKGWQ0!LT5D?\(U8_P!C?V7Y^J?9]^_?_:UUYV?^NWF>9CVW
M8]J;IGA;3])O!=6MQJTD@4KMNM8N[E,'_8EE9<^^* -FBN=D\#Z5+*\C7>O!
MG8L0OB&_49/H!-@#V%6]2\-6.J^1]JGU2/R$V)]EU:ZM\C_:\N1=Q]VR?>@#
M7HK(M?#5C::;<V,4^J-#<_?:75KJ20?[DC2%T_X"14-EX.TRPO(KJ"YUII(F
MW*L^NWLR$^Z/*58>Q!H W:*PKWP=IE_>2W4]SK2R2MN98-=O84!]D24*H]@!
M4UUX:L;O3;:QEGU18;;[C1:M=1R'_?D60.__  (F@!NN:9<7^L>'+BW"F/3]
M2>YGRV"$-I<1#'J=TJ_K6S7#:IX>M-'\0>%ELKK5BMWJLD4HN=7NK@%?L%V>
M/,D;:<@'(P>!Z5KQ^!]*BE21;O7BR,& ;Q#?L,CU!FP1[&@#HJ*QM3\+:?JU
MX;JZN-6CD*A=MKK%W;)@?[$4JKGWQ3O^$:L?[&_LOS]4^S[]^_\ M:Z\[/\
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M<]2MROD@KR[?YEN_\3:MXOO)-+\&HT-H#MGU)LK@>WI_,^U='X:\(Z?X:@S
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M]*BE21;O7BR,& ;Q#?L,CU!FP1[&K.I^%M/U:\-U=7&K1R%0NVUUB[MDP/\
M8BE5<^^* -FBLC_A&K'^QO[+\_5/L^_?O_M:Z\[/_7;S/,Q[;L>U-TSPMI^D
MW@NK6XU:20*5VW6L7=RF#_L2RLN??% &S7-_$?\ Y)9XK_[ MY_Z(>G2>!]*
MEE>1KO7@SL6(7Q#?J,GT FP!["LOXH:#:7?PVU^XEFU!7L]%NO*$6I7$:-B%
MB-Z*X63ISO#9Z'.: .VHHHH **** "BBB@ HHHH *YOQ1_R,7@S_ +#4G_IO
MO*Z2N;\4?\C%X,_[#4G_ *;[R@#I**** "BBB@ HHHH **** "BBB@ HHHH
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M^S:?=V_D'[[^9);MN'L/*P?]X4 :]%%% !1110 4444 %%%% !1110 4444
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M 'VW&IKJY\1IIML]EI6ERWK?\?$,NIR1QQ_[D@@8O^*K6O10!D:;<^(Y?/\
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MP9_V&I/_ $WWE=)7-^*/^1B\&?\ 8:D_]-]Y0!TE%%% !1110 4444 %%%%
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M(V\^(S7MRUGX1TR;4Y_^>K(1&OOCKCZXJ)?!>O>(W6;QCJ[+#G(LK4C ^O\
M"/U^M=Q9V5KI]NL%C;QV\2]$C4*/TJ>BU]P^KN>M:5_+9?\ !/)K[X7VUC>6
M%O/KI5]1N#;P!;+(WB*24@_O.!MB;]*[;0_!EEINCK8ZG':ZH48E)9;100I[
M<DYP<\Y_E5K7-,N+_6/#EQ;A3'I^I/<SY;!"&TN(ACU.Z5?UK9H44AT\)0IN
M\8G/S^!?#-Q_K-(@'_7,LG_H)%9T_P +O#<N?+BN(/\ KG,3_P"A9KL:*=D7
M+#T9;Q7W'"?\*NMX/^0;KFHVOI\P./RQ1_PA?BBU_P"/+QC<2>@G#?U9J[NB
MERHCZI1Z*WHV<)_9_P 1K3_5ZK87:CH&4 _^@#^=']K?$2T_U^AV5RH_BC<9
M/Y/_ $KNZ*.4/J]MIR^__,X3_A.?$-M_Q_\ @Z[QW>(M@?\ CI_G0/BKI\1Q
MJ&E:A;'_ '%/\R*[N@@,,,,@]C19]P]E66U3[TO^ <C!\3O#,V/,NIH/^ND#
M'_T'-:,'C7PW<8\O6+8?]=&V?^A8K0GT72[G/VG3;27/]^!6_F*S9_ _AJXS
MYFD6X_ZYY3_T$BCW@MB5U3^]&I!JVG76/LU_:S9Z>7,K?R-6^M<?/\+_  U+
MGRX;B#_KG.3_ .A9JI_PJRU@_P"0=K6HVOI\X./RQ1J'/B%O!/T?^:.[HKA/
M^$)\36O_ !X^,;EQV68-@?FQH_LWXC6G^JU>PNU'0.H!_P#0!_.B[[![>:^*
MF_P?ZG=T5PG]J?$6T_UVBV-THZLC#)_)_P"E'_"<>)+7_C^\'73#NT); _\
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M .R-?TN_^SIYDWV6]CE\I?[S;2<#W-5(_B%X+FE2*'Q?H,DCL%1%U.$EB>@
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M_.W/MFFZ9XQ\,ZU>"ST;Q%I.H7)4L(+6^BE<@=3M5B<4 ;-<W\1_^26>*_\
ML"WG_HAZ=)\0O!<,KQ3>+]!CD1BKHVIP@J1U!&[@UE_%#Q'H=G\-M?M;S6=/
MM[B_T6Z^R12W2*]QNA8+L!.6R2 ,9SF@#MJ*** "BBB@ K'\5>'(?%GANZT2
M[O;JSMKM?+F>T\L.R'JN75@ ?4#/H:V** .:U'PA<ZA>Z?=GQ7K4$UA$4C,:
M6A#.1AI2K0$>85)7(  !8  ,V9-0\(17\5H5U?4[6[M[=K5[Z"5!-<1-C>KE
MD(Y*@Y4*RG.TKD@]#10!!96=OIUA;V5C"L%M;1+##$@X1%&%4>P  K"\4?\
M(Q>#/^PU)_Z;[RNDKF_%'_(Q>#/^PU)_Z;[R@#I**** "BBB@ HHHH ****
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M\/QW=KY\UQJ#QVLF?]1(+6=R_P#WPKK_ ,#K7H **** "BBB@ HHHH ****
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M3K/3+<0:?;16\0_AC4#/U]:LT459Z*22L@HHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% &1K.F_;M6\/W'VB.+^S]0>XV/UES:SQ;5]_WN[Z*:UZY
MWQ-&[^(/"#(C,L>L2,Y R%'V"[&3Z#) _$5T5 !1110 4444 %%%% !1110
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M+#[Q,C*,#OSGV- %K6_$5Y9:Q#I.AZ8FIWS6[7<R27/D+%"I"C#;6R[,<*N
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M(6)W[HBPST.PKUXQ0!VU%%% !1110 4444 %%%% !7-^*/\ D8O!G_8:D_\
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M+%;-O=VUVNZUN(IU]8W##]*XZE&K3^.+7JK&T9QEL[DU%%%9%!1110 4444
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M18I*PMIM*OII(NS.DMH%;Z@2./\ @1H W:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YOXC_\DL\5_P#8%O/_ $0]=)7-_$?_ ))9XK_[
M MY_Z(>@#I**** "BBB@ HHHH **H:MKNDZ#;I/KFJ66FPR-L22\N$A5FQG
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M.Y?_ +X5U_X'6O61K.F_;M6\/W'VB.+^S]0>XV/UES:SQ;5]_P![N^BFM>@
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M6\7@[6;Z)3M$\,MD(Y!Z@/<*V/JHKG/$?A'2]1TZ"]B\'ZHE[/DO#I\MK'+
M?]L-,(S_ ,!+&N/7X@_$/X8NMO\ $C1CKFD*=JZQ8 %@/5N #]&"$^IKU#PI
MX\\-^-;7SO#NIQ7+J,R6Y.V6/_>0\CZ]/0TU#$X3]Y2EIWB]/Z]291A45I(X
M?2(?B/I$D@L+*^DLH0"L.K26S%QZ+Y<SD8^H^E+K'Q9UNP\F#^PTL;M=WGI>
M(Y!Z8*\J?7U[<UZQ7*>-_!'_  F7V'_B8?8_LGF?\L?,W[MO^T,8V_K79A<;
MAZM9?78*W\UK=.J6_P!QS5*-2,'[%OT_X<\_\)?%)]#$MKJUD9K.6>XN0;-
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MILFQ_P \=TO_ *"#6T:%67PQ;^0KH[:BO,+K]H;X>6^?*U.YNO\ KC9R#/\
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MB@ J&YL[:]C\N\MH;A/[LL88?D:FHHV YF^^&W@K4L_:_"VDLQZLEHB,?Q4
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MB:&1M5U&8*W4I)>S.C?0JRG\:W: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,C6;6SN-6\/R7=UY$UOJ#R6L>/\ 7R&UG0I_WPSM_P
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M/^A-\/\ _@K@_P#B:/\ A7'@C_H3?#__ (*X/_B:Z2B@#F_^%<>"/^A-\/\
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MY1E.1QG([&MJ@#F_^%<>"/\ H3?#_P#X*X/_ (FC_A7'@C_H3?#_ /X*X/\
MXFNDHH YO_A7'@C_ *$WP_\ ^"N#_P")H_X5QX(_Z$WP_P#^"N#_ .)KI**
M.;_X5QX(_P"A-\/_ /@K@_\ B:/^%<>"/^A-\/\ _@K@_P#B:Z2B@#F_^%<>
M"/\ H3?#_P#X*X/_ (FC_A7'@C_H3?#_ /X*X/\ XFNDHH YO_A7'@C_ *$W
MP_\ ^"N#_P")H_X5QX(_Z$WP_P#^"N#_ .)KI** .;_X5QX(_P"A-\/_ /@K
M@_\ B:/^%<>"/^A-\/\ _@K@_P#B:Z2B@#F_^%<>"/\ H3?#_P#X*X/_ (FC
M_A7'@C_H3?#_ /X*X/\ XFNDHH YO_A7'@C_ *$WP_\ ^"N#_P")H_X5QX(_
MZ$WP_P#^"N#_ .)KI** .;_X5QX(_P"A-\/_ /@K@_\ B:/^%<>"/^A-\/\
M_@K@_P#B:Z2B@#F_^%<>"/\ H3?#_P#X*X/_ (FL_0/A7X2TWPWIECJ/AC0;
MV\M;2*&>Y;38F,TBH SDE<DD@G)YYK;G\1I#JD-LME<2V\ES]E>\0H8XY<9
M(W;L9^7('!(]R-F@#F_^%<>"/^A-\/\ _@K@_P#B:/\ A7'@C_H3?#__ (*X
M/_B:Z2B@#F_^%<>"/^A-\/\ _@K@_P#B:/\ A7'@C_H3?#__ (*X/_B:Z2B@
M#F_^%<>"/^A-\/\ _@K@_P#B:/\ A7'@C_H3?#__ (*X/_B:Z2B@#F_^%<>"
M/^A-\/\ _@K@_P#B:/\ A7'@C_H3?#__ (*X/_B:Z2B@#F_^%<>"/^A-\/\
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M27,H&^=E4*7;'\1QDU9HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** ([FY@L[66ZO)HX+>%#)++*X5(U R68G@  9)-<_\ \+&\$?\
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MC_H<O#__ (-(/_BJ/^%C>"/^AR\/_P#@T@_^*KI** .;_P"%C>"/^AR\/_\
M@T@_^*H_X6-X(_Z'+P__ .#2#_XJNDHH YO_ (6-X(_Z'+P__P"#2#_XJC_A
M8W@C_H<O#_\ X-(/_BJZ2B@#F_\ A8W@C_H<O#__ (-(/_BJ/^%C>"/^AR\/
M_P#@T@_^*KI** .;_P"%C>"/^AR\/_\ @T@_^*H_X6-X(_Z'+P__ .#2#_XJ
MNDHH YO_ (6-X(_Z'+P__P"#2#_XJC_A8W@C_H<O#_\ X-(/_BJZ2B@#F_\
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MPI^E-E\)^'9Y/,FT#2Y'^TF[W/9QD^><9ESC[YP/FZ\#F@#6KF['_DJ>N_\
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M ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\
MX_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D
M?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_P
MH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UT
ME% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\
M"!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _
MGB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/
M4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_
MP@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_G
MB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_
M^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '
M-_\ "!Z1_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1
M_P _GB#_ ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_
M ,*/4/\ X_1_P@>D?\_GB#_PH]0_^/UTE% '-_\ "!Z1_P _GB#_ ,*/4/\
MX_5W1O#&FZ#=7-U8?;'N+I(XY9;R_GNG94+E%!E=B #(YP,?>-:]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>gild-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:gild="http://www.gilead.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20201231.xsd" xlink:type="simple"/>
    <context id="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie96afe3a1df84576aaaff813a6240267_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if218098f852d48df84d6fe5e15c309b0_I20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="ie4a66ea3e27c41739673ae6a3e75680b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa2d477c63034d369b25d6854cf06afa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85124ea043f44d21b8b54a8de5bdf919_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1854fd7993394c05bb3e013f00d725cb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c26f4bd16b4406da90ed77b81c4e690_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id688d136833640ac9c6d94d4ddc9632a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c8670361a0047c5abdca258af5b3b44_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a0d2f065cd0476e9fe09cf97a3daa95_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4434b84f088145049b702ceb08c39437_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i835488bd375d4a09af99788bd9e27362_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6f6356b044964174974ec7dc3f4bbd36_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1e30e15c134641879f2e452fd14665e2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ieb5c937c29a64935bd5513af5cd17eb8_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3219b6982b334ae49d4a68c7befc5d27_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6ad04f35896042aeb313604ac52c806c_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ic6f63899ea2f45c8b3d163ffca4733cc_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i2747bd2827c1444bb8598c30d980ccac_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if3c9515f11a04c63b1fc167cf59c9e73_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i93892be161ed46f0b59daf9d2cb4f947_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib5da7a2ef9a64a11a7b170d14e808fd2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i54dde75a77af4f3b89a86ac2a4228e70_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i70493ea7576f4f75bf9315161efe8129_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i31731035ecc946909f7611c79f589644_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie7af2bcb42b64317aa982dc29f82941d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iad1fdea1fe7d4a078ed1a4602d02bb20_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i65708ddeaac5432bbbd3d6edf2afc67b_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide81d63cf6c54f098b1ff7c66544b644_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iecfc48f8ba344985b35fcd2a8cb7d81c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i36fcd6ecd6054ae299896dca5929ff08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8823d4c8e7b94b01a4ee9918a81621f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i169f1c5f92244d9c9d8b552d1f30c6c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7814341554194d39a8d33cf13d7c7a78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38c06042926b4ec6a8d780769c247d9f_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i481ded537ec44be2aa528514e17583c9_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="ida37295fbd814545a3765e7f4773f2f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia719d90905124e9b9418db557c451735_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i644e2dd1361545818a945c69c56a8198_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7100af96680046f2a2500612bc8d8730_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf1aad86406e4fb6bb4aa4b7bd2a85cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a5ad62f62cb4ef6968f09d3363ab76e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b2e43234fc04521af2344e4b1244e9f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i987c3ed14ae840e7ba9dc6b6834ee87b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i398df6a52dd9464d8dd45e089b73014d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27efdec092714a19b30f4a1ad8aa6133_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf9fe67d86404ee58fc08434776ac75a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a198ee4eaba43a9be336a94d8a87b2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fa4ce37886b4a34b696be088b6209dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if280de1dfeb24360a98d1085d3ec01d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42acdb68c96f40139d8ef2dd48ec4aad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic93a08630ddf4d8daa910c80941d2f49_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a1fc5480ae54692850a590af2530f85_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia42eea57788b437d80b0100bf5308e5e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74b227c5b6d24b36a063e59f6b31eddb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd51a66da7cf40eb80804c8cb98cf1a4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia729850536324dc7a891febe1ef57425_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a2f412468e04e8e990eda8c053e9023_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i573540eac6ce41b9ba0a37a14d578dcd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib9e0aaddda8242649f4cce16f7480e3f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1e6f27d389c4470791b5097d66ee6fb2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsAtriplaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec241db8005b4fb59360d2304f6a40ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dce80f6a5d043fabec1581e37b038e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ba9195c2f9b45e392656f86c6f8865c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5630aee9b8e34051b2267852a2167c72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if9bf33c47a6342328f4b4a359e831dc0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01bd5e69cc2242e9937e99d06f49412c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc7657c224364338aaec9e8f7e531475_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i479222aa62ba4959b945991f45167506_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i732f9de4021249caa5c12dd71d663337_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i51323f6fd23840a6a3a8153facb4a542_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8120081236ab4ada86875183d3516a0d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic9d9ac1bed894e8ebd3a9a07adec3780_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i423cb85373ec46cd90ab88681133fed7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bca99eea6724544b1989f1c71ff8e7b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib925542d3c9a449f9451287b1948794d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7fe1a6f3e2a4443bfadf5e3b18575a8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i397a1aaa80ac42d8b7d7547d7a425c70_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e6650f4df60426daa34dc4ca653bc0c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i96967e4c10914e109e43c4c43838be39_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6bbd726607304250949dffcf3aa8a682_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaac1e36447014421822582a862cdaadd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0e01036f80124b668ee600a97070f563_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab9ad0800ab14c06a5eb9fc8ed1492dd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3f83bbac170c4124b1506d033c0044f6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iff45aaf7fa4b4df1b955bc6bf7844c83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fcce9db6610413494337c100307fc4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ba09d37db0e466f905cbca86c3d7dc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i914f59558f254e77910de66c2a838a2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia05a4d813f594dffabe58b494a022cce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71b7ceb3521340179dc6fb26acff9127_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9ed9dfdc9e84991bcf49d834722ae9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6155a1372b794cfc98808510fd0f6aa0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1451f5b027bb41a4847584b7f596fd2f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2d167e5e90304b3cb0fa2437ed97d58d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i148057a263804622a6ab50305a09929a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie30b81a7f7314bf597308792e530d56d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i24aca176c89041e39835e536b01a5caa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iffa4c3f449f34e3ca5b0429151183789_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaee8311b76724420b4e775d0c80dce90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82451c9a5fc840db91ee5a3c49612ddf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70a33cadbf614a8480b0f3f1046c5ae5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fb475376a1c4eab860991d825204c02_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i31b4a13728764a0eba034f51b801c879_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic46aeadee3584d9d87c1b87143a83acd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1d8548ebbc24499af4a1bfcc9d5e0ac_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibdb71020bf354a20a7eb5c17cbe9527a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i73e2d26072ce41babea393a33fe5028b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec1334107b9d4287be103de88544e8c2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie56b0d69dc4443c38f7f201f8cf0560a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i19165ee38eb44b368716095e6b79b8ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49a83d33cd594375ad102b2d5a901d14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e25273ce6ff4d95913b6a378db136fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1354418ec0a142bf80aa75673f9dc7ff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic50ed561675c40659815e6bbfcfe85f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d77fd8a2cd542c187eb7beb450a9bd5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25ce8efc83ec4d46a7d9d78b23565594_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i307fd96efd864668a53c14e22b45b3df_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i51752bd1d33b45d99eeaeb4bc0e7aa30_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i837c38f09aec40bea2af72ce62bb55e4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3a72addb6d6c4f8f901283e58f4db7e5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i85e16d8591f64ebd8ed80e3b3d51a9bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa5568bc36104cc3bd4575c08d5bd2a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1eb6ef7264624b6b88e49bf1fdcc8084_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24b4931148e643fcbe49c4f9d12ba1d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3245979d6cb647f1a9f0228da2e8828a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib830ff48e9c547759f55cd54a403715f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8bffa555d06d4f78813ba77778839fd2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id33ba5d575e9416a8fbf45cdcba038c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i383f0ccfdd634300bb105e23b2743b3e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if8fc3d812ef541ae8ae75cfd0c10bd4b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i971bd58c2a104fa58633b760bd1bcc49_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9bff96a7eee3471ea92c5a5728abafb6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie7e671960e24493caa9e67137c00b67f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i601dd6fe3b1a427b9e877264c2a50cc1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ae5bb92838f42e185c2fdac7cb74c5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id82ff04803a44a739676620ac878f839_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99fb37b1c0334cada10080d435ac5f5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id136b7bd1fbf487ca2f4096e63868995_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09c63bb8f77347f5b4447f81ccb53bce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea5f53f6dc9d4ac08d0693f368244332_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09e084e4904f4eec869ea6250e39cb0f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic3e0d6d757fe42eb80d7eace0eca26d4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5873767e398449f49bed3571f29dfb2c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i63723f5c740941a983de991985232fb3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5d3efda2c81540b28f3d08dd5de9755f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b99b05d92954eca83863f0bf00a778f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i881bd67c6b4d4c32ae44c9cecd6b6cb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0469e8d7b3941ffa027e0d65422b55f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1378a285d3541119968e5a408b282db_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iade7d753f59a4127a6ee33601d7bb46f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if86f743bdebd4241a992f10cc32afce2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0499c86d7cb249e79e4e9514392025b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4380b2c4b087466e96212e805752c452_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2c65abc055694fa093ee3d1a90844e56_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id536d58f3ef742cfa5620869742d07f2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7e7cb86cb8124bfba88a83abe2dbea50_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i41251b77296c4f1c896b094d88169d6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f6faa09d5af4cbb9ffd71fb56eb0943_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfe492680a244d69a015e5f447b30fb9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc9c5bcc6ec24e9fbf91a218a0ec316c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9f80e96782c40c7ae4aeb93329d6569_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibefbcda1973840c1a30941cf065c6d7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id549332482954a04928a406aa2aa8ce1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic3153057cb844d0f85ec934a049701a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52fb0ee83c0e437385e9166f9c973f27_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5ddbe44d21304dbdb6f1f137c5fbf5e2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f62e6dfb68b40d2a30db38faaef056c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i55935a228d7349a0b68ecf40aea95522_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if5d7a8c92b7b499c925cd2e1b63d5674_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09483a086d8344418fea4c38597c601d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i816c10bfc97f4bd3a31a63ce6248693a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e93f9118e4d40739ac1f86ecf2503a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e010182efaf422cb20cdb14830ec5b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i50c5df52b2384dad827ce8d5ed8becd0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7b5382709394ef0902ac805a3fba467_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i35a796d1ca3647aca0c0cf94e9e84834_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibed79b72cddf47108dc5adb16f1c6e0d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i308e3d02bbe24f73995a88d9dffbeb6e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if5e9639e6b4f4a93bef391904c7ba7c9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8e99b9e4abc6439caf1635dde53641e6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i784a2e611fc6427c9c5e4418b57df0b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87f26b0b8d9a42e1b8b6392b60d37f56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id210bf00395f48528f93b74e8bcf8963_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i356cdb8eb49e4b5fa6d74cde3aee0fa5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0399583abbfa4b70a9826bd3f34fc3e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i971e8c17f58441c796ae21856d69fecd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e3c000c64e74a5997c3ce62426eab73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf4791ac34254f20a211ff631970f1df_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i44a776ce3ca04751a6acd137246eadbf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if61ad645329c4f84a5ca1f8858e4a105_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i789b3a29153346629c85ec22950b2443_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2449c7232a1542d8961f78873606cd5c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if98307d1f71d4a57b90d117c72387c97_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i709dc81b1e0b4ad18ed1a3516087e006_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52257540c09044d483783ee0e873ddb2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0d14fe1cf6741a38f337376d9b09937_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ead59eb11954802b58faf4295471c59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8fce49b484e4fbe8b7118a57fd949ff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24b3fa2ba952448ab0308cc83860110a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie19c5edf94af43d38aea8ff9a812b9bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1510ef46b1564c908317e3e7ed9ae838_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf8fc952f7ea48e19ed2627867ef4e34_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9e85b0a40a6f4651aeb814864a67e2d5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1520f66d45ff4fc99578172eae43f525_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iafba755ee21149148b5687e8c622242c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3418497bf64641e89450ddf47541cc00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43a0f15448df4521b3252b863920fd4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa04a1897acb43a8935771581a2294d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25cf3186547645e18a12e54737ff3f20_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66a055454e634859b9e4d1183c8ce86b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f360e299e954e01a740de35c1825eda_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbfb0cd1316443b2a3450b33ba196076_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i909b8bd81dd94054add30d019a9039b1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib81493ecf2c148c3b066878a096034fc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id8d6ae2564f7486fb11225a0eaadac69_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8c76d4fd2017462795348867f8cdcf28_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7742e26504ad407fbe00062a7dd0687f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2a76126042a4ae6b749183870511d1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibea13b5f060d4a69a6a698a8df908663_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b63e3d135704c9abeb409724a97d925_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5ef5470931747bb983f03b0991cd741_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8780e4b3e8474e2cbe7f7e27d5ca7b6a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if67fc940422441b0ad55ee1a90ed0adf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4f7a3e3e83d47fba6ac8b13a9f5610d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ce8b095baec43b9a6b48fa3f625b855_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibcdb328dbec54ee98bcab35be1c9d7be_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib23482e8bcdc43c88946e03e12a9d121_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id09f10d7c83d4df6818e86cf8d921ffa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i859d13747a854b698617069a85edd654_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65fb0f65e47c4aebad73abab7f3d668c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1eb1c210d43842dc83ff399b1433b853_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i630b6c887763456b9fc85ec6d3ce087a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief9f1a4dc71044d6a03833cd32ab6427_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea6b44faba3c4c3997faba3148afcff0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida618eeb5e0c4c0fa85d55c4d046e885_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1ba2cc8ba7fa4f4ea047c155d67eb4bc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i109a8b80496843409ed73dee8466e5f2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib288b9089b0c44789133829c737173c8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if2d4ab01235446e18963ca74e84b4ee4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3ce39b3aecd24bc6b4e8956650a90f41_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsVekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2c0e1109ab13490eb642fa4d06a36587_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i413eb3a40a8b42d988fa602ebb2ca91f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4dea6420e00e4e8d9730f2afce5768f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0f3a8d6d4864089b0117d15c03f54c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9a38838e3584d7098ad47e06cbd413d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i580e219bcf66429da65491757ea55918_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie55279b9ee5c4b128d5d5228052e4f29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9a3932fa2ff4271b07b0b741b9f2e16_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i201995b3520443f09a408794644c73ca_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i889b1eb7b37749da92f1bf1c86dea272_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i35db01b6963a4942bb80c530e3cf0eab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i468e6f1044534b1fa35b2fbd7924b327_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if08394a404854722bf7e616cb19ae8fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d4c798eb7224a9cacdb473b8ff5c063_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb8d59cb650742a4a8ec1678152225c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c1749278d3a468faec493fac747a15a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb15b0bfbfcf4fecb6e417adb32d14cc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia5679c3ac945499eaa165d356e44c345_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie2021dd665b74bfd84ef3c205aee77de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7ef427af36e6444fb807bafc1dd97ed2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i983b0b11a6c84a078f5acef269da5f01_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib9f00902a9e047f1bf5e98edae0c114d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie1527f16620140d3b0bc8763e514b4e2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i18b4cf44e0b44448a2dcdc6b970704a1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CallTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5fc912cbab8848d1af83924b72da7f38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i738e00cc411942688a5f051bbc58789a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5fc84cbd707c4080b153a838a03d48c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5e9650394f04aeb94d242d32a12e8bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iedebf7a896304b22ace657a8e1c8486c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib09a5278cb5a49f0a7699635ac23b161_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief07e0bd49214929beab0135a7c7dc3c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2e0f3e3ca6b14a30b76b4f150c9ee957_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic0b3071aa2974bbf9886daa645933440_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i883994858d314ba48462d6cb3c2af453_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iab10c90724184ec98c3bd8679e022adc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88bd06fa86a24206ad6519770cbbf504_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i74d46f4d0a9742b3811281fb61e7d0e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62f879d917734de09114d93c9296efc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i829cfcdf44354f36b769778dcca6ea95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33c157b8f9e44197a7c0c60493c89067_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c23f8c25d144cd7be8fbb3776eb33c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib54469a0949b4fc0a59210e6ef5f4c5f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i857e28fb6733458686888944ec0abcec_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4fd0e8f161841919bc51b121342b374_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2079180ac67341b99d32045a11aef376_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id94b0e9d86a249e7ba66251f8d5f185f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1967de1c5a82446488fc2307733a2f25_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib157d6d05afd413fbf032738706b0c74_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:COVID19ProductsTrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia6a212bda0e54ab3b525dd5891bf887e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79495b272c824538bfb4875c67e764f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5738b64989fe4499bd71a4261fe9cd53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0a03686d6ac48f48e3b9bc50f36d666_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc02389377974b6585a7c609eb64806c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i47b0e346a3004c339a6cd887facee047_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5896ac21bdf49a6a7472cad2027abf6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i22cc8196c9ec45ab9f1de39dc4a69f10_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief49933c94874a7288705eed5a22b841_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic8a28ab5c7fb4105aefaa14b53daf143_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id68873060904412cae3451300eaf1465_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9385611a51014144a8857f90be3bf8df_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18e1f5ddacd74e36860d63ef63816443_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0e5f0db282f4e87a91f73ee0f751c64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1da7341e9594d21a608bad106da29bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i356273c8d56b44b0b5a77cf594e9c798_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b29db06821842aa88c87560b1140102_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46fbf481784d46df9cd01a3ed0d6545d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ea757664b6d4a1ab8eec797ffb2d767_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5ddef75a147542598e9eeae5bd12bd75_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3ec4e20f64114d7d9926a8c80f9a5728_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i268bb32842bd412986cc0065b81f5ec3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i395a7db3cb484d78bbf89146a3e077d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ba42c93200d4f8b8304c65a06ccf517_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib33bcf8c71124c9f9f2ac08771f1c913_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5e9314f39916471fa92a7b99ba58f5cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f91458243294b9c9c142625d0f38738_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib21c75ed2e5e4a0785b473551c580aaf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifad692520c784ea4abc27df55521f56e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i57e47ad7e13b4bf69d68ce9974de21b2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6b6f0bfe6a0f4a34812997b067f29ed4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i43afc88178954f07b425ff4523b10503_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsRanexaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5b488bb036614037b341e5cf1b62388d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1acd6c6fbb76414daa5db831c8743f1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib433847287a34715a932ae68acaeb709_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18325e923e9c47fcbb342e3aa696ccfc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5dc0423d455d47bea3200f2044dda0b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib4b200ae598541c98d2a1ed430747f3a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib937cdde175b4314b5243e750587f636_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice4f48c959ab41ee88040efcbcea0d9f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id7e97d5163a44218b733238cd69431ad_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibfb3da24a50f484bbfcb5f5691037fd3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9885f4a5984a4acfac50c45d81501317_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ide045b122d2b4c9da0649764f92f82cf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i66ba333691004582b0bfe3cf23e00905_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib98481f2446747c5b3c54ea39b7ef10c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9f307f1d85849869339a3dd1db1df84_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9db84ac85e404173a8e1cb30a6decd26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91187b7f1d854ab7ba6257b9a17a971b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5da15e7f08745208039280810556724_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09a59d3e994e417497f2f6e81c591584_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i37fab06fed904a5da3ee5fbccc5f0375_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if6a89708946c4f75aeffc28c28e30c9d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8eec496ec02f4593bd2a62da7c33299b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad31f51a98be414c964b9e2b9a577bc1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iedf02763ce85454bba606a3d45b058a0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf2157f2cecf4cd0a6d21dfba9a135ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e5df38c8d924b2893c58f2be02de301_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b69aedcfde94c8f985123b13ec54c43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14b05d44e0ea438ab49cc731f8134505_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c52e1ae94bc42c58506819cae4f100f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6e3fa876eab46ff9f325ca98b6b49d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec928fa7546b459695f84f5045fdd004_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i403ec9cdcb59480d92d5fa47b3653c0f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia89b449def3646cd95f5c38f3912f3eb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i73020476831d48dc952d089610d805a1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia15d33d7c7794a1690e9ff92bfdeccba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i891f5e003fe345e49586b7f0ea1a1a45_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsZydeligMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib01f5ca90cb941ada3953be0fb43eb53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73acf81cff124012959bdba4df022c6e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25e47d06bc5444c9881da32e0c8c1cee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88c3894232694ae58965e4dd7cbc5b54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib81cae5d5fb646aaa416523f96ff4dc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67c94bcb38db4efab1dd4b707e869ea4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5904987b8e054f0e8bd5a3b2351b251c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0dfe8e689257463db42f9737c01eba0a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic6606449fe534eb2a6045bd62f8f24cd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4fd40469a0a4494997d70f0d4a34aaec_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5cccf7ba7db24688a39f333d661af293_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4038976843844c049725bed7eedc17c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i711402d60b6842f9bf49e2f038e529c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02968faa82754adb9368cdefe9c4fe3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8ca668f89aa4b6c8e0216455acf3560_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i471af2619c5a4230a84f5531a471377a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i007512ae8dda41e5a9f544b584b8b898_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7995dc4952d4992b95339207eb9a85c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie748c67418e941ab866c173f95e2e4c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i32ead5f4db724373bbe26f3ea23629f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia787882ee4864cee85ddd5bdd5978cc9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0c0fa5cf50f94ef79e636b3c7f721374_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i115f5c61450a4ca3a4ae2df3bbb688e6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9493b54209da48aaa35d8e714d4decc6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5749630d7d6b4757afcd624c8e7ba7af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18f9086e97774b9ca925fc4a60860be7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0fc749c3c7c4c0797d0c18e3830a490_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff38adcd98344d5688d2b7c42eb4d546_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6b68dc0514ef48d4959838e63c0ec733_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8c409ba8f5914054bea31b89ef69134a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i13ea489570e94e849c567c2748c27b83_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4e40bb38a566430ba935851046aca72c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie87b24e3cc774ee496e9f4e9fe3259a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3b37655a4024424baec1bc2e6b93c53b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b386ce4d117451092994876209c5a7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8fc9a58a4ab4e06acb145d4d9fc938c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifbf1b72c9bc5437e93fbb59118a89b11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i37d1dcf382f0457c87f65fd2c8d9ff06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e1d16ebcc6c4a9ca3e4100c1dac49d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib18a5881f11747ddbaf96b26b1d744c9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i70edfabacb9d4ab89289cb74d03d9883_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic7faea72409640a49a435de615dc7102_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia2ccc7e7e5524a3280968384eaa7914d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibff4f9ede79c4c67aa7a3250803dc3d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i065f333a6d934bca92cd111bef4577bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i423ab7bdc2094bf0abc5c971cd107ff1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdd28ea07c0f45ddb0ee2c099f46b450_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83da63a7df68404bb8a5d3bf6f9e82d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02abe7b617b74a5399a1101c5b6f2a83_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3649ae2389f94d3892ad79a3dd0a2c98_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id51835942cfa4433ba52343a2cc2e074_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3d5490822d34a2a99d663996669b4f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9126e641d024fb0b335f3046e9ed3ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iadd8f355bff34661aa70ef78c021e5e9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i72e0cdd23483485f9ed6c6ee0844369f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie13c70a71c4c421abd1362ea62569117_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf5c0818833647d3a25ea25ebe359b5c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if74eda1b891b4ab79e2ca96ed9eada38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i087aad162b0642ff8db64f6a05885c60_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib33ce3a5097547a6b8d4a0f1ba3e9fe4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a2652179d8b4b0ea00c6e7c08a3f988_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifbc8462d720446f4b9207d710a136bcb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b3598bfff834885b69c49aee403e0db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:ChangeinestimatevariableconsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc3429c7b8484213bf017f41a196b549_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis">gild:ChangeinestimatevariableconsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6cdc1a99bb8647ea8e9692070dabd0e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6b90eadc154444fb19c9a01d59bf33f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb6397a7dd8a4e959ad085826f07f21e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia19b4456b05d409e95fc69cc5a327fe7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i689f540e21ea4cc0ab92a8b3e7bc2336_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33fb3025f9a545e3b9aa62b16b54b596_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4c0dd0b8e294840a0967d56255d0758_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71dcab1fa94847e09339d54b040213a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71d9226cf83c47e8975915ff0788e426_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e924b85a8594cbb8c57fd8d907feee8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43f4d18853c24b45892069de276317e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i992f0d769b004f95844a081bc36172fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51b2c1dd010f46709c3e2a7ecbecafe1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53dde5e597fc4c8c9f9392994230aefd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e7ddb0e37dc4971959f70137bd43e78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6980afe038e45579c072cc6b1f18611_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0313e101274d4d69af2e1f0fe44be664_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e2b91e05cc6441ea9289dac6014f9d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1569fa49e674423a1c2924dd5b61f56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iddb3c647adb04138be2978c1bc0e7c55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e53260d7b76425c956afc0063e9e182_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i589cf24d12624979854f176c47f77cc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69b13783318c438397f0b5c7220581e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id230907331084b6ebd637c4cbd8e25f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7eb2069f86d24b03827a9e9d8f97e538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6caabcbcf4dc4ebd86cd6edd6a29e8f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7cae3a2b8ad849299af80dca8054aee7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i847c77713b0c4b30952627ab78b5d9c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i102f4590cd5742c1899de653a60628e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc748cd30e344577abfa0acf8a8c1844_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0bfeb4f55a1452cb6a3d4b5b1ec025b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2044183092a4b149a34f91bca641feb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1b95610d80114557965c7323d44db873_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cacafade6b2473683f93e114273f77e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55cea2844ac74eb395212db775cb345a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if91268be96b54e30bdf5db6bd9878dbc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7513aaabb5f4272b2cacd3804a15a28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee66dbb093f14358827b89e7e0dcd966_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2e78ecedd654614959bcb071f7acadc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f2ed1b955d740f2b0927118ddcb4df3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia906d2214220429abfdad1e08150f915_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib97dd6c44c604681b3098926fc081208_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c4ac453a767416c8e1f4e02b40d3382_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a1ef2a73f9a48a4986b5abce37bdb95_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib79fe00c16824d8d9660be7d01074024_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i245cd04d75b64741b3e002da6bb2c48f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0413ebf760a34b8898709dbf0402b2ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a81f06d2f0d45df85572d4243c7b338_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1cb997734a76456bbb02c472d8bda07c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35fb84b762b84b7aa1431739434b9b21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a3e9c9d067843908408309f57f08a32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84a64ac1b4c94676835b5826fa5f20c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2d69c8fb1e1480c8b25d127290a2aaa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4fd341ae13d453bb4c6a2495482ad7f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic41eb8f855f04ab18ec5a45dc18339c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c4d7e36c9834ea2a50375607652e3ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:EquityinvestmentinGalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie2dffdc39d4e4c498f9847e218524a71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d94a45eedcf462b8e2ad22dd4dc36e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idf015395242a44bda73d3642656c5f16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifad52fe076ec4556b05b0b1bd02f7c11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i014468a50cb14ec0b4f015914180f3c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01262868b33640a197ec1f4edf4d999e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i74c40eca549f4c34976283d9d6ed1e15_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6a4193ff8f34e439051dd12ffb9dbb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f5cae775b7f463ea40bc9792ac6e442_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1eccad0947fb47f0ab3c1aa00d140b19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifeb4f3afe2714d6db05b71cdf7349336_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4710ffafb664853b06fb84f1f903262_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefb3298102714119abcc23920b0fbc5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc33840c250349a384747a52147ce1b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab16ab242dcd40f99168ba8f52458d66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5db613f5d89d457781afd75124915704_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6760924221ed4b5cba60ea7d2547a8cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i823810b00b57487a84c912f0198b1fc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5a2765b359a4c069d0d5da473baa6c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87f2798614104859bbe54d4ec9712a0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if63750d09d394e93bf20d847c07a673e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd825c3a419d40c89740d90e5802b238_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb6a848a7d8944b99e06faadeba12110_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i620b03a7ceff4498b7ef8db0524ac079_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb1ffad7978e479885f4f62b24f36dc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i284a56e4feb84fa9b3f54659b24ed623_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib17a07fc344b4439808bd61c45decb70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98db09bcfe5b4e588506f6849925a677_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d3b63ebc98b4fc8bc4ead7f256ad433_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia600e92a5fee4aec9bd9a77aa48c46f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6eefcd80ffa146259d29c8ec79bcd8fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i451fd8be53df45b88a7acf78165a771b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c1257e571bc436ebc3359c9c23418d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i501409456a97436db0b9b79612bb915b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c91186d780d4a76b4dcca46016e88b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43d13c3320274c64bc19f9627e57686b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31162f66edd14b10a6a33b68539c40b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fe5dab1d5f643f9bce8a2eadf2aa51e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c54d9501afc40c6a54d229dda2f8f02_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib88622965efe4116a7e9094e9f179d61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16426d78ce7c4baeb60f73d40c7360a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a5e7f31b83842cd95af2e19292bd16e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff3e3a8f25534e47821628e02a0a3563_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1322bc486afc430a880d2d9343dc7c55_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2100cafa2bd04f0fa1ca7fd4b3cfcbfe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fc2d816fd7043748729bb6623b61959_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3eded22e6e7b4c3b9606256b7f9aa791_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i053b4f6a4ee446758474a88c7466df66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i743c158a26c1458b8cc125718d80bd03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i120926cc5cde493e8d537eff1e3bf7e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0847197eb84c4ea6b02eec2146463bd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7fb21110182421cb22d46b7cd3b631f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i595ca0a2d84447909de4d92345625390_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bfed0ec9b354312b4fddd01563207c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i390292299b6b4a5486f594d72b417724_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b54212c105142999597c1d3fb250563_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie18832e6e6f64234bff6179e17fdedbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iceb1445e2fcc4c789894cb276a5414d5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9150b394a9d4e499d6e0b58b1920391_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f8f006f881a4957896607c58789822b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61fc82ab7f9c4eaba8049dcccb0fabcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3e58eabfb144b2b803232b6b3af397d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d35182bfdc94f2e9d411da9d4df6871_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28cbe18165a844a88047e90985c3a97c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i993dfcf3896148f697a431026afd4f27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10964ae7f7a549f6ab1ff180665f69ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bf3fc79d1fa49ce89bbe681181cd43d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61bac09c30bc4649b266ae9b0b2f845d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedaad0d104904edbae770e12c309829c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ac161d27eca4bbdbc92850f94d7212a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic70691dc9abb4d69a28b5f9142fd5dd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82be8c76fac444ae8b5be2464102adda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18b7ffc02a4648be92cdc6a03d99c1c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i784d730b592f4dda968b2f2a0865acb7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7830a932cee94f22aa34ced72f487d72_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9cd75011da414b8599c1d9723149a895_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89c3d1c8982e40339444fa81b506c130_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac4066de7a73468a997dd8cb92bf3a1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaab6fcb4f58b4822ad8e346558c2c980_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85193bddbf1d4369b3eed33741718ebf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if38a8065706742818aa8f128c9d384dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dad5026e5bc4d748d8400db3eeac8e2_I20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="i1ebcc5583e8449d2977a0c7e88f011e4_D20200407-20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-07</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="i94aca37dece54db88d94195652d7be2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91c056cec2314052b0ad7bf56bb9f361_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i007de77796ce442bb17cf6397fc2f2b4_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gild:PaymentstoOutstandingCommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="iead588e99e254c5682217485bb77e1dd_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">gild:PaymentsToEquityAwardHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b27400d62ea401b8ae3613d26aae982_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i8644568592004cfc961c871471a2665e_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i3d0d69f623804c20b69d4aaa63420c60_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i48328e269350428eaf5fc46371917dc9_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i8a7d2971f9e04bd8a1de84efaccec570_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="i07cc7232a64946abb68b060bdcf121a6_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ia544b37590e74cd9b7228b42939d36ed_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i8903c926354a40a881da8a83728d0f0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id970621751c6420ca530ab3e07f6cbca_D20201210-20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="if51626d380ad4bb2aa86f7539b1a1a7c_I20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="i9420f0406eae42c8b4f99ad3276f48ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia01ff2fb62994e059a1d6fa4ee99a6c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8678846271ab442c97e55730184bbb1f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idfef2fedfcb34cf49d5ac0ac1e7e9e08_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6d4279a507124f3ca8496850b7e31956_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91dd4f13fd1443a0bb2d19e5d92b1991_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81e9d6e5f883421587e150d19ce229b1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4f76f60b0dc144768d3cda731d8c7cd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife2f98a6a4fe4a41b4e2e388608c97f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47f7a6ee87fc404481ff08ed83281586_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i58f1f76b76904d83b316fbb983869d34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ca166c8883f43c39c1ddefe732e5d75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic66b58065448410d88d6fe6479e1992b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibca01e23b54043618df5703b720be264_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyForMTNBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if0508d4b5e1c46bf97925917f958f9b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c593b70322648b8855aec1be0938cc8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8000203400804727bf1a4e40c93f3c16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icbb578eac6714200a5377073798b8f1b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe4376a44dc14cc2a76b854d11662987_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8df8c75c0ccd41708b9a841f5afbd2fa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:FinitelivedintangibleassetimpairmentbyprogramAxis">gild:Kite585ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia16ced64a7e645e781114e8469e73643_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="if681ee16d60745e59f58ea94a5a22cc6_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="iffef91ebd0344347af71595936327ea0_I20210208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedArcusCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-08</instant>
        </period>
    </context>
    <context id="i52b270d003824c77b29b5398d6d3083c_I20210208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedArcusCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-08</instant>
        </period>
    </context>
    <context id="i8af407247e1d4bb483def9e87402f03a_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i80831b6a43e144288ee6887aa81b9527_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="id99b5612dbd4404ba21f6f1b905e2fff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i37eb10dcc178427ab1244846e835f528_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="i93263403f73c4d28b597082de10c84d1_I20200619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-19</instant>
        </period>
    </context>
    <context id="ifbc35450bfed4ce1b3b6d598e9f11a83_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="i6f9442c5e7f742a5918ea65c554e30f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if78171fbfd924018a723f12dc3bd832a_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i2d3771f3eacb401d97c063d22f14874f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0a6b60bf1fb4c95bf249cf35ab97877_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i34c05527ff1f41b18c4eaf4e2b69ad93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd832b1814dc41c2855ec98618a3809f_D20210201-20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="i9eb304537d4c49c5921792c6d16c44b1_I20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="iffcb20e38446438fac262691e10ede58_D20200825-20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-08-25</endDate>
        </period>
    </context>
    <context id="ia485fc53f8774d4bbbe1c1dbe9ba40a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if33df116f5f941209af85885b37007ea_I20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-25</instant>
        </period>
    </context>
    <context id="i7aa72b0e47084ac4b180eb22cea3779e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-17</startDate>
            <endDate>2020-08-17</endDate>
        </period>
    </context>
    <context id="ida137ca5e8244cb0ae5f91885ad73166_I20200827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-27</instant>
        </period>
    </context>
    <context id="ia9888aea06ac4afc8425a218b65655b0_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i454bf1f356114d009c08e1da60df6588_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i740dfff7a05d4e5e8dd476392363eb90_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i8f9917b07dc845fa8fe5d3c889a19c8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-19</instant>
        </period>
    </context>
    <context id="ic14136643b7342e68c68c63cc70e88de_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70ea464b37414fe3830d04118e06ee1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68443d5a14c140e5b3fb3ff26e44562f_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8b08c2b1e8994a8386e2f87e19b2f94e_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i809a5f73da45450ca7e822b925dcfa95_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i8146d0695ec4432692851cb70914ad5f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9933f47e878d468f83ba0ec2b8775652_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b237db0dba14d1f8cd562ae2e0c1500_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i960fec8ecc464f7f9fdf9acc6db7076c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ba7404849984dafb0475afcb806dc0e_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i70e3ac2edb384dcd87ba36967240d6a6_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="if741a8ddd11548bca6696dcc16ea06ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee332949c6714cb9ac12a12334a0d199_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibf43160183dd4615964265dbc7e94547_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6c6d33288a694080a10decb9745df341_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32869178bb374083a5691c4c47f7e162_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia23e8ec8f5a94be1a0800fd9ca20d3e2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i10e8f707b4a2423885556304b9c14459_D20181201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if4142852a6d94d81b33b11f3c2bf3444_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie52274b0a3fd40f79ccc454513656539_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="ia16d123600754634a5bcf2ed111b7be5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GadetaBVCollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia37d42b05ac242459b8ca53417f3c881_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:BristolMyersSquibbCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ife61ff89d12b4fd3ace02e9f26886498_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:BristolMyersSquibbCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i32f211cb92aa41f0a97038b010abc03d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:BristolMyersSquibbCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3c008f74ae7741bebc87087598c24b61_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie87f8e54cb4a410db675109bd66255a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief4a90e396444c1698d4940439fd9f6c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1af6afc5f8e54ba59cb9793eef93e885_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueInFebruary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied16c88db1234c66aedf0dc0e80bf0da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueInFebruary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33544e3e9bf8466189835e7d6f721350_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76142ba97a5247fd8b93aaddb16c8fd9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8ad657ef10246598ee1f2d6d2eb3a7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcb35118d4c9442e94273ba0799d1e3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a7777335ed04cf59f807114fe7a66bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i079f3e090c534879a46df4da2d4f54af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5cfc1706eed466ea24db728b779b02d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5975f2be2634b6193ebe5e4518e0b67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3670ca9b3f7f4e67bf432cd8f3e3dd6e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i068021f3eade41599edf59a5a127fefd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4a14e35256c4e9b99448ff4ab266069_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d3bff642f2142629af6b9cd0108692d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e913054de0540cfa8dfe947549c1af3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11d7b8db766a40b4915b3e488cb97f03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac7f8e63064f4893a1648dc50ce5ffd8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6845673544a4170be8f0594b2341c6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8a2ab9d1b9a48a0964021dec398e682_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d4e35afb27045a0a512b4300478000b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0cf198ca9f14127aac65bf348fd3646_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie429e3caea7d425b84413a3c28d65099_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c543bc5eea4422e9442c1624ec8ab90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7238cb6a890463c9d26c7c09431cb24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib268c4735aac4a7894a222f05f1e7ebe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:VariableTermLoanNoteDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f80a26646664c12af8af332d1630212_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i588786d4c5b04ceb86b3104e6b1dbde9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f90cd187b864231b694a710210de89a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86263ea980a0478086ecfafe984d7563_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e89e8f308084febab4d3c4b09ec137b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f36c3515ec9482dba6b429c4a71e17b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbe5e2da225448318d6e7ce30d2a5b44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2644728c1aa4257bb5ac872b6fa8552_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief2d0ff77d1d4377995f3b52034e38fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47a08b08ea6742dab3cb313aea60e574_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b4ff001607a4d4e86f6ece76b1cb4a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i601d3d19bbbd40c9be8b03ece2ad21ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i917a67bd025e47c18737842312fd65e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94d1d8ac11bc404f91be62f8fd6239e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c65c238d0cd4bdaa6748c4a0d9248e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie386ac3bda26490e9b7780e1e62a038d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i116ad184d5dc456e90f07d8331609037_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a3d522c920c4eaf98d9423edd359180_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28f0ddee26a6400e90f15437dbf5aafd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25cb38188cc44e84a8c402adba11be30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c50be0096dd408eb2b0af525d5453d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3341333ea70c407da5e3d68a2db6c9dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d3e46a170ac41afb9968e742e88e06e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i861f7cc25fb44ef5a805d427c6d41708_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b2a2c92c9bc4c019c117fcccc6fbd78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic99295727180471890cc95afa2e4192a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i624388aa63954f5c96041bc516796f34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04e043d95be44884a92667d375737a0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i016f2c24896d41729056d15a9007c6e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b17acdedffc4fc1bd0b4b188bb173cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61afb70e61ba4c8aa5270a4e11c0914b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i180ad2d40440498ea05cf2425660478c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dd068f90f2441228adf1a8ce9668e2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b5f5e11f4c842dfbe349568ca25c17d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7af8fb6957bc4c20b9649de1e7fe1110_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i71abf35a67c349dabfb936d03b474a47_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5c1faea29102437aa26bf1071aaa87fc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9ff57f2a7eef4231a0e859065a5afd5d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2e55cf66183242569e946df901102514_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i796d7c545dcd490c93f7b990f3264b66_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1f8b79007ae445a3bfd27b69829de9a4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i66e3e8a86c104591a0f8120347df1468_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedSeptember2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="id20d9ac4b58549aab5a3e792776164f4_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedSeptember2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if038f51729a24a2da8b265e610a51eee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4137a356fc414084a24897805d41c93b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueApril2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8ca5a2ac1db347aeab2b0dc69d1d1bc0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50551ba0e3694af9afb0a78f8b769781_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2c456ffa7a147bbbcc6146cf6a5c52e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i362bd4a2c0a74dd5b55702363f9ac9ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3b239e1b3ad417081b0cd98df44abaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie106ddcf610645b9a3a7b3fe329ce835_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9f85bd04d2e648e9b5df6a64f170cf3f_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i561ca9ac62a24c86b2e01e36240808fc_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="i48284e9ef26a4194b5c4901f6e5e4bc6_D20160531-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-31</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="i204030d3773f4af78e0d6df4e9417215_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueMay2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibdc7aa7015ec49fcb95e9effaeaa1a5b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6aa41df238d34894bcd7a6ba42b01248_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibdfdb0b6b6174cdaae4a05f26000ab2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i919f90af93194b0f8ce1c1dfb232c4eb_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:IdenixPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="if9f82513a9f94dd7a549cc436cc58d8c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:IdenixPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5f7210bf9b704da3b00654f5387c8418_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="id4a501179a0c4d10a7471e189ee30e56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieed6db4dd53c4a86afcc8c65e474d496_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i844383cc25214e31ad2596ee61b72eee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4281b1de2ca446dacc33382d882ca0a_D20180207-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ViiVHealthcareCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-07</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2902027c39a417f91f8f33f93f2f77c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">gild:ActivePharmaceuticalIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i676b993c500e4814bfc126d01c700bce_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ib489d1a178c64897a715f8a20a2aa447_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2d9aac36dbf242fbbc1e60f05511aa07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4830709842f45418b3c333d24ffd5a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b6402e854a642ccaecbd191f676e641_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:PubliclyAnnouncedProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib10c7000f4c647a2b89591cb924c9b7e_D20210204-20210204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-04</endDate>
        </period>
    </context>
    <context id="i80decbd404fa4810a481f263b6dbbc28_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3d477cb7874f4bfd96a09be4ca3fd0c7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6040cf00a6f04094a6d26c4f32df7e7c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i14ff8312abf74fc68d269603e3776270_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib99fd8d434aa478fa9b18fec33d3e230_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icb3593a4df8f4b348d04321ee946cf2a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5468af7521ac455985434b5f19b7bbb9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1fecafa85db046288d32b5acb380096d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ed215bd7b494fbe89f89a8b6e2b2a64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5707d2a1fdef4bd29d50dcedf69cf5db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3cf73804142f4a5a8699854aa476d33f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f513a45782a4d148af987a580b897fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81b95bfbb00a4bee81e1cd96a5d51ca7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3903462c6c24250b51ed2304b4c2329_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8565010ef19410480a12c5243b09982_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2f11fdc536f400994934dad7faee301_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2004EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iade23e2d742345dd981025a2118869e5_I20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2018EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="i86b3338567b348fd91d9138a1c4c1f6d_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="iaa1d5481adee40849cb658b58a5e6799_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75d7b35235ad4232b8705dbc79802f56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60943a7163f448b5a6c2157080ad7985_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc447ebbb9884a78a958aa20b56841f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ied46b5b50bca4d0998e9bb06b1fc9bc4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9db8741b4d8842f1bb640976d2a45d96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62891fc164b04b4e8264bd225dfeb876_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6aa115e88017417cb54eaf2b28abc9ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37406a81513b4400ab5caf494643ae52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iede55c4650474e14803be5cd10e0b4b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic717d0c503c143968d6471b329f28be4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i131142515dae41e291f717d69305bc41_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d4423b8d04646d3a954612daf594dac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i982d3c7d11dc4c84a981217fe59bf232_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i109c30251de2477081720f87d8a28594_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c6dd7d6dd0d45e6a2043541078d3796_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i76feedf9c6014726a00c27da12c8de28_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i22b4c383c26c48c892d88beb1d9d2292_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifdc506af41e54853895ac3a3ed8d114c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38d54fab5ace4e28898af9b5fd4628d8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3702dbcc04054cdd86bc26be99367a19_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatGrantDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i347b4c9b1da2453f8b5c69693ae0fe5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia29bb89cacab4917ad78178e3cc39d53_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c985006e29e4ce693bf89616e366745_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gild:TotalFairValueAxis">gild:FairValueatVestingDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie2c93d478ae74471acc0268f5b36f929_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i009c4559c5ee4dcca45e50ed6dafe35f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gild:RestrictedStockandPerformanceShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia929926fabb04040b30c9fcb5647aad5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42fad2d6b4d14144ac2fb0e8b3cd8fab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8c99d40ca3b4653938ea4dd23e12064_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7be4f110329145dfbfde538bee9a676d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iff3394e3bd2e4809af80fd7faf8770e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i80dd52732e7f44da975a903d2cf2542d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2e09efc6fa77468ea8742717d97b0509_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia623662c706d409a83107f00f6077a04_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2f77d5dbabfc4c67bbc7902204dbe301_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if89c7b93f0a5477d94803cdd6f0a3319_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9779a570996452dbbd3c83239ccf707_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id3086aba7396431180029057c2ad4ece_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id342243123964d40bc3ebc4517f36cd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic67c62aea4714cc1bdf529a34a43a13a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia2ce6de3160c42fcbad2f1b836b16a69_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:DeferredIncomeTaxExpenseBenefitComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifcde38bda2ec4ee2a91607db91272226_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:UnrealizedGainComponentAxis">gild:IntangibleAssetTransferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i911b942fdd1a48718de383949eab2834_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">gild:InventoryWritedownsforExcessRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf9604006e3f48c2b90d9c9dd73c4174_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gild:EPSImpactbyTransactionAxis">gild:FavorableEPSImpactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>gild:security</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="study">
        <measure>gild:study</measure>
    </unit>
    <unit id="program">
        <measure>gild:program</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl8zLTEtMS0xLTA_203a70ed-334a-4ed0-9a78-215e8b3a2e04">0000882095</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl81LTEtMS0xLTA_11f14248-f569-400d-aa58-27f2174c38d4">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl82LTEtMS0xLTA_4dcb0c9e-aa19-4ff4-97db-c27c66d2b517">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF80L2ZyYWc6MzNiNDUwNWE1MGExNDUxZTgzMDI5ZmFhNTU1Y2QwMzUvdGFibGU6NmM5MjdiNjJlOTQzNDg2YWI1MGJlZWI3NzgyNjIwZDIvdGFibGVyYW5nZTo2YzkyN2I2MmU5NDM0ODZhYjUwYmVlYjc3ODI2MjBkMl83LTEtMS0xLTA_da271d22-3be1-4c74-b120-1f4d6557d88c">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8yMTI2L2ZyYWc6YWE4YmQ5MDUzMmI0NDRlYzgyZjNhNjI3ZGVmOGU0ZDgvdGV4dHJlZ2lvbjphYThiZDkwNTMyYjQ0NGVjODJmM2E2MjdkZWY4ZTRkOF8yNzQ4Nzc5MDY5NDc4_267e84f6-6e71-4775-b36b-3b9c34d26ca1">us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8yMTI2L2ZyYWc6YWE4YmQ5MDUzMmI0NDRlYzgyZjNhNjI3ZGVmOGU0ZDgvdGV4dHJlZ2lvbjphYThiZDkwNTMyYjQ0NGVjODJmM2E2MjdkZWY4ZTRkOF8yNzQ4Nzc5MDY5NDc4_77fd3619-2e1c-4b6c-93d9-6da205eabd6a">us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iaa1d5481adee40849cb658b58a5e6799_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0Nzg_3e0bf107-df4c-42b5-99e9-a7dcf78020b1">P3Y0M0D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ied46b5b50bca4d0998e9bb06b1fc9bc4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNjQ_4b3408a6-98fc-4b69-98be-510a6fbd1b22">P3Y0M0D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i37406a81513b4400ab5caf494643ae52_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDA_af92dcc3-2fe4-41b3-aed3-392d48d636df">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iede55c4650474e14803be5cd10e0b4b9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDU_17e1fc1d-af04-402c-9a3d-30ce2e48473b">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV85MQ_8470be95-8de6-47d4-a55c-a159a386a304">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6MzhkNWQ1ZThhYzY4NDEwYjk2MDI4NTVmMDFjMTk4NzIvdGFibGVyYW5nZTozOGQ1ZDVlOGFjNjg0MTBiOTYwMjg1NWYwMWMxOTg3Ml8wLTAtMS0xLTA_39fd5779-0d92-4ee2-944c-a118d054034d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xMTM_9e0b3e6d-2c6f-41d0-b71a-83c1f6a361d1">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xMTM_f320e9b6-4606-47b6-9c30-ca0ac629d05e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6OWViYWM3YjMyMmFiNDFmMjk4NTVjYzZmZWFjYmVmMzEvdGFibGVyYW5nZTo5ZWJhYzdiMzIyYWI0MWYyOTg1NWNjNmZlYWNiZWYzMV8wLTAtMS0xLTA_42a8f5cc-fcf2-4ada-9dd8-fdaa1b291858">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yMTk_d20e5789-57ff-4c27-9b5c-d8be21ec3a12">0-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yMjY_2a7af509-a17d-4db9-b259-7f215c52b5ef">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6NTEwMjc2MDQ5MTE3NDBhNGE2NzY4MWViZWYzMGFmYWEvdGFibGVyYW5nZTo1MTAyNzYwNDkxMTc0MGE0YTY3NjgxZWJlZjMwYWZhYV8wLTAtMS0xLTA_207d1ec7-c817-4854-9559-3c1716b75052">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6NTEwMjc2MDQ5MTE3NDBhNGE2NzY4MWViZWYzMGFmYWEvdGFibGVyYW5nZTo1MTAyNzYwNDkxMTc0MGE0YTY3NjgxZWJlZjMwYWZhYV8wLTEtMS0xLTA_4fd85ff0-c295-445c-ab0f-a17187f9d4fb">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yOTE_71b7f887-9ccf-4de3-8a40-6c8c06da1ba0">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yOTU_5921d1e7-6f61-48df-b073-a554c2e3bf9d">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yOTk_c4f9bbc7-570d-406f-beea-5410d2aaeb25">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zMDI_44c1fc00-30b1-4880-84fb-817e3ee85354">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNTg_26e84ac4-aac7-4045-a251-bef3439c6643">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNjE_12803a4d-5c31-4a5c-9688-34e5324cc668">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6YzkzYmJhYTZmMTRmNGI1Njk2MjdjMzQyMzVkNWM4OTQvdGFibGVyYW5nZTpjOTNiYmFhNmYxNGY0YjU2OTYyN2MzNDIzNWQ1Yzg5NF8xLTAtMS0xLTA_962c87e3-5ffd-41e0-a998-f10bd7840aac">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6YzkzYmJhYTZmMTRmNGI1Njk2MjdjMzQyMzVkNWM4OTQvdGFibGVyYW5nZTpjOTNiYmFhNmYxNGY0YjU2OTYyN2MzNDIzNWQ1Yzg5NF8xLTItMS0xLTA_cfd87f97-a950-4f1f-be1b-4a129aca26e4">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGFibGU6YzkzYmJhYTZmMTRmNGI1Njk2MjdjMzQyMzVkNWM4OTQvdGFibGVyYW5nZTpjOTNiYmFhNmYxNGY0YjU2OTYyN2MzNDIzNWQ1Yzg5NF8xLTQtMS0xLTA_5480bfd0-76f0-4dae-b8af-60852a510d51">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV82MDQ_b3876a28-45f6-4d64-9784-a81bf59ebf05">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV83NTQ_f2f22ec2-fcba-4303-a700-23160f91985b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xMTA4_6929e4d0-9a17-4fb3-9937-6ac684815299">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xNDQ1_81d37c7e-9ac0-4e84-ae84-7acefa35cc19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8xNzc2_3b14efd4-8c48-494a-a704-0cf10e3638ee">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNDM2_e1ce8e0c-bcbc-40fb-a794-41a9bc688271">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNDM3_e1e03fac-9c97-4125-959a-8d143cf9a04a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zMjk4NTM0ODg4Mjgx_9057183f-e722-477a-a471-fd587bc63b72">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8zNDM4_004a1762-977c-493e-85b4-a65eb0d57c94">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ie96afe3a1df84576aaaff813a6240267_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yNTAz_e700179a-6211-42bc-91d7-360a6d97e4a4"
      unitRef="usd">69900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if218098f852d48df84d6fe5e15c309b0_I20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yNTg1_a7ffd7c5-3e8b-44b5-9d49-b7052fd74363"
      unitRef="shares">1256593156</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xL2ZyYWc6Y2M0OGRkZjdjODFlNGRmZTg1N2ZmOGQyNTg4NTgyODEvdGV4dHJlZ2lvbjpjYzQ4ZGRmN2M4MWU0ZGZlODU3ZmY4ZDI1ODg1ODI4MV8yNzQ4Nzc5MDcyODgx_fd0093bc-d9e2-4a61-ac81-16dcfe568f6c">Specified portions of the registrant&#x2019;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2021 Annual Meeting of Stockholders, to be held on May 12, 2021, are incorporated by reference into Part&#160;III of this Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNC0xLTEtMS0w_028f1eda-bf40-4fc4-8b9b-5b433ad33259"
      unitRef="usd">5997000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNC0zLTEtMS0w_0e32991b-20d2-4555-94fc-58a9f5014ca7"
      unitRef="usd">11631000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNS0xLTEtMS0w_6650ca7c-9280-498b-a30c-a9c184dbefb9"
      unitRef="usd">1411000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNS0zLTEtMS0w_b14471f4-cacb-4ff9-a5fb-6a8aedf9c39a"
      unitRef="usd">12721000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNi0xLTEtMS0w_b5bf9d16-aec8-4de1-91d0-5f3ec0ba4374"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNi0zLTEtMS0w_5bd0a820-38f0-42b1-9d95-cee1bdc48a68"
      unitRef="usd">3582000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNy0xLTEtMS0w_7c105b41-e882-445d-9574-53328bbcb0e2"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfNy0zLTEtMS0w_9cdbeda2-9c1b-4a48-8e3e-b05f46184547"
      unitRef="usd">922000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOC0xLTEtMS0w_5255fd4e-f592-483b-bb9d-432e172534d2"
      unitRef="usd">2013000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOC0zLTEtMS0w_24b5bda5-d2a4-4aff-89c2-78d105c899d5"
      unitRef="usd">1440000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOS0xLTEtMS0w_399b7759-a4de-4079-bd02-291fa5932b06"
      unitRef="usd">15996000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfOS0zLTEtMS0w_720660a1-c7e1-44c2-b92f-a75d64361ec9"
      unitRef="usd">30296000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTAtMS0xLTEtMA_36e72c8f-e635-47ca-b9b5-e629af4045bd"
      unitRef="usd">4967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTAtMy0xLTEtMA_d9f7377f-bfed-480e-a4cf-42af0a224686"
      unitRef="usd">4502000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTEtMS0xLTEtMA_d1f9dbe6-0943-45e3-8aec-22c8ba76ad62"
      unitRef="usd">502000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTEtMy0xLTEtMA_2c479097-e33e-4367-8a89-aaaa9d86a374"
      unitRef="usd">1488000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTItMS0xLTEtMA_2afc35c8-696d-4f51-a48a-17f2a7ed4236"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTItMy0xLTEtMA_92567c06-9363-4d97-a194-aa303da1f6d1"
      unitRef="usd">13786000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTMtMS0xLTEtMA_d69c9561-4fbd-4a19-97c0-b671ec46c7a9"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTMtMy0xLTEtMA_a53d41c6-d6ee-44df-bb8d-160051da533d"
      unitRef="usd">4117000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTQtMS0xLTEtMA_a4e77731-ab4e-49fe-9de9-ac4c703e6125"
      unitRef="usd">5708000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTQtMy0xLTEtMA_485515c4-af28-49ea-8a09-24b58ca1d6ea"
      unitRef="usd">7438000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTUtMS0xLTEtMA_259a38ac-b9aa-4553-ada0-8b78fcfff9bf"
      unitRef="usd">68407000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTUtMy0xLTEtMA_6625c65a-97b1-4f0d-b775-371395d9c38a"
      unitRef="usd">61627000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTgtMS0xLTEtMA_22f93ecf-aa8a-47df-90ad-123d7b67c5ac"
      unitRef="usd">844000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTgtMy0xLTEtMA_f7b4776f-0ca0-482a-a02b-7a59ac77b923"
      unitRef="usd">713000000</us-gaap:AccountsPayableCurrent>
    <gild:Accruedgovernmentandotherrebates
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTktMS0xLTEtMA_37339287-8e11-4885-a240-adb2ef64ddd8"
      unitRef="usd">3460000000</gild:Accruedgovernmentandotherrebates>
    <gild:Accruedgovernmentandotherrebates
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMTktMy0xLTEtMA_e0d57f80-42d1-4ca4-b490-4da38c8dac56"
      unitRef="usd">3473000000</gild:Accruedgovernmentandotherrebates>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjAtMS0xLTEtMA_a3b6f10d-3823-4ff9-87db-dcfaf6a65b66"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjAtMy0xLTEtMA_e755bc45-ad92-4809-a038-d1d2f09b5fff"
      unitRef="usd">3074000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjEtMS0xLTEtMA_c2e29151-25a3-4276-8b85-83c231df3ae7"
      unitRef="usd">2757000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjEtMy0xLTEtMA_ac99cd76-a32d-47f7-91bc-227c8b28484f"
      unitRef="usd">2499000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjItMS0xLTEtMA_eb6037bb-141f-44b0-b95c-a073e570806e"
      unitRef="usd">11397000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjItMy0xLTEtMA_0685dff4-4217-4b68-ae6e-d75070d8d173"
      unitRef="usd">9759000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjMtMS0xLTEtMA_882f40eb-a127-47fd-84ff-8701810dd639"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjMtMy0xLTEtMA_aea6fd42-7962-47b5-86a5-0618b59da5d4"
      unitRef="usd">22094000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjQtMS0xLTEtMA_122596b0-0bcc-4b02-9da5-eb3732eb037b"
      unitRef="usd">5016000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjQtMy0xLTEtMA_66410e62-53f4-4e83-a7f5-85d1dd0441b3"
      unitRef="usd">6115000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjUtMS0xLTEtMA_66449bbf-f88e-4345-a3ca-510a7613ef90"
      unitRef="usd">5128000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjUtMy0xLTEtMA_1eb237c4-edc9-4377-b7d7-0d5aebae4265"
      unitRef="usd">1009000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjYtMS0xLTEtMA_16c8390a-16b6-455b-97bd-0356645bd695"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjYtMy0xLTEtMA_44bff6f0-ed21-46d1-88c5-09fddf93f472"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc4Njk_6667fac0-1a47-4fd6-8dae-7571ab568fc2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc4Njk_d06f7966-efa7-4376-b4b7-89ca5fce0bf2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTE_eae52c01-6823-4235-a18c-82961f44a59c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTE_f2ed3f04-2ee5-477e-8f30-0f481e912f21"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTg_b72e9655-c82c-429e-8f33-6584e96028cd"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOmZlM2I0ZjE0Y2ZmMzRiNzE5YjAzOGUzYWU1Y2E4MDRiXzEwOTk1MTE2Mjc5NTg_b916ca6a-6e46-4750-bf31-fdd0c45c48e5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMS0xLTEtMA_bed57806-75a0-4c6b-9e3d-2e1c7c295951"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjgtMy0xLTEtMA_c9226f11-4912-4ce6-94a1-5b2a44b6aca8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MTU_5587c431-00c5-4629-b6b1-c55991f0e4e1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MTU_66e8c7f7-6d8f-44d7-9545-ca256c3d8f77"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MzM_0a9ea8d0-ce60-4fc9-9399-d5efb6bf9223"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4MzM_2b47cd6b-274a-41b9-9bab-697c33fe1ccb"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4Mzg_1fb0dfad-9d6a-481e-9bda-2110fa7f800a"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4Mzg_58a5842f-c628-4478-8f53-9f4d30335755"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4NDY_caf1b514-7623-40bb-8cb4-a1d880280af8"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjBmMDRhMjhkZDljNzQwYzE4MjBjYzkyYWE5YWZkNmUwXzE2NDkyNjc0NDE4NDY_dee3b335-ee1e-4dcc-984c-08b7498c0b8d"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMS0xLTEtMA_83dc5dfa-fa0b-4b37-8ff4-d6f2465a4f26"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMjktMy0xLTEtMA_ea240297-58d6-48b3-82c6-4cebb2ab0c3b"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzAtMS0xLTEtMA_c4438fbe-5513-4100-bfa3-9d7936c4dbf2"
      unitRef="usd">3880000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzAtMy0xLTEtMA_f6909c23-7c93-4280-a43e-7b55a43046d2"
      unitRef="usd">3051000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzEtMS0xLTEtMA_c6b9a2ae-0a6a-4906-9446-c94dbcbf0a04"
      unitRef="usd">-60000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzEtMy0xLTEtMA_c26879c9-edb7-44be-b073-00963c74f91e"
      unitRef="usd">85000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzItMS0xLTEtMA_3e9cfa5b-e8c6-4054-9e5b-90e9b54cc464"
      unitRef="usd">14381000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzItMy0xLTEtMA_3d7ed5c3-94c6-4588-8377-cb3f57e7cac3"
      unitRef="usd">19388000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzMtMS0xLTEtMA_0d72fd04-39d9-4b74-91e7-fcbafc761eda"
      unitRef="usd">18202000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzMtMy0xLTEtMA_1e584330-e833-48ef-a8d8-524f8b7f7b4a"
      unitRef="usd">22525000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzQtMS0xLTEtMA_266b836e-0475-4f50-b1a4-3c4f445fd2aa"
      unitRef="usd">19000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzQtMy0xLTEtMA_ef94cd3c-ce53-475b-bdff-a492059544b2"
      unitRef="usd">125000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzUtMS0xLTEtMA_6b93ecaa-7a83-49f6-9b0a-f91c824cdf14"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzUtMy0xLTEtMA_2e2c9ec7-4eaa-4ebf-8e57-e59e8eb62864"
      unitRef="usd">22650000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzYtMS0xLTEtMA_2ab441b1-0278-44c2-9d55-ea259d4fc38f"
      unitRef="usd">68407000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF83OS9mcmFnOjM3ZTFiNzMxMzUzMjQ3ODNiNmJmMmFhYzQwMmQ2MTBiL3RhYmxlOjhlZWY2NmNlZmE5NTQwYzRhM2MxZWE5NmZjZWRlZjE4L3RhYmxlcmFuZ2U6OGVlZjY2Y2VmYTk1NDBjNGEzYzFlYTk2ZmNlZGVmMThfMzYtMy0xLTEtMA_31d76e0a-baf6-4f00-be34-d59154e74ef1"
      unitRef="usd">61627000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85124ea043f44d21b8b54a8de5bdf919_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMy0yLTEtMS0w_bf1cdd2d-6c04-4936-b54e-e84b8565c07d"
      unitRef="usd">24355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1854fd7993394c05bb3e013f00d725cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMy00LTEtMS0w_cc529563-a003-4234-86fc-ca5e2fdf08ba"
      unitRef="usd">22119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c26f4bd16b4406da90ed77b81c4e690_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMy02LTEtMS0w_ea2a3b52-8ec6-4457-bf11-a1f9c37e8fa9"
      unitRef="usd">21677000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id688d136833640ac9c6d94d4ddc9632a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNC0yLTEtMS0w_9aa9140f-e895-4c7b-8b18-5e9862f48bc3"
      unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c8670361a0047c5abdca258af5b3b44_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNC00LTEtMS0w_87fd81ba-6dc8-4dc2-bf4b-a0af51bb2c2e"
      unitRef="usd">330000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a0d2f065cd0476e9fe09cf97a3daa95_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNC02LTEtMS0w_36856f63-34bb-4f70-8887-d71abd903f74"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNS0yLTEtMS0w_e55d29a6-f11c-4d37-9b07-b54efb58cc52"
      unitRef="usd">24689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNS00LTEtMS0w_4a57d4b3-9cc8-4368-8429-8841c509c025"
      unitRef="usd">22449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNS02LTEtMS0w_9ffbb873-c3e6-4b64-b2f3-75e4ae68fd61"
      unitRef="usd">22127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNy0yLTEtMS0w_c9dfae79-8394-4a65-a0de-35360fff195d"
      unitRef="usd">4572000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNy00LTEtMS0w_1ae36cc4-e041-4fcb-9663-2ef21ffb4902"
      unitRef="usd">4675000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfNy02LTEtMS0w_4db1a570-b91d-4a39-9032-4d59e788e098"
      unitRef="usd">4853000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOC0yLTEtMS0w_01eec112-8756-4aa7-b2db-7f516a77c131"
      unitRef="usd">5039000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOC00LTEtMS0w_22f32163-0c74-4728-ba94-aa9f5ed56e75"
      unitRef="usd">4055000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOC02LTEtMS0w_fc9b73e3-e0e5-4e48-a6e5-7b1c80478fdf"
      unitRef="usd">3920000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <gild:ResearchAndDevelopmentInProcessIncludingImpairment
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS0yLTEtMS0yODEw_a9516ea6-f07d-4edd-858d-c326fedf7c48"
      unitRef="usd">5856000000</gild:ResearchAndDevelopmentInProcessIncludingImpairment>
    <gild:ResearchAndDevelopmentInProcessIncludingImpairment
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS00LTEtMS0yODEw_1d4a7ded-8f45-472a-bca4-52c5fb2f024e"
      unitRef="usd">5051000000</gild:ResearchAndDevelopmentInProcessIncludingImpairment>
    <gild:ResearchAndDevelopmentInProcessIncludingImpairment
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS02LTEtMS0yODEw_17afaf3e-0e9f-47fe-8c3f-8012c1217a4f"
      unitRef="usd">1098000000</gild:ResearchAndDevelopmentInProcessIncludingImpairment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS0yLTEtMS0w_c9547426-de9a-4e59-970d-f53f29db308e"
      unitRef="usd">5151000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS00LTEtMS0w_0c5826ec-4362-43f6-be79-4ded1ff5af1e"
      unitRef="usd">4381000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfOS02LTEtMS0w_7df8a041-187a-4d1a-8b4b-ad9759f61055"
      unitRef="usd">4056000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTAtMi0xLTEtMA_282ae9b9-ed98-4bc7-a93b-36dd78fa0991"
      unitRef="usd">20618000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTAtNC0xLTEtMA_8533cc95-3556-4484-8f26-1d3aaf73fed0"
      unitRef="usd">18162000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTAtNi0xLTEtMA_676b07cf-1088-4c5d-aa04-7548f2227eed"
      unitRef="usd">13927000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTEtMi0xLTEtMA_35b4fa7e-bf87-486d-a8e6-997cc726303a"
      unitRef="usd">4071000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTEtNC0xLTEtMA_50ad79b0-0666-46f7-afcf-28c1a8882f8b"
      unitRef="usd">4287000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTEtNi0xLTEtMA_68bafbbc-4cef-4112-9865-4cbc87585750"
      unitRef="usd">8200000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTItMi0xLTEtMA_f5dd9c79-eae4-401f-b841-258ffc6845e0"
      unitRef="usd">984000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTItNC0xLTEtMA_6144e580-5f10-486b-9501-cf92815d1cd2"
      unitRef="usd">995000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTItNi0xLTEtMA_4f822c26-57d9-40db-8a3c-b763131acc92"
      unitRef="usd">1077000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTMtMi0xLTEtMA_e3c84094-a8a8-4169-8a8a-3b7a4d36109f"
      unitRef="usd">-1418000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTMtNC0xLTEtMA_4c015e98-84bf-4fd8-a228-8750ab2245c8"
      unitRef="usd">1868000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTMtNi0xLTEtMA_799baed5-7fd5-41af-9b7b-52ff9075c11e"
      unitRef="usd">676000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTQtMi0xLTEtMA_9c513f54-8ae3-4e87-b0e0-ed69f08e8213"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTQtNC0xLTEtMA_c3cb1366-23ca-4c93-81f9-85bad92e16eb"
      unitRef="usd">5160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTQtNi0xLTEtMA_69bec4c7-1f64-4b83-aa0f-d59d1ee70813"
      unitRef="usd">7799000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTUtMi0xLTEtMA_066288b9-af94-4c38-b6c4-b821012269e0"
      unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTUtNC0xLTEtMA_4e5a9856-395c-4c9f-b60d-2a4a16c23e58"
      unitRef="usd">-204000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTUtNi0xLTEtMA_cb68f8b2-35f5-4653-8ff2-8ed10244957d"
      unitRef="usd">2339000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTYtMi0xLTEtMA_d3b20e9f-817f-4dfe-9cca-af6f287e40a3"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTYtNC0xLTEtMA_657c7bb9-035a-487a-a2e5-cbf5f296e535"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTYtNi0xLTEtMA_bab184d8-25c8-4724-b089-4dd18c652b02"
      unitRef="usd">5460000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTctMi0xLTEtMA_45d5844b-8579-4319-9278-bd2768e8ed4a"
      unitRef="usd">-34000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTctNC0xLTEtMA_fe35d2a6-8975-4e0d-8733-7b29ac2ec05c"
      unitRef="usd">-22000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTctNi0xLTEtMA_e2899c5a-ef3f-46fd-b6de-d01a15d1968c"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTgtMi0xLTEtMA_c46efd6b-8e9f-41de-bee2-216161b5d925"
      unitRef="usd">123000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTgtNC0xLTEtMA_fcde1c31-3ed6-4668-979c-512f73c1ae73"
      unitRef="usd">5386000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTgtNi0xLTEtMA_4052b884-9aa5-45e1-ba0e-fdf3d71b01e0"
      unitRef="usd">5455000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTktMi0xLTEtMA_6a3db572-386c-4231-b8b3-b3b0351d3567"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTktNC0xLTEtMA_1eb20a22-2260-49f6-afbb-d5c6004eb201"
      unitRef="usdPerShare">4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMTktNi0xLTEtMA_a0d0b0d9-c4eb-47dd-a6cd-87a9745bea93"
      unitRef="usdPerShare">4.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjAtMi0xLTEtMA_fcec0690-ed87-44f1-b673-4a50221bc2a4"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjAtNC0xLTEtMA_95b43e39-7e25-4659-8f3e-0cf7c7f921e0"
      unitRef="shares">1270000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjAtNi0xLTEtMA_e4eddad7-cbfc-414b-80f7-83086cc39cff"
      unitRef="shares">1298000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjEtMi0xLTEtMA_2e59c578-2e2b-4c3f-a20d-12a6dc11d78a"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjEtNC0xLTEtMA_a1181978-2403-4fc5-84d6-cac0f0285eb7"
      unitRef="usdPerShare">4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjEtNi0xLTEtMA_032a4a55-478f-4dff-9e78-885f6cbecb49"
      unitRef="usdPerShare">4.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjItMi0xLTEtMA_59a22b3c-0ba9-47ff-8a30-18e1594bf181"
      unitRef="shares">1263000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjItNC0xLTEtMA_45acfb25-7ca7-4821-ae8b-63d0974bec38"
      unitRef="shares">1277000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84NS9mcmFnOmU3MDEyMTlmZWU0NzQzZGFhOTc3MDdlYzUwMjEzN2MzL3RhYmxlOmMzOTcyNDFiZjBhYTRlODdhY2ViNzM4MDRhMmIzNTZkL3RhYmxlcmFuZ2U6YzM5NzI0MWJmMGFhNGU4N2FjZWI3MzgwNGEyYjM1NmRfMjItNi0xLTEtMA_db1858b3-be01-40a4-967d-0a6627c9cb31"
      unitRef="shares">1308000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMi0yLTEtMS0w_d3b20e9f-817f-4dfe-9cca-af6f287e40a3"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMi00LTEtMS0w_657c7bb9-035a-487a-a2e5-cbf5f296e535"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMi02LTEtMS0w_bab184d8-25c8-4724-b089-4dd18c652b02"
      unitRef="usd">5460000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNC0yLTEtMS0w_fb37cc92-394b-42a6-b50f-60fcb49e5cd5"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNC00LTEtMS0w_03a85dee-6a2a-49f5-9c41-d1b3896f3a56"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNC02LTEtMS0w_aadc8fc3-f01d-4ba5-9b7c-58958ef38ff8"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNi0yLTEtMS0w_eea44bb1-6f25-4268-b490-2fc86ad21171"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNi00LTEtMS0w_e49e8a0d-afee-4ffe-8828-fafe96870049"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNi02LTEtMS0w_defac6f2-a632-44f5-b3c6-cc30be7d0f16"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNy0yLTEtMS0w_93f3a898-7116-4b3e-89cd-e26fa6698970"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNy00LTEtMS0w_8440872d-7cce-440c-95af-90a0ad4660df"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfNy02LTEtMS0w_39deb842-26bd-4e6f-b593-397ecd5c0cb6"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfOC0yLTEtMS0w_9730cc45-fe69-4a36-99e4-5e6d8834b257"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfOC00LTEtMS0w_df9b545d-1e97-4af1-95df-26858b231c0a"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfOC02LTEtMS0w_4162f58f-e6c7-4402-9ac1-9b79a992a3be"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTAtMi0xLTEtMA_0e82571a-5a04-4112-891c-168332cdd5f4"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTAtNC0xLTEtMA_5d9286a3-6090-44a9-9558-67213506699b"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTAtNi0xLTEtMA_32f8bf52-c890-409c-99dd-cac33ea0f6d9"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTEtMi0xLTEtMA_693dd512-7f4a-4506-888a-b81e57076aa8"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTEtNC0xLTEtMA_3fff6632-cdfa-4464-a1bc-bda47e2df707"
      unitRef="usd">126000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTEtNi0xLTEtMA_42b79a87-2221-4b94-a446-557b26849bde"
      unitRef="usd">-87000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTItMi0xLTEtMA_727718ae-0b9b-42a5-af33-f141eed7dffd"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTItNC0xLTEtMA_7a74234d-0fc3-4664-9ccb-bb39a336ca1e"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTItNi0xLTEtMA_2e38828d-ada5-4824-aee9-7ed41c40f88b"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTMtMi0xLTEtMA_517944cd-c89b-4d4f-8259-11b8a5b6efe3"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTMtNC0xLTEtMA_f7fd6627-6fbe-486b-9d19-55f80e27ebd4"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTMtNi0xLTEtMA_2a69cc08-fdc6-43e4-a8d1-6876f3c005b9"
      unitRef="usd">208000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTQtMi0xLTEtMA_59dcc39c-36e2-429c-a7c6-6b782465cf98"
      unitRef="usd">-56000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTQtNC0xLTEtMA_995a027b-b738-4e36-a397-9a4061920b69"
      unitRef="usd">5369000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTQtNi0xLTEtMA_383e7190-3456-4e51-9a06-076d0a529165"
      unitRef="usd">5668000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTUtMi0xLTEtMA_4da5bbbc-7690-402d-8256-91b4724d3195"
      unitRef="usd">-34000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTUtNC0xLTEtMA_db8a2d2e-ffe0-4b53-9ce5-9ed1b21be69d"
      unitRef="usd">-22000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTUtNi0xLTEtMA_441b18d9-95cc-42a4-a708-65ba11222600"
      unitRef="usd">5000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTYtMi0xLTEtMA_cb1e081c-1d3b-46a9-9f2b-41d1cbc0e8b3"
      unitRef="usd">-22000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTYtNC0xLTEtMA_a557b89a-2621-43e8-acd9-a465233a9c26"
      unitRef="usd">5391000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF84OC9mcmFnOmJmNjAzNzA5M2MxODQzN2Y5M2NhMzYxZTYzNmVkMDYwL3RhYmxlOmQ3ZjlhYmM4MGY3NTRlZTM5NzM2Y2RkZWE5NDgyNDRiL3RhYmxlcmFuZ2U6ZDdmOWFiYzgwZjc1NGVlMzk3MzZjZGRlYTk0ODI0NGJfMTYtNi0xLTEtMA_fe12cb7b-6e79-4804-a2c7-2530dab89d4c"
      unitRef="usd">5663000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMi0xLTEtMA_1654a1f8-c1c3-4030-a255-350f845a0e5c"
      unitRef="shares">1308000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItNC0xLTEtMA_2dabce6f-f2aa-40a9-b241-bd49a9206fb4"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i835488bd375d4a09af99788bd9e27362_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItNi0xLTEtMA_fde60e22-1401-46a2-8256-5c52cf25691d"
      unitRef="usd">1264000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f6356b044964174974ec7dc3f4bbd36_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItOC0xLTEtMA_13ce52e2-3b28-408d-ac83-fdaee1e39748"
      unitRef="usd">165000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e30e15c134641879f2e452fd14665e2_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMTAtMS0xLTA_b32690d9-c6ea-43c6-9f53-ce50b53738df"
      unitRef="usd">19012000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb5c937c29a64935bd5513af5cd17eb8_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMTItMS0xLTA_f827977c-43e6-49a4-b6ad-09f5e01b3f49"
      unitRef="usd">59000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3219b6982b334ae49d4a68c7befc5d27_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTItMTQtMS0xLTA_b799f581-c34a-4fa6-8952-29dbde4641a6"
      unitRef="usd">20501000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i6ad04f35896042aeb313604ac52c806c_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfNC04LTEtMS0xODkwNw_3c2f3e8a-b30b-458b-ac6d-0ec60a2a2882"
      unitRef="usd">-293000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="ic6f63899ea2f45c8b3d163ffca4733cc_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfNC0xMC0xLTEtMTg5MDc_d4f316ec-7491-4bad-8fb2-f4821d13c247"
      unitRef="usd">483000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i2747bd2827c1444bb8598c30d980ccac_I20180101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfNC0xNC0xLTEtMTg5MDk_effefcb5-4fff-4cc3-a0fc-93295bbd927b"
      unitRef="usd">190000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTMtNi0xLTEtMA_097f5188-376c-46a3-baae-eea968098fff"
      unitRef="usd">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="if3c9515f11a04c63b1fc167cf59c9e73_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTMtMTItMS0xLTA_a16d53db-3e20-42fa-83d1-6d45328cd4d9"
      unitRef="usd">83000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTMtMTQtMS0xLTA_017c86d9-6357-4d7a-b791-a39a35a63de5"
      unitRef="usd">83000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:ProfitLoss
      contextRef="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTAtMS0xLTA_53425d50-7438-4807-afc6-36cdfaa0ed82"
      unitRef="usd">5455000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if3c9515f11a04c63b1fc167cf59c9e73_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTItMS0xLTA_6eca3bf4-82a7-44a5-a00d-aa909dee3d52"
      unitRef="usd">5000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTQtMS0xLTA_2ec54a27-dc37-4adf-a713-6314e7240b17"
      unitRef="usd">5460000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTUtOC0xLTEtMA_983a5fd9-36c7-4567-8116-d34429cd0ee8"
      unitRef="usd">208000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTUtMTQtMS0xLTA_d7d9972d-d89e-4fa6-bc6a-4dd9be45c879"
      unitRef="usd">208000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTYtMi0xLTEtMA_2604bdb8-2b12-44a5-a350-168525a71e50"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTYtNi0xLTEtMA_fe0fd69f-0c07-4d5d-8c71-62d00c1aa1e5"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTYtMTQtMS0xLTA_002675b0-6883-45b7-8daf-a306ed1c004b"
      unitRef="usd">91000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTctMi0xLTEtMA_d9f695aa-6274-43b6-9f67-0c4d3824efc4"
      unitRef="shares">14000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTctNi0xLTEtMA_1ee22f44-ab5c-4bcf-bcf7-772f14e35684"
      unitRef="usd">197000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTctMTQtMS0xLTA_01bfa4d6-1998-4efd-bb24-7cd9b1fca54f"
      unitRef="usd">197000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTgtNi0xLTEtMA_5446afc7-57bf-4ba3-85ba-f0d59ab264ef"
      unitRef="usd">842000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTgtMTQtMS0xLTA_62212bac-d9af-440f-a66b-804552fc3aef"
      unitRef="usd">842000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iae7c1e74992641d5b0b8489da94b43d1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktMi0xLTEtMA_0ee4cfca-2dd3-4dbb-96f3-fce248e7732e"
      unitRef="shares">42000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia3f96fea11eb4af8850cb3372349e901_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktNi0xLTEtMA_8729ae01-6c11-434b-9f9f-d24a93cd994c"
      unitRef="usd">112000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktMTAtMS0xLTA_c8b4a9a1-6c0e-4576-99ff-e523272cae65"
      unitRef="usd">2940000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTktMTQtMS0xLTA_f28fdcec-6320-460b-acd9-646b9d7c3b56"
      unitRef="usd">3052000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMDQzMmJhYThkNzRjNzg5ZTYwOWE5OGI2NGJkYjUwXzEwOTk1MTE2Mjc4MjE_b9964440-0f1b-4fec-936f-4dc106015a3e"
      unitRef="usdPerShare">2.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ib29741c29d004500bf7b61195bc76ef8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjAtMTAtMS0xLTA_e080565e-e414-4a10-89f6-9c6dbf91ac00"
      unitRef="usd">2986000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjAtMTQtMS0xLTA_ea2a3b0b-0cc2-468e-a629-8703601c52c5"
      unitRef="usd">2986000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i93892be161ed46f0b59daf9d2cb4f947_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMi0xLTEtMA_6865d6c2-7881-4b74-977c-7c85978ac127"
      unitRef="shares">1282000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93892be161ed46f0b59daf9d2cb4f947_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItNC0xLTEtMA_c9b7f36d-0f70-44d5-89bf-9be84f15e5fe"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5da7a2ef9a64a11a7b170d14e808fd2_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItNi0xLTEtMA_3f5686b8-6ab9-4a3e-86bf-e31f1c5a1c5e"
      unitRef="usd">2282000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54dde75a77af4f3b89a86ac2a4228e70_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItOC0xLTEtMA_bf00e0dd-f146-4bc7-bba7-bd23657f7b20"
      unitRef="usd">80000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70493ea7576f4f75bf9315161efe8129_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMTAtMS0xLTA_e7632627-b36b-406a-8578-f168193fad23"
      unitRef="usd">19024000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31731035ecc946909f7611c79f589644_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMTItMS0xLTA_82f8b7d8-c994-4941-bc5d-e6370a6bec5a"
      unitRef="usd">147000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjItMTQtMS0xLTA_2b631d94-8a98-445d-a2a9-dfabb7fd6b5d"
      unitRef="usd">21534000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="iad1fdea1fe7d4a078ed1a4602d02bb20_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTAtMS0xLTE4OTEx_59ff0fc9-34aa-4aa0-b744-5ec543ea13a3"
      unitRef="usd">8000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i65708ddeaac5432bbbd3d6edf2afc67b_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMTQtMTQtMS0xLTE4OTEz_7af5e074-65a5-43bf-b158-779abffc4f8a"
      unitRef="usd">8000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:ProfitLoss
      contextRef="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTAtMS0xLTA_e71b558b-c473-48a7-93e2-959e9ca6e88b"
      unitRef="usd">5386000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ide81d63cf6c54f098b1ff7c66544b644_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTItMS0xLTA_12173d8f-0fef-4ecc-98ed-d20ca9d3675b"
      unitRef="usd">-22000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTQtMS0xLTA_87b53e50-4fd1-4dbd-a56c-a577122afbcb"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtOC0xLTEtMA_5cee8ac5-0b8d-4f4e-81a3-e80dbec18662"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtMTQtMS0xLTA_3f3ca3c2-cd79-40ba-8dc8-472c7959f569"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMi0xLTEtMA_ae6c6c74-c82a-404d-9c16-6fa79793dbff"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtNi0xLTEtMA_168cc869-ef7d-4d19-a74b-725eb8096290"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTQtMS0xLTA_3613184f-427c-47c2-99c7-792fe9396ebd"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMi0xLTEtMA_5d66a8f2-73a4-4027-896a-8c73fc0aae0f"
      unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtNi0xLTEtMA_e223ae0f-005e-459c-b25e-53c44d8b25ec"
      unitRef="usd">118000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMTQtMS0xLTA_49a3bd42-4e30-45c2-bc24-747ee45f3a8f"
      unitRef="usd">118000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctNi0xLTEtMA_bbb8a234-042f-4073-8770-0549f21f7d5f"
      unitRef="usd">638000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctMTQtMS0xLTA_6dee79c3-9f2f-4296-820c-ba03a2b6c0fc"
      unitRef="usd">638000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i1f9d2fae698346039fcfc3538e9fb4eb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMi0xLTEtMA_778f440f-8ef9-4931-8df4-5d0dfd3b4daf"
      unitRef="shares">28000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9a1cef90bfab433f8eabf25c7ad53560_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtNi0xLTEtMA_24c67644-409e-42b4-adff-f543b25ea24e"
      unitRef="usd">77000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMTAtMS0xLTA_0aa65644-75dc-4d12-986a-59a4de60b576"
      unitRef="usd">1791000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMTQtMS0xLTA_47a106fb-e524-40c7-82e6-b11ba73fd893"
      unitRef="usd">1868000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmJmMWZlMWM0ODdjYjRjMTI5ZmNlNTUwMWViYzZkNTg3XzEwOTk1MTE2Mjc4MjE_24d4dd52-3670-4fd7-b7d5-68bfc04df7dc"
      unitRef="usdPerShare">2.52</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ia6d99c06a9e043a089ef67cc50f37f84_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMTAtMS0xLTA_4819c352-95ea-4a48-8f1b-28f225d253dd"
      unitRef="usd">3239000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMTQtMS0xLTA_48f6ced7-2101-4445-9cef-1589cd4ab44a"
      unitRef="usd">3239000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iecfc48f8ba344985b35fcd2a8cb7d81c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMi0xLTEtMA_2bd5b356-a45e-4f8d-9386-2796b7ea1762"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecfc48f8ba344985b35fcd2a8cb7d81c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtNC0xLTEtMA_2b94ac48-4e1c-44b1-b788-7dd00c8b7392"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36fcd6ecd6054ae299896dca5929ff08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtNi0xLTEtMA_83cb3a6a-18cd-4422-9b97-1ad585a4f506"
      unitRef="usd">3051000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8823d4c8e7b94b01a4ee9918a81621f1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtOC0xLTEtMA_47db3c6e-bbcb-4120-913c-614190d802d4"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i169f1c5f92244d9c9d8b552d1f30c6c4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTAtMS0xLTA_cbc40000-2a09-4b68-8c56-fc12b0c7691e"
      unitRef="usd">19388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7814341554194d39a8d33cf13d7c7a78_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTItMS0xLTA_0ee145e1-6715-4648-a514-18a910c15c13"
      unitRef="usd">125000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTQtMS0xLTA_5626e4ea-3544-4088-a034-bf6b80e96adf"
      unitRef="usd">22650000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i38c06042926b4ec6a8d780769c247d9f_I20200101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTAtMS0xLTI5MDk_2cb10d7b-de9a-4087-b585-028ec2392b40"
      unitRef="usd">-7000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="i481ded537ec44be2aa528514e17583c9_I20200101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjMtMTQtMS0xLTI5MDk_9cd8e268-8b7b-4f45-87f1-6a1ed4e82287"
      unitRef="usd">-7000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="ida37295fbd814545a3765e7f4773f2f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtMTItMS0xLTI5MDk_e7e4fc73-57eb-43a8-ac56-34b3ac773e52"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjQtMTQtMS0xLTI5MDk_9a8905d2-6d47-4112-b442-4c8f13e9c0df"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:ProfitLoss
      contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTAtMS0xLTI5MDk_34217256-761d-4028-94dd-7ecafa5da5f4"
      unitRef="usd">123000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ida37295fbd814545a3765e7f4773f2f4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTItMS0xLTI5MDk_c951787b-66ca-46d2-9e46-8c2278530923"
      unitRef="usd">-34000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjUtMTQtMS0xLTI5MDk_580b3d3f-0f68-42e3-bd2c-409ebe6ed6a7"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtNi0xLTEtMjkwOQ_94ef02a4-19e5-4dd1-a35e-11dd74d0fd20"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtOC0xLTEtMjkwOQ_4331e484-0415-464e-9926-7c06c1af0b4c"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMTAtMS0xLTI5MDk_d497a55a-b651-4060-9357-b637fc589a99"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjYtMTQtMS0xLTI5MDk_598491c3-a533-40d1-9647-70b81c543e49"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i644e2dd1361545818a945c69c56a8198_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctMi0xLTEtMjkwOQ_949b5aa7-c044-4b74-bd17-dfea2818c24a"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctNi0xLTEtMjkwOQ_72140b87-1352-40be-96ab-8db0703df0b7"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjctMTQtMS0xLTI5MDk_03628d08-da60-4e2e-a4b8-f3c7661e3d25"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i644e2dd1361545818a945c69c56a8198_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMi0xLTEtMjkwOQ_061e3d6c-fe15-4658-9e67-5ca885a227d8"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtNi0xLTEtMjkwOQ_018ecf1c-d592-4ffb-982c-09104f04c1d9"
      unitRef="usd">156000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjgtMTQtMS0xLTI5MDk_53945778-3d09-4447-8743-45c1503e6ec9"
      unitRef="usd">156000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktNi0xLTEtMjkwOQ_6b5ee246-3437-4bdd-b99c-495074c45998"
      unitRef="usd">642000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMjktMTQtMS0xLTI5MDk_018f128f-0243-44ac-8f48-c53a21a338c0"
      unitRef="usd">642000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i644e2dd1361545818a945c69c56a8198_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtMi0xLTEtMjkwOQ_afd52a2f-b0c8-4800-8ab4-08d3cb583db8"
      unitRef="shares">25000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia719d90905124e9b9418db557c451735_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtNi0xLTEtMjkwOQ_d470c41c-d221-4a7f-b7ae-95a4bc995891"
      unitRef="usd">70000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtMTAtMS0xLTI5MDk_9523053a-27d2-457b-b285-aba638c45ad1"
      unitRef="usd">1658000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzAtMTQtMS0xLTI5MDk_9daa09ac-e8a1-4c70-8d02-6d03438f00d7"
      unitRef="usd">1728000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMC0xLTEtMjkwOS90ZXh0cmVnaW9uOjI1NmU5NzQyZjFmZjRmNjJhZDVhZjZmZGY1OTc0MjE0XzEwOTk1MTE2Mjc4MjA_9763beca-e2be-418c-8de7-581d6344805a"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="iac6e268bc9394141a241f4417ff337a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTAtMS0xLTI5MDk_6aec0be3-780e-4dbd-a6b9-2d27d8796f68"
      unitRef="usd">3464000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzEtMTQtMS0xLTI5MDk_6d154c3a-629c-4b9b-b71a-7b9a9ac24f75"
      unitRef="usd">3464000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7100af96680046f2a2500612bc8d8730_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMi0xLTEtMjkwOQ_cff7c74e-c642-45a8-a51b-04d168ad9d51"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7100af96680046f2a2500612bc8d8730_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItNC0xLTEtMjkwOQ_13b69ea4-c04a-4058-a065-8a852d6e8d3f"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf1aad86406e4fb6bb4aa4b7bd2a85cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItNi0xLTEtMjkwOQ_3d3103b6-a701-4950-8f22-56abbff2c619"
      unitRef="usd">3880000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a5ad62f62cb4ef6968f09d3363ab76e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItOC0xLTEtMjkwOQ_6088d103-b24c-4948-93af-67ddcfd73218"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b2e43234fc04521af2344e4b1244e9f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMTAtMS0xLTI5MDk_a1105dcd-7750-498e-9c40-776565d51ab4"
      unitRef="usd">14381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i987c3ed14ae840e7ba9dc6b6834ee87b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMTItMS0xLTI5MDk_45c1a86f-2cfa-4aa4-b8c8-47936347a317"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF85NC9mcmFnOmY3NzMxNWEzZDdmNzRiNmZhN2QyZDgxYWFiNDQ2MzdmL3RhYmxlOjA4ZmIzMGY5N2I3MTRlODZhZmRkMTllNmQzZDU1NWU0L3RhYmxlcmFuZ2U6MDhmYjMwZjk3YjcxNGU4NmFmZGQxOWU2ZDNkNTU1ZTRfMzItMTQtMS0xLTI5MDk_a07bb7c5-023c-4998-988d-d21332d99454"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMtMi0xLTEtMA_d3b20e9f-817f-4dfe-9cca-af6f287e40a3"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMtNC0xLTEtMA_657c7bb9-035a-487a-a2e5-cbf5f296e535"
      unitRef="usd">5364000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMtNi0xLTEtMA_b92b3c2c-ee22-48d4-b277-2dea53ee9ce6"
      unitRef="usd">5460000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzUtMi0xLTEtMA_14f3e8ea-4b1d-4b52-ad63-f748ebab65e9"
      unitRef="usd">288000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzUtNC0xLTEtMA_91e8d048-4772-47c9-8706-e6c3c84b4be3"
      unitRef="usd">255000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzUtNi0xLTEtMA_b74ff89a-dcd4-4a21-a59b-4308633ff352"
      unitRef="usd">226000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzYtMi0xLTEtMA_600e5792-a2e3-423d-b7ae-94896d1f79d8"
      unitRef="usd">1192000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzYtNC0xLTEtMA_caea76c2-f77c-4b74-8e69-fb9e62e5c847"
      unitRef="usd">1149000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzYtNi0xLTEtMA_994563c6-cf84-492e-a169-8a4babf064df"
      unitRef="usd">1203000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzctMi0xLTEtMA_af35204a-9d03-4729-9c4e-97b397c964cf"
      unitRef="usd">643000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzctNC0xLTEtMA_6fea776d-35dd-4a5c-8b66-679836842927"
      unitRef="usd">636000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzctNi0xLTEtMA_76c98886-db2a-4b58-97b5-defa43b5a53e"
      unitRef="usd">845000000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzgtMi0xLTEtMA_f8e872f6-e651-4b80-94ca-a00ed0efcc4e"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzgtNC0xLTEtMA_18cbb2d8-71b0-4fbd-a204-4b102a830f0c"
      unitRef="usd">2098000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzgtNi0xLTEtMA_a1764aa4-a436-40df-b539-e52abef85b49"
      unitRef="usd">-289000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzktMi0xLTEtMA_ba4d98d7-2b17-4bb4-afb6-49cc14ab968a"
      unitRef="usd">-1662000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzktNC0xLTEtMA_fa8d4514-e90b-4f95-9367-262bb0f8ba0e"
      unitRef="usd">1241000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzktNi0xLTEtMA_def20ecc-90db-42ee-a7cc-4a14d77b61cb"
      unitRef="usd">115000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEwLTItMS0xLTA_f46579f1-6342-4505-8c87-d1c27d39e3db"
      unitRef="usd">5856000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEwLTQtMS0xLTA_111ee775-6763-4548-8403-b5766afa3016"
      unitRef="usd">4251000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEwLTYtMS0xLTA_13ce674d-16ee-4ae0-afd9-636f7151b734"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzExLTItMS0xLTA_3e6f53bc-7690-4e03-bcb6-db7c583af287"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzExLTQtMS0xLTA_4dbeecb2-1bc5-40b3-8ddd-01272cf1eafa"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzExLTYtMS0xLTA_d43abc9b-a60e-4a58-b47f-02af3d050ef6"
      unitRef="usd">820000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <gild:Inventoryreserveforexcessrawmaterials
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEyLTItMS0xLTA_19745028-c10f-40bc-8bbc-ecab9848278c"
      unitRef="usd">40000000</gild:Inventoryreserveforexcessrawmaterials>
    <gild:Inventoryreserveforexcessrawmaterials
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEyLTQtMS0xLTA_8ed87eb8-480b-4f3c-aaea-845e93c39c0c"
      unitRef="usd">547000000</gild:Inventoryreserveforexcessrawmaterials>
    <gild:Inventoryreserveforexcessrawmaterials
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEyLTYtMS0xLTA_e6cbe99a-3555-4f37-98f4-e64e6ab5bc30"
      unitRef="usd">440000000</gild:Inventoryreserveforexcessrawmaterials>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEzLTItMS0xLTA_441b5243-4497-4bb6-92d4-08ce89246df2"
      unitRef="usd">-250000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEzLTQtMS0xLTA_99bb9c47-bb70-4df5-8a89-f7a4eb51f7b9"
      unitRef="usd">-279000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzEzLTYtMS0xLTA_8bc754b9-1892-401a-80c5-0339c9e9a633"
      unitRef="usd">-171000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE1LTItMS0xLTA_572d60ec-f819-484f-897d-2c8242337f4c"
      unitRef="usd">1171000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE1LTQtMS0xLTA_e99270be-4611-4711-81f1-0663f02d622f"
      unitRef="usd">218000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE1LTYtMS0xLTA_62608f23-06f1-43dc-9681-1a59d37bcd11"
      unitRef="usd">-480000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE2LTItMS0xLTA_382902f9-b77b-4d07-8345-66e5ff762acd"
      unitRef="usd">195000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE2LTQtMS0xLTA_841d9512-8b1c-45af-b532-5c354ec5f919"
      unitRef="usd">95000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE2LTYtMS0xLTA_44cb3743-097d-46c0-bf22-ed82e9361505"
      unitRef="usd">310000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE3LTItMS0xLTA_a41f1dc5-c70e-4cd4-b2a7-2e9439e2c96e"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE3LTQtMS0xLTA_7e4167a6-093b-4c98-9661-2c91d6be8c3e"
      unitRef="usd">307000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE3LTYtMS0xLTA_67fbd5d2-8a08-4f26-a765-cb4d137dee1f"
      unitRef="usd">-903000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE4LTItMS0xLTA_594c8295-47ee-4108-a920-c293db84e1bd"
      unitRef="usd">80000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE4LTQtMS0xLTA_4ad015c0-aad8-444f-b9ad-8a1ee7afe8e6"
      unitRef="usd">-61000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE4LTYtMS0xLTA_7811840d-adf8-468e-a34a-616c0cc90d1b"
      unitRef="usd">-39000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE5LTItMS0xLTA_ab7b4521-2f2d-4c66-875a-642a5089dd8b"
      unitRef="usd">-778000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE5LTQtMS0xLTA_deffc69f-b8db-4d38-8313-3ae9481ccee9"
      unitRef="usd">272000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzE5LTYtMS0xLTA_543bc0b8-6d26-4883-beae-2e0b97a75c32"
      unitRef="usd">-1459000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIwLTItMS0xLTA_9807cb5a-91d1-4abe-ad05-045ed89e5005"
      unitRef="usd">640000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIwLTQtMS0xLTA_beb6fc30-9269-4880-ac1f-3dc0d74fbaf9"
      unitRef="usd">-389000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIwLTYtMS0xLTA_19776ea3-5a80-440b-858e-03df4887d0b9"
      unitRef="usd">-514000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIxLTItMS0xLTA_682c23a9-0ca6-4f87-b3e2-78a78024bba4"
      unitRef="usd">8168000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIxLTQtMS0xLTA_6b2cf796-caf8-429a-8966-ddf397a23021"
      unitRef="usd">9144000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzIxLTYtMS0xLTA_7b251d67-c79b-41ed-8d8b-da3963550416"
      unitRef="usd">8400000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI0LTItMS0xLTA_c61a3b91-ce33-4e5b-9f1b-728538da582a"
      unitRef="usd">20315000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI0LTQtMS0xLTA_70ef8a34-421f-4cea-a7ed-9f1e6454b60e"
      unitRef="usd">30455000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI0LTYtMS0xLTA_6bb12eb2-f040-4556-bb0b-a32646aaf900"
      unitRef="usd">10233000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI1LTItMS0xLTA_295ae059-574c-4d30-ad6a-6705b0de6062"
      unitRef="usd">23239000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI1LTQtMS0xLTA_f8d4dbb4-3c6d-450a-9758-e05dab8d17cc"
      unitRef="usd">7523000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI1LTYtMS0xLTA_d286cda7-fb4a-4f4e-b598-6d93e7dc928a"
      unitRef="usd">1522000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI2LTItMS0xLTA_accc9800-957d-4225-9b99-1a0dd51532c7"
      unitRef="usd">9479000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI2LTQtMS0xLTA_1a409b4c-8af2-4106-a6ef-0507cb0a4519"
      unitRef="usd">22398000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI2LTYtMS0xLTA_a0addc4c-1b7d-4e77-ac21-390a0974783b"
      unitRef="usd">24336000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI3LTItMS0xLTA_d6aac05f-9f79-4958-a5ea-f455982c1ece"
      unitRef="usd">25742000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI3LTQtMS0xLTA_71b31114-e680-415f-96ea-8491ee9e036f"
      unitRef="usd">4251000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI3LTYtMS0xLTA_520af8f8-6a65-4038-b7e5-b83ccf628a5d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI4LTItMS0xLTA_992f1c66-f62d-4725-85b8-e46ba0fc6cc8"
      unitRef="usd">455000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI4LTQtMS0xLTA_4d278262-2e1f-4f68-a8d8-a090e9fea0ad"
      unitRef="usd">1773000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzI4LTYtMS0xLTA_4e61cd09-80e0-4483-9402-4ef2bc7a7d0b"
      unitRef="usd">156000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMwLTItMS0xLTA_7434268b-369a-44f9-85ed-edb22f67449e"
      unitRef="usd">650000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMwLTQtMS0xLTA_26ba3b6d-1b2e-4397-8e82-449d55426dda"
      unitRef="usd">825000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMwLTYtMS0xLTA_46a712a9-bfc0-48b0-94e9-f4c2b47150e2"
      unitRef="usd">924000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMxLTItMS0xLTA_8a9caf87-6dd7-48da-a638-85d76d2951eb"
      unitRef="usd">171000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMxLTQtMS0xLTA_c068221f-a351-4633-a1f5-aecad16723f2"
      unitRef="usd">434000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMxLTYtMS0xLTA_86a8c786-5c9c-41dc-824b-9c34f900c74c"
      unitRef="usd">190000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMyLTItMS0xLTA_0e26bf4b-3f82-41fd-a062-b7d8cce8a062"
      unitRef="usd">-14615000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMyLTQtMS0xLTA_abc25051-42fc-4f55-9487-3586ba99dc55"
      unitRef="usd">-7817000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzMyLTYtMS0xLTA_c0609089-0bac-4dc4-8bca-17e09c851038"
      unitRef="usd">14355000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM1LTItMS0xLTA_9edbdd36-7bf6-4d91-9222-16976d487719"
      unitRef="usd">8184000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM1LTQtMS0xLTA_74c47e18-6299-4a78-9fdd-045acdf89a66"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM1LTYtMS0xLTA_f9de1519-8aa9-42f1-8f56-b6718201c899"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM2LTItMS0xLTA_8f46a4ec-798c-4135-a987-fa032ee7d6a5"
      unitRef="usd">256000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM2LTQtMS0xLTA_1879d63f-d02e-41e3-ae1b-7d0229a5c619"
      unitRef="usd">209000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM2LTYtMS0xLTA_45158e8f-1c86-4bd3-95dd-920691ca5a21"
      unitRef="usd">289000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM3LTItMS0xLTA_8f001fae-06cf-4815-9f1a-375f83c3d171"
      unitRef="usd">1583000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM3LTQtMS0xLTA_23b96232-6d41-433f-9045-f754c763514d"
      unitRef="usd">1749000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM3LTYtMS0xLTA_61c2bfdc-5cba-4fee-acb1-bd3b639af65c"
      unitRef="usd">2900000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM4LTItMS0xLTA_c051c418-c6be-4131-a738-85f429b01f1e"
      unitRef="usd">2500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM4LTQtMS0xLTA_57beeadd-f6ed-435e-8d0a-52cb6a692b20"
      unitRef="usd">2750000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM4LTYtMS0xLTA_fbfa4270-ee3e-4c85-aa71-0af2e709a1ac"
      unitRef="usd">6250000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM5LTItMS0xLTA_f248d40f-1bbb-45dd-b72f-0b022f0f914f"
      unitRef="usd">3449000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM5LTQtMS0xLTA_bfc50581-f135-4343-930d-abf3ed7566ae"
      unitRef="usd">3222000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzM5LTYtMS0xLTA_4d4dafbd-9254-401b-ad42-aa495cf455cd"
      unitRef="usd">2971000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQwLTItMS0xLTA_3a53e406-60ea-4bfb-bb83-7afb30e8208c"
      unitRef="usd">-138000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQwLTQtMS0xLTA_ade4048e-3bb3-4312-9e50-2ac37547e8fa"
      unitRef="usd">-122000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQwLTYtMS0xLTA_a4b46dba-b48e-49e6-9f6b-0070531f1ea4"
      unitRef="usd">-486000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQxLTItMS0xLTA_76d3eedb-0d48-4392-8b7b-f0eb7e8dcf05"
      unitRef="usd">770000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQxLTQtMS0xLTA_fd2f6b4e-96b1-4269-9115-7e158368ade9"
      unitRef="usd">-7634000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQxLTYtMS0xLTA_916597b3-97b5-4453-906b-b46008d0894f"
      unitRef="usd">-12318000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQyLTItMS0xLTA_cea84141-d8d7-418c-a8c5-b90aa5c54869"
      unitRef="usd">43000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQyLTQtMS0xLTA_04365520-6167-44d4-bdd6-7e5b762398f9"
      unitRef="usd">-2000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQyLTYtMS0xLTA_9d6709d1-72c5-49a9-bcdb-c4ebb3988699"
      unitRef="usd">-85000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQzLTItMS0xLTA_093d9baf-ded0-4367-add1-73868d1232d9"
      unitRef="usd">-5634000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQzLTQtMS0xLTA_39ffc5b3-bfc0-453a-b2a3-2a96f0060057"
      unitRef="usd">-6309000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQzLTYtMS0xLTA_85da6464-6f3c-4f79-b1af-6b40d8c68d6b"
      unitRef="usd">10352000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTItMS0xLTA_66295759-d36e-4eea-9b17-6e4f68bbb1e0"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTItMS0xLTA_6db309da-b098-440a-b992-867d8a3c8e3b"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTQtMS0xLTA_7f1b2fea-817c-4533-96bd-cd7574fbafde"
      unitRef="usd">17940000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3219b6982b334ae49d4a68c7befc5d27_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ0LTYtMS0xLTA_a3a8f75c-563b-460b-a46c-b0321346ef35"
      unitRef="usd">7588000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTItMS0xLTA_98be3f51-4ce9-4de7-a374-ed5ea811adce"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTQtMS0xLTA_66295759-d36e-4eea-9b17-6e4f68bbb1e0"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTQtMS0xLTA_6db309da-b098-440a-b992-867d8a3c8e3b"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ1LTYtMS0xLTA_259c3b78-5c5a-4d7b-868d-9e53612b72f0"
      unitRef="usd">17940000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ4LTItMS0xLTA_3819e9a1-ef1d-4c82-9516-fc2477b1e056"
      unitRef="usd">951000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ4LTQtMS0xLTA_50bdcecf-4439-4496-907f-23da72c09475"
      unitRef="usd">982000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ4LTYtMS0xLTA_dabff689-d93f-4e0c-8779-da34169b7cac"
      unitRef="usd">1070000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ5LTItMS0xLTA_e490ef21-e63c-4d32-a3a9-08becb541b19"
      unitRef="usd">2639000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ5LTQtMS0xLTA_dd3ffcd9-c459-4ec5-bbf3-e67b9c8cc102"
      unitRef="usd">1793000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDAvZnJhZzplMTQ4OTk2OTk3OTg0MTk0YTlkMTlkZmI4NTRiYTBkMi90YWJsZTpmZDRlMzAwMDMyY2E0Y2Q0OGNkZjM0NGM4NWE5YzI2NS90YWJsZXJhbmdlOmZkNGUzMDAwMzJjYTRjZDQ4Y2RmMzQ0Yzg1YTljMjY1XzQ5LTYtMS0xLTA_87870973-7310-4473-8024-1a8c82a848ec"
      unitRef="usd">3198000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjUx_683ea991-fbe4-4b07-ae33-a748d4a60b6b">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d; or &#x201c;us&#x201d;), incorporated in Delaware on June&#160;22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we strive to transform and simplify care for people with life-threatening illnesses around the world. We have operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead&#x2019;s primary areas of focus include HIV, viral hepatitis and cancer. We seek to add to our existing portfolio of products through our internal discovery and clinical development programs, product acquisition, in-licensing and strategic collaborations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of marketed products includes AmBisome&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Atripla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Biktarvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cayston&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Complera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Descovy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Descovy for PrEP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Emtriva&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Epclusa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Eviplera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Genvoya&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Harvoni&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Hepsera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Jyseleca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Letairis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Odefsey&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Ranexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Sovaldi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Stribild&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Tecartus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Truvada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Truvada for PrEP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Tybost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Veklury&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Vemlidy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Viread&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Vosevi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Yescarta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Zydelig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The approval status of Jyseleca varies worldwide, and Jyseleca is not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess whether we are the primary beneficiary of a variable interest entity (&#x201c;VIE&#x201d;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer (&#x201c;CEO&#x201d;), as the chief operating decision-maker, manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies, Estimates and Judgments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent coronavirus disease (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning 2020, acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Acquired IPR&amp;amp;D expenses on our Consolidated Statements of Income reflect IPR&amp;amp;D impairments as well as the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;amp;D projects. Our Consolidated Statements of Income for the years ended December 31, 2019 and 2018 have been conformed to separately present acquired IPR&amp;amp;D expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Consolidated Statement of Cash Flows for the year ended December 31, 2019, has been conformed to separately present acquired IPR&amp;amp;D expenses exclusive of IPR&amp;amp;D impairments. Comparative amounts in our Consolidated Statement of Cash Flows for the year ended December 31, 2018 were not material. There was no change in income from operations or operating cash flow as a result of these reclassifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized, net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions, and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and in some instances by type of product. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a significant financing component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross to Net Deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates every quarter to reflect actual claims and other current information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Distributor Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty, Contract and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, payments under collaborative and other arrangements, including milestone payments, license and option fees, as well as expense reimbursements to the collaboration partners and overhead allocations consisting of various support and infrastructure costs. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We charge R&amp;amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;amp;A expenses also include the branded prescription drug (&#x201c;BPD&#x201d;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $795 million, $784 million and $587 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable and Nonmarketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) as a separate component of stockholders&#x2019; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of the investment. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted Accounting Standards Update No. 2016-02 (Topic 842) &#x201c;Leases,&#x201d; which requires lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. We adopted Topic 842 using the modified retrospective method. As such, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840 &#x201c;Leases.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in our Consolidated Statements of Income unless there is an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Contingent Consideration Resulting from a Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value in R&amp;amp;D expense within our Consolidated Statement of Income until such time that the related product candidate receives marketing approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Changes in the fair value of derivatives designated as part of a hedge transaction are recorded each period in current earnings or AOCI. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in current earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record liabilities related to unrecognized tax benefits in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for the tax on Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;), enacted as part of the Tax Cuts and Jobs Act (&#x201c;Tax Reform&#x201d;), as a component of tax expense in the period in which the tax is incurred (&#x201c;period cost method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our other significant accounting policies are described in the remaining appropriate notes to the Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016,&#160;the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13 &#x201c;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&#x201d; and has since modified the standard with several ASUs (collectively, &#x201c;Topic 326&#x201d;).&#160;Topic 326 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, we adopted this standard using a modified retrospective approach.&#160;The adoption did not have a material impact on our Consolidated Financial Statements. In connection with the adoption of Topic 326, we made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018,&#160;the FASB issued Accounting Standards Update No. 2018-18 &#x201c;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (&#x201c;ASU 2018-18&#x201d;).&#160;ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as customer revenue if the counterparty is not a customer for that transaction. On January 1, 2020, we adopted this standard and applied it retrospectively to January 1, 2018 when we initially adopted Topic 606. The adoption did not have an impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTU_0f8fcdae-b01c-4994-aa9d-fbaca2218b0e">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;We assess whether we are the primary beneficiary of a variable interest entity (&#x201c;VIE&#x201d;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTQ_3338a658-40d0-4b74-9214-b4cb36da77a4">Segment InformationWe have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer (&#x201c;CEO&#x201d;), as the chief operating decision-maker, manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzYx_e27fe0d2-bce0-49ff-9664-bac28364ae08">Significant Accounting Policies, Estimates and Judgments The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent coronavirus disease (&#x201c;COVID-19&#x201d;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxMTY0MTE_69562ac8-ed72-4ffe-87ed-a5eacca22f18">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning 2020, acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Acquired IPR&amp;amp;D expenses on our Consolidated Statements of Income reflect IPR&amp;amp;D impairments as well as the initial costs of externally developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;amp;D projects. Our Consolidated Statements of Income for the years ended December 31, 2019 and 2018 have been conformed to separately present acquired IPR&amp;amp;D expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Consolidated Statement of Cash Flows for the year ended December 31, 2019, has been conformed to separately present acquired IPR&amp;amp;D expenses exclusive of IPR&amp;amp;D impairments. Comparative amounts in our Consolidated Statement of Cash Flows for the year ended December 31, 2018 were not material. There was no change in income from operations or operating cash flow as a result of these reclassifications.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjkz_5f89fdc4-21ab-4f91-aa6c-3c1e0b60dc26">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized, net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions, and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and in some instances by type of product. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a significant financing component. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross to Net Deductions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates every quarter to reflect actual claims and other current information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Distributor Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty, Contract and Other Revenues&lt;/span&gt;&lt;/div&gt;Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzUx_2a527c97-6e8e-46c6-9335-cde788129916">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, payments under collaborative and other arrangements, including milestone payments, license and option fees, as well as expense reimbursements to the collaboration partners and overhead allocations consisting of various support and infrastructure costs. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We charge R&amp;amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzYy_f697836e-7c42-407f-8aee-0d17b98a224a">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;amp;A expenses also include the branded prescription drug (&#x201c;BPD&#x201d;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.&lt;/span&gt;&lt;/div&gt;We expense the costs of advertising, including promotional expenses, as incurred.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3Xzk5NzQ_f0f250f3-f8b3-4525-80ff-a23a0debc236"
      unitRef="usd">795000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3Xzk5Nzg_fedae04d-fd78-49f1-8411-5549a3c5bcdd"
      unitRef="usd">784000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3Xzk5ODU_650156e4-d70f-4dc7-ada7-c72b7fdd7f12"
      unitRef="usd">587000000</us-gaap:AdvertisingExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjA0_8af82562-c79a-4dbe-9bf4-55d6635a2baf">Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjQx_9302a789-8cff-4837-a1a8-5c2947e66535">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable and Nonmarketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in accumulated other comprehensive income (loss) (&#x201c;AOCI&#x201d;) as a separate component of stockholders&#x2019; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable and Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of the investment. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjMz_7289b943-42fd-4b09-88e2-b0d997c0d309">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzEwOTk1MTE2Njk2MjU_f7afe135-0661-4cae-b158-6bd615339aba"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzAy_8fe6d336-0157-42bf-a17c-30c2529e7130">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjk3_a9afd276-010a-421b-a8ac-cbf2ea24c4bc">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMTk4_91f729ad-892d-4a56-a579-48e9bbecafbe">Estimated useful lives in years are generally as follows: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i398df6a52dd9464d8dd45e089b73014d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzEtMS0xLTEtMC90ZXh0cmVnaW9uOjliYWQxZjhmZWZiMTRhZmJiYzY4MWVmZTUzNTliZGNhXzEwOTk1MTE2Mjc4MTY_94e82f7e-5a83-46d2-b145-06417eaef140">P35Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i27efdec092714a19b30f4a1ad8aa6133_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzItMS0xLTEtMC90ZXh0cmVnaW9uOmI5ZWRkZDZjMDQ3ZDRiNmZhM2NiNjljNjc4ZDliYWUwXzEwOTk1MTE2Mjc3ODU_e28698a2-58dc-49ef-9e93-bb37864b7e33">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icf9fe67d86404ee58fc08434776ac75a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzItMS0xLTEtMC90ZXh0cmVnaW9uOmI5ZWRkZDZjMDQ3ZDRiNmZhM2NiNjljNjc4ZDliYWUwXzEwOTk1MTE2Mjc3OTA_cd5bdca3-f192-4e20-b461-f3a33d3ea3a1">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4a198ee4eaba43a9be336a94d8a87b2e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjVhM2FmNGU1ZjU0OTQyMjJhMDJkMDZmM2M3MTcwM2QzXzEwOTk1MTE2Mjc3ODQ_48e824bb-9cf5-4c35-86e3-3b3004b11d76">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0fa4ce37886b4a34b696be088b6209dc_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90YWJsZTplMGZhODQ1YmFjYzY0NzJkOThiZjFiOGU2YTIyN2Q0Yy90YWJsZXJhbmdlOmUwZmE4NDViYWNjNjQ3MmQ5OGJmMWI4ZTZhMjI3ZDRjXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjVhM2FmNGU1ZjU0OTQyMjJhMDJkMDZmM2M3MTcwM2QzXzEwOTk1MTE2Mjc3ODg_08663da4-0666-4792-9649-83e9b97b8146">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTE_e55910a1-b9e3-4825-93c7-cc0e6f7cb778">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted Accounting Standards Update No. 2016-02 (Topic 842) &#x201c;Leases,&#x201d; which requires lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. We adopted Topic 842 using the modified retrospective method. As such, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840 &#x201c;Leases.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjY4_a5033e0b-88b7-424b-9f86-af82a0f3f9e8">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in our Consolidated Statements of Income unless there is an alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzAz_5bff3921-b112-4150-8f55-883a1e9d6057">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjgy_31ff852b-f705-44a3-9b3e-769f5200bb0b">Impairment of Long-Lived AssetsLong-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzI3NDg3NzkxNzc3MTc_faf0917c-3ab2-4c45-af49-86f4daaba2f5">&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Contingent Consideration Resulting from a Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value in R&amp;amp;D expense within our Consolidated Statement of Income until such time that the related product candidate receives marketing approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzQ3_5d8846cf-81e0-4d3b-9ae5-6e9eb2ea7bc4">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjU3_2ae1b181-2eab-4ac5-841e-2fb570814a61">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMjE1_161c883b-db16-4070-ac9c-98431e5b5615">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Changes in the fair value of derivatives designated as part of a hedge transaction are recorded each period in current earnings or AOCI. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in current earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMTk5_65fc3811-8ab0-409f-865e-4b16a8cbc237">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record liabilities related to unrecognized tax benefits in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for the tax on Global Intangible Low-Taxed Income (&#x201c;GILTI&#x201d;), enacted as part of the Tax Cuts and Jobs Act (&#x201c;Tax Reform&#x201d;), as a component of tax expense in the period in which the tax is incurred (&#x201c;period cost method&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMDYvZnJhZzo2NjQ5MTU1NzZkMTg0MWJlOGZmZDQzM2I1YmQ5MWRjNy90ZXh0cmVnaW9uOjY2NDkxNTU3NmQxODQxYmU4ZmZkNDMzYjViZDkxZGM3XzMwMzI2_11c58c13-8369-45f6-8a47-eef4e1d9aa27">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016,&#160;the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13 &#x201c;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&#x201d; and has since modified the standard with several ASUs (collectively, &#x201c;Topic 326&#x201d;).&#160;Topic 326 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, we adopted this standard using a modified retrospective approach.&#160;The adoption did not have a material impact on our Consolidated Financial Statements. In connection with the adoption of Topic 326, we made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018,&#160;the FASB issued Accounting Standards Update No. 2018-18 &#x201c;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (&#x201c;ASU 2018-18&#x201d;).&#160;ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as customer revenue if the counterparty is not a customer for that transaction. On January 1, 2020, we adopted this standard and applied it retrospectively to January 1, 2018 when we initially adopted Topic 606. The adoption did not have an impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzk3OQ_961df134-2dec-4ea2-bf1f-e668f79098d8">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenues &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HIV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HIV product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;) Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HCV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HCV product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy Products &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other Products &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston, Hepsera and Jyseleca.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues From Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $841 million and $741 million for the years ended December&#160;31, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $101 million increase and a $257 million increase in revenues for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $198 million and $144 million as of December&#160;31, 2020 and 2019, respectively. Contract liabilities were&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$97 million and $45 million as of December&#160;31, 2020 and 2019, respectively. During 2020 and 2019, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzk3Nw_ab66848f-ab95-461e-91d0-6d179cd9cd35">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Product Sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;HIV Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Atripla&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HIV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HIV product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;) Products&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ledipasvir/Sofosbuvir &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HCV &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HCV product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cell Therapy Products &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Cell Therapy product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other Products &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ranexa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Zydelig&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Other product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes Cayston, Hepsera and Jyseleca.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if280de1dfeb24360a98d1085d3ec01d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMi0xLTEtNjEw_babb792c-9285-45b7-9279-9f2052fd861d"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42acdb68c96f40139d8ef2dd48ec4aad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtNC0xLTEtNjEw_76c23358-cc58-49bb-840e-901d8be6ddb4"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic93a08630ddf4d8daa910c80941d2f49_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtNi0xLTEtNjEw_962cf6d3-2651-4fe2-b9ab-a9b6329cead0"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a1fc5480ae54692850a590af2530f85_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtOC0xLTEtNjEw_5575e731-377b-4a7b-941e-f5bd732c97bb"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia42eea57788b437d80b0100bf5308e5e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTAtMS0xLTYxMA_d96ed5dc-0a99-4273-9b3e-de969b8a386d"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74b227c5b6d24b36a063e59f6b31eddb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTItMS0xLTYxMA_e2db55d8-cb60-4373-b532-7994a30f240b"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd51a66da7cf40eb80804c8cb98cf1a4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTQtMS0xLTYxMA_958208ad-7c22-484f-a43a-4aacef82d972"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia729850536324dc7a891febe1ef57425_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTYtMS0xLTYxMA_81f848f3-1f0f-4354-a7ad-0a96194848bd"
      unitRef="usd">600000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a2f412468e04e8e990eda8c053e9023_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMTgtMS0xLTg3MDk_207e06b2-8b2e-4ce7-81f5-5ae40c421297"
      unitRef="usd">967000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i573540eac6ce41b9ba0a37a14d578dcd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMjAtMS0xLTg3MTg_3c8937a2-c3f1-477f-8e55-a2f2137ff326"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9e0aaddda8242649f4cce16f7480e3f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMjItMS0xLTg3MjA_823baaf9-ede6-4811-b4ad-79da4467d989"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e6f27d389c4470791b5097d66ee6fb2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQtMjQtMS0xLTg3MjI_daa4cfaa-ef17-4cfc-b4e4-e554ee3b30cc"
      unitRef="usd">1206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec241db8005b4fb59360d2304f6a40ca_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMi0xLTEtNjEw_221a0709-e181-44f7-a67b-337d36f7f02a"
      unitRef="usd">6095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dce80f6a5d043fabec1581e37b038e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtNC0xLTEtNjEw_08b45953-a33f-4b71-8fa0-a9391f935e69"
      unitRef="usd">735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ba9195c2f9b45e392656f86c6f8865c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtNi0xLTEtNjEw_c0b19c35-c7e4-45f7-af77-a45410718456"
      unitRef="usd">429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5630aee9b8e34051b2267852a2167c72_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtOC0xLTEtNjEw_c68f4ad3-2469-4940-9337-abde038ddab8"
      unitRef="usd">7259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9bf33c47a6342328f4b4a359e831dc0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTAtMS0xLTYxMA_9cb997db-b58e-4afd-83f7-e0ed4f67d082"
      unitRef="usd">4225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01bd5e69cc2242e9937e99d06f49412c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTItMS0xLTYxMA_e4c511b8-0093-4029-a8f1-3350e51ce812"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc7657c224364338aaec9e8f7e531475_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTQtMS0xLTYxMA_9671fc75-f2f6-48b4-a965-d89366dc8459"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i479222aa62ba4959b945991f45167506_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTYtMS0xLTYxMA_e1141edd-6397-4e94-822f-c6f10ac9b3ae"
      unitRef="usd">4738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i732f9de4021249caa5c12dd71d663337_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMTgtMS0xLTg3MjQ_ccc4677f-e2f9-40f7-a4ba-9edb11aef801"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51323f6fd23840a6a3a8153facb4a542_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMjAtMS0xLTg3MzE_4fd6ceb6-8378-4242-9629-bf90a21f5154"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8120081236ab4ada86875183d3516a0d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMjItMS0xLTg3MzM_1292a0de-6230-498c-bc2c-5e32eac5baf0"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9d9ac1bed894e8ebd3a9a07adec3780_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzUtMjQtMS0xLTg3MzU_25c3a89d-9031-4f57-b4c6-391d4cb7a1e2"
      unitRef="usd">1184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i423cb85373ec46cd90ab88681133fed7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMi0xLTEtNjEw_998996ae-5eaa-4197-9717-430fecee20ac"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bca99eea6724544b1989f1c71ff8e7b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtNC0xLTEtNjEw_14ec27b0-44b2-411f-9346-9aa8eb5ac356"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib925542d3c9a449f9451287b1948794d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtNi0xLTEtNjEw_f4cd7e5b-1643-491f-b180-cab33ef8818f"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7fe1a6f3e2a4443bfadf5e3b18575a8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtOC0xLTEtNjEw_c7960d3a-a291-46b0-a254-c80d34f9826e"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i397a1aaa80ac42d8b7d7547d7a425c70_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTAtMS0xLTYxMA_dc3d3d49-dd07-40a2-9bfc-5de333c8a8c8"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e6650f4df60426daa34dc4ca653bc0c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTItMS0xLTYxMA_66905b25-ce45-47f0-9629-edba37433b31"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96967e4c10914e109e43c4c43838be39_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTQtMS0xLTYxMA_1462b120-080d-4425-b0eb-f75e0427af29"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bbd726607304250949dffcf3aa8a682_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTYtMS0xLTYxMA_711f0d04-5697-409b-bf5e-775bfbd10443"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaac1e36447014421822582a862cdaadd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMTgtMS0xLTg3Mzc_7dc7600c-479a-4c49-ada8-e56ffffa5bf6"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e01036f80124b668ee600a97070f563_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMjAtMS0xLTg3Mzk_f4f6c663-554c-4163-96cc-64ab5fabe61e"
      unitRef="usd">327000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab9ad0800ab14c06a5eb9fc8ed1492dd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMjItMS0xLTg3NDE_8ae999a1-8bdb-4ec9-a87f-fced83de7e4d"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f83bbac170c4124b1506d033c0044f6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzYtMjQtMS0xLTg3NDM_2d45c94d-a44c-4f1c-b4d0-4526a63cef6b"
      unitRef="usd">653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff45aaf7fa4b4df1b955bc6bf7844c83_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMi0xLTEtNjEw_b4a93531-a758-4e2a-8d51-fcf403f89187"
      unitRef="usd">1526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fcce9db6610413494337c100307fc4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctNC0xLTEtNjEw_54500995-c950-4d77-a63d-5409a9a4f350"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ba09d37db0e466f905cbca86c3d7dc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctNi0xLTEtNjEw_83e5003a-10f1-499f-856a-d83c5ff9747a"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i914f59558f254e77910de66c2a838a2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctOC0xLTEtNjEw_2402eaa8-84e0-43ab-ac56-302d4c0251fa"
      unitRef="usd">1861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia05a4d813f594dffabe58b494a022cce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTAtMS0xLTYxMA_5e9b6454-7a78-4b44-b9d2-d9f4c1072f88"
      unitRef="usd">1078000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71b7ceb3521340179dc6fb26acff9127_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTItMS0xLTYxMA_371d66f5-d55c-42cd-a288-2e175702668e"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9ed9dfdc9e84991bcf49d834722ae9b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTQtMS0xLTYxMA_fc5011a6-28d4-4e5d-9865-86636aa4fbed"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6155a1372b794cfc98808510fd0f6aa0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTYtMS0xLTYxMA_b0d39657-beda-4ef6-82d1-2d55e79acd8e"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1451f5b027bb41a4847584b7f596fd2f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMTgtMS0xLTg3NDU_802dd58c-394d-4803-82a8-0077034a75e6"
      unitRef="usd">1217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d167e5e90304b3cb0fa2437ed97d58d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMjAtMS0xLTg3NDc_f352e108-754a-4ac1-bf9b-4353cf15dd4e"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i148057a263804622a6ab50305a09929a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMjItMS0xLTg3NDk_11a4bf88-76f0-4b61-ab7c-e7a001972c4b"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie30b81a7f7314bf597308792e530d56d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzctMjQtMS0xLTg3NTE_7a27bbdb-bf55-4fc2-84e7-f4ecc7f9f164"
      unitRef="usd">1581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24aca176c89041e39835e536b01a5caa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMi0xLTEtNjEw_6e7bf092-2f58-498b-b493-fe326b608d71"
      unitRef="usd">2605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffa4c3f449f34e3ca5b0429151183789_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtNC0xLTEtNjEw_7b73c859-d461-42ca-ae82-e7308dbcfbc1"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaee8311b76724420b4e775d0c80dce90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtNi0xLTEtNjEw_72c4b1a6-dbe4-4a6a-9735-b4d94b7c3b86"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82451c9a5fc840db91ee5a3c49612ddf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtOC0xLTEtNjEw_655a5742-f472-4d57-8e3e-77056d586d2f"
      unitRef="usd">3338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70a33cadbf614a8480b0f3f1046c5ae5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTAtMS0xLTYxMA_05615b75-8291-41ba-b608-827348088f3e"
      unitRef="usd">2984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fb475376a1c4eab860991d825204c02_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTItMS0xLTYxMA_bb98ea06-bb2d-4cec-b7df-92f557228915"
      unitRef="usd">664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31b4a13728764a0eba034f51b801c879_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTQtMS0xLTYxMA_f587b4be-91af-479d-a529-9a29a4c6c7c6"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic46aeadee3584d9d87c1b87143a83acd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTYtMS0xLTYxMA_d143d787-6083-4665-8685-9e7e225478b8"
      unitRef="usd">3931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1d8548ebbc24499af4a1bfcc9d5e0ac_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMTgtMS0xLTg3NTM_7db3d3ec-7335-48cd-99b9-7c9761d05cf8"
      unitRef="usd">3631000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdb71020bf354a20a7eb5c17cbe9527a_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMjAtMS0xLTg3NTU_65e5f925-ff91-4f3d-b59f-be0bcc685ff5"
      unitRef="usd">794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73e2d26072ce41babea393a33fe5028b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMjItMS0xLTg3NTc_15556ebe-fa7f-4fd3-abbc-90758e085187"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec1334107b9d4287be103de88544e8c2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzgtMjQtMS0xLTg3NTk_ef55cba4-28b2-4cbe-9641-656004c51034"
      unitRef="usd">4624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie56b0d69dc4443c38f7f201f8cf0560a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMi0xLTEtNjEw_32b7d3c0-969b-4aa8-8bde-3ed879606445"
      unitRef="usd">1172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19165ee38eb44b368716095e6b79b8ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktNC0xLTEtNjEw_f1e39922-857e-4dd5-a92b-1fd0ca5041bb"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49a83d33cd594375ad102b2d5a901d14_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktNi0xLTEtNjEw_7a5ce950-8482-46db-8872-040107a3e71c"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e25273ce6ff4d95913b6a378db136fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktOC0xLTEtNjEw_e6f4ff6d-67db-4eee-8863-9a8a9662e5de"
      unitRef="usd">1672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1354418ec0a142bf80aa75673f9dc7ff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTAtMS0xLTYxMA_42d70c15-6b9e-46c7-b91a-a5f5408d6968"
      unitRef="usd">1180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic50ed561675c40659815e6bbfcfe85f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTItMS0xLTYxMA_e626213f-af3c-4ec5-be4c-ba33ddc3326f"
      unitRef="usd">438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d77fd8a2cd542c187eb7beb450a9bd5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTQtMS0xLTYxMA_0454b2a0-7c1a-4804-8af4-9cdd0eac835f"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25ce8efc83ec4d46a7d9d78b23565594_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTYtMS0xLTYxMA_7a763d2e-e610-4473-9b70-e07b8452d536"
      unitRef="usd">1655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i307fd96efd864668a53c14e22b45b3df_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMTgtMS0xLTg3NjE_3eba8fbf-fdb0-417b-9ae6-78fc507ae49b"
      unitRef="usd">1242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51752bd1d33b45d99eeaeb4bc0e7aa30_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMjAtMS0xLTg3NjM_34cfe874-14bf-43d8-a63a-692ae5bd0d4f"
      unitRef="usd">335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i837c38f09aec40bea2af72ce62bb55e4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMjItMS0xLTg3NjU_4345dd46-92e9-4f37-a8e4-4b045173899e"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a72addb6d6c4f8f901283e58f4db7e5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzktMjQtMS0xLTg3Njc_2e6297d0-134b-42b3-adfe-a715b09c4c12"
      unitRef="usd">1598000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85e16d8591f64ebd8ed80e3b3d51a9bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTItMS0xLTYxMA_d19f304e-c240-495a-a525-888d2c885538"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa5568bc36104cc3bd4575c08d5bd2a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTQtMS0xLTYxMA_85aa12f7-3779-4948-9214-9114f2a47e62"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eb6ef7264624b6b88e49bf1fdcc8084_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTYtMS0xLTYxMA_056fc7c4-c11d-40cb-9b6f-91169621ee39"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24b4931148e643fcbe49c4f9d12ba1d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTgtMS0xLTYxMA_79fa4c87-7a5b-4705-bf0b-9c9d37e861c2"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3245979d6cb647f1a9f0228da2e8828a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTEwLTEtMS02MTA_d1c5e877-07ca-4ba9-93f1-5dac1c0a2fdb"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib830ff48e9c547759f55cd54a403715f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTEyLTEtMS02MTA_7ce78926-bb1a-4391-b451-1dfa985dd8b0"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bffa555d06d4f78813ba77778839fd2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTE0LTEtMS02MTA_48f80b3f-e926-4bdc-9ed5-59d024e0f3c8"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id33ba5d575e9416a8fbf45cdcba038c1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTE2LTEtMS02MTA_8f56036a-cbe1-48bc-aabb-833433fbe46d"
      unitRef="usd">369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i383f0ccfdd634300bb105e23b2743b3e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTE4LTEtMS04NzY5_694f066b-82ef-4941-9ec1-8774c7591bc8"
      unitRef="usd">505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8fc3d812ef541ae8ae75cfd0c10bd4b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTIwLTEtMS04Nzcx_32d8bb71-3c81-4059-acec-7c91dd8c98f4"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i971bd58c2a104fa58633b760bd1bcc49_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTIyLTEtMS04Nzcz_28895d9c-7864-4fab-a8fc-b18a6bafb0f7"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bff96a7eee3471ea92c5a5728abafb6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEwLTI0LTEtMS04Nzc1_72dc9586-22c7-4bbc-a988-544e2b5aa4be"
      unitRef="usd">644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7e671960e24493caa9e67137c00b67f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTItMS0xLTYxMA_17608c79-6f38-4ae6-b8d7-4ff12267c594"
      unitRef="usd">1376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i601dd6fe3b1a427b9e877264c2a50cc1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTQtMS0xLTYxMA_1b34689a-8cab-4bfc-bcd3-d8902c2b4c86"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ae5bb92838f42e185c2fdac7cb74c5f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTYtMS0xLTYxMA_b63af4ac-c829-4b1c-9295-c69f644d4579"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id82ff04803a44a739676620ac878f839_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTgtMS0xLTYxMA_7b3baa2d-e0ce-42de-a152-5394d563cea6"
      unitRef="usd">1448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99fb37b1c0334cada10080d435ac5f5d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTEwLTEtMS02MTA_21bcd450-95b2-4fce-86d0-3fde8b01b3f5"
      unitRef="usd">2640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id136b7bd1fbf487ca2f4096e63868995_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTEyLTEtMS02MTA_4a3749f8-61e1-4049-8014-b01774f5d03e"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09c63bb8f77347f5b4447f81ccb53bce_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTE0LTEtMS02MTA_f5a39756-cc53-4335-9fac-5b6f04cdcc3a"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea5f53f6dc9d4ac08d0693f368244332_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTE2LTEtMS02MTA_2538d565-bb38-4900-9468-e3c248984ebb"
      unitRef="usd">2813000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09e084e4904f4eec869ea6250e39cb0f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTE4LTEtMS04Nzc3_bad01bff-d55f-4b1f-bbfc-87bdd60e9cf5"
      unitRef="usd">2605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3e0d6d757fe42eb80d7eace0eca26d4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTIwLTEtMS04Nzc5_8321a65d-ce81-4678-8f09-b8d65fd34dfb"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5873767e398449f49bed3571f29dfb2c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTIyLTEtMS04Nzgx_2252c4a4-7ea0-4fbe-a64f-5c369757795d"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63723f5c740941a983de991985232fb3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzExLTI0LTEtMS04Nzgz_5650ce75-84ed-4198-b274-95101d943266"
      unitRef="usd">2997000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d3efda2c81540b28f3d08dd5de9755f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTItMS0xLTg0MTE_36123ed9-526f-4d35-aefc-be88f53ebff2"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b99b05d92954eca83863f0bf00a778f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTQtMS0xLTg0MTM_d94534d0-d686-4cc9-b8fe-5f3130224bb7"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i881bd67c6b4d4c32ae44c9cecd6b6cb3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTYtMS0xLTg0MTU_fbbe9cf3-2dad-4e26-9289-dc71d66a38b1"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0469e8d7b3941ffa027e0d65422b55f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTgtMS0xLTg0MTc_37621bcc-5c73-4b3e-a5f8-421623283909"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1378a285d3541119968e5a408b282db_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTEwLTEtMS04NDE5_5373c94e-c3f8-48ce-b563-8fb4067583be"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iade7d753f59a4127a6ee33601d7bb46f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTEyLTEtMS04NDIx_fb3a1b6f-790e-463c-8ebb-94daf4b7301b"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if86f743bdebd4241a992f10cc32afce2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTE0LTEtMS04NDIz_9211cf00-9a2d-4196-aee8-b8e0b1bdeb25"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0499c86d7cb249e79e4e9514392025b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTE2LTEtMS04NDI1_ca19424f-ad15-4827-a59d-7353bdff78e7"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4380b2c4b087466e96212e805752c452_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTE4LTEtMS04Nzg1_55a2bc7f-26bc-45f8-8f0a-61c18e69f9ee"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c65abc055694fa093ee3d1a90844e56_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTIwLTEtMS04Nzg3_9046a473-c1c2-45fa-9b2b-986fab498fa0"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id536d58f3ef742cfa5620869742d07f2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTIyLTEtMS04Nzg5_0812cc2e-028e-467b-87f7-95df528c616f"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e7cb86cb8124bfba88a83abe2dbea50_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEyLTI0LTEtMS04Nzkx_7781e7d1-aca0-40f9-94f9-37063f3e5aa9"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41251b77296c4f1c896b094d88169d6a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTItMS0xLTg0Mjc_c7c1bd07-7ab7-4c9d-a922-ea28de6738c2"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f6faa09d5af4cbb9ffd71fb56eb0943_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTQtMS0xLTg0Mjk_327e2459-fc2c-4ef4-95c1-c6f7e91bda4b"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfe492680a244d69a015e5f447b30fb9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTYtMS0xLTg0MzE_227e9611-ed28-47ba-84f0-a16989a383d0"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc9c5bcc6ec24e9fbf91a218a0ec316c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTgtMS0xLTg0MzM_9408f383-55f7-4323-885a-e324293e84e3"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9f80e96782c40c7ae4aeb93329d6569_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTEwLTEtMS04NDM1_46f8397f-2287-4288-9ead-709641230b4f"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibefbcda1973840c1a30941cf065c6d7f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTEyLTEtMS04NDM3_95cb6f0b-c1ac-4b09-a38f-c9e2cc0af52a"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id549332482954a04928a406aa2aa8ce1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTE0LTEtMS04NDM5_2891552b-2a70-4848-b892-4ef8294ca1b8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3153057cb844d0f85ec934a049701a6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTE2LTEtMS04NDQx_7cada7de-55f7-4173-adfa-15eaa1005066"
      unitRef="usd">379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52fb0ee83c0e437385e9166f9c973f27_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTE4LTEtMS04Nzkz_a952e39d-48a3-4db1-8e9b-2ce3784b0aad"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ddbe44d21304dbdb6f1f137c5fbf5e2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTIwLTEtMS04Nzk1_e8e433c0-fc09-426a-ac96-f8644939c435"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f62e6dfb68b40d2a30db38faaef056c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTIyLTEtMS04Nzk3_a5362d98-719c-4ff6-b314-b20b26a3b819"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55935a228d7349a0b68ecf40aea95522_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzEzLTI0LTEtMS04Nzk5_8b7cf01a-dfe4-4516-a816-6dbccb3c3d17"
      unitRef="usd">79000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5d7a8c92b7b499c925cd2e1b63d5674_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTItMS0xLTEwNjIz_e4608499-2987-49f0-ad73-364385a3c299"
      unitRef="usd">13651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09483a086d8344418fea4c38597c601d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTQtMS0xLTEwNjIz_48285788-f9bf-4b94-b9fe-5f4995ad19b4"
      unitRef="usd">2287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i816c10bfc97f4bd3a31a63ce6248693a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTYtMS0xLTEwNjIz_83eb1cf8-51c1-437f-89ec-9901b02bd788"
      unitRef="usd">1000000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e93f9118e4d40739ac1f86ecf2503a0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTgtMS0xLTEwNjIz_463d443b-6e4e-4a4a-adeb-7d7694703f72"
      unitRef="usd">16938000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e010182efaf422cb20cdb14830ec5b7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTEwLTEtMS0xMDYyOA_fca639f9-dac1-444f-90a6-cd25258d7aeb"
      unitRef="usd">13315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50c5df52b2384dad827ce8d5ed8becd0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTEyLTEtMS0xMDYyOA_1ed2c186-4424-4689-ae56-f808f5b96d8c"
      unitRef="usd">2312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7b5382709394ef0902ac805a3fba467_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTE0LTEtMS0xMDYyOA_407968e8-5ef6-47bf-ab68-d1825af3da24"
      unitRef="usd">811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35a796d1ca3647aca0c0cf94e9e84834_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTE2LTEtMS0xMDYyOA_3a3dfab7-8936-4117-a285-1117a03a8c2d"
      unitRef="usd">16438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibed79b72cddf47108dc5adb16f1c6e0d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTE4LTEtMS0xMDYzMA_6c8649f6-4369-409b-89dc-49ecf0b6b67f"
      unitRef="usd">11654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i308e3d02bbe24f73995a88d9dffbeb6e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTIwLTEtMS0xMDYzMA_45a692be-f6bc-4ad3-8083-0cee96ea52f3"
      unitRef="usd">2350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5e9639e6b4f4a93bef391904c7ba7c9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTIyLTEtMS0xMDYzMA_9cd2c2e8-d8e8-4aef-8a71-1072a2a840be"
      unitRef="usd">623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e99b9e4abc6439caf1635dde53641e6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE0LTI0LTEtMS0xMDYzMA_49955d77-1b99-4201-9e4a-0407b14bb7e4"
      unitRef="usd">14627000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i784a2e611fc6427c9c5e4418b57df0b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTItMS0xLTYxMA_ead1c823-8e92-492f-92d3-d059abbcbd4c"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87f26b0b8d9a42e1b8b6392b60d37f56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTQtMS0xLTYxMA_21629bf6-1d82-4c0f-b8e7-7cbae97596f2"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id210bf00395f48528f93b74e8bcf8963_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTYtMS0xLTYxMA_ece1415c-36c1-4328-b857-d116f6f8d598"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i356cdb8eb49e4b5fa6d74cde3aee0fa5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTgtMS0xLTYxMA_f9e655a4-017d-4c65-80e4-07d7e33460f7"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0399583abbfa4b70a9826bd3f34fc3e5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTEwLTEtMS02MTA_044a76a2-1d93-45ab-b200-d293eff729b9"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i971e8c17f58441c796ae21856d69fecd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTEyLTEtMS02MTA_0731bdcd-9d98-4693-9b61-8eb7b11e42d3"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e3c000c64e74a5997c3ce62426eab73_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTE0LTEtMS02MTA_dbe0b252-2fd8-4a67-abd0-a4ba73b27fe8"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf4791ac34254f20a211ff631970f1df_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTE2LTEtMS02MTA_b8c66b4f-3131-4d2b-99b7-ebca3f78b166"
      unitRef="usd">643000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44a776ce3ca04751a6acd137246eadbf_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTE4LTEtMS04ODAx_997620b1-bc00-4fb7-88b4-723a32813feb"
      unitRef="usd">802000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if61ad645329c4f84a5ca1f8858e4a105_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTIwLTEtMS04ODAz_fb118636-07ee-4806-b10d-d16c0dddd995"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i789b3a29153346629c85ec22950b2443_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTIyLTEtMS04ODA1_e60a7d93-a05e-46bf-accf-5401c33a65b2"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2449c7232a1542d8961f78873606cd5c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE2LTI0LTEtMS04ODA3_2a60cacb-8e22-4d65-bc53-9c9dffd532ba"
      unitRef="usd">1222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if98307d1f71d4a57b90d117c72387c97_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTItMS0xLTYxMA_3ef4ba23-0382-42a9-9a3c-c288604eb99d"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i709dc81b1e0b4ad18ed1a3516087e006_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTQtMS0xLTYxMA_d1ad1aae-b53f-4c0f-8522-39dfddb29510"
      unitRef="usd">337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52257540c09044d483783ee0e873ddb2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTYtMS0xLTYxMA_a836fd69-3f97-4b39-9038-02985276df58"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0d14fe1cf6741a38f337376d9b09937_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTgtMS0xLTYxMA_53377215-69e2-47cc-a293-ed000da44643"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ead59eb11954802b58faf4295471c59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTEwLTEtMS02MTA_845cc650-1beb-44b3-a463-2be09bade431"
      unitRef="usd">971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8fce49b484e4fbe8b7118a57fd949ff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTEyLTEtMS02MTA_743199e6-63a4-4f01-b7a4-2744c3fff23d"
      unitRef="usd">553000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24b3fa2ba952448ab0308cc83860110a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTE0LTEtMS02MTA_a9951964-9078-4daf-9085-ad592b177bca"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie19c5edf94af43d38aea8ff9a812b9bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTE2LTEtMS02MTA_7411e64e-1c62-4bde-beea-0b09753e73ff"
      unitRef="usd">1965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1510ef46b1564c908317e3e7ed9ae838_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTE4LTEtMS04ODA5_5f548f95-d874-4a3f-a96f-4e65d339ad6a"
      unitRef="usd">934000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf8fc952f7ea48e19ed2627867ef4e34_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTIwLTEtMS04ODEx_5b9ecf0a-e9c0-4dbf-a6da-cb3ae1fe4c47"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e85b0a40a6f4651aeb814864a67e2d5_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTIyLTEtMS04ODEz_47fe71af-fb74-48dc-a0d8-c8cab215d2a3"
      unitRef="usd">378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1520f66d45ff4fc99578172eae43f525_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE3LTI0LTEtMS04ODE1_e4541956-419c-460b-8e57-c1ec62db1c45"
      unitRef="usd">1966000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafba755ee21149148b5687e8c622242c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTItMS0xLTg0NzY_665292e2-0ec9-442c-aeb7-6130aec4d0f9"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3418497bf64641e89450ddf47541cc00_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTQtMS0xLTg0Nzg_651a5faf-945a-47dd-a066-e89c562ea877"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43a0f15448df4521b3252b863920fd4f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTYtMS0xLTg0ODA_dd2bcde8-96a7-4857-a5d5-d5abdea93dea"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa04a1897acb43a8935771581a2294d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTgtMS0xLTg0ODI_550c0dbd-6780-4fc9-9aaf-34f5a9b281d5"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25cf3186547645e18a12e54737ff3f20_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTEwLTEtMS04NDg0_99beb593-d07d-4cd1-b13b-6462b9feff70"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66a055454e634859b9e4d1183c8ce86b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTEyLTEtMS04NDg2_4dee8464-d9cc-415f-9501-15113eacbf2b"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f360e299e954e01a740de35c1825eda_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTE0LTEtMS04NDg4_f7e8e102-9342-44dd-a637-919f63196cc4"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbfb0cd1316443b2a3450b33ba196076_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTE2LTEtMS04NDkw_fd86ac56-e158-4b04-80eb-08667d8b6286"
      unitRef="usd">328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i909b8bd81dd94054add30d019a9039b1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTE4LTEtMS04ODE3_0088b78b-1d21-4f43-b049-71e26c5ab477"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib81493ecf2c148c3b066878a096034fc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTIwLTEtMS04ODE5_e3ada6a7-e186-4027-98e6-3375e3f0d5e6"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8d6ae2564f7486fb11225a0eaadac69_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTIyLTEtMS04ODIx_2e3d7222-da46-4e0c-ad9a-ff6c645b31c7"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c76d4fd2017462795348867f8cdcf28_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE4LTI0LTEtMS04ODIz_2627c1f6-4d29-4a3f-83f5-03f02730d549"
      unitRef="usd">498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7742e26504ad407fbe00062a7dd0687f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTItMS0xLTEwNjQ5_4a339fba-9eb5-41c9-b80e-2b4fda8735f8"
      unitRef="usd">1088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2a76126042a4ae6b749183870511d1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTQtMS0xLTEwNjQ5_3e5d5063-9925-4e5c-9ce5-3e907e0bcf91"
      unitRef="usd">414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibea13b5f060d4a69a6a698a8df908663_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTYtMS0xLTEwNjQ5_944e0de3-7283-4c57-a292-0b78d17b68d5"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b63e3d135704c9abeb409724a97d925_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTgtMS0xLTEwNjQ5_01a51f88-0dd3-43cc-9475-3c94d04ca370"
      unitRef="usd">2064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5ef5470931747bb983f03b0991cd741_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTEwLTEtMS0xMDY0OQ_0eed799f-78c0-41d7-8065-b2e62908e80b"
      unitRef="usd">1465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8780e4b3e8474e2cbe7f7e27d5ca7b6a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTEyLTEtMS0xMDY0OQ_8738ede4-ca5f-4d3e-9078-eb103bfc0458"
      unitRef="usd">742000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if67fc940422441b0ad55ee1a90ed0adf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTE0LTEtMS0xMDY0OQ_8ae6745e-f880-4a6e-a98f-8d7b872ebd62"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4f7a3e3e83d47fba6ac8b13a9f5610d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTE2LTEtMS0xMDY0OQ_5f25d29b-85b4-4a87-8d9d-8282c42fb236"
      unitRef="usd">2936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ce8b095baec43b9a6b48fa3f625b855_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTE4LTEtMS0xMDY0OQ_de578a62-d564-409c-b354-670cdc2a84b0"
      unitRef="usd">2023000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcdb328dbec54ee98bcab35be1c9d7be_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTIwLTEtMS0xMDY0OQ_727eaa76-2558-45c3-8e3d-5dca7a50f502"
      unitRef="usd">896000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib23482e8bcdc43c88946e03e12a9d121_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTIyLTEtMS0xMDY0OQ_612e06b4-70d4-44a0-89af-e89cbc4e87ea"
      unitRef="usd">767000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id09f10d7c83d4df6818e86cf8d921ffa_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzE5LTI0LTEtMS0xMDY0OQ_f87da01b-5a6f-4bb7-bba4-cb08b1b9c5ed"
      unitRef="usd">3686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i859d13747a854b698617069a85edd654_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTItMS0xLTg0OTM_c4a43af4-45c0-41c5-aa7c-38d8a984c776"
      unitRef="usd">2026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65fb0f65e47c4aebad73abab7f3d668c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTQtMS0xLTg0OTU_e519d05e-364f-4cd3-8555-cde8f4d8b2d6"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eb1c210d43842dc83ff399b1433b853_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTYtMS0xLTg0OTc_77bfad0d-9c25-4b14-88a9-c7b72856584a"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i630b6c887763456b9fc85ec6d3ce087a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTgtMS0xLTg0OTk_8683bf0f-c020-416b-9924-8cac8bfbfdb8"
      unitRef="usd">2811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief9f1a4dc71044d6a03833cd32ab6427_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTEwLTEtMS04NTAx_c6f16861-3a95-49b2-b5dd-3e9b0996dcfa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea6b44faba3c4c3997faba3148afcff0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTEyLTEtMS04NTAz_8b3fe92b-6c3f-47ed-8743-069aaead668a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida618eeb5e0c4c0fa85d55c4d046e885_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTE0LTEtMS04NTA1_6cf1a05f-8a04-465d-92be-9759fac8c831"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ba2cc8ba7fa4f4ea047c155d67eb4bc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIwLTE2LTEtMS04NTA3_56f497c1-79aa-4e31-9a54-43dcb7bdf78e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i109a8b80496843409ed73dee8466e5f2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTE4LTEtMS04ODI1_9f8ba82b-93aa-438f-9967-e4e03d310db7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib288b9089b0c44789133829c737173c8_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTIwLTEtMS04ODI3_a7908744-ea60-4aba-a025-a98797c627b2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2d4ab01235446e18963ca74e84b4ee4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTIyLTEtMS04ODI5_74bd2d17-71a3-4eee-abfa-7748201238be"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ce39b3aecd24bc6b4e8956650a90f41_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTI0LTEtMS04ODMx_33d70546-9523-4aef-af4e-d83f2efc9f82"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c0e1109ab13490eb642fa4d06a36587_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTItMS0xLTYxMA_c12fd205-871f-461d-8d78-61ac3610d196"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i413eb3a40a8b42d988fa602ebb2ca91f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTQtMS0xLTYxMA_19a78557-94f7-4591-8c90-659a739037b0"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dea6420e00e4e8d9730f2afce5768f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTYtMS0xLTYxMA_febc33c2-23ca-4fe3-a5e2-a6ec926459a6"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0f3a8d6d4864089b0117d15c03f54c9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTgtMS0xLTYxMA_6fde7fba-1e86-45b1-baac-becd607172c8"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9a38838e3584d7098ad47e06cbd413d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTEwLTEtMS02MTA_52f4527c-6ff1-4065-913a-edbdccd80e42"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i580e219bcf66429da65491757ea55918_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTEyLTEtMS02MTA_b9542fc0-ebf2-4d18-8357-6acfc314b803"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie55279b9ee5c4b128d5d5228052e4f29_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTE0LTEtMS02MTA_0679bd64-9b0f-4d94-9997-0d8eefbf33ef"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9a3932fa2ff4271b07b0b741b9f2e16_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzIxLTE2LTEtMS02MTA_7c237008-ec4f-4184-b5d9-8bb4d6b7d2a3"
      unitRef="usd">456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i201995b3520443f09a408794644c73ca_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE4LTEtMS04ODQ1_8e81941b-f9bb-474a-b18b-6dd4782fc814"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i889b1eb7b37749da92f1bf1c86dea272_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTIwLTEtMS04ODQ3_c807391a-6684-487a-a0d8-d989c0227745"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35db01b6963a4942bb80c530e3cf0eab_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTIyLTEtMS04ODUz_8c69ed63-2934-4d0e-b478-fa842fa18ef1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i468e6f1044534b1fa35b2fbd7924b327_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTI0LTEtMS04ODU1_dee70116-8c9f-47d7-9cbb-ab632f78f683"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if08394a404854722bf7e616cb19ae8fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTItMS0xLTg1NTM_6f671d0e-8142-47de-84b2-e12b7b8f0081"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d4c798eb7224a9cacdb473b8ff5c063_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTQtMS0xLTg1NTU_8016b4d5-fa5c-42b1-a08f-b6ce62725d93"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb8d59cb650742a4a8ec1678152225c6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTYtMS0xLTg1NTc_69d0fb65-3adf-4fbf-a713-eb5951496ae2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c1749278d3a468faec493fac747a15a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTgtMS0xLTg1NTk_1f2a5531-adb6-49b7-a60c-32a623759b50"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb15b0bfbfcf4fecb6e417adb32d14cc_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEwLTEtMS04NTYx_224af4fa-1309-413a-ae16-55692cebee67"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5679c3ac945499eaa165d356e44c345_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEyLTEtMS04NTYz_5f8d4aaf-c865-4a1e-b73d-2aa8bbf11a48"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2021dd665b74bfd84ef3c205aee77de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE0LTEtMS04NTY1_a7bb8f87-5de3-44b4-a8d3-9bae3390c711"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ef427af36e6444fb807bafc1dd97ed2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE2LTEtMS04NTY3_049d5c17-94d1-446a-85c5-8571df781cda"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i983b0b11a6c84a078f5acef269da5f01_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE4LTEtMS04ODU3_cbdcaa8c-d774-4492-aae1-b526bf57ed8f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9f00902a9e047f1bf5e98edae0c114d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTIwLTEtMS04ODU5_7c3eca73-13ac-4ddd-8196-d45bb51f17a4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1527f16620140d3b0bc8763e514b4e2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTIyLTEtMS04ODYx_7aae85ae-1683-4999-a9a9-88051b4e3b33"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18b4cf44e0b44448a2dcdc6b970704a1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTI0LTEtMS04ODYz_3c3c4ac9-68a1-4b79-9699-6c91e395c8c4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fc912cbab8848d1af83924b72da7f38_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTItMS0xLTEwNjc3_4d2e59cb-0f4a-4e03-8eca-65b4fdd5ffd7"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738e00cc411942688a5f051bbc58789a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTQtMS0xLTEwNjc3_14933ab4-7e64-4842-b72d-caad298beaa6"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fc84cbd707c4080b153a838a03d48c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTYtMS0xLTEwNjc3_45c5d6e3-6bbf-40c7-a587-f86c6f5705c8"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5e9650394f04aeb94d242d32a12e8bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTgtMS0xLTEwNjc3_699ac47e-f78b-406a-bad1-8a59932099dd"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedebf7a896304b22ace657a8e1c8486c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEwLTEtMS0xMDY3Nw_ab1dc61a-7e41-474f-86c0-c0188f92d796"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib09a5278cb5a49f0a7699635ac23b161_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEyLTEtMS0xMDY3Nw_d871ab11-908f-45bc-9dad-f8d68249649f"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief07e0bd49214929beab0135a7c7dc3c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE0LTEtMS0xMDY3Nw_617df4d8-b81c-423f-8a41-d00d63c59162"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e0f3e3ca6b14a30b76b4f150c9ee957_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE2LTEtMS0xMDY3Nw_d048c093-c47a-4b31-9ffd-9feeb9cea883"
      unitRef="usd">456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0b3071aa2974bbf9886daa645933440_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE4LTEtMS0xMDY3Nw_4fe0e10c-8f69-4f37-b3a5-851629184e3c"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i883994858d314ba48462d6cb3c2af453_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTIwLTEtMS0xMDY3Nw_db0c6f5c-80fc-462f-94ed-fab76f5a6d7e"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab10c90724184ec98c3bd8679e022adc_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTIyLTEtMS0xMDY3Nw_47ce4070-9610-4071-8c00-d73c9adeb5f3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88bd06fa86a24206ad6519770cbbf504_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTI0LTEtMS0xMDY3Nw_f0497950-d6e0-4943-8433-398f38c140d9"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74d46f4d0a9742b3811281fb61e7d0e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTItMS0xLTEzNDA0_7fef90cb-6ae3-40cd-876f-af6976c8d355"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62f879d917734de09114d93c9296efc0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTQtMS0xLTEzNDA0_ec7a3d05-ec86-4701-9af8-64d03a839736"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i829cfcdf44354f36b769778dcca6ea95_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTYtMS0xLTEzNDA0_7b6be9d8-21f3-4e83-9a38-5dfed9259c65"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33c157b8f9e44197a7c0c60493c89067_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTgtMS0xLTEzNDA0_ced87f97-1f5f-46a5-94c9-026f36778f94"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c23f8c25d144cd7be8fbb3776eb33c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTEwLTEtMS0xMzQwNA_17030e96-50ae-4421-b7c1-7015e05fc85c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54469a0949b4fc0a59210e6ef5f4c5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTEyLTEtMS0xMzQwNA_48f9cb64-d220-46b5-90b4-86fcd693b9e2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i857e28fb6733458686888944ec0abcec_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE0LTEtMS0xMzQwNA_59a3e585-ddf3-48e2-84b3-7389553eed05"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4fd0e8f161841919bc51b121342b374_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE2LTEtMS0xMzQwNA_929d9951-259a-4227-9e6a-0e2a4b5f4b69"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2079180ac67341b99d32045a11aef376_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE4LTEtMS0xMzQwNA_ac450c69-6b62-4c24-bc4c-68c579d2a3f1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id94b0e9d86a249e7ba66251f8d5f185f_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIwLTEtMS0xMzQwNA_ce524371-26c1-4842-9d09-f56e3ae2d58c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1967de1c5a82446488fc2307733a2f25_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIyLTEtMS0xMzQwNA_b97f67ad-55a0-4c46-a333-b6b2438f2028"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib157d6d05afd413fbf032738706b0c74_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTI0LTEtMS0xMzQwNA_73812517-54df-4c9f-b777-de6bb4ffd2ac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6a212bda0e54ab3b525dd5891bf887e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTItMS0xLTYxMA_4f37de32-c619-4c27-a32f-3993ce7f17b0"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79495b272c824538bfb4875c67e764f7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTQtMS0xLTYxMA_609f8365-baa9-4921-a09d-928d0a51fb4f"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5738b64989fe4499bd71a4261fe9cd53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTYtMS0xLTYxMA_f1d5e60c-edb1-4844-9836-dc49412bf0bd"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0a03686d6ac48f48e3b9bc50f36d666_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTgtMS0xLTYxMA_f4838584-b31b-4d46-aed9-9db8a1601922"
      unitRef="usd">436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc02389377974b6585a7c609eb64806c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTEwLTEtMS02MTA_9e472feb-9f37-471f-b354-9631fe64f671"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47b0e346a3004c339a6cd887facee047_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTEyLTEtMS02MTA_2623d6df-dcde-4f11-bd5d-4df4296adf38"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5896ac21bdf49a6a7472cad2027abf6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTE0LTEtMS02MTA_02340608-4bec-4dc4-b44f-7b7a1b9fc0b6"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22cc8196c9ec45ab9f1de39dc4a69f10_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI0LTE2LTEtMS02MTA_04ab9297-69db-4da7-828d-0c67b52e6e48"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief49933c94874a7288705eed5a22b841_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTE4LTEtMS04ODY1_11313474-5b2e-4a34-b615-8fe988886e4b"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8a28ab5c7fb4105aefaa14b53daf143_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIwLTEtMS04ODY3_6ca89cc2-43ad-418c-ba99-bc7eb5cd9997"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id68873060904412cae3451300eaf1465_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTIyLTEtMS04ODY5_1aabbb9e-629b-4248-9b79-353f8578eb4f"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9385611a51014144a8857f90be3bf8df_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMwLTI0LTEtMS04ODcx_d6a591f1-101e-4472-8b1e-74318c1adc17"
      unitRef="usd">420000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTItMS0xLTYxMA_788fbbd7-8e00-47bf-ad71-e42016eef486"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTItMS0xLTYxMA_a84ad2ba-41dc-4362-a749-248a6ddd5f9f"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18e1f5ddacd74e36860d63ef63816443_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTQtMS0xLTYxMA_ff95cfcd-5a22-47dd-aa3f-a10d24ffcbab"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0e5f0db282f4e87a91f73ee0f751c64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTYtMS0xLTYxMA_13e65b29-2027-4238-a172-0e2d3306f59f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTgtMS0xLTYxMA_788fbbd7-8e00-47bf-ad71-e42016eef486"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9fed3c4304f9d9c41c1dc312ae680_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTgtMS0xLTYxMA_a84ad2ba-41dc-4362-a749-248a6ddd5f9f"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1da7341e9594d21a608bad106da29bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTEwLTEtMS02MTA_bf4325aa-610e-474c-aa97-e8688121eba7"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i356273c8d56b44b0b5a77cf594e9c798_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTEwLTEtMS02MTA_d9e04581-148d-4853-a6bc-7f29e980976b"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b29db06821842aa88c87560b1140102_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTEyLTEtMS02MTA_911fc0cb-ad90-4647-b901-a423b44e3993"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46fbf481784d46df9cd01a3ed0d6545d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTE0LTEtMS02MTA_c936e78f-d0b9-4b8f-b3cd-9d1a043d9c2b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1da7341e9594d21a608bad106da29bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTE2LTEtMS02MTA_bf4325aa-610e-474c-aa97-e8688121eba7"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i356273c8d56b44b0b5a77cf594e9c798_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI1LTE2LTEtMS02MTA_d9e04581-148d-4853-a6bc-7f29e980976b"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ea757664b6d4a1ab8eec797ffb2d767_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTE4LTEtMS04ODcz_045c2825-5533-42e0-b4af-2e0ddd436c29"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ddef75a147542598e9eeae5bd12bd75_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTE4LTEtMS04ODcz_c5fc439e-10cd-4512-a125-bcbb8174be61"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ec4e20f64114d7d9926a8c80f9a5728_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTIwLTEtMS0xMDY4MQ_944a5b36-e516-4fab-9a07-d1d2a0c4bc25"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i268bb32842bd412986cc0065b81f5ec3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTIyLTEtMS0xMDY4MQ_ef24407b-965a-40e0-a599-8f87b1117f09"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ea757664b6d4a1ab8eec797ffb2d767_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTI0LTEtMS04ODc1_045c2825-5533-42e0-b4af-2e0ddd436c29"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ddef75a147542598e9eeae5bd12bd75_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMxLTI0LTEtMS04ODc1_c5fc439e-10cd-4512-a125-bcbb8174be61"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTItMS0xLTYxMA_15021001-1dd9-47a9-ae50-a111e010fa28"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTItMS0xLTYxMA_4d6ef00d-6ed4-4230-bf31-1a75a8fb8cfc"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i395a7db3cb484d78bbf89146a3e077d0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTQtMS0xLTYxMA_4a9012f3-7b71-4178-a5dd-914c248da4da"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ba42c93200d4f8b8304c65a06ccf517_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTYtMS0xLTYxMA_dfe3c717-2852-4b02-8fae-af5ed6404978"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTgtMS0xLTYxMA_15021001-1dd9-47a9-ae50-a111e010fa28"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa1e5b72764849699985b97ca4d8bfa8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTgtMS0xLTYxMA_4d6ef00d-6ed4-4230-bf31-1a75a8fb8cfc"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib33bcf8c71124c9f9f2ac08771f1c913_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTEwLTEtMS02MTA_b6a1b8b4-73d8-47d0-bc6d-9b5f6acad0d8"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9314f39916471fa92a7b99ba58f5cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTEwLTEtMS02MTA_e4723bf6-2ce0-48d6-a029-55539f949c7c"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f91458243294b9c9c142625d0f38738_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTEyLTEtMS02MTA_ade97b74-9dbc-488c-bfb6-3f9ffd166a62"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib21c75ed2e5e4a0785b473551c580aaf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE0LTEtMS02MTA_d94c83e8-89c1-4b0f-a35b-2ce18e6ca710"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib33bcf8c71124c9f9f2ac08771f1c913_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE2LTEtMS02MTA_b6a1b8b4-73d8-47d0-bc6d-9b5f6acad0d8"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9314f39916471fa92a7b99ba58f5cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI2LTE2LTEtMS02MTA_e4723bf6-2ce0-48d6-a029-55539f949c7c"
      unitRef="usd">216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifad692520c784ea4abc27df55521f56e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTE4LTEtMS04ODc3_53e95773-f0cd-4855-bb01-361e56011c12"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57e47ad7e13b4bf69d68ce9974de21b2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTE4LTEtMS04ODc3_b6a4437c-cf1a-4bd5-b8d6-9daf65d4109d"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b6f0bfe6a0f4a34812997b067f29ed4_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTIwLTEtMS0xMDY4MQ_1e46aef9-e2e3-4860-bad8-983b0bf120c5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43afc88178954f07b425ff4523b10503_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTIyLTEtMS0xMDY4MQ_18ed777c-b1b1-4b75-a17b-3bf72bc10fa7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifad692520c784ea4abc27df55521f56e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTI0LTEtMS04ODc5_53e95773-f0cd-4855-bb01-361e56011c12"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57e47ad7e13b4bf69d68ce9974de21b2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMyLTI0LTEtMS04ODc5_b6a4437c-cf1a-4bd5-b8d6-9daf65d4109d"
      unitRef="usd">758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b488bb036614037b341e5cf1b62388d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTItMS0xLTYxMA_76706578-0d73-4919-bc4a-218a5ebb957b"
      unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1acd6c6fbb76414daa5db831c8743f1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTQtMS0xLTYxMA_f4bf23ca-daf7-4c07-b95c-324ee13a2c59"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib433847287a34715a932ae68acaeb709_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTYtMS0xLTYxMA_e633ab06-c7ba-4831-9363-7640e7be264e"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18325e923e9c47fcbb342e3aa696ccfc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTgtMS0xLTYxMA_550d8244-e302-48cc-a8f3-da5c3534fa8d"
      unitRef="usd">657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dc0423d455d47bea3200f2044dda0b7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEwLTEtMS02MTA_c8ca7b63-d8ce-403d-aefc-354e78b12cfd"
      unitRef="usd">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4b200ae598541c98d2a1ed430747f3a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTEyLTEtMS02MTA_805ea715-6ee5-4a5c-8bf3-88064a4e73db"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib937cdde175b4314b5243e750587f636_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE0LTEtMS02MTA_7fd6c7c8-a946-4a9c-8b17-8a6b7f3c4171"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice4f48c959ab41ee88040efcbcea0d9f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI3LTE2LTEtMS02MTA_df2d9b92-f232-457d-89fa-8dd8c9b51414"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7e97d5163a44218b733238cd69431ad_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTE4LTEtMS04ODgx_e9046ad7-e337-4442-857e-1e8cbc8804da"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfb3da24a50f484bbfcb5f5691037fd3_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTIwLTEtMS04ODgz_285e8ba2-6c4c-41e3-a1b9-a790dfa8fa3b"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9885f4a5984a4acfac50c45d81501317_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTIyLTEtMS04ODg1_836f268d-b454-4b27-9c08-a72754b61f45"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide045b122d2b4c9da0649764f92f82cf_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTI0LTEtMS04ODg3_ebc02520-fdb3-473b-bd6c-391a5b2f061b"
      unitRef="usd">321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66ba333691004582b0bfe3cf23e00905_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTItMS0xLTYxMA_46520c06-ce68-49ac-a718-e4ff519952d5"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib98481f2446747c5b3c54ea39b7ef10c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTQtMS0xLTYxMA_3f3234bf-10b1-47d0-868c-f7101b9cd1ad"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9f307f1d85849869339a3dd1db1df84_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTYtMS0xLTYxMA_f408821b-2691-48df-9997-3a56caa756c9"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9db84ac85e404173a8e1cb30a6decd26_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTgtMS0xLTYxMA_68d3e162-bad3-4ec7-9e23-db8bba137648"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91187b7f1d854ab7ba6257b9a17a971b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEwLTEtMS02MTA_d8a678ef-3467-41ce-9cef-8feba5d80e90"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5da15e7f08745208039280810556724_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTEyLTEtMS02MTA_51abbfa2-0aa2-4932-814b-0e1296758472"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09a59d3e994e417497f2f6e81c591584_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE0LTEtMS02MTA_ef92c4dc-e0af-4fc5-ae6a-1c18dacb3f7b"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37fab06fed904a5da3ee5fbccc5f0375_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI4LTE2LTEtMS02MTA_ca7314ed-68da-42f6-b960-d65a866964a8"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6a89708946c4f75aeffc28c28e30c9d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTE4LTEtMS04ODg5_852d9856-46d4-48c2-a555-4c86b2eec42d"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eec496ec02f4593bd2a62da7c33299b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTIwLTEtMS04ODkx_a7910776-3c6d-42eb-aed4-b778d8f2b178"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad31f51a98be414c964b9e2b9a577bc1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTIyLTEtMS04ODkz_52fdeafb-64a0-425a-9062-0aa5c96ec669"
      unitRef="usd">175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf02763ce85454bba606a3d45b058a0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM0LTI0LTEtMS04ODk1_72940025-434c-47f9-87f4-14a14f89792b"
      unitRef="usd">307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf2157f2cecf4cd0a6d21dfba9a135ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTItMS0xLTYxMA_2347d01a-9897-442d-99c0-ae73654a9690"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e5df38c8d924b2893c58f2be02de301_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTQtMS0xLTYxMA_904dfe55-6886-40b4-b9a0-1fd690dace8a"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b69aedcfde94c8f985123b13ec54c43_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTYtMS0xLTYxMA_dbe14f42-4323-4e15-9af0-fb523cd54318"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14b05d44e0ea438ab49cc731f8134505_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTgtMS0xLTYxMA_6e61d2eb-33fd-44f8-bcae-e0ddcf61c272"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c52e1ae94bc42c58506819cae4f100f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTEwLTEtMS02MTA_2977be68-d91d-4e2a-94f3-cb0ae09938c1"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6e3fa876eab46ff9f325ca98b6b49d5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTEyLTEtMS02MTA_29d4699c-4f0d-4d19-82ff-43bc92599c09"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec928fa7546b459695f84f5045fdd004_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTE0LTEtMS02MTA_b216e102-59ed-45ca-82b7-7bce2df4d603"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i403ec9cdcb59480d92d5fa47b3653c0f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzI5LTE2LTEtMS02MTA_82655ef8-d77a-42c7-8b18-65a4526f91ee"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia89b449def3646cd95f5c38f3912f3eb_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTE4LTEtMS04ODk3_316e8564-58f4-40ed-8e5c-f802e9088956"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73020476831d48dc952d089610d805a1_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTIwLTEtMS04OTAw_70553295-d379-4220-9500-46bf6a2795c9"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia15d33d7c7794a1690e9ff92bfdeccba_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTIyLTEtMS04OTAz_1e9c02a8-65c6-4ec2-b451-eb9f26d726ce"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i891f5e003fe345e49586b7f0ea1a1a45_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM1LTI0LTEtMS04OTA1_b7bcaab8-b202-4ae4-99da-f7fa5d93ba8a"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib01f5ca90cb941ada3953be0fb43eb53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTItMS0xLTg2NTE_9f4793ef-c103-4882-8916-470961f84d33"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73acf81cff124012959bdba4df022c6e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTQtMS0xLTg2NTM_0b3252fe-e4a8-42d4-b86f-54d68f7b2edd"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25e47d06bc5444c9881da32e0c8c1cee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTYtMS0xLTg2NTU_40a0bf65-b6db-4068-9ddb-cc19d5a7e7f6"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88c3894232694ae58965e4dd7cbc5b54_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTgtMS0xLTg2NTc_121d9268-8618-4f69-88e6-e7c48aa565c4"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib81cae5d5fb646aaa416523f96ff4dc6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTEwLTEtMS04NjU5_1437aeb8-f2c0-4ce5-a870-927f159a818f"
      unitRef="usd">153000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67c94bcb38db4efab1dd4b707e869ea4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTEyLTEtMS04NjYx_62fe0c9c-9707-4adb-848f-881776b427d8"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5904987b8e054f0e8bd5a3b2351b251c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTE0LTEtMS04NjYz_48502f27-358a-44ef-9eea-2601965b2ef2"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dfe8e689257463db42f9737c01eba0a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTE2LTEtMS04NjY1_f9c218c4-9227-4c18-86d6-92cc2ba43747"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6606449fe534eb2a6045bd62f8f24cd_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTE4LTEtMS04OTE3_06f416d7-9b86-4d1f-b5fe-84380759983a"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fd40469a0a4494997d70f0d4a34aaec_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTIwLTEtMS04OTE5_a950435c-6196-46df-95f0-f81b984e6c9a"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cccf7ba7db24688a39f333d661af293_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTIyLTEtMS04OTI1_a7e8b734-538f-4da6-8798-83cd99762080"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4038976843844c049725bed7eedc17c0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM2LTI0LTEtMS04OTI3_5318a6e8-0c47-4243-bd0a-8baee593ef38"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i711402d60b6842f9bf49e2f038e529c5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTItMS0xLTEwNjgx_708024f1-892e-48e1-a711-7eead83e53da"
      unitRef="usd">931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02968faa82754adb9368cdefe9c4fe3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTQtMS0xLTEwNjgx_aca861d1-d0e7-4cfc-8705-9d285b52bca9"
      unitRef="usd">385000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ca668f89aa4b6c8e0216455acf3560_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTYtMS0xLTEwNjgx_57099c15-0d95-478c-83f5-01a762cbd18c"
      unitRef="usd">570000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i471af2619c5a4230a84f5531a471377a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTgtMS0xLTEwNjgx_981becf2-26aa-4334-995e-84b539a4d0a6"
      unitRef="usd">1886000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i007512ae8dda41e5a9f544b584b8b898_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTEwLTEtMS0xMDY4MQ_3d14db50-a16e-4493-9b9c-bfad40ac4953"
      unitRef="usd">1412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7995dc4952d4992b95339207eb9a85c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTEyLTEtMS0xMDY4MQ_5156ee8a-fdc0-40ab-a724-0072f23e6d4c"
      unitRef="usd">430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie748c67418e941ab866c173f95e2e4c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTE0LTEtMS0xMDY4MQ_8a9e8565-aa9b-42f3-97fc-03ad2c555563"
      unitRef="usd">447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32ead5f4db724373bbe26f3ea23629f3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTE2LTEtMS0xMDY4MQ_ed3d7759-9bb5-4542-97fb-0da7d03ca90e"
      unitRef="usd">2289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia787882ee4864cee85ddd5bdd5978cc9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTE4LTEtMS0xMDY4MQ_9ca6eda1-025d-4e80-a10e-82106b1b484d"
      unitRef="usd">2257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c0fa5cf50f94ef79e636b3c7f721374_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTIwLTEtMS0xMDY4MQ_bac121ba-869b-46ad-adb1-803cbd07e57b"
      unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i115f5c61450a4ca3a4ae2df3bbb688e6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTIyLTEtMS0xMDY4MQ_e973c96f-ffa3-45cd-a7be-ef24ca251dba"
      unitRef="usd">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9493b54209da48aaa35d8e714d4decc6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM3LTI0LTEtMS0xMDY4MQ_0e2474a6-0118-4e2b-bfc8-417c442e0596"
      unitRef="usd">3100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5749630d7d6b4757afcd624c8e7ba7af_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTItMS0xLTEwNjU4_f071a54b-e34f-4fc7-943e-83f5cb93644c"
      unitRef="usd">18141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18f9086e97774b9ca925fc4a60860be7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTQtMS0xLTEwNjU4_c31e0a8b-3b0c-4d8d-a17c-68bd62d569b8"
      unitRef="usd">3894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0fc749c3c7c4c0797d0c18e3830a490_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTYtMS0xLTEwNjU4_7301cd1e-a373-4b99-bfcf-693455084bb1"
      unitRef="usd">2320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85124ea043f44d21b8b54a8de5bdf919_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTgtMS0xLTEwNjU4_3774ee0c-1190-4970-84fc-18888bcea3ce"
      unitRef="usd">24355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff38adcd98344d5688d2b7c42eb4d546_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTEwLTEtMS0xMDY2MA_cb2c8086-c441-4131-8eb1-ef5f34185810"
      unitRef="usd">16565000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b68dc0514ef48d4959838e63c0ec733_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTEyLTEtMS0xMDY2MA_89b1a35d-3863-4ee8-a3cc-49050591f242"
      unitRef="usd">3567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c409ba8f5914054bea31b89ef69134a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTE0LTEtMS0xMDY2MA_be531a0d-2e70-447a-86dc-c78453c0a3f4"
      unitRef="usd">1987000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1854fd7993394c05bb3e013f00d725cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTE2LTEtMS0xMDY2MA_02e80804-2e98-4baf-ac3e-60a039cce2b9"
      unitRef="usd">22119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13ea489570e94e849c567c2748c27b83_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTE4LTEtMS0xMDY2Mg_56648cb2-950f-4754-9253-3541f06b86fc"
      unitRef="usd">16197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e40bb38a566430ba935851046aca72c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTIwLTEtMS0xMDY2Mg_54aa0412-11a7-4e80-9b96-32ed754d68ce"
      unitRef="usd">3696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie87b24e3cc774ee496e9f4e9fe3259a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTIyLTEtMS0xMDY2Mg_aa33028c-922d-4501-80ef-7ddab7b516a9"
      unitRef="usd">1784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c26f4bd16b4406da90ed77b81c4e690_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM4LTI0LTEtMS0xMDY2Mg_f165e446-ae14-42b1-8452-2d596c4bb149"
      unitRef="usd">21677000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i3b37655a4024424baec1bc2e6b93c53b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTItMS0xLTYxMA_94bd4566-eccf-4231-9d34-dae46cb673c6"
      unitRef="usd">76000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b386ce4d117451092994876209c5a7a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTQtMS0xLTYxMA_7b1e482b-9d2b-4932-81e3-701906caac16"
      unitRef="usd">241000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8fc9a58a4ab4e06acb145d4d9fc938c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTYtMS0xLTYxMA_6ca277ed-87fc-4cea-aa7e-2f5ec1496632"
      unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id688d136833640ac9c6d94d4ddc9632a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTgtMS0xLTYxMA_8332b228-ad6b-4317-9c41-055e2f6513b3"
      unitRef="usd">334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbf1b72c9bc5437e93fbb59118a89b11_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTEwLTEtMS02MTA_84e1d2a6-9fdf-4fbb-a555-a1587214feee"
      unitRef="usd">80000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37d1dcf382f0457c87f65fd2c8d9ff06_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTEyLTEtMS02MTA_2d342304-21bb-4cc8-927e-af4824aed43b"
      unitRef="usd">244000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e1d16ebcc6c4a9ca3e4100c1dac49d3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTE0LTEtMS02MTA_302caa8e-5fdd-428b-81ba-19c651ea7146"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c8670361a0047c5abdca258af5b3b44_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzMzLTE2LTEtMS02MTA_25577644-cca3-4610-8b82-ab9c42759c2d"
      unitRef="usd">330000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib18a5881f11747ddbaf96b26b1d744c9_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTE4LTEtMS04Njgx_93e7c72a-79d4-4482-a2af-089bf6848019"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70edfabacb9d4ab89289cb74d03d9883_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTIwLTEtMS04Njg0_2f47bc16-8e95-48aa-8cfb-a7f91b5c566c"
      unitRef="usd">310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7faea72409640a49a435de615dc7102_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTIyLTEtMS04Njg3_f799f0e8-d43b-4c55-89ed-43a601ff3fff"
      unitRef="usd">68000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a0d2f065cd0476e9fe09cf97a3daa95_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzM5LTI0LTEtMS04Njkw_4e26658a-0f13-4bbd-9042-326055be3904"
      unitRef="usd">450000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2ccc7e7e5524a3280968384eaa7914d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTItMS0xLTEwNjg5_d0477bca-9b53-46ad-b780-72a2ae70530f"
      unitRef="usd">18217000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibff4f9ede79c4c67aa7a3250803dc3d9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTQtMS0xLTEwNjg5_2dd0c6e8-1d44-48bc-9d09-f8b93757368f"
      unitRef="usd">4135000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i065f333a6d934bca92cd111bef4577bc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTYtMS0xLTEwNjg5_0d83fe34-aa5e-4bc5-874d-010802a435ed"
      unitRef="usd">2337000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTgtMS0xLTEwNjg5_6adac766-b1cd-41f3-b108-57ac9f5e9f06"
      unitRef="usd">24689000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i423ab7bdc2094bf0abc5c971cd107ff1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTEwLTEtMS0xMDY4OQ_9d7a619a-8c43-40dd-a54d-a374a4a236d5"
      unitRef="usd">16645000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibdd28ea07c0f45ddb0ee2c099f46b450_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTEyLTEtMS0xMDY4OQ_9f9d252b-305f-4818-bcc4-cbb93aa65ddb"
      unitRef="usd">3811000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83da63a7df68404bb8a5d3bf6f9e82d3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTE0LTEtMS0xMDY4OQ_24c8fd1f-3993-4abf-8877-181ad0b55edf"
      unitRef="usd">1993000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTE2LTEtMS0xMDY4OQ_e073d9f0-e136-4179-9e4d-2575214fabf5"
      unitRef="usd">22449000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i02abe7b617b74a5399a1101c5b6f2a83_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTE4LTEtMS0xMDY4OQ_92fcf3b3-6617-4beb-aef2-53dcffe00d6f"
      unitRef="usd">16269000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3649ae2389f94d3892ad79a3dd0a2c98_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTIwLTEtMS0xMDY4OQ_58035d70-b568-4769-bc07-b4660a5ea15d"
      unitRef="usd">4006000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id51835942cfa4433ba52343a2cc2e074_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTIyLTEtMS0xMDY4OQ_db78f70c-5199-4415-967f-64dee1620845"
      unitRef="usd">1852000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZToxM2RhMTQyMzUyYTE0YjE2YTExM2JmZGUwZGU4YWM4ZS90YWJsZXJhbmdlOjEzZGExNDIzNTJhMTRiMTZhMTEzYmZkZTBkZThhYzhlXzQwLTI0LTEtMS0xMDY4OQ_aea903fb-56fd-441a-b9bd-13c36643d8b8"
      unitRef="usd">22127000000</us-gaap:Revenues>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzI3NDg3NzkwNzQ3MTI_9c58e3bb-cb66-442c-80de-854b9d38cc00">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia3d5490822d34a2a99d663996669b4f1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzItMi0xLTEtMjI4MTQ_39dc68fd-2e42-4a12-8c74-0b656113df8c"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib9126e641d024fb0b335f3046e9ed3ef_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzItNC0xLTEtMjI4MTQ_17f3b17a-64fe-442f-8822-3a8d29c7bda7"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iadd8f355bff34661aa70ef78c021e5e9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzItNi0xLTEtMjI4MTQ_ffa27423-e0a8-4e91-803d-de2d639d02c5"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72e0cdd23483485f9ed6c6ee0844369f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzMtMi0xLTEtMjI4MTQ_c5f4fdbf-2d6e-433c-a539-13e8e25f98d0"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie13c70a71c4c421abd1362ea62569117_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzMtNC0xLTEtMjI4MTQ_6241aa77-2fb1-494f-bdef-b5708161b93f"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idf5c0818833647d3a25ea25ebe359b5c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzMtNi0xLTEtMjI4MTQ_3287edf7-b219-4885-9806-fd4510268a91"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if74eda1b891b4ab79e2ca96ed9eada38_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzQtMi0xLTEtMjI4MTQ_9df2753d-5687-40f8-ba9c-a67a9c40ca70"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i087aad162b0642ff8db64f6a05885c60_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzQtNC0xLTEtMjI4MTQ_3ae05aeb-f590-4058-82df-904cf47165fb"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib33ce3a5097547a6b8d4a0f1ba3e9fe4_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90YWJsZTo2Y2FhOThjZjYyYTM0NWIyOTIzODZjM2UxMzFlYWM3Yi90YWJsZXJhbmdlOjZjYWE5OGNmNjJhMzQ1YjI5MjM4NmMzZTEzMWVhYzdiXzQtNi0xLTEtMjI4MTQ_ac1d71ca-945e-4598-bad6-5ca3b35ac0c8"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i6a2652179d8b4b0ea00c6e7c08a3f988_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzQ0NQ_3e426941-16bd-492f-b1fe-e728d77d4a47"
      unitRef="usd">841000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ifbc8462d720446f4b9207d710a136bcb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzQ1Mg_b5fe6d93-71a0-4fb5-9876-954f2b7b0b5a"
      unitRef="usd">741000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i0b3598bfff834885b69c49aee403e0db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzU5OQ_78fcc73c-ea94-463c-bdd5-4cdb23962f7d"
      unitRef="usd">101000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ifc3429c7b8484213bf017f41a196b549_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzYxMQ_6d9699eb-5fc4-4126-8959-f46a51e632e2"
      unitRef="usd">257000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzg4MA_fc38fb1d-990c-4230-addc-4b45474b8825"
      unitRef="usd">198000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzg4Nw_de84d300-8fee-46f2-8e3c-382dd08573c2"
      unitRef="usd">144000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzExNTQ0ODcyMDk0MjY5_31ae3af2-483c-4a42-846e-12b5ec227f81"
      unitRef="usd">97000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTIvZnJhZzpjMDk3OWJmOGUzZjk0YWExOGY3ZGE2OTg4ZTVhODBmMi90ZXh0cmVnaW9uOmMwOTc5YmY4ZTNmOTRhYTE4ZjdkYTY5ODhlNWE4MGYyXzExNTQ0ODcyMDk0Mjc4_b56b9b82-4e39-4417-b4d3-e38ea3626a14"
      unitRef="usd">45000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzY0Nzc_275100cc-22fc-4931-bfb5-c962ea9c95cf">FAIR VALUE MEASUREMENTS &lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities, and foreign currency exchange contracts are reported at their respective fair values in our Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs in our Consolidated Balance Sheets. The remaining financial instruments are reported in our Consolidated Balance Sheets at amounts that approximate current fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments not measured at fair value and excluded from the above table were limited partnerships and other equity method investments of $58 million and $24 million at December&#160;31, 2020 and 2019, respectively and other equity investments without readily determinable fair values of $204 million and $82 million at December&#160;31, 2020 and 2019, respectively. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of equity securities resulted in net unrealized losses of $1.7 billion and net unrealized gains of $1.2 billion for the years ended December&#160;31, 2020 and 2019, respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities in our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Consolidated Balance Sheets. See Note 4. Available-for-Sale Debt Securities for additional information. See Note 11. Collaborations and Other Arrangements for additional information on our equity investment in Galapagos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18 month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our aggregate short-term and long-term senior unsecured notes and term loan facility, determined using Level 2 inputs based on their quoted market values, were approximately $34.6 billion and $27.3 billion at December&#160;31, 2020 and 2019, respectively, and the carrying values were $30.3 billion and $24.6 billion at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, in connection with our acquisition of Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;). See Note 6. Acquisitions for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, in connection with collaborations and other equity arrangements we entered into separately with Pionyr Immunotherapeutics, Inc. (&#x201c;Pionyr&#x201d;) and Tizona Therapeutics, Inc. (&#x201c;Tizona&#x201d;), we also measured fair values of our exclusive options to acquire the remaining outstanding capital stock of Pionyr and Tizona on a nonrecurring basis. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019 and 2018, we measured IPR&amp;amp;D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (&#x201c;Kite&#x201d;) at fair value on a nonrecurring basis, and recognized pre-tax impairment charges of $800 million and $820 million, respectively. The fair values of the acquired IPR&amp;amp;D assets are estimated based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&amp;amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;amp;D efforts. See Note 9. Goodwill and Intangible Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other level 3 liabilities were our contingent consideration liabilities, which were not material at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzY0NjE_4c8b6c47-11ab-411b-b32b-3da6500da74c">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cdc1a99bb8647ea8e9692070dabd0e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMS0xLTEtMA_e864aaed-d54f-41d9-96ad-d388e1fe3e80"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6b90eadc154444fb19c9a01d59bf33f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMy0xLTEtMA_15a75190-6591-42a5-afd2-c517ca0bd3d0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb6397a7dd8a4e959ad085826f07f21e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtNS0xLTEtMA_057226e4-723e-4f8e-932c-e86097591c4d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia19b4456b05d409e95fc69cc5a327fe7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtNy0xLTEtMA_c28b4e12-58ff-456e-b964-9315530b216f"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i689f540e21ea4cc0ab92a8b3e7bc2336_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtOS0xLTEtMA_71f6cfd7-f96c-4ed9-881b-7e177012e319"
      unitRef="usd">2433000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33fb3025f9a545e3b9aa62b16b54b596_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMTEtMS0xLTA_6664be8e-8faf-4645-82ae-3b5c41baeca2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4c0dd0b8e294840a0967d56255d0758_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMTMtMS0xLTA_d1be6431-17be-488a-be8d-bccb816b3f69"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71dcab1fa94847e09339d54b040213a8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzQtMTUtMS0xLTA_769dca4e-ee94-4d6c-b118-56f580b983dc"
      unitRef="usd">2433000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71d9226cf83c47e8975915ff0788e426_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMS0xLTEtMA_0c51e3d3-d4ae-4a66-a072-00155b8656f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e924b85a8594cbb8c57fd8d907feee8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMy0xLTEtMA_45e73c1d-f18b-4b65-b7fa-7b1c3b414704"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43f4d18853c24b45892069de276317e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtNS0xLTEtMA_0990e058-c2b1-49d3-904c-108907551444"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i992f0d769b004f95844a081bc36172fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtNy0xLTEtMA_5c52fb8b-9831-41c4-89ae-0499eadecfdf"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51b2c1dd010f46709c3e2a7ecbecafe1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtOS0xLTEtMA_0e6b3bd0-8e3e-4b0f-8821-964515caced9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53dde5e597fc4c8c9f9392994230aefd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMTEtMS0xLTA_bdd5bdb8-720c-4feb-b4f9-d88c31a28cd3"
      unitRef="usd">3517000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e7ddb0e37dc4971959f70137bd43e78_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMTMtMS0xLTA_d155d57e-34a1-4f67-936e-6a2247e915f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6980afe038e45579c072cc6b1f18611_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzUtMTUtMS0xLTA_b4d2bc37-fa9e-45c0-9a2a-4ff816866fa6"
      unitRef="usd">3517000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0313e101274d4d69af2e1f0fe44be664_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMS0xLTEtMA_5ffdb508-7407-40f1-bebd-997c92afeb63"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e2b91e05cc6441ea9289dac6014f9d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMy0xLTEtMA_ae5af3b5-8247-4ddd-ba85-61767408733a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1569fa49e674423a1c2924dd5b61f56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtNS0xLTEtMA_97216bd8-1d2c-4918-8ab6-157e60c170d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddb3c647adb04138be2978c1bc0e7c55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtNy0xLTEtMA_e3dde888-a8aa-4d51-a21b-c45e36cf9eca"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e53260d7b76425c956afc0063e9e182_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtOS0xLTEtMA_c95f98f2-b374-4033-b475-8d1d964f9946"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i589cf24d12624979854f176c47f77cc6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMTEtMS0xLTA_993d8c0b-1881-4b2e-8d97-f9fdbff1a035"
      unitRef="usd">1081000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69b13783318c438397f0b5c7220581e1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMTMtMS0xLTA_ba3f8566-289b-456b-b777-1a55d712a898"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id230907331084b6ebd637c4cbd8e25f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzYtMTUtMS0xLTA_d7bb2718-2ea9-471e-a75e-4339132218bb"
      unitRef="usd">1081000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7eb2069f86d24b03827a9e9d8f97e538_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMS0xLTEtMA_f9782c29-178c-462f-900f-0cc2cd216dd5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6caabcbcf4dc4ebd86cd6edd6a29e8f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMy0xLTEtMA_7248f426-07a9-4dc4-b9d6-bf9266ec46eb"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7cae3a2b8ad849299af80dca8054aee7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctNS0xLTEtMA_52bd0f34-939c-4df9-848e-54f027bd2824"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i847c77713b0c4b30952627ab78b5d9c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctNy0xLTEtMA_e0b47c9e-b97b-4a30-b669-dfc3b8911cfc"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i102f4590cd5742c1899de653a60628e5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctOS0xLTEtMA_e19a1976-fc2c-4f3c-b7a0-d3d2322cd956"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc748cd30e344577abfa0acf8a8c1844_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMTEtMS0xLTA_9905b264-967f-4d6a-801f-a0b0c3a97239"
      unitRef="usd">174000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0bfeb4f55a1452cb6a3d4b5b1ec025b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMTMtMS0xLTA_a7c401d3-28df-4f1a-8c1a-dad67dbe5a25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2044183092a4b149a34f91bca641feb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzctMTUtMS0xLTA_f72434b2-2699-445c-88bf-63eeb7b8d2c8"
      unitRef="usd">174000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b95610d80114557965c7323d44db873_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMS0xLTEtMA_5795836e-6b68-4998-b7d3-24093dc057fb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9cacafade6b2473683f93e114273f77e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMy0xLTEtMA_53084f19-9523-4b56-bac9-07dd466c2a6c"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55cea2844ac74eb395212db775cb345a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtNS0xLTEtMA_413d9ffb-651d-4375-bb9b-268e3fbd2626"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if91268be96b54e30bdf5db6bd9878dbc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtNy0xLTEtMA_6c4caa5c-8c8a-4cd5-8e73-499c3e429299"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7513aaabb5f4272b2cacd3804a15a28_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtOS0xLTEtMA_35818662-8cce-4909-b52f-df6df6dea4d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee66dbb093f14358827b89e7e0dcd966_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMTEtMS0xLTA_182264f2-a4b6-4df9-85fa-d638d1dbe3cf"
      unitRef="usd">9204000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2e78ecedd654614959bcb071f7acadc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMTMtMS0xLTA_19a2c074-0580-4bb3-8adb-ea8e458eb6f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f2ed1b955d740f2b0927118ddcb4df3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzgtMTUtMS0xLTA_570baead-a9cd-48c9-acef-6d7d7335a852"
      unitRef="usd">9204000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia906d2214220429abfdad1e08150f915_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMS0xLTEtMA_30560fc9-5bce-430d-8bc6-6ef98cb51c5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib97dd6c44c604681b3098926fc081208_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMy0xLTEtMA_99788287-baaf-427c-8c0b-c9ffc72b8acc"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c4ac453a767416c8e1f4e02b40d3382_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktNS0xLTEtMA_276f2ba8-c0ee-4e48-a4fa-d1ba43ea4cb7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a1ef2a73f9a48a4986b5abce37bdb95_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktNy0xLTEtMA_d7838381-7c67-4733-8d72-adc8efb429a1"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib79fe00c16824d8d9660be7d01074024_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktOS0xLTEtMA_b2226cbf-1d1f-4e85-879d-6324e373063a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i245cd04d75b64741b3e002da6bb2c48f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMTEtMS0xLTA_9087435d-1b91-4783-a053-0adb5bef15b2"
      unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0413ebf760a34b8898709dbf0402b2ac_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMTMtMS0xLTA_26dc0120-f1cb-40c7-b078-949427a679c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a81f06d2f0d45df85572d4243c7b338_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzktMTUtMS0xLTA_09299480-9fe8-4e44-9dc9-c9e57a85bf63"
      unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1cb997734a76456bbb02c472d8bda07c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTEtMS0xLTA_1485acfd-3019-44fa-aaf9-8fd450d178c7"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i35fb84b762b84b7aa1431739434b9b21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTMtMS0xLTA_ab744c05-f48d-4d08-abd3-39dfba5e334e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2a3e9c9d067843908408309f57f08a32_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTUtMS0xLTA_217f7df2-b59c-45e0-b113-833cde37edb5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i84a64ac1b4c94676835b5826fa5f20c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTctMS0xLTA_ff97b625-e5d3-4243-8b64-aa85c40f3674"
      unitRef="usd">1648000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if2d69c8fb1e1480c8b25d127290a2aaa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTktMS0xLTA_34716170-807e-485f-bc55-da4a3be736f5"
      unitRef="usd">3477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie4fd341ae13d453bb4c6a2495482ad7f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTExLTEtMS0w_8cb09849-1d37-40fe-962f-dd4bec18ae32"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic41eb8f855f04ab18ec5a45dc18339c9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTEzLTEtMS0w_01cb047f-95bd-412d-b9d4-1823d681a844"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8c4d7e36c9834ea2a50375607652e3ba_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzExLTE1LTEtMS0w_ea1f8359-44d3-4a2c-a803-4df53ccd624d"
      unitRef="usd">3477000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie2dffdc39d4e4c498f9847e218524a71_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTEtMS0xLTA_fd581fb5-eb01-4cf5-a96c-c0c52c99070d"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1d94a45eedcf462b8e2ad22dd4dc36e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTMtMS0xLTA_1f5f070b-caf5-42cc-9e40-32a3ed5b59b4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idf015395242a44bda73d3642656c5f16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTUtMS0xLTA_f5b14ca5-e2db-4a0c-bc86-701f8e7f8a54"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifad52fe076ec4556b05b0b1bd02f7c11_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTctMS0xLTA_3162fbfe-2851-4667-8536-17ca749582e9"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i014468a50cb14ec0b4f015914180f3c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTktMS0xLTA_8ab7210f-831f-4730-84ba-473131a9246e"
      unitRef="usd">7069000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i01262868b33640a197ec1f4edf4d999e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTExLTEtMS0w_d4df1021-dcb3-4c59-9c75-523dfcb72a05"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i74c40eca549f4c34976283d9d6ed1e15_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTEzLTEtMS0w_b2c72f60-c886-433a-8646-da00c3dcf064"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie6a4193ff8f34e439051dd12ffb9dbb8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEyLTE1LTEtMS0w_fe9c7c0c-e33b-4be0-a3bb-27f647aaf55d"
      unitRef="usd">7069000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9f5cae775b7f463ea40bc9792ac6e442_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTEtMS0xLTA_c8bbedc2-f406-4c46-96e3-73e4126d7695"
      unitRef="usd">743000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1eccad0947fb47f0ab3c1aa00d140b19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTMtMS0xLTA_f1116b5c-3a66-44ef-8ffa-c4f6169b68bf"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifeb4f3afe2714d6db05b71cdf7349336_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTUtMS0xLTA_00f19146-ce18-4158-b332-e2cef48730dc"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id4710ffafb664853b06fb84f1f903262_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTctMS0xLTA_00005436-b523-4b74-adb2-c0bb2b76dbc4"
      unitRef="usd">743000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iefb3298102714119abcc23920b0fbc5f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTktMS0xLTA_cffcb696-a0f4-4344-acb2-aea06a1be3aa"
      unitRef="usd">322000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icc33840c250349a384747a52147ce1b4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTExLTEtMS0w_4825a42e-dddf-4cd7-bdea-3a689646f3fe"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iab16ab242dcd40f99168ba8f52458d66_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTEzLTEtMS0w_2782ad9f-e846-4a02-a7d4-d6fd1fefbb70"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5db613f5d89d457781afd75124915704_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzEzLTE1LTEtMS0w_4e4d9ff1-7e99-4b4c-9a54-12fdab4385b9"
      unitRef="usd">322000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6760924221ed4b5cba60ea7d2547a8cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTEtMS0xLTA_6848f293-85ed-4c1d-aff7-38014634617f"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i823810b00b57487a84c912f0198b1fc2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTMtMS0xLTA_91c2343d-5d59-47b6-8767-0a7cf77e2623"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if5a2765b359a4c069d0d5da473baa6c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTUtMS0xLTA_18e1140a-a116-444f-a07f-ff4ee650ffe5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i87f2798614104859bbe54d4ec9712a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTctMS0xLTA_1f6e783c-4b76-4581-82b1-65b46e7eed35"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if63750d09d394e93bf20d847c07a673e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTktMS0xLTA_9dab7fa7-f316-47f2-8a7a-d640a0520d74"
      unitRef="usd">171000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibd825c3a419d40c89740d90e5802b238_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTExLTEtMS0w_596f3529-22f4-49e8-ad1b-226824b1501d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibb6a848a7d8944b99e06faadeba12110_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTEzLTEtMS0w_23bc6ba2-cc01-41e0-b1c6-8089c221ccf5"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i620b03a7ceff4498b7ef8db0524ac079_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE0LTE1LTEtMS0w_7003ec90-6884-416b-b06e-076431288cd3"
      unitRef="usd">171000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="idb1ffad7978e479885f4f62b24f36dc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTEtMS0xLTA_004556e7-4537-4272-9095-eb536417e783"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i284a56e4feb84fa9b3f54659b24ed623_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTMtMS0xLTA_2d1ff0d2-26a9-4725-bd51-05d6f4400446"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib17a07fc344b4439808bd61c45decb70_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTUtMS0xLTA_8aec9d0a-8329-46aa-b074-10ad7172279d"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i98db09bcfe5b4e588506f6849925a677_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTctMS0xLTA_9d2f7345-2ba0-4723-bc81-d980916e3657"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2d3b63ebc98b4fc8bc4ead7f256ad433_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTktMS0xLTA_d421e8da-ee6c-4997-886f-2308d4556baa"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia600e92a5fee4aec9bd9a77aa48c46f5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTExLTEtMS0w_b41590f4-54b5-4474-87e9-65033d379128"
      unitRef="usd">37000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6eefcd80ffa146259d29c8ec79bcd8fc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTEzLTEtMS0w_fec578f8-e951-4756-b830-ff7ecddf6836"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i451fd8be53df45b88a7acf78165a771b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE1LTE1LTEtMS0w_68eb38b9-f957-4ce7-b6bc-d04acd3ff588"
      unitRef="usd">37000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c1257e571bc436ebc3359c9c23418d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTEtMS0xLTA_385b5f07-1f70-4211-9601-6ed1ba3c6af9"
      unitRef="usd">7279000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i501409456a97436db0b9b79612bb915b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTMtMS0xLTA_1941f880-507b-4cc9-b996-6891565c26f1"
      unitRef="usd">1729000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c91186d780d4a76b4dcca46016e88b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTUtMS0xLTA_8c5bdf58-c912-44c8-b61d-ce8533fc4832"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i43d13c3320274c64bc19f9627e57686b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTctMS0xLTA_d25287e2-2868-463c-a03e-e5e16a6bacd7"
      unitRef="usd">9008000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31162f66edd14b10a6a33b68539c40b9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTktMS0xLTA_84542bf9-85d2-497c-96b5-faf02d52682d"
      unitRef="usd">13472000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3fe5dab1d5f643f9bce8a2eadf2aa51e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTExLTEtMS0w_66196afa-bfcc-468c-b4fd-a50505e884c4"
      unitRef="usd">14104000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c54d9501afc40c6a54d229dda2f8f02_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTEzLTEtMS0w_3a00c508-e262-460a-85f0-38a0b7dfca54"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib88622965efe4116a7e9094e9f179d61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE2LTE1LTEtMS0w_8737786c-46e8-4ed0-9911-046ede677f91"
      unitRef="usd">27576000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i6760924221ed4b5cba60ea7d2547a8cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTEtMS0xLTA_275f339f-c95a-4770-a09a-ee6b8dabc023"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i823810b00b57487a84c912f0198b1fc2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTMtMS0xLTA_f94e889b-27ad-4d3c-aff6-0cc47708133f"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if5a2765b359a4c069d0d5da473baa6c0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTUtMS0xLTA_08612b06-a22e-4931-9d61-a71af45cd83f"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i87f2798614104859bbe54d4ec9712a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTctMS0xLTA_ba343366-7c8a-41f0-af1b-bd04276def1f"
      unitRef="usd">218000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if63750d09d394e93bf20d847c07a673e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTktMS0xLTA_52bb6420-48ac-4e6b-9449-d59902e75fcb"
      unitRef="usd">171000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ibd825c3a419d40c89740d90e5802b238_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTExLTEtMS0w_44286abc-2564-4630-9d14-ca72ccc4c4bd"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ibb6a848a7d8944b99e06faadeba12110_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTEzLTEtMS0w_e5f7da11-c3fb-4bff-9c9a-e9ca1a9d5cf2"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i620b03a7ceff4498b7ef8db0524ac079_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE4LTE1LTEtMS0w_91e88250-b263-414b-a083-c5e95ec33366"
      unitRef="usd">171000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="idb1ffad7978e479885f4f62b24f36dc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTEtMS0xLTA_576a3b32-69db-4594-a643-b9cbfa852eef"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i284a56e4feb84fa9b3f54659b24ed623_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTMtMS0xLTA_d17457a7-bbea-4f40-902b-b59c0fafd200"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib17a07fc344b4439808bd61c45decb70_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTUtMS0xLTA_907357db-915f-414a-b17b-046bfaaec010"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i98db09bcfe5b4e588506f6849925a677_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTctMS0xLTA_9e86673b-2fa5-4529-af52-223fe1f18656"
      unitRef="usd">121000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2d3b63ebc98b4fc8bc4ead7f256ad433_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTktMS0xLTA_f07d97b8-a0e4-4900-817f-0e0863f1eda6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia600e92a5fee4aec9bd9a77aa48c46f5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTExLTEtMS0w_8cb0208e-8e3b-40ec-a5f1-48633d43ccfa"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6eefcd80ffa146259d29c8ec79bcd8fc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTEzLTEtMS0w_2fe6c38f-210e-4615-9c71-0fdd795d6312"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i451fd8be53df45b88a7acf78165a771b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzE5LTE1LTEtMS0w_dac04bbe-f3f3-4462-a035-7f43f6b8bbd8"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9c1257e571bc436ebc3359c9c23418d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTEtMS0xLTA_c5111e76-81fd-434c-80d1-f544e73f9e90"
      unitRef="usd">218000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i501409456a97436db0b9b79612bb915b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTMtMS0xLTA_ac685721-61cc-4932-840a-10663d94c581"
      unitRef="usd">121000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5c91186d780d4a76b4dcca46016e88b0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTUtMS0xLTA_a526a89f-9fe4-4bf3-8305-b7685b445601"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i43d13c3320274c64bc19f9627e57686b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTctMS0xLTA_66ab0741-52e6-48d2-949c-6d822e2e897f"
      unitRef="usd">339000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i31162f66edd14b10a6a33b68539c40b9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTktMS0xLTA_affb58e1-b381-42eb-9e40-8ed274067395"
      unitRef="usd">171000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3fe5dab1d5f643f9bce8a2eadf2aa51e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTExLTEtMS0w_cc8ebaea-b597-432a-96e1-89b38f5416a0"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2c54d9501afc40c6a54d229dda2f8f02_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTEzLTEtMS0w_b84657aa-4a7d-454c-bc58-f490d59a5e6a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib88622965efe4116a7e9094e9f179d61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo3ZWNiNDhlYzI5OGU0NDQxODA4NzZiNGMyMGVlY2IxMy90YWJsZXJhbmdlOjdlY2I0OGVjMjk4ZTQ0NDE4MDg3NmI0YzIwZWVjYjEzXzIwLTE1LTEtMS0w_2a482361-9900-4b48-b55e-78bef9152439"
      unitRef="usd">179000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzIzODQ_f204faad-3fe8-473c-9215-243d1ef37cf7"
      unitRef="usd">58000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzI0MDE_a3b00820-1062-46e9-a25a-b5cd118b7ea4"
      unitRef="usd">24000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzI0MjA_dfdfdf63-0f9d-4672-853c-8cca77ff14f6"
      unitRef="usd">204000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzE2NDkyNjc0NzI0MzY_85e766fd-03c0-4e9f-8954-241e23b21b1e"
      unitRef="usd">82000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzI3MTA_eff3d97d-c491-44d6-9a29-7031bd2f9ff6"
      unitRef="usd">1700000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzI3MTc_5f057a17-6b3d-4066-99da-41e42b31345e"
      unitRef="usd">1200000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzY0NjM_1c5f0713-5273-468a-90c2-1e93f222348e">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities in our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i16426d78ce7c4baeb60f73d40c7360a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzEtMS0xLTEtMA_2217bf26-34e1-4881-9584-7072607cb525"
      unitRef="usd">4361000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3a5e7f31b83842cd95af2e19292bd16e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzEtMy0xLTEtMA_a94c8c3a-b05c-40e0-9ff5-41206543d8ba"
      unitRef="usd">7069000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iff3e3a8f25534e47821628e02a0a3563_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzItMS0xLTEtMA_f22b9b42-9548-449d-9653-ef470ab5a16a"
      unitRef="usd">853000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1322bc486afc430a880d2d9343dc7c55_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzItMy0xLTEtMA_830779f6-e7fe-4a0b-9c48-d946e0f0f512"
      unitRef="usd">319000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2100cafa2bd04f0fa1ca7fd4b3cfcbfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzMtMS0xLTEtMA_117fb482-77d7-4d49-865c-45325185d703"
      unitRef="usd">1756000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9fc2d816fd7043748729bb6623b61959_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzMtMy0xLTEtMA_727a595d-afa8-40f8-92ca-6c7a625df44e"
      unitRef="usd">3651000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzQtMS0xLTEtMA_951df179-af07-444d-a9c2-6e29b46fe645"
      unitRef="usd">6970000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90YWJsZTo5ZjIyYjY3YWY0YTc0YzllYjdhMDNlZTU2OGIyNWRjMC90YWJsZXJhbmdlOjlmMjJiNjdhZjRhNzRjOWViN2EwM2VlNTY4YjI1ZGMwXzQtMy0xLTEtMA_7b80822f-de65-4956-92ba-409062e80694"
      unitRef="usd">11039000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LongTermDebtFairValue
      contextRef="i3eded22e6e7b4c3b9606256b7f9aa791_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQ5NDk_11de2ad1-22ad-4019-8112-2d6f94f603f3"
      unitRef="usd">34600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i053b4f6a4ee446758474a88c7466df66_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQ5NTY_563b51dc-dac1-40cf-8047-a3a519ac8901"
      unitRef="usd">27300000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i743c158a26c1458b8cc125718d80bd03_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzUwMTY_bb848566-255f-486d-a103-f3c517f1b489"
      unitRef="usd">30300000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i120926cc5cde493e8d537eff1e3bf7e5_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzUwMjM_f1b5ee63-d8a7-473b-b21a-41bc336e1a65"
      unitRef="usd">24600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQzOTgwNDY1NDA2MTY_8a18dc50-79da-47b0-91c2-98148d479d91"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTUvZnJhZzo4OTc3MTk3MzQ1NjE0YTQ3OGZjYzFiMjVmYjE1MGRjYy90ZXh0cmVnaW9uOjg5NzcxOTczNDU2MTRhNDc4ZmNjMWIyNWZiMTUwZGNjXzQzOTgwNDY1NDA2MzE_7a9e9845-de54-49d3-8c5f-f86b1914c453"
      unitRef="usd">820000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTQ_03976de2-b6d0-4150-88e7-5f6a2e53de54">AVAILABLE-FOR-SALE DEBT SECURITIES &lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was $9 million and $37 million as of December&#160;31, 2020 and 2019, respectively, and is recorded in Prepaid and other current assets on our Consolidated Balance Sheets. There were no write-offs of accrued interest receivable during the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held a total of 75 and 305 positions which were in an unrealized loss position as of December&#160;31, 2020 and 2019, respectively. Aggregated gross unrealized losses on available-for-sale corporate debt securities were not material, and accordingly, no impairments were recognized for the years ended December&#160;31, 2020 and 2019. Gross realized gains and gross realized losses on available-for-sale debt securities were not material for the years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMTM_4a24dff9-e4d9-4fb2-b3c5-99c7575e3631">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMi0xLTEtMA_c6fad58b-c964-4df3-81df-08daf8f81707"
      unitRef="usd">308000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItNC0xLTEtMA_c28a2771-3717-4c21-b73c-4c96f4fb13a7"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItNi0xLTEtMA_7f7fc449-6f4c-4104-bc53-3429de658838"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0847197eb84c4ea6b02eec2146463bd8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItOC0xLTEtMA_8c1608f7-fd18-44bf-8438-ab406b8308b6"
      unitRef="usd">309000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTAtMS0xLTA_1b05fc2f-8138-4bba-910c-165c6e2a8695"
      unitRef="usd">2433000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTItMS0xLTA_9778835e-e0d2-4873-925b-518b0f0f2298"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTQtMS0xLTA_c13baf2f-0873-4ee2-9933-26c5b0832115"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7fb21110182421cb22d46b7cd3b631f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzItMTYtMS0xLTA_fba4c363-2c50-40e0-82c7-a39157163e2b"
      unitRef="usd">2433000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i595ca0a2d84447909de4d92345625390_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMi0xLTEtMA_55c1babb-4518-4f61-9c04-35325a30e6a8"
      unitRef="usd">216000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i595ca0a2d84447909de4d92345625390_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtNC0xLTEtMA_a270f7c4-84de-4afe-9c5e-c2e270f2a3f3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i595ca0a2d84447909de4d92345625390_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtNi0xLTEtMA_1b5e052b-634a-4103-8770-fe958e4a81be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i595ca0a2d84447909de4d92345625390_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtOC0xLTEtMA_eac6c4ad-7514-484d-a41e-c564f996b3fb"
      unitRef="usd">216000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTAtMS0xLTA_9655b1d6-158e-4dc9-9d5b-8474ceddbf9b"
      unitRef="usd">3517000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTItMS0xLTA_dee0e7ba-2ee1-406d-a20a-9cb9e34a537d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTQtMS0xLTA_7edf7677-079f-4302-84b0-5eefcb1b92b8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9bfed0ec9b354312b4fddd01563207c0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzMtMTYtMS0xLTA_1aa1146c-4adf-4565-8707-e362835aa053"
      unitRef="usd">3517000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i390292299b6b4a5486f594d72b417724_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMi0xLTEtMA_61816ff5-6d1e-4f36-9158-65f6df8d7286"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i390292299b6b4a5486f594d72b417724_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtNC0xLTEtMA_d47f0e83-b2c7-4cb2-a481-ef1136f6b800"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i390292299b6b4a5486f594d72b417724_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtNi0xLTEtMA_3b0c9eaf-b5ae-4a41-a6e3-1507111c96e9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i390292299b6b4a5486f594d72b417724_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtOC0xLTEtMA_0df7388f-a718-4d6a-8437-164d75346e87"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0b54212c105142999597c1d3fb250563_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTAtMS0xLTA_fa3aa130-cdd7-4f09-ad94-f3acb500591b"
      unitRef="usd">1081000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0b54212c105142999597c1d3fb250563_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTItMS0xLTA_7f78b66a-5b2e-40a7-9258-a11e946ef9b1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0b54212c105142999597c1d3fb250563_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTQtMS0xLTA_13629ae0-1051-4875-8ea4-e808217b84a1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b54212c105142999597c1d3fb250563_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzQtMTYtMS0xLTA_76b2ccce-45dd-4f48-bf57-11f24375eaf5"
      unitRef="usd">1081000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMi0xLTEtMA_e4d66bec-a815-40ba-856b-239f48adaee2"
      unitRef="usd">43000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtNC0xLTEtMA_ab533db2-9ecc-471a-a560-6a7c2a27374c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtNi0xLTEtMA_69540feb-fa45-460b-a97f-56418cb66329"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e8f5b38c3ef424fb7bee53b8b3525ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtOC0xLTEtMA_2ec66c17-0c11-4415-afa2-9d1a61e67a71"
      unitRef="usd">43000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTAtMS0xLTA_76f731f1-90fc-4dfd-8340-da1144e49c25"
      unitRef="usd">174000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTItMS0xLTA_2f4d844e-8e6e-4590-b833-43b1fc18bb84"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTQtMS0xLTA_91ca76fe-59a0-4a5c-919f-8e10b33918a4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39a769c9ac944bd2bcc1f3daae2efb56_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzUtMTYtMS0xLTA_793fc35b-486f-4285-8324-086d86c014df"
      unitRef="usd">174000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMi0xLTEtMA_cff4f806-926b-4ae8-97a2-a0344ca2f5f1"
      unitRef="usd">1140000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtNC0xLTEtMA_b4cc6bf8-748a-4024-9f93-7ca2b42a305c"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtNi0xLTEtMA_c3ab8796-77b8-4637-9734-214d4c70785b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie18832e6e6f64234bff6179e17fdedbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtOC0xLTEtMA_beec92c1-25dc-4475-b436-69882625a78d"
      unitRef="usd">1142000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTAtMS0xLTA_2f193496-5987-4837-9e40-f3e827515447"
      unitRef="usd">9203000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTItMS0xLTA_76745d66-998a-4a5d-b5a7-e821f77a7aa4"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTQtMS0xLTA_b49baa26-79f7-4029-aa9f-f2ae0889f6b3"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzYtMTYtMS0xLTA_28e18c1d-4bf7-4b96-98b9-4db79df24a52"
      unitRef="usd">9204000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMi0xLTEtMA_37fa6f0c-c752-4926-9067-f333ff874a85"
      unitRef="usd">316000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctNC0xLTEtMA_886cdc1d-c06e-455b-83fd-af02bd6beb77"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctNi0xLTEtMA_9cf596fe-c144-490d-ab24-df29d43f0571"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9150b394a9d4e499d6e0b58b1920391_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctOC0xLTEtMA_da872f57-90f6-4e53-8165-342fb6d7fdde"
      unitRef="usd">316000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0f8f006f881a4957896607c58789822b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTAtMS0xLTA_12eba07b-2d12-4686-b3b2-831d794471ef"
      unitRef="usd">91000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0f8f006f881a4957896607c58789822b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTItMS0xLTA_9c1ac3a1-db1c-4cbe-af39-c76aed29c68a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0f8f006f881a4957896607c58789822b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTQtMS0xLTA_9d0390ee-bc60-444b-8570-357a92bba59e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0f8f006f881a4957896607c58789822b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzctMTYtMS0xLTA_7fa1f1ad-ef6c-40c0-97c4-aabfa168517d"
      unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMi0xLTEtMA_88658ddc-38ce-4b87-9a42-e07574c25a3c"
      unitRef="usd">2023000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtNC0xLTEtMA_2608dc84-59b7-4af9-b7cf-c5abd361a377"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtNi0xLTEtMA_95f7cf74-748d-4f36-91f6-042a92e34d4a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtOC0xLTEtMA_6a88803a-ffe6-4c6b-9b7a-9080f7304b86"
      unitRef="usd">2026000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTAtMS0xLTA_734bef67-9084-4b86-96eb-097277acbdf8"
      unitRef="usd">16499000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTItMS0xLTA_db63755c-5616-4b30-8344-4d6ce858b9e9"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTQtMS0xLTA_fc6c039e-9640-448e-a8e8-06b784b1a3c2"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTozM2JlNmFiMDVkMmY0NDQ2OGJlYWQ3NzdiMzU0ZTJjYS90YWJsZXJhbmdlOjMzYmU2YWIwNWQyZjQ0NDY4YmVhZDc3N2IzNTRlMmNhXzgtMTYtMS0xLTA_cb436c84-18b7-44f8-8147-f1d82f2316b3"
      unitRef="usd">16500000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMTU_5ff2a813-92a4-42a0-8ed1-404f84e05489">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16426d78ce7c4baeb60f73d40c7360a7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzEtMS0xLTEtMA_cd3da68b-45c4-4feb-b2a4-7f5dac68747e"
      unitRef="usd">113000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a5e7f31b83842cd95af2e19292bd16e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzEtMy0xLTEtMA_746a4156-42e1-4b3e-a627-a40b68459741"
      unitRef="usd">2291000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i61fc82ab7f9c4eaba8049dcccb0fabcc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzItMS0xLTEtMA_df081b93-7cfc-4a6f-8ec6-9faeea715ff2"
      unitRef="usd">1411000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3e58eabfb144b2b803232b6b3af397d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzItMy0xLTEtMA_579ab7b4-586a-4278-9da2-7650f17fd9ac"
      unitRef="usd">12721000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d35182bfdc94f2e9d411da9d4df6871_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzMtMS0xLTEtMA_13bbce5b-7ba6-44d6-9b35-986f51780dd7"
      unitRef="usd">502000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28cbe18165a844a88047e90985c3a97c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzMtMy0xLTEtMA_51aaf5c7-6b95-440d-9bac-6377c52a002e"
      unitRef="usd">1488000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzQtMS0xLTEtMA_e07b6bf5-21c8-4968-ae0c-bcbbc8c39e47"
      unitRef="usd">2026000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTowYjM5ZmUwN2Q0MTg0NzZmOWEyMDAxOWQ2ZTg0YjAwNC90YWJsZXJhbmdlOjBiMzlmZTA3ZDQxODQ3NmY5YTIwMDE5ZDZlODRiMDA0XzQtMy0xLTEtMA_52375883-6acb-4c05-b400-7bb1f0fcd400"
      unitRef="usd">16500000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivableCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzAzODQ_d124de41-8645-4a71-b455-2db3c09e3458"
      unitRef="usd">9000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzAzOTg_6e9fb634-e1d4-4c0a-9e8b-ee32a1aae41f"
      unitRef="usd">37000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMTc_bbc93a08-7fc4-44a9-b400-85a87d885b87">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzItMS0xLTEtMA_75943f8d-9355-48a3-a503-f676c389e61c"
      unitRef="usd">1522000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzItMy0xLTEtMA_983a3c3d-3321-4b3f-bad9-a9ad4b9d354f"
      unitRef="usd">1524000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzMtMS0xLTEtMA_1a1174fe-630a-4e5f-a85e-0106f41494ab"
      unitRef="usd">489000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzMtMy0xLTEtMA_e43de84a-ef3e-4aa9-89d2-85419d2d65a3"
      unitRef="usd">490000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <gild:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzQtMS0xLTEtMA_c8839e0e-bd72-423b-b84e-554da0723dd2"
      unitRef="usd">12000000</gild:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <gild:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzQtMy0xLTEtMA_68b55fb0-08cd-4dad-94ff-dac0f78fca6c"
      unitRef="usd">12000000</gild:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzUtMS0xLTEtMA_5099f728-59fd-4275-ad3b-e67702e9a210"
      unitRef="usd">2023000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTplNGMzMTFjODU3Yzg0OGY0Yjc5NDJkZWVlZWM0NzI1Mi90YWJsZXJhbmdlOmU0YzMxMWM4NTdjODQ4ZjRiNzk0MmRlZWVlYzQ3MjUyXzUtMy0xLTEtMA_add346e0-513e-4192-a4f0-c87201e564d3"
      unitRef="usd">2026000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzExMDg_3612590a-1e11-49ae-9adf-ee57e85cf77d">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTItMS0xLTA_88bcaf60-733b-4a92-b4f3-e33438a4d3d2"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTQtMS0xLTA_2daa7bac-ed2b-43f4-9361-d0ba5a581282"
      unitRef="usd">1866000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTYtMS0xLTA_4cac7063-fc80-421c-9b80-24745432c046"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTgtMS0xLTA_f2b85c0f-3f21-426b-97f0-5fd14914f3f9"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTEwLTEtMS0w_2ac2d499-fca9-42ad-8de8-3da83834d494"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iceb1445e2fcc4c789894cb276a5414d5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90YWJsZTo1NjZjMTEzNGIxMzg0ZjIzOTljOTc2NTBkOTllOWRkOC90YWJsZXJhbmdlOjU2NmMxMTM0YjEzODRmMjM5OWM5NzY1MGQ5OWU5ZGQ4XzE1LTEyLTEtMS0w_f61fe5fd-2ddc-4386-985a-0eb13bbe96dc"
      unitRef="usd">1870000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzU3NA_49c27b6d-55b0-4ee9-8b68-9f7601ab679f"
      unitRef="security">75</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzU4MQ_b4a05796-23dd-43dd-afac-1a26b354331f"
      unitRef="security">305</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzA0MjA_96c54133-0a5f-40f5-8989-19a31c6807d0"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMTgvZnJhZzozMTdiMTY3MTMwYWE0N2Y5ODlhZThkNTczM2FmZTM4MC90ZXh0cmVnaW9uOjMxN2IxNjcxMzBhYTQ3Zjk4OWFlOGQ1NzMzYWZlMzgwXzEwOTk1MTE2MzA0MjA_e7a23423-3416-4849-b5b5-1fd4bd0e7d8f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM1Nzk_cc481c77-4f8c-4e68-8099-c0a1aea90ec8">DERIVATIVE FINANCIAL INSTRUMENTS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates, and as a result, varies over time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in Other income (expense), net, on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI at December&#160;31, 2020 are expected to be reclassified to product sales within 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the years ended December&#160;31, 2020, 2019 and 2018 are included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had notional amounts on foreign currency exchange contracts outstanding totaling $2.4 billion and $2.9 billion at December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from AOCI into product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, we only held foreign currency exchange contracts.&#160;The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts of Recognized Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral Received/Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount (Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i993dfcf3896148f697a431026afd4f27_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzE5NDg_1fd8cc3c-e544-45ae-817b-8a02df8cc5c4">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="i993dfcf3896148f697a431026afd4f27_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzIzNjc_9882b12f-5fac-4cdd-a99b-1b881a064644">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzI2NDc_ec73a101-ab5b-44ef-8839-48fb6b75f5e8"
      unitRef="usd">2400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzI2NTQ_c02dacff-d981-40af-8e72-33d406333476"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM2MDc_13a61721-fb48-4515-9e90-95d6e12deaa9">The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: &lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;accrued&#160;liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other&#160;current&#160;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i10964ae7f7a549f6ab1ff180665f69ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzQtNC0xLTEtMA_f3579cd1-cb6e-4d4f-89b3-c9192367c601"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3bf3fc79d1fa49ce89bbe681181cd43d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzQtOC0xLTEtMA_8d9f7af2-77c1-4037-b6c4-9c239c7e0779"
      unitRef="usd">113000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i61bac09c30bc4649b266ae9b0b2f845d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzUtNC0xLTEtMA_52eeb7f6-a32a-47e9-a0f1-ef50ed3572fc"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="iedaad0d104904edbae770e12c309829c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzUtOC0xLTEtMA_1f8d0155-0f2b-4e34-9b06-b891c309bd4c"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3ac161d27eca4bbdbc92850f94d7212a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzYtNC0xLTEtMA_f0b43d09-f8f5-455d-846c-64c527b7b8e0"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i3ac161d27eca4bbdbc92850f94d7212a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzYtOC0xLTEtMA_384fe2f8-3466-4f19-9d13-592afd1588f2"
      unitRef="usd">120000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ic70691dc9abb4d69a28b5f9142fd5dd6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzgtNC0xLTEtMA_440fccee-83bd-4e49-9e8d-d5430c2c26c4"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i82be8c76fac444ae8b5be2464102adda_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzgtOC0xLTEtMA_6b27b0a9-fcad-467a-a6fb-17cc965eba79"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i18b7ffc02a4648be92cdc6a03d99c1c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzktNC0xLTEtMA_bf331011-00f4-42e3-ab6d-9adbef917388"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i18b7ffc02a4648be92cdc6a03d99c1c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzktOC0xLTEtMA_9752df41-7ba1-476a-b08b-bb648e8d11d5"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzEwLTQtMS0xLTA_b6ae89ab-38cb-49b8-9afd-d4fbd76ef541"
      unitRef="usd">12000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo4Y2UxMTljYmQzMGE0N2I1YjkyNWJjNDI1YTJhYWMyNS90YWJsZXJhbmdlOjhjZTExOWNiZDMwYTQ3YjViOTI1YmM0MjVhMmFhYzI1XzEwLTgtMS0xLTA_67bcbb3c-a7f2-4f7b-ad10-8d063093d27a"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i784d730b592f4dda968b2f2a0865acb7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzQtNC0xLTEtMA_87707c6b-3e32-4fa3-ad3b-f03e49e72b76"
      unitRef="usd">36000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i7830a932cee94f22aa34ced72f487d72_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzQtOC0xLTEtMA_48865e3d-502f-41e3-be55-60444a6017f3"
      unitRef="usd">6000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i9cd75011da414b8599c1d9723149a895_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzUtNC0xLTEtMA_aa2172ca-b003-440c-8be0-65f8904540a6"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i89c3d1c8982e40339444fa81b506c130_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzUtOC0xLTEtMA_ce819ee9-6533-43cc-b4d8-110ccb868418"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="iac4066de7a73468a997dd8cb92bf3a1b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzYtNC0xLTEtMA_e2df348e-b88d-4caa-8c62-3ba0b789ac3e"
      unitRef="usd">36000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="iac4066de7a73468a997dd8cb92bf3a1b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzYtOC0xLTEtMA_f9792245-2c25-48e5-a345-dd3c8c2d8fa4"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="iaab6fcb4f58b4822ad8e346558c2c980_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzgtNC0xLTEtMA_d965461e-3d8c-410b-9d22-791723149a35"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i85193bddbf1d4369b3eed33741718ebf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzgtOC0xLTEtMA_dbe98eca-049c-443e-af0f-59e334736688"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="if38a8065706742818aa8f128c9d384dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzktNC0xLTEtMA_7f2b23e5-ad18-45ce-8a84-80e1e93f3e0d"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="if38a8065706742818aa8f128c9d384dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzktOC0xLTEtMA_96c88bc7-8db0-4043-a42b-0d3fd46a98c6"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzEwLTQtMS0xLTA_5da90f9f-676e-41f0-a14a-80cf1fa56a9d"
      unitRef="usd">37000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTpiM2MzOTA5OTkzYTA0OGEzYjMwNDA4ODIwYWUxMDhhZS90YWJsZXJhbmdlOmIzYzM5MDk5OTNhMDQ4YTNiMzA0MDg4MjBhZTEwOGFlXzEwLTgtMS0xLTA_58a6882e-754d-4180-a866-3ec6c213b39b"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM1ODE_ec6c5064-06cf-40ee-8a69-77d9bb551862">&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from AOCI into product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzMtMi0xLTEtMA_6cad157c-698a-48e8-ad6b-f4ec3c1ae221"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzMtNC0xLTEtMA_d38d3f04-e8ab-4291-9211-d1cbf24a2170"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzMtNi0xLTEtMA_5d219869-7356-4c3f-bf9e-243dde4ee17f"
      unitRef="usd">114000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzQtMi0xLTEtMA_f92b52ca-b349-40e5-bc45-d8daed210789"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzQtNC0xLTEtMA_1e0d9c08-f2fe-484d-9710-99f1c82b6ec0"
      unitRef="usd">127000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzQtNi0xLTEtMA_b87abd02-d94d-4093-8309-eab3df48dd1c"
      unitRef="usd">-87000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzctMi0xLTEtMA_408df38a-0c09-43f2-8117-e148cd1d0daf"
      unitRef="usd">-51000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzctNC0xLTEtMA_c81fb7eb-dc3e-4421-b1bf-cb560d0afeef"
      unitRef="usd">22000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo5Yjc0ZGRlNDFhYzg0MDUwYWIyOGQ5NWEwNDZiN2QwOC90YWJsZXJhbmdlOjliNzRkZGU0MWFjODQwNTBhYjI4ZDk1YTA0NmI3ZDA4XzctNi0xLTEtMA_73e766ef-ff23-4ca0-acd0-4c7eef690d48"
      unitRef="usd">-2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzMyODg_695ea1b0-4ec0-4532-9cbc-de4ff0e09423"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzMyODg_97d1c896-5720-402b-a5ce-0e52591b3447"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzMyODg_d1741cda-97db-4063-ae8e-b8e1e87ccc2e"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90ZXh0cmVnaW9uOjUxZWNjYjcyNWU2ODRiMjhiN2Q2YTllNjhlNTBiNGNmXzM2MDE_11ac2c4a-5e25-4f4e-abdf-267a780fae74">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Not Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts of Recognized Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Amounts Offset on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash Collateral Received/Pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Amount (Legal Offset)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtMi0xLTEtMA_d373a732-dbd3-401a-8d07-f9f11fef219a"
      unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtNC0xLTEtMA_a2e9a722-1f5b-484d-b54f-d05ded3defc5"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtNi0xLTEtMA_fe7b9ca3-049b-4567-8d08-6b0cce131c68"
      unitRef="usd">12000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtOC0xLTEtMA_057cf406-b160-400d-b95a-574eedc93693"
      unitRef="usd">12000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtMTAtMS0xLTA_02f586be-3b41-43ff-b7bf-fb03de985302"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzMtMTItMS0xLTA_ea2cc2c3-a8d2-48af-9a9e-c81bab40c786"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtMi0xLTEtMA_30412c7d-201c-4bbd-b260-38dce4434ddb"
      unitRef="usd">121000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtNC0xLTEtMA_45c098df-717b-4690-b918-fc6ecd7b548c"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtNi0xLTEtMA_13275c5d-66f6-4f34-b16b-8427edcd497a"
      unitRef="usd">121000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtOC0xLTEtMA_a09581fb-cc3e-4f31-a04f-ea5bdddd8eb0"
      unitRef="usd">12000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtMTAtMS0xLTA_a95f3d5f-e0d1-4dbc-9cec-7e762af44a1f"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzQtMTItMS0xLTA_078cdb05-e124-4827-81d3-9f6523325799"
      unitRef="usd">109000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtMi0xLTEtMA_3e9e8e4b-1f55-47c6-b274-df1023f8c431"
      unitRef="usd">37000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtNC0xLTEtMA_4fff6864-7c32-4fd6-af09-a44832a13681"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtNi0xLTEtMA_039abb73-46a2-4e9c-838e-2ee312a61070"
      unitRef="usd">37000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtOC0xLTEtMA_896f773b-d961-43f6-b37e-618bec9519ed"
      unitRef="usd">6000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtMTAtMS0xLTA_5cb96dc0-8bc5-4dfa-95b2-ebca9f2b164d"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzYtMTItMS0xLTA_dc954eeb-5f78-4f52-9ae4-b8ed46602bd8"
      unitRef="usd">31000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctMi0xLTEtMA_3fa6e350-970f-4d8f-a3e3-98ac62cf58c7"
      unitRef="usd">8000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctNC0xLTEtMA_967181ea-2e5b-4600-a5a5-89dedc39ee28"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctNi0xLTEtMA_68d93832-d174-41c0-b7dd-3df8a7de249c"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctOC0xLTEtMA_ea550c60-8fbe-4fa0-adbd-02a56ee979b0"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctMTAtMS0xLTA_3e00ce15-c63b-436c-9ec8-85b9ccd662a5"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMjQvZnJhZzo1MWVjY2I3MjVlNjg0YjI4YjdkNmE5ZTY4ZTUwYjRjZi90YWJsZTo1ODkyMmQ4ODM1YTQ0NjUzYTA5NDE5YThmZGE4YmQyYy90YWJsZXJhbmdlOjU4OTIyZDg4MzVhNDQ2NTNhMDk0MTlhOGZkYThiZDJjXzctMTItMS0xLTA_0c63bad6-ada9-44cc-bc66-eeeac9d170b6"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzQ3ODQ_5cb77ec7-c58b-4354-ae55-74acd5c8f7ad">ACQUISITIONS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forty Seven, Inc. (&#x201c;Forty Seven&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On&#160;April 7, 2020, we acquired all of the then issued and outstanding common stock of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $95.50 per share in cash, for total consideration of $4.7 billion, net of acquired cash. As a result, Forty Seven became our wholly-owned subsidiary. Forty Seven&#x2019;s lead program, magrolimab, is an investigational monoclonal antibody in clinical development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. At the acquisition date, we recorded a $4.5 billion charge representing an acquired IPR&amp;amp;D asset with no alternative future use in Acquired in-process research and development expenses on our Consolidated Statements of Income. In connection with this acquisition, we recorded $202 million of assets acquired primarily consisting of deferred tax assets. Liabilities assumed were not material. We also recorded stock-based compensation expense of $144 million related to the cash settlement of unvested Forty Seven employee stock awards attributable to post-acquisition services, which was primarily recorded in Research and development expenses on our Consolidated Statements of Income, for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Immunomedics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On September 13, 2020, we entered into an agreement and plan of merger (&#x201c;Agreement and Plan of Merger&#x201d;) to acquire Immunomedics, a company focused on the development of antibody-drug conjugate (&#x201c;ADC&#x201d;) technology. Immunomedics researches and develops biopharmaceutical products, particularly antibody-based products for patients with solid tumors and blood cancers, and manufactures and markets Trodelvy. Trodelvy, a Trop-2-directed ADC developed by Immunomedics, is the first ADC FDA approved for the treatment of adult patients with metastatic triple-negative breast cancer (&#x201c;mTNBC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 23, 2020, the acquisition was completed and Immunomedics became a wholly-owned subsidiary of Gilead. The financial results of Immunomedics were included in our consolidated financial results for the year ended December 31, 2020 from the date of the acquisition. Immunomedics contributed $49 million of revenues and an immaterial net loss from the date of the acquisition through December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash consideration for the acquisition was $20.6 billion, consisting of a $20.4 billion cash payment to the outstanding Immunomedics common stockholders and a $242 million cash payment to equity award holders of Immunomedics for the vested equity awards and accelerated vesting of stock-based awards attributable to the pre-combination period. We financed the acquisition with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. See Note 12. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also recorded share-based compensation expense of $289 million related to the cash settlement of the accelerated share-based compensation expense attributable to the post combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. We also recorded other acquisition-related expenses of $39 million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value step-up adjustment of $881 million, included in the inventories of $946 million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment is being recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory is sold to customers from the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $4.6 billion represents the estimated fair value of Trodelvy for mTNBC as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for mTNBC and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired intangible assets related to IPR&amp;amp;D consist of Trodelvy for hormone receptor positive (&#x201c;HR+&#x201d;), human epidermal growth factor receptor 2 negative (&#x201c;HER2-&#x201d;), metastatic breast cancer, Trodelvy for non-small cell lung cancer (&#x201c;NSCLC&#x201d;) and Trodelvy for urothelial cancer. The estimated aggregate fair value of&#160;$15.8 billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to these assets and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development costs, sales and marketing expenses); probability of success; the discount rate selected to measure inherent risk of future cash flows; and the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;amp;D efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also recorded an intangible asset related to a license and supply agreement with a third party, which was entered into by Immunomedics prior to the acquisition. Under the agreement, the third party was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $175 million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of 7.0%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 15 years on a straight-line basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust, a Delaware statutory trust (&#x201c;RPI&#x201d;), prior to the completion of our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $1.1 billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and effective annual interest rate of 2.5%. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 12. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $4.0 billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supplemental Pro Forma Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following pro forma information presents the combined results of operations of Gilead and Immunomedics as if the acquisition of Immunomedics had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary adjustments include: (i) post-combination compensation expense of $289 million related to the acceleration of unvested share-based awards of Immunomedics, (ii) the impact of additional interest expense in connection with the Immunomedics acquisition borrowings as well as the liability related to future royalties, (iii) amortization of the finite-lived intangible asset related to Trodelvy for mTNBC beginning on April 22, 2020 when it received FDA accelerated approval, (iv) amortization of the acquired Immunomedics&#x2019; inventory related to Trodelvy mTNBC over the period in which the inventory was expected to be sold beginning on April 22, 2020, (v) amortization of the license and supply agreement with a third party over an estimated useful life of 15 years, (vi) the impacts of the sale of marketable securities based on their use as a source of liquidity to fund the acquisition, and (vii) acquisition-related transaction costs. The unaudited pro forma financial results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the operations of Gilead and Immunomedics. Accordingly, these unaudited pro forma financial results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of 2019, nor are they indicative of future results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;MYR GmbH (&#x201c;MYR&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 10, 2020, we entered into a definitive agreement pursuant to which we expect to acquire MYR, a German biotechnology company, for approximately &#x20ac;1.2 billion in cash (or approximately $1.4 billion using a foreign currency exchange rate of 1.2 at December 31, 2020), which is payable upon closing of the transaction and a potential future milestone payment of up to &#x20ac;300 million (or approximately $360 million using a foreign currency exchange rate of 1.2 at December 31, 2020), upon FDA approval of Hepcludex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Both payments are subject to customary adjustments. MYR focuses on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (&#x201c;HDV&#x201d;). The acquisition will provide Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#x201c;EMA&#x201d;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consummation of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act, and receipt of merger control and foreign direct investment approvals in certain European jurisdictions and certain other customary closing conditions. We anticipate that the closing of the transaction will occur by the end of the first quarter of 2021 and expect our acquisition of MYR to be accounted for as a business combination using the acquisition method of accounting upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:SharePrice
      contextRef="i8dad5026e5bc4d748d8400db3eeac8e2_I20200407"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5MjA_eaed6e16-c3b3-4448-a9fe-61553a26add8"
      unitRef="usdPerShare">95.50</us-gaap:SharePrice>
    <gild:AssetAcquisitionCashOutflowNetOfCashAcquired
      contextRef="i8dad5026e5bc4d748d8400db3eeac8e2_I20200407"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5MzU_efbad826-a46a-4f84-aba8-f4abf7b54587"
      unitRef="usd">4700000000</gild:AssetAcquisitionCashOutflowNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i1ebcc5583e8449d2977a0c7e88f011e4_D20200407-20200407"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5NTM_fdeb498a-e1d7-4aae-bbb6-6377e57ee26a"
      unitRef="usd">4500000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash
      contextRef="i1ebcc5583e8449d2977a0c7e88f011e4_D20200407-20200407"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5NzE_b438e919-5f8a-47e6-b73c-7af37e5146e8"
      unitRef="usd">202000000</gild:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i94aca37dece54db88d94195652d7be2a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjY5OTA_053312f0-7678-4f0c-a6da-70dd1616d630"
      unitRef="usd">144000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwOTI_f128f593-f2eb-4a84-9c22-20988e4ac38d"
      unitRef="usd">49000000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i91c056cec2314052b0ad7bf56bb9f361_D20201023-20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwMTk_ad16f880-953d-4eb2-9084-1798a6445bfc"
      unitRef="usd">20600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i007de77796ce442bb17cf6397fc2f2b4_D20201023-20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwMzg_fe3da8bd-a4ae-4e5c-8836-273781b1729a"
      unitRef="usd">20400000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iead588e99e254c5682217485bb77e1dd_D20201023-20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwNTY_aa020f6e-4a07-435f-9935-56a6cb181985"
      unitRef="usd">242000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcwNzU_6b92a0a8-4320-40b7-a979-71e525a50a2b"
      unitRef="usd">1000000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcxMTE_6dee6ca2-bdef-40ac-910d-ec0fd65d40f8"
      unitRef="usd">289000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcxMjk_322c6ff3-d090-4d2c-86cb-bc2fe9d8c851"
      unitRef="usd">39000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1Xzk4OTU2MDQ3MjM1MDU_daa21937-129c-4bd5-8e3d-aa1761585d6b">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzAtMi0xLTEtMTAwNjM_ab47e772-e83b-458b-85ab-0155f650b5d0"
      unitRef="usd">726000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzEtMi0xLTEtMTAwNjY_574135eb-6182-4548-970e-47ad3a4a8b93"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8644568592004cfc961c871471a2665e_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzMtMi0xLTEtMTAwNjk_f93a1d77-869d-456c-b78f-9235d9f84362"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i3d0d69f623804c20b69d4aaa63420c60_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzQtMi0xLTEtMTAwNzI_9686dd85-a640-42b6-81c2-6350e4794b86"
      unitRef="usd">15760000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzUtMi0xLTEtMTAwNzU_39ae15c3-b53c-4c84-b2d3-a12891ad4ae7"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzYtMi0xLTEtMTAwNzg_8657ce19-8af3-4235-aadd-f69e8f6d5e42"
      unitRef="usd">4565000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzctMi0xLTEtMTAwODE_68c6d88e-2ea1-448b-968d-7abf504f7c94"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzgtMi0xLTEtMTAwODQ_1fac414b-7382-4aee-940a-1f5fa1c7c2d6"
      unitRef="usd">64000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzktMi0xLTEtMTIxMTk_5270191a-39c9-4155-a484-39d3ab2897b4"
      unitRef="usd">16606000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzEwLTItMS0xLTEwMDg3_c46ba93e-6ea0-4ae0-86a6-d491ddb087ca"
      unitRef="usd">3991000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowNWI3OGY4MDMxMzU0MWRhOWI3YTUzMTBlZTAwOWZhNy90YWJsZXJhbmdlOjA1Yjc4ZjgwMzEzNTQxZGE5YjdhNTMxMGVlMDA5ZmE3XzExLTItMS0xLTEyMTIz_d31e4f1c-0712-4985-b996-2025ecdf38c2"
      unitRef="usd">20597000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="i91c056cec2314052b0ad7bf56bb9f361_D20201023-20201023"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzcwMTY_82fd04ce-b785-45c0-b6bd-d885465f380f"
      unitRef="usd">881000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTM5NjM_81dd7866-5e04-4749-b113-2e03c5ecc8a6"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8644568592004cfc961c871471a2665e_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTM5OTU_441983f2-83be-4238-97d5-6d1f18ef4ebc"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i8644568592004cfc961c871471a2665e_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzExNzI_6064fa87-fa0b-4bbe-87a0-98d41ee48c69"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i48328e269350428eaf5fc46371917dc9_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcyMjY_07dd4b80-e609-4f15-8df3-6076b2ba6277">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i3d0d69f623804c20b69d4aaa63420c60_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQwMjc_9bc6c725-ff5f-440a-babd-39fa2c5ef791"
      unitRef="usd">15800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="i3d0d69f623804c20b69d4aaa63420c60_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzEyODU_937f3b91-620d-49d8-99af-d4cb64bc0f77"
      unitRef="number">0.070</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQwNjM_970f892a-52ea-4452-89e4-c6415f44087f"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="ie43d0afbb0b244ab91d88b9f08d8d3ad_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzEzOTA_36f6929f-f17d-47e6-a55f-2771ae04c586"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8a7d2971f9e04bd8a1de84efaccec570_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcyNTA_e2ae0e10-88fb-4a80-a535-a1162c601de8">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQwOTc_bcc172c1-27a7-443d-ab71-24bdf0d255ab"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput
      contextRef="i07cc7232a64946abb68b060bdcf121a6_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQ0ODE_9cb8e5da-0e0a-4e8e-abe9-c299b59de04f"
      unitRef="number">0.025</gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput>
    <gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput
      contextRef="ia544b37590e74cd9b7228b42939d36ed_I20201023"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjcyNzc_1933944a-2ace-4fc0-873a-b369123fc890"
      unitRef="number">16</gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput>
    <us-gaap:GoodwillGross
      contextRef="i8b27400d62ea401b8ae3613d26aae982_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3OTQxMzE_a585d17a-c49f-4cc5-9169-43587d8ab50e"
      unitRef="usd">4000000000.0</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1Xzk4OTU2MDQ3MjM1MDc_d3c96589-e61d-430a-ac53-0ae502fd9275">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following pro forma information presents the combined results of operations of Gilead and Immunomedics as if the acquisition of Immunomedics had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzItMi0xLTEtMTAxNzA_376f6697-6b07-4638-adc6-1eedf2cfd31b"
      unitRef="usd">24778000000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i8903c926354a40a881da8a83728d0f0e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzItNC0xLTEtMTAxNjY_c7941405-66e7-449b-937b-b5aa6bd9dd5d"
      unitRef="usd">22449000000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzMtMi0xLTEtMTAxNzA_f1498d2d-47d5-45b4-94b2-229231e8e083"
      unitRef="usd">-323000000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i8903c926354a40a881da8a83728d0f0e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90YWJsZTowODEzMWMwMzQ3MjY0MGE5YmIzNjk2ZTUzNzI1YjA2NC90YWJsZXJhbmdlOjA4MTMxYzAzNDcyNjQwYTliYjM2OTZlNTM3MjViMDY0XzMtNC0xLTEtMTAxNjY_6a74b76c-34df-49be-97cf-380d612f6802"
      unitRef="usd">4488000000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczMTM_6dee6ca2-bdef-40ac-910d-ec0fd65d40f8"
      unitRef="usd">289000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8a7d2971f9e04bd8a1de84efaccec570_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzQzOTgwNDY1ODkxODg_e2ae0e10-88fb-4a80-a535-a1162c601de8">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id970621751c6420ca530ab3e07f6cbca_D20201210-20201210"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczMjk_5ee4cc7e-d1fa-4529-bce3-9fbc78de9307"
      unitRef="eur">1200000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id970621751c6420ca530ab3e07f6cbca_D20201210-20201210"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczNDU_6e9204d2-5c0a-4539-a3af-079a1c05aae9"
      unitRef="usd">1400000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczNTI_aa1fab0b-e3ce-4e54-bad2-9ce947798491"
      unitRef="number">1.2</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="if51626d380ad4bb2aa86f7539b1a1a7c_I20201210"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NjczNjc_6059ef7d-8261-48a7-b06b-fed9dc3e73c6"
      unitRef="eur">300000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="if51626d380ad4bb2aa86f7539b1a1a7c_I20201210"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzA5NjI_569c5900-b974-4de3-8e96-2b2233c5f697"
      unitRef="usd">360000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzAvZnJhZzo2OTRlMmZjNmFiNjU0ZWY0OGU4NTJmYzM3YzAxZGFkNS90ZXh0cmVnaW9uOjY5NGUyZmM2YWI2NTRlZjQ4ZTg1MmZjMzdjMDFkYWQ1XzM4NDgyOTA3NzEwNDM_aa1fab0b-e3ce-4e54-bad2-9ce947798491"
      unitRef="number">1.2</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzY3Ng_87149127-b821-4e4d-be93-7895118adbc2">INVENTORIES&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported as other long-term assets primarily consisted of raw materials as of December&#160;31, 2020 and 2019. Total inventories at December 31, 2020 include fair value adjustments resulting from the Immunomedics acquisition which will be recognized in future periods. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;Inventory write down charges for the year ended December&#160;31, 2020 were not material. During the year ended December&#160;31, 2019, we recorded inventory write down charges of $649 million, of which $547 million was related to slow moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products. During the year ended December&#160;31, 2018, we recorded inventory write down charges of $572 million, of which $440 million was related to excess raw materials primarily due to a sustained decrease in demand for Harvoni.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzY2OA_6fde85e2-82c4-449b-934d-4ae08c9034ea">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzItMi0xLTEtMA_5d7f4195-3672-4df2-8236-717f9425d453"
      unitRef="usd">1080000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzItNC0xLTEtMA_0ef6ddfc-ef44-4796-a4a2-73a4508bd400"
      unitRef="usd">1348000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzMtMi0xLTEtMA_4909bdb7-d261-4eb7-b4c3-9ca1206881b7"
      unitRef="usd">976000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzMtNC0xLTEtMA_ea58855b-25a8-4b3d-a18b-8d1119c761f1"
      unitRef="usd">170000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzQtMi0xLTEtMA_234ef1e4-edc4-40d3-8238-129f42f468f4"
      unitRef="usd">958000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzQtNC0xLTEtMA_68fbc693-daae-4213-b2ff-c6b637af212c"
      unitRef="usd">549000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i9420f0406eae42c8b4f99ad3276f48ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzUtMi0xLTEtMA_d05a2cf3-cc2f-47df-839b-55357d15d56f"
      unitRef="usd">3014000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia01ff2fb62994e059a1d6fa4ee99a6c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzUtNC0xLTEtMA_24e5daac-78f6-48d5-9bcf-ef1a669d45cc"
      unitRef="usd">2067000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzgtMi0xLTEtMA_225e7ef0-783e-44e1-b876-1f7086bb0cfc"
      unitRef="usd">1683000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzgtNC0xLTEtMA_2b7b196e-dcbe-4a83-991d-322cdcadcd0f"
      unitRef="usd">922000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzktMi0xLTEtMA_5906195d-bca3-49b7-9c15-119bb5236e0d"
      unitRef="usd">1331000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzktNC0xLTEtMA_93f56417-f4df-43e7-93fe-711dba01474e"
      unitRef="usd">1145000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i9420f0406eae42c8b4f99ad3276f48ba_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzEwLTItMS0xLTA_5e384d74-06d9-4c77-bfd2-a044a8a86145"
      unitRef="usd">3014000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia01ff2fb62994e059a1d6fa4ee99a6c2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90YWJsZTpkMGFkZTgzNzk3MGM0NDUwOTFkODk5MDRkODA1NmJiNC90YWJsZXJhbmdlOmQwYWRlODM3OTcwYzQ0NTA5MWQ4OTkwNGQ4MDU2YmI0XzEwLTQtMS0xLTA_83f6b7ba-235f-4c6a-86c3-31f6367f3cc7"
      unitRef="usd">2067000000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzQ3OQ_79effa1f-ed6b-400e-83ce-0f4d2a6a8ea5"
      unitRef="usd">649000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i8678846271ab442c97e55730184bbb1f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzQ5Mg_9ca9eb52-2b34-4022-b7d0-a73e8ac9e02b"
      unitRef="usd">547000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzEwOTk1MTE2Mjk5NDU_b81ae776-62e4-4ea1-952c-eb43d1d01f59"
      unitRef="usd">572000000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="idfef2fedfcb34cf49d5ac0ac1e7e9e08_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzMvZnJhZzoyZmE2YzI2MWE4ODk0NTNlOTRjZTJjMzcxZTFiMTk3MC90ZXh0cmVnaW9uOjJmYTZjMjYxYTg4OTQ1M2U5NGNlMmMzNzFlMWIxOTcwXzEwOTk1MTE2Mjk5NTE_82b04826-ec4f-4d1d-b342-628872f7229f"
      unitRef="usd">440000000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzQ0NA_67f6a62d-b03d-4f83-9996-e6ae712a4e25">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Property, plant and equipment, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements (including leasehold improvements)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had unamortized capitalized software costs, included in Office, computer equipment and other, of $124 million and $108 million as of December&#160;31, 2020 and 2019, respectively. Capitalized interest on construction in-progress is included in Property, plant and equipment. Interest capitalized in 2020, 2019 and 2018 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net book value of our property, plant and equipment (less office, computer equipment and other) in the United States was $3.8 billion as of December&#160;31, 2020, $3.5 billion as of December&#160;31, 2019 and $3.2 billion as of December&#160;31, 2018. The corresponding amount in international locations was $897 million as of December&#160;31, 2020, $791 million as of December&#160;31, 2019 and $620 million as of December&#160;31, 2018. All individual international locations accounted for less than 10% of the total balances.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzQzNQ_ddb101db-99fc-49d2-84e3-7761d088eaae">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Property, plant and equipment, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements (including leasehold improvements)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzItMi0xLTEtMA_19ea4a00-d896-4a3a-9865-c2c4869d6cde"
      unitRef="usd">404000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzItNC0xLTEtMA_225e1c0c-1db1-46d8-8d4c-689d47c158c6"
      unitRef="usd">404000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzMtMi0xLTEtMA_31bc1aa7-ec6e-4a39-9060-83b7122f6b9c"
      unitRef="usd">3678000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzMtNC0xLTEtMA_97ec93e5-d22d-4ffc-9ddf-79c8047a1e60"
      unitRef="usd">3358000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzQtMi0xLTEtMA_6481cd65-8a29-4259-8626-594158b5f754"
      unitRef="usd">904000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzQtNC0xLTEtMA_4fc2eaa1-2911-4cde-9f1a-a0df1a68f9e9"
      unitRef="usd">805000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzUtMi0xLTEtMA_adebf5c3-582c-4cec-bcd6-7ed6f1dfc0b7"
      unitRef="usd">793000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzUtNC0xLTEtMA_47c85cf3-c8ac-4429-8200-7b761055892b"
      unitRef="usd">634000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzYtMi0xLTEtMA_c63c558c-3277-4159-a432-73873b076898"
      unitRef="usd">856000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzYtNC0xLTEtMA_7858cf34-64f4-40bd-9588-0bc6c10ef4e8"
      unitRef="usd">723000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzctMi0xLTEtMA_c5ee8e38-7a4f-4141-8382-c537c6ee2789"
      unitRef="usd">6635000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzctNC0xLTEtMA_9f16c0c2-17c2-448b-949d-faa2de0f0c5c"
      unitRef="usd">5924000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzgtMi0xLTEtMA_1255624f-3343-4461-a2d5-e167a27ae3a6"
      unitRef="usd">1668000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzgtNC0xLTEtMA_d869ad93-a847-4de8-9b63-c27bce46de3a"
      unitRef="usd">1422000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzktMi0xLTEtMA_1e580e54-4218-4a4e-9dde-65c4200dc181"
      unitRef="usd">4967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90YWJsZTo1NWMwZTRmOGI2YmY0YjNmOTVmNzMzNTMyNGQ1ODExZS90YWJsZXJhbmdlOjU1YzBlNGY4YjZiZjRiM2Y5NWY3MzM1MzI0ZDU4MTFlXzktNC0xLTEtMA_13d01f2f-1219-4e01-8850-2453180d2eae"
      unitRef="usd">4502000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzI0MQ_be89405f-d23f-49f2-a32b-65a3a4f1a8a6"
      unitRef="usd">124000000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzI0OA_f8da8d5f-0108-45d7-910e-ccfa41659a5d"
      unitRef="usd">108000000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:NoncurrentAssets
      contextRef="i6d4279a507124f3ca8496850b7e31956_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg2NDQ_c1083498-35d2-49c7-b47e-ce57667863f2"
      unitRef="usd">3800000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i91dd4f13fd1443a0bb2d19e5d92b1991_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg2NTk_22325a7f-7f69-4bc4-9c25-d86f28bad74e"
      unitRef="usd">3500000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i81e9d6e5f883421587e150d19ce229b1_I20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg2Nzc_0e52bcd3-fc2e-4b62-bea6-68c6052d5b4b"
      unitRef="usd">3200000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4f76f60b0dc144768d3cda731d8c7cd0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg3NDg_a43d54c6-3977-441b-9adf-1f3d8045abef"
      unitRef="usd">897000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ife2f98a6a4fe4a41b4e2e388608c97f5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg3NjM_b14e7119-4319-490a-9dba-8da3ae65c1fb"
      unitRef="usd">791000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i47f7a6ee87fc404481ff08ed83281586_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzYvZnJhZzo1MDdiOGJjYzhmY2M0ZmU5OWJkZDMwYWM2ZTc2Zjg3NS90ZXh0cmVnaW9uOjUwN2I4YmNjOGZjYzRmZTk5YmRkMzBhYzZlNzZmODc1XzEwOTk1MTE2Mjg3ODE_c1cb4ad4-378e-4bbc-8dac-e07f636a71b0"
      unitRef="usd">620000000</us-gaap:NoncurrentAssets>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzNTU_33299275-9cf6-4934-8d35-263ac5dd3752">GOODWILL AND INTANGIBLE ASSETS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from the acquisition of Immunomedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform an annual goodwill impairment assessment in the fourth quarter, or earlier if impairment indicators exist. As of December&#160;31, 2020, there were no accumulated goodwill impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel (DLBCL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy for mTNBC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $1.2 billion, $1.1 billion and $1.2 billion for the years ended December&#160;31, 2020, 2019 and 2018, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts capitalized as IPR&amp;amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;amp;D efforts&lt;/span&gt;&lt;span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we performed quantitative impairment testing of our IPR&amp;amp;D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate of 8%. No IPR&amp;amp;D impairment charges were recorded in 2020. During 2019, we performed quantitative impairment testing of our IPR&amp;amp;D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of 9.5%, which is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. In comparison to the 2018 assessment, we used lower estimated revenues in 2019 due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&amp;amp;D intangible assets, primarily related to axicabtagene ciloleucel for the treatment of indolent B-cell non-Hodgkin lymphoma (&#x201c;iNHL&#x201d;), below carrying value resulting in the recognition of an impairment charge of $800 million, which was recorded within Research and development expenses on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, we concluded that the KITE-585 program did not justify further efforts based on the totality of the clinical data gathered and discontinued the program. As a result, the carrying value of the IPR&amp;amp;D relating to the KITE-585 program was written down to zero and we recorded an impairment charge of $820 million within Research and development expenses on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzI3NDg3NzkwODE2MzM_c2b685b1-6614-4dc5-896c-9d78bd417c7f">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from the acquisition of Immunomedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo4ZjI3MDc5YTRhYzI0ZDg2YjdkZjE2MTY1ZjVlMTYwNS90YWJsZXJhbmdlOjhmMjcwNzlhNGFjMjRkODZiN2RmMTYxNjVmNWUxNjA1XzAtMS0xLTEtMTI1ODg_2b5c9080-7ab4-44f8-8d44-8f9dd4ceab74"
      unitRef="usd">4117000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo4ZjI3MDc5YTRhYzI0ZDg2YjdkZjE2MTY1ZjVlMTYwNS90YWJsZXJhbmdlOjhmMjcwNzlhNGFjMjRkODZiN2RmMTYxNjVmNWUxNjA1XzEtMS0xLTEtMTI1ODg_17b8ee13-bd0f-4de7-b58c-29683f52a703"
      unitRef="usd">3991000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo4ZjI3MDc5YTRhYzI0ZDg2YjdkZjE2MTY1ZjVlMTYwNS90YWJsZXJhbmdlOjhmMjcwNzlhNGFjMjRkODZiN2RmMTYxNjVmNWUxNjA1XzItMS0xLTEtMTI1ODg_6a35ebe4-89ad-43d0-b12c-eba64f007fcc"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzI3NDg3NzkwODE2Mzg_ab0c12f0-f94a-4ac2-9481-9f662e62ee5b"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzMTg_075aa6b5-3205-4a8f-a246-cbec05c895eb">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel (DLBCL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy for mTNBC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzNTY_4426aba9-e5ca-456d-8685-03bb88401a60">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - axicabtagene ciloleucel (DLBCL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset - Trodelvy for mTNBC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets - IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMi0xLTEtMA_1cdbd959-4358-4c84-b19f-7b24d037902f"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtNC0xLTEtMA_863d5412-592e-4462-97be-ef9094455ba4"
      unitRef="usd">4952000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtNi0xLTEtMA_e6625518-4c9c-46a9-8580-cdbec9f970f7"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icdb68d48db2c4831831bc73ddbcd7ab9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtOC0xLTEtMA_0e304820-3eae-4fa0-aea7-db9ab51564d2"
      unitRef="usd">5768000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTAtMS0xLTA_a4c8ce6f-0301-4cf3-bb01-bf505ee6f21d"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTItMS0xLTA_edc54c0d-0701-4669-9a40-04b04736b68b"
      unitRef="usd">4253000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTQtMS0xLTA_4bbbffd1-bb6d-457a-a183-5c6134eed488"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic84d42f453ef4fd6b3cb578f65cd1d65_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzMtMTYtMS0xLTA_6c72b8b8-8a7d-402a-b285-31f53d2d6892"
      unitRef="usd">6467000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMi0xLTEtMA_207da6a3-dbc0-462b-bed7-1f56c6dceb6d"
      unitRef="usd">6200000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtNC0xLTEtMA_900f6d61-63f5-4e38-9eae-6f787427ab7e"
      unitRef="usd">1105000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtNi0xLTEtMA_dc677b4e-cb04-4479-950f-c781853ee44b"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i58f1f76b76904d83b316fbb983869d34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtOC0xLTEtMA_cfb6c0ce-81ea-4ec0-b0d2-0ab5d208e609"
      unitRef="usd">5095000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTAtMS0xLTA_ec0a8828-c3fa-472d-af1e-3ad9ea75db77"
      unitRef="usd">6200000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTItMS0xLTA_ac383fb3-02a8-47fe-af0d-522206586067"
      unitRef="usd">761000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTQtMS0xLTA_253b11b6-6990-4467-86e5-f5bcb4c89ec3"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0ca166c8883f43c39c1ddefe732e5d75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzQtMTYtMS0xLTA_d6df3c88-3279-4ab7-b8cf-4340f68fca95"
      unitRef="usd">5439000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMi0xLTEtMTM4NzQ_c6169dad-dfd1-469c-9560-410415980b05"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtNC0xLTEtMTM4NzQ_db902cae-55df-4a11-8ee6-92efebb2f558"
      unitRef="usd">63000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtNi0xLTEtMTM4NzQ_6be01809-bbf7-455c-99b1-0b978f8ce710"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic66b58065448410d88d6fe6479e1992b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtOC0xLTEtMTM4NzQ_12534249-8986-44ec-b100-64f078fcf68c"
      unitRef="usd">4537000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibca01e23b54043618df5703b720be264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTAtMS0xLTEzODc0_86c43366-dcdd-4039-93f3-b6fb0e551f16"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibca01e23b54043618df5703b720be264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTItMS0xLTEzODc0_bdcd28c7-fa28-4131-a893-0eb49ea7fd6f"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ibca01e23b54043618df5703b720be264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTQtMS0xLTEzODc0_58be42f6-d07d-4489-9e16-063f6506b62e"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibca01e23b54043618df5703b720be264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzUtMTYtMS0xLTEzODc0_d564bc3f-0e38-466e-8bb3-6d38ce0c4fe6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMi0xLTEtMA_1be2db12-9b7e-4fe1-9d8c-5d8c55b84bef"
      unitRef="usd">1377000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtNC0xLTEtMA_013b325a-b3e1-4d9f-ac3c-22f89838fdb3"
      unitRef="usd">540000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtNi0xLTEtMA_dca842bb-b9ed-4510-b126-bd559dd15145"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if0508d4b5e1c46bf97925917f958f9b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtOC0xLTEtMA_0748cf1a-2ca5-440a-b0de-bc6dc9decad0"
      unitRef="usd">836000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTAtMS0xLTA_76614134-679e-4035-9882-cc9cfee6033b"
      unitRef="usd">1098000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTItMS0xLTA_3395d91e-6420-499a-b2bb-3c51d245dbbe"
      unitRef="usd">454000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTQtMS0xLTA_26362272-f4bd-49a0-afe1-b59e6f635aa8"
      unitRef="usd">-6000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id4b8460b1c0347e2bbb1e90b22b00fa6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzYtMTYtMS0xLTA_6885feec-e6ad-41f0-8880-29d475998e9f"
      unitRef="usd">638000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMi0xLTEtMA_bf78164b-3592-4b2b-8c8c-5714e980f5e2"
      unitRef="usd">22897000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctNC0xLTEtMA_28e7970b-29c8-4cf6-ba03-a25e91c038c3"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctNi0xLTEtMA_aa521f83-7bb9-403a-8b57-18413ee25695"
      unitRef="usd">-1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctOC0xLTEtMA_cf9eca88-ee32-4543-9192-b7b537e94599"
      unitRef="usd">16236000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTAtMS0xLTA_c8fdfaa9-4cab-436d-a13c-f681042840f2"
      unitRef="usd">18018000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTItMS0xLTA_74f67fb5-321d-4a4e-b9d9-841a34e5ffde"
      unitRef="usd">5468000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTQtMS0xLTA_613d7981-36af-464c-897c-e7240a9e732f"
      unitRef="usd">-6000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzctMTYtMS0xLTA_4926e29d-d47b-4c95-adda-12e4413e9efc"
      unitRef="usd">12544000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMi0xLTEtMA_6c121a2a-b771-485c-b7f1-afa8cacfdc5e"
      unitRef="usd">16890000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtNi0xLTEtMA_51dedebd-2ff7-4316-88fd-b86d5f825418"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib19b12d3eef54bfdbaee6b36694e6d8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtOC0xLTEtMA_890d1922-83f8-4876-beec-8887a3a38026"
      unitRef="usd">16890000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3c593b70322648b8855aec1be0938cc8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMTAtMS0xLTA_629b6bee-5ccd-4648-aaae-7d7cab6a02e7"
      unitRef="usd">1247000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i3c593b70322648b8855aec1be0938cc8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMTQtMS0xLTA_349de998-b309-417d-a635-d038d5785dc6"
      unitRef="usd">-5000000</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3c593b70322648b8855aec1be0938cc8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzgtMTYtMS0xLTA_7e14e391-7609-4c28-adef-a766431a38b1"
      unitRef="usd">1242000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMi0xLTEtMA_898195d9-938c-43bc-b7d3-36191e6b4829"
      unitRef="usd">39787000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktNC0xLTEtMA_8e3f24e4-3128-4c43-bd73-0e46827f9652"
      unitRef="usd">6660000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktNi0xLTEtMA_97c9904d-ef97-40d2-b9ae-7fab094a60cb"
      unitRef="usd">-1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktOC0xLTEtMA_06de0195-016c-4e02-8eaf-f4e76be6668b"
      unitRef="usd">33126000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTAtMS0xLTA_1c2e0aca-520e-494e-9598-eca344f17893"
      unitRef="usd">19265000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTItMS0xLTA_84935d18-10c5-4bb9-aed6-da21255922dd"
      unitRef="usd">5468000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTQtMS0xLTA_223d1817-f9d3-44e0-8ad7-a9d5bb29944d"
      unitRef="usd">-11000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTo1NzI4YTc3MmYxOTA0MDkwYWFlYjQ5OTFiM2IwZWQwZC90YWJsZXJhbmdlOjU3MjhhNzcyZjE5MDQwOTBhYWViNDk5MWIzYjBlZDBkXzktMTYtMS0xLTA_bf63a618-5e84-484f-83c5-f1d9dac715fb"
      unitRef="usd">13786000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8000203400804727bf1a4e40c93f3c16_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE2NQ_e131fc66-ec27-4696-aa36-2171a1b96398"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icbb578eac6714200a5377073798b8f1b_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE2OQ_227b0989-c6eb-4a06-8fea-e0d5cec96e42"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ibe4376a44dc14cc2a76b854d11662987_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE3Ng_79bec1a4-7103-471a-8696-beda5bd78b41"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIxOTkwMjMyNjY2Nzg_4543e4eb-49f4-4e9a-8729-4756b4e152df"
      unitRef="number">0.08</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzczNA_7e89543b-e826-4445-a6fb-a85dc761b658"
      unitRef="number">0.095</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE2MDk_8a18dc50-79da-47b0-91c2-98148d479d91"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8df8c75c0ccd41708b9a841f5afbd2fa_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzE5NzU_b1a7f4e7-58c2-4052-98dd-9e1a3d851455"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIwMTg_7a9e9845-de54-49d3-8c5f-f86b1914c453"
      unitRef="usd">820000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90ZXh0cmVnaW9uOmUzNDA0MTM3MTc5ZDQ0OGZiNjgzMjUzYTVlYTI0Y2M5XzIzMjc_c19bb117-a5b8-4d09-be78-783f327c2b17">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzEtMS0xLTEtMA_1c85cdbf-cf82-4807-9da9-16e9989b587f"
      unitRef="usd">1527000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzItMS0xLTEtMA_667891f6-41b6-44bc-b79e-98581d892016"
      unitRef="usd">1527000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzMtMS0xLTEtMA_90a74f2d-3f93-4395-942f-06b7d6531dad"
      unitRef="usd">1527000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzQtMS0xLTEtMA_c25495cb-6cb0-4607-8681-5599001e4e10"
      unitRef="usd">1527000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzUtMS0xLTEtMA_2c03ccf3-595f-4eeb-90d1-fc76dc997bbd"
      unitRef="usd">1521000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzYtMS0xLTEtMA_6db81031-3fc5-49b3-a700-3c82d61d6a07"
      unitRef="usd">8607000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xMzkvZnJhZzplMzQwNDEzNzE3OWQ0NDhmYjY4MzI1M2E1ZWEyNGNjOS90YWJsZTpmMGJjZDM2MzBhOTM0ZDY0Yjg1NjUzZWQ3OTM3NjUwZS90YWJsZXJhbmdlOmYwYmNkMzYzMGE5MzRkNjRiODU2NTNlZDc5Mzc2NTBlXzctMS0xLTEtMA_ec9d631f-ee2b-46d5-b5ee-443088310533"
      unitRef="usd">16236000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90ZXh0cmVnaW9uOmRhNWIyY2MxZThmNzRmY2FhY2VlZmU0Y2M5M2VjMTZmXzEzOQ_3e0d9db6-4f1c-43c0-8c82-fbd8d245d1b9">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Other accrued liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90ZXh0cmVnaW9uOmRhNWIyY2MxZThmNzRmY2FhY2VlZmU0Y2M5M2VjMTZmXzI3NDg3NzkwNzAwMTg_59bfe910-d3e1-429d-b9d3-ab01f9b42c18">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzEtMi0xLTEtMjU4NTY_ffafaab8-af14-454c-a0bc-8daece841c1d"
      unitRef="usd">5560000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzEtNC0xLTEtMjU4NTY_5bca1275-abdf-4237-abc0-9c7516cd5bdd"
      unitRef="usd">4351000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtMi0xLTEtMjY2MjE_931af6b7-9e56-4d1b-bdb6-c850f1b4f7af"
      unitRef="usd">552000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtNC0xLTEtMjY2MjE_8d3b66d9-928b-45a7-b948-c96d0391df2c"
      unitRef="usd">655000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzItMi0xLTEtMjU4NTY_7714a9fa-e101-4b7b-ba97-6d5fff362b14"
      unitRef="usd">72000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzItNC0xLTEtMjU4NTY_a7f97b15-1086-4ecb-b503-407d09c03dc7"
      unitRef="usd">74000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtMi0xLTEtMjU4NTY_47bf08ce-6d72-48d2-a13f-63a4128121d6"
      unitRef="usd">44000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzMtNC0xLTEtMjU4NTY_7be77b2e-be04-42db-8518-1e3923d01f16"
      unitRef="usd">40000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzQtMi0xLTEtMjU4NTY_2ddc1576-ca4d-4fe6-88da-91c239de3995"
      unitRef="usd">4892000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTozYTEyNjM1NTg3OTM0M2VhYjE2MTI1ZjcxOWQxYzJiNy90YWJsZXJhbmdlOjNhMTI2MzU1ODc5MzQzZWFiMTYxMjVmNzE5ZDFjMmI3XzQtNC0xLTEtMjU4NTY_d82acd21-e0d9-4702-9223-5ba8e180b21e"
      unitRef="usd">3582000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90ZXh0cmVnaW9uOmRhNWIyY2MxZThmNzRmY2FhY2VlZmU0Y2M5M2VjMTZmXzEzMg_3a2ceeaa-bb81-42d9-973e-924eb2dcb50a">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Other accrued liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzItMi0xLTEtMA_c981acee-48ca-4f84-ab57-1b820ed18ddf"
      unitRef="usd">864000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzItNC0xLTEtMA_821c2e4a-66f0-44df-99c8-f045f1739f94"
      unitRef="usd">599000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzMtMi0xLTEtMA_5c4216c8-dfbf-4fd5-b030-41e7372c9978"
      unitRef="usd">598000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzMtNC0xLTEtMA_993ec2c8-37fd-4606-b3de-61eb5bad5db5"
      unitRef="usd">287000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzQtMi0xLTEtMjc0MzQ_e90a9fb8-b545-45f1-a626-35bded095072"
      unitRef="usd">587000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzQtNC0xLTEtMjc0MzQ_73be9ac1-1be4-41c9-9d78-5fa846643253"
      unitRef="usd">137000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzUtMi0xLTEtMA_a4f01bfa-d3e0-43b0-96a3-c60657624bb8"
      unitRef="usd">2287000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzUtNC0xLTEtMA_48e5cc74-df95-4b8c-a85f-47593c108859"
      unitRef="usd">2051000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzYtMi0xLTEtMA_98c7b92b-efdb-4f22-afa5-b9a6a36f2791"
      unitRef="usd">4336000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDIvZnJhZzpkYTViMmNjMWU4Zjc0ZmNhYWNlZWZlNGNjOTNlYzE2Zi90YWJsZTpjYjBlNTg5ZDJmNzE0ZjJlOGE1NjljZmM1MzM1ZmQwMy90YWJsZXJhbmdlOmNiMGU1ODlkMmY3MTRmMmU4YTU2OWNmYzUzMzVmZDAzXzYtNC0xLTEtMA_85d0657c-9a87-45a8-a4b1-f225ac11c843"
      unitRef="usd">3074000000</us-gaap:AccruedLiabilitiesCurrent>
    <gild:CollaborativeandOtherArrangementsTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3MjM_2e679000-6c14-4805-8dd7-2ce82c1474ff">COLLABORATIONS AND OTHER ARRANGEMENTS &lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for, and equity investments in third parties focused on, the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 29, 2020, we acquired 2.2 million shares of the common stock of Arcus, a publicly traded oncology-focused biopharmaceutical company, for approximately $61 million in a secondary equity offering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, on&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#x201c;Arcus Collaboration Agreement&#x201d;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended, the &#x201c;Arcus Stock Purchase Agreements&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing of the Arcus Collaboration Agreement and Arcus Stock Purchase Agreements, on July 13, 2020, we made an upfront payment of $175 million and acquired approximately 6.0 million additional shares of Arcus&#x2019; common stock for $200 million in accordance with the terms of the Arcus Collaboration Agreement and Arcus Stock Purchase Agreements. Of the total $391 million initial cash payments made under the agreements and direct transactional costs, we recorded $135 million as an equity investment, which was calculated based on Arcus&#x2019; closing stock price of $22.67 on the closing date of the transaction. We recorded our equity investments in Arcus in Other long-term assets on our Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions for a period up to 2 years from the closing date of the agreements, subject to certain conditions. We account for our equity investments in Arcus at fair value with changes in fair value recognized in Other income (expense), net for each reporting period. The remaining $256 million was attributed to the acquired license and option rights of $175 million representing IPR&amp;amp;D assets with no alternative future use, $65 million of an issuance premium for the equity purchase and $16 million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income. In an event subsequent to December 31, 2020, on January 31, 2021, we amended and restated the common stock purchase agreement, pursuant to which we acquired approximately 5.7 million additional shares of Arcus&#x2019; common stock for $220 million on February 8, 2021. As a result, combined with our existing share holdings, we own 13.8 million shares of Arcus, representing approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead has the right to opt-in to all current and future investigational product candidates that emerge from Arcus&#x2019; research portfolio for the ten years following the closing of the transaction. Upon our exercise of an option for a program, unless Arcus opts out according to the terms of the Arcus Collaboration Agreement, the companies will co-develop and share global development costs and co-commercialize and share profits in the U.S. We will obtain exclusive rights to commercialize any optioned programs outside of the U.S., subject to any rights of Arcus&#x2019; existing partners, for which we will pay to Arcus tiered royalties ranging from the high teens to the low twenties on net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Arcus Collaboration Agreement, subject to certain limited exceptions, we are required to provide $100&#160;million to Arcus on the second anniversary of the agreement and may pay an additional $100 million at our option on each of the fourth, sixth, and eighth anniversaries of the agreement, unless terminated early, as ongoing research and development support to extend our collaboration term to up to 10 years. Accordingly, during the year ended December 31, 2020, we recorded a $100 million charge representing the contractually committed payment in Acquired in-process research and development expenses on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Arcus Collaboration Agreement, we will potentially provide up to $1.2 billion in opt-in and milestone payments with respect to current clinical product candidates, if and when such payments are triggered under the Arcus Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Arcus Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the next five years, up to a maximum of 35% of the outstanding voting stock. We are subject to a three-year standstill restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Arcus Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pionyr&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#x201c;Pionyr Merger and Option Agreements&#x201d;) and a research and development service agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2020, we closed the transaction with Pionyr and paid $269 million in cash and accrued an additional $6 million payable, subject to certain customary adjustments, to Pionyr&#x2019;s shareholders in accordance with the terms of the Pionyr Merger and Option Agreements. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#x2019;s IPR&amp;amp;D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, &#x201c;Business Combinations.&#x201d; As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount was recorded in Other long-term assets on our Consolidated Balance Sheets. From the first anniversary of the closing date, we may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#x2019;s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the research and development service agreement, we made an initial cash funding of $80 million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $115 million to Pionyr upon achievement of certain development milestones. We accrued $70&#160;million milestone payments, related to the initiation of two Phase-1 studies, with a charge to Research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. Subsequently, in February 2021, milestone cash payments of $70 million were made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tizona&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#x201c;Tizona Merger and Option Agreements&#x201d;) and a development agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2020, we closed the transaction with Tizona and paid $302 million in cash to Tizona&#x2019;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#x2019;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#x2019;s IPR&amp;amp;D with no alternative future use and that Tizona is not a business as defined in ASC 805, &#x201c;Business Combinations.&#x201d; As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $272 million in Acquired in-process research and development expenses on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $41 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount was recorded in Other long-term assets on our Consolidated Balance Sheets. From the first anniversary of the closing date, we may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#x2019;s current shareholders for up to $1.3 billion, including an option fee and potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the development agreement, we committed to provide funding to Tizona of $115 million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tango Therapeutics, Inc. (&#x201c;Tango&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#x201c;Tango Collaboration and Stock Purchase Agreements&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into this transaction, we made an upfront payment of $125 million and a $20 million equity investment in Tango, representing approximately 7% of the issued and outstanding voting stock of Tango immediately following the transaction, in accordance with the terms of the Tango Collaboration and Stock Purchase Agreements. During the year ended December 31, 2020, we recorded the $125 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. Our equity investment in Tango is recorded at cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of Tango.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Jounce Therapeutics, Inc. (&#x201c;Jounce&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#x201c;Jounce License and Stock Purchase Agreement&#x201d;). In October 2020, we closed this transaction and made a total payment of $120 million in accordance with the terms of the Jounce License and Stock Purchase Agreement and recorded $56 million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately 14% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#x2019;s closing stock price of $10.06 on the closing date of the transaction. During the year ended December 31, 2020, we recorded $64 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In addition, we will provide up to $685 million in future potential clinical, regulatory and commercial milestone payments upon achievement of certain milestones, and pay Jounce royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Galapagos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Filgotinib Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#x201c;filgotinib agreement&#x201d;). Upon closing, we made an upfront license fee payment and an equity investment in Galapagos by subscribing for 6.8 million new ordinary shares of Galapagos at a price of &#x20ac;58 per share. The equity investment, net of issuance premium, was $357 million. We amended the terms of the filgotinib agreement in 2019 and then in 2020 agreed to amend the terms further. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the filgotinib agreement, as amended in 2019 (the &#x201c;2019 Agreement&#x201d;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. As of December&#160;31, 2019, Galapagos was eligible to receive from us potential future development and regulatory milestone-based payments of up to $640 million, sales-based milestone payments of up to $600 million, plus tiered royalties on global net sales ranging from 20% to 30%, with the exception of certain co-commercialization territories where profits would be shared equally. The co-commercialization territories were the UK, Germany, France, Italy, Spain, Belgium, the Netherlands and Luxembourg. We shared global development costs for filgotinib equally. Termination of the agreement could be on a country-by-country basis and depends on the circumstances, including expiration of royalty term or in the co-commercialization territories, sale of a generic product, or material breach by either party. We could also terminate the entire agreement without cause following a certain period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, following a Type A meeting with FDA to discuss the points raised in the Complete Response Letter related to the New Drug Application for filgotinib in the treatment of rheumatoid arthritis, Gilead and Galapagos agreed to amend the 2019 Agreement where Galapagos will assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe. Through a phased transition including the transfer of filgotinib&#x2019;s marketing authorization to Galapagos, the parties intend to transfer most activities by December 31, 2021 and complete the transition by December 31, 2022. The transfer will be subject to applicable local legal, regulatory and consultation requirements. Beginning on January 1, 2021, Galapagos bears the development costs for certain studies, in lieu of the equal cost split contemplated by the 2019 Agreement. All commercial economics on filgotinib in Europe will transfer to Galapagos as of January 1, 2022, subject to payment of tiered royalties of 8% to 15% of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#x20ac;160 million (or approximately $190 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is subject to certain adjustments for higher than budgeted development costs. Of this total amount, Gilead paid &#x20ac;35 million (or approximately $42 million) in January 2021 and will pay an additional &#x20ac;75 million (or approximately $89 million) in 2021 and will pay &#x20ac;50 million (or approximately $60 million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe. For the periods presented, the payments between Galapagos and us for the development costs and milestones were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Global Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In&#160;August 2019, we closed an option, license and collaboration Agreement (the &#x201c;Galapagos Collaboration Agreement&#x201d;) and a subscription agreement (the &#x201c;Galapagos Subscription Agreement&#x201d;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#x2019; current and future product portfolio (other than filgotinib). Upon closing, we paid $5.05 billion for the license and option rights and for 6.8 million new ordinary shares of Galapagos at a subscription price of &#x20ac;140.59 per share with a fair value of $1.13 billion, which included an issuance discount of $63 million calculated based on Galapagos&#x2019; closing stock price on the date of closing of the Galapagos Subscription Agreement. The remaining $3.92 billion of the payment was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Galapagos Subscription Agreement, we were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. In 2019, we exercised a warrant to subscribe for 2.6 million ordinary shares of Galapagos at &#x20ac;140.59 per share and purchased shares on the open market with an aggregate fair value of $586 million, which brought the number of shares owned by us to 16.7 million or approximately 25.8% of the shares then issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, our equity investment in Galapagos was initially classified as Other long-term assets on our Consolidated Balance Sheets as it is subject to contractual lock-up provisions. We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. We have two designees appointed to Galapagos&#x2019; board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the initial contractual lock-up provision for certain Galapagos shares will expire in August 2021, the corresponding equity investment balance of $351 million was included within Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2020. At December 31, 2020 and 2019, Gilead&#x2019;s total investment balance in Galapagos was $1.65 billion and $3.48 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos&#x2019; shares. We believe the fair value option best reflects the underlying economics of the investment. During the year ended December 31, 2020, we recorded a pre-tax unrealized loss of $1.83 billion related to our investment in Galapagos in Other income (expense), net on our Consolidated Statements of Income due to a decline in Galapagos&#x2019; stock price. See Note 3. Fair Value Measurements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Galapagos Collaboration Agreement, we have an exclusive license for the development and commercialization of GLPG-1690, a Phase 3 candidate for idiopathic pulmonary fibrosis, in our territories and have an option to participate in the development and commercialization of Galapagos&#x2019; other current and future clinical programs that have entered clinical development during the first ten years of the collaboration, subject to extension in certain circumstances. We may exercise our option for a program after the receipt of a data package from a completed, qualifying Phase 2 study for such program (or, in certain circumstances, the first Phase 3 study). If GLPG-1690 receives marketing approval in the U.S., we will pay Galapagos $325 million as well as tiered royalties described below. With respect to all other programs in Galapagos&#x2019; current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us (including GLPG-1690). If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. Galapagos retains exclusive commercialization rights for the optioned programs in the European Union, the UK, Iceland, Norway, Lichtenstein and Switzerland, and we have exclusive commercialization rights for all other countries globally. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. In 2020, Galapagos delivered to us a data package with respect to our option to participate in the development and commercialization of GLPG-1972, a Phase 2b candidate for osteoarthritis, under the Galapagos Collaboration Agreement, which we declined to exercise in November 2020. In addition, Gilead and Galapagos announced the decision to halt the ISABELA Phase 3 clinical studies with GLPG-1690 in February 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Complera/Eviplera and Odefsey&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#x2019;s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and European Union in 2011 and is sold under the brand name Complera in the U.S. and Eviplera in the European Union.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#x2019;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#x201c;Odefsey&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#x2019;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#x2019;s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen&#x2019;s shares of revenues are included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#x2019;s shares were $570 million, $574 million and $608 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Symtuza&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#x2019;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide. This combination was approved in the U.S. and European Union in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to cobicistat, emtricitabine and tenofovir alafenamide (&#x201c;Gilead Compounds&#x201d;) and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#x2019;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza. See Note 2. Revenues for additional information on revenue recognized for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Japan Tobacco, Inc. (&#x201c;Japan Tobacco&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights and paid a royalty to us based on its product sales in Japan. Under the agreement, we are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Japan Tobacco also marketed and distributed certain other products in our HIV portfolio in Japan and paid a royalty to us based on these product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received approval for Stribild and Genvoya (elvitegravir-containing products) in 2012 and 2015, respectively. Our sales of these products are included in Product sales. Royalties due to Japan Tobacco based on our product sales are included in Cost of goods sold. Royalties due from Japan Tobacco based on its product sales in Japan are included in Royalty, contract and other revenues on our Consolidated Statements of Income. Royalty expenses recognized were $291 million, $358 million and $452 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Royalty income recognized was not material for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective in December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we paid Japan Tobacco $559 million in cash, of which $194 million was paid as an upfront payment in 2018, and the remaining $365 million was paid in 2019. We recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco with the remaining $9 million recorded as Prepaid and other current assets on our Consolidated Balance Sheets. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gadeta&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, we entered into a collaboration arrangement with Gadeta and made a purchase of equity in Gadeta from Gadeta&#x2019;s shareholders. We determined that Gadeta was a VIE, and we were its primary beneficiary because we had the power to direct the activities of Gadeta that most significantly impact its economic performance. Upon the initial consolidation of Gadeta, we recorded $82 million to Noncontrolling interest, primarily reflecting acquired intangible assets related to IPR&amp;amp;D on our Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we effectively terminated the agreement with Gadeta. Upon the effective termination, we ceased to have a controlling interest and deconsolidated this VIE by removing the related net assets and noncontrolling interest of $82 million from our Consolidated Balance Sheets. The net loss from the deconsolidation was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;North America&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had a collaboration arrangement with BMS to develop and commercialize a single tablet regimen containing our Truvada and BMS&#x2019;s Sustiva (efavirenz) in the U.S. and Canada. This combination is sold under the brand name Atripla. We and BMS structured this collaboration as a joint venture that operated as a limited liability company, which we consolidated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2017, we terminated BMS&#x2019;s participation in the collaboration following the launch of a generic version of&#160;Sustiva&#160;in the U.S. and became the sole owner of the joint venture. BMS is not permitted to commercialize Atripla in the U.S. and Canada but is entitled to receive from us certain fees based on net sales of Atripla in 2018, 2019 and 2020 on a declining annual scale. BMS supplies Sustiva to us at cost plus a markup during this three-year period but may terminate the supply agreement after a notice period. BMS notified us of their voluntary termination of the supply agreement in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $19 million, $58 million and $198 million, respectively, of fee expenses within Cost of goods sold on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Sciences Ireland UC, our wholly-owned subsidiary, and BMS have a collaboration agreement which sets forth the terms and conditions under which we and BMS commercialize and distribute Atripla in the European Union, Iceland, Liechtenstein, Norway and Switzerland (collectively, the &#x201c;European Territory&#x201d;). The parties formed a limited liability company which we consolidate, to manufacture Atripla for distribution in the European Territory using efavirenz that it purchases from BMS at BMS&#x2019;s estimated net selling price of efavirenz in the European Territory. The parties also formed a limited liability company to hold the marketing authorization for Atripla in the European Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in 2012, except for a limited number of activities that are jointly managed, the parties no longer coordinate detailing and promotional activities in the European Territory. We are responsible for manufacturing, product distribution, inventory management and warehousing and have primary responsibility for regulatory activities. Through our local subsidiaries, we have primary responsibility for order fulfillment, collection of receivables, customer relations and handling of sales returns in all the territories where we and BMS promote Atripla. In general, the parties share revenues and out-of-pocket expenses in proportion to the net selling prices of the components of Atripla, Truvada and efavirenz. As of December&#160;31, 2020 and 2019, efavirenz purchased from BMS at BMS&#x2019;s estimated net selling price of efavirenz in the European Territory was included in Inventories on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, BMS elected to voluntarily terminate the agreement effective March 31, 2020. Post termination, BMS is not permitted to commercialize Atripla in the European territory but is entitled to receive from us certain fees based on net sales of Atripla on a declining annual scale for a three-year period following the effective date of the termination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other collaboration arrangements that are not individually significant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 2019 and 2018, we entered into several other collaborative, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $129 million, $331 million and $278 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income. Cash payments made related to our equity investments for the years ended December&#160;31, 2020, 2019 and 2018 were $72 million, $118 million and $156 million, respectively, which were primarily recorded within Prepaid and other current assets and Other long-term assets on our Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made were capitalized as intangible assets and are being amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</gild:CollaborativeandOtherArrangementsTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ia16ced64a7e645e781114e8469e73643_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4NTM_39b50b63-e146-4884-9fcb-e2021f7e5801"
      unitRef="shares">2200000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
      contextRef="ia16ced64a7e645e781114e8469e73643_I20200529"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4Njk_7467fe1f-29aa-4f06-85ea-a1ac3f6b63e6"
      unitRef="usd">61000000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4ODU_761015b0-6ff3-482e-950d-8937f9340595"
      unitRef="usd">175000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:InvestmentOwnedBalanceAdditionalShares
      contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5MDE_c065d522-dd65-4049-aad5-5470aa231e4c"
      unitRef="shares">6000000.0</gild:InvestmentOwnedBalanceAdditionalShares>
    <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
      contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5MzA_bd4095e0-a33a-49da-a5fb-a20a2953f521"
      unitRef="usd">200000000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent>
    <gild:TotalUpfrontPaymentsMade
      contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5NDk_37e7bb3d-9556-4d2e-a571-ce399357806e"
      unitRef="usd">391000000</gild:TotalUpfrontPaymentsMade>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5Njg_d20e0eff-6841-4416-8774-5005f2d09f0a"
      unitRef="usd">135000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:SharePrice
      contextRef="if681ee16d60745e59f58ea94a5a22cc6_I20200713"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU5ODE_2377e560-bb0d-4e94-90c7-eeeebba086df"
      unitRef="eurPerShare">22.67</us-gaap:SharePrice>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwMjA_c75ca038-44fc-42e3-ad20-ab055667c113"
      unitRef="usd">256000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwMzk_02d3bbda-dc7b-41f0-8ab3-8d173c519607"
      unitRef="usd">175000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:IssuanceDiscountPremium
      contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwNTc_b7546605-664b-40cd-ac9b-604d6ec9c474"
      unitRef="usd">-65000000</gild:IssuanceDiscountPremium>
    <gild:PaymentsForDirectTransactionalExpense
      contextRef="ia1c8e9ca32734b08a69312657eb1f287_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwNzU_ca8d58a5-ea20-4a9b-957f-61f356ad4325"
      unitRef="usd">16000000</gild:PaymentsForDirectTransactionalExpense>
    <gild:InvestmentOwnedBalanceAdditionalShares
      contextRef="iffef91ebd0344347af71595936327ea0_I20210208"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIwMjM_4095fa66-c232-44e0-a4b1-d731165978ab"
      unitRef="shares">5700000</gild:InvestmentOwnedBalanceAdditionalShares>
    <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
      contextRef="iffef91ebd0344347af71595936327ea0_I20210208"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIwNzI_9002b5c6-ec9c-41e1-9dba-b3654c6e34b1"
      unitRef="usd">220000000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesNoncurrent>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="iffef91ebd0344347af71595936327ea0_I20210208"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIxNjA_33c59f2e-f870-4288-aad6-586bbb52334a"
      unitRef="shares">13800000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i52b270d003824c77b29b5398d6d3083c_I20210208"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjIyMDg_dd51b46c-ef92-4f15-a42e-0b05e1265fb3"
      unitRef="number">0.195</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <gild:EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary
      contextRef="i8af407247e1d4bb483def9e87402f03a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA4NzI_6945403a-fe00-4d2e-864a-335aefd36453"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary>
    <gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
      contextRef="i8af407247e1d4bb483def9e87402f03a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxMzY_a1ed7d77-379a-4070-ad35-23b52bc8d8ec"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries>
    <gild:CollaborativeArrangementTerm
      contextRef="i80831b6a43e144288ee6887aa81b9527_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA4OTM_3442d42f-9e9f-479d-9a7c-3ea32dba49bc">P10Y</gild:CollaborativeArrangementTerm>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id99b5612dbd4404ba21f6f1b905e2fff_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNTU_616a4e62-bbfb-4995-bfd7-4ce2a4239eb4"
      unitRef="usd">100000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:EquitySecuritiesFVNIFutureMaximumMilestonePayments
      contextRef="i8af407247e1d4bb483def9e87402f03a_I20200713"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYwOTg_9ae643ad-3a39-4159-a381-8cd79a1b9248"
      unitRef="usd">1200000000</gild:EquitySecuritiesFVNIFutureMaximumMilestonePayments>
    <gild:EquitySecuritiesFVNIPurchasePeriod
      contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3MjQ_bffe21bb-8c2b-455d-bff9-8dc5e04d09a2">P5Y</gild:EquitySecuritiesFVNIPurchasePeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNjE_097b6557-456e-465b-8098-f9bdf15db225"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:EquitySecuritiesFVNIRestrictionPeriod
      contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3NDg_f56713f9-4722-42ad-bd9a-baa9cdd89518">P3Y</gild:EquitySecuritiesFVNIRestrictionPeriod>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i37eb10dcc178427ab1244846e835f528_D20200713-20200713"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNjc_097b6557-456e-465b-8098-f9bdf15db225"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:NumberOfAgreements
      contextRef="i93263403f73c4d28b597082de10c84d1_I20200619"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3NTM_5a5909bb-f05e-4e02-a218-d0c4ba750f2f"
      unitRef="agreement">2</gild:NumberOfAgreements>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i93263403f73c4d28b597082de10c84d1_I20200619"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxNzU_3dacabbd-c593-4a4d-ba7d-2194d84e5d8a"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ifbc35450bfed4ce1b3b6d598e9f11a83_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYxOTA_0d2cf698-a875-49ed-89ec-529d387d10d5"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <gild:InvestmentOwnedBalanceAdditionalPayable
      contextRef="ifbc35450bfed4ce1b3b6d598e9f11a83_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyMDc_556212a7-77c2-405f-8b2a-89b1c851853e"
      unitRef="usd">6000000</gild:InvestmentOwnedBalanceAdditionalPayable>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6f9442c5e7f742a5918ea65c554e30f1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyMjY_780af2db-4d83-4523-a4fb-b9c193716e0a"
      unitRef="usd">215000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="if78171fbfd924018a723f12dc3bd832a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyNDQ_04958d62-2810-4561-94bc-3f2e9416e7f9"
      unitRef="usd">70000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <gild:EquityMethodInvestmentOptionExerciseFee
      contextRef="if78171fbfd924018a723f12dc3bd832a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyNjM_0b4c4ae9-588c-40fd-a09a-8a4ad45f3b12"
      unitRef="usd">315000000</gild:EquityMethodInvestmentOptionExerciseFee>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="if78171fbfd924018a723f12dc3bd832a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyODI_6a8cd345-814d-4c94-aa99-5c1bc6bdb0ad"
      unitRef="usd">1200000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2d3771f3eacb401d97c063d22f14874f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYyOTk_eef3ce8c-b0d5-4184-9d6e-b01932ebcb65"
      unitRef="usd">80000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:ResearchAndDevelopmentFutureMaximumPayments
      contextRef="ib0a6b60bf1fb4c95bf249cf35ab97877_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzMTg_cc92aa02-fb24-4604-95e9-e1f9ad9320ce"
      unitRef="usd">115000000</gild:ResearchAndDevelopmentFutureMaximumPayments>
    <gild:AccruedResearchAndDevelopmentMilestonePayments
      contextRef="i34c05527ff1f41b18c4eaf4e2b69ad93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA5MDc_b54fece7-696b-4ac2-a9b2-3cb249f1104d"
      unitRef="usd">70000000</gild:AccruedResearchAndDevelopmentMilestonePayments>
    <gild:NumberOfStudies
      contextRef="i34c05527ff1f41b18c4eaf4e2b69ad93_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA5MjQ_30a82417-5d74-420f-b0c0-4fc96d37817f"
      unitRef="study">2</gild:NumberOfStudies>
    <gild:PaymentsForResearchAndDevelopmentMilestones
      contextRef="icd832b1814dc41c2855ec98618a3809f_D20210201-20210225"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NTQzMzk_8d767ce9-c0e5-409b-9194-575d096aaafd"
      unitRef="usd">70000000</gild:PaymentsForResearchAndDevelopmentMilestones>
    <gild:NumberOfAgreements
      contextRef="i9eb304537d4c49c5921792c6d16c44b1_I20200717"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3NjA_16bd7cc0-83a1-4bd4-a9fc-4b7a580f1a99"
      unitRef="agreement">2</gild:NumberOfAgreements>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9eb304537d4c49c5921792c6d16c44b1_I20200717"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzMzA_8fb2caa8-55ad-4d5a-80c6-ca703369f7e2"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iffcb20e38446438fac262691e10ede58_D20200825-20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzNDU_368f3298-660a-4dc4-bd68-00c1762459c7"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia485fc53f8774d4bbbe1c1dbe9ba40a7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NzAwOTU_fddd4fc4-4616-49cd-b35f-5ec265ee5b0f"
      unitRef="usd">272000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="if33df116f5f941209af85885b37007ea_I20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzNjM_ac956f6e-8649-4326-8dee-0b1df643f48e"
      unitRef="usd">41000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
      contextRef="if33df116f5f941209af85885b37007ea_I20200825"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDYzODI_64cb1e7e-cea5-470b-81f2-9eafdafbc166"
      unitRef="usd">1300000000</gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i7aa72b0e47084ac4b180eb22cea3779e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0MDA_7cac058d-4ed4-419c-852e-b644a54d8fe5"
      unitRef="usd">115000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0MTk_c1c193cd-cc23-4057-b89b-8482d2d3d77d"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0Mzc_56791e5f-577d-4835-b087-a7302544dd73"
      unitRef="usd">20000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="ida137ca5e8244cb0ae5f91885ad73166_I20200827"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0NDY_6a630d8f-14a7-44d4-8918-cbc7f9663dd2"
      unitRef="number">0.07</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0NjE_4c05a652-344f-4cf7-9b89-caf212c7b9b8"
      unitRef="usd">125000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:NumberOfPrograms
      contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3Njc_3c4a1446-fe23-4c8a-8c2c-e93b18004291"
      unitRef="program">15</gild:NumberOfPrograms>
    <gild:CollaborativeArrangementTerm
      contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzk4OTU2MDQ3MDI3ODI_f4d81bbe-082d-406b-9586-70aab0a9a0bc">P7Y</gild:CollaborativeArrangementTerm>
    <gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments
      contextRef="ib6c2a39851d54226810f425b59f2723a_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0ODA_8e76ecc2-42a8-4ce8-836b-7b7163efec1a"
      unitRef="usd">410000000</gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments>
    <gild:TotalUpfrontPaymentsMade
      contextRef="ia9888aea06ac4afc8425a218b65655b0_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY0OTk_d2f276ab-5040-47bb-b3c8-aa3a60301a2a"
      unitRef="usd">120000000</gild:TotalUpfrontPaymentsMade>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="ia9888aea06ac4afc8425a218b65655b0_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1MTc_e883d58c-8d11-4637-8f39-4b9610048262"
      unitRef="usd">56000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i454bf1f356114d009c08e1da60df6588_I20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1Mjc_019658de-f83b-4ab5-8079-06093a478885"
      unitRef="number">0.14</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SharePrice
      contextRef="i740dfff7a05d4e5e8dd476392363eb90_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1MzY_475c8cef-e8a0-464a-a10a-abba2d9c6117"
      unitRef="eurPerShare">10.06</us-gaap:SharePrice>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8f9917b07dc845fa8fe5d3c889a19c8e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjkwMTE_879d7de8-285a-4c4a-9541-63a664d9222f"
      unitRef="usd">64000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum
      contextRef="i740dfff7a05d4e5e8dd476392363eb90_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY1NTE_4f8630e6-fc89-4ba2-bbb3-536f36688532"
      unitRef="usd">685000000</gild:PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEyMDI_ae93240f-613e-4a39-b50f-c9518a344636"
      unitRef="shares">6800000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEyNTI_f3c96be5-fd62-48c0-ae9d-2f42421d74a6"
      unitRef="eurPerShare">58</us-gaap:SharePrice>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9d36edd2ef5b4eb196b8d28125c008c8_I20160119"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMTg_915d028c-43e1-42af-b473-1fd0215880f6"
      unitRef="usd">357000000</us-gaap:EquitySecuritiesFvNi>
    <gild:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE2Mzk_7692745f-ea6a-4fba-af67-bbf037db258e"
      unitRef="usd">640000000</gild:PotentialDevelopmentAndRegulatoryMilestones>
    <gild:PotentialFutureSalesbasedMilestone
      contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE2ODM_8daa9552-61ee-4728-967c-da985478953d"
      unitRef="usd">600000000</gild:PotentialFutureSalesbasedMilestone>
    <gild:PotentialFutureTieredRoyaltyPaymentLowend
      contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE3NDI_ee721b43-8729-4c48-9c62-f5186018dfa4"
      unitRef="number">0.20</gild:PotentialFutureTieredRoyaltyPaymentLowend>
    <gild:PotentialFutureTieredRoyaltyPaymentHighend
      contextRef="ic14136643b7342e68c68c63cc70e88de_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE3NDg_926cd4c7-7c0e-4b05-8e84-f79d26346226"
      unitRef="number">0.30</gild:PotentialFutureTieredRoyaltyPaymentHighend>
    <gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU3NDA_88f77905-3a41-4437-a3e9-df9924dc0696"
      unitRef="number">0.08</gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage>
    <gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU3NTM_1e47b5dd-e6e9-43cd-82b4-9432995e2122"
      unitRef="number">0.15</gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage>
    <gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU3MDE_d6a21ca2-f030-445b-8aa7-c3cc4fe5add6"
      unitRef="eur">160000000</gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NTA3NTg_cafe2594-7d83-4fea-b422-5f6f12f9c43c"
      unitRef="usd">190000000</gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i68443d5a14c140e5b3fb3ff26e44562f_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDkzMjk_f146c4d7-687d-4605-a912-c5cbba3baccd"
      unitRef="eur">35000000</gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i68443d5a14c140e5b3fb3ff26e44562f_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjI5NzM_da3ef070-a7bf-4b27-beb5-3fb8f3ee4a88"
      unitRef="usd">42000000</gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY5MzE_70924372-420e-41ba-8060-9a4c52e87128"
      unitRef="eur">75000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjI5ODc_99d99783-7c9d-43ac-a6c3-d9ef2bd8f688"
      unitRef="usd">89000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDY5NDg_e973068e-bd43-4504-ba76-bb64a629e852"
      unitRef="eur">50000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo
      contextRef="i70ea464b37414fe3830d04118e06ee1b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NjMwMTM_07afb82e-ee1f-4a5e-8833-cbf2badea5bb"
      unitRef="usd">60000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo>
    <gild:PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing
      contextRef="i8b08c2b1e8994a8386e2f87e19b2f94e_D20190801-20190831"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI4Njg_d3a210dc-ddf1-4659-8845-130c5bc5dd29"
      unitRef="usd">5050000000.00</gild:PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI5MTM_d6dc7397-dd2b-401b-921e-a776461a9d5d"
      unitRef="shares">6800000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI5NzY_d6f5756e-af4c-4071-a124-e04ffc65a0bb"
      unitRef="eurPerShare">140.59</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzMwMTA_2fe4ff32-422e-40dd-af2f-71386a74dac7"
      unitRef="usd">1130000000</us-gaap:EquityMethodInvestments>
    <gild:Issuancediscount
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzMwNTM_0f52a440-d47e-41c9-be13-3d450d528a39"
      unitRef="usd">63000000</gild:Issuancediscount>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8146d0695ec4432692851cb70914ad5f_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzMxNzU_4e6b816d-64f4-4ee0-be60-4e970af89e21"
      unitRef="usd">3920000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM1MTc_b2cebfd5-bdaf-4839-88d0-f25b0c847aba"
      unitRef="number">0.299</gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <gild:InvestmentOwnedBalanceAdditionalShares
      contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM2NTg_34f85c1a-83b0-4160-8980-da6783670b5a"
      unitRef="shares">2600000</gild:InvestmentOwnedBalanceAdditionalShares>
    <us-gaap:SharePrice
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxNDA5Nzc_d6f5756e-af4c-4071-a124-e04ffc65a0bb"
      unitRef="eurPerShare">140.59</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM3Nzg_46247729-4d4c-4ea5-bfcd-284e7ebea76b"
      unitRef="usd">586000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4MzI_a3bd8a62-ba1e-4a4b-85c3-7a28e2dcfa21"
      unitRef="shares">16700000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NTI_0079206d-6af0-4509-8106-391a31effa3d"
      unitRef="number">0.258</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <gild:StandstillRestrictingTerm
      contextRef="i8b08c2b1e8994a8386e2f87e19b2f94e_D20190801-20190831"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzI3NDg3NzkxMzUyNzk_18effe1b-31f4-4994-9911-91aa4745d38e">P10Y</gild:StandstillRestrictingTerm>
    <gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQxODY_e0d70c98-e3fc-4f03-b7c8-f2f2700e17f6"
      unitRef="number">0.299</gild:MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i809a5f73da45450ca7e822b925dcfa95_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQ2MTc_fa5f26da-5f51-4352-b2f5-a165beff344d"
      unitRef="number">0.201</gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2b237db0dba14d1f8cd562ae2e0c1500_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NDYxMDQ_1eeed056-5e69-4955-907a-0433efe1ecb6"
      unitRef="usd">351000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i2b237db0dba14d1f8cd562ae2e0c1500_I20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEwOTk1MTE2OTk1OTM_874e205d-9751-4d8a-9fa0-6e37276ae5a2"
      unitRef="usd">1650000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9933f47e878d468f83ba0ec2b8775652_I20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEwOTk1MTE2OTk1OTc_2bf299cd-b5d2-4ada-bfd5-370dbf18cc0b"
      unitRef="usd">3480000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i960fec8ecc464f7f9fdf9acc6db7076c_D20200101-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEwOTk1MTE2ODEyOTk_2f97b417-6525-4c78-8471-14c30c565d8e"
      unitRef="usd">1830000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <gild:PotentialMilestonePaymentUponMarketingApprovalGLPG1690
      contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzU5NTk_6f7da248-8ecc-4201-92ce-b3d483920be8"
      unitRef="usd">325000000</gild:PotentialMilestonePaymentUponMarketingApprovalGLPG1690>
    <gild:PotentialOptionExerciseFeePerProgram
      contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzYzNzg_d6b6b6ec-9b4e-4829-857a-4a760c584e2e"
      unitRef="usd">150000000</gild:PotentialOptionExerciseFeePerProgram>
    <gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage
      contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzY0ODA_c5e045d0-c88a-476a-92a3-8b2c9bb86b0a"
      unitRef="number">0.20</gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage>
    <gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage
      contextRef="i4ba7404849984dafb0475afcb806dc0e_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzY0ODY_e4ce2f62-9770-4d31-a4c8-bd1c750927f3"
      unitRef="number">0.24</gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage>
    <gild:PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage
      contextRef="i70e3ac2edb384dcd87ba36967240d6a6_I20141231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkwMjU_e206938a-814c-419b-9a4e-ee218d3cd1d0"
      unitRef="number">0.30</gild:PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if741a8ddd11548bca6696dcc16ea06ff_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkyNjM_49cc0ddb-70f3-46c1-b373-582ed9c927fc"
      unitRef="usd">570000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iee332949c6714cb9ac12a12334a0d199_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkyNjc_0a6fefd3-9a94-4bcd-b67b-1556edb3d3eb"
      unitRef="usd">574000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibf43160183dd4615964265dbc7e94547_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzkyNzQ_35334625-088a-4e8a-a7b6-4c1f7578e61f"
      unitRef="usd">608000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RoyaltyExpense
      contextRef="i6c6d33288a694080a10decb9745df341_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMzIz_cabfd85f-f671-4a47-8f58-264b7c737b99"
      unitRef="usd">291000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i32869178bb374083a5691c4c47f7e162_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMzI3_81e91d0b-1988-482d-a928-1cbc9856f786"
      unitRef="usd">358000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ia23e8ec8f5a94be1a0800fd9ca20d3e2_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzMzM0_b8274968-a982-4421-a01c-ce81eda8369c"
      unitRef="usd">452000000</us-gaap:RoyaltyExpense>
    <gild:InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan
      contextRef="i10e8f707b4a2423885556304b9c14459_D20181201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzODQz_f3cc405f-da33-4f5b-8874-1675d702456e"
      unitRef="usd">559000000</gild:InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan>
    <us-gaap:PaymentsToAcquireManagementContractRights
      contextRef="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzODY0_2b4c4e30-5dd6-4fff-80f7-40f86982a363"
      unitRef="usd">194000000</us-gaap:PaymentsToAcquireManagementContractRights>
    <us-gaap:PaymentsToAcquireManagementContractRights
      contextRef="i32869178bb374083a5691c4c47f7e162_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzOTI0_8992d291-1fb3-4941-a2fd-ab36c103c081"
      unitRef="usd">365000000</us-gaap:PaymentsToAcquireManagementContractRights>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzEzOTgw_82998a66-4931-459e-82d6-9fa1677bce45"
      unitRef="usd">550000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if4142852a6d94d81b33b11f3c2bf3444_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE0MDk4_46cee162-d8ba-4a6f-aeb4-8140e514ba6d"
      unitRef="usd">9000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i29ecaf81619b4fd0aeef0e9f06f7222e_D20181201-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE0MjI3_c82e0bfc-cb9b-4a8b-a6d3-6d5559b3675f">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="ie52274b0a3fd40f79ccc454513656539_I20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4MzU_ba81d709-e32b-40c1-8d52-32c4c63c6af9"
      unitRef="usd">82000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:NoncontrollingInterestInVariableInterestEntity
      contextRef="ia16d123600754634a5bcf2ed111b7be5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzM4NDgyOTA3NDU4MDk_29570ac3-e35d-45e9-9289-f38532f57c06"
      unitRef="usd">82000000</us-gaap:NoncontrollingInterestInVariableInterestEntity>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia37d42b05ac242459b8ca53417f3c881_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTA4OTA_6b743a33-92e5-4241-936a-a54a37d307a4"
      unitRef="usd">19000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ife61ff89d12b4fd3ace02e9f26886498_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE3MTk2_2873587d-275e-4110-8acc-8b3b17896144"
      unitRef="usd">58000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i32f211cb92aa41f0a97038b010abc03d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTA5Mjc_1c8f4221-b63b-4b2c-8488-c3749d0badec"
      unitRef="usd">198000000</us-gaap:CostOfGoodsAndServicesSold>
    <gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="i3c008f74ae7741bebc87087598c24b61_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTUzNzI_ce83fd2a-b900-4ba3-a0c6-c3cb4ccf6745"
      unitRef="usd">129000000</gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="ie87f8e54cb4a410db675109bd66255a6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE5NzMz_a7dfae80-203d-4c3f-a68c-207bd7a96bec"
      unitRef="usd">331000000</gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="ief4a90e396444c1698d4940439fd9f6c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzE5NzQw_e4d79573-c117-4ab3-b707-d72e1cab5671"
      unitRef="usd">278000000</gild:UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i3c008f74ae7741bebc87087598c24b61_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTUzNTY_1c3c101e-6670-4ebb-9a50-8c70ce28e162"
      unitRef="usd">72000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="ie87f8e54cb4a410db675109bd66255a6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTUzODc_d988cf03-7edf-496e-bc4b-53ee7b23285f"
      unitRef="usd">118000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="ief4a90e396444c1698d4940439fd9f6c_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNDUvZnJhZzphNmEwYTEzODMyMGE0NWNhODQ0YWY4NWFkODEzOTA5Mi90ZXh0cmVnaW9uOmE2YTBhMTM4MzIwYTQ1Y2E4NDRhZjg1YWQ4MTM5MDkyXzQzOTgwNDY1NTU0MDM_860826c9-1cf8-4518-90ca-b81e1a2b1c8d"
      unitRef="usd">156000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwNDQ1MzYwNDg3Nzk3_62f5b0b3-8035-4d8d-afcc-7572e1e9d4e3">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Due Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we issued senior unsecured notes consisting of (i) $500 million principal amount of floating rate notes due September 2021 and $500 million principal amount of floating rate notes due September 2023 (together, the &#x201c;Floating Rate Notes&#x201d;); and (ii) $2.0 billion principal amount of 0.75% senior notes due September 2023, $750 million principal amount of 1.20% senior notes due October 2027, $1.0 billion principal amount of 1.65% senior notes due October 2030, $1.0 billion principal amount of 2.60% senior notes due October 2040 and $1.5 billion principal amount of 2.80% senior notes due October 2050, the terms of which are summarized in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, we repaid at maturity $500 million of principal balance related to our 2014 senior unsecured notes. In September 2020, we repaid at maturity $2.0&#160;billion principal balance related to our 2015 senior unsecured notes. In 2019, we repaid $2.75 billion of our senior unsecured notes upon maturity. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. The senior unsecured fixed rate notes also have a call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from one month to two years prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The September 2023 floating rate notes also have a call feature, exercisable at our option, to redeem the notes at par, in whole, or in part, approximately two years prior to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of the occurrence of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#x2019;s Investors Service, Inc. and S&amp;amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our senior unsecured notes and as of December&#160;31, 2020 and 2019, we were not in violation of any covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Loan Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a commitment letter with a group of institutional lenders to provide for a three-year senior unsecured term loan facility in an aggregate principal amount of $1.0&#160;billion. Pursuant to the commitment letter, in October 2020, in connection with our acquisition of Immunomedics, we entered into a term loan credit agreement (the &#x201c;Term Loan Facility&#x201d;) and borrowed an aggregate principal amount of $1.0&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan Facility contains customary representations, warranties, affirmative and negative covenants and events of default. The Term Loan Facility bears interest at the Eurodollar Rate plus the Applicable Percentage as defined in the Term Loan Facility. We may terminate or reduce the amount borrowed under the Term Loan Facility in whole or in part at any time without premium or penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI, prior to the completion of our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revolving Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, we entered into a $2.5 billion five-year revolving credit facility agreement maturing in May 2021 (the &#x201c;2016 Revolving Credit Facility&#x201d;). In June 2020, we terminated the 2016 Revolving Credit Facility. As of December&#160;31, 2019, there were no amounts outstanding under the 2016 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, we entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#x201c;2020 Revolving Credit Facility&#x201d;), which has terms substantially similar to the 2016 Revolving Credit Facility. The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2020, there were no amounts outstanding under the 2020 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. At December&#160;31, 2020, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Eurodollar Rate plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the new credit facility in whole or in part at any time without premium or penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Maturities of Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate future principal maturities of our senior unsecured notes and Term Loan Facility as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $994 million, $1.0 billion and $1.1 billion in 2020, 2019 and 2018, respectively.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM5MzY_f6c95b1b-f5fe-4e33-97dd-74c757129e90">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Due Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-month LIBOR + 0.52%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;variable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes and term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1af6afc5f8e54ba59cb9793eef93e885_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzYtNi0xLTEtMA_549672d8-4fb5-487b-b7b4-f3b89872de69"
      unitRef="number">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1af6afc5f8e54ba59cb9793eef93e885_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzYtOC0xLTEtMA_f67ee16b-b98f-49b3-a121-8c33f0be8aa4"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ied16c88db1234c66aedf0dc0e80bf0da_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzYtMTAtMS0xLTA_1400bb3b-0421-469b-ad94-1a2370b3c299"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i33544e3e9bf8466189835e7d6f721350_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzctNi0xLTEtMA_6e3a6578-6221-40d3-ae6e-fee78ab617ff"
      unitRef="number">0.0255</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i33544e3e9bf8466189835e7d6f721350_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzctOC0xLTEtMA_b474b62d-45e5-4f34-a667-a9ed7ab119cf"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i76142ba97a5247fd8b93aaddb16c8fd9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzctMTAtMS0xLTA_009bc552-4535-4705-aa98-e9392857dcb9"
      unitRef="usd">1999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8ad657ef10246598ee1f2d6d2eb3a7b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzgtNi0xLTEtMA_cbf32969-fbf9-4e67-875f-48e790e211c0"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id8ad657ef10246598ee1f2d6d2eb3a7b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzgtOC0xLTEtMA_0cd9af25-f0f6-43c5-809d-1d9c38317d5e"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibcb35118d4c9442e94273ba0799d1e3d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzgtMTAtMS0xLTA_1928c13e-1fad-4f54-835b-669a074055f2"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0a7777335ed04cf59f807114fe7a66bd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzUtNC0xLTEtNDM4Ni90ZXh0cmVnaW9uOmI4MjE5YzZiZTMwNDRkN2FhYzI4NGQzNmZkMmVmYTAwXzE2NDkyNjc0NDE2OTU_c35aff8f-016c-4de7-8678-1123acfb8c69"
      unitRef="number">0.0015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i079f3e090c534879a46df4da2d4f54af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzUtNi0xLTEtNDM5OQ_e7f5a5be-c119-4e2e-8368-19a8c2dab3de"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id5cfc1706eed466ea24db728b779b02d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzUtOC0xLTEtNDM5OQ_1937bd92-c06e-4315-aecb-054809a8eaa2"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib5975f2be2634b6193ebe5e4518e0b67_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzktNi0xLTEtMA_c8714531-cd96-45ba-bdb3-10a0dc86ce0c"
      unitRef="number">0.0440</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib5975f2be2634b6193ebe5e4518e0b67_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzktOC0xLTEtMA_2d952d4c-d12a-4d0c-b03b-bd4ee9514abf"
      unitRef="usd">1249000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3670ca9b3f7f4e67bf432cd8f3e3dd6e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzktMTAtMS0xLTA_3c2fdbc2-5a92-4d44-ac4b-66560a375f6e"
      unitRef="usd">1248000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i068021f3eade41599edf59a5a127fefd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTYtMS0xLTA_143eb346-9af7-4848-859e-800d19660198"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i068021f3eade41599edf59a5a127fefd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTgtMS0xLTA_e14d7f86-8948-49fe-a373-1345105aa09b"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id4a14e35256c4e9b99448ff4ab266069_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTEwLTEtMS0w_b5b09c87-99cb-42fe-991b-f0c0e0a26f7a"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3d3bff642f2142629af6b9cd0108692d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTYtMS0xLTA_c308696c-22c4-4bc3-9666-0f023f8add80"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i3d3bff642f2142629af6b9cd0108692d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTgtMS0xLTA_b7862736-8ff8-486f-92f4-b1734e8f14cf"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3e913054de0540cfa8dfe947549c1af3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTEwLTEtMS0w_6714874d-5a6f-4d1e-94e2-80686479972e"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i11d7b8db766a40b4915b3e488cb97f03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTYtMS0xLTA_6ffb72e6-324c-488b-b5fe-f60e44c7b0ff"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i11d7b8db766a40b4915b3e488cb97f03_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTgtMS0xLTA_f27ac786-0a8e-4f51-a730-47038243a2b9"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iac7f8e63064f4893a1648dc50ce5ffd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTEwLTEtMS0w_f3b367a0-8ad5-4e00-a442-8b7999d6930c"
      unitRef="usd">747000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id6845673544a4170be8f0594b2341c6f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTQtMS0xLTQ0MDMvdGV4dHJlZ2lvbjpjNWM3ZTZlYzcwMDI0ZjY1YTFlNmFhY2E0NGZlYzc5NV8xNjQ5MjY3NDQxNjk0_4e74caa7-6ea5-4e02-afbe-68445508cc9c"
      unitRef="number">0.0052</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="ia8a2ab9d1b9a48a0964021dec398e682_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTYtMS0xLTQ0MDM_c0557cd3-2b6c-49ca-bb92-8a3a26920d5f"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4d4e35afb27045a0a512b4300478000b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEwLTgtMS0xLTQ0MDM_63dd7256-69d1-422c-ad46-99fababb2759"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie0cf198ca9f14127aac65bf348fd3646_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTQtMS0xLTQ0MDM_cbbcf466-83ea-407c-a7be-2533c7035056"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie429e3caea7d425b84413a3c28d65099_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTYtMS0xLTQ0MDM_799aa726-d12b-4029-ab09-db5820363b70"
      unitRef="usd">1992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i8c543bc5eea4422e9442c1624ec8ab90_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzExLTgtMS0xLTQ0MDM_0c48ae51-ee12-44d4-b3f1-af24572bfbdd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic7238cb6a890463c9d26c7c09431cb24_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTgtMS0xLTEyMDE1_6d55a80d-bf50-4666-8f61-d54701578294"
      unitRef="usd">998000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib268c4735aac4a7894a222f05f1e7ebe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEyLTEwLTEtMS0xMjAxNQ_9a4cfc6c-68be-43ba-baf3-05a4ce2ffa79"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0f80a26646664c12af8af332d1630212_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEzLTYtMS0xLTA_38d73195-1601-4e6d-b0ae-c728bb10878b"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0f80a26646664c12af8af332d1630212_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEzLTgtMS0xLTA_f6e342f1-d20b-438f-8698-74a5bf1e8fb6"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i588786d4c5b04ceb86b3104e6b1dbde9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzEzLTEwLTEtMS0w_a4b6454e-8c73-411a-9b37-e12a4f990355"
      unitRef="usd">1745000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f90cd187b864231b694a710210de89a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE0LTYtMS0xLTA_6062f838-2303-4bc2-875e-ff313c90fab2"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5f90cd187b864231b694a710210de89a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE0LTgtMS0xLTA_351bbc68-24a8-40b1-be17-c1714f23860a"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i86263ea980a0478086ecfafe984d7563_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE0LTEwLTEtMS0w_ac040e00-4984-44e0-8347-c99ccc5064f5"
      unitRef="usd">1746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4e89e8f308084febab4d3c4b09ec137b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE1LTYtMS0xLTA_a4987c12-fd48-489b-9886-3c40aa5e2309"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4e89e8f308084febab4d3c4b09ec137b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE1LTgtMS0xLTA_4b9cd38c-b44a-4b8b-a847-ff4fa6c44e96"
      unitRef="usd">2737000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4f36c3515ec9482dba6b429c4a71e17b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE1LTEwLTEtMS0w_7a7779a5-5c25-4de5-81c9-985d66dd8331"
      unitRef="usd">2734000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idbe5e2da225448318d6e7ce30d2a5b44_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTYtMS0xLTA_50ee1b33-4b23-4a9a-96f6-e8ffbef59e73"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idbe5e2da225448318d6e7ce30d2a5b44_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTgtMS0xLTA_7733354a-458c-4554-8955-5a73ce60b0d9"
      unitRef="usd">1246000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id2644728c1aa4257bb5ac872b6fa8552_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTEwLTEtMS0w_50c4dcb3-3533-42ea-83d1-653033f8082e"
      unitRef="usd">1245000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ief2d0ff77d1d4377995f3b52034e38fe_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTQtMS0xLTQ0MDc_fb445a8c-01ba-46e6-905f-797d5ceb0691"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ief2d0ff77d1d4377995f3b52034e38fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTYtMS0xLTQ0MDc_b2061330-8c08-4b85-a2f9-0bbd060310f2"
      unitRef="usd">745000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i47a08b08ea6742dab3cb313aea60e574_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE2LTgtMS0xLTQ0MDc_0c8e21f5-8018-4b29-a858-40181dc9f280"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b4ff001607a4d4e86f6ece76b1cb4a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTQtMS0xLTQ0MDc_4d0b736f-c336-4ab7-9985-394e7000626b"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0b4ff001607a4d4e86f6ece76b1cb4a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTYtMS0xLTQ0MDc_a45a534a-eb91-4e25-91ce-cd41fad4f71d"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i601d3d19bbbd40c9be8b03ece2ad21ad_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTgtMS0xLTQ0MDc_852a1233-cc3b-40a0-948d-f8b5f60fb89e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i917a67bd025e47c18737842312fd65e1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTYtMS0xLTA_47a2c919-b8cb-48bb-9779-a68ee0edda15"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i917a67bd025e47c18737842312fd65e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTgtMS0xLTA_4a727767-b904-4adf-b223-bf605ccda578"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i94d1d8ac11bc404f91be62f8fd6239e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE3LTEwLTEtMS0w_ce463b40-1dc6-49e6-ba11-af63fa3663b4"
      unitRef="usd">991000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5c65c238d0cd4bdaa6748c4a0d9248e5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE4LTYtMS0xLTA_7dae33bb-c433-45d2-889c-4d49fc807e14"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5c65c238d0cd4bdaa6748c4a0d9248e5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE4LTgtMS0xLTA_dc04424f-142d-4c90-a35d-953ff1036179"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie386ac3bda26490e9b7780e1e62a038d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE4LTEwLTEtMS0w_0789c5ac-c269-47b7-aad1-864c75df71d7"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i116ad184d5dc456e90f07d8331609037_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTQtMS0xLTQ0MTE_fbe77f8d-4e07-443d-bb4f-5a47e4093a68"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i116ad184d5dc456e90f07d8331609037_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTYtMS0xLTQ0MTE_617dcf1f-a797-4237-999b-600f3b16b4dd"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3a3d522c920c4eaf98d9423edd359180_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTgtMS0xLTQ0MTE_686f2b38-dced-4bfb-b7a5-4ed3c3792384"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28f0ddee26a6400e90f15437dbf5aafd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE5LTYtMS0xLTA_58a6935a-8012-49df-9603-28408150f5da"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i28f0ddee26a6400e90f15437dbf5aafd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE5LTgtMS0xLTA_9b88ecf8-5fa3-446b-8342-2f8c0c0c4dd3"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i25cb38188cc44e84a8c402adba11be30_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzE5LTEwLTEtMS0w_b63b6dea-4d89-44af-bfe3-98c45c648e9b"
      unitRef="usd">995000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0c50be0096dd408eb2b0af525d5453d9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTYtMS0xLTA_40f57f20-f32b-4197-8eec-2903fae725ac"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0c50be0096dd408eb2b0af525d5453d9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTgtMS0xLTA_1c629003-0efd-4be2-9636-d81fe6c7123c"
      unitRef="usd">1735000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3341333ea70c407da5e3d68a2db6c9dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIwLTEwLTEtMS0w_92fa6100-aba4-4ff5-b7df-5cadc425ef0d"
      unitRef="usd">1734000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d3e46a170ac41afb9968e742e88e06e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIxLTYtMS0xLTA_1acb79ba-2c43-4296-bc3c-cf359cb956a5"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5d3e46a170ac41afb9968e742e88e06e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIxLTgtMS0xLTA_fde6b6be-5393-4b23-9124-0650b6b939cf"
      unitRef="usd">1732000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i861f7cc25fb44ef5a805d427c6d41708_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIxLTEwLTEtMS0w_c5339e71-dcd5-4907-9ff8-09db7c12b511"
      unitRef="usd">1731000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0b2a2c92c9bc4c019c117fcccc6fbd78_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIyLTYtMS0xLTA_85590423-699c-47be-9712-59d30cd9c5b4"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i0b2a2c92c9bc4c019c117fcccc6fbd78_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIyLTgtMS0xLTA_c2c2bcb1-c9ae-4036-a800-0cc7d4f948a9"
      unitRef="usd">2219000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic99295727180471890cc95afa2e4192a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIyLTEwLTEtMS0w_17ea0e92-148a-4007-89f2-e397cda17e20"
      unitRef="usd">2217000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i624388aa63954f5c96041bc516796f34_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIzLTYtMS0xLTA_b19634cc-2864-43f3-b490-049b25180afd"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i624388aa63954f5c96041bc516796f34_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIzLTgtMS0xLTA_77136c3a-f7a5-41ff-b625-46b929735495"
      unitRef="usd">1726000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i04e043d95be44884a92667d375737a0d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzIzLTEwLTEtMS0w_6a45ca70-b921-4ad6-b730-5b9349b90f35"
      unitRef="usd">1725000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i016f2c24896d41729056d15a9007c6e4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTQtMS0xLTQ0MjU_bdf02767-becc-4f56-86b0-cdca6fd60ffa"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i016f2c24896d41729056d15a9007c6e4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTYtMS0xLTQ0MjU_92c829bc-4572-4431-8a25-3bbf985c73c7"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4b17acdedffc4fc1bd0b4b188bb173cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTgtMS0xLTQ0MjU_d5f7d605-e7b9-4c0d-a1ef-4ce2531a1672"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i61afb70e61ba4c8aa5270a4e11c0914b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI0LTgtMS0xLTA_9ce47af7-bf53-46c5-a2f9-f2d9507258e2"
      unitRef="usd">30295000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i180ad2d40440498ea05cf2425660478c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI0LTEwLTEtMS0w_855e6597-e187-4f8a-aa22-0f0d863568bd"
      unitRef="usd">24593000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4dd068f90f2441228adf1a8ce9668e2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI5LTgtMS0xLTE4MjE0_8bd6765a-27dd-4426-8ab0-0b36f8ddc28b"
      unitRef="usd">1107000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3b5f5e11f4c842dfbe349568ca25c17d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI5LTEwLTEtMS0xODIxNA_597007ec-4adc-4a31-ad4b-bc799c3adf68"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzMwLTgtMS0xLTE4MjE0_97272474-f5de-4045-a284-f5934e4d5e68"
      unitRef="usd">31402000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzMwLTEwLTEtMS0xODIxNA_e303c06d-76af-4837-8dd6-d76108da0921"
      unitRef="usd">24593000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI1LTgtMS0xLTA_63dc47e8-930b-4ec7-acac-d897ebfc2c87"
      unitRef="usd">2757000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI1LTEwLTEtMS0w_bdf1acc7-6fa5-404f-bd27-70799d1caddd"
      unitRef="usd">2499000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTgtMS0xLTA_e0dcd9a4-1c53-4411-93d2-c1491feeb4b5"
      unitRef="usd">28645000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTo1NDNkMGE3OTM1Yjg0ZGQ1YWQxZmQzNWE3ZmJjNDUxNy90YWJsZXJhbmdlOjU0M2QwYTc5MzViODRkZDVhZDFmZDM1YTdmYmM0NTE3XzI2LTEwLTEtMS0w_eb6390a1-4f15-4a7d-81c8-2f911a42a114"
      unitRef="usd">22094000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7af8fb6957bc4c20b9649de1e7fe1110_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NTU_09e78203-5307-4dae-9eae-7d448b5ee0ae"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i71abf35a67c349dabfb936d03b474a47_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NjM_07c1ef50-884c-49ad-8042-84a10ad44e24"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5c1faea29102437aa26bf1071aaa87fc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5Njc_3cdeac64-43be-4fe0-a5aa-1c9ae49f4bd5"
      unitRef="usd">2000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5c1faea29102437aa26bf1071aaa87fc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMDc_52b6f71f-4489-4b91-801b-1213d6c13700"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9ff57f2a7eef4231a0e859065a5afd5d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NzE_9bd7450a-3f0d-4555-886a-6f85f487faf2"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9ff57f2a7eef4231a0e859065a5afd5d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMTE_d2a36625-d448-48f2-9a96-276b048ded8b"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2e55cf66183242569e946df901102514_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5NzU_b2bd9516-6ff6-4654-850f-64e0149571d6"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e55cf66183242569e946df901102514_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMTU_79a940cb-cdd8-4c8c-857d-90361cc642c2"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i796d7c545dcd490c93f7b990f3264b66_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5ODM_bca24ae9-6138-41d0-ab66-f0fd2724ca7a"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i796d7c545dcd490c93f7b990f3264b66_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMjY_fa657085-1d63-46a7-ba41-46cab4dd72db"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1f8b79007ae445a3bfd27b69829de9a4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTk5ODc_bac15d09-6761-4166-8ef1-3ece1fb697a7"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1f8b79007ae445a3bfd27b69829de9a4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjAwMzA_806b2c00-4b9b-4041-b730-df4bcb901d3c"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i66e3e8a86c104591a0f8120347df1468_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjYzNTU_2b0ba957-6cd1-45e3-b67a-38db4ca8283d"
      unitRef="usd">500000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="id20d9ac4b58549aab5a3e792776164f4_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjY0NDg_5993a8c2-8778-4325-93ab-e0ee2677f1bb"
      unitRef="usd">2000000000.0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="if038f51729a24a2da8b265e610a51eee_D20190101-20191231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjY1OTU_4dbe97a1-afdd-49b6-87e2-8414524a0492"
      unitRef="usd">2750000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="i4137a356fc414084a24897805d41c93b_D20210101-20210131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0ODYwOTQ_47ea1fda-b873-4cc4-8c66-8957c5cd9007"
      unitRef="usd">1000000000.0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i8ca5a2ac1db347aeab2b0dc69d1d1bc0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzk4OA_d2264517-0e38-48ea-b58f-bc921eacabcf"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="i50551ba0e3694af9afb0a78f8b769781_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjQzMzA_bed51c8d-d892-4f35-b411-a223b706a563">P1M</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="ib2c456ffa7a147bbbcc6146cf6a5c52e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjQzMzc_723f1d90-8804-4de0-a427-0ac4b3dffd0d">P2Y</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="i362bd4a2c0a74dd5b55702363f9ac9ea_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwOTk1MTE2NjQ2MTc_b162327a-3337-4c02-bc54-a378be6b21bd">P2Y</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ib3b239e1b3ad417081b0cd98df44abaa_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE5ODA_589a8f04-8450-4e73-872f-1f3828e84ed7"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzEwNDQ1MzYwNDg3Nzk2_6c883aea-77a2-45fa-8c69-fee4c3b6e95f">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie106ddcf610645b9a3a7b3fe329ce835_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjI5NjI_2c3c8f8b-dd87-4a84-a785-14d0b5efb0d2"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9f85bd04d2e648e9b5df6a64f170cf3f_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjI5NzA_a10b7b64-6b26-4dfc-ac6b-434639191318"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i561ca9ac62a24c86b2e01e36240808fc_I20160531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NTEwNjk_bd633166-b012-4239-ac15-930aa9a8cfb8"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i48284e9ef26a4194b5c4901f6e5e4bc6_D20160531-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzI3NDg3NzkxMTUyNTI_b693dc59-1b66-498f-98a6-9638a2da1a7e">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="i204030d3773f4af78e0d6df4e9417215_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjM4MDg_16528239-6b78-4ecb-9fb5-9707d99ff9e3"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibdc7aa7015ec49fcb95e9effaeaa1a5b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjQxMTM_ea89a923-f35e-431f-aa66-2caba3c9d8b3"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i6aa41df238d34894bcd7a6ba42b01248_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzI3NDg3NzkxMTUyNTM_a8374cf0-13f8-4ad6-8f1f-72f0cafd4c85">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="ibdfdb0b6b6174cdaae4a05f26000ab2f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzE2NDkyNjc0NjM4MTc_4f3a3515-e83d-4a88-bdad-df1f5a1f822e"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM5MzA_6cd03020-f0c5-4d81-a978-bb9f171cd75e">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate future principal maturities of our senior unsecured notes and Term Loan Facility as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzEtMS0xLTEtMjU5MzA_7d1cac96-6c22-4ff7-9680-b085acdb4dac"
      unitRef="usd">2750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzItMS0xLTEtMjU5MzA_20f737dc-4087-4a9c-a4a5-a9a0844aaec9"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzMtMS0xLTEtMjU5MzA_f78dce10-b8c2-421b-a908-a4d3bf409568"
      unitRef="usd">4250000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzQtMS0xLTEtMjU5MzA_86f29fda-ce9c-481f-bd0c-09df525b81b3"
      unitRef="usd">1750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzUtMS0xLTEtMjU5MzA_e6dc365c-f36e-4d66-aa84-2a2614df888d"
      unitRef="usd">1750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzYtMS0xLTEtMjU5MzA_c86aa6a1-469c-4163-a785-2df2b7c51f96"
      unitRef="usd">18500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90YWJsZTplNGIxMTIyNzljNmY0YWMzYWQzYzY1MWE5YTUwYTdlOC90YWJsZXJhbmdlOmU0YjExMjI3OWM2ZjRhYzNhZDNjNjUxYTlhNTBhN2U4XzctMS0xLTEtMjU5MzA_4af035c7-b5c1-4a5a-be16-ba8d11bf99f1"
      unitRef="usd">30500000000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM4NDgyOTA3NDIzNjA_ff4ca8ec-de9a-4530-9ccf-57d183b6b209"
      unitRef="usd">994000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM4NDgyOTA3NDIzNjU_5c63abbf-a47a-4f78-8e93-b4acdcce0c8d"
      unitRef="usd">1000000000.0</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTEvZnJhZzoxZjlkMTI2YWE2ZjI0ZWFkYTFmNTAwMzdkNTI0OGUxMS90ZXh0cmVnaW9uOjFmOWQxMjZhYTZmMjRlYWRhMWY1MDAzN2Q1MjQ4ZTExXzM4NDgyOTA3NDIzNzM_63ef18ef-ccfa-46e0-8498-2175f6d11042"
      unitRef="usd">1100000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDM_5f1b970e-53d1-4465-8f55-275bce976458">LEASES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;amp;D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December&#160;31, 2020 and 2019, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $171 million and $162 million in 2020 and 2019, respectively. Operating lease expense under the prior lease accounting standard was $109 million in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balance sheet and other information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except weighted average amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703"&gt;Other long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other supplemental information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzU4OA_635ea2ec-8548-4e35-b2a4-93a86710d6d1">P15Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzY0Ng_b7c98600-ab5e-4c13-8d3a-5d3d83af291f">one year</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:OperatingLeaseExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzEzMjM_059adc3f-22b0-4ebf-9989-53b808fec419"
      unitRef="usd">171000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzEwOTk1MTE2MzA3MjM_7ec3542a-cb43-4f26-a77d-f4d81e1b7f07"
      unitRef="usd">162000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzEzOTY_3b6c619b-2a01-4152-b10f-8718905e518e"
      unitRef="usd">109000000</us-gaap:LeaseAndRentalExpense>
    <gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDQ_03349fd1-c22f-4ad2-aa48-dbb5e46da0c5">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balance sheet and other information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except weighted average amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703"&gt;Other long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzEtNC0xLTEtMA_6f2a21c3-08d0-418a-bfce-94904c522d5b"
      unitRef="usd">646000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzItNi0xLTEtNTMyMw_cc426cc8-a4c1-4650-8a41-9c57e425534d"
      unitRef="usd">668000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzItNC0xLTEtMA_ec3a94d5-8130-41bb-acbf-8dbf93271e62"
      unitRef="usd">107000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtNi0xLTEtNTMzMA_56340a10-9a49-492a-9987-0290d0b926f6"
      unitRef="usd">99000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtNC0xLTEtMA_db8fd0f2-5a35-40ea-8132-531618a0ec75"
      unitRef="usd">608000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzQtNi0xLTEtNTMzMA_3a51ff1b-1b28-46e6-b027-119706482e66"
      unitRef="usd">626000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzQtNC0xLTEtMA_8cc67176-b04c-4d54-b8e5-20e7c31dee40">P8Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzUtNi0xLTEtNTMzNg_9e233c57-b578-4eac-b847-62f988284453">P8Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzUtNC0xLTEtMA_d5a41399-22b2-4587-ac5b-def3fe0d6bb8"
      unitRef="number">0.0332</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzYtNi0xLTEtNTMzNg_b78b1ce6-83c7-40c9-a6de-1d2710fe127c"
      unitRef="number">0.0347</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDU_cdacdd1e-7da8-4c04-97d7-4517dc4432ed">&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other supplemental information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzItMi0xLTEtMA_7c217443-5622-42b0-926d-63bdd1b2944f"
      unitRef="usd">66000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzItNC0xLTEtNTMxMg_fb52b9cd-7caf-44aa-91eb-7abb32d95300"
      unitRef="usd">66000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzMtMi0xLTEtMA_ef6508a5-0747-4b36-8cc7-0d139c91a286"
      unitRef="usd">88000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTpkODkzZmNlZTlmN2E0YmFhYjc0MGU2Mzc5ODIyNTg5Mi90YWJsZXJhbmdlOmQ4OTNmY2VlOWY3YTRiYWFiNzQwZTYzNzk4MjI1ODkyXzMtNC0xLTEtNTMxMg_3b494136-9615-4da5-ab1f-9416d780bdfc"
      unitRef="usd">313000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90ZXh0cmVnaW9uOmMzNWNhNWNlMTNhYzRhNGE4MWViMWYxOTFlNTJmNTZmXzIwNDY_f721b988-bbf3-43a0-a6d2-b2ffdb1e2ffb">&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzEtMi0xLTEtMA_abca38f3-020a-4883-942f-323cbc5e7593"
      unitRef="usd">127000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzItMi0xLTEtMA_8fa3fe90-aca5-4939-950c-67126a891842"
      unitRef="usd">122000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzMtMi0xLTEtMA_570c8aec-ce66-419d-b0e8-ed28df54718b"
      unitRef="usd">112000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzQtMi0xLTEtMA_f59fad2c-867a-4b6a-ac87-df175ced4397"
      unitRef="usd">97000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzUtMi0xLTEtMA_bf74d463-af4f-4389-b03e-73ef2b2b0f91"
      unitRef="usd">70000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzYtMi0xLTEtMA_a88ab244-76ad-4e60-bea8-c3f03c814381"
      unitRef="usd">300000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzctMi0xLTEtMA_3ac03fb5-9131-432d-aadf-5c03392eca78"
      unitRef="usd">828000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzgtMi0xLTEtMA_b1019544-581b-4b99-927d-76f84d5331f8"
      unitRef="usd">113000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTozYzNhNDdiNTlkNTQ0MDE5YTEyZmIxZDExZjA1YjhiNi90YWJsZXJhbmdlOjNjM2E0N2I1OWQ1NDQwMTlhMTJmYjFkMTFmMDViOGI2XzktMi0xLTEtMA_b83d28bf-ed3f-4a79-a773-294fa5d5fae2"
      unitRef="usd">715000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIzMDg0_07f44a9e-6b79-48fb-acc2-8a82124f4d13">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. It is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any material accruals for the matters described below in our Consolidated Balance Sheets as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with Idenix Pharmaceuticals, Inc. (&#x201c;Idenix&#x201d;), Universita Degli Studi di Cagliari (&#x201c;UDSG&#x201d;), Centre National de la Recherche Scientifique and L&#x2019;Universit&#xe9; Montpellier II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013, Idenix, UDSG, Centre National de la Recherche Scientifique and L&#x2019;Universit&#xe9; Montpellier II sued us in the U.S. District Court for the District of Delaware alleging that the commercialization of sofosbuvir infringes U.S. Patent No. 7,608,600 (the &#x201c;&#x2019;600 patent&#x201d;). We prevailed at all phases of litigation concerning the &#x2019;600 patent, and in 2018, the U.S. Supreme Court denied Idenix&#x2019;s petition for certiorari. Also in 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the &#x201c;&#x2019;054 patent&#x201d;) and 7,608,597 (the &#x201c;&#x2019;597 patent&#x201d;). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the &#x2019;054 patent related to sofosbuvir and withdrew that patent from the trial. A jury trial was held in 2016 on the &#x2019;597 patent, and the jury found that we willfully infringed the asserted claims of the &#x2019;597 patent and awarded Idenix $2.54&#160;billion in past damages. In 2018, the judge invalidated Idenix&#x2019;s &#x2019;597 patent and vacated the jury&#x2019;s award of $2.54&#160;billion in past damages. Idenix appealed this decision to the U.S. Court of Appeals for the Federal Circuit (&#x201c;CAFC&#x201d;), and in October 2019, the CAFC issued an opinion affirming the trial court&#x2019;s decision that the &#x2019;597 patent is invalid. In April 2020, the CAFC denied Idenix&#x2019;s petition for rehearing en banc. In January 2021, the U.S. Supreme Court denied Idenix&#x2019;s petition for review, making the judgment against Idenix final. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and has scheduled a merits hearing for February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated, which we expect will occur in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Axicabtagene Ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#x201c;Juno&#x201d;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#x201c;&#x2019;190 patent&#x201d;). A jury trial was held on the &#x2019;190 patent, and in December 2019, the jury found that the asserted claims of the &#x2019;190 patent were valid, and that we willfully infringed the asserted claims of the &#x2019;190 patent. The jury also awarded Juno damages in amounts of $585&#160;million in an up-front payment and a 27.6% running royalty from October 2017 through the date of the jury&#x2019;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#x2019;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing whether we should accrue a liability for this litigation in our Consolidated Financial Statements, we considered various factors, including the legal and factual circumstances of the case, the jury&#x2019;s verdict, the district court&#x2019;s pre- and post-trial orders, the current status of the proceedings, applicable law, the views of legal counsel and the likelihood that the judgment will be upheld on appeal. As a result of this review, we have determined, in accordance with applicable accounting standards, that it is not probable that we will incur a material loss as a result of this litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the judgment is reversed on appeal, the loss is expected to be zero. If the judgment is upheld in its entirety on appeal, we estimate a loss through the fourth quarter of 2020 to be approximately $1.4&#160;billion, which consists primarily of (i) approximately $811&#160;million, which represents damages on Yescarta revenues through December 12, 2019, and prejudgment interest thereon, (ii) approximately $389&#160;million, which represents a 50% enhancement of past damages and (iii) approximately&lt;/span&gt;&lt;span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$172&#160;million for royalties on Yescarta revenues from December 13, 2019 to December 31, 2020. The estimated loss does not include post-judgment interest on the foregoing, which is not estimated to be material as of December 31, 2020. Although we cannot predict with certainty the ultimate outcome of this litigation on appeal, we believe the jury&#x2019;s verdict and the judgment to be in error. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Related to Bictegravir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV Healthcare Company (&#x201c;ViiV&#x201d;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#x2019;s U.S. Patent No. 8,129,385 (the &#x201c;&#x2019;385 patent&#x201d;) covering ViiV&#x2019;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the sole asserted claim of the &#x2019;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#x2019;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $11.46&#160;billion through December 31, 2020. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#x2019;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#x2019;s Canadian Patent No. 2,606,282 (the &#x201c;&#x2019;282 patent&#x201d;), which was issued to Shionogi &amp;amp; Co. Ltd. and ViiV. The &#x2019;282 patent is the compound patent covering ViiV&#x2019;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#x2019;282 patent. In January 2020, the court held a summary trial to assess ViiV&#x2019;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#x2019;282 patent and dismissed the case. ViiV has appealed this decision. Argument on the appeal is expected to take place later in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#x201c;EP &#x2019;206&#x201d;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#x201c;KR &#x2019;819&#x201d;) and 1363875. These patents all relate to molecules which ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#x2019;s patents. In 2019, we filed an opposition in the European Patent Office (&#x201c;EPO&#x201d;) requesting revocation of EP &#x2019;206. The EPO hearing is scheduled for 2021. In 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#x2019;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#x2019;819 to be invalid. ViiV may appeal this decision. The court in Germany has scheduled a hearing on the issue of infringement in April 2021. In all jurisdictions, to the extent that the claims of ViiV&#x2019;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and a clinical trial agreement (&#x201c;CTA&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the District Court of Delaware has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#x201c;generic manufacturers&#x201d;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#x201c;TAF&#x201d;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing is scheduled for July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing is scheduled for March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigations and Related Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2011, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Northern District of California requesting documents related to the manufacture, quality and distribution practices of Complera, Atripla, Truvada, Viread, Emtriva, Hepsera and Letairis. We cooperated with the government&#x2019;s inquiry. In 2014, the U.S. Department of Justice informed us that it had declined to intervene in a False Claims Act lawsuit filed by two former employees. In 2019, the District Court granted the Department of Justice&#x2019;s motion to dismiss plaintiffs&#x2019; federal claims. In April 2020, plaintiffs refiled their California False Claims Act and California retaliation claims in the Superior Court of California, County of San Mateo. In July 2020, the California Attorney General declined to intervene in the case, and the state court complaint was unsealed. In September 2020, we filed a demurrer requesting that the Superior Court dismiss plaintiffs&#x2019; claims, which was overruled in November 2020. We have sought an appeal of the Superior Court&#x2019;s order overruling our demurrer. Although we cannot predict the ultimate outcome of this lawsuit, we believe the action is without merit and we intend to vigorously defend against it.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a voluntary request for information from the U.S. Attorney&#x2019;s Office for the Eastern District of Pennsylvania requesting information related to our reimbursement support offerings, clinical education programs and interactions with specialty pharmacies for Sovaldi and Harvoni. In 2018, we received another voluntary request for information related to our speaker programs and advisory boards for our HCV and HBV products. In October 2019, the government informed us that, following its investigation, it declined to intervene in two False Claims Act lawsuits against us. Notwithstanding the government&#x2019;s declination, relators have continued to pursue the lawsuit relating to HBV speaker programs and advisory boards and served us with the Second Amended Complaint in November 2019. In December 2020, the lawsuit relating to HCV sales and marketing issues was unsealed. The relator has indicated that he intends to pursue the case against Gilead. Although we cannot predict the ultimate outcome of these lawsuits, we believe the actions are without merit and we intend to vigorously defend against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we also received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, Health Choice Advocates, LLC (&#x201c;Health Choice Advocates&#x201d;) filed a qui tam lawsuit against us under seal in New Jersey state court alleging violations of the New Jersey False Claims Act through our clinical education programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In July 2020, the New Jersey Attorney General&#x2019;s Office declined to intervene in the lawsuit and the complaint was unsealed. In May 2020, Health Choice Advocates filed a qui tam lawsuit under seal against us in Texas state court making similar allegations under the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;). This lawsuit seeks all available relief under the TMFPA. In October 2020, the Texas Attorney General&#x2019;s Office declined to intervene in the lawsuit and the complaint was unsealed. Health Choice Advocates previously filed a lawsuit making similar allegations under the federal False Claims Act and various state False Claims Acts, including the TMFPA, in federal court in the Eastern District of Texas in June 2017 and the court entered an order dismissing that matter without prejudice in July 2018. Although we cannot predict the ultimate outcome of these lawsuits, we believe these actions are without merit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in two class action lawsuits and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, New Jersey and Missouri, involve more than 21,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We (along with Japan Tobacco, BMS and Johnson &amp;amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#x2019; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been or may be consolidated, are all pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesales, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (&#x201c;Cipla&#x201d;) were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs seek damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019. The lawsuits were consolidated in September 2019, and plaintiffs filed a consolidated complaint in November 2019. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the United States District Court for the District of New Jersey. In January 2020, Immunomedics filed a motion to dismiss the consolidated complaint, which was denied in July 2020. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Commitments &lt;/span&gt;&lt;/div&gt;In the normal course of business, we enter into various firm purchase commitments primarily related to active pharmaceutical ingredients (&#x201c;API&#x201d;) and certain inventory related items. As of December&#160;31, 2020, these commitments for the next five years were approximately $1.2 billion in 2021, $486 million in 2022, $192 million in 2023, $70 million in 2024 and $55 million in 2025. The amounts related to API represent minimum purchase commitments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i919f90af93194b0f8ce1c1dfb232c4eb_D20161201-20161231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzNjA_3a760e54-75d5-487b-913c-dd938e98acb2"
      unitRef="usd">2540000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:LossContingencyMotionInvalidatedForPastDamagesValue
      contextRef="if9f82513a9f94dd7a549cc436cc58d8c_D20180101-20181231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzNDU_eafae0ee-f32f-4b90-865d-657f3e9a036a"
      unitRef="usd">2540000000</gild:LossContingencyMotionInvalidatedForPastDamagesValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i5f7210bf9b704da3b00654f5387c8418_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzNzU_355cacd5-2ae3-4837-9b87-e079fc55c8b5"
      unitRef="usd">585000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:JudgmentRoyaltyRateFromOctober2017
      contextRef="i5f7210bf9b704da3b00654f5387c8418_D20191201-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzODk_7bb10bd5-ea9d-42cd-a2b0-3fdd22bc6354"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateFromOctober2017>
    <gild:JudgmentEnhancedDamagesonPastSales
      contextRef="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTEzOTY_5554ffce-bd85-4047-8ec0-c26200428cdf"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesonPastSales>
    <gild:JudgmentRoyaltyRateOnFutureSales
      contextRef="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MDE_dc2c8dc8-f580-4c73-93cb-6d1ecf7694fd"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateOnFutureSales>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="id4a501179a0c4d10a7471e189ee30e56_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0NzQ_a9e45729-0381-4ea0-8e84-bb98ec10011b"
      unitRef="usd">0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ieed6db4dd53c4a86afcc8c65e474d496_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MDg_fbf69962-5a80-47ce-bf07-2bd0bfdfa8ef"
      unitRef="usd">1400000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <gild:LossContingencyEstimateofPossibleLossPastSales
      contextRef="i844383cc25214e31ad2596ee61b72eee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MjI_671d7433-7618-41be-872e-9c386f5eef7f"
      unitRef="usd">811000000</gild:LossContingencyEstimateofPossibleLossPastSales>
    <gild:LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages
      contextRef="i844383cc25214e31ad2596ee61b72eee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0MzY_77044f10-b1af-4749-873f-7d091111cc4c"
      unitRef="usd">389000000</gild:LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages>
    <gild:JudgmentEnhancedDamagesonPastSales
      contextRef="i5378ac74bc8f46c7af53c5450ed2b36e_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzMyOTg1MzUxMDUzODQ_5554ffce-bd85-4047-8ec0-c26200428cdf"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesonPastSales>
    <gild:LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest
      contextRef="i844383cc25214e31ad2596ee61b72eee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0NTU_da980250-0059-491e-a7da-9d4e22ad2a3a"
      unitRef="usd">172000000</gild:LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ia4281b1de2ca446dacc33382d882ca0a_D20180207-20201231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE2NDk_06b072f0-f588-42d9-b03a-5c70910d3139"
      unitRef="usd">11460000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzI3NDg3NzkyOTE0ODA_3580033e-e63e-4907-a91b-356da922412a"
      unitRef="plaintiff">21000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary
      contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzIy_230374c4-46e2-4d2b-936f-28d57dc32e0c"
      unitRef="usd">1200000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary
      contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzMy_62a394a5-63d4-4ba6-9610-4caf19c0d840"
      unitRef="usd">486000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary
      contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzQy_77d8adb4-c8a0-4739-8a7f-b00dc64705d8"
      unitRef="usd">192000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary
      contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzUy_59b79af4-eefb-4bd5-bd11-78d4be8d5f36"
      unitRef="usd">70000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary
      contextRef="ie2902027c39a417f91f8f33f93f2f77c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjAvZnJhZzoxZDFmMDJkZjY0ZWM0ZGZmYTI1ODNkNTYyMWMzZWUzZi90ZXh0cmVnaW9uOjFkMWYwMmRmNjRlYzRkZmZhMjU4M2Q1NjIxYzNlZTNmXzIyNzY1_5ff7350b-bd91-4211-80ff-1f8e1d5432eb"
      unitRef="usd">55000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwODA_97d0c7b5-9b41-49c9-a5b3-dff2f9f51b27">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#x201c;2016 Program&#x201d;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#x201c;2020 Program&#x201d;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the remaining authorized repurchase amount from both programs was $6.8 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases under the 2016 Program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to repurchases from the 2016 Program and 2020 Program, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations, which are immaterial and excluded from the table above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital (&#x201c;APIC&#x201d;) based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash dividends declared on our common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our restricted stock and performance share awards or units have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;4, 2021, we announced that our Board of Directors declared a quarterly cash dividend of $0.71 per share of our common stock, with a payment date of March&#160;30, 2021 to all stockholders of record as of the close of business on March&#160;15, 2021. Future dividends are subject to declaration by our Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 5 million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was no preferred stock outstanding as of December&#160;31, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net, on our Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for the periods presented.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i676b993c500e4814bfc126d01c700bce_I20160331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzEwNQ_691f4df7-b65f-41c7-beb1-60d6bf78ea0e"
      unitRef="usd">12000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ib489d1a178c64897a715f8a20a2aa447_I20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzEwOTk1MTE2MzE2NDM_a9581861-21e6-4aa7-bc9d-50d66dd73b67"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMyNA_0f6ebc07-74f6-4b57-aa66-0492353699c3"
      unitRef="usd">6800000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwNzI_aa6b1b74-927c-4ac8-8445-f2fa4861ddcc">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases under the 2016 Program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2d9aac36dbf242fbbc1e60f05511aa07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzItMi0xLTEtMA_867bfe99-2888-43c4-b145-5cfa03bc1c38"
      unitRef="shares">22000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ia4830709842f45418b3c333d24ffd5a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzItNC0xLTEtMA_ad6ac2d0-74ce-4aa0-9cb0-a26fef06c78f"
      unitRef="shares">26000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i9b6402e854a642ccaecbd191f676e641_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzItNi0xLTEtMA_624daac9-9fa9-4a49-a262-75a7c23f3d8b"
      unitRef="shares">40000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzMtMi0xLTEtMA_4a1b87fb-6fce-4274-bdaf-6a9763f34480"
      unitRef="usd">1583000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzMtNC0xLTEtMA_368f1f02-3866-4940-a9d5-352a3cbad66a"
      unitRef="usd">1749000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzMtNi0xLTEtMA_7dbbd340-10c5-4c74-a6d1-a51a6440499d"
      unitRef="usd">2900000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzQtMi0xLTEtMA_8d5d42c7-1a7d-4aef-ad35-739d60242b11"
      unitRef="usdPerShare">70.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzQtNC0xLTEtMA_57d28c10-3322-4875-a95c-d6f69f9f0756"
      unitRef="usdPerShare">66.36</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTowOTJjNGUzNGZjZTc0NTBhOTRjYTFkOTM1YTA5OWRmYS90YWJsZXJhbmdlOjA5MmM0ZTM0ZmNlNzQ1MGE5NGNhMWQ5MzVhMDk5ZGZhXzQtNi0xLTEtMA_f730b624-4ad1-40ba-a774-5f33ad0580c7"
      unitRef="usdPerShare">72.95</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwNDQ_0720659e-1bc9-4bcb-b429-1683c6e48657">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash dividends declared on our common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItMi0xLTEtMA_82e35860-830f-4d73-aec4-f4ad60026055"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItNC0xLTEtMA_f3105e85-41a7-40a8-aded-004440464b77"
      unitRef="usd">867000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItNi0xLTEtMA_15333856-a193-4f94-88af-3eb07a4f93fe"
      unitRef="usdPerShare">0.63</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzItOC0xLTEtMA_e027c968-cd22-4322-a930-74ef955c8dec"
      unitRef="usd">814000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtMi0xLTEtMA_125bb56b-7f44-406a-9ad2-5892829bb5f6"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtNC0xLTEtMA_943b7bbd-6f0b-49f1-bbba-09621c0b4fa2"
      unitRef="usd">866000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtNi0xLTEtMA_83c9bf9f-d8ca-4cb4-be74-84a8bdce74aa"
      unitRef="usdPerShare">0.63</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzMtOC0xLTEtMA_ab5270ee-cc2f-4386-a49d-d4acc415a443"
      unitRef="usd">810000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtMi0xLTEtMA_600e3687-fe36-4d4c-a6b5-f66284c0ada0"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtNC0xLTEtMA_5d5d2334-111e-48e7-941d-507a0d9167a6"
      unitRef="usd">866000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtNi0xLTEtMA_0788ac66-42f6-4a25-91e9-072fce736fbd"
      unitRef="usdPerShare">0.63</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzQtOC0xLTEtMA_933e2b2f-7444-4d32-9dfa-f7124d1a4adc"
      unitRef="usd">807000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtMi0xLTEtMA_8e057370-d0fd-4a25-8df5-160aafd8971b"
      unitRef="usdPerShare">0.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtNC0xLTEtMA_0a81ac1b-4d83-4253-afd4-7e7bea30255e"
      unitRef="usd">865000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtNi0xLTEtMA_0c85d9e0-3b72-4529-8e5f-8b49d9769cfd"
      unitRef="usdPerShare">0.63</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzUtOC0xLTEtMA_ef25000b-0dfa-47f6-a71f-6e7f644a704f"
      unitRef="usd">808000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtMi0xLTEtMA_8f593842-fb9b-472b-964f-97769f68c008"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtNC0xLTEtMA_f3dbf4fa-6368-45b5-95fd-63c50f5390b4"
      unitRef="usd">3464000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtNi0xLTEtMA_bdc2f86b-ad78-4b6b-87b6-e994fc671513"
      unitRef="usdPerShare">2.52</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo5M2NjZTQ3ZmNhMTA0ZThmOTY4Y2U4Njg1MmI4YzE0ZC90YWJsZXJhbmdlOjkzY2NlNDdmY2ExMDRlOGY5NjhjZTg2ODUyYjhjMTRkXzYtOC0xLTEtMA_9697ae6f-6e0f-4943-a4ee-dcd92f2990cc"
      unitRef="usd">3239000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib10c7000f4c647a2b89591cb924c9b7e_D20210204-20210204"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzE5NDQ_059a2d88-32cf-4342-9e71-fa3c450c39fa"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzIxNjU_d6ff3117-b2c4-4818-96df-c46a9ddec216"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzIzNDA_1658bf10-4dff-4c4a-b87b-49b3e8d622ac"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzIzNDA_27bb08b5-c97b-48ed-a779-11da0a3abbb3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90ZXh0cmVnaW9uOmNhNGVjNDAzZTY3MjQ3Mjk4NzE1ZDZhZDI3MThhMGM3XzMwNzY_87c49297-7b8b-4895-9a12-dc5e537b2803">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in AOCI by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="i80decbd404fa4810a481f263b6dbbc28_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtMi0xLTEtMA_e3a5dafd-0628-4c1f-903d-2aec40a01243"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="i3d477cb7874f4bfd96a09be4ca3fd0c7_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtNC0xLTEtMA_57c3094c-9ef0-4938-aab8-66ab46f69731"
      unitRef="usd">-99000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="i6040cf00a6f04094a6d26c4f32df7e7c_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtNi0xLTEtMA_9993b041-d839-4035-aa8d-0c5c67f453ab"
      unitRef="usd">-114000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
      contextRef="i6f6356b044964174974ec7dc3f4bbd36_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzMtOC0xLTEtMA_36ac4789-02eb-4fea-9aeb-06c21d4c2b2d"
      unitRef="usd">-128000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i14ff8312abf74fc68d269603e3776270_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtMi0xLTEtMA_d5cbd1f9-b026-499a-ac0e-76141b67ba0e"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtNC0xLTEtMA_a37bea47-8486-4608-a019-d4d0b6b7928d"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtNi0xLTEtMA_2c554d25-af51-43a0-9b36-0ef23deab93d"
      unitRef="usd">112000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzQtOC0xLTEtMA_b831e12d-3913-4c0d-90d3-96c17cace769"
      unitRef="usd">117000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i14ff8312abf74fc68d269603e3776270_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtMi0xLTEtMA_6283c079-c6b5-4e47-915b-b8f4a474155d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtNC0xLTEtMA_168f2504-a4a8-4959-9b56-90a709717cea"
      unitRef="usd">-4000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtNi0xLTEtMA_873eae28-6deb-4af7-88d8-fe3ad6140a22"
      unitRef="usd">-87000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzUtOC0xLTEtMA_4473f5b1-be98-4dea-be2f-811739a3ea7a"
      unitRef="usd">-91000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i14ff8312abf74fc68d269603e3776270_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtMi0xLTEtMA_e6dd996d-7dfc-490c-848e-9a3a72c3a7dd"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i75edc459429c4da1822e6dcb60d4556b_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtNC0xLTEtMA_f9087775-d403-4a1a-9c0a-965771489b57"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60cb26a484ff403d819e0e6be96caa29_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtNi0xLTEtMA_4de48bcd-0739-43b1-b61b-c133f0c87524"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i18efd47d66c04e36a41a22e5fdc079a6_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzYtOC0xLTEtMA_86d9676c-56c9-4c25-a79e-9b8b4a1ab82f"
      unitRef="usd">208000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib99fd8d434aa478fa9b18fec33d3e230_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctMi0xLTEtMA_33385067-9365-46a9-b723-10c10f98b037"
      unitRef="usd">47000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb3593a4df8f4b348d04321ee946cf2a_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctNC0xLTEtMA_d5113b64-9669-4008-aee8-be50185f492e"
      unitRef="usd">-52000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5468af7521ac455985434b5f19b7bbb9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctNi0xLTEtMA_15ea493b-e0d3-49ec-8708-4462d122c1e5"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54dde75a77af4f3b89a86ac2a4228e70_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzctOC0xLTEtMA_d143b9e1-a104-42fb-9281-3da0a4987b47"
      unitRef="usd">80000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i1fecafa85db046288d32b5acb380096d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtMi0xLTEtMA_e0b31f5e-fb6c-40f1-900c-0a20f2266366"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtNC0xLTEtMA_15abe48f-7b10-426f-8e14-be4742e983e0"
      unitRef="usd">54000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtNi0xLTEtMA_beaf69ac-492f-432d-8aa3-d7447de6a82e"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzgtOC0xLTEtMA_320bf6fa-d0eb-4545-b9be-1b8d3bdc163c"
      unitRef="usd">132000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i1fecafa85db046288d32b5acb380096d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktMi0xLTEtMA_3b303164-5261-4d35-8363-1b770d8f87a8"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktNC0xLTEtMA_978d0640-4f4f-4742-a8e8-bf4a9a4a19e4"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktNi0xLTEtMA_41657835-21e5-4a41-aa27-ff69bed0f91a"
      unitRef="usd">126000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzktOC0xLTEtMA_865efbe1-b538-4297-aff3-fada865a04b4"
      unitRef="usd">127000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1fecafa85db046288d32b5acb380096d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTItMS0xLTA_d9bca810-a6f8-489c-a47f-68d6099847d3"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe255e4c84034ad9b41553d694a7cdba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTQtMS0xLTA_b18eba03-b854-44fd-98c0-c56104232185"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7651b777b2fe444f81f3cb3df75bc8ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTYtMS0xLTA_d7871301-43cf-4da6-9429-ab1631809469"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b0aee4dc51448af8baab758df6520c3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEwLTgtMS0xLTA_8cd999d4-bb55-4df6-91a7-7a5d8baa6e94"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ed215bd7b494fbe89f89a8b6e2b2a64_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTItMS0xLTA_db3919f9-6c7a-4374-a7af-b6ea45e1f392"
      unitRef="usd">53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5707d2a1fdef4bd29d50dcedf69cf5db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTQtMS0xLTA_b35ca758-5907-4698-9428-fc6b2f16e100"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cf73804142f4a5a8699854aa476d33f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTYtMS0xLTA_c354c3de-8182-456c-817b-5c114c0b6fd9"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8823d4c8e7b94b01a4ee9918a81621f1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzExLTgtMS0xLTA_826be518-d19c-47b0-9258-5bdcdb39e69f"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTItMS0xLTY1MDg_c7a12aca-93f9-45f3-beca-40e6948f52fa"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7f513a45782a4d148af987a580b897fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTQtMS0xLTY1MDg_fa31006e-1a08-4571-871f-3b9910539525"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTYtMS0xLTY1MDg_21bbb94c-9a81-401b-a612-62794df4feaf"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEyLTgtMS0xLTY1MDg_84ddf5e6-779f-4495-b5a1-3068b8f7befb"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTItMS0xLTY1MDg_d0f140b7-9037-4349-91f7-38f8f50623b8"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7f513a45782a4d148af987a580b897fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTQtMS0xLTY1MDg_c399bc48-6891-4624-a5bc-52a8dd349cca"
      unitRef="usd">42000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTYtMS0xLTY1MDg_a9ffef43-0c88-44b6-909c-6806bc53fe0f"
      unitRef="usd">41000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzEzLTgtMS0xLTY1MDg_d5214fa8-2614-44c2-9aa6-e55e6360b110"
      unitRef="usd">83000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8feae765b9bc411ca7584a583e089b06_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTItMS0xLTY1MDg_fa620d3b-eb42-4e04-8a5d-5e972482262e"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7f513a45782a4d148af987a580b897fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTQtMS0xLTY1MDg_4b4c7253-dc00-41e1-a389-eb077f5a9a67"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4ca0390a48ba4d94a7d1d947d947f0f9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTYtMS0xLTY1MDg_6e6da711-74a8-439c-ba68-2b247efde319"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8bd8e048c21426ea4fef76dba14833e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE0LTgtMS0xLTY1MDg_4e27243a-5b11-42e4-bb2b-27bd1f7e66bf"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81b95bfbb00a4bee81e1cd96a5d51ca7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTItMS0xLTY1MDg_57f47bb1-9b5e-413c-b38b-f87a85dd7c31"
      unitRef="usd">51000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3903462c6c24250b51ed2304b4c2329_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTQtMS0xLTY1MDg_fd1b512f-e126-48a2-8f5e-17e9b01d164f"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8565010ef19410480a12c5243b09982_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTYtMS0xLTY1MDg_93a5b291-a5ce-4bf9-bde0-b9068ca4baea"
      unitRef="usd">-113000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a5ad62f62cb4ef6968f09d3363ab76e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjYvZnJhZzpjYTRlYzQwM2U2NzI0NzI5ODcxNWQ2YWQyNzE4YTBjNy90YWJsZTo1ZmMwMGUwMTE4OWY0OTc5OGNlYTdjMDI5NzgzYjRhZi90YWJsZXJhbmdlOjVmYzAwZTAxMTg5ZjQ5Nzk4Y2VhN2MwMjk3ODNiNGFmXzE1LTgtMS0xLTY1MDg_f9b58984-3e33-4f5d-bb1a-afc710d63ae3"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NjQ_a9714988-b8e4-4970-8dd9-a31d6503ff2d">EMPLOYEE BENEFITS &lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#x201c;RSU&#x201d;s), performance share awards or units (&#x201c;PSU&#x201d;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, estimated fair value is based on either the Monte Carlo valuation methodology or the stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#x201c;2004 Plan&#x201d;). The 2004 Plan authorized the issuance of a total of 309 million&#160;shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the Forty Seven acquisition, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#x201c;2018 Plan&#x201d;). The aggregate amount of shares that may be issued under the 2018 Plan on or after the assumption date will not exceed 12&#160;million shares. As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan (the &#x201c;Immunomedics Plan&#x201d; and referred together with the 2004 Plan and 2018 Plan as the &#x201c;Plans&#x201d;), which we subsequently merged into the 2004 Plan. The aggregate amount of shares that may be issued under the Immunomedics Plan on or after the assumption date will not exceed 26&#160;million shares. See Note 6. Acquisitions for additional information on the settlement of stock awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plans are broad based incentive plans that provide for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. As of December&#160;31, 2020, a total of 96&#160;million shares remain available for future grant under the Plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plans provide for option grants designated as either non-qualified or incentive stock options. All stock options granted after January&#160;1, 2006 have been non-qualified stock options. Employee stock options generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0Nzg_3e0bf107-df4c-42b5-99e9-a7dcf78020b1"&gt;three&lt;/span&gt; or four years. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the Plans&#x2019; previously authorized and available pool of shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt; Intrinsic &lt;br/&gt;Value &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest, net of estimated forfeitures at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $179 million for 2020, $209 million for 2019 and $412 million for 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of the stock options granted was $11.69 per share for 2020, $12.15 per share for 2019 and $17.03 per share for 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $55 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock and Performance Share Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNjQ_4b3408a6-98fc-4b69-98be-510a6fbd1b22"&gt;three&lt;/span&gt; or four years from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDA_af92dcc3-2fe4-41b3-aed3-392d48d636df"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDU_17e1fc1d-af04-402c-9a3d-30ce2e48473b"&gt;two&lt;/span&gt; year period. The fair value of such an award is equal to the closing price of our common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs granted was $70.94 per share for 2020, $64.31 per share for 2019, and $77.98 per share for 2018. The weighted-average grant date fair value of PSUs granted was $83.64 per share for 2020, $68.30 per share for 2019, and $88.76 per share for 2018. The total grant date fair value of our vested RSUs and PSUs was $479 million for 2020, $450 million for 2019 and $481 million for 2018, and total fair value as of the respective vesting dates was $459 million for 2020, $372 million for 2019 and $446 million for 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $860 million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the ESPP), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP&#x2019;s previously authorized and available pool of shares. During 2020, 2 million shares were issued under the ESPP for $100 million. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 7 million shares available for issuance under the ESPP as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1,076&#160;million included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altera Corp v. Commissioner&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.&lt;/span&gt;&lt;span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of options granted under our 2004 Plan and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. We used the following assumptions to calculate the estimated fair value of the awards: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $144 million during 2020, $110 million during 2019 and $91 million during 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $218 million as of December&#160;31, 2020 and $171 million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic2f11fdc536f400994934dad7faee301_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExMTY_ace01837-0b38-4bf5-afce-195bfadae1e0"
      unitRef="shares">309000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iade23e2d742345dd981025a2118869e5_I20200407"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwMDI_a13c4216-efd7-4d5d-afc4-7b77d6b7ebfe"
      unitRef="shares">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i86b3338567b348fd91d9138a1c4c1f6d_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwMTQ_3533a2fe-20df-4231-8dbb-bdf254cc6b0a"
      unitRef="shares">26000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic2f11fdc536f400994934dad7faee301_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA3MzE2_dbf9cc49-e091-4962-8137-a674be1a7942"
      unitRef="shares">96000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i75d7b35235ad4232b8705dbc79802f56_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0ODQ_f3b9f600-9d4e-4133-beaf-890fa54c7e40">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE1Njg_fc883cbf-5c5c-4d4d-8f98-c877f3616dcb">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1Mzg_5056c96f-da46-4d1a-afe6-0e3bd4747eff">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual Term &lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt; Intrinsic &lt;br/&gt;Value &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest, net of estimated forfeitures at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i60943a7163f448b5a6c2157080ad7985_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzEtMi0xLTEtMA_9a0102e9-83bf-4bcd-beb1-cb32c90c7ac6"
      unitRef="shares">19500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i60943a7163f448b5a6c2157080ad7985_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzEtNC0xLTEtMA_1fdd41b1-d459-4e67-a5ae-66f32d8c6867"
      unitRef="usdPerShare">61.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzItMi0xLTEtMA_7b37f512-1cd3-4465-bc4a-0cf72d14b646"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzItNC0xLTEtMA_f1ba7e92-392c-43a3-852c-bb907512f07d"
      unitRef="usdPerShare">71.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzMtMi0xLTEtMA_89e8a1b3-0da8-421f-a904-da7b0ffdaf06"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzMtNC0xLTEtMA_d3442a08-a201-4ccb-8b3b-ea852e6ec8c0"
      unitRef="usdPerShare">72.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzQtMi0xLTEtMA_99410ee4-e36e-4a3a-b308-6f80f920090f"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzQtNC0xLTEtMA_22e5fe5d-fca9-4981-b493-d8cd78a26656"
      unitRef="usdPerShare">81.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzUtMi0xLTEtMA_20e213f5-b486-48c7-9312-445924470627"
      unitRef="shares">4600000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzUtNC0xLTEtMA_a3a1b5b0-14eb-40f3-a3ad-d901fd807cb8"
      unitRef="usdPerShare">34.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtMi0xLTEtMA_c83088bc-9855-468c-9eb6-350d9c016d27"
      unitRef="shares">16600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtNC0xLTEtMA_4933cbe2-1fee-4504-b7f8-fcc407a5532b"
      unitRef="usdPerShare">69.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtNi0xLTEtMA_abf9c6c0-ecaa-42ff-b3c5-d0bcebf30454">P5Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzYtOC0xLTEtMA_719c3b45-caef-4a81-9414-1d8dcd741f3f"
      unitRef="usd">70000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctMi0xLTEtMA_4b3fe57f-14e2-44c5-8ff9-68ff758b79f9"
      unitRef="shares">11600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctNC0xLTEtMA_450337a6-8fb7-4982-bb7a-811a931c8bfb"
      unitRef="usdPerShare">68.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctNi0xLTEtMA_5828aa95-ce04-41f7-aad2-a72e0e5b099b">P3Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzctOC0xLTEtMA_8ebc458d-d947-49e2-89bc-0361ab443e22"
      unitRef="usd">70000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtMi0xLTEtMA_d9c18e1e-d7f2-4c41-8a2c-b51c6f7aabda"
      unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtNC0xLTEtMA_cc495105-2ada-4408-9f15-b62b072637fd"
      unitRef="usdPerShare">70.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtNi0xLTEtMA_253e5a45-3ffb-4ddd-9d6b-69e4c6da23c8">P8Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo0NWJhOTA1N2MwYzk0MDg2ODFjNmRkODdkNDM5NTQ4OC90YWJsZXJhbmdlOjQ1YmE5MDU3YzBjOTQwODY4MWM2ZGQ4N2Q0Mzk1NDg4XzgtOC0xLTEtMA_b467c20f-f7d7-40c9-aad3-dd7d54440f7b"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzIzNDk_d41ea683-72b3-427a-9bc6-58e1d626f01a"
      unitRef="usd">179000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzIzNjA_ecc8d987-b453-4797-881f-42ce71a5b00d"
      unitRef="usd">209000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzIzNzQ_a5d0946e-1e88-4f64-a36a-acfd3aa80510"
      unitRef="usd">412000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI0NjI_9cf97a2c-681e-43a1-85c5-df9563bb3d02"
      unitRef="usdPerShare">11.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI0ODM_c76f1a53-53cd-4b78-b745-c3c1221b6ace"
      unitRef="usdPerShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI1MDc_e2bc088e-9570-4421-8559-0d1157122a0a"
      unitRef="usdPerShare">17.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ifc447ebbb9884a78a958aa20b56841f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3MzM_2f3d6079-1f1d-43b7-9cbc-0ff89735c771"
      unitRef="usd">55000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI4NzY_1fe82ccd-8e54-4c08-9a6a-6aa0d03f8d65">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9db8741b4d8842f1bb640976d2a45d96_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNzA_45369d85-d47b-4e91-b869-789198a34d93">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage
      contextRef="i62891fc164b04b4e8264bd225dfeb876_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzM3NDQ_5d377f66-74d9-4a13-ac13-1c845c6062b8"
      unitRef="number">0</gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage>
    <gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage
      contextRef="i6aa115e88017417cb54eaf2b28abc9ec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzM3NTA_7c2b7860-46ef-4e96-8074-f0007c9a107b"
      unitRef="number">2</gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NTY_109f4854-5d92-4f3b-93de-8acd9772da4b">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU and PSU activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;(1) &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic717d0c503c143968d6471b329f28be4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItMi0xLTEtMA_01de1809-b74f-4efc-aac8-fefc3c81f437"
      unitRef="shares">17200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic717d0c503c143968d6471b329f28be4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItNC0xLTEtMA_ad351f57-8646-4a10-9486-d327579b97f3"
      unitRef="usdPerShare">70.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i131142515dae41e291f717d69305bc41_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItNi0xLTEtMA_8c8d138e-aeef-4218-a2ea-0417d95bbc24"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i131142515dae41e291f717d69305bc41_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzItOC0xLTEtMA_ad2989a4-9cd8-4cac-8270-94feef69a831"
      unitRef="usdPerShare">80.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtMi0xLTEtMA_305253d6-4713-426e-8fca-d083c0ace87d"
      unitRef="shares">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtNC0xLTEtMA_e89aa23f-8efe-4dc1-872e-a4ac018641bd"
      unitRef="usdPerShare">70.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtNi0xLTEtMA_7e8fe931-7339-4af0-af37-2376a6d2092e"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzMtOC0xLTEtMA_16b1f8ce-910f-46c5-8949-d7c51e5d3a26"
      unitRef="usdPerShare">83.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtMi0xLTEtMA_0c9a5b69-7dec-4414-a255-febe81c07900"
      unitRef="shares">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtNC0xLTEtMA_555ab616-a2e9-4e6f-809a-ae90289d4605"
      unitRef="usdPerShare">72.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtNi0xLTEtMA_64e9d64a-a0ff-4f51-937d-b9e3a369f435"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzQtOC0xLTEtMA_8ab44d21-97c5-48f3-b58c-280f092cbff7"
      unitRef="usdPerShare">73.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtMi0xLTEtMA_9ed1a82e-8ce2-4059-aa2a-8f843db0280d"
      unitRef="shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtNC0xLTEtMA_4840bc6d-bfc6-4e4f-a936-09a27dcd8b54"
      unitRef="usdPerShare">70.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtNi0xLTEtMA_b5d72f6a-6399-446b-ac39-2f82b62b1802"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzUtOC0xLTEtMA_050fe4ef-c13f-40b3-9f6f-adb1d3c006de"
      unitRef="usdPerShare">81.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7d4423b8d04646d3a954612daf594dac_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtMi0xLTEtMA_55ccc54f-e13a-48fd-ba52-c8950ae9678c"
      unitRef="shares">19500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7d4423b8d04646d3a954612daf594dac_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtNC0xLTEtMA_c09125c7-cddf-4faf-bd77-6bb3f71f48e4"
      unitRef="usdPerShare">69.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i982d3c7d11dc4c84a981217fe59bf232_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtNi0xLTEtMA_3d778d75-7598-4327-854c-12e85eb874b0"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i982d3c7d11dc4c84a981217fe59bf232_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTphN2VlODVjZjBlY2E0NDIxOWJiNWE2Nzg4NzU3YzlkNi90YWJsZXJhbmdlOmE3ZWU4NWNmMGVjYTQ0MjE5YmI1YTY3ODg3NTdjOWQ2XzYtOC0xLTEtMA_626cc4cb-50b1-4a0d-9eec-0685bc6bc040"
      unitRef="usdPerShare">84.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f879e6e10d34057ab69d795b1881232_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzQ5MzM_a014d66a-ab00-4289-8264-fe04562640a5"
      unitRef="usdPerShare">70.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i109c30251de2477081720f87d8a28594_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzQ5NTQ_ab61732e-261e-4968-8cc9-34064d15379a"
      unitRef="usdPerShare">64.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c6dd7d6dd0d45e6a2043541078d3796_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzQ5Nzk_12ce19d2-8b07-4291-aea9-c791d70d3493"
      unitRef="usdPerShare">77.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id36aff6aa5b1435e90046831abfad68c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUwNjM_16b1f8ce-910f-46c5-8949-d7c51e5d3a26"
      unitRef="usdPerShare">83.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i76feedf9c6014726a00c27da12c8de28_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUwODQ_f6334b49-3494-49ce-8706-d81d7d62612b"
      unitRef="usdPerShare">68.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i22b4c383c26c48c892d88beb1d9d2292_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUxMDk_6e1926e8-188c-48f2-8f67-55eb52b5e704"
      unitRef="usdPerShare">88.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ifdc506af41e54853895ac3a3ed8d114c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUxOTQ_30886fab-ebdd-44d7-bf71-5bdc821edfa3"
      unitRef="usd">479000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i38d54fab5ace4e28898af9b5fd4628d8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyMDM_637a2a5c-d8ed-4fdb-bc12-4e8f37b39f96"
      unitRef="usd">450000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3702dbcc04054cdd86bc26be99367a19_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyMTc_d1884078-ba28-41ac-9527-8c079119c3dc"
      unitRef="usd">481000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i347b4c9b1da2453f8b5c69693ae0fe5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyODg_54fdca19-ebdf-4a51-a120-d3894cb309ec"
      unitRef="usd">459000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ia29bb89cacab4917ad78178e3cc39d53_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUyOTk_42fb9553-b77c-462f-b26d-31272dd08a0a"
      unitRef="usd">372000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i5c985006e29e4ce693bf89616e366745_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUzMTM_d38680d3-1f0d-4df9-93e0-9c41f18d5a1c"
      unitRef="usd">446000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ie2c93d478ae74471acc0268f5b36f929_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzUzNDU_86e3080a-3d88-4d97-9557-c21bf2c7910d"
      unitRef="usd">860000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i009c4559c5ee4dcca45e50ed6dafe35f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzU0ODY_d1ff6a94-e5be-4093-af4f-7ef85d2ec06e">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzU4MjQ_8f3f39ad-783a-40dd-9636-a5a9350c457c"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzYzMDI_2ce57e9b-4bf8-42ec-8280-d7d24148cb71"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzYzNDM_be7fa176-b95a-47be-9725-b1dae84071d4"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia929926fabb04040b30c9fcb5647aad5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzYzNTg_5a569a09-4ca1-46c4-bf9d-9903d9f9766b"
      unitRef="shares">79000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia929926fabb04040b30c9fcb5647aad5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzY0NDk_74c8f768-2835-4a93-8126-6ef7eeb47a17"
      unitRef="shares">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NTk_5736913a-5738-4509-952e-8b38efc539c8">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1,076&#160;million included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Altera Corp v. Commissioner&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.&lt;/span&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8000203400804727bf1a4e40c93f3c16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzItMi0xLTEtMA_7d539bed-8448-41d9-9d0f-270d57b6f19a"
      unitRef="usd">109000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icbb578eac6714200a5377073798b8f1b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzItNC0xLTEtMA_65336efb-d13b-4821-af1f-b12e3fca4639"
      unitRef="usd">48000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe4376a44dc14cc2a76b854d11662987_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzItNi0xLTEtMA_30617146-8949-4a3f-87ff-aaef3596509c"
      unitRef="usd">61000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i42fad2d6b4d14144ac2fb0e8b3cd8fab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzMtMi0xLTEtMA_830e48d9-1660-4ea9-a22b-2be0ba41674a"
      unitRef="usd">462000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8c99d40ca3b4653938ea4dd23e12064_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzMtNC0xLTEtMA_9eabfc68-7122-4f7d-9d03-904c443fa74d"
      unitRef="usd">289000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7be4f110329145dfbfde538bee9a676d_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzMtNi0xLTEtMA_6d5efdef-e1f6-478b-a9ae-cdd0e7687633"
      unitRef="usd">379000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff3394e3bd2e4809af80fd7faf8770e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzQtMi0xLTEtMA_164f2c8f-6bc9-4c9f-82f0-9dde0ab4db7f"
      unitRef="usd">505000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80dd52732e7f44da975a903d2cf2542d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzQtNC0xLTEtMA_83ae9db2-21a2-4e2b-a868-d97d950a4bd4"
      unitRef="usd">299000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e09efc6fa77468ea8742717d97b0509_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzQtNi0xLTEtMA_4e959a26-3e08-4e91-85bc-efc55964843e"
      unitRef="usd">405000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzUtMi0xLTEtMA_5370ac95-3eb1-4fa8-ae04-8864bdae2e4b"
      unitRef="usd">1076000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzUtNC0xLTEtMA_335fb418-3ac9-4cf3-a460-04a6a94199e1"
      unitRef="usd">636000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzUtNi0xLTEtMA_03075bdd-27b2-4f81-93a4-d90afdff6dab"
      unitRef="usd">845000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzYtMi0xLTEtMA_3bb7ebe1-e3ca-4c88-83e9-c658eb527c0c"
      unitRef="usd">222000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzYtNC0xLTEtMA_6e75bab8-7ed0-43d6-8b77-ece88f67bb90"
      unitRef="usd">-2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzYtNi0xLTEtMA_76eb3031-daa9-43aa-8ec7-bc8819eb734d"
      unitRef="usd">164000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzctMi0xLTEtMA_07c21b8f-0b11-4764-b9ed-f6e53e485a42"
      unitRef="usd">854000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzctNC0xLTEtMA_17fc2bdc-6b2c-4c69-80f1-632c6fb26d2b"
      unitRef="usd">638000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTo4MDNjNjI1OGVlZjg0MDBmODk3MjA0ZDVjMjAwMGVmNC90YWJsZXJhbmdlOjgwM2M2MjU4ZWVmODQwMGY4OTcyMDRkNWMyMDAwZWY0XzctNi0xLTEtMA_c826e605-0042-4100-9fca-0168189a117d"
      unitRef="usd">681000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTEwNjQx_5370ac95-3eb1-4fa8-ae04-8864bdae2e4b"
      unitRef="usd">1076000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzEwOTk1MTE2NDY2MDA_c1965d3f-3996-4264-92b5-24e2d0032f20"
      unitRef="usd">643000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA5NTQ1_6dee6ca2-bdef-40ac-910d-ec0fd65d40f8"
      unitRef="usd">289000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i94aca37dece54db88d94195652d7be2a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA5NTk3_053312f0-7678-4f0c-a6da-70dd1616d630"
      unitRef="usd">144000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTA3MzY4_69773122-2cdf-43bd-88c1-c87c0d640d65"
      unitRef="usd">114000000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1NzQ_6de98495-c975-4acf-aaea-00c58b51a255">We used the following assumptions to calculate the estimated fair value of the awards: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gild:ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzMtMi0xLTEtMA_4c8e9f4a-b814-4bff-9c6e-a018867b6a28"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzMtNC0xLTEtMA_4d1d42d6-246d-489c-b696-c4eeb0417ebc"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzMtNi0xLTEtMA_021538ee-2504-433f-b226-51cdcd838958"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzQtMi0xLTEtMA_397aea4f-b4b2-457f-88fe-c84c9d1d2b7d"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzQtNC0xLTEtMA_c5822fcc-661d-461f-9d14-dfc3fd7ce238"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia623662c706d409a83107f00f6077a04_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzQtNi0xLTEtMA_0fae5ad0-06fb-460d-83d0-63852450804b"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzYtMi0xLTEtMA_902adf58-899f-45f7-bb6e-da8c7fc3f6be">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzYtNC0xLTEtMA_896d287a-70d9-4afa-88e7-c0272b8db44a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzYtNi0xLTEtMA_c01e2638-ed15-4597-97d7-dcc3f95dc975">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzctMi0xLTEtMA_37ad728a-73d6-4e6c-8361-2a9d4887f92a">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzctNC0xLTEtMA_d7911968-f454-44be-85f0-bbcb69f7e7d2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia623662c706d409a83107f00f6077a04_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzctNi0xLTEtMA_6dfee5bc-aaed-4a05-8d9b-dcda1d41f5aa">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id4149ca153914ecaa8a96e9a8b63a205_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzktMi0xLTEtMA_6bc65c12-3e4e-4b71-ba0d-995b8c6d768f"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic409f08886184a578a8ba91c9d0a0f7b_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzktNC0xLTEtMA_317e1df4-6e2b-44e8-b8e7-7acb3cb36dd6"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id5db77026c0942649e1ecd8f939f863e_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzktNi0xLTEtMA_54660604-0b56-44c2-a636-cc3930a212ca"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i042094ccb6d74ba19f5c9e945ddf0b71_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzEwLTItMS0xLTA_12dc2f55-3c3a-4ef2-8707-d76c1b6c7a7a"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ifa1449112bf94d5b90cbc693a1d8ced7_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzEwLTQtMS0xLTA_f1835b8f-b19b-4ef5-8c55-f351bf4c1b35"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia623662c706d409a83107f00f6077a04_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzEwLTYtMS0xLTA_137e110c-361a-4735-9783-ed35bf659b44"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzExLTItMS0xLTA_ae0969e0-f30b-4df5-bac8-3c5fb11b5432"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzExLTQtMS0xLTA_59c75e80-0e72-4e8b-a0e4-8dc17c5fa5d4"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90YWJsZTowOWJkOWIyYjVmNzM0Y2VlOWRiYmEwZWYxN2I4YjMxZS90YWJsZXJhbmdlOjA5YmQ5YjJiNWY3MzRjZWU5ZGJiYTBlZjE3YjhiMzFlXzExLTYtMS0xLTA_530886bf-a198-4031-b7e6-0b4f6e675b2c"
      unitRef="number">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzkyMDQ_32444193-5fb6-47d2-ae5b-c784df06f749"
      unitRef="usd">144000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzkyMTg_7c1e3ed8-2207-42c6-a90e-a8a60d27e1d3"
      unitRef="usd">110000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzkyMzU_edbea6a2-c1eb-475e-a919-60d8c48e8bbc"
      unitRef="usd">91000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6760924221ed4b5cba60ea7d2547a8cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzk1MTA_6848f293-85ed-4c1d-aff7-38014634617f"
      unitRef="usd">218000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i620b03a7ceff4498b7ef8db0524ac079_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzExNTQ0ODcyMTAxNjg0_7003ec90-6884-416b-b06e-076431288cd3"
      unitRef="usd">171000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzEwMTY_74c9cab6-daa0-4925-9023-67cd3e92f566">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common shareholders because their effect would have been antidilutive were 13 million, 14 million and 13 million during 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzc4Mw_e01abb5f-bbba-43ec-9686-e94773daf323"
      unitRef="shares">13000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzc4Nw_ab415ecf-4f48-40f4-a3b0-dd9d2c8112a7"
      unitRef="shares">14000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzc5NA_bd0f59a6-ab58-4de1-a34e-a9dd0c6b5a61"
      unitRef="shares">13000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90ZXh0cmVnaW9uOjFlNTVkMTc2ZGQ5MzQ2YjA5NzQ3NDBlMWRiMTAzYmMyXzEwMDc_9afd4f0f-a238-46fa-bc7b-95ff72eb7f64">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in per share calculation - diluted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzItMi0xLTEtMA_c46efd6b-8e9f-41de-bee2-216161b5d925"
      unitRef="usd">123000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzItNC0xLTEtMA_fcde1c31-3ed6-4668-979c-512f73c1ae73"
      unitRef="usd">5386000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzItNi0xLTEtMA_4052b884-9aa5-45e1-ba0e-fdf3d71b01e0"
      unitRef="usd">5455000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzMtMi0xLTEtMA_fcec0690-ed87-44f1-b673-4a50221bc2a4"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzMtNC0xLTEtMA_95b43e39-7e25-4659-8f3e-0cf7c7f921e0"
      unitRef="shares">1270000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzMtNi0xLTEtMA_e4eddad7-cbfc-414b-80f7-83086cc39cff"
      unitRef="shares">1298000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzQtMi0xLTEtMA_d375a579-8e00-41c3-854d-fca792d66172"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzQtNC0xLTEtMA_84676e79-d74f-49ca-9669-d635d5467fec"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzQtNi0xLTEtMA_6c3e20a8-f083-4066-b4b0-579919dc5e8f"
      unitRef="shares">10000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzUtMi0xLTEtMA_12b3f5c5-a7ee-43c2-af0f-f82f08691868"
      unitRef="shares">1263000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzUtNC0xLTEtMA_b48c7525-9365-4b94-b8d7-8d6858e423d4"
      unitRef="shares">1277000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzUtNi0xLTEtMA_b097c157-2586-47a6-910f-f99d1e418fa1"
      unitRef="shares">1308000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzYtMi0xLTEtMA_6a3db572-386c-4231-b8b3-b3b0351d3567"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzYtNC0xLTEtMA_1eb20a22-2260-49f6-afbb-d5c6004eb201"
      unitRef="usdPerShare">4.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzYtNi0xLTEtMA_a0d0b0d9-c4eb-47dd-a6cd-87a9745bea93"
      unitRef="usdPerShare">4.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzctMi0xLTEtMA_2e59c578-2e2b-4c3f-a20d-12a6dc11d78a"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzctNC0xLTEtMA_a1181978-2403-4fc5-84d6-cac0f0285eb7"
      unitRef="usdPerShare">4.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNzUvZnJhZzoxZTU1ZDE3NmRkOTM0NmIwOTc0NzQwZTFkYjEwM2JjMi90YWJsZTpiMGMzYmVlMjVhMDk0ZjI3OTM5YTVhNzRhZTRlZGVhYi90YWJsZXJhbmdlOmIwYzNiZWUyNWEwOTRmMjc5MzlhNWE3NGFlNGVkZWFiXzctNi0xLTEtMA_032a4a55-478f-4dff-9e78-885f6cbecb49"
      unitRef="usdPerShare">4.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY2ODI_b6ae4b3f-9961-497d-a80b-d4e37f282b47">INCOME TAXES &lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.59pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense (benefit) consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2019 income tax benefit included a $1.2 billion deferred tax benefit related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In the fourth quarter of 2019, we completed an intra-entity asset transfer of certain intangible assets from a foreign subsidiary to Ireland. The transaction resulted in a step-up of the Irish tax-deductible basis in the transferred assets, and accordingly, created a temporary difference where the tax basis exceeded the book basis of such intangible assets. As a result, we recognized a deferred tax asset of $1.2 billion on our Consolidated Financial Statements. We expect to be able to realize the deferred tax asset resulting from this intra-entity asset transfer. The impact of the intangible asset transfer from a foreign subsidiary to the United States was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2018 income tax expense included a $588 million deferred tax charge related to a transfer of acquired intangible assets from a foreign subsidiary to the United States. This transaction did not result in a step-up of the U.S. tax-deductible basis; and as a result, we recognized a deferred tax liability of $588 million for the temporary difference where the book basis exceeded the tax basis of these acquired intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rate applied to income before taxes and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax - intra-entity transfer of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of tax examinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D and related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable unrealized gain / loss on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of tax basis over book basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of book basis over tax basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance was $398 million and $217 million at December&#160;31, 2020 and 2019, respectively. The increase of our valuation allowance in 2020 was primarily related to acquired attributes related to Forty Seven and Immunomedics acquisitions, and unrealized losses on our equity method investments reflected as acquired IPR&amp;amp;D expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance decreased to $217 million at December&#160;31, 2019 from $331&#160;million at December&#160;31, 2018, primarily due to a reduction in net operating loss carryforwards under the asset recognition framework and corresponding valuation allowance with respect to certain foreign jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we had U.S. federal net operating loss and tax credit carryforwards of approximately $1.5 billion. and $61 million, respectively, which will start to expire in 2021, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $1.8 billion and $673 million, respectively. The state net operating loss will start to expire in 2021 if not utilized and state tax credit carryforwards will start to expire in 2022 if not utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2013 and onwards and 2010 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.&lt;/span&gt;&lt;span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total unrecognized tax benefits, $1.2 billion and $1.6 billion at December&#160;31, 2020 and 2019, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included as part of income tax expense (benefit) on our Consolidated Statements of Income were $(82) million and $105 million for the years ended December&#160;31, 2020 and 2019, respectively. Interest and penalties related to unrecognized tax benefits for the year ended December 31, 2018 was not material. Accrued interest and penalties related to unrecognized tax benefits were $177 million and $259 million at December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we do not believe that it is reasonably possible that our unrecognized tax benefits will significantly change in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY3MTc_37f3d5aa-e5d2-4ffd-a8ae-1e7ea3417120">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzItMi0xLTEtMA_e59ad15e-cb9f-4e05-9757-e96c0f1f28da"
      unitRef="usd">2505000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzItNC0xLTEtMA_2bc97978-aa24-4fe5-955b-a21267e03dfa"
      unitRef="usd">4112000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzItNi0xLTEtMA_acaf3c5c-4af9-4f1e-a000-bbb5997f2c48"
      unitRef="usd">7074000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzMtMi0xLTEtMA_ac9288de-3258-48cf-ab7b-6c60ea08b4de"
      unitRef="usd">-836000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzMtNC0xLTEtMA_7fc45188-1c16-4658-a60f-6867fa5e3f28"
      unitRef="usd">1048000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzMtNi0xLTEtMA_b37dae04-564f-490b-a3d7-30d9925a5abf"
      unitRef="usd">725000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzQtMi0xLTEtMA_2f037272-69cc-424f-b438-e9e30fdf4915"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzQtNC0xLTEtMA_5c3e62f0-0c34-48df-b8d2-a6b1c5112522"
      unitRef="usd">5160000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo4ZjljOTZlMzkyZTY0ZDgxOGM2N2Q1YzJjYzM2YTQwYi90YWJsZXJhbmdlOjhmOWM5NmUzOTJlNjRkODE4YzY3ZDVjMmNjMzZhNDBiXzQtNi0xLTEtMA_e6641c71-2a0b-4c44-84e8-b90f0031430b"
      unitRef="usd">7799000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY2OTU_e8b70716-6c3d-4ef4-a5d5-733bd8ba510d">&lt;div style="margin-top:4.59pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense (benefit) consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzMtMi0xLTEtMA_71accbd1-09eb-498c-a687-01121d57864e"
      unitRef="usd">1450000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzMtNC0xLTEtMA_a2e08e91-f744-411e-b87c-eeb2fed9df4c"
      unitRef="usd">1646000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzMtNi0xLTEtMA_30ebefda-b639-4b1e-b4a5-7524d5413571"
      unitRef="usd">1716000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzQtMi0xLTEtMA_2d20979c-8bea-4aa3-80e4-600a79797628"
      unitRef="usd">-164000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzQtNC0xLTEtMA_314426d4-20e1-4adb-9d51-789b8ba34f17"
      unitRef="usd">-843000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzQtNi0xLTEtMA_27cb4108-907b-492d-b625-73e4aee1ae9f"
      unitRef="usd">324000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzUtMi0xLTEtMA_7104eac7-348a-45a9-bea3-dc7637ad7e87"
      unitRef="usd">1286000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzUtNC0xLTEtMA_b1265d80-2e0b-4f41-b386-84cdad53fc1d"
      unitRef="usd">803000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzUtNi0xLTEtMA_09c465aa-10a7-4e59-84d1-4fb1d900504e"
      unitRef="usd">2040000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzctMi0xLTEtMA_be84cb39-937a-44fe-83c1-0331ec473f87"
      unitRef="usd">198000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzctNC0xLTEtMA_b56c4ce0-aa04-4e7d-9185-2c7053e5d87d"
      unitRef="usd">135000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzctNi0xLTEtMA_bc649543-73ac-4917-9cd3-783efa9b9223"
      unitRef="usd">162000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzgtMi0xLTEtMA_edb0c4ef-7be0-4c54-acec-857fc79c6097"
      unitRef="usd">-97000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzgtNC0xLTEtMA_abb7b94c-e44a-4596-a748-4aad5dc67fae"
      unitRef="usd">-42000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzgtNi0xLTEtMA_dc84acae-089c-4571-82b1-ba85c5fe611c"
      unitRef="usd">-17000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzktMi0xLTEtMA_be46d200-27a0-4e8b-81b2-d8e825f6f9d5"
      unitRef="usd">101000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzktNC0xLTEtMA_67397f80-97e3-470b-9c54-4ae1c1901a97"
      unitRef="usd">93000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzktNi0xLTEtMA_d6aee982-d9a9-4d33-be06-b08bb2033d2b"
      unitRef="usd">145000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzExLTItMS0xLTA_c4a631cf-110c-46e3-8a15-a6c8f573afb0"
      unitRef="usd">155000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzExLTQtMS0xLTA_048341e5-1067-471c-838a-91a23bae6203"
      unitRef="usd">124000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzExLTYtMS0xLTA_7099d3f8-21af-4d78-94a6-d6f9f6a7f8b4"
      unitRef="usd">175000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEyLTItMS0xLTA_0d57f3c3-974e-491e-a883-6b12b0736a7d"
      unitRef="usd">38000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEyLTQtMS0xLTA_112827fa-47b8-4e8d-8cb7-fd07d4cad22f"
      unitRef="usd">-1224000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEyLTYtMS0xLTA_5aaa8b7c-3c74-4588-87b0-e6d0d04d73b7"
      unitRef="usd">-21000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEzLTItMS0xLTA_2f59ff37-d4fe-43a4-ac6c-bc10a4efaf45"
      unitRef="usd">193000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEzLTQtMS0xLTA_e3e6d397-f9f5-43ce-bf73-d965338eab0f"
      unitRef="usd">-1100000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzEzLTYtMS0xLTA_50f35f1b-5cde-446d-b9da-5c166865f819"
      unitRef="usd">154000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzE0LTItMS0xLTA_889651f8-1dcb-43a2-93de-c7ae71a0c85a"
      unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzE0LTQtMS0xLTA_32fb746c-9a42-4977-9b05-c08d13157706"
      unitRef="usd">-204000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo1YmNlMzFjZTlkNGE0MzczOTA5NmU1ZmRjM2E0Y2RmOC90YWJsZXJhbmdlOjViY2UzMWNlOWQ0YTQzNzM5MDk2ZTVmZGMzYTRjZGY4XzE0LTYtMS0xLTA_b26e498b-ff68-4b6b-9e4e-4b87b48cc962"
      unitRef="usd">2339000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2f77d5dbabfc4c67bbc7902204dbe301_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzIxOA_cd11b35a-a159-4149-9d28-a29483c88e35"
      unitRef="usd">-1200000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="if89c7b93f0a5477d94803cdd6f0a3319_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2Xzc1MQ_8174e4cd-2150-4cc2-807c-028de74c7cf6"
      unitRef="usd">1200000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9779a570996452dbbd3c83239ccf707_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEyNDg_f7fda088-f6bf-4c62-a90e-d5feb1d2422c"
      unitRef="usd">588000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="id3086aba7396431180029057c2ad4ece_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzE1MDk_6e891aff-5e25-45e3-9443-aa57c24278bc"
      unitRef="usd">588000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY2OTY_8e19ceb7-d082-4c05-827f-92713cf48def">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rate applied to income before taxes and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax - intra-entity transfer of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of tax examinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D and related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable unrealized gain / loss on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzItMi0xLTEtMA_750f3676-dc71-4c31-91c6-ba480c4ba1f4"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzItNC0xLTEtMA_5c75a518-8be4-4a40-b908-3196ee97c709"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzItNi0xLTEtMA_74e4111c-b3dc-499e-8284-0b35a9daefe1"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzMtMi0xLTEtMA_519f7ce7-f5ef-4f2e-b8f5-aaf3cede2a75"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzMtNC0xLTEtMA_8ebe1c3f-a4ee-4c56-bbe5-fefb07f159be"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzMtNi0xLTEtMA_1f0a2da6-1278-4787-bfce-a7a8e5b799f1"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzQtMi0xLTEtMA_06758358-c130-4502-922b-4da5f7364f09"
      unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzQtNC0xLTEtMA_82eab6f4-7df0-4dee-a8be-2b43653530bc"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzQtNi0xLTEtMA_9457e1fe-7a7a-49d3-977e-e0dfb15a181a"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzUtMi0xLTEtMA_4d168804-776f-41c0-94b8-13de9016f19e"
      unitRef="number">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzUtNC0xLTEtMA_ce3f52cf-bfa6-45ca-b5da-df1c3494de80"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzUtNi0xLTEtMA_92634e1a-7590-419c-ace5-18a245a05f57"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzYtMi0xLTEtMA_416b11b0-2508-46b5-8ee4-97d4998ae6ff"
      unitRef="number">0.072</gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings>
    <gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzYtNC0xLTEtMA_9da6a8cc-2956-4c6c-8330-da6cd888db1d"
      unitRef="number">0.043</gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings>
    <gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzYtNi0xLTEtMA_2c30b36b-242b-41e3-8dc6-dc18b5d7ab77"
      unitRef="number">0.021</gild:EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzctMi0xLTEtMA_492f72f7-6d85-4bee-a067-e1b3be77fcbf"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzctNC0xLTEtMA_191d8a73-d7bb-43e7-8885-7fd0d1edfe57"
      unitRef="number">-0.240</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzctNi0xLTEtMA_c3036878-e9d6-4125-9908-58a7ea0c394e"
      unitRef="number">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTItMS0xLTA_e1ceb80d-0be5-44bc-abbb-0c0164a4ccf0"
      unitRef="number">-0.102</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTQtMS0xLTA_ff4cdb1a-23ba-42cf-8c62-b7b097b58c84"
      unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTYtMS0xLTA_3b6c71ea-4e8e-4b00-81c4-c4fa529d85a5"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTItMS0xLTEyODg2_7fab425f-f8c9-4315-8601-4f5b985c4046"
      unitRef="number">0.562</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzktNC0xLTEtMjY4NzE_388a62ae-eca2-4e11-96eb-5befcbda5d33"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzktNi0xLTEtMjY4NzE_307443f8-e2d4-4653-8510-1a3ae975e43c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTItMS0xLTEyODg2_3c7a2fb0-0e09-4a8e-9d2f-4c73f8f6bcfa"
      unitRef="number">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTQtMS0xLTI2ODcx_698d2f1e-59bf-43ef-8892-ad4070c06130"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEwLTYtMS0xLTI2ODcx_25605df5-256a-4a55-9d03-dc002b9267e7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEzLTItMS0xLTEyODg2_a9bf4f8e-a750-40d8-bbf8-561d1eb0b62a"
      unitRef="number">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTQtMS0xLTE4MTY1_8d80a880-8381-4a71-88b2-31f9cf0a4b2f"
      unitRef="number">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTYtMS0xLTI2ODcx_52937d4e-6a14-4167-bea5-56b804a720d2"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTItMS0xLTA_9f03d7de-0ed1-4666-9c4c-fbdcacca87e8"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTQtMS0xLTA_d0d2e325-a1c5-4945-85ef-5e8b59d60df3"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzExLTYtMS0xLTA_9e40a662-4d17-45f5-8222-3e6f5972ab60"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTItMS0xLTA_176acc95-2cb6-450f-a346-cdcdfd8df7e0"
      unitRef="number">0.947</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTQtMS0xLTA_d592e0e8-3bac-478a-9072-54516331fa61"
      unitRef="number">-0.040</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTo2OTgxY2YxOThmZmU0NjVlOTQwNzZlNzZhMmQxMGM5MC90YWJsZXJhbmdlOjY5ODFjZjE5OGZmZTQ2NWU5NDA3NmU3NmEyZDEwYzkwXzEyLTYtMS0xLTA_bc91a366-c5d7-4528-935a-7f4238f5c992"
      unitRef="number">0.300</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY3MDM_3cf75024-9324-404e-982e-f24cead27811">Significant components of our deferred tax assets and liabilities are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of tax basis over book basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of book basis over tax basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzMtMi0xLTEtMA_9bc3833a-0925-4b96-9a5a-502a4397e191"
      unitRef="usd">587000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzMtNC0xLTEtMA_43571bb6-99d3-4311-af47-371aeefe1a07"
      unitRef="usd">184000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzQtMi0xLTEtMA_55f39679-9ab6-4c48-83e3-721dc32aa5e9"
      unitRef="usd">113000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzQtNC0xLTEtMA_b57ed7f5-1e93-4619-9a53-55f25740c8ab"
      unitRef="usd">113000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzUtMi0xLTEtMA_705d317e-8b1b-45ac-973f-674bc8240bc8"
      unitRef="usd">444000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzUtNC0xLTEtMA_10b10ed1-8b2d-45b3-a85a-e96c62f2f905"
      unitRef="usd">423000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzYtMi0xLTEtMA_ff15cc92-c5a2-4fc5-9a28-61e703d745f6"
      unitRef="usd">1177000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzYtNC0xLTEtMA_901ac9ae-a754-42c0-bac4-b18481254913"
      unitRef="usd">1232000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <gild:DeferredTaxAssetsUpfrontAndMilestonePayments
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzctMi0xLTEtMA_d0492209-70bb-49f7-9108-1af3ecfbdf69"
      unitRef="usd">1144000000</gild:DeferredTaxAssetsUpfrontAndMilestonePayments>
    <gild:DeferredTaxAssetsUpfrontAndMilestonePayments
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzctNC0xLTEtMA_ef77b876-55fb-4298-ad38-b6e4f92591f8"
      unitRef="usd">988000000</gild:DeferredTaxAssetsUpfrontAndMilestonePayments>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzgtMi0xLTEtMA_98ef2f54-fb16-44f8-8c1a-3e73368ff9d8"
      unitRef="usd">219000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzgtNC0xLTEtMA_56e535be-62d3-403e-97f8-9762fbf32178"
      unitRef="usd">247000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktMi0xLTEtMTI4OTA_ee90c456-e340-434d-bd37-536d2affa2d1"
      unitRef="usd">116000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktNC0xLTEtMjYxODE_14303c00-46e6-403c-b712-a88524ebfb1c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTItMS0xLTEyODkw_edbf2190-8612-40b1-ae3a-c513256099a7"
      unitRef="usd">247000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTQtMS0xLTI2MTgx_d520cf9c-49cc-407e-8314-dc3ab56bf416"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktMi0xLTEtMA_90a189c2-fea6-41f6-8c9a-de3bdcd5d0b3"
      unitRef="usd">311000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzktNC0xLTEtMA_8ae9312b-e88b-4291-9fce-3a79c4e0e3e7"
      unitRef="usd">168000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTItMS0xLTA_87b31ec1-5ab1-403b-8a49-e57c92b23f6a"
      unitRef="usd">4358000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEwLTQtMS0xLTA_b713c702-365d-46d0-b23f-076856f2c7c4"
      unitRef="usd">3355000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzExLTItMS0xLTA_a3b7177b-9304-413f-be1c-305544056bd2"
      unitRef="usd">398000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzExLTQtMS0xLTA_b64d45bb-3ecf-4e24-b9b1-88a50192abb0"
      unitRef="usd">217000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEyLTItMS0xLTA_6c2a534e-b609-4955-8c09-e457a2cc6c64"
      unitRef="usd">3960000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzEyLTQtMS0xLTA_dfb01586-499c-4f20-8183-2d82b24ff97f"
      unitRef="usd">3138000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE0LTItMS0xLTA_15f70c94-cfd5-4169-8bae-23bfc2f1190c"
      unitRef="usd">202000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE0LTQtMS0xLTA_9b1be412-5ca3-48a3-b5bc-c98298680f13"
      unitRef="usd">88000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE1LTItMS0xLTA_45c6f660-713d-4459-818d-82c7f9229359"
      unitRef="usd">6168000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE1LTQtMS0xLTA_4f78f19d-edde-400f-9ab0-ea14ad04e01a"
      unitRef="usd">1401000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE2LTItMS0xLTA_3609742c-2331-4960-9c4e-937ca4b404a8"
      unitRef="usd">202000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE2LTQtMS0xLTA_255362da-1711-46f6-b396-18289c92fae6"
      unitRef="usd">93000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE3LTItMS0xLTA_b93d3b2b-48bb-4f95-9b4e-a1c807c94e28"
      unitRef="usd">6572000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE3LTQtMS0xLTA_69d6813a-7eca-4c73-b2b1-961e4b34afb6"
      unitRef="usd">1582000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE4LTItMS0xLTA_040f6cb8-005b-42d9-a2c2-688f2753ba7d"
      unitRef="usd">2612000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZToyNWQyZjM5N2VmOTE0MWY0YjU3ZWQ3NTRmMzY4NTVkOS90YWJsZXJhbmdlOjI1ZDJmMzk3ZWY5MTQxZjRiNTdlZDc1NGYzNjg1NWQ5XzE4LTQtMS0xLTA_5fc79638-dafe-4370-8948-dfde64976ad3"
      unitRef="usd">1556000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzI3Njk_c316353c-2961-4c41-afbd-8ca1ab0c0691"
      unitRef="usd">398000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzI3NzY_3fb7b5b1-b075-487b-b9b5-34568a89c403"
      unitRef="usd">217000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzExNTQ0ODcyMTA3MDEx_3fb7b5b1-b075-487b-b9b5-34568a89c403"
      unitRef="usd">217000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzExNTQ0ODcyMTA3MjE4_8d997281-5f69-4d4c-bff6-77f487fe7fbc"
      unitRef="usd">331000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id342243123964d40bc3ebc4517f36cd7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEwOTk1MTE2Mzk0ODI_a807536b-5568-4e2a-8e5d-f7a1e449d9c6"
      unitRef="usd">1500000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id342243123964d40bc3ebc4517f36cd7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzMyODg_c64dc5a9-4e71-446b-bec5-6ecf410c1291"
      unitRef="usd">61000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic67c62aea4714cc1bdf529a34a43a13a_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzM0MzU_3de6796c-00a1-4332-8654-db0f4d55b91c"
      unitRef="usd">1800000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic67c62aea4714cc1bdf529a34a43a13a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzM0NDI_1ca9e7af-8ce1-49b7-b86d-51d99f9a3472"
      unitRef="usd">673000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzQ5NzY_0525f093-52e6-4908-ba1c-29279d16997f"
      unitRef="usd">1200000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzQ5ODM_a1d177d6-37af-4ded-a391-97c0856c5751"
      unitRef="usd">1600000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEwOTk1MTE2Mzk1MDE_53b3c329-e9ac-4534-a994-152bc57f7e8e"
      unitRef="usd">-82000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzEwOTk1MTE2MzU1Mjk_b6e040a0-daf0-45df-af96-d0a69fe8c201"
      unitRef="usd">105000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzU0NzQ_e4975096-e575-4444-9c12-3930ed2ffec7"
      unitRef="usd">177000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzU0ODE_d840fc72-0c1c-43d2-965e-321460232390"
      unitRef="usd">259000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90ZXh0cmVnaW9uOmVkYmQwY2VmMWEyODQ3Yjk4YmJhNDZkZjg4MDliZDE2XzY3MDY_cd293575-16b4-4935-9bc1-e1b518e46bbf">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzItMi0xLTEtMA_3fb89553-80da-441e-9220-9e5c915dbd4b"
      unitRef="usd">2031000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzItNC0xLTEtMA_4bfce405-2ed9-4828-9857-091b14b7a668"
      unitRef="usd">1595000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3219b6982b334ae49d4a68c7befc5d27_I20171231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzItNi0xLTEtMA_aef63622-1ac5-45f2-9f9b-0101f6c4dd01"
      unitRef="usd">2181000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzQtMi0xLTEtMA_4c0722d1-6f01-4e72-8a96-9df418eb8d9f"
      unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzQtNC0xLTEtMA_81314ab4-e6be-4ccb-83cc-9b83bf65fd61"
      unitRef="usd">138000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzQtNi0xLTEtMA_f0edb34a-67f5-4b70-bb1f-874f725bfca1"
      unitRef="usd">64000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzUtMi0xLTEtMA_ea558acd-92ce-43f3-b35d-d484f60c478f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzUtNC0xLTEtMA_e5a0023a-d4fb-4d6f-9715-4df5195db77e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzUtNi0xLTEtMA_6ef30095-45f1-43b1-bc7c-a1573de6ecc7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzctMi0xLTEtMA_ba387e03-51be-479b-a423-4e4e7f3c59eb"
      unitRef="usd">398000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzctNC0xLTEtMA_bafcdfb2-8713-437e-b476-bff40610296e"
      unitRef="usd">405000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzctNi0xLTEtMA_d5eb2d5a-3f12-4c89-82db-946f1726387c"
      unitRef="usd">125000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzgtMi0xLTEtMA_c3f8016f-ef9d-4d55-a81e-1b215c631e02"
      unitRef="usd">481000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzgtNC0xLTEtMA_94550528-b0ae-489e-9875-12be3008e57e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzgtNi0xLTEtMA_4bc7a0b7-4527-4c9b-974c-cd028383fb59"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzktMi0xLTEtMA_5da4d534-96f7-46a8-bf5d-d3c2c1e2f380"
      unitRef="usd">454000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzktNC0xLTEtMA_eacb8210-7470-4741-94e5-1501d83ff76a"
      unitRef="usd">104000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzktNi0xLTEtMA_8ea095cc-3f3e-4a0d-add3-7e0a336b26bc"
      unitRef="usd">774000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzEwLTItMS0xLTA_99d9196d-96e0-4579-8f57-21592334dc40"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzEwLTQtMS0xLTA_823f5266-d6ec-4d4e-8ffc-4d16c0ac4d58"
      unitRef="usd">3000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i4434b84f088145049b702ceb08c39437_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzEwLTYtMS0xLTA_42ff9123-136a-4a31-970c-949a376eb97b"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie4a66ea3e27c41739673ae6a3e75680b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzExLTItMS0xLTA_076bf62d-73c1-4368-8e6f-c2e32067852a"
      unitRef="usd">1614000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iaa2d477c63034d369b25d6854cf06afa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzExLTQtMS0xLTA_4bdabb9b-91c4-49d4-992d-49ea337ba793"
      unitRef="usd">2031000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7af2bcb42b64317aa982dc29f82941d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODEvZnJhZzplZGJkMGNlZjFhMjg0N2I5OGJiYTQ2ZGY4ODA5YmQxNi90YWJsZTplMjIyYzVmM2Y3NDc0NjUyOTRhMTU4MTA1ZGZhYjgzMy90YWJsZXJhbmdlOmUyMjJjNWYzZjc0NzQ2NTI5NGExNTgxMDVkZmFiODMzXzExLTYtMS0xLTA_6971f786-bd3e-46b7-8c94-d973ad69b7a4"
      unitRef="usd">1595000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2OTU_1754b449-44e5-4567-b152-3e2a35ff96b2">&lt;div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1st&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2nd&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3rd&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4th&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit on product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit on product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the second quarter of 2020 included an acquired IPR&amp;amp;D expenses of $4.5&#160;billion, or $3.58 per basic and diluted share, primarily related to our acquisition of Forty Seven. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the third quarter of 2020 included acquired IPR&amp;amp;D expenses of $1.0&#160;billion, or $0.82 per basic and diluted share, related to collaborations and other investments we entered into separately with Arcus, Pionyr, Tango and Tizona and $983&#160;million or $0.78 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos. See Note 3. Fair Value Measurements and Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2020 included $628 million, or $0.50 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos and $615&#160;million, or $0.49 per basic and diluted share of acquisition-related expenses primarily from amortization of intangible assets, inventory step-up charges and accelerated stock-based compensation expenses related to our acquisition of Immunomedics. See Note 3. Fair Value Measurements, Note 6. Acquisitions and Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the third quarter of 2019 included upfront collaboration and licensing expenses of $3.92&#160;billion, or $2.40 per basic and diluted share related to the collaboration with Galapagos. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;(5) &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2019 included a $1.2&#160;billion favorable tax effect related to intra-entity intangible asset transfers and $929 million of pre-tax net gains from equity securities primarily our equity investment in Galapagos, partially offset by an $800&#160;million pre-tax impairment charge related to IPR&amp;amp;D intangible assets acquired in connection with the acquisition of Kite and pre-tax write-down charges of $500 million for slow moving and excess raw material and work in process inventory. The impact of these factors resulted in a net favorable impact of $0.83 per basic share and $0.81 per diluted share. See Note 3. Fair Value Measurements, Note 7. Inventories, Note 9. Goodwill and Intangible Assets and Note 18. Income Taxes for additional information</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i539368d6dc914976bc65d538c3d266ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE3MDM_8c299c1a-b0d7-4986-a21e-ebd284fcba3f">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1st&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2nd&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3rd&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4th&#160;Quarter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit on product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross profit on product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Gilead&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share attributable to Gilead common stockholders - diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the second quarter of 2020 included an acquired IPR&amp;amp;D expenses of $4.5&#160;billion, or $3.58 per basic and diluted share, primarily related to our acquisition of Forty Seven. See Note 6. Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the third quarter of 2020 included acquired IPR&amp;amp;D expenses of $1.0&#160;billion, or $0.82 per basic and diluted share, related to collaborations and other investments we entered into separately with Arcus, Pionyr, Tango and Tizona and $983&#160;million or $0.78 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos. See Note 3. Fair Value Measurements and Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2020 included $628 million, or $0.50 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos and $615&#160;million, or $0.49 per basic and diluted share of acquisition-related expenses primarily from amortization of intangible assets, inventory step-up charges and accelerated stock-based compensation expenses related to our acquisition of Immunomedics. See Note 3. Fair Value Measurements, Note 6. Acquisitions and Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts for the third quarter of 2019 included upfront collaboration and licensing expenses of $3.92&#160;billion, or $2.40 per basic and diluted share related to the collaboration with Galapagos. See Note 11. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;(5) &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2019 included a $1.2&#160;billion favorable tax effect related to intra-entity intangible asset transfers and $929 million of pre-tax net gains from equity securities primarily our equity investment in Galapagos, partially offset by an $800&#160;million pre-tax impairment charge related to IPR&amp;amp;D intangible assets acquired in connection with the acquisition of Kite and pre-tax write-down charges of $500 million for slow moving and excess raw material and work in process inventory. The impact of these factors resulted in a net favorable impact of $0.83 per basic share and $0.81 per diluted share. See Note 3. Fair Value Measurements, Note 7. Inventories, Note 9. Goodwill and Intangible Assets and Note 18. Income Taxes for additional information</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItMi0xLTEtMA_19b95157-1327-4251-a786-1993f1f602c4"
      unitRef="usd">5548000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItNC0xLTEtMA_1441604a-5def-4f02-8ea5-e676dbb5fcf2"
      unitRef="usd">5143000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItNi0xLTEtMA_a02f4329-47a4-4c33-9085-7dcc8fca0e12"
      unitRef="usd">6577000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzItOC0xLTEtMA_c3fdde12-61b4-41b9-bf15-572ab307a7b7"
      unitRef="usd">7421000000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtMi0xLTEtMA_e749a3d6-ffd8-466f-ab79-434e424c6566"
      unitRef="usd">4498000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtNC0xLTEtMA_4c366f7f-268d-4e2d-85f0-14f0297ea317"
      unitRef="usd">4003000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtNi0xLTEtMA_a9d0380c-2537-4806-9d3a-990bc1a148dc"
      unitRef="usd">5352000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzMtOC0xLTEtMA_58c0923d-d701-4170-975a-0b3c98ec24f9"
      unitRef="usd">5930000000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtMi0xLTEtMA_2e7b1a56-31a4-4227-89aa-987ccba286ee"
      unitRef="usd">1538000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtNC0xLTEtMA_ab97887c-a93f-4834-bfbe-688f7cdea8fb"
      unitRef="usd">-3346000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtNi0xLTEtMA_9f6bc14f-5636-4a65-8f2b-a0fc70de119f"
      unitRef="usd">353000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzQtOC0xLTEtMA_2ac3ce4f-36a7-4499-a943-d6f6df279c56"
      unitRef="usd">1544000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtMi0xLTEtMA_ef84ebbb-8c75-4aa6-a412-13e2c41bc2bf"
      unitRef="usd">1551000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtNC0xLTEtMA_2071bb95-a40c-4dc0-8e43-bf249928b38d"
      unitRef="usd">-3339000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtNi0xLTEtMA_a3e92725-6d04-428e-b8ec-0b8c3a2af508"
      unitRef="usd">360000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzUtOC0xLTEtMA_390e443d-2385-4fd7-8a5c-ca6d6a811777"
      unitRef="usd">1551000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtMi0xLTEtMA_26b0fac4-55a2-431b-8f3f-110986ad6dce"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtNC0xLTEtMA_58486946-7a0e-4b1d-9236-8338917673c1"
      unitRef="usdPerShare">-2.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtNi0xLTEtMA_b3501333-5613-44c1-8ef4-961a328cbe93"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzYtOC0xLTEtMA_a1dc9452-173e-4b13-b766-80ccfa4a97c1"
      unitRef="usdPerShare">1.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia3f1d854478d4c5c8dc8e86c6b71bdb2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctMi0xLTEtMA_cbca6b48-3fac-4fd9-9ada-84497532fdd3"
      unitRef="usdPerShare">1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief2c3a12885b4047bc7c88d5e62cbbab_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctNC0xLTEtMA_7f816c6b-0ab0-46f5-a1ff-76d828abbaef"
      unitRef="usdPerShare">-2.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i77cef37fc6234580adbbfa6567c55239_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctNi0xLTEtMA_c3184e0e-9240-437c-b81d-3525656846a3"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9948876c76f3482dab23bee8b78d894e_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzctOC0xLTEtMA_251b1c27-6673-4518-b9b0-9ae3f9d9c231"
      unitRef="usdPerShare">1.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktMi0xLTEtMA_46df461b-a428-44a3-b1b1-86ade95aeb12"
      unitRef="usd">5281000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktNC0xLTEtMA_c3f74033-a42b-4eb3-8a95-1e7814c8e3d3"
      unitRef="usd">5685000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktNi0xLTEtMA_68cc0bf8-edf2-489a-abdb-fc6bd7ad46db"
      unitRef="usd">5604000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzktOC0xLTEtMA_b804db79-ec81-4927-b508-05df28697ea0"
      unitRef="usd">5879000000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTItMS0xLTA_bfaf0192-f704-4c63-ab31-5d1534954e9c"
      unitRef="usd">4243000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTQtMS0xLTA_5fa878e4-0b45-4a8a-880b-3bc820122c75"
      unitRef="usd">4607000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTYtMS0xLTA_c2cc8b3c-dbaf-4c26-8a42-bde7ac89a06a"
      unitRef="usd">4481000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEwLTgtMS0xLTA_9fda3f61-5ec5-497a-bce2-54045c118093"
      unitRef="usd">4113000000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTItMS0xLTA_f7733950-acc3-4aa0-a099-4f2014ff3462"
      unitRef="usd">1968000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTQtMS0xLTA_8bd3e0dd-2189-43d6-ad05-f3c7bd5a1a88"
      unitRef="usd">1875000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTYtMS0xLTA_7c367c9c-02fa-44fd-9877-69590e993a94"
      unitRef="usd">-1168000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzExLTgtMS0xLTA_82fab593-c4af-4c7d-bd25-d4a2f400c76c"
      unitRef="usd">2689000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTItMS0xLTA_c9512055-1cca-4cba-b08b-565308a3980c"
      unitRef="usd">1975000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTQtMS0xLTA_9276baca-2d90-4a34-810e-193e34b71375"
      unitRef="usd">1880000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTYtMS0xLTA_fbf89c91-306f-477e-a823-e9242c5cd498"
      unitRef="usd">-1165000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEyLTgtMS0xLTA_af0be3ed-e703-47f0-bad5-f7e064fc6a60"
      unitRef="usd">2696000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTItMS0xLTA_3d98c38b-d79e-43e9-b890-1c704848a597"
      unitRef="usdPerShare">1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTQtMS0xLTA_6be0ef00-c4d6-4f61-8781-5d4e2c3dbffd"
      unitRef="usdPerShare">1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTYtMS0xLTA_3297227e-0854-41aa-ad38-e94dbcd3005c"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzEzLTgtMS0xLTA_90d3ce29-4e97-4adb-819a-3973e0260ff3"
      unitRef="usdPerShare">2.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie1e1b632b3f34186bd0f907c79d89660_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTItMS0xLTA_b3a79f09-6fff-43c9-ad7c-78a91154ff39"
      unitRef="usdPerShare">1.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id66cb14ab8a24879be29e46cbe0050f0_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTQtMS0xLTA_b6812613-ed23-4c2a-9652-cb967f85ac2a"
      unitRef="usdPerShare">1.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia936f732d5874444bc071590f7cdf9f1_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTYtMS0xLTA_78c16e42-42d2-406c-8bbc-642d23d6ad2f"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90YWJsZToyY2QwZGQzNGUzYzE0M2Y4OWVmOGM0NGRjN2YwMWFjYy90YWJsZXJhbmdlOjJjZDBkZDM0ZTNjMTQzZjg5ZWY4YzQ0ZGM3ZjAxYWNjXzE0LTgtMS0xLTA_ab181423-fb1c-4484-9253-f67f529a21da"
      unitRef="usdPerShare">2.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5Mzc_c7af923c-85cc-41bd-bb17-771a27157db3"
      unitRef="usd">4500000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4Njg_8863507a-8d16-4ed2-b169-bf4184430d9e"
      unitRef="usdPerShare">3.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3966f87ce2cd4f969fbf6dbbb9019128_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4Njg_a426c3ff-e5c8-42eb-90c1-f34a930435ba"
      unitRef="usdPerShare">3.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4NTQ_342f7a50-3b60-45d5-bb04-8dbd8068cb0b"
      unitRef="usd">1000000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4NzU_2ccf23be-7c08-40d3-9e91-c02be0d097d7"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iecbc024738a74f15992e6eb45cbb619c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4NzU_8a2b1ca3-faac-4151-a672-ff0ab39601a4"
      unitRef="usdPerShare">0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4ODI_7c6cc2c3-5e22-4c4b-89fc-89fa41eff96f"
      unitRef="usd">983000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4OTY_26c12b8b-52c5-4c32-955f-1c8c84f5524e"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie3c49f7d13614e309f0311c81a77ef38_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI4OTY_f47aab2d-240d-4905-a4f9-2955ce958220"
      unitRef="usdPerShare">0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2NDkyNjc0NTU1NTE_3219e5d1-53be-4d9b-89cb-d2bebf8e92c7"
      unitRef="usd">628000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2Mzc5MjI_bcb173d1-b2a3-4f54-a71a-49e67a768466"
      unitRef="usdPerShare">0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i14c2b0e90105463796fcb88cb47c8666_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2Mzc5MjI_f36668b7-b721-468f-9c17-b0981f627a1f"
      unitRef="usdPerShare">0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5MDM_92d6def2-28d3-4349-9b01-b2047d34e996"
      unitRef="usd">615000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5MTc_5f44d77e-200b-483b-bdd4-6e58e41aa199"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3bfc492413ac4430bcb3ca69ed274a16_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5MTc_a39964db-6fcc-4e67-b49b-af110c01cc98"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5NjU_500349de-406e-400a-b4d9-c3d83ce28f73"
      unitRef="usd">3920000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzIwOA_46824141-bd55-41b5-be57-8b5d60190101"
      unitRef="usdPerShare">2.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia16f946cbcd54d41a65b638f863babc9_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzIwOA_f07398ac-73a6-4c14-85de-9c56dfd368eb"
      unitRef="usdPerShare">2.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia2ce6de3160c42fcbad2f1b836b16a69_D20191001-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDI5OTM_c84293aa-20a3-4196-923d-8457d6bee3e5"
      unitRef="usd">1200000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="ifcde38bda2ec4ee2a91607db91272226_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2MzQxMzU_d93719f4-515c-4b1f-bfde-bf3f8383b372"
      unitRef="usd">929000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i87a9b56954af4cc390dcc55eaacaf572_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzMyOTg1MzQ5MDMwMjA_70d4231b-3508-4aad-bffa-ac2a214121ea"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="i911b942fdd1a48718de383949eab2834_D20191001-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzEwOTk1MTE2MzkyODc_91f75d54-1466-4dec-b1e3-17c2a59e2659"
      unitRef="usd">500000000</us-gaap:InventoryWriteDown>
    <us-gaap:EarningsPerShareBasic
      contextRef="idf9604006e3f48c2b90d9c9dd73c4174_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2NDkyNjc0NTY1Mjg_3807f0de-3144-46df-95d2-753f056fc454"
      unitRef="usdPerShare">0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idf9604006e3f48c2b90d9c9dd73c4174_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xODQvZnJhZzo2MzY2NDAyZjMwOGI0YzQ4ODgxNmYwOWVhZGRkMDBjNi90ZXh0cmVnaW9uOjYzNjY0MDJmMzA4YjRjNDg4ODE2ZjA5ZWFkZGQwMGM2XzE2NDkyNjc0NTY1NTI_71cc463a-50bf-40fd-ae2a-f03b83d4a194"
      unitRef="usdPerShare">0.81</us-gaap:EarningsPerShareDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256138024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,256,593,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Specified portions of the registrant&#8217;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders, to be held on May 12, 2021, are incorporated by reference into Part&#160;III of this Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288176971736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,997<span></span>
</td>
<td class="nump">$ 11,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">12,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,892<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">15,996<span></span>
</td>
<td class="nump">30,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,967<span></span>
</td>
<td class="nump">4,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,126<span></span>
</td>
<td class="nump">13,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,108<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">5,708<span></span>
</td>
<td class="nump">7,438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">68,407<span></span>
</td>
<td class="nump">61,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_Accruedgovernmentandotherrebates', window );">Accrued government and other rebates</a></td>
<td class="nump">3,460<span></span>
</td>
<td class="nump">3,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">4,336<span></span>
</td>
<td class="nump">3,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,397<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">28,645<span></span>
</td>
<td class="nump">22,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">5,016<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 authorized; 1,254 and 1,266 shares issued and outstanding, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,381<span></span>
</td>
<td class="nump">19,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">18,202<span></span>
</td>
<td class="nump">22,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">18,221<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 68,407<span></span>
</td>
<td class="nump">$ 61,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_Accruedgovernmentandotherrebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued government and other rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_Accruedgovernmentandotherrebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257552184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600,000,000<span></span>
</td>
<td class="nump">5,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="nump">1,266,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,254,000,000<span></span>
</td>
<td class="nump">1,266,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181513752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 24,689<span></span>
</td>
<td class="nump">$ 22,449<span></span>
</td>
<td class="nump">$ 22,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,572<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
<td class="nump">4,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">5,039<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ResearchAndDevelopmentInProcessIncludingImpairment', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">5,151<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">20,618<span></span>
</td>
<td class="nump">18,162<span></span>
</td>
<td class="nump">13,927<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">4,071<span></span>
</td>
<td class="nump">4,287<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(984)<span></span>
</td>
<td class="num">(995)<span></span>
</td>
<td class="num">(1,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,418)<span></span>
</td>
<td class="nump">1,868<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">5,160<span></span>
</td>
<td class="nump">7,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interest</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
<td class="nump">$ 5,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 24,355<span></span>
</td>
<td class="nump">$ 22,119<span></span>
</td>
<td class="nump">$ 21,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ResearchAndDevelopmentInProcessIncludingImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development in Process, Including Impairment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ResearchAndDevelopmentInProcessIncludingImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256455912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 5,364<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss), net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain, net of tax</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income, net of tax</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain (loss), net of tax</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassification to net income, net of tax</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">5,369<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interest</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Gilead</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="nump">$ 5,391<span></span>
</td>
<td class="nump">$ 5,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288182201704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning period (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 20,501<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1,264<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 19,012<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,455<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(3,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(2,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">21,534<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,282<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">19,024<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,386<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (3,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 22,650<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">19,388<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (3,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3,880<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
<td class="nump">$ 14,381<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257083272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181975576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 5,364<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(2,098)<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net (gains) losses from equity securities</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="num">(1,241)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">5,856<span></span>
</td>
<td class="nump">4,251<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_Inventoryreserveforexcessrawmaterials', window );">Write-downs for slow moving and excess raw material and work in process inventory</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(1,171)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(778)<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">640<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="num">(514)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">8,168<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities</a></td>
<td class="num">(20,315)<span></span>
</td>
<td class="num">(30,455)<span></span>
</td>
<td class="num">(10,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">23,239<span></span>
</td>
<td class="nump">7,523<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">9,479<span></span>
</td>
<td class="nump">22,398<span></span>
</td>
<td class="nump">24,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(25,742)<span></span>
</td>
<td class="num">(4,251)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(455)<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
<td class="num">(924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(14,615)<span></span>
</td>
<td class="num">(7,817)<span></span>
</td>
<td class="nump">14,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt financing, net of issuance costs</a></td>
<td class="nump">8,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(1,583)<span></span>
</td>
<td class="num">(1,749)<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="num">(2,750)<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(3,449)<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
<td class="num">(2,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">770<span></span>
</td>
<td class="num">(7,634)<span></span>
</td>
<td class="num">(12,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">43<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(5,634)<span></span>
</td>
<td class="num">(6,309)<span></span>
</td>
<td class="nump">10,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">11,631<span></span>
</td>
<td class="nump">17,940<span></span>
</td>
<td class="nump">7,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">11,631<span></span>
</td>
<td class="nump">17,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid, net of amounts capitalized</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 2,639<span></span>
</td>
<td class="nump">$ 1,793<span></span>
</td>
<td class="nump">$ 3,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_Inventoryreserveforexcessrawmaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve for excess raw materials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_Inventoryreserveforexcessrawmaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175375224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead&#8221;, &#8220;we&#8221;, &#8220;our&#8221; or &#8220;us&#8221;), incorporated in Delaware on June&#160;22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we strive to transform and simplify care for people with life-threatening illnesses around the world. We have operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead&#8217;s primary areas of focus include HIV, viral hepatitis and cancer. We seek to add to our existing portfolio of products through our internal discovery and clinical development programs, product acquisition, in-licensing and strategic collaborations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Jyseleca varies worldwide, and Jyseleca is not approved in the United States. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the United States through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether we are the primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer (&#8220;CEO&#8221;), as the chief operating decision-maker, manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies, Estimates and Judgments </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Acquired IPR&amp;D expenses on our Consolidated Statements of Income reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. Our Consolidated Statements of Income for the years ended December 31, 2019 and 2018 have been conformed to separately present acquired IPR&amp;D expenses. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Statement of Cash Flows for the year ended December 31, 2019, has been conformed to separately present acquired IPR&amp;D expenses exclusive of IPR&amp;D impairments. Comparative amounts in our Consolidated Statement of Cash Flows for the year ended December 31, 2018 were not material. There was no change in income from operations or operating cash flow as a result of these reclassifications.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized, net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions, and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and in some instances by type of product. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a significant financing component. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross to Net Deductions</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates every quarter to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty, Contract and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, payments under collaborative and other arrangements, including milestone payments, license and option fees, as well as expense reimbursements to the collaboration partners and overhead allocations consisting of various support and infrastructure costs. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge R&amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;A expenses also include the branded prescription drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $795 million, $784 million and $587 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable and Nonmarketable Securities</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) as a separate component of stockholders&#8217; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and Non-Marketable Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investment in Galapagos NV (&#8220;Galapagos&#8221;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of the investment. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the year ended December&#160;31, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted Accounting Standards Update No. 2016-02 (Topic 842) &#8220;Leases,&#8221; which requires lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. We adopted Topic 842 using the modified retrospective method. As such, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840 &#8220;Leases.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in our Consolidated Statements of Income unless there is an alternative future use.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Contingent Consideration Resulting from a Business Combination</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value in R&amp;D expense within our Consolidated Statement of Income until such time that the related product candidate receives marketing approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Changes in the fair value of derivatives designated as part of a hedge transaction are recorded each period in current earnings or AOCI. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in current earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities related to unrecognized tax benefits in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;), enacted as part of the Tax Cuts and Jobs Act (&#8220;Tax Reform&#8221;), as a component of tax expense in the period in which the tax is incurred (&#8220;period cost method&#8221;).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Significant Accounting Policies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other significant accounting policies are described in the remaining appropriate notes to the Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016,&#160;the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13 &#8220;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; and has since modified the standard with several ASUs (collectively, &#8220;Topic 326&#8221;).&#160;Topic 326 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, we adopted this standard using a modified retrospective approach.&#160;The adoption did not have a material impact on our Consolidated Financial Statements. In connection with the adoption of Topic 326, we made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018,&#160;the FASB issued Accounting Standards Update No. 2018-18 &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221; (&#8220;ASU 2018-18&#8221;).&#160;ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606, &#8220;Revenue from Contracts with Customers&#8221; when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as customer revenue if the counterparty is not a customer for that transaction. On January 1, 2020, we adopted this standard and applied it retrospectively to January 1, 2018 when we initially adopted Topic 606. The adoption did not have an impact on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173844248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenues </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.906%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">HIV Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;) Products</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy Products </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Cell Therapy product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Other Products </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Hepsera and Jyseleca.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues From Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $841 million and $741 million for the years ended December&#160;31, 2020 and 2019, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $101 million increase and a $257 million increase in revenues for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $198 million and $144 million as of December&#160;31, 2020 and 2019, respectively. Contract liabilities were</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$97 million and $45 million as of December&#160;31, 2020 and 2019, respectively. During 2020 and 2019, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173791384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows: </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities; </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. For our marketable securities, we review trading activity and pricing as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data; and </span></div><div style="margin-top:4.5pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist primarily of cash and cash equivalents, marketable debt securities, accounts receivable, foreign currency exchange contracts, equity securities, accounts payable and short-term and long-term debt. Cash and cash equivalents, marketable debt securities, certain equity securities, and foreign currency exchange contracts are reported at their respective fair values in our Consolidated Balance Sheets. Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Short-term and long-term debt are reported at their amortized costs in our Consolidated Balance Sheets. The remaining financial instruments are reported in our Consolidated Balance Sheets at amounts that approximate current fair values. </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments not measured at fair value and excluded from the above table were limited partnerships and other equity method investments of $58 million and $24 million at December&#160;31, 2020 and 2019, respectively and other equity investments without readily determinable fair values of $204 million and $82 million at December&#160;31, 2020 and 2019, respectively. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of equity securities resulted in net unrealized losses of $1.7 billion and net unrealized gains of $1.2 billion for the years ended December&#160;31, 2020 and 2019, respectively, which were included in Other income (expense), net, on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities in our Consolidated Balance Sheets:</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale debt securities are classified as cash equivalents, short-term marketable securities and long-term marketable securities in our Consolidated Balance Sheets. See Note 4. Available-for-Sale Debt Securities for additional information. See Note 11. Collaborations and Other Arrangements for additional information on our equity investment in Galapagos.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair values of Level 2 instruments by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18 month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, London Interbank Offered Rates and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our aggregate short-term and long-term senior unsecured notes and term loan facility, determined using Level 2 inputs based on their quoted market values, were approximately $34.6 billion and $27.3 billion at December&#160;31, 2020 and 2019, respectively, and the carrying values were $30.3 billion and $24.6 billion at December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3 Inputs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we measured assets acquired and liabilities assumed at fair value on a nonrecurring basis, in connection with our acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;). See Note 6. Acquisitions for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, in connection with collaborations and other equity arrangements we entered into separately with Pionyr Immunotherapeutics, Inc. (&#8220;Pionyr&#8221;) and Tizona Therapeutics, Inc. (&#8220;Tizona&#8221;), we also measured fair values of our exclusive options to acquire the remaining outstanding capital stock of Pionyr and Tizona on a nonrecurring basis. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019 and 2018, we measured IPR&amp;D intangible assets acquired in connection with the acquisition of Kite Pharma, Inc. (&#8220;Kite&#8221;) at fair value on a nonrecurring basis, and recognized pre-tax impairment charges of $800 million and $820 million, respectively. The fair values of the acquired IPR&amp;D assets are estimated based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs include estimated revenues, costs, probability of technical and regulatory success and discount rates. Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts. See Note 9. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other level 3 liabilities were our contingent consideration liabilities, which were not material at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize transfers into or out of Level 3 classification as of the actual date of the event or change in circumstances that caused the transfer. There were no transfers between Level 1, Level 2 and Level 3 in the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257110040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available-for-sale debt securities</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities was $9 million and $37 million as of December&#160;31, 2020 and 2019, respectively, and is recorded in Prepaid and other current assets on our Consolidated Balance Sheets. There were no write-offs of accrued interest receivable during the years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a total of 75 and 305 positions which were in an unrealized loss position as of December&#160;31, 2020 and 2019, respectively. Aggregated gross unrealized losses on available-for-sale corporate debt securities were not material, and accordingly, no impairments were recognized for the years ended December&#160;31, 2020 and 2019. Gross realized gains and gross realized losses on available-for-sale debt securities were not material for the years ended December&#160;31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175158024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative financial instruments</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we may hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward or option contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates, and as a result, varies over time. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for certain monetary assets and liabilities that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are not designated as hedges, and as a result, changes in their fair value are recorded in Other income (expense), net, on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge our exposure to foreign currency exchange rate fluctuations for forecasted product sales that are denominated in a non-functional currency. The derivative instruments we use to hedge this exposure are designated as cash flow hedges and have maturities of 18 months or less. Upon executing a hedging contract and quarterly thereafter, we assess hedge effectiveness using regression analysis. The unrealized gains or losses in AOCI are reclassified into product sales when the respective hedged transactions affect earnings. The majority of gains and losses related to the hedged forecasted transactions reported in AOCI at December&#160;31, 2020 are expected to be reclassified to product sales within 12 months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the years ended December&#160;31, 2020, 2019 and 2018 are included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had notional amounts on foreign currency exchange contracts outstanding totaling $2.4 billion and $2.9 billion at December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts on a gross basis. The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.339%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may discontinue cash flow hedges and, as a result, record related amounts in Other income (expense), net on our Consolidated Statements of Income. There were no discontinuances of cash flow hedges for the years presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we only held foreign currency exchange contracts.&#160;The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174150184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">ACQUISITIONS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forty Seven, Inc. (&#8220;Forty Seven&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On&#160;April 7, 2020, we acquired all of the then issued and outstanding common stock of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $95.50 per share in cash, for total consideration of $4.7 billion, net of acquired cash. As a result, Forty Seven became our wholly-owned subsidiary. Forty Seven&#8217;s lead program, magrolimab, is an investigational monoclonal antibody in clinical development for the treatment of myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma and solid tumors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. At the acquisition date, we recorded a $4.5 billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses on our Consolidated Statements of Income. In connection with this acquisition, we recorded $202 million of assets acquired primarily consisting of deferred tax assets. Liabilities assumed were not material. We also recorded stock-based compensation expense of $144 million related to the cash settlement of unvested Forty Seven employee stock awards attributable to post-acquisition services, which was primarily recorded in Research and development expenses on our Consolidated Statements of Income, for the year ended December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunomedics</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 13, 2020, we entered into an agreement and plan of merger (&#8220;Agreement and Plan of Merger&#8221;) to acquire Immunomedics, a company focused on the development of antibody-drug conjugate (&#8220;ADC&#8221;) technology. Immunomedics researches and develops biopharmaceutical products, particularly antibody-based products for patients with solid tumors and blood cancers, and manufactures and markets Trodelvy. Trodelvy, a Trop-2-directed ADC developed by Immunomedics, is the first ADC FDA approved for the treatment of adult patients with metastatic triple-negative breast cancer (&#8220;mTNBC&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the acquisition was completed and Immunomedics became a wholly-owned subsidiary of Gilead. The financial results of Immunomedics were included in our consolidated financial results for the year ended December 31, 2020 from the date of the acquisition. Immunomedics contributed $49 million of revenues and an immaterial net loss from the date of the acquisition through December&#160;31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration for the acquisition was $20.6 billion, consisting of a $20.4 billion cash payment to the outstanding Immunomedics common stockholders and a $242 million cash payment to equity award holders of Immunomedics for the vested equity awards and accelerated vesting of stock-based awards attributable to the pre-combination period. We financed the acquisition with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. This method requires, among other things, that assets acquired and liabilities assumed be generally recognized at fair value as of the acquisition date. The fair value estimates for the assets acquired and liabilities assumed were based upon valuations using information known and knowable as of the date of this filing. Changes to these assumptions and estimates could cause an impact to the valuation of assets acquired, including intangible assets, goodwill and the related tax impacts of the acquisition, as well as legal and other contingencies. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded share-based compensation expense of $289 million related to the cash settlement of the accelerated share-based compensation expense attributable to the post combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. We also recorded other acquisition-related expenses of $39 million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December 31, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value step-up adjustment of $881 million, included in the inventories of $946 million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment is being recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory is sold to customers from the acquisition date. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $4.6 billion represents the estimated fair value of Trodelvy for mTNBC as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for mTNBC and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 12 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets related to IPR&amp;D consist of Trodelvy for hormone receptor positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;), metastatic breast cancer, Trodelvy for non-small cell lung cancer (&#8220;NSCLC&#8221;) and Trodelvy for urothelial cancer. The estimated aggregate fair value of&#160;$15.8 billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to these assets and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing of projected future cash flows (including revenue, cost of sales, research and development costs, sales and marketing expenses); probability of success; the discount rate selected to measure inherent risk of future cash flows; and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived assets until the completion or abandonment of the associated R&amp;D efforts. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded an intangible asset related to a license and supply agreement with a third party, which was entered into by Immunomedics prior to the acquisition. Under the agreement, the third party was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $175 million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of 7.0%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 15 years on a straight-line basis. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used for valuing these identifiable intangibles are unobservable and considered Level 3 under the fair value measurement and disclosure guidance. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated book basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust, a Delaware statutory trust (&#8220;RPI&#8221;), prior to the completion of our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $1.1 billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and effective annual interest rate of 2.5%. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 12. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $4.0 billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Pro Forma Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following pro forma information presents the combined results of operations of Gilead and Immunomedics as if the acquisition of Immunomedics had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary adjustments include: (i) post-combination compensation expense of $289 million related to the acceleration of unvested share-based awards of Immunomedics, (ii) the impact of additional interest expense in connection with the Immunomedics acquisition borrowings as well as the liability related to future royalties, (iii) amortization of the finite-lived intangible asset related to Trodelvy for mTNBC beginning on April 22, 2020 when it received FDA accelerated approval, (iv) amortization of the acquired Immunomedics&#8217; inventory related to Trodelvy mTNBC over the period in which the inventory was expected to be sold beginning on April 22, 2020, (v) amortization of the license and supply agreement with a third party over an estimated useful life of 15 years, (vi) the impacts of the sale of marketable securities based on their use as a source of liquidity to fund the acquisition, and (vii) acquisition-related transaction costs. The unaudited pro forma financial results do not reflect any operating efficiencies or potential cost savings which may result from the consolidation of the operations of Gilead and Immunomedics. Accordingly, these unaudited pro forma financial results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of 2019, nor are they indicative of future results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYR GmbH (&#8220;MYR&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2020, we entered into a definitive agreement pursuant to which we expect to acquire MYR, a German biotechnology company, for approximately &#8364;1.2 billion in cash (or approximately $1.4 billion using a foreign currency exchange rate of 1.2 at December 31, 2020), which is payable upon closing of the transaction and a potential future milestone payment of up to &#8364;300 million (or approximately $360 million using a foreign currency exchange rate of 1.2 at December 31, 2020), upon FDA approval of Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Both payments are subject to customary adjustments. MYR focuses on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;). The acquisition will provide Gilead with Hepcludex, which was conditionally approved by the European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consummation of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act, and receipt of merger control and foreign direct investment approvals in certain European jurisdictions and certain other customary closing conditions. We anticipate that the closing of the transaction will occur by the end of the first quarter of 2021 and expect our acquisition of MYR to be accounted for as a business combination using the acquisition method of accounting upon closing.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175838120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES<div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported as other long-term assets primarily consisted of raw materials as of December&#160;31, 2020 and 2019. Total inventories at December 31, 2020 include fair value adjustments resulting from the Immunomedics acquisition which will be recognized in future periods. See Note 6. Acquisitions for additional information.</span></div>Inventory write down charges for the year ended December&#160;31, 2020 were not material. During the year ended December&#160;31, 2019, we recorded inventory write down charges of $649 million, of which $547 million was related to slow moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products. During the year ended December&#160;31, 2018, we recorded inventory write down charges of $572 million, of which $440 million was related to excess raw materials primarily due to a sustained decrease in demand for Harvoni.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175256968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had unamortized capitalized software costs, included in Office, computer equipment and other, of $124 million and $108 million as of December&#160;31, 2020 and 2019, respectively. Capitalized interest on construction in-progress is included in Property, plant and equipment. Interest capitalized in 2020, 2019 and 2018 was not material.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net book value of our property, plant and equipment (less office, computer equipment and other) in the United States was $3.8 billion as of December&#160;31, 2020, $3.5 billion as of December&#160;31, 2019 and $3.2 billion as of December&#160;31, 2018. The corresponding amount in international locations was $897 million as of December&#160;31, 2020, $791 million as of December&#160;31, 2019 and $620 million as of December&#160;31, 2018. All individual international locations accounted for less than 10% of the total balances.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174129336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and intangible assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of Immunomedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an annual goodwill impairment assessment in the fourth quarter, or earlier if impairment indicators exist. As of December&#160;31, 2020, there were no accumulated goodwill impairment losses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel (DLBCL)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy for mTNBC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $1.2 billion, $1.1 billion and $1.2 billion for the years ended December&#160;31, 2020, 2019 and 2018, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts capitalized as IPR&amp;D are subject to impairment testing until the completion or abandonment of the associated R&amp;D efforts</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we performed quantitative impairment testing of our IPR&amp;D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate of 8%. No IPR&amp;D impairment charges were recorded in 2020. During 2019, we performed quantitative impairment testing of our IPR&amp;D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of 9.5%, which is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. In comparison to the 2018 assessment, we used lower estimated revenues in 2019 due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&amp;D intangible assets, primarily related to axicabtagene ciloleucel for the treatment of indolent B-cell non-Hodgkin lymphoma (&#8220;iNHL&#8221;), below carrying value resulting in the recognition of an impairment charge of $800 million, which was recorded within Research and development expenses on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we concluded that the KITE-585 program did not justify further efforts based on the totality of the clinical data gathered and discontinued the program. As a result, the carrying value of the IPR&amp;D relating to the KITE-585 program was written down to zero and we recorded an impairment charge of $820 million within Research and development expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2020:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175829848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other financial information</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Accrued Liabilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other accrued liabilities:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174133512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeandOtherArrangementsTextBlock', window );">Collaborations and other arrangements</a></td>
<td class="text">COLLABORATIONS AND OTHER ARRANGEMENTS <div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue licensing and strategic collaborations and other similar arrangements with third parties for, and equity investments in third parties focused on, the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements and cost-sharing arrangements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2020, we acquired 2.2 million shares of the common stock of Arcus, a publicly traded oncology-focused biopharmaceutical company, for approximately $61 million in a secondary equity offering. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, on&#160;May 27, 2020, we entered into a transaction with Arcus, which included entry into an option, license and collaboration agreement (the &#8220;Arcus Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended, the &#8220;Arcus Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Arcus Collaboration Agreement and Arcus Stock Purchase Agreements, on July 13, 2020, we made an upfront payment of $175 million and acquired approximately 6.0 million additional shares of Arcus&#8217; common stock for $200 million in accordance with the terms of the Arcus Collaboration Agreement and Arcus Stock Purchase Agreements. Of the total $391 million initial cash payments made under the agreements and direct transactional costs, we recorded $135 million as an equity investment, which was calculated based on Arcus&#8217; closing stock price of $22.67 on the closing date of the transaction. We recorded our equity investments in Arcus in Other long-term assets on our Consolidated Balance Sheets as the investments are subject to contractual lock-up provisions for a period up to 2 years from the closing date of the agreements, subject to certain conditions. We account for our equity investments in Arcus at fair value with changes in fair value recognized in Other income (expense), net for each reporting period. The remaining $256 million was attributed to the acquired license and option rights of $175 million representing IPR&amp;D assets with no alternative future use, $65 million of an issuance premium for the equity purchase and $16 million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income. In an event subsequent to December 31, 2020, on January 31, 2021, we amended and restated the common stock purchase agreement, pursuant to which we acquired approximately 5.7 million additional shares of Arcus&#8217; common stock for $220 million on February 8, 2021. As a result, combined with our existing share holdings, we own 13.8 million shares of Arcus, representing approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the transaction. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead has the right to opt-in to all current and future investigational product candidates that emerge from Arcus&#8217; research portfolio for the ten years following the closing of the transaction. Upon our exercise of an option for a program, unless Arcus opts out according to the terms of the Arcus Collaboration Agreement, the companies will co-develop and share global development costs and co-commercialize and share profits in the U.S. We will obtain exclusive rights to commercialize any optioned programs outside of the U.S., subject to any rights of Arcus&#8217; existing partners, for which we will pay to Arcus tiered royalties ranging from the high teens to the low twenties on net sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Arcus Collaboration Agreement, subject to certain limited exceptions, we are required to provide $100&#160;million to Arcus on the second anniversary of the agreement and may pay an additional $100 million at our option on each of the fourth, sixth, and eighth anniversaries of the agreement, unless terminated early, as ongoing research and development support to extend our collaboration term to up to 10 years. Accordingly, during the year ended December 31, 2020, we recorded a $100 million charge representing the contractually committed payment in Acquired in-process research and development expenses on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Arcus Collaboration Agreement, we will potentially provide up to $1.2 billion in opt-in and milestone payments with respect to current clinical product candidates, if and when such payments are triggered under the Arcus Collaboration Agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Arcus Stock Purchase Agreements, we have the right to purchase additional shares of Arcus from Arcus over the next five years, up to a maximum of 35% of the outstanding voting stock. We are subject to a three-year standstill restricting our ability to acquire voting stock of Arcus exceeding more than 35% of the then issued and outstanding voting stock of Arcus, subject to certain exceptions. Additionally, we agreed not to dispose of any equity securities of Arcus prior to the second anniversary of the closing of the Arcus Stock Purchase Agreements without the prior consent of Arcus, subject to certain exceptions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#8220;Pionyr Merger and Option Agreements&#8221;) and a research and development service agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, we closed the transaction with Pionyr and paid $269 million in cash and accrued an additional $6 million payable, subject to certain customary adjustments, to Pionyr&#8217;s shareholders in accordance with the terms of the Pionyr Merger and Option Agreements. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#8217;s IPR&amp;D which has no alternative future use and that Pionyr is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount was recorded in Other long-term assets on our Consolidated Balance Sheets. From the first anniversary of the closing date, we may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#8217;s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the research and development service agreement, we made an initial cash funding of $80 million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $115 million to Pionyr upon achievement of certain development milestones. We accrued $70&#160;million milestone payments, related to the initiation of two Phase-1 studies, with a charge to Research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. Subsequently, in February 2021, milestone cash payments of $70 million were made.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tizona</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#8220;Tizona Merger and Option Agreements&#8221;) and a development agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, we closed the transaction with Tizona and paid $302 million in cash to Tizona&#8217;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#8217;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#8217;s IPR&amp;D with no alternative future use and that Tizona is not a business as defined in ASC 805, &#8220;Business Combinations.&#8221; As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $272 million in Acquired in-process research and development expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $41 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount was recorded in Other long-term assets on our Consolidated Balance Sheets. From the first anniversary of the closing date, we may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#8217;s current shareholders for up to $1.3 billion, including an option fee and potential future milestone payments upon achievement of certain development and regulatory milestones, in each case subject to certain negotiated adjustments. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the development agreement, we committed to provide funding to Tizona of $115 million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tango Therapeutics, Inc. (&#8220;Tango&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#8220;Tango Collaboration and Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this transaction, we made an upfront payment of $125 million and a $20 million equity investment in Tango, representing approximately 7% of the issued and outstanding voting stock of Tango immediately following the transaction, in accordance with the terms of the Tango Collaboration and Stock Purchase Agreements. During the year ended December 31, 2020, we recorded the $125 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. Our equity investment in Tango is recorded at cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of Tango.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#8220;Jounce License and Stock Purchase Agreement&#8221;). In October 2020, we closed this transaction and made a total payment of $120 million in accordance with the terms of the Jounce License and Stock Purchase Agreement and recorded $56 million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately 14% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#8217;s closing stock price of $10.06 on the closing date of the transaction. During the year ended December 31, 2020, we recorded $64 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In addition, we will provide up to $685 million in future potential clinical, regulatory and commercial milestone payments upon achievement of certain milestones, and pay Jounce royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Galapagos</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Filgotinib Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#8220;filgotinib agreement&#8221;). Upon closing, we made an upfront license fee payment and an equity investment in Galapagos by subscribing for 6.8 million new ordinary shares of Galapagos at a price of &#8364;58 per share. The equity investment, net of issuance premium, was $357 million. We amended the terms of the filgotinib agreement in 2019 and then in 2020 agreed to amend the terms further. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the filgotinib agreement, as amended in 2019 (the &#8220;2019 Agreement&#8221;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. As of December&#160;31, 2019, Galapagos was eligible to receive from us potential future development and regulatory milestone-based payments of up to $640 million, sales-based milestone payments of up to $600 million, plus tiered royalties on global net sales ranging from 20% to 30%, with the exception of certain co-commercialization territories where profits would be shared equally. The co-commercialization territories were the UK, Germany, France, Italy, Spain, Belgium, the Netherlands and Luxembourg. We shared global development costs for filgotinib equally. Termination of the agreement could be on a country-by-country basis and depends on the circumstances, including expiration of royalty term or in the co-commercialization territories, sale of a generic product, or material breach by either party. We could also terminate the entire agreement without cause following a certain period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, following a Type A meeting with FDA to discuss the points raised in the Complete Response Letter related to the New Drug Application for filgotinib in the treatment of rheumatoid arthritis, Gilead and Galapagos agreed to amend the 2019 Agreement where Galapagos will assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe. Through a phased transition including the transfer of filgotinib&#8217;s marketing authorization to Galapagos, the parties intend to transfer most activities by December 31, 2021 and complete the transition by December 31, 2022. The transfer will be subject to applicable local legal, regulatory and consultation requirements. Beginning on January 1, 2021, Galapagos bears the development costs for certain studies, in lieu of the equal cost split contemplated by the 2019 Agreement. All commercial economics on filgotinib in Europe will transfer to Galapagos as of January 1, 2022, subject to payment of tiered royalties of 8% to 15% of net sales in Europe to Gilead, starting in 2024. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#8364;160 million (or approximately $190 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is subject to certain adjustments for higher than budgeted development costs. Of this total amount, Gilead paid &#8364;35 million (or approximately $42 million) in January 2021 and will pay an additional &#8364;75 million (or approximately $89 million) in 2021 and will pay &#8364;50 million (or approximately $60 million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe. For the periods presented, the payments between Galapagos and us for the development costs and milestones were not material.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;August 2019, we closed an option, license and collaboration Agreement (the &#8220;Galapagos Collaboration Agreement&#8221;) and a subscription agreement (the &#8220;Galapagos Subscription Agreement&#8221;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#8217; current and future product portfolio (other than filgotinib). Upon closing, we paid $5.05 billion for the license and option rights and for 6.8 million new ordinary shares of Galapagos at a subscription price of &#8364;140.59 per share with a fair value of $1.13 billion, which included an issuance discount of $63 million calculated based on Galapagos&#8217; closing stock price on the date of closing of the Galapagos Subscription Agreement. The remaining $3.92 billion of the payment was recorded within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2019. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Galapagos Subscription Agreement, we were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. In 2019, we exercised a warrant to subscribe for 2.6 million ordinary shares of Galapagos at &#8364;140.59 per share and purchased shares on the open market with an aggregate fair value of $586 million, which brought the number of shares owned by us to 16.7 million or approximately 25.8% of the shares then issued and outstanding. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, our equity investment in Galapagos was initially classified as Other long-term assets on our Consolidated Balance Sheets as it is subject to contractual lock-up provisions. We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. We have two designees appointed to Galapagos&#8217; board of directors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the initial contractual lock-up provision for certain Galapagos shares will expire in August 2021, the corresponding equity investment balance of $351 million was included within Prepaid and other current assets on our Consolidated Balance Sheets as of December 31, 2020. At December 31, 2020 and 2019, Gilead&#8217;s total investment balance in Galapagos was $1.65 billion and $3.48 billion, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected the fair value option to account for our equity investment in Galapagos whereby the investment is marked to market through earnings each reporting period based on the market price of Galapagos&#8217; shares. We believe the fair value option best reflects the underlying economics of the investment. During the year ended December 31, 2020, we recorded a pre-tax unrealized loss of $1.83 billion related to our investment in Galapagos in Other income (expense), net on our Consolidated Statements of Income due to a decline in Galapagos&#8217; stock price. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Galapagos Collaboration Agreement, we have an exclusive license for the development and commercialization of GLPG-1690, a Phase 3 candidate for idiopathic pulmonary fibrosis, in our territories and have an option to participate in the development and commercialization of Galapagos&#8217; other current and future clinical programs that have entered clinical development during the first ten years of the collaboration, subject to extension in certain circumstances. We may exercise our option for a program after the receipt of a data package from a completed, qualifying Phase 2 study for such program (or, in certain circumstances, the first Phase 3 study). If GLPG-1690 receives marketing approval in the U.S., we will pay Galapagos $325 million as well as tiered royalties described below. With respect to all other programs in Galapagos&#8217; current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us (including GLPG-1690). If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. Galapagos retains exclusive commercialization rights for the optioned programs in the European Union, the UK, Iceland, Norway, Lichtenstein and Switzerland, and we have exclusive commercialization rights for all other countries globally. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. In 2020, Galapagos delivered to us a data package with respect to our option to participate in the development and commercialization of GLPG-1972, a Phase 2b candidate for osteoarthritis, under the Galapagos Collaboration Agreement, which we declined to exercise in November 2020. In addition, Gilead and Galapagos announced the decision to halt the ISABELA Phase 3 clinical studies with GLPG-1690 in February 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Complera/Eviplera and Odefsey</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#8217;s non-nucleoside reverse transcriptase inhibitor, rilpivirine. This combination was approved in the U.S. and European Union in 2011 and is sold under the brand name Complera in the U.S. and Eviplera in the European Union.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#8217;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#8220;Odefsey&#8221;).</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#8217;s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen&#8217;s shares of revenues are included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#8217;s shares were $570 million, $574 million and $608 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symtuza</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#8217;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide. This combination was approved in the U.S. and European Union in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to cobicistat, emtricitabine and tenofovir alafenamide (&#8220;Gilead Compounds&#8221;) and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza. See Note 2. Revenues for additional information on revenue recognized for the periods presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights and paid a royalty to us based on its product sales in Japan. Under the agreement, we are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Japan Tobacco also marketed and distributed certain other products in our HIV portfolio in Japan and paid a royalty to us based on these product sales.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval for Stribild and Genvoya (elvitegravir-containing products) in 2012 and 2015, respectively. Our sales of these products are included in Product sales. Royalties due to Japan Tobacco based on our product sales are included in Cost of goods sold. Royalties due from Japan Tobacco based on its product sales in Japan are included in Royalty, contract and other revenues on our Consolidated Statements of Income. Royalty expenses recognized were $291 million, $358 million and $452 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Royalty income recognized was not material for the periods presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective in December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we paid Japan Tobacco $559 million in cash, of which $194 million was paid as an upfront payment in 2018, and the remaining $365 million was paid in 2019. We recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco with the remaining $9 million recorded as Prepaid and other current assets on our Consolidated Balance Sheets. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gadeta</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we entered into a collaboration arrangement with Gadeta and made a purchase of equity in Gadeta from Gadeta&#8217;s shareholders. We determined that Gadeta was a VIE, and we were its primary beneficiary because we had the power to direct the activities of Gadeta that most significantly impact its economic performance. Upon the initial consolidation of Gadeta, we recorded $82 million to Noncontrolling interest, primarily reflecting acquired intangible assets related to IPR&amp;D on our Consolidated Balance Sheets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we effectively terminated the agreement with Gadeta. Upon the effective termination, we ceased to have a controlling interest and deconsolidated this VIE by removing the related net assets and noncontrolling interest of $82 million from our Consolidated Balance Sheets. The net loss from the deconsolidation was not material.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bristol-Myers Squibb Company (&#8220;BMS&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">North America</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a collaboration arrangement with BMS to develop and commercialize a single tablet regimen containing our Truvada and BMS&#8217;s Sustiva (efavirenz) in the U.S. and Canada. This combination is sold under the brand name Atripla. We and BMS structured this collaboration as a joint venture that operated as a limited liability company, which we consolidated. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2017, we terminated BMS&#8217;s participation in the collaboration following the launch of a generic version of&#160;Sustiva&#160;in the U.S. and became the sole owner of the joint venture. BMS is not permitted to commercialize Atripla in the U.S. and Canada but is entitled to receive from us certain fees based on net sales of Atripla in 2018, 2019 and 2020 on a declining annual scale. BMS supplies Sustiva to us at cost plus a markup during this three-year period but may terminate the supply agreement after a notice period. BMS notified us of their voluntary termination of the supply agreement in 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $19 million, $58 million and $198 million, respectively, of fee expenses within Cost of goods sold on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Europe</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences Ireland UC, our wholly-owned subsidiary, and BMS have a collaboration agreement which sets forth the terms and conditions under which we and BMS commercialize and distribute Atripla in the European Union, Iceland, Liechtenstein, Norway and Switzerland (collectively, the &#8220;European Territory&#8221;). The parties formed a limited liability company which we consolidate, to manufacture Atripla for distribution in the European Territory using efavirenz that it purchases from BMS at BMS&#8217;s estimated net selling price of efavirenz in the European Territory. The parties also formed a limited liability company to hold the marketing authorization for Atripla in the European Territory.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2012, except for a limited number of activities that are jointly managed, the parties no longer coordinate detailing and promotional activities in the European Territory. We are responsible for manufacturing, product distribution, inventory management and warehousing and have primary responsibility for regulatory activities. Through our local subsidiaries, we have primary responsibility for order fulfillment, collection of receivables, customer relations and handling of sales returns in all the territories where we and BMS promote Atripla. In general, the parties share revenues and out-of-pocket expenses in proportion to the net selling prices of the components of Atripla, Truvada and efavirenz. As of December&#160;31, 2020 and 2019, efavirenz purchased from BMS at BMS&#8217;s estimated net selling price of efavirenz in the European Territory was included in Inventories on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, BMS elected to voluntarily terminate the agreement effective March 31, 2020. Post termination, BMS is not permitted to commercialize Atripla in the European territory but is entitled to receive from us certain fees based on net sales of Atripla on a declining annual scale for a three-year period following the effective date of the termination. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other collaboration arrangements that are not individually significant </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, we entered into several other collaborative, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $129 million, $331 million and $278 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income. Cash payments made related to our equity investments for the years ended December&#160;31, 2020, 2019 and 2018 were $72 million, $118 million and $156 million, respectively, which were primarily recorded within Prepaid and other current assets and Other long-term assets on our Consolidated Balance Sheets. </span></div>Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made were capitalized as intangible assets and are being amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeandOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeandOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174137544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and credit facilities</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-bottom:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.234%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we issued senior unsecured notes consisting of (i) $500 million principal amount of floating rate notes due September 2021 and $500 million principal amount of floating rate notes due September 2023 (together, the &#8220;Floating Rate Notes&#8221;); and (ii) $2.0 billion principal amount of 0.75% senior notes due September 2023, $750 million principal amount of 1.20% senior notes due October 2027, $1.0 billion principal amount of 1.65% senior notes due October 2030, $1.0 billion principal amount of 2.60% senior notes due October 2040 and $1.5 billion principal amount of 2.80% senior notes due October 2050, the terms of which are summarized in the table above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we repaid at maturity $500 million of principal balance related to our 2014 senior unsecured notes. In September 2020, we repaid at maturity $2.0&#160;billion principal balance related to our 2015 senior unsecured notes. In 2019, we repaid $2.75 billion of our senior unsecured notes upon maturity. In January 2021, we repaid $1.0 billion of senior unsecured notes prior to the April 2021 maturity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium as defined in the indenture. The senior unsecured fixed rate notes also have a call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from one month to two years prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The September 2023 floating rate notes also have a call feature, exercisable at our option, to redeem the notes at par, in whole, or in part, approximately two years prior to maturity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the occurrence of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our senior unsecured notes and as of December&#160;31, 2020 and 2019, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Loan Facility</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a commitment letter with a group of institutional lenders to provide for a three-year senior unsecured term loan facility in an aggregate principal amount of $1.0&#160;billion. Pursuant to the commitment letter, in October 2020, in connection with our acquisition of Immunomedics, we entered into a term loan credit agreement (the &#8220;Term Loan Facility&#8221;) and borrowed an aggregate principal amount of $1.0&#160;billion.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan Facility contains customary representations, warranties, affirmative and negative covenants and events of default. The Term Loan Facility bears interest at the Eurodollar Rate plus the Applicable Percentage as defined in the Term Loan Facility. We may terminate or reduce the amount borrowed under the Term Loan Facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI, prior to the completion of our acquisition of Immunomedics. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Note 6. Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revolving Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, we entered into a $2.5 billion five-year revolving credit facility agreement maturing in May 2021 (the &#8220;2016 Revolving Credit Facility&#8221;). In June 2020, we terminated the 2016 Revolving Credit Facility. As of December&#160;31, 2019, there were no amounts outstanding under the 2016 Revolving Credit Facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;), which has terms substantially similar to the 2016 Revolving Credit Facility. The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2020, there were no amounts outstanding under the 2020 Revolving Credit Facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. At December&#160;31, 2020, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Eurodollar Rate plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the new credit facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes and Term Loan Facility as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div>Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $994 million, $1.0 billion and $1.1 billion in 2020, 2019 and 2018, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175859048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December&#160;31, 2020 and 2019, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $171 million and $162 million in 2020 and 2019, respectively. Operating lease expense under the prior lease accounting standard was $109 million in 2018.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174129336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. The most significant of these are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. It is not possible to determine the outcome of these matters or, unless otherwise noted, the outcome (including in excess of any accrual) is not expected to be material, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below in our Consolidated Balance Sheets as of December&#160;31, 2020 and 2019.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of the HCV. In 2013, we received approval from FDA for sofosbuvir, now known commercially as Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Litigation with Idenix Pharmaceuticals, Inc. (&#8220;Idenix&#8221;), Universita Degli Studi di Cagliari (&#8220;UDSG&#8221;), Centre National de la Recherche Scientifique and L&#8217;Universit&#233; Montpellier II</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Idenix, UDSG, Centre National de la Recherche Scientifique and L&#8217;Universit&#233; Montpellier II sued us in the U.S. District Court for the District of Delaware alleging that the commercialization of sofosbuvir infringes U.S. Patent No. 7,608,600 (the &#8220;&#8217;600 patent&#8221;). We prevailed at all phases of litigation concerning the &#8217;600 patent, and in 2018, the U.S. Supreme Court denied Idenix&#8217;s petition for certiorari. Also in 2013, Idenix and UDSG sued us in the U.S. District Court for the District of Massachusetts alleging that the commercialization of sofosbuvir infringes U.S. Patent Nos. 6,914,054 (the &#8220;&#8217;054 patent&#8221;) and 7,608,597 (the &#8220;&#8217;597 patent&#8221;). In 2014, the court transferred the Massachusetts litigation to the U.S. District Court for the District of Delaware.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to trial in 2016, Idenix committed to give us a covenant not to sue with respect to any claims arising out of the &#8217;054 patent related to sofosbuvir and withdrew that patent from the trial. A jury trial was held in 2016 on the &#8217;597 patent, and the jury found that we willfully infringed the asserted claims of the &#8217;597 patent and awarded Idenix $2.54&#160;billion in past damages. In 2018, the judge invalidated Idenix&#8217;s &#8217;597 patent and vacated the jury&#8217;s award of $2.54&#160;billion in past damages. Idenix appealed this decision to the U.S. Court of Appeals for the Federal Circuit (&#8220;CAFC&#8221;), and in October 2019, the CAFC issued an opinion affirming the trial court&#8217;s decision that the &#8217;597 patent is invalid. In April 2020, the CAFC denied Idenix&#8217;s petition for rehearing en banc. In January 2021, the U.S. Supreme Court denied Idenix&#8217;s petition for review, making the judgment against Idenix final. </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and has scheduled a merits hearing for February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concludes the inter partes review that it has initiated, which we expect will occur in 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes on U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $585&#160;million in an up-front payment and a 27.6% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing whether we should accrue a liability for this litigation in our Consolidated Financial Statements, we considered various factors, including the legal and factual circumstances of the case, the jury&#8217;s verdict, the district court&#8217;s pre- and post-trial orders, the current status of the proceedings, applicable law, the views of legal counsel and the likelihood that the judgment will be upheld on appeal. As a result of this review, we have determined, in accordance with applicable accounting standards, that it is not probable that we will incur a material loss as a result of this litigation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the judgment is reversed on appeal, the loss is expected to be zero. If the judgment is upheld in its entirety on appeal, we estimate a loss through the fourth quarter of 2020 to be approximately $1.4&#160;billion, which consists primarily of (i) approximately $811&#160;million, which represents damages on Yescarta revenues through December 12, 2019, and prejudgment interest thereon, (ii) approximately $389&#160;million, which represents a 50% enhancement of past damages and (iii) approximately</span><span style="color:#929292;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$172&#160;million for royalties on Yescarta revenues from December 13, 2019 to December 31, 2020. The estimated loss does not include post-judgment interest on the foregoing, which is not estimated to be material as of December 31, 2020. Although we cannot predict with certainty the ultimate outcome of this litigation on appeal, we believe the jury&#8217;s verdict and the judgment to be in error. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Related to Bictegravir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV Healthcare Company (&#8220;ViiV&#8221;) filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the commercialization of bictegravir, sold commercially in combination with tenofovir alafenamide and emtricitabine as Biktarvy, infringes ViiV&#8217;s U.S. Patent No. 8,129,385 (the &#8220;&#8217;385 patent&#8221;) covering ViiV&#8217;s dolutegravir. Bictegravir is structurally different from dolutegravir, and we believe that bictegravir does not infringe the sole asserted claim of the &#8217;385 patent. The court has set a trial date of January 2022 for this lawsuit. ViiV is seeking billions of dollars for alleged damages comprised of ViiV&#8217;s lost profits and a royalty on sales of bictegravir from launch through the trial. ViiV calculates these damages based on the cumulative U.S. revenues from Biktarvy since launch, which have totaled $11.46&#160;billion through December 31, 2020. In addition, should a court find that we are liable for infringement, we expect ViiV will seek a royalty on sales after the trial. Although we cannot predict with certainty the ultimate outcome of this litigation, an adverse judgment could result in substantial monetary damages, including ViiV&#8217;s lost profits and royalties through trial, and a going-forward royalty stream on future sales. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, ViiV also filed a lawsuit against us in the Federal Court of Canada, alleging that our activities relating to our bictegravir compound have infringed ViiV&#8217;s Canadian Patent No. 2,606,282 (the &#8220;&#8217;282 patent&#8221;), which was issued to Shionogi &amp; Co. Ltd. and ViiV. The &#8217;282 patent is the compound patent covering ViiV&#8217;s dolutegravir. We believe that bictegravir does not infringe the claims of the &#8217;282 patent. In January 2020, the court held a summary trial to assess ViiV&#8217;s infringement allegations. In April 2020, the court determined that bictegravir does not infringe the claims of the &#8217;282 patent and dismissed the case. ViiV has appealed this decision. Argument on the appeal is expected to take place later in 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019, ViiV filed lawsuits in France, Germany, Ireland and the UK asserting the relevant national designations of European Patent No. 3 045 206 (&#8220;EP &#8217;206&#8221;); in Australia asserting Australian Patent No. 2006239177; in Japan asserting Japanese Patent No. 4295353; and in Korea asserting Korean Patent Nos. 1848819 (&#8220;KR &#8217;819&#8221;) and 1363875. These patents all relate to molecules which ViiV claims would act as integrase inhibitors. We believe that bictegravir does not infringe the claims of any of ViiV&#8217;s patents. In 2019, we filed an opposition in the European Patent Office (&#8220;EPO&#8221;) requesting revocation of EP &#8217;206. The EPO hearing is scheduled for 2021. In 2020, we filed a petition in the Korean Intellectual Property Office requesting invalidation of KR &#8217;819. Following a trial, a tribunal of the Korean Intellectual Property Trial and Appeal Board found KR &#8217;819 to be invalid. ViiV may appeal this decision. The court in Germany has scheduled a hearing on the issue of infringement in April 2021. In all jurisdictions, to the extent that the claims of ViiV&#8217;s patents are interpreted to cover bictegravir, we believe that those claims are invalid. We cannot predict the ultimate outcome of intellectual property claims related to bictegravir. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of emtricitabine and tenofovir or TDF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the Court of Federal Claims, alleging violations of four material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and a clinical trial agreement (&#8220;CTA&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial date for the lawsuit in the District Court of Delaware has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in December 2019, we received letters from Lupin Ltd., Apotex Inc., Shilpa Medicare Ltd., Sunshine Lake Pharma Co. Ltd., Laurus Labs, Natco Pharma Ltd., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of certain of our tenofovir alafenamide (&#8220;TAF&#8221;)-containing products. Between them, these generic manufacturers seek to market generic versions of Odefsey, Descovy and Vemlidy. Some generic manufacturers have challenged the validity of four patents listed on the Orange Book and associated with TAF, while others have challenged the validity of two of our Orange Book-listed patents associated with TAF. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing is scheduled for July 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. Two of the original opposing parties have appealed, requesting full revocation. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, several parties filed oppositions in the EPO requesting revocation of our granted European patent covering TAF that expires in 2026. In 2017, the EPO upheld the validity of the claims of our TAF patent. Three parties have appealed this decision. The appeal hearing is scheduled for March 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, three parties filed oppositions in the EPO requesting revocation of our granted European patent covering cobicistat that expires in 2027. In 2017, the EPO upheld the validity of the claims of our cobicistat patent. Two parties have appealed this decision. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir, TAF, TAF hemifumarate and cobicistat in the European Union could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations and Related Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, we received a subpoena from the U.S. Attorney&#8217;s Office for the Northern District of California requesting documents related to the manufacture, quality and distribution practices of Complera, Atripla, Truvada, Viread, Emtriva, Hepsera and Letairis. We cooperated with the government&#8217;s inquiry. In 2014, the U.S. Department of Justice informed us that it had declined to intervene in a False Claims Act lawsuit filed by two former employees. In 2019, the District Court granted the Department of Justice&#8217;s motion to dismiss plaintiffs&#8217; federal claims. In April 2020, plaintiffs refiled their California False Claims Act and California retaliation claims in the Superior Court of California, County of San Mateo. In July 2020, the California Attorney General declined to intervene in the case, and the state court complaint was unsealed. In September 2020, we filed a demurrer requesting that the Superior Court dismiss plaintiffs&#8217; claims, which was overruled in November 2020. We have sought an appeal of the Superior Court&#8217;s order overruling our demurrer. Although we cannot predict the ultimate outcome of this lawsuit, we believe the action is without merit and we intend to vigorously defend against it.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a voluntary request for information from the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania requesting information related to our reimbursement support offerings, clinical education programs and interactions with specialty pharmacies for Sovaldi and Harvoni. In 2018, we received another voluntary request for information related to our speaker programs and advisory boards for our HCV and HBV products. In October 2019, the government informed us that, following its investigation, it declined to intervene in two False Claims Act lawsuits against us. Notwithstanding the government&#8217;s declination, relators have continued to pursue the lawsuit relating to HBV speaker programs and advisory boards and served us with the Second Amended Complaint in November 2019. In December 2020, the lawsuit relating to HCV sales and marketing issues was unsealed. The relator has indicated that he intends to pursue the case against Gilead. Although we cannot predict the ultimate outcome of these lawsuits, we believe the actions are without merit and we intend to vigorously defend against them. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we also received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Health Choice Advocates, LLC (&#8220;Health Choice Advocates&#8221;) filed a qui tam lawsuit against us under seal in New Jersey state court alleging violations of the New Jersey False Claims Act through our clinical education programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In July 2020, the New Jersey Attorney General&#8217;s Office declined to intervene in the lawsuit and the complaint was unsealed. In May 2020, Health Choice Advocates filed a qui tam lawsuit under seal against us in Texas state court making similar allegations under the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;). This lawsuit seeks all available relief under the TMFPA. In October 2020, the Texas Attorney General&#8217;s Office declined to intervene in the lawsuit and the complaint was unsealed. Health Choice Advocates previously filed a lawsuit making similar allegations under the federal False Claims Act and various state False Claims Acts, including the TMFPA, in federal court in the Eastern District of Texas in June 2017 and the court entered an order dismissing that matter without prejudice in July 2018. Although we cannot predict the ultimate outcome of these lawsuits, we believe these actions are without merit.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in two class action lawsuits and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, New Jersey and Missouri, involve more than 21,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We (along with Japan Tobacco, BMS and Johnson &amp; Johnson, Inc.) have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Japan Tobacco was dismissed from the lawsuit after a favorable court ruling on the defendants&#8217; motion to dismiss. Plaintiffs allege that we (and the other remaining defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been or may be consolidated, are all pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of two nationwide classes - one of direct purchasers consisting largely of wholesales, and another of end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we along with generic manufacturers Cipla Ltd. and Cipla USA Inc. (&#8220;Cipla&#8221;) were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and Cipla, which settled a patent dispute relating to patents covering our Emtriva, Truvada, and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. Plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019. The lawsuits were consolidated in September 2019, and plaintiffs filed a consolidated complaint in November 2019. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the United States District Court for the District of New Jersey. In January 2020, Immunomedics filed a motion to dismiss the consolidated complaint, which was denied in July 2020. While we believe this case is without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated business, financial position or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments </span></div>In the normal course of business, we enter into various firm purchase commitments primarily related to active pharmaceutical ingredients (&#8220;API&#8221;) and certain inventory related items. As of December&#160;31, 2020, these commitments for the next five years were approximately $1.2 billion in 2021, $486 million in 2022, $192 million in 2023, $70 million in 2024 and $55 million in 2025. The amounts related to API represent minimum purchase commitments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173806008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2016, our Board of Directors authorized a $12.0 billion stock repurchase program (&#8220;2016 Program&#8221;) under which repurchases may be made in the open market or in privately negotiated transactions. We started repurchases under the 2016 Program in April 2016. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), which will commence upon the completion of the 2016 Program. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the remaining authorized repurchase amount from both programs was $6.8 billion.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases under the 2016 Program:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to repurchases from the 2016 Program and 2020 Program, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations, which are immaterial and excluded from the table above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital (&#8220;APIC&#8221;) based on an estimated average sales price per issued share with the excess amounts charged to retained earnings. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock and performance share awards or units have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;4, 2021, we announced that our Board of Directors declared a quarterly cash dividend of $0.71 per share of our common stock, with a payment date of March&#160;30, 2021 to all stockholders of record as of the close of business on March&#160;15, 2021. Future dividends are subject to declaration by our Board of Directors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 5 million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was no preferred stock outstanding as of December&#160;31, 2020 and 2019. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The amounts reclassified to net income for gains and losses on cash flow hedges are recorded as part of Product sales on our Consolidated Statements of Income. See Note 5. Derivative Financial Instruments for additional information. The amounts reclassified to net income for gains and losses on available-for-sale debt securities are recorded as part of Other income (expense), net, on our Consolidated Statements of Income. The income tax impact allocated to each component of other comprehensive income was not material for the periods presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288178997496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee benefits</a></td>
<td class="text">EMPLOYEE BENEFITS <div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide share-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSU&#8221;s), performance share awards or units (&#8220;PSU&#8221;s) and stock options. Compensation expense is recognized on the Consolidated Statements of Income based on the estimated fair value of the award on the grant date. The estimated fair value of RSUs is based on the closing price of our common stock. For PSUs, estimated fair value is based on either the Monte Carlo valuation methodology or the stock price on the date of grant. For stock option awards, estimated fair value is based on the Black-Scholes option valuation model. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#8220;2004 Plan&#8221;). The 2004 Plan authorized the issuance of a total of 309 million&#160;shares of common stock. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Forty Seven acquisition, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#8220;2018 Plan&#8221;). The aggregate amount of shares that may be issued under the 2018 Plan on or after the assumption date will not exceed 12&#160;million shares. As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan (the &#8220;Immunomedics Plan&#8221; and referred together with the 2004 Plan and 2018 Plan as the &#8220;Plans&#8221;), which we subsequently merged into the 2004 Plan. The aggregate amount of shares that may be issued under the Immunomedics Plan on or after the assumption date will not exceed 26&#160;million shares. See Note 6. Acquisitions for additional information on the settlement of stock awards.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans are broad based incentive plans that provide for the grant of equity-based awards, including stock options, restricted stock units, restricted stock awards and performance share awards, to employees, directors and consultants. As of December&#160;31, 2020, a total of 96&#160;million shares remain available for future grant under the Plans. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plans provide for option grants designated as either non-qualified or incentive stock options. All stock options granted after January&#160;1, 2006 have been non-qualified stock options. Employee stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzE0Nzg_3e0bf107-df4c-42b5-99e9-a7dcf78020b1">three</span> or four years. All options are exercisable over a period not to exceed the contractual term of ten years from the date the stock options are issued and are granted at prices not less than the fair market value of our common stock on the grant date. Stock option exercises are settled with common stock from the Plans&#8217; previously authorized and available pool of shares. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: </span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average <br/>Remaining <br/>Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/> Intrinsic <br/>Value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. Total intrinsic value of options exercised was $179 million for 2020, $209 million for 2019 and $412 million for 2018. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of the stock options granted was $11.69 per share for 2020, $12.15 per share for 2019 and $17.03 per share for 2018. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $55 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.3 years.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock and Performance Share Awards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzMyNjQ_4b3408a6-98fc-4b69-98be-510a6fbd1b22">three</span> or four years from the date of grant. The fair value of an RSU is equal to the closing price of our common stock on the grant date. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs which vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. The fair value of each PSU is estimated at the date of grant or when performance objectives are defined for the grants. Depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have also granted other PSUs to certain of our employees under the 2004 Plan. The vesting of these awards is subject to the achievement of specified individual performance goals, typically within a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDA_af92dcc3-2fe4-41b3-aed3-392d48d636df">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNjkvZnJhZzphNjI0NmU5MmRiNTA0N2ExOTJjMWYzZTNlOWY3ODEyZC90ZXh0cmVnaW9uOmE2MjQ2ZTkyZGI1MDQ3YTE5MmMxZjNlM2U5Zjc4MTJkXzI3NDg3NzkwOTEwNDU_17e1fc1d-af04-402c-9a3d-30ce2e48473b">two</span> year period. The fair value of such an award is equal to the closing price of our common stock on the grant date.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity and related information:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted was $70.94 per share for 2020, $64.31 per share for 2019, and $77.98 per share for 2018. The weighted-average grant date fair value of PSUs granted was $83.64 per share for 2020, $68.30 per share for 2019, and $88.76 per share for 2018. The total grant date fair value of our vested RSUs and PSUs was $479 million for 2020, $450 million for 2019 and $481 million for 2018, and total fair value as of the respective vesting dates was $459 million for 2020, $372 million for 2019 and $446 million for 2018. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $860 million of unrecognized compensation cost related to unvested RSUs and PSUs, which is expected to be recognized over a weighted-average period of 2.2 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the ESPP), employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature as well as an automatic reset feature that provides for an offering period to be reset to a new lower-priced offering if the offering price of the new offering period is less than that of the current offering period. ESPP purchases are settled with common stock from the ESPP&#8217;s previously authorized and available pool of shares. During 2020, 2 million shares were issued under the ESPP for $100 million. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 7 million shares available for issuance under the ESPP as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1,076&#160;million included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Altera Corp v. Commissioner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.</span><span style="color:#6d6d6d;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is recognized as expense over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of options granted under our 2004 Plan and purchases under our ESPP were estimated at grant or purchase dates using a Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including expected stock price volatility and expected award life. We used the following assumptions to calculate the estimated fair value of the awards: </span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted was calculated using the single option approach. We use a blend of historical volatility along with implied volatility for traded options on our common stock to determine our expected volatility. The expected term of stock-based awards represents the weighted-average period the awards are expected to remain outstanding. We estimate the weighted-average expected term based on historical cancellation and historical exercise data related to our stock options as well as the contractual term and vesting terms of the awards. The risk-free interest rate is based upon observed interest rates appropriate for the term of the stock-based awards. The dividend yield is based on our history and expectation of dividend payouts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the Gilead Sciences 401k Plan). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $144 million during 2020, $110 million during 2019 and $91 million during 2018.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $218 million as of December&#160;31, 2020 and $171 million as of December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175408632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net income per share attributable to GIlead common stockholders</a></td>
<td class="text">NET INCOME PER SHARE ATTRIBUTABLE TO GILEAD COMMON STOCKHOLDERS<div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock outstanding during the period. Diluted net income per share attributable to Gilead common stockholders is calculated based on the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents were determined under the treasury stock method.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of diluted net income per share attributable to Gilead common shareholders because their effect would have been antidilutive were 13 million, 14 million and 13 million during 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173847992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">INCOME TAXES <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,799&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.59pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2019 income tax benefit included a $1.2 billion deferred tax benefit related to intangible asset transfers from a foreign subsidiary to Ireland and the United States. In the fourth quarter of 2019, we completed an intra-entity asset transfer of certain intangible assets from a foreign subsidiary to Ireland. The transaction resulted in a step-up of the Irish tax-deductible basis in the transferred assets, and accordingly, created a temporary difference where the tax basis exceeded the book basis of such intangible assets. As a result, we recognized a deferred tax asset of $1.2 billion on our Consolidated Financial Statements. We expect to be able to realize the deferred tax asset resulting from this intra-entity asset transfer. The impact of the intangible asset transfer from a foreign subsidiary to the United States was not material. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 income tax expense included a $588 million deferred tax charge related to a transfer of acquired intangible assets from a foreign subsidiary to the United States. This transaction did not result in a step-up of the U.S. tax-deductible basis; and as a result, we recognized a deferred tax liability of $588 million for the temporary difference where the book basis exceeded the tax basis of these acquired intangible assets. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to income before taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax - intra-entity transfer of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and related charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized gain / loss on investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,572)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,612)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance was $398 million and $217 million at December&#160;31, 2020 and 2019, respectively. The increase of our valuation allowance in 2020 was primarily related to acquired attributes related to Forty Seven and Immunomedics acquisitions, and unrealized losses on our equity method investments reflected as acquired IPR&amp;D expenses. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance decreased to $217 million at December&#160;31, 2019 from $331&#160;million at December&#160;31, 2018, primarily due to a reduction in net operating loss carryforwards under the asset recognition framework and corresponding valuation allowance with respect to certain foreign jurisdictions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we had U.S. federal net operating loss and tax credit carryforwards of approximately $1.5 billion. and $61 million, respectively, which will start to expire in 2021, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $1.8 billion and $673 million, respectively. The state net operating loss will start to expire in 2021 if not utilized and state tax credit carryforwards will start to expire in 2022 if not utilized.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state and foreign income tax returns in the United States and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2013 and onwards and 2010 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by various state and foreign jurisdictions. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits, $1.2 billion and $1.6 billion at December&#160;31, 2020 and 2019, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included as part of income tax expense (benefit) on our Consolidated Statements of Income were $(82) million and $105 million for the years ended December&#160;31, 2020 and 2019, respectively. Interest and penalties related to unrecognized tax benefits for the year ended December 31, 2018 was not material. Accrued interest and penalties related to unrecognized tax benefits were $177 million and $259 million at December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we do not believe that it is reasonably possible that our unrecognized tax benefits will significantly change in the next 12 months.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174160024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected quarterly financial information (unaudited)</a></td>
<td class="text"><div style="margin-top:13.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)</span></div><div style="margin-bottom:9pt;margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1st&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2nd&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3rd&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4th&#160;Quarter</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit on product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit on product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the second quarter of 2020 included an acquired IPR&amp;D expenses of $4.5&#160;billion, or $3.58 per basic and diluted share, primarily related to our acquisition of Forty Seven. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the third quarter of 2020 included acquired IPR&amp;D expenses of $1.0&#160;billion, or $0.82 per basic and diluted share, related to collaborations and other investments we entered into separately with Arcus, Pionyr, Tango and Tizona and $983&#160;million or $0.78 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos. See Note 3. Fair Value Measurements and Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2020 included $628 million, or $0.50 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos and $615&#160;million, or $0.49 per basic and diluted share of acquisition-related expenses primarily from amortization of intangible assets, inventory step-up charges and accelerated stock-based compensation expenses related to our acquisition of Immunomedics. See Note 3. Fair Value Measurements, Note 6. Acquisitions and Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the third quarter of 2019 included upfront collaboration and licensing expenses of $3.92&#160;billion, or $2.40 per basic and diluted share related to the collaboration with Galapagos. See Note 11. Collaborations and Other Arrangements for additional information.</span></div>(5) &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2019 included a $1.2&#160;billion favorable tax effect related to intra-entity intangible asset transfers and $929 million of pre-tax net gains from equity securities primarily our equity investment in Galapagos, partially offset by an $800&#160;million pre-tax impairment charge related to IPR&amp;D intangible assets acquired in connection with the acquisition of Kite and pre-tax write-down charges of $500 million for slow moving and excess raw material and work in process inventory. The impact of these factors resulted in a net favorable impact of $0.83 per basic share and $0.81 per diluted share. See Note 3. Fair Value Measurements, Note 7. Inventories, Note 9. Goodwill and Intangible Assets and Note 18. Income Taxes for additional information<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256304200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div>We assess whether we are the primary beneficiary of a variable interest entity (&#8220;VIE&#8221;) at the inception of the arrangement and at each reporting date. This assessment is based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationWe have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer (&#8220;CEO&#8221;), as the chief operating decision-maker, manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Significant Accounting Policies, Estimates and Judgments</a></td>
<td class="text">Significant Accounting Policies, Estimates and Judgments The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent coronavirus disease (&#8220;COVID-19&#8221;) could have on our significant accounting estimates. Actual results may differ significantly from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning 2020, acquired in-process research and development (&#8220;IPR&amp;D&#8221;) expenses are reported separately from Research and development expenses on our Consolidated Statements of Income. Acquired IPR&amp;D expenses on our Consolidated Statements of Income reflect IPR&amp;D impairments as well as the initial costs of externally developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront payments related to various collaborations and the initial costs of rights to IPR&amp;D projects. Our Consolidated Statements of Income for the years ended December 31, 2019 and 2018 have been conformed to separately present acquired IPR&amp;D expenses. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Statement of Cash Flows for the year ended December 31, 2019, has been conformed to separately present acquired IPR&amp;D expenses exclusive of IPR&amp;D impairments. Comparative amounts in our Consolidated Statement of Cash Flows for the year ended December 31, 2018 were not material. There was no change in income from operations or operating cash flow as a result of these reclassifications.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by our customer to a third party. The revenues are recognized, net of estimated government and other rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions, and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and in some instances by type of product. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a significant financing component. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross to Net Deductions</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other rebates and chargebacks include amounts payable to payers and healthcare providers under various programs, and may vary by product, by payer and individual payer plans. Rebates and chargebacks are based on contractual arrangements or statutory requirements which may vary by product, payer and individual payer plans. For qualified programs that can purchase our products through wholesalers or other distributors at a lower contractual price, the wholesalers or distributors charge back to us the difference between their acquisition cost and the lower contractual price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, and expected payer mix and discount rates, which require significant estimates and judgment. Additionally, in developing our estimates we consider: historical and estimated payer mix; statutory discount requirements and contractual terms; historical claims experience and processing time lags; estimated patient population; known market events or trends; market research; channel inventory data obtained from our major U.S. wholesalers; and other pertinent internal or external information. We assess and update our estimates every quarter to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government and other chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Government and other rebates that are payable to third party payers and healthcare providers are recorded in Accrued government and other rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually determined covenants such as the maintenance of agreed upon inventory levels. These distributor fees are based on a contractually determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the United States we typically permit returns six months prior to and up to one year after the product expiration date. Outside the United States returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling activities are considered to be fulfillment activities and not considered to be a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty, Contract and Other Revenues</span></div>Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, payments under collaborative and other arrangements, including milestone payments, license and option fees, as well as expense reimbursements to the collaboration partners and overhead allocations consisting of various support and infrastructure costs. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge R&amp;D costs, including clinical study costs, to expense when incurred. Clinical study costs are a significant component of R&amp;D expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our Consolidated Balance Sheets and are expensed as the services are provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses relate to sales and marketing, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs. SG&amp;A expenses also include the branded prescription drug (&#8220;BPD&#8221;) fee. In the United States, we, along with other pharmaceutical manufacturers of branded drug products, are required to pay a portion of the BPD fee, which is estimated based on select government sales during the prior year as a percentage of total industry government sales.</span></div>We expense the costs of advertising, including promotional expenses, as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable and Nonmarketable Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable and Nonmarketable Securities</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable debt securities are considered available-for-sale and carried at estimated fair values and reported in cash equivalents, short-term marketable securities or long-term marketable securities. Unrealized gains and losses on available-for-sale debt securities are excluded from net income and reported in accumulated other comprehensive income (loss) (&#8220;AOCI&#8221;) as a separate component of stockholders&#8217; equity. Other income (expense), net, includes interest, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and expected credit losses, if any. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in AOCI.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable and Non-Marketable Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities, other than equity method investments, are recorded at fair market value, if fair value is readily determinable and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. We have elected the fair value option to account for our equity investment in Galapagos NV (&#8220;Galapagos&#8221;) over which we have significant influence. We believe the fair value option best reflects the underlying economics of the investment. See Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Certain investments in equity securities of non-public companies are accounted for using the equity method based on our ownership percentage and other factors that indicate we have significant influence over the investee. See Note 11. Collaborations and Other Arrangements for additional information. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are recorded in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets. We regularly review our securities for indicators of impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. We are not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales. Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and credit losses. Estimates of our allowance for credit losses consider a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. The majority of our trade accounts receivable arises from product sales in the United States, Europe and Japan. There were no material write-offs charged against the allowance for the year ended December&#160;31, 2020.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the raw materials and components that we utilize in our operations are obtained through single suppliers. Certain of the raw materials that we utilize in our operations are made at only one facility. Since the suppliers of key components and raw materials must be named in a new drug application filed with U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from our suppliers is interrupted for any reason, we may be unable to ship our commercial products or to supply our product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div>When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted Accounting Standards Update No. 2016-02 (Topic 842) &#8220;Leases,&#8221; which requires lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. We adopted Topic 842 using the modified retrospective method. As such, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840 &#8220;Leases.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div>As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in our Consolidated Statements of Income unless there is an alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When development is successfully completed, which generally occurs when regulatory approval is obtained, the associated assets are deemed finite-lived and amortized over their respective estimated useful lives beginning at that point in time. Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Valuation of Contingent Consideration Resulting from a Business Combination</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Contingent Consideration Resulting from a Business Combination</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value in R&amp;D expense within our Consolidated Statement of Income until such time that the related product candidate receives marketing approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. entity operations are recorded in the functional currency of each entity. Results of operations for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency rates. Assets and liabilities are translated using currency rates at period end. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Foreign currency transaction gains and losses are recorded in Other income (expense), net, on our Consolidated Statements of Income. Net foreign currency transaction gains and losses were not material for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-bottom:4pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Changes in the fair value of derivatives designated as part of a hedge transaction are recorded each period in current earnings or AOCI. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in current earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities related to unrecognized tax benefits in accordance with the guidance that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income (&#8220;GILTI&#8221;), enacted as part of the Tax Cuts and Jobs Act (&#8220;Tax Reform&#8221;), as a component of tax expense in the period in which the tax is incurred (&#8220;period cost method&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016,&#160;the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13 &#8220;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; and has since modified the standard with several ASUs (collectively, &#8220;Topic 326&#8221;).&#160;Topic 326 requires measurement and recognition of expected credit losses for financial assets. On January 1, 2020, we adopted this standard using a modified retrospective approach.&#160;The adoption did not have a material impact on our Consolidated Financial Statements. In connection with the adoption of Topic 326, we made an accounting policy election to not measure an allowance for credit losses for accrued interest receivable. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018,&#160;the FASB issued Accounting Standards Update No. 2018-18 &#8220;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&#8221; (&#8220;ASU 2018-18&#8221;).&#160;ASU 2018-18 clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under Topic 606, &#8220;Revenue from Contracts with Customers&#8221; when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as customer revenue if the counterparty is not a customer for that transaction. On January 1, 2020, we adopted this standard and applied it retrospectively to January 1, 2018 when we initially adopted Topic 606. The adoption did not have an impact on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175406952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock', window );">Property, Plant and Equipment, Estimated Useful Life</a></td>
<td class="text">Estimated useful lives in years are generally as follows: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181485304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.906%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product Sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">HIV Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Atripla</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;) Products</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/Sofosbuvir </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,686&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Cell Therapy Products </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Cell Therapy product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Other Products </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ranexa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Zydelig</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Emtriva and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes Cayston, Hepsera and Jyseleca.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Summarized revenues from major customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174058088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities measured at fair value</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of classification of other equity securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities in our Consolidated Balance Sheets:</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256788088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Debt Securities at Estimated Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of the Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-bottom:5pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock', window );">Summary of Available-for-Sale Debt in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investments in an unrealized loss position for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), including: (a) the aggregate related fair value of investments with unrealized losses, (b) the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175251928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of classification and fair value of derivative instruments</a></td>
<td class="text">The following table summarizes the classification and fair values of derivative instruments in our Consolidated Balance Sheets: <div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.339%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;accrued&#160;liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other&#160;current&#160;assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of effect of foreign currency exchange contracts</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our foreign currency exchange contracts on our Consolidated Financial Statements:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from AOCI into product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Summary of potential effect of offsetting derivatives</a></td>
<td class="text">The following table summarizes the potential effect of offsetting our foreign currency exchange contracts on our Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Not Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets/Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Amounts Offset on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Collateral Received/Pledged</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Amount (Legal Offset)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174077384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summarized fair values of assets acquired and liabilities assumed</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Supplemental pro forma information</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following pro forma information presents the combined results of operations of Gilead and Immunomedics as if the acquisition of Immunomedics had been completed on January 1, 2019, with adjustments to give effect to pro forma events that are directly attributable to the acquisition:</span></div><div style="margin-bottom:6pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175256968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175858216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256570184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from the acquisition of Immunomedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel (DLBCL)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy for mTNBC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - sofosbuvir</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - axicabtagene ciloleucel (DLBCL)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset - Trodelvy for mTNBC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets - IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,265&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes indefinite-lived assets - IPR&amp;D recognized as part of the Immunomedics acquisition in October 2020. See Note 6. Acquisitions for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Future Amortization Expense of Finite-Lived Intangible Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175254808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Accounts receivable, net</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other accrued liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other accrued liabilities:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174083544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of financing arrangements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="margin-bottom:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.375%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.234%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.15%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-month LIBOR + 0.52%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes and term loan facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,593&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,094&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of contractual maturities of financing obligations</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes and Term Loan Facility as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175540456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock', window );">Balance sheet and other information related to operating leases</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_a6a7fb63-e82b-4640-b255-04012152db71"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI5Mzc2NmIzOGE3OTRmODNhNmEyODNmYTBhODVjMTdkL3NlYzpiOTM3NjZiMzhhNzk0ZjgzYTZhMjgzZmEwYTg1YzE3ZF8xNTcvZnJhZzpjMzVjYTVjZTEzYWM0YTRhODFlYjFmMTkxZTUyZjU2Zi90YWJsZTphYzE3YmU4ZWFkNjg0NDE2OWExMGRjZTU1M2YyYmJmNi90YWJsZXJhbmdlOmFjMTdiZThlYWQ2ODQ0MTY5YTEwZGNlNTUzZjJiYmY2XzMtMi0xLTEtMA_c417816d-f57f-45a7-aa7f-30fa27ba5703">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Supplemental information related to operating leases</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease aggregate future lease payments</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2020:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Schedule of Lease Assets and Liabilities and Other Information [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173828632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of stock repurchases</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases under the 2016 Program:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of dividends declared</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-bottom:5pt;margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated OCI by component</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in AOCI by component, net of tax:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256677528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Activity under stock option plans</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity and related information under our stock option plans. All option grants presented in the table had exercise prices not less than the fair value of the underlying common stock on the grant date: </span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average <br/>Remaining <br/>Contractual Term <br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/> Intrinsic <br/>Value <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">RSU and PSU activity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU and PSU activity and related information:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div>(1) &#160;&#160;&#160;&#160;Weighted-average grant-date fair value per share excludes shares related to grants that currently have no grant date as the performance objectives have not yet been defined.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation expenses -included in consolidated statement of income</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock-based compensation expenses included on our Consolidated Statements of Income:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Pre-tax stock-based compensation expense for the year ended December&#160;31, 2020 of $1,076&#160;million included $643 million non-cash stock-based expense and $289 million and $144 million of accelerated post-acquisition stock-based expense related to the acquisitions of Immunomedics and Forty Seven, respectively. See Note 6. Acquisitions for additional information.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Income tax effect for the year ended December&#160;31, 2019 included a $114 million income tax expense following the U.S. Court of Appeals decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Altera Corp v. Commissioner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which requires related parties in an intercompany cost sharing arrangement to share expenses related to stock-based compensation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of assumptions to calculate the estimated fair value of awards</a></td>
<td class="text">We used the following assumptions to calculate the estimated fair value of the awards: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174071160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share, basic and diluted</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted net income per share attributable to Gilead common stockholders:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in per share calculation - diluted </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,308&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share attributable to Gilead common stockholders - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256666024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income (loss) before income taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,799&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense (benefit)</a></td>
<td class="text"><div style="margin-top:4.59pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of difference between provision for income taxes and federal statutory income tax rate to income before provision for income taxes</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to income before taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax - intra-entity transfer of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D and related charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized gain / loss on investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,572)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,612)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits roll forward</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174059208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly financial information</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1st&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2nd&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3rd&#160;Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4th&#160;Quarter</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit on product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit on product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share attributable to Gilead common stockholders - diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the second quarter of 2020 included an acquired IPR&amp;D expenses of $4.5&#160;billion, or $3.58 per basic and diluted share, primarily related to our acquisition of Forty Seven. See Note 6. Acquisitions for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the third quarter of 2020 included acquired IPR&amp;D expenses of $1.0&#160;billion, or $0.82 per basic and diluted share, related to collaborations and other investments we entered into separately with Arcus, Pionyr, Tango and Tizona and $983&#160;million or $0.78 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos. See Note 3. Fair Value Measurements and Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2020 included $628 million, or $0.50 per basic and diluted share, of unrealized losses from changes in the fair value of our equity investments largely with Galapagos and $615&#160;million, or $0.49 per basic and diluted share of acquisition-related expenses primarily from amortization of intangible assets, inventory step-up charges and accelerated stock-based compensation expenses related to our acquisition of Immunomedics. See Note 3. Fair Value Measurements, Note 6. Acquisitions and Note 11. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts for the third quarter of 2019 included upfront collaboration and licensing expenses of $3.92&#160;billion, or $2.40 per basic and diluted share related to the collaboration with Galapagos. See Note 11. Collaborations and Other Arrangements for additional information.</span></div>(5) &#160;&#160;&#160;&#160;Amounts for the fourth quarter of 2019 included a $1.2&#160;billion favorable tax effect related to intra-entity intangible asset transfers and $929 million of pre-tax net gains from equity securities primarily our equity investment in Galapagos, partially offset by an $800&#160;million pre-tax impairment charge related to IPR&amp;D intangible assets acquired in connection with the acquisition of Kite and pre-tax write-down charges of $500 million for slow moving and excess raw material and work in process inventory. The impact of these factors resulted in a net favorable impact of $0.83 per basic share and $0.81 per diluted share. See Note 3. Fair Value Measurements, Note 7. Inventories, Note 9. Goodwill and Intangible Assets and Note 18. Income Taxes for additional information<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181604760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 795,000,000<span></span>
</td>
<td class="nump">$ 784,000,000<span></span>
</td>
<td class="nump">$ 587,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Office, computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Office, computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288160097752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,689<span></span>
</td>
<td class="nump">$ 22,449<span></span>
</td>
<td class="nump">$ 22,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 7,421<span></span>
</td>
<td class="nump">$ 6,577<span></span>
</td>
<td class="nump">$ 5,143<span></span>
</td>
<td class="nump">$ 5,548<span></span>
</td>
<td class="nump">$ 5,879<span></span>
</td>
<td class="nump">$ 5,604<span></span>
</td>
<td class="nump">$ 5,685<span></span>
</td>
<td class="nump">$ 5,281<span></span>
</td>
<td class="nump">24,689<span></span>
</td>
<td class="nump">22,449<span></span>
</td>
<td class="nump">22,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,217<span></span>
</td>
<td class="nump">16,645<span></span>
</td>
<td class="nump">16,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,355<span></span>
</td>
<td class="nump">22,119<span></span>
</td>
<td class="nump">21,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,141<span></span>
</td>
<td class="nump">16,565<span></span>
</td>
<td class="nump">16,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,938<span></span>
</td>
<td class="nump">16,438<span></span>
</td>
<td class="nump">14,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,651<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
<td class="nump">11,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">HIV Products, Atripla</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">HIV Products, Atripla | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">HIV Products, Atripla | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember', window );">HIV Products, Atripla | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">HIV Products, Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,259<span></span>
</td>
<td class="nump">4,738<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">HIV Products, Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">HIV Products, Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">HIV Products, Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">HIV Products, Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">HIV Products, Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">HIV Products, Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">HIV Products, Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">HIV Products, Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">HIV Products, Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">HIV Products, Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">HIV Products, Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">HIV Products, Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">4,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">HIV Products, Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">HIV Products, Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">HIV Products, Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">HIV Products, Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">HIV Products, Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">HIV Products, Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">HIV Products, Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">HIV Products, Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">HIV Products, Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">HIV Products, Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">HIV Products, Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">HIV Products, Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">HIV Products, Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">HIV Products, Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">HIV Products, Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total Cell Therapy product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Cell Therapy Products, Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Cell Therapy Products, Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Cell Therapy Products, Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Cell Therapy Products, Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Call Therapy Products, Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Call Therapy Products, Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Call Therapy Products, Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember', window );">Call Therapy Products, Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">Other Products, AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">Other Products, AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">Other Products, AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">Other Products, AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember', window );">Ranexa | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember', window );">Other Products, Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember', window );">Other Products, Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember', window );">Other Products, Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember', window );">Other Products, Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVireadMember', window );">Other Products, Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVireadMember', window );">Other Products, Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVireadMember', window );">Other Products, Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsVireadMember', window );">Other Products, Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Other Products, Zydelig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Other Products, Zydelig | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Other Products, Zydelig | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember', window );">Other Products, Zydelig | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_COVID19ProductsVekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CallTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_COVID19ProductsTrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256750248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summarized Revenues from Major Customers (Details) - Revenue benchmark - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179444888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems', window );"><strong>Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis=gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember', window );">Revenue recognized related to royalties for licenses of our intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems', window );"><strong>Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized from performance obligations satisfied in prior years</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis=gild_ChangeinestimatevariableconsiderationMember', window );">Change in estimate variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems', window );"><strong>Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized from performance obligations satisfied in prior years</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis=gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis=gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis=gild_ChangeinestimatevariableconsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis=gild_ChangeinestimatevariableconsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288178242856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of assets and liabilities recorded at fair value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,026<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,970<span></span>
</td>
<td class="nump">11,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">9,008<span></span>
</td>
<td class="nump">27,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">9,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">4,361<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,279<span></span>
</td>
<td class="nump">13,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">4,361<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,729<span></span>
</td>
<td class="nump">14,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">9,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Equity investment in Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_EquityinvestmentinGalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_EquityinvestmentinGalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179055800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Limited partnerships and other equity method investments</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Other equity investments without readily determinable fair values</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt</a></td>
<td class="nump">24,593<span></span>
</td>
<td class="nump">31,402<span></span>
</td>
<td class="nump">24,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">27,300<span></span>
</td>
<td class="nump">34,600<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Fair Value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="nump">$ 30,300<span></span>
</td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256151416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Classification on Balance Sheet (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 6,970<span></span>
</td>
<td class="nump">$ 11,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">4,361<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="nump">$ 3,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179737752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 16,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">2,026<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">9,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">9,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256287976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,026<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">12,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 1,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256443592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">After five years</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">$ 16,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">After five years</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,026<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173943304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in an Unrealized Loss Position (Details) - Corporate debt securities<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 Months, Unrealized Losses</a></td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 Months, Fair Value</a></td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater, Fair Value</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Estimated Fair Value</a></td>
<td class="nump">$ 1,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288258059688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale Debt Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 37,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Securities in unrealized loss positions, number of positions (securities) | security</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairment loss recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179764104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of asset derivatives</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of liability derivatives</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of asset derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of liability derivatives</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of asset derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other&#160;accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of liability derivatives</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of asset derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other&#160;long-term&#160;obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of liability derivatives</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of asset derivatives</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of liability derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of asset derivatives</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument | Other&#160;accrued&#160;liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Fair value of liability derivatives</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256794008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in AOCI</a></td>
<td class="num">$ (118)<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from AOCI into product sales</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) recognized in Other income (expense), net</a></td>
<td class="num">$ (51)<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256616200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsAbstract', window );"><strong>Derivative assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Gross Amounts Offset on the Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash Collateral Received/Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Gross Amounts of Recognized Assets/Liabilities</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Gross Amounts Offset on the Consolidated Balance Sheets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative Financial Instruments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash Collateral Received/ Pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net Amount (Legal Offset)</a></td>
<td class="num">$ (109)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174168248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Outstanding notional amounts on foreign currency exchange contracts</a></td>
<td class="nump">$ 2,400,000,000<span></span>
</td>
<td class="nump">$ 2,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Gain (loss) on discontinuance of cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity on derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Estimate of time to transfer</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288178355992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 10, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 10, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,856,000<span></span>
</td>
<td class="nump">$ 4,251,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 643,000<span></span>
</td>
<td class="nump">$ 636,000<span></span>
</td>
<td class="nump">$ 845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember', window );">Three year senior unsecured term loan facility | Medium-term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing under the senior unsecured term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory', window );">Fair value step-up adjustment of inventories acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,991,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput', window );">Liability related to future royalties, measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput', window );">Liability related to future royalties, measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Payments to outstanding common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments made for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Payments to equity award holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments made for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Intangible asset - Trodelvy for mTNBC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Outlicense contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">&#8364; 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AssetAcquisitionCashOutflowNetOfCashAcquired', window );">Total consideration, net of acquired cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash', window );">Assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AssetAcquisitionCashOutflowNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition Cash Outflow Net Of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AssetAcquisitionCashOutflowNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Net of Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Future Royalties, Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets Acquired, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gild_PaymentstoOutstandingCommonStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gild_PaymentstoOutstandingCommonStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=gild_PaymentsToEquityAwardHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=gild_PaymentsToEquityAwardHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257747384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details) - Immunomedics, Inc.<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes</a></td>
<td class="num">(4,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">16,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration transferred</a></td>
<td class="nump">20,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="nump">15,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Intangible asset - Trodelvy for mTNBC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Outlicense contract</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175532712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Supplemental Pro Forma Information (Details) - Immunomedics, Inc. - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenues</a></td>
<td class="nump">$ 24,778,000<span></span>
</td>
<td class="nump">$ 22,449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income (loss) attributable to Gilead</a></td>
<td class="num">$ (323,000)<span></span>
</td>
<td class="nump">$ 4,488,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179025176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="nump">$ 1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,331<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 3,014<span></span>
</td>
<td class="nump">$ 2,067<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleofInventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure of information about inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleofInventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AssetsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173894312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember', window );">Inventory Write-downs for Excess Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ScheduleofInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleofInventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Disclosure of information about inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleofInventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288258019288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of property, plant and equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land and land improvements</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements (including leasehold improvements)</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Laboratory and manufacturing equipment</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Office, computer equipment and other</a></td>
<td class="nump">793<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">6,635<span></span>
</td>
<td class="nump">5,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 4,967<span></span>
</td>
<td class="nump">$ 4,502<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257417992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Unamortized capitalized software costs</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Net book value of long-lived assets</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Net book value of long-lived assets</a></td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256018136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2019</a></td>
<td class="nump">$ 4,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2020</a></td>
<td class="nump">8,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from the acquisition of Immunomedics</a></td>
<td class="nump">$ 3,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181650824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="nump">$ 820,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FinitelivedintangibleassetimpairmentbyprogramAxis=gild_Kite585ProgramMember', window );">Kite 585 Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets Acquired, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FinitelivedintangibleassetimpairmentbyprogramAxis=gild_Kite585ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FinitelivedintangibleassetimpairmentbyprogramAxis=gild_Kite585ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181688232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">$ 22,897<span></span>
</td>
<td class="nump">$ 18,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,660)<span></span>
</td>
<td class="num">(5,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">16,236<span></span>
</td>
<td class="nump">12,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">39,787<span></span>
</td>
<td class="nump">19,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,660)<span></span>
</td>
<td class="num">(5,468)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">33,126<span></span>
</td>
<td class="nump">13,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived assets - IPR&amp;D</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">16,890<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">16,890<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset - sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,952)<span></span>
</td>
<td class="num">(4,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">6,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,952)<span></span>
</td>
<td class="num">(4,253)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember', window );">Intangible asset - axicabtagene ciloleucel (DLBCL)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,105)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,095<span></span>
</td>
<td class="nump">5,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,105)<span></span>
</td>
<td class="num">(761)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember', window );">Intangible asset - Trodelvy for mTNBC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">4,537<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(540)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (540)<span></span>
</td>
<td class="num">$ (454)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyForMTNBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175228072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 16,236<span></span>
</td>
<td class="nump">$ 12,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257413368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 5,560<span></span>
</td>
<td class="nump">$ 4,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: chargebacks</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: cash discounts and other</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,892<span></span>
</td>
<td class="nump">$ 3,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257953768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">$ 599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">598<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 4,336<span></span>
</td>
<td class="nump">$ 3,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118944142&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288149366136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details)<br> &#8364; / shares in Units, &#8364; in Millions, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jul. 13, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>study</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>study</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 08, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>study</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Aug. 27, 2020</div></th>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jul. 13, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 19, 2020 </div>
<div>agreement</div>
</th>
<th class="th">
<div>May 29, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 19, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 19, 2016 </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,856<span></span>
</td>
<td class="nump">$ 4,251<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
<td class="nump">4,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_AmendedArcusCommonStockPurchaseAgreementMember', window );">Amended arcus common stock purchase agreement | Arcus | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember', window );">Janssen pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage', window );">Purchase price of goods less specified amount, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember', window );">Tango collaboration and stock purchase agreement | Tango</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember', window );">Jounce license and stock purchase agreement | Jounce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember', window );">Japan tobacco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireManagementContractRights', window );">Payments to acquire management contract rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember', window );">Gadeta collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestInVariableInterestEntity', window );">Noncontrolling interest in variable interest entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_BristolMyersSquibbCollaborativeArrangementMember', window );">BMS collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember', window );">Other collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant', window );">Upfront collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent', window );">Collaboration and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus collaboration agreement and stock purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent', window );">Collaboration and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalShares', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalUpfrontPaymentsMade', window );">Total upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 22.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_IssuanceDiscountPremium', window );">Issuance discount (premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsForDirectTransactionalExpense', window );">Direct transactional costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Amended arcus common stock purchase agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent', window );">Collaboration and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalShares', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary', window );">Additional option fee on second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries', window );">Additional option fee on fourth, sixth, and eighth anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments', window );">Future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeArrangementTerm', window );">Collaborative Arrangement, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased', window );">Maximum percentage of outstanding stock allowed to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIRestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Pionyr merger and option agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalPayable', window );">Additional payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Research and development service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_ResearchAndDevelopmentFutureMaximumPayments', window );">Research and development future maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AccruedResearchAndDevelopmentMilestonePayments', window );">Accrued research and development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfStudies', window );">Number of studies | study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Research and development service agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentsForResearchAndDevelopmentMilestones', window );">Cash payments made for research and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Tizona merger and option agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments', window );">Option fee and potential future milestone payments</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember', window );">Tango | Tango collaboration and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_NumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CollaborativeArrangementTerm', window );">Collaborative Arrangement, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments', window );">Opt-in, extension and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember', window );">Jounce | Jounce license and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalUpfrontPaymentsMade', window );">Total upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum', window );">Future potential clinical, regulatory and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Filgotinib agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | 2019 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential development and regulatory milestone-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialFutureSalesbasedMilestone', window );">Potential future sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialFutureTieredRoyaltyPaymentLowend', window );">Potential future tiered royalty payment low-end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialFutureTieredRoyaltyPaymentHighend', window );">Potential future tiered royalty payment high-end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Amended 2019 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage', window );">Payment of tiered royalties, low-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage', window );">Payment of tiered royalties, high-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts', window );">Potential payment for adjustments of budgeted development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths', window );">Additional payment for adjustments of budgeted development costs in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo', window );">Payment for adjustments of budgeted development costs in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Amended 2019 agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts', window );">Payment for adjustments of budgeted development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Galapagos subscription agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalShares', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments balancce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
<td class="nump">$ 3,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_StandstillRestrictingTerm', window );">Standstill restricting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement', window );">Maximum ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement', window );">Minimum ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing', window );">Payment for license and option rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_Issuancediscount', window );">Issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Galapagos collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690', window );">Potential milestone payment upon marketing approval GLPG-1690</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialOptionExerciseFeePerProgram', window );">Potential option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage', window );">Payment of tiered royalties, low-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage', window );">Payment of tiered royalties, high-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedResearchAndDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedResearchAndDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of Budgeted Development Costs, Payments, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CashPaymentsMadeRelatedToEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Payments Made Related to Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CashPaymentsMadeRelatedToEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquityMethodInvestmentOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquityMethodInvestmentOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Option Fee And Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Additional Option Fee on Second Anniversary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Future Maximum Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial consideration for acquisition of rights to market and distribute certain products in Japan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InvestmentOwnedBalanceAdditionalPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Balance, Additional Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InvestmentOwnedBalanceAdditionalPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InvestmentOwnedBalanceAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Balance, Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InvestmentOwnedBalanceAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IssuanceDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Discount (Premium)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IssuanceDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_Issuancediscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_Issuancediscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for Adjustments of Budgeted Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>payment for license, option rights and equity investments upon closing of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForDirectTransactionalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Direct Transactional Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForDirectTransactionalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForResearchAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Research and Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForResearchAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureSalesbasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Sales-based Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureSalesbasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureTieredRoyaltyPaymentHighend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Tiered Royalty Payment High-end</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureTieredRoyaltyPaymentHighend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureTieredRoyaltyPaymentLowend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Future Tiered Royalty Payment Low-end</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureTieredRoyaltyPaymentLowend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment Upon Marketing Approval GLPG-1690</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialOptionExerciseFeePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Option Exercise Fee Per Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialOptionExerciseFeePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Payment for Adjustments of Budgeted Development Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalties High-end, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalty, Low-end, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price of Goods Less Specified Amount, Maximum Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ResearchAndDevelopmentFutureMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Future Maximum Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ResearchAndDevelopmentFutureMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_StandstillRestrictingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Standstill Restricting Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_StandstillRestrictingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalUpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Upfront Payments Made</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalUpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities categorized neither as held-to-maturity nor trading which are intended be sold more than one year from the balance sheet date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestInVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestInVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireManagementContractRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from amounts paid for the rights to manage the property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireManagementContractRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedArcusCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedArcusCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_JounceTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_JounceTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_BristolMyersSquibbCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_BristolMyersSquibbCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GalapagosCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288149162520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt</a></td>
<td class="nump">31,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current maturities</a></td>
<td class="nump">2,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">28,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 30,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.35% Senior Unsecured Notes Due In February 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.55% Senior Unsecured Notes Due in September 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.50% Senior Unsecured Notes Due in April 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.40% Senior Unsecured Notes Due In December 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.95% Senior Unsecured Notes Due in March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.25% Senior Unsecured Notes Due in September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.50% Senior Unsecured Notes Due in September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.75% Senior Unsecured Notes Due in September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | Variable Term Loan Note Due October 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.70% Senior Unsecured Notes Due in April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.50% Senior Unsecured Notes Due in February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.65% Senior Unsecured Notes Due in March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 2,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.95% Senior Unsecured Notes Due in March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.60% Senior Unsecured Notes Due in September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.00% Senior Unsecured Notes Due in September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.65% Senior Unsecured Notes Due in December 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.80% Senior Unsecured Notes Due in April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.50% Senior Unsecured Notes Due in February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.75% Senior Unsecured Notes Due in March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 2,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.15% Senior Unsecured Notes Due in March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR rate | Senior notes | 0.15% LIBOR Senior Unsecured Notes Due September 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">LIBOR rate | Senior notes | 0.52% LIBOR Senior Unsecured Notes Due September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueInFebruary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueInFebruary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_VariableTermLoanNoteDueOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288261174456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,295,000,000<span></span>
</td>
<td class="nump">24,593,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member', window );">0.15% LIBOR Senior Unsecured Notes Due September 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member', window );">0.52% LIBOR Senior Unsecured Notes Due September 2023 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member', window );">0.75% Senior Unsecured Notes Due September 2023 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member', window );">1.20% Senior Unsecured Notes Due October 2027 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 745,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member', window );">1.65% Senior Unsecured Notes Due October 2030 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 992,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member', window );">2.60% Senior Unsecured Notes Due October 2040 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 986,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member', window );">2.80% Senior Unsecured Notes Due October 2050 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,476,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2014Member', window );">the "2014 Senior Notes" | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2015Member', window );">the "2015 Senior Notes" | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member', window );">4.50% Senior Unsecured Notes Due in April 2021 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">998,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member', window );">4.50% Senior Unsecured Notes Due in April 2021 | Senior notes | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayments of unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember', window );">Three year senior unsecured term loan facility | Medium-term notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueMay2021Member', window );">2016 revolving credit facility | Line of credit | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under the facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member', window );">2020 revolving credit facility | Line of credit | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under the facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2020Member', window );">Senior Unsecured Note Issued September 2020 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Call Feature, Period Before Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtInstrumentCallFeaturePeriodBeforeMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueApril2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueMay2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueMay2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNoteIssuedSeptember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257629624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Contractual Maturities of Financing Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">4,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">18,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 30,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256855976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term extension</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Termination period</a></td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense under ASC 842</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease expense under ASC 840</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288255860504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Location Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 646<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities - current</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, noncurrent [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities - noncurrent</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">3.32%<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, current [Extensible List]</a></td>
<td class="text">us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288174084104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288177206616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Liabilities Maturity (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases, Summary of Aggregate Future Lease Payments After Adoption of 842</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">$ 715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179673944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=gild_ActivePharmaceuticalIngredientMember', window );">Active pharmaceutical ingredient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_IdenixPharmaceuticalsIncMember', window );">Indenix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyMotionInvalidatedForPastDamagesValue', window );">Past damages vacated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="nump">$ 585,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateFromOctober2017', window );">Running royalty rate from October 2017</a></td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentEnhancedDamagesonPastSales', window );">Enhancement rate on past damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateOnFutureSales', window );">Running royalty rate on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyEstimateofPossibleLossPastSales', window );">Estimate of possible loss representing past sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages', window );">Estimate of possible loss representing enhancement of past damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest', window );">Estimate of possible loss representing royalties and prejudgment interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember', window );">ViiV | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Value of damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Juno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Juno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentEnhancedDamagesonPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Enhanced Damages on Past Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentEnhancedDamagesonPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateFromOctober2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate from October 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateFromOctober2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate on Future Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss (Royalties and Post-Judgment Interest)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyEstimateofPossibleLossPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss (Past Sales)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyEstimateofPossibleLossPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMotionInvalidatedForPastDamagesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Motion Invalidated For Past Damages, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMotionInvalidatedForPastDamagesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77896938&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=gild_ActivePharmaceuticalIngredientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=gild_ActivePharmaceuticalIngredientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_IdenixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_IdenixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ViiVHealthcareCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288256566728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Repurchases of Common Stock (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Amount</a></td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="nump">$ 1,749<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share</a></td>
<td class="nump">$ 70.64<span></span>
</td>
<td class="nump">$ 66.36<span></span>
</td>
<td class="nump">$ 72.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember', window );">2016 stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember', window );">2020 stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_PubliclyAnnouncedProgramMember', window );">Publicly announced program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_PubliclyAnnouncedProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_PubliclyAnnouncedProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181680536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 867<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 3,464<span></span>
</td>
<td class="nump">$ 3,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend Per Share</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173917368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288159991192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 22,650<span></span>
</td>
<td class="nump">$ 21,534<span></span>
</td>
<td class="nump">$ 20,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">18,221<span></span>
</td>
<td class="nump">22,650<span></span>
</td>
<td class="nump">21,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Balance at January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Balance at January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Balance at January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1', window );">Balance at January 1, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(145)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (60)<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288267047800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Stock Options (Details) - Stock option<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at December 31, 2019 | shares</a></td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired | shares</a></td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at December 31, 2020 | shares</a></td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2020 | shares</a></td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest, net of estimated forfeitures at December 31, 2020 | shares</a></td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 61.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">71.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">72.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">81.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised | $ / shares</a></td>
<td class="nump">34.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at December 31, 2020 | $ / shares</a></td>
<td class="nump">69.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2020 | $ / shares</a></td>
<td class="nump">68.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Expected to vest, net of estimated forfeitures at December 31, 2020 | $ / shares</a></td>
<td class="nump">$ 70.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at December 31, 2020, weighted-average remaining contractual term</a></td>
<td class="text">5 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Expected to vest, net of estimated forfeitures at December 31, 2020, weighted-average remaining contractual term</a></td>
<td class="text">3 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Expected to vest, net of estimated forfeitures at December 31, 2020, weighted-average remaining contractual term</a></td>
<td class="text">8 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at December 31, 2020, aggregate intrinsic value | $</a></td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2020, aggregate intrinsic value | $</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Expected to vest, net of estimated forfeitures at December 31, 2020, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288178301912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Restricted Stock and Performance Share Awards (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2019</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2020</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at December 31, 2019</a></td>
<td class="nump">$ 80.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">83.64<span></span>
</td>
<td class="nump">$ 68.30<span></span>
</td>
<td class="nump">$ 88.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">73.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">81.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at December 31, 2019</a></td>
<td class="nump">$ 84.87<span></span>
</td>
<td class="nump">$ 80.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2019</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(6.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2020</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at December 31, 2019</a></td>
<td class="nump">$ 70.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">70.94<span></span>
</td>
<td class="nump">$ 64.31<span></span>
</td>
<td class="nump">$ 77.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">72.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">70.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at December 31, 2019</a></td>
<td class="nump">$ 69.80<span></span>
</td>
<td class="nump">$ 70.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181631176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Summary of Stock-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(222)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation expense, net of tax</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Income tax expense following U.S. Court of Appeals decision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288177465192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility:</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years:</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate:</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility:</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years:</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate:</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288177130216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Value of stock issued</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Matching contribution expense</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2004EquityIncentivePlanMember', window );">2004 Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2018EquityIncentivePlanMember', window );">2018 Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember', window );">Immunomedics Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 11.69<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
<td class="nump">$ 17.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 70.94<span></span>
</td>
<td class="nump">64.31<span></span>
</td>
<td class="nump">77.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 83.64<span></span>
</td>
<td class="nump">$ 68.30<span></span>
</td>
<td class="nump">$ 88.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gild_RestrictedStockandPerformanceShareAwardsMember', window );">Restricted stock and performance share awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Value of stock issued</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember', window );">Deferred compensation plan | Level 1 | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalFairValueAxis=gild_FairValueatGrantDateMember', window );">Fair value at grant date | Restricted stock and performance share awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested stock awards as of vesting date</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_TotalFairValueAxis=gild_FairValueatVestingDateMember', window );">Fair value at vesting date | Restricted stock and performance share awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested stock awards as of vesting date</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2004EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_GileadSciencesInc2004EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_GileadSciencesInc2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gild_RestrictedStockandPerformanceShareAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gild_RestrictedStockandPerformanceShareAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalFairValueAxis=gild_FairValueatGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalFairValueAxis=gild_FairValueatGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalFairValueAxis=gild_FairValueatVestingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalFairValueAxis=gild_FairValueatVestingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288175526232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288159975736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="num">$ (3,339)<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="num">$ (1,165)<span></span>
</td>
<td class="nump">$ 1,880<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
<td class="nump">$ 5,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in per share calculation - basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in per share calculation - diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (2.66)<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (2.66)<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288173978360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 2,505<span></span>
</td>
<td class="nump">$ 4,112<span></span>
</td>
<td class="nump">$ 7,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(836)<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">$ 1,669<span></span>
</td>
<td class="nump">$ 5,160<span></span>
</td>
<td class="nump">$ 7,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288257061016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal - current</a></td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">$ 1,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal - deferred</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax expense (benefit), continuing operations</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State - current</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State - deferred</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State and local income tax expense (benefit), continuing operations</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign - current</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign - deferred</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(1,224)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Foreign income tax expense (benefit), continuing operations</a></td>
<td class="nump">193<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="num">$ (204)<span></span>
</td>
<td class="nump">$ 2,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)-(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288255835368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings at different rates</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research and other credits</a></td>
<td class="num">(6.90%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings', window );">US tax on foreign earnings</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Deferred tax - intra-entity transfer of intangible assets</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Settlement of tax examinations</a></td>
<td class="num">(10.20%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquired IPR&amp;D and related charges</a></td>
<td class="nump">56.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Non-taxable unrealized gain / loss on investment</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">94.70%<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate impacts related to US tax on foreign earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288179487592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals not currently deductible</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DeferredTaxAssetsUpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credit carryforwards</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Liability related to future royalties</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">4,358<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="num">$ (331)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">3,960<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Excess of book basis over tax basis of intangible assets</a></td>
<td class="num">(6,168)<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(6,572)<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (2,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DeferredTaxAssetsUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Upfront and Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DeferredTaxAssetsUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288176959224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of period</a></td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">$ 2,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Tax Positions Related to Current Year: Additions</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Tax Positions Related to Current Year: Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Tax Positions Related to Prior Years: Additions</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Tax Positions Related to Prior Years: Reductions</a></td>
<td class="num">(481)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of period</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288181787368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes - Narrative (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="num">$ (204)<span></span>
</td>
<td class="nump">$ 2,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability</a></td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">6,168<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Total gross unrecognized tax benefits</a></td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">$ 2,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and income tax penalties</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes - Narrative (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes - Narrative (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember', window );">Intangible Asset Transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes - Narrative (Details)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288176145704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Information (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,421<span></span>
</td>
<td class="nump">$ 6,577<span></span>
</td>
<td class="nump">$ 5,143<span></span>
</td>
<td class="nump">$ 5,548<span></span>
</td>
<td class="nump">$ 5,879<span></span>
</td>
<td class="nump">$ 5,604<span></span>
</td>
<td class="nump">$ 5,685<span></span>
</td>
<td class="nump">$ 5,281<span></span>
</td>
<td class="nump">$ 24,689<span></span>
</td>
<td class="nump">$ 22,449<span></span>
</td>
<td class="nump">$ 22,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit on product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,930<span></span>
</td>
<td class="nump">5,352<span></span>
</td>
<td class="nump">4,003<span></span>
</td>
<td class="nump">4,498<span></span>
</td>
<td class="nump">4,113<span></span>
</td>
<td class="nump">4,481<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="num">(3,346)<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="num">$ (3,339)<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="num">$ (1,165)<span></span>
</td>
<td class="nump">$ 1,880<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
<td class="nump">$ 5,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (2.66)<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.23<span></span>
</td>
<td class="nump">0.29<span></span>
</td>
<td class="num">(2.66)<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="num">(0.92)<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,856<span></span>
</td>
<td class="nump">$ 4,251<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge related to IPR&amp;D intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_EPSImpactbyTransactionAxis=gild_FavorableEPSImpactMember', window );">Favorable EPS Impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember', window );">Inventory Write-downs for Excess Raw Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_UnrealizedGainComponentAxis=gild_IntangibleAssetTransferMember', window );">Intangible Asset Transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember', window );">Intangible Asset Transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember', window );">Arcus, Pionyr, Tango and Tizona</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember', window );">Galapagos subscription agreement | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gild_SelectedQuarterlyFinancialInformationLineItems', window );"><strong>Selected Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share attributable to Gilead common stockholders - diluted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SelectedQuarterlyFinancialInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Selected Quarterly Financial Information [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SelectedQuarterlyFinancialInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EPSImpactbyTransactionAxis=gild_FavorableEPSImpactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EPSImpactbyTransactionAxis=gild_FavorableEPSImpactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=gild_InventoryWritedownsforExcessRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UnrealizedGainComponentAxis=gild_IntangibleAssetTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UnrealizedGainComponentAxis=gild_IntangibleAssetTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DeferredIncomeTaxExpenseBenefitComponentAxis=gild_IntangibleAssetTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140288178943208">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">Accounting Standards Update 2016-13 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (7,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">Accounting Standards Update 2016-13 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(7,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">483,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member] | AOCI Attributable to Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">$ (293,000,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>117
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(Z81QI&/>ZL3F4$O,W#*O-L*J<X5DR64D'Q@BJX+AFJ6[257G%G5MAZCL9
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M97N;WWY08M=<B*^%4J)L'K=0WTQJ _C]7L"VH/N@[]C[OZFL_@-02P,$%
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M3-OM6LC?2<6C'(891#3.WO@U7X<3 .R4 UX.>.= JP)HYD#3%&CE0,L4:.=
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M6<4F4\#"IPL+'R54=.B)/XNF,0M73_>6MT*"901S#P8P3JAM]2!8FMN'+4L
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MFA<5;PU _WTE97?X8EXP7H>[_3]02P,$%     @ ZH%94MQ"%/,T*P  PH8
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MFRQ9<64(S%R)$ 6*1*DEJI@EP^8=/P9.JB;973,&MBX$JRB40A^.3 XL1N3
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M7A$OL4GK), ;8:K9^6;!08W1]")@E(;ZYI!SBP-$'."H]M)LQKAB52UR*^T
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MV8QP9;;#=HSG-$7&)G4J\"6)/'$=5HKIDQ%*2=PO4,L?D9.FOI\^%"J$I6Y
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MHI1U"&K=& H9?TC.]Q<MTJ.3P<?461R!+_O#6A7]<2SYD3PIKI8D!YW6ZAP
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MGSUX2&^&QY\_VY&;\2YOU_"W*[>B5Q_-?_KQ@11CVA]]L\.2,//Z9LO_Q+!
MU^(!^G[5$%WI']@ D10&[_E_ U!+ P04    " #J@5E273Y)WK\*  "Z&
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M^%(^O'1Z[;Y.SW6'8NZ&*UQCI.$-6%]HW>U?F,'XWQ4O_@-02P,$%     @
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M-+)G[#?^B>[?FBU_M;_KO@8D5#1,*+G7O=/G_(42SV4F4 +^&)P1<:BYP1;
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MF>9I8//O4!5PU'W]PE<8Z^-<.3ST4!-I_:ZY!B[0J:*#!A7OP]>]YHZ%=@!
M_*WD@Y]\_%3X1U)C<PKYV8]$HSP&]V#1YS!BY8<!.S9O)$Y=$A _KLGF>XOM
M?ZR4F?KR_956%#1(?2@'OSU$O774&2;J&SJ9<G3P0A8)K([[#RJ\NM#X'@"Q
M]D<QPY)@2&<K<RHZRV;EVW)10===NE.[6UQ5!&P.4\-!?4MQ9T-^>W#X?@M
M5+TF@+Z"KP6$@GY25W8TV 'M; -8J(<;J#I-9ZC]RDEV(LS,G]?;<#P9#K7+
MN^5? J-P$KY>'OY/^,3-C%Y(E9ABZV'O]%TKO%@4/YQ>^'/QB79.)_YR+CB:
M&2W \ZE&7N8_2$'Y1\G5?P%02P,$%     @ ZH%94IA08](Q%   K3L  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&ULU5MI<QNY=OTK*,5Y956:%$E1
MB]<J6;;'?C5>(GG>U*M4/H#=(-GCWJ:!%LW\^IQ[@0;0).5EXJHD'V8LLAO
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MH3\(&F] WRM- 0T;[V#W3UK^ U!+ P04    " #J@5E28IV:DA,$  "<"0
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MGTUZH.NW0#VPJO3W[U99NLU]-Z?G$VHG0.N94O8P< ;:!]GR'U!+ P04
M" #J@5E2CU%A&F@(   Z%0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6S56&MOVS@6_2N$-S-( ,6VY'>:!'"23FM,)BV:[/;#8K&@)=KF5!)5DHKC
M_OH]EY1L96RWLXO=#UL4,262E^>^SKW4Y5KI+V8EA&4O69J;J];*VN*BTS'Q
M2F3<M%4A<LPLE,ZXQ:->=DRA!4_<IBSM1-WNL)-QF;>N+]V[C_KZ4I4VE;GX
MJ)DILXSKS8U(U?JJ%;;J%Y_D<F7I1>?ZLN!+\2CL7XN/&D^=K91$9B(W4N5,
MB\55:QI>W/1IO5OP-RG6IC%FI,E<J2_T,$NN6ET")%(16Y+ \?,L;D6:DB#
M^%K);&V/I(W-<2W]%Z<[=)ES(VY5^EDF=G75&K=8(A:\3.TGM7XO*GT&)"]6
MJ7%_V=JO'?1:+"Z-55FU&0@RF?M?_E+9H;%AW#VR(:HV1 ZW/\BAO..67U]J
MM6::5D,:#9RJ;C? R9R<\F@U9B7VV>MW2B5KF::,YPF;Y9;G2SE/!9L:(ZRY
M[%B<02L[<27OQLN+CL@+(_:;RNW*L+=Y(I+7 CH MT48U0AOHN]*O!-QF_7"
M@$7=J/L=>;VMQCTGK_<?:<SNI(E394HMV-^G<V,UXN8?WSFVOSVV[X[M_YEC
MY>Y8?M30WY5'R7IA"AZ+JQ:RT0C]+%K7[SY\N/L\N[]GTX<[-GMXFCZ\F]W<
MOV73Q\>W3X]LB^%I)=A"I<A(F2^9Y03$IZ7\)@RSF(Y70(BQS/TCUWI#BWFF
MRMPRM6#+2MH%.\6B#".DF3EC4[_BAJ<\CZ&@97"AR.9"5VX,)^R$]8,P'.T0
M007D$1VPT"IS1_+X:RF-=,F+XV995N8J$XF,#>L%DTGXG2.B+HX8!V%WS#X+
M5@A-] 73XW]>\G2+G<FLX%*#9:SSA#%N6"F]4*6V*_:UY-H*'3"EF> ZE3A&
M+II;90Y4W"IMF'B1QK81381Y#U5 <A%::_J3*^@8EUF9<BN2@Y@0B0#5/A"G
M/W AD#<W^2@+6"[LQ0%;[3OHM4O?:>!@TP984"((+V>WI=8BCS?L2?/<8(Z\
M-4U^!W,Y!1Y05V[KV*DBX[\K[1>92RO.4Y![4NFYISD[9T8ME)F7SU(C,L)N
M,'(A<MH/)H/H#*.?_S*.PN@-1H-@-!S_85$TZ+U>- SZP]&A<_@+(F%N4=!R
M9(U,52K*6*3L].[^YO;^#!M1+]EIB-@<G&T%#H+N9%#/C89A<Z;?FQPZZ$FK
M1*3/&T2!9MG3P\TM<FI(^X>]W?9^,.B-MD_'?C]05+(PZ(U&['30[YX!X!D;
M]X9XUYV,88%!'^^&@-\;LR=ED4*+ W:/HF \@8AA,!Q60D(H17+&03>$(*@S
M''M1810,^GVHAB)Z0-8YFWW\]#//BC=WM:#QI+L'O7H=!E%_I^<I3$MOH@KK
M'M_"@[U),!J/R+T5VA-W#"9Z01@-*0 F030<T/L*-:UP2\(>]@[9/W_PSPF<
MY7%:)HY)?ZRH%K%:YLA@FF4%>(=HA+CH%?TUJ1&)^B&VBK*7<KG-'H5@#\H*
M-@0-[18:%R@\2=R3,XKOZ?"$A<NE%DLD(Q&\MO*;SSWQ@N[/".#RB6K5:[_O
M&W8-W"=A.V)SSQX!/87UDZM^S6D'BO3;@%G!GM0T'*)-1TJT&8-Q0.6B$*ZA
M2S>!+ZDPEY9$?^D&L)S-"1^[569;K@QH($T8%13PXRV,HE*9.,T>+7Z(9!QQ
MPVFP=;OB&(/R5T@$4NV8G<.X)MJ=_PXP9)P&=5MA7#W#?IGZ&JJR(A6^GL$3
M<\!6N5M;^1@F5+%T<&KY8@$# 4";W96:Q'ESK+=%#6M1GW &\,,<AQ! NBL'
M6]#[7BN-J^TPH9ISN$;:S?G:=;3.B&0,Q@O,\G@%J"BX"?HD;QN*D9C6+4I+
M;5/,S8HM4)@,6<0U)P#SS--2;,^I=S--(0> XY_:"-HFQIT>:$4TM2*N:%*&
MZ,JU/MZWAD&^_K\:INWJ.<'*G/M1IYO+G>:U8$P?->.D/?@)1EA)H$%&T'W%
MA;M]);U6X)P_"XU*A<CT.5*%N4M*BE:>2[*[1!,$%1<RQ9.1Z NX)A7(>-5[
MEX-:5$KY%M*!<C9!6GZ!1L1G,I802T2ARI0T$23)1P=MVG.!-TU#^:U=6$85
MD'SDPX&$N&9H!1 '?,E3HX 1C*C]670XM+X7H!'68PO$1X4D$YRN )X/?,=>
ME-94Q$*'[*RIL3TO!;HK,J/Q=-2(%Y?=(E[E: S2RDY+:GR4WH [XAA=)W5X
MWN):&O*7<@")[!I]J0MOIRVT!SWN8_!9 :I,2F?7/W3QNPV51U11@%Y*,#HY
M&LR6XQY-S0 "@;I(%P9SF7-?0:")ZV\K*U>K7'2Z)$!)\.XZBD^+!.U0XMOK
MG;WK(G<\$X,&O3>JT;%VJRXK5@MN:XY%!<8\W4W.L29% YZ?OU?)\@O,DVZR
M8J4RSDZIB8BZ;^3#^WLW#-^<!6Q.GR]VMR"/>G=IJ>Q;E>_ZRH+[QAZ-T?N3
M,=JTK*Z//ENI;FZYC3(.(C\ACKG&) 5-0E&J"B>J*LOFWZADL[PJG6M*][H^
MNNPDY+_.GMZ>#\8#"MREYAD2#BRD+*/>6R[09=)5B'Q:%:17U&*IRZI#G2H=
M;JLNVH&(,[05=.E)O!J4R&!E1(./@NI =V7BE4F#UW?.(S'BPL"%HCJL ]ET
MK:6U(F>)6KNT^B:T<D#6C5IRW%'1UE'_"Z?\B7OX+H>J*G*P/VMT#HZMZ?P?
M-&K\\ WUR&T>4R$UOL$@&M%#M!OV=L/^;CAPPY!41 HN<'_&?7S8'54=^4E]
M,3CT::73^)Z5"?B"OMJA"2,D_M/6]NWVP^#4?P_;+?=?%7^#*R68*Q4+;.VV
M1X,6T_Y+G7^PJG!?Q^;*6I6YX4KP1&A:@/F%0BM=/= !V\^EU_\"4$L#!!0
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MU';R^L/'OZC%\KN7%LMTPQ+$= &X+]ELGK9-"V@$Q3, 7>)7@I51A-9U2T0
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M =Z=I;,'/SW*M,@7.8HG@)MF_Y!%6(6J2^0.QAY0JP-XCD:!]>?N(Z8+.R(
MJA+@7]4H3+H:G9")+B["0T6"*UH:N 8)62@7_D<J5E:;PE?-'*Z3?\$_*&2!
MJ)D'6P>N?2!?A>:1IO.2Q#*P&#I'"B\Q,XB#K6JG;I?(IWAM_07XD\VOV-4A
M$PL>8&MG=,H\#++4LA5N=J#:BJU1%0,(5 ?*E$B,,OLYDPR$(%)^WN ]K:.
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M;-GD\T:##6;U )L-(;90K ,Z"$F]B=R]D&93M<PQ=.&(5I 51*6"P)-\^5:
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M,_!F@RMF#$5MIQG %5E7* *X[5L'C0$KTQ:@2#6S068M;N:'_6MIB0S__'=
M"Q BN50_5(HLQ-=@"L$_;\'I@IL[T8;/OR,+K<"Z6,+#F_8+8!F4'*<9Y#!;
MNQXZU.0/+67J-HT;%=*G]JH4=::,3P5TNSZ6OTJ(GK4P-J>[,OTTK])V@99,
MJJ.@'@4'W7:V%YO,*I*M4F"^&XI,2IRCG.E2@YBRO#&@IGV%\0Z PZ2B\"8(
M0YUSBA)\I?60IQ[@W511&U^JSS0"Y%_ICH;"PEE.<WF+2_E9 ]*,!TK0,1\;
M.N'3G]9+L$23!5B&^ $1Y0\O;Z0V.&UK]E*7)D=NJ%0N&@X_?,'!3HT9]"66
M[29O= /G[B;EWX%<?UFUL^1F"0Y@ZGW6 />R9 .P::S94<UUBRHMQYD$S1PK
MDKW_C/@--$./J(WEH3!,('1R\C?K=A')DP$@JFRGV$G @G 3Z:3 !<J<9!:/
M9O-.K]K*+$DM<5P0U-><1 V9J)S5CH/+],44UHP, F<3+U3UF5&E6J" RA&B
M">V5T /'W$#)N+!++S"4$HR" %+LVL,C:Z8PAMW)^,@]+XQ9UK@]"+R3N)J>
MT4_ZQ&"@I="S7ONTQ/2=^(K<BR,VWW-P(\M2IDW8%D37@1@8&M1 UC6\O-"Q
MV'-%(=00I%LK;4@2<<2)8Q:^/@']E74/?8&BHZXO9UMCB3P'=I':>ZB"0>0
M%F*0VG*FG1N.(YLX\$TW]= TN?J&PTCDSGEMY#?'[8B3!MC8P/V[;+B<D\R
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MA44XK!D#M/VP)IT28(7H]B!)C>M3X:L3D>$)K8J+NPR?5R"X3''\=HV=<K>
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MR-PER; *Q0/NM^->%7!?_*:XZ+8=,S!Q"N.N-$(@4#:7;!Z845+6<N=&!ZS
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M":J]^]Q4L"^7P<@"O'VZ=JPJ<D56"]!N\R6(SI+TXI36D@I54&T\E>)!P@D
M54+3$N(!UMG8I[M#I\-"=#H'MT7M^>(!OA<+S9HXW]E7&NO/V)H."!*%HY-T
MDJ(^M0ZM!G0GZ3C;'<#()UHB"QH9.I+>/*L*M:BMZ! D@NG"@^#EIJT#N?.
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M.-H7V#AF&D.V*/OCUBJ44]638'^;B_H"[VH$0EUM#U[Y+\;\DKS&U,V<JDS
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M+S;'UA7.UCY%D5\659C+X_5&I=H9>KQQ0!NO(Z$"9]*J>>5-[=!"+X%+I]'
M<XP-[3%PB\VH5G"4R=$H0JG@@@, *_V-97B3Q'Q7^=8AGAX_FDX7'6% 2=.Z
MK M?YJYAFZ$+S$Y&YOP>"5BN*@1>?J\X^2#FHIK[2D[3ZXLKC@&/8;H"03J8
MD'P)1V\[WJE);22WP:M@11>U8>]7=,<35-&@\\]P[@X]\5.%M^C"(_H3RFA
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M(% DM-6_["%B3X830+2Q[S#7\IM0.$7P<^< ?N># ?X.,'X"Z'AJ[5 >)"I
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M+W=O<FMS:&5E=',O<VAE970R-2YX;6S-5EV/ZC80_2NC:!]:B4M"^%CN"I"
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M9EF,\4< G]B?)(1'"9/P*N(]1DUHMQH0!F%P!:]]"DG;X;4OX,V8RGBVU[6
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M/1,+A4Q40G>8BK1$DEAG1;D4;J7$LLR1;+JXOQ#_4M)XYPB85JT7RK!Y![I
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MA[.0WZINRT37KTTAY\"Y$%<-OL1L#KA&L^PD 7C9EKIV]GY^/$J^TY:ZU&D
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M>A18$\X+3\^(H']Z$?3/6<'PSJTJPC=O=,I$^+05LN>.5%F-<\(_("&^8CD
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MUIF"@'DR#DN-V8$5/FU[))-SV,U)9D<2&U7)N.3%O<L0L,.1"V"(>1')'S(
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MS>3R9CB6:D>(&N?(WUH,[:A(1J-JM*' $2Q]^^8!I1^G3,(((B8.P6$C48I
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MGLH_195!):!X[1,W[?"8I158ADY>'4)'T;&=Q1%ZG:8VU>T(PUR3(8OQ947
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M@+(7D+Z0TNP/5D']OV3Z'U!+ P04    " #J@5E2@J2JMXP$  "(#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU5VUOXS8,_BN$-PPMD#9^RUN7
M!&C3N]N =BB:]N[#L ^*S<1";2LGR<UUOWZ4[#K.ZP7;#DALB9+(AWI(2AZN
MA'Q1":*&;UF:JY&3:+V\:K=5E&#&U*588DXC<R$SIJDK%VVUE,ABNRA+V[[K
M=ML9X[DS'EK9@QP/1:%3GN.#!%5D&9-O-YB*U<CQG'?!(U\DV@C:X^&2+7"*
M^GGY(*G7KK7$/,-<<9&#Q/G(N?:N;GIFOIWPF>-*-=I@/)D)\6(ZO\<CQS6
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M3.A3":690.-S(?1[QQBH/[[&_P!02P,$%     @ ZH%94I&![@._!   3Q
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M>]=FO=1[)X7":P-VWS3,/%RBU(=5-(Z.&Q_%KG9^(UXO6[;#3^@^M]>&5O&
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M75V&IM'(<F]4BS")HC2L&9?!9N7''O1FI5HKN,0'#::M:Z9?[E"HW3J(@_W
M!UY6U@V$FU7#2GQ$^W/SH*D7#B@YKU$:KB1H+-;!;;R\2]UZO^ 7CCMST ;G
MR5:ISZ[S8[X.(D<(!6;6(3#Z/>$]"N& B,8?/68P;.D,#]M[].^][^3+EAF\
M5^(3SVVU#A8!Y%BP5M@/:O<#]O[,'%ZFA/%?V'5KTVD 66NLJGMC8E!SV?W9
M<Q^' X-%=,8@Z0T2S[O;R+-\RRS;K+3:@7:K"<TUO*O>FLAQZ9+R:#7-<K*S
MFY^07#+P^B/;"C27J] 2J)L*LQ[@K@-(S@#$";Q3TE8&OI,YYL< (;$9*"5[
M2G?)*.);S*YA$K^!)$JB$;S)X.+$XTW&7?SM=FNL)A7\/H(Y'3"G'G-Z!O..
M"28SA*YPF,Q!V0HU<-G522=9P2SF8!50#6D:E"4(3^94F,<W_%@A%$I0#3D4
MZ[+5%Q+_DYS;_DL^K?Z&TQ(H\%AOR<H%_S67I#<AR-*\ 7S.L+&P\R(G#/9$
MQB4"JU4KK;F$>\&,X07/NKU<ZN@3WX O\RM57+6&EAN#EN DD7SO"0HERRN+
MNN[GX +2:>J^Z0)\YD!PMN6"6TY^7E%-:(UR;\ZR3+?$YW#-!<31G+XW-R<!
MI)+'&%\HJ*W@I7? \X@6[IND\.EKMS6Z\VZ('7CKQ74*+\BTH=:\;WUCF7.3
MN9 !Q1YA<CU)X!7]IG-X-2++V2#+V:A*'MNF$4AGIF7B_VAQ=!=W3RQ-PS)<
M!W01&-1/&/R=0#LYFG_"[Z0V?Z5P=B?,>9E>'LCNGID*&L9S(J7W,J4M,]$Z
M#+(B0E 3>JL](5!%G\QC+:6=&$_IF/1B208='%5(Q62)?K]30 NGIDD\@9$\
MIT.>T]$\OS^.#["RU%@Z116M)8?ZX8:].-=.IGAT@_^48D;W$FW.[0L=0$R\
M&&Y<4$_D\R@RINKQJD,_CAV@@#NHH\R[7"^_RO^MS[.;BMTQD,Q=,Z%&XAH3
MB&/?F,*-GYG!/ +RBEXSA76P$765TV8K]X7J#I=C+HO$G4R&1,GKIK4^_62-
MQA+^I <X;WX!\WAV4@3AP35>HR[]8\6 Q^EN]&%T> _==L^ +\N[Q]0[IDM.
MIYC @DRCZSE5M.X>*%W'JL8_"K;*TA/#-RMZTZ%V"VB^4,KN.VZ#X96X^0M0
M2P,$%     @ ZH%94KK;S!S!!   #0P  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&ULG5=M<^(V$/XK.S33P@P'?L=0P@Q)+KWK]%HF<.UT.OT@;($U
M9UN.)$/27]]=&3B2$IK+%R19VI=GG]V5&&^E^J(SS@T\%'FI+UN9,=6HW]=)
MQ@NF>[+B)>ZLI"J8P:5:]W6E.$NM4)'W/<>)^@4396LRMM]F:C*6M<E%R6<*
M=%T43#U>\5QN+UMN:__A3JPS0Q_ZDW'%UGS.S>=JIG#5/VA)1<%++60)BJ\N
M6U-W=!71>7O@=\&W^F@.A&0IY1=:?$PO6PXYQ'.>&-+ <-CP:Y[GI C=N-_I
M;!U,DN#Q?*_]UF)'+$NF^;7,_Q"IR2Y;<0M2OF)U;N[D]@/?X0E)7R)S;7]A
MVYP-PQ8DM3:RV FC!X4HFY$][.)P)! [+PAX.P'/^MT8LE[>,,,F8R6WH.@T
M:J.)A6JET3E1$BESHW!7H)R9S(U,OF0R3[G2/\#[^UJ81V@OV#+GNC/N&S1!
M!_O)3MU5H\Y[09WKP2=9FDS#^S+EZ5,%??3MX*"W=_#*.ZOQAB<]\-TN>([G
MG-'G'P#[5I__+8"GQBBQK W!!B-AQA0O#?PU76JC,''^/F,X.!@.K.'@)<-8
M3VF-^N4*-#F!.5W5*LDPI_2I2)]51\4ZTA5+^&4+JU%SM>&MR2+CL)(Y5IHH
MU]# :<I-_,,UR%K]US34R)0"@Z*>XT8P4W*M6#&"/SE3P(E&0!)XL<131$1;
ME)B)>8Y%I;O 'Q)>&:AP4V<8-F"%K$NC.Y8P4CFDGQCFM*N/+*? RA371BB<
M>QYX$00.3*T\7(#;#6/?CH-@B*/7'3JXO>$*NP542B3\R.P%#)Q>%. 813T_
MHK77&X9PAKGPP%SX:N92L1$I!D5CZ2<Y&DY/47=6WYNH2YC.3A@';&S$:B*+
M J>6W-%1Y%_+U<U.,\QPSS*UY^'EG5NAM('[FBF#6Q> X8]QB*-!LR#N8C>
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MAP'HMB^W"ZMJWPL7RE)G]9\EN8+:7:#S0BF[63B"[N<X_P502P,$%     @
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MN1(<LYT[@/=+I6Q_XP0,GZTN_@-02P,$%     @ ZH%94LR,F+Y<!0  1P\
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MR\7G2O"22@7'II:P8I?8CXSJP\C/K"6!'TW=]#Y+_B-MR7AGTOL1<;2?.,:
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MY>Z)^1[3BZ%BG"Y0% M:.@#IGFUNH$5KGTISH?'A9;L5'J]4F@7X?2'0U-7
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M][)NBX=BGK?JMJ)N. NYKIJBY5R&D 6AH_<1:H#'&DOO1[ICH0_7!J$@@F3
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M%&:#7D\X5[N!N9[<Y\CH+U!+ P04    " #J@5E2[A56_9D"  #_!@  &0
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M6L$52&F!2,;/&M-K*&WBYO@5_=K53K5,N($K);^)&69]+_'8#.9\*?%!K;]
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M:!M ^W.E\'5BNV9SYPW^ %!+ P04    " #J@5E2Y:XU2[ "  #4!@  &0
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M>F9.UH0:FJ5*KHFRUHAF%RXWSAO5,&&K.#4*;QGZF6RXHHS3&8=+[(C+*>5
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M$3*ZZF/BE)^A?F-DY<;03!H<:FZYQ,\.*&N ]W,IS69C [0?LNP_4$L#!!0
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MJS>5R&YZLH'B"WM9,N%*\<0^S@G69$V _C[E7&T&YOZEN&\;_@502P,$%
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MN7;_9%/:CM X*K21O )C!)R)\DFW51[V -WA$4!0 8)#P. (H%<!>H> _A%
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MO=FL/0"N04CW6Q$R+TE$@B?R+%DD::8.T"V37]"E+FV+!$"=2H5N:RA4U<'
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M\F%ET\W:@G=(ZLH1WV"A;^\(+Z1B<5Z:,TE7680BMOJ'NG=(Q&Y^7F*#<M^
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MW9T;;J"?ILH>@/U,2O,\L2U>W:'/?@%02P,$%     @ ZH%94E^DOQ*- @
M_04  !D   !X;"]W;W)K<VAE971S+W-H965T-C0N>&ULC53;;MLP#/T5P>A#
M"[2U8SM-6B0&FF27 .L0-.WV,.Q!L9E8J"RYDIQT?S]*=KRTN6 OMD3Q'!Y2
M(@<;J5YT#F#(6\&%'GJY,>6=[^LTAX+J:UF"P).E5 4UN%4K7Y<*:.9 !??#
M(+CQ"\J$EPR<;::2@:P,9P)FBNBJ**CZ,P(N-T.OXVT-CVR5&VOPDT%)5S '
M\US.%.[\EB5C!0C-I" *ED/OOG,W[EI_Y_"#P4;OK(G-9"'EB]U,LZ$76$'
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M68"Y/Y,27S=VZ+=_"D9_ 5!+ P04    " #J@5E2,LPPMGX"  !"!@  &0
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MI<$3T@TKO,- V0#\OI#2O$[L,=G=BOE?4$L#!!0    ( .J!65+]V@QLGP(
M !8'   9    >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;)V56T_;,!3'OXH5
M\0#21JY-"DHCE59H2$-#,+:':0].<MI8.'9FN[1\>VPG1(6D%=I+XLOYG_,[
MQ[=TR\63K  4VM64R9E3*=5<NJXL*JBQ/.<-,#VSXJ+&2G?%VI6- %Q:44W=
MP/-BM\:$.5EJQ^Y$EO*-HH3!G4!R4]=8O%P!Y=N9XSMO _=D72DSX&9I@]?P
M .JQN1.ZY_9>2E(#DX0S)& U<^;^Y2(Q]M;@%X&MW&LCDTG.^9/IW)0SQS-
M0*%0Q@/6OV=8 *7&D<;XU_ET^I!&N-]^\WYM<]>YY%C"@M/?I%35S)DZJ(05
MWE!US[??H,MG8OP5G$K[1=O.UG-0L9&*UYU8$]2$M7^\Z^JP)_"C X*@$P2?
M%82=(+2)MF0VK256.$L%WR)AK+4WT["UL6J=#6%F%1^4T+-$ZU3V0U4@T#5A
MF!4$4W3#VIUA2OP5M;/SHA ;*-%W@G-"B2(@T>D2%"94GFFKQX<E.CTY0R>(
M,'1+*-5BF;I*XYD@;M&A7+4HP0&4)13G*/2_H, +O!'YXM-R_^*]W-5%Z2L3
M])4)K+_P/RKS9YY+)?06_'LD4-@'"FV@Z$"@!:_UF92M9\Q*!'5#^0L RH'!
MBJC16K8^$^O3'-7G;!I'J?N\7["AS>3BHK=Y!QOUL-%1V!M6\!J0PCN]"1K\
M@G,*8WBME_A=Z.D'O*%-,$W&\28]WN0HWISJ:TDO&""]6$ABJBD%J(T8WY"3
M(>4>04LYM/'# Y1Q3QD?I6RW%NZ.%>S,\L,H8#PL43 @'#'R)OXX8M(C)D<1
M?W*%Z1A1,MA341C&'XB&1J&71!^(W+U;R[P8MUBL"9.(PDK+O/-$5UZTMW#;
M4;RQ%UG.E;X6;;/2#Q<(8Z#G5YRKMXZY&_NG,'L%4$L#!!0    ( .J!65*T
MBA(IBA$  'UL   9    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;+U=67/;
M.!+^*RSO[%:FRI$)WIQ-4N58.9R,+8\59XXWFH(E;BA2P\..I^;'+T 1!$A<
ME"W-2R++0*/1C?ZZT4##KQ[RXENY@K ROJ_3K'Q]M*JJS4\G)V6\@NNHG.0;
MF*'?W.7%.JK0C\7RI-P4,%HTG=;IB66:WLDZ2K*C-Z^:[ZZ*-Z_RNDJ3#%X5
M1EFOUU'Q^!:F^</K(W!$OKA.EJL*?W'RYM4F6L(YK&XV5P7ZZ:2CLDC6,"N3
M/#,*>/?ZZ!3\=#H%7M.E:?,U@0\E\]G D[G-\V_XA_/%ZR,3\P13&%>82(3^
MNX=G,$TQ+<3)GRW9HVY4W)']3*B_;Z:/IG,;E? L3W]-%M7J]5%P9"S@752G
MU77^\!&V4W(QO3A/R^9?XZ%M:QX9<5U6^;KMC#A8)]GV_^A[*PJF@P4D':RV
M@S7L$$@ZV&T'>]C!EW1PV@[.6);<MH,[MH/7=O#&=O#;#O[8#D';(1@[Z;#M
M$(X= 9A$<^:PBR?KTBE[M+8!43?@]"WM0A0..(U+&2,J!YS.9?("1.E@M-8!
M43O@]"X=A2@><)J7=B&J!YSNI=,GR@><]AV9%1+M6T/M VD7HGV+T[XMZ](9
M.Z=]Z2A$^Q:G?>DH1/L6IWV9Q"RB?8O3OI0QHGUKM-5;1/O6:.U;1/L6IWTI
M8T3[UE#[4E7:1/MVH_V3+=PWOF(:5=&;5T7^8!2X/:*'/S0.I^F/7$228>\X
MKPKTVP3UJ]X@GY)&MWD184]5&E&V,&;5"A;&:5%$V1(B1UB5QHLIK*(D+7\T
M_O.OP/:<_QHG1KF*"E@:26;<9$E5'G>_0M]<)&F*Z1TSK>AW/[ _OCJIT#0P
M,R=QR_+;+<N6A.73>CDQ+/?8L$S+O)E/C1<__"B@<C:""O![5#9%OBRBM8#8
M5$WL4YTB8G:/V';F EKOU+3>P]MN>D ^O?<:CJ)L8MA 1^7##E3>W5P;+UHE
MBVA]5-.:Q55'2Z&V\Q%JVU(!H4[2G]2TIC#N: 5RCCZ/ID)U7]6+1P&IG]6D
MYG"#2)DZ$5V,IM*)2$#E<G_3FHV7LU9G5WO1V2][Y.AZA+V:0<_2I+3F.PB]
M9V\RT7_9P>B&V"T@=S,&>EO0%'3_.@8FV^[1LH"->Q'0^74'N!TQJ]]TY!#*
M@5#/UN]J.A?1HV&%XYS 'SO W(@9GIZ.D)C>;$XUKK?Q!UM) 4\WQ5.-!^X1
M&S-'C1-FC=KI]S]!45$7&EE=:&0U]&Q]:'0/>_&0@KC=$;<;XHY,P?&?=5+
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M>CJXENR1(+Z5(.;]NTH0>T;>>I-W@+Q._QGY?HK0*0%/$L3!0@2(=2:9R N
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MP$V646I:A3.\W^ER"$"N/U;0^K:@]>U%$+T%K0^P]@<)6M9U/X*,<K#GL3X
MV9]$S_J 5/_R>K;#)+-O1_N,&M[O]*2 TOY8'>S;.MB>FOJ]JP,^\-T?I('%
MW!M4PW,P$>P#R/U)1+!OK'&ZO CN,%F&"G,.,.V/%<&^+8*E9/7TL#6PV>C4
M.4"\/_ Y/QV6()@,#H#)P20R. "R!I>7P1TFRU!AS@%U@[$R.+!EL"_J"1+8
M*MAL=.H<$#L8*(([" +W)('=DP*@:S")!@Z D<'E-7"'26[#8W]/&M[O]*0
MN<%8[1S8VED&=>D<V-*YY9X4 *R#0;K9[3'K-M8M"&S=0F"L-IU$.P< UN#R
MVKG#I-NA6"3P5H[5P+*IJ%O/#FEK8"E;YE426"T'J6 Q#WJ7=056UI4 9#F)
M#)8 57EY&=QAL@P3YAP 5XZ5L[*IK.O49TBRJ:S;5I61@&LY4-(.*NL*3-%*
MP*N<1-%*@*2\O*+M,-FU.%$"/.5812N;RKI.?<8CF\JZ3HMDD<;2_X&:MON1
MZ*%N)S ]RZBY.V 21<NHL;Z?7E[3=MDL8X7Z9RS]IV-E[<'"27F7L_KZIT.S
MTQTGK&7] J/&Y@$Z2-R*<AUKSTS!:GB,&GL$Z"3ZEE%CK3^]O,+MLEG&"O7/
MV 5 QXK5@X53H/"Z(#DT.R4*;Y$DC!K[".@@T<J[1 E,@UQTJP0U=@O0220K
MH\:B?WIYT=IED]O"9#\7.J-C;2N4@>/QN[4:MFLQX5L9UK!=JVTSSLE>+9R[
MG_.U.F37+OQ1+!]!S]R@\$0[L,PM6!T;IOH$UU[GJB-9?X[7U*PUN 9AN[9A
ME4O2BI365^[$6Q>8N06+3;+VE9G[JQA.UMLPBS*R?R< 26+R_; VJ8A&\TCA
M!FD7]LV]61T[J?!QN>QB0F9NRV+3@-;<7=6QO>J,<<$-EO%J<FYAO!M@J]*7
M\AT+&5D6&_CWKPDX?GM\D</[\NT%"VB^?PN$ECXO49R1C7K678N5AC.2[M^K
ML/^0)[OR30-/29XGV_+/M3Y!E18-]/^?$SUPU8?B ,?76]S\'U!+ P04
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M^JN!N\? *@VLK@9V:6!W;1(K#=BO!O8> Z<T<+K6X)8&;M<^3$N#:=<:O-+
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MU+Z]$<E&'5]>)$(DD;I<<U\*H2@@?[]-9)C+F^)$=/5?"T[^!U!+ P04
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M#E!V@UDOI,3WP':S]EN4O@%02P,$%     @ ZH%94G"C%JN/ @  )@<  !D
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M*WU>VV&B;U0@C('^O^1<[2;FT"[O:*._4$L#!!0    ( .J!65+4'JTHB (
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MP#<E,#H!#,&]AMI(L&0)22S^BPY_U 5PZP;P P? 4)>IKA7:U^H&.1$7)+X
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M$R*,@?Y^Q;G:WY@ ]7'T[%]02P,$%     @ ZH%94H"FM%-Z P  5PP  !D
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M3Z0Q@/<;(?1A81PT_R46_P%02P,$%     @ ZH%94K)^IE L P  & T  !D
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M%/TK%B]KI2XFD'1;19#29-/V,"EJM.UAVH.!FV#%V-2^A':_?K8A+-V:?O
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MTFX/PQX8F;:%2F(JTG&R7S_J(Z+%KSA9D9=$DL^]Y-6]]QR*/-ZQ\CO?4"K
M?9X5_&2P$>+VPVC$DPW-"7_/;FDA?UFQ,B="WI;K$;\M*5G61GDV0D$P&>4D
M+0;SX_K993D_9EN1I06]+ '?YCDI'\YHQG8G SAX?'"5KC>B>C":']^2-;VF
MXMOM92GO1IV799K3@J>L "5=G0Q.X8=S'%4&->+/E.[XWC6H0KEA['MU\WEY
M,@BJ&=&,)J)R0>2_.[J@659YDO/XT3H==&-6AOO7C]X_UL'+8&X(IPN6_94N
MQ>9D$ W DJ[(-A-7;/>)M@&-*W\)RWC]%^Q:;#  R98+EK?&<@9Y6C3_R7W[
M(O8,X,1A@%H#I!N$#@/<&N!##<+6(#S48-P:U*&/FMCK%Q<30>;')=N!LD)+
M;]5%_?9K:_F^TJ(JE&M1RE]3:2?FUX(EWS<L6]*2_P+.?VQ3\0"&8+$AQ9IR
MD!;@-$FV^38C@B[!'V)#2[!@N2S*354M=Q1\+A*64_ VIH*D&3^2UM^N8_#V
MS1%X4]E?I%DF2X(?CX2<;S7J*&GG=M;,#3GF!A&X8(78<'!>+.FR[V D ^VB
M18_1GB&OQY@F[P&&[P *4&"9T.)@<SBSF,>'FT<6\_/#S:>>EX&[U./:'W;X
MDXF3U,+KU#571U6^K!7Q]Q7+,B!;<T?*Y3^>P<-N\+ >/'0,?D;7:5&DQ5JV
M>4:*A-K*HW$QK5U4C'<W1V@REHF[V\^9!07'..RC8@LJ& >P0_6B&'=1C+U1
M-/V0]/HA;?LA8YP?V:)J7$[V9C*$X5@+R@1IB-A$H""RAS/IPIEXPY%M]D1&
M)L:@,$((:I,W49:\Q194+V^]$*9="%-O"+)$I3848+$M2UHD#^!K20HNV4M2
MT#OPNU1>M@)?R;VGA*-NJ.CU^V?6#3[S]T^3(T $^(T46ZGQP$,L,Z/XH[']
M/<- "4?P_SNX]=&K8ZQ5BP433AVSVY,UZ)U=E>EM(;.2I?]*X5K+)9.G)5MG
MO9Y$^C1-S$2K:)L;[.A)B%0HR!O*%4TRPGFZ2I.ZC#D0#!0ROH9IK/$@8R(Z
M:SX-B;V0?C!*<R#^^8S9^O2GQ\08Z;&X<:9'"1GT*]G3I-DZZ#6!3IDV#-;G
M;V*<C:(4#/HE[)MJDE]EDW! BB7X(C,A5W]R(7]Z)Q=UY":C0_E1,KPF&04Q
MO1'@FB;;,A4IY0>R*E0B!">OSZM0"0CT*\CSF+5UUJNIV<R1%*4L,/H)W!J9
M8JQ7E0D9CI%C=DIZH%][GLFM,[-J#0DP,6-] >?WT_\<4"*&_"+V FY%IEP-
M0YV-;" M.;$%XUC\("5[R"][+Z)79,J67D@6B$%/%HR+GI 2/^07OZ?9%9DJ
M963#A!C),"'.3D%*[9!?[9X@UP7A&_ QDUX_T>7Z8"I%2IM0^/I4BI2V(+^V
M/(]*D>W#"+I:0LD)\G_4',2ER/P8P48/F!C7*AHIM4%^M7D>ER*+VL! 9U,+
M:HKT>C<Q$+KJ7>D6\NO62^C4(E&A\>HM((CT]9T%%;D(2(D=\HO=RQC5U"KY
MC1_J45E0ANQ90-"UP,!*][!?]YZF56Q3,*B7F@6E]TULP;CZ!BNAPWZA.W17
M\HN9HOZ(2HDP>GTNQ7N;=7XI>1Z7MLZF_89Q?.M@I2?X)^S:8?,S)=*WMVP8
M_?/3@H$35^$H3<)^37H>X6*+)DWTY84%!+%.N#80=+ 35N*&_>+V L+%IHP-
M(Z.O+2"(IGI,)FKFV%'%2A&Q7Q%?1+C8)HS&IJH%I>^J6B#.;56L=!'[=?$
MNHW,AIWH>S86D-Y9L0VC[]J,]LZ+<EJNZX,Z+M_YMA#-84KWM#L,/*V/P+3G
M9_!#W!SI*3?-">,%*=?5@C>C*^DR>#^5Y5\VAW;-C6"W]:G4#1."Y?7EAA+)
MHA5 _KYB3#S>5 -T1Z?S_P!02P,$%     @ ZH%94A?C8$NJ!   IA,  !D
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MCK&[J/RD(G\P<I?MW1^E,3+);K? (U 6@/^OI33'!SM >5XT_Q]02P,$%
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M1B0CH@5 O%\1PO>-PD%]JS3Z%U!+ P04    " #J@5E2=6A$(ZL"  !!!P
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M-R-=8]$V[':B^-JVL 57NB':8:7?.! &H/>7G*OMQ"3H7\WL+U!+ P04
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MQO**;TBB?UER$6.EEV+5EQM!<)0IQ:R/',?OQY@FO<DX>_<H)F.^58PFY%$
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MJ8#^?<FY.BQ2 ^7MXN1_4$L#!!0    ( .J!65*PEG_X7P@  !,N   :
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M>047<4:R*"8)F&6;S%!&V,%M1M;+6$ /P<&(<A(GQ2$X K<W(W#PTR'X"0Q
M\4@8+4"<@=LLYL4'\:5X7L1)(E8HC@=<,%QN.XAJYCYNF$,MS)VM6!\XPP\
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MJMX6H+=5O2U ;Z=Z.X#>3O5V +V=ZNT >KOJ80E ;Z=Z.X#>3O5V +V=ZNT
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .J!65+?'MR6@P8  /@9   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #J@5E2. )V/4$&  !?&0  &               @(''#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ZH%94C3]2,BS @  W@@
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M965T-RYX;6Q02P$"% ,4    " #J@5E2)RM@NY\(   :)P  &
M    @('<+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MZH%94MQ"%/,T*P  PH8  !@              ("!L34  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .J!65)=/DG>OPH  +H8   9
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M970Q-"YX;6Q02P$"% ,4    " #J@5E2CF3C&QX#  "?!@  &0
M    @(&FFP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M .J!65)BG9J2$P0  )P)   9              " @?N>  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ ZH%94H]181IH"   .A4  !D
M             ("!1:,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #J@5E2\(1Z^"X#  #S!@  &0              @('DJP  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .J!65)S,Y6[F2,
M %*&   9              " @4FO  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ ZH%94O/Q\YQM"P  >",  !D              ("!
M&=,  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #J@5E2
M"4V -K$$  #U"@  &0              @(&]W@  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .J!65(0/7-!>"$  (IJ   9
M      " @:7C  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ ZH%94O9>BG'@!P  ?A,  !D              ("!5 4! 'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #J@5E2#]Q(LQX1  "!,@
M&0              @(%K#0$ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( .J!65*6/'VX* 0  , *   9              " @< > 0!X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ZH%94IPZ'(Q$
M#   *R(  !D              ("!'R,! 'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #J@5E20!0^=H8%  "(#P  &0
M@(&:+P$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .J!
M65)2D9&.\"@  (V)   9              " @5<U 0!X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ ZH%94B_[<SFH @  PP4  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( .J!65)NMXG-"P0  -L(   9
M  " @=%X 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MZH%94L4#:+>? @  >04  !D              ("!$WT! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #J@5E20R/]\?0"  !#!@  &0
M            @('I?P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( .J!65(\IX*FP00  &L0   9              " @12# 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ZH%94CZ^PA(9 P
M30<  !D              ("!#(@! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " #J@5E2Y_Y,'R<%  !W#@  &0              @(%<
MBP$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .J!65(\
MVT.,X0,  #$*   9              " @;J0 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ ZH%94KK;S!S!!   #0P  !D
M     ("!TI0! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .J!65(F]FCVD ,  +T.   9              "
M@<VP 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ZH%9
M4A'U:)L*&   =L\  !D              ("!E+0! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " #J@5E2;MDX#M@"    "@  &0
M        @('5S $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( .J!65*6VD\9) ,  +\)   9              " @>3/ 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ZH%94O@XZD,6"P  (%@
M !D              ("!/],! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " #J@5E2KL9/D_(#  !=#@  &0              @(&,W@$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .J!65);:]/J
MS0(  -0(   9              " @;7B 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ ZH%94M!SK???!   IAH  !D
M ("!N>4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #J
M@5E2JE4:F,H"  !W"0  &0              @('/Z@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .J!65+IU=M;RP(  )H(   9
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M970U.2YX;6Q02P$"% ,4    " #J@5E2%4S>@UH#  #G#   &0
M    @('!_0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M .J!65+25XEG]@(  'T(   9              " @5(! @!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ ZH%94C:GYNRS!P  Q"4  !D
M             ("!?P0" 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " #J@5E29[\CM[ #  "M"P  &0              @(%I# ( >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( .J!65)?I+\2C0(
M /T%   9              " @5 0 @!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ ZH%94EU\=1FV @  ,0@  !D              ("!
M%!," 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #J@5E2
MQVYL.9 "  !:!P  &0              @($!%@( >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( .J!65)U#6E0+P,  )8)   9
M      " @<@8 @!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%
M  @ ZH%94L0.TSRH @  ( @  !D              ("!+AP" 'AL+W=O<FMS
M:&5E=',O<VAE970V."YX;6Q02P$"% ,4    " #J@5E2,LPPMGX"  !"!@
M&0              @($-'P( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+
M 0(4 Q0    ( .J!65+$RFPN=P,  $,+   9              " @<(A @!X
M;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ ZH%94JU-8O5X
M!0  IAT  !D              ("!<"4" 'AL+W=O<FMS:&5E=',O<VAE970W
M,2YX;6Q02P$"% ,4    " #J@5E2B^:IW(H"  !0!P  &0
M@($?*P( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( .J!
M65(;S@Y/D@(  "$'   9              " @> M @!X;"]W;W)K<VAE971S
M+W-H965T-S,N>&UL4$L! A0#%     @ ZH%94OW:#&R? @  %@<  !D
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M=#<X+GAM;%!+ 0(4 Q0    ( .J!65)PHQ:KCP(  "8'   9
M  " @6I9 @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @
MZH%94DO,*2P$ P  KPD  !D              ("!,%P" 'AL+W=O<FMS:&5E
M=',O<VAE970X,"YX;6Q02P$"% ,4    " #J@5E2U!ZM*(@"   2!@  &0
M            @(%K7P( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4
M Q0    ( .J!65*/V6D/M (  ,$'   9              " @2IB @!X;"]W
M;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ ZH%94GW2W4C^!
MFA8  !D              ("!%64" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX
M;6Q02P$"% ,4    " #J@5E2@*:T4WH#  !7#   &0              @(%*
M:@( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( .J!65*R
M?J90+ ,  !@-   9              " @?MM @!X;"]W;W)K<VAE971S+W-H
M965T.#4N>&UL4$L! A0#%     @ ZH%94J>KA<PI @  2 4  !D
M     ("!7G$" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .J!65+_%X5XCP,  #P.   9              "
M@<B( @!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ ZH%9
M4NBIQI'(!P  G"L  !D              ("!CHP" 'AL+W=O<FMS:&5E=',O
M<VAE970Y,BYX;6Q02P$"% ,4    " #J@5E2!K^W,7\"   &!@  &0
M        @(&-E ( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0
M   ( .J!65(I:.>*D00  &$2   9              " @4.7 @!X;"]W;W)K
M<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ ZH%94G5H1".K @  00<
M !D              ("!"YP" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q0
M2P$"% ,4    " #J@5E2I$E,%Z0#  !;#0  &0              @('MG@(
M>&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( .J!65(2B!S6
MDP0   82   9              " @<BB @!X;"]W;W)K<VAE971S+W-H965T
M.3<N>&UL4$L! A0#%     @ ZH%94KM-F""-!   V1   !D
M ("!DJ<" 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " #J
M@5E2'0.?SYT#  #R"P  &0              @(%6K ( >&PO=V]R:W-H965T
M<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( .J!65)HZ79$R 0  &D4   :
M          " @2JP @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4
M Q0    ( .J!65*PEG_X7P@  !,N   :              " @2JU @!X;"]W
M;W)K<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( .J!65*^()=Q]0(
M +4.   :              " @<&] @!X;"]W;W)K<VAE971S+W-H965T,3 R
M+GAM;%!+ 0(4 Q0    ( .J!65*9UZ9*AP(  $ /   -              "
M >[  @!X;"]S='EL97,N>&UL4$L! A0#%     @ ZH%94I>*NQS     $P(
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9>&UL4$L%!@    !N &X /!X  &O1 @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>862</ContextCount>
  <ElementCount>645</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>203</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Available-for-Sale Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecurities</Role>
      <ShortName>Available-for-Sale Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122105 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128106 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133107 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147110 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2151111 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2153112 - Disclosure - Debt and Credit Facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilities</Role>
      <ShortName>Debt and Credit Facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2158113 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2164114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2166115 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2172116 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2179117 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2183118 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2191119 - Disclosure - Selected Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Selected Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2306302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Revenues</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Available-for-Sale Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables</Role>
      <ShortName>Available-for-Sale Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AvailableforSaleDebtSecurities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Acquisitions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Inventories</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2342309 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OtherFinancialInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2354311 - Disclosure - Debt and Credit Facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesTables</Role>
      <ShortName>Debt and Credit Facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DebtandCreditFacilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2359312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2367313 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/StockholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2373314 - Disclosure - Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsTables</Role>
      <ShortName>Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/EmployeeBenefits</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2380315 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2384316 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2392317 - Disclosure - Selected Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Revenues - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails</Role>
      <ShortName>Revenues - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails</Role>
      <ShortName>Revenues - Summarized Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements - Summary of assets and liabilities recorded at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of assets and liabilities recorded at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Summary of Classification on Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Classification on Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Available-for-Sale Debt Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Available-for-Sale Debt Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Derivative Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Derivative Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Acquisitions - Supplemental Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails</Role>
      <ShortName>Acquisitions - Supplemental Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Inventories - Schedule of inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails</Role>
      <ShortName>Inventories - Schedule of inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Property, Plant and Equipment - Schedule of property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails</Role>
      <ShortName>Other Financial Information - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Debt and Credit Facilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails</Role>
      <ShortName>Debt and Credit Facilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails</Role>
      <ShortName>Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Leases - Balance Sheet Location Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails</Role>
      <ShortName>Leases - Balance Sheet Location Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2462436 - Disclosure - Leases - Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2463437 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Liabilities Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/CommitmentsandContingencies</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Repurchases of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2469440 - Disclosure - Stockholders' Equity - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityDividendsDetails</Role>
      <ShortName>Stockholders' Equity - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2470441 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2471442 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2474443 - Disclosure - Employee Benefits - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails</Role>
      <ShortName>Employee Benefits - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - Employee Benefits - Restricted Stock and Performance Share Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails</Role>
      <ShortName>Employee Benefits - Restricted Stock and Performance Share Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails</Role>
      <ShortName>Employee Benefits - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails</Role>
      <ShortName>Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - Employee Benefits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails</Role>
      <ShortName>Employee Benefits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2481448 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2482449 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2485450 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2486451 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2487452 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2488453 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2489454 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2490455 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2493456 - Disclosure - Selected Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="gild-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - gild-20201231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - gild-20201231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="gild-20201231.htm">gild-20201231.htm</File>
    <File>gild-20201231.xsd</File>
    <File>gild-20201231_cal.xml</File>
    <File>gild-20201231_def.xml</File>
    <File>gild-20201231_lab.xml</File>
    <File>gild-20201231_pre.xml</File>
    <File>gild2020form10-kexhibit211.htm</File>
    <File>gild2020form10-kexhibit231.htm</File>
    <File>gild2020form10-kexhibit311.htm</File>
    <File>gild2020form10-kexhibit312.htm</File>
    <File>gild2020form10-kexhibit32.htm</File>
    <File>gild20ormex102amendmentto2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gild-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20201231.htm": {
   "axisCustom": 7,
   "axisStandard": 38,
   "contextCount": 862,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 985,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 8,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 12
   },
   "keyCustom": 77,
   "keyStandard": 568,
   "memberCustom": 127,
   "memberStandard": 65,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.gilead.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105102 - Disclosure - Revenues",
     "role": "http://www.gilead.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2490455 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i9948876c76f3482dab23bee8b78d894e_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2493456 - Disclosure - Selected Quarterly Financial Information (Unaudited) (Details)",
     "role": "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails",
     "shortName": "Selected Quarterly Financial Information (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i9948876c76f3482dab23bee8b78d894e_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Fair Value Measurements",
     "role": "http://www.gilead.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Available-for-Sale Debt Securities",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecurities",
     "shortName": "Available-for-Sale Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122105 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128106 - Disclosure - Acquisitions",
     "role": "http://www.gilead.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133107 - Disclosure - Inventories",
     "role": "http://www.gilead.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147110 - Disclosure - Other Financial Information",
     "role": "http://www.gilead.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeandOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151111 - Disclosure - Collaborations and Other Arrangements",
     "role": "http://www.gilead.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeandOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.gilead.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153112 - Disclosure - Debt and Credit Facilities",
     "role": "http://www.gilead.com/role/DebtandCreditFacilities",
     "shortName": "Debt and Credit Facilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158113 - Disclosure - Leases",
     "role": "http://www.gilead.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.gilead.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166115 - Disclosure - Stockholders' Equity",
     "role": "http://www.gilead.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172116 - Disclosure - Employee Benefits",
     "role": "http://www.gilead.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179117 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2183118 - Disclosure - Income Taxes",
     "role": "http://www.gilead.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2191119 - Disclosure - Selected Quarterly Financial Information (Unaudited)",
     "role": "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited",
     "shortName": "Selected Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:PropertyPlantandEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306302 - Disclosure - Revenues (Tables)",
     "role": "http://www.gilead.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Available-for-Sale Debt Securities (Tables)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables",
     "shortName": "Available-for-Sale Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Acquisitions (Tables)",
     "role": "http://www.gilead.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Inventories (Tables)",
     "role": "http://www.gilead.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342309 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Other Financial Information (Tables)",
     "role": "http://www.gilead.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354311 - Disclosure - Debt and Credit Facilities (Tables)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesTables",
     "shortName": "Debt and Credit Facilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Income",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359312 - Disclosure - Leases (Tables)",
     "role": "http://www.gilead.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2367313 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.gilead.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2373314 - Disclosure - Employee Benefits (Tables)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsTables",
     "shortName": "Employee Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2380315 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders (Tables)",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2384316 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.gilead.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2392317 - Disclosure - Selected Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables",
     "shortName": "Selected Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Revenues - Disaggregation of Revenues (Details)",
     "role": "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails",
     "shortName": "Revenues - Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ia2ccc7e7e5524a3280968384eaa7914d_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ia3d5490822d34a2a99d663996669b4f1_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)",
     "role": "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails",
     "shortName": "Revenues - Summarized Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ia3d5490822d34a2a99d663996669b4f1_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.gilead.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements - Summary of assets and liabilities recorded at fair value (Details)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails",
     "shortName": "Fair Value Measurements - Summary of assets and liabilities recorded at fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i43d13c3320274c64bc19f9627e57686b_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "iaa2d477c63034d369b25d6854cf06afa_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Summary of Classification on Balance Sheet (Details)",
     "role": "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
     "shortName": "Fair Value Measurements - Summary of Classification on Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i16426d78ce7c4baeb60f73d40c7360a7_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i16426d78ce7c4baeb60f73d40c7360a7_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "iceb1445e2fcc4c789894cb276a5414d5_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
     "shortName": "Available-for-Sale Debt Securities - Summary of Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "iceb1445e2fcc4c789894cb276a5414d5_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Available-for-Sale Debt Securities - Additional Information (Details)",
     "role": "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails",
     "shortName": "Available-for-Sale Debt Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i1b8a5a32ea6b47e8b21a4dd3a000d1af_I20171231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails",
     "shortName": "Derivative Financial Instruments - Summary of Potential Effect of Offsetting Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Derivative Financial Instruments - Additional Information (Details)",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Derivative Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i83b1aa2032cd47dd86894b1acbc8ee7d_D20200901-20200930",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i8b27400d62ea401b8ae3613d26aae982_I20201023",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i8b27400d62ea401b8ae3613d26aae982_I20201023",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Acquisitions - Supplemental Pro Forma Information (Details)",
     "role": "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails",
     "shortName": "Acquisitions - Supplemental Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Inventories - Schedule of inventories (Details)",
     "role": "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails",
     "shortName": "Inventories - Schedule of inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "id847cdd6afbf44a989121a3eeea8d6d1_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://www.gilead.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Property, Plant and Equipment - Schedule of property, plant and equipment (Details)",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails",
     "shortName": "Property, Plant and Equipment - Schedule of property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "iaa2d477c63034d369b25d6854cf06afa_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i40c1c1d6b1f94e42b99fd95c41911a89_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i9948876c76f3482dab23bee8b78d894e_D20201001-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)",
     "role": "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails",
     "shortName": "Other Financial Information - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)",
     "role": "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Collaborations and Other Arrangements (Details)",
     "role": "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i52b270d003824c77b29b5398d6d3083c_I20210208",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails",
     "shortName": "Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Debt and Credit Facilities - Narrative (Details)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
     "shortName": "Debt and Credit Facilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
     "shortName": "Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.gilead.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Leases - Balance Sheet Location Detail (Details)",
     "role": "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails",
     "shortName": "Leases - Balance Sheet Location Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462436 - Disclosure - Leases - Supplemental Information Related to Leases (Details)",
     "role": "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463437 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)",
     "role": "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails",
     "shortName": "Leases - Summary of Operating Lease Liabilities Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNumberOfPlaintiffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plaintiff",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails",
     "shortName": "Stockholders' Equity - Repurchases of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i9948876c76f3482dab23bee8b78d894e_D20201001-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469440 - Disclosure - Stockholders' Equity - Dividends (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
     "shortName": "Stockholders' Equity - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i9948876c76f3482dab23bee8b78d894e_D20201001-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470441 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "iaa2d477c63034d369b25d6854cf06afa_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471442 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i80decbd404fa4810a481f263b6dbbc28_I20171231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i60943a7163f448b5a6c2157080ad7985_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474443 - Disclosure - Employee Benefits - Stock Options (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails",
     "shortName": "Employee Benefits - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i60943a7163f448b5a6c2157080ad7985_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i131142515dae41e291f717d69305bc41_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - Employee Benefits - Restricted Stock and Performance Share Awards (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
     "shortName": "Employee Benefits - Restricted Stock and Performance Share Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "id36aff6aa5b1435e90046831abfad68c_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
     "shortName": "Employee Benefits - Summary of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
     "shortName": "Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - Employee Benefits - Narrative (Details)",
     "role": "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
     "shortName": "Employee Benefits - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481448 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i9948876c76f3482dab23bee8b78d894e_D20201001-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482449 - Disclosure - Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Net Income Per Share Attributable to Gilead Common Shareholders - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485450 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486451 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487452 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488453 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "ie4a66ea3e27c41739673ae6a3e75680b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "iaa2d477c63034d369b25d6854cf06afa_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2489454 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)",
     "role": "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails",
     "shortName": "Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i539368d6dc914976bc65d538c3d266ba_D20200101-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20201231.htm",
      "contextRef": "i481ded537ec44be2aa528514e17583c9_I20200101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - gild-20201231.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - gild-20201231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 203,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A015LIBORSeniorUnsecuredNotesDueSeptember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.15% LIBOR Senior Unsecured Notes Due September 2021",
        "label": "0.15% LIBOR Senior Unsecured Notes Due September 2021 [Member]",
        "terseLabel": "0.15% LIBOR Senior Unsecured Notes Due September 2021"
       }
      }
     },
     "localname": "A015LIBORSeniorUnsecuredNotesDueSeptember2021Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A052LIBORSeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.52% LIBOR Senior Unsecured Notes Due September 2023",
        "label": "0.52% LIBOR Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.52% LIBOR Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A052LIBORSeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueInSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023",
        "label": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due in September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueInSeptember2023Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "0.75% Senior Unsecured Notes Due September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueSeptember2023Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2016StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Repurchase Program [Member]",
        "label": "2016 Stock Repurchase Program [Member]",
        "terseLabel": "2016 stock repurchase program"
       }
      }
     },
     "localname": "A2016StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2020StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Repurchase Program [Member]",
        "label": "2020 Stock Repurchase Program [Member]",
        "terseLabel": "2020 stock repurchase program"
       }
      }
     },
     "localname": "A2020StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedResearchAndDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Milestone Payments",
        "label": "Accrued Research and Development Milestone Payments",
        "terseLabel": "Accrued research and development milestone payments"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentMilestonePayments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_Accruedgovernmentandotherrebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued government and other rebates",
        "label": "Accrued government and other rebates",
        "terseLabel": "Accrued government and other rebates"
       }
      }
     },
     "localname": "Accruedgovernmentandotherrebates",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Intangible Assets, Discount Rate",
        "label": "Acquired Finite-lived Intangible Assets, Discount Rate",
        "terseLabel": "Discount rate of finite-lived intangible asset acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_ActivePharmaceuticalIngredientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Active Pharmaceutical Ingredient [Member]",
        "label": "Active Pharmaceutical Ingredient [Member]",
        "terseLabel": "Active pharmaceutical ingredient"
       }
      }
     },
     "localname": "ActivePharmaceuticalIngredientMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months",
        "label": "Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months",
        "terseLabel": "Additional payment for adjustments of budgeted development costs in 2021"
       }
      }
     },
     "localname": "AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of Budgeted Development Costs, Payments, Due Year Two",
        "label": "Adjustments of Budgeted Development Costs, Payments, Due Year Two",
        "terseLabel": "Payment for adjustments of budgeted development costs in 2022"
       }
      }
     },
     "localname": "AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AgreementWithJapanTobaccoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with Japan Tobacco, Inc. [Member]",
        "label": "Agreement with Japan Tobacco, Inc. [Member]",
        "terseLabel": "Japan tobacco"
       }
      }
     },
     "localname": "AgreementWithJapanTobaccoIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement",
        "label": "Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement [Member]",
        "terseLabel": "Tango collaboration and stock purchase agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedArcusCommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Arcus Common Stock Purchase Agreement",
        "label": "Amended Arcus Common Stock Purchase Agreement [Member]",
        "terseLabel": "Amended arcus common stock purchase agreement"
       }
      }
     },
     "localname": "AmendedArcusCommonStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Filgotinib License and Collaboration Agreement in 2019",
        "label": "Amended Filgotinib License and Collaboration Agreement in 2019 [Member]",
        "terseLabel": "2019 agreement"
       }
      }
     },
     "localname": "AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Filgotinib License and Collaboration Agreement in December 2020",
        "label": "Amended Filgotinib License and Collaboration Agreement in December 2020 [Member]",
        "terseLabel": "Amended 2019 agreement"
       }
      }
     },
     "localname": "AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc., Pionyr Immunotherapeutics, Inc., Tango Therapeutics, Inc. and Tizona Therapeutics, Inc.",
        "label": "Arcus Biosciences, Inc., Pionyr Immunotherapeutics, Inc., Tango and Tizona [Member]",
        "terseLabel": "Arcus, Pionyr, Tango and Tizona"
       }
      }
     },
     "localname": "ArcusBiosciencesIncPionyrImmunotherapeuticsIncTangoAndTizonaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement and Stock Purchase Agreements",
        "label": "Arcus Collaboration Agreement and Stock Purchase Agreements [Member]",
        "terseLabel": "Arcus collaboration agreement and stock purchase agreements"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementAndStockPurchaseAgreementsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement",
        "label": "Arcus Collaboration Agreement [Member]",
        "terseLabel": "Arcus collaboration agreement"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Stock Purchase Agreement",
        "label": "Arcus Stock Purchase Agreement [Member]",
        "terseLabel": "Arcus stock purchase agreement"
       }
      }
     },
     "localname": "ArcusStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_AssetAcquisitionCashOutflowNetOfCashAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Cash Outflow Net Of Cash Acquired",
        "label": "Asset Acquisition Cash Outflow Net Of Cash Acquired",
        "terseLabel": "Total consideration, net of acquired cash"
       }
      }
     },
     "localname": "AssetAcquisitionCashOutflowNetOfCashAcquired",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Net of Cash",
        "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Net of Cash",
        "terseLabel": "Assets acquired"
       }
      }
     },
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsNetOfCash",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
        "label": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
        "label": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
        "terseLabel": "After five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AxicabtageneciloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "axicabtagene ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset - axicabtagene ciloleucel (DLBCL)"
       }
      }
     },
     "localname": "AxicabtageneciloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_BristolMyersSquibbCollaborativeArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers-Squibb Collaborative Arrangement [Member]",
        "label": "Bristol-Myers-Squibb Collaborative Arrangement [Member]",
        "terseLabel": "BMS collaborative arrangement"
       }
      }
     },
     "localname": "BristolMyersSquibbCollaborativeArrangementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Future Royalties, Liability, Measurement Input",
        "label": "Business Combination, Future Royalties, Liability, Measurement Input",
        "terseLabel": "Liability related to future royalties, measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "negatedTerseLabel": "Liability related to future royalties",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "terseLabel": "Other assets (and liabilities), net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_COVID19ProductsTrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Products, Trodelvy",
        "label": "COVID-19 Products, Trodelvy [Member]",
        "terseLabel": "Trodelvy"
       }
      }
     },
     "localname": "COVID19ProductsTrodelvyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_COVID19ProductsVekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Products, Veklury",
        "label": "COVID-19 Products, Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "COVID19ProductsVekluryMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CallTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Call Therapy Products, Tecartus",
        "label": "Call Therapy Products, Tecartus [Member]",
        "terseLabel": "Call Therapy Products, Tecartus"
       }
      }
     },
     "localname": "CallTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CashPaymentsMadeRelatedToEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payments Made Related to Equity Investments",
        "label": "Cash Payments Made Related to Equity Investments",
        "terseLabel": "Cash payments made related to equity investments"
       }
      }
     },
     "localname": "CashPaymentsMadeRelatedToEquityInvestments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total Cell Therapy product sales"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ChangeinestimatevariableconsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in estimate variable consideration [Member]",
        "label": "Change in estimate variable consideration [Member]",
        "terseLabel": "Change in estimate variable consideration"
       }
      }
     },
     "localname": "ChangeinestimatevariableconsiderationMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaborative Arrangement, Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeandOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Abstract]",
        "label": "Collaborative and Other Arrangements [Abstract]",
        "terseLabel": "Collaborative and Other Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsAbstract",
     "nsuri": "http://www.gilead.com/20201231",
     "xbrltype": "stringItemType"
    },
    "gild_CollaborativeandOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Text Block]",
        "label": "Collaborative and Other Arrangements [Text Block]",
        "terseLabel": "Collaborations and other arrangements"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsTextBlock",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]",
        "terseLabel": "Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]"
       }
      }
     },
     "localname": "ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Contract with Customer, Performance Obligation Satisfied in Previous Period [Axis]",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period [Domain]",
        "terseLabel": "Contract with Customer, Performance Obligation Satisfied in Previous Period [Domain]"
       }
      }
     },
     "localname": "ContractwithCustomerPerformanceObligationSatisfiedinPreviousPeriodDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "2020 revolving credit facility"
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueMay2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due May 2021 [Member]",
        "label": "Credit Facility Due May 2021 [Member]",
        "terseLabel": "2016 revolving credit facility"
       }
      }
     },
     "localname": "CreditFacilityDueMay2021Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DebtInstrumentCallFeaturePeriodBeforeMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Call Feature, Period Before Maturity",
        "label": "Debt Instrument, Call Feature, Period Before Maturity",
        "terseLabel": "Call feature, period prior to maturity"
       }
      }
     },
     "localname": "DebtInstrumentCallFeaturePeriodBeforeMaturity",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredIncomeTaxExpenseBenefitComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Expense (Benefit) Component [Axis]",
        "label": "Deferred Income Tax Expense (Benefit) Component [Axis]",
        "terseLabel": "Deferred Income Tax Expense (Benefit) Component [Axis]"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitComponentAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_DeferredIncomeTaxExpenseBenefitComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Deferred Income Tax Expense (Benefit) Component [Axis]",
        "label": "Deferred Income Tax Expense (Benefit) Component [Domain]",
        "terseLabel": "Deferred Income Tax Expense (Benefit) Component [Domain]"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitComponentDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredTaxAssetsUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Upfront and Milestone Payments",
        "label": "Deferred Tax Assets, Upfront and Milestone Payments",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "DeferredTaxAssetsUpfrontAndMilestonePayments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Agreement",
        "label": "Development Agreement [Member]",
        "terseLabel": "Development agreement"
       }
      }
     },
     "localname": "DevelopmentAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EPSImpactbyTransactionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EPS Impact by Transaction [Axis]",
        "label": "EPS Impact by Transaction [Axis]",
        "terseLabel": "EPS Impact by Transaction [Axis]"
       }
      }
     },
     "localname": "EPSImpactbyTransactionAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_EPSImpactbyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for EPS Impact by Transaction [Axis]",
        "label": "EPS Impact by Transaction [Domain]",
        "terseLabel": "EPS Impact by Transaction [Domain]"
       }
      }
     },
     "localname": "EPSImpactbyTransactionDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate impacts related to US tax on foreign earnings",
        "label": "EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings",
        "terseLabel": "US tax on foreign earnings"
       }
      }
     },
     "localname": "EffectiveTaxRateImpactsRelatedToUStaxOnForeignEarnings",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_EquityMethodInvestmentOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Option Exercise Fee",
        "label": "Equity Method Investment, Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionExerciseFee",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Option Fee And Potential Future Milestone Payments",
        "label": "Equity Method Investment, Option Fee And Potential Future Milestone Payments",
        "terseLabel": "Option fee and potential future milestone payments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries",
        "label": "Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries",
        "terseLabel": "Additional option fee on fourth, sixth, and eighth anniversaries"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Additional Option Fee on Second Anniversary",
        "label": "Equity Securities, FV-NI, Additional Option Fee on Second Anniversary",
        "terseLabel": "Additional option fee on second anniversary"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Future Maximum Milestone Payments",
        "label": "Equity Securities, FV-NI, Future Maximum Milestone Payments",
        "terseLabel": "Future milestone payments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIFutureMaximumMilestonePayments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "label": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "terseLabel": "Maximum percentage of outstanding stock allowed to be purchased"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments",
        "label": "Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments",
        "terseLabel": "Opt-in, extension and milestone payments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Purchase Period",
        "label": "Equity Securities, FV-NI, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIPurchasePeriod",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restriction Period",
        "label": "Equity Securities, FV-NI, Restriction Period",
        "terseLabel": "Restriction period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictionPeriod",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquityinvestmentinGalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investment in Galapagos [Member]",
        "label": "Equity investment in Galapagos [Member]",
        "terseLabel": "Equity investment in Galapagos"
       }
      }
     },
     "localname": "EquityinvestmentinGalapagosMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueatGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value at Grant Date",
        "label": "Fair Value at Grant Date [Member]",
        "terseLabel": "Fair value at grant date"
       }
      }
     },
     "localname": "FairValueatGrantDateMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueatVestingDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value at Vesting Date [Member]",
        "label": "Fair Value at Vesting Date [Member]",
        "terseLabel": "Fair value at vesting date"
       }
      }
     },
     "localname": "FairValueatVestingDateMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurements summary of classification on the balance sheet [Abstract]",
        "label": "Fair value measurements summary of classification on the balance sheet [Abstract]",
        "terseLabel": "Fair value measurements summary of classification on the balance sheet [Abstract]"
       }
      }
     },
     "localname": "FairvaluemeasurementssummaryofclassificationonthebalancesheetAbstract",
     "nsuri": "http://www.gilead.com/20201231",
     "xbrltype": "stringItemType"
    },
    "gild_FavorableEPSImpactMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Favorable EPS Impact [Member]",
        "label": "Favorable EPS Impact [Member]",
        "terseLabel": "Favorable EPS Impact"
       }
      }
     },
     "localname": "FavorableEPSImpactMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Filgotinib License and Collaboration Agreement with Galapagos [Member]",
        "label": "Filgotinib License and Collaboration Agreement with Galapagos [Member]",
        "terseLabel": "Filgotinib agreement"
       }
      }
     },
     "localname": "FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FinitelivedintangibleassetimpairmentbyprogramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite- lived intangible asset impairment by program [Axis]",
        "label": "Finite- lived intangible asset impairment by program [Axis]",
        "terseLabel": "Finite- lived intangible asset impairment by program [Axis]"
       }
      }
     },
     "localname": "FinitelivedintangibleassetimpairmentbyprogramAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_FinitelivedintangibleassetimpairmentbyprogramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Finite- lived intangible asset impairment by program [Axis]",
        "label": "Finite- lived intangible asset impairment by program [Domain]",
        "terseLabel": "Finite- lived intangible asset impairment by program [Domain]"
       }
      }
     },
     "localname": "FinitelivedintangibleassetimpairmentbyprogramDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Rate Senior Unsecured Note Issued September 2020",
        "label": "Fixed Rate Senior Unsecured Note Issued September 2020 [Member]",
        "terseLabel": "the \"2020 Fixed Rate Notes\""
       }
      }
     },
     "localname": "FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FortySevenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forty Seven, Inc. [Member]",
        "label": "Forty Seven, Inc. [Member]",
        "terseLabel": "Forty Seven, Inc."
       }
      }
     },
     "localname": "FortySevenIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GadetaBVCollaborationArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gadeta B.V. Collaboration Arrangement",
        "label": "Gadeta B.V. Collaboration Arrangement [Member]",
        "terseLabel": "Gadeta collaboration arrangement"
       }
      }
     },
     "localname": "GadetaBVCollaborationArrangementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos Collaboration Agreement",
        "label": "Galapagos Collaboration Agreement [Member]",
        "terseLabel": "Galapagos collaboration agreement"
       }
      }
     },
     "localname": "GalapagosCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos, a clinical-stage biotechnology company based in Belgium",
        "label": "Galapagos [Member]",
        "terseLabel": "Galapagos"
       }
      }
     },
     "localname": "GalapagosMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos Subscription Agreement",
        "label": "Galapagos Subscription Agreement [Member]",
        "terseLabel": "Galapagos subscription agreement"
       }
      }
     },
     "localname": "GalapagosSubscriptionAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadSciencesInc2004EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc. 2004 Equity Incentive Plan",
        "label": "Gilead Sciences, Inc. 2004 Equity Incentive Plan [Member]",
        "terseLabel": "2004 Plan"
       }
      }
     },
     "localname": "GileadSciencesInc2004EquityIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadSciencesInc2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc. 2018 Equity Incentive Plan",
        "label": "Gilead Sciences, Inc. 2018 Equity Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "GileadSciencesInc2018EquityIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV product sales"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV product sales"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsAtriplaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Atripla [Member]",
        "label": "HIV Products, Atripla [Member]",
        "terseLabel": "HIV Products, Atripla"
       }
      }
     },
     "localname": "HIVProductsAtriplaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "HIV Products, Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "HIV Products, Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "HIV Products, Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "HIV Products, Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "HIV Products, Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "HIV Products, Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "HIV Products, Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IdenixPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idenix Pharmaceuticals, Inc. (\u201cIdenix\u201d)",
        "label": "Idenix Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Indenix"
       }
      }
     },
     "localname": "IdenixPharmaceuticalsIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics Amended and Restated 2014 Long-Term Incentive Plan",
        "label": "Immunomedics Amended and Restated 2014 Long-Term Incentive Plan [Member]",
        "terseLabel": "Immunomedics Plan"
       }
      }
     },
     "localname": "ImmunomedicsAmendedAndRestated2014LongTermIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics, Inc."
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-lived Intangible Assets Acquired, Discount Rate",
        "label": "Indefinite-lived Intangible Assets Acquired, Discount Rate",
        "terseLabel": "Discount rate of acquired IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsAcquiredDiscountRate",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial consideration for acquisition of rights to market and distribute certain products in Japan",
        "label": "Initial Consideration for Acquisition of Rights to Market and Distribute Certain Products in Japan",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset - sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IntangibleAssetTransferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset Transfer [Member]",
        "label": "Intangible Asset Transfer [Member]",
        "terseLabel": "Intangible Asset Transfer"
       }
      }
     },
     "localname": "IntangibleAssetTransferMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryWritedownAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Write-down [Abstract]",
        "label": "Inventory Write-down [Abstract]",
        "terseLabel": "Inventory Write-down [Abstract]"
       }
      }
     },
     "localname": "InventoryWritedownAbstract",
     "nsuri": "http://www.gilead.com/20201231",
     "xbrltype": "stringItemType"
    },
    "gild_InventoryWritedownsforExcessRawMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Write-downs for Excess Raw Materials [Member]",
        "label": "Inventory Write-downs for Excess Raw Materials [Member]",
        "terseLabel": "Inventory Write-downs for Excess Raw Materials"
       }
      }
     },
     "localname": "InventoryWritedownsforExcessRawMaterialsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_Inventoryreserveforexcessrawmaterials": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory reserve for excess raw materials",
        "label": "Inventory reserve for excess raw materials",
        "terseLabel": "Write-downs for slow moving and excess raw material and work in process inventory"
       }
      }
     },
     "localname": "Inventoryreserveforexcessrawmaterials",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InvestmentOwnedBalanceAdditionalPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Owned, Balance, Additional Payable",
        "label": "Investment Owned, Balance, Additional Payable",
        "terseLabel": "Additional payable"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceAdditionalPayable",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InvestmentOwnedBalanceAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Owned, Balance, Additional Shares",
        "label": "Investment Owned, Balance, Additional Shares",
        "terseLabel": "Additional shares acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceAdditionalShares",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_IssuanceDiscountPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Discount (Premium)",
        "label": "Issuance Discount (Premium)",
        "terseLabel": "Issuance discount (premium)"
       }
      }
     },
     "localname": "IssuanceDiscountPremium",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_Issuancediscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance discount",
        "label": "Issuance discount",
        "terseLabel": "Issuance discount"
       }
      }
     },
     "localname": "Issuancediscount",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_JanssenPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration with Janssen Pharmaceuticals",
        "label": "Janssen Pharmaceuticals [Member]",
        "terseLabel": "Janssen pharmaceuticals"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_JounceTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jounce Therapeutics, Inc.",
        "label": "Jounce Therapeutics, Inc. [Member]",
        "terseLabel": "Jounce"
       }
      }
     },
     "localname": "JounceTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_JudgmentEnhancedDamagesonPastSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Enhanced Damages on Past Sales",
        "label": "Judgment: Enhanced Damages on Past Sales",
        "terseLabel": "Enhancement rate on past damages"
       }
      }
     },
     "localname": "JudgmentEnhancedDamagesonPastSales",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateFromOctober2017": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate from October 2017",
        "label": "Judgment: Royalty Rate from October 2017",
        "terseLabel": "Running royalty rate from October 2017"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateFromOctober2017",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate on Future Sales",
        "label": "Judgment: Royalty Rate on Future Sales",
        "terseLabel": "Running royalty rate on future sales"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateOnFutureSales",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, \u201cJuno\u201d)",
        "label": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]",
        "terseLabel": "Juno"
       }
      }
     },
     "localname": "JunoTherapeuticsIncAndSloanKetteringCancerCenterMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_Kite585ProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite-585 Program [Member]",
        "label": "Kite 585 Program [Member]",
        "terseLabel": "Kite 585 Program"
       }
      }
     },
     "localname": "Kite585ProgramMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Registration Rights and Stock Purchase Agreement",
        "label": "License, Registration Rights and Stock Purchase Agreement [Member]",
        "terseLabel": "Jounce license and stock purchase agreement"
       }
      }
     },
     "localname": "LicenseRegistrationRightsAndStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Possible Loss (Royalties and Post-Judgment Interest)",
        "label": "Loss Contingency, Estimate of Possible Loss (Royalties and Post-Judgment Interest)",
        "terseLabel": "Estimate of possible loss representing royalties and prejudgment interest"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLossRoyaltiesAndPostJudgmentInterest",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)",
        "label": "Loss Contingency, Estimate of Possible Loss (50% Enhancement of Past Damages)",
        "terseLabel": "Estimate of possible loss representing enhancement of past damages"
       }
      }
     },
     "localname": "LossContingencyEstimateofPossibleLoss50EnhancementofPastDamages",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LossContingencyEstimateofPossibleLossPastSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Possible Loss (Past Sales)",
        "label": "Loss Contingency, Estimate of Possible Loss (Past Sales)",
        "terseLabel": "Estimate of possible loss representing past sales"
       }
      }
     },
     "localname": "LossContingencyEstimateofPossibleLossPastSales",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_LossContingencyMotionInvalidatedForPastDamagesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Motion Invalidated For Past Damages, Value",
        "label": "Loss Contingency, Motion Invalidated For Past Damages, Value",
        "terseLabel": "Past damages vacated"
       }
      }
     },
     "localname": "LossContingencyMotionInvalidatedForPastDamagesValue",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH (\u201cMYR\u201d), a German biotechnology company",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "label": "Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "terseLabel": "Maximum ownership percentage"
       }
      }
     },
     "localname": "MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "label": "Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "terseLabel": "Minimum ownership percentage"
       }
      }
     },
     "localname": "MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Agreements",
        "label": "Number of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Programs",
        "label": "Number of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_NumberOfStudies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Studies",
        "label": "Number of Studies",
        "terseLabel": "Number of studies"
       }
      }
     },
     "localname": "NumberOfStudies",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_OtherCollaborationArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaboration Arrangements [Member]",
        "label": "Other Collaboration Arrangements [Member]",
        "terseLabel": "Other collaboration arrangements"
       }
      }
     },
     "localname": "OtherCollaborationArrangementsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20201231",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHCVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other HCV",
        "label": "Other HCV [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHCVMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "Other Products, AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsRanexaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Ranexa [Member]",
        "label": "Other Products, Ranexa [Member]",
        "terseLabel": "Ranexa"
       }
      }
     },
     "localname": "OtherProductsRanexaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total Other product sales"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Vemlidy [Member]",
        "label": "Other Products, Vemlidy [Member]",
        "terseLabel": "Other Products, Vemlidy"
       }
      }
     },
     "localname": "OtherProductsVemlidyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Viread [Member]",
        "label": "Other Products, Viread [Member]",
        "terseLabel": "Other Products, Viread"
       }
      }
     },
     "localname": "OtherProductsVireadMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Yescarta [Member]",
        "label": "Other Products, Yescarta [Member]",
        "terseLabel": "Cell Therapy Products, Yescarta"
       }
      }
     },
     "localname": "OtherProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsZydeligMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Zydelig [Member]",
        "label": "Other Products, Zydelig [Member]",
        "terseLabel": "Other Products, Zydelig"
       }
      }
     },
     "localname": "OtherProductsZydeligMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Adjustments of Budgeted Development Costs",
        "label": "Payment for Adjustments of Budgeted Development Costs",
        "terseLabel": "Payment for adjustments of budgeted development costs"
       }
      }
     },
     "localname": "PaymentForAdjustmentsOfBudgetedDevelopmentCosts",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "payment for license, option rights and equity investments upon closing of collaboration agreement",
        "label": "Payment for License, Option Rights and Equity Investments Upon Closing",
        "terseLabel": "Payment for license and option rights"
       }
      }
     },
     "localname": "PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsForDirectTransactionalExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Direct Transactional Expense",
        "label": "Payments for Direct Transactional Expense",
        "terseLabel": "Direct transactional costs"
       }
      }
     },
     "localname": "PaymentsForDirectTransactionalExpense",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsForResearchAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Research and Development Milestones",
        "label": "Payments for Research and Development Milestones",
        "terseLabel": "Cash payments made for research and development milestones"
       }
      }
     },
     "localname": "PaymentsForResearchAndDevelopmentMilestones",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToEquityAwardHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Equity Award Holders",
        "label": "Payments to Equity Award Holders [Member]",
        "terseLabel": "Payments to equity award holders"
       }
      }
     },
     "localname": "PaymentsToEquityAwardHoldersMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentstoOutstandingCommonStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Outstanding Common Stockholders",
        "label": "Payments to Outstanding Common Stockholders [Member]",
        "terseLabel": "Payments to outstanding common stockholders"
       }
      }
     },
     "localname": "PaymentstoOutstandingCommonStockholdersMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PionyrImmunotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Immunotherapeutics, Inc.",
        "label": "Pionyr Immunotherapeutics, Inc. [Member]",
        "terseLabel": "Pionyr"
       }
      }
     },
     "localname": "PionyrImmunotherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PionyrMergerAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Merger and Option Agreements",
        "label": "Pionyr Merger and Option Agreements [Member]",
        "terseLabel": "Pionyr merger and option agreements"
       }
      }
     },
     "localname": "PionyrMergerAndOptionAgreementsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum",
        "label": "Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum",
        "terseLabel": "Future potential clinical, regulatory and commercial milestone payments"
       }
      }
     },
     "localname": "PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Development and Regulatory Milestones",
        "label": "Potential Development and Regulatory Milestones",
        "terseLabel": "Potential development and regulatory milestone-based payments"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialFutureMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments, Maximum",
        "label": "Potential Future Milestone Payments, Maximum",
        "terseLabel": "Maximum potential future milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsMaximum",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialFutureSalesbasedMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Sales-based Milestone",
        "label": "Potential Future Sales-based Milestone",
        "terseLabel": "Potential future sales-based milestone payments"
       }
      }
     },
     "localname": "PotentialFutureSalesbasedMilestone",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialFutureTieredRoyaltyPaymentHighend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Tiered Royalty Payment High-end",
        "label": "Potential Future Tiered Royalty Payment High-end",
        "terseLabel": "Potential future tiered royalty payment high-end"
       }
      }
     },
     "localname": "PotentialFutureTieredRoyaltyPaymentHighend",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PotentialFutureTieredRoyaltyPaymentLowend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Tiered Royalty Payment Low-end",
        "label": "Potential Future Tiered Royalty Payment Low-end",
        "terseLabel": "Potential future tiered royalty payment low-end"
       }
      }
     },
     "localname": "PotentialFutureTieredRoyaltyPaymentLowend",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Milestone Payment Upon Marketing Approval GLPG-1690",
        "label": "Potential Milestone Payment Upon Marketing Approval GLPG-1690",
        "terseLabel": "Potential milestone payment upon marketing approval GLPG-1690"
       }
      }
     },
     "localname": "PotentialMilestonePaymentUponMarketingApprovalGLPG1690",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialOptionExerciseFeePerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Option Exercise Fee Per Program",
        "label": "Potential Option Exercise Fee Per Program",
        "terseLabel": "Potential option exercise fee"
       }
      }
     },
     "localname": "PotentialOptionExerciseFeePerProgram",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Payment for Adjustments of Budgeted Development Costs",
        "label": "Potential Payment for Adjustments of Budgeted Development Costs",
        "terseLabel": "Potential payment for adjustments of budgeted development costs"
       }
      }
     },
     "localname": "PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalties High-end, Percentage",
        "label": "Potential Sales Based Tiered Royalties High-end, Percentage",
        "terseLabel": "Payment of tiered royalties, high-end percentage"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltiesHighEndPercentage",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalty, Low-end, Percentage",
        "label": "Potential Sales Based Tiered Royalty, Low-end, Percentage",
        "terseLabel": "Payment of tiered royalties, low-end percentage"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltyLowEndPercentage",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PropertyPlantandEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Useful Lives [Table Text Block]",
        "label": "Property Plant and Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantandEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_PubliclyAnnouncedProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Publicly Announced Program(s)",
        "label": "Publicly Announced Program [Member]",
        "terseLabel": "Publicly announced program"
       }
      }
     },
     "localname": "PubliclyAnnouncedProgramMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price of Goods Less Specified Amount, Maximum Percentage",
        "label": "Purchase Price of Goods Less Specified Amount, Maximum Percentage",
        "terseLabel": "Purchase price of goods less specified amount, maximum percentage"
       }
      }
     },
     "localname": "PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_ResearchAndDevelopmentFutureMaximumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Future Maximum Payments",
        "label": "Research and Development Future Maximum Payments",
        "terseLabel": "Research and development future maximum payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentFutureMaximumPayments",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ResearchAndDevelopmentInProcessIncludingImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development in Process, Including Impairment",
        "label": "Research and Development in Process, Including Impairment",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessIncludingImpairment",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ResearchAndDevelopmentServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Service Agreement",
        "label": "Research And Development Service Agreement [Member]",
        "terseLabel": "Research and development service agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServiceAgreementMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RestrictedStockandPerformanceShareAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Performance Share Awards [Member]",
        "label": "Restricted Stock and Performance Share Awards [Member]",
        "terseLabel": "Restricted stock and performance share awards"
       }
      }
     },
     "localname": "RestrictedStockandPerformanceShareAwardsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognized related to royalties for licenses of our intellectual property [Member]",
        "label": "Revenue recognized related to royalties for licenses of our intellectual property [Member]",
        "terseLabel": "Revenue recognized related to royalties for licenses of our intellectual property"
       }
      }
     },
     "localname": "RevenuerecognizedrelatedtoroyaltiesforlicensesofourintellectualpropertyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]",
        "label": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]",
        "terseLabel": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Line Items]"
       }
      }
     },
     "localname": "RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsLineItems",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]",
        "label": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]",
        "terseLabel": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods [Table]"
       }
      }
     },
     "localname": "RevenuesRecognizedfromPerformanceObligationsSatisfiedinPriorPeriodsTable",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ScheduleofInventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Disclosure of information about inventory.",
        "label": "Schedule of Inventory [Line Items]",
        "terseLabel": "Schedule of Inventory [Line Items]"
       }
      }
     },
     "localname": "ScheduleofInventoryLineItems",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ScheduleofInventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory.",
        "label": "Schedule of Inventory [Table]",
        "terseLabel": "Schedule of Inventory [Table]"
       }
      }
     },
     "localname": "ScheduleofInventoryTable",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Schedule of Lease Assets and Liabilities and Other Information [Table]",
        "label": "Schedule of Lease Assets and Liabilities and Other Information [Table Text Block]",
        "terseLabel": "Balance sheet and other information related to operating leases"
       }
      }
     },
     "localname": "ScheduleofLeaseAssetsandLiabilitiesandOtherInformationTableTextBlock",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options and Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions to calculate the estimated fair value of awards"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsandEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_SelectedQuarterlyFinancialInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Selected Quarterly Financial Information [Table]",
        "label": "Selected Quarterly Financial Information [Line Items]",
        "terseLabel": "Selected Quarterly Financial Information [Line Items]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationLineItems",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SelectedQuarterlyFinancialInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selected Quarterly Financial Information [Table]",
        "label": "Selected Quarterly Financial Information [Table]",
        "terseLabel": "Selected Quarterly Financial Information [Table]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationTable",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SeniorUnsecuredNoteIssuedSeptember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Note Issued September 2014",
        "label": "Senior Unsecured Note Issued September 2014 [Member]",
        "terseLabel": "the \"2014 Senior Notes\""
       }
      }
     },
     "localname": "SeniorUnsecuredNoteIssuedSeptember2014Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNoteIssuedSeptember2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Note Issued September 2015 [Member]",
        "label": "Senior Unsecured Note Issued September 2015 [Member]",
        "terseLabel": "the \"2015 Senior Notes\""
       }
      }
     },
     "localname": "SeniorUnsecuredNoteIssuedSeptember2015Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNoteIssuedSeptember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Note Issued September 2020",
        "label": "Senior Unsecured Note Issued September 2020 [Member]",
        "terseLabel": "Senior Unsecured Note Issued September 2020"
       }
      }
     },
     "localname": "SeniorUnsecuredNoteIssuedSeptember2020Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueApril2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due April 2021 [Member]",
        "label": "Senior Unsecured Notes Due April 2021 Member",
        "terseLabel": "4.50% Senior Unsecured Notes Due in April 2021"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueApril2021Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due December 2021",
        "label": "Senior Unsecured Notes Due December 2021 [Member]",
        "terseLabel": "4.40% Senior Unsecured Notes Due In December 2021"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueDecember2021Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due December 2041 [Member]",
        "label": "Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due in December 2041"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueInFebruary2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due In February 2020",
        "label": "Senior Unsecured Notes Due In February 2020 [Member]",
        "terseLabel": "2.35% Senior Unsecured Notes Due In February 2020"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueInFebruary2020Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in April 2024 [Member]",
        "label": "Senior Unsecured Notes Due in April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due in April 2024"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinApril2024Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in April 2044 [Member]",
        "label": "Senior Unsecured Notes Due in April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due in April 2044"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinApril2044Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in February 2025 [Member]",
        "label": "Senior Unsecured Notes Due in February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due in February 2025"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinFebruary2025Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in February 2045 [Member]",
        "label": "Senior Unsecured Notes Due in February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due in February 2045"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinFebruary2045Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2022 [Member]",
        "label": "Senior Unsecured Notes Due in March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due in March 2022"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2022Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2026",
        "label": "Senior Unsecured Notes Due in March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due in March 2026"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2026Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2027 [Member]",
        "label": "Senior Unsecured Notes Due in March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due in March 2027"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2027Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2046",
        "label": "Senior Unsecured Notes Due in March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due in March 2046"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2046Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2047 [Member]",
        "label": "Senior Unsecured Notes Due in March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due in March 2047"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2047Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2020",
        "label": "Senior Unsecured Notes Due in September 2020 [Member]",
        "terseLabel": "2.55% Senior Unsecured Notes Due in September 2020"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2020Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2022",
        "label": "Senior Unsecured Notes Due in September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due in September 2022"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2022Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "Senior Unsecured Notes Due in September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due in September 2023"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2023Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2035",
        "label": "Senior Unsecured Notes Due in September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due in September 2035"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2035Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2036",
        "label": "Senior Unsecured Notes Due in September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due in September 2036"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2036Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant-Date Fair Value Per Share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_StandstillRestrictingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standstill Restricting Term",
        "label": "Standstill Restricting Term",
        "terseLabel": "Standstill restricting term"
       }
      }
     },
     "localname": "StandstillRestrictingTerm",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_StockRepurchasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Repurchases [Abstract]",
        "label": "Stock Repurchases [Abstract]",
        "terseLabel": "Stock Repurchases [Abstract]"
       }
      }
     },
     "localname": "StockRepurchasesAbstract",
     "nsuri": "http://www.gilead.com/20201231",
     "xbrltype": "stringItemType"
    },
    "gild_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_TangoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tango Therapeutics, Inc.",
        "label": "Tango Therapeutics, Inc. [Member]",
        "terseLabel": "Tango"
       }
      }
     },
     "localname": "TangoTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Year Senior Unsecured Term Loan Facility",
        "label": "Three Year Senior Unsecured Term Loan Facility [Member]",
        "terseLabel": "Three year senior unsecured term loan facility"
       }
      }
     },
     "localname": "ThreeYearSeniorUnsecuredTermLoanFacilityMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TizonaMergerAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tizona Merger and Option Agreements",
        "label": "Tizona Merger and Option Agreements [Member]",
        "terseLabel": "Tizona merger and option agreements"
       }
      }
     },
     "localname": "TizonaMergerAndOptionAgreementsMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TizonaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tizona Therapeutics, Inc.",
        "label": "Tizona Therapeutics, Inc. [Member]",
        "terseLabel": "Tizona"
       }
      }
     },
     "localname": "TizonaTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalFairValueAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Fair Value",
        "label": "Total Fair Value [Axis]",
        "terseLabel": "Total Fair Value [Axis]"
       }
      }
     },
     "localname": "TotalFairValueAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_TotalGrantDateFairValueDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Total Grant Date Fair Value [Axis]",
        "label": "Total Grant Date Fair Value [Domain]",
        "terseLabel": "Total Grant Date Fair Value [Domain]"
       }
      }
     },
     "localname": "TotalGrantDateFairValueDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TotalUpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Upfront Payments Made",
        "label": "Total Upfront Payments Made",
        "terseLabel": "Total upfront payments made"
       }
      }
     },
     "localname": "TotalUpfrontPaymentsMade",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyForMTNBCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy for mTNBC [Member]",
        "label": "Trodelvy for mTNBC [Member]",
        "terseLabel": "Intangible asset - Trodelvy for mTNBC"
       }
      }
     },
     "localname": "TrodelvyForMTNBCMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_UnrealizedGainComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain Component [Axis]",
        "label": "Unrealized Gain Component [Axis]",
        "terseLabel": "Unrealized Gain Component [Axis]"
       }
      }
     },
     "localname": "UnrealizedGainComponentAxis",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_UnrealizedGainComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Unrealized Gain Component [Axis]",
        "label": "Unrealized Gain Component [Domain]",
        "terseLabel": "Unrealized Gain Component [Domain]"
       }
      }
     },
     "localname": "UnrealizedGainComponentDomain",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant",
        "label": "Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant",
        "terseLabel": "Upfront collaboration expenses"
       }
      }
     },
     "localname": "UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_VariableTermLoanNoteDueOctober2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Term Loan Note Due October 2023",
        "label": "Variable Term Loan Note Due October 2023 [Member]",
        "terseLabel": "Variable Term Loan Note Due October 2023"
       }
      }
     },
     "localname": "VariableTermLoanNoteDueOctober2023Member",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ViiVHealthcareCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Company (\u201cViiV\u201d)",
        "label": "ViiV Healthcare Company [Member]",
        "terseLabel": "ViiV"
       }
      }
     },
     "localname": "ViiVHealthcareCompanyMember",
     "nsuri": "http://www.gilead.com/20201231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r192",
      "r315",
      "r320",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r189",
      "r315",
      "r318",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r191",
      "r315",
      "r319",
      "r568",
      "r578",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r193",
      "r194",
      "r316"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r20",
      "r531",
      "r557"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r22",
      "r531",
      "r557"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r276"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r81",
      "r88",
      "r91",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r88",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r85",
      "r88",
      "r91",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r80",
      "r88",
      "r91",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of finite-lived intangible asset acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other financial information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r132",
      "r266"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r326",
      "r328",
      "r363",
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r328",
      "r358",
      "r362"
     ],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense included in total costs and expenses",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Stock-based compensation expense, net of tax"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r34",
      "r195",
      "r225"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Write-offs charged against allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r132",
      "r256",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r185",
      "r529",
      "r556"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r68"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date.",
        "label": "Assets, Total [Member]",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r200",
      "r232"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r204",
      "r207",
      "r545"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r204",
      "r206",
      "r544"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r197",
      "r201",
      "r232"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale debt securities",
        "totalLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity securities categorized neither as held-to-maturity nor trading which are intended be sold more than one year from the balance sheet date or operating cycle, if longer.",
        "label": "Available-for-sale Securities, Equity Securities, Noncurrent",
        "terseLabel": "Collaboration and stock purchase agreement"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesEquitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r330",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r452",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r9",
      "r275"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements (including leasehold improvements)"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Supplemental pro forma information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income (loss) attributable to Gilead"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r417",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory",
        "terseLabel": "Fair value step-up adjustment of inventories acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r377",
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r138",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Unamortized capitalized software costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r43",
      "r134"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r135",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r127",
      "r134",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r127",
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r283",
      "r538",
      "r563"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r282",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r290",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Contingent Consideration Resulting from a Business Combination"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Capital shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend Per Share",
        "verboseLabel": "Dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending period (in shares)",
        "periodStartLabel": "Beginning period (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 authorized; 1,254 and 1,266 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r94",
      "r96",
      "r97"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Gilead"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r94",
      "r96",
      "r435",
      "r436",
      "r444"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r94",
      "r96",
      "r434",
      "r444"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Office, computer equipment and other"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r491",
      "r492",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r491",
      "r492",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r171",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r175",
      "r176",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r310",
      "r312",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r310",
      "r311",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized from performance obligations satisfied in prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r323",
      "r325",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect from the adoption of new accounting standards"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r403",
      "r410"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal - current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r406"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign - current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r403",
      "r410"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State - current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and credit facilities"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r20",
      "r21",
      "r530",
      "r533",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r21",
      "r293",
      "r533",
      "r554"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Short-term and long-term debt",
        "totalLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r501",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r143",
      "r301",
      "r304",
      "r305",
      "r306",
      "r500",
      "r501",
      "r503",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r213",
      "r237",
      "r240"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r213",
      "r237"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Greater, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r213",
      "r237",
      "r240"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r213",
      "r237"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less than 12 Months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of the Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r209",
      "r233",
      "r240"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r210",
      "r234"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r211",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Securities in unrealized loss positions, number of positions (securities)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r322",
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Matching contribution expense"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r405",
      "r410"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal - deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r405",
      "r410"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign - deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r393",
      "r532",
      "r553"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r405",
      "r410"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State - deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r372",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Excess of tax basis over book basis of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r394"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r370",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r372",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r399",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and other credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r370",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r371",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves and accruals not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "auth_ref": [
      "r370",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r378",
      "r397"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r372",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Excess of book basis over tax basis of intangible assets",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r372",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r372",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r132",
      "r274"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Fair value of asset derivatives"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r70",
      "r78",
      "r455"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "negatedTerseLabel": "Gross Amounts Offset on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r74",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r72",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.",
        "label": "Derivative Asset, Not Offset, Policy Election Deduction",
        "negatedTerseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r71",
      "r75",
      "r488"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Abstract]",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r73",
      "r76",
      "r466"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative, Collateral, Obligation to Return Cash",
        "negatedTerseLabel": "Cash Collateral Received/Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r73",
      "r76",
      "r466"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative, Collateral, Right to Reclaim Cash",
        "terseLabel": "Cash Collateral Received/ Pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r69",
      "r77",
      "r455",
      "r525"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r69",
      "r77",
      "r455",
      "r525"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "negatedTerseLabel": "Gross Amounts of Recognized Assets/Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Estimate of time to transfer"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r71",
      "r75",
      "r488"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedTotalLabel": "Amounts of Assets/Liabilities Presented on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r70",
      "r78",
      "r455"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Fair Value, Gross Asset",
        "terseLabel": "Gross Amounts Offset on the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "negatedTerseLabel": "Fair value of liability derivatives"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r74",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "negatedTotalLabel": "Net Amount (Legal Offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r72",
      "r76"
     ],
     "calculation": {
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.",
        "label": "Derivative Liability, Not Offset, Policy Election Deduction",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofPotentialEffectofOffsettingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r447",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Outstanding notional amounts on foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturity on derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r148",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r457",
      "r461",
      "r464",
      "r467",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r149",
      "r446",
      "r448",
      "r450",
      "r451",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r307",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Abstract]",
        "terseLabel": "Dividends [Abstract]"
       }
      }
     },
     "localname": "DividendsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of dividends declared"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic tax authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r103",
      "r154",
      "r157",
      "r159",
      "r160",
      "r161",
      "r164",
      "r540",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share attributable to Gilead common stockholders - basic (usd per share)",
        "verboseLabel": "Net income per share attributable to Gilead common stockholders - basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r103",
      "r154",
      "r157",
      "r159",
      "r160",
      "r161",
      "r164",
      "r540",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share attributable to Gilead common stockholders - diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net income per share attributable to GIlead common stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r146",
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "negatedTerseLabel": "Non-taxable unrealized gain / loss on investment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings at different rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Acquired IPR&amp;D and related charges"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Deferred tax - intra-entity transfer of intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Research and other credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r380",
      "r381",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Settlement of tax examinations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock option",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r44",
      "r186",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity investments balancce"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Unrealized gain on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Unrealized loss on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r15",
      "r19",
      "r217",
      "r537",
      "r555",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Other equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r473",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r473",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r474",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r473",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r473",
      "r474",
      "r477",
      "r478",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r474",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r474",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r474",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r480",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r138",
      "r484",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r452",
      "r457",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r145",
      "r379"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Federal income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r236",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r257",
      "r261",
      "r265",
      "r269",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r265",
      "r527"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r257",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign currency exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r494",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation, Transaction Gains and Losses, and Hedging Contracts"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r323",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Foreign income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "verboseLabel": "Gain (loss) on discontinuance of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at December 31, 2020",
        "periodStartLabel": "Balance at December 31, 2019",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill resulting from the acquisition of Immunomedics"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r253",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r250",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit on product sales"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r450",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r132",
      "r270"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "In-process research and development impairment",
        "verboseLabel": "Impairment charge related to IPR&amp;D intangible asset"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r273",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r184",
      "r411"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense (benefit)",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r138",
      "r375",
      "r376",
      "r391",
      "r392",
      "r398",
      "r412",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r129",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net (gains) losses from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r158",
      "r163"
     ],
     "calculation": {
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived assets - IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r255",
      "r263"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r100",
      "r183",
      "r499",
      "r502",
      "r542"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest paid or due on all long-term debt.",
        "label": "Interest Expense, Long-term Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r124",
      "r128",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid, net of amounts capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r64",
      "r242"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r65",
      "r138",
      "r166",
      "r243",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r37",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r36",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesScheduleofinventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Shares of common stock acquired"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Marketable and Nonmarketable Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Limited partnerships and other equity method investments"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r528",
      "r547",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r8",
      "r46"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land and land improvements"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease expense under ASC 840"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Supplemental information related to operating leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating lease aggregate future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r535",
      "r561"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Outlicense contract"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r21",
      "r533",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amounts outstanding under the facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR rate"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r294",
      "r533",
      "r558"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Contractual Maturities of Financing Obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Long-term debt, current maturities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r151",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r151",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r151",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r151",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r151",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r151",
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r56",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r283",
      "r284",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r283",
      "r284",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Value of damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r285",
      "r287",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r9",
      "r275"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r52"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of classification of other equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instruments with maturities ranging from five to ten years.",
        "label": "Medium-term Notes [Member]",
        "terseLabel": "Medium-term notes"
       }
      }
     },
     "localname": "MediumTermNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r63",
      "r534",
      "r560"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Change in noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r127",
      "r130",
      "r133"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r92",
      "r95",
      "r102",
      "r133",
      "r163",
      "r539",
      "r564"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r95",
      "r438",
      "r443"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestInVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).",
        "label": "Noncontrolling Interest in Variable Interest Entity",
        "terseLabel": "Noncontrolling interest in variable interest entity"
       }
      }
     },
     "localname": "NoncontrollingInterestInVariableInterestEntity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Net book value of long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense under ASC 842"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases, Summary of Aggregate Future Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total discounted lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, current [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating lease, noncurrent [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r509",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r515",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r514",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationDetailDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income Taxes - Narrative (Details)"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Income Taxes Narrative [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r152",
      "r180",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r53"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r82",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r88",
      "r99"
     ],
     "calculation": {
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r81",
      "r86",
      "r454",
      "r458",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassification to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r86",
      "r89",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain (loss) reclassified from AOCI into product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r79",
      "r496"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r93",
      "r96",
      "r99",
      "r300"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income, net of tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r86",
      "r89",
      "r90",
      "r216"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r82",
      "r86"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net unrealized gain, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other\u00a0accrued\u00a0liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Impairment loss recognized"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r114",
      "r117",
      "r150"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r115",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash payments made for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire equity method investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Payments to acquire in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireManagementContractRights": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from amounts paid for the rights to manage the property.",
        "label": "Payments to Acquire Management Contract Rights",
        "terseLabel": "Payments to acquire management contract rights"
       }
      }
     },
     "localname": "PaymentsToAcquireManagementContractRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r330",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r41",
      "r42"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofClassificationonBalanceSheetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt financing, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowing under the senior unsecured term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r111",
      "r112",
      "r198"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r120",
      "r123",
      "r150"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r113",
      "r198"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r92",
      "r95",
      "r126",
      "r185",
      "r188",
      "r434",
      "r437",
      "r439",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r275"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r277",
      "r562"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Office, computer equipment and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofpropertyplantandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r138",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesNarrativeDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected quarterly financial information (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r88",
      "r91",
      "r99"
     ],
     "calculation": {
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Repayments of unsecured debt"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r138",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r307",
      "r559"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Product revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r139",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r101",
      "r181",
      "r182",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r513",
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of accumulated OCI by component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "verboseLabel": "Available-for-Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities at Estimated Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r205",
      "r208",
      "r212",
      "r213",
      "r214",
      "r215",
      "r543",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/AcquisitionsSupplementalProFormaInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r56",
      "r143",
      "r301",
      "r304",
      "r305",
      "r306",
      "r500",
      "r501",
      "r503",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of financing arrangements"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r453",
      "r461",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of effect of foreign currency exchange contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of classification and fair value of derivative instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r148",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r457",
      "r461",
      "r464",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Summary of potential effect of offsetting derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of earnings per share, basic and diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of difference between provision for income taxes and federal statutory income tax rate to income before provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r328",
      "r357",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r328",
      "r357",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based compensation expenses -included in consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r257",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r257",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of income (loss) before income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r38",
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of contractual maturities of financing obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Quarterly financial information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summarized fair values of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Summarized revenues from major customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r330",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r336",
      "r347",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Activity under stock option plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r59",
      "r142",
      "r296",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock Repurchases"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r140",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of stock repurchases"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investments in an unrealized loss position for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), including: (a) the aggregate related fair value of investments with unrealized losses, (b) the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Temporary Impairment Losses, Investments [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt in an Unrealized Loss Position"
       }
      }
     },
     "localname": "ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r390",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unrecognized tax benefits roll forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated Future Amortization Expense of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Selected Quarterly Financial Information [Abstract]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r108",
      "r241"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Accelerated stock-based expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at December 31, 2020",
        "periodStartLabel": "Outstanding at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at December 31, 2019",
        "periodStartLabel": "Outstanding at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of vested stock awards as of vesting date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at December 31, 2020, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r338",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at December 31, 2020",
        "periodStartLabel": "Outstanding at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at December 31, 2020",
        "periodStartLabel": "Outstanding at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Expected to vest, net of estimated forfeitures at December 31, 2020, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Expected to vest, net of estimated forfeitures at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Expected to vest, net of estimated forfeitures at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockandPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "RSU and PSU activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r352",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years:"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at December 31, 2020, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected to vest, net of estimated forfeitures at December 31, 2020, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at December 31, 2020, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected to vest, net of estimated forfeitures at December 31, 2020, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r145",
      "r404",
      "r409"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "State and local income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r61",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan",
        "verboseLabel": "Value of stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r307",
      "r329",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "verboseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of common stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r26",
      "r27",
      "r300",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r196"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r432",
      "r433",
      "r442"
     ],
     "calculation": {
      "http://www.gilead.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets",
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance",
        "terseLabel": "Balance at January 1, 2018"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "auth_ref": [
      "r369",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "verboseLabel": "Income tax expense following U.S. Court of Appeals decision"
       }
      }
     },
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price per share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SelectedQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r323",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies securities",
        "verboseLabel": "U.S. government agencies securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r323",
      "r325",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/AvailableforSaleDebtSecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofassetsandliabilitiesrecordedatfairvalueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r374",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Total gross unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedTerseLabel": "Tax Positions Related to Current Year: Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Tax Positions Related to Prior Years: Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and income tax penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Tax Positions Related to Current Year: Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Tax Positions Related to Prior Years: Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Unrecorded Unconditional Purchase Obligation, Due within Five Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Unrecorded Unconditional Purchase Obligation, Due within Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Unrecorded Unconditional Purchase Obligation, Due within Two Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Unrecorded Unconditional Purchase Obligation, Due within Three Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r169",
      "r170",
      "r172",
      "r173",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies, Estimates and Judgments"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r156",
      "r161"
     ],
     "calculation": {
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in per share calculation - diluted (in shares)",
        "totalLabel": "Shares used in per share calculation - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r155",
      "r161"
     ],
     "calculation": {
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in per share calculation - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.gilead.com/role/ConsolidatedStatementsofIncome",
      "http://www.gilead.com/role/NetIncomePerShareAttributabletoGileadCommonShareholdersScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118950378&loc=SL82887624-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130611-203046-203046"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28511-109314"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14.Column B)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r586": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r587": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r588": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r589": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r591": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r592": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0000882095-21-000008-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-21-000008-xbrl.zip
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M:L^5<C.RT6CJ;-VQ2.W<*VF"7+)+UAUDSR)QG'H9="[FEJ!@*2096D1+R>V
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MZ-)JTXHMK\"VS*XQ5LR>3FF,@!1 $*4"EUI*"M*HTB!8UW+)BG%D'@I58PL
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M2%'[0">,5'2U*MW-6!4=:QL_LF:U,5,:/K5&D4MC:YA%><1NP+VA%+\==I-
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M?QQH*7.TM\DW[1R%=$1UO<M3KR.HQC!4\S1F=VKE&N/R ^RU.JJY9ESVV-L
M2B-@KHWJ*'GT- VF&2.L(+F[;D<U4[[78H_%M+724+@)&,806NS2D/M2\KU[
M1S7C-&_W2)DHCDDAU]Y5!A=-16.OB/O=EUO,EWDJGX/U(>J2F+O+8^)$W+1B
M#]"9UI #7KFCFF<F8QUB4A,&+CCM<1"$W*W$W%N-(2V?-;ODJ.9I49]::]6J
MY9Q0()%3B8#01"I'[,L/RG^#HUID+*QCX&#K5KEA*]4!<_QR('<9S;W&\I%;
M]W:UX)$H $CI#*C3ML;68XQJ Z\F:R\?OQWJHHP)1*OVYJ<6=031EAO7Z)"&
M.L9N)*:6&:GUGL@DU!;\PO-(+9BE%IC'U7BXL'SD5K[G"KH4D-I'(0RHZH%W
M!QW%?2.EW4W6+!+,D$2M:HG58U_)P"S1D6M9RTBRAC#X/9C1>;80%(\^+0'Q
M8.S^(TFO+-![\!#C55.412.W[HU#/4>"S)C:$$0 E9P 80H/DX7%E/QNG1E]
M7V ^/=F\1/+DZ?3%WV!S;'+^],P^>74,O_GZ *^?>7U_.L*OIPB@9^1 R;TI
M2A+F7HJ;YE(**[[4MEL>J+S>P_7YZ4FS*:DS8?_UYOSQ9Y>?V4E[>"QGC]_>
M[755<?FU/;.3IW;;KF53XJ$\.CW[_.GYQ>FQG9W_A)2?^OW-^>G3LV;^M@=V
M\OGIV9,_^HG_XE>^>_GD9WO;7G^K7[QXC;&:N@@L5C#VD'!H4 "/Q ,68^M@
M2YC?N^?S5O)YIDXOO=. G'4,P*EAMM1@HU(+*5JV):PU[OF\G7R>9RUT&EW7
MN\M/\O_SE.,NK9@%<F%:> D] ;:;SY_+6=^X]/UODZ.+A[=.VBYP>1ZM81%:
M#5)CPX8IBO8()9F4E O'6/=:8\_EI>B,/G(+%(D "M8.DK)-?]4@L^8E%*'M
MN;Q]7)Y%8XR*UF6JS8Z*HI4M->%BG6T:SDU[C?$'N7S8'MOY^>G.2.69]A!0
M%>FQ) T%TQC4M> H$C)1;F4)BY=[&F\3C6=:@P=H!I(#UXQ5BE)'"2.JP%2Z
MO(3%ASV-MXK&LXB*(JGD%"MW4M1@$D(K5ETT"PRF)8B*ESKTU;[7'S87#U\#
M^#<[&Z=GQ^(PWM&CS8,K(+_Q?\_]@URU_NW,GFU.GY[_[>IT_70O[4N&GUD[
M?7"R>6']S([\_/:+T[.K7;8;._<#^]?QKV#GI^/TZ=G&S^G1D;6+IW+T9%IP
M/;NX7*/W'MH(2^HU!<0R4*=!$+W&(!&*-EV ]]Y1OLRT.T8]T"8=KO, 7>!I
MX3;MNC ,8*$OH4W#]?/E\X=R\L V)W9^L3GV$_M,SC:BSH93_\AN+SW.*JU'
M TS<JA(2I@@Z0JP#HT0NFG$)@T!6R8:9:E9;;U&85:E@-2'C,KF3T$5[L/K/
M6]MJ$EY+Q2]D<_:='#VUS]QX7VU-F0[PQ9G]SU,7T)=OZ\HW+_[)2UU,MZ=G
M[@T>7)?$_<E7^O3\W"X^/Y+S\[>_R+??W#V[^@J7WTR?OIG\TSOX^#<W_]O/
ML9RUAY=?N9\\^E].RJV3)T\OSJ]>$:^?[)L3I[2_]I?6[/4S_XDU*\JNF)W$
M&?W/T,B-)<2>60? V/-W)@*E[;Z8MH6_I@6X2NV=!(TS2P^4*941ZDC1]OS=
M&LJ\U\L'%L)?5XV*F(N&W#&P,W@T#R]:%DAU[/7#'R703S[G,SG?_(S%-U_)
MU3OCS5O>W+BQ.6]'I].;M_NRVA8F%YKFL09SHRO86A#E)*1@55L"*!.3MS,<
M6@:3EVJ)WZD2_GDD]P?XZV)7(:0\6#)F V61DC1.0;UFWO-WKX2WFK]N=$/O
M0<D2(V&0P*7V7%+./=1,>_YN#676HX2OD;\U]B8:ATSLK188@+N;WH A19 ]
M?_=*>#E,YI1*&P3-F4Q<,\<\1JA$AJGL8[IW0YG/[6SZQ9O3^/S.N&%/3L]?
M'W$[3/%2DL)@G% I"V7&IDHMU]&I<ZC#S&A/X!TE\+^3XMM"8(2!/1)E:$YD
MS,0I%.Z6:H%8]P3>60(O)2W,G$;HM;"&@(,S(4J@J U*K&GLES463N#W(,:W
MA<HY:FJQ]Q##P%(#-[ DU9I:DV%Q']<MF\K;J8:O,9S+T+MERUQ'PT:-!\/5
MY)T$06ST/8%WE,#O5 U?(X&3U:O^BE![0ZZ1,X\:(E3M"%;WF;5=)?!24L.C
M, 77"@'(,.?*+=346M$X(I6XEQ +)_"VJ^%KI'* "!8]<JO8L1>6D2R., Q1
MK13<!W;O:CGAR]-G=G8R?8%/'_@7W=CY#=.+[5RS6TJB.%E2CA:R&V/$:#+-
M3^G22H@XN.]WKVVK--VJ2VM;V*PQ%QZ";*7BU%D^ML0)>\]:XLC[=;MMU:E[
M-O\*FSWD [?*53STPPBDEKC2-& Z6&TY[]F\]:)US^M?X358AE1"KUH+IMPX
M%QDMA/^?O7=MCNO(L47_"J-/G'O.1 P]^4"^W',[0M:KU6-*;HFVK_2E T@@
MI;+)*G6Q*%O^]1=9)/6R;-'6)FOO8CDLB63M>G"OE< "$@E$+T5L=KM@<*0$
MVAX%/61R.9?:5&-8%QV45'* 9E.LD%I*JJIW;-XIZ.E4OL5"UJ?LO<T5?/8E
M-4.A)N=,R':WU[=3T%-B,SMOBDG*9I.!HA!'GRI4XBPN-+-C\TY!3Y'72:B7
MP[4<V0$9GUW"(H5S*TG%]:XZ[HH(=&^QE-GS^5L6W5#Y/.2ATXI(E6H#KJ &
M.L?*49@CNB*Y[:A\$^3SYZVKL5 Y512/CC)RAEY?A"T;KIA- )1=)X ;H9VW
M@\H94DTI64^F JF(#BZJQJ"4*7"INTWNFR6<MX/4UK@&H9C*(8&K-I?"$H/'
M:*++$G;1X!C9LSVJ><  D&J"7-D;\="'WB,U-%A;QJR\!MA1>:>:)T+E:J@)
M00L!+017*:)GH$!6JG&!=E3>J>:)4!E[.W*;52X[!+)0T$,KEBI&L$KR'95W
MJGERI+940K2&L[%V7;H?0TW>J8T&IIS\+A2\HM+]Q?+E8JE\OJ%J><BSV!4K
M-M1@CQPD'[-OQ8O2V27?4MJ=Q;ZY%)Y*/XP0JJ#K300T\A/R)3CKF%(*E3P$
MW%'XQE)X*ATQ5 F[F$G60S;$&^(6F")QR2DSU1V%IT[AL9\"'++K=PK6(R)1
M:"HC'#G5&.RS ;1!#?4NU)LZF<>IB@<,[$1B9")3?+/@@S(L42Z2Q'#E$G>%
MRS>7PE/IBR%.4I;:RX4"1 LE%*IDDFU)(SZN.PK?6 I/I3-&:4ZXY]@")S#-
MJ3UVR=K,7 FX^1V%IT[AL:OB(3= BHGLG 7G#+B"U!C9BLDV& W_IG5B]4/F
MG ]9/3E[&SPZ6"Q7S_&YW)KS^M*OL/XH?%U4&LOZ&J=,'K*G0$DJ+RI C09B
MMKT:+A<76U5:.S.M N4=IZ>KFP?=$ &L$#RFF,#&FL4V$.,(#'M_=@)[Q^D=
MIZ>47@:TTAPFWPI"1B@Y4D"JTKLDJK[><7KK.#UV93VD"DFEB3'5QNR@#W*(
MT9"DWI-9PT8WK8+/';NGJZR'[&H+H;(!3H$BJ XAKPQWC)'(5<AMQ^D=IZ>6
MD>Z-NH1:B@8]4,XE)U.86I^!1@ZGE9'><7JZRGK(#D>8;>N)O688 K<<0G(,
M#GQ-Y/VT]KIWG-X&93UD?7.E4E+R@"GV,>Y$1M6'$CP3HTF[LJ2!-V#6"^[N
MOT_U#L[FK^1DU3_!;'X?C_ E/E^,:A-Q*CEJ'QIEH!3=^A]$"]XF7T U2"%G
M=QP>J6P=P8(:"X<=>BFUL(DI@R\F@^DGJ5I(S63TT\I)CY##4[;#4\E!9\ (
M6"U!+1!3S#Y0R"XV#,V9.JV]PA%R>"(' +?$(C?'L=3<R(J%K/0E%]BZY(I!
MAXB3BOM&R.8I6^2IY)@%&GNP*-8S!$]JF2,Z* &R0T[3RC&/D,,[97P-'3+
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M^_%4W/F#?S@9AR7GC((FJI?&5K.:3G0V4PPQ!'HS&._"49NM==3_6)S.JVR
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MD NVK1LB*>S'LU5_YLF[%7]U-7LE[T=K#^;/>[Y$KN(,QM7,UDV12E%5;HQ
MMD"M6A?9V)J,H2KG=0M^O @]40#DL;P\7=87NG:_62Z>+_'XO>/)^AL\62WJ
MC[^ZZJIW]?U .U*0"UNT2658/[:%R8:6T1ETJ,;^HH/1Q$%RYOI!ZN'30" Y
M+HC5JW3N[10;4;423>O'2RRB21,J1_TD6M^<DK[$T>M;\_GB5*427QE4FZ\+
M1<C>)%.R@@H!;";?E14[:(T#F@F=@!TIKILY$5LH@G&2 V $5RM*)5;\FKI$
MB6 GD$P>.ZX;22RC;Y8554B9H8::N6;)L49*EIC<!W;X.KSFE=JY]_S79]6_
MBZ7H'?GFU<I%8M.*2345SB7&#^W<"._;'[,C@]VWYJI'ZW(.! 82U51SYB#1
M52*D<[[!-99I_ F^P;47"'",E2P@Y=Z+(!728%% ?R;&!-5-YWR#"[Z-[[YU
M$EWROO5+![IO&C9+\ZG5Z#R$WLV;J&$,,=40G"_G?$O7V.#E3_ M77LG$RP^
MMN0=AYQ _Z-J-(PJIJ7*K31[SK=TP;?QW;=.HDO>MW[I0/>M%,@YQ9KZ+*#L
M&,EY$LFD_C47.#]N;,TUQC5_G&_67'O<D!,6"K&HOFQ0JR^&JZY0T2 16TCN
M?(/;7&/<\,?Y=MG[-J N)VMZ[LGH38N0T%$NH=A*Q4$ME.2\4XU3TWOQQ6AU
M^>CZMCCU6)=9!A]<^CG+P' /K%09-8VDK>E_-1<]1?5;U9W-ITRCCJY6^JOW
MY]S]]ZE^KKX'L)B_S05?7':KUM/CTR.]E@^7.#\Y6F\GW.(?3D_6J>,KS36F
MX:8=,*C"4..>H $U+A&-:C.H&E>QKLQMQ.NAK+Z=+P6/9K\(/YB_DC/$[N-L
M_O7BY&KG( R'7%2M7)LQ&)M^50 CNUBAJ>1I2<XV6[80N0N4[BT7QW?D9/9\
MWA]XM/SGJ>+97J]W<T]>W#M:_/1WX>=7/-5B.#0MM):]=4A-5V*-6<$LT7CQ
M*467S)324V,UH)M/5J4@7"$4<*4"H\W.2>1*T3"$$&FK4;YVL[MYO*.IU(_F
M9EW=8#QG6\1()"FQ(KJR[7AOWEAOG@-42N/,X $14FX:)MK<I'K/7IQ?SRO:
M-NBO7Q'GP3QQ)1^*1^"651%[R&S .RM]Y$-MYT.SMPRO32KBX9 +$#.V%)Q%
M=;*AY*"+CD*SA7K?O+*ER&W>R%X)FE9M)#;,@<E =#FS=Q10EV<VID2>TD;\
M6 WHYK?E25P(TD<M&G607 AL")Y[<]94F7"K4=ZL(MX(WBD&2RDE<DT H&7;
MO"YI5K---4O;=KPW;ZPWSP$G[&P@3@0%&DDN+1?,%,61PPCC;_PR6H-^)1U2
M0C*)'=K&HHJ87>%@N JW6&I3][R->&U2$0^'G*\MJ5P"VXL9,6".I:OB'HA&
M]F==#+<0N<T;V2M!,S=!40=*A2I86S&%K*AF+R87,G%*)<=C-:";+T!.K;<\
M@)"R0V +&M*6G!1F0[FD-J4^QQ,PNYO'&RH:7_I&.2G>/>YAJ_^D_J>95K8=
M[\T;Z\US(%LJ@1J141[T:BLKMO:]^,"AV_GQ'YP;K4&_DF-TO;S+0W0UUCX/
MV%"P&M-X P35>5>V$:\-*N(!D:,<8E!C*LT6L :R0>MJ<.#)J#9V6XK<YHWL
MU:Q#UZR&I37XV, H@% \,++*I-[%Q(X?S6^.</X0C]\]@WY_=B3(3^I,YE5Z
MOX)^G. ,;/VFO^4KZ4\;JA?<&T+=/L*3DT=M?2SS?3+U$]']>+X^,!%F((OS
MXCA!+YMG+KE/:D=G;=8@6"[&.X!)8V7&H+ ,S$>;_S@?/Y<9_>Q%&H 9.5+O
ME!%BZIN[C8NJ;>LSV@K5ML@7DQV<'RLS/H+1@^/CT_GB6'A63V[I$UCXUIP?
MJX_N=KX//^X])ONPA1M@0LR^\T.8$+0<(%LU)=)GJ)9*,60*&8/$5*84F-WZ
M"9?\ZWKTN\<OCQ:O1=:H/'HY5'>5FS.;+P56*Q*<#\CJ:!SE9 )3324;U\*4
M,G*;I<CV#L-CL&HYT 9?+$A%S%BBK+>[/#H3;B)%)@ED- 4\)AM] U W@!K[
MVY!,/Y*IZWT"XRHVB=^5;(BT"I"DEW;E#)AT9:ESUD5%(6:P;0+AWS@@&3(B
M!U.:WJ@<;=^;4DPR8;&UL$'3$DVHOF,LYFXS11JL.B8EXV)5N^<B%+%2.;?B
M2\O1RX1*UT<#Y$;JSX4A4J!@J")P3W)*(3*1;*M](WGZ J2'N<M9U4!W#>6W
M\]GJY/&3;W>AS!\Z]\\:O( EX-Q;7UGJ_9)*BNP0 I<M"&6ND2;;&\Y$EXL:
M#AN!^FZ79'4-Q,X%;J($&GFWZ#^UG#^7=]_(LBV6Q[W'\+ISUU0V5R*BM4&R
M.GDU#*E2 ,'FR&6D6F3$W5S_])*\J5#[!"9BML%Z N@3FT+%!@6BAKP2/FRB
M-A7,MV5Y;][L"TL(%6(PD$ L9.-)0F5KQ!#0%'+AVVP4-D^0FFQB4X/QU8(O
M,7.$9,F[TEPFF4!-_Z"J<2P9,NNM!1=L8!2PXE2[=:!B\2;T(N+)PG*MGG9
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M66.U@<FO!))]ALCSP^X^8+?L]$?";^_ZN]N T[W-]N[FKFCO!-U!WQ_MBLY
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M"Q+I!N!E,E8T="M-$>7UPI)XG."O$0!@7-P>QA>(%OJ7*3>O;-4O'NFIH(/
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MEX>:$?NLS/&P6HD>>V2JV/G/,GSRM(" ^2Z#-GX95;EA& OC.T'^A)[D5&;
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M^.O+%QM&>;^,\G_GV"!QW(PPNXV!%@+L8%TJ'+ZZ,O1R#M9%B=?4\I421^%
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M0M-9#FP,?QIRN#SD\<*A(OIP'^>6'-;M+$RRN?&Q([(B&2*W\W(@@TQW/(T
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M"\Z:!&" 71XQ98#HOS_X!^Z@\D7\ARXZ?6G\G?#-"]1*\%GRXL!=(/.9&H?
M&5_9FF\<]M'RAF3W:"9H=ZB_X5TD4<Y]44'G'K79+S32C79:%<:-&QYT_^']
M/@FQE7<?MK>G0@'W=>'7#R'B>.BWO*U_>.\B=.80$/[A?<;C78_0\8="%SLE
M76Q-6(612:HL];DI (M*U#V-,CK79IJ/I&>9.3,))&*#9DXL%H@VO@C3)*9&
MO-&B5NO-$CB#N?8&:-_EA0 M.E=N?I0K(HTTH/!KP7+HL]H3C[TF4M,KACW$
MLDP+2!S%'ISQ$[0_8FX'[*YD-A)P!2"EOWW^=G30[NYZ<&0!YMFTN/!2@Y/J
M&@NG["B2WTF+H1HG9*/%&G#4)N72H0=CDDRY>T<D*P81^A[X:+"1ZV2N=.,:
MS4J,L8+]Q[1[$^2Z\4KK-EGH7Z!0=>@#1-4K6]<8V%6(\A8(GJZ^@K_">4[P
M0(K&0^CHH*8?"<[%=J.G^K"5GTH9<PLC"[I2Z"<>A>,\M0Z-2Y-)B6>+,GTF
M? 86[#JYI.V26R6BA$/64%M&Y6194L83/F O\?T<SLRWB8UZGV9B%V90&B2D
MQEX)J"/4L"-#_0&U"!-GB)."8Y;"A)@V:94M/+R4NB6I8NMV@ JHG D-8RI2
M):C9L&;'%$><ZXX.L&"@(W*AP.F9:2WPJ_-:R[@)I]?$,#LCH_>$C=ZUXKNN
MUE2VR(>@4(]";L_"7(][N6&3+*;7B8QF1J]M572F5)H>R-9583]%?(K59O:+
MLI!G&Z$$:O-M[R4[X9 G2\4]-+ OV_Q5$8)SIZ$,*90E(E,)#C<A.E_(TC8Q
M"HPM6(7V98B"*^HKQGOK 3+'V MIT.F^/ ?3!*P:[ 6)/[-/E2-=2"J@D.GN
MI!ZF3()N.9U2=J^,RAZ52U![A'8[<O"7/*K(I0WLB[">9>#*=M?U"08TS3$,
MN,=C,AJU/,865.&P5ZK^E\\Q.NN7%D$RLT>M\A3@C-..!) TMUYQ7#O%CQ87
M6E8GE5%$IE(JP^D0NQ!9#U"6LS7DOE, *QWKM&[2O#>\0VR)@Z,)B %AEVU%
MAMPB+NB:-O;ICL#N10\SIW%CF=)(TG0#C;6E8S<)5DB*A0_<=66!1 NC1"4@
MV-;%!K-6/P9%V)%QE?9P69:S[C@!#"V ^ 9B,L^U==<GOP95?23O$CJP4,+,
M"XY*3[@;$7HGR)[2J>R8\\PI+ O/^G Z@6^H!9]O*W^2)!'G#"O3!E)P.RKJ
MP#QWU80BTUYK+H4F9!OU$"NB'#B0F-68-C:6BDGY*#041QV+A;$%=0>N).*1
M0T;^E^T9IW<76*+_@??XQ:BMPCC3,]+,(:T+9M9[^0+RF=&YH8T]K_B,B)V;
M4GT.(3&$N&JCS=8F*"9CXR%*B74AVJ$2@UTCG>YONJJ"N!JI>7"[3$MN[%1>
MA/)2^ZZTB1 JT\K8$9<!H%PQQ9E:EIE6C9SMH5NM*$J=AY-&B0F@XQ(-0S=C
MQ$+@@BD[I_ L6IZM34$"RE!QAK^%8RSM 5[80MU31Z(PE/8]ISLQ?T%+.'YI
MD75!K?T0P92Y##+3+X?D4@EXPT8XR"1LM$4H ACN%/F8L!KY'JDC9W%R&G)N
MU[<RP,@F<I7DC!R')BK"#371M- I7V8;I%F@J13+' MLFAE.Y2R-;I.E\;0,
MBT-#'@>5\-FA#9^M"<_7(E.K::YV@1EMS(^P^7PER\!Q1+JLF?PJ-M:B73)D
MCY3]*Z97DI\F2K5-?1NFU)V'D6U)E'"BR#@%NY[%-TN#Z@"&XKW8DE"/@ZAH
MON0&T9HOCRR@*5*4V!IHQPJ8%2JG[KW(U6#]04X&N/F;IT=XZ0E1NKTG53XB
MN_5]'(V <A,;D,LQW0]JA(YAK(N6L*>XF?DY*4<DUE&,(NQ81(CI,#3N&NJ_
MR'Z1NDAZ)6I.;26QG>S"K"7LZ!H&>IQ-&,_RK-2[E'6!""0W.9.*2 _B'B.1
M((O$RCU^!WD6P;1Q<HPH1%CQ[UW:*C]*.*"HM[&TX-D+.6</%)M(3M-?-[26
M.8TOBRA\RZQL)&4P-"YRZM,E=+*PHX4)M,,J\IM&OX.]Y@3QR*8H36$RJZ0I
M+YB+X/3JY'Q8@?\=Y5%AJI7ZR=?8)NX 2;R!!\$X1>DF$C-.*/\S2=&B6P^O
M_Z'KN6YYI^QQI!A1$8NVX=/37VWT=$V8@ V<Z>EH&'7.R-MB2@FT$]:&ZCDM
MRSB.V%E@>^=)"HY+"A4X_LLBV(!S#=F[PZG;E,>/ZJHAB!S.(B-GN!M;JZD@
MHL" 60:)]--?N4B#NU&3>>(F_U4<<KT.D #Z1=A^)X6:Y$7UQDLY-';I),MF
MZI?7KR\O+S?&=-<&L,77,5@Q;5A"FQ3_UZROM]DG_!H_ 6?=YD^T\;,KD<[#
M):Z=\B2V2'<R^FPK(M8$YS^SJT!GBYH&7]CET [(2.4(1PN0;[YN:L$(I$<!
M)*PS@=//%1FXL#YW>F;=3,F6-XIRG%S @@&G,4X2^#PLP;16QE .Q7])B@J=
M7UM:+!F+V7RF T7)$+Z/Z:%9BDY YXWL@QRVG9^,YW7): Y*$$BS"6;,IMA_
MC5L?Z]&6Q0J#5%RVJ>!I.'>^J&H^:=^,DW7 CB5ECN:1Z6_@> F6R+;A [=P
M+H)-G!]$>N P#\:2W5)D'=,(3\^?^Y'.RAO)@%Y&*T&H8_N%0'='K_'/%6[B
M83[7HVLPYQ8_P08Y)JCJLW"*4S7B<'63U*-"G4[9=G>WS\^E*D?'@162DHK!
M-,EC6*4ON+R?US+4P^WT@!"W(I(&X/#D+RJ6)&PMG'=NFX$JBFJ4<4%#@R07
M,??1C[ZXDOW]6B!941:Y1JS/K7!#-U[1,*)2\%97_(=T#J:E3#%T[Y"CR+.)
MR8FMYWA7]HEQYN@6U!Z)2]-WO:[VD O@=839R3,O>K9(Q'OAS]V.. KPDSQ[
MY7+$EAW$V^*BKBQ43@<%S"ITQH39"@9G-%21L>@LUTY=6\C?-;_;Z=#.1#;,
MUY3 7>U(/K8EPBG;3_F4%LPA.]+<2C+*B LVR4PR+[T+U"E; E?;S)X3))V2
M1NVBUYD /*G+S$^M-MPA;#+;J1:>DH4) (OG>NI1J7QV;DU0K$5P!)Z#K*4I
M=&MCA)M(JU4WJ_6D3NTA%E<N'5%]98TL*\CF*F6!LW)N4N#+E-FJFH363>[2
MN18O%:(^YMP\0_933*[0G:5-ER8](KT8/:&2R [?UF6*'$PFT/!@"#L?'#%4
M5PB5DC+HU<6P]3HXA1@-F *&P D%E%5XN8%ET/.KV% Q/4V_L[+AEPO0Y]_9
MF!"F615]TI:AOFIQ+H@JER[CJ8/^EA,C6Y.>+%^ TYK:H#/FUVM"O.\8C[D9
M",DB@^$VXQAQAJHJ]!!JI :5Y0$''NE>G+==I&_1C*>PR+RB4$XXU;5VMA2*
M>HY5TI_*7[8,I:A6+@7O64B2#0%\&LNNR*(V+]:\1L0+K:G VN5/V;* 3T5)
M@#M0&%1;RM</,U70)3JAJ-QF(NT\Q )(ZX'Q^Q;=UVF<QM&(^S'X.)F*Q0*<
M?*L&]9@<L#H1>3M@>RB+,UXH%"Q-&PI'=>]#OHVY?>1R-3,K3?UH]7V KTE$
M#9+05%<2;#%JB<'F+D^&&@%)4-53)&8M7BYZ:BEQ!ATV182[K(B9;_*[^95N
MOPQ7X]&>;E*7"I6PI>/F(+(PSU']TC28?]B&:U\H :W+>L4BWHU#G(#-XRNG
MU-K*!M9,PK1&ZX2[<&H4X!FOW.M T1P.GAEN?/DT;HT+(X,0G4F<SD*\D7)?
MM0T3T&1F,+%3SO#2'6JHJP2F-X"&)3,0'U&HIJUR9W&BEN\X6POS4)NV?@^/
M9;T5L(Q*H%%5U#TZ9LG,V-X+\^!USY*DGFG" SA:TMC*!9J9DE?"K=J'6]:D
MF"6*Z_-*+4Z<W'ZN@:]]RX9WE)F9DWFL$[U'/""WO%9.'YS-B/6BO<W6-XZI
M9?*LDQHC$5H]GQQK:3A.R#'!F&^\%QKVU5<T'4A*N2V])K>EX84_D1?V:0KD
M B<P3(!30HL!Y;:T&#,T9MS'DL*3NL)(MVVR'&.!W%OZ0G^Q28G.E<3. H&;
M_LQS*[6C;..:YTU: <V4!#:>Q&-,<P!NW;(J:<E1ASGD@%P8C+$LOE5Y&7!%
MZVWEDB/88%& .Y88_IR!^HD:9N'2Q7? 'Z,<XT)N28$9!8LIB*28ZG["IF:4
MK+]R!RVG:LK:C\GBP=T=KU\XN9OS^H4S6@^[$LVO/6-(KU=;QM_16KQTN]OJ
M-O2$D:0TU_474CQM6QNE;FU'VY2L(5L@WXOU<L@2 X'KY$[/%2<PV_@G, #"
M<]SA :+PGN/;,+Z/3P=[QO?1\M[9&2X?0Y_:F=0]\NZC?<1VU9&Z=-)QG[2X
MD +/W#A27">*TBWYJM3%).?$'W,EJ6KZ/:^47$+8K)?-@A9] )WN$_3!PI/8
M4M]'VX;,%>Z2S].A;1Z_""Y"14[[HIW(2$\G-Q>Q+1+V1BI2./Z3HQO)\"C,
M.^.H*3+>0/OXRZRGRF'.)DX5J]2O$)67&.>5F6I(C8U"KNG14\Z+_E)LA-O6
MA222R,F!87[E8"&N!$,M4]TIRI8N<(TV)@04?-+$G6H/@W+CJ NP\8IKC+2(
M0BR<BB!SM7C4M8[MD9EY3:?M<F)"ZQ:<KDY'P#MUD\: _+(4R[$.^KBT$A-(
M#C-#F%68E*P8_"+Y:63,\QU2 PJJ]-6_O@PW8(U!(OF!.J&N:1B=+PH>=$GY
M%0_IMNNR[ZGG'$ST-'50%5*/)TUKH;<VH21.5YGA8''&$DZ0XC:,!)'RV*D%
MR6RB,;#AF1X#ZB82IY3RHIS0B,9YG;NH]/P2GYH_D>W)J1I\FE=-B*<:V*K4
MURFCI,UPW]IH;G0CW:8;GW-22RFB6HH3VJGUW"B3\CZY:14K1YC P,U+*-6'
MJZZD#K:B)SX)-CS=(@T+HI!^-07A3YH- -FUF*(B,6>FKG@F<%U//-XN?2'$
M)EF%SHL[L3XCW/=0XD:!LU)G=214C"LYTD[7.Q*%\*CS&M*T-,(?HEQN"CX5
MTV$73VM-J,*<%.7PF.-B+7$ ,,&\O'%(:<8Z<9W<U8KS'V81JIHTVH62Q1T9
MACHI=S=Q"H[^EK5B0%>CE:>DFF0"/*L-KW:9S/Z-SNZ(4F)MU+;%R20RJ<K)
M0D]CIR^STP<W22L3KUV$+C1JRC@&(J),6*P@2D#RZ*BQWBQQY,(T6#*[F''=
M.K",*QYG )$*5J IU>(C29H>C1(!4'2%6F:3&-2OEA6@;RW4@IT%G1D81,+8
M;3U(%8-*5EZ'3_JZ%!E3WJPF9G=5*X4N;1W>+**4,K>Y-X=Z3=]KIMV"D>H4
M5Q?$%IWPG6AB@71$>S.EE@? "]$A8U>V+O3KG&31EY(F-]O3!(*@^E<L=.9#
M!<#K!I:EN_29+NW-;EH[$/M$BP$4+S<3@/T!6/5 M>BA[MQ1;7"*CQ<C*_:B
MJ$@-JDQ$=L)%+&NH5+#47IRT4N(.E$B![,$H:QA\QH)KVVR-H\:$>NZ:;%8?
M^U3<9(O:-)+5UNF@<;'DNH[JSKN<"=#%0$7=D@.W!ZN+V'*RM;FT-.J!43R
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M2;?5$V"HW!WCW2U#Q=JZ#4TW 7>*Y4S,J;1\H;\/$8(BQ8AJWTIUR;:=B;'
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MO(C8S]O4Q"Q)G?JJVN[K;O5_&^5VS5V:L17VKQ<DL?$,)B5%%S.$G/'O-O[
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MG0F&JW-3'Q9)3&/OJ>6_0,N<L9_2U*_524I"?-D^GHKFTKIO#>24I3=J>T
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MZM?UX3?LB'E(]=(6G$^C188")0N6+AU&X\;"P7_?N%Q^3[TP)MLZ1NGGI28
M'@%!4[4.PCPWJ5470.UCK1QR;)KZW2(2SO%36R 2U^*=,IF4JC(E): B% *[
M9RUS2D$/>(43G'R1LD03VY):!XY%H>8A/8G07 3G<(GV!0%T$H@Q$(6ZZJQ9
M89ID4X*12;+VN@<2YLI+ ;H[2 LN*M']]7@Y3K$9R24?1DNK/<M;4DZ,,Y0A
MI:0(1@(EE@;/"2[B2%]4>F6@H\/FK+*(2$XG[OEE(@_.>TX7,V"5*Y5)8&9^
MRA3!ROU\:0V,W)2M@G,'U0?8]@/V W$0<_DA(V)KU3JO94AMU27"BY#J=)G
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M3R8WJF:7P0[S#/H/,W.,,/(@E"A6-"G]R7+-J&N,NJV--)Q[23%)4+M@Y8(
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MBXL>D3EHM<MMF5IT]/KK\[;(:%/GGLM/=0CUE'G>IH!<ATNV5;C\]&03VLN
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MO8+U7@:8U] &H/Z.MMEG8)H0DU<C3@UT!%R<2(5LRFRLWFTPKA%E?BX,S3P
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M!]%'D(;^KD2 WXA&&+/1D<,F/$YQ3F40.;PCM'ZLKJPJB4I/(7N0) :#AHU
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M36QYCKFBQ$VXBU03LH='36&:=%AB+(D(M4",59W<W9J<_*:KZ%*U9!LA4
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MX5G,(3WGF!-T&%%XD\-X@T,)[HKQ:7".&A4)/%YAP,/B!0IW'.H3HD>>)1&
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M:R)<"9)=R)TLJG!J;DWU?]WWPY8^*K[3;B!?B,;2D' !#@/O[5YPZ)Q'YO9
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MK<]K9==[[)K0<]\6L>B10'BMA]9*O;\$'XBWA+9!"#L0_^NCL>]^1.LW7Y1
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M[X7]G3LVX'1BUXG=7<5N&.[?VCWLQ*X3NZ\4NWZXOS?LQ*X3N_L5NT&XN_V
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M(M>3 %62+^#DF!,(9;D1%MOB#/4B5(M"KW.17U53_=Q*KX=^PVVJ6KW.^"U
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M&=CYQ1O[]GTD_I*:"KJ'K'IG_6Z'%@4FF"\OR)=K\'(\=X%U+2'!EVDE^RK
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M^Y6-B:-Y:'T3V%98]WN6[91E&VCX^)T(1AY\.O&P:.;]Y[IQ1^V258OG1RN
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MLQTI^9B=6G9JEYS:E<3N_&YMU:-UNP,JN?<\3OXL>N<SBTGF*\7:"P^HEE*
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MUMA2P:5W:\&E8TCDF>=Y5F,5YQ1WO0Y]>^Y8G([ZM$*2!C?P*9Q#.3V0B]:
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MP9 12SE+>?6E?(^O<4(NA;QO_0R.130*@PRB> P'KC*>:/47<DYI"=>S'^W
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MV+*60V5%,RAW.B!'PEEXLE7-\S57X0S*?<YIL7:S\&3K1WVZ<?!3]C0YV_=
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MJ_?B^ Y;B*T6XD#0$;80Y520BR;'?=DN',$NY'4F.<7_#)+CJ[&*<X+#N?/
MA*HX.0-]/RE\QDC?Q7,HKS?$2-\L/!GOOVIMDP%P"N=1;@7/D>?""EYQX=E]
MI*DU.P6B^9\3WO<FIY,QOP_$_#ZT02<'X8K;E4Q&X&'AR:3>[5:!N,#,H</4
MFSOLLNQDT^YV@1T[SCW,R<C?QZ@.R(U;ST&1H@UULYA$L%*LG0,C!VQ2W.2P
M< YQ9C"K^#,&D08G#,[!N<'/<]_5[Q]8^<FY?^4TC!<F]QIDTW"4F[+^@7$+
M-@WE5)&+9I=- YN&ISN2-?B[I*;AB9G!F3Q,3JT]AU6\-"Q)80'SN>^-HQ$0
MQ')@9,X/?M*!JE\SVYPB7#B3\D;2BKG?*,7:.9*67\N[M4XW;T86:WG1DEY,
M9G<IELY*?HB2FX/3SQ4^5?^34X4//9SW<]_S<#9AT?:YF RQ4BR]\.A<*>5G
MCXYWNGEW)M;QH@7]@AMOLNQDU._NX(P F4OF>7+*\%&NCUM-3AHNG$=YXZ#%
MG'=+L78.D1R0/C;H<]IPX3S*J^3%W$^58NVLY <H>:]?@<3A9J?>ZQP]=SAC
MOHM<$J:A&&,O&CHBSGEY6FI0V=SJ5P?F QV#/J56HF:[UNH<B.%P/!IQP*?<
M604<]6%KR];V"-:V63/-IR6OL[4]-6O+W4S9V+*Q+<#8FK5N[\#;R.*-+1TO
MWX06O/2?JEW@MOZ0*^@G?T9!:$\6\B/;'0LW?'LY.'X+R=X^+C21"__9_=]R
M0\34"F>6?V^[1.#6QO45LYR/'XQ+XZ,7&A^$Y0(')I&S=0E+3,(FGGNY]!R=
M/C-TVFP>WFG3+*C39E-UVD3E7O_SBYC[(@"2!H87^88O'H0;"6/B>S/8@H;V
MR Y"*S0N;E[7##$+??@ - W&-RY^NKMY;5CNV B%ZTV\!]LW+,>:"!?F/X;O
M[ZY_>FW8KO%U,0NCORSC8FSYD6O![][<O(&'W^ /:H9E3.SO8@QF(Q#PRAD,
M3E=V\=4>?#83_L@&BOX%OQLNC'\!(6#.QM>1+=P1$.D660$S^<UU[)D=PJ]N
MO!E0>5$_:Y%KEE+D;MV1$XWA/>]1GAXLDJ&[Q= +PO-F5ZN4[+J>P:X/YF'D
MN0$8 \.;J,MV^,<OEO_@N;:T E-A6%$X]7Q2TWOAPCQ&!BPW0&U._1I< %)C
M-#B!F%N^%0HCB(:!/;8M?U$SK@-Q'UG&W53XUEQ$0*[ ^/77F_.6CO;)2<?[
M.2AZ8&64#OUKEHY#I*-32NF(3?WOL+D_2#OQU7NPG+%]WNPJJNUZ1G;=6(L@
M]-R:\8N8PSND"O]K =,7(VL[YU(GD6<X19F-E=7U-J[N!OR(@";\_OM<N($(
MLLRW7>_L%[1F6U] /N_"-K,-#)XQ\1S'>P3M,.B\"W9Q!HN 00*RL',8V1M?
M>B!XE_+?QFAJN??P-3CB:%%',76$HLY;8Q]]U-F^"[/,0#&LTI=S4Y$#>?X'
M*CD6"--;_8^KL1W,'6OQUG9IK?30JLK BZX>[7$XQ4A%O4'1"GV5K,977]?I
MJY6HA?RNW:^WN^;6KQOU0[_KM+:_=->3NR;;KS<[79XKS_5TYMKM9!IU3QI(
M*5./U[88609PZQHPJ@/[?E #0SH2\Q!M[P@V"0N,[5J1P([EY@#(V$ 9?*/P
MRT2;9J/9../EW]!V>\8$:#;,P1DOG_G?,/M+RS^T%"7/O=&^S0(&>7FGO:%/
M(QC=N/>\<4"QC>=(7ST:+0N^Q\U(U.P7N;G77] ];<:%MVN=WH$0&*7)>3EB
M)O;)@/(E[,V9%I*G#?P+,+H<1'F6"@ VH>=B0KN] W&?V(2>I G-WSJ:32B;
M4#:A.TQHOW-@WY*7 @]^;LBMX@Z4GU56%*PB" QY'\/P'+G)V#?K%<@VS[C8
MY\5O>9IVG<)NV6PUC.$\8#7++7F]?KT"N&BL9B^B9B:KV:%JUJL7 S95O)J]
M$-)5<0[?%Q$(RQ]-*6EG+!Z$X\UGP@V-"T2[:C:NOOS=FLVOWM'_F5>OX\2>
M(HYX9W"*.Z&#6J?6:.7=?AG<I_!]L%D,5DLY%E](9(K-5IG6UJXU<@.ML-DJ
M7',KT,J8K19;K4/7UJH-BH1+K7S@^WKTOY'MB[%Q^UF=>)YVTGDB=D:5E6_3
M$LNM?)U:OU,@W#9'J0Z,^%4J:O4B/@.;K4J9K48G+Y1OB<U6]:\H/GY@I3UW
MI35KC4&_\JT]BG/TOPH'/KRO29 (RZ&+#VL\LUT["'TJLH_O/K[^3$>!:[[\
MX//XVMYJYMY;.8I8^ YKYC6M'$9DLU4AL]6NM?ILMD[.;+'58JMUUE:KD3O^
M>NS+CZT0P&5!Q'TBP*^"89*X2Q4 _5W%DBJ#/8L1Q+!F_V>JV?^*>(1X!-65
M%S]3Y<6'Y<J+TX86NW4-Q&VI$3S8,ER!,18C7UB!1-Y]939:&OH&@7GG%M[(
MA9Z!L!\U8^[;"$?F+(QQ)/!C!"7#KPS;?8!E>O[">/3M4%R.O4<7L<G\>XD5
M^:K;'NB!:_C!X]0>38U7G78O?M^C%1@$LR=?&3C>HS'S'A -30*:C00PQK?@
M4_B-;ZO0P:/G?T/XL[GOT0^2J:Q-%T84/OSIWE_" #-8^PQ'F'@^@:?]<O.[
M1B4.Z@A &1,'Q]] .YPQD"B$J<!+O,DD$"&2<0JTAQ?!X-'$&H61CVOPK=G\
M,IK'(8ST6G\7WYP(9@SC648(KPPI!10G=O/I]]MWET!B"I/@):E$)+S4C\?C
M$:BS-?-@/G])B&68[<1VD1^._0 _M=W0<N]M1&^S IBK1(I+"!:$@J:H&%?#
M^3P*QZ%Y@3UWA$^O#$)O].UR2%*#4@+OER_<M#:D;&K>.*G;V2QRO9D8VR,@
M-$@G[A$AB8;O+2PG7"0CK<AGLQO+BYU(]5Y!E9R/H4LUEQ'7-+1L-&6&<!Z
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M!%AE#AHQTA#"4;>Z[2L0-_W9:PD)Y;IB1!-ZM&$8'-&Z]P7AC>#$+?@'(0'
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M'CSG@2[A)"WB_5CZ=W059WRPI/MH7*#!4082W-DNV O]_ HMM>V4L?*T&;;
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M@ ,TIU3.^XW<(NK=+/>_/Z/Q_4QA!:%EG4SH%H4N@G%E.!.=(SE1H#NUY>;
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ML$-L71"_=BS[.& '9J![:%,[ _A#]Y^86#;VQ74B O 'MPB;Y,@WT01\V?3
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M)9=WY22L] IT@U9+"SHE#%"'TW3 &$223%/M$:GEV3(!QTJLC+V4TX*Y#A^
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M-7)FH</D%]?>#4>]T/!4(YZ5K%%5M]!4[IA! ?-E58=#5M9YL%7NA4K4G<<
MUG"4+M(<K58(= RA/AJ@WS/C=IIR (QX[G9O4'5R-U,Y2VDS)ZLV@%7,LA(!
M=WN7IIYWJUJ%RS/6T71R^"]^8YE54S,G&#>AF^QJUJD6C35%8$50:FS:0X6"
MB*F$8U",:V=#.6.Q-PZ_HJ>P.JBK%G0K->$)I]-=U*(<4XMQ6SEOF[SQ2%XK
M=>)8O=PXJ/2I<E3&U2/%L-@:IY77(D7.9*HU,]4\DZEF,M5,IIIQ++=>]6^_
M8WD+W<FW#-WXF1_3S_S?Y4KJ]5I<SO_]7)W-#_8US^67QO#N\D6OZ(:^U77]
M*'[I_]ZL1_JZB=7+N*3UH63M.QGE?=[BDN8P:G7_>CS28%JBF-3FU,S@1U;1
M[<99-8GF1B\Z<515FZE$SVB)@8$D9^5,3LL2QDM3A:4;J)HP'P1_*W^S#HL^
M4+=R\EB?P4J^L-Z__]"68@^W5]F#V]&'596 F]X\Q?Y Y<!& (5.3.ELZM'3
MC/\,7OF_>0F,=X"5JO*BG[%9&?HT8YM?8FL9,VY2GM]A_KU(X]U?2[G9T)2;
MO;.;]9)+&>^L\*['(Y?ENM)KCL36]'?JVQ63Q/,. +=E>K>VCUQJ>D_8G1P8
M9M?63+.J(RCR=T-O\=?W=039NQ[UU^X(<N#&('J$P<;A_7QA=PTV7&YE-Y@B
M$"_CVM'$NIDD 7H7>]HZTCT^9?"(P?VGG.(KL)MZ.BZ)Q\]^8!E;M(OK>(S.
M5_]UO?Z]"H"4X@^O4Q!HU5/=*@K!H/T2:[/4A%_8PCGQ*BRU<.;W[L2QUDG'
M2TUZ?_94VV9X:;UQRM5?N0UX.;V%\SJ4@,96GV=56_GZ<>(>3Y\?N+EN;+1^
M2*;* [\FC^!267)K,7=F5-$?$S*^L^YL!X9UMBU;9;5M:PO8XY=IAEAIAK]/
MF\=MFMH_LA^O^WG_;5'EQ0W[V> C-B4:EF)'19=@\.J#3/HL#"7SI!MQWXF\
M.(P\)D/X( I":B=_'Z'>X+B>LV,)R;,>ZY;_LT/"'?2F]M@ 'O%C\+H_[(E\
M4'V_8_593^++R 5C5Z^16/?[ O\Y'%/J_N"@.FF(R:P2"!/6#NZ")RMO@/#^
MO$G>Y-_?NQ^_?_:.A^+KX?<O[^*OI[VCX/@G=T]Z1S]/WQUZI^<?>Z=O3BY/
M>H<W\&_O\_D?EZ=O_OQZ?"Z^O?=.NI]_7F6GY\?>R=<OV?'/R\N3G]_L+U\O
M?GX^_W)Y#/]^Z1U>?SZ_<#[_//2^O*7>Z5G<X[VW_=.OQ]Z7\[?9R<_C'\<_
M/_T\_OIO#YZ?G?3^MW?<>WOY^>>_KX][_W:/S__(WGL?+S_W?G1/OUYVO_SU
M&<9VTH7G!B?G_[[^_//CY;%[_./+7_![[\O7+W]]['[Y>NC7]\"[AE_<3^'I
MNS_A\\_N9_=/F,,WY^3-'U]/WAW^_/SS;1=^=[_@,]_]V3L^OTQ/#NP?[\\/
M!\=G]O7?MDM31PI&DM2WB9]RG] D3DB0^)['A.>Y0;RS%W3B./K';Y.$L:=]
M% ]A!)2J*S*$026#2G>@$F.N\*.(AY[M^<(+X\0-1$@#GZ=VR%*&J.3$!I7:
MADH_QZ@D/3>.G82XMG")'P0!B0&;2$!9G :VXW,6[>PY3B?TG!;!4FLZ=[9'
MUSR[S(L!P;R *DRN_;.CUA0;:'+IKK8!<X%^F^%P TK:\6AKQTU'*@/2@. J
M('C64,W",+ !YSB)70JJ64P3PCR;$Q9SA_HBD6D"JIG3\9T'8^!\''I4U<QP
M;VN4&<.]:^/>L0J3.+X?.:E/..,)&%9I3%B0)B1DE$F1QMR+&7"OVXG<-K'O
MFMQEF@OC.;K,M%K2)K;<K[M@%))+4.H33)?KRV62OE>V/9<"N&7MT&T&N VH
M)_6^?AQMZXD<&(2[!\)E#?TD"9(T%DY(F.24^$(Z)':$38+4D]Q.F.]%_LZ>
MWZ&QVR(;S;#OUNDGAGW7Q[YC!25(A,VH:Q./IF!>N FPKX@# C3K)(+[E(5T
M9\_K!+1-[&M<+#/,>M3'0HYY8;PIST1=J3?T!F#.X-LJ^';34$\B[MA!XCM$
M4NH2WP\$B8/()X'GN31)>&)+%]TG(?5:9'\9=FV+>F)X<ET\.=8Y8BX2*9A+
M8NXDQ&<^)51ZDB1VD/JA0_W CW;V8O?!&D?[/"+/2>/X4,@KEHG&844^D2WV
M>'E$QNS:G!I2[?+ACRO9+^5^7YSB5NO43F-]K8Z$I\V\F\ -@E3XDJ1!#-H)
M]1*2)+$@ON=*)W(#$%:@G;@=VWFP=F*<)ZWEX@TX3PP7KYV+Q_J,ZR=!(EA
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M)@F-/,(]&1(_"7V2N*E'HD#Z3(8T%:&C@\GK/G#<HEI ;:JSN"3O'N3E0!<
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M(ABM&69KJK8Y+\\I3_!:>*PI\E]2!;'?E"TO<;%131!\2H&QYN?/F>%BV1?
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MF<\J[1%Q> ;4C?_QPW]N7#Y-5=]6WU;?]C=O6]H*Q^C?+7&\Z>Z V(%0^CI
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M9'@UQ!/HQHOJ9LW&V*"FUCT):7!FW/,*\V>[_IO]V&0$3(XL5FJ;C]K$K&8
MR1*+09%@RI'$$"7Q' S)O":%0QZ<7KCS2XU3MAG%#Z 9*HKO!<53,6%0,FU
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M-40HFTG?N1B4*M6[+#.5&9X%,[3TZ'OE@WOD@W>S81#JJ'6$YAE/9 R26!^
M,(/4!:L8%;9Q%<0-V=-W.PE2NQ.MRI\^F>Y$OW3[T ^U.U'M3G1#$;VF5EXZ
MGR$7-2&ZH]%I?@KS8(S&]<35TZR@MYUMWYPMW3VS]E8Q=O4HYO,H+E7_=AA]
MC$(3XY/.'H5CQ''."=/9KC%K#5,*9=EU9I?5 [7NK[01TDL^DO7#0^,5S<M'
M\TSU!QFD06:)YLX1"<82EV(D5"H(,5D'6B_MJ'C%<XOQ_%!%("J>EX_GJ=Y/
M+B)3S!$+X$H0D!&;2HLB;9C-=@O6N3;B^1D=VKJL3LYE2%,((@R.CP?EB@;A
MTV/OGCYQNEM^;N8,L9WSV4'::BSZMABT\MI\O':I*+=-4H/$0(RS)1]$*))=
M3I/G$14<T60_5)7Z<PL7Z:P'05H,VN5G9%;0+AVT,S6UK7%1BT0B+0>W& H"
M6!H:Y]^Y Q5T4U.;UBYA3QFTR\_#K*!=.FAGSFPIIBS:1+)6T$3Z*(A3,1+'
MJ78L@ +.,FAMFT#[C/8VWN#);.FXA17#,P^0M+VP]2^#X=3BE>06(#EQ64YD
M.R5 0G5(1%JF2DMV(,*H9$4V*#.LZ8-F:Q6JIPKGQZ@I5^&\1#C/5(@0WFDN
M.-%1,B)%EAR.2D6243(8+123DZ)R\KK74N'\-.#\H'U[*IR7#^>I!-$L<)]B
M("KXTJ44D4#PC&0MXK5PD+0*68*L._JTCG^MB/XXF_Q%?C2Y5:7KSJ <@NP,
M?+X\:%KUU.V+IR-&IC8_2&7/MI+;?.1VJ9AUH(H%R2P)VI>@J& $3%-7(DGN
M?)8EK'3265<+D5N-B+89O \I/2IX%P;O5&@HX[.-8B1)8\Q"0R&QD0)1/'@-
MVG'/:0&OJ64DGRQX'U)H5/ N#-Z9W"B?0')#":+(*V^PB@ 81B@DCH8Z8)!E
MA5[G;0'O,]K6.%/4C:;HEA.!_5C/9#PA"?%J2F/GYJU<-A^7J5D5D;BT4=)$
MF/>>R+)!ZPU/A'K*>:(I6S2M;8AU62.>3Q:_C[&!4?&["'ZG0L*GH*BRC*22
MRI@]2D&<H)& 3P*C45H#%OQROD@[W8K?-N/W,78L*GX7P>],EE24,?-N28M2
MDDC*/($H>184TJE0NF*'V&Q1M*4^[#/:HKA[;>L:!7F4^G(_3N^<V6AMK'I1
MZ*&6A[DCC;V^U!1'@!(HJ2::(A#IDR?>6T%,YC9!T?*\%JUM,&';$1"I.&ZC
MB*@X?B0<SY1]BQG%TB(1WHLL)Q@G#A4E'((P2AJT"3*.%Q(3%<=MQO$2Q$3%
M\2/A>"HK0'JIHP?B"YBE0TU<TIY0:J@2)34 Y-J&M(NTVFS?!D6+M<1%V>O9
M8M?3$M@79:46+7N]Q+#)<ZY@N?13W3\H4UEY;V'>N]1LQ^B87<Z8B2Y*6UK\
M<6*]\211]-EYB2'14K;67-^8O5O)BM94KJVX;Y^,6;2&;26'99##5-RDR+,/
M))$X[4MA:^V(8TP1@TS93/=9_+A2TUHOHYE/988GQ@S+%$:5&=K #%.YY)A6
MSGA!\@]%I%3Y$<UR*8LH2FVDUI4L",;7!5LD@OE0U/#TNPCMI(2AR?+"K^$(
M^A^P,X0Q=B:/1YT,Y49ME2,ES0/\W]/NYXR/_AU+]#[S"-)C2J>)K0_2SIFE
MWV1#'_0++99_.U/#OL'1>-@-8XSEA<U^O/S$S%]6LIR/+"]U#0K9%99,,A)M
M:6C*;"!@@R+>40 5E+3:E8Z(+:KK45'>:J%4\=X^O$]E$Y5"*\4IT4QGO,LH
MB<^&S[))>:.Y<#:5ZEOMB"17I+=:^%2DMP_I,S(H:D-=9,3PO)Y+!X[X$#T)
M$KW/.,\+>RG)OX1>@'73Z-:;1A-UTUVVH*EAH?;EK]TZ++001;[*HS*(N_TP
M1!CA-D[^S[_W3HNE9LEX0M"54^?CU.^7>JPZ$9V'1")&2K(K94A&1*988?.T
MR=.!Q\RIJ@:=*[NT93NJLDO+V66JS81+*2@OB$\ALXL20#P'03@XG2C5E"I3
MCB*+&VHC5W9YBNS2TG-#E5-:SBE3%6A5!"VU)#J)TOK99!7(L@.CO:31AN+L
M^K4-1M>%NA[T:6D:S=/?$=OZD3KLP+CC\4.WWR_IA8/4.6G05'?![I5; 7B4
MQ@0MJ)!1:.>YBMHJ&1+-WAS\N;OP4>H:)WM AJ2SFDYK[I11CF3#(I'9&2?.
M,T,TRJ2M]YXAK;.ESI:SV1)]=K]C]LRILT1*FA^YDIBJ3;0@@D51UE.VKL7U
M,[YU$_4)+Q)H('$?O.1>2\$,9('/8^ N6>XDBPWL']'OKK"?&_8S'5$3\SSE
MI<$R$XHT%R7O-,_P:)21R4.*F&%OUIU<.!N]HKS%*!><.:\SLKT0$E"Z*$';
M8#RFH"(W#<I-1?D*H7SFH)T FXP*1&GAB=34$Y ZY+4^FUU(C4F4 R?KREY/
M'%WY/D>K*H>Q%!I?2 C_303R?J..-PWUX[+A?]U;P&>.F=WV=0 S[6L$@=P$
MR8QPV@A G9\P2EOJRSJP8'7$N@X\X#K 9D6>LQY%4HS(@([(B(: ,))@5 B6
M,8@!RS:O<V958J:5"RL7UO!HY<);<N'K&AZML^4NL^4QPZ-U+:UKZ:JOI36*
M_.38<1I?XLH%X8TE*BC(NL)X4O)&2U4VH1DOM=KILJ+(#YR,<7XA9_->-$QW
M,U'^;93Y3G\Z<Z/YRSMQ<.I[>.U.G^5W_DV <,XXX$-1J;F12M^>GISTL)2;
M@UXG=D>A-QB=#K'I>EZ"@ZDW^-+I]B=DF&'S\A81P?LQ5#O_=*G=8_@+KMHS
M86Y>>W?SXCK,JUGG!+IQO=/'IM  '.=['(_RG#GIYIF4/_!10L?/P8M[HH[:
MTBLCG$_45WF>[F/->IW3T;K43E-8YM !(YA8+$V].'&*:9("E\:4D(72:QOY
MJ25Y62ND*BOEM.OF'O;\4*6<Y5+.3!-0ZF/ D(B4PN4?3A-'32)<1# \4">-
MRI1CEY5E7RFG4L[3.E54V6A1-II&FB+XE+1U)#J1*0EI(-:8_"L(R72V8BA=
M3=DZ75KQW!8=[%DE<1H&Q]@9P]?\H46@WL=!GH4S-MLW;K>GYYON\>G0\T,V
M:YW,U<,R50M#5WJ>CYXO-6I%Z2@FGO6I+J<RH^ $!#A"K<?@E62>E2I<ZUI<
M/^F]\MGDE8^>+!\]9//9RD>+\M%4O,8H4@K1D2!5%J]8"H#Z)#(]&>^"#8%1
M7MQ%XYY@(=#*1T^6CQY6OE8^6HR/9JI6&&NH,X(8P2B1,C^RE$O"P ;+P4J+
MH33"9JYU!W'^.0;?P_Q_['[>^)_\X_RKCV'XH=MO-NZO=,H-6"(?9W#:^!\_
M_.?&Q>6W^5-^]+:E,0*C?T<(O,D)0.Q R.C+W_VMU,7H#\8X>O'#ZSY[L^0O
M3(D0G Q&W2958(@]&'<_XT]?NG%\=,XV,V^<F/LEG;X%_&C0.QW_^"UM&2/E
M+@_'[,]RN0U%>2=,EHW"@G$R60$:N!4)*%@5F(E_,BK6SM]U=)'S<P(?D/@A
MPB<"*=_B2^A]@6^CM7]>GG-YPET9^:N#-N^L:S Y]US]NW>U8)Y?RWUI;/CK
M[F\[F]N=MUN[._M;.V_7.[O[6S^>Y3,8ER_47Z#\H6]C_^!PYVWG\*"S=;#_
M]N"WW>W-PYWMSB^[^YO[6[N;OW7>'N8G]G;V#]]>O[?;3E.]]M<CPD0S)&>L
M3XH']Y++R:R<&:>/IZ-Q-WV;/-7MQSQL+PGGY;V/-'CLPN"/P2*3M?7ZSX>Y
MIIM'Y,P=W#\]SN\/2XB/77;K#H8?H-_]WB23;0WZ30)E\\MF/[X:XJADHI5?
M#])9'Q_HO<W/-"EJH^V+!+7\UV_SC.JF[#WTQYMYM3KMC_/4>Y4_+W1Q=)BO
M^>?>('QZ=&_QW9FW..#['U^KO</?V?[W]]E#S-[B'__J'?SZ/GN$K[_O\5WV
M[CB__L>;C_O?''W_GR,:CO_=AS_<Z<''=WQ_^]/7_</?Q?[QZZ\'VZ^_OCO^
M7;XO'N'VWO=W'__=?9]??__KGOC/][TO>Q]___JGM@+!.4:21TFDIX8 "D'
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M>G[(I[MI SY.&_-!)]&W[46*X?.@;_+Z?9.S^04"_W2@;;_KM>V>V-D?/L/
M="C3-G!)8M3B)M./H%(S*B"D6/Q5IN3-YL3W8/,VS.ZY9.$"R+R_S2"\[E [
M:])\SZI&TP3//:3KRR_/3PQ8H:?7#!2>W4$%6A4"5P\ >3G*R>4$R19>MD=F
MY9-B7[:.Z].# B K8$"3J!?#E%^U8N#2"I^OEVFL]>#J"E@?4+H!5/RRA&%Y
M0096>P5:T<Q.,B)P^&K9()3CIHU[C*XNTS2#>8)U6Z\JP@;L63XG&VC3^7+(
M\9NS'UU*Y)H![$V"X6-;JW=3>LA2M]U&GLA!!9* /8.OYWUR.G_?UFYD3VT&
M.0:P,'G7U8TXLA;;SV[OSN[7FA!P8B#5U6;?YA7@TE_WKK?!WPP/2(=GJH/Q
M?3N0C'Z80Q$I1K5?_>P7?3N\M3LQ\]/5YA%L3:W""--3TSXRQ^FRX1 NYIEN
M>G&>W9/%V;>S-V> _*XGMN"K%.&]2!O6IXOK!VVR]MN<WS@+)YE:_*R\@[DP
MLX6MV.J2[EC#F>OK=)_G=W^Y.Y29;P>J\!PJH\[*,6>+!EKVR*#!V6>I(2HH
MJO[$=&,90N;8KESAP\/4.HMUSOKG;SEDW1<"[:VF9RAJW6'VP,[ =%80=._(
MPW=Z9[Y-1T$4 8%-%Z(D)^Q^6QM1\,K%M=V2?ON7.<E0Z%]>A0!INX^:R6WC
M',1\G[2-;138QCIID,OUIX*_&XQZG[RPG )]T(:V?YP$_#6]>J[-<;2:83-T
MW^J\9!5[,%*Q;=C2!C1)>X)F6G48_F)Z.N#%L5GF *B>D%Q[_>V+13ZV>1X,
MDA[?AS\R1_8UM\_S[%(7'&MKYPK8N*B,KI2SQ..;H)A-JY<CW+0/KGB0!A)%
M(W!VP2:?S+.RR3?O<F3]=LUG@;!EL\D%_':*>"]6(X30*:0.X/<N9QCRD'W)
ML/7OE&'(?<II(X$U]O7-]2.(\_?@7HP*LK*/]HGSB@G(LPGD:28@SQ#(\TE@
MSL9!2J!$.])X1;UBC=>62^R43K^344KOKD.,?OH 9J/L5SM,O9:-XH9Q;A3W
M)@U/"$$XTZ2Y]HCFMJCU^R<I",VZ U12/OV8/<UY[#W1\-T+%BUW:GQYU3Y:
M&B;OKYP^K+J\^C69]&$"O<T!SU>#-'".:2XNS\'9@$-PT*47W>/FX^.6=*4W
MITGL/93IQ%*D>M E,=[-5^#FG$$&U69PAF]K6ML!9YZ#J[P)[SXRAE6*I4_3
M1+[*&?%%.7')T5>.%MHL;E9!H]$FQVA>D[6E!O/)^@+"XRW/;Y]5^FT!H!;6
MI<QF;_C:YE#9"D%=,]RA5.KLQVY\,L99QXW-U]OAWE7(]4?FY++6ZL/F''BO
M[5*T9T_5]X1$AD\OO[P<1KV#FMFR;?,U.7.296*59OS$#!)JFPF*SA\J?G1/
M^7$!Z/CDARPV<O@EZ[!8]NF;@IM8M5)4\@[G)R9IH Y'GFY3L-/MX<X^.=*_
MO)J?G[<59_^3_H#"\_W8W:-7>U5?;5AD#?N[W2#E1-,"TNPDSD].BL,]^&ZZ
M!^BY*]\W/?'+L.*ZK[2^=4'[G7M/%Y?F)'>Z:\_JX/6?Y&Q%6]?V&=CXVY7$
MNH:4X).N5YVT[6;W8P?>@Z)\.$9-/ZU*JJOFY3^&2KC* 50.RC]9S/!G8[9*
MXO;^F7_00V$?%EA=06S]'8%:'YZ_/R*&$^FT1"*H@)AP FE*.7(^2*4:HG4C
M;B?P:H!_'BSZK*[ZOARO7L&(9HNPNACZ2!'D?+7()Q898#P$+2<!SAP]!SVS
M1FFNN7!O:E]7R,6DFU=L=->[<W61[@! D6)GBK?=P2DZ9/MBT+]ZU1=8/7TR
MZ#[;PDCKL]?GYR=Y2!V2>BN56)>R'AZZ#M\MS7> [GJANQ%4&$(/T7IUX5(I
M,*4!!+U.9GJ'^:E=+U<UR]7"MX80[E[3Y1N^#4OHU=H5R\,KUQ7)1V:Q.Z%N
MB[O+06]<FN2/)G<N)TUAC>[.GE<X>3[!OO(F)5AK#P)0.0CHA[:H:?_Z*OFD
M(DW,.H.E2NR2#<!B7M ERW ,IV&0#FNI\.[.#J]Y:LZ?;;FBN##F/%OV#]5F
MF%/PJN%?,#O5MX:\7(;,KT+R<'(GW19<MP&XNCO[/F-HX"@/!IW^+H6=D* J
M7O55RH;A @W2E)V= X*[5X/IJ1E,L['#ZMIF3[X2/ VP_9F/9G#6M_7:#E ]
M7]9'UM<<#KJ@_BOXN9XF55J$CQ9Q[,M!W6^A10VTZNR*FAIIG<OV<XB%JJQF
MR%B[P^_.OMOR_5* .LI1=]@HF.ZKM0R' $AHV3(V]5X^8QOJOJ$D@G[+^^9T
MD4+]C/&")'-5QIU?7O1:CN?&P^I!:74"!@ \N$<]Q YG0,ZU<8(WB!-:T >P
MF*S/6@!]GZ_OAFGRD6"=IYR _ZB:A^MZ>5Y!QW77NI.K-E;M_<SV?6K"J,#;
M1@?7!Y#LJ>?__J#&^5G/9**H6M>=G-EYVG)5A#KZD!!CJTKK0K?I^4[EU410
M>5]@CZNKVEH>^&0X3&#ORHG]?-Z:KDXJ.P_GW7)^D58!HJ]Y11Q4MJ_^@#CG
M<$X*,#'S;90$09VF53G<R)V<^V&-./*2+XQR#^Y"A=)IJ>YUX#SX[+)7WW6L
M!2;P[U9'O0NE,A_&<*TNZ4;5I;<&2PI%*V7BSTJ4.4KVF57A#YC[MEQ\6Z7)
M^-"XA^(.+-/HB8.S:_]52SU^"9GW[H>RKBEXN._3),]SW_&DXEM/<BKY2+^Y
M/(I"2T5%0-(Q@AB6$2D3 L*^D58K0P@SFR<(*5Y-@6M@+&#&L-&6$D>=5"(J
M+RWAMS'RJ+LF-TF$?9,W_'CG[%L0TKWR\>"5S?B56\?_EQ^RE;U_M9ZU.'ZY
M+*[@^S-R$S*@^=X%T)R<OU?K-.">;BFY].&X/K/:O_&3>W-X=]8^_7/CI6A<
MRX Q\O/KQXN:VA\,U_C,>;UJ,WYED.UC#P;#_<BDU4C@ZJAS7GG(R6I3!.2S
MU]S7Q\_\<GW<3?R__MW7$*>(9_M1"+C6:6S -E6=A )22][9J7&9,3J--,W_
M.IH<K"RS2],^/3^P39 ?5&-1ZQD+AC?Y7SG+WE-8IG'!>%IT(I"'=:=/W;%[
MIMJ^& *6RA[QZV7K'!7S50YCP)/>8$9=7&0T7<W[;][H$W;FUDKF]NSA)]5N
M1@Y5Q[KX;[4L>;"KA]XY% $M"DYTN,5[AV5;!O#^0$+Z. RJ2/]/->S?+VO)
M-C"C9;.^7OD[?X"=!PJ]TR1#_WT'B3NS<@24[O7^XINS]:E?7-3/-QV"P8BK
M!K\S2_8)%E3\[<S^&_[XP\]'$4?"<:0H*DL1XX0CA6-$AE"#?;".4''GGM2\
ME:EV3>]!3N,D9Y0^9[F]8M)Y+TRTD3&CE6Y(8V@(P< F:&"Y&UV7N]'3<O^1
MRWU\%$/2&YAY%+U40._6(,6:!G'.M*&.V[0V:;D5NW:YLYG[G!5GC#*K6,1*
M-8QCIJW$Q 6+DXAK1F5><=6NN)I6_(];\2</GA\)CALN D->XHB8=Q(9;R1R
MDE@9O9>Q(7?N<26O7_&/\5#\W_^O$?C;0BP )"DC2HJ# 1GYR>7$.+FQ6P&R
MG*)2^.MA<K+>IGV:HOXI'#U\?1\?*1,5X8*DC:I-VK<V()U,1M)47@C*#;$F
M;H:CV$1,HN2$\,"X5T8H9@GL\*31L+K"0) QX[EL#WX8K,'?BVGRD].6$[P5
MJ3![E>Z7TV-INGQ&X19BKYJ5G)\-$Z%]VX),L3M?O2EA$L!FYFGB<C"2XA#@
MS<_QQ#*$HE(J9JM6U[9$SUUIG*^AIJW(^- OWD2]]_F(73(A=H<2\4D$[B:2
MEF+F7"-(Y(Y%%97S+E"I+4FVEP?_IYN21YT83N;C\/7/[X\TQ<1(I9%R*9IA
MBB:WIS$*<4<TDR$%T/169B</<X:J(UA_O#@[[7_S2W"@2N=?EIC<&=S8X%T?
M!'OQ![W>#IGCWT)??U+8(N @_GPYSP5?(]*L_KRKFQ,/<[+JYJ3M,9-/VB$'
MVIK*PI32$2GG\AH?P$K7 _;:<\;6<YX5G/-4S//HI.WZ)X^1CUT/ )0B!P3Y
MN7(X9I;+>3G[ZC.$T<R7+6MQ&6@E1"Q\.B/#?I"&ECXL-/J#X0Q& NY"Q[2_
M]2MW9\_/@/6_=.LS\UH*UW:M.=LV^FWOF[G<?(L?&/2-VGP+XRJ12NA*6!>G
MY\OP*H6GD",>MYMJL[WWGWSWJ.\>M!KB0D=GWAGG\VIQ G6BM6E/GC)@$BH(
MR_;^-47WSTPBU";_\IED<=$.6J1'M]^Z'91&>SI?U[+CK@:Q=$^X=AXKT4X<
M3=RPUMVEO3*_J%?D\V-S5OF/7#VW'UR:/"D_:GN4SQQ;4/4<I+D7EM-P\6KA
M*^X#8"[+3")3#I]K/5SKM<9,\03'Y06XW>](X/*&!A:%YZ"#P>3!%5KN#%YI
M!;AM'M525A=*OUSUL,Z^:GEAU )D( ._* 0,T*AKZX>%HJB.O%NRG-+-WW^7
M!O6J$&#6='R=LLOTW-4Z5^UE6J!U)@ <3^D\<ZZO>W& I9BUWNM!O=W;T'OG
M8?/;A96@:YJ5*2@+'V9&.ES4?IF#@;7;H+UJGF<H36Y((<4;8%+,S)X CFXI
MU5O*G>%1Q+;;VA 7M6L7'''G2OHR[&O6+VT00)V\&ZOA3)^Q<<BQ.4G]HD+[
ME"T[NFLJ5PC*"B'&:M7R :6I_ZAT=G"F(5;7=.5,)@O<-N[W*]L 5B6)3I&K
M3[S5@.^TVYP]V>I(7J_BD4%C?1&@:1?]CNICH<&O'F;MNG_.R*.!3DS+68S(
M0+P.AGNA?EKT[%"='FP@3"Z*/JT,''F+9E4_T+)Y)Y5&!*T8=G.__HBMA@<-
MZ<\^(E"?09:\)ZOY_6)LY>9G?:/(C/OJ@)199X]S-C$M2V;Z67<LRJ?@$Q;-
M.N!XB:.6G.WI0+XC7)0/?4,I.Q@L^.*\:U.\K@>4X_T$!Y5]1X:^.'V(ORQ%
M1Y>E!V=>\NS[%4,X;HPY],;^F$W2-BO[Z MFZU!>(T]4QLN5]^Q7!L;T0W*\
MS\WQ(BW^KYT#V/VR\P)ONFRE\4G;AF3KR&SI))J995:;T]DU1FVGNA_MW;XG
M5=, 5_$5,NPRO_>'+%H90=?Q$.TC4<W#35V9]RPT9]FJV$8QSU!;KE<M&.(T
M&&B,4X"A ^+RS".8UB[G1'LGL_6>#RHV$QQ(V'$60'GYF84-<E"?"$\$KWC4
M>!<N*JZT*SQ&;='D4)6T'H8!VLKL9*:=4(&/FRKGRL2DBP$<>;ZV)SD-!AWL
MVI"J"DL=?#\98^4PZGO:-\@=P$5Z:$[KQ62G#NC8<J>WCRN]#A5;W@60-G_L
MIM\7$_-D?=7$7%GOS>+R?[=XTRL$5A6!FN:M3&<?Q[>?W("&Z;J ;S"BO,?+
M5E@4]%,O1U\5KII>#'9PV5A/YZLWWV6'&W[Z6V9Q#S\<2:*TU8PB1J)'S&*-
ME H$6>RUE@Y[BO5MS.*.ECKO05CE/=$+OQ4X_6IM7^>6<6WBHQS_=>4V?2M-
M,&H;J;X!>'1+_FY(:U3=J-P#[C+[E)E:8= [(6OQOE_Z,&%PV0W-%-1G>Q@Y
MH!@X7B[6YP?#9V5ZYESWE:T?M+<#ZN'",C!(K\"G78E 9E/J88NE:*-V81CT
MJH>J@(U*DHV=<F4R2Y>%V+7Y@\S <EW;24#4?[PP)QV]PI8Y:[V!0CD]7Y0)
M*-W>TDM!UF'U3;+W,0"+\UD!J8)CT24*E\FAGI]7#*P'MO1QYAH&^VT],J[)
MI*'E6*VAC>Z\9HQRJ-'WE!@&'(5XT92*1O#N 1X,1Y'HPKPO9\RY[ JH'_;%
MN:S[)".&/R539@M[X2"I,^"3K;#9V;,E% 1NNVYDN2OOO.GY9F"S]R1@(UK&
MP1.W,A3VY+Z?Y*,O!P?#Q-.P(6'=TF9$\S-.4W6P!3/(@;9N80^ #>]KA>>(
MKW;(Z'XPI//M:/$V6CD.N4LV"??:,K26>^<@5PN.ZJ$6N2-EVQ0QG+V=+Q?]
MY$%I[_D"\JI9RDM3Q,4@_?@ISK[2"+A?D;BN><5\8C$HE4V+ !%!;O_X+/.8
MO%ZT26!XAXN/;)HYS/J6/@SSK6CUA^OEHBK3'U.X>];UH8$__CH4\:/'WX]0
MADE6'2 -WZ7=OPIG5V"&[8;[?K%\L%C;B[@^:8E#GW:3\5N:LO DQM7?&(/X
M\-V39V^:PV</T_/>D,/7SX^B3':DH1QA(1K$G G(-EPA8;UH.*7:6'/GWMEB
M"QRQ+?6#$KZ %FEFJ]KQHX3X6!VTP,6/XA;WQ5:T87A;BFW>;93F=V>'?</:
M]<4<$JQMZ=^@R5/.MK64R&TE*D3EX)"5&G\XH?KH0V_VE%R5;BY*X274J]=Z
MG<L4>T-?AY)P:!\)3WH3+H<ODU78Z,&G4*)J0Y;<<@Z;C-B[4N%BX$;5.XGS
MD[8A17;1OE_4AK8/X)O#NJ_TY38Y]_V#OOZI-&3OZ-^'SIM/AO!RE3G=,X]*
M2XA6R=][_ZB,K7W!DA$O9UVYXT7;@0:^VDE!9_3[>9G7T]SE^KS-HH _69H0
M'Y1RTLO,K7;6TA#GW$FI?C]--B,[D!U#5BDGS?>_'#D/Z8U\CL W:HTO\MQ/
M?)F?B;ZC$_IN1([T*33=!OK.,]E$U;B@K6+!<V.<=<GTVX!=^FW\2]!WF8IV
M M\=?KA_>:1B$)Y2@7##)6+$1F0:Z1#%CG"B@VPHOH+=MIJ&&!7QV"<QH<F[
M=#AJFQ;>F,!N99JGW1?[=4A<W^C*06_?]*,]I0!D2^Z[ $>XV>+4 ^!""0U?
M&? O9U[,.%^NX%T/ZD]PB-)B-5J"BDKTN8'G:8>5+%9% UW" <@"B!J26894
MPNGB;<[R0+YFM1H3CZ[/($[)@TS>)= _)L/[R>LWKZH^$V1'>LJU99OIZ8YR
M\L%GWZNSH[+N4"-+R'(4/]<#R61ZJ6TSV7EEIB5@25_\KH*GCA>9RP-P4S<_
MV7SVJ@?#=.[)UD=7#V75=1L9LKV,>#*SUY+\D!IV'W0,WR.RT!J]MBZ&#^D:
M?]#].S<V*W7JY3 +T@?MT<%9%_Q6H($#R$Q_0-.'S>WMRLJN7,@EZ>84"J;S
M9OB;E1)_4NW>RQ"I-K70.8DM3'"^&B(_NVYP+=E@O:[+:52.LEPEWJ8M2A5'
MB_,XZ _X>J[ZBFSL]UH6E)ZI"C*2Z,2LSZ  O>.%+U7/'2W*5HJL^UO20F,X
MZ[!.NG 1ETV7^]]T>8UM;%JUD\W!.&L3_'Q$1[;Y]4XZ:L(5^&4A/6H@56O@
M:'9^G@6X:Q^<>T^#<]SVD%JL 2M9$D1%O_@VV!A11>8 :@U@O(JP \[E@]G;
MN;$Y^BJ*?'/)^]1\8;8M77:^-D?DOR&1M+RX_/=)FJ/[9Q[.Y,^G@HC:T9<>
M&6VB)Q)\,FR23]989)1QR-E(@B',,>MNHX_5KOO!+*]\WIW=VN^)U]6_XWGW
MCJ%]Q\SR>E%ZHEX,T"%#W+D/24%"[\U6?H=0[[NS!Q_[>*,'[0"7 6D1&"6"
M$7>8ZZ=PP+]L3_#Z]AT]A=LV3L.[LS])/QS/3_Q8.9B!<GB>^0M_ MWY# S7
MWUI-/'O#CG03)='&(Z6)1\QP@0R7&C&5HFL;G(DV;(9NSA*"J8Y>4)/B=:6P
MLU@I(GS$EG"ZJ58>=M4?'7WDVW)"4"K,QV1LPS/(SRW+K4DA$/"!Q&_(>Y?[
MV>H@??+E[OV_>D3=YJ'@*!5E,LGS5?BF_>%;/U\EZ;W\9GZ6!3Q?]&VF*TCA
M3!U*&EU-UVA]5W$*;MO%,OWGV]O79,[=[-']UX6_^IG0=T4CK_T8WVVN_>QC
MMR7J;J/HC6[[7WG(9=CI]6&)_OM.V@5=(LN#,_4-.7\_:\9+<1+BQ>:<E#7\
MHS6O^I1QP9_H&-73-'6;L,[+'_C*?V6R\DMGI)/J<K12-&OY^:=Y#.TL_:EC
MOF(^/S'F,KR-@.\&6QC.N0$7<N91?0?G0O+2O_W,A4[R_M>[%#D1_*]ULHMI
MI,5.IU@AQ2 E&W"#[?Q'O?Y7V><WG*!?H-2P/2=<Q+I3/N*C4*U\%(83[S43
MS"OO&0]8:2LI;IC?ZJ-LGCG[]1)LX(V#F]9_B>&6.BPO?OMQ]?+9^<GA#R_3
M\W].GWW_^L6'%_CQAQ_?/'GV:O[R]??S)S\\)R^>/;I\3'[&+]IK_O/C*WOJ
M3YZ</G^7QL(>/_AU_N*WQZ_3L^EANO^3'WX\/?SM$7N9Q_N(OGSP]/5_/CR\
M./P%O__I6?K[NTUGZ21=__/[EZ]?G;[\+;WSLZ>O7I[^.$]C88>__7KZ\MGS
M#X^?G<Q?_O#XU?!8^_"U8X?/7AQI%A2),B!N%$5,>()LP^"4FS4RF! ;AN_<
MHWS3@ZDN3\8[]PKS9* POT0KQ?R_WRV67T/N?FKYSR]K!-%2%6:8SI7 [G.4
MU!?.Q@XJJ8_I(R)#3%8/:R(;9AIM*8[I;^.5,:*A=-)'7U\?/;I>'Z7Y>?G;
MTS<O'[Q\??C@9_C^_/%INI8\GC]^?9+NZ]C+!Z"SGK_;T$<4:+\"40)(>Q%7
MWB&F0T0Z:(JLI5()9F6@*71AF^H(?6Q'N:AC$-*GZS$+@:OHL&*422F,DWQ[
M%#[MJ'W84<_N'SG/K7>&HMAH@E@@&%DF&A2IH=338*AI[MQK\,=C]+_2N_ZJ
M=NP)Y.S#0<ZQKZ'519^PZY"PDZO]22L&EDN%P(*QAE$#!U-4&)W<:Z.D)6'2
M.5]?YQQ^Q*O^->F7[T\?__"\>?GZ.7[R[.?+P]<_OCI\\..;PP<O3P_)(3U\
MYMX=DI\_7+5B/Q\QE;QJ9BW2+G+$'.5(B4 13<X,9K9IO!3)J_XL*X:C80 G
M4DI89BBS0@N;XC1E!<':NVE'[>^..C["2@CJ#0/XL4!,)E.F!=-(T:"MEE8U
M+.VHYDJ<]O6BL:^7(_HIF%5XM3CY _)#GW[U8H%VRH1O30%MANF%H3)-5/D5
M(&=&,Y1WR7_E;/\VZ.O7*#3]*:Q6(>35_=NSS3ZBCQ\<TS2N]X\_N*0Y'AX%
MSG6#38.L3I:&*<*1IDXBZ*0NHG162G7U! P,25H,%A4SDA@M TF&RA,2K;V=
M-:IE?^Q'[]XG9[,?39*YY>6L*1S5&4!D_"(#Y>_W9"._P/&P6?K5[/EYYIA]
MO+@+%PB$R>P?SQ;G21X5(_^<U4J ,DL'M1J@8FLZ:-Q)EK1501^U7% 9&8T6
M$0'Y2:UM+QU&@&OMI()OVE+U6BF1AI8_[SK=E6_G^OCC93 7+3-/V]&\%)C6
M%^S&/:286/C2XVL9+I:+EJ:[.\:_7X!(F<)[?5*+\_H6VVVK,!O2+LBM $L'
M]8UIKLV@PBID7H?2+JT;3>X9<M*V_JC-;-O"W;8XMF.T:/MU@]AUH+$1S]YB
MZ3/4H&.,&=3C#0AEQJ/ XZ6\6Y=R/S;^B&$R<X0,FVWFZ2RT2G4_99H,*&;.
MN)"G-]ZI&QB1B@;.V+%TN_RL+$TC]KZZ+\;$9>7>79O&CHVCW^^#3C.9VF[<
M:ZWNHHJ(V>A?-Z9' 4QJ(<19E4Z$%P$B\V77C:WM2GA1.:I6"ZB;N>S:O(T(
MZL)[@,FM*H/<XF-3"(#@X4#:)FSC=S^H_Y[G"O ,D2C-1N<92NB3AG%M[\D>
M1O-DK"^Z-C MUACJF4[7IYOS/*9SRU#L,;RG$!YN68X_L';N*TO*D*RIBD-N
MTWY6_C$H-ZM5;/5+?8/20M19*N0V+H)K6E'L5V<H5+TXY=Y.+7M,ME25A6M,
M*'BM(=DP(4/#T:];J4BNUJ+E6?\3P<]?<W&O@_9\PFN[=Q^8*?L6HE=L<5V6
MVNT0M&N*E))#/=]@OL]KV$.:VF+(VJ_V GY=:11=83I(\FT7R^7B76[>F.^0
MBQ;;4L:>/"/#AX&^-ZNJ93@);PW@HT>:=D _U//;7J^E1[2FO;2W^^KR:V-]
M_P5>3-JMWRU.;2U36/U]V\"_?L&.#,>4!FR14A8JKIA%.BJ!H(F&P9%&'=1M
M#$+NN^1)EWK.?2FAVC TMNYE$,-N,P_<=-//P%9ZQ-8;ZK5+%WT4*MMJ%US;
MFK>O9GCT[[:$(*D0X!6I;0U'CMUJM<X]@Z_4>LV78R*[CAAN..*L3FY W%62
M)_>30];65L7-(J+6\QBR&9;2I(U7;'V9ML4MU$&!AW9-<=,V+O)^#M?9-<Q=
M>(>5W7WE4H9+PR051S('3J8&35W)=5O2E9V^4?7'< IA73=>Y;KE %M>?=LA
M56!U?O]1&L1WQKVE";JR-/\L3D&Q D.J82!7"!>%P:6;O9XIL.MXOEH ;+PM
MH-^^E[<T"[YLR5O;YH+[(=E7R*2W[<Y-0E4?8G;I6R: ;9-80]:;Z8/<!&"P
M5O/5!K,B>*EGHQL-=A[4W.6:1>#2/H"BQ78'C.6J"\:/:R YD-6V@JF++G+G
M[>2D "7I:66N?VO27DWB->AE;4X.1H54A;"BI25(*Y;$;@$T[;VR2V,:.<9=
M[+FYU8M/?5;><_CI01I=$I"SBWZXP"#B6@JCJUKRND?D :_6=I64![QD-^#!
MG9>AXRS)(6<)SK:UW=Y6GYGV0:[M*$6E\[*. WK06FZ7XH&)@^$S.1C8Q,$P
MC(T^R:FPD0$WS"BCJ:-4,D8543BZ)L530@DLG#%_.@?##U5+W3_SCZ#&YWB>
M0IS[6:G]W<\X,BO#AR-N8Z2:-,@V#4&LX1BIR'D*&:AI@O8"<WD;8X1VY;/Z
M[==^5A9_/[)3W3LN0\V:EN1G[RW7-.? "F<?( ;PL'KO>:NW^QF.9\X^;'-1
M[@ZG?I#HK.[I(&KH>X+>-( H0.#,7#1@0.R]Z8^[PVV$U'(?W= WWO9" V;#
M;6[!N U2.:* W9,=O("@S W.0"[F)UWY]4DH#ECRRFQZS4KWUTY$[U^W#PLQ
M^665Z;AZDFUGD]Y1*VGBS<'7]HSM<$;%=W=G/XPOWACTU;O!RUZ$+H4]:'AC
MSI(E2;[9 ;Q5;NP2E\4C G\M!5QOBU.S'-*1CX@4>ZKN0MS]B18Q=:K:496A
MY)+2O9#]'%8,O.1<\+MV(/AI_4XNVWT4_-5<0*8=6[6YP:L4!9#2KPQO!YM;
M;C"E'A+<?C;:$H,ZX8&"&<MWV%[I.3@TK$MXOIB7%#ET+]LF>7GS;MFXY3!E
MVS"V/QL(1=*OE_-,-%?2#EN/.DHJI)QK <_,U7V>)Q5J$\I>_L@&OK9-3Y^W
M!^4$&]IVO8L@1?N[TO$[99S_;.:M;CF>+!_,5RGN,"=/XD^+LV.HZ?:3_]?F
MB(\OCV@3H^+$HB@Q1XP9BK2E 4FA(T_S;"VVFVX]D:;1VGI.8F#)=U2:&!%9
M$T4TE'&VZ2_VZP$['-8!Y87HG+&_45OE3\[=O3P_59OF^1EF9\\_2OJ0*8\^
M:J$//JF\H+7;=0HLS&NCG)Q<R*9DF4_(Z[] 7]U$R749EVL4W.R75YFMIF0T
M;#E#Z^EJ1MT9<CH5?(Z*1:EW*50UMMA!L^RZAO3Z_ZREF!Z0)+?\XF,BHI*W
M[9U".%GMG;&2$1V]:.WG-OI.3K'!#YDZ/A.)7?=A;B374Z!5E[$Z, <9H;#A
MXF_M]K;UUMD6 FGT5I]_?.!?4H*#_0'TV5_[F.^[Q>GIO*3+4U3_79MM=/,)
MMK@)6W1'T42L,\FBL2FZ=XPC$P'8G%2.-RFX(/&F#8__^@9]'W4A?LV-:ZLV
MZ';!1<Z6]M'NTRRY(!E9>,VL/22>#4Z)]R,@> 3G+V=GH:3W"Y=B120-@MC5
MD/!WV#KS//VJXW,;)0QRL+4:YO5SXKY$QZ/D?6V\FJF%NL#D8&N( 4TQ@ $>
M%41"GQ0O<6#MV9//QZX]4%AN+N[60Y(<*JY&B8VS:T+[AX"8^-^U61;<9+(]
M.9];^1=;;D7PSQ<V;8)!KZ<ZU(S4R!B0TCZV_J,D(49'H_"[+GJO^?Z:K[@^
MYS]*^4.^(!^IY-;.G;%MDQ%72)DK(7]859JV;*=:QKM]$8'KIG^<UFK!?UMW
MU3"_!1S=0^._/B_TUI!GZD]WNY.MDGMK_8;Y:3XS75;^PXX[KPA-1Y?5R4Q_
MDG4PS('41%*&Y";96(?-)$GKQF1$T JXT?L3Z9Z%,QG\T_.3Q67)U@TQ9UW$
MV;W/)Y)NX&?EWN"#4ZV25+M;\=%79JB0#^;^:F;<8:UK6+'(+8T+JAB053T7
M?.Y(?#D[3IOWK'O0_=*-H[T"-)J?QQAJ[JX[BO^JS;N^7RS3_CS[+I-#)L]D
MT%4O^2[YGR=#H-+?UW6!TXB?Z1'W2C'A(E)-P(AY:I$V@2,1=+ D&&G=E>CR
M-B0\ZD:8M3MA-EC[@Q&&XH>NH>U/M9,V_/P_P1^#K'Y7(<M[<H !391S?P6
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M= >IC?-@JIL#CJ=>,_LKY WC3>06$VDM:PQ33'+%K$R!-K!=QXE)\[8)^?$
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MQO &"4U,X-9CS\ EIY.YWE]!5E0"F@PG'>X8ML$0$P&^+XBUG <V"?)."O(
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M'13VC'*3+#7W$ZWF;1/R,<J>-,G[9APCS:%99TRBKH3'B$8?E,7)6X?.VN1
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M<&!LP-+3I&I]YA(]M-@"\= $XNFM",*314304 TMH*!XCF$:VFB5L468+;M
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MP= B#$AQ:-NZL'7A[?X;(N5(K)Y'8"-. )2Y-VBI0;_+F(>M"T?1A?-Y3)_
M29HO;$,,)G5U^5 )$G-9K3Z:QQ$U-\U;%[8NO+7'1QZ^8=8;R()8+1%7Z-+0
M P9%,]RZ\)!TX7R\4SDUU)%':J$E <\CS(+HE- :TIN7SJ0[C]BZ\%9=@&[
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M+9!4=3'NF%JZNDYO>6FX0;X4D+OA])R*"XMB,G,-Q^A1F7:3./@N-LT-\GL
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M8JJC!=;576JD&;1,\_@:*+;"3+"JD=[=0;M)/BS). =&K.S'K_.,S&VT..-
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M6]XW'\@CT3S>>U>FLWF)L/'>Z$?<P;?X>K][/%YO1JM$,7IO +UK%5:)I$[
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M 2BC-]DXT,ZZ9*OJN!T";E>*4%M2D)"EK<[$-JA,@E)PPDNV38NO 6W'[7W
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M5NG"&@?*MWW@[IQ[#R"M R O!*BE!9!B)%,M.!L9TR4[;2Y[&-/!>]W@77I
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MMV:'L>OCMS45@APT&_WOI+Q%'K?E ?>B#N3LZ%2H%WZ\3IZKU12#H6IK62T
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M\(CWDN6J*0!CPQ; S4F%.>.]8JD^:'J<Q>1S,8X^D(JL!Y7#4)TZW3BP\">
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MJ^3>WX99MN#?T/K^:M*U[5$'5,=/-&'\Y[SH"V:8U$$&;P@W2CHO11#Y4/1
MI73VZV9>6L $$S1=8Y@7[07:L"#HN_GW77C?'^V>__9(A?K+/P?8=_[NVL]F
M! +Z X3PQ_:A_]$\_>-@;_<]^W+XC>]\?MO>>?>>;)^" '_^TFZ>[A__<_H&
MWOGIJTB)6DT8,M2"TT0MN$\Q$,0QR"B/6'!MUAH15/\(!G;8'T6879C*B?AU
M;'^_U:V$:"']^G T&+;22?U1JYL+D[VD=%U41O.>89=6Z=<'$5"QW>X=@V W
M*K%L#$8=Z $\9- 8PM>^;0>#5@*)KH"YEQJ]4;]A)X*# %31 $1G\2BT1JM;
M7?FZUZW4*%/3QA^V;;L^-CX>Q#@<O&R<*7"E">?'<*RIN<K<S*@N%)WS,(RQ
M#R,X;O\8!&I5AI%LVZ-!?#GYY??0&ARU[<G+5K<:C^JF1:6%M_Q^W K#@VR>
MUG%MHL8Y^>/GC[]>K[Y: *#Z.ZG6B>*7?HW7R0V_8_IF3_U98PE?)_@N&BO8
MY2^]56/UE1[[B]T4"YC^,.Q1+^BJNMCI!(6"I[9!"P?G7(J?=.W2G5Q7&H5:
MN59I'#:CCQT7^PU&7C2RF2MC,1D+8N;&XJ8[B2YE08L4:*6=K==V<%"5^O3Y
ME_A_H]9W,%/=X9T<TGGC(7U>CNQS\E.)Y%0&I7U4GCL;G<QY(X%CKYC$5I4:
M2Q<[H\=[ATWQI?/I>)N^Q_ LO UOV/G\YJ2YN?%CY_-[^@4^VSO<.-Y^O>B,
M_@'M:\/S-MB7S?<_=C;!>>WLB;W=K>/FYAOQ9?-+>V?S SBY&QBX_M@1K0\V
M"RQ8J1WBP@/E3]$AE\F_2B)8+[7B"D@^(4M.67\J ;P":\\'UI@5425&G 8W
MA/I@A$TT$D,-=8'(6,)O*XQX)V>(I[BTG B).$Q>7B..R$JJD.782<V%49SD
M]$9Z^[WQ]X5Y2ZIMO]((]?&@UQ\B\$(ZC8[M?XOCD$>I7W\OV"=)\II:IY+Q
M/%IG->8F>.\=3M9Y7U*[5Q7[MF;97DA8$U>=3)T\XE8FI*.7R"0;HU4D!X#S
ML9><K%)=D*+-2];FP*+0H,7)$<X==1HSRJB3CN4*;BH4)K/"VCQE,D(90&3'
MD=#2 IU1&IE@*5)2X)0/)#;6@S;3%XJNDCHOJ<S/2K.5/WO=_663E7+0V!7A
M304FB*8N!6\XN&@F@#T+N>!W2%*K4N/[83&L.<M("'/.1^&0<A9<,AZ C#@F
MD-$R":(T#D&MO1*X'/'YA!66:N\BR;7=K>;<:G N5#38:.&9-<H7/K+"NCS#
M1XBU27B%I#,"=!D'T&7KD61*>4$MQC16WH76*Z3-S^U@P*L6'OQ59+QDL"Y[
M')X,GI=" (\5S]_/<K.(E9,N"42)UX@;J9&-V"/G@;-ISTSDZF:% !X\&W5)
M(:6"A04+2]+^T\7"&6Y+F1):,R2M=XA[+) #V0"WU9&$DP_PQPUS]A\<#*^0
MFI__SF+=ZHZJ;.BYE.6Q:G"ZKC+Y/>H-6OF:E_W8AHN_QVE"\7_/YXN/^XRG
MMU@'W1L-+[_EHNSGA\@?5W@^@WOVYT%_RJ'W(W+]:+\AFZ"Q+VW[V)X,UGZ;
M3_EN=='"&"YVO^[DJ_]Q?;CULM3QQ5E?6_9=]<\%4:BAA#A%/?9!@^_'=8P.
M8"]%QCB-$GQ"_V@W"FQXWQ_%T&AE88N#8:,??6Q]KP*Z\8=OCP)\F?J]3@.D
M^:#:.)!LJ]_X;MNC\8'KD_(I8!C@?I<+J.3=!/G2*^PF.+:#QG^M%OG>&H_%
MA[.A>#WJ]V&J'KV%N<4.FN.=W6^DN?N&-D\W3L&R? V$\A Y05IR@;A5!$R&
M #8='//81,:%7GMUOL3+)->]$I[KS/P]4(TR\[^<^=W]KS*:Y"3C*)+ ,UFP
MR$3M4(R,6F(M"$5:>\743Z:^0HA)DGO-'R99_Y5<Y)E\ 5@T.(H^V]CVR8OJ
M<X 6 *C,&#)D-?[JQR,+="%_!? 4^PU?SQ>\81"'\)9?[E5:;^S"?;%QG']T
M>XUCP*6(>BE53;0_@<< $)8W5P'.G43;'S1B-S?K%[U:G[<Y=[LI<*O['1K=
MR<GQK\?;O6+XXP2&8YCG9&3;33O,2'RR"4-3-@GN^J_@^QMFL48JY8QA;DW-
MA+6P6@6MA=/JBIL$^?I9L'053/TO]@1><?>?.ZFD="P^C<Y8?FZZY4]=R(_*
MGK^RY^_F>_ZNL1GLTDO-D]@WMK"'KNR9O()H7"<>L=K"<%;8LJ8BN;SE53)S
MKM+_9S6.;[/#^W=V>,LNS+-!^=P:'N1* -V:_9:]EV63TG-8>AW[2_!7K0 [
MW;@'XC]70_C1!POJA8BC]O:[)MSW]G!G\Q/;.]W'.^_V\-ZA%]N;__GVY?/?
M[2^?FWC[=(LT6PL+$9U/>.^T^:/YN<FW=P/<_YY_.?S0RNUM=CZT\[U[I^]9
M\_#3R4(*OQ*&LZ0#,DP(Q+5ER K,4))*>J9-E"0G_;X0=,EE+A]^,;:@84'#
MIX&&F3!5?*D@X761<+HD:S2SS+. &*/51LZ$G T&66,#=R8PP5.-A/RQ(.%S
MV,BYD1="SVAQ8W@ '=H_:*36]W&8N.SD7$U(O!GN5=,-L+=;S_-;F.:,@(-"
M"&\.@_,[*"PABJ>(),,6\2@2LEI$A F6B1-NN'5KK[B^]5D294=GT>I?:74A
M-C?6Z"FQB9R%J+E%,;&(N+4&:1,HTH(3^#=(81EHM+EU<=BRJ?,&S.661*5L
M"KLG2-MOM</U\*QPDR4@V=P. J\U,Q%'Y(*BB%/FD-,\(B%XL%A1%D*N-U$V
M=Q8]O@L]+FSDQCH\92-2.R&2PPAK'Q#H;4"&IX2"]3@IG;R5?L5TN&SI7/+^
MILON*QN?[F^ BD$HYYFNB'WX-,OQ!#8F*:J1,"GD*D0"V0!$+TJE,(W&4H+K
M7:*WKB&[=*6ZI_C5C3*&"O86['T*V/O$=Z/>(^9..3G()N,R8B1(CA 20Y'E
M"2.O%<Q>%)('=K.=^:N+N0]^@-1'?Q##J!UWTF[L'/7ZMG^RU3D"%S-O'\F'
M3<;!S':2LE=D<_\KDX0*@RTBD1#$C8W(V)!0C$)%+7Q2*CR/ Z6N?G24S0 ^
M.<.TT0:Y:IQMCW[2IT9Q^!*+1[(I0ZUK<K4]&:6MI:VEK==L*[T:#CR&_3K\
M2AS^8E;VC#9F_1G!T.T>P'L);33A\H.KK*\^U=$X&X-&K]]X!VP VO>,A^-\
M@/LQ:'[9J;>T07K7!QY<5:3Y=,:-JS]KOZOLVKO!F+X!#ZJ3"SY4 WG)'KXB
M@T4&[U4&:R)4!+$(XNJ!X2](QR12TNUUX\_'K5SYU*\LHE*N+*)2KBRB4JXL
MHE*N7.4KBZB4*XNHE"N+J)0K5U%45KP>W(T*3Q+S -'-9=3]+*\LK[R*SCZ%
M#=^O>_V<YSD\EZ?W@,4<+\_ ?<HI_3<:@]7.VO_7-=+V?72$<Q%I\IY[I8TV
MW#NJI!6<\" N/]EA/H5Y81_40J9^KGK?ZHYZH\%T72DO*?TU3C_-*3HY0X?0
M.C=EP_M19]3.JR;YLK6GD=#?(_ >>/>;T^UW6S^:I_OP+FCG;OMP9Q?:O/O'
M-_B]O?/YP[>=<\=+?8(^->']3;QW^.9T9_-#IWG8%#N?FV+[=(\TW[V'WS^)
M+^_>\W].WY _=R>5'3>^:NV\31(CQ9A#W!J*'$\,Y2-TF+8\L&JG_+EL_G,9
M(TM5H<=1T;% XA.!Q'M!Q"MO9%HN6!9TO#8ZOC]#1QJL5?DHZ1@HH"-+'!DF
M"0K866&%)E1G='RAY:WW.Q68+#!98'(>)D]COQ?LX&"Y"#E!QIW^G[WN?NP7
M.GE;P-P[ TSNK5=8,I2\QHA3XI%Q\!OEB@O.J,=<YDT'FA+Z>X', ID%,E?+
MUUX$QX*&UT;#_3,T3-1IX7%"+.5*X50Z9%3"2*1 N"'@9R>S]FK)5<(+#A8<
M7#D<7+V@X\7P5[C@;='OS7%5*^0C/OY*K:>!&P-DT!J /QN0#E$C%JQFFG'X
MCI?88D&^)XU\CRFV>#$F%A"\/@B>G(%@DB1%('R(AN 19UHBHX5%&":;.1>-
M#-6Y65K=NJSZ?:+A%:HB/<YZ.I]CXR"V0\,VAGGS=SYK_%(5'B_,GRREV!E>
MAJ["X+O8WTF3OZ<,!C]2Y;UY*:A/;'OC*S>>*B<#$L)AQ&,T2#NID4E*8F*=
M5":MO5+BG.Y5Y\)?=^:M!<*CE)<, [UATC@J@M2"^X2E3?9B!"\SO^R9Y\WW
M7QVW6"@C4:[V#L +/V &/"(6_' F.&,$9I[A"Z9^4O=JT#@^:/F#QG'LQU^4
MR&K808:*2;9=C=R3LYXK6<HS_Z+1CX.C"*_Y'MLGZXV-_?U^W,_>1F,_;ZY=
M?'PNX-6]J'Z7ORQ#J&YKMS?,!\ # MKVB^KMUL,M&?7;)R\N%^OSG"1HKGP(
M(+PN<6Z!DA!* ,EBM+FJ'<GUZX@9UZ\[+]I;VV_GV F@LL\,Y1@:,XC=1<'?
M&1[$?EZ]O*32W<\5XQE+_)OCG=UO!,@-;9YNX.;AQE<C/;!&QA"V(B&.DT"9
M4")B+",>S) *^%KL]$:5#(LD/+PD1&4IXY0AQHE$7'.#G' "D12X"SBJH $(
MN[US.'@>&%MG<S &FG[TO?UNA5<PMPV8M/J(FD8$*A=^!8?KC:JD0.,,\_9M
M"T W?[T__\5/P?"7$'BCMLW7/,Q#X>O8N:T')]/;2K:<80H4@&FK#$^:66FI
M9LEBJX4G*GPEE*^]NK1V8I7[RC+CG1!SE#WXEY2O*_%KLHSNB2V?RRZOV+(X
M&Z:'X.KUU)W_>3]MNGA$[K@8["8\];O-_&&K.QCV1Y4N;G3#_\8 PK2_D:E%
M7?2X-?"@-:/^ZA2#/7P_P4+2_/SWX1[=8LW#O]O;A_O@5F_QO</P#=XEONSN
M\2^[GX[W#C_ DQ>Q\-./+Y^W#_<._<GVYT\47/%6\_"@M4W?TSUPW[</#]K@
MRK>VWVUW_CEM C9^^^H]U\0KA4 YP0./P/XU-@9Y;(F-UN#H=6WK0+ECV,CV
MB<8(KKD"3\XG;EVRVB>=M(Y4"E!RNE@\=O/-AZV_-W:W_G[3>+NUO;']>FOC
MS\;6]L?=#Y^:;[9W/YYSCN? 90%;ZFGZ=1/FFVPU37!E=)([[D0P*2C/-(F>
M.H\%0/PM//(:BQ[()=\9]1N]H]BW-2<'(@YX#A=T801&W6$_8W[\ 4P\-D8#
M<-L!]_O?XK#1;PV^ 2\?]'RKHMC'K>'!]-91OQ^[_@3N]$ S]L&693J=VB,_
M'(W?Y.+P.,9N93H^K7]<;X1<G+9?V8COMM_JP>L6G@=M>=$XZK=R_=WV277G
MFU&_M][8S<WJ6GC/\* UJ-KV BP5?'C2. #EC0T+SD2_FG]P)'+=W@N:>E1I
M=#:,U1I%[FQO-!P,H46Y_&^GUXU#X$JYUW%86])VR[I6N[:,-AO'=CO_FQ_N
M[2 _Y*C?"]#K1C:FX((,\I,N'R;XYMCV0RX0V#NJFIOE,%.$P7ICJ]O8CUV8
M*G [<M]G9V*FS?#5($[O:[2R\Y2@R0UWDGV;["7UZBY-*<&4 ^0G5V,&#^N#
M8-7T!%Z?BR'[?@RM2R;_@O<&P%.8XOS>JG^5?+5RF: X&%;OO5A2!F._"MJ6
MG;I1>_BBDHG<PN\1Z 9HP'KC5X63L_[Q]2N8^8?5P,_C\:[$<B*%>2*OHTV9
MA/G8']I<>/ 7@CH\L##X_<SMNKU.JUM-8?; @==U41IUJQD'9C=Y<3WWX<PZ
MPL5GYC&KV6A0M;?N1:6!9]VP8[88X@"Z4KT)9K6Z\J))GA$3$*<6J&DNVO0]
M%VVJ'I4I<3_4S:V\&/C%]SJQ\2]X8^P.XK]?-*#S+[(@Y^%\#6.3MSU5+_XX
MA'_J1@,(;%4W%BE:E*)+L>N^Q69>9*!)8%_:O>.Q\%2R<V"_9QB<'!0W$T^^
MD"(:PP*8<::-)%PG:93EC& J+7AKB:H+*>*B6QU&_4[.XKF</'Z('5!#P-?Q
M$78GY-F1PS=B>W/_*SC!VGOF412<(RYL1)HHA[3%- !?],+G-6J]2. :G;,R
MN2!X8'H^@<$"X0 O=)C-EJUD(/\VL3:5-/S?R/;!M-3, +S;?&Q@10,R#@[&
MJ-.(*=4QPF[^K#;(_;@/"#2H0HT@P2>#UMC>S80,:UN9FU2;2I#\C9W76Q-8
M:L-+6JE5J00(];SJ'!^,B<XT0GF1C6W8JFT-<*2S^(S;T+&'O2Q%6;K/&>QY
MNS]YZ(P.SSV_'S,+JM6V;OSP4E<=NI4QU8^?[A9Z>;Z/P '@L2N@?S/.VSL8
MKQS1^G#6=%]!W=M^KS.3C@)#L=NK#<*D9N!.RO"\V]O-XY=B__GI\-;I]J'_
M:K2FCM"$1([O<Y\C_<8X1)S6Q&+))>>S)T4NZ/#Z$S&O%?D],T$UA@PFOL2,
MB9O2WZN'Q>K2 9/@F*Y4#VA->Q3&U!K4:AOH>_5^4+KOK?P%D.JQWY81\2PT
M<07F\SH_YRWTX\G,3B8_-F2B63,0V\F^:S46E].?Z53->GG5PG3^Y;_N_@0N
M?:WDDHF,;8][N5%U\BP:;YX?0-'M3?\U>ACK;#*L$PYQ'A/*!U0C,#!..B62
MB'KM%5T_GPG<<'6%]DKSKC/=-UN)+M-]Z^G>??_5 W6T/A]5;#1!'%N8[J@H
M8BQP+!EC7,D\W>8GTWTYZ;EX*?DJJQ5CQ!O#$J?U^L+9(4\53X.G34]4^N_Y
MF.$XHPA/;[$. 'PTO/R6BXY_>@CT561A@&9^'O2GA4OV(W) I[^ABIF_M.UC
M>S)8^VW>[H#161C#Q>[7G7Q5U72^U'XM)ERM+?NNGP27?QDL7@@N<^Y8\$Q8
M3QAG.7$W>6U"8)%+0;&^-+C\&"SS0:L-#EB[?3E1LOE\M2JXG!VD?&\5>:U#
MEA>'L"JOKG+^CT!1L^R'69MOQRN<SE:.W+T=(7BA"[+5/6-?.^EMJVN[OF7;
MDTRBL]/LG_%"$FV"&2?,2J(H0<EQC;@@ IEH,#)@62.A(5IK%A5')Z6YL<&H
MF+B@Q'EO51(N2L($Y6IQ(>D7Q_EE^9MW$RNYFX8@*_9\23RK=0'M_L.V8;9C
MX^-!!"%^V;C!0M4ON_CD3@QD;%V:QW)B(!7K6)I'TEBQSM5C.2Z.DG4MV"-I
M+ RL7NK9=LNH T?)8B&X,2P\\D,]%FHN4GR3(\26,<#F>H7V'L7@;F2ZU9CR
MF+L_=^8ICN*?8Z9Z<NE(EI/NGM5!1*_G6.4C.,OIIU)VGR&(JXWO^:.=[K01
M%V]&7,@D*#KPR'5@]88PBWD5BKKV*68K7FW[BMM]9ZSIA0E%+TOY[2?ZROLN
M3#UCXN;W#9AU>A9'F6P2(/HAPJLU(OQZ=?/*5NG:U1:>:H7PO_KQR()$YN!?
M+Z<2U:M$]1@/ZS_JN/1#E Q_!B4JGF8%"H*-Y#:JI*S@)DGK2$I$8RE%DL;9
M2Y($KERV<6(;*Q_^;%VAV@16?;15I93 N&[WAA]'[C#ZX6ZOF;/$^MMQF--(
M-OK]C!TYH+TZ=2ENN!XQKDO!]^BG'\W=]N%>Y_UI\UW>&+A%]@Z_G6Q__L_A
M]B;\OON?@[W/S9/MCXMU*0X.O^R^^;'S>;OU9;-YG#<&[AW^#6V'>SI-#&TX
M:';>'NR=;I%_3M\/MU_GLF1OALV-KXD)97P@R#L9$0\\(6T<0]X00YE47F*R
M[#J-*U2$YZF:A9VI*;#>]T<QU'_,K$L6>_#<[<%U:K$QEUCRR@22+#<^ DBX
M*#4AFOC 6;C<(%P&_6>!QWGX/_NXF("[- $[4Q.@@P$SGRA2RN<L)::0DYXC
MXRDS7D6LE%E[10B[?7VVI14<NHY[E:K_BGMU*_=J81!O9$=O.1$/;$?;/9AY
M )_.K9VJJXXEO=Y87FA05\_J7,/H2 (=Q\8S[#R7W#@JI8W&84>3YN(G1J=X
M(:MN@C[->B$B[W%722++J$5<18,L3@3%)' ,X*+0Y)?FA5P,0W?JA13T7$#/
MGH/6U1LY"X3>*7&/P=J  \'<8!Z#LU$I' D%4#6:&E^(^^-"S1GB3I(.F B!
M<,J'$D4&G-UAB9PV)$^O"QQ04]V"MB\1*E=E520S])7A[+M59='PBZ7"U5H5
MN=-G_ ROYZO:_GJ)_)& ^76",-8320)5T5ON7'#>4"UP,CPH8$8E*O^(D7UO
M+BJ/'6<!&Y1T$H@+$9#FTB/)O:#**:<COJ/3DZZ4>O+80O8%LQXP<GQCT"H$
M=!5A:H: ,LU3I$DCQJ5$/!&#3" ,"4-M"D1HG?*IF/1\0?N;GNQQ=^ATWV'E
MA\Y)NZS0U57RTNXEP/'0SUA:2N>J=_1A!FM5_,'GM8SS3-,A'C9+[CI,\1&2
MP>L<;*2P-"1X8YWC01I+M1/)$$Y3$"'(ZW/!XJK>/P?<GW55.<<IRR[2S 7$
M(P<.&'5 07"&/?54^KF:6R5W;-7!LJY5.DX;:]QQQM@3Q\;K.,J:NJB]DLEZ
MSKF- (TN4BXYP11Z7ASE1P:2,XZR=%0Y;*L#, $DI;+(RN004=X;*:*S58I5
M2;!Z1"LUESG0JY5D=:?/N,+J^E.+?%YG#X5V*B4/X T8KETTU <O+6;!&$\\
M*63W,>#XMUFRZQ)C!!.",$X<<1H9LOE,06.#B^#'**;U,LCN=97G$>8O%6!Z
M.*:Y?&0J3/,A$6J&:1HE:$B<(.4L05Q)BQS6#CD',PU^.2%!W(YIWA<VW7>
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M0,)](LD*,&A PIDJI;$+T!>@?\Q ?ZT<M*4C??%?'A;QIZ6QA;92:QJ1$CP
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M114YAP :_VKW!H-_-_K1]_:[<'-HP(<;.Z^W2F')4ECRZG';&P6LY@.XV9+
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MOA,.5 CKP*G;6% 1[T85\8L&(T_'P"/=\(-N<3XP&3,_.218E*C)FEH$$Z4
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MZ\I+3XS?=(O8QT[[$!7/)[]QO8RE%K2__&E;A;O\Y2@6915?8JPU.H SA&Z
MZSS\CG=PP\U^[;WUH^'.>0=S0VN_:!.$;QSW"3[#B&S4K?UR4D)E55G\6712
M#=V7:_D>)JI]QPG?C]-_>)N"R,6T+J_<\X;OWSZP>68]419Y;A+BW@MDB#2(
M,Z%5T-8)''.7RWS^?]SEDM%H<ES<*SKL\F:/7/()(G5C:A4U(6507%H8D(7.
M::[OC>V8FD7!2+-P>PJ;T)FFYAQ+7G&0X(M#@W:G/RPH:?YHAD&1&1BE.(<R
MVHMGMEM&JQ,KLE$;J_F4:<DX-I-' #N0OV%L!\ORE5 &W=D4Y$],..9K9X/N
M60?,WC.$O2_Y\+ZP48#@?W4[M?=9O6I3/=^S]_2+\Q/!#),ZR. -X49)YZ4(
M@FF?M5HZ6YZ?@$Z3\OR$,G+=2?/F)*L :RJ6-+6B/?C*/UL=?_+J5/F$[^Y]
MI?6M3ZQ^7"?U+7\0F#=2:(.B) $4&"(1ZP5#V$:!:0J&*K$&GI6W9[ERICN(
MS[A.I6B"Z[1:G?-ADW!I#*8]C]K,4:0O@HZB&#5'2H5!&V:3<Z0.OWUHMJ(M
M$6,VE0@H,%^,?27=5SN"C[J<$A_U,A?)AG];B/6[%S6R7@,Q-^O#@IAQKW*1
M83C,85T9X.5?)S>3ZRN+Y0/:97<S /CY?BZP67 T/[6X-[\#GV'MFH2MOED'
M<OE-X\JW@M<$'G7+GO7BF]$/?X!;>]:R%V^:[>*!%1^ZRF "7S0I$-O 99'8
MD&QK>/WARQO%2U?86,K7I-Z03%[[,MX@=WQ-L.N_]%>?_-5B"=M@BCW 8IGF
M#[-8=:/+_H8F[18C7W_[5C/WU@6D7F5)Y>.05^DK(*46<E?M0[A=VVYGOV@K
M^IC3*C5&9GB&;KB)3\IA=K.;_0>$F</ZH]XZ^/MV .%@#'.D]?<3E=MP*JVV
M<&3'YR;4>C>YX5>V<<3<1H>NY8J\=DN>%?=LR=XX[,5XD!%7=]['.:K!%\;%
M>.O[?S%4BQQ[XDF0CB3#(Z?.& @PA.?$$&*U61C@W9.2;"H2[(U"P<^EV#_[
M^N$1?^+NUO9E_5O]O'Z9X[I]7,\<B+#6QO$)_;[W];)QN4/VCS=IX]T<?R*O
M[]5_PC4O&UO^HG'\"=;5:NX?UV$=WUL-N(?Z\=_-^M8^_L_ESO28AI^-R\T#
MIF22TB@D'5:(2Z:1#5XB$F-(U*? B /DY>M*S?>NWHVI]\'9$2OTJ]#O@8AF
M#6;>4,D$MQQ;K4FPVFJFJ XXX9C1CY@A^A%3H=^*H5_CW13Z'>\?>&5X9M9$
M4L9<?F(<,DPYY(2UT@43@@B ?G0=7GHNZ/<:IAHV<NE_F7O_1ZX'_>=<8JS,
MZ3T%@_E+1OY%M[C:X'Z;.8U+\&USVS[\=!LL!UDN:\P_OJ3)$X^#Z/4Y?S81
M;G2@N:,I9(I=QY'ACB)*#3RNJ"/6;.TMHVPUABQ6F/0*,>D9.IP52-T'I*ZZ
MG=(J[I3TB/&0$'B=$1GE$V(:!TEHDAH7D[*YOG?,O>R!L'<<.K#R1\IEK<K%
MS GMF"_G'\U_9MZ[/O*3 M:2$*;=*W\9%]C>K@+JOA[';3KXOQS9;OPS%\._
MFUKYYJ26_<^+R5O^*JL]-\]M-VQ"Y-+*Y^6SG\R\VL\>"994G7L):' @0XS2
M6XI<B*#5V'ID" XH>IR"%('CI"&8U/.1Y+A]?ZKVLSS9'^[\L.Y@T/X1>P77
M>GY0J.QLR$U-8:X?;AV$%J2V/ZFTS75\TX6:5RIE,]]%I]V.I<P6U0KYP[,%
M$5-E$!#'=HL:C*).XCRS+PZ[FFY4REJL#Q8X+'F?*L#]'2GWU$47$ ^["*C3
M+NBLVK5-T.I6#<+W6M:>VOE1;->:_5&W5:B]W]J<[''>RMS@],.V\N)^+%[;
MN!)M>F.&O%%3//&+%EDN<%QC619#YWTOJ^5FB>:+-JG9VK.">/X7]P>KOF;1
MMV1JJ5KH7P1"?;K<W3L\;VSMD]VMDY^[6X?W;*'/\C4#*>.*XMQMF'\N&1[*
MBJ'H!]VR.GBZ.;'9+<@>0+@MR/.@6TZ*:#7AL8:,& 52C$C:)FBS7H@N?'U&
MC,F?T5C-<A'ST-P67'-E4?VX%F&JM"H5?:'-XN2TK <+G:+2<UBC"M]T,=5M
M'%-J^F:$3^12Z$Q_V\\EIL78O%[NL_Q10&"IPJ?V8GC5R4P(/ZZRGU+(&]6?
M;=3RC)UN]MM:%^O#)OZ;W5*N&1L6P0UK6Z?*XW*'];!8%9Y*ZV+<U)!W 0P
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M*W/L5N%:A6NW=$<Q28DF)ZDQ/&)A+ DR61XCP)OT=)G';A6NW1[7IEQ2RJ,
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MV!TLDYR8Q3AO<F1A,)[DKX31#-FR2JVLX\>8=;*Q%.(ST"C3MAYS=6)X(ZO
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M5.E(7! 05D@JB+.U(LXI814S44ML(?]F8\^MC'R*1CDXAY\/:6W!:V&1P(:
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M0A0B[E/C=>;#=-B?_8B'L46UPSUSS%TNGT?1P'7#=''<NE/CB\9=PA\N;UW
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MZGKEDLWOK2)/E*\\\J>+$OH2VB;D^@75[;B4&]J!Q+8=:*4=Z*;VGK5V(&]
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M.G&O]8/BQ+=D3-</]3[:$W"]H7*UX(A),BQ* IM2$<.5)58*W"U.:RL0@/)
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M\HBZYJ#T7OT;Y*UY69"X5^7K>Z8&MQ/D&91M*",D>RB@[R0;W4 CKLJ;K8#
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ME 6!0Z-:YQ[L1H4&8M&7E=UU,X-KL5*/-N^.BQ8&HL !$UQ:8H301!AIB)8
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M09C/  8-)N,3/9Q5?MJ[8[ZI7><<+610%*2<R!B3VH5,2^M548">[.M^OZ_
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M!/SZ4'_RY/A@/(Q;<%C-#],FAKB#M<\ER1Y@]LW!+F[UA1( .&D\.-#PCGH
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MT.#?S_X"T177QN-30.EX,%#=0!^!HO@,M!XFX\/!R^=;2?ETGCT"^OX$?XQ
MWQP"!++ &2!%@)[?X86NVNP<(THE8)CQ4I=?^'W3T@!.\Y/'PX<5H8IR<WB!
MJ(DB]RV6-4C37:*@7I".'>KJ$.7\OIY$\;A8*-SDH +A=%S?RH*^#7-<*:C)
M*>P;[FD2Q_5=:C59(6^/(PMVVC0LGTS\%EB] JV'WYU$;8Y:$43V ''A;*,C
M;(_@695-IS$?-MITH16B;J]7L:J2'I%@C:CI&/]$[:%GJ2<%[&3Z.])>0ZBP
M#\?80,\ OCJH)BYB+>QS$:D\'JCQ !K&2$(G#3P(\QDJ*E![0&)^/UT?-[>]
M? S'_]DGZ8T=^VHZ7":_5V'EJ:FA'^ \]#CABCW.JK ^ JKZ39*&A:>A=DZ4
MAJR$("A,T)1K.EH#D4S;JW"%JPM(I#.>#Y'&@+AK 0!K/X)W[8+)P_'(S_3D
M9.#TH=[WB7,N2708!(5=LC/0:/CH(X]HMN6HI?D;Z[ES>@1O4 .+"GBZ,6+P
M*OP.4$QWL1,_A7O![H"Z#/ M\I7>AWV=SI88\;$JO;0R!_!^$FG\YSGPY01_
MM:0.48H,7@''5E]J36']//HLI[6Z^.D__X\$R_&7]*/XC^R7?VT,WH] 5DY
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M+MX7KT5&FMH#[^:)+*/W'"V0I WP>2^]F;1J8 7EG4>K.\!,!WXR6B+:Q6&
MM-$G-=+K&+5S>#O8@S"K3S&^2Q-;3Y2Y[HSB[E6S^#Y UK.JCA]'SC[V=6 V
M4>38VODDV5?P0BM98GV&X4J&H3H[P_"1YPJNSR:Z*#MH)9O(9Q0,C\R!V>6%
MT;G,M9-4Y84N15:4],QLHGL.9<X*(F]] 5T(FAGL($"(U7 \]'/KAX\$LKQ:
M OB@D7Z?C\8H<R?Z*,8)FB@!RM9WPS&L\+]CU@T*TV<)(SR+[#SX";NR>\0+
M?GBRT: 4O%^K&VZ&%:*+')3/>O%[:="@NP=JVP/=P QP=RH*_0&3^2:(219H
M NYSVK4M1+&1J;40#3]>]9.N]Y$M^\86U[766#L[>V&.K7K++G:++>X+F@24
M<53%C?OM)OZVQ8V3WHY+B]"D<;U%\JIMV1B\K\?V7M$/DN/8!VJ",B453G-#
M:9&+D'-96BDRF0;$-.ZXM0-BOH4[[KN7A7QOS\?7]WL\SZVV+B=,>TZ$Y"51
M1I;$TU(%"U]*DS]Y"FKC#,?'X<+Q <)F?D3"!#:_*45+]LG@3%))>1VW2RU\
MR3/V>VWHOQV?Z.'LY"V0^\O)^+"6HBA$6W(@[ >GA]?//^V5QL#> SUXK1P1
MS#JB<;8N#\XQ9FS!<_'D*2LW3\^A_(_!9#Z*)MTD;7:*-'05%DB?1;*3J]-*
M3_E:P5;%Y(4DE)HLC-I:&D]G)$GA9':UJBA4$U!-_SM'6!XSA9(7J@E2I&N2
M5S@JP*C96C=0U?5=I0=WKTC.LG5^X7JM&W#3 ]2OZ2=='R :G%=D %Y*;4MA
MK RBL*4&VK>YR*EWS/#"I[(X*CCMTCU;2_<OZF75<G \0C_P.Z#W:4_W+=WO
M?MC+<Q QP8(5X61.!!4ED=Y28EF!6\VD=0'DX.D>-O\12>P0D%'M#HI9=Y$!
MJ@0^ZL2D!IH,IKC[&!^_"ZJX4!J^'KV,Z^MIHDL36&*YYRRSTEE)0BXI$;;D
M1'%K2.$R;T-9*!'<6;+PE#O\V#=X>E1' P93[Y-#>HQN!#^ID\Q;H01 NLX]
MTX,1.AFB1'(IQ\I/)N/)% C/^<:EU9%8CR7(#IN(&'8:@^#'!QX].KB5TX.8
M(5?7#.AV&M9);7Y42YD*ZS*R7U8C$(RX8>]F\,%ARN)+A11-AFA3VA'@5&&S
M-P:+5/SH-DH5'Y@KJE,FG<40S>%TAB*W1=OH"-PX1W-$7=@82<LAF*.))RE)
M<J'W8AWLM'9&SB<3I!1XXFS>/O!H476ST>15QE1]?9PN0Y=5RLF);X!=!*9^
MN*B.J#[Y874P'G=,E)8HHPO+>(!ZC0F4J!EL),QOF/CI?%CG*E33-O32).*V
MM1%N(T)&:^%U8F9\<FPO%HM?S2.,Q[<;.<#O\:63GZTINVCJ6KJ&$)X2G/9J
M28A>L[P%C5P<\WDH'!.6SRL= @J7SF%M+*I@X/N5JI&K3/X4.J=95BI-K7 9
MU:4H,Y])Y3VG/B_6%_"_VGFY9-#!JUHTZHZ!%J9^=(%%]Z*N6'D=WM0U*/B#
M5G/1'UQQ[7S]<T\K+_*2*4*YS(CPF@*8D8(8HP#49!2.S#QY^M5/QJ<45YW_
MO$Q -:\#PZ)S'A,;)QXC9@MR.EZ4335E8EVH'U"J':RB\YK>8M7!EWCM\.1*
M?@40<H4SPCE 0D++0@=KI2UR+["3JCJ#_(B\OCOA N+[P7,I #7M[P43"J4*
M1G*-J*E$3!UH29AQ8-2[H*4'))UM7I!*T01/HCJ>SE 75C@F<Q@CM3]5_[H!
MW4@AN.36LIQEPO-,.Y:KPOLB,R7SWI_==^1:Z3@-T8R7B.:T(?:#^Z/H]L=7
M>T69N5)P3LHBDT1DQA,)9T*4Y;((N?>A!.J167:^/ZJAGHD'"#6-M1:-.0ZD
MT9IBJ!E'<[\05JW#%LNVDM,VPJ^)[[@*4O\X%&P3CX_ZJ7KXU)C3VE. [PA?
M+;+%>O)LR//KA[VRI$*$C!*3Z0#"32@@3QY(Z:C*X#_6"AR/C5'+*Y+GE;VD
MO9/H&Y_^-ISZ?K;]]?V7[>?OO[Y^_N=-G$1^P5VI *[C($0) S)D58B<T^Y$
M,?R_;VA%#+YG_Y<'(#R7\=_;QMVW-7+P^:SAJU>UJNA%:&.<[+[?<UI)RG)*
M*,T5$2KS1)=.$^6$9PS.3W,-^+ \:X)4$W&*F9U=/^MIK1[C#PN5SI-*1[.C
M_;"IND\^_[;U0S)AW-@G/T-=P)S<,*>10!T'AA7Y_3%02B/>FZX,[5V7VS*L
MM 'HK&5KB,7$^P=KRHBCGP3KFM#C?')F@>>J"VS95NNFT:US2G5J.^IW32O'
M!A3H=[R9M^2>IY#\"AO@]R?ZL34BD!N#OZKJK\&_@0IF!U@2/W@V/CS":J,F
M-1"_OV'Z1Z?2Z](Y'F:QX^OR.JK8;<!4HVYZLA^-PSC6.0UU\""Q4S<$-_"'
MN!R@ 8,M6(#%?JT^S?3D\TDW)Z1YT4CTIQ-X,Z8VN,S798?@QRN5=S%+%]]R
MZ:XN)MBEM]KL$A6*!=BRN9W-)_']7!6"G[2E6=T+V\XM"XZ%C>SL5U=&I9>+
MVPR;N)K]L9+\L7B/)/I27FO,Q_383Z<.-M0QVDXJ/NNXV!-E;":ZPM>J(QJU
M#1_%&[S.4$]2>FM3F=\@'SA6,.NC:S(L[]X06R<!& I5W29 MU%E(($40ENF
MG+1Y0ST?V8,EYU-=YA;7"&K8SI'3IW4Z:ANDU;6#-+G5#^<II3+1QK)":>AI
M,*W0<9V>V(C\Z.6>87]>N-U5@(P&^)B9S'EFM1"%T]9RSB5S4L(G5->U0@P]
M*>L0S<U+UM[ACLWZXJ .8&$[SS_MT<+0D@6*84!)!'-Q+I,FN2W!Z*..9UQA
M1^Q-<3H.N%P==,K+L-#X&.ARKN[\TD2W:J8,52?5"\4V1KN&ODX87_27V.AD
M&D=JC]$0Y,EUW+/(<6[J0&\;=&S$6*=+D<T62:3>%G4@!D3[=&XPP#-+.1W+
M+2VZ$;?SQ<,"";:LO^A\I0<1EA'8L%C&U^P%2&&O#SLQ^K@SCR<4M*3V.S4'
MY^GTMMJLT>;/]$B[4_F:&$^MJTTJ7[<,J6/9^%57+J.0C_F.438N$A27#C0^
MI8(]ZNAAME'08H-)MDX/X\?K"VDP/;.N=\.N4@= B>/]:O"?^O#H%WBMS<$?
M,Y<R9'$%2?N=NBEJLQJOI,77'U]&U_]]976]-CUSL9C5:CC:+46)H1D-;'1X
MJ-L45:PBCW'SY74N=:.)!ZKK=H5KBO=L75_71&QOZ67BSKMJ>@AG5*?+8(2\
M5M (0-872X* FNS/DP,ED6J=1K$2P9SI3V"H#754S2CBFDJ+1\36.T"%48'@
M7JXD&<=M3'Q><WGD;5!)@%8V!K_!:0+DWQB\0IX=N=;4>__?-6!LTAO@>_\Y
MMBI8=#G!ECY-CZ8P>#''SD'+3,L'5.2PE*(U*EZ\:8F %@VS_A)3[F!O0=94
MNO/D]K-E44!IP;C*RC)>^+O&?5]<%/^-<*YSB6 JYSG_I<G%_F^PSKL/BO\>
M+;7<R*20,E/MRO_[;5MDEJFE1AL9+[@L\R@\.OV<L'XJ=6- 2CP$$ YH$ZOV
MHF!*"#1QQW&=OS(;Q(JAR%)3W[1N&T^F-Q,CL;_F"J2N%]F44*GEG*3Q45,<
MU&B"U=.MB\P6Q_JZW1)L4X5>#LS]])_'BWYS2V>?1"U<U]9W5=WJ+X0SG1JO
MY:2I145OO;KZ^%YU&UF]:1I9U4OM+*OM!% O;.EH-P<OVV9ON@4.^!<S1[JO
M1=FYCSRCZ"YE^B\]K?6EU'73D2RPD5DMSU:DWL(X@S>ON?=4W5RSH;5DC.HO
M]?GJ"/QNDFO:9:37CW.PP!#E(5=OK.LNNTQ:ZVBJ+A($:0N(L9;#J79UR;1?
MM6-3,[33=8;?HI-99R&KFJ ONEO1,(KV17?=HKL+B^A6BNX$SYG1-G?>&,%#
MH:P1\$$PQL%5TCV>HKL:\K^9>/*B:16,(O'@9*B_5(^EZ3>"X_D^+&M5;RZ*
MF9=4S>GZ8!!4IQI\J0TJQ$9.X89J(R_5!N<<_ZIXN9&I+.$,"I_F&X+Q,PKV
M_OWO=_5-IZTV-B>Q;#FICLX/4@_.*6*X&BJW/ER/RVV"D\E!')__[SELWN"=
MGWRN,*/UI\53E^!0W;L@BOWH:]0I"35UJH:_SG#A4;O&-!X0X0=HP4=_&N@H
MG]QCL'!X6G5X.!^-G0<57J%["O9P-D%7[SS64FB'[<&G=5&C7G(-P\-6W+\(
M;EM7,0",W><O%VU>%]VMDX*/:ZKWY9Q5;'1>#QW5X]'PI.Z*JU/.;GOCHP4O
M+.KO)R_>+'5@:]'\HDIPS:G\CFQA_;=QRZ/C W^S.YE_!FN_MBNFH,-31C5V
M2X5WPZ6O]&GHT%=\F6ZY/B"X6#\/8&98U337]@6(?H*+NQ\T38M7'K,^M7Z
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M=IZW.FAC5?3$4.5@=G*$SP#P-)^FQDS++])$D[N'J=OCQ"<GB-N EPL.>CJ
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MD>'=IZR,_I[XZM#,)].473:='\4LSS&6JZ?NHFTFFG?SVB8'$ 1"ZG!:U]W
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M#51+!RK.&7>:)ZPUX0)SXQ2F/CH,U,EPIF[@IM9 M0I =4&<5' N,( G@KU
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MP^B< UAD5C"ZT?YQS TR 8EN)X(6P)4KY27#C <FC:,B2"VX3QB\$YM%\(H
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MGSER>;'(4)YB0IE.N]WV19QAGB ];,["1W\<P[ =1^3Y$JB6J1C1G"W@@=_
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M2KN&G#;ONGM7=O)N#WN33?C5OI3IK::3EUQ3UEOA^Z=IRDIQI(0E :BN<V]
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MQPH,Y<:F;%X&P$N;2.Z"/RNZ./J<Z=ZB1UQM''O6X:U9**OIWK*Q;BJ\)80
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MI$:)"XXX=Q%ID3!XJP"R)JFH BV:]I":=J]CP:)I"Z)IYWN:#"E&X7SN@Q'
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M^XD@7/CPF6^/Z((Z8^.S;'"LOGS;I;O?MG?VCSX??<!;!Q\[VSMO3[:^?^[
MO_N;\/G-/S?%YI6S[%VQO?;'P>>#=;C'YZ//<(^M3Q_$UMHJVSKZP/+S@?-V
MLOO]\.2?[QM- @"5L_&EDBAX1<"/8P09XB5REFOLN;,D\5Q_O#SCC,H'.:A^
M"O7Y/P6/GA*/ILQ +'@T#WC4(",07@DKB$;:Q4Q!P#%R!FO$B)$Q&N45-@6/
M"A[-*QY-F=I7\&@N\*AA'_'("2$>.18RD[2)2%/-$<XI12;8F"(I>'1K/'H)
M#62JT]PZOO^JU:WSA28G!./DL:?N+O/L8?@IW-3KB6OBH.#OW?!WL^F?"F*2
M\E&A)&)"/-&(G$X"69N8!Z6B5HFE%7Y-MM:3M-Y]>H0M:/(\G,R")K-"DX9W
MJ:.+Q+.$+(\1<2\D<BX*E&)R6"4BC(M+*WAY3EKO%S1YCFCR%"YB09.9H<FY
M;4(2MC18B0A5&G&E%7+)1V25U5$X94PB&4UD09,7=&@Y3O:-MM^%,0]:=GB6
M)SFL#C '3QVA6T"$O;DIP0.Y?S>T);@-UEYN)Y8_L3:1@'9.;BZ8>Q?,?=OT
M![%40C.AD2<,(]@^*3*4.L2#%4DQ"=MJ;AZ&KXG'/7;'Y*?'VX(MS\,7+(@R
M:T1I^H0T6B<31RHD0)00,SV*BX@ZSJ1@@N%<&4&7IR9W*JCRDE#ECA;+]$YA
ML5CF"5_.+1;#A8HD1:3 +T3<A$S$I"**."1'A(7%M-E+O-HJY.49+"_A>/!=
M'(!OZ/?KVI_A?NSG-@>A/;R?7_BR(V^/[A?>'5SAQ3?U^A88O1N,?F@Z?CP0
MJ34&,TW)A#CQ&!G8,1%A(8*Y+1,Q<6E%3@6CSR7.5K#C ;#C*1R_@AWWQXZ&
MB^<C2X+ZA%RR$G'A+7(B6!02\8P;\/DTSBU?"G84[)A3[ZY@QZ-B1\-]HY+Q
M2"Q2PF"P.XQ'UD>!B+:4"XM%$BICQS0,?<\%.U["^=Z']U6+AKH?RH63OA(D
M6Y"DSB_M3CB'T#%X;E3=TP;OZC9/.[T/[V&9MR>AL?7Q&A<HO1N4[EYPX8AT
MA#B,J, :<>D$TC%R9%3@QF@;94I+*VKZ7,[G$@XK(#*_YW<%1!X11!J^G E6
M6NT]HD;(W-[/(\T81O"R#UKKX$C(">%3LXL6$"D@\M#^7 &1QP21<TN$>H8=
MDPY1GG.'2&1(!Y^;(!#M1%#6J<RZ?HU3]T)!Y"4<S*TUNZ&BB_V6FPU?KS2K
M+/&S!7'\[A(^V\XGLV<O=;]L#./1X._8S[VA"O;>#7O]!2_0T*3@_T@&+1!W
M.=\*2X4B<<Q%I9)WJ63-%T29]].\*?*M"K;,$EL:SB$L5- V\\@KEPE"HT+@
M$@JD4L"!Q)!B#M93/E5V>,&5EX0K\W_05]!DIFAR;JF DPAFI](HFB#!2Z0"
MF=R+2@#$1(OSBL8<KYXZ,_RY(,I+./]['X?#3D7O4_$85)PQ<)]NI8KE#' !
M4CBG,-S@Q?/U+R&X.X+K^DF3S#T2V!<U#@CG#@R<.X^L ZL->TPDM]S[A*M*
MOJO'@2\O,;Y R7/S 0N43 LEY\3F*7$?'+&(,F<1SYF>.O-^.>6P44YHKW,3
MXVO:NA0D*4@R%_F=!4F>$$G.F;V9DUZ1"" 2=>;SQAAIXCGR/%E!3=#"BFDS
MQ9\+DKR$,\'5"4/=QM_O_J\].OYMK2K;FY!!UMR0Y0#P.1X ;O6ZYY2:8X[5
M2>WF:C>LQ:^QTSL^*D&VNT/NMW,_,#_W%[JGDG6<BH22]@9Q1@32$E:3)^&,
M%IYC+I=6A"Q]/@O,S'-N:)/1]GOL]X(=[!?PF2?P.3P_+SS8Y5O?U_>8UE92
M&U'TEH+A1P@R,CHD7$S>!2L"8TL ,YH2^EN!GP(_\WMX6.!G >"G?0E^L(*%
M3QI%&CCB4C"D!<$(-AX;C1*1,U_@YP6>-+[9MUUP+EOM;NNK[8QJVFF;.:!M
MUS\Y#>*S1^.G\#GK)=_H3E*1X4.K58KQQXD K$[6OP#O'9W.TRM.)_/*TN0P
MPA&#TVEU1";0A+A7@,<)5CS9W%)&E2J  C//W^<LX/,HQY4;='O-?]N31@/6
MD(B$<2FGJB:DM:'(!HX5]E@2AF=F]A4 *@ T_UYG :!'.>4< Q 5$HN0!()?
M+%@_0H#U@QD*'F/J#)4JJ@) +_#,<ZO714/[S>8"QU&W'V%(WV-H?;'@B/[:
MZO0&@]S]IMW]&@?#' (J<<&Y]T2GR"Y9_]^H/3S=.*L[_R^L?QQLIP_PE6[%
M3II/PM^/W* =VK9_6I#YCLC\_8I?:L$BY$EG(B&!$<=!(^>21D*20&!C=I*"
M7TK9])RSSR4<6%!G+M-C"]K,'=I\.W=$U_GFSB[9TT%CJS5&FFD"=J BX(@Z
MBAA)QB=LN:-I:464DLF",\_<_RS@\_#@<\D)%=0P%7A$TA*..)$*N6@%F#I.
M8\ BB@,MAY\O\/"S*FHNL;^Y]RSO6:Z^&@Y&=?2@%"Q,D3V[NF<29D&%B' ,
M8+U)*9'QW*/D@K?>6ZVBSJ5/5PL67F@$K\#(/)YA%AAY2D]P=2^ G149%<@2
M+Q W7" M8D(B:B=,D#@D=GV7^P(C!4;FQA,L,/*4/AU8(Y%C*R5%/!"%N$@
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M[YW:3N[M5,(A"VF;W"J%KFYE^B5V/2QT@;H[0=WZR44.ZL.3O=S?D!*#D9:
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MJ.QUK>N<YO#5H&J-6KU=A79O!K+JA.D\Q =?'Q^*C,W9+@ALB]#6$<CN_N6
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MYW#3"JD(?"EL%@<((M 9*P2BIZZ:6TM#GUBRY*K VS,)YK$<&$E/I%UI['1
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MU@-TT%4]1B@"A]B6XYA$"+"#1<C-T/)#TW$=:OF<!KXE5(SPX:ZYGA?7+-K
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M"9UX[YEGH&4<X%(H$3DL BB[3NA2/_9=&O)0!#>5/_;TS//2@7O\[=-7Q[+
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MC+R:8!FIS3(X4/Y5-L!K8\=^>7WGJC>9O(,RH?#!L8GS&MYPH$A X^!6/?N
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M/1TX+YNA2/887[8,<A6F<^EX@$L8)YW"B@2KMHL6^?BU)]Y5S;@4WN5N%8O
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MN;XGHW.>[45\P/=\W[8"9P^?-G L\#%MRR*>;]M[49]0E_G65_G3LBW2N!A
MES1QS[G1GHIJ$3'(^Y',SK'>2AFMQ KT"$2#T%%%S&X*UM>\$LWE\LBV2-#.
M*C\NEP4/D_+21GL8%M\H]W=3NX 0B[E. %U@>\RS]P9=:'AB.S2RH1=LL^R$
MQO51P2FGO]@$[YXR/(NR.XC[?0_=,$UA;[*FL+6FV#I-<4M,7:\KPF)?Y$(Q
MO$NSP14HCA^R5^F%8OT(EII2QYVE63JC#"J-<\3A>8VR_+*&XSK!D6XN'*DV
MH[<7CB2P;-\FSAXG@1FXGO^5R)\ R *-IU(%DB-5&">)U99S54IP$7\L/>DQ
M!376--96XMVHMODTUJ:P1DN+K]SC% VV$>+>7G7X9:YA]J"'7B]$L%6Q?)[E
M[4]'1842W,(E4L6%JJD", K+6MS5W_:\*/FVB,"ZZ'.VN?J<:7V^E?H\H,1V
M0*W[KD_87B1_LC)N<ZBR-K"&N$H/*RI]MV4O23-#92)689=B^S<5?"EWP+(P
M!$/(KA'*P:64O>DHSF?9Z>3&.YZ=I[O&L7H7K):6YZE(ROTVX:)GV3 ?R$6+
MH#0A-2&?FI!4$U(3$@A9AF_>)5D^,-K#?K^C MS L/M TU@N+XV=\58:F,ZH
MUI'5GN"E!NHZ =799* R#=3M!2JE 7&\O<AV YLZ-<NS+7%/^@>!M=J2M<P]
M>0RVOBO9JC;"PD?8K7W$BH\T:]>*M>XFL];1K-U:UC++#RP&K'5]GP5^C;5G
M%TGV,-06-JRG,,L>%;-L%K-,8W;],.MM,F9=C=GMQ2PC#O'97N3;Q'7<&F;?
MI<-L</$@SAZG/TJ3]BE8:\VPUG9F\>MH_*X??OU-QJ^G\;NU^'4H"1S70BO7
ML8,Z?9-X(7PG(5M;M,(499W;4-9XRWO?EXE:>_8C=^8C6M!7/4R-R:YF\OHQ
M.=AD)ON:R5O+9-<C++#=O<AV@H"0>I0W^7EG*-O%3)G[^%">0V Z^Y$W"V5W
M+I0]#>7U@S*Q-IG*@:;R%E*Y7+('OQ#?44OVP&AFEEJRQZHE>RU\AKNRN<AB
M0$)7;,::25C6FO>NE@#G*I>AIY,8UH^D&UPF@S6(I5&Z=2BUBE_MXM'=O?.D
M$P%7 \04L<SO@-.@H.E459RQQ5I6],X!HF*8)8-$+BK<J;&VFEC;X)H.Q&J0
M_VBN;1W7*L?=(Z[O>O9>1 /7H@P<=U)5_YE?JP=(R,K-"? #D%?<R 3K/6#=
MG_&*P*Q:$7C$KPQ2./0W;(2Q+=S;V)6  !/[/[O_T3Q9>YX49@[8.,@#6\DU
M.HB#U*ZM_5757H[3AD%P2EOC8MO-I TN@P!DHQIK:X^U^V>Q$VHSR]E3]M%H
M85 9JI+=?B>]DEC?.17?C;3P ?FH()9ZC&M(:.R -VF<HZ]8+B%/>BJ;W1A<
M9.GP_ +_\'4L;+UHN,%+)(&&3--P^VA8!L-(@+_;E@J&_6-C.$QA\6FH&&@0
MKA<(-WAI(X#0T2#<=A!Z!0AI!4)G$H3GG33DG27PD!E7DF<&/-7@Y9+HZ&@Z
M/C,=-W@Q(M#1U73<6CH6<Z:$%G0DF#3R+'04:1<N(3"Y1#'2MK0%N5Z,W."5
MA,!(3S-R^QA9!A:M@+B.8[E%8)$$DVSLI3US!,8HR:08I-F2_6DKJ$<9;8W&
M]4+C!J_R S3Z&HW;A\;*N:;X._7+*".AQ#+_47%&^@!*[GQJM!LO[QU\I)J/
MFH\K\G+ QT#S4?-QAH_L(7S$HS4CMXJ1&[PJ&=.;+0W)[84D*R&IP.B8BGH%
M]$;,>WJ?FS"=V;/&O-SLS!ZBUX-L,2_GI_8\65QRHS=\OE4;HY;0K:!SO=92
M-=H;7$H#5:.]S:J1.*NN&J]_PN6D,P0C8!7I#$0E-O32I]*0SYK-L.J';AI.
M-[B>!N)4+ZE::9P^KOWGXN_,'66'$5?%:,@D2/LRPU(;'#?8S"]X)@U^R;.H
M1D_3.&N?&N]3WLFKV;W+9'!A'%34/94#^%4=^S%+?R0YO$=^[]"-JT,WZPO4
M30_=Z%596PS4^0XUL9< 5+U6:TOXN-FK$8A>K+6]?%RP'('0I^;C0SUXO69+
MN^6/2DF]:&M[*;G(+;\')4_E#]D;RN58DMKMUL!<66#J%5P:F-/ 9$L"YJK&
M,JF&JHYE/B94]=JO+8;J@EBF\\Q6J(YGKADC-SR>J==_;2\C%\4SO>=@I(YI
MKCLI-[MXLZT7@6TA*>=6;W:\!75*L01]E@@L0E\D:@Y[R<!(\GRHX/FD]9SW
M!CSLR.IS^#'%2V8W/&S4?IHGJK'4WO+P *\ODVAP40[\^HG%"'QEC4_A89YV
MAH/%ITR,AGS8[?+L:A9DRY9J8MTT6.Q"J+VIQJO]O,C&<GHNS3"3_+O)8WC:
M5[QSR:_R%WL3;]I->N94RTXW2O&6;_XOS/:F>JUVG5KC9'BU%\L^:^9<Z)-S
M>/BR=\'A>%U^,DC[KY@2O-KEOPWS01)?H:K%\34>&QF,:!.ZKL/[N7Q5_?(Z
M2O)^AU^]2GJJ ]1)TVB#&XT;JV$5#58JQO+ZY=<-]54%U8GOG ;S_(7?@J5[
MK^_LAN-Y]SKSNF=U&P%;_.U]G]5J./1^5[WN67VKX7G.K2ZK7=C5-,PV.\QG
MZ]6F6VB8W1#F>S8+3<?WU@R.FUU;WM[J]88:CM:<XO+3-4*GZR<OD9%T^?7F
M-3$U,1^5F'I)H2;F%#%MZ\F(^0@[=&AB/C<Q-]P!UVL&MYZ8,PZX?YMJ%MH;
MUZ3<IFP;6Z\>W%Y2+LBVL>GS>^-Z?R/-S97FIEY/J+DYS4WV_#ZYYN::<W/#
MJTW:6[VL4%>;M.94F[3=VU>;?!S_7->?U(#=%,!N]1)##=BY@/4P-UO^4P#V
M?=*1/#+:(@'DR7P7P=A0V=OS2;EK<(!C!,3EO4@!F"-^F_TLZ1C>KL*EIN6F
MTI*^-#8:EWJUX4KC\G%GBAR%2V>O?"-B$5/F_?YUG&Q5)FE;F9\?AW CGE]+
MRM]Y;\BS*\.V$9;$T0[Y.A%PPZ?*J5Y$N,4 G#]57B47+;(4+<<XD+',,H#;
M?MKMRUZN'NQF<Y$$"H&N1N Z(7##76:ZU<MUM,L\SV6F5BZAF_AU(&RK(S#L
M> WWCOB5X3RUDZRAIR>P;X*>7H:STM![E@EL_SK<[:=9'Y]$&LT>.+2=VX4)
M*^>7: :N'P/M#?=]]<*:[64@\97O&XP7UO@W,_!4#A!YZ.IFZ7G&NP;.(K=^
M2C%4(#R)XT3(+->86R?,;;JIIU?#;"_F%IAZ]-H0WWS,M64O@7_^2M#C!0,O
MB20FSZ"Y-R;@U+<:A.L$0GNS%U)3O=AE"T%(B,5<)P![SX./_#U.?),1,/B^
M$ODS"*)R+T$PW61F?) #$$LCE(-+*7L PO,D'V"2H,+< >\ELF.<_/M?ODV\
MUP?\:M>(E)M[G/Z0W1#.I)::X? U^-8)?)L^R:M7JVPA^&Z8Y"T+DA5Y+&E?
MF7OC_&DT^&9Q=V-:M<:>QMYJO!QB;ZL7FVCLS<5>&=_[>.,6 @L(J-:-C#=+
MK:HZ:#)J,JX1&;=ZE8@FXUPR!LL@X^2V*YJ.FHYK2$>]*$33<0$=J^7)MUZ(
MO B6&HT:C>N'1J:7BV@T3J/1O?T,RN_I!>_UN'$D,Y'(K)H^P2QI6Z4(DD#S
M;IUXM^%K0]A6KPW9<MXM6!O"Z$4ZS)->0;V2=\V1P7=W\C%=1&&C&;GA^85,
M+R79>D9.YQ>R*K^PJ(&8+YYDGN*B=HPU!-<2@GHMB8;@- 1) <'3N\0*9WB(
M'];G9$[";U(@!$?3*Z:J6*AYJ7FY1KS4BU(T+Z=Y:4\8C7>:8M%FI,;B)F!1
M+U'16)S&(KW]_ K@+^*1\9%GN1PM3FG+_J!8G6('>HY%,V^57@Z9IU>G:.9-
M,X_=-GXX03QM]FD$KB4"]4H5C<!I!#KW]X8U%+<!BO:&0W%5%JD\2P-4B<:'
M(++='HKJ.,5$#48 0=(;I(L\P620C[9-*HJTR%&1EG14IJK6O%K(M9 _@Y"O
MREJ+9Q7RT:X2'[.TGR5R@"4S#WMJSJ_P>4!^#WL_RJI,=R,!2/J @PD ]T$H
M5,*OOOL.YD&URYK&P3K@P-MH'#AZ?<$6.D*$!)38CN59#-P?NA>I$G63"ZY6
M Y'&3B9_)'D]J/[O?Q'7>@T^E:NWVETGE!;]]K\[MK_91"6K =1G>?\FEB17
M%!CQH)H4.P'':"R]SB[T9D!WYP!BUQA<2"!+/D@&PP$Z3\9)=LY[B3#V+V07
MC[I2H'B;I&+TP<[AR?[;E^ISN!0WVM H%P-H..-'XU?CLF'LG+;>-U_"Q=-S
M"3?(C,MD<*%N%:>=3GJ)AY9DSU^ISS\ DWJYG'V5 REJ)"+%NY#Y[X*/53P5
MW-[8P>OBP;,7?_GZ^IM.M%]Y3_O6]RS/5B?-O3<>?I>7ON/]J[,7/8 VA=>'
MW\%F\]M>#7YK@_@I9P8"L(,=SX++>SXC>]Q&RYC27_*G2:ROA#8&/P=SU=LB
M"Q<9N(?\F\]/6VWD:UGE+AZH?!:KAA&<;Z"H-H?7$*=TLQ?T.E3C=.MP6L47
M7-NF0>!.Q!?:R4^PN^>1=) NLD KQHZ@6MGY(Y.S8&QS>#[,!Z6%ZBO"NE.$
MO=X0UJ3=9-*2S28MTZ3=.M)6E6(H_L[<O7\HH1BB)9;YS\_1-NM>6805=]#L
M/1I]?Q]VRGWG"-74U=0MJ6MO-G4=3=TMH2ZQ;!LLVEJ\( @LBY+ JGUD!H%9
M?%B$#%H_16>88Q+0+/;"(HX])X*PPW,C'PHA\SS-$,UG6<)[YQUI?+S@69<+
M.52CH-Q ZN6N\;[#?Z;&^RP=]N%.W02 O&N< 5,_RTY'I%UIO$OAQ8NIN]$!
MQ5FC0]1F5&I_J6Z:71F?>O#<69X,KFK5<PJY=E7\5Z]K64LBT\TFLJN)O"5$
MGHTX.#9Q7184$8=R>?-I>L4[@RNCS3MSZ,N[*1BI=6MV&GZC3(=<I7:>9<-\
M8/R;=_NOC7WX-8T2WC':,OL!@,^-G<-,=N",EV/*YFE'@FF<]%2R@^!]+M1E
MRVM)-<=9/64!^+I-/1'/<#1R-7)7ZAT1N9Y&KD9N#;G-VM;TI]76]'<P@%<5
MPD7-W.V \-Z AQU9O1_\F'HM9C<\''K]%/H'AQ0V.2YW>'V91(.+D@[U$PLY
M?66-3^$A=,MPL/B4"9G)A]TNSZYFH;]L]!'K)I&R"_+Y4X.@]O,B&S?QN33#
M3/+O)H_A:5_QSB6_RE_L3;QI-^F94RT[W2C%6[[YOS#;FQI]M>O4&B?#J[U8
M]EDSYT*?G,/#E[T+H_UU^<D@[;]B"D^URW\#84OB*Y0('%_CL9$!D$SHN@[O
MY_)5]<OK*,G['7[U*NFI#E G32L N-&XL1I6T6"E$5%>O_RZH;ZJY&'B.Z?!
M/'_AMU:#W.L[&Y2C=Z\SKWM6MQ&PQ=_>]UEQMO9^5[WN67VKX7G.K2Z[D<8?
M6'^;O4>!XVOK;^NLOXDM"BQ?K:7&?9C+R:?O?#3YQ*ZS"5M_O;_9+OR=8Z>>
MI2$7(AT'*6=GH$:[0I=U=_2NT)J7*\C+0/-2\W(Q+\M$J2.>3VUTL-A;?I]T
M)(^,MDAD#_W?/QI_%(R<1:=FY0:Q<H<Z&XU*U]*HW%I4.B4J,:[HN2;/5$P@
M+&^$!7BN,2SWZ\?>9M9G&J%E!-'XM*]*@G?AI:YF#BJCBR]+UO;R',&LPI('
MU16F%P 8-E7 91JXZPC<S2X/XJ[(ZE4-W,=/9W*(Y?A6;2J',)L&MN/M19[E
MV(&K9G2(5^Z[M<A++U#Z!W!P-&U2V)G[/.29'. ZW8$4%\:'0508I0=9P_A;
M0H<;K?P"3IDA)+&++%)-R/4CY/_ND VW2?4"T6U!Y*(=6;VB="2M=F1URMVW
M3E3!W-U11!-A=X,A6GGS[WD'7/7S%-K@KVOSZ]E35Q1?]4-O2=$[H'^]D&23
M!OG/-E=Q(LZJ,^GZ)RR95$0$;:N*")8/:)-R5ZOV,,R3*.%9(G.5JS("A#:3
M-EO J1;P319P6@KX?@HV U@&91':/D:UX,]"SE5)M8_#L),(HRE$.NRIXD;O
MDJRK30%-BH(45)L"FTP*6ID"^]CF,;2Z\BF %_L7B8R-UJC@]$E14'$7TULS
M^<\P07J QW$Z[$B#4&X2ML-?&FE6?N)$U2>Q6HC;A@MER0 MC=9/<<%[YQ*H
MH]!$ LK4=7D1=M?&QZ8CQ=9(V6"DV-<BY5W2XSV!N?4:*1HI2T(* $4396.)
M,@\H^35&2A$EO0=MPAG:A,5$?!OWZP:*$>I8Q8UY'U.I7(I_G24#/,.OP/2I
MEZA-&S%O(#?VTT@:._#MIT:[L=\P<%;#>XU7TM6F-QM+Q"*-P^/VJJ#I6=K@
MOV]//ZC2RVJ/JX-4#-5<A:DJ2235YU'U>93"O7OIP.#]ON09+JXK:C>#M &S
M4,@/^("#7(/$A5+P82[5\CMUGP$_!Y6?20,G?2/,X,&2S*-KX-,5!U;W>Z8B
MP8:E1J^6OL>6OO;^;ULM??4Q?\9_IKVT>P7Z<B![.:JS-E8[YR.IU-*PV=*P
MW_R@I6&Q-.SSCAAVJGI&O>\ASZ66C2V1C8/6.RT;BV7C0,9)+]&BL8VB\:'Y
M5HO&8M'XP$/9T5*Q;5+Q\;2EI6*Q5'S,)*8>:&MJ"X5CQ<N&VPS_]WB!;LR[
M@6<R/O+S!9&K7:/8]'"@-C6<B$SM)#W1&:K%9SBMI0+@!O#FY:(X\<*B2K62
M.711P9RE#A#O5B6.=LC+(J]_]B<VC7IO>*@R]H^5:L=IB?_^EV\3[W5N[ ^S
MK,ADZJ?9P #$J$TF??,/(U87P>!&M;UCF>%LX]8XN*UV3Z19'R<AX+@+F4GH
M@?#*R&0,O_>$;-RFI-'S-J']1$UXQ#-Q8=@;UGKTR5KORBA6P@?W;;OG:2#V
M1 W4[&=)9[3['[036:]V<IZHG<:KV.@Z-I/[I+3RBJ70Z]5$WA,UT:A$!UG+
M9O*?R73 S5'7J9V")V\G- ^@G=SU:B=B/7E#4>MAUM0S-=0RC/9FKS?DG>EV
M(A8V%.Y)@1LG)SDX<L853OT7)3A&NH^2=32ER-.9ZE?5(G=OS9IH&?;XGT.>
M#51!E=GA]>=H>/U3'%4.+64O%#>B:VE_DF48ZO=IN=^'/5DVG+664KD,R_T^
M#3>M!]:GX51<:X<LPY:_MZR6.F#ME.<RK/MEB*FU-J.M;+AEV/OW;;A*0NGM
MVFQ5FFP9IO]#FVQMO,H":O8RO( 'MMFZ,<U>AD.P'*-MS7Q.^RD] G\=HQ?V
M<SD$=8;Y:]9FS^4*S%BTZ]9P3Q_$7\]V6H;E7WVDDD+4\BBUZ*-JK[9)C)WC
MM&%0:CJ.ZULOZVLXUZR]EF'T+R-B9JV;?ER&T7^OAILR+4@0K(TA6S;=,HS_
M!XVYNF%FK9E)2Y_+#1BIT E??<W$ECZ70S!C@-S285^9AKNS/W#]SMVW:\R]
MYNRD<#G\BGVXUZP1G\MEF"^[:^9PT64X#ZIFOC+GT((C>-1B55(??BH+R"@V
M(UZ?>'C9<LOP'I:F<=<G\%:VWIU]BIF:X'=P+6#,E<X%-4G@6CYY.1Z$RO5_
M:%+,BF?>_F=18Q_Q'C\OVDO 53!=&>M@B+3;E[V<#W#?W'X'GA<^Y%F&A7;P
MX-5/]?S/PE<NQA?V*E8(6(<W6?PJPZR7Y!>W>ITRE=[$O/E7U)T[.(N/$E4J
M\I5)BW48S_#*_[OHA;$.# =AA+$:)_B46-X%V5F5A1E<)./<^4MH%"/M)BK9
M'N2W*WEQ%$CI=RQXF0_%Q?AT;#^$CMHJ*\F_&SO(7W -O[]L&&?U"U\ G4(L
MM%U ))=]CJP \T%=HZQ0E<D!!_&9+5F%B!F5K=I/N]TD5PMG\.1T.#"JVQK]
M898/05\LTA[]?J<JLG4J_QG*7)7QW*\WSEDF^4#)MZJY4U2XL5EHVN4'=RRG
MM2$#[!E'V*AWJQHF^$%QJSB1T8([8VF3G>2E*I#2Y3A X5L<2#L)?'J9#CM8
M_KT ]R#!-2<P&E%;QL..D<0PE+#:*WP6@3W12?/K>E+OR3W:DSN8;*3I3:N3
MZ/^]2,* >JX;4I][ 8M]REUN^S3F%O<=0;SHJTWM%]596[>3-YI"A*K54Q.$
M<-@M"($'/7K?>W/[_O"L=50@P2!N8Z$&/CD]*NSU]J>CH^;IE]M8AL'-;VXS
MU=?/-.Z/TYYL&"O!AY5! ;&6@P)G"U'P])TX7Z;;A^^/FV>?3EOMQ8-[GIRN
MA%!^K!F#:#*4E0S1ME,F1UFHL. 2H>BQ$6<G*OWLVQ9.+:Y<F9K*THUPJQAE
MJD2%]9,5X0IX#K X<NC5PI'&6FRAO."=&$TAO)"R,(L#U)4S.>S!6>J"? C&
M;@;O'UU#FEIG.)/0K,:@6@([YDL&-S0%[I+3S^6KZI?78/2 %WOU*E'+;4UU
MTO3B8;A)*4^,-GPG0)$JUW*7ER^EK:&DK5JU//F=U0BLQ5];#;+XU&LNZ[NW
MONS<)>@+UY4_SW+RFP>\>MGWAQ]:S0.CO7_8.MYOM7>-P^/]L=&ZN'Q \(B[
M$MQ_E[65:]ZW5Z_NL%C_F?>-N^4[[>5[BRRU@^;Q8>N#\;%AG)0.]$'SR[S1
MM-)]R^ZP>]XM>K<$IK+1^P,#;+$D,JK'>T#QA152_*I!#G@OD1W5^56K/,?P
M+ ?>TSS"HI:XNHV)]ZR]M7_!DZR+D;A1,>>90L\/J8E!_'D@>R:;]./)Y]:I
M<?+.:)Z=G9P>M[[<S31=51?RC^.3ST;S P"W==H^.6X;;[\89[^UVBWC(YC?
MK>.S-EJ$?&!(CA$R,!,Q 'J1YH5%R0?#3):5@-&J[*27&!B#MQP,!V4(%;Y-
M$S1^:])=H9T7&R*^S>1@8#0;QL>.'(@+50,</E;W+"SBK@INHE4[R(;%)HL=
M?HE!,PXXRWKR*H<&A38"(UG=]!SM[=TBE >'88CN4F9XM7P8%L^'\5@\-I/U
MCU3E%[A3%RWSB[)4>=)3]RX_Z?&NW,7Y%B&+!\T'DH/IG.#UR@URX8Z"][E0
M1OPN&N'87A/?\VH^-B]\A20O9QB+B\)G&+=6%GJN[EA$ON',<KXM+XSU05J<
MD.)?H\+)N5&$1WME8?1!-?>P.Q']OB'8O6N<HX.!,5+E$^0<-,_U33[;<[7V
M5P<6+L7@"E\Q2M5G,+*PX$YQHKH"J"UHJO+:6"+ZO'"E<IQ@Q,_@Q62>8^B^
M\'"BM"<7OS.,'GP,=3 V(8Q(U4CJYL.L#R,Z5T-,&EV4CV)Z#<.U\(1PU6+H
M[ZH9')QCY"C(^%!X 14+SKKXIQ(6O,$M6@HGZWK5S(,:;_!ODJEA!H-A-"HE
M?C+^"\[L@N 4XQ]#Q:EZV")(/6X*>,H?238 :<%G3N/;^6\K3ZR;_.L[3I3L
MU@5O/&-4NLL%T4HW.08W-;W$3BX&0X[>=.E)ES>NN>0E-O#3,0@*.2T^C=3>
M ]"F.#<TU[U><@,'MVK?*:-4!Q4QJ$@6!Q6W)SQ84J+L2'SPQ7&?47\]1N G
M"!J^0^\3^,&0$?/O%?BY_KO N]^9USTL;L/E>&ORL"2 AZ7WCWVM7"C#OY4/
MU*Z,X"<KJ+AZ;: VU]GB]S\ ]?W >.>M CS+W0]H+6ZY'JAXBJCG9I0NOF5+
MW2FRM$G N67[O)-A-D3/UW;4TG1REP#Y8P>3)\U$JS!Q5\"4GXXPCV-0<X*4
MFR9NZHJOD@'<3=RBF78^9DE/)'W>F16\EX\C>?.X_X0SAL]^Z+:HNN;QP6GK
MLW'0, X.]_\X/&Z?'&^SHIN[!:;6;5JWW;WEFKTH@RNA9"7B>]++TY[6;-=H
MMAFQTYI-:[:'.'&'S>.6T6H8GP\_O#LY?K^]:JTM>TF:&7^!4*EM9M0ZB9HS
MUQ0B'1:SBEKC:8UW?V\NX3VI)"[IP-'G6MU=H^YFA4[K.ZWO[J7O?F_N__FI
M]>$0U-T?#>-M\_1LFYVX@R238I!J':9UV#U:[G<N_AE*M;T8RA+/!IAF]/&B
M<=!X3'7V=!S4Z%]3F9Z/_M:[=Z>M+YBL^?;#IU8;R-_2Z-?HU^B_!_IE'&?R
M2LE2!\M"I#VIT;]*[Z'17_O9QJF;IO%[P_CMY/3X<)L#7)K[FOL/"(_R7I1Q
M)4AIUH,WW36.-/-7Y3TT\VL__VA]^*",_3].FT>M4TU\37Q-_+NWW!\2%VJA
M&&6\.W=5[+.S3)-^NTE?\?ZOPV.<4?MP\DX']37O->_OR?L?24^)41H/'C<-
M2_->\_[^O/^M>7K8_LTX:AY_;AX?:MQKW&O<W[WE?N-9DE\81[QWR7N)IOU*
MO(>F_9R\G;\.6Z<8>#P].3@]?/^I];=&OD:^1OY]TG9^)#)3HI1&67(^E+\T
M]U?B/33WYZRY._OMY/B+\;GUX:QUVM;,U\S7S+_/ KO!1=J[,C[+#CQ$KGF_
M$N^A>3_S\_1P_[?FZ0%:)Y]_.SS[T-KB6B(:^1KY]V^YTT1<\"Q2DG2!=:ZN
M=*[."KV'9O_,SX^M4^/SR8<#\^1#NZ4G<#7W-??OT7(?969\3CN1>=+)Y4;,
MWRZLN+\"3:ZJ["ZJ?WQ#1=OM+$AL+RY(O!>FT17\<S'H=M[\_U!+ P04
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M>)83>%]42#XE%_-Q6'?HX-X0.J3U8JWP?P^3"QRYI'PVM%)D&2A(<2E D%X
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M:]518\2<25KJ"#E19*:$2Q!CI, H<Q:YS.AYI]32-O!VC(C[G@[MR:!F.NK
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M ABI: X[9:SKLNS?!-'2H'\5[%O\&+ZL(IW7Y<U\3!+^6/=3OA;KQ^"=\%$
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MT5IU#'P_^XVP_OYZ>KF3='6Z=*24Q>Q\@BHJ4%)%< 0=;&11*BEE5/RI\.N
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M<+!U&QR/(T%B_^/PQ?EXC,-T5=RUMOIR&'W9G]1=%G(*>MPXD41,]>9ASW1
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M;]^NE5+=/(/0D'+(2FG0SMNBO+"&*YV*2WI]=ON=K^MTIY?BL6OU?=9T"/K
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MEKGF-;1]?O%WS!^I42]QTO\XG'UVOO"<).HL"V?@0J0^*B2#1+TU2,LY>JN
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M .J;[+,OV_?;:#Y7/#L;G0^G/0,Q!J0XAH<8")?%>>*<KL4U+,U^O,TRPR9
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M H.ZE]Y#GS!IBG9L]KF.,, HJ*V+[-34PK7CZ5C7'7;8K =QWG\_7;:\;^%
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MM=[:,9-<9-K4D4#5+G#"J&1-1.-=+TOH1YV$LY=.>DS"V4>@1YV$(WR.7MO
M<H!,)IM(S!<AF>(V@>(<H4VPY0>>A',(-\95Q#.8A".T"JDB#<9RIHNLG3<B
M9^C >N,<(C;)?C_523A#;.B6NFLP4?*0Z09](/]S$DYK+HPPCN0013Z323@\
M8> ^.U:2"TR#<\P;)5GM28/9BJQ%DUJ'9\.]D2?A')MZ^^COR2;A"'(OR! P
MS/":K!UB9J ,,I$A%YY*X*F)/79"DW#VTO-!DW#V4=).:[Y9UX:O7R\O:N&,
MWH7\D'-X/2OU/_7/1^O-T&N5D3LP[/]F6WT6,DC,L6BGT6FG9*3W\X %71+:
MYC Y8+V&W12*-=J4=2-<C[5R@WP"$$0[YZ76X$L037K['*.;PFU);Z3[@;ZT
MV05.$)QPNJ;$2*]J%SC.8DF)%2Z\U\J'Z)JTS^N![5G<XAS&D!Y7=(,TT; Y
M01?$WW'U>D8;!;ZYS DT2 8%,AXS5$$H%A.GG=_RI*33Y+,WZ;C:&^%/0IS#
MM=+ Y-K;"T>HH5XOF*E3T+42A7G!/<LJ:NYB,-HUB6K\D EN0RC45#///<'-
M"516>,DBCV2@"@[,:Y*>2L:4I%-VL6G1_(^:X+87!WHFN.VCBR=)5>H#\)\)
M;H?I<^^<I4.4\30);M(+Y= PK'T4M+:*!6XCL_0-90$*I?MG@EMCLNRC@^,D
MN 6-46F.3&5>W[>61RE!2HQ1^"A]0M5OA,V/D^"VCPX>3W#;1X#'"/QL6G#5
M)@$'1'1N_^^#0S4[L6SWNM0H=; Q!Q&TL3J&DCB&( 2 +I F.U =*)>UZ3!4
M.E</&5-&7;BV)!63@HQ"VA11EY*!YTB/X^"B42#LY$&$!\IK8Y7-Z?VN?S@@
M:MCWT6/*MO\[;$E<^>"!>RR<B%D00L@II1BUH*/"9#WIN\B K?OFN=<-]FY\
MKLC11NT< YG(Y^+2LAB]8ZB2A2+K?-5^LVH?6F7X3<?5$S_ GV]AA8LIG"U_
MQ]6[4J/JBV^XG&@?M4_T'M;5NY\8(XOH#0,$,%[0N=RFUO%Q:,<[Q<;5]OV;
MC%&5T""X=XWP/^>+?UQ?O-R%B*@3NH#,('=, [U\<$AJA1)-S*G(-@&9'MA.
MCB@CJ:')U>D5Q)JJM?QR65F[!9$[!0$"67HB%Z83).9#E"Q!Y#P0T9UL$@#N
M@>WDF#*2&AKDZ%]#7)=72]K O$=F?:W ];(0:Z-CCC8]D>@\M,DWI<11J^"/
MI/M]!=LD@6R#93Y+%XL%_6:2>'(9I6?9^AH;I&T*A/9,U4Q**>FGGK?5]366
MTU/Y86(>NT-5QXM>QH4='46Z^$A0T->7#"P&SVLI6RCD5P8A^S5$V[5"Z^N6
M-GH<3VC/YD(%SF"6\.,7Q-6;^K<W@3SB'GG($9E0M2.,"(7Y7#03B20C2W#.
MM&D9L /0L:]41E3U=IAS#)&W"(%WX-JDF/9 UO3&9">T)[HJ&46%/7@Q0/Y'
M9HATB:Q1PU) VDT52!83:%:XU]9'X4 V,0R/S8S'KD6.38P]Q-Z $)<IHY_F
M*SB["N?7SLTB.<M4%)'I6)T5+(EI:3+7'NB?)D/=[R%Y@JN3D=0T'U/&1[XR
M^1T6"WKQ;SA.>/O>X\8,:3^,=3N,'97-V7*AM-<QERA=YL7QD/6Z?>?DH0<W
M"UTG99#7+EA2D=-H>&:AF,!LR:9P4"F4?I>/1PE=_^=BNL)?YW_.)M([0?:3
M9>!5[2=-SJX/L3!)3K J-BJ>VWJ6UU">E6.YAS9W1QP/$O*(H>B'[69AO76>
M7-S+[$4O/(/@"500)D"P";$<RMCGXE<>H,;QA/9<_,KW%_%LFOY8775HO'ZC
MM3$4L];&^<1,K*-<$T1RG)*B4PQ-4-R0+]XD6^\A4,_+O]Q+Y?-&HF]@,.["
M=FL\;!^$+7W-QR$^C<\YGEI[\F6@3IZ(/4(DA8E &BWJZ$?/HI.9\9(<]RC)
M0&[2K>6I6/.(/_JDI-E#%:,GZ]VQAS+90\LR7_SVU[H.\=;M_:;ZD+PP:XU@
M.2E?IT0H%DU13 1CHT6!1MI>9LE^ZQ[?1QU;;?/CR/P87NS[Q9R.[=7W]^3%
MK^!RH.RZ0O40'W;WPP9[L#UQ;J<(.N_I8[?<T%?/;?&0E8T8K71&9F<GO1"/
M(L_#TP<?>V0[V?9)+30YRXC%9 %:5#/?Y>QT",Z[6$K:+>%AB88['WMC7'Z]
M^BM?K_X*;O[*@"C-&,NVT]>A[[ZET\)5"=G8))75+DE/[V_(F>-!8HQH=NOT
M,"F,HO<Q8G#]']Y.A_O%YX))=&#PD IJYR%RJ52=N)-0<:D?^/I&BM9=G["W
MUWEQ:YV;"($@(\N!ERP(0*:MY,R;.ES%9@4Z9AM3&QOU46A##?27\'6Z@K,Z
MP^'E_/SK!9WX'^=E]2<L<#U0!HK%J"WS,M2<-RD90";J013.QQ12;E)"\S"L
M)[#"QN7(MFT^HA8:Y*C>I+Y<S=%T1DL9(N%)J08J70V=@6/2U9^+K()K,F5R
M&\C)\6"0I)O6CN]\\<OH5[ !HZ'W-=K5&O>$+* U+"NOO5"5P$T8T1?@L6K%
M&_.CB3Z>.@"]7*PF'U?D:]:'_ WGGQ?P]<LTP=DZY&'!@^"*,XZ./-R<R>GT
MSE5?MWBI@"R&/NU?:)%;K*+?;3/J011/7QT^IK[G8\M]Q)UG#>J23[<A744Z
M^H#:(]+<CQ2[T!PWJ#RBMN:M1'TT'F )PCC:.5U0Z^%WR&+(ECE'SA^Y@)J7
M/F;I<]3_CO#PL=6_CX1'5'N:7\Q6B^^3/SY.G!(\Y%Q('2J2Z<,M QX+$\(H
M%Y(/QG:DLRXW8EYB^M?/\V__=O7$JF>W^4U5L[NEYIM5CV=1CBC^^2#9M7$8
M_M@$C54(24<(+"FCF7:"?!=/U@]A$CP:IXUO,F/D%H8?6:E#1;KSVQPQ#K\9
M\0BS>[TI#XED/?2XP;&KWEBWHE5<<"USX,%ZU#DE$G.4T12;D2LCRZ0GZI'D
M>GA$_O&'MI1QCZB\5+D -S&0RZM#%L$(8WBN^?O.9[0/27I87/Z!!V_^:$"
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MH$QFB<N,]-&2A]]F+-8UA--2]X&BO:]D.\YW_A977^;YYLQ93H)).00#=)R
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M;DBGQ9211-_!BL%M5#_,O\/9ZONFLY8MPF*L5Q.A&GR&D\$G36+@4P""29K
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MH?6[.?AU-LTR5N_O&N!$>:B3_10KCA-(Y6IE1RZ,[#&O-""!-/M18>=:I\B
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MC-90[_[RIV'J#!3KR%V$[Z*YU1:@#Z:Q#:!=8(YO#0U5TDY]#Y1PTT_\%C8
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M++2ZLAV H2^T2]5@Q4_3V6H@,)G@ I5, K3VM<Q*T"EFZ-0)*2M3N+'<G=<
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M$,K\8E$]UJ/;I<[A%'&[RRV-<1^T;#0@71N6%;[AM7"6R;?'M4#=HRE$#R4
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M+IRV>^1!>6(N#\=J2TF<ULXI>@ B5>'!@@J:J:G>X$/UL6L\6#^HOPZ1I2<
M]>>PI(.?YO'%2XN[7X*LT?9(1U'-OHRJ:D@2W\((C_6'>7'YMD&GD85+54J7
MILK3B2:64"X+!O(NR<]OC+WA3O3"K5_(1SY1*2M;V/E>1&\F-D+<'//5.+6Q
M"%?OFE?O"("#0+S+<H+''D^%TM X)EDE%P?#2\$M1Q\/$X!"1=/X"%CE-FD5
ML=Y:OYV2;T)C: @SD*&.'75+'\7R4>&=F_)3[/O!\DZ9RJ"6@81U2_.,HJ"B
M(4NOTR>/;=.3]=S19XD+L7<MXE[6MHMZ/%^G2%R@1@_AR-D6K%;90_P=R)0A
M:YW4YUT!2>5 [&I!M6:?,\<VMVUCP]Y1%N*F*2[X8[Q0_F.LL"5W#VVK7A<.
MSTJ$PH18TJ^[;#,*\RVH4>'7"ZS0!T<I6!Q#[-U,E9:*[2*_':\[Z,\8-9R!
MEWU6J8DHG<&3P*2K=3I<4/^N9/F@OQP%1:V";SI_W^M'5%7YLBFAKOM\:YA1
MPX7>F_12B\;L*[.7X-A0/B.\]1,IVX*('35[>$D#4C[\WA(>9W_07OVUC  8
M^31<9L<[K6H>HL DR,J474H]I]5#]<(1DE-MS6JF=*;%;9M<;*=7!,<.56!$
M36%YJ!)[4[K^(A[^F*& $=/;#H+JIERK"R#;]@@6C'!6!AP&5)\MVR_5,J49
MS'N8VI?Z:_G)>?\*+PRWT"[:>4(WK3WVQRA16GLQKW5R/." ,4*WK)\[1J+#
MEB=06.0SF-LU1,<_PZE,Y!@W#^"M366E; DF0E6_#P$H?9>G.L.WC=>-=G.,
M/.B.9UE1[(A>UN'^N7C_ARY>?2:I"L=I3:D%#02J!+SMU B-V(HLCYT=/SAR
M5XP D*<--E5(>T$[-[7MPFA1X_JNB3DS2BLJ/4'PG6.2747!PDBE$"_A9L2+
M<DY-*=SPYY0;M0%GU'B1EA3)G  7_\R:6/N,)7E56G&1CT76 Q,-B$)%>>\-
MK'[JIR+K:[ D+L'&D;/WC#UC6]":%?6QM'?>5.'#&*/=>/SW=P;$YPG D2,D
M(S!<NJE"MB@%]T#RYMZS,0)@U^N V% :_LIMW#KL#,O+^ -M!\SE%'H;K+>$
M3.Y?&5IP'FEUF?T6FM9U]X5"!K8X!=K?MI#,O<X4O(3QOBDJD72J^)X\8[21
M%J=BV)FRR(.YMRM]B9=R32[YY.N[FPX$Z4UQL,T;D+/"6C;POS!^8GL)8\81
MG>@GU1PAM793IJ>[,"8)MW4_B)P/JB0 4PV"J(D:TQ/#HP6RT-B"[68-R;$W
MZ<;OMAH[SN3M7XY>->C]]Q-V4;_NX_[SA47]^6'?HMS,#%LO]P#(##@VEYH
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M<^_94(I5?R%B0PFS,6/<.EH*FR,W"6U#KO6'9R6Z6-#ODD@EC+$!B52*D@A
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MW\[F#YG7^W^@24DK-?P0*_#B^*&:E$3:0P\Q G4R_KTFU:925K:T.\P(/,P
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M@[BHPI0TVS(LY?Y(].*9IB4%=1I= .\@*=G?'8S6K/ 6!GU/8C!USDV&E,2
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M::^$5_Y9]B1W(CC#.D-?N#?=E;6<9V31P9]L&*=#Z;YPK-G*R&<^JRRHV/G
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ME2I+:TE.KN\GL+D"*>AV?M?RLTW2PI;T\*6R92+ @O1P(F!\J#MQH[*DZX<
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MN$^FN,CXWB-6^'^@7_K[#B?F^"-(<HXE5W*&/=5T>3K-Q9T0;;;9'6/U>6A
MJ.>T%Z.FHYBQZIC A;CQ^H^[ X1K;,WU_J&K+?/KIAD]3[797X:/?"GTZY8
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MH[&L=3[0H .>12\,?:GO\TO K6C.;WVX:K;]=2.KHP7EZNIXTI7++S[N4K2
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M-*E[\-QO[JSUS9WOG+DS<]>LN>='K=4_GKUW[]JUWWJJ=E6]OZI.<Y:[+[!
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MRNB76MB]D2>;U%Y"A1^8!@0T4QC\"&B6$1PMG27S<%9!O!9V0+1E^PPTS-$
M(-?@EQ9U<ZU*[8WB4N2RE65O]D>AT';SI!D+P2ZJ[_3LFO>T7\^](;LN\MER
MGH5T;=3=K0H>7)H#A8W<<"6AT4A531,C^^;8O"+%>"2#^+3<P[GE()OD9+E
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M>D&JZNI;5LW3(.$,!R$,(Z2X,4I2B,,PA)*'7IIZ*K8@I-?1LN<C38T%&^E
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MMQ>7<L1J<B^NZZ%]]>E(U:<NGGZCFG.\7\2#(H8[HI]?W);D?E58#$E*/!%
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MB06#01@@B%B20!('"<2<)3+T, O-VF6-+/?4>&VEN5[%)ANA=54!1A:L:0
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MH6,/&QO9]S,>&$"G#9&'DG7<CLH#([[7DGGH\?K-!<VBT%8M[@_K@_$\C8+
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MW-2DK,?Q+0VEM_ENGNLPW">T)3P@]:888^C/@)Y9QW4P35\$%"0IER2%F),
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M>.-X[M@IN7?<J9,7]JR[H[PS(78+YGT1N?B#+'3EC3D)TB1)O00RJG@-)8S
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M/6D\Q\Q*LQWOS.[.OCUV=(3]E7P3U37)^%PD<4"2,-*]_1A$"/DPE2&&C.(
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ME4!3F_"U/J!1:+8J^4EV*WW:3=$7&\QL8AW3# -/A]L6Z+0!C3I@I<]LJ^;
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MQQ0E*0U3*Z?X]'!3FQ>Z_D#=D5S1=GJV7&8X ["99^L.MH%9OFM;WB&V)>H
M-3C-0''IJIX9<53?U$S[Y\ZHX5T7<,DF7[5=I.MFVR0,PRCP0L@IY\K;3$*(
M.:$PE"%+ DF)X,B:2 Z/-4T6613Y+6P*>?<IRGL*6@L*N1RP4?AC(^9JI=>=
M1V*!AW/J.#+<^+QQ6N^#I''FEIZG=Q:-H43;%??5\VV@M^V,.Y<IIEXB$(P3
M%.N"OP@2SXNA\'W/ES$EE%H=R3,;=FH\TO0,[G:9V?9N=.>8Z$I@BR57?\UR
M4+=UP(NJ6U/JY[P8VH<%$0DD\V"*%<,C/THAX;J.D- 5F1%/ Q;9)=>YM] X
MZ7;G;#0(_&83@'M(1\R^6&=5;#:&9^#M&4SMST)90>3T])/9R..>=[)"8^^$
MD]W=[KK'K-S:I^Z=J=XLQ954!/TW0<IWV:.8IPA+)+P$\@!)B!B)8$JB $8>
M]S'V"1+4*KVZEQ13FUV^JCE>$"WAY?UESIO C+(&!W9@!CO:BV:MQ&S%;"I
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M64QY% HCW]]0 >;&7%H^P&L!P1-A6FR+G>&0*3#8?X\,[,@TIJ4''?&O0*T
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MR"3F//)"3.D%-<I/CVSTX4Q?LGPG;55\@G4RRX95+N_!WHR#'$$Y<5US9?&
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M-&/%1NTQ99!*SJDRT7$JU'[?XQ"GBO5)2@-."&+4CVQ8_P)9YD;QC5@@:\E
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MZ64$-,>VKQP .2 XU0B>BV-5^T>9.'352.7#2%:SVP8:+-DJ6XM/RF#B1UH
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MK+A.,EXUD@+R4'\;NCUX7HCL;@64,5J(E5JJQ4]EB*[NA#YRKF**!F=R[\V
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M77)+GO6OKG5'PKIDW<VJ7!>5P[NLHJ._WY/5E\?*4? Y7SV)4DG[>5-M(:-
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M)2U^%8_U7J#\(F^+;,6R1[*\66F2U&2YD"3Q9.@QZ#%?0)02JHQM2J @%-$
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M^9D];!X6V(L"7U ,$QHJ DE0!&F8!E!P'8]*I%"<8FQ%&0XZ-R9IQ */K?A
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MZL*N !C%.S?=S#BG]'&EGGY]F&06CBXVTXP\Q.%P^TT7.F)K^OR](*N25 T
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M73OLFW\OBNQ)K3-/37;!0J9IF @L8*0SX9%VSV)& B@)P<3W4HXIMDF"WQ_
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M)I^Z4>6JKZKL$QU^4&#,9+=2RB:E<F7_^@MPT"P*@$ FSX/M="9)K+T@+6X
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M:NW_6?+CT_DS'7I4S\^2CV.WS_9VYP"W<B/V<P2[15(2LRA+>0(Y"E*(<AI
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M=:I1QB'F3$!&\HABJOZ#C?((;D8R-:UL;:F+CBP::_9+1Y6U339IZK?,DH'
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M:>V?-;LJ%2B6;>'\&>A8 "T-H.,!U$2,N /C?_9&W93Q"']:^S3^Y\5ZZV8
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ME\QSG"4I"Y0S%L5,K[HES .9P##*$X8323&W"@US1C(U:=H"!T];Y+K8Y_(
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MN5H7F?? N3+8U+[".[B :+P @FH+V>(5?HUC ^_'(W.#+Y.VI-VUI.W0NCA
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M'R8%BV&0< H1#SE4;H;2%98E/$5"!MS*Y[ <?WH*HP&"C=[Y*98Z @=4^E>
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MS[CZ?QOC^CIQIF9U;V4'<TTYM6#+AX5>8,L^+-<MDMF^,1[T@3>&5A&X4IK
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MS<SD=04C,.T:XV!MDQY3V*=EN3?^J/;A,<U>6GE'/^/2K3C&V0DZN&.KI6*
M)$HW&Y=(LES$*<1,4&6LT0A2F3"8<58HXDPX3PKSQL46,T_M[8Y_QN>MM5X#
MH%6PZ<=KLQH&IEHHC .3AA6\3GV/K;[U%BV0 ^$]DKWFYVMMV1S9 ;+S?9)M
M!ARQ9;*#GOO=DUT&<+/:WJR;:M%&@S[2JLMT_U(O/^@;O9V+O3Y#\4[V4:3B
M:Z5@:']IVNY$.F;JEJW61+$4B601(67P\4CH3B$,DDSM(8R1-$ZY) Q9=5[S
M+N'4=I@A[;>IVGIW6Y$M@D?#+:>92?JJBQ1XBQIT SO*W>BX>M#JMQO;H/LB
M=XNYE$,4_K"P.VJV 9LWH-/4GYD<;!%\VMK^A1S58 ^&\4NK/]Q$#JY#?P^A
M9M\V56[NY)LU?Q KL9MVH+,*FAF6J> )4HO/D'+_241@&1$.4^7_\X(5)$O,
M:Z%;3CXU>A_N<'0O=+)50#,$[5782Z-B6@D+ ]=V;0Q\B8"(ASZ#V '[=A_L
M0?J]Y*FW@<&V<"@"@CZ23^$7?#O?PA&]L^Z%[9CC>1B.VNXY&:YCN/D9[T1=
M?5??O^]=[85-O/0O];)IAD;2S[,4Y9BD.(.%[J2!>); (I<(EB4F&4Y(G-+(
M(5K#;/:)1F.T0H+;Q^6Z;3$D9:,3ZQ=@]4WH*D'-<EYI1X&#H63VUV]"F+*:
MY?J8>0,>X1YGV]@*W)5]N=GIPW0#N@78R.W/8+?#R:<5;CCSJ*:U'1HO[67+
MIQUS,=@WP==S96]_J!;52GQ2TQV4E;DGZL=[\6/U1FGWCUG&\H+SF$%<Z';T
M@L2P3.,"1D6&RJC$E".K1"\'&:9F$G>"PU;RPY)+EBD8#DMBQF*!@0X=!-%+
MKZVO\WB#/ULE@-8"M&KX3,QP!]%K>H:#&.,F:;CC=)"J<<50#F<#?Y"ZZ@:K
M'S\MR4*?5.\>5"?I$/^5\D+?_$.<1!BB.$*0"HIAE.2E^C^,N=G!L-6L4Z.^
M06Z@!0=:\O;.Y<652Y):^*3&"V#@^8> -3#1F2+J<GEH#*V%GQ\"XI$<_*N_
MO'8^O2U29YUYX\'&\^)M]=MSWZT?=K-XMV<#^J#@<5FOJO_NO^1%E#)2II Q
MW9"J+"DL.4NA1+3$I4RC*,(V=NW)F:9&X;NR#46O[&S6TZ":6:9>H I,R[MB
M^3,G+VKNTV@\/=FHIN%%G5\:@)<?N#HOMTTU:.[6JT:9E;J\U*Q(J4P3EL$B
MSW.(",EA46AV0(7,4][>^3CF@AY,-C5&Z#,9FRZ3<;D5M$W%;=-O&_?\VT.L
M\S3/9:F^L#C"*40(,4@8DS#E5,:XR"-1"/N6BKX0'['-HGBH%@N-<S=G(+@E
M*C#B-((B)FJG8YCJQ!7EO6!&"$_3B*;4MO6B7[##MV-\WWV?@^)LMOGY0B[P
M_K>?W=Q)>@-V9 V2TGP2D4"IS(?SO58*\TG-SZ0NGW[FRH)?'Q=/:M!/^@HM
M[CW$+)8HQZ*$I6B;0XI(_92FD'!6<H[B!-ME1)R9:VK;8RL;B!V+>AW!THPH
M/"$4F"=V+YHZ06] #UB #I &F 0IZG5DNM>IZ75:[Y,EO<X\8D<37%2S]XM5
MM7I^*W2;C_G'!1<__E_Q/,L%3JC &&8T*R$2-($E8C&,=,7_F'!EW1F5FSXY
MP]0HH1,2]%*"5DR@Y#3CB-- GF<&+_ $Y@-K9(PYX*+VVS>_&5[]1K"?'Y;?
M_ZZ>_;L^4],_M(=K.R_[Z7%'><4OJC6\V)<_Z!X9V2A/^UU5"[:ZK\FB(4R[
MVV0^E++(LQPGB?+0.(T3B'A*8%F6"<RS3&0Y(<IY-BJ49#[EU%[X3E*PVA75
M-=3Q M@&UQS>(0Q,"H.\;6A=#^6>R$-1$.]@V@<P^@-UW+#%*\!U"E4TP\DD
M0/'"2*.')9II=BP8T?!)U\;;RN7[MIRK)QK=TGOUW-Z9; JV;N-#:!Z7&"N+
M5J1JFT-,Q) R5,(BHYB5:4:4,V?7C]MPYJFQ]J[@_P\0K>BV3;I-03=SZH)
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MM,"[W0:OWW;P(E*]">!V/E_^U18OU$&X;Q5U5*OV/EIM9IT>'FL(&*#EM8S
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M6A5TDR=D$=!@O SG&3T8N*'9V1!1EPYEQM!:1(B$@'BDN!!_4-N%@MA"=C8
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M!BOBV;P*[0%ZY[GJ6DP",Y M'%8594_I?47]V(,A1ZL6>TJ9W=JP)S\S<@&
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MXQ3RM$2X$'&:)8E5MJG-[%/CEU[X&_#0B=]NNF1/@:'EJ*6S9;<H9NP3#.K
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MK3#[#W[N2D9HA:>PWC;';A-8][%.Y%YW_2U/[@*OR_E#O5"3CWC>%QB__:/
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M#'VF:2WL2$R]47HWL6NW-E>G.NAU!UOE;\#G+GE9 0!Z!,!J"3H,0 _"?H1
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M *0OR9TE2 8& 6608]6B-\L#U=%&0!+P&*5)CG-JU/5*;]BI$<;&:E KLV_
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MC :Y5^,UXW&POD][7&SPF-V6^<VZ+A>JWP7]U[JL&UV<NVKY0<D<[Z@=;\N
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MB^KMCXPORC_O9/CP*+\2ZU5)\5REOW:YE#B(LIAD.<1"-5HG800E4V20Y$5
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M1"1-(4DD944\(U0D11 PK?[,.H--;8UH;-VIK@*=M>#WUE[3_A-#.!N<%3M
M;XQS72O@[$Y=+R#B_(3TW'CCGV9>\/SDR>.E9ZZHC/U8U^M3!6JG3SQG62+C
M>1)$,$EY"%%8!)"(((><1#DF!28)-Y*@M+!A:IRCK,=R_L%Z(;$'_%]K)<=3
MRC]9-,JR3_+3-?BA7+1"Z?7YHG%GLZ1)37ZQ'X.Q:M#:WY?*WIR^=]J>T]\
M+.270K6P%KQ4>>*.JVOM\'1>9&MHQOBUMG8XG2RYM7R5K:K32GZ72C+GK>SG
M9[YZ_R>=KYD<_.?EDOU1SN>WI%Y5F*YF1(9@8:[.-!F56W>24UBHR$SE%T69
MW%)F9G(")H-/C2;;4ZERXP' C0NF E &Z.NQH"],/=/?UNR-^J^T'/RPL1WT
MQO\(?N_M=RH:90Z;6Q$I@_%'%I4R1^989,KB'7:$]ET^]D7<LF5S4=V=M<2<
M)WD1!C#)::@J9"DD**)0Q$25QQ8!"8WZ'IX:9'($)=^HJE][*RWWC"?QU*.B
M:U'R?1EC#) QJPPAX)(]3HXS*DL,>7K(!H.??1VE\=]XO6H43M3M,%5%ZDOU
M1U_6JUHREZ*IP3R[1(9!1#76BD.&(.()ACCE$60YQF&&\B+.S+:1K^K.U)BL
M=T+5GC]+-YKF"4W;KGI5/BI) 2 V^Y\:X!5XQVE;&1&'-ZHZ(AA7[?S*;Y/!
M2=S_$]^1,7;.CC346U":S)_=;]UOS;=N!YHI976.,L]3DFB_TJ-I97R.,GNN
MA=\=6661=/6?Z\7R^X-\YU,CK*AD%:49W^9+O/A??"57(SGV6W5\6;V5-O.J
MKQY,E)(\Y[!(B*J00JD20@P@3@(NP_\D"9!6#\PK;)C:JJJ\,$@ZL@1^>"T;
M"4[/"Y!R .QZT&FLJE6D<0-L_ "M(Z#UQ*9PUO8'H)\:YG\^1DH<LY^7'^AR
M/N>J(QJ?O]R 3BM7O<^Q4NYU6 _FI5F^>KRLM>M\W\MIN_)5CL39[JKE$Z]6
M+W?R6[A2BZ/\TR;E>$92%""289B%1.X/::Z2@7$(48J3G!<1RPLG"FUG+=#Z
M=8XOT_86/Y7J&)VKG&S6[M^NU&0[/PEZVRK'F+Z>.EMO]PUH++]I-S6]\1YE
MVBX"YE6K[?SHKRO8=A&5BZIME]]@6\3PLXS[5^_DC_X#+JO?\'S-NYR@/$0)
MBHL$,A[$$#&10,R2!.9(Q$E&TH11K=RKRT--+3INK_<::X$R%RA[06.PX4&Z
M!LP:0;(S\'P?JH^)FVF]@PO\1HI=>ZS4R288!/7VS[)VI=NKA=+E:HBS;QBY
M).*2)\=U$1>?L*#83\NZ?KM<K&0,RA?TY7UW:+T4=_(OU)VH^D 2O%\\J A5
M?;?D7^%:FO&([WD]PV$6,)%F4 @B0\9(4)AC=8,91S3#B0APDFF3\)7&3(VF
M>_O5;<!3YP&8RW]1?1[D0+SQ%/"M.\TGI4. M1X9D-&U$ZE!\R-.C^>%0!D*
M=ERY ;MSU;L#FH_]D 3_!M[OSY'R"G1N::88.IDD@S5EQ,D::=499]+,UB1'
M* ^N6M>.,=ZZY@B-O97/U3OMCE$^\;KF_(O<VF!EP2>.Y:I18E+.2[G7Z39!
M[];\_W!<?2B?^2R,@C@+60%%++C<E 0!+-*$0!2$&6=IF$0)-KEL-S5@:FN@
M_#HG9H<FQI#K'9WX!-+W:M68KBZ".^-!8_T-V-A_LZ/]JP08E1- >>'N),46
M/Y?G*<8VC'JJ8HO0X=F*]7OL*.X=K\IGK&X3FO3'S=[BYTH2:_-''Q==-N3G
MY>K;FOR#T]7WY2^28WGUF:^4C3N7L[,"HTS$+((Q3PJ(<,Q@P5$$18A)C!.2
M9[%129QC^Z9&D,UN^;G9+<L8I<G3!FSCLN&!L^NYU*/65YPAS\R[]:Q-_+[9
M.=RX 8U_[5^ C8=*!A=T/JH3[]9+T+FYF_;CCIL]38!+ZG9MXJC,[@G?0^+W
M-8QEUBI]X&P]YU_$UJZ/BWI5-7N]^N/BF]SP-0-]$1_*A8R^2SR707FI=H$;
MV[<MPQ/"2!R@&.8AC64\G*H>4(C!- Q%0$B8%HE6EHLG^Z:V+GQ;/S[BZD4M
M"G0NEX52E+3-'%1796)OU=BN%Z#<(F"85NIXNO66CE><1,]+1^^9FI^=963'
MN48FO7=/?6SC(.@]O-D[3/_>=+/R(NCF:1Z<)F8Z-G'<3$L_^!ZE3GH:QFX%
M>;.NRP57QS>/1 ZFQOC*Z?)^4?X79ZH/]4J2&M[4774WR2ISL]_NE%RM>])X
M]G'QK(YVJI<90E$LHB2%(LH%1$FJ].0YAD4B>!I$F ;$2"S:BY536TUZPXP5
M@_S,H=[B\.HSXWF)Z/T#.PZJ3D^]BV#7QZ[RM,^@:<L =OP$G:,JC;!SU=WR
MX'4F7"X2?@P==:GPBO7A@N%W,)MNC=*"E^KCX^-ZL5SM)TUVR<((%1D.&85$
MA!@B@2-(5 ?NF!&Y&/! \(SHMV.\--S4B+PUV*07WT5 -6Y^G<+DF55;6\&Q
ML5V"M45:^V4,31H6NL1RK(Z$PYBZZC.HB\QP(\&+;QFQ4Z"N1_NM +6?LB#8
M]W??/C[*:5Z1E^\57M3RW^1P7<Y:3(N 9!F!!14(HD($L A4(Q:>TB3.DCP*
MF3:W#HTT-5J5MH+66%6,N6.N35[@(,0:;.L*.,]$.QYF!NSJ"KO7R*0< -1E
M'J4.1(,,._B"\<A5QX\]7M5ZP%:IBE;JGO8=;__WX^*6TFJM@F*Z?.3?\9^\
MOL,O*I*>T4R$" =<1JPT@R@H I@7A?RWD&6QP$P@JI4R:3'VU&BWM1"LE(E*
MEE_9:"I2I0^\WJF#)S@]DW%O-?BAM_M'=;[< =P8#>XN &RA2V4,E5M9*OWA
M1U:E,L;E6)3*_!5VU'7+6'/\B^=WN)2O[\K>NHU-%J:9ZO8,HSA1JGI,D15G
M$&'$(Q137!1&^6R#HTV-GK;& F4M_+@ G;UF)#4,L1XM.0/.,Q$=8E9N,/,@
MJJX%BDO*&1YP5)+1\OV05O0>LFV$]LP7:_Y!6JH2=I5<WM_+U</;=;V2C%5M
MKX9#PI(D2@J(E9HQPIA"$H8<%BBC+"(4Y6:9 +H#3XU>.KN-.Y]IPJS'*S[
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M'/1M_?B(JQ>5=R7*!5[0IC'L3N&)80;69<SU*,@MDIX9J#>V:2>_7-Q#U0
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MW.JHPGUDP?X!Q55'=7LIF]6ME*H-_&?]OU_^U+RB?QAFP5_^]#]02P,$%
M  @ ZH%94BZ*6IJ?& $ ).T, !4   !G:6QD+3(P,C Q,C,Q7W!R92YX;6SD
MO=EV6SFR)GQ_GB*[^K91B7FH=<[IY2&=Y=7.M'_;6=7=-UP8 O+NI$@522FM
M\_1_@!0U4O(6N<$-5ZW*LF59)F+X$(@(!"+^_7]^/9W^< &+93>?_<>?V)_I
MGWZ 69RG;G;R'W_Z[?,;8O_T/__SW_[MW_\;(?_[Y<=W/[R>Q_-3F*U^>+4
MOX+TPQ_=ZLL/?T^P_/V'O)B?_O#W^>+W[L(3\I_K?_1J?G:YZ$Z^K'[@E+/[
M?[OX2W0*-#.2>,\TD=9&$FC6)$9N(\M"0%+_X^0O5@?N D_$&\>(#(P3KZ4D
M@BKF6=)!P.9#I]WL][^47X)?P@_(W&RY_N-__.G+:G7VEQ]__..//_[\-2RF
M?YXO3G[DE(H?MS_]IZL?__K@Y_\0ZY]FSKD?UW][_:/+;M</XL>R'__W+^\^
MQ2]PZDDW6Z[\+)8%EMU?ENMOOIM'OUK+_)MT_?#H3Y0_D>V/D?(M@H(1[,]?
ME^E/__EO/_RP$<=B/H6/D'\HO__V\>V=)4^Z*?CTYS@__;'\]8^OY@@&)'3]
M#U>79_ ??UIVIV=3V'[ORP+R?_P)_UG"!3EE?+/<?]_\PQ]O5CU;P!*!LN;R
M'7[CZM^759Y+ 7Q=P2S!AJ?MYT_G\<X/38M$Y]?_<NH#3-??G23H)NM/?1&6
MJX6/JTD0EC/#.3%9&2)I2"1 X"1Q8Z.D*82D[S)<"%XBQ6L%+"'^^61^\2-^
M\(]%".6+M30(95?B_^\/%MW(9C_JM[ON,_[LA#$?>8R"^$03D5H$XE@*1"/M
MRFO.L^,#$'][S;NTW];LBT7\8;Y(L$#CL5W4+^(#+=\%[M5/_'CF%_A!)'Y!
M.&W_=;$B0^AM-1] ?AOE(+E_^@&YSK!80'JWT<VCS*TY6Z%)A?5/#J'W%[/9
MN9]^A+/Y8C41R>AL74"NH9A,Y8@/EA-J1;&$S OK!]3_[;5[X8"WCX.]Y=D(
M'C[ HINGGV;I-9[!DT0U\HQDQ^@RD=$$A+9QA)MH. 2FO9$# N+.XKT0(=I'
MQ/X2'1D2K\X715)ONF7TT_\#?K'EP4EJH[,959@4D4XE8D%Y A(9$V"==(.<
M<8^LWPL8LEU@#"+71LS%YX6?+;LB^RN3I[WR5G @B45'),=ST J=2$Z"!6N
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M%9S,%Y<3'[30.AH\%2DE,M$27:&''9+DSAIM,>@:M$SG>NE^L&@^;;F_.)M
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M',C2K[#:\F(S-5$:C'^ EGMQ0'N.D2&A3@H'R0-&%E5.NB>(&J<_73TL#::
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MXLJ1D((DDG+<&3%SPK($[B@75M9)(SY!5#/^3CUD#::3!O"USJK?DMHM3@0
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M"7ERF?$F0@W[_'E@@8[<5N$3JF ]D>-GF)\L_-F7+OKINH4 RW@&>J-+QWM
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MV 2_??J\6/-^>5.ZN!V2+ (7,6;"@D;Q&C07(7N#OA*D&/#_TE4IEWJ<I$:
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M]<WY+&VYX R<EE26><#(18)(/*!'S(SPN%6<]J%*/G,W.;U0:/\E4#B@WAI
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MF>5*YITNBSL]GI_8#:NWW^]\=7DM5 KM LT3A+")RF,!S[6%F&+Q@?N,MLE
MVJ&$=GS #L'1]@.V@;XF/$&K;3G9^ =W.+BL4W"5T&K2B_%U1*H$[[("';S*
M(=G(DWK)3FW]]&E1TE:9BS$EVQLTKB;CA%BXEZX =P;I^,\"?/ >>";'(&G,
MSNT'CBGG,(ZDL>?TOX?XID8 ^67K[Y_P&\[?S]-5!0HJ[\AR*DBF/@D4F,#;
MF$"4E)F6-CKUH@^S[<,[TOT^VEJ,*+H^(ZO-CA :2R+! !-T@BHCR/^7WD#-
MQ17A92BZR:2<+?1,&RD=Y3P94R.= NLR08%7VZYP)XT.]2K=UUDI3(#3GJ+
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MUW/_TY/Z^]P%>R>";X4@Z<"QV0@(2I.G3W8!@DP2)*(MM4V%:S,[M0DWN^V
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MN SS-+LW&WF?C.SV#QLAD[HCI0=F0#?745N7NL%4Y"PHEAGD&#(Y=H)!,,8
M\\Y)U,9BW*UGV8M+'3S\XV;P]5.KW&Z7SR2XM_07_WGBB\]!E=H$T=4)P9'B
M+)XISLK*Q*B=0]<DG3N8T@GG2HZ+D$=#0IKJK,]^Y%LENNDCL-<%T4L?V=(H
M/47UD4R30D'>CP4GBP>%EJ" =2A@L%$GRW+TN0_3=-M&XDW:C"=9_;Y8X^K#
M(LQ7=+1?+3T__8@)9]^J0&\!;X3*W 8/6FC:7D8$"-%&$#)9Q9DQJ)L,]CB
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MP FK+]>3"JOC>/= /]$JN1AY!"5*K:SQ$:(S"%CY+2JC9GI?"#VS[C27\A.
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MSA)/W<S!L1T7FK1HZ0T)?8EP!(_MZVTS_O.*)/?;M^HST3_;')-<H9.2.?+
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MW;>+?^$\3V)TP;!,7#'+:G1,IE5Y!HD9Z9QD,OAN!3^=E^P&H?.[XF@C\S-
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MW;NG<KG9P;?\62:,%\K5X3\4&*2B(!2?P%MC9%+&4'#0%FW=".W6T/TLL==
M4V=U"GZ\NKP,R^^+S29\%9;+[_66=-,GXE=<A^FLSQ.RPV+M3L]].6U[LG*)
M11L? !7M3^6D A],@A)Y$(9Y;K#)UF_GM-]:\,W>F=3GY2G4!M*V7H]2B N^
M$)N1*>M\4='%)GV6'J%EE&?G/@AXS%D_1MXC."QW&9,/88T7?TU7D^*,T,Y9
MX"+K>MA'B 8=T)\$>IZ2;/-\YB$APX/E*,TN>A3SR&#RZ^(R3.<39"JA<1H<
M9YYDPAPXS>K83>M8L-JB:C(:]4=2AH7*<:I]!B<'R'D$2"'O+2_FFP1L#/-_
MO"ME<_%-_+Q]\\N[#[]C;70_,3QM'$0(5M&&TM[6K'RM+_6RV&@CS[H%>#I1
M-QX\'0*!16M]C -DG]>[$('^S?6^D]X+4R\9C7%UTE@$+PJ#2(>ZM08C[;Y&
MF/J!F.%#M3Y/KZ/%/4+(;+<68TDXGSA8:4DVDL)*'Y. (GS&6!A%EZT,T2/D
M#&MYCE?S"[@Y0.8C0,Y'G$\7RS\6:UQMK67V&'.V"HRI,S)=B.#JL!:I;<':
M"2)QUP(T/U R+KP<HMZ'&:&C9#T"L&Q(WTX5WS0\W'Z_8X<A2L84>8.>.%$F
M%_#)U;%Q6LA2F!&^R2'U EW#GE<-@-2G'D8 J_LG^L8P1^4IDE!T@@M/TD$4
MX(/PD&5@,NDB@@TMD/0C*=VZLY^+LW.DJ$<'EC_"Y6Y#45Q:ZDL;"(5G4-'[
M6NQI0%H75)3:2]7DW'J*H#'E>/97]+.X.5#J0]>=79^_?\Y7=6(*YHT5_?4*
MW\Q?8UQ>A>7W>K^P,Z'6JJA%@#KHDG8:A8LAV03H3*J/<EB0W<IK]UAT3(@Y
M5,6+$\A[I#B:SC_BU_6&G3N,)5$P!U,@V'J%R#!#\,(!DUS3AHS!EFYCB_=9
M=4P1>D,D'2_QD4+IXNMR.B.6^)8E%50.@A60T@E0(=4Z7V3$4N2)1VD8[_:T
MI-MZ8_)Y&L+G&"D/#9P+QO4FQ_D$;W<WQHZ_B)Y')R5PS;=3YT)P#GP6R85B
MN>/=&JT?L'BW_H7G ZG6\A\:7T^P]2NFAUP%@9PQ$\'P4-LIU#YW]6XH%2VC
M4465W'$$6]<ENSW?/1\LM9'U2!$TK8T2TA=B2FR9*KQDH^B49IPLKJJ7B[%H
M#HXYJW2Q1K)N9JGKBMW><9P]?HZ3]&CA<]>R[ABS@1L3:FCKZ[PUIVT=9AG
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M.[OI%K6)UT?2#=Z=(X8J!.11PG7Z*W,'SI*9Y='42=*:*]6LHVDW$L?TAOM
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MZDF*QI1VZL= ]2/\$:!H=YS_]M=7)#[N348@>VK16-H0S)$;F1R=ZX5$)45
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MPP7WS*BI+$- 1[O)FOJ0*ND S@D/RF0MK3>9#?1BZ,P'T.V%K5,,H-M'T2,
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M2^ \.JYU*IH_N%_N.T/^$HEG>CT\9.:[5ZW_U#[N_>#@TV(=9K=6PKM2_].
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M!U9O@*8@TL3, Q8(*"THD6CC,4E 5(E<I:30L[Z.:W\[*%_G#'448SJH9P;
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M;0.BS<HGI.;668T@LJGI\1@@>!U 6YEL]%BL:C?$8X@5=)X0? 8=.#L.>E&
M8_C^Q^4\!5RFZ:K>TFP9L&GK^7J^7D[GJVG:%"I/C"T4V1D!F.L%C1<)? H.
M"LM62Z%YMGW-Y3A@<9VG+W>Z=;1"SS/0J(U'><60O^/TXZ<UYA=?<1D^XMU^
MN1-N2A;!&)"%BSJ"3D",/@,QC8NHC&E467?F=8Z<V?VT]:PEICI0N:N:"5Q^
MG>XJ=NYPZ\UB_I5\5=RZK:N-I;G^?AV<\6:Q_K^X:6#Y<5Z/0:X5Y:XFS$02
M6DY@,ZM][!6'6,]%LDG.":F,;SS;N>7J1DY^'%>]^L//<U:JK1%ZM5CN7JJ?
MXQ-D7G$A VF!*J!<K7&*C@'*5$)@7+O;(U4ZUZY[ESER<L,S5;/3$35V6M@/
MX\_X0/SYQ_H3+M>?PGQG9>B]Q<6:&%)3EFASGSBGHV':@TV,N)"+!"]-@22+
MD$*ZI-)^^:S-2!SY*G,<G>A(ZAWL-4<+X3(I=+5>7FQNFS><^?"=,X=ZONA\
M'1$C0(O,005AP2O-P'@1;=;!BKWJT,X730W-@?WN4=DS4\?NQ' 0$)^U!O]M
MXPW<."#ZSB42:!%H!;#L-MF_"H+B&8+UR;K,E)=]C<X^:;G[Z>;_3W(8#6(=
M*.*+V>8S%'O>RZXZ_WB^PHGT6@8K$^12#U7KM74@@LDY9DI(HUW*3:9*[$?>
M?D!_KFD*#41X-#!I?XJ+L2];WUXLTR=Z\>V2PL;-U-O+S-6=RSO1%*J@CAY"
MJKT35!80,\O@I"[,)*N<;Y>FTV1)^ZG L\Y)&!\J'=CS#>VO5ZL+S"\OEE>9
M%MM,I!O-@JZ6/@OSU80VIHRZ9EZ4G&L/(@V!DXDPLO@ZC[4.>FY3UW,4O?O!
M_=FF'YQ!R'UL ?<O=.-I/;C.B61.%LT1#*L]T^MP'$<,!6E]CLRQDEV3;F5'
M4;L?DI]M1D!S 7>!XVO[RL_ARY0"AJVNOL,Z"@_K6?2KB_7%$BLK:A?!2=%1
M25/;L1B+I*I6@4?BL2F&R2183E*WP/#!E.Z'W^=ZT]Y6L!WX$_?-4+S&W;]/
MUY]>S_/TZS1?W+QXN0H[<C!*Z0(Q1@,J<0[!H "AN'-2HO/?3P>'!/*IA.^'
MZ^=ZQ7U6L7< \^V9S_LZ%F6ZGN+JU=<WTTETA465"Q0?ZXU@2A"BT" Q)N-T
M$HA-?.+[B-D/CL_V*OA4\0P&L?_Q;W<$0$O\Q^:MS3OU?[W#\E_KOW^^>WWC
M^S]N&I7\][3XO/WR-[A^/:??D+R>#?M>K-?+:;Q8UVJ1]6+;UV2WQ=2W/RUF
M).?5S46MIN0GW3JMN'LG>^RC_NW[RFZO>??$.SAKLDK\:[WIN?'?3M3SL)R3
ME[FZ(B6NULN0UA/%C.>:!3 J*5#9>T)G0I!>B^*+,[:TF7OQ $$G&[1;W_N!
M&/@3?> ?$QD">FDL6(R7!]0A.]!2.QV<5T*VZ>7\$$7CEF(.@H@[]FH0[C\K
MH[6IWSZGZ=H]<#P#=M^*6YLQ+=%B80)0D+.E@B*W*]-.&P/G)J.SM&<^)3/V
MO7/ [2>0IS%-+^;YY71VL<9M>X#O:L9%T8YC@<1*5;.4P27'P6'0T2H94J.\
MC./H[=0$'H*F.R<[9Y#<LS*0;\*R5H9]Q9>X#M/9.4WEG4>/9S0?YT)K\RF-
M#+PVAJ/-6(.*,8/G7D-&$0H6$;UIT@2VE?E\,5]/<U4S8NCWZ.F7O]+L@KCX
MBBQ!#><NMM*]JZDO/B\NYNO:,T]%RR6%:@I!D4V X%($4D>O"B_>Z299,X-0
MWZEI/01I=R[\SR[59V5H+W>FQ?T[4[C:F<YOB \F;3Q#?1H76QMREJ.RCC'P
MNK;YU.@@5B\BJ#H'S)BH1),><*T,^960?ENL5A.G?4)/\2/J8D"1DP0^%4NJ
MFZ1+EEX-3;S\&U1T:E@/D?QMPWH\ESLXPKZ5(WRS!\T?%^O5FG226+91STGD
MI8X-UZ!-Y+67MJ3%B0Q*BA25]I*Y)O>+!U$Y;O>A)A!K)Z4.($C*LQTPO[D3
MNMPP5M<WE ^+N_<$U[K_371P+# 1P*8<0'$?P5=61ZV9S4;[(IHDFIY.^KA-
M@9J ]<SR[ #!#ZCGSI6YHZ43RW7149AMRSNE2%5C[4P90H[%&FMR:=+-ZD Z
MQVW6<TY#.HBDC@=BK048YD+Z/J=Z@H:<#^<H3-P4%U1MBD9Z,"5:X>IDV]SF
M1OH^:L9M9=,$5*=SO8MTL]O+V"G%1,D28I$&$B?RE0T(/O@ J7@K:B]"8\]R
M];>C9]P>+6<!T#&<[_.P91L8?0A_'7>)=_V_#W!H\2 U QTL7'W_R^DJS1:K
MBVOX,,)@1*XAQ&A!I:3!VQ( HQ"1<:0_3>Z6'J%I ,?]]E=_OY'Q3D7G:PF;
M3@E4#(%^X@XH,G$.&6;1IO;K,:+&/7P8"AWW^-O#B*%[$W)\-L#=+QG6G#2\
MM7\,-CEHGXN@Z @%1?K%%_",' VE@R#H6!/;9.4T-"K?;X"W#_D)RV*)WQ](
M_ZS6FYO@5_3Z]./\UDTPDI->%+>@A53U]ID1X(T%27Z[0I.B-J'M'?Y1=/=K
MF@[!V,/7^>V%V<$YP/?EUJNTQ7Q3!EZNEKO+<OX)YUBFZUM+)6/,D"<#-NA0
MSXT9.%F;N]H0C-?,\MRFP^+Q-(][T-H>LVV%V!5>?RD%4[T9OEKGN[#&VNEJ
MGJ:SZ4:HM];*-(LR!T\AB16UQ+7Z&,1REH(DE544!K6I_3R!Z'%/6]LCMK$8
MNX+L9;$)+?+%:H7K%>TBOTU#I'76Q(9;RPQ:D?XQ"2(+"<IA;1E/,3HM/:7(
M+:)L[!8<1.^X1Z_M@=I.>%UA],_Y\JI_("UUMVFLWBUF,W)XK@94?5]I*:X>
M#7((GA=0K$XVJ(W=G4Y<4XA8F&N2@7 \R>.>Y[9':E,1=A]Q?\_7^9[B<,N)
MQ]4)&4_'/FK8Z/WX59XAQO<2BR@<@:!3.]-'\BDM)QASF3QCWFALTK.V^<%A
MY?(V[7"^GLXOIO./?WS![9B+>[B_"Q4G0@G)D@W@K6:@1';@HHXU&=(CPU12
M:I)6>@+-_<;VAV#K_F/']D+L8$,_8JF[\XQ)2%P502%@*AK)=9$60JT,T]R5
MVCHXF=@DK#^>Y'ZC^C.C]1@1/DVP_CZ=+Y:;[H5$!FDH.>,WOV5;2?T[KC\M
MZ)W:.GN;IV.)?N<8>3BFYJ-KFR 6F0&Y"4EGASPU.0,XXQK[/3(XLSJ<!22#
MY="<RR&^<R+8QAE^\#%M'>']5C>0$[S'<>M]0/T>[PG2 25KYU1!@9=D$KR2
MFT8/48I +D6;_/83Z3ZY2]3%LEJ25TB6*,SN/'HB;=),F9I+R5FM2.<0<^V"
M93,Y6R%GPYN<?/V KI''W)\1:W>Z/PTHL [\C<NCO-UZ'N#F1.>0E)8>A RT
M*JS%N270;B6<TJS$+&*3(LG]R!O7Z1T3C0W$UP$H'U_-?<R<,.X2(KDI)4AR
M4[*JZ>;>0XHE>NL"2[S)T>OAI([KDHX)UL9B[2"#>[<YO"=Y8KT3H?]PSQ;!
M,3/G*1!5T==V!]Y X,;1CB%T*H7'$)J<*NQ%W;AW5QWL[ ,*KP-3>KE!W%C5
M0]N$S"5&6R)(K$43.I#OXET"Q;(74:;LVV1]'D+DN#=6/>SU@XNR YCNLZ;[
M-PBF>,FU6I+^(<]&6 A)1N!1ZIP#:M>FO.%8@L>M?Q@3OF<1<3\^P%5*Y&W-
M%-8970SQD&G23"X0G.$*/.,\LH1:MKD1_ %=XTYW[6#?'T1@'9C2JY!PNYZ'
M-@A.?G5 JR KFVH_=0Y!! ^A)&>#DT;S)E6L^Y$W[A#4'G;Y <77 2@?7\V]
M9E\SHS&BI15*<K2-5^ $U\ BQA0*)I:;'#D=3NJXTTE'C>C;BK6#W?PA_2/?
M0SER/R G5NO+B771TQZ1A0E26LE<;-)+Y11[V6XDYY@8'$)"3^CB\N6T$'TX
M3[30]3\1YV^7BZ_3%3V(E/':_PCSRT/AZGA?$,J_W4@K7R^N%_5<?4FY\25#
M7X>.0GRK2];Q)=')U2UW,J%2 ;06"E2) H+T$I30,K"BN&IS]C[RU>T^Y1HO
MUH^*?L**BZ*V&I/<,E"*:7 R2."9Z22=*EZTZ<YP.NU/^PKX$,S>:?AP9L%W
MX+_OL^3[#WAP-2E*Y<WL469532$*%KSV"#QQ@TJCMZI-A]T3B'[:5\JMT3V(
MJ)\(K&_'./43EUO_>AIF$ZER*%H@F*3(T8S.0A2(4*S0 86R*K3I.SH \4_[
M,KHUS <5_1.!.[WX,U$V79,R2X\!<X$@- =E&?T4BP>;8C3>>V2V28Q[&)E/
M^\*Z-82/%.?A8/5;L,[Q8QU+?A)<:S#Y?7&[9;W^_(7XM7J'L_K]'Q9_TA[T
MUQ^7*GK9@VN2F%-!\@C2UX+H7"CJ5\P!2];I%)EVQO\H=#WA^4_[=OH8,)Y+
M6$_$?/ZQ_H3+JY?F'S=S\"[GBA-OC7:8P;IZD^EXAL@5 R8#_6QMH:A@+(/Z
M&.%/^]*ZM8D=3.1/!.+TXGM<KV>[;K]",C0V!@BL3C<3/H"/UI/S7ZI)I3#7
MVA&]A&ND/NTK[C-X"L>*]8D ]\VB'I9>T,?B#'><KT.;B?!/=385?L79XDM=
M_B0GRY4UGI35U_0IVJ.<SARL\,9F@2[IT6*Z_9?QM&_16P.^$1R>B#+\_*DV
M;'\]O]/+Y6]A=K'%R&RV^.=F?KD(7.EH)219K^>"K ,QF 8A7-9%:\_3:'[+
M >MXVO?TK=6A%2">B#YLZU]?7P4GM2X65[6##'UJM9A-<PUEWE_$U31/P_+;
MQ":%7*("H;RJT\YU34LTQ))0?,D<8QGM=.30Q3SQ]('6JM$4&Z<>M7PX?WS[
M(O^_B\OZ<.>-BD(CF!KEJ!J^!T,_%6_19*T3K7[4F/8:L?O!_%_VSO(DV79K
MYN_-0E,\*&-U JT"@HI*DD-'7AUM8$EXZ1,[YYW-T4F%_%_H!O)D.3ZE)*_;
M/EBXT6!Q\+2L_1[7+)'JB-6>H76;J\/67#*0K6&@>!T'XBCHPXP^N&*UT V;
M/]U+TU"U 5><_G5)KLS5BF,JTLF(8)TBMU[4Z8=662A%&[+V%.7F)CTX'B>K
MWP9LAR#DH3S_ 431P=9[9S4[&SW_6'WEG\-R^:UL^VVN)BS%G'T*4$2JTS)<
MA" *JRN5,H1$_^)94/8PC>-";DAH_ AU \FI1PA6G=V]MG-<JE-#_VX%.<^7
MW6"_3S.\_H&?%ZMUK3UT4AB$5(@12K "7G@!5J/42D2#J8F?V&(QXZ:TG1/4
MYY;\TT!_/=M>?L7:K/M%2LN+,%M-4#,I;?3@\J8XO+8[SK2-Z<*BU-*0#6C:
MU^<P<L?-5AL7P:=*KT>,_KI8Y'].9[--,\)UF'^L-S';MR:1ZTC!&X<ZYPJ4
M] B.@CKP&@V*&$@UFS2G/(3(<5//SHG'H20U(@HWB4IW%O;G%V+LO+;#_)U"
MU=5Z,<?=2./51&MC3+82E([UY(+3PDH1$%D4WCC'LKW5>^^!7+)#GCIN!ED#
M3+7E>X]F[2KG\H8_?7FU/!%,Y1RKF69U/';4%CP3=7@@Q8Q!\)3$>2S;XW2.
MF_1UYLUV*'GU",>'.OM*@<D[3DS#6H*D0P+'M:E%MYQXJX([TVG/*;V;FZ5K
MG1. 0TBH1^3MY<5NS_4_XCQ-<34Q66-@-@/]1;;?&P^!8P9/>H=62^;;U-4/
M0/NXV5;=12?'R[5'*&_N1B=6)Y6C,& ]K]=-&"&8:  Y+ZB+,%(UR76]GYQQ
M\YG.>DIY,/=[Q-"&01,60S&<"1!>5*/N"P1I$W#C=>*%7-RVC9=NDC-RYL]9
M8]B#V=]!_YE]LO&B4SGQK"!Q68= 2@;1H@?CD_4V.LE8DR8"0Z5<MLNX.2>\
M3A1,/VE@=U;V!FL'<9:-MH&,;<B@0F#@M(G@#8O(: ^7K,D<@ON(&3DUYIR@
M.I3U?5FL:TD<5^Q!6X+BMI(OZS30*,$GP<$C<S9FSW5LVF/X?K+Z'9LU4([!
MJ:+HRY^ZMIJWR\477*Z_O9V%S7%BC:6W11M%<J8L>8HA4K2A"NF-%\@@"*]R
M<$$HVSK/8!\ZN\DU.!DB>Z%O&'EUN5M>6^4C]R5W[D\8J7,L,H*2AL(:6BG$
M+ J([+,(G$R_:+VU'D=Y-PD%YT%N*YGVCN5M\)U985($"\DZ<FLHA +GI29<
M:<,X^;>&M[ZUN$U3-^D Y\'?X7+H#UE7GLZU=4U*'<7IZH!XG\GP,ZLA*D,1
MNL[UF%LG&YN>JMU'5#=7^ZVP=;(D3@97XXACDG7T7F8-/JA -CA;\)X;T#P4
MF[$HS5O?;QT*J%$FD0X?81S$^BYQM-W&KRVI!N*&.Y82>:2QU)DJ+$D(7"+X
M(DH1F+5,YTE<ODG7N*;J;/GQ)PBC^\J?=XO9;)=WL"@;0/\Y7V):?)Q/_^.V
M<@U3_'/,$X>M_SEYS9UT/XZ!.Q.= <^1@Q+*U$1AVCB%U"D02$5H<I\S<O?C
M6Z6CY9;P+C.L?_DKS2XR4?#B\^*":'U+L7^8UBKJ#XM?_@J?I_/-Q]_A^F(Y
MWV#BU183$YFSE4G6/)MZCBI5_8D<$A,#"BDIIC)-4I-;+^QI]TT^!.VW37I7
MD.G@0/.!]4^*T%9G2UN;(Q=*14:./M*J8H[TBQ<"V\PT>X"><0';%V@6PTOP
M:""2<DX7=1K@<MT2CF0EEAA66!,B+V8UI><5"6DW-.OMA@;Z]-O%:KHKR?:*
MQ<@S^60>0=D0P;G: ",'&R,FF663_7 8\L<]TWR*8&^)CWZ-]$L\;-52*<=C
M\B!<JD<VPH.+K(#$E+5"B_)V+4%3K3B0_'$/+YZB5K3$1S_'N@>9A+>TZ.4]
M2[>,%:T\ ^3,@C)1U'N_#-*RS)SA19LF-;9#$#_NV<M35(QVV'AJF\5#:U8\
ML.RU@* 2;9!%<W",,\A,:<%#44F>4Q\.(G[<ZK6GJ _ML-']-G'_TJ\U(?[[
M=/V)/E\E=;'^M%AN+Q=2] EK 4'&XNOM%X-:# -6$F-2-DI8/[I^_&@5XU;7
M/1]%&10MW6O,NVV_8K($-YCP6_BRPC_*BR]?9M,4X@RW0\?HI=^FGZ?K7:\T
MXU4)CB&4X'>35Z,*%J2T7J)S0>8F77P;K&7<TL"GJ#UG0T[W.C1!E3-%60J\
MUZIVS9 U-RM#0%=T0NE0GS,4'[=L\"EB^2 )GGB\^LL\G^'^]TU8UHN6KSC,
MY>Z=KQOVYO9Q:CNYEL5B2J@9!S;5P2M"!_#2UCGC/%<HHDJBA9:/?"W[<#^W
M#]6\3PIRS9--4")%U2H; YX":<BDIIST)R;7Y&[I!W0][4O10[!VV\8-*;!>
MNNL\R,,=FU_\-5U-M%3>86)@,4C:&&I[05L,,";0"B=R4?M-:CODJ>/B;%!9
MW]=>9W#&/Q5$O5Q\)G=D(AQ7,6H$AZ4>%TH!07L#T3KT+F8>I!T44]OGCH.J
MQI(_!E]'B&%LA-TJW?BP#/,54?$[?HZXG!B6=8F! T-%&BGK^+;  XA2G(]9
MIL#W ]2CCWD"^#E&LHLF;.[@F/^*69<'3=\VZL6]C%B[E25A*"SQO-0>>!ZX
M95YS44RR33(?[B=GW$R&%EO=@.SO$D0['=/!AQ L F*M@\Q:0/0D>.Y"MDP4
MIFR3NH6'".JD__H)POXA?H[@? <((JIQM9ZFG^N1S/+;SI8&CYJBC@1*R[*=
M2>Z9I^4D7XP5/(K4IAO(?=3TAIUC!'V[,.%DKG< G7K,BR_F^3?ZY.Q_7RRG
MJSS=' ]?+L?8HBT%LQI9 ,6R *>T)D43](9/Q@?5 D0_H*N3-@U#PFE(270
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M;(1%)C6W*)UF>Z%D\"[8@Y>!G^V>MID G@JR=CK("[(@90 7:E==1SH8HLK
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M6GLU6,/W&*O"7; @5?]"&9&S_P!02P,$%     @ ZH%94K_OV+0#!   E@H
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MAROX.ES]0(7K%D/*J-!M)AG('09"4\8KQI%N8M@<@.,<<TQ3/6402[PE0K:
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MI&%<D/".04*RT!"+1&B#%!R#NI0(*<1&%C0_O0/O4J&QI-QPA= N,9C*BNW
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M4$L! A0#%     @ ZH%94F9?!T]+E@4 )8I$ !$              ( !
M &=I;&0M,C R,#$R,S$N:'1M4$L! A0#%     @ ZH%94K2P#.IQ)   V:<!
M !$              ( !>I8% &=I;&0M,C R,#$R,S$N>'-D4$L! A0#%
M  @ ZH%94LV%7"%S0   N=$" !4              ( !&KL% &=I;&0M,C R
M,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .J!65)EZU6L0LL  &O+"  5
M          "  <#[!0!G:6QD+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4
M" #J@5E2?7ZJ?0ZP  #K$0$ %               @ $UQP8 9VEL9"TR,#(P
M,3(S,5]G,2YJ<&=02P$"% ,4    " #J@5E2&?;+SF3D 0#A_!, %0
M        @ %U=P< 9VEL9"TR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @
MZH%94BZ*6IJ?& $ ).T, !4              ( !#%P) &=I;&0M,C R,#$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( .J!65(69)%*KP<  $V:   >
M      "  =YT"@!G:6QD,C R,&9O<FTQ,"UK97AH:6)I=#(Q,2YH=&U02P$"
M% ,4    " #J@5E2O^_8M ,$  "6"@  '@              @ ')? H 9VEL
M9#(P,C!F;W)M,3 M:V5X:&EB:70R,S$N:'1M4$L! A0#%     @ ZH%94OA9
M4FZ]!P  9B   !X              ( !"($* &=I;&0R,#(P9F]R;3$P+6ME
M>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( .J!65+M@M^ MP<  $ @   >
M          "  0&)"@!G:6QD,C R,&9O<FTQ,"UK97AH:6)I=#,Q,BYH=&U0
M2P$"% ,4    " #J@5E28H4T:G,%  #A$@  '0              @ 'TD H
M9VEL9#(P,C!F;W)M,3 M:V5X:&EB:70S,BYH=&U02P$"% ,4    " #J@5E2
MV6FI8Z4(  !O+   '@              @ &BE@H 9VEL9#(P;W)M97@Q,#)A
E;65N9&UE;G1T;S(N:'1M4$L%!@     -  T DP,  (.?"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
